Down	B-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
of	O
interferon	O
regulatory	O
factor	O
4	O
gene	O
expression	B-Gene_expression
in	O
leukemic	O
cells	O
due	O
to	O
hypermethylation	O
of	O
CpG	O
motifs	O
in	O
the	O
promoter	O
region	O

Although	O
the	O
bcr	O
-	O
abl	O
translocation	O
has	O
been	O
shown	O
to	O
be	O
the	O
causative	O
genetic	O
aberration	O
in	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
,	O
there	O
is	O
mounting	O
evidence	O
that	O
the	O
deregulation	B-Regulation
of	O
other	O
genes	O
,	O
such	O
as	O
the	O
transcription	O
factor	O
interferon	O
regulatory	O
factor	O
4	O
(	O
IRF	O
-	O
4	O
)	O
,	O
is	O
also	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
CML	O
.	O

Promoter	O
methylation	O
of	O
CpG	O
target	O
sites	O
or	O
direct	O
deletions/insertions	O
of	O
genes	O
are	O
mechanisms	O
of	O
a	O
reversible	O
or	O
permanent	O
silencing	O
of	O
gene	O
expression	O
,	O
respectively	O
.	O

Therefore	O
,	O
we	O
investigated	O
whether	O
IRF	O
-	O
4	O
promoter	O
methylation	O
or	O
mutation	O
may	O
be	O
involved	O
in	O
the	O
regulation	B-Regulation
of	O
IRF	O
-	O
4	O
expression	B-Gene_expression
in	O
leukemia	O
cells	O
.	O

Whereas	O
promoter	O
mutations	O
or	O
structural	O
rearrangements	O
could	O
be	O
excluded	O
as	O
a	O
cause	O
of	O
altered	B-Regulation
IRF	O
-	O
4	O
expression	B-Gene_expression
in	O
hematopoietic	O
cells	O
,	O
the	O
IRF	O
-	O
4	O
promoter	O
methylation	O
status	O
was	O
found	O
to	O
significantly	O
influence	B-Regulation
IRF	O
-	O
4	O
transcription	B-Transcription
.	O

First	O
,	O
treatment	O
of	O
IRF-4	O
-	O
negative	B-Gene_expression
lymphoid	O
,	O
myeloid	O
and	O
monocytic	O
cell	O
lines	O
with	O
the	O
methylation	O
-	O
inhibitor	O
5-aza-2	O
-	O
deoxycytidine	O
resulted	B-Positive_regulation
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
increase	B-Positive_regulation
of	O
IRF	O
-	O
4	O
mRNA	O
and	O
protein	O
levels	O
.	O

Second	O
,	O
using	O
a	O
restriction-PCR	O
-	O
assay	O
and	O
bisulfite	O
-	O
sequencing	O
we	O
identified	O
specifically	O
methylated	O
CpG	O
sites	O
in	O
IRF-4	O
-	O
negative	B-Gene_expression
but	O
not	O
in	O
IRF-4	O
-	O
positive	B-Gene_expression
cells	O
.	O

Third	O
,	O
we	O
clearly	O
determined	O
promoter	O
methylation	O
as	O
a	O
mechanism	O
for	O
IRF	O
-	O
4	O
down	B-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
via	O
reporter	O
gene	O
assays	O
,	O
but	O
did	O
not	O
detect	O
an	O
association	O
of	O
methylational	O
status	O
and	O
mRNA	O
expression	O
of	O
DNA	O
methyltransferases	O
or	O
methyl-CpG	O
-	O
binding	O
proteins	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
CpG	O
site	O
-	O
specific	O
IRF	O
-	O
4	O
promoter	O
methylation	O
as	O
a	O
putative	O
mechanism	O
of	O
down	B-Negative_regulation
-	I-Negative_regulation
regulated	I-Negative_regulation
IRF	O
-	O
4	O
expression	B-Gene_expression
in	O
leukemia	O
.	O

INTRODUCTION	O

Chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
is	O
a	O
clonal	O
myeloproliferative	O
disorder	O
with	O
a	O
typical	O
three	O
phased	O
course	O
(	O
chronic	O
,	O
accelerated	O
and	O
blastic	O
phase	O
)	O
reflecting	O
the	O
loss	O
of	O
differentiation	O
and	O
malignant	O
progress	O
which	O
inevitably	O
leads	O
to	O
death	O
after	O
the	O
blastic	O
phase	O
(	O
1	O
,	O
2	O
)	O
.	O

The	O
hallmark	O
genetic	O
aberration	O
of	O
CML	O
is	O
a	O
reciprocal	O
chromosomal	O
translocation	O
t	O
(	O
9	O
;	O
22	O
)	O
leading	B-Positive_regulation
to	O
expression	B-Gene_expression
of	O
a	O
bcr	O
-	O
abl	O
fusion	O
gene	O
,	O
an	O
aberrant	O
activated	O
tyrosine	O
kinase	O
(	O
2	O
)	O
.	O

Treatment	O
with	O
interferon	O
alpha	O
(	O
IFN	O
-	O
alpha	O
)	O
prolongs	O
survival	O
of	O
CML	O
patients	O
and	O
is	O
associated	O
with	O
a	O
complete	O
cytogenetic	O
response	O
in	O
5	O
-	O
33	O
%	O
of	O
CML	O
patients	O
(	O
1	O
,	O
2	O
)	O
.	O

Recently	O
,	O
we	O
described	O
an	O
impaired	B-Negative_regulation
expression	B-Gene_expression
of	O
the	O
interferon	O
regulatory	O
factor	O
4	O
(	O
IRF	O
-	O
4	O
)	O
in	O
CML	O
,	O
correlating	O
with	O
poor	O
response	O
to	O
IFN	O
-	O
alpha	O
treatment	O
(	O
3	O
)	O
.	O

The	O
cause	O
of	O
the	O
silencing	B-Negative_regulation
of	O
IRF	O
-	O
4	O
level	O
remained	O
unclear	O
.	O

Interferon	O
regulatory	O
factors	O
(	O
IRFs	O
)	O
are	O
a	O
family	O
of	O
transcriptional	O
regulators	O
defined	O
by	O
a	O
characteristic	O
homology	O
in	O
their	O
DNA	O
-	O
binding	O
domain	O
.	O

They	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
various	O
genes	O
(	O
such	O
as	O
IFNs	O
,	O
interleukins	O
,	O
MHC	O
class	O
I/II	O
)	O
,	O
apoptosis	O
and	O
differentiation/maturation	O
(	O
4	O
-	O
6	O
)	O
.	O

IRF	O
-	O
4	O
(	O
ICSAT/Pip/MUM1/LSIRF	O
)	O
is	O
one	O
member	O
with	O
very	O
restricted	O
expression	B-Gene_expression
pattern	O
:	O
Predominately	O
B	O
-	O
and	O
activated	O
T	O
-	O
lymphocytes	O
are	O
IRF	O
-	O
4	O
positive	B-Gene_expression
(	O
7	O
-	O
11	O
)	O
.	O

In	O
contrast	O
to	O
other	O
IRFs	O
,	O
expression	B-Gene_expression
of	O
IRF	O
-	O
4	O
can	O
not	O
be	O
induced	B-Positive_regulation
by	O
IFNs	O
,	O
but	O
by	O
antigen	O
stimulation	O
,	O
crosslinking	O
of	O
T	O
-	O
or	O
B	O
-	O
cell	O
receptors	O
or	O
phorbol-myristate	O
-	O
acetate	O
(	O
10	O
,	O
11	O
)	O
.	O

Consistent	O
with	O
the	O
restriction	O
of	O
expression	O
to	O
immunocompetent	O
cells	O
,	O
mice	O
with	O
deletion	B-Negative_regulation
of	O
IRF	O
-	O
4	O
failed	O
to	O
develop	O
mature	O
and	O
functionally	O
active	O
B	O
-	O
and	O
T	O
-	O
lymphocytes	O
(	O
12	O
)	O
,	O
and	O
the	O
impaired	O
expression	B-Gene_expression
of	O
IRF	O
-	O
4	O
in	O
CML	O
was	O
predominately	O
found	O
in	O
T	O
-	O
cells	O
(	O
3	O
)	O
.	O

These	O
data	O
suggest	O
a	O
crucial	O
role	O
for	O
IRF	O
-	O
4	O
in	O
the	O
function	O
of	O
immune	O
cells	O
.	O

Methylation	O
of	O
dinucleotide	O
cytosine	O
-	O
guanosine	O
motifs	O
(	O
CpG	O
)	O
,	O
especially	O
in	O
CpG	O
islands	O
located	O
in	O
promoter	O
regions	O
,	O
is	O
one	O
of	O
the	O
mechanisms	O
of	O
gene	O
regulation	O
in	O
mammals	O
and	O
a	O
common	O
event	O
of	O
gene	O
silencing	O
in	O
human	O
neoplasias	O
(	O
13	O
,	O
14	O
)	O
.	O

As	O
opposed	O
to	O
normal	O
cells	O
,	O
hypermethylation	O
of	O
CpG	O
islands	O
is	O
a	O
frequently	O
observed	O
phenomenon	O
in	O
every	O
cancer	O
type	O
.	O

De	O
novo	O
DNA	O
methylation	O
of	O
genes	O
such	O
as	O
cell	O
cycle	O
,	O
DNA	O
repair	O
,	O
apoptosis	O
and	O
tumor	O
suppressor	O
genes	O
is	O
therefore	O
thought	O
to	O
be	O
involved	O
in	O
tumorigenesis	O
(	O
15	O
-	O
17	O
)	O
.	O

Examples	O
for	O
such	O
aberrated	O
genes	O
are	O
MGMT	O
,	O
DAPK	O
,	O
p14ARF	O
,	O
p15INK4b	O
,	O
p16INK4a	O
,	O
BRCA1	O
,	O
CDH13	O
and	O
APAF	O
-	O
1	O
(	O
17	O
-	O
19	O
)	O
.	O

In	O
CML	O
,	O
methylation	O
is	O
known	O
to	O
regulate	B-Regulation
expression	B-Gene_expression
of	O
the	O
c	O
-	O
abl	O
,	O
the	O
bcr	O
gene	O
and	O
others	O
(	O
20	O
-	O
23	O
)	O
,	O
and	O
the	O
extent	O
of	O
methylation	O
in	O
the	O
c	O
-	O
abl	O
promoter	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
advanced	O
disease	O
(	O
24	O
)	O
.	O

Hypermethylation	O
due	O
to	O
overexpression	O
of	O
DNA	O
methyltransferases	O
(	O
DNMTs	O
)	O
remains	O
one	O
possible	O
explanation	O
for	O
de	O
novo	O
methylation	O
in	O
tumorigenesis	O
.	O

Recently	O
,	O
DNMTs	O
have	O
been	O
shown	O
to	O
be	O
up	O
-	O
regulated	O
in	O
hematopoietic	O
malignancies	O
(	O
25	O
)	O
.	O

Methyl-CpG	O
-	O
binding	O
proteins	O
(	O
MBPs	O
)	O
are	O
thought	O
to	O
inhibit	O
the	O
binding	O
of	O
transcriptional	O
factors	O
to	O
the	O
promoter	O
and	O
are	O
therefore	O
discussed	O
as	O
one	O
mechanism	O
of	O
transcription	O
inhibition	O
by	O
hypermethylation	O
(	O
26	O
)	O
.	O

In	O
this	O
work	O
,	O
we	O
studied	O
mechanisms	O
of	O
IRF	O
-	O
4	O
gene	O
expression	B-Gene_expression
silencing	B-Negative_regulation
in	O
leukemic	O
cells	O
.	O

We	O
analyzed	O
the	O
IRF	O
-	O
4	O
promoter	O
region	O
for	O
genetic	O
aberrations	O
and	O
methylational	O
status	O
in	O
IRF-4	O
-	O
positive	B-Gene_expression
and	O
-	O
negative	B-Gene_expression
hematopoietic	O
cells	O
.	O

Cell	O
lines	O

K	O
-	O
562	O
,	O
Jurkat	O
and	O
U	O
-	O
937	O
were	O
obtained	O
from	O
the	O
ATCC	O
(	O
American	O
Type	O
Culture	O
Collection	O
,	O
Rockville	O
,	O
USA	O
)	O
and	O
EM	O
-	O
2	O
,	O
LAMA	O
-	O
84	O
,	O
CML	O
-	O
T1	O
,	O
BV	O
-	O
173	O
,	O
SD	O
-	O
1	O
and	O
RPMI	O
-	O
8226	O
from	O
the	O
DSMZ	O
(	O
Deutsche	O
Sammlung	O
von	O
Mikroorganismen	O
und	O
Zellkulturen	O
GmbH	O
,	O
Braunschweig	O
,	O
Germany	O
)	O
.	O

All	O
cell	O
lines	O
,	O
except	O
BV	O
-	O
173	O
,	O
SD	O
-	O
1	O
and	O
RPMI	O
-	O
8226	O
,	O
were	O
IRF-4	O
-	O
negative	B-Gene_expression
.	O

Cell	O
culture	O
and	O
stimulation	O

All	O
cell	O
lines	O
were	O
maintained	O
at	O
5	O
%	O
CO2	O
in	O
RPMI	O
1640	O
medium	O
with	O
1	O
%	O
glutamine	O
(	O
Gibco/BRL	O
Eggenstein	O
,	O
Germany	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
calf	O
serum	O
(	O
Gibco/BRL	O
)	O
,	O
1	O
%	O
penicillin/streptomycin	O
(	O
Biochrom	O
,	O
Berlin	O
,	O
Germany	O
)	O
.	O

When	O
indicated	O
,	O
cells	O
were	O
treated	O
with	O
5-aza-2	O
-	O
deoxycytidine	O
(	O
AzadC	O
)	O
or	O
5	O
-	O
azacytidine	O
(	O
AzaC	O
)	O
(	O
Sigma	O
,	O
Taufkirchen	O
,	O
Germany	O
)	O
for	O
different	O
time	O
periods	O
.	O

Owing	O
to	O
their	O
chemical	O
instability	O
fresh	O
substances	O
were	O
re	O
-	O
added	O
every	O
24	O
h	O
.	O

Sequencing	O
of	O
the	O
IRF	O
-	O
4	O
promoter	O

For	O
analysis	O
of	O
the	O
IRF	O
-	O
4	O
promoter	O
region	O
for	O
permanent	O
aberrations	O
such	O
as	O
insertions/deletions	O
or	O
mutation	O
,	O
we	O
PCR	O
-	O
amplified	O
two	O
fragments	O
from	O
genomic	O
DNA	O
,	O
which	O
was	O
extracted	O
from	O
depicted	O
cell	O
lines	O
with	O
a	O
commercial	O
kit	O
(	O
Qiagen	O
,	O
Hilde	O
,	O
Germany	O
)	O
as	O
recommended	O
.	O

The	O
primers	O
were	O
1	O
-	O
forward	O
:	O
5'-TTGAGATGGAGTCTTGCTCTGT	O
-	O
3	O
'	O
,	O
1	O
-	O
reverse	O
:	O
5'-CCAGGACCTCAGGAGGCCAGTCA	O
-	O
3	O
'	O
;	O
2	O
-	O
forward	O
:	O
5'-AGCGGTGAAACTGAGAGTGCGAGGT	O
-	O
3	O
'	O
,	O
2	O
-	O
reverse	O
:	O
5'-GCCACATCGCTGCAGTTTAG	O
-	O
3	O
'	O
.	O

The	O
products	O
were	O
cloned	O
with	O
the	O
'TOPO	O
TA	O
cloning	O
kit	O
'	O
(	O
Invitrogen	O
,	O
Groningen	O
,	O
The	O
Netherlands	O
)	O
.	O

After	O
bacterial	O
amplification	O
of	O
the	O
cloned	O
PCR	O
fragments	O
by	O
standard	O
procedures	O
,	O
at	O
least	O
three	O
clones	O
from	O
each	O
sample	O
were	O
sequenced	O
with	O
an	O
automated	O
sequencer	O
(	O
ABI	O
Prism	O
377	O
,	O
Applied	O
Bio	O
-	O
systems	O
,	O
Foster	O
City	O
,	O
USA	O
)	O
as	O
recommended	O
by	O
the	O
manufacturer	O
.	O

Expression	O
analysis	O

To	O
analyze	O
the	O
IRF	O
-	O
4	O
transcriptional	B-Transcription
level	O
,	O
RNA	O
was	O
extracted	O
from	O
cells	O
using	O
the	O
commercial	O
RNAzol	O
-	O
kit	O
(	O
Paesel	O
,	O
Frankfurt	O
,	O
Germany	O
)	O
.	O

An	O
aliquot	O
of	O
1	O
mug	O
total	O
RNA	O
was	O
used	O
for	O
cDNA	O
synthesis	O
as	O
described	O
previously	O
(	O
27	O
)	O
.	O

RNA	B-Transcription
expression	I-Transcription
analysis	O
for	O
IRF	O
-	O
4	O
and	O
the	O
reference	O
gene	O
beta	O
-	O
actin	O
was	O
carried	O
out	O
by	O
semi	O
-	O
quantitative	O
PCR	O
as	O
described	O
previously	O
(	O
3	O
,	O
27	O
)	O
.	O

PCR	O
products	O
were	O
verified	O
by	O
automated	O
sequencing	O
.	O

PCR	O
primers	O
and	O
conditions	O
for	O
expression	B-Gene_expression
analysis	O
of	O
DNMT	O
or	O
MBP	O
(	O
DNMT1	O
DNMT3A	O
,	O
DNMT3B	O
,	O
MeCP	O
,	O
MBD1	O
,	O
MBD2	O
and	O
MBD4	O
)	O
were	O
published	O
elsewhere	O
(	O
28	O
)	O
.	O

For	O
analysis	O
of	O
IRF	O
-	O
4	O
protein	O
expression	B-Gene_expression
,	O
a	O
standard	O
immunoblotting	O
assay	O
was	O
performed	O
as	O
described	O
previously	O
(	O
29	O
)	O
.	O

Briefly	O
,	O
protein	O
lysates	O
were	O
generated	O
by	O
incubating	O
1	O
x	O
106	O
cells	O
in	O
100	O
microl	O
RIPA	O
buffer	O
(	O
1	O
%	O
NP	O
-	O
40	O
,	O
0.5	O
%	O
sodiumdesoxycholate	O
,	O
0.1	O
%	O
SDS	O
,	O
100	O
microg/ml	O
phenylmethylsulfonyl	O
fluoride	O
,	O
10	O
microl/ml	O
protease-inhibitory	O
-	O
mix	O
,	O
1	O
micromol/ml	O
sodiumorthovanadate	O
in	O
phosphate	O
-	O
buffered	O
saline	O
)	O
for	O
30	O
min	O
on	O
ice	O
.	O

After	O
centrifugation	O
,	O
protein	O
concentration	O
of	O
the	O
supernatant	O
was	O
determined	O
by	O
BCA	O
-	O
method	O
(	O
Pierce	O
,	O
Rockford	O
,	O
IL	O
)	O
as	O
recommended	O
.	O

Protein	O
lysates	O
(	O
70	O
-	O
100	O
microg	O
)	O
were	O
electrophoresed	O
on	O
polyacrylamide	O
gels	O
and	O
transferred	O
to	O
a	O
PVDF	O
-	O
membrane	O
(	O
Immobilon	O
P	O
,	O
0.45	O
microm	O
;	O
Millipore	O
,	O
Eschborn	O
,	O
Germany	O
)	O
.	O

Membranes	O
were	O
blocked	O
with	O
2.5	O
%	O
blocking	O
reagent	O
(	O
Boehringer	O
Mannheim	O
,	O
Germany	O
)	O
in	O
TBST	O
buffer	O
(	O
4.44	O
g/l	O
Tris	O
-	O
HCL	O
,	O
2.65	O
g/l	O
TrisOH	O
,	O
8.07	O
g/l	O
NaCl	O
,	O
0.2	O
g/l	O
KCl	O
and	O
500	O
microl/l	O
Tween	O
-	O
20	O
in	O
H2O	O
)	O
and	O
subsequently	O
incubated	O
with	O
primary	O
antibody	O
as	O
indicated	O
and	O
horseradish	O
peroxidase	O
-	O
conjugated	O
secondary	O
antibody	O
,	O
anti	O
-	O
mouse	O
or	O
anti	O
-	O
goat	O
IgG	O
(	O
DAKO	O
,	O
Hamburg	O
,	O
Germany	O
)	O
,	O
respectively	O
.	O

The	O
membranes	O
were	O
then	O
developed	O
with	O
an	O
ECL	O
detection	O
kit	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
,	O
Freiburg	O
,	O
Germany	O
)	O
.	O

The	O
primary	O
antibodies	O
were	O
goat	O
anti-IRF	O
-	O
4/ICSAT	O
(	O
M	O
-	O
17	O
)	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
CA	O
)	O
and	O
mouse	O
anti-beta	O
-	O
actin	O
(	O
AC	O
-	O
74	O
)	O
(	O
Sigma	O
)	O
.	O

Methylation	O
-	O
specific	O
restriction-PCR	O
-	O
assay	O

DNA	O
was	O
extracted	O
with	O
a	O
commercial	O
kit	O
(	O
Qiagen	O
)	O
as	O
recommended	O
.	O

Since	O
the	O
restriction	O
ability	O
of	O
several	O
endonucleases	O
is	O
inhibited	O
by	O
methylation	O
of	O
their	O
target	O
sequence	O
,	O
we	O
used	O
methylation	O
-	O
sensitive	O
enzymes	O
HpaII	O
and	O
HaeII	O
-	O
isochizomer	O
Bsp143II	O
and	O
Bsh1236I	O
(	O
MBI	O
Fermentas	O
,	O
St	O
Leon	O
-	O
Rot	O
,	O
Germany	O
)	O
(	O
20	O
,	O
24	O
)	O
.	O

As	O
control	O
the	O
methylation	O
-	O
resistant	O
enzyme	O
MspI	O
and	O
an	O
enzyme	O
with	O
no	O
recognition	O
site	O
in	O
the	O
target	O
promoter	O
,	O
EcoRI	O
,	O
were	O
used	O
.	O

DNA	O
(	O
0.8	O
microg	O
)	O
was	O
digested	O
by	O
40	O
U	O
the	O
respective	O
enzyme	O
for	O
6	O
h	O
and	O
,	O
to	O
ensure	O
complete	O
cleavage	O
,	O
additional	O
20	O
U	O
for	O
16	O
h	O
.	O

Thereafter	O
100	O
ng	O
of	O
digested	O
DNA	O
was	O
used	O
to	O
a	O
PCR	O
amplification	O
of	O
two	O
fragments	O
(	O
F1	O
and	O
F2	O
)	O
spanning	O
part	O
of	O
the	O
IRF	O
-	O
4	O
promoter	O
(	O
30	O
)	O
(	O
GenBank	O
U52683	O
;	O
see	O
Figure	O
3A	O
)	O
.	O

The	O
sequences	O
of	O
the	O
primers	O
were	O
F1	O
-	O
forward	O
:	O
5'-TTGAGATGGAGTCTTGCTCTGT	O
-	O
3	O
'	O
,	O
F1	O
-	O
reverse	O
:	O
ATCACTTCCAGACTTCAGTTCACCT	O
-	O
3	O
'	O
(	O
341	O
bp	O
)	O
;	O
F2	O
-	O
forward	O
:	O
5'-AAGGTGAACTGAAGTCTGGAAGTGA	O
-	O
3	O
'	O
,	O
F2	O
-	O
reverse	O
:	O
5'-CCAGGACCTCAGGAGGCCAGTCA	O
-	O
3	O
'	O
(	O
474	O
bp	O
)	O
.	O

The	O
PCR	O
conditions	O
were	O
described	O
elsewhere	O
(	O
3	O
)	O
.	O

PCR	O
was	O
performed	O
with	O
an	O
annealing	O
temperature	O
of	O
62degreesC	O
and	O
35	O
cycles	O
.	O

When	O
DNA	O
was	O
methylated	O
at	O
specific	O
sites	O
,	O
the	O
sensitive	O
enzymes	O
were	O
not	O
able	O
to	O
digest	O
the	O
DNA	O
and	O
amplification	O
took	O
place	O
;	O
in	O
case	O
of	O
no	O
methylation	O
,	O
DNA	O
was	O
digested	O
and	O
no	O
product	O
was	O
generated	O
.	O

The	O
PCR	O
products	O
were	O
electrophoresed	O
on	O
a	O
3	O
%	O
agarose	O
gel	O
,	O
were	O
stained	O
with	O
ethidium	O
bromide	O
and	O
photographed	O
.	O

PCR	O
products	O
were	O
verified	O
by	O
automated	O
sequencing	O
.	O

Bisulfite	O
treatment	O

DNA	O
was	O
extracted	O
as	O
described	O
above	O
.	O

Bisulfite	O
treatment	O
of	O
DNA	O
,	O
leading	O
to	O
conversion	O
of	O
unmethylated	O
cytosine	O
to	O
uracil	O
residues	O
and	O
no	O
change	O
of	O
methylated	O
cytosine	O
residues	O
,	O
was	O
performed	O
as	O
described	O
as	O
follows	O
.	O

Briefly	O
,	O
1	O
microg	O
of	O
DNA	O
and	O
2	O
microg	O
of	O
poly	O
(	O
dA	O
-	O
dT	O
)	O
(	O
poly	O
(	O
dA	O
-	O
dT	O
)	O
copolymers	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
)	O
were	O
denaturated	O
for	O
20	O
min	O
at	O
42degreesC	O
in	O
0.3	O
M	O
NaOH	O
in	O
a	O
volume	O
of	O
50	O
microl	O
.	O

Fresh	O
solutions	O
of	O
30	O
microl	O
of	O
10	O
mM	O
hydrochinon	O
(	O
Sigma	O
)	O
and	O
530	O
microl	O
of	O
3	O
M	O
sodium	O
bisulfite	O
(	O
pH	O
5.0	O
;	O
Sigma	O
)	O
were	O
added	O
,	O
the	O
solution	O
was	O
gently	O
mixed	O
,	O
overlayed	O
with	O
mineral	O
oil	O
and	O
incubated	O
in	O
the	O
dark	O
for	O
12	O
-	O
13	O
h	O
at	O
50degreesC	O
.	O

The	O
aqueous	O
phase	O
was	O
recovered	O
using	O
the	O
'Wizard	O
DNA	O
clean	O
-	O
up	O
system	O
'	O
(	O
Promega	O
,	O
Mannheim	O
,	O
Germany	O
)	O
.	O

The	O
purified	O
DNA	O
was	O
subsequently	O
mixed	O
with	O
1	O
M	O
NaOH	O
to	O
a	O
final	O
concentration	O
of	O
0.3	O
M	O
and	O
incubated	O
for	O
20	O
min	O
at	O
37degreesC	O
to	O
ensure	O
complete	O
desulfonisation	O
.	O

DNA	O
was	O
ethanol	O
precipitated	O
in	O
the	O
presence	O
of	O
1/10	O
vol	O
of	O
3	O
M	O
sodium	O
acetate	O
,	O
washed	O
with	O
70	O
%	O
ethanol	O
and	O
resuspended	O
in	O
50	O
microl	O
H2O	O
.	O

Subsequent	O
PCR	O
amplification	O
of	O
4	O
microl	O
bisulfite	O
-	O
treated	O
DNA	O
was	O
used	O
for	O
cloning	O
of	O
two	O
fragments	O
of	O
the	O
IRF	O
-	O
4	O
promoter	O
(	O
BS	O
-	O
I	O
and	O
BS	O
-	O
II	O
)	O
into	O
pCR2.1	O
vector	O
with	O
the	O
'TOPO	O
TA	O
cloning	O
kit	O
'	O
(	O
Invitrogen	O
)	O
(	O
see	O
Figure	O
3A	O
)	O
.	O

The	O
primers	O
used	O
for	O
PCR	O
amplification	O
of	O
the	O
BS	O
-	O
I	O
and	O
BS	O
-	O
II	O
fragments	O
contain	O
the	O
putative	O
altered	O
sequence	O
of	O
the	O
sense	O
strand	O
due	O
to	O
bisulfite	O
treatment	O
(	O
converted	O
cytosine	O
residues	O
are	O
written	O
in	O
bold	O
letters	O
)	O
:	O
BS-I	O
-	O
forward	O
5'-TATTTGGATTTTTAGGGAGTTTTTTTT	O
-	O
3	O
'	O
,	O
BS-I	O
-	O
reverse	O
5'-ACCCAACTCCCTTAAACTATTAAACT	O
-	O
3	O
'	O
(	O
187	O
bp	O
)	O
;	O
BS-II	O
-	O
forward	O
5'-AGTTTAATAGTTTAAGGGAGTTGGGT	O
-	O
3	O
'	O
,	O
BS-II	O
-	O
reverse	O
5'-CTCACCCTAAACTCAAAACTAAAAAC	O
-	O
3	O
'	O
(	O
674	O
bp	O
)	O
.	O

After	O
bacterial	O
amplification	O
of	O
the	O
cloned	O
PCR	O
fragments	O
by	O
standard	O
procedures	O
,	O
eight	O
clones	O
from	O
each	O
sample	O
were	O
sequenced	O
with	O
an	O
automated	O
sequencer	O
(	O
ABI	O
Prism	O
377	O
,	O
Applied	O
Biosystems	O
)	O
.	O

In	O
vitro	O
methylation	O
and	O
reporter	O
gene	O
assays	O

The	O
IRF	O
-	O
4	O
promoter	O
-	O
reporter	O
gene	O
construct	O
was	O
generously	O
provided	O
by	O
J.Hiscott	O
(	O
31	O
)	O
.	O

Constructs	O
were	O
methylated	O
in	O
vitro	O
with	O
CpG	O
Methylase	O
(	O
M.Sss	O
I	O
)	O
as	O
recommended	O
by	O
the	O
manufacturer	O
(	O
NE	O
Biolabs	O
)	O
and	O
complete	O
methylation	O
was	O
checked	O
via	O
restriction	O
analysis	O
(	O
Figure	O
5A	O
)	O
.	O

Reporter	O
gene	O
assays	O
using	O
the	O
dual	O
luciferase	O
assay	O
(	O
Promega	O
)	O
were	O
performed	O
similar	O
to	O
previous	O
reports	O
(	O
29	O
)	O
.	O

Briefly	O
,	O
5	O
nM	O
of	O
the	O
reporter	O
construct	O
and	O
the	O
transfection	O
control	O
construct	O
expressing	B-Gene_expression
the	O
renilla	O
luciferase	O
gene	O
were	O
transiently	O
co	O
-	O
expressed	B-Gene_expression
via	O
electroporation	O
.	O

The	O
control	O
construct	O
served	O
as	O
an	O
internal	O
reference	O
for	O
transfection	O
efficiency	O
.	O

Forty	O
-	O
eight	O
hours	O
after	O
transfection	O
,	O
luciferase	O
activity	O
was	O
measured	O
with	O
a	O
LB	O
96	O
P	O
microlumat	O
(	O
EG	O
&	O
G	O
Berthold	O
,	O
Bad	O
Wildbad	O
,	O
Germany	O
)	O
.	O

IRF	O
-	O
4	O
promoter	O
activation	B-Positive_regulation
was	O
quantified	O
as	O
a	O
ratio	O
of	O
measured	O
firefly	O
light	O
units	O
(	O
flu	O
)	O
relative	O
to	O
renilla	O
(	O
rlu	O
)	O
.	O

Each	O
experiment	O
was	O
carried	O
out	O
at	O
least	O
three	O
times	O
.	O

Absence	B-Negative_regulation
of	O
IRF	O
-	O
4	O
expression	B-Gene_expression
in	O
leukemia	O
cells	O
is	O
not	O
due	B-Positive_regulation
to	O
promoter	O
alterations	O

We	O
have	O
previously	O
demonstrated	O
a	O
lack	B-Negative_regulation
of	O
IRF	O
-	O
4	O
expression	B-Gene_expression
in	O
leukemia	O
patients	O
and	O
specifically	O
in	O
CML	O
T	O
-	O
cells	O
(	O
3	O
)	O
.	O

Here	O
,	O
we	O
demonstrate	O
the	O
absence	O
of	O
IRF	O
-	O
4	O
expression	B-Gene_expression
in	O
various	O
hematopoietic	O
cell	O
lines	O
,	O
such	O
as	O
Jurkat	O
,	O
a	O
T	O
-	O
cell	O
leukemia	O
,	O
CML	O
-	O
T1	O
,	O
a	O
bcr-abl	O
-	O
positive	B-Gene_expression
T	O
-	O
cell	O
line	O
,	O
K	O
-	O
562	O
,	O
a	O
bcr-abl	O
-	O
positve	B-Gene_expression
erythroleukemia	O
,	O
U	O
-	O
937	O
,	O
a	O
monocytic	O
leukemia	O
,	O
EM	O
-	O
2	O
and	O
LAMA	O
-	O
84	O
,	O
bcr-abl	O
-	O
positve	B-Gene_expression
myeloid	O
leukemia	O
,	O
but	O
not	O
in	O
SD	O
-	O
1	O
,	O
a	O
bcr-abl	O
-	O
positive	B-Gene_expression
acute	O
lymphoblastic	O
leukemia	O
(	O
pre	O
B	O
-	O
ALL	O
)	O
,	O
RPMI	O
-	O
8226	O
,	O
a	O
multiple	O
myeloma	O
and	O
BV	O
-	O
173	O
,	O
a	O
bcr-abl	O
-	O
positive	B-Gene_expression
B	O
-	O
cell	O
line	O
(	O
Figures	O
1A	O
and	O
5D	O
)	O
.	O

After	O
sequencing	O
of	O
the	O
IRF	O
-	O
4	O
promoter	O
,	O
it	O
could	O
be	O
excluded	O
that	O
absence	B-Negative_regulation
of	O
IRF	O
-	O
4	O
expression	B-Gene_expression
in	O
any	O
of	O
the	O
above	O
cell	O
lines	O
was	O
due	O
to	O
genetic	O
aberrations	O
.	O

However	O
,	O
2	O
bp	O
changes	O
(	O
nucleotide	O
-	O
1081	O
,	O
T	O
-	O
-	O
>	O
C	O
and	O
-	O
1068	O
,	O
A	O
-	O
-	O
>	O
C	O
)	O
could	O
be	O
detected	O
in	O
both	O
the	O
IRF-4	O
-	O
positive	B-Gene_expression
BV	O
-	O
173	O
and	O
the	O
IRF-4	O
-	O
negative	B-Gene_expression
LAMA	O
-	O
84	O
,	O
EM	O
-	O
2	O
and	O
K	O
-	O
562	O
(	O
Figure	O
1B	O
)	O
.	O

At	O
position	O
-	O
116	O
an	O
A	O
-	O
-	O
>	O
C	O
substitution	O
was	O
found	O
in	O
EM	O
-	O
2	O
,	O
K	O
-	O
562	O
and	O
CML	O
-	O
T1	O
,	O
whereas	O
Jurkat	O
,	O
BV	O
-	O
173	O
and	O
SD	O
-	O
1	O
exhibited	O
a	O
mixed	O
A/C	O
sequence	O
and	O
U	O
-	O
937	O
,	O
LAMA	O
-	O
84	O
and	O
RPMI	O
-	O
8226	O
no	O
substitution	O
at	O
all	O
(	O
Figure	O
1B	O
)	O
.	O

Consequently	O
,	O
these	O
alterations	O
are	O
unlikely	O
to	O
affect	B-Regulation
IRF	O
-	O
4	O
expression	B-Gene_expression
.	O

Increase	B-Positive_regulation
of	O
IRF	O
-	O
4	O
expression	B-Gene_expression
in	O
hematopoietic	O
cells	O
after	O
demethylating	O
treatment	O

We	O
next	O
analyzed	O
whether	O
promoter	O
methylation	O
could	O
be	O
responsible	O
for	O
down	O
-	O
regulation	O
of	O
IRF	O
-	O
4	O
expression	B-Gene_expression
.	O

A	O
region	O
including	O
exon1	O
in	O
the	O
IRF	O
-	O
4	O
promoter	O
exhibited	O
a	O
large	O
number	O
of	O
CpG	O
-	O
rich	O
sequences	O
(	O
Figure	O
3A	O
)	O
.	O

Several	O
chemical	O
substances	O
such	O
as	O
5-aza-2	O
-	O
deoxycytidine	O
(	O
AzadC	O
)	O
or	O
5	O
-	O
azacytidine	O
(	O
AzaC	O
)	O
inhibit	O
de	O
novo	O
and	O
maintenance	O
methylation	O
,	O
and	O
thus	O
can	O
be	O
used	O
to	O
discern	O
promoter	O
methylation	O
(	O
32	O
,	O
33	O
)	O
.	O

We	O
used	O
AzadC	O
to	O
generate	O
unmethylated	O
DNA	O
.	O

A	O
72	O
h	O
AzadC	O
-	O
treatment	O
resulted	O
in	O
a	O
concentration	O
-	O
dependent	O
activation	B-Positive_regulation
of	O
IRF	O
-	O
4	O
transcription	B-Transcription
in	O
Jurkat	O
and	O
CML	O
-	O
T1	O
T	O
-	O
cells	O
as	O
well	O
as	O
in	O
U	O
-	O
937	O
,	O
K	O
-	O
562	O
and	O
EM	O
-	O
2	O
cell	O
lines	O
(	O
Figure	O
2A	O
)	O
.	O

IRF	O
-	O
4	O
transcription	B-Transcription
was	O
induced	B-Positive_regulation
in	O
a	O
time	O
-	O
dependent	O
manner	O
and	O
was	O
observed	O
as	O
early	O
as	O
24	O
h	O
after	O
treatment	O
with	O
AzadC	O
and	O
increased	B-Positive_regulation
over	O
time	O
until	O
72	O
h	O
(	O
Figure	O
2B	O
)	O
.	O

Time	O
and	O
strength	O
of	O
the	O
appearance	O
of	O
IRF	O
-	O
4	O
transcripts	B-Transcription
varied	O
among	O
cell	O
lines	O
,	O
i.e	O
.	O

CML	O
-	O
T1	O
responded	O
strongest	O
to	O
AzadC	O
-	O
treatment	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
line	O
with	O
this	O
,	O
AzadC	O
-	O
treatment	O
of	O
CML	O
-	O
T1	O
and	O
LAMA	O
-	O
84	O
cells	O
also	O
translated	O
in	O
an	O
induction	O
of	O
IRF	O
-	O
4	O
protein	O
expression	O
(	O
Figure	O
2C	O
)	O
.	O

Accordingly	O
,	O
treatment	O
of	O
the	O
IRF-4	O
-	O
positive	B-Gene_expression
cell	O
line	O
BV	O
-	O
173	O
,	O
SD	O
-	O
1	O
and	O
RPMI	O
-	O
8226	O
with	O
AzadC	O
had	O
no	O
effect	B-Regulation
on	O
IRF	O
-	O
4	O
expression	B-Gene_expression
(	O
Figure	O
2D	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
effects	O
of	O
AzaC	O
versus	O
AzadC	O
,	O
as	O
both	O
increased	B-Positive_regulation
the	O
IRF	O
-	O
4	O
mRNA	B-Transcription
level	I-Transcription
in	O
CML	O
-	O
T1	O
cells	O
as	O
well	O
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
implied	O
that	O
promoter	O
methylation	O
may	O
control	B-Regulation
IRF	O
-	O
4	O
expression	B-Gene_expression
,	O
but	O
an	O
alternative	O
explanation	O
may	O
be	O
activation	O
of	O
positive	O
transcriptional	O
regulators	O
of	O
IRF	O
-	O
4	O
by	O
AzadC	O
(	O
or	O
AzaC	O
)	O
.	O

Methylation	O
-	O
sensitive	O
enzymes	O
do	O
not	O
cut	O
specific	O
sites	O
in	O
the	O
IRF	O
-	O
4	O
promoter	O
in	O
hematopoietic	O
cells	O

To	O
further	O
investigate	O
promoter	O
methylation	O
as	O
a	O
regulatory	O
mechanism	O
of	O
IRF	O
-	O
4	O
gene	O
expression	B-Gene_expression
,	O
restriction-PCR	O
-	O
assays	O
were	O
performed	O
(	O
20	O
,	O
24	O
)	O
,	O
where	O
only	O
methylated	O
DNA	O
would	O
not	O
be	O
cut	O
enabling	O
subsequent	O
PCR	O
amplification	O
and	O
vice	O
versa	O
.	O

Genomic	O
DNA	O
from	O
leukemic	O
cells	O
Jurkat	O
,	O
CML	O
-	O
T1	O
,	O
U	O
-	O
937	O
,	O
K	O
-	O
562	O
,	O
EM	O
-	O
2	O
and	O
BV	O
-	O
173	O
was	O
digested	O
with	O
the	O
methylation	O
-	O
sensitive	O
enzymes	O
HpaII	O
,	O
Bsh1236I	O
and	O
HaeII	O
-	O
isochizomer	O
Bsp143II	O
.	O

EcoRI	O
,	O
which	O
has	O
no	O
recognition	O
site	O
within	O
the	O
IRF	O
-	O
4	O
promoter	O
,	O
and	O
the	O
methylation	O
-	O
resistant	O
enzyme	O
MspI	O
served	O
as	O
controls	O
.	O

Two	O
separate	O
amplification	O
reactions	O
were	O
performed	O
,	O
generating	O
two	O
fragments	O
,	O
F1	O
and	O
F2	O
(	O
Figure	O
3A	O
)	O
.	O

After	O
digestion	O
with	O
HpaII	O
and	O
Bsp143II	O
a	O
sufficient	O
PCR	O
amplification	O
of	O
F1	O
and	O
F2	O
was	O
detected	O
in	O
DNA	O
from	O
IRF-4	O
-	O
negative	B-Gene_expression
Jurkat	O
,	O
CML	O
-	O
T1	O
,	O
U	O
-	O
937	O
,	O
K	O
-	O
562	O
and	O
EM	O
-	O
2	O
cells	O
,	O
suggesting	O
a	O
promoter	O
methylation	O
(	O
and	O
restriction	O
protection	O
)	O
at	O
the	O
respective	O
recognition	O
sites	O
(	O
Figure	O
3B	O
and	O
C	O
)	O
.	O

Notably	O
,	O
in	O
IRF-4	O
-	O
positive	B-Gene_expression
SD	O
-	O
1	O
cells	O
digestion	O
with	O
the	O
methylation	O
-	O
sensitive	O
enzymes	O
completely	O
inhibited	O
amplification	O
of	O
F1	O
and	O
F2	O
.	O

In	O
IRF-4	O
-	O
positive	B-Gene_expression
BV	O
-	O
173	O
cells	O
a	O
HpaII	O
,	O
but	O
not	O
a	O
Bsh1236I	O
digestion	O
,	O
significantly	O
reduced	O
the	O
amplifiable	O
DNA	O
message	O
of	O
F2	O
(	O
Figure	O
3C	O
)	O
,	O
whereas	O
amplification	O
of	O
F1	O
was	O
not	O
affected	O
(	O
Figure	O
3B	O
)	O
.	O

This	O
implied	O
that	O
IRF	O
-	O
4	O
transcription	B-Transcription
in	O
SD	O
-	O
1	O
and	O
BV	O
-	O
173	O
cells	O
is	O
associated	O
with	O
less	O
promoter	O
methylation	O
(	O
in	O
BV	O
-	O
173	O
especially	O
at	O
HpaII	O
sites	O
)	O
as	O
compared	O
with	O
the	O
tested	O
IRF-4	O
-	O
negative	B-Gene_expression
cells	O
.	O

Specific	O
CpG	O
sites	O
in	O
the	O
IRF	O
-	O
4	O
promoter	O
are	O
methylated	O
in	O
hematopoietic	O
cells	O

In	O
order	O
to	O
exactly	O
map	O
the	O
methylation	O
sites	O
within	O
the	O
IRF	O
-	O
4	O
promoter	O
,	O
we	O
treated	O
DNA	O
of	O
Jurkat	O
,	O
CML	O
-	O
T1	O
,	O
U	O
-	O
937	O
,	O
K	O
-	O
562	O
and	O
EM	O
-	O
2	O
cells	O
as	O
well	O
as	O
of	O
SD	O
-	O
1	O
,	O
RPMI	O
-	O
8226	O
and	O
BV	O
-	O
173	O
control	O
cells	O
with	O
bisulfite	O
,	O
which	O
chemically	O
converts	O
unmethylated	O
cytosine	O
to	O
uracil	O
,	O
whereas	O
it	O
has	O
no	O
effect	O
on	O
methylated	O
cytosine	O
,	O
i.e.	O
in	O
CpG	O
(	O
34	O
)	O
.	O

This	O
technique	O
is	O
especially	O
useful	O
for	O
detection	O
of	O
unknown	O
methylation	O
patterns	O
.	O

PCR	O
amplification	O
,	O
cloning	O
and	O
sequencing	O
of	O
the	O
bisulfite	O
-	O
treated	O
DNA	O
showed	O
a	O
specific	O
methylation	O
pattern	O
of	O
the	O
analyzed	O
62	O
CpG	O
sites	O
in	O
all	O
cell	O
lines	O
(	O
Figure	O
4	O
and	O
Table	O
1	O
)	O
.	O

In	O
general	O
,	O
the	O
methylational	O
status	O
ranged	O
from	O
one	O
cell	O
line	O
with	O
a	O
nearly	O
non	O
-	O
methylated	O
IRF	O
-	O
4	O
promoter	O
(	O
SD	O
-	O
1	O
,	O
IRF-4	O
-	O
positive	B-Gene_expression
)	O
to	O
a	O
completely	O
methylated	O
IRF	O
-	O
4	O
promoter	O
in	O
CML	O
-	O
T1	O
(	O
IRF-4	O
-	O
negative	B-Gene_expression
)	O
.	O

Interestingly	O
,	O
the	O
percentage	O
of	O
CpG	O
methylation	O
in	O
the	O
IRF	O
-	O
4	O
promoter	O
from	O
IRF-4	O
-	O
positive	B-Gene_expression
cells	O
was	O
very	O
low	O
(	O
mean	O
24	O
%	O
)	O
as	O
compared	O
with	O
IRF-4	O
-	O
negative	B-Gene_expression
cells	O
(	O
mean	O
94	O
%	O
)	O
(	O
Figure	O
4A	O
and	O
Table	O
1	O
)	O
.	O

A	O
5'	O
-	O
region	O
(	O
R1	O
)	O
with	O
13	O
hypermethylated	O
CpG	O
sites	O
(	O
mean	O
number	O
of	O
methylated	O
clones	O
5.5	O
of	O
8	O
with	O
77	O
%	O
methylated	O
CpGs	O
)	O
was	O
found	O
in	O
most	O
cells	O
(	O
except	O
SD	O
-	O
1	O
and	O
RPMI	O
-	O
8226	O
)	O
and	O
a	O
3'	O
-	O
region	O
(	O
R3	O
)	O
of	O
6	O
hypomethylated	O
CpG	O
sites	O
(	O
mean	O
number	O
of	O
methylated	O
clones	O
1.7	O
of	O
8	O
with	O
33	O
%	O
methylated	O
CpGs	O
)	O
was	O
found	O
in	O
most	O
cells	O
(	O
except	O
CML	O
-	O
T1	O
and	O
U	O
-	O
937	O
)	O
(	O
Figure	O
4A	O
and	O
Table	O
1	O
)	O
.	O

Intriguingly	O
,	O
a	O
stretch	O
of	O
13	O
CpG	O
sites	O
(	O
#	O
10	O
-	O
22	O
;	O
R2	O
)	O
was	O
detected	O
in	O
between	O
these	O
regions	O
,	O
which	O
were	O
highly	O
methylated	O
in	O
IRF-4	O
-	O
negative	B-Gene_expression
(	O
mean	O
number	O
of	O
methylated	O
clones	O
7.1	O
of	O
8	O
with	O
89	O
%	O
methylated	O
CpGs	O
)	O
but	O
totally	O
non	O
-	O
methylated	O
in	O
IRF-4	O
-	O
positive	B-Gene_expression
cells	O
(	O
Figure	O
4A	O
and	O
B	O
)	O
.	O

Furthermore	O
,	O
three	O
CpG	O
sites	O
at	O
the	O
5	O
'	O
end	O
(	O
#	O
54	O
,	O
56	O
,	O
58	O
)	O
and	O
two	O
CpG	O
motifs	O
at	O
the	O
3	O
'	O
end	O
(	O
#	O
1	O
,	O
2	O
)	O
showed	O
this	O
direct	O
correlation	O
between	O
high	O
methylation	O
status	O
and	O
absence	B-Negative_regulation
of	O
IRF	O
-	O
4	O
expression	B-Gene_expression
.	O

In	O
addition	O
,	O
two	O
CpG	O
sites	O
located	O
in	O
a	O
NFkappaB	O
(	O
#	O
48	O
)	O
and	O
a	O
SP1element	O
(	O
#	O
45	O
)	O
are	O
less	O
methylated	O
in	O
IRF-4	O
-	O
positive	B-Gene_expression
than	O
in	O
IRF-4	O
-	O
negative	B-Gene_expression
cells	O
(	O
mean	O
number	O
of	O
methylated	O
clones	O
:	O
1/8	O
versus	O
8/8	O
)	O
.	O

These	O
results	O
indicate	O
the	O
involvement	O
of	O
CpG	O
methylation	O
in	O
the	O
regulation	B-Regulation
of	O
IRF	O
-	O
4	O
expression	B-Gene_expression
in	O
leukemic	O
cells	O
.	O

In	O
vitro	O
methylation	O
of	O
an	O
IRF	O
-	O
4	O
promoter	O
-	O
reporter	O
construct	O
decreases	O
its	O
activity	O

To	O
provide	O
evidence	O
for	O
a	O
direct	O
effect	O
of	O
methylational	O
status	O
on	O
IRF	O
-	O
4	O
promoter	O
activity	O
we	O
performed	O
reporter	O
gene	O
assays	O
with	O
IRF	O
-	O
4	O
promoter	O
constructs	O
before	O
and	O
after	O
their	O
in	O
vitro	O
methylation	O
.	O

A	O
complete	O
methylation	O
of	O
these	O
constructs	O
was	O
checked	O
via	O
restriction	O
assays	O
with	O
methylation	O
-	O
sensitive	O
endonucleases	O
(	O
Figure	O
5A	O
)	O
.	O

Intriguingly	O
,	O
methylation	O
of	O
the	O
IRF	O
-	O
4	O
promoter	O
significantly	O
decreased	B-Negative_regulation
promoter	O
activity	O
in	O
IRF-4	O
-	O
positive	B-Gene_expression
SD	O
-	O
1	O
cells	O
by	O
85.0	O
%	O
(	O
Figure	O
5B	O
)	O
.	O

The	O
silencing	O
effect	O
of	O
CpG	O
methylation	O
was	O
not	O
restricted	O
to	O
IRF-4	O
-	O
positive	B-Gene_expression
cells	O
,	O
since	O
in	O
vitro	O
methylation	O
led	O
to	O
a	O
92.9	O
%	O
abrogation	B-Negative_regulation
of	O
promoter	O
activity	O
in	O
IRF-4	O
-	O
negative	B-Gene_expression
Jurkat	O
cells	O
(	O
Figure	O
5C	O
)	O
.	O

In	O
contrast	O
,	O
control	O
methylation	O
of	O
a	O
reporter	O
construct	O
with	O
a	O
different	O
promoter	O
(	O
FasL	O
)	O
as	O
well	O
as	O
an	O
empty	O
vector	O
had	O
no	O
effect	O
on	O
the	O
reporter	O
activity	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
data	O
proved	O
a	O
direct	O
association	O
between	O
methylation	O
and	O
activity	O
of	O
the	O
IRF	O
-	O
4	O
promoter	O
.	O

mRNA	O
expression	O
of	O
DNA	O
methyltransferases	O
and	O
methyl-CpG	O
-	O
binding	O
proteins	O
may	O
not	O
be	O
associated	O
with	O
IRF	O
-	O
4	O
promoter	O
methylation	O

Since	O
abundance	O
of	O
DNMT	O
and	O
MBP	O
contribute	O
to	O
promoter	O
regulation	B-Regulation
via	O
methylation	O
(	O
25	O
,	O
26	O
,	O
28	O
)	O
,	O
we	O
studied	O
their	O
mRNA	O
expression	O
to	O
investigate	O
a	O
possible	O
mechanism	O
for	O
the	O
observed	O
methylation	O
differences	O
in	O
the	O
IRF	O
-	O
4	O
promoter	O
.	O

To	O
this	O
end	O
,	O
we	O
did	O
not	O
detect	O
a	O
significant	O
difference	O
in	O
DNMT	O
(	O
DNMT1	O
,	O
DNMT3A	O
and	O
DNMT3B	O
)	O
or	O
MBP	O
(	O
MBD1	O
,	O
MBD2	O
,	O
MBD4	O
and	O
MeCP	O
)	O
mRNA	B-Transcription
expression	I-Transcription
between	O
IRF-4	O
-	O
positive	B-Gene_expression
and	O
-	O
negative	B-Gene_expression
cells	O
(	O
Figure	O
5D	O
)	O
.	O

In	O
fact	O
,	O
all	O
analyzed	O
cells	O
had	O
moderate	O
to	O
high	O
mRNA	B-Transcription
levels	I-Transcription
of	O
these	O
tested	O
DNMT/MBPs	O
and	O
differences	O
in	O
expression	B-Transcription
were	O
not	O
correlated	O
with	O
IRF	O
-	O
4	O
status	O
.	O

These	O
results	O
indicate	O
a	O
distinct	O
cause	O
of	O
the	O
methylation	O
differences	O
in	O
IRF-4	O
-	O
positive	B-Gene_expression
and	O
-	O
negative	B-Gene_expression
cells	O
rather	O
than	O
changes	O
in	O
the	O
DNMT	O
and	O
MBP	O
mRNA	O
transcription	B-Transcription
.	O

DISCUSSION	O

Many	O
genetic	O
lesions	O
are	O
known	O
to	O
influence	O
gene	O
expression	O
of	O
tumor	O
suppressor	O
genes	O
.	O

Whereas	O
mutations	O
and	O
deletions	O
or	O
insertions	O
have	O
permanent	O
effects	O
,	O
reversible	O
mechanisms	O
are	O
gene	O
methylation	O
,	O
or	O
expression	O
and	O
activation	O
of	O
transcription	O
factors	O
,	O
respectively	O
.	O

We	O
studied	O
a	O
putative	O
cause	O
for	O
absent	B-Negative_regulation
IRF	O
-	O
4	O
expression	B-Gene_expression
in	O
leukemia	O
cells	O
and	O
first	O
focused	O
on	O
genetic	O
aberrations	O
of	O
the	O
promoter	O
.	O

We	O
observed	O
no	O
genetic	O
alterations	O
in	O
the	O
IRF	O
-	O
4	O
promoter	O
,	O
which	O
can	O
account	O
for	O
the	O
lack	B-Negative_regulation
of	O
IRF	O
-	O
4	O
expression	B-Gene_expression
:	O
The	O
detected	O
base	O
pair	O
changes	O
at	O
position	O
-	O
1081	O
(	O
T	O
-	O
-	O
>	O
C	O
substitution	O
)	O
,	O
at	O
position	O
-	O
1068	O
(	O
A	O
-	O
-	O
>	O
C	O
substitution	O
)	O
and	O
at	O
position	O
-	O
116	O
(	O
A	O
-	O
-	O
>	O
C	O
substitution	O
)	O
are	O
unlikely	O
responsible	B-Positive_regulation
for	O
absent	B-Negative_regulation
IRF-4	O
-	O
expression	B-Gene_expression
since	O
the	O
first	O
two	O
mutations	O
were	O
found	O
both	O
in	O
IRF-4	O
-	O
positive	B-Gene_expression
and	O
-	O
negative	B-Gene_expression
cells	O
whereas	O
the	O
latter	O
change	O
was	O
not	O
detected	O
consistently	O
in	O
all	O
IRF-4	O
-	O
negative	B-Gene_expression
or	O
-	O
positive	B-Gene_expression
cells	O
and	O
may	O
thus	O
be	O
a	O
polymorphism	O
.	O

All	O
three	O
substitutions	O
did	O
not	O
change	B-Regulation
any	O
known	O
putative	O
transcription	O
factor	O
binding	O
sites	O
(	O
30	O
,	O
31	O
)	O
and	O
also	O
do	O
not	O
affect	B-Regulation
any	O
restriction	O
sites	O
or	O
primer	O
binding	O
sites	O
of	O
the	O
used	O
assays	O
.	O

However	O
,	O
permanent	O
genetic	O
variations	O
in	O
the	O
IRF	O
-	O
4	O
coding	O
sequence	O
,	O
such	O
as	O
deletions	O
or	O
mutations	O
resulting	O
in	O
stop	O
-	O
codons	O
have	O
not	O
been	O
excluded	O
by	O
sequence	O
analysis	O
.	O

Since	O
IRF	O
-	O
4	O
expression	B-Gene_expression
in	O
cell	O
lines	O
and	O
CML	O
can	O
be	O
induced	B-Positive_regulation
by	O
demethylation	O
and	O
successful	O
IFN	O
-	O
alpha	O
therapy	O
(	O
3	O
)	O
,	O
respectively	O
,	O
the	O
existence	O
of	O
such	O
genetic	O
aberrations	O
seems	O
unlikely	O
.	O

We	O
then	O
investigated	O
whether	O
the	O
previously	O
described	O
down	B-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
of	O
IRF	O
-	O
4	O
expression	B-Gene_expression
in	O
human	O
myeloid	O
leukemias	O
was	O
due	B-Positive_regulation
to	O
a	O
differential	O
hypermethylation	O
of	O
the	O
promoter	O
,	O
since	O
the	O
presented	O
re	B-Gene_expression
-	I-Gene_expression
expression	I-Gene_expression
due	O
to	O
AzadC	O
-	O
treatment	O
might	O
also	O
be	O
a	O
result	B-Positive_regulation
of	O
activation	O
of	O
positive	O
transcriptional	O
regulators	O
of	O
IRF	O
-	O
4	O
.	O

Methylation	O
of	O
CpG	O
sites	O
is	O
a	O
common	O
mechanism	O
of	O
silencing	O
genes	O
in	O
leukemia	O
and	O
has	O
also	O
been	O
shown	O
for	O
another	O
IRF	O
,	O
IRF	O
-	O
7	O
(	O
35	O
)	O
and	O
for	O
PU.1	O
(	O
36	O
)	O
,	O
an	O
interacting	B-Binding
partner	O
of	O
IRF	O
-	O
4	O
.	O

To	O
elucidate	O
the	O
relevance	O
of	O
this	O
mechanism	O
for	O
the	O
regulation	B-Regulation
of	O
IRF	O
-	O
4	O
expression	B-Gene_expression
,	O
various	O
leukemic	O
cells	O
were	O
treated	O
with	O
demethylating	O
agents	O
and	O
promoters	O
were	O
sequenced	O
after	O
bisulfite	O
treatment	O
.	O

We	O
found	O
that	O
IRF	O
-	O
4	O
expression	B-Gene_expression
could	O
indeed	O
be	O
connected	O
to	O
the	O
methylation	O
status	O
of	O
distinct	O
CpG	O
motifs	O
in	O
the	O
IRF	O
-	O
4	O
promoter	O
.	O

In	O
Figure	O
4A	O
,	O
those	O
CpG	O
sites	O
are	O
shown	O
(	O
bottom	O
line	O
)	O
,	O
whose	O
hypermethylation	O
may	O
account	B-Positive_regulation
for	O
the	O
absence	B-Negative_regulation
of	O
IRF	O
-	O
4	O
expression	B-Gene_expression
in	O
the	O
respective	O
cells	O
.	O

One	O
of	O
them	O
(	O
#	O
54	O
)	O
is	O
adjacent	O
to	O
an	O
identified	O
regulatory	O
element	O
(	O
NFkappaB	O
-	O
site	O
)	O
,	O
indicating	O
a	O
possible	O
involvement	O
of	O
this	O
site	O
.	O

At	O
two	O
further	O
CpG	O
sites	O
(	O
#	O
48	O
,	O
45	O
)	O
the	O
methylation	O
status	O
in	O
IRF-4	O
-	O
positive	B-Gene_expression
was	O
lower	O
than	O
that	O
of	O
IRF-4	O
-	O
negative	O
cells	O
.	O

These	O
CpG	O
sites	O
are	O
located	O
in	O
an	O
NFkappaB	O
and	O
an	O
SP1	O
element	O
(	O
31	O
)	O
and	O
thus	O
may	O
also	O
play	O
a	O
role	B-Regulation
in	O
regulation	B-Regulation
of	O
IRF	O
-	O
4	O
expression	B-Gene_expression
.	O

It	O
has	O
been	O
shown	O
that	O
NFkappaB	O
elements	O
play	O
an	O
important	B-Regulation
role	I-Regulation
in	O
IRF	O
-	O
4	O
induction	B-Positive_regulation
as	O
IRF	O
-	O
4	O
expression	B-Gene_expression
depends	B-Positive_regulation
on	O
binding	B-Binding
of	O
the	O
transactivator	O
c	O
-	O
Rel	O
to	O
these	O
elements	O
in	O
the	O
IRF	O
-	O
4	O
promoter	O
(	O
31	O
,	O
37	O
)	O
.	O

Furthermore	O
,	O
methylation	O
of	O
the	O
central	O
CpG	O
in	O
the	O
NFkappaB	O
element	O
inhibits	B-Negative_regulation
binding	B-Binding
of	O
the	O
NFkappaB	O
protein	O
complexes	O
(	O
38	O
)	O
,	O
promoting	O
the	O
significance	O
of	O
the	O
observed	O
methylation	O
differences	O
in	O
IRF-4	O
-	O
positive	B-Gene_expression
and	O
-	O
negative	B-Gene_expression
cells	O
.	O

Via	O
in	O
vitro	O
methylation	O
and	O
reporter	O
gene	O
assays	O
we	O
could	O
clearly	O
appoint	O
the	O
silencing	B-Negative_regulation
of	O
the	O
IRF	O
-	O
4	O
promoter	O
to	O
a	O
methylation	O
effect	O
,	O
which	O
may	O
thus	O
be	O
the	O
mechanism	O
of	O
IRF	O
-	O
4	O
deregulation	B-Regulation
in	O
vivo	O
.	O

One	O
possible	O
cause	O
for	O
the	O
aberrant	O
methylation	O
in	O
tumorigenesis	O
is	O
an	O
increased	O
level	O
of	O
DNMTs	O
during	O
the	O
pathogenetic	O
process	O
.	O

In	O
colon	O
,	O
lung	O
and	O
hematologic	O
malignancies	O
,	O
overexpression	B-Positive_regulation
of	O
DNMT1	O
,	O
a	O
maintenance	O
DNMT	O
,	O
has	O
been	O
detected	O
(	O
39	O
-	O
41	O
)	O
.	O

Furthermore	O
,	O
it	O
has	O
been	O
shown	O
that	O
CML	O
cells	O
in	O
the	O
acute	O
phase	O
exhibited	O
elevated	O
levels	O
of	O
the	O
three	O
known	O
DNMTs	O
,	O
while	O
CML	O
cells	O
in	O
chronic	O
phase	O
expressed	O
normal	O
levels	O
of	O
DNMTs	O
if	O
compared	O
with	O
normal	O
bone	O
marrow	O
cells	O
(	O
25	O
)	O
.	O

Interestingly	O
,	O
a	O
positive	O
correlation	O
between	O
DNMT1	O
expression	B-Gene_expression
levels	O
and	O
hypermethylation	O
of	O
p15INK4b	O
has	O
been	O
detected	O
in	O
AML	O
(	O
25	O
)	O
.	O

In	O
this	O
work	O
,	O
we	O
did	O
not	O
detect	O
significant	O
mRNA	O
expression	O
differences	O
of	O
selected	O
DNMT	O
or	O
MBP	O
,	O
making	O
it	O
an	O
unlikely	O
cause	O
for	O
the	O
observed	O
methylation	O
and	O
thus	O
IRF	O
-	O
4	O
expression	B-Gene_expression
differences	O
in	O
leukemia	O
cells	O
.	O

The	O
finding	O
that	O
IRF	O
-	O
4	O
expression	B-Gene_expression
is	O
silenced	O
by	O
promoter	O
hypermethylation	O
might	O
represent	O
a	O
mechanism	O
that	O
accounts	O
for	O
the	O
previously	O
observed	O
loss	B-Negative_regulation
of	O
IRF	O
-	O
4	O
expression	B-Gene_expression
in	O
CML	O
.	O

Indeed	O
,	O
several	O
clinical	O
trials	O
with	O
leukemia	O
patients	O
and	O
patients	O
with	O
myelodysplastic	O
syndromes	O
demonstrated	O
the	O
potential	O
clinical	O
benefit	O
of	O
a	O
treatment	O
with	O
demethylating	O
agents	O
(	O
42	O
-	O
45	O
)	O
.	O

The	O
expression	B-Gene_expression
of	O
another	O
IRF	O
,	O
IFN	O
consensus	O
sequence	O
binding	O
protein	O
(	O
ICSBP/IRF	O
-	O
8	O
)	O
,	O
is	O
impaired	B-Negative_regulation
in	O
myeloid	O
leukemias	O
especially	O
CML	O
(	O
27	O
,	O
46	O
,	O
47	O
)	O
.	O

But	O
in	O
contrast	O
to	O
IRF	O
-	O
4	O
,	O
the	O
loss	B-Negative_regulation
of	O
this	O
IRF	O
could	O
not	O
be	O
reverted	B-Negative_regulation
in	O
ICSBP	O
-	O
negative	B-Gene_expression
cell	O
lines	O
(	O
EM	O
-	O
2	O
,	O
CML	O
-	O
T1	O
,	O
K	O
-	O
562	O
and	O
LAMA	O
-	O
84	O
)	O
by	O
treatment	O
with	O
AzadC	O
(	O
Figure	O
6	O
)	O
and	O
AzadC	O
has	O
no	O
effect	B-Regulation
on	O
ICSBP	O
levels	B-Gene_expression
in	O
ICSBP	O
-	O
positive	B-Gene_expression
U	O
-	O
937	O
cells	O
(	O
Figure	O
6	O
)	O
.	O

These	O
data	O
suggest	O
a	O
distinct	O
regulatory	O
mechanism	O
for	O
these	O
two	O
IRFs	O
.	O

IRF	O
-	O
4	O
,	O
similar	O
to	O
many	O
other	O
classical	O
tumor	O
suppressor	O
genes	O
p15INK4b	O
,	O
p16INK4a	O
or	O
p53	O
,	O
may	O
thus	O
be	O
a	O
subject	O
of	O
alterations	O
in	O
the	O
promoter	O
methylation	O
status	O
leading	O
to	O
expression	B-Gene_expression
changes	B-Regulation
,	O
which	O
might	O
contribute	O
to	O
the	O
initiation	O
and/or	O
progression	O
of	O
cancer	O
.	O

Still	O
,	O
the	O
obvious	O
functional	O
diversity	O
of	O
IRF	O
-	O
4	O
remains	O
remarkable	O
and	O
can	O
not	O
be	O
fully	O
explained	O
by	O
the	O
IRF	O
-	O
4	O
promoter	O
methylation	O
status	O
.	O

For	O
example	O
,	O
IRF	O
-	O
4	O
is	O
primarily	O
known	O
for	O
its	O
oncogenic	O
features	O
.	O

In	O
multiple	O
myeloma	O
(	O
MM	O
)	O
a	O
translocation	O
on	O
chromosome	O
14q	O
was	O
reported	O
to	O
lead	O
to	O
a	O
fusion	O
gene	O
of	O
immunoglobulin	O
heavy	O
-	O
chain	O
(	O
IgH	O
)	O
and	O
IRF	O
-	O
4	O
resulting	B-Positive_regulation
in	O
a	O
subsequent	O
overexpression	B-Positive_regulation
of	O
IRF	O
-	O
4	O
(	O
48	O
,	O
49	O
)	O
.	O

In	O
addition	O
,	O
abundant	O
IRF	O
-	O
4	O
expression	B-Gene_expression
was	O
found	O
to	O
be	O
a	O
marker	O
for	O
various	O
subsets	O
of	O
lymphomas	O
,	O
such	O
as	O
diffuse	O
large	O
B	O
-	O
cell	O
lymphomas	O
,	O
primary	O
effusion	O
lymphoma	O
,	O
and	O
marginal	O
zone	O
lymphoma	O
,	O
and	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
11	O
,	O
31	O
,	O
50	O
-	O
52	O
)	O
.	O

This	O
draws	O
a	O
more	O
complex	O
picture	O
of	O
the	O
role	O
of	O
IRF	O
-	O
4	O
.	O

Down	B-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
of	O
IRF	O
-	O
4	O
may	O
promote	O
leukemogenesis	O
in	O
myeloid	O
cell	O
context	O
(	O
3	O
)	O
,	O
which	O
was	O
recently	O
confirmed	O
in	O
IRF-4-/	O
-	O
ICSBP-/	O
-	O
double	O
knock	B-Gene_expression
-	I-Gene_expression
out	I-Gene_expression
mice	O
(	O
53	O
)	O
,	O
while	O
IRF	O
-	O
4	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
may	O
induce	O
a	O
growth	O
advantage	O
in	O
lymphomas	O
or	O
MM	O
(	O
48	O
)	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
IRF	O
-	O
4	O
promoter	O
methylation	O
regulates	B-Regulation
IRF	O
-	O
4	O
expression	B-Gene_expression
,	O
and	O
that	O
aberrant	O
expression	B-Gene_expression
of	O
IRF	O
-	O
4	O
in	O
certain	O
types	O
of	O
leukemia	O
may	O
be	O
a	O
consequence	B-Positive_regulation
of	O
IRF	O
-	O
4	O
promoter	O
hypermethylation	O
.	O

Foxp3	O
Represses	O
Retroviral	O
Transcription	O
by	O
Targeting	O
Both	O
NF	O
-	O
kappaB	O
and	O
CREB	O
Pathways	O

Forkhead	O
box	O
(	O
Fox	O
)	O
/winged	O
-	O
helix	O
transcription	O
factors	O
regulate	O
multiple	O
aspects	O
of	O
immune	O
responsiveness	O
and	O
Foxp3	O
is	O
recognized	O
as	O
an	O
essential	O
functional	O
marker	O
of	O
regulatory	O
T	O
cells	O
.	O

Herein	O
we	O
describe	O
downstream	O
signaling	O
pathways	O
targeted	O
by	O
Foxp3	O
that	O
may	O
negatively	O
impact	O
retroviral	O
pathogenesis	O
.	O

Overexpression	B-Positive_regulation
of	O
Foxp3	O
in	O
HEK	O
293T	O
and	O
purified	O
CD4+	O
T	O
cells	O
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
and	O
time	O
-	O
dependent	O
decrease	O
in	O
basal	O
levels	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
activation	O
.	O

Deletion	B-Negative_regulation
of	O
the	O
carboxyl	O
-	O
terminal	O
forkhead	O
(	O
FKH	O
)	O
domain	O
,	O
critical	B-Positive_regulation
for	O
nuclear	O
localization	B-Localization
and	O
DNA	O
-	O
binding	B-Binding
activity	O
,	O
abrogated	O
the	O
ability	O
of	O
Foxp3	O
to	O
suppress	O
NF	O
-	O
kappaB	O
activity	O
in	O
HEK	O
293T	O
cells	O
,	O
but	O
not	O
in	O
Jurkat	O
or	O
primary	O
human	O
CD4+	O
T	O
cells	O
.	O

We	O
further	O
demonstrate	O
that	O
Foxp3	O
suppressed	O
the	O
transcription	O
of	O
two	O
human	O
retroviral	O
promoters	O
(	O
HIV	O
-	O
1	O
and	O
human	O
T	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
[	O
HTLV	O
-	O
I	O
]	O
)	O
utilizing	O
NF-kappaB	O
-	O
dependent	O
and	O
NF-kappaB	O
-	O
independent	O
mechanisms	O
.	O

Examination	O
of	O
the	O
latter	O
identified	O
the	O
cAMP	O
-	O
responsive	O
element	O
binding	O
protein	O
(	O
CREB	O
)	O
pathway	O
as	O
a	O
target	O
of	O
Foxp3	O
.	O

Finally	O
,	O
comparison	O
of	O
the	O
percent	O
Foxp3+CD4+CD25+	O
T	O
cells	O
to	O
the	O
HTLV	O
-	O
I	O
proviral	O
load	O
in	O
HTLV-I	O
-	O
infected	O
asymptomatic	O
carriers	O
and	O
patients	O
with	O
HTLV-I	O
-	O
associated	O
myelopathy/tropical	O
spastic	O
paraparesis	O
suggested	O
that	O
high	B-Positive_regulation
Foxp3	O
expression	B-Gene_expression
is	O
associated	O
with	O
low	O
proviral	O
load	O
and	O
absence	O
of	O
disease	O
.	O

These	O
results	O
suggest	O
an	O
expanded	O
role	O
for	O
Foxp3	O
in	O
regulating	O
NF-kappaB	O
-	O
and	O
CREB	O
-	O
dependent	O
cellular	O
and	O
viral	O
gene	O
expression	O
.	O

Synopsis	O

Over	O
the	O
past	O
several	O
years	O
,	O
mounting	O
evidence	O
has	O
shown	O
that	O
immune	O
tolerance	O
in	O
healthy	O
individuals	O
can	O
be	O
maintained	O
by	O
a	O
population	O
of	O
T	O
lymphocytes	O
known	O
as	O
regulatory	O
T	O
cells	O
(	O
Tregs	O
)	O
.	O

As	O
a	O
component	O
of	O
this	O
system	O
,	O
a	O
protein	O
known	O
as	O
Foxp3	O
has	O
been	O
shown	O
to	O
be	O
absolutely	O
required	O
for	O
the	O
development	O
and	O
function	O
of	O
Tregs	O
.	O

While	O
Foxp3	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
immune	O
tolerance	O
by	O
blocking	O
T	O
cell	O
proliferation	O
and	O
production	O
of	O
inflammatory	O
proteins	O
known	O
as	O
cytokines	O
,	O
little	O
is	O
known	O
about	O
the	O
molecular	O
mechanisms	O
that	O
are	O
used	O
by	O
Foxp3	O
to	O
accomplish	O
these	O
events	O
.	O

The	O
present	O
study	O
expands	O
our	O
understanding	O
of	O
how	O
Foxp3	O
maintains	O
a	O
check	O
on	O
inappropriate	O
immune	O
responses	O
by	O
demonstrating	O
that	O
Foxp3	O
can	O
block	O
activation	O
of	O
key	O
inducible	O
proteins	O
such	O
as	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
and	O
cAMP	O
-	O
responsive	O
element	O
binding	O
protein	O
(	O
CREB	O
)	O
.	O

Since	O
NF	O
-	O
kappaB	O
and	O
CREB	O
are	O
integrally	O
involved	O
in	O
controlling	O
cell	O
cycle	O
progression	O
,	O
inflammatory	O
cytokine	O
production	O
,	O
and	O
the	O
replication	O
of	O
numerous	O
viruses	O
at	O
the	O
level	O
of	O
transcription	O
,	O
understanding	O
the	O
mechanisms	O
by	O
which	O
Foxp3	O
functions	O
to	O
regulate	O
cellular	O
and	O
viral	O
gene	O
expression	O
may	O
aid	O
in	O
the	O
discovery	O
of	O
therapeutic	O
approaches	O
designed	O
to	O
rescue	O
the	O
expression	B-Gene_expression
and/or	O
function	O
of	O
Foxp3	O
,	O
which	O
have	O
been	O
found	O
to	O
be	O
deficient	O
in	O
several	O
autoimmune	O
diseases	O
and	O
virus	O
-	O
induced	O
disorders	O
.	O

Introduction	O

Immunological	O
tolerance	O
to	O
self	O
-	O
antigens	O
is	O
the	O
result	O
of	O
the	O
deletion	O
of	O
self	O
-	O
reactive	O
T	O
lymphocytes	O
in	O
the	O
thymus	O
(	O
central	O
tolerance	O
)	O
and	O
suppression	O
of	O
the	O
activation	O
of	O
potentially	O
self	O
-	O
reactive	O
T	O
lymphocytes	O
in	O
the	O
periphery	O
(	O
peripheral	O
tolerance	O
)	O
[	O
1	O
]	O
.	O

Suppression	O
of	O
pathogenic	O
T	O
cell	O
responses	O
is	O
mediated	O
by	O
naturally	O
arising	O
CD4+CD25+	O
T	O
regulatory	O
cells	O
(	O
Tregs	O
)	O
[	O
2	O
,	O
3	O
]	O
.	O

Deficiencies	O
in	O
Treg	O
development	O
and	O
function	O
have	O
been	O
linked	O
to	O
the	O
severe	O
autoimmune	O
disorder	O
known	O
as	O
immune	O
dysregulation	O
,	O
polyendocrinopathy	O
,	O
enteropathy	O
,	O
X	O
-	O
linked	O
syndrome	O
(	O
IPEX	O
)	O
[	O
4	O
]	O
.	O

In	O
addition	O
,	O
recent	O
studies	O
have	O
provided	O
strong	O
evidence	O
that	O
dysregulation	O
of	O
Treg	O
development	O
and/or	O
function	O
may	O
be	O
a	O
significant	O
factor	O
in	O
the	O
pathogenesis	O
of	O
several	O
autoimmune	O
disorders	O
(	O
e.g.	O
,	O
multiple	O
sclerosis	O
[	O
5	O
]	O
,	O
myasthenia	O
gravis	O
[	O
6	O
]	O
,	O
and	O
type	O
1	O
diabetes	O
[	O
7	O
]	O
)	O
and	O
virus	O
-	O
induced	O
immunologic	O
disorders	O
(	O
e.g.	O
,	O
human	O
T	O
lymphotropic	O
virus	O
type	O
I	O
[	O
HTLV	O
-	O
I	O
]	O
-	O
associated	O
myelopathy/tropical	O
spastic	O
paraparesis	O
[	O
HAM/TSP	O
]	O
,	O
and	O
HIV	O
-	O
induced	O
AIDS	O
[	O
8	O
-	O
10	O
]	O
)	O
.	O

The	O
transcription	O
factor	O
Foxp3	O
is	O
a	O
431	O
-	O
amino	O
acid	O
(	O
48	O
-	O
kDa	O
)	O
protein	O
expressed	B-Gene_expression
at	O
very	O
high	O
levels	O
in	O
CD4+CD25hi	O
T	O
cells	O
and	O
has	O
previously	O
been	O
shown	O
to	O
be	O
absolutely	O
critical	O
for	O
Treg	O
development	O
and	O
function	O
[	O
11	O
-	O
14	O
]	O
.	O

Foxp3	O
contains	O
a	O
proline	O
-	O
rich	O
amino	O
-	O
terminal	O
domain	O
reported	O
to	O
function	O
as	O
a	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
and	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
binding	O
domain	O
,	O
a	O
central	O
region	O
containing	O
a	O
zinc	O
finger	O
and	O
leucine	O
zipper	O
potentially	O
important	B-Positive_regulation
for	O
protein	O
-	O
protein	O
interactions	B-Binding
,	O
and	O
a	O
carboxyl	O
-	O
terminal	O
forkhead	O
(	O
FKH	O
)	O
domain	O
required	B-Positive_regulation
for	O
nuclear	O
localization	B-Localization
and	O
DNA	O
-	O
binding	B-Binding
activity	O
[	O
14	O
-	O
16	O
]	O
.	O

Functional	O
inactivation	B-Negative_regulation
of	O
Foxp3	O
by	O
genetic	O
mutations	O
affecting	B-Regulation
the	O
Foxp3	O
coding	O
region	O
,	O
as	O
demonstrated	O
in	O
IPEX	O
,	O
or	O
repression	B-Negative_regulation
of	O
Foxp3	O
expression	B-Gene_expression
by	O
the	O
HTLV-I	O
-	O
encoded	O
transactivator	O
protein	O
Tax	O
,	O
as	O
recently	O
reported	O
in	O
patients	O
with	O
HAM/TSP	O
,	O
results	O
in	O
loss	O
of	O
regulatory	O
activity	O
in	O
CD4+CD25hi	O
T	O
cells	O
[	O
4	O
,	O
8	O
,	O
17	O
]	O
.	O

Although	O
it	O
is	O
clear	O
that	O
Foxp3	O
regulates	O
T	O
cell	O
proliferation	O
and	O
cytokine	O
production	O
,	O
very	O
little	O
is	O
known	O
concerning	O
the	O
molecular	O
mechanisms	O
of	O
Foxp3	O
function	O
.	O

The	O
first	O
evidence	O
to	O
indicate	O
how	O
Foxp3	O
promotes	O
the	O
development	O
and	O
function	O
of	O
regulatory	O
T	O
cells	O
came	O
from	O
a	O
report	O
by	O
Ziegler	O
and	O
colleagues	O
[	O
16	O
]	O
,	O
which	O
suggested	O
that	O
Foxp3	O
could	O
inhibit	B-Negative_regulation
transcriptional	B-Positive_regulation
activation	I-Positive_regulation
by	O
physically	O
interacting	B-Binding
with	O
forkhead	O
binding	O
sites	O
located	O
immediately	O
adjacent	O
to	O
critical	O
cis	O
-	O
acting	O
NF	O
-	O
AT	O
binding	O
sites	O
found	O
in	O
various	O
cytokine	O
promoters	O
(	O
e.g.	O
,	O
IL	O
-	O
2	O
promoter	O
)	O
.	O

That	O
study	O
also	O
demonstrated	O
that	O
Foxp3	O
could	O
repress	O
activation	O
of	O
a	O
synthetic	O
reporter	O
vector	O
containing	O
an	O
SV40	O
promoter	O
and	O
three	O
tandem	O
copies	O
of	O
a	O
forkhead	O
binding	O
site	O
.	O

These	O
results	O
provided	O
additional	O
evidence	O
suggesting	O
that	O
Foxp3	O
transcriptional	O
repression	O
was	O
mediated	O
by	O
binding	B-Binding
in	O
a	O
sequence	O
-	O
specific	O
manner	O
to	O
promoters	O
containing	O
forkhead	O
binding	O
sites	O
.	O

A	O
recent	O
study	O
by	O
Bettelli	O
and	O
colleagues	O
[	O
15	O
]	O
further	O
demonstrated	O
that	O
Foxp3	O
could	O
inhibit	O
NF	O
-	O
AT	O
as	O
well	O
as	O
NF	O
-	O
kappaB	O
activation	O
,	O
although	O
the	O
mechanism	O
of	O
suppression	O
was	O
shown	O
to	O
involve	O
direct	O
protein	O
-	O
protein	O
interactions	B-Binding
between	O
NF	O
-	O
AT	O
or	O
NF	O
-	O
kappaB	O
and	O
Foxp3	O
rather	O
than	O
binding	B-Binding
of	O
Foxp3	O
to	O
promoter	O
elements	O
adjacent	O
to	O
cis	O
-	O
acting	O
NF	O
-	O
AT	O
or	O
NF	O
-	O
kappaB	O
sites	O
.	O

Collectively	O
,	O
these	O
data	O
suggested	O
that	O
Foxp3	O
may	O
function	O
as	O
a	O
transcriptional	O
repressor	O
,	O
potentially	O
through	O
the	O
formation	B-Positive_regulation
of	O
both	O
DNA	O
-	O
protein	O
and	O
protein	O
-	O
protein	O
interactions	B-Binding
.	O

In	O
the	O
present	O
study	O
,	O
we	O
expanded	O
upon	O
these	O
observations	O
by	O
defining	O
additional	O
requirements	O
of	O
Foxp3	O
-	O
mediated	O
repression	O
of	O
NF	O
-	O
kappaB	O
activation	O
,	O
and	O
investigated	O
whether	O
Foxp3	O
could	O
target	O
additional	O
signaling	O
pathways	O
by	O
examining	O
transcriptional	O
activation	O
of	O
NF-kappaB	O
-	O
dependent	O
and	O
NF-kappaB	O
-	O
independent	O
retroviral	O
pathogens	O
.	O

The	O
characterization	O
of	O
the	O
molecular	O
targets	O
of	O
Foxp3	O
and	O
the	O
mechanism	O
(	O
s	O
)	O
utilized	O
by	O
Foxp3	O
to	O
support	O
Treg	O
development	O
and	O
function	O
will	O
aid	O
in	O
our	O
understanding	O
of	O
the	O
role	O
Tregs	O
play	O
in	O
the	O
pathogenesis	O
of	O
human	O
autoimmune	O
disease	O
.	O

Foxp3	O
Suppresses	O
NF	O
-	O
kappaB	O
Dependent	O
Transcriptional	O
Activation	O

To	O
ascertain	O
the	O
molecular	O
mechanisms	O
by	O
which	O
Foxp3	O
functions	O
to	O
promote	O
the	O
regulatory	O
function	O
of	O
CD4+CD25hi	O
T	O
cells	O
,	O
we	O
first	O
confirmed	O
the	O
function	O
of	O
Foxp3	O
as	O
a	O
repressor	O
of	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
previously	O
implicated	O
as	O
a	O
target	O
of	O
other	O
forkhead/winged	O
-	O
helix	O
family	O
transcription	O
factors	O
(	O
e.g.	O
,	O
Foxj1	O
and	O
Foxo3a	O
)	O
[	O
19	O
,	O
20	O
]	O
.	O

We	O
analyzed	O
the	O
effect	O
of	O
Foxp3	O
overexpression	B-Positive_regulation
on	O
NF	O
-	O
kappaB	O
activation	O
in	O
HEK	O
293T	O
cells	O
in	O
dose	O
-	O
response	O
and	O
time	O
course	O
analyses	O
.	O

Transfection	O
of	O
HEK	O
293T	O
cells	O
with	O
an	O
NF	O
-	O
kappaB	O
luciferase	O
reporter	O
vector	O
in	O
the	O
presence	O
or	O
absence	O
of	O
increasing	O
concentrations	O
of	O
a	O
Foxp3	O
expression	B-Gene_expression
vector	O
or	O
a	O
control	O
vector	O
(	O
enhanced	O
green	O
fluorescent	O
protein	O
[	O
EGFP	O
]	O
)	O
was	O
performed	O
,	O
and	O
cells	O
were	O
harvested	O
after	O
24	O
h	O
to	O
assay	O
for	O
luciferase	O
activity	O
and	O
Foxp3	O
mRNA	B-Transcription
expression	I-Transcription
.	O

Results	O
indicated	O
that	O
as	O
the	O
concentration	B-Gene_expression
of	O
Foxp3	O
transfected	O
into	O
cells	O
increases	B-Positive_regulation
(	O
from	O
50	O
to	O
2	O
,	O
400	O
ng	O
)	O
,	O
the	O
level	O
of	O
NF	O
-	O
kappaB	O
activation	O
decreases	O
proportionally	O
(	O
Figure	O
1A	O
)	O
.	O

Foxp3	O
mRNA	O
was	O
also	O
assayed	O
to	O
monitor	O
activity	O
of	O
the	O
Foxp3	O
expression	B-Gene_expression
vector	O
(	O
Figure	O
1B	O
)	O
.	O

Since	O
NF	O
-	O
kappaB	O
activation	O
was	O
partially	O
affected	O
by	O
transfection	O
of	O
high	O
concentrations	O
of	O
the	O
control	O
vector	O
,	O
we	O
determined	O
the	O
fold	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
Foxp3	O
compared	O
to	O
the	O
control	O
vector	O
at	O
each	O
concentration	O
(	O
Figure	O
1A	O
)	O
.	O

Fold	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
was	O
directly	O
proportional	O
to	O
the	O
level	O
of	O
Foxp3	O
mRNA	B-Transcription
expression	I-Transcription
detected	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

To	O
determine	O
the	O
level	O
of	O
Foxp3	O
-	O
mediated	O
suppression	O
of	O
NF	O
-	O
kappaB	O
activation	O
over	O
time	O
,	O
HEK	O
293T	O
cells	O
were	O
transfected	O
with	O
an	O
NF	O
-	O
kappaB	O
luciferase	O
reporter	O
vector	O
and	O
an	O
expression	B-Gene_expression
vector	O
encoding	O
Foxp3	O
or	O
EGFP	O
(	O
control	O
vector	O
)	O
and	O
harvested	O
over	O
4	O
d	O
.	O

As	O
shown	O
in	O
Figure	O
1C	O
,	O
NF	O
-	O
kappaB	O
activation	O
was	O
suppressed	O
by	O
overexpression	B-Positive_regulation
of	O
Foxp3	O
at	O
all	O
time	O
points	O
.	O

Extending	O
these	O
results	O
from	O
established	O
,	O
in	O
vitro	O
HEK	O
cell	O
lines	O
to	O
primary	O
human	O
lymphocytes	O
,	O
overexpression	B-Positive_regulation
of	O
Foxp3	O
in	O
purified	O
CD4+	O
T	O
cells	O
from	O
three	O
healthy	O
donors	O
also	O
down	O
-	O
regulated	O
the	O
steady	O
-	O
state	O
level	O
of	O
NF	O
-	O
kappaB	O
activation	O
(	O
Figure	O
1D	O
)	O
.	O

These	O
results	O
recapitulate	O
those	O
from	O
Bettelli	O
and	O
colleagues	O
[	O
15	O
]	O
demonstrating	O
that	O
Foxp3	O
functions	O
,	O
in	O
part	O
,	O
to	O
block	O
NF-kappaB	O
-	O
dependent	O
transcription	O
in	O
human	O
cell	O
lines	O
as	O
well	O
as	O
in	O
primary	O
human	O
CD4+	O
T	O
cells	O
.	O

The	O
Carboxyl	O
-	O
Terminal	O
FKH	O
Domain	O
Is	O
Not	O
Required	O
for	O
Suppression	O
of	O
NF	O
-	O
kappaB	O
Activation	O
in	O
T	O
Cells	O

To	O
define	O
the	O
requirements	O
of	O
Foxp3	O
with	O
respect	O
to	O
inhibition	O
of	O
NF-kappaB	O
-	O
dependent	O
transcription	O
,	O
we	O
utilized	O
a	O
mutant	O
of	O
Foxp3	O
lacking	B-Negative_regulation
the	O
FKH	O
domain	O
(	O
Figure	O
2A	O
)	O
[	O
16	O
]	O
,	O
similar	O
to	O
the	O
scurfy	O
mutant	O
Foxp3	O
of	O
mice	O
,	O
and	O
a	O
mutant	O
Foxp3	O
protein	O
from	O
a	O
patient	O
with	O
IPEX	O
[	O
4	O
,	O
11	O
,	O
14	O
,	O
17	O
]	O
.	O

Unlike	O
full	O
-	O
length	O
Foxp3	O
,	O
which	O
localizes	B-Localization
almost	O
exclusively	O
to	O
the	O
nucleus	O
and	O
can	O
bind	B-Binding
in	O
a	O
sequence	O
-	O
specific	O
manner	O
to	O
forkhead	O
binding	O
sites	O
,	O
the	O
DeltaFKH	O
mutant	O
fails	O
to	O
localize	B-Localization
to	O
the	O
nucleus	O
and	O
thus	O
can	O
not	O
interact	B-Binding
with	O
promoter	O
elements	O
or	O
nuclear	O
proteins	O
[	O
16	O
]	O
.	O

Therefore	O
,	O
we	O
utilized	O
the	O
DeltaFKH	O
mutant	O
to	O
determine	O
whether	O
nuclear	O
localization	B-Localization
(	O
or	O
other	O
function	O
associated	O
with	O
the	O
FKH	O
domain	O
)	O
of	O
Foxp3	O
was	O
a	O
prerequisite	O
for	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O

Although	O
Foxp3	O
interaction	B-Binding
with	O
NF	O
-	O
kappaB	O
presumably	O
takes	O
place	O
in	O
the	O
nucleus	O
,	O
it	O
may	O
also	O
be	O
possible	O
for	O
a	O
cytoplasmic	O
Foxp3	O
protein	O
to	O
bind	B-Binding
to	O
NF	O
-	O
kappaB	O
in	O
the	O
cytoplasm	O
and	O
prevent	B-Negative_regulation
localization	B-Localization
to	O
the	O
nucleus	O
following	B-Positive_regulation
an	O
activation	O
stimulus	O
.	O

Overexpression	B-Positive_regulation
of	O
full	O
-	O
length	O
Foxp3	O
,	O
but	O
not	O
of	O
DeltaFKH	O
,	O
was	O
able	O
to	O
suppress	O
activation	O
of	O
a	O
cotransfected	O
NF	O
-	O
kappaB	O
reporter	O
vector	O
in	O
HEK	O
293T	O
cells	O
(	O
Figure	O
2B	O
)	O
.	O

Both	O
Foxp3	O
and	O
DeltaFKH	O
were	O
expressed	B-Positive_regulation
at	O
very	O
high	O
levels	O
following	B-Positive_regulation
transfection	O
as	O
detected	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
(	O
unpublished	O
data	O
)	O
.	O

These	O
data	O
appear	O
to	O
suggest	O
that	O
the	O
carboxyl	O
-	O
terminal	O
FKH	O
domain	O
is	O
critically	O
important	O
for	O
Foxp3	O
to	O
down	O
-	O
regulate	O
NF-kappaB	O
-	O
dependent	O
transcription	O
.	O

However	O
,	O
NF	O
-	O
kappaB	O
activation	O
was	O
blocked	O
to	O
a	O
similar	O
extent	O
by	O
both	O
full	O
-	O
length	O
Foxp3	O
and	O
DeltaFKH	O
in	O
Jurkat	O
T	O
cells	O
(	O
Figure	O
2C	O
)	O
and	O
primary	O
human	O
CD4+	O
T	O
cells	O
(	O
Figure	O
2D	O
)	O
.	O

Western	O
blot	O
analysis	O
of	O
NF	O
-	O
kappaB	O
p65	O
expression	B-Gene_expression
demonstrated	O
that	O
Foxp3	O
and	O
DeltaFKH	O
does	O
not	O
block	B-Negative_regulation
NF	O
-	O
kappaB	O
activation	O
at	O
the	O
level	O
of	O
p65	O
protein	O
expression	B-Gene_expression
(	O
Figure	O
2E	O
)	O
.	O

These	O
results	O
are	O
very	O
interesting	O
with	O
respect	O
to	O
Foxp3	O
function	O
,	O
because	O
they	O
suggest	O
that	O
the	O
carboxyl	O
-	O
terminal	O
FKH	O
domain	O
,	O
and	O
possibly	O
nuclear	O
localization	B-Localization
,	O
are	O
dispensable	O
for	O
Foxp3	O
function	O
in	O
T	O
cell	O
populations	O
.	O

Alternative	O
interpretations	O
may	O
include	O
the	O
possibility	O
that	O
the	O
localization	B-Localization
of	O
DeltaFKH	O
differ	O
between	O
epithelial	O
cells	O
and	O
T	O
cells	O
.	O

In	O
either	O
case	O
,	O
these	O
results	O
suggest	O
a	O
cell	O
type	O
-	O
specific	O
mechanism	O
of	O
action	O
for	O
this	O
Foxp3	O
mutant	O
.	O

Foxp3	O
Suppresses	O
HIV	O
-	O
1	O
Gene	O
Expression	O
in	O
Part	O
through	O
Blocking	O
Activation	O
of	O
NF	O
-	O
kappaB	O

If	O
Foxp3	O
functions	O
as	O
a	O
repressor	O
of	O
NF-kappaB	O
-	O
dependent	O
gene	O
expression	O
,	O
then	O
we	O
hypothesized	O
that	O
Foxp3	O
overexpression	B-Positive_regulation
could	O
selectively	O
down	O
-	O
regulate	O
transcription	O
from	O
promoters	O
previously	O
shown	O
to	O
be	O
responsive	O
to	O
NF	O
-	O
kappaB	O
.	O

To	O
address	O
this	O
question	O
,	O
we	O
examined	O
the	O
transcriptional	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
,	O
which	O
contains	O
two	O
tandem	O
cis	O
-	O
acting	O
NF	O
-	O
kappaB	O
binding	O
sites	O
located	O
between	O
positions	O
-	O
102	O
and	O
-	O
81	O
with	O
respect	O
to	O
the	O
transcription	O
initiation	O
site	O
[	O
21	O
]	O
.	O

NF	O
-	O
kappaB	O
plays	O
a	O
crucial	O
role	O
in	O
regulating	O
gene	O
expression	O
directed	O
from	O
the	O
HIV	O
-	O
1	O
LTR	O
in	O
CD4+	O
T	O
cells	O
[	O
21	O
]	O
.	O

Overexpression	B-Positive_regulation
of	O
full	O
-	O
length	O
Foxp3	O
,	O
but	O
not	O
DeltaFKH	O
,	O
in	O
HEK	O
293T	O
cells	O
was	O
able	O
to	O
inhibit	O
basal	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
(	O
Figure	O
3A	O
)	O
,	O
similar	O
to	O
what	O
was	O
previously	O
demonstrated	O
with	O
the	O
synthetic	O
NF	O
-	O
kappaB	O
reporter	O
vector	O
(	O
Figure	O
2B	O
)	O
.	O

Furthermore	O
,	O
HIV	O
-	O
1	O
LTR	O
activation	O
was	O
suppressed	O
by	O
full	O
-	O
length	O
Foxp3	O
and	O
DeltaFKH	O
in	O
Jurkat	O
T	O
cells	O
(	O
Figure	O
3B	O
)	O
.	O

To	O
demonstrate	O
that	O
Foxp3	O
-	O
mediated	O
HIV	O
-	O
1	O
LTR	O
repression	O
was	O
associated	O
with	O
interactions	B-Binding
with	O
NF	O
-	O
kappaB	O
bound	O
to	O
the	O
HIV	O
-	O
1	O
LTR	O
,	O
we	O
compared	O
basal	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
or	O
an	O
identical	O
HIV	O
-	O
1	O
LTR	O
lacking	O
the	O
NF	O
-	O
kappaB	O
sites	O
located	O
between	O
-	O
102	O
and	O
-	O
81	O
(	O
HIV	O
-	O
1	O
Delta	O
-	O
kappaB	O
LTR	O
)	O
(	O
Figure	O
3C	O
)	O
.	O

This	O
mutant	O
HIV	O
-	O
1	O
LTR	O
construct	O
exhibited	O
reduced	O
levels	O
of	O
transcription	O
compared	O
to	O
the	O
parental	O
HIV	O
-	O
1	O
LTR	O
in	O
purified	O
healthy	O
donor	O
CD4+	O
T	O
cells	O
(	O
unpublished	O
data	O
)	O
.	O

However	O
,	O
directly	O
comparing	O
the	O
effect	O
of	O
Foxp3	O
overexpression	B-Positive_regulation
on	O
the	O
activation	O
of	O
these	O
two	O
viral	O
promoters	O
demonstrated	O
that	O
Foxp3	O
was	O
more	O
capable	O
of	O
suppressing	O
transcriptional	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
(	O
Figure	O
3D	O
)	O
compared	O
to	O
the	O
mutated	O
HIV	O
-	O
1	O
LTR	O
(	O
Figure	O
3E	O
)	O
.	O

These	O
results	O
suggest	O
that	O
Foxp3	O
down	O
-	O
regulation	O
of	O
HIV	O
-	O
1	O
LTR	O
activation	O
was	O
mediated	O
at	O
least	O
in	O
part	O
by	O
cis	O
-	O
acting	O
NF	O
-	O
kappaB	O
binding	O
sites	O
.	O

Residual	O
levels	O
of	O
inhibition	O
of	O
the	O
HIV	O
-	O
1	O
Delta	O
-	O
kappaB	O
LTR	O
by	O
Foxp3	O
may	O
be	O
due	O
to	O
NF	O
-	O
AT	O
binding	O
sites	O
located	O
upstream	O
of	O
the	O
NF	O
-	O
kappaB	O
sites	O
within	O
the	O
HIV	O
-	O
1	O
LTR	O
[	O
22	O
,	O
23	O
]	O
.	O

The	O
Transactivation	O
Functions	O
of	O
HTLV	O
-	O
I	O
Tax	O
Are	O
Suppressed	O
by	O
Foxp3	O

Previous	O
studies	O
by	O
Bettelli	O
and	O
colleagues	O
have	O
demonstrated	O
that	O
Foxp3	O
can	O
repress	O
both	O
the	O
basal	O
levels	O
of	O
NF	O
-	O
kappaB	O
activation	O
as	O
well	O
as	O
tumor	O
necrosis	O
factor-alpha	O
-	O
stimulated	O
NF	O
-	O
kappaB	O
activation	O
[	O
15	O
]	O
.	O

Our	O
next	O
step	O
was	O
to	O
determine	O
whether	O
Foxp3	O
could	O
also	O
suppress	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
caused	O
by	O
a	O
strong	O
viral	O
transactivator	O
protein	O
.	O

HTLV	O
-	O
I	O
encodes	O
a	O
multifunctional	O
transactivator	O
protein	O
,	O
Tax	O
,	O
capable	O
of	O
activating	O
both	O
the	O
NF	O
-	O
kappaB	O
and	O
CREB	O
pathways	O
[	O
24	O
-	O
29	O
]	O
.	O

Since	O
the	O
HTLV	O
-	O
I	O
Tax	O
protein	O
can	O
function	O
at	O
multiple	O
levels	O
in	O
both	O
the	O
cytoplasm	O
and	O
the	O
nucleus	O
to	O
stimulate	O
activation	O
of	O
NF	O
-	O
kappaB	O
[	O
28	O
,	O
29	O
]	O
,	O
we	O
hypothesized	O
that	O
overexpression	B-Positive_regulation
of	O
Foxp3	O
may	O
interfere	O
with	O
this	O
process	O
.	O

However	O
,	O
since	O
Tax	O
-	O
dependent	O
HTLV	O
-	O
I	O
gene	O
expression	O
is	O
independent	O
of	O
NF	O
-	O
kappaB	O
[	O
18	O
]	O
,	O
we	O
also	O
hypothesized	O
that	O
Foxp3	O
would	O
not	O
affect	O
Tax	O
-	O
dependent	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
.	O

To	O
test	O
these	O
hypotheses	O
,	O
we	O
overexpressed	B-Positive_regulation
HTLV	O
-	O
I	O
Tax	O
,	O
full	O
-	O
length	O
Foxp3	O
,	O
and/or	O
DeltaFKH	O
in	O
HEK	O
293T	O
cells	O
cotransfected	O
with	O
an	O
HTLV	O
-	O
I	O
LTR	O
or	O
NF	O
-	O
kappaB	O
reporter	O
vector	O
.	O

As	O
shown	O
in	O
Figure	O
4A	O
,	O
HTLV	O
-	O
I	O
Tax	O
strongly	O
up	O
-	O
regulated	O
NF-kappaB	O
-	O
dependent	O
transcriptional	O
activation	O
(	O
~60	O
-	O
fold	O
)	O
.	O

Interestingly	O
,	O
overexpression	B-Gene_expression
of	O
Foxp3	O
,	O
but	O
not	O
DeltaFKH	O
,	O
suppressed	O
Tax	O
-	O
mediated	O
activation	O
of	O
NF-kappaB	O
-	O
dependent	O
transcription	O
.	O

These	O
observations	O
further	O
suggest	O
that	O
the	O
carboxyl	O
-	O
terminal	O
FKH	O
domain	O
is	O
required	O
for	O
inhibiting	O
activation	O
of	O
NF	O
-	O
kappaB	O
in	O
the	O
presence	O
of	O
Tax	O
in	O
HEK	O
293T	O
cells	O
,	O
strikingly	O
similar	O
to	O
the	O
requirements	O
of	O
Foxp3	O
inhibition	O
of	O
basal	O
NF	O
-	O
kappaB	O
activation	O
shown	O
in	O
Figure	O
2B	O
.	O

Transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
was	O
stimulated	O
about	O
55	O
-	O
fold	O
by	O
overexpression	B-Positive_regulation
of	O
Tax	O
(	O
Figure	O
4B	O
)	O
,	O
while	O
transfection	B-Gene_expression
of	O
Foxp3	O
suppressed	O
Tax	O
-	O
dependent	O
HTLV	O
-	O
I	O
LTR	O
activation	O
,	O
although	O
HTLV	O
-	O
I	O
LTR	O
activation	O
in	O
the	O
presence	O
or	O
absence	O
of	O
Tax	O
is	O
independent	O
of	O
NF	O
-	O
kappaB	O
or	O
NF	O
-	O
AT	O
(	O
another	O
transcriptional	O
activator	O
known	O
to	O
interact	B-Binding
with	O
Foxp3	O
)	O
.	O

Furthermore	O
,	O
overexpression	B-Positive_regulation
of	O
DeltaFKH	O
also	O
led	O
to	O
suppression	O
of	O
HTLV	O
-	O
I	O
transactivation	O
by	O
Tax	O
to	O
a	O
similar	O
extent	O
as	O
full	O
-	O
length	O
Foxp3	O
(	O
Figure	O
4B	O
)	O
.	O

The	O
suppressive	O
effects	O
shown	O
in	O
Figure	O
4A	O
and	O
4B	O
were	O
not	O
the	O
result	O
of	O
Foxp3	O
down	B-Negative_regulation
-	I-Negative_regulation
regulating	I-Negative_regulation
the	O
expression	B-Gene_expression
of	O
the	O
transfected	O
Tax	O
plasmid	O
as	O
determined	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
(	O
Figure	O
4C	O
)	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
Foxp3	O
interacts	B-Binding
with	O
transcriptional	O
regulators	O
in	O
addition	O
to	O
NF	O
-	O
kappaB	O
and	O
NF	O
-	O
AT	O
,	O
and	O
that	O
the	O
carboxyl	O
-	O
terminal	O
FKH	O
domain	O
,	O
and	O
therefore	O
localization	B-Localization
to	O
the	O
nucleus	O
,	O
are	O
not	O
required	O
for	O
inhibition	O
of	O
Tax	O
-	O
mediated	O
HTLV	O
-	O
I	O
LTR	O
activation	O
(	O
even	O
in	O
HEK	O
293T	O
cells	O
)	O
.	O

To	O
determine	O
whether	O
Foxp3	O
inhibited	O
the	O
transactivation	O
functions	O
of	O
Tax	O
by	O
directly	O
associating	B-Binding
with	O
this	O
viral	O
protein	O
,	O
we	O
generated	O
an	O
expression	O
vector	O
in	O
which	O
HTLV	O
-	O
I	O
Tax	O
was	O
fused	O
in	O
-	O
frame	O
to	O
the	O
carboxyl	O
terminus	O
of	O
the	O
Gal4	O
DNA	O
-	O
binding	O
domain	O
(	O
Gal4	O
-	O
BD	O
)	O
.	O

This	O
Gal4-BD	O
-	O
Tax	O
fusion	O
protein	O
activated	O
transcription	O
of	O
a	O
synthetic	O
promoter	O
containing	O
five	O
Gal4	O
binding	O
sites	O
,	O
while	O
Gal4	O
-	O
BD	O
was	O
insufficient	O
to	O
stimulate	O
transcription	O
by	O
itself	O
(	O
Figure	O
4D	O
)	O
.	O

Transactivation	O
of	O
the	O
Gal4	O
-	O
resposive	O
promoter	O
by	O
Gal4-BD	O
-	O
Tax	O
remained	O
relatively	O
unaffected	O
by	O
overexpression	B-Positive_regulation
of	O
either	O
EGFP	O
(	O
control	O
)	O
,	O
Foxp3	O
,	O
or	O
DeltaFKH	O
,	O
suggesting	O
that	O
Foxp3	O
does	O
not	O
repress	O
Tax	O
transactivation	O
by	O
directly	O
interfacing	B-Negative_regulation
with	O
the	O
HTLV	O
-	O
I	O
Tax	O
protein	O
.	O

To	O
confirm	O
that	O
Foxp3	O
had	O
a	O
direct	O
effect	O
on	O
HTLV	O
-	O
I	O
replication	O
,	O
we	O
transfected	O
HEK	O
293T	O
cells	O
with	O
a	O
well	O
-	O
characterized	O
HTLV	O
-	O
I	O
infectious	O
molecular	O
clone	O
(	O
termed	O
ACH	O
)	O
[	O
30	O
]	O
in	O
the	O
presence	O
of	O
full	O
-	O
length	O
Foxp3	O
,	O
DeltaFKH	O
,	O
or	O
control	O
vector	O
.	O

ACH	O
has	O
been	O
previously	O
shown	O
to	O
direct	O
the	O
expression	O
of	O
viral	O
antigens	O
,	O
produce	O
infectious	O
virus	O
,	O
and	O
transform	O
CD4+	O
T	O
cells	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
31	O
,	O
32	O
]	O
.	O

After	O
24	O
h	O
,	O
the	O
amount	O
of	O
viral	O
antigen	O
expression	B-Transcription
,	O
in	O
this	O
case	O
Tax	O
mRNA	O
,	O
was	O
detected	O
by	O
a	O
sensitive	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assay	O
.	O

As	O
illustrated	O
in	O
Figure	O
5	O
,	O
the	O
level	O
of	O
Tax	O
mRNA	O
synthesized	B-Transcription
from	O
ACH	O
was	O
down	B-Negative_regulation
-	I-Negative_regulation
regulated	I-Negative_regulation
in	O
the	O
presence	O
of	O
Foxp3	O
compared	O
to	O
the	O
level	O
produced	B-Transcription
in	O
the	O
presence	O
of	O
the	O
control	O
vector	O
.	O

DeltaFKH	O
did	O
not	O
have	O
a	O
discernable	O
affect	B-Regulation
on	O
Tax	O
expression	B-Gene_expression
.	O

These	O
data	O
indicate	O
that	O
Foxp3	O
is	O
capable	O
of	O
repressing	B-Negative_regulation
the	O
expression	B-Gene_expression
of	O
Tax	O
from	O
an	O
infectious	O
HTLV	O
-	O
I	O
molecular	O
clone	O
.	O

Increased	B-Positive_regulation
Foxp3	O
Protein	O
Expression	B-Gene_expression
Is	O
Associated	O
with	O
Low	O
HTLV	O
-	O
I	O
Proviral	O
Load	O

Since	O
Foxp3	O
is	O
expressed	B-Gene_expression
almost	O
exclusively	O
within	O
CD4+CD25+	O
T	O
cells	O
,	O
a	O
major	O
viral	O
reservoir	O
for	O
HTLV	O
-	O
I	O
[	O
33	O
]	O
,	O
it	O
was	O
important	O
to	O
determine	O
whether	O
there	O
was	O
an	O
association	O
between	O
Foxp3	O
and	O
HTLV	O
-	O
I	O
replication	O
in	O
infected	O
patients	O
.	O

We	O
therefore	O
quantitated	O
the	O
Foxp3	O
protein	O
expression	B-Gene_expression
in	O
CD4+CD25+	O
T	O
cells	O
by	O
flow	O
cytometry	O
and	O
the	O
HTLV	O
-	O
I	O
proviral	O
load	O
(	O
a	O
surrogate	O
marker	O
of	O
viral	O
replication	O
)	O
by	O
real	O
-	O
time	O
PCR	O
from	O
eight	O
patients	O
with	O
HAM/TSP	O
and	O
eight	O
asymptomatic	O
carriers	O
(	O
ACs	O
)	O
.	O

The	O
data	O
from	O
this	O
analysis	O
is	O
summarized	O
in	O
Table	O
1	O
.	O

As	O
expected	O
,	O
patients	O
with	O
HAM/TSP	O
exhibited	O
significantly	O
higher	O
proviral	O
loads	O
(	O
indicated	O
as	O
HTLV	O
-	O
I	O
proviral	O
DNA	O
copies/100	O
cells	O
)	O
(	O
34.68	O
+/	O
-	O
23.19	O
)	O
compared	O
to	O
ACs	O
(	O
4.75	O
+/	O
-	O
5.47	O
)	O
(	O
p	O
=	O
0.0008	O
)	O
.	O

The	O
percentage	O
of	O
Foxp3+	O
cells	O
within	O
the	O
CD4+CD25+	O
T	O
cell	O
population	O
was	O
significantly	O
greater	O
in	O
ACs	O
(	O
43.23	O
+/	O
-	O
12.95	O
)	O
than	O
in	O
HAM/TSP	O
patients	O
(	O
18.59	O
+/	O
-	O
5.77	O
)	O
(	O
p	O
=	O
0.0033	O
)	O
.	O

These	O
data	O
suggest	O
that	O
high	B-Positive_regulation
levels	O
of	O
Foxp3	O
protein	O
expression	B-Gene_expression
are	O
associated	O
with	O
reduced	O
HTLV	O
-	O
I	O
replication	O
in	O
vivo	O
.	O

They	O
also	O
support	O
our	O
recent	O
reports	O
that	O
high	O
proviral	O
loads	O
,	O
which	O
have	O
been	O
shown	O
to	O
correlate	O
with	O
high	B-Positive_regulation
Tax	O
mRNA	O
in	O
HTLV-I	O
-	O
infected	O
patients	O
,	O
are	O
associated	O
with	O
reduced	B-Negative_regulation
Foxp3	O
expression	B-Gene_expression
[	O
8	O
,	O
34	O
]	O
.	O

CREB	O
Is	O
a	O
Target	O
for	O
Transcriptional	O
Repression	O
by	O
Foxp3	O

Although	O
Foxp3	O
could	O
down	O
-	O
regulate	O
Tax	O
-	O
dependent	O
transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
(	O
Figure	O
4B	O
)	O
and	O
inhibit	B-Negative_regulation
Tax	O
expression	B-Gene_expression
from	O
an	O
infectious	O
molecular	O
clone	O
(	O
Figure	O
5	O
)	O
,	O
Foxp3	O
failed	O
to	O
modulate	B-Regulation
Tax	O
function	O
in	O
the	O
absence	O
of	O
the	O
viral	O
promoter	O
(	O
Figure	O
4D	O
)	O
.	O

These	O
results	O
led	O
us	O
to	O
hypothesize	O
that	O
Foxp3	O
acts	O
on	O
HTLV	O
-	O
I	O
gene	O
expression	O
by	O
interacting	B-Binding
with	O
proteins	O
important	O
for	O
driving	O
HTLV	O
-	O
I	O
LTR	O
activity	O
in	O
vivo	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
Tax	O
-	O
responsive	O
elements	O
within	O
the	O
HTLV	O
-	O
I	O
LTR	O
play	O
a	O
crucial	O
role	O
in	O
driving	O
Tax	O
-	O
mediated	O
transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
[	O
18	O
]	O
.	O

The	O
Tax	O
-	O
responsive	O
elements	O
have	O
been	O
shown	O
to	O
resemble	O
CREB	O
binding	O
sites	O
,	O
bind	O
CREB	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
and	O
facilitate	O
HTLV	O
-	O
I	O
LTR	O
activation	O
both	O
in	O
the	O
presence	O
and	O
in	O
the	O
absence	O
of	O
Tax	O
[	O
35	O
,	O
36	O
]	O
.	O

Ching	O
and	O
colleagues	O
[	O
18	O
]	O
demonstrated	O
that	O
addition	O
of	O
a	O
dominant	O
-	O
negative	O
CREB	O
expression	O
vector	O
resulted	O
in	O
nearly	O
complete	O
inhibition	O
of	O
Tax	O
-	O
mediated	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
,	O
while	O
blocking	O
NF	O
-	O
kappaB	O
activation	O
by	O
addition	O
of	O
a	O
dominant	O
-	O
negative	O
IKKbeta	O
expression	B-Gene_expression
vector	O
had	O
no	O
effect	O
on	O
Tax	O
transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
.	O

Therefore	O
,	O
we	O
hypothesized	O
that	O
Foxp3	O
may	O
inhibit	O
Tax	O
transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
via	O
disruption	O
of	O
the	O
CREB	O
signaling	O
pathway	O
.	O

To	O
test	O
this	O
possibility	O
,	O
HEK	O
293T	O
cells	O
were	O
transfected	O
with	O
an	O
HTLV	O
-	O
I	O
LTR	O
or	O
synthetic	O
CREB	O
reporter	O
vector	O
along	O
with	O
a	O
control	O
expression	O
vector	O
(	O
EGFP	O
)	O
or	O
expression	O
vectors	O
encoding	O
Foxp3	O
or	O
DeltaFKH	O
.	O

As	O
shown	O
in	O
Figure	O
6A	O
,	O
Foxp3	O
down	O
-	O
regulated	O
basal	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
and	O
transcription	O
of	O
a	O
synthetic	O
CREB	O
reporter	O
vector	O
,	O
suggesting	O
that	O
Foxp3	O
down	O
-	O
regulates	O
HTLV	O
-	O
I	O
LTR	O
activation	O
by	O
targeting	O
the	O
CREB	O
pathway	O
.	O

Deletion	B-Negative_regulation
of	O
the	O
FKH	O
domain	O
of	O
Foxp3	O
dampened	O
the	O
suppressive	O
effect	O
of	O
Foxp3	O
,	O
but	O
did	O
not	O
completely	O
abrogate	O
suppression	O
,	O
as	O
is	O
seen	O
with	O
NF-kappaB	O
-	O
responsive	O
promoters	O
in	O
HEK	O
293T	O
cells	O
.	O

Like	O
NF	O
-	O
kappaB	O
activation	O
,	O
CREB	O
transcriptional	O
activation	O
was	O
also	O
suppressed	O
by	O
expression	B-Gene_expression
of	O
Foxp3	O
,	O
and	O
to	O
a	O
similar	O
extent	O
DeltaFKH	O
,	O
in	O
healthy	O
donor	O
CD4+	O
T	O
cells	O
(	O
Figure	O
6B	O
)	O
.	O

Similarly	O
,	O
Foxp3	O
and	O
DeltaFKH	O
also	O
repressed	O
basal	O
HTLV	O
-	O
I	O
LTR	O
activation	O
in	O
primary	O
human	O
CD4+	O
T	O
cells	O
(	O
Figure	O
6C	O
)	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
evidence	O
implicating	O
CREB	O
as	O
a	O
molecular	O
target	O
of	O
Foxp3	O
.	O

As	O
observed	O
with	O
NF	O
-	O
kappaB	O
activation	O
,	O
DeltaFKH	O
was	O
a	O
more	O
potent	O
inhibitor	B-Negative_regulation
of	O
CREB	O
activation	B-Positive_regulation
in	O
CD4+	O
T	O
cells	O
than	O
in	O
HEK	O
293T	O
cells	O
,	O
further	O
indicating	O
that	O
a	O
cell	O
type	O
-	O
specific	O
mechanism	O
of	O
action	O
may	O
govern	O
the	O
function	O
of	O
this	O
Foxp3	O
mutant	O
.	O

To	O
determine	O
whether	O
Foxp3	O
functioned	O
by	O
directly	O
signaling	O
through	O
CREB	O
,	O
we	O
utilized	O
expression	B-Gene_expression
vectors	O
encoding	O
CREB	O
-	O
1	O
or	O
c	O
-	O
Jun	O
(	O
a	O
member	O
of	O
the	O
activator	O
protein	O
1	O
family	O
of	O
transcription	O
factors	O
)	O
fused	O
in	O
-	O
frame	O
to	O
the	O
Gal4	O
-	O
BD	O
(	O
Gal4-BD-CREB	O
-	O
1	O
and	O
Gal4-BD-c	O
-	O
Jun	O
)	O
.	O

As	O
shown	O
in	O
Figure	O
6D	O
,	O
activation	O
of	O
a	O
Gal4	O
-	O
responsive	O
reporter	O
vector	O
by	O
Gal4-BD-CREB	O
-	O
1	O
was	O
down	O
-	O
regulated	O
by	O
Foxp3	O
compared	O
to	O
control	O
vector	O
(	O
EGFP	O
)	O
,	O
indicating	O
that	O
Foxp3	O
functions	O
by	O
directly	O
or	O
indirectly	O
interacting	B-Binding
with	O
CREB	O
-	O
1	O
.	O

However	O
,	O
Foxp3	O
failed	O
to	O
markedly	O
affect	O
transcriptional	O
activation	O
of	O
Gal4-BD-c	O
-	O
Jun	O
(	O
c	O
-	O
Jun	O
has	O
also	O
been	O
demonstrated	O
to	O
bind	B-Binding
to	O
the	O
HTLV	O
-	O
I	O
LTR	O
)	O
and	O
Gal4-BD	O
-	O
Tax	O
(	O
see	O
Figure	O
5	O
)	O
.	O

Importantly	O
,	O
the	O
mechanism	O
of	O
Foxp3	O
-	O
mediated	O
inhibition	O
of	O
CREB	O
-	O
dependent	O
transcription	O
was	O
not	O
due	O
to	O
a	O
block	B-Negative_regulation
in	O
CREB	O
-	O
1	O
protein	O
expression	B-Gene_expression
,	O
as	O
determined	O
by	O
Western	O
blot	O
analysis	O
(	O
Figure	O
6E	O
)	O
.	O

Although	O
these	O
results	O
demonstrate	O
that	O
Foxp3	O
functions	O
as	O
a	O
co	O
-	O
repressor	O
of	O
CREB	O
activation	O
(	O
in	O
addition	O
to	O
NF	O
-	O
kappaB	O
and	O
NF	O
-	O
AT	O
)	O
,	O
we	O
were	O
unable	O
to	O
detect	O
a	O
direct	O
physical	O
interaction	B-Binding
between	O
CREB	O
-	O
1	O
and	O
Foxp3	O
by	O
coimmunoprecipitation	O
or	O
mammalian	O
two	O
-	O
hybrid	O
analysis	O
(	O
unpublished	O
data	O
)	O
.	O

Therefore	O
,	O
our	O
data	O
suggest	O
that	O
Foxp3	O
may	O
interfere	B-Negative_regulation
with	O
CREB	O
signaling	O
at	O
an	O
upstream	O
event	O
,	O
such	O
as	O
phosphorylation	O
of	O
CREB	O
or	O
recruitment/function	O
of	O
coactivator	O
proteins	O
CREB	O
-	O
binding	O
protein	O
(	O
CBP	O
)	O
/p300	O
.	O

Foxp3	O
Antagonizes	O
CREB	O
Transcriptional	O
Activation	O
by	O
Disrupting	O
Coactivator	O
Recruitment	O

Stimulation	O
of	O
CREB	O
-	O
dependent	O
transcription	O
by	O
reagents	O
that	O
activate	O
adenylate	O
cyclase	O
and	O
increase	O
cAMP	O
levels	O
(	O
e.g.	O
,	O
forskolin	O
)	O
increase	O
the	O
transactivation	O
potential	O
of	O
CREB	O
through	O
phosphorylation	O
of	O
serine	O
133	O
by	O
protein	O
kinase	O
A	O
,	O
which	O
permits	B-Positive_regulation
binding	B-Binding
and	O
recruitment	O
of	O
coactivators	O
CBP/p300	O
to	O
the	O
promoter	O
[	O
37	O
,	O
38	O
]	O
.	O

Phosphorylation	O
of	O
serine	O
133	O
does	O
not	O
,	O
however	O
,	O
affect	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
CREB	O
in	O
most	O
cases	O
[	O
39	O
-	O
41	O
]	O
.	O

Addition	O
of	O
forskolin	O
to	O
HEK	O
293T	O
cells	O
stimulated	O
activation	O
of	O
a	O
CREB	O
reporter	O
vector	O
about	O
65	O
fold	O
(	O
Figure	O
7A	O
)	O
.	O

Overexpression	B-Positive_regulation
of	O
Foxp3	O
was	O
capable	O
of	O
down	O
-	O
regulating	O
forskolin	O
-	O
induced	O
CREB	O
transcriptional	O
activation	O
.	O

The	O
functional	O
interaction	B-Binding
between	O
Foxp3	O
and	O
CREB	O
did	O
not	O
affect	B-Regulation
the	O
DNA	O
-	O
binding	B-Binding
activity	O
of	O
CREB	O
-	O
1	O
,	O
but	O
did	O
show	O
a	O
modest	O
decrease	B-Negative_regulation
in	O
activating	O
transcription	O
factor	O
2	O
(	O
ATF	O
-	O
2	O
)	O
DNA	O
-	O
binding	B-Binding
activity	O
in	O
the	O
presence	O
of	O
forskolin	O
as	O
determined	O
by	O
transcription	O
factor	O
ELISA	O
(	O
Figure	O
7B	O
)	O
.	O

While	O
Foxp3	O
has	O
been	O
shown	O
to	O
bind	B-Binding
to	O
and	O
repress	O
activation	O
of	O
both	O
NF	O
-	O
kappaB	O
and	O
NF	O
-	O
AT	O
,	O
exactly	O
how	O
Foxp3	O
functions	O
to	O
bring	O
about	O
this	O
affect	O
has	O
not	O
been	O
elucidated	O
.	O

To	O
determine	O
how	O
Foxp3	O
blocks	O
CREB	O
-	O
dependent	O
transcription	O
,	O
we	O
examined	O
whether	O
Foxp3	O
was	O
capable	O
of	O
(	O
1	O
)	O
disrupting	O
the	O
recruitment	O
of	O
coactivator	O
proteins	O
and/or	O
(	O
2	O
)	O
preventing	O
phosphorylation	O
of	O
CREB	O
at	O
serine	O
133	O
(	O
which	O
is	O
a	O
prerequisite	O
for	O
coactivator	O
recruitment	O
)	O
.	O

Since	O
both	O
of	O
these	O
events	O
are	O
required	O
for	O
CREB	O
-	O
dependent	O
gene	O
expression	O
,	O
we	O
hypothesized	O
that	O
Foxp3	O
may	O
affect	O
CREB	O
activation	O
at	O
both	O
steps	O
.	O

To	O
determine	O
whether	O
Foxp3	O
can	O
disrupt	O
the	O
function/recruitment	O
of	O
the	O
coactivator	O
protein	O
p300	O
,	O
we	O
introduced	O
a	O
Gal4	O
reporter	O
vector	O
and	O
a	O
Gal4-BD-CREB	O
-	O
1	O
expression	B-Gene_expression
vector	O
into	O
HEK	O
293T	O
cells	O
in	O
the	O
absence	O
or	O
presence	O
of	O
Foxp3	O
,	O
p300	O
,	O
and/or	O
control	O
expression	B-Gene_expression
vectors	O
(	O
Figure	O
7C	O
)	O
.	O

As	O
expected	O
,	O
p300	O
overexpression	B-Positive_regulation
stimulated	B-Positive_regulation
transcription	B-Transcription
of	O
the	O
Gal4-BD-CREB	O
-	O
1	O
fusion	O
protein	O
.	O

Foxp3	O
,	O
again	O
,	O
repressed	B-Negative_regulation
basal	O
levels	O
of	O
Gal4-BD-CREB	O
-	O
1	O
activation	B-Positive_regulation
by	O
more	O
than	O
2	O
-	O
fold	O
,	O
while	O
effectively	O
neutralizing	B-Negative_regulation
Gal4-BD-CREB	O
-	O
1	O
activation	B-Positive_regulation
in	O
the	O
presence	O
of	O
p300	O
.	O

We	O
next	O
analyzed	O
the	O
effect	O
of	O
Foxp3	O
on	O
phosphorylation	O
of	O
CREB	O
at	O
serine	O
133	O
in	O
forskolin	O
-	O
treated	O
HEK	O
293T	O
cells	O
by	O
Western	O
blot	O
analysis	O
.	O

Overexpression	B-Positive_regulation
of	O
Foxp3	O
failed	O
to	O
reduce	O
the	O
detectable	O
levels	O
of	O
CREB	O
phosphorylation	O
using	O
a	O
phosphospecific	O
antibody	O
for	O
CREB	O
-	O
1	O
(	O
unpublished	O
data	O
)	O
.	O

However	O
,	O
when	O
we	O
attempted	O
to	O
determine	O
whether	O
Foxp3	O
could	O
physically	O
interact	B-Binding
with	O
the	O
coactivator	O
protein	O
p300	O
,	O
we	O
found	O
that	O
p300	O
immunoprecipitated	B-Binding
Foxp3	O
when	B-Positive_regulation
both	O
proteins	O
were	O
overexpressed	B-Gene_expression
in	O
HEK	O
293T	O
cells	O
(	O
Figure	O
7D	O
)	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
Foxp3	O
antagonizes	O
CREB	O
-	O
dependent	O
gene	O
expression	O
by	O
directly	O
interacting	B-Binding
with	O
coactivator	O
p300	O
and	O
interfering	B-Negative_regulation
with	O
its	O
function	O
and/or	O
recruitment	B-Binding
to	O
CREB	O
-	O
responsive	O
promoter	O
sequences	O
.	O

Discussion	O

In	O
the	O
present	O
study	O
,	O
we	O
show	O
that	O
Foxp3	O
functions	O
as	O
a	O
potent	O
repressor	O
of	O
NF-kappaB	O
-	O
and	O
CREB	O
-	O
dependent	O
transcriptional	O
activation	O
.	O

Furthermore	O
,	O
the	O
carboxyl	O
-	O
terminal	O
FKH	O
domain	O
appears	O
to	O
be	O
dispensable	O
for	O
mediating	O
these	O
effects	O
,	O
at	O
least	O
in	O
T	O
cell	O
populations	O
.	O

This	O
observation	O
may	O
become	O
important	O
in	O
light	O
of	O
recent	O
reports	O
suggesting	O
that	O
Foxp3	O
expression	B-Gene_expression
in	O
thymic	O
epithelial	O
cells	O
was	O
crucial	O
for	O
directing	O
development	O
of	O
T	O
cells	O
in	O
the	O
thymus	O
[	O
42	O
]	O
.	O

Interestingly	O
,	O
the	O
majority	O
of	O
the	O
genetic	O
mutations	O
associated	O
with	O
IPEX	O
,	O
a	O
severe	O
autoimmune	O
disorder	O
caused	O
by	O
functional	O
inactivation	B-Negative_regulation
of	O
Foxp3	O
,	O
map	O
to	O
the	O
carboxyl	O
-	O
terminal	O
FKH	O
domain	O
or	O
the	O
leucine	O
zipper	O
domain	O
in	O
the	O
central	O
region	O
of	O
the	O
protein	O
.	O

Only	O
one	O
mutation	O
associated	O
with	O
IPEX	O
to	O
date	O
has	O
been	O
mapped	O
to	O
the	O
amino	O
-	O
terminal	O
proline	O
-	O
rich	O
region	O
[	O
43	O
]	O
.	O

It	O
is	O
possible	O
that	O
the	O
FKH	O
domain	O
has	O
a	O
complex	O
tertiary	O
structure	O
that	O
is	O
particularly	O
sensitive	O
to	O
misfolding	O
caused	O
by	O
genetic	O
mutations	O
and	O
that	O
an	O
intact	O
FKH	O
domain	O
is	O
absolutely	O
critical	O
for	O
promoting	O
Foxp3	O
function	O
in	O
the	O
nucleus	O
,	O
whereas	O
the	O
structure	O
of	O
the	O
amino	O
-	O
terminal	O
proline	O
-	O
rich	O
region	O
may	O
tolerate	O
certain	O
mutations	O
as	O
long	O
as	O
the	O
NF-kappaB/NF	O
-	O
AT	O
binding	O
motif	O
remains	O
unaltered	O
.	O

This	O
motif	O
may	O
also	O
include	O
the	O
zinc	O
finger	O
domain	O
.	O

A	O
logical	O
region	O
that	O
may	O
be	O
targeted	B-Binding
by	O
the	O
amino	O
-	O
terminal	O
proline	O
-	O
rich	O
region	O
of	O
Foxp3	O
is	O
the	O
Rel	O
homology	O
domain	O
found	O
in	O
both	O
NF	O
-	O
kappaB	O
and	O
NF	O
-	O
AT	O
family	O
proteins	O
.	O

A	O
region	O
that	O
may	O
also	O
be	O
important	O
with	O
respect	O
to	O
Foxp3	O
function	O
is	O
the	O
leucine	O
zipper	O
domain	O
,	O
as	O
demonstrated	O
by	O
the	O
number	O
of	O
mutations	O
associated	O
with	O
IPEX	O
that	O
have	O
been	O
mapped	O
in	O
this	O
region	O
of	O
Foxp3	O
.	O

The	O
role	O
of	O
this	O
domain	O
in	O
Foxp3	O
function	O
remains	O
uncharacterized	O
,	O
but	O
may	O
play	B-Regulation
a	I-Regulation
role	I-Regulation
in	O
dimer	B-Binding
formation	I-Binding
as	O
it	O
does	B-Regulation
in	O
other	O
Foxp	O
family	O
members	O
[	O
44	O
]	O
.	O

Because	O
the	O
pathogenesis	O
of	O
a	O
number	O
of	O
retroviral	O
-	O
induced	O
immunologic	O
disorders	O
such	O
as	O
HIV	O
-	O
1/AIDS	O
and	O
HTLV	O
-	O
I/HAM/TSP	O
have	O
been	O
associated	O
with	O
dysregulation	B-Regulation
of	O
Foxp3	O
expression	B-Gene_expression
[	O
8	O
,	O
45	O
]	O
,	O
we	O
also	O
examined	O
the	O
role	O
of	O
Foxp3	O
in	O
retroviral	O
gene	O
expression	O
.	O

HIV	O
-	O
1	O
LTR	O
activation	O
in	O
CD4+	O
T	O
cells	O
is	O
critically	O
dependent	O
on	O
two	O
tandem	O
NF	O
-	O
kappaB	O
sites	O
located	O
between	O
nucleotide	O
positions	O
-	O
102	O
and	O
-	O
81	O
within	O
the	O
HIV	O
-	O
1	O
enhancer	O
region	O
,	O
whereas	O
HTLV	O
-	O
I	O
LTR	O
activation	O
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
HTLV-I	O
-	O
encoded	O
transactivator	O
protein	O
Tax	O
is	O
independent	O
of	O
NF	O
-	O
kappaB	O
[	O
18	O
]	O
.	O

To	O
our	O
knowledge	O
for	O
the	O
first	O
time	O
,	O
Foxp3	O
was	O
shown	O
to	O
have	O
a	O
direct	O
effect	O
on	O
HIV	O
-	O
1	O
LTR	O
transcription	O
.	O

Deletion	O
of	O
the	O
NF	O
-	O
kappaB	O
sites	O
within	O
the	O
HIV	O
-	O
1	O
enhancer	O
region	O
reduced	O
the	O
responsiveness	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
to	O
Foxp3	O
-	O
mediated	O
suppression	O
.	O

In	O
addition	O
,	O
the	O
FKH	O
domain	O
of	O
Foxp3	O
was	O
required	O
for	O
this	O
inhibitory	O
effect	O
in	O
HEK	O
293T	O
cells	O
,	O
but	O
not	O
in	O
Jurkat	O
T	O
cells	O
,	O
similar	O
to	O
Foxp3	O
-	O
mediated	O
suppression	O
of	O
a	O
synthetic	O
NF	O
-	O
kappaB	O
reporter	O
.	O

The	O
direct	O
effect	O
of	O
Foxp3	O
down	O
-	O
regulating	O
HIV	O
-	O
1	O
gene	O
expression	O
correlates	O
well	O
with	O
recently	O
reported	O
evidence	O
indicating	O
that	O
higher	O
regulatory	O
activity	O
of	O
CD4+CD25+	O
T	O
cells	O
from	O
HIV-1	O
-	O
infected	O
patients	O
was	O
associated	O
with	O
lower	O
HIV	O
-	O
1	O
viral	O
loads	O
in	O
these	O
patients	O
[	O
46	O
]	O
.	O

Foxp3	O
also	O
affected	O
two	O
well	O
-	O
known	O
functions	O
of	O
HTLV	O
-	O
I	O
Tax	O
:	O
transactivation	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
and	O
,	O
most	O
surprisingly	O
,	O
transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
.	O

Transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
by	O
Tax	O
involves	O
the	O
interaction	B-Binding
of	O
ATF/CREB	O
factors	O
with	O
Tax	O
in	O
the	O
nucleus	O
.	O

Binding	B-Binding
of	O
Tax	O
enhances	O
ATF/CREB	O
dimerization	O
and	O
promotes	B-Positive_regulation
assembly	B-Binding
of	O
Tax	O
-	O
ATF/CREB	O
complexes	O
onto	O
specific	O
sequences	O
in	O
the	O
viral	O
promoter	O
known	O
as	O
Tax	O
-	O
responsive	O
elements	O
.	O

This	O
series	O
of	O
steps	O
allows	O
Tax	O
to	O
recruit	B-Binding
coactivator	O
proteins	O
CBP/p300	O
to	O
the	O
viral	O
promoter	O
and	O
facilitate	O
a	O
high	O
level	O
of	O
viral	O
gene	O
expression	O
[	O
24	O
-	O
26	O
]	O
.	O

Transactivation	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
by	O
Tax	O
was	O
inhibited	O
by	O
overexpression	B-Positive_regulation
of	O
full	O
-	O
length	O
Foxp3	O
,	O
but	O
not	O
DeltaFKH	O
,	O
as	O
seen	O
with	O
basal	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
and	O
a	O
synthetic	O
NF	O
-	O
kappaB	O
reporter	O
in	O
HEK	O
293T	O
cells	O
.	O

However	O
,	O
Tax	O
-	O
mediated	O
transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
was	O
inhibited	O
by	O
overexpression	B-Gene_expression
of	O
both	O
full	O
-	O
length	O
Foxp3	O
as	O
well	O
as	O
DeltaFKH	O
in	O
both	O
HEK	O
293T	O
cells	O
and	O
CD4+	O
T	O
cells	O
.	O

We	O
demonstrated	O
that	O
Foxp3	O
did	O
not	O
directly	O
affect	O
the	O
functioning	O
of	O
Tax	O
,	O
but	O
rather	O
Foxp3	O
targeted	O
the	O
transcription	O
factors	O
required	O
for	O
Tax	O
transactivation	O
(	O
i.e.	O
,	O
NF	O
-	O
kappaB	O
and	O
a	O
then	O
-	O
unknown	O
cellular	O
factor	O
,	O
which	O
we	O
identified	O
in	O
this	O
study	O
as	O
CREB	O
)	O
.	O

The	O
negative	O
effect	O
of	O
Foxp3	O
on	O
HTLV	O
-	O
I	O
gene	O
expression	O
was	O
confirmed	O
utilizing	O
an	O
HTLV	O
-	O
I	O
infectious	O
molecular	O
clone	O
.	O

Importantly	O
,	O
we	O
demonstrated	O
that	O
HTLV-I	O
-	O
infected	O
individuals	O
with	O
the	O
highest	B-Positive_regulation
levels	O
of	O
Foxp3	O
protein	O
expression	B-Gene_expression
within	O
the	O
CD4+CD25+	O
T	O
cells	O
population	O
exhibited	O
lower	O
proviral	O
loads	O
than	O
did	O
individuals	O
with	O
the	O
lowest	B-Negative_regulation
levels	O
of	O
Foxp3	O
protein	O
expression	B-Gene_expression
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
HTLV	O
-	O
I	O
proviral	O
load	O
directly	O
correlates	O
with	O
HTLV	O
-	O
I	O
Tax	O
mRNA	O
load	O
,	O
the	O
frequency	O
of	O
immunopathogenic	O
virus	O
-	O
specific	O
CD8+	O
T	O
cells	O
,	O
and	O
disease	O
severity	O
in	O
patients	O
with	O
HAM/TSP	O
[	O
47	O
]	O
.	O

These	O
results	O
have	O
important	O
implications	O
on	O
the	O
utility	O
of	O
Foxp3	O
in	O
controlling	O
viral	O
gene	O
expression	O
and	O
thus	O
pathogenesis	O
of	O
HAM/TSP	O
.	O

Therefore	O
,	O
Foxp3	O
becomes	O
an	O
attractive	O
target	O
for	O
the	O
development	O
of	O
novel	O
therapeutic	O
applications	O
directed	O
at	O
modulating	B-Regulation
the	O
expression	B-Gene_expression
of	O
this	O
important	O
regulatory	O
protein	O
,	O
especially	O
in	O
light	O
of	O
recent	O
observations	O
that	O
the	O
expression	B-Gene_expression
of	O
Foxp3	O
can	O
also	O
be	O
down	B-Negative_regulation
-	I-Negative_regulation
regulated	I-Negative_regulation
by	O
HTLV	O
-	O
I	O
Tax	O
[	O
8	O
]	O
.	O

As	O
the	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
depends	O
primarily	O
on	O
ATF/CREB	O
proteins	O
(	O
whether	O
in	O
the	O
presence	O
or	O
the	O
absence	O
of	O
Tax	O
)	O
,	O
we	O
investigated	O
whether	O
Foxp3	O
could	O
interact	O
with	O
this	O
additional	O
cellular	O
signaling	O
pathway	O
.	O

While	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
CREB	O
is	O
,	O
in	O
most	O
cases	O
,	O
constitutive	O
,	O
the	O
transactivation	O
potential	O
of	O
CREB	O
is	O
regulated	O
by	O
the	O
phosphorylation	O
of	O
CREB	O
and	O
recruitment	B-Binding
of	O
CBP/p300	O
[	O
48	O
]	O
.	O

Our	O
data	O
demonstrate	O
that	O
Foxp3	O
interferes	B-Negative_regulation
with	O
the	O
latter	O
of	O
these	O
two	O
processes	O
and	O
that	O
the	O
recruitment	B-Binding
of	O
the	O
coactivator	O
protein	O
p300	O
,	O
and	O
resulting	O
transcriptional	O
activation	O
are	O
blocked	B-Negative_regulation
by	O
Foxp3	O
.	O

This	O
may	O
be	O
the	O
result	B-Positive_regulation
of	O
the	O
physical	O
interaction	B-Binding
we	O
detected	O
between	O
Foxp3	O
and	O
p300	O
.	O

With	O
respect	O
to	O
HTLV	O
-	O
I	O
LTR	O
activity	O
,	O
while	O
full	O
-	O
length	O
Foxp3	O
inhibited	O
both	O
basal	O
and	O
Tax	O
-	O
dependent	O
transcription	O
by	O
~50	O
%	O
,	O
DeltaFKH	O
appeared	O
less	O
effective	O
in	O
suppressing	O
basal	O
activation	O
(	O
~25	O
%	O
inhibition	O
)	O
compared	O
to	O
Tax	O
-	O
dependent	O
activation	O
(	O
~50	O
%	O
inhibition	O
)	O
.	O

The	O
effect	O
of	O
DeltaFKH	O
on	O
basal	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
in	O
HEK	O
293T	O
cells	O
was	O
very	O
similar	O
to	O
that	O
shown	O
for	O
a	O
synthetic	O
CREB	O
reporter	O
,	O
suggesting	O
that	O
the	O
FKH	O
domain	O
of	O
Foxp3	O
is	O
important	O
at	O
some	O
level	O
.	O

As	O
observed	O
with	O
NF	O
-	O
kappaB	O
activation	O
,	O
the	O
Foxp3	O
mutant	O
lacking	B-Negative_regulation
the	O
FKH	O
domain	O
was	O
a	O
stronger	O
inhibitor	O
of	O
CREB	O
activation	O
in	O
CD4+	O
T	O
cells	O
than	O
in	O
HEK	O
293T	O
epithelial	O
cells	O
.	O

Therefore	O
,	O
it	O
appears	O
that	O
in	O
CD4+	O
T	O
cells	O
,	O
the	O
FKH	O
domain	O
is	O
dispensable	O
for	O
the	O
proper	O
functioning	O
of	O
Foxp3	O
with	O
respect	O
to	O
both	O
NF	O
-	O
kappaB	O
and	O
CREB	O
activation	O
.	O

In	O
summary	O
,	O
this	O
is	O
,	O
to	O
our	O
knowledge	O
,	O
the	O
first	O
direct	O
evidence	O
implicating	O
a	O
role	O
for	O
the	O
Treg	O
-	O
specific	O
transcription	O
factor	O
Foxp3	O
in	O
regulating	O
retroviral	O
gene	O
expression	O
.	O

In	O
addition	O
,	O
we	O
identify	O
the	O
CREB	O
pathway	O
as	O
a	O
molecular	O
target	O
of	O
Foxp3	O
.	O

Since	O
CREB	O
has	O
been	O
shown	O
to	O
regulate	B-Regulation
multiple	O
genes	O
involved	O
in	O
transcription	O
(	O
e.g.	O
,	O
JunD	O
,	O
c	O
-	O
Fos	O
,	O
signal	O
transducer	O
of	O
activated	O
T	O
cells	O
3	O
[	O
STAT3	O
]	O
)	O
,	O
cell	O
cycle	O
(	O
e.g.	O
,	O
p15INK4b	O
,	O
cyclin	O
A	O
,	O
cyclin	O
D1	O
)	O
,	O
and	O
immune	O
regulation	O
(	O
e.g.	O
,	O
IL	O
-	O
2	O
,	O
IL	O
-	O
6	O
,	O
T	O
-	O
cell	O
receptor	O
alpha	O
)	O
(	O
reviewed	O
in	O
[	O
48	O
]	O
)	O
,	O
the	O
findings	O
presented	O
in	O
this	O
report	O
broaden	O
the	O
potential	O
range	O
of	O
signaling	O
pathways	O
under	O
the	O
control	O
of	O
the	O
regulatory	O
protein	O
Foxp3	O
.	O

Our	O
evidence	O
stresses	O
the	O
importance	O
of	O
Foxp3	O
expression	B-Gene_expression
and	O
Treg	O
function	O
in	O
the	O
development	O
and	O
maintenance	O
of	O
protective	O
immunity	O
against	O
HIV	O
-	O
1	O
and	O
HTLV	O
-	O
I	O
.	O

Based	O
on	O
recent	O
findings	O
,	O
Foxp3	O
may	O
limit	O
HIV	O
-	O
1	O
and	O
HTLV	O
-	O
I	O
transcription	O
by	O
interfering	O
with	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
CREB	O
pathways	O
.	O

However	O
,	O
observing	O
that	O
this	O
inhibitory	O
effect	O
is	O
not	O
absolute	O
,	O
a	O
low	O
level	O
of	O
viral	O
gene	O
expression	O
may	O
persist	O
in	O
CD4+	O
T	O
cells	O
(	O
in	O
particular	O
regulatory	O
T	O
cells	O
,	O
which	O
are	O
known	O
reservoirs	O
of	O
HIV	O
-	O
1	O
and	O
HTLV	O
-	O
I	O
)	O
and	O
result	O
in	O
the	O
accumulation	O
of	O
viral	O
proteins	O
that	O
either	O
stimulate	O
NF	O
-	O
kappaB	O
and/or	O
CREB	O
activation	O
or	O
directly	O
inhibit	B-Negative_regulation
Foxp3	O
expression	B-Gene_expression
or	O
function	O
.	O

The	O
imbalance	O
of	O
NF	O
-	O
kappaB	O
and	O
CREB	O
activation	O
caused	O
by	O
these	O
viral	O
gene	O
products	O
may	O
be	O
a	O
crucial	O
step	O
in	O
the	O
pathogenesis	O
of	O
virus	O
-	O
induced	O
immunological	O
disorders	O
such	O
as	O
AIDS	O
and	O
HAM/TSP	O
.	O

Future	O
studies	O
will	O
be	O
directed	O
at	O
identifying	O
and	O
characterizing	O
cellular	O
proteins	O
that	O
interact	B-Binding
with	O
Foxp3	O
both	O
in	O
the	O
nucleus	O
and	O
cytoplasm	O
,	O
in	O
order	O
to	O
better	O
address	O
how	O
Foxp3	O
functions	O
to	O
guide	O
the	O
development	O
and	O
function	O
of	O
regulatory	O
T	O
cells	O
in	O
health	O
and	O
disease	O
.	O

Cell	O
culture	O
.	O

HEK	O
293T	O
cells	O
were	O
cultured	O
in	O
Dulbecco	O
's	O
modified	O
Eagle	O
medium	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

Jurkat	O
T	O
cells	O
and	O
primary	O
human	O
CD4+	O
T	O
cells	O
were	O
cultured	O
in	O
RPMI	O
-	O
1640	O
medium	O
(	O
Invitrogen	O
)	O
.	O

Media	O
were	O
supplemented	O
with	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
100	O
U/ml	O
penicillin	O
,	O
100	O
mug/ml	O
streptomycin	O
(	O
Cambrex	O
,	O
East	O
Rutherford	O
,	O
New	O
Jersey	O
,	O
United	O
States	O
)	O
,	O
and	O
10	O
%	O
fetal	O
bovine	O
serum	O
(	O
Atlanta	O
Biologicals	O
,	O
Norcross	O
,	O
Georgia	O
,	O
United	O
States	O
)	O
.	O

Patients	O
and	O
cell	O
preparation	O
.	O

PBMCs	O
were	O
prepared	O
by	O
centrifugation	O
over	O
Ficoll	O
-	O
Hypaque	O
gradients	O
(	O
BioWhittaker	O
,	O
Walkersville	O
,	O
Maryland	O
,	O
United	O
States	O
)	O
from	O
eight	O
HAM/TSP	O
patients	O
and	O
eight	O
ACs	O
,	O
and	O
the	O
cells	O
were	O
viably	O
cryopreserved	O
in	O
liquid	O
nitrogen	O
until	O
tested	O
.	O

HAM/TSP	O
was	O
diagnosed	O
according	O
to	O
WHO	O
guidelines	O
[	O
49	O
]	O
.	O

HTLV	O
-	O
I	O
seropositivity	O
was	O
determined	O
by	O
ELISA	O
(	O
Abbott	O
Laboratories	O
,	O
Abbott	O
Park	O
,	O
Illinois	O
,	O
United	O
States	O
)	O
,	O
with	O
confirmation	O
by	O
Western	O
blot	O
analysis	O
(	O
Genelabs	O
Technologies	O
,	O
Redwood	O
City	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

Blood	O
samples	O
were	O
obtained	O
after	O
informed	O
consent	O
as	O
part	O
of	O
a	O
clinical	O
protocol	O
reviewed	O
and	O
approved	O
by	O
the	O
NIH	O
institutional	O
review	O
panel	O
.	O

Plasmids	O
.	O

Expression	B-Gene_expression
vectors	O
encoding	O
human	O
Foxp3	O
(	O
pCMV-Foxp3-IRES	O
-	O
EGFP	O
)	O
and	O
human	O
Foxp3	O
lacking	B-Negative_regulation
the	O
forkhead	O
(	O
FKH	O
)	O
domain	O
(	O
pCMV-DeltaFKH-IRES	O
-	O
EGFP	O
)	O
were	O
generous	O
gifts	O
from	O
S.	O
Ziegler	O
(	O
Benaroya	O
Research	O
Institute	O
)	O
.	O
pEGFP	O
-	O
C2	O
was	O
provided	O
by	O
I	O
.	O

Lipinski	O
(	O
NIDDK/NIH	O
)	O
.	O
pcDNA3	O
was	O
provided	O
by	O
K	O
.	O

T	O
.	O

Jeang	O
(	O
NIAID/NIH	O
)	O
.	O
pCMV4	O
-	O
Tax	O
was	O
a	O
generous	O
gift	O
from	O
W	O
.	O

Greene	O
(	O
University	O
of	O
California	O
San	O
Francisco	O
)	O
.	O
pGL4	O
-	O
luc2	O
and	O
pGL4	O
-	O
TKhRluc2	O
were	O
purchased	O
from	O
Promega	O
(	O
Madison	O
,	O
Wisconsin	O
,	O
United	O
States	O
)	O
.	O
pUC18	O
was	O
purchased	O
from	O
Stratagene	O
(	O
La	O
Jolla	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

HIV	O
-	O
1	O
wt	O
LTR	O
and	O
HIV	O
-	O
1	O
Delta	O
-	O
kappaB	O
LTR	O
luciferase	O
reporter	O
vectors	O
were	O
constructed	O
by	O
cloning	O
the	O
XhoI/HindIII	O
LTR	O
fragments	O
from	O
pHIV	O
-	O
CAT	O
and	O
pDelta-kappaB-HIV	O
-	O
CAT	O
(	O
AIDS	O
Research	O
and	O
Reference	O
Reagent	O
Program	O
,	O
NIAID/NIH	O
)	O
into	O
the	O
multiple	O
cloning	O
site	O
of	O
pGL4	O
-	O
luc2	O
.	O

NF	O
-	O
kappaB	O
,	O
HTLV	O
-	O
I	O
LTR	O
,	O
and	O
CREB	O
luciferase	O
reporter	O
and	O
pCMV-p300	O
-	O
HA	O
expression	B-Gene_expression
vectors	O
were	O
generously	O
provided	O
by	O
B	O
.	O

Wigdahl	O
(	O
Drexel	O
University	O
College	O
of	O
Medicine	O
)	O
.	O

HTLV	O
-	O
I	O
pACH	O
infectious	O
molecular	O
clone	O
has	O
been	O
described	O
previously	O
[	O
30	O
]	O
.	O

pFR	O
-	O
luc	O
,	O
pFA	O
-	O
CMV	O
,	O
pFA2-CREB	O
-	O
1	O
,	O
and	O
pFA2-c	O
-	O
Jun	O
were	O
purchased	O
from	O
Stratagene.	O
pFA	O
-	O
Tax	O
(	O
encoding	O
a	O
fusion	O
protein	O
consisting	O
of	O
the	O
Gal4	O
DNA	O
-	O
binding	O
domain	O
fused	O
in	O
-	O
frame	O
to	O
HTLV	O
-	O
I	O
Tax	O
)	O
was	O
constructed	O
by	O
PCR	O
amplification	O
of	O
HTLV	O
-	O
I	O
Tax	O
using	O
pCMV4	O
-	O
Tax	O
as	O
a	O
template	O
and	O
BamHI/BglII	O
-	O
tagged	O
primers	O
.	O

The	O
amplified	O
insert	O
was	O
digested	O
and	O
ligated	O
into	O
the	O
BamHI/BglII	O
sites	O
of	O
pFA	O
-	O
CMV	O
.	O

Plasmid	O
contents	O
were	O
confirmed	O
by	O
DNA	O
sequencing	O
.	O

Isolation	O
of	O
primary	O
human	O
CD4+	O
T	O
cells	O
.	O

CD4+	O
T	O
cells	O
were	O
isolated	O
from	O
cryopreserved	O
healthy	O
donor	O
PBMCs	O
by	O
negative	O
selection	O
with	O
the	O
CD4+	O
T	O
Cell	O
Isolation	O
Kit	O
II	O
(	O
Miltenyi	O
Biotech	O
,	O
Bergisch	O
Gladbach	O
,	O
Germany	O
)	O
according	O
to	O
manufacturer	O
's	O
guidelines	O
.	O

Purity	O
of	O
negatively	O
selected	O
CD4+	O
T	O
cells	O
was	O
consistently	O
higher	O
than	O
96	O
%	O
as	O
determined	O
by	O
flow	O
cytometry	O
.	O

Transient	O
expression	O
and	O
luciferase	O
assays	O
.	O

HEK	O
293T	O
cells	O
were	O
plated	O
at	O
a	O
density	O
of	O
5	O
x	O
105	O
cells/well	O
in	O
six	O
-	O
well	O
culture	O
plates	O
(	O
BD	O
Biosciences	O
,	O
San	O
Diego	O
,	O
California	O
,	O
United	O
States	O
)	O
1	O
d	O
prior	O
to	O
transfection	O
with	O
the	O
appropriate	O
plasmid	O
DNA	O
(	O
~2	O
mug	O
total	O
)	O
using	O
FuGene	O
6	O
transfection	O
reagent	O
(	O
Roche	O
,	O
Basel	O
,	O
Switzerland	O
)	O
.	O

Jurkat	O
T	O
cells	O
were	O
plated	O
at	O
1	O
x	O
106	O
cells/well	O
in	O
six	O
-	O
well	O
culture	O
plates	O
the	O
day	O
of	O
transfection	O
with	O
the	O
appropriate	O
plasmid	O
DNA	O
(	O
~2	O
mug	O
total	O
)	O
using	O
FuGene	O
6	O
transfection	O
reagent	O
.	O

Primary	O
human	O
CD4+	O
T	O
cells	O
(	O
2	O
x	O
106	O
)	O
were	O
nucleofected	O
with	O
the	O
specified	O
plasmid	O
DNA	O
(	O
5	O
mug	O
total	O
)	O
using	O
the	O
Human	O
T	O
Cell	O
Nucleofection	O
Kit	O
(	O
Amaxa	O
,	O
Gaithersburg	O
,	O
Maryland	O
,	O
United	O
States	O
)	O
.	O

Forskolin	O
(	O
10	O
muM	O
;	O
Calbiochem	O
,	O
San	O
Diego	O
,	O
California	O
,	O
United	O
States	O
)	O
was	O
added	O
in	O
some	O
experiments	O
20	O
h	O
posttransfection	O
.	O

Cells	O
were	O
harvested	O
24	O
h	O
posttransfection	O
and	O
luciferase	O
activity	O
was	O
analyzed	O
using	O
the	O
Dual	O
-	O
luciferase	O
Reporter	O
Assay	O
System	O
(	O
Promega	O
)	O
and	O
a	O
Monolight	O
2010	O
luminometer	O
(	O
Analytical	O
Luminescence	O
Laboratory	O
,	O
San	O
Diego	O
,	O
California	O
,	O
United	O
States	O
)	O
according	O
to	O
manufacturer	O
's	O
guidelines	O
.	O

pGL4	O
-	O
TKhRluc2	O
was	O
used	O
as	O
an	O
internal	O
control	O
to	O
normalize	O
for	O
transfection	O
efficiency	O
.	O

Nucleofected	O
CD4+	O
T	O
cells	O
were	O
also	O
monitored	O
for	O
transfection	O
efficiency	O
and	O
cell	O
viability	O
24	O
h	O
posttransfection	O
as	O
follows	O
.	O

Transfection	O
efficiency	O
was	O
routinely	O
~30	O
%	O
as	O
determined	O
by	O
flow	O
cytometric	O
analysis	O
of	O
EGFP	O
expression	O
.	O

Cell	O
viability	O
,	O
determined	O
by	O
staining	O
with	O
7-amino	O
-	O
actinomycin	O
D	O
(	O
7	O
-	O
AAD	O
;	O
BD	O
Biosciences	O
)	O
,	O
was	O
routinely	O
~70	O
%	O
.	O

Both	O
transfection	O
efficiency	O
and	O
cell	O
viability	O
in	O
nucleofected	O
CD4+	O
T	O
cells	O
was	O
independent	O
of	O
the	O
plasmids	O
used	O
.	O

Foxp3	O
and	O
HTLV	O
-	O
I	O
Tax	O
expression	B-Gene_expression
analysis	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

Real	O
-	O
time	O
RT	O
-	O
PCR	O
analysis	O
of	O
Foxp3	O
and	O
HTLV	O
-	O
I	O
Tax	O
expression	B-Gene_expression
was	O
performed	O
as	O
previously	O
described	O
[	O
8	O
,	O
47	O
]	O
.	O

Briefly	O
,	O
total	O
RNA	O
was	O
extracted	O
using	O
the	O
RNeasy	O
Mini	O
Kit	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
California	O
,	O
United	O
States	O
)	O
according	O
to	O
manufacturer	O
's	O
guidelines	O
,	O
and	O
cDNA	O
was	O
synthesized	O
by	O
reverse	O
transcription	O
using	O
TaqMan	O
Gold	O
RT	O
-	O
PCR	O
Kit	O
using	O
random	O
hexamer	O
primers	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

Foxp3	O
and	O
HTLV	O
-	O
I	O
Tax	O
mRNA	B-Transcription
expression	I-Transcription
was	O
quantified	O
by	O
real	O
-	O
time	O
PCR	O
using	O
ABI	O
PRISM	O
7700	O
Sequence	O
Detection	O
System	O
(	O
Applied	O
Biosystems	O
)	O
.	O

The	O
normalized	O
values	O
in	O
each	O
sample	O
were	O
calculated	O
as	O
the	O
relative	O
quantity	O
of	O
Foxp3	O
or	O
HTLV	O
-	O
I	O
Tax	O
mRNA	B-Transcription
expression	I-Transcription
divided	O
by	O
the	O
relative	O
quantity	O
of	O
HPRT	O
mRNA	B-Transcription
expression	I-Transcription
.	O

The	O
values	O
were	O
calculated	O
by	O
the	O
following	O
formula	O
:	O
normalized	O
Foxp3	O
or	O
HTLV	O
-	O
I	O
Tax	O
expression	B-Gene_expression
=	O
2Ct	O
value	O
of	O
HPRT	O
-	O
Ct	O
value	O
of	O
Foxp3	O
or	O
HTLV	O
-	O
I	O
Tax	O
.	O

Real	O
-	O
time	O
PCR	O
.	O

Real	O
-	O
time	O
PCR	O
analysis	O
of	O
HTLV	O
-	O
I	O
(	O
Tax	O
)	O
proviral	O
load	O
was	O
performed	O
as	O
previously	O
described	O
[	O
47	O
,	O
50	O
]	O
.	O

DNA	O
was	O
extracted	O
from	O
1	O
x	O
106	O
cells	O
using	O
Puregene	O
DNA	O
Isolation	O
Kit	O
(	O
Gentra	O
,	O
Minneapolis	O
,	O
Minnesota	O
,	O
United	O
States	O
)	O
,	O
and	O
100	O
ng	O
of	O
the	O
sample	O
DNA	O
solution	O
was	O
analyzed	O
by	O
this	O
system	O
.	O

The	O
HTLV	O
-	O
I	O
proviral	O
DNA	O
load	O
was	O
calculated	O
by	O
the	O
following	O
formula	O
:	O
copy	O
number	O
of	O
HTLV	O
-	O
I	O
(	O
pX	O
)	O
per	O
100	O
cells	O
=	O
(	O
copy	O
number	O
of	O
pX	O
)	O
/	O
(	O
copy	O
number	O
of	O
beta	O
-	O
actin/2	O
)	O
x	O
100	O
.	O

Western	O
blot	O
analysis	O
.	O

HEK	O
293T	O
cells	O
were	O
plated	O
at	O
a	O
density	O
of	O
5	O
x	O
105	O
cells/well	O
in	O
six	O
-	O
well	O
culture	O
plates	O
(	O
BD	O
Biosciences	O
)	O
1	O
d	O
prior	O
to	O
transfection	O
with	O
the	O
appropriate	O
plasmid	O
DNA	O
(	O
2	O
mug	O
total	O
)	O
using	O
FuGene	O
6	O
transfection	O
reagent	O
(	O
Roche	O
)	O
.	O

Cells	O
were	O
harvested	O
24	O
h	O
posttransfection	O
for	O
whole	O
-	O
cell	O
lysates	O
in	O
RIPA	O
buffer	O
(	O
50	O
mM	O
Tris	O
-	O
HCl	O
[	O
pH	O
7.4	O
]	O
,	O
150	O
mM	O
NaCl	O
,	O
1	O
%	O
Igepal	O
(	O
NP	O
-	O
40	O
)	O
,	O
0.5	O
%	O
sodium	O
deoxycholate	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
mM	O
DTT	O
,	O
1	O
mM	O
PMSF	O
,	O
and	O
1x	O
Complete	O
Mini	O
Protease	O
Inhibitor	O
[	O
Roche	O
]	O
)	O
.	O

Protein	O
concentration	O
was	O
determined	O
by	O
Lowry	O
assay	O
(	O
Bio	O
-	O
Rad	O
,	O
Hercules	O
,	O
California	O
,	O
United	O
States	O
)	O
and	O
colorimetric	O
reactions	O
were	O
read	O
using	O
a	O
VersaMax	O
microplate	O
reader	O
(	O
Molecular	O
Devices	O
,	O
Sunnyvale	O
,	O
California	O
,	O
United	O
States	O
)	O
at	O
an	O
absorbance	O
of	O
750	O
nm	O
.	O

Size	O
fractionation	O
was	O
performed	O
on	O
20	O
mug	O
of	O
protein/sample	O
by	O
SDS	O
-	O
PAGE	O
,	O
and	O
the	O
protein	O
was	O
transferred	O
to	O
nitrocellulose	O
or	O
PVDF	O
membranes	O
and	O
subjected	O
to	O
immunoblotting	O
using	O
the	O
indicated	O
antibodies	O
.	O

Foxp3	O
was	O
detected	O
using	O
rabbit	O
anti	O
-	O
human	O
Foxp3	O
polyclonal	O
antibody	O
(	O
ab4728	O
or	O
ab10563	O
;	O
Abcam	O
,	O
Cambridge	O
,	O
United	O
Kingdom	O
)	O
and	O
anti	O
-	O
rabbit	O
IgG	O
-	O
HRP	O
secondary	O
antibody	O
(	O
Cell	O
Signaling	O
Technology	O
,	O
Beverly	O
,	O
Massachusetts	O
,	O
United	O
States	O
)	O
.	O

NF	O
-	O
kappaB	O
p65	O
and	O
CREB	O
-	O
1	O
were	O
detected	O
using	O
rabbit	O
anti	O
-	O
human	O
polyclonal	O
(	O
p65	O
)	O
or	O
monoclonal	O
antibody	O
(	O
CREB	O
-	O
1	O
;	O
48H2	O
)	O
(	O
Cell	O
Signaling	O
Technology	O
)	O
.	O

Beta	O
-	O
actin	O
was	O
detected	O
using	O
a	O
mouse	O
monoclonal	O
antibody	O
(	O
AC	O
-	O
15	O
;	O
Sigma	O
,	O
St	O
.	O

Louis	O
,	O
Missouri	O
,	O
United	O
States	O
)	O
.	O

For	O
coimmunoprecipitation	O
analysis	O
,	O
cell	O
lysates	O
were	O
precleared	O
with	O
30	O
mul	O
of	O
protein	O
A/G	O
plus	O
-	O
agarose	O
beads	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
California	O
,	O
United	O
States	O
)	O
and	O
then	O
incubated	O
with	O
mouse	O
monoclonal	O
anti	O
-	O
HA	O
antibody	O
(	O
6E2	O
;	O
1	O
:	O
100	O
;	O
Cell	O
Signaling	O
Technology	O
)	O
and	O
30	O
mul	O
of	O
protein	O
A/G	O
plus	O
-	O
agarose	O
beads	O
overnight	O
.	O

The	O
immunoprecipitates	O
were	O
washed	O
four	O
times	O
with	O
RIPA	O
buffer	O
,	O
resuspended	O
in	O
SDS	O
sample	O
buffer	O
,	O
and	O
heated	O
at	O
95	O
degreesC	O
for	O
5	O
min	O
.	O

Proteins	O
were	O
then	O
treated	O
as	O
described	O
for	O
Western	O
blot	O
analysis	O
.	O

Transcription	O
factor	O
DNA	O
-	O
binding	O
analysis	O
(	O
TF	O
-	O
ELISA	O
)	O
.	O

CREB	O
-	O
1	O
and	O
ATF	O
-	O
2	O
DNA	O
-	O
binding	B-Binding
activity	O
was	O
analyzed	O
with	O
the	O
TransFactor	O
Profiling	O
(	O
Inflammation	O
1	O
)	O
Kit	O
(	O
BD	O
Biosciences	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

Nuclear	O
extracts	O
were	O
prepared	O
from	O
HEK	O
293T	O
cells	O
transfected	O
with	O
a	O
control	O
vector	O
(	O
EGFP	O
)	O
or	O
Foxp3	O
expression	B-Gene_expression
vector	O
(	O
1	O
,	O
000	O
ng	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
forskolin	O
(	O
10	O
muM	O
for	O
4	O
h	O
)	O
using	O
the	O
TransFactor	O
Extraction	O
Kit	O
(	O
BD	O
Biosciences	O
)	O
.	O

Protein	O
concentration	O
was	O
determined	O
using	O
a	O
Biophotometer	O
(	O
Eppendorf	O
,	O
Hamburg	O
,	O
Germany	O
)	O
.	O

Nuclear	O
extracts	O
(	O
20	O
mug	O
)	O
were	O
incubated	O
in	O
preblocked	O
wells	O
containing	O
plate	O
-	O
bound	O
double	O
-	O
stranded	O
oligonucleotides	O
corresponding	O
to	O
an	O
ATF/CREB	O
consensus	O
sequence	O
(	O
emTGACATCAem	O
)	O
.	O

Wells	O
were	O
washed	O
,	O
incubated	O
with	O
the	O
appropriate	O
primary	O
antibody	O
,	O
washed	O
,	O
incubated	O
with	O
secondary	O
antibody	O
(	O
HRP	O
-	O
labeled	O
)	O
,	O
washed	O
again	O
,	O
and	O
finally	O
developed	O
with	O
TMB	O
substrate	O
.	O

Colorimetric	O
reactions	O
were	O
read	O
using	O
a	O
VersaMax	O
microplate	O
reader	O
(	O
Molecular	O
Devices	O
)	O
at	O
an	O
absorbance	O
of	O
655	O
nm	O
.	O

Flow	O
cytometric	O
analysis	O
of	O
Foxp3	O
protein	O
expression	B-Gene_expression
.	O

Cryopreserved	O
PBMCs	O
from	O
HAM/TSP	O
patients	O
or	O
HTLV-I	O
-	O
infected	O
ACs	O
were	O
thawed	O
and	O
washed	O
with	O
FACS	O
buffer	O
(	O
1x	O
PBS	O
,	O
0.1	O
%	O
NaN3	O
,	O
5	O
%	O
FBS	O
)	O
.	O

Cells	O
(	O
1.5	O
x	O
106	O
)	O
were	O
fixed	O
by	O
sequential	O
formaldehyde/methanol	O
fixation	O
as	O
follows	O
.	O

Cells	O
were	O
carefully	O
resuspended	O
in	O
FACS	O
buffer	O
and	O
fixed	O
with	O
100	O
mul	O
of	O
reagent	O
A	O
(	O
Fix	O
&	O
Perm	O
kit	O
;	O
Caltag	O
Laboratories	O
,	O
Burlingame	O
,	O
California	O
,	O
United	O
States	O
)	O
at	O
room	O
temperature	O
for	O
3	O
min	O
followed	O
by	O
2	O
ml	O
of	O
70	O
%	O
methanol	O
for	O
5	O
min	O
at	O
4	O
degreesC	O
.	O

Cells	O
were	O
washed	O
twice	O
and	O
permeabilized	O
with	O
100	O
mul	O
of	O
reagent	O
B	O
(	O
Fix	O
&	O
Perm	O
kit	O
)	O
and	O
stained	O
for	O
intracellular	O
Foxp3	O
with	O
mouse	O
anti	O
-	O
human	O
Foxp3	O
monoclonal	O
antibody	O
(	O
0.5	O
mug	O
of	O
ab22510	O
;	O
Abcam	O
)	O
or	O
the	O
appropriate	O
isotype	O
control	O
for	O
30	O
min	O
.	O

Cells	O
were	O
washed	O
twice	O
and	O
stained	O
with	O
Cy5	O
-	O
conjugated	O
goat	O
anti	O
-	O
mouse	O
immunoglobulin	O
F	O
(	O
ab	O
'	O
)	O
2	O
secondary	O
antibody	O
(	O
Caltag	O
Laboratories	O
)	O
for	O
an	O
additional	O
30	O
min	O
.	O

Cells	O
were	O
washed	O
twice	O
and	O
stained	O
for	O
surface	O
CD4	O
expression	B-Gene_expression
with	O
PE	O
-	O
labeled	O
anti	O
-	O
CD4	O
(	O
BD	O
)	O
and	O
CD25	O
expression	B-Gene_expression
with	O
FITC	O
-	O
labeled	O
anti	O
-	O
CD25	O
(	O
BD	O
)	O
.	O

Cells	O
were	O
washed	O
twice	O
and	O
analyzed	O
on	O
a	O
FACSCalibur	O
(	O
BD	O
)	O
.	O

Data	O
analysis	O
was	O
performed	O
using	O
FlowJo	O
(	O
Tree	O
Star	O
,	O
Ashland	O
,	O
Oregon	O
,	O
United	O
States	O
)	O
.	O

Statistical	O
analyses	O
.	O

The	O
Mann	O
-	O
Whitney	O
U	O
test	O
was	O
used	O
to	O
compare	O
the	O
data	O
between	O
patients	O
with	O
HAM/TSP	O
and	O
AC	O
.	O

EBV	O
Latent	O
Membrane	O
Protein	O
1	O
Activates	B-Positive_regulation
Akt	O
,	O
NFkappaB	O
,	O
and	O
Stat3	O
in	O
B	O
Cell	O
Lymphomas	O

Latent	O
membrane	O
protein	O
1	O
(	O
LMP1	O
)	O
is	O
the	O
major	O
oncoprotein	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
.	O

In	O
transgenic	O
mice	O
,	O
LMP1	O
promotes	O
increased	O
lymphoma	O
development	O
by	O
12	O
mo	O
of	O
age	O
.	O

This	O
study	O
reveals	O
that	O
lymphoma	O
develops	O
in	O
B	O
-	O
1a	O
lymphocytes	O
,	O
a	O
population	O
that	O
is	O
associated	O
with	O
transformation	O
in	O
older	O
mice	O
.	O

The	O
lymphoma	O
cells	O
have	O
deregulated	O
cell	O
cycle	O
markers	O
,	O
and	O
inhibitors	B-Negative_regulation
of	O
Akt	O
,	O
NFkappaB	O
,	O
and	O
Stat3	O
block	O
the	O
enhanced	O
viability	O
of	O
LMP1	O
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
in	O
vitro	O
.	O

Lymphoma	O
cells	O
are	O
independent	O
of	O
IL4/Stat6	O
signaling	O
for	O
survival	O
and	O
proliferation	O
,	O
but	O
have	O
constitutively	O
activated	O
Stat3	O
signaling	O
.	O

These	O
same	O
targets	O
are	O
also	O
deregulated	B-Regulation
in	O
wild	O
-	O
type	O
B	O
-	O
1a	O
lymphomas	O
that	O
arise	O
spontaneously	O
through	O
age	O
predisposition	O
.	O

These	O
results	O
suggest	O
that	O
Akt	O
,	O
NFkappaB	O
,	O
and	O
Stat3	O
pathways	O
may	O
serve	O
as	O
effective	O
targets	O
in	O
the	O
treatment	O
of	O
EBV	O
-	O
associated	O
B	O
cell	O
lymphomas	O
.	O

Author	O
Summary	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
linked	O
to	O
the	O
development	O
of	O
multiple	O
cancers	O
,	O
including	O
post	O
-	O
transplant	O
lymphoma	O
,	O
Hodgkin	O
disease	O
,	O
and	O
nasopharyngeal	O
carcinoma	O
.	O

Latent	O
membrane	O
protein	O
1	O
(	O
LMP1	O
)	O
is	O
expressed	B-Gene_expression
in	O
many	O
EBV	O
-	O
associated	O
cancers	O
and	O
is	O
responsible	O
for	O
most	O
of	O
the	O
altered	O
cellular	O
growth	O
properties	O
that	O
are	O
induced	O
by	O
EBV	O
infection	O
.	O

This	O
study	O
reveals	O
that	O
LMP1	O
induces	O
lymphomas	O
in	O
B	O
-	O
1a	O
lymphocytes	O
,	O
a	O
cell	O
type	O
that	O
is	O
susceptible	O
to	O
transformation	O
in	O
aged	O
mice	O
.	O

The	O
lymphomas	O
require	O
Akt	O
,	O
NFkappaB	O
,	O
and	O
Stat3	O
signaling	O
for	O
enhanced	O
growth	O
and	O
survival	O
.	O

The	O
activation	O
of	O
the	O
Stat3	O
,	O
Akt	O
,	O
and	O
NFkappaB	O
signaling	O
pathways	O
likely	O
underlies	O
the	O
ability	O
of	O
LMP1	O
to	O
promote	O
malignant	O
transformation	O
.	O

Introduction	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
a	O
ubiquitous	O
gamma	O
-	O
herpesvirus	O
that	O
infects	O
humans	O
predominantly	O
at	O
an	O
early	O
age	O
with	O
greater	O
than	O
90	O
%	O
of	O
the	O
adult	O
population	O
infected	O
with	O
EBV	O
[	O
1	O
]	O
.	O

EBV	O
is	O
linked	O
to	O
the	O
development	O
of	O
both	O
B	O
lymphocyte	O
and	O
epithelial	O
cell	O
malignancies	O
,	O
including	O
Burkitt	O
lymphoma	O
,	O
Hodgkin	O
disease	O
(	O
HD	O
)	O
,	O
and	O
nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
,	O
and	O
cancers	O
linked	O
to	O
immunosuppression	O
,	O
including	O
post	O
-	O
transplant	O
lymphoma	O
and	O
AIDS	O
-	O
associated	O
lymphomas	O
[	O
2	O
,	O
3	O
]	O
.	O

In	O
vitro	O
infection	O
of	O
B	O
lymphocytes	O
with	O
EBV	O
induces	O
permanent	O
growth	O
transformation	O
,	O
and	O
this	O
ability	O
to	O
affect	O
cell	O
growth	O
regulation	O
likely	O
contributes	O
to	O
the	O
development	O
of	O
cancer	O
.	O

Many	O
of	O
the	O
viral	O
proteins	O
expressed	O
in	O
transformed	O
cells	O
,	O
including	O
the	O
EBV	O
nuclear	O
antigens	O
and	O
latent	O
membrane	O
proteins	O
,	O
have	O
profound	O
effects	O
on	O
cell	O
growth	O
regulation	O
and	O
are	O
required	O
for	O
EBV	O
latent	O
infection	O
and	O
B	O
cell	O
transformation	O
[	O
1	O
]	O
.	O

Latent	O
membrane	O
protein	O
1	O
(	O
LMP1	O
)	O
is	O
considered	O
the	O
major	O
oncoprotein	O
of	O
EBV	O
,	O
as	O
it	O
transforms	O
rodent	O
fibroblasts	O
to	O
tumorigenicity	O
in	O
nude	O
mice	O
and	O
is	O
expressed	B-Gene_expression
in	O
HD	O
,	O
NPC	O
,	O
and	O
immunosuppression	O
-	O
associated	O
tumors	O
[	O
4	O
-	O
8	O
]	O
.	O

In	O
B	O
lymphocytes	O
,	O
LMP1	O
mimics	O
CD40	O
signaling	O
,	O
and	O
both	O
LMP1	O
and	O
CD40	O
are	O
essential	O
for	O
EBV	O
-	O
mediated	O
B	O
cell	O
transformation	O
[	O
9	O
-	O
11	O
]	O
.	O

While	O
CD40	O
interacts	B-Binding
with	O
CD40	O
ligand	O
expressed	B-Gene_expression
on	O
activated	O
T	O
cells	O
to	O
induce	O
B	O
cell	O
activation	O
and	O
differentiation	O
,	O
LMP1	O
acts	O
as	O
a	O
constitutive	O
signal	O
through	O
ligand	O
-	O
independent	O
oligomerization	B-Binding
.	O

LMP1	O
and	O
CD40	O
interact	B-Binding
with	O
the	O
same	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factors	O
(	O
TRAFs	O
)	O
leading	O
to	O
activation	O
of	O
NFkappaB	O
,	O
c	O
-	O
Jun	O
N	O
terminal	O
kinase	O
(	O
JNK	O
)	O
,	O
and	O
p38	O
MAPK	O
signaling	O
pathways	O
[	O
12	O
-	O
16	O
]	O
.	O

Activation	O
of	O
NFkappaB	O
is	O
required	O
for	O
EBV	O
-	O
induced	O
B	O
cell	O
transformation	O
and	O
its	O
inhibition	O
rapidly	O
results	O
in	O
cell	O
death	O
[	O
17	O
,	O
18	O
]	O
.	O

Recent	O
studies	O
indicate	O
that	O
LMP1	O
also	O
activates	O
phosphatidylinositol	O
3	O
kinase	O
(	O
PI3K	O
)	O
/Akt	O
signaling	O
and	O
that	O
this	O
activation	O
is	O
required	O
for	O
LMP1	O
-	O
mediated	O
transformation	O
of	O
rodent	O
fibroblasts	O
[	O
5	O
,	O
19	O
]	O
.	O

In	O
vitro	O
,	O
primary	O
B	O
cells	O
can	O
be	O
maintained	O
by	O
CD40	O
ligation	B-Binding
in	O
combination	O
with	O
IL4	O
treatment	O
.	O

In	O
vivo	O
,	O
CD40	O
signaling	O
is	O
necessary	O
for	O
germinal	O
center	O
(	O
GC	O
)	O
formation	O
such	O
that	O
mice	O
deficient	B-Negative_regulation
for	O
CD40	O
or	O
CD40L	O
are	O
unable	O
to	O
form	O
GCs	O
in	O
response	O
to	O
T	O
cell	O
-	O
dependent	O
antigens	O
[	O
20	O
,	O
21	O
]	O
.	O

Both	O
the	O
membrane	O
proximal	O
and	O
distal	O
cytoplasmic	O
regions	O
of	O
CD40	O
that	O
bind	B-Binding
TRAF6	O
and	O
TRAFs2/3/5	O
,	O
respectively	O
,	O
are	O
necessary	O
for	O
GC	O
formation	O
,	O
but	O
either	O
region	O
is	O
sufficient	O
to	O
induce	O
extrafollicular	O
B	O
cell	O
differentiation	O
and	O
restore	O
low	O
affinity	O
antibody	O
production	O
[	O
22	O
]	O
.	O

Functionally	O
,	O
LMP1	O
can	O
rescue	B-Negative_regulation
CD40	O
-	O
deficient	B-Negative_regulation
mice	O
and	O
restore	O
immunoglobulin	O
(	O
Ig	O
)	O
class	O
switching	O
,	O
most	O
likely	O
because	O
LMP1	O
recruits	B-Binding
similar	O
TRAF	O
molecules	O
,	O
TRAFs	O
1/2/3/5	O
and	O
TRAF6	O
,	O
through	O
the	O
C	O
-	O
terminal	O
activation	O
regions	O
1	O
and	O
2	O
domains	O
,	O
respectively	O
.	O

However	O
,	O
LMP1	O
is	O
unable	O
to	O
restore	O
affinity	O
maturation	O
and	O
GC	O
formation	O
[	O
23	O
]	O
.	O

Several	O
EBV	O
transforming	O
proteins	O
have	O
been	O
studied	O
in	O
transgenic	O
mouse	O
models	O
,	O
however	O
,	O
only	O
LMP1	O
induces	O
tumor	O
development	O
when	O
expressed	B-Gene_expression
under	B-Positive_regulation
the	I-Positive_regulation
control	I-Positive_regulation
of	O
the	O
Ig	O
heavy	O
chain	O
promoter	O
and	O
enhancer	O
[	O
24	O
-	O
26	O
]	O
.	O

The	O
LMP1	O
transgenic	O
mice	O
(	O
IgLMP1	O
)	O
express	B-Gene_expression
LMP1	O
in	O
B	O
lymphocytes	O
,	O
and	O
in	O
mice	O
older	O
than	O
12	O
mo	O
,	O
lymphoma	O
develops	O
with	O
increased	O
incidence	O
(	O
40	O
%	O
-	O
50	O
%	O
)	O
compared	O
to	O
wild	O
-	O
type	O
control	O
mice	O
(	O
11	O
%	O
)	O
,	O
suggesting	O
that	O
LMP1	O
contributes	O
to	O
tumor	O
development	O
[	O
26	O
]	O
.	O

The	O
LMP1	O
lymphomas	O
have	O
rearranged	O
Ig	O
genes	O
and	O
have	O
activated	B-Positive_regulation
Akt	O
,	O
JNK	O
,	O
p38	O
,	O
and	O
NFkappaB	O
,	O
with	O
specific	O
activation	B-Positive_regulation
of	O
the	O
NFkappaB	O
family	O
member	O
cRel	O
[	O
27	O
]	O
.	O

In	O
this	O
study	O
,	O
the	O
LMP1	O
transgenic	O
lymphocytes	O
and	O
lymphomas	O
were	O
further	O
characterized	O
and	O
their	O
growth	O
properties	O
in	O
vitro	O
were	O
determined	O
.	O

To	O
obtain	O
pure	O
populations	O
of	O
malignant	O
lymphocytes	O
and	O
to	O
enable	O
more	O
detailed	O
biochemical	O
analyses	O
,	O
examples	O
of	O
primary	O
lymphomas	O
were	O
inoculated	O
and	O
passaged	O
in	O
SCID	O
mice	O
.	O

Interestingly	O
,	O
lymphoma	O
development	O
was	O
restricted	O
to	O
B	O
-	O
1a	O
lymphocytes	O
,	O
a	O
self	O
-	O
replenishing	O
population	O
of	O
cells	O
that	O
are	O
prone	O
to	O
malignancy	O
[	O
28	O
,	O
29	O
]	O
.	O

LMP1	O
transgenic	O
lymphocytes	O
had	O
increased	O
viability	O
in	O
vitro	O
and	O
viability	O
was	O
increased	O
by	O
the	O
addition	O
of	O
IL4	O
.	O

In	O
contrast	O
,	O
both	O
LMP1	O
-	O
positive	O
and	O
-	O
negative	O
lymphoma	O
cells	O
were	O
independent	O
of	O
IL4	O
co	O
-	O
stimulation	O
for	O
survival	O
and	O
proliferation	O
in	O
vitro	O
with	O
a	O
complete	O
absence	B-Negative_regulation
of	O
activated	B-Positive_regulation
Stat6	O
,	O
the	O
IL4	O
target	B-Regulation
.	O

The	O
lymphomas	O
were	O
also	O
distinguished	O
by	O
constitutive	O
activation	B-Positive_regulation
of	O
Stat3	O
and	O
deregulation	O
of	O
the	O
Rb	O
cell	O
cycle	O
pathway	O
.	O

Inhibition	O
of	O
the	O
PI3K/Akt	O
,	O
NFkappaB	O
,	O
and	O
Stat3	O
signaling	O
pathways	O
blocked	O
the	O
enhanced	O
growth	O
of	O
both	O
LMP1	O
transgenic	O
and	O
malignant	O
lymphocytes	O
,	O
suggesting	O
that	O
these	O
pathways	O
are	O
required	O
for	O
their	O
growth	O
and	O
survival	O
.	O

These	O
appear	O
to	O
be	O
the	O
same	O
targets	O
that	O
are	O
deregulated	B-Regulation
in	O
wild	O
-	O
type	O
B	O
-	O
1a	O
lymphomas	O
that	O
arise	O
spontaneously	O
through	O
age	O
predisposition	O
.	O

This	O
study	O
reveals	O
that	O
LMP1	O
promotes	O
malignancy	O
in	O
cells	O
with	O
the	O
inherent	O
ability	O
to	O
proliferate	O
and	O
that	O
the	O
Akt	O
,	O
NFkappaB	O
,	O
and	O
Stat3	O
signaling	O
pathways	O
are	O
required	O
for	O
its	O
growth	O
stimulatory	O
effects	O
.	O

High	B-Positive_regulation
Levels	I-Positive_regulation
of	O
LMP1	O
Expression	B-Gene_expression
Correlates	O
with	O
the	O
Development	O
of	O
Lymphoma	O

LMP1	O
expression	B-Gene_expression
in	O
IgLMP1	O
mice	O
was	O
directed	O
to	O
B	O
cells	O
under	B-Regulation
the	I-Regulation
control	I-Regulation
of	O
the	O
Ig	O
heavy	O
chain	O
promoter	O
and	O
enhancer	O
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
in	O
these	O
transgenic	O
mice	O
,	O
LMP1	O
expression	B-Gene_expression
was	O
restricted	B-Positive_regulation
to	O
B220+	O
B	O
cells	O
with	O
lymphoma	O
detected	O
in	O
greatly	O
enlarged	O
spleens	O
[	O
23	O
,	O
26	O
]	O
.	O

To	O
investigate	O
whether	O
LMP1	O
expression	B-Gene_expression
contributes	O
to	O
lymphoma	O
development	O
,	O
B	O
cells	O
were	O
purified	O
from	O
splenocytes	O
by	O
positive	O
selection	O
using	O
anti	O
-	O
CD19	O
MACS	O
magnetic	O
beads	O
,	O
and	O
equivalent	O
amounts	O
of	O
B	O
cells	O
were	O
analyzed	O
by	O
immunoblotting	O
.	O

LMP1	O
was	O
detectable	B-Gene_expression
in	O
LMP1	O
transgenic	O
B	O
cells	O
,	O
but	O
upon	O
development	O
of	O
lymphoma	O
,	O
LMP1	O
expression	B-Gene_expression
was	O
stronger	B-Positive_regulation
in	O
5/7	O
lymphomas	O
analyzed	O
with	O
concomitant	O
appearance	O
of	O
degradation	O
products	O
(	O
Figure	O
1A	O
)	O
.	O

To	O
determine	O
whether	O
the	O
higher	B-Positive_regulation
level	I-Positive_regulation
of	O
LMP1	O
detected	O
was	O
due	O
to	O
an	O
expansion	O
of	O
malignant	O
lymphocytes	O
,	O
expression	B-Gene_expression
of	O
LMP1	O
in	O
the	O
spleen	O
was	O
further	O
evaluated	O
by	O
immunohistochemical	O
staining	O
.	O

Immunohistochemistry	O
analysis	O
of	O
spleen	O
sections	O
detected	B-Gene_expression
LMP1	O
in	O
the	O
plasma	O
membrane	O
of	O
cells	O
in	O
both	O
the	O
follicular	O
white	O
pulp	O
and	O
circulating	O
lymphocytes	O
in	O
the	O
red	O
pulp	O
(	O
Figure	O
1B	O
)	O
.	O

LMP1	O
expression	B-Gene_expression
was	O
heterogeneous	O
with	O
strong	B-Positive_regulation
LMP1	O
staining	O
interspersed	O
amongst	O
a	O
background	O
of	O
cells	O
staining	O
weakly	B-Positive_regulation
for	O
LMP1	O
.	O

Upon	O
development	O
to	O
lymphoma	O
,	O
LMP1	O
expression	B-Gene_expression
was	O
more	O
abundantly	B-Positive_regulation
detected	O
with	O
multiple	O
foci	O
of	O
intense	B-Positive_regulation
LMP1	O
staining	O
.	O

This	O
demonstrates	O
that	O
the	O
increased	B-Positive_regulation
LMP1	O
detected	O
by	O
immunoblotting	O
upon	O
malignant	O
progression	O
reflects	O
an	O
increase	B-Positive_regulation
in	O
LMP1	O
expression	B-Gene_expression
and	O
an	O
accumulation	O
of	O
cells	O
expressing	B-Gene_expression
high	B-Positive_regulation
levels	I-Positive_regulation
of	O
LMP1	O
.	O

This	O
correlation	O
between	O
high	B-Positive_regulation
LMP1	O
expression	B-Gene_expression
and	O
the	O
development	O
of	O
lymphoma	O
suggests	O
that	O
progression	O
to	O
lymphoma	O
results	O
from	O
increased	B-Positive_regulation
levels	B-Gene_expression
of	O
LMP1	O
.	O

LMP1	O
Promotes	O
B	O
-	O
1a	O
Lymphomas	O
That	O
Can	O
Escape	O
Allelic	O
Exclusion	O

To	O
determine	O
if	O
LMP1	O
signaling	O
affects	O
B	O
cell	O
differentiation	O
and	O
to	O
immunophenotype	O
the	O
lymphomas	O
that	O
arise	O
from	O
LMP1	O
expression	B-Gene_expression
,	O
surface	O
Ig	O
expression	O
of	O
heavy	O
chains	O
(	O
IgM	O
,	O
IgG	O
,	O
IgD	O
)	O
and	O
light	O
chains	O
(	O
kappa	O
,	O
lambda	O
)	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
.	O

Similar	O
numbers	O
of	O
naive	O
(	O
IgM+IgD+IgG	O
-	O
)	O
splenic	O
B	O
cells	O
with	O
a	O
strong	O
bias	O
towards	O
kappa	O
light	O
chain	O
were	O
detected	O
from	O
wild	O
-	O
type	O
or	O
LMP1	O
transgenic	O
mice	O
,	O
indicating	O
that	O
LMP1	O
signaling	O
does	O
not	O
affect	O
B	O
cell	O
maturation	O
(	O
unpublished	O
data	O
)	O
.	O

Flow	O
cytometry	O
analysis	O
of	O
the	O
SCID	O
-	O
passaged	O
wild	O
-	O
type	O
and	O
LMP1	O
transgenic	O
lymphomas	O
revealed	O
an	O
IgMhighIgDlow	O
phenotype	O
(	O
Figure	O
2A	O
)	O
,	O
indicative	O
of	O
marginal	O
zone	O
,	O
B	O
-	O
1	O
,	O
or	O
memory	O
B	O
cells	O
.	O

B	O
-	O
1	O
cells	O
are	O
further	O
separated	O
into	O
CD5+	O
(	O
B	O
-	O
1a	O
)	O
and	O
CD5	O
-	O
(	O
B	O
-	O
1b	O
)	O
subsets	O
.	O

To	O
differentiate	O
between	O
these	O
cell	O
types	O
,	O
lymphoma	O
cells	O
were	O
further	O
analyzed	O
for	O
the	O
B	O
-	O
1a	O
marker	O
CD5	O
.	O

All	O
(	O
5/5	O
)	O
of	O
the	O
tested	O
LMP1	O
transgenic	O
lymphomas	O
displayed	O
an	O
IgMhighIgDlowCD5+	O
phenotype	O
(	O
Figure	O
2A	O
)	O
,	O
an	O
expression	O
pattern	O
that	O
distinguishes	O
B	O
-	O
1a	O
cells	O
.	O

Interestingly	O
,	O
a	O
spontaneous	O
wild	O
-	O
type	O
lymphoma	O
also	O
developed	O
in	O
B	O
-	O
1a	O
cells	O
(	O
Figure	O
2A	O
)	O
.	O

These	O
cells	O
are	O
an	O
interesting	O
population	O
that	O
is	O
self	O
replenishing	O
with	O
an	O
increased	O
likelihood	O
to	O
become	O
malignant	O
in	O
aged	O
mice	O
[	O
30	O
]	O
.	O

Analysis	O
of	O
LMP1	O
transgenic	O
mice	O
before	O
the	O
development	O
of	O
lymphoma	O
showed	O
similar	O
numbers	O
of	O
splenic	O
B	O
-	O
1a	O
(	O
CD19+CD5+	O
)	O
and	O
B	O
-	O
1b	O
or	O
B	O
-	O
2	O
populations	O
(	O
CD19+CD5	O
-	O
)	O
,	O
indicating	O
that	O
LMP1	O
does	O
not	O
affect	O
B	O
cell	O
differentiation	O
(	O
Figure	O
2B	O
)	O
.	O

Due	O
to	O
allelic	O
exclusion	O
,	O
mature	O
B	O
cells	O
that	O
have	O
been	O
exposed	O
to	O
antigen	O
will	O
typically	O
express	O
only	O
one	O
heavy	O
chain	O
isotype	O
(	O
IgG	O
,	O
IgE	O
,	O
or	O
IgA	O
)	O
and	O
either	O
a	O
kappa	O
or	O
lambda	O
light	O
chain	O
.	O

Interestingly	O
,	O
2/5	O
LMP1	O
transgenic	O
lymphomas	O
analyzed	O
(	O
lymphomas	O
2	O
and	O
4	O
)	O
were	O
doubly	O
positive	O
for	O
low	O
levels	O
of	O
both	O
kappa	O
and	O
lambda	O
light	O
chains	O
(	O
Figure	O
2A	O
)	O
.	O

Previous	O
characterization	O
of	O
the	O
LMP1	O
lymphomas	O
had	O
revealed	O
that	O
the	O
lymphomas	O
were	O
clonal	O
as	O
determined	O
by	O
Ig	O
heavy	O
chain	O
rearrangement	O
[	O
26	O
]	O
,	O
and	O
analysis	O
of	O
kappa	O
chain	O
rearrangement	O
(	O
Figure	O
S1	O
)	O
of	O
the	O
samples	O
analyzed	O
in	O
this	O
study	O
confirmed	O
clonality	O
.	O

To	O
further	O
assess	O
light	O
chain	O
expression	O
,	O
the	O
passaged	O
samples	O
were	O
tested	O
by	O
immunoblotting	O
for	O
kappa	O
and	O
lambda	O
light	O
chains	O
(	O
Figure	O
2C	O
)	O
.	O

Interestingly	O
,	O
very	O
low	O
levels	O
of	O
expression	O
of	O
both	O
light	O
chains	O
were	O
detected	O
by	O
flow	O
cytometry	O
.	O

The	O
low	O
levels	O
of	O
expression	O
may	O
reflect	O
a	O
limitation	O
of	O
the	O
total	O
number	O
of	O
light	O
chains	O
that	O
can	O
be	O
expressed	O
on	O
the	O
surface	O
of	O
a	O
B	O
cell	O
.	O

In	O
agreement	O
with	O
the	O
flow	O
cytometry	O
analysis	O
,	O
LMP1	O
transgenic	O
lymphomas	O
2	O
and	O
4	O
were	O
also	O
positive	O
for	O
kappa	O
and	O
lambda	O
light	O
chains	O
by	O
immunoblot	O
analysis	O
(	O
Figure	O
2C	O
)	O
,	O
confirming	O
that	O
these	O
lymphomas	O
express	O
both	O
light	O
chains	O
.	O

A	O
previous	O
study	O
of	O
mice	O
that	O
developed	O
leukemia	O
due	O
to	O
an	O
expansion	O
of	O
self	O
-	O
reactive	O
B	O
-	O
1a	O
cells	O
determined	O
that	O
the	O
B	O
-	O
1a	O
leukemias	O
were	O
also	O
doubly	O
positive	O
for	O
kappa	O
and	O
lambda	O
light	O
chains	O
[	O
31	O
]	O
.	O

These	O
findings	O
indicate	O
that	O
expression	B-Gene_expression
of	O
LMP1	O
in	O
B	O
-	O
1a	O
cells	O
promotes	O
the	O
development	O
of	O
malignancy	O
and	O
can	O
result	O
in	O
the	O
aberrant	O
escape	O
from	O
allelic	O
exclusion	O
.	O

LMP1	O
Promotes	O
B	O
Cell	O
Survival	O
and	O
Proliferation	O
In	O
Vitro	O

Primary	O
B	O
cell	O
cultures	O
can	O
be	O
maintained	O
through	O
CD40	O
ligation	B-Binding
and	O
supplementation	O
with	O
IL4	O
[	O
32	O
]	O
.	O

To	O
investigate	O
whether	O
LMP1	O
affects	O
primary	O
B	O
cell	O
survival	O
and	O
proliferation	O
,	O
splenocytes	O
were	O
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
IL4	O
and	O
analyzed	O
by	O
MTS	O
as	O
a	O
metabolic	O
marker	O
,	O
by	O
ethidium	O
monoazide	O
(	O
EMA	O
)	O
exclusion	O
for	O
viability	O
,	O
and	O
by	O
5-bromo-2'-deoxy	O
-	O
uridine	O
(	O
BrdU	O
)	O
incorporation	O
for	O
proliferation	O
.	O

In	O
the	O
MTS	O
assay	O
,	O
as	O
expected	O
,	O
splenocytes	O
from	O
wild	O
-	O
type	O
mice	O
did	O
not	O
survive	O
even	O
with	O
the	O
addition	O
of	O
IL4	O
due	O
to	O
a	O
lack	B-Negative_regulation
of	O
CD40	O
ligation	B-Binding
(	O
Figure	O
3A	O
)	O
.	O

In	O
contrast	O
,	O
LMP1	O
splenocytes	O
had	O
increased	O
metabolism	O
even	O
in	O
the	O
absence	B-Negative_regulation
of	O
IL4	O
,	O
which	O
was	O
further	O
enhanced	O
upon	O
addition	O
of	O
IL4	O
.	O

Wild	O
-	O
type	O
and	O
LMP1	O
transgenic	O
lymphoma	O
cells	O
had	O
high	O
levels	O
of	O
MTS	O
activity	O
even	O
in	O
the	O
absence	B-Negative_regulation
of	O
IL4	O
(	O
Figure	O
3A	O
)	O
.	O

The	O
LMP1	O
transgenic	O
lymphoma	O
cells	O
had	O
approximately	O
4	O
-	O
fold	O
higher	O
MTS	O
activity	O
than	O
the	O
normal	O
transgenic	O
lymphocytes	O
and	O
were	O
at	O
least	O
2	O
-	O
fold	O
higher	O
than	O
the	O
control	O
lymphoma	O
.	O

As	O
previously	O
published	O
,	O
lymphoma	O
usually	O
develops	O
in	O
mice	O
over	O
12	O
mo	O
of	O
age	O
and	O
all	O
mice	O
are	O
sacrificed	O
by	O
18	O
-	O
20	O
mo	O
.	O

The	O
ages	O
of	O
the	O
transgenic	O
mice	O
with	O
or	O
without	O
lymphoma	O
ranged	O
between	O
6	O
and	O
20	O
mo	O
old	O
.	O

There	O
was	O
no	O
correlation	O
between	O
age	O
and	O
MTS	O
activity	O
.	O

EMA	O
exclusion	O
of	O
CD19+	O
gated	O
B	O
cells	O
prepared	O
from	O
two	O
wild	O
-	O
type	O
and	O
two	O
LMP1	O
transgenic	O
mice	O
indicated	O
a	O
2	O
-	O
fold	O
increase	O
in	O
viability	O
in	O
the	O
LMP1	O
transgenic	O
lymphocytes	O
compared	O
to	O
wild	O
-	O
type	O
lymphocytes	O
.	O

Two	O
examples	O
of	O
LMP1	O
transgenic	O
lymphoma	O
cells	O
had	O
greatly	O
increased	O
viability	O
that	O
was	O
not	O
increased	O
by	O
IL4	O
treatment	O
,	O
indicating	O
that	O
the	O
lymphoma	O
cells	O
are	O
independent	O
of	O
IL4	O
co	O
-	O
stimulation	O
(	O
Figure	O
3B	O
)	O
.	O

Enhancement	O
in	O
MTS	O
activity	O
was	O
observed	O
in	O
LMP1	O
transgenic	O
lymphoma	O
cells	O
by	O
the	O
addition	O
of	O
IL4	O
;	O
however	O
,	O
EMA	O
exclusion	O
did	O
not	O
reveal	O
a	O
similar	O
increase	O
.	O

This	O
could	O
reflect	O
a	O
difference	O
for	O
IL4	O
requirement	O
in	O
the	O
metabolic	O
activity	O
versus	O
the	O
viability	O
of	O
LMP1	O
transgenic	O
lymphoma	O
cells	O
.	O

Although	O
expression	B-Gene_expression
of	O
LMP1	O
could	O
enhance	O
survival	O
of	O
non	O
-	O
malignant	O
primary	O
lymphocytes	O
,	O
BrdU	O
incorporation	O
revealed	O
that	O
LMP1	O
expression	B-Gene_expression
alone	O
was	O
not	O
sufficient	O
to	O
induce	O
proliferation	O
in	O
culture	O
(	O
unpublished	O
data	O
)	O
.	O

Only	O
lymphoma	O
cells	O
had	O
detectable	O
levels	O
of	O
BrdU	O
incorporation	O
detected	O
by	O
flow	O
cytometry	O
(	O
Figure	O
3C	O
)	O
.	O

Interestingly	O
,	O
LMP1	O
lymphoma	O
cells	O
had	O
significantly	O
higher	O
levels	O
of	O
proliferation	O
in	O
comparison	O
to	O
the	O
spontaneous	O
lymphoma	O
that	O
developed	O
in	O
an	O
LMP1	O
-	O
negative	B-Negative_regulation
littermate	O
(	O
25	O
%	O
versus	O
4	O
%	O
)	O
.	O

This	O
higher	O
level	O
of	O
proliferation	O
was	O
observed	O
in	O
lymphomas	O
that	O
express	B-Gene_expression
both	O
high	B-Positive_regulation
(	O
Table	O
1	O
,	O
LMP1	O
-	O
L2	O
and	O
LMP1	O
-	O
L3	O
)	O
and	O
low	B-Positive_regulation
(	O
Table	O
1	O
,	O
LMP1	O
-	O
L5	O
)	O
levels	O
of	O
LMP1	O
,	O
suggesting	O
that	O
even	O
small	O
amounts	O
of	O
LMP1	O
is	O
sufficient	O
to	O
induce	O
dramatic	O
effects	O
in	O
proliferation	O
.	O

The	O
level	O
of	O
proliferation	O
was	O
not	O
enhanced	O
upon	O
IL4	O
addition	O
,	O
confirming	O
the	O
IL4	O
independence	O
observed	O
in	O
the	O
viability	O
studies	O
(	O
Figure	O
3C	O
;	O
Table1	O
)	O
.	O

Wild	O
-	O
Type	O
and	O
LMP1	O
Transgenic	O
Lymphoma	O
Cells	O
Do	O
Not	O
Require	O
IL4	O
and	O
Stat6	O
Signaling	O

To	O
investigate	O
whether	O
IL4	O
independence	O
was	O
due	O
to	O
endogenous	O
IL4	O
expression	B-Gene_expression
,	O
IL4	O
transcription	B-Transcription
was	O
assessed	O
by	O
an	O
Rnase	O
protection	O
assay	O
(	O
RPA	O
)	O
.	O

IL4	O
transcription	B-Transcription
was	O
detectable	O
with	O
control	O
RNA	O
and	O
faintly	O
in	O
the	O
mouse	O
lymphoma	O
cell	O
line	O
K46mu	O
(	O
Figure	O
4A	O
)	O
.	O

However	O
,	O
IL4	O
transcription	B-Transcription
was	O
not	O
detectable	O
in	O
CD19+	O
MACS	O
-	O
purified	O
B	O
cells	O
from	O
wild	O
-	O
type	O
lymphocytes	O
(	O
unpublished	O
data	O
)	O
,	O
LMP1	O
transgenic	O
lymphocytes	O
,	O
or	O
lymphoma	O
cells	O
,	O
although	O
the	O
GAPDH	O
and	O
L32	O
controls	O
were	O
effectively	O
protected	O
(	O
Figure	O
4A	O
)	O
.	O

Activated	B-Positive_regulation
Stat6	O
(	O
pStat6	O
)	O
,	O
a	O
target	B-Regulation
of	O
the	O
IL4	O
receptor	O
pathway	O
,	O
was	O
detected	O
in	O
the	O
wild	O
-	O
type	O
and	O
LMP1	O
transgenic	O
lymphocytes	O
(	O
Figure	O
4B	O
)	O
.	O

In	O
contrast	O
,	O
pStat6	O
was	O
barely	O
detected	O
in	O
either	O
the	O
wild	O
-	O
type	O
or	O
LMP1	O
transgenic	O
lymphoma	O
cells	O
.	O

However	O
,	O
the	O
pathway	O
was	O
not	O
disabled	O
,	O
as	O
treatment	O
of	O
the	O
lymphoma	O
cells	O
with	O
IL4	O
induced	B-Positive_regulation
Stat6	O
phosphorylation	B-Phosphorylation
(	O
Figure	O
4C	O
)	O
.	O

Although	O
wild	O
-	O
type	O
lymphocytes	O
can	O
not	O
be	O
maintained	O
in	O
culture	O
with	O
IL4	O
supplementation	O
alone	O
(	O
Figure	O
3A	O
)	O
,	O
slight	O
enhancement	O
in	O
MTS	O
activity	O
could	O
be	O
detected	O
if	O
the	O
cells	O
were	O
analyzed	O
at	O
an	O
earlier	O
time	O
point	O
,	O
at	O
1	O
d	O
(	O
Figure	O
4D	O
)	O
versus	O
3	O
d	O
(	O
Figure	O
3A	O
)	O
post	O
-	O
harvest	O
.	O

The	O
enhancement	O
of	O
MTS	O
activity	O
induced	O
by	O
IL4	O
in	O
wild	O
-	O
type	O
lymphocytes	O
could	O
be	O
neutralized	O
by	O
the	O
addition	O
of	O
IL4	O
antibody	O
(	O
Figure	O
4D	O
)	O
.	O

However	O
,	O
neutralizing	O
antibodies	O
to	O
IL4	O
did	O
not	O
affect	O
the	O
MTS	O
activity	O
of	O
LMP1	O
transgenic	O
lymphoma	O
cells	O
(	O
Figure	O
4E	O
)	O
.	O

In	O
summary	O
,	O
the	O
wild	O
-	O
type	O
and	O
LMP1	O
transgenic	O
lymphoma	O
cells	O
grew	O
independently	O
of	O
IL4	O
treatment	O
and	O
did	O
not	O
require	O
Stat6	O
signaling	O
.	O

LMP1	O
Upregulates	B-Positive_regulation
IL10	O
and	O
Constitutively	O
Activates	B-Positive_regulation
Stat3	O

To	O
identify	O
cytokines	O
that	O
may	O
contribute	O
to	O
the	O
increased	O
survival	O
and	O
growth	O
of	O
lymphomas	O
,	O
the	O
expression	O
levels	O
of	O
a	O
panel	O
of	O
cytokines	O
were	O
screened	O
on	O
CD19+	O
MACS	O
-	O
purified	O
B	O
cells	O
,	O
using	O
an	O
RPA	O
probe	O
set	O
for	O
IL4	O
,	O
IL5	O
,	O
IL10	O
,	O
IL13	O
,	O
IL15	O
,	O
IL9	O
,	O
IL2	O
,	O
IL6	O
,	O
and	O
IFNgamma	O
.	O

Expression	O
levels	O
were	O
quantified	O
with	O
a	O
phosphorimager	O
and	O
normalized	O
to	O
the	O
ribosomal	O
housekeeping	O
gene	O
L32	O
.	O

None	O
of	O
the	O
tested	O
cytokines	O
were	O
detected	B-Gene_expression
in	O
wild	O
-	O
type	O
lymphocytes	O
,	O
therefore	O
cytokine	O
:	O
L32	O
ratios	O
were	O
set	O
to	O
1	O
in	O
the	O
mouse	O
B	O
cell	O
lymphoma	O
line	O
967	O
.	O

Transcription	B-Transcription
of	O
IL10	O
,	O
IL15	O
,	O
and	O
IFNgamma	O
were	O
reproducibly	O
detected	O
in	O
LMP1	O
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
and	O
was	O
higher	B-Positive_regulation
than	O
in	O
the	O
B	O
cell	O
lymphoma	O
cell	O
lines	O
967	O
and	O
K46mu	O
(	O
Figure	O
5A	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
expression	B-Gene_expression
of	O
IL15	O
and	O
IFNgamma	O
between	O
LMP1	O
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
,	O
suggesting	O
that	O
upregulation	B-Positive_regulation
of	O
IL15	O
and	O
IFNgamma	O
is	O
induced	B-Positive_regulation
by	O
LMP1	O
expression	B-Gene_expression
in	O
healthy	O
lymphocytes	O
but	O
is	O
not	O
a	O
unique	O
property	O
of	O
malignant	O
lymphocytes	O
.	O

Strikingly	O
,	O
IL10	O
,	O
a	O
B	O
lymphocyte	O
stimulatory	O
cytokine	O
,	O
was	O
increased	B-Positive_regulation
1.5	O
-	O
to	O
5	O
-	O
fold	O
in	O
the	O
wild	O
-	O
type	O
and	O
LMP1	O
transgenic	O
lymphoma	O
cells	O
compared	O
to	O
LMP1	O
transgenic	O
lymphocytes	O
(	O
Figure	O
5A	O
)	O
.	O

Production	B-Gene_expression
of	O
IL15	O
and	O
IFNgamma	O
has	O
been	O
associated	O
with	O
induction	O
of	O
cytotoxic	O
effector	O
responses	O
in	O
cells	O
latently	O
infected	O
with	O
EBV	O
[	O
33	O
,	O
34	O
]	O
.	O

However	O
,	O
transformation	O
and	O
growth	O
properties	O
induced	O
by	O
EBV	O
are	O
associated	O
with	O
the	O
upregulation	B-Positive_regulation
of	O
IL10	O
[	O
35	O
-	O
38	O
]	O
;	O
hence	O
,	O
the	O
effects	O
of	O
IL10	O
upregulation	B-Positive_regulation
on	O
the	O
growth	O
properties	O
of	O
the	O
lymphoma	O
cells	O
were	O
further	O
examined	O
.	O

Immunoblot	O
analysis	O
indicated	O
that	O
LMP1	O
transgenic	O
lymphocytes	O
and	O
wild	O
-	O
type	O
and	O
LMP1	O
transgenic	O
lymphoma	O
cells	O
had	O
corresponding	O
increased	B-Positive_regulation
levels	O
of	O
phosphorylated	B-Phosphorylation
alpha	O
and	O
beta	O
isoforms	O
of	O
activated	B-Positive_regulation
Stat3	O
,	O
a	O
target	B-Regulation
of	O
the	O
IL10	O
receptor	O
(	O
Figure	O
5B	O
)	O
.	O

However	O
,	O
when	O
comparing	O
the	O
same	O
lymphomas	O
,	O
there	O
was	O
no	O
correlation	B-Regulation
between	O
the	O
levels	O
of	O
IL10	O
induction	B-Positive_regulation
and	O
the	O
levels	O
of	O
Stat3	O
activation	B-Positive_regulation
.	O

This	O
suggests	O
that	O
the	O
activation	B-Positive_regulation
of	O
Stat3	O
is	O
not	O
solely	O
induced	B-Positive_regulation
by	O
IL10	O
or	O
that	O
Stat3	O
activation	O
may	O
be	O
constitutive	O
.	O

Additionally	O
,	O
there	O
was	O
no	O
correlation	B-Regulation
between	O
the	O
levels	O
of	O
LMP1	O
expression	B-Gene_expression
and	O
the	O
levels	O
of	O
IL10	O
induction	B-Positive_regulation
(	O
Figures	O
1A	O
and	O
5A	O
)	O
.	O

This	O
indicates	O
that	O
the	O
induction	B-Positive_regulation
of	O
IL10	O
is	O
a	O
general	O
property	O
associated	O
with	O
enhanced	O
survival	O
and	O
may	O
only	O
be	O
indirectly	O
affected	B-Regulation
by	O
LMP1	O
.	O

Neutralizing	B-Negative_regulation
antibodies	O
to	O
IL10	O
did	O
not	O
affect	O
the	O
survival	O
of	O
lymphoma	O
cells	O
as	O
determined	O
by	O
the	O
MTS	O
assay	O
(	O
unpublished	O
data	O
)	O
,	O
suggesting	O
constitutive	O
activation	B-Positive_regulation
of	O
Stat3	O
.	O

This	O
was	O
confirmed	O
by	O
immunoblot	O
analysis	O
such	O
that	O
in	O
the	O
presence	O
of	O
anti	O
-	O
IL10	O
neutralizing	O
antibodies	O
,	O
pStat3	O
levels	O
remained	O
activated	B-Positive_regulation
in	O
lymphoma	O
cells	O
isolated	O
from	O
wild	O
-	O
type	O
and	O
LMP1	O
transgenic	O
lymphomas	O
(	O
Figure	O
5C	O
)	O
.	O

Exogenous	O
addition	O
of	O
IL10	O
enhanced	B-Positive_regulation
pStat3	O
activation	B-Positive_regulation
above	O
constitutive	O
levels	O
,	O
indicating	O
that	O
lymphoma	O
cells	O
are	O
responsive	O
to	O
IL10	O
treatment	O
(	O
Figure	O
5C	O
)	O
.	O

This	O
means	O
that	O
although	O
the	O
lymphoma	O
cells	O
have	O
constitutive	O
Stat3	O
activation	B-Positive_regulation
,	O
it	O
may	O
be	O
further	O
enhanced	B-Positive_regulation
by	O
IL10	O
induction	O
.	O

The	O
neutralizing	B-Negative_regulation
effect	I-Negative_regulation
of	O
the	O
anti	O
-	O
IL10	O
antibody	O
was	O
confirmed	O
by	O
pre	O
-	O
incubation	O
of	O
IL10	O
with	O
anti	O
-	O
IL10	O
antibody	O
compared	O
to	O
a	O
rat	O
IgG1	O
isotype	O
control	O
(	O
Figure	O
5C	O
)	O
.	O

Nuclear	O
translocation	B-Localization
of	O
pStat3	O
is	O
a	O
consequence	B-Positive_regulation
of	O
activation	B-Positive_regulation
,	O
and	O
nuclear	O
pStat3	O
was	O
not	O
detected	B-Localization
by	O
immunohistochemistry	O
staining	O
of	O
spleen	O
sections	O
from	O
control	O
mice	O
.	O

However	O
,	O
nuclear	O
pStat3	O
was	O
detectable	B-Localization
in	O
LMP1	O
transgenic	O
mice	O
and	O
wild	O
-	O
type	O
lymphomas	O
and	O
was	O
detected	B-Localization
more	O
homogeneously	O
in	O
LMP1	O
transgenic	O
lymphomas	O
(	O
Figure	O
5D	O
)	O
.	O

The	O
constitutive	O
activation	B-Positive_regulation
of	O
pStat3	O
and	O
abundant	O
nuclear	O
Stat3	O
suggests	O
that	O
Stat3	O
signaling	O
contributes	O
to	O
LMP1	O
-	O
mediated	O
lymphoma	O
development	O
.	O

LMP1	O
Activates	O
Akt	O
Signaling	O
and	O
Deregulates	O
the	O
Rb	O
Cell	O
Cycle	O
Pathway	O

LMP1	O
transformation	O
of	O
rodent	O
fibroblasts	O
requires	B-Positive_regulation
activation	B-Positive_regulation
of	O
PI3K	O
and	O
Akt	O
[	O
5	O
]	O
.	O

Additionally	O
,	O
activated	B-Positive_regulation
pAkt	O
is	O
frequently	O
detected	O
in	O
NPC	O
and	O
the	O
neoplastic	O
Reed	O
-	O
Sternberg	O
cells	O
of	O
classical	O
HD	O
[	O
39	O
,	O
40	O
]	O
.	O

To	O
determine	O
if	O
Akt	O
signaling	O
is	O
activated	O
in	O
LMP1	O
transgenic	O
mice	O
,	O
pAkt	O
and	O
several	O
of	O
its	O
targets	O
were	O
assessed	O
by	O
immunoblotting	O
of	O
splenic	O
CD19+	O
MACS	O
-	O
purified	O
B	O
cells	O
.	O

LMP1	O
transgenic	O
B	O
cells	O
had	O
increased	B-Positive_regulation
levels	O
of	O
pAkt	O
compared	O
to	O
wild	O
-	O
type	O
lymphocytes	O
;	O
however	O
,	O
progression	O
to	O
lymphoma	O
in	O
both	O
LMP1	O
-	O
positive	O
and	O
-	O
negative	O
lymphoma	O
cells	O
did	O
not	O
further	O
increase	B-Positive_regulation
pAkt	O
levels	O
.	O

The	O
Akt	O
target	B-Binding
glycogen	O
synthase	O
kinase	O
3	O
(	O
GSK3	O
)	O
is	O
inactivated	B-Negative_regulation
by	O
phosphorylation	O
;	O
however	O
,	O
increased	B-Positive_regulation
phosphorylated	B-Phosphorylation
GSK3	O
was	O
not	O
detected	O
in	O
the	O
transgenic	O
lymphocytes	O
and	O
was	O
almost	O
absent	O
in	O
the	O
lymphoma	O
samples	O
(	O
Figure	O
6A	O
)	O
.	O

This	O
finding	O
indicates	O
that	O
GSK3	O
is	O
not	O
a	O
target	B-Binding
of	O
activated	B-Positive_regulation
Akt	O
in	O
the	O
LMP1	O
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
.	O

Similarly	O
,	O
activation	B-Positive_regulation
of	O
Akt	O
without	O
phosphorylation	B-Phosphorylation
of	O
GSK3	O
has	O
been	O
previously	O
shown	O
in	O
EBV	O
-	O
positive	O
HD	O
[	O
40	O
]	O
.	O

In	O
contrast	O
,	O
the	O
wild	O
-	O
type	O
lymphocytes	O
lacked	O
activated	B-Positive_regulation
Akt	O
but	O
did	O
have	O
detectable	O
phosphorylated	B-Phosphorylation
GSK3	O
.	O

This	O
further	O
suggests	O
that	O
additional	O
pathways	O
are	O
involved	O
in	O
the	O
regulation	B-Regulation
of	O
GSK3	O
.	O

To	O
identify	O
other	O
potential	O
Akt	O
targets	B-Binding
,	O
immunoblot	O
analysis	O
for	O
p	O
-	O
mTOR	O
was	O
performed	O
.	O

Activated	B-Positive_regulation
p	O
-	O
mTOR	O
was	O
not	O
increased	B-Positive_regulation
in	O
LMP1	O
transgenic	O
lymphocytes	O
or	O
lymphoma	O
cells	O
,	O
indicating	O
that	O
this	O
pathway	O
is	O
not	O
affected	B-Regulation
by	O
LMP1	O
-	O
induced	B-Positive_regulation
Akt	O
activation	B-Positive_regulation
and	O
does	O
not	O
contribute	O
to	O
lymphoma	O
development	O
(	O
Figure	O
6B	O
)	O
.	O

Akt	O
is	O
also	O
known	O
to	O
phosphorylate	O
and	O
induce	O
the	O
degradation	O
of	O
the	O
pro	O
-	O
apoptotic	O
Forkhead	O
family	O
of	O
transcription	O
factors	O
,	O
leading	O
to	O
cell	O
cycle	O
progression	O
and	O
survival	O
in	O
some	O
human	O
tumors	O
[	O
41	O
,	O
42	O
]	O
.	O

Immunoblot	O
analysis	O
of	O
splenic	O
B	O
cells	O
did	O
not	O
consistently	O
detect	O
p	O
-	O
FoxO1	O
levels	O
,	O
a	O
signal	O
that	O
targets	B-Regulation
FoxO1	O
for	O
degradation	O
.	O

Hence	O
,	O
degradation	O
of	O
FoxO1	O
was	O
assessed	O
by	O
detection	O
of	O
total	O
FoxO1	O
levels	O
.	O

Immunoblot	O
analysis	O
indicated	O
that	O
total	O
FoxO1	O
levels	O
were	O
greatly	O
decreased	B-Negative_regulation
in	O
wild	O
-	O
type	O
and	O
LMP1	O
transgenic	O
lymphomas	O
(	O
Figure	O
6B	O
)	O
,	O
suggesting	O
that	O
inhibition	O
of	O
the	O
Forkhead	O
signaling	O
pathway	O
is	O
an	O
important	O
target	O
of	O
Akt	O
in	O
lymphoma	O
development	O
.	O

However	O
,	O
considering	O
that	O
Akt	O
activation	B-Positive_regulation
did	O
not	O
induce	B-Positive_regulation
FoxO1	O
degradation	B-Negative_regulation
in	O
LMP1	O
transgenic	O
B	O
cells	O
,	O
Akt	O
may	O
not	O
be	O
the	O
sole	O
regulator	B-Regulation
of	O
FoxO1	O
,	O
and	O
it	O
may	O
be	O
that	O
progression	O
to	O
lymphoma	O
requires	O
modulation	O
of	O
multiple	O
pathways	O
.	O

The	O
Forkhead	O
family	O
of	O
transcription	O
factors	O
is	O
known	O
to	O
induce	O
the	O
expression	B-Gene_expression
of	O
the	O
Cdk	O
inhibitor	O
p27	O
[	O
43	O
,	O
44	O
]	O
.	O

LMP1	O
-	O
transformed	O
rodent	O
fibroblasts	O
have	O
decreased	O
expression	O
of	O
p27	O
,	O
upregulation	O
of	O
Cdk2	O
,	O
and	O
subsequent	O
phosphorylation	O
and	O
inactivation	O
of	O
the	O
tumor	O
suppressor	O
gene	O
Rb	O
[	O
45	O
]	O
.	O

To	O
investigate	O
whether	O
LMP1	O
affected	O
cell	O
cycle	O
regulation	O
through	O
the	O
Rb	O
pathway	O
in	O
B	O
cells	O
,	O
immunoblot	O
analyses	O
for	O
pRb	O
,	O
Cdk2	O
,	O
and	O
p27	O
were	O
performed	O
on	O
splenic	O
CD19+	O
MACS	O
-	O
purified	O
B	O
cells	O
.	O

LMP1	O
transgenic	O
B	O
cells	O
had	O
enhanced	B-Positive_regulation
levels	O
of	O
pRb	O
with	O
concomitant	O
stabilization	O
of	O
total	O
Rb	O
levels	O
and	O
Cdk2	O
compared	O
to	O
wild	O
-	O
type	O
B	O
lymphocytes	O
(	O
Figure	O
6C	O
)	O
.	O

Progression	O
to	O
lymphoma	O
in	O
both	O
wild	O
-	O
type	O
and	O
LMP1	O
transgenic	O
lymphoma	O
cells	O
led	B-Positive_regulation
to	O
increased	B-Positive_regulation
levels	O
of	O
Rb	O
,	O
correspondingly	O
high	B-Positive_regulation
levels	I-Positive_regulation
of	O
Cdk2	O
,	O
and	O
decreased	B-Negative_regulation
levels	O
of	O
p27	O
(	O
Figure	O
6C	O
)	O
.	O

These	O
data	O
indicate	O
that	O
the	O
Rb	O
pathway	O
is	O
deregulated	O
in	O
LMP1	O
transgenic	O
lymphocytes	O
and	O
that	O
lymphoma	O
cells	O
are	O
distinguished	O
by	O
loss	B-Negative_regulation
of	O
FoxO1	O
and	O
decreased	B-Negative_regulation
p27	O
.	O

LMP1	O
Promotes	O
Tumor	O
Growth	O
and	O
Survival	O
through	O
Activation	O
of	O
Akt	O
,	O
NFkappaB	O
,	O
and	O
Stat3	O
Pathways	O

To	O
explore	O
which	O
pathways	O
were	O
required	O
for	O
the	O
enhanced	O
growth	O
and	O
survival	O
of	O
LMP1	O
-	O
induced	O
lymphomas	O
,	O
splenocytes	O
from	O
wild	O
-	O
type	O
and	O
LMP1	O
transgenic	O
mice	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
inhibitors	B-Negative_regulation
for	O
Akt	O
,	O
NFkappaB	O
,	O
Stat3	O
,	O
mTOR	O
,	O
or	O
MAPK	O
and	O
assayed	O
for	O
growth	O
and	O
survival	O
by	O
the	O
MTS	O
assay	O
.	O

As	O
previously	O
shown	O
,	O
wild	O
-	O
type	O
lymphocytes	O
were	O
not	O
viable	O
in	O
culture	O
and	O
could	O
not	O
be	O
tested	O
with	O
the	O
inhibitors	O
.	O

However	O
,	O
the	O
enhanced	O
viability	O
of	O
LMP1	O
transgenic	O
lymphocytes	O
was	O
effectively	O
blocked	O
by	O
treatment	O
with	O
triciribine	O
,	O
BAY11	O
-	O
7085	O
,	O
cucurbitacin	O
I	O
,	O
and	O
slightly	O
with	O
SB203580	O
,	O
but	O
not	O
by	O
treatment	O
with	O
rapamycin	O
,	O
U0126	O
,	O
or	O
AG490	O
(	O
Figure	O
7	O
)	O
.	O

Triciribine	O
inhibits	B-Negative_regulation
the	O
activation	B-Positive_regulation
of	O
Akt	O
and	O
at	O
20	O
muM	O
has	O
been	O
shown	O
to	O
induce	O
growth	O
arrest	O
in	O
cancer	O
cells	O
with	O
aberrant	O
Akt	O
activity	O
[	O
46	O
]	O
.	O

The	O
effects	O
of	O
triciribine	O
on	O
cell	O
growth	O
of	O
the	O
transgenic	O
lymphocytes	O
and	O
lymphomas	O
were	O
apparent	O
as	O
low	O
as	O
1	O
muM	O
,	O
suggesting	O
that	O
activation	B-Positive_regulation
of	O
Akt	O
is	O
required	O
for	O
the	O
survival	O
and	O
growth	O
of	O
LMP1	O
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
(	O
Figure	O
7	O
)	O
.	O

The	O
effects	O
of	O
the	O
inhibitors	O
were	O
assessed	O
by	O
identifying	O
phosphorylated	B-Phosphorylation
Akt	O
,	O
Stat3	O
,	O
and	O
total	O
levels	O
of	O
IkappaBalpha	O
(	O
Figure	O
8	O
)	O
.	O

Treatment	O
with	O
triciribine	O
effectively	O
blocked	B-Negative_regulation
phosphorylation	B-Phosphorylation
of	O
Akt	O
,	O
and	O
phosphorylated	B-Phosphorylation
Akt	O
was	O
no	O
longer	O
detected	B-Positive_regulation
past	O
5	O
muM	O
.	O

Phosphorylated	B-Phosphorylation
Stat3	O
and	O
IkappaBalpha	O
were	O
still	O
present	O
at	O
25	O
muM	O
.	O

These	O
findings	O
suggest	O
that	O
triciribine	O
specifically	O
targets	B-Regulation
Akt	O
and	O
that	O
Akt	O
activation	B-Positive_regulation
is	O
required	O
for	O
the	O
enhanced	O
viability	O
of	O
the	O
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
.	O

Inhibition	O
of	O
NFkappaB	O
signaling	O
rapidly	O
induces	O
cell	O
death	O
of	O
EBV	O
-	O
transformed	O
lymphocytes	O
[	O
17	O
,	O
18	O
]	O
.	O

BAY11	O
-	O
7085	O
,	O
an	O
inhibitor	O
of	O
NFkappaB	O
signaling	O
,	O
also	O
greatly	O
decreased	O
the	O
viability	O
of	O
the	O
LMP1	O
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
at	O
doses	O
as	O
low	O
as	O
1	O
muM	O
,	O
and	O
at	O
5	O
muM	O
the	O
cells	O
were	O
completely	O
nonviable	O
(	O
Figure	O
7	O
)	O
.	O

This	O
is	O
well	O
within	O
the	O
reported	O
IC50	O
of	O
10	O
muM	O
.	O

Phosphorylated	B-Phosphorylation
Akt	O
,	O
Stat3	O
,	O
and	O
total	O
IkappaBalpha	O
were	O
still	O
present	B-Positive_regulation
up	O
to	O
treatment	O
with	O
15	O
muM	O
and	O
then	O
were	O
no	O
longer	O
detected	B-Positive_regulation
(	O
Figure	O
8	O
)	O
.	O

This	O
finding	O
suggests	O
that	O
inhibition	O
of	O
NFkappaB	O
can	O
induce	O
cell	O
death	O
in	O
LMP1	O
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
without	O
significant	O
effects	B-Regulation
on	O
activation	B-Positive_regulation
of	O
Akt	O
or	O
Stat3	O
.	O

Cucurbitacin	O
I	O
inhibits	B-Negative_regulation
activation	B-Positive_regulation
of	O
Stat3	O
by	O
suppressing	O
the	O
activation	O
of	O
its	O
kinase	O
JAK2	O
.	O

It	O
has	O
been	O
shown	O
to	O
selectively	O
inhibit	O
the	O
growth	O
of	O
tumors	O
with	O
constitutively	O
activated	B-Positive_regulation
Stat3	O
[	O
47	O
]	O
.	O

Similarly	O
,	O
LMP1	O
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
were	O
susceptible	O
to	O
cucurbitacin	O
I	O
treatment	O
starting	O
at	O
0.1	O
muM	O
,	O
a	O
dose	O
that	O
corresponds	O
closely	O
to	O
the	O
reported	O
IC50	O
of	O
500	O
nM	O
(	O
Figure	O
7	O
)	O
[	O
47	O
]	O
.	O

Phosphorylated	B-Phosphorylation
Akt	O
,	O
Stat3	O
,	O
and	O
total	O
IkappaBalpha	O
were	O
not	O
detectable	B-Positive_regulation
past	O
1	O
muM	O
and	O
at	O
higher	O
doses	O
all	O
protein	O
levels	O
were	O
greatly	O
decreased	B-Negative_regulation
,	O
indicative	O
of	O
the	O
total	O
loss	O
of	O
viability	O
(	O
Figure	O
8	O
)	O
.	O

A	O
second	O
reported	O
inhibitor	B-Negative_regulation
of	O
Stat3	O
,	O
AG490	O
,	O
had	O
no	O
effect	O
on	O
growth	O
(	O
Figure	O
7	O
)	O
,	O
but	O
activation	O
of	O
Akt	O
,	O
Stat3	O
,	O
or	O
levels	O
of	O
IkappaBalpha	O
were	O
also	O
not	O
affected	B-Regulation
(	O
Figure	O
8	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
inhibition	B-Negative_regulation
of	O
Stat3	O
can	O
induce	O
cell	O
death	O
in	O
LMP1	O
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
,	O
but	O
Stat3	O
inhibition	B-Negative_regulation
also	O
has	O
considerable	O
crossover	O
effects	O
on	O
Akt	O
and	O
NFkappaB	O
signaling	O
.	O

LMP1	O
has	O
also	O
been	O
shown	O
to	O
activate	O
JNK	O
and	O
p38	O
MAPK	O
pathways	O
[	O
13	O
,	O
48	O
]	O
,	O
and	O
LMP1	O
transgenic	O
lymphocytes	O
were	O
mildly	O
susceptible	O
to	O
growth	O
inhibition	O
by	O
SB202190	O
,	O
an	O
inhibitor	O
of	O
p38	O
MAPK	O
,	O
but	O
not	O
U0126	O
,	O
an	O
inhibitor	B-Negative_regulation
of	O
MEK1/2	O
activity	O
.	O

However	O
,	O
effects	O
of	O
SB202190	O
were	O
only	O
apparent	O
at	O
high	O
doses	O
(	O
>	O
10	O
muM	O
)	O
,	O
much	O
higher	O
than	O
the	O
reported	O
IC50	O
of	O
0.35	O
muM	O
,	O
suggesting	O
that	O
p38	O
MAPK	O
does	O
not	O
significantly	O
contribute	O
to	O
the	O
enhanced	O
viability	O
in	O
LMP1	O
transgenic	O
lymphocytes	O
or	O
lymphoma	O
cells	O
(	O
Figure	O
7	O
)	O
.	O

Interestingly	O
,	O
both	O
wild	O
-	O
type	O
and	O
LMP1	O
transgenic	O
lymphomas	O
were	O
similarly	O
susceptible	O
to	O
triciribine	O
,	O
BAY11	O
-	O
7085	O
,	O
and	O
cucurbitacin	O
I	O
treatments	O
,	O
but	O
not	O
SB202190	O
,	O
AG490	O
,	O
or	O
U0126	O
treatment	O
,	O
suggesting	O
that	O
activation	O
of	O
Akt	O
,	O
NFkappaB	O
,	O
and	O
Stat3	O
but	O
not	O
MAPK	O
pathways	O
are	O
characteristics	O
associated	O
with	O
malignant	O
transformation	O
(	O
Figure	O
7	O
)	O
.	O

rapamycin	O
,	O
an	O
inhibitor	B-Negative_regulation
of	O
mTOR	O
,	O
did	O
not	O
affect	O
the	O
viability	O
of	O
the	O
transgenic	O
lymphocytes	O
or	O
lymphoma	O
cells	O
,	O
confirming	O
that	O
mTOR	O
is	O
not	O
targeted	B-Regulation
by	O
Akt	O
activation	O
in	O
LMP1	O
transgenic	O
lymphocytes	O
or	O
malignant	O
lymphoma	O
cells	O
(	O
Figure	O
7	O
)	O
.	O

Discussion	O

This	O
study	O
defines	O
the	O
oncogenic	O
properties	O
of	O
LMP1	O
in	O
promoting	O
B	O
cell	O
lymphomagenesis	O
.	O

LMP1	O
transgenic	O
mice	O
have	O
a	O
higher	O
incidence	O
of	O
lymphoma	O
[	O
26	O
]	O
and	O
the	O
progression	O
to	O
lymphoma	O
correlates	O
with	O
higher	B-Positive_regulation
expression	B-Gene_expression
levels	O
of	O
LMP1	O
(	O
Figure	O
1A	O
and	O
1B	O
)	O
,	O
suggesting	O
that	O
LMP1	O
is	O
directly	O
involved	O
in	O
tumor	O
development	O
.	O

Table	O
1	O
summarizes	O
the	O
biological	O
and	O
molecular	O
properties	O
that	O
were	O
identified	O
in	O
wild	O
-	O
type	O
and	O
LMP1	O
transgenic	O
lymphomas	O
.	O

Although	O
many	O
of	O
the	O
molecular	O
properties	O
studied	O
were	O
similar	O
between	O
wild	O
-	O
type	O
and	O
LMP1	O
transgenic	O
lymphomas	O
,	O
there	O
were	O
distinguishing	O
biological	O
properties	O
,	O
namely	O
the	O
ability	O
of	O
LMP1	O
transgenic	O
lymphomas	O
to	O
induce	O
higher	O
levels	O
of	O
survival	O
and	O
proliferation	O
.	O

Interestingly	O
,	O
although	O
LMP1	O
transgenic	O
mice	O
develop	O
lymphomas	O
in	O
the	O
same	O
B	O
-	O
1a	O
cell	O
type	O
as	O
spontaneous	O
wild	O
-	O
type	O
lymphomas	O
(	O
Figure	O
2	O
)	O
,	O
some	O
signaling	O
effects	O
induced	O
by	O
LMP1	O
may	O
explain	O
the	O
enhanced	O
promotion	O
to	O
lymphomagenesis	O
.	O

Since	O
CD40	O
-	O
deficient	B-Negative_regulation
mice	O
have	O
decreased	O
numbers	O
of	O
IgMhighIgDlow	O
cells	O
,	O
a	O
phenotype	O
associated	O
with	O
B	O
-	O
1	O
,	O
marginal	O
zone	O
,	O
and	O
memory	O
B	O
cells	O
,	O
the	O
mimicry	O
of	O
CD40	O
signaling	O
by	O
LMP1	O
could	O
possibly	O
contribute	O
to	O
the	O
expansion	O
of	O
B	O
-	O
1	O
cells	O
[	O
20	O
]	O
.	O

It	O
is	O
noteworthy	O
that	O
expression	B-Gene_expression
of	O
LMP1	O
in	O
transgenic	O
mice	O
has	O
been	O
shown	O
to	O
inhibit	O
the	O
formation	O
of	O
GCs	O
[	O
23	O
,	O
49	O
]	O
,	O
preventing	O
typical	O
B	O
-	O
2	O
cells	O
from	O
antigen	O
-	O
driven	O
selection	O
and	O
expansion	O
.	O

The	O
lack	O
of	O
GC	O
reactions	O
may	O
contribute	O
to	O
the	O
bias	O
of	O
LMP1	O
transgenic	O
mice	O
towards	O
B	O
-	O
1	O
cell	O
lymphomas	O
.	O

Interestingly	O
,	O
LMP2	O
signaling	O
also	O
favors	O
development	O
of	O
B	O
-	O
1	O
cells	O
,	O
but	O
this	O
occurs	O
in	O
the	O
absence	O
of	O
transformation	O
.	O

These	O
results	O
suggest	O
that	O
the	O
mimicry	O
of	O
B	O
cell	O
receptor	O
signaling	O
by	O
LMP2	O
promotes	O
B	O
-	O
1	O
cell	O
differentiation	O
but	O
not	O
transformation	O
[	O
24	O
,	O
50	O
,	O
51	O
]	O
.	O

This	O
promotion	O
of	O
B	O
-	O
1	O
differentiation	O
may	O
account	O
for	O
the	O
ability	O
of	O
LMP2	O
to	O
exacerbate	O
autoimmunity	O
and	O
bypass	O
anergy	O
induction	O
[	O
52	O
,	O
53	O
]	O
.	O

In	O
contrast	O
,	O
the	O
preponderance	O
of	O
tumors	O
of	O
B	O
-	O
1a	O
origin	O
does	O
not	O
reflect	O
effects	O
of	O
LMP1	O
signaling	O
on	O
B	O
cell	O
differentiation	O
,	O
as	O
splenic	O
B	O
cells	O
from	O
healthy	O
LMP1	O
transgenic	O
mice	O
contain	O
similar	O
numbers	O
of	O
B	O
-	O
1	O
and	O
B	O
-	O
2	O
cells	O
as	O
wild	O
-	O
type	O
mice	O
.	O

In	O
support	O
of	O
this	O
lack	O
of	O
effect	O
,	O
the	O
differentiation	O
of	O
B	O
-	O
1	O
versus	O
B	O
-	O
2	O
cells	O
is	O
thought	O
to	O
be	O
independent	O
of	O
CD40	O
signaling	O
[	O
54	O
]	O
.	O

B	O
-	O
1	O
cells	O
constitute	O
the	O
predominant	O
lymphocyte	O
population	O
in	O
the	O
peritoneal	O
and	O
pleuropericardial	O
cavities	O
,	O
while	O
B	O
-	O
2	O
cells	O
are	O
mainly	O
found	O
in	O
the	O
spleen	O
,	O
lymph	O
node	O
,	O
and	O
peripheral	O
blood	O
.	O

B	O
-	O
1	O
cells	O
produce	O
the	O
main	O
source	O
of	O
IgM	O
and	O
IgA	O
antibodies	O
in	O
serum	O
,	O
which	O
are	O
involved	O
in	O
T	O
cell	O
-	O
independent	O
responses	O
to	O
common	O
microbial	O
antigens	O
.	O

Importantly	O
,	O
B	O
-	O
1	O
cells	O
have	O
the	O
unique	O
capacity	O
to	O
self	O
replenish	O
and	O
are	O
also	O
predisposed	O
to	O
transformation	O
[	O
28	O
,	O
29	O
]	O
.	O

Clonal	O
expansion	O
of	O
B	O
-	O
1	O
cells	O
can	O
be	O
detected	O
in	O
aging	O
mice	O
above	O
18	O
mo	O
of	O
age	O
,	O
and	O
B	O
-	O
1	O
cells	O
are	O
thought	O
to	O
be	O
the	O
murine	O
progenitor	O
of	O
B	O
cell	O
chronic	O
lymphocytic	O
leukemia	O
[	O
30	O
]	O
.	O

The	O
data	O
presented	O
in	O
this	O
study	O
indicate	O
that	O
although	O
LMP1	O
is	O
expressed	B-Gene_expression
in	O
all	O
B	O
lymphocytes	O
in	O
the	O
transgenic	O
mice	O
,	O
malignancy	O
develops	O
in	O
this	O
specific	O
subset	O
of	O
B	O
cells	O
.	O

The	O
elevated	B-Positive_regulation
expression	B-Gene_expression
of	O
LMP1	O
in	O
B	O
-	O
1a	O
cells	O
and	O
the	O
activation	O
of	O
specific	O
pathways	O
apparently	O
induce	O
malignant	O
growth	O
.	O

These	O
same	O
pathways	O
can	O
also	O
become	O
sporadically	O
activated	O
in	O
aged	O
mice	O
and	O
also	O
result	O
in	O
lymphoma	O
development	O
.	O

This	O
is	O
similar	O
to	O
EBV	O
-	O
associated	O
cancers	O
in	O
vivo	O
,	O
where	O
pathways	O
that	O
are	O
activated	O
by	O
LMP1	O
are	O
also	O
activated	O
in	O
the	O
less	O
prevalent	O
EBV	O
-	O
negative	O
forms	O
of	O
the	O
cancers	O
[	O
40	O
,	O
55	O
-	O
58	O
]	O
.	O

Thus	O
,	O
the	O
contribution	O
of	O
EBV	O
and	O
LMP1	O
to	O
tumor	O
development	O
is	O
apparently	O
the	O
continuous	O
activation	O
of	O
pathways	O
that	O
can	O
also	O
be	O
sporadically	O
activated	O
and	O
contribute	O
to	O
tumor	O
development	O
.	O

The	O
lymphomas	O
were	O
marked	O
by	O
the	O
upregulation	B-Positive_regulation
of	O
IL10	O
,	O
constitutive	O
activation	O
of	O
Stat3	O
signaling	O
,	O
and	O
a	O
requirement	O
for	O
activation	O
of	O
Akt	O
,	O
NFkappaB	O
,	O
and	O
Stat3	O
pathways	O
(	O
Figures	O
5	O
and	O
7	O
)	O
.	O

Induction	B-Positive_regulation
of	O
IL10	O
is	O
associated	O
with	O
the	O
transformation	O
of	O
B	O
-	O
1	O
lymphomas	O
in	O
mice	O
[	O
59	O
,	O
60	O
]	O
and	O
is	O
frequently	O
associated	O
with	O
EBV	O
-	O
positive	O
B	O
cell	O
malignancies	O
acting	O
as	O
a	O
B	O
cell	O
growth	O
factor	O
[	O
35	O
-	O
38	O
]	O
.	O

In	O
addition	O
,	O
LMP1	O
has	O
been	O
shown	O
to	O
stimulate	B-Positive_regulation
IL10	O
expression	B-Gene_expression
in	O
Burkitt	O
lymphoma	O
cell	O
lines	O
[	O
61	O
,	O
62	O
]	O
.	O

This	O
suggests	O
that	O
although	O
Stat3	O
is	O
constitutively	O
activated	B-Positive_regulation
in	O
the	O
lymphoma	O
cells	O
,	O
the	O
induction	B-Positive_regulation
of	O
IL10	O
may	O
further	O
enhance	B-Positive_regulation
Stat3	O
activation	B-Positive_regulation
or	O
may	O
contribute	O
to	O
other	O
IL10	O
-	O
responsive	O
signaling	O
pathways	O
.	O

LMP1	O
activates	O
both	O
the	O
canonical	O
and	O
non	O
-	O
canonical	O
pathways	O
of	O
NFkappaB	O
signaling	O
[	O
14	O
,	O
63	O
-	O
65	O
]	O
,	O
and	O
inhibition	O
of	O
NFkappaB	O
blocked	O
the	O
survival	O
of	O
LMP1	O
transgenic	O
lymphocytes	O
and	O
LMP1	O
-	O
positive	O
and	O
-	O
negative	O
lymphoma	O
cells	O
.	O

NFkappaB	O
and	O
PI3K	O
signaling	O
are	O
crucial	O
for	O
CD40	O
-	O
induced	O
proliferation	O
,	O
and	O
mice	O
deficient	B-Negative_regulation
for	O
cRel	O
or	O
the	O
p85	O
regulatory	O
subunit	O
of	O
PI3K	O
are	O
unresponsive	O
to	O
mitogenic	O
stimuli	O
,	O
including	O
CD40	O
ligation	B-Binding
[	O
66	O
-	O
68	O
]	O
.	O

We	O
have	O
previously	O
shown	O
that	O
cRel	O
is	O
specifically	O
activated	B-Positive_regulation
in	O
both	O
wild	O
-	O
type	O
and	O
LMP1	O
transgenic	O
lymphomas	O
,	O
suggesting	O
that	O
activation	B-Positive_regulation
of	O
cRel	O
is	O
associated	O
with	O
B	O
cell	O
transformation	O
[	O
27	O
]	O
.	O

Our	O
observations	O
suggest	O
that	O
similar	O
to	O
CD40	O
-	O
induced	O
proliferation	O
,	O
LMP1	O
induces	B-Positive_regulation
proliferation	O
through	O
PI3K	O
-	O
mediated	O
activation	B-Positive_regulation
of	O
Akt	O
and	O
activation	B-Positive_regulation
of	O
NFkappaB	O
components	O
such	O
as	O
cRel	O
.	O

CD40	O
also	O
induces	B-Positive_regulation
downregulation	B-Negative_regulation
of	O
the	O
cell	O
cycle	O
inhibitor	O
p27	O
through	O
a	O
PI3K	O
-	O
dependent	O
manner	O
,	O
and	O
the	O
LMP1	O
lymphoma	O
cells	O
also	O
had	O
decreased	B-Negative_regulation
levels	O
of	O
p27	O
with	O
phosphorylation	B-Phosphorylation
of	O
Rb	O
and	O
increased	B-Positive_regulation
Cdk2	O
(	O
Figure	O
6C	O
)	O
[	O
66	O
]	O
.	O

Although	O
LMP1	O
has	O
been	O
shown	O
to	O
deregulate	O
the	O
Rb	O
pathway	O
in	O
epithelial	O
cells	O
[	O
69	O
]	O
,	O
to	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
demonstration	O
of	O
this	O
property	O
in	O
B	O
lymphocytes	O
.	O

The	O
requirement	B-Positive_regulation
for	O
Akt	O
activation	B-Positive_regulation
was	O
confirmed	O
by	O
the	O
striking	O
inhibition	O
of	O
lymphoma	O
viability	O
by	O
triciribine	O
,	O
an	O
Akt	O
inhibitor	B-Negative_regulation
.	O

However	O
,	O
the	O
activated	B-Positive_regulation
pAkt	O
did	O
not	O
lead	B-Positive_regulation
to	O
phosphorylation	B-Phosphorylation
and	O
inactivation	B-Negative_regulation
of	O
the	O
downstream	O
target	O
GSK3	O
(	O
Figure	O
6A	O
)	O
.	O

This	O
effect	O
has	O
also	O
been	O
described	O
in	O
EBV	O
-	O
positive	O
HD	O
biopsies	O
[	O
40	O
]	O
.	O

In	O
contrast	O
,	O
rapamycin	O
,	O
U0126	O
,	O
and	O
SB202190	O
did	O
not	O
affect	O
the	O
survival	O
of	O
LMP1	O
transgenic	O
lymphocytes	O
or	O
the	O
wild	O
-	O
type	O
and	O
LMP1	O
transgenic	O
lymphoma	O
cells	O
(	O
Figure	O
7A	O
,	O
7C	O
,	O
and	O
7E	O
)	O
.	O

This	O
lack	O
of	O
effect	O
by	O
rapamycin	O
confirmed	O
the	O
absence	B-Negative_regulation
of	O
activated	B-Positive_regulation
p	O
-	O
mTOR	O
levels	O
(	O
Figure	O
6B	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
other	O
Akt	O
targets	O
contribute	O
to	O
malignant	O
progression	O
.	O

One	O
key	O
target	B-Regulation
is	O
likely	O
the	O
inhibition	B-Negative_regulation
of	O
the	O
Fox01	O
transcription	O
factors	O
.	O

Repression	B-Negative_regulation
of	O
the	O
pro	O
-	O
apoptotic	O
transcription	O
factor	O
FoxO1	O
in	O
a	O
PI3K	O
-	O
dependent	O
manner	O
can	O
inhibit	B-Negative_regulation
expression	B-Gene_expression
of	O
bcl6	O
,	O
a	O
transcription	O
factor	O
necessary	O
for	O
GC	O
formation	O
[	O
49	O
,	O
70	O
]	O
.	O

It	O
has	O
been	O
shown	O
that	O
overstimulation	O
of	O
CD40	O
signaling	O
with	O
agonistic	O
antibodies	O
inhibits	O
GC	O
formation	O
[	O
71	O
]	O
.	O

Similarly	O
,	O
due	O
to	O
mimicry	O
of	O
CD40	O
signaling	O
,	O
transgenic	O
LMP1	O
mice	O
are	O
also	O
defective	O
in	O
GC	O
formation	O
[	O
23	O
,	O
49	O
]	O
.	O

The	O
constitutive	O
signaling	O
by	O
LMP1	O
likely	O
blocks	O
GC	O
formation	O
through	O
downregulation	B-Negative_regulation
of	O
bcl6	O
.	O

Interestingly	O
,	O
clinical	O
studies	O
indicate	O
that	O
expression	B-Gene_expression
of	O
LMP1	O
and	O
bcl6	O
are	O
mutually	O
exclusive	B-Negative_regulation
in	O
non	O
-	O
HD	O
and	O
classical	O
HD	O
[	O
72	O
,	O
73	O
]	O
.	O

Thus	O
,	O
the	O
LMP1	O
transgenic	O
lymphomas	O
mirror	O
aspects	O
of	O
EBV	O
-	O
induced	O
HD	O
.	O

Although	O
the	O
activation	B-Positive_regulation
of	O
Akt	O
and	O
the	O
lack	B-Negative_regulation
of	O
Fox01	O
in	O
the	O
lymphoma	O
cells	O
suggest	O
that	O
LMP1	O
affects	B-Regulation
bcl6	O
and	O
GC	O
formation	O
through	O
this	O
pathway	B-Regulation
,	O
regulation	B-Regulation
of	O
other	O
Forkhead	O
targets	O
involved	O
in	O
cell	O
cycle	O
progression	O
,	O
such	O
as	O
p27	O
and	O
CyclinD2	O
,	O
likely	O
contribute	O
to	O
malignant	O
transformation	O
.	O

Indeed	O
,	O
loss	B-Negative_regulation
of	O
FoxO1	O
expression	B-Gene_expression
in	O
lymphoma	O
cells	O
correlated	B-Positive_regulation
with	O
a	O
loss	B-Negative_regulation
of	O
p27	O
(	O
Figure	O
6B	O
and	O
6C	O
)	O
.	O

CyclinD2	O
has	O
also	O
been	O
shown	O
to	O
be	O
upregulated	B-Positive_regulation
by	O
LMP1	O
through	O
release	O
of	O
FoxO1	O
-	O
mediated	O
repression	O
[	O
70	O
]	O
.	O

In	O
summary	O
,	O
in	O
this	O
transgenic	O
model	O
of	O
lymphomagenesis	O
,	O
LMP1	O
promotes	O
malignancy	O
in	O
B	O
-	O
1a	O
cells	O
,	O
a	O
population	O
that	O
is	O
predisposed	O
to	O
clonal	O
expansion	O
with	O
age	O
.	O

The	O
malignant	O
lymphocytes	O
were	O
distinguished	O
by	O
constitutively	O
active	O
Stat3	O
signaling	O
,	O
decreased	B-Negative_regulation
p27	O
,	O
and	O
activated	O
Akt	O
and	O
NFkappaB	O
pathways	O
,	O
properties	O
that	O
are	O
associated	O
with	O
promoting	O
the	O
growth	O
and	O
survival	O
of	O
B	O
lymphocytes	O
.	O

Importantly	O
,	O
Akt	O
,	O
NFkappaB	O
,	O
and	O
Stat3	O
pathways	O
were	O
critically	O
required	O
for	O
the	O
growth	O
and	O
survival	O
of	O
malignant	O
lymphocytes	O
as	O
well	O
as	O
healthy	O
LMP1	O
transgenic	O
lymphocytes	O
.	O

The	O
growth	O
of	O
EBV	O
-	O
transformed	O
lymphocytes	O
also	O
requires	O
activation	O
of	O
NFkappaB	O
,	O
and	O
these	O
studies	O
provide	O
insight	O
into	O
how	O
LMP1	O
contributes	O
to	O
EBV	O
-	O
associated	O
transformation	O
.	O

The	O
transgenic	O
lymphomas	O
mirror	O
multiple	O
aspects	O
of	O
EBV	O
-	O
induced	O
tumors	O
and	O
suggest	O
that	O
in	O
vivo	O
these	O
properties	O
of	O
LMP1	O
are	O
major	O
factors	O
in	O
the	O
development	O
of	O
cancer	O
.	O

Transgenic	O
mice	O
.	O

Generation	O
of	O
LMP1	O
mice	O
under	O
the	O
Ig	O
heavy	O
chain	O
promoter	O
and	O
enhancer	O
have	O
been	O
described	O
previously	O
and	O
were	O
maintained	O
as	O
heterozygotes	O
on	O
a	O
Balbc	O
background	O
[	O
26	O
]	O
.	O

LMP1	O
mice	O
were	O
genotyped	O
by	O
Southern	O
blot	O
and	O
PCR	O
analysis	O
of	O
tail	O
DNA	O
as	O
described	O
previously	O
[	O
26	O
]	O
.	O

Spleen	O
and	O
liver	O
sections	O
were	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
and	O
embedded	O
in	O
paraffin	O
,	O
and	O
5	O
-	O
mum	O
sections	O
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
for	O
histopathological	O
analysis	O
.	O

Lymphomas	O
were	O
passaged	O
by	O
intraperitoneal	O
injection	O
of	O
1	O
x	O
108	O
splenocytes	O
into	O
SCID	O
mice	O
and	O
sacrificed	O
upon	O
development	O
of	O
an	O
extended	O
abdomen	O
.	O

Animals	O
were	O
housed	O
in	O
the	O
Association	O
for	O
Assessment	O
and	O
Accreditation	O
for	O
Animal	O
Care	O
-	O
approved	O
animal	O
facility	O
at	O
the	O
University	O
of	O
North	O
Carolina	O
at	O
Chapel	O
Hill	O
.	O

All	O
protocols	O
were	O
approved	O
by	O
the	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
.	O

Isolation	O
and	O
growth	O
of	O
B	O
cells	O
.	O

Splenocytes	O
were	O
prepared	O
by	O
homogenizing	O
spleen	O
tissue	O
with	O
two	O
frosted	O
slides	O
and	O
debris	O
was	O
filtered	O
through	O
a	O
100	O
-	O
mum	O
cell	O
strainer	O
.	O

Erythrocytes	O
were	O
lysed	O
using	O
0.8	O
%	O
ammonium	O
chloride	O
solution	O
(	O
StemCell	O
Technologies	O
)	O
for	O
10	O
min	O
on	O
ice	O
and	O
washed	O
twice	O
with	O
PBS	O
.	O

B	O
cells	O
were	O
isolated	O
using	O
CD19	O
-	O
MACS	O
beads	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
(	O
Miltenyi	O
Biotec	O
)	O
and	O
grown	O
in	O
Iscove	O
's	O
medium	O
supplemented	O
with	O
heat	O
-	O
inactivated	O
10	O
%	O
fetal	O
bovine	O
serum	O
and	O
antibiotic/antimycotic	O
(	O
GIBCO	O
)	O
.	O

Splenocytes	O
isolated	O
from	O
SCID	O
-	O
passaged	O
lymphomas	O
consisted	O
of	O
80	O
%	O
-	O
90	O
%	O
B	O
cells	O
as	O
determined	O
by	O
flow	O
cytometry	O
,	O
and	O
were	O
hence	O
not	O
further	O
purified	O
with	O
CD19	O
-	O
MACS	O
beads	O
.	O

Splenocytes	O
were	O
seeded	O
at	O
1.25	O
x	O
106	O
cells/ml	O
and	O
where	O
applicable	O
,	O
recombinant	O
mouse	O
IL4	O
was	O
added	O
at	O
100	O
ng/ml	O
,	O
recombinant	O
mouse	O
IL10	O
at	O
10	O
ng/ml	O
,	O
and	O
rat	O
IgG1	O
anti	O
-	O
mouse	O
IL10	O
and	O
rat	O
IgG1	O
isotype	O
control	O
at	O
10	O
mug/ml	O
(	O
R	O
&	O
D	O
Systems	O
)	O
.	O

For	O
BrdU	O
incorporation	O
assays	O
,	O
splenocytes	O
were	O
pulsed	O
for	O
24	O
h	O
with	O
10	O
muM	O
BrdU	O
1	O
d	O
post	O
-	O
harvest	O
.	O

MTS	O
assay	O
.	O

The	O
3	O
-	O
(	O
4	O
,	O
5-dimethylthiazol-2	O
-	O
yl	O
)	O
-5	O
-	O
(	O
3	O
-	O
carboxymethoxyphenyl	O
)	O
-2	O
-	O
(	O
4	O
-	O
sulfophenyl	O
)	O
-2H	O
-	O
tetrazolium	O
inner	O
salt	O
(	O
MTS	O
)	O
cell	O
cytotoxicity/proliferation	O
assays	O
were	O
performed	O
using	O
the	O
CellTiter	O
96	O
aqueous	O
one	O
-	O
solution	O
cell	O
proliferation	O
assay	O
(	O
Promega	O
)	O
,	O
according	O
to	O
manufacturer	O
's	O
instructions	O
.	O

For	O
IL4	O
studies	O
,	O
splenocytes	O
were	O
cultured	O
for	O
3	O
d	O
in	O
the	O
presence	O
or	O
absence	O
of	O
100	O
ng/ml	O
IL4	O
.	O

Cells	O
were	O
seeded	O
on	O
day	O
3	O
in	O
triplicate	O
in	O
a	O
96	O
-	O
well	O
plate	O
at	O
2.5	O
x	O
106	O
cells/ml	O
at	O
100	O
mul	O
per	O
well	O
.	O

MTS	O
reagent	O
was	O
added	O
for	O
4	O
h	O
and	O
absorbance	O
was	O
read	O
at	O
540	O
nm	O
;	O
values	O
plotted	O
were	O
subtracted	O
from	O
blanks	O
.	O

For	O
neutralization	O
assays	O
,	O
splenocytes	O
were	O
seeded	O
at	O
5	O
x	O
106	O
cells/ml	O
at	O
100	O
mul	O
per	O
well	O
on	O
day	O
of	O
harvest	O
and	O
IL4	O
,	O
rat	O
IgG1	O
anti	O
-	O
mouse	O
IL4	O
,	O
or	O
rat	O
IgG1	O
isotype	O
control	O
(	O
R	O
&	O
D	O
Systems	O
)	O
were	O
added	O
at	O
the	O
concentrations	O
indicated	O
in	O
the	O
figures	O
.	O

Cultures	O
were	O
pulsed	O
for	O
4	O
h	O
with	O
MTS	O
reagent	O
1	O
d	O
post	O
-	O
seeding	O
.	O

For	O
inhibitor	O
studies	O
,	O
splenocytes	O
were	O
seeded	O
at	O
1	O
x	O
107	O
cells/ml	O
at	O
100	O
mul	O
per	O
well	O
on	O
day	O
of	O
harvest	O
,	O
and	O
inhibitors	O
were	O
added	O
at	O
the	O
concentrations	O
indicated	O
in	O
the	O
figures	O
.	O

The	O
inhibitors	O
BAY11	O
-	O
7085	O
,	O
rapamycin	O
,	O
triciribine	O
,	O
U0126	O
,	O
SB202190	O
,	O
and	O
cucurbitacin	O
I	O
were	O
purchased	O
from	O
EMD	O
Biosciences	O
.	O

For	O
non	O
-	O
malignant	O
splenocyte	O
cultures	O
,	O
B	O
cell	O
activation	O
was	O
induced	O
with	O
10	O
mug/ml	O
of	O
goat	O
F	O
(	O
ab	O
'	O
)	O
anti	O
-	O
mouse	O
IgM	O
(	O
Jackson	O
ImmunoResearch	O
)	O
.	O

Cultures	O
were	O
pulsed	O
for	O
4	O
h	O
with	O
MTS	O
reagent	O
1	O
d	O
post	O
-	O
seeding	O
.	O

Immunohistochemistry	O
.	O

Paraffin	O
-	O
embedded	O
spleen	O
sections	O
were	O
deparaffinized	O
in	O
Histoclear	O
(	O
National	O
Diagnostics	O
)	O
and	O
rehydrated	O
in	O
graded	O
ethanol	O
.	O

Sections	O
were	O
antigen	O
retrieved	O
by	O
microwaving	O
in	O
citrate	O
buffer	O
(	O
pH	O
6.0	O
)	O
for	O
15	O
min	O
(	O
LMP1	O
staining	O
)	O
and	O
10	O
min	O
(	O
pStat3	O
staining	O
)	O
.	O

For	O
LMP1	O
staining	O
,	O
sections	O
were	O
blocked	O
with	O
1	O
%	O
BSA	O
and	O
0.1	O
%	O
cold	O
fish	O
skin	O
gelatin	O
followed	O
with	O
streptavidin/biotin	O
block	O
(	O
Vector	O
Labs	O
)	O
.	O

Rat	O
IgG	O
anti	O
-	O
LMP1	O
(	O
clones	O
8G3	O
and	O
1G6	O
,	O
Ascenion	O
)	O
were	O
used	O
at	O
1	O
:	O
10	O
dilution	O
from	O
tissue	O
culture	O
supernatants	O
,	O
followed	O
with	O
8	O
mug/ml	O
biotinylated	O
mouse	O
F	O
(	O
ab	O
'	O
)	O
anti	O
-	O
rat	O
IgG	O
(	O
H+L	O
)	O
pre	O
-	O
adsorbed	O
to	O
mouse	O
serum	O
(	O
Jackson	O
ImmunoResearch	O
)	O
and	O
2	O
mug/ml	O
streptavidin	O
-	O
alkaline	O
phosphatase	O
conjugate	O
(	O
Jackson	O
ImmunoResearch	O
)	O
.	O

Stains	O
were	O
developed	O
with	O
BCIP/NBT	O
and	O
counterstained	O
in	O
Nuclear	O
Fast	O
Red	O
(	O
Dako	O
)	O
.	O

Phospho	O
-	O
Stat3	O
was	O
detected	O
with	O
4	O
mug/ml	O
of	O
pStat3	O
antibody	O
(	O
Tyr705	O
,	O
Cell	O
Signaling	O
)	O
and	O
detected	O
with	O
anti	O
-	O
rabbit	O
Poly	O
-	O
HRP	O
IHC	O
detection	O
kit	O
(	O
Chemicon	O
)	O
.	O

Flow	O
cytometry	O
.	O

One	O
million	O
splenocytes	O
were	O
stained	O
with	O
the	O
appropriate	O
primary	O
antibody	O
unconjugated	O
or	O
conjugated	O
to	O
FITC	O
,	O
PE	O
,	O
or	O
APC	O
diluted	O
in	O
stain	O
buffer	O
(	O
PBS	O
with	O
3	O
%	O
FBS	O
)	O
.	O

For	O
BrdU	O
detection	O
,	O
the	O
FITC	O
-	O
BrdU	O
flow	O
kit	O
was	O
used	O
as	O
instructed	O
by	O
the	O
manufacturer	O
(	O
BD	O
Bioscience	O
)	O
.	O

Briefly	O
,	O
cells	O
were	O
exposed	O
to	O
EMA	O
(	O
Molecular	O
Probes	O
)	O
for	O
exclusion	O
of	O
dead	O
cells	O
,	O
stained	O
for	O
surface	O
antigens	O
,	O
fixed	O
in	O
paraformaldehyde	O
,	O
and	O
permeabilized	O
with	O
saponin	O
.	O

To	O
expose	O
BrdU	O
epitopes	O
,	O
cells	O
were	O
treated	O
with	O
Dnase	O
and	O
stained	O
with	O
FITC	O
-	O
conjugated	O
anti	O
-	O
BrdU	O
antibody	O
.	O

Flow	O
cytometry	O
was	O
performed	O
on	O
FACScalibur	O
using	O
the	O
CellQuest	O
program	O
(	O
Becton	O
Dickinson	O
)	O
.	O

Further	O
analysis	O
was	O
conducted	O
on	O
the	O
Summit	O
v4.2	O
program	O
(	O
Dako	O
)	O
.	O

Rnase	O
protection	O
assay	O
.	O

Total	O
RNA	O
was	O
isolated	O
from	O
CD19+	O
MACS	O
-	O
purified	O
B	O
cells	O
using	O
the	O
Rneasy	O
midi	O
purification	O
kit	O
with	O
Dnase	O
treatment	O
,	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
(	O
Qiagen	O
)	O
.	O

The	O
mCK	O
-	O
1	O
probe	O
template	O
set	O
(	O
BD	O
Biosciences	O
)	O
was	O
labeled	O
using	O
the	O
In	O
Vitro	O
Transcription	O
Kit	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
(	O
BD	O
Biosciences	O
)	O
.	O

Briefly	O
,	O
50	O
ng	O
of	O
mCK	O
-	O
1	O
probe	O
set	O
was	O
labeled	O
with	O
[	O
alpha	O
-	O
32P	O
]	O
UTP	O
using	O
T7	O
RNA	O
polymerase	O
and	O
purified	O
using	O
Sephadex	O
G	O
-	O
50	O
columns	O
(	O
NucAway	O
Spin	O
column	O
,	O
Ambion	O
)	O
.	O

The	O
labeled	O
probe	O
was	O
quantitated	O
using	O
a	O
scintillation	O
counter	O
,	O
and	O
6	O
x	O
105	O
cherenkov	O
cpm	O
was	O
used	O
to	O
hybridize	O
to	O
4	O
mug	O
of	O
total	O
RNA	O
using	O
the	O
RPA	O
kit	O
(	O
BD	O
Biosciences	O
)	O
.	O

Samples	O
were	O
denatured	O
at	O
90	O
degreesC	O
and	O
hybridized	O
at	O
56	O
degreesC	O
overnight	O
.	O

Single	O
-	O
stranded	O
RNA	O
was	O
digested	O
with	O
a	O
mixture	O
of	O
Rnase	O
A	O
and	O
T1	O
,	O
and	O
precipitated	O
using	O
isopropanol	O
.	O

Protected	O
probes	O
were	O
resolved	O
on	O
a	O
denaturing	O
4.75	O
%	O
acrylamide	O
gel	O
,	O
dried	O
,	O
and	O
imaged	O
using	O
a	O
phosphorImager	O
(	O
Molecular	O
Dynamics	O
)	O
.	O

Densitometry	O
was	O
performed	O
using	O
the	O
ImageQuant	O
TL	O
v2005	O
software	O
(	O
GE	O
Healthcare	O
)	O
.	O

PCR	O
analysis	O
of	O
kappa	O
chain	O
rearrangement	O
.	O

DNA	O
was	O
isolated	O
from	O
splenocytes	O
using	O
the	O
Dneasy	O
Tissue	O
Kit	O
(	O
Qiagen	O
)	O
,	O
with	O
Rnase	O
treatment	O
.	O

PCR	O
reactions	O
contained	O
100	O
ng	O
of	O
genomic	O
DNA	O
,	O
0.2	O
muM	O
each	O
primer	O
,	O
0.2	O
mM	O
dNTPs	O
,	O
and	O
2.5	O
U	O
Taq	O
DNA	O
polymerase	O
(	O
NEB	O
)	O
performed	O
in	O
1X	O
ThermoPol	O
buffer	O
(	O
NEB	O
)	O
.	O

Primers	O
used	O
were	O
Vkappacon	O
and	O
Jkappa5	O
-	O
1degrees	O
and	O
have	O
been	O
described	O
previously	O
[	O
74	O
]	O
.	O

PCR	O
conditions	O
were	O
94	O
degreesC	O
for	O
2	O
min	O
,	O
40	O
cycles	O
of	O
94	O
degreesC	O
for	O
30	O
s	O
,	O
63	O
degreesC	O
for	O
90	O
s	O
,	O
and	O
72	O
degreesC	O
for	O
1	O
min	O
,	O
followed	O
by	O
1	O
cycle	O
of	O
72	O
degreesC	O
for	O
5	O
min	O
.	O

Immunoblot	O
analysis	O
.	O

Whole	O
cell	O
lysates	O
were	O
prepared	O
in	O
radioimmunoprecipitation	O
assay	O
(	O
RIPA	O
)	O
buffer	O
(	O
20	O
mM	O
Tris	O
-	O
HCl	O
[	O
pH	O
7.5	O
]	O
,	O
150	O
mM	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
%	O
NP	O
-	O
40	O
,	O
0.1	O
%	O
SDS	O
,	O
0.1	O
%	O
sodium	O
deoxycholate	O
)	O
supplemented	O
with	O
2	O
mM	O
phenylmethylsulfonyl	O
fluoride	O
,	O
1	O
mM	O
Na3VO4	O
,	O
and	O
1	O
:	O
100	O
protease/phosphatase	O
inhibitor	O
cocktails	O
(	O
Sigma	O
)	O
.	O

Crude	O
lysates	O
were	O
centrifuged	O
at	O
13	O
,	O
000	O
rpm	O
for	O
10	O
min	O
at	O
4	O
degreesC	O
and	O
the	O
supernatants	O
were	O
collected	O
for	O
further	O
analysis	O
.	O

Protein	O
concentrations	O
were	O
determined	O
with	O
the	O
Bio	O
-	O
Rad	O
DC	O
protein	O
assay	O
system	O
.	O

Lysates	O
were	O
boiled	O
in	O
the	O
presence	O
of	O
2.5	O
%	O
beta	O
-	O
mecaptoethanol	O
,	O
separated	O
by	O
denaturing	O
SDS	O
-	O
PAGE	O
,	O
and	O
transferred	O
to	O
0.45	O
-	O
mum	O
Optitran	O
membranes	O
(	O
Schleicher	O
&	O
Schuell	O
)	O
in	O
a	O
Bio	O
-	O
Rad	O
transfer	O
unit	O
.	O

Membranes	O
were	O
immunoblotted	O
with	O
the	O
appropriate	O
primary	O
antibody	O
followed	O
by	O
horseradish	O
peroxidase	O
-	O
tagged	O
secondary	O
antibodies	O
(	O
Amersham	O
Biosciences	O
and	O
Dako	O
)	O
and	O
detected	O
with	O
the	O
SuperSignal	O
West	O
Pico	O
System	O
(	O
Pierce	O
)	O
.	O

Antibodies	O
.	O

FITC	O
-	O
conjugated	O
goat	O
anti	O
-	O
mouse	O
IgM	O
,	O
rat	O
IgG2akappa	O
anti	O
-	O
mouse	O
IgD	O
(	O
clone	O
11	O
-	O
26	O
)	O
,	O
rat	O
IgG1kappa	O
anti	O
-	O
mouse	O
kappa	O
(	O
clone	O
187.1	O
)	O
,	O
rat	O
IgG2bkappa	O
anti	O
-	O
mouse	O
lambda	O
(	O
clone	O
JC5	O
-	O
1	O
)	O
;	O
PE	O
-	O
conjugated	O
goat	O
anti	O
-	O
mouse	O
IgG	O
;	O
un	O
-	O
conjugated	O
goat	O
anti	O
-	O
mouse	O
kappa	O
and	O
anti	O
-	O
mouse	O
lambda	O
were	O
purchased	O
from	O
Southern	O
Biotech	O
.	O

APC	O
-	O
conjugated	O
rat	O
IgG2akappa	O
anti	O
-	O
mouse	O
CD19	O
(	O
clone	O
6D5	O
)	O
,	O
PE	O
-	O
conjugated	O
mouse	O
IgG2akappa	O
anti	O
-	O
LMP1	O
(	O
clone	O
S12	O
)	O
,	O
un	O
-	O
conjugated	O
mouse	O
IgG2a	O
anti	O
-	O
Rb	O
(	O
clone	O
2	O
)	O
,	O
and	O
anti	O
-	O
Cdk2	O
(	O
clone	O
55	O
)	O
were	O
purchased	O
from	O
BD	O
Bioscience	O
.	O

PE	O
-	O
conjugated	O
rat	O
IgG2akappa	O
anti	O
-	O
mouse	O
CD5	O
(	O
clone	O
53	O
-	O
7.3	O
)	O
was	O
purchased	O
from	O
eBioscience	O
.	O

Rat	O
anti	O
-	O
LMP1	O
(	O
clones	O
8G3	O
,	O
1G6	O
,	O
7E10	O
,	O
and	O
7G8	O
)	O
was	O
purchased	O
from	O
Ascenion	O
.	O

Rabbit	O
anti	O
-	O
pAkt	O
(	O
Ser473	O
)	O
,	O
anti	O
-	O
pGSK3alpha/beta	O
(	O
Ser21/9	O
)	O
,	O
anti	O
-	O
pStat3	O
(	O
Tyr705	O
)	O
,	O
anti	O
-	O
pStat6	O
(	O
Tyr641	O
)	O
,	O
anti	O
-	O
pmTOR	O
(	O
Ser2448	O
)	O
,	O
anti	O
-	O
Stat6	O
,	O
anti	O
-	O
Akt	O
,	O
anti	O
-	O
FoxO1	O
,	O
and	O
anti	O
-	O
p27	O
were	O
purchased	O
from	O
Cell	O
Signaling	O
.	O

Rabbit	O
anti	O
-	O
Stat3	O
(	O
H	O
-	O
190	O
)	O
,	O
anti	O
-	O
IkappaBalpha	O
(	O
C	O
-	O
21	O
)	O
,	O
and	O
goat	O
anti	O
-	O
beta	O
actin	O
(	O
I	O
-	O
19	O
)	O
were	O
purchased	O
from	O
Santa	O
Cruz	O
Biotechnology	O
.	O

Mouse	O
IgG1kappa	O
anti	O
-	O
GSK3	O
was	O
purchased	O
from	O
Upstate	O
Biotechnology	O
.	O

Rabbit	O
anti	O
-	O
pRb	O
(	O
Thr373	O
)	O
was	O
purchased	O
from	O
EMD	O
Biosciences	O
.	O

Accession	O
Numbers	O

The	O
GenBank	O
(	O
http	O
:	O
//www.ncbi.nlm.nih.gov/Genbank/	O
)	O
accession	O
number	O
for	O
the	O
EBV	O
genome	O
sequence	O
is	O
AJ507799	O
.	O

The	O
gene	O
identifier	O
for	O
LMP1	O
is	O
BNLF1	O
.	O

High	B-Positive_regulation
LMP1	O
Expression	B-Gene_expression
Correlates	O
with	O
the	O
Development	O
of	O
Lymphoma	O

LMP1	O
expression	B-Gene_expression
is	O
shown	O
by	O
(	O
A	O
)	O
immunoblotting	O
of	O
purified	O
B	O
cells	O
(	O
CD19+	O
)	O
and	O
(	O
B	O
)	O
immunohistochemistry	O
staining	O
of	O
spleen	O
tissue	O
from	O
wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
LMP1	O
transgenic	O
mice	O
.	O

(	O
A	O
)	O
Lymphomas	O
are	O
identified	O
with	O
a	O
number	O
(	O
1	O
-	O
7	O
)	O
.	O

Arrows	O
indicate	O
the	O
LMP1	O
-	O
specific	O
band	O
and	O
its	O
degradation	O
products	O
as	O
well	O
as	O
a	O
non	O
-	O
specific	O
band	O
.	O

Actin	O
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

(	O
B	O
)	O
White	O
and	O
red	O
pulps	O
are	O
shown	O
,	O
but	O
this	O
architecture	O
is	O
lost	O
upon	O
development	O
of	O
lymphoma	O
.	O

Scale	O
bar	O
,	O
20	O
mum	O
.	O

LMP1	O
Promotes	O
B	O
-	O
1a	O
Lymphomas	O
That	O
Can	O
Escape	O
Allelic	O
Exclusion	O

(	O
A	O
)	O
Flow	O
cytometry	O
analysis	O
of	O
splenocytes	O
from	O
a	O
WT	O
or	O
LMP1	O
transgenic	O
lymphoma	O
for	O
the	O
pan	O
-	O
B	O
cell	O
(	O
CD19	O
)	O
,	O
B	O
-	O
1a	O
cell	O
(	O
CD5	O
)	O
,	O
and	O
Ig	O
heavy	O
chain	O
(	O
IgM	O
and	O
IgD	O
)	O
and	O
light	O
chain	O
(	O
kappa	O
and	O
lambda	O
)	O
markers	O
.	O

Shown	O
are	O
the	O
results	O
from	O
WT	O
lymphoma	O
1	O
and	O
LMP1	O
transgenic	O
lymphoma	O
4	O
.	O

This	O
analysis	O
was	O
repeated	O
on	O
four	O
other	O
LMP1	O
transgenic	O
lymphomas	O
(	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
6	O
)	O
showing	O
a	O
similar	O
B	O
-	O
1a	O
phenotype	O
,	O
of	O
which	O
lymphomas	O
2	O
and	O
4	O
were	O
also	O
doubly	O
positive	O
for	O
kappa	O
and	O
lambda	O
light	O
chains	O
.	O

(	O
B	O
)	O
Flow	O
cytometry	O
analysis	O
of	O
WT	O
or	O
LMP1	O
transgenic	O
splenocytes	O
for	O
B	O
-	O
1a	O
(	O
CD19+CD5+	O
)	O
and	O
B	O
-	O
1b	O
or	O
B2	O
subsets	O
(	O
CD19+CD5	O
-	O
)	O
.	O

Percentages	O
of	O
B	O
-	O
1a	O
and	O
B	O
-	O
1b	O
or	O
B2	O
subsets	O
are	O
shown	O
in	O
each	O
quadrant	O
.	O

This	O
analysis	O
was	O
repeated	O
on	O
three	O
other	O
WT	O
and	O
two	O
other	O
LMP1	O
transgenic	O
mice	O
with	O
similar	O
results	O
.	O

(	O
C	O
)	O
Immunoblot	O
analysis	O
for	O
kappa	O
and	O
lambda	O
light	O
chains	O
of	O
B	O
cells	O
(	O
CD19+	O
)	O
purified	O
from	O
WT	O
and	O
LMP1	O
transgenic	O
mice	O
.	O

Actin	O
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

LMP1	O
Promotes	O
B	O
Cell	O
Survival	O
and	O
Proliferation	O
In	O
Vitro	O

(	O
A	O
)	O
MTS	O
assay	O
of	O
splenocytes	O
from	O
WT	O
and	O
LMP1	O
transgenic	O
mice	O
.	O

Splenocytes	O
were	O
cultured	O
in	O
the	O
presence	O
(	O
grey	O
bars	O
)	O
or	O
absence	O
(	O
black	O
bars	O
)	O
of	O
IL4	O
for	O
3	O
d	O
.	O

The	O
results	O
are	O
the	O
mean	O
+/	O
-	O
SEM	O
of	O
triplicate	O
samples	O
averaged	O
from	O
multiple	O
mice	O
where	O
"	O
n	O
"	O
the	O
number	O
of	O
mice	O
analyzed	O
is	O
as	O
follows	O
:	O
n	O
=	O
2	O
for	O
WT	O
lymphocytes	O
and	O
WT	O
lymphomas	O
,	O
n	O
=	O
11	O
for	O
LMP1	O
transgenic	O
lymphocytes	O
,	O
and	O
n	O
=	O
13	O
for	O
LMP1	O
transgenic	O
lymphomas	O
.	O

(	O
B	O
)	O
EMA	O
exclusion	O
of	O
CD19+	O
gated	O
splenocytes	O
from	O
WT	O
and	O
LMP1	O
transgenic	O
mice	O
showing	O
percentage	O
of	O
viable	O
B	O
cells	O
cultured	O
with	O
(	O
white	O
bars	O
)	O
or	O
without	O
(	O
black	O
bars	O
)	O
IL4	O
for	O
2	O
d	O
.	O

(	O
C	O
)	O
Flow	O
cytometry	O
analysis	O
for	O
incorporated	O
BrdU	O
in	O
WT	O
and	O
LMP1	O
transgenic	O
lymphoma	O
cells	O
cultured	O
with	O
or	O
without	O
IL4	O
for	O
2	O
d	O
.	O

Shown	O
are	O
the	O
results	O
from	O
WT	O
lymphoma	O
1	O
and	O
LMP1	O
transgenic	O
lymphoma	O
2	O
.	O

Percentages	O
of	O
cells	O
in	O
each	O
quadrant	O
are	O
shown	O
.	O

Summary	O
of	O
Analysis	O
Performed	O
on	O
Wild	O
-	O
Type	O
and	O
LMP1	O
Transgenic	B-Gene_expression
Lymphomas	O

Wild	O
-	O
Type	O
and	O
LMP1	O
Transgenic	O
Lymphoma	O
Cells	O
Survive	O
Independently	O
of	O
IL4/Stat6	O
Signaling	O
in	O
Culture	O

(	O
A	O
)	O
Rnase	O
protection	O
assay	O
for	O
IL4	O
mRNA	O
from	O
purified	O
B	O
cells	O
(	O
CD19+	O
)	O
from	O
WT	O
and	O
LMP1	O
transgenic	O
splenocytes	O
.	O

The	O
L32	O
and	O
GAPDH	O
housekeeping	O
genes	O
were	O
used	O
as	O
a	O
loading	O
control	O
.	O

Arrow	O
indicates	O
the	O
position	O
of	O
the	O
protected	O
probe	O
.	O

(	O
B	O
and	O
C	O
)	O
Immunoblot	O
analysis	O
of	O
WT	O
and	O
LMP1	O
transgenic	O
mice	O
for	O
activated	B-Positive_regulation
pStat6	O
in	O
(	O
B	O
)	O
purified	O
B	O
cells	O
(	O
CD19+	O
)	O
at	O
the	O
time	O
of	O
harvest	O
or	O
in	O
(	O
C	O
)	O
whole	O
splenocytes	O
cultured	O
with	O
or	O
without	O
IL4	O
.	O

(	O
B	O
)	O
Actin	O
was	O
used	O
as	O
a	O
loading	O
control	O
,	O
and	O
the	O
white	O
line	O
indicates	O
that	O
intervening	O
lanes	O
have	O
been	O
spliced	O
out	O
.	O

(	O
D	O
and	O
E	O
)	O
MTS	O
assay	O
of	O
(	O
D	O
)	O
WT	O
lymphocytes	O
and	O
(	O
E	O
)	O
LMP1	O
transgenic	O
lymphoma	O
cells	O
cultured	O
with	O
IL4	O
,	O
a	O
neutralizing	O
antibody	O
to	O
IL4	O
,	O
or	O
a	O
rat	O
IgG	O
isotype	O
control	O
at	O
the	O
indicated	O
concentrations	O
.	O

Shown	O
are	O
the	O
results	O
from	O
LMP1	O
transgenic	O
lymphoma	O
3	O
.	O

The	O
results	O
are	O
the	O
mean	O
+/	O
-	O
SEM	O
of	O
triplicate	O
samples	O
from	O
a	O
single	O
representative	O
experiment	O
that	O
was	O
repeated	O
twice	O
with	O
similar	O
results	O
.	O

LMP1	O
Upregulates	B-Positive_regulation
IL10	O
Expression	B-Gene_expression
and	O
Constitutively	O
Activates	B-Positive_regulation
Stat3	O

(	O
A	O
)	O
Relative	O
expression	B-Transcription
of	O
IL10	O
,	O
IL15	O
,	O
and	O
IFNgamma	O
mRNA	O
in	O
WT	O
and	O
LMP1	O
transgenic	O
B	O
cells	O
(	O
CD19+	O
)	O
,	O
as	O
detected	O
with	O
an	O
Rnase	O
protection	O
assay	O
.	O

Mouse	O
lymphoma	O
cell	O
lines	O
967	O
and	O
K46mu	O
were	O
used	O
as	O
controls	O
.	O

Expression	O
levels	O
were	O
quantified	O
with	O
a	O
phosphorimager	O
and	O
values	O
were	O
normalized	O
to	O
the	O
ribosomal	O
housekeeping	O
gene	O
L32	O
.	O

The	O
cytokine	O
:	O
L32	O
ratio	O
was	O
set	O
to	O
1	O
in	O
the	O
mouse	O
B	O
cell	O
lymphoma	O
line	O
967	O
.	O

(	O
B	O
and	O
C	O
)	O
Immunoblot	O
analysis	O
of	O
activated	B-Positive_regulation
pStat3	O
in	O
purified	O
B	O
cells	O
(	O
CD19+	O
)	O
from	O
WT	O
and	O
LMP1	O
transgenic	O
mice	O
(	O
B	O
)	O
at	O
the	O
time	O
of	O
harvest	O
,	O
and	O
(	O
C	O
)	O
4	O
h	O
after	O
culture	O
with	O
or	O
without	O
IL10	O
,	O
a	O
neutralizing	O
antibody	O
to	O
IL10	O
,	O
or	O
a	O
rat	O
IgG1	O
isotype	O
control	O
.	O

(	O
C	O
)	O
Shown	O
are	O
the	O
results	O
for	O
WT	O
lymphoma	O
1	O
and	O
LMP1	O
transgenic	O
lymphoma	O
1	O
.	O

Arrows	O
indicate	O
the	O
positions	O
of	O
the	O
alpha	O
and	O
beta	O
isoforms	O
of	O
Stat3	O
.	O

Actin	O
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

(	O
D	O
)	O
Immunohistochemistry	O
detection	O
of	O
activated	B-Positive_regulation
nuclear	O
pStat3	O
in	O
the	O
spleens	O
of	O
WT	O
and	O
LMP1	O
transgenic	O
mice	O
.	O

Scale	O
bar	O
,	O
20	O
mum	O
.	O

LMP1	O
Activates	O
Akt	O
Signaling	O
and	O
Deregulates	O
the	O
Rb	O
Cell	O
Cycle	O
Pathway	O

(	O
A	O
and	O
B	O
)	O
Immunoblot	O
analysis	O
of	O
purified	O
B	O
cells	O
(	O
CD19+	O
)	O
from	O
the	O
spleens	O
of	O
WT	O
and	O
LMP1	O
transgenic	O
mice	O
for	O
Akt	O
signaling	O
,	O
probing	O
for	O
(	O
A	O
)	O
activated	O
pAkt	O
and	O
downstream	O
targets	B-Regulation
,	O
including	O
inactivated	B-Positive_regulation
pGSK3alpha/beta	O
,	O
and	O
(	O
B	O
)	O
activated	B-Positive_regulation
p	O
-	O
mTOR	O
,	O
and	O
total	O
levels	O
of	O
FoxO1	O
.	O

Arrows	O
indicate	O
the	O
positions	O
of	O
alpha	O
and	O
beta	O
isoforms	O
of	O
GSK3	O
.	O

The	O
white	O
line	O
indicates	O
that	O
intervening	O
lanes	O
have	O
been	O
spliced	O
out	O
.	O

(	O
C	O
)	O
Immunoblot	O
analysis	O
for	O
cell	O
cycle	O
proteins	O
regulating	O
the	O
Rb	O
pathway	O
,	O
probing	O
for	O
activated	B-Positive_regulation
pRb	O
,	O
and	O
total	O
levels	O
of	O
Cdk2	O
and	O
the	O
Cdk	O
inhibitor	O
p27	O
.	O

Actin	O
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

Akt	O
,	O
NFkappaB	O
,	O
and	O
Stat3	O
Signaling	O
Are	O
Required	O
for	O
the	O
Growth	O
and	O
Survival	O
of	O
Lymphoma	O
Cells	O

MTS	O
assay	O
of	O
splenocytes	O
from	O
(	O
A	O
and	O
B	O
)	O
WT	O
or	O
(	O
C	O
and	O
D	O
)	O
LMP1	O
transgenic	O
lymphomas	O
and	O
(	O
E	O
and	O
F	O
)	O
LMP1	O
transgenic	O
lymphoctyes	O
.	O

Splenocytes	O
were	O
cultured	O
with	O
or	O
without	O
inhibitors	B-Negative_regulation
of	O
NFkappaB	O
(	O
BAY11	O
)	O
,	O
mTOR	O
(	O
rapamycin	O
)	O
,	O
Akt	O
(	O
triciribine	O
)	O
,	O
MEK1/2	O
(	O
U0126	O
)	O
,	O
p38	O
(	O
SB202190	O
)	O
,	O
or	O
Stat3	O
(	O
cucurbitacin	O
I	O
and	O
AG490	O
)	O
at	O
the	O
indicated	O
concentrations	O
.	O

The	O
results	O
are	O
the	O
mean	O
+/	O
-	O
SEM	O
of	O
triplicate	O
samples	O
.	O

Shown	O
are	O
the	O
results	O
for	O
(	O
A	O
and	O
B	O
)	O
WT	O
lymphoma	O
1	O
,	O
(	O
C	O
and	O
D	O
)	O
LMP1	O
transgenic	O
lymphoma	O
2	O
,	O
and	O
(	O
E	O
and	O
F	O
)	O
one	O
out	O
of	O
two	O
LMP1	O
transgenic	O
mice	O
analyzed	O
.	O

This	O
analysis	O
was	O
repeated	O
with	O
LMP1	O
transgenic	O
lymphoma	O
4	O
yielding	O
similar	O
results	O
.	O

Analysis	O
of	O
Akt	O
,	O
NFkappaB	O
,	O
and	O
Stat3	O
Pathways	O
in	O
Contribution	O
to	O
the	O
Growth	O
and	O
Survival	O
of	O
Lymphoma	O
Cells	O

(	O
A	O
-	O
D	O
)	O
Immunoblot	O
analysis	O
of	O
wild	O
-	O
type	O
and	O
LMP1	O
transgenic	O
lymphomas	O
for	O
Akt	O
,	O
NFkappaB	O
,	O
and	O
Stat3	O
signaling	O
after	O
treatment	O
with	O
(	O
A	O
)	O
an	O
Akt	O
inhibitor	B-Negative_regulation
,	O
triciribine	O
,	O
(	O
B	O
)	O
an	O
NFkappaB	O
inhibitor	O
,	O
BAY11	O
-	O
7085	O
,	O
and	O
the	O
Stat3	O
inhibitors	B-Negative_regulation
(	O
C	O
)	O
cucurbitacin	O
I	O
and	O
(	O
D	O
)	O
AG490	O
,	O
at	O
the	O
indicated	O
concentrations	O
.	O

Arrows	O
indicate	O
the	O
positions	O
of	O
alpha	O
and	O
beta	O
isoforms	O
of	O
Stat3	O
.	O

Actin	O
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

Lymphomas	O
Are	O
Clonal	O
by	O
kappa	O
Light	O
Chain	O
Rearrangement	O

PCR	O
analysis	O
of	O
total	O
spleen	O
genomic	O
DNA	O
for	O
the	O
mouse	O
kappa	O
locus	O
.	O

Primers	O
were	O
designed	O
to	O
amplify	O
all	O
V	O
-	O
J	O
rearrangements	O
,	O
including	O
VJ1	O
,	O
VJ2	O
,	O
VJ4	O
,	O
and	O
VJ5	O
.	O

Specific	O
PCR	O
products	O
for	O
the	O
four	O
rearrangements	O
corresponding	O
to	O
the	O
calculated	O
sizes	O
are	O
indicated	O
with	O
arrows	O
.	O

Bands	O
of	O
other	O
sizes	O
are	O
due	O
to	O
non	O
-	O
specific	O
products	O
.	O

If	O
a	O
tumor	O
was	O
present	O
in	O
the	O
background	O
of	O
normal	O
spleen	O
cells	O
,	O
a	O
single	O
band	O
appears	O
brighter	O
than	O
all	O
the	O
other	O
specific	O
bands	O
.	O

Wild	O
-	O
type	O
and	O
LMP1	O
transgenic	O
lymphocytes	O
are	O
positive	O
for	O
all	O
four	O
V	O
-	O
J	O
rearrangements	O
and	O
serve	O
as	O
positive	O
controls	O
.	O

Clonality	O
is	O
determined	O
by	O
the	O
appearance	O
of	O
a	O
predominant	O
band	O
at	O
the	O
correct	O
size	O
for	O
a	O
single	O
V	O
-	O
J	O
rearrangement	O
.	O

(	O
739	O
KB	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Runx3	O
and	O
T	O
-	O
box	O
proteins	O
cooperate	O
to	O
establish	O
the	O
transcriptional	O
program	O
of	O
effector	O
CTLs	O

Activation	O
of	O
naive	O
CD8+	O
T	O
cells	O
with	O
antigen	O
induces	O
their	O
differentiation	O
into	O
effector	O
cytolytic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
.	O

CTLs	O
lyse	O
infected	O
or	O
aberrant	O
target	O
cells	O
by	O
exocytosis	O
of	O
lytic	O
granules	O
containing	O
the	O
pore	O
-	O
forming	O
protein	O
perforin	O
and	O
a	O
family	O
of	O
proteases	O
termed	O
granzymes	O
.	O

We	O
show	O
that	O
effector	O
CTL	O
differentiation	O
occurs	O
in	O
two	O
sequential	O
phases	O
in	O
vitro	O
,	O
characterized	O
by	O
early	O
induction	B-Positive_regulation
of	O
T	O
-	O
bet	O
and	O
late	O
induction	B-Positive_regulation
of	O
Eomesodermin	O
(	O
Eomes	O
)	O
,	O
T	O
-	O
box	O
transcription	O
factors	O
that	O
regulate	B-Regulation
the	O
early	O
and	O
late	O
phases	O
of	O
interferon	O
(	O
IFN	O
)	O
gamma	O
expression	B-Gene_expression
,	O
respectively	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
a	O
critical	O
role	O
for	O
the	O
transcription	O
factor	O
Runx3	O
in	O
CTL	O
differentiation	O
.	O

Runx3	O
regulates	B-Regulation
Eomes	O
expression	B-Gene_expression
as	O
well	O
as	O
expression	B-Gene_expression
of	O
three	O
cardinal	O
markers	O
of	O
the	O
effector	O
CTL	O
program	O
:	O
IFN	O
-	O
gamma	O
,	O
perforin	O
,	O
and	O
granzyme	O
B	O
.	O

Our	O
data	O
point	O
to	O
the	O
existence	O
of	O
an	O
elaborate	O
transcriptional	O
network	O
in	O
which	O
Runx3	O
initially	O
induces	O
and	O
then	O
cooperates	O
with	O
T	O
-	O
box	O
transcription	O
factors	O
to	O
regulate	O
gene	O
transcription	O
in	O
differentiating	O
CTLs	O
.	O

INTRODUCTION	O

Naive	O
CD8+	O
T	O
cells	O
differentiate	O
into	O
effector	O
CTLs	O
with	O
the	O
ability	O
to	O
lyse	O
antigen	O
-	O
bearing	O
target	O
cells	O
by	O
exocytosis	O
of	O
lytic	O
granules	O
containing	O
perforin	O
and	O
granzymes	O
,	O
and	O
to	O
produce	B-Gene_expression
inflammatory	O
cytokines	O
such	O
as	O
IFN	O
-	O
gamma	O
and	O
TNF	O
upon	O
restimulation	O
through	O
the	O
TCR	O
(	O
1	O
,	O
2	O
)	O
.	O

In	O
vivo	O
experiments	O
have	O
elucidated	O
many	O
critical	O
parameters	O
governing	O
the	O
development	O
and	O
evolution	O
of	O
primary	O
CTL	O
responses	O
(	O
3	O
,	O
4	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
used	O
in	O
vitro	O
systems	O
such	O
as	O
those	O
developed	O
to	O
study	O
CD4+	O
T	O
cell	O
differentiation	O
to	O
define	O
the	O
molecular	O
basis	O
of	O
effector	O
CTL	O
differentiation	O
(	O
5	O
,	O
6	O
)	O
.	O

The	O
T	O
-	O
box	O
transcription	O
factors	O
Eomesodermin	O
(	O
Eomes	O
)	O
and	O
T	O
-	O
bet	O
are	O
needed	O
for	O
important	O
aspects	O
of	O
effector	O
and	O
memory	O
CTL	O
differentiation	O
(	O
7	O
)	O
.	O

In	O
uninfected	O
mice	O
,	O
compound	O
deletion	B-Negative_regulation
of	O
the	O
Tbx21	O
(	O
encoding	O
T	O
-	O
bet	O
)	O
and	O
eomesodermin	O
genes	O
is	O
associated	O
with	O
a	O
selective	O
loss	O
of	O
CD8+	O
T	O
cells	O
with	O
an	O
IL-2Rbeta	O
-	O
high	O
,	O
memory	O
phenotype	O
(	O
8	O
)	O
.	O

Mice	O
deficient	B-Negative_regulation
for	O
both	O
T	O
-	O
bet	O
and	O
Eomes	O
in	O
T	O
cells	O
have	O
impaired	O
expression	O
of	O
cytolytic	O
mediators	O
,	O
manifest	O
poor	O
cytolytic	O
activity	O
,	O
and	O
fail	O
to	O
control	O
acute	O
lymphocytic	O
choriomeningitis	O
virus	O
infection	O
(	O
9	O
)	O
.	O

Nevertheless	O
,	O
the	O
specific	O
roles	O
of	O
T	O
-	O
bet	O
and	O
Eomes	O
in	O
clonal	O
expansion	O
and	O
CTL	O
differentiation	O
have	O
not	O
yet	O
been	O
resolved	O
:	O
in	O
particular	O
,	O
it	O
is	O
not	O
known	O
whether	O
these	O
transcription	O
factors	O
function	O
redundantly	O
to	O
control	O
effector	O
CD8+	O
T	O
cell	O
differentiation	O
,	O
and	O
whether	O
they	O
do	O
so	O
directly	O
by	O
targeting	B-Binding
specific	O
effector	O
cytokine	O
and	O
cytolytic	O
genes	O
.	O

Runx	O
proteins	O
,	O
a	O
family	O
of	O
three	O
DNA	O
-	O
binding	O
transcription	O
factors	O
,	O
control	O
thymocyte	O
differentiation	O
and	O
the	O
CD4/CD8	O
lineage	O
decision	O
(	O
10	O
-	O
13	O
)	O
.	O

Runx3	O
and	O
perforin	O
mRNA	O
are	O
expressed	B-Transcription
by	O
double	O
-	O
positive	O
(	O
DP	O
)	O
thymocytes	O
and	O
CD8+	O
single	O
-	O
positive	O
(	O
SP	O
)	O
thymocytes	O
but	O
not	O
in	O
CD4+	O
SP	O
cells	O
(	O
14	O
)	O
.	O

Although	O
Runx3	O
is	O
not	O
expressed	B-Gene_expression
in	O
naive	O
CD4+	O
T	O
cells	O
,	O
its	O
expression	B-Gene_expression
is	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
during	O
Th1	O
cell	O
differentiation	O
,	O
and	O
Runx3	O
influences	O
Th1	O
cell	O
differentiation	O
and	O
function	O
through	O
direct	O
regulation	B-Regulation
of	O
the	O
Il4	O
and	O
Ifng	O
cytokine	O
genes	O
(	O
15	O
,	O
16	O
)	O
.	O

In	O
contrast	O
,	O
all	O
three	O
Runx	O
proteins	O
are	O
expressed	O
in	O
mature	O
CD8+	O
T	O
cells	O
(	O
10	O
,	O
12	O
)	O
,	O
and	O
Runx3	O
-	O
deficient	B-Negative_regulation
CD8+	O
T	O
cells	O
show	O
reduced	O
cytolytic	O
activity	O
(	O
12	O
,	O
13	O
)	O
.	O

We	O
therefore	O
tested	O
whether	O
Runx3	O
influenced	O
cytolytic	O
T	O
cell	O
differentiation	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
Runx3	O
and	O
T	O
-	O
box	O
factors	O
synergistically	O
regulate	O
CTL	O
differentiation	O
and	O
function	O
.	O

T	O
-	O
bet	O
is	O
induced	B-Positive_regulation
quickly	O
upon	O
TCR	O
stimulation	O
and	O
is	O
required	O
for	O
early	O
programming	O
of	O
cytokine	O
production	O
(	O
17	O
)	O
,	O
whereas	O
Eomes	O
is	O
induced	B-Positive_regulation
later	O
during	O
differentiation	O
and	O
sustains	B-Positive_regulation
IFN	O
-	O
gamma	O
expression	B-Gene_expression
.	O

Runx3	O
is	O
required	B-Positive_regulation
for	O
Eomes	O
and	O
perforin	O
expression	B-Gene_expression
,	O
and	O
both	O
Eomes	O
and	O
Runx3	O
bind	B-Binding
at	O
the	O
Prf1	O
locus	O
;	O
in	O
contrast	O
,	O
perforin	O
expression	B-Gene_expression
is	O
unaffected	B-Regulation
in	O
T-bet	O
-	O
deficient	B-Negative_regulation
cells	O
.	O

T	O
cells	O
lacking	B-Negative_regulation
Runx3	O
show	O
decreased	B-Negative_regulation
expression	B-Gene_expression
of	O
IFN	O
-	O
gamma	O
and	O
granzyme	O
B	O
,	O
and	O
Runx3	O
also	O
binds	B-Binding
the	O
promoter	O
regions	O
of	O
the	O
Ifng	O
and	O
Gzmb	O
genes	O
.	O

Collectively	O
,	O
these	O
results	O
provide	O
evidence	O
for	O
a	O
complex	O
transcriptional	O
network	O
in	O
which	O
Runx3	O
is	O
a	O
primary	O
regulator	B-Regulation
of	O
Gzmb	O
expression	B-Gene_expression
but	O
synergizes	O
with	O
T	O
-	O
bet	O
and	O
Eomes	O
,	O
respectively	O
,	O
to	O
promote	B-Positive_regulation
transcription	B-Transcription
of	O
the	O
Ifng	O
and	O
Prf1	O
genes	O
.	O

A	O
cell	O
culture	O
system	O
to	O
monitor	O
effector	O
CTL	O
differentiation	O

We	O
used	O
a	O
simple	O
cell	O
culture	O
system	O
to	O
examine	O
the	O
kinetics	O
of	O
effector	O
gene	O
expression	O
during	O
CD8+	O
T	O
cell	O
differentiation	O
.	O

Naive	O
CD8+	O
T	O
cells	O
from	O
P14	O
TCR	O
transgenic	O
mice	O
were	O
activated	O
for	O
2	O
d	O
with	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	O
or	O
with	O
splenic	O
APCs	O
in	O
the	O
presence	O
of	O
Gp33	O
peptide	O
,	O
and	O
were	O
cultured	O
in	O
media	O
containing	O
100	O
U/ml	O
of	O
recombinant	O
human	O
IL	O
-	O
2	O
(	O
rhIL	O
-	O
2	O
)	O
.	O

We	O
used	O
TCR	O
transgenic	O
mice	O
for	O
these	O
experiments	O
because	O
they	O
provide	O
a	O
reliable	O
source	O
of	O
CD8+	O
T	O
cells	O
that	O
are	O
truly	O
naive	O
;	O
however	O
,	O
we	O
chose	O
not	O
to	O
stimulate	O
cells	O
with	O
antigen	O
in	O
most	O
experiments	O
so	O
as	O
to	O
avoid	O
contamination	O
with	O
proteins	O
and	O
nucleic	O
acids	O
derived	O
from	O
APCs	O
.	O

There	O
were	O
only	O
minor	O
differences	O
in	O
gene	O
expression	O
during	O
differentiation	O
induced	O
by	O
antigen/APC	O
versus	O
anti-CD3/anti	O
-	O
CD28	O
,	O
and	O
the	O
major	O
conclusions	O
presented	O
in	O
this	O
report	O
are	O
the	O
same	O
for	O
both	O
activating	O
conditions	O
.	O

Under	O
our	O
culture	O
conditions	O
,	O
activated	O
CD8+	O
T	O
cells	O
expanded	O
exponentially	O
and	O
accumulated	O
for	O
>	O
8	O
d	O
.	O

We	O
limited	O
our	O
analysis	O
to	O
the	O
first	O
6	O
-	O
8	O
d	O
after	O
activation	O
,	O
a	O
period	O
that	O
coincides	O
with	O
clonal	O
expansion	O
of	O
CD8+	O
T	O
cells	O
after	O
activation	O
in	O
vivo	O
.	O

Distinct	O
expression	B-Gene_expression
kinetics	O
of	O
perforin	O
and	O
granzyme	O
B	O
during	O
CTL	O
development	O
in	O
culture	O

Our	O
experiments	O
revealed	O
clear	O
differences	O
in	O
the	O
kinetics	O
of	O
perforin	O
,	O
granzyme	O
B	O
,	O
and	O
cytokine	O
expression	B-Gene_expression
during	O
CD8+	O
T	O
cell	O
activation	O
(	O
Fig	O
.	O

1	O
)	O
.	O

Naive	O
T	O
cells	O
showed	O
detectable	O
expression	B-Gene_expression
of	O
perforin	O
mRNA	O
as	O
well	O
as	O
perforin	O
protein	O
(	O
Fig	O
.	O

1	O
,	O
A	O
-	O
D	O
)	O
.	O

Relative	O
to	O
its	O
expression	B-Gene_expression
in	O
naive	O
T	O
cells	O
,	O
perforin	O
(	O
Prf1	O
)	O
mRNA	B-Transcription
expression	I-Transcription
did	O
not	O
increase	B-Positive_regulation
appreciably	O
at	O
day	O
2	O
but	O
showed	O
a	O
reproducible	O
decrease	B-Negative_regulation
at	O
day	O
4	O
,	O
followed	O
by	O
robust	O
reexpression	B-Positive_regulation
between	O
days	O
4	O
and	O
8	O
(	O
Fig	O
.	O

1	O
,	O
A	O
-	O
D	O
)	O
.	O

In	O
contrast	O
,	O
granzyme	O
B	O
(	O
Gzmb	O
)	O
mRNA	O
was	O
low	B-Transcription
or	I-Transcription
undetectable	I-Transcription
in	O
naive	O
T	O
cells	O
but	O
was	O
strongly	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
by	O
day	O
2	O
after	O
stimulation	O
and	O
increased	B-Positive_regulation
progressively	O
until	O
day	O
6	O
(	O
Fig	O
.	O

1	O
,	O
A	O
and	O
B	O
)	O
;	O
similarly	O
,	O
granzyme	O
B	O
protein	O
was	O
expressed	O
by	O
day	O
4	O
and	O
remained	B-Positive_regulation
high	I-Positive_regulation
until	O
day	O
6	O
(	O
Fig	O
.	O

1	O
E	O
)	O
.	O

As	O
expected	O
,	O
a	O
small	O
fraction	O
of	O
naive	O
T	O
cells	O
expressed	B-Gene_expression
the	O
cytokines	O
IFN	O
-	O
gamma	O
and	O
TNF	O
in	O
response	O
to	O
stimulation	O
,	O
and	O
this	O
capacity	O
increased	B-Positive_regulation
significantly	O
in	O
differentiated	O
cells	O
(	O
Fig	O
.	O

1	O
E	O
;	O
see	O
also	O
Fig	O
.	O

2	O
A	O
)	O
.	O

We	O
evaluated	O
antigen	O
-	O
dependent	O
cytolytic	O
function	O
in	O
a	O
short	O
-	O
term	O
assay	O
in	O
which	O
target	O
cell	O
death	O
was	O
measured	O
within	O
2	O
h	O
(	O
Fig	O
.	O

1	O
F	O
)	O
.	O

By	O
limiting	O
the	O
duration	O
of	O
TCR	O
stimulation	O
,	O
this	O
strategy	O
minimizes	O
cytolysis	O
secondary	O
to	O
new	O
gene	O
expression	O
during	O
the	O
period	O
of	O
the	O
assay	O
.	O

Naive	O
T	O
cells	O
did	O
not	O
display	O
significant	O
cytolytic	O
function	O
in	O
this	O
short	O
-	O
term	O
assay	O
(	O
unpublished	O
data	O
)	O
,	O
most	O
likely	O
because	O
they	O
express	B-Gene_expression
immature	O
(	O
unprocessed	O
)	O
forms	O
of	O
perforin	O
and	O
lack	O
the	O
capacity	O
to	O
degranulate	O
(	O
18	O
,	O
19	O
)	O
.	O

Even	O
after	O
activation	O
for	O
2	O
or	O
4	O
d	O
,	O
the	O
cells	O
showed	O
poor	O
cytolytic	O
activity	O
(	O
Fig	O
.	O

1	O
F	O
)	O
,	O
in	O
striking	O
contrast	O
to	O
their	O
capacity	O
for	O
efficient	O
cytokine	O
production	O
(	O
Fig	O
.	O

1	O
E	O
)	O
.	O

Only	O
cells	O
cultured	O
until	O
day	O
6	O
displayed	O
robust	O
cytotoxicity	O
,	O
as	O
judged	O
by	O
their	O
ability	O
to	O
induce	O
apoptosis	O
in	O
a	O
large	O
number	O
of	O
target	O
cells	O
(	O
Fig	O
.	O

1	O
F	O
)	O
.	O

These	O
results	O
show	O
that	O
after	O
a	O
strong	O
priming	O
stimulus	O
through	O
TCRs	O
and	O
co	O
-	O
stimulatory	O
receptors	O
in	O
vitro	O
,	O
granzyme	O
B	O
expression	B-Gene_expression
and	O
the	O
ability	O
to	O
produce	O
effector	O
cytokines	O
are	O
programmed	O
early	O
,	O
whereas	O
perforin	O
expression	B-Gene_expression
and	O
cytolytic	O
function	O
are	O
induced	B-Positive_regulation
later	O
,	O
during	O
the	O
phase	O
of	O
clonal	O
expansion	O
in	O
IL	O
-	O
2	O
.	O

Therefore	O
,	O
the	O
two	O
major	O
effector	O
functions	O
of	O
CTL	O
,	O
cytokine	O
production	O
and	O
cytolytic	O
activity	O
,	O
are	O
not	O
intrinsically	O
coregulated	O
.	O

Distinct	O
kinetics	O
of	O
T	O
-	O
bet	O
and	O
Eomes	O
expression	B-Gene_expression
during	O
CTL	O
differentiation	O

The	O
T	O
-	O
box	O
transcription	O
factors	O
T	O
-	O
bet	O
and	O
Eomes	O
have	O
been	O
linked	B-Regulation
to	O
the	O
regulation	B-Regulation
of	O
genes	O
encoding	O
effector	O
cytokines	O
(	O
e.g.	O
,	O
Ifng	O
)	O
and	O
genes	O
important	O
for	O
cytolytic	O
function	O
(	O
e.g.	O
,	O
Prf1	O
and	O
GzmB	O
)	O
(	O
20	O
)	O
.	O

We	O
investigated	O
the	O
kinetics	O
of	O
expression	B-Gene_expression
of	O
these	O
transcription	O
factors	O
in	O
our	O
in	O
vitro	O
cultures	O
(	O
Fig	O
.	O

1	O
,	O
A	O
-	O
D	O
)	O
.	O

T	O
-	O
bet	O
mRNA	O
and	O
protein	O
were	O
not	O
detectable	B-Gene_expression
in	O
naive	O
CD8+	O
T	O
cells	O
,	O
but	O
were	O
strongly	O
induced	B-Positive_regulation
upon	O
TCR	O
priming	O
(	O
day	O
2	O
)	O
and	O
remained	B-Positive_regulation
expressed	B-Gene_expression
through	O
day	O
6	O
of	O
differentiation	O
(	O
Fig	O
.	O

1	O
,	O
A	O
and	O
C	O
;	O
quantified	O
in	O
Fig	O
.	O

1	O
,	O
B	O
and	O
D	O
)	O
.	O

In	O
contrast	O
,	O
Eomes	O
expression	B-Gene_expression
was	O
low	B-Positive_regulation
or	I-Positive_regulation
undetectable	I-Positive_regulation
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
in	O
naive	O
CD8+	O
T	O
cells	O
,	O
and	O
TCR	O
priming	O
in	O
culture	O
had	O
only	O
a	O
modest	O
effect	B-Regulation
on	O
its	O
expression	B-Gene_expression
at	O
day	O
2	O
(	O
Fig	O
.	O

1	O
,	O
A	O
and	O
C	O
)	O
.	O

Strong	O
induction	B-Positive_regulation
of	O
Eomes	O
mRNA	O
and	O
protein	O
was	O
only	O
observed	O
at	O
day	O
4	O
and	O
later	O
(	O
Fig	O
.	O

1	O
,	O
A	O
and	O
C	O
)	O
.	O

T	O
-	O
bet	O
mRNA	B-Transcription
expression	I-Transcription
slightly	O
preceded	O
the	O
expression	B-Gene_expression
of	O
GzmB	O
mRNA	O
;	O
similarly	O
,	O
Eomes	O
mRNA	O
and	O
protein	O
were	O
expressed	B-Gene_expression
approximately1	O
d	O
ahead	O
of	O
the	O
reexpression	B-Gene_expression
of	O
perforin	O
mRNA	O
and	O
protein	O
,	O
respectively	O
(	O
Fig	O
.	O

1	O
,	O
B	O
and	O
D	O
)	O
.	O

This	O
detailed	O
kinetic	O
analysis	O
suggested	O
that	O
,	O
under	O
our	O
culture	O
conditions	O
,	O
T	O
-	O
bet	O
and	O
Eomes	O
contribute	O
to	O
distinct	O
aspects	O
of	O
gene	O
transcription	O
during	O
CTL	O
differentiation	O
.	O

T	O
-	O
bet	O
is	O
required	B-Positive_regulation
early	O
for	O
IFN	O
-	O
gamma	O
production	B-Gene_expression
,	O
and	O
our	O
data	O
suggested	O
that	O
Eomes	O
might	O
not	O
function	O
during	O
this	O
early	O
period	O
but	O
rather	O
might	O
contribute	B-Positive_regulation
later	O
to	O
the	O
control	B-Regulation
of	O
perforin	O
expression	B-Gene_expression
.	O

Our	O
data	O
seemed	O
most	O
consistent	O
with	O
a	O
model	O
in	O
which	O
TCR	O
signals	O
induce	B-Positive_regulation
T	O
-	O
bet	O
,	O
which	O
in	O
turn	O
induces	B-Positive_regulation
IFN	O
-	O
gamma	O
(	O
17	O
)	O
and	O
possibly	O
granzyme	O
B	O
;	O
subsequently	O
,	O
Eomes	O
is	O
induced	B-Positive_regulation
during	O
the	O
period	O
of	O
clonal	O
expansion	O
in	O
IL	O
-	O
2	O
and	O
activates	B-Positive_regulation
perforin	O
expression	B-Gene_expression
.	O

Perforin	O
and	O
granzyme	O
B	O
expression	B-Gene_expression
are	O
not	O
appreciably	O
regulated	B-Regulation
by	O
T	O
-	O
bet	O

To	O
test	O
the	O
model	O
outlined	O
in	O
the	O
previous	O
paragraph	O
directly	O
,	O
we	O
compared	O
the	O
expression	B-Gene_expression
of	O
IFN	O
-	O
gamma	O
,	O
perforin	O
,	O
and	O
granzyme	O
B	O
in	O
CD8+	O
T	O
cells	O
from	O
WT	O
and	O
Tbx21	O
(	O
T	O
-	O
bet	O
)	O
-	O
deficient	B-Negative_regulation
mice	O
.	O

As	O
expected	O
(	O
17	O
,	O
21	O
)	O
,	O
naive	O
Tbx21-/	O
-	O
CD8+	O
T	O
cells	O
produced	B-Gene_expression
IFN	O
-	O
gamma	O
poorly	O
upon	O
activation	O
(	O
Fig	O
.	O

2	O
A	O
)	O
.	O

Notably	O
,	O
this	O
deleterious	O
effect	O
of	O
T	O
-	O
bet	O
deficiency	B-Negative_regulation
was	O
only	O
observed	O
in	O
differentiating	O
CD8+	O
T	O
cells	O
until	O
day	O
4	O
of	O
culture	O
but	O
was	O
almost	O
completely	O
mitigated	O
by	O
day	O
6	O
(	O
Fig	O
.	O

2	O
A	O
)	O
.	O

This	O
most	O
likely	O
reflected	O
compensation	O
by	O
Eomes	O
,	O
which	O
was	O
strongly	O
induced	B-Positive_regulation
between	O
days	O
4	O
and	O
6	O
(	O
Fig	O
.	O

1	O
)	O
.	O

In	O
contrast	O
,	O
T-bet	O
-	O
deficient	B-Negative_regulation
T	O
cells	O
cultured	O
for	O
6	O
d	O
showed	O
no	O
defect	B-Negative_regulation
in	O
perforin	O
mRNA	B-Transcription
expression	I-Transcription
(	O
Fig	O
.	O

2	O
B	O
,	O
compare	O
lanes	O
1	O
and	O
4	O
)	O
.	O

We	O
consistently	O
observed	O
a	O
modest	O
reduction	B-Negative_regulation
in	O
GzmB	O
mRNA	O
in	O
T-bet	O
-	O
deficient	B-Negative_regulation
T	O
cells	O
(	O
Fig	O
.	O

2	O
B	O
,	O
compare	O
lanes	O
1	O
and	O
4	O
)	O
,	O
which	O
did	O
not	O
translate	O
into	O
a	O
decrease	B-Negative_regulation
in	O
expression	B-Gene_expression
of	O
granzyme	O
B	O
protein	O
(	O
Fig	O
.	O

2	O
C	O
)	O
.	O

To	O
examine	O
the	O
role	O
of	O
Eomes	O
,	O
we	O
transduced	O
naive	O
CD8+	O
T	O
cells	O
from	O
WT	O
and	O
Tbx21-/	O
-	O
mice	O
with	O
retroviruses	O
containing	O
internal	O
ribosome	O
entry	O
site	O
(	O
IRES	O
)	O
-	O
GFP	O
that	O
were	O
either	O
empty	O
or	O
encoded	O
a	O
strongly	O
transactivating	O
version	O
of	O
Eomes	O
(	O
Eo	O
-	O
VP16	O
)	O
(	O
8	O
)	O
,	O
and	O
expanded	O
them	O
for	O
6	O
d	O
under	O
our	O
culture	O
conditions	O
.	O

Eo	O
-	O
VP16	O
,	O
but	O
not	O
the	O
empty	O
GFP	O
retrovirus	O
,	O
increased	B-Positive_regulation
perforin	O
expression	B-Gene_expression
in	O
both	O
WT	O
and	O
T-bet	O
-	O
deficient	B-Negative_regulation
CD8+	O
T	O
cells	O
(	O
Fig	O
.	O

2	O
B	O
,	O
lanes	O
2	O
,	O
3	O
,	O
5	O
,	O
and	O
6	O
)	O
.	O

As	O
expected	O
,	O
Eo	O
-	O
VP16	O
also	O
rescued	B-Negative_regulation
the	O
early	O
defect	B-Negative_regulation
in	O
IFN	O
-	O
gamma	O
production	B-Gene_expression
observed	O
in	O
T-bet	O
-	O
deficient	B-Negative_regulation
CD8+	O
T	O
cells	O
(	O
Fig	O
.	O

2	O
D	O
)	O
.	O

However	O
,	O
Eo	O
-	O
VP16	O
did	O
not	O
induce	B-Positive_regulation
GzmB	O
mRNA	B-Transcription
expression	I-Transcription
in	O
either	O
WT	O
or	O
T-bet	O
-	O
deficient	B-Negative_regulation
cells	O
;	O
thus	O
,	O
the	O
partial	O
T	O
-	O
bet	O
dependence	B-Positive_regulation
of	O
GzmB	O
mRNA	B-Transcription
expression	I-Transcription
can	O
not	O
be	O
compensated	O
for	O
by	O
Eo	O
-	O
VP16	O
.	O

Runx3	O
controls	O
multiple	O
aspects	O
of	O
the	O
CTL	O
differentiation	O
program	O
,	O
in	O
part	O
through	O
induction	B-Positive_regulation
of	O
Eomes	O

Because	O
Runx3	O
is	O
highly	O
expressed	B-Gene_expression
in	O
peripheral	O
CD8+	O
T	O
cells	O
,	O
and	O
because	O
of	O
the	O
T-bet	O
-	O
Runx3	O
cooperation	O
we	O
observed	O
earlier	O
in	O
CD4+	O
T	O
cells	O
(	O
15	O
)	O
,	O
we	O
examined	O
the	O
role	O
of	O
Runx3	O
in	O
effector	O
CTL	O
differentiation	O
.	O

We	O
isolated	O
CD8+	O
T	O
cells	O
from	O
Runx3-/	O
-	O
(	O
KO	O
)	O
mice	O
of	O
the	O
outbred	O
ICR	O
background	O
and	O
their	O
WT	O
Runx3+/+	O
littermates	O
by	O
positive	O
selection	O
with	O
anti	O
-	O
CD8	O
magnetic	O
beads	O
(	O
Figs	O
.	O

S1	O
and	O
S2	O
,	O
available	O
at	O
http	O
:	O
//www.jem.org/cgi/content/full/jem.20081242/DC1	O
)	O
.	O

Strikingly	O
,	O
Runx3-/	O
-	O
CD8+	O
T	O
cells	O
were	O
strongly	O
impaired	O
in	O
their	O
ability	O
to	O
differentiate	O
into	O
effector	O
CTLs	O
,	O
as	O
judged	O
by	O
expression	B-Gene_expression
of	O
perforin	O
,	O
granzyme	O
B	O
,	O
and	O
IFN	O
-	O
gamma	O
(	O
Fig	O
.	O

3	O
)	O
.	O

Compared	O
with	O
WT	O
T	O
cells	O
,	O
perforin	O
mRNA	O
and	O
protein	O
expression	B-Gene_expression
were	O
essentially	O
undetectable	B-Positive_regulation
in	O
Runx3-/	O
-	O
T	O
cells	O
at	O
day	O
6	O
of	O
culture	O
(	O
Fig	O
.	O

3	O
,	O
A	O
and	O
B	O
)	O
.	O

Runx3-/	O
-	O
T	O
cells	O
also	O
had	O
no	O
detectable	O
Eomes	O
expression	B-Gene_expression
;	O
in	O
contrast	O
,	O
T	O
-	O
bet	O
expression	B-Gene_expression
was	O
unimpaired	B-Negative_regulation
(	O
Fig	O
.	O

3	O
A	O
)	O
.	O

Furthermore	O
,	O
Runx3	O
was	O
required	B-Positive_regulation
for	O
maximal	O
production	B-Gene_expression
of	O
IFN	O
-	O
gamma	O
,	O
but	O
not	O
TNF	O
or	O
IL	O
-	O
2	O
,	O
by	O
CD8+	O
T	O
cells	O
restimulated	O
at	O
day	O
6	O
(	O
Fig	O
.	O

3	O
C	O
)	O
.	O

We	O
previously	O
reported	O
that	O
Th1	O
cell	O
differentiation	O
was	O
regulated	O
through	O
a	O
feed	O
-	O
forward	O
loop	O
in	O
which	O
T	O
-	O
bet	O
is	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
early	O
and	O
induces	B-Positive_regulation
Runx3	O
,	O
after	O
which	O
T	O
-	O
bet	O
and	O
Runx3	O
cooperate	O
to	O
induce	B-Positive_regulation
IFN	O
-	O
gamma	O
and	O
silence	B-Negative_regulation
IL	O
-	O
4	O
,	O
thus	O
promoting	O
stable	O
differentiation	O
toward	O
the	O
Th1	O
lineage	O
(	O
15	O
,	O
22	O
)	O
.	O

Because	O
(	O
a	O
)	O
Runx3	O
appeared	O
necessary	B-Positive_regulation
for	O
Eomes	O
induction	B-Positive_regulation
(	O
Fig	O
.	O

3	O
A	O
)	O
,	O
(	O
b	O
)	O
the	O
kinetics	O
of	O
Eomes	O
expression	B-Gene_expression
paralleled	O
those	O
of	O
perforin	O
expression	B-Gene_expression
(	O
Fig	O
.	O

2	O
)	O
,	O
and	O
(	O
c	O
)	O
overexpression	B-Positive_regulation
of	O
Eo	O
-	O
VP16	O
in	O
either	O
WT	O
or	O
T-bet	O
-	O
deficient	B-Negative_regulation
T	O
cells	O
led	B-Positive_regulation
to	O
an	O
increase	B-Positive_regulation
in	O
both	O
perforin	O
and	O
IFN	O
-	O
gamma	O
expression	B-Gene_expression
(	O
Fig	O
.	O

2	O
,	O
B	O
and	O
D	O
)	O
,	O
we	O
asked	O
whether	O
CTL	O
differentiation	O
was	O
also	O
potentially	O
regulated	O
by	O
a	O
feed	O
-	O
forward	O
loop	O
involving	O
these	O
same	O
two	O
classes	O
of	O
Runx	O
and	O
T	O
-	O
box	O
transcription	O
factors	O
.	O

Specifically	O
,	O
we	O
asked	O
whether	O
Runx3	O
,	O
which	O
was	O
necessary	B-Positive_regulation
for	O
Eomes	O
induction	B-Positive_regulation
,	O
then	O
cooperated	O
with	O
Eomes	O
to	O
regulate	B-Regulation
transcription	B-Transcription
of	O
the	O
effector	O
CTL	O
markers	O
perforin	O
,	O
IFN	O
-	O
gamma	O
,	O
and	O
granzyme	O
B	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
used	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assays	O
to	O
ask	O
whether	O
Eomes	O
and	O
Runx3	O
bound	B-Binding
regulatory	O
regions	O
of	O
the	O
Prf1	O
,	O
Ifng	O
,	O
and	O
Gzmb	O
genes	O
(	O
Fig	O
.	O

3	O
D	O
)	O
.	O

Both	O
proteins	O
associated	B-Binding
with	O
gene	O
regulatory	O
regions	O
in	O
differentiated	O
CTLs	O
.	O

Runx3	O
bound	B-Binding
to	O
the	O
Prf1	O
and	O
Gzmb	O
transcription	O
start	O
sites	O
(	O
TSS	O
)	O
;	O
to	O
a	O
known	O
IL	O
-	O
2	O
responsive	O
enhancer	O
located	O
near	O
-	O
1	O
kb	O
of	O
the	O
Prf1	O
gene	O
(	O
23	O
)	O
;	O
to	O
the	O
distal	O
CTL	O
-	O
specific	O
DNase	O
I	O
hypersensitive	O
site	O
9	O
in	O
the	O
Prf1	O
locus	O
(	O
24	O
)	O
;	O
to	O
the	O
Ifng	O
promoter	O
near	O
the	O
TSS	O
,	O
as	O
previously	O
reported	O
for	O
Th1	O
cells	O
(	O
10	O
)	O
;	O
and	O
to	O
several	O
DNase	O
I	O
hypersensitive	O
sites	O
in	O
the	O
Ifng	O
locus	O
(	O
Fig	O
.	O

3	O
D	O
and	O
not	O
depicted	O
)	O
(	O
25	O
)	O
.	O

Eomes	O
bound	B-Binding
primarily	O
to	O
the	O
Prf1	O
TSS	O
and	O
the	O
-	O
1	O
kb	O
enhancer	O
;	O
this	O
binding	O
was	O
substantially	O
greater	O
than	O
that	B-Binding
observed	O
at	O
the	O
promoter	O
of	O
the	O
Il2rb	O
gene	O
,	O
a	O
known	O
direct	O
target	B-Binding
of	O
Eomes	O
(	O
8	O
)	O
,	O
and	O
comparable	O
to	O
that	B-Binding
observed	O
at	O
the	O
Ifng	O
TSS	O
,	O
a	O
known	O
target	B-Binding
of	O
T	O
-	O
box	O
proteins	O
in	O
both	O
Th1	O
and	O
CD8+	O
T	O
cells	O
(	O
Fig	O
.	O

3	O
D	O
)	O
(	O
17	O
)	O
.	O

To	O
determine	O
whether	O
Runx3	O
controlled	O
the	O
expression	O
of	O
CTL	O
effector	O
genes	O
through	O
its	O
induction	B-Positive_regulation
of	O
Eomes	O
,	O
we	O
retrovirally	O
expressed	B-Gene_expression
Runx3	O
and	O
Eo	O
-	O
VP16	O
in	O
CD8+	O
T	O
cells	O
from	O
Runx3-/	O
-	O
mice	O
.	O

Because	O
of	O
the	O
limited	O
number	O
of	O
CD8+	O
T	O
cells	O
in	O
these	O
mice	O
,	O
and	O
because	O
we	O
saw	O
no	O
difference	O
between	O
Runx3-/	O
-	O
CD8+CD4	O
-	O
SP	O
and	O
CD8+CD4+	O
DP	O
cells	O
in	O
our	O
previous	O
experiments	O
,	O
we	O
used	O
total	O
Runx3-/	O
-	O
CD8+	O
T	O
cells	O
without	O
further	O
fractionation	O
as	O
recipients	O
for	O
retroviral	O
transduction	O
.	O

Reconstitution	O
of	O
Runx3-/	O
-	O
CD8+	O
T	O
cells	O
with	O
Runx3	O
restored	B-Positive_regulation
expression	B-Gene_expression
of	O
Eomes	O
as	O
well	O
as	O
perforin	O
,	O
granzyme	O
B	O
,	O
and	O
IFN	O
-	O
gamma	O
(	O
Fig	O
.	O

4	O
,	O
A	O
and	O
B	O
)	O
.	O

In	O
addition	O
,	O
Runx3-/	O
-	O
T	O
cells	O
showed	O
a	O
compensatory	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
Runx1	O
,	O
which	O
was	O
suppressed	B-Negative_regulation
upon	O
reconstitution	O
with	O
Runx3	O
,	O
indicating	O
that	O
Runx1	O
is	O
a	O
target	O
of	O
repression	B-Negative_regulation
by	O
Runx3	O
.	O

Notably	O
,	O
Eo	O
-	O
VP16	O
did	O
not	O
up	B-Positive_regulation
-	I-Positive_regulation
regulate	I-Positive_regulation
perforin	O
expression	B-Gene_expression
when	O
expressed	B-Gene_expression
in	O
Runx3-/	O
-	O
cells	O
,	O
even	O
though	O
it	O
restored	B-Positive_regulation
the	O
capacity	O
to	O
induce	B-Positive_regulation
IFN	O
-	O
gamma	O
expression	B-Gene_expression
upon	O
TCR	O
restimulation	O
(	O
Fig	O
.	O

4	O
,	O
A	O
and	O
B	O
)	O
.	O

This	O
result	O
suggests	O
strongly	O
that	O
perforin	O
expression	B-Gene_expression
requires	B-Positive_regulation
Runx3	O
and	O
Eomes	O
.	O

As	O
expected	O
from	O
their	O
defect	B-Positive_regulation
in	O
perforin	O
and	O
granzyme	O
B	O
expression	B-Gene_expression
,	O
Runx3-/	O
-	O
CD8+	O
T	O
cells	O
showed	O
defective	O
cytolytic	O
activity	O
in	O
a	O
mixed	O
lymphocyte	O
reaction	O
(	O
12	O
)	O
.	O

However	O
,	O
TCR	O
-	O
stimulated	O
Runx3-/	O
-	O
CD8+	O
cells	O
were	O
as	O
effective	O
as	O
WT	O
cells	O
in	O
killing	O
tumor	O
cells	O
in	O
a	O
redirected	O
CTL	O
assay	O
(	O
12	O
)	O
.	O

Furthermore	O
,	O
CD8+	O
cells	O
from	O
the	O
peritoneal	O
cavity	O
of	O
Runx3-/	O
-	O
mice	O
immunized	O
with	O
certain	O
tumor	O
cells	O
effectively	O
killed	O
these	O
targets	O
(	O
13	O
)	O
.	O

Therefore	O
,	O
although	O
activation	B-Positive_regulation
of	O
the	O
perforin/granzyme	O
B	O
machinery	O
is	O
defective	B-Negative_regulation
in	O
Runx3-/	O
-	O
CD8+	O
cells	O
,	O
these	O
cells	O
are	O
not	O
entirely	O
devoid	O
of	O
cytolytic	O
activity	O
and	O
could	O
still	O
effectively	O
kill	O
targets	O
,	O
possibly	O
by	O
alternative	O
mechanisms	O
such	O
as	O
the	O
Fas	O
-	O
Fas	O
ligand	O
pathway	O
.	O

Runx3	O
and	O
T	O
-	O
box	O
factors	O
control	O
a	O
complex	O
program	O
of	O
transcriptional	O
regulation	O
during	O
CTL	O
differentiation	O

Collectively	O
,	O
these	O
data	O
provide	O
evidence	O
that	O
Runx3	O
,	O
together	O
with	O
T	O
-	O
box	O
factors	O
,	O
orchestrates	O
a	O
complex	O
program	O
of	O
transcriptional	O
regulation	O
in	O
differentiating	O
CTL	O
(	O
Fig	O
.	O

4	O
C	O
)	O
.	O

Runx3	O
is	O
present	B-Gene_expression
in	O
naive	O
CD8+	O
T	O
cells	O
before	O
activation	O
(	O
12	O
)	O
.	O

It	O
represses	B-Negative_regulation
Runx1	O
and	O
has	B-Positive_regulation
a	I-Positive_regulation
positive	I-Positive_regulation
role	I-Positive_regulation
in	O
the	O
induction	B-Positive_regulation
of	O
Eomes	O
,	O
granzyme	O
B	O
,	O
perforin	O
,	O
and	O
IFN	O
-	O
gamma	O
.	O

Runx3	O
binds	B-Binding
to	O
promoters	O
and	O
putative	O
regulatory	O
regions	O
of	O
the	O
latter	O
three	O
genes	O
,	O
suggesting	O
a	O
direct	O
effect	B-Regulation
on	O
gene	O
expression	B-Gene_expression
.	O

Additional	O
experiments	O
are	O
needed	O
to	O
determine	O
whether	O
Eomes	O
and	O
Runx1	O
are	O
also	O
direct	O
target	B-Binding
genes	O
of	O
Runx3	O
.	O

Surprisingly	O
,	O
Runx3	O
contributed	B-Positive_regulation
to	O
the	O
optimal	O
expression	B-Gene_expression
of	O
TNF	O
,	O
IL	O
-	O
2	O
,	O
and	O
IFN	O
-	O
gamma	O
at	O
day	O
4	O
(	O
Fig	O
.	O

S2	O
)	O
.	O

For	O
TNF	O
and	O
IL	O
-	O
2	O
,	O
the	O
requirement	B-Positive_regulation
for	O
Runx3	O
subsides	B-Negative_regulation
by	O
day	O
6	O
(	O
Fig	O
.	O

3	O
C	O
)	O
,	O
possibly	O
because	O
of	O
compensation	O
by	O
Runx1	O
,	O
which	O
is	O
derepressed	B-Negative_regulation
in	O
Runx3-/	O
-	O
cells	O
(	O
Fig	O
.	O

4	O
A	O
)	O
.	O

Runx3	O
continues	O
to	O
be	O
required	B-Positive_regulation
for	O
IFN	O
-	O
gamma	O
expression	B-Gene_expression
even	O
at	O
day	O
6	O
,	O
perhaps	O
because	O
of	O
its	O
role	B-Regulation
in	O
the	O
induction	B-Positive_regulation
of	O
Eomes	O
expression	B-Gene_expression
(	O
Fig	O
.	O

4	O
A	O
)	O
.	O

An	O
unexpected	O
finding	O
was	O
that	O
the	O
two	O
T	O
-	O
box	O
transcription	O
factors	O
,	O
T	O
-	O
bet	O
and	O
Eomes	O
,	O
are	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
with	O
very	O
different	O
kinetics	O
in	O
CD8+	O
T	O
cells	O
under	O
our	O
culture	O
conditions	O
and	O
have	O
nonredundant	O
roles	O
in	O
the	O
subsequent	O
expression	O
of	O
key	O
effector	O
proteins	O
(	O
Fig	O
.	O

4	O
C	O
)	O
.	O

T	O
-	O
bet	O
is	O
needed	B-Positive_regulation
early	O
to	O
confer	O
on	O
activated	O
CD8+	O
T	O
cells	O
the	O
competence	O
to	O
produce	B-Gene_expression
IFN	O
-	O
gamma	O
upon	O
restimulation	O
,	O
but	O
its	O
function	O
is	O
less	O
important	O
at	O
later	O
times	O
.	O

Eomes	O
,	O
which	O
is	O
induced	B-Positive_regulation
late	O
and	O
functions	B-Regulation
downstream	I-Regulation
of	O
Runx3	O
,	O
may	O
substitute	O
for	O
T	O
-	O
bet	O
in	O
promoting	B-Positive_regulation
the	O
acute	O
expression	B-Gene_expression
of	O
IFN	O
-	O
gamma	O
in	O
restimulated	O
CTLs	O
(	O
8	O
)	O
.	O

Indeed	O
,	O
T	O
-	O
bet	O
and	O
Eomes	O
both	O
contribute	B-Positive_regulation
to	O
perforin	O
expression	B-Gene_expression
in	O
NK	O
cells	O
(	O
8	O
,	O
26	O
)	O
,	O
and	O
Eomes	O
induces	B-Positive_regulation
granzyme	O
B	O
as	O
effectively	O
as	O
T	O
-	O
bet	O
in	O
developing	O
Th2	O
cells	O
(	O
7	O
)	O
;	O
thus	O
,	O
the	O
relative	O
roles	O
of	O
these	O
T	O
-	O
box	O
transcription	O
factors	O
vary	O
depending	O
on	O
cell	O
type	O
.	O

Surprisingly	O
,	O
however	O
,	O
Eomes	O
and	O
T	O
-	O
bet	O
appeared	O
nonredundant	O
in	O
their	O
ability	O
to	O
induce	B-Positive_regulation
two	O
other	O
markers	O
of	O
CTL	O
function	O
,	O
Prf1	O
and	O
Gzmb	O
(	O
Fig	O
.	O

4	O
C	O
)	O
.	O

Rather	O
,	O
T	O
-	O
bet	O
and	O
Eomes	O
were	O
involved	O
in	O
regulating	B-Regulation
granzyme	O
B	O
and	O
perforin	O
expression	B-Gene_expression
,	O
respectively	O
:	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
T	O
-	O
bet	O
and	O
Eomes	O
mRNA	O
and	O
protein	O
closely	O
preceded	B-Positive_regulation
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
Gzmb	O
and	O
Prf1	O
mRNA	O
and	O
protein	O
,	O
respectively	O
.	O

T	O
-	O
bet	O
had	B-Regulation
no	I-Regulation
role	I-Regulation
in	O
perforin	O
expression	B-Gene_expression
under	O
our	O
culture	O
conditions	O
,	O
and	O
Eo	O
-	O
VP16	O
did	O
not	O
affect	B-Regulation
granzyme	O
B	O
expression	B-Gene_expression
when	O
expressed	B-Gene_expression
in	O
T-bet-/	O
-	O
or	O
Runx3-/	O
-	O
cells	O
.	O

Because	O
conventional	O
Eomes	O
-	O
deficient	B-Negative_regulation
mice	O
die	O
before	O
precursor	O
cells	O
can	O
be	O
isolated	O
for	O
bone	O
marrow	O
transfers	O
(	O
27	O
)	O
and	O
because	O
T	O
cells	O
conditionally	O
deficient	B-Negative_regulation
in	O
Eomes	O
have	O
only	O
recently	O
been	O
described	O
(	O
9	O
)	O
,	O
we	O
were	O
unable	O
to	O
introduce	O
Runx3	O
into	O
Eomes	O
-	O
deficient	B-Negative_regulation
CD8+	O
T	O
cells	O
to	O
test	O
formally	O
whether	O
Eomes	O
cooperated	O
with	O
Runx3	O
to	O
induce	B-Positive_regulation
perforin	O
expression	B-Gene_expression
.	O

Collectively	O
,	O
our	O
data	O
are	O
consistent	O
with	O
a	O
transcriptional	O
network	O
in	O
which	O
preexisting	O
Runx3	O
cooperates	O
with	O
the	O
induced	B-Positive_regulation
T	O
-	O
box	O
factors	O
T	O
-	O
bet	O
and	O
Eomes	O
and	O
IL	O
-	O
2Rbeta	O
signals	O
(	O
unpublished	O
data	O
)	O
to	O
orchestrate	O
CTL	O
differentiation	O
(	O
Fig	O
.	O

4	O
C	O
)	O
.	O

Our	O
data	O
recall	O
the	O
"	O
feed	O
-	O
forward	O
"	O
interaction	B-Regulation
between	O
T	O
-	O
bet	O
and	O
Runx3	O
that	O
we	O
previously	O
described	O
in	O
CD4+	O
(	O
Th1	O
)	O
T	O
cells	O
(	O
15	O
)	O
but	O
are	O
distinct	O
in	O
two	O
respects	O
:	O
in	O
differentiating	O
Th1	O
cells	O
,	O
T	O
-	O
bet	O
is	O
induced	B-Positive_regulation
by	O
TCR	O
signals	O
and	O
IFN	O
-	O
gamma	O
,	O
and	O
in	O
turn	O
induces	B-Positive_regulation
Runx3	O
(	O
15	O
)	O
,	O
whereas	O
in	O
differentiating	O
CD8+	O
T	O
cells	O
,	O
preexisting	O
Runx3	O
is	O
required	B-Positive_regulation
to	O
induce	B-Positive_regulation
the	O
T	O
-	O
box	O
transcription	O
factor	O
Eomes	O
.	O

Whole	O
-	O
genome	O
experiments	O
in	O
these	O
and	O
other	O
systems	O
will	O
be	O
required	O
to	O
establish	O
whether	O
cooperation	O
between	O
T	O
-	O
box	O
and	O
Runx	O
family	O
transcription	O
factors	O
is	O
a	O
general	O
feature	O
of	O
cellular	O
differentiation	O
programs	O
.	O

Antibodies	O
and	O
reagents	O
.	O

The	O
following	O
antibodies	O
used	O
for	O
intracellular	O
or	O
surface	O
stains	O
were	O
obtained	O
from	O
eBioscience	O
:	O
anti-IL	O
-	O
2	O
,	O
anti-IFN	O
-	O
gamma	O
,	O
anti	O
-	O
TNF	O
,	O
anti	O
-	O
granzyme	O
B	O
,	O
anti	O
-	O
CD8	O
,	O
anti	O
-	O
CD25	O
,	O
and	O
anti	O
-	O
CD44	O
.	O

Anti	O
-	O
CD69	O
was	O
purchased	O
from	O
BD	O
.	O

For	O
ChIP	O
experiments	O
,	O
the	O
anti	O
-	O
Eomes	O
antibody	O
was	O
obtained	O
from	O
Abcam	O
and	O
the	O
anti	O
-	O
Runx3	O
antibody	O
was	O
produced	O
by	O
the	O
Groner	O
laboratory	O
.	O

The	O
following	O
antibodies	O
were	O
used	O
for	O
immunoblotting	O
:	O
antiperforin	O
(	O
Abcam	O
)	O
,	O
anti	O
-	O
Eomes	O
(	O
Abcam	O
)	O
,	O
and	O
anti-Pol	O
-	O
II	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc.	O
)	O
.	O

The	O
T	O
-	O
bet	O
antibody	O
was	O
provided	O
by	O
L	O
.	O

Glimcher	O
(	O
Harvard	O
School	O
of	O
Public	O
Health	O
,	O
Boston	O
,	O
MA	O
)	O
.	O

The	O
following	O
reagents	O
were	O
used	O
for	O
the	O
experiments	O
presented	O
in	O
this	O
report	O
:	O
Annexin	O
V	O
-	O
FITC	O
Apoptosis	O
Detection	O
Kit	O
(	O
BD	O
)	O
,	O
CD8	O
Negative	O
Isolation	O
Kit	O
(	O
Invitrogen	O
)	O
,	O
CD8	O
MicroBeads	O
(	O
Miltenyi	O
Biotec	O
)	O
,	O
and	O
SYBR	O
Green	O
PCR	O
Core	O
Reagents	O
(	O
Applied	O
Biosystems	O
)	O
.	O

The	O
Gp33	O
peptide	O
(	O
KAVYNFATC	O
)	O
was	O
synthesized	O
by	O
the	O
Tufts	O
University	O
Core	O
Facility	O
,	O
and	O
10	O
mM	O
of	O
stock	O
solutions	O
was	O
prepared	O
in	O
DMSO	O
.	O

Isolation	O
and	O
culture	O
of	O
primary	O
CD8+	O
T	O
cells	O
.	O

CD8+	O
T	O
cells	O
from	O
4-8-wk	O
-	O
old	O
Tcra-/	O
-	O
x	O
P14	O
TCR	O
transgenic	O
(	O
Taconic	O
)	O
,	O
C57BL/6J	O
WT	O
,	O
or	O
Tbx21-/	O
-	O
(	O
The	O
Jackson	O
Laboratory	O
)	O
mice	O
were	O
purified	O
(	O
>	O
95	O
%	O
purity	O
)	O
by	O
negative	O
selection	O
(	O
Invitrogen	O
)	O
from	O
pooled	O
spleen	O
and	O
lymph	O
node	O
cells	O
.	O

CD8+	O
T	O
cells	O
from	O
Runx3-/	O
-	O
mice	O
on	O
the	O
ICR	O
background	O
were	O
purified	O
by	O
positive	O
selection	O
(	O
Miltenyi	O
Biotec	O
)	O
.	O

All	O
mice	O
were	O
maintained	O
in	O
specific	O
pathogen	O
-	O
free	O
barrier	O
facilities	O
and	O
used	O
according	O
to	O
protocols	O
approved	O
by	O
the	O
Immune	O
Disease	O
Institute	O
and	O
the	O
Harvard	O
Medical	O
School	O
Animal	O
Care	O
and	O
Use	O
Committees	O
.	O

For	O
stimulation	O
,	O
purified	O
CD8+	O
T	O
cells	O
were	O
cultured	O
at	O
106	O
cells/ml	O
(	O
10	O
ml	O
)	O
in	O
T25	O
flasks	O
coated	O
with	O
1	O
mug/ml	O
each	O
of	O
anti	O
-	O
CD3	O
(	O
clone	O
2C11	O
)	O
and	O
anti	O
-	O
CD28	O
(	O
clone	O
37.51	O
)	O
by	O
pretreatment	O
with	O
300	O
mug/ml	O
goat	O
anti	O
-	O
hamster	O
IgG	O
.	O

After	O
48	O
h	O
,	O
cells	O
were	O
removed	O
from	O
the	O
TCR	O
stimulation	O
and	O
recultured	O
at	O
a	O
concentration	O
of	O
5	O
x	O
105	O
cells/ml	O
in	O
media	O
supplemented	O
with	O
100	O
U/ml	O
rhIL	O
-	O
2	O
.	O

Every	O
24	O
h	O
,	O
viable	O
cells	O
were	O
counted	O
and	O
readjusted	O
to	O
5	O
x	O
105	O
cells/ml	O
with	O
fresh	O
media	O
containing	O
the	O
corresponding	O
amount	O
of	O
rhIL	O
-	O
2	O
.	O

Isolation	O
of	O
CD8+	O
T	O
cells	O
from	O
Runx3-/	O
-	O
mice	O
.	O

Runx3	O
-	O
deficient	B-Negative_regulation
T	O
cells	O
fail	O
to	O
silence	B-Negative_regulation
CD4	O
expression	B-Gene_expression
normally	O
(	O
Fig	O
.	O

S1	O
)	O
(	O
12	O
,	O
13	O
)	O
.	O

We	O
therefore	O
further	O
fractionated	O
the	O
positively	O
selected	O
CD8+	O
T	O
cells	O
from	O
Runx3	O
KO	O
mice	O
into	O
CD8+CD4	O
-	O
SP	O
or	O
CD8+CD4+	O
DP	O
cells	O
by	O
separation	O
using	O
anti	O
-	O
CD4	O
magnetic	O
beads	O
.	O

This	O
yielded	O
a	O
Runx3	O
KO	O
SP	O
"	O
enriched	O
"	O
population	O
that	O
contained	O
75	O
%	O
CD8+CD4	O
-	O
cells	O
and	O
a	O
KO	O
DP	O
enriched	O
population	O
that	O
contained	O
85	O
%	O
CD8+CD4+	O
cells	O
(	O
Fig	O
.	O

S1	O
)	O
.	O

The	O
cells	O
were	O
stimulated	O
with	O
anti	O
-	O
CD3+	O
anti	O
-	O
CD28	O
for	O
2	O
d	O
before	O
removing	O
them	O
from	O
the	O
TCR	O
stimulus	O
and	O
culturing	O
them	O
in	O
media	O
containing	O
100	O
U/ml	O
IL	O
-	O
2	O
.	O

As	O
previously	O
reported	O
,	O
TCR	O
-	O
induced	O
proliferation	O
of	O
Runx3-/	O
-	O
CD8+	O
T	O
cells	O
was	O
severely	O
impaired	O
,	O
irrespective	O
of	O
CD4	O
expression	B-Gene_expression
(	O
Fig	O
.	O

S1	O
)	O
(	O
12	O
,	O
13	O
)	O
.	O

However	O
,	O
the	O
Runx3-/	O
-	O
cells	O
showed	O
cell	O
-	O
surface	O
expression	O
patterns	O
indicative	O
of	O
activated	O
cells	O
,	O
including	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
CD25	O
and	O
CD69	O
(	O
Fig	O
.	O

S1	O
)	O
.	O

As	O
expected	O
from	O
their	O
ability	O
to	O
up	B-Positive_regulation
-	I-Positive_regulation
regulate	I-Positive_regulation
CD25	O
,	O
Runx3-/	O
-	O
CD8+	O
T	O
cells	O
responded	O
to	O
IL	O
-	O
2	O
supplementation	O
after	O
day	O
2	O
and	O
efficiently	O
expanded	O
until	O
day	O
6	O
of	O
the	O
culture	O
period	O
,	O
albeit	O
at	O
slower	O
rates	O
compared	O
with	O
WT	O
cells	O
(	O
Fig	O
.	O

S1	O
)	O
.	O

Although	O
a	O
fraction	O
of	O
the	O
KO	O
DP	O
cells	O
silenced	B-Negative_regulation
CD4	O
expression	B-Gene_expression
after	O
activation	O
,	O
the	O
ratio	O
of	O
SP/DP	O
cells	O
in	O
each	O
enriched	O
population	O
remained	O
constant	O
thereafter	O
,	O
and	O
we	O
did	O
not	O
observe	O
any	O
major	O
differences	O
between	O
these	O
two	O
populations	O
throughout	O
the	O
culture	O
period	O
,	O
indicating	O
that	O
in	O
terms	O
of	O
effector	O
CTL	O
differentiation	O
and	O
under	O
our	O
culture	O
conditions	O
,	O
Runx3-/	O
-	O
CD8+	O
T	O
cells	O
that	O
also	O
coexpress	B-Gene_expression
CD4	O
are	O
indistinguishable	O
from	O
those	O
that	O
do	O
not	O
.	O

The	O
data	O
presented	O
in	O
Fig	O
.	O

S2	O
are	O
from	O
Runx3	O
KO	O
SP	O
cells	O
,	O
whereas	O
those	O
shown	O
in	O
Figs	O
.	O

3	O
and	O
4	O
are	O
from	O
total	O
Runx3	O
KO	O
CD8	O
cells	O
.	O

FACS	O
-	O
based	O
cytotoxicity	O
assay	O
.	O

To	O
measure	O
cytotoxicity	O
,	O
EL4	O
thymoma	O
target	O
cells	O
were	O
loaded	O
with	O
0	O
or	O
1	O
muM	O
Gp33	O
peptide	O
for	O
2	O
h	O
before	O
a	O
2	O
-	O
h	O
coincubation	O
with	O
P14	O
CD8+	O
T	O
cells	O
at	O
the	O
effector-to	O
-	O
target	O
ratios	O
indicated	O
in	O
the	O
figures	O
in	O
96	O
-	O
well	O
round	O
-	O
bottom	O
plates	O
.	O

After	O
the	O
coincubation	O
period	O
,	O
cells	O
were	O
stained	O
with	O
Annexin	O
V	O
-	O
FITC	O
and	O
anti-CD8	O
-	O
allophycocyanin	O
.	O

Data	O
analysis	O
was	O
performed	O
with	O
FlowJo	O
software	O
(	O
Tree	O
Star	O
,	O
Inc.	O
)	O
;	O
EL4	O
target	O
cells	O
(	O
CD8	O
-	O
negative	O
events	O
)	O
were	O
gated	O
,	O
and	O
the	O
percentage	O
of	O
Annexin	O
V+	O
target	O
cells	O
was	O
determined	O
.	O

Cytokine	O
and	O
surface	O
marker	O
staining	O
.	O

To	O
assess	O
cytokine	O
production	O
,	O
cells	O
were	O
restimulated	O
with	O
10	O
nM	O
PMA	O
+	O
1	O
muM	O
ionomycin	O
for	O
6	O
h	O
(	O
unless	O
indicated	O
otherwise	O
in	O
the	O
figures	O
)	O
,	O
and	O
intracellular	O
cytokine	O
stains	O
were	O
performed	O
as	O
previously	O
described	O
(	O
28	O
)	O
.	O

To	O
detect	O
expression	O
of	O
surface	O
molecules	O
,	O
cells	O
were	O
washed	O
in	O
PBS	O
,	O
resuspended	O
in	O
FACS	O
wash	O
buffer	O
(	O
3	O
%	O
FBS	O
,	O
0.1	O
%	O
sodium	O
azide	O
,	O
30	O
mM	O
Hepes	O
,	O
1x	O
PBS	O
)	O
containing	O
the	O
antibodies	O
indicated	O
in	O
the	O
figures	O
at	O
previously	O
optimized	O
concentrations	O
,	O
incubated	O
for	O
15	O
min	O
at	O
room	O
temperature	O
(	O
RT	O
)	O
,	O
washed	O
,	O
and	O
resuspended	O
in	O
2	O
%	O
formaldehyde	O
fixative	O
solution	O
before	O
acquisition	O
on	O
a	O
FACSCalibur	O
(	O
BD	O
)	O
.	O

Retroviral	O
transduction	O
of	O
primary	O
CD8+	O
T	O
cells	O
.	O

For	O
transduction	O
experiments	O
,	O
viral	O
supernatants	O
were	O
generated	O
by	O
calcium	O
phosphate	O
transfection	O
of	O
Phoenix	O
cells	O
and	O
concentration	O
by	O
overnight	O
centrifugation	O
at	O
6	O
,	O
000	O
g	O
.	O

At	O
approximately42	O
h	O
after	O
the	O
initial	O
TCR	O
activation	O
of	O
106	O
CD8+	O
T	O
cells	O
per	O
well	O
in	O
12	O
-	O
well	O
plates	O
,	O
the	O
culture	O
media	O
was	O
removed	O
and	O
replaced	O
with	O
complete	O
media	O
supplemented	O
with	O
8	O
mug/ml	O
polybrene	O
containing	O
fresh	O
plus	O
concentrated	O
virus	O
.	O

The	O
plates	O
were	O
centrifuged	O
at	O
700	O
g	O
for	O
1	O
h	O
at	O
RT	O
before	O
returning	O
to	O
37degreesC	O
for	O
an	O
additional	O
5	O
h	O
.	O

Retroviral	O
constructs	O
for	O
Eomes	O
-	O
VP16	O
and	O
the	O
MIG	O
control	O
empty	O
vector	O
were	O
a	O
gift	O
from	O
S.L	O
.	O

Reiner	O
(	O
University	O
of	O
Pennsylvania	O
,	O
Philadelphia	O
,	O
PA	O
)	O
(	O
8	O
)	O
.	O

ChIP	O
and	O
real	O
-	O
time	O
PCR	O
analysis	O
.	O

20	O
x	O
106	O
CD8+	O
T	O
cells	O
per	O
immunoprecipitation	O
were	O
fixed	O
by	O
adding	O
a	O
1/10th	O
volume	O
of	O
fixation	O
solution	O
(	O
11.1	O
%	O
formaldehyde	O
,	O
100	O
mM	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
,	O
0.5	O
mM	O
EGTA	O
,	O
50	O
mM	O
Hepes	O
)	O
to	O
1	O
volume	O
of	O
culture	O
media	O
and	O
were	O
incubated	O
for	O
10	O
or	O
30	O
min	O
at	O
RT	O
.	O

Fixation	O
was	O
stopped	O
with	O
120	O
mM	O
glycine	O
on	O
ice	O
for	O
5	O
min	O
.	O

Fixed	O
cells	O
were	O
washed	O
2x	O
with	O
cold	O
PBS	O
,	O
1x	O
with	O
cold	O
solution	O
I	O
(	O
10	O
mM	O
Tris	O
[	O
pH	O
7.5	O
]	O
,	O
10	O
mM	O
EDTA	O
,	O
0.5	O
mM	O
EGTA	O
,	O
1	O
%	O
Triton	O
X	O
-	O
100	O
)	O
,	O
and	O
1x	O
with	O
cold	O
solution	O
II	O
(	O
10	O
mM	O
Tris	O
[	O
pH	O
7.5	O
]	O
,	O
1	O
mM	O
EDTA	O
,	O
0.5	O
mM	O
EGTA	O
,	O
200	O
mM	O
NaCl	O
)	O
.	O

After	O
washes	O
,	O
cell	O
pellets	O
were	O
resuspended	O
at	O
40	O
x	O
106	O
cells/ml	O
in	O
ChIP	O
lysis	O
buffer	O
(	O
150	O
mM	O
NaCl	O
,	O
25	O
mM	O
Tris	O
[	O
pH	O
7.5	O
]	O
,	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
0.1	O
%	O
SDS	O
,	O
0.5	O
%	O
deoxycholate	O
plus	O
protease	O
and	O
phosphatase	O
inhibitors	O
)	O
,	O
and	O
chromatin	O
was	O
sheared	O
with	O
a	O
sonicator	O
to	O
yield	O
0.5-1	O
-	O
kb	O
DNA	O
fragments	O
.	O

After	O
preclearing	O
the	O
sheared	O
chromatin	O
with	O
protein	O
A	O
-	O
sepharose	O
beads	O
and	O
removing	O
5	O
%	O
as	O
input	O
chromatin	O
,	O
immunoprecipitation	O
was	O
performed	O
by	O
adding	O
optimized	O
antibody	O
amounts	O
(	O
per	O
20	O
x	O
106	O
cell	O
equivalents	O
:	O
2.5	O
mug	O
anti	O
-	O
Eomes	O
,	O
1	O
:	O
100	O
dilution	O
anti	O
-	O
Runx3	O
)	O
,	O
followed	O
by	O
overnight	O
incubation	O
at	O
4degreesC	O
;	O
protein	O
A	O
-	O
sepharose	O
beads	O
were	O
added	O
for	O
the	O
last	O
3	O
h	O
of	O
the	O
incubation	O
period	O
.	O

Beads	O
were	O
washed	O
2x	O
with	O
RIPA	O
buffer	O
(	O
50	O
mM	O
Tris	O
[	O
pH	O
8	O
]	O
,	O
150	O
mM	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
%	O
NP	O
-	O
40	O
,	O
0.1	O
%	O
SDS	O
,	O
0.5	O
%	O
deoxycholate	O
)	O
,	O
1x	O
with	O
high	O
salt	O
buffer	O
(	O
50	O
mM	O
Tris	O
[	O
pH	O
8	O
]	O
,	O
500	O
mM	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
%	O
NP	O
-	O
40	O
,	O
0.1	O
%	O
SDS	O
)	O
,	O
and	O
1x	O
with	O
TE	O
buffer	O
.	O

After	O
the	O
last	O
wash	O
,	O
DNA	O
was	O
eluted	O
by	O
resuspending	O
the	O
beads	O
in	O
elution	O
buffer	O
(	O
1	O
%	O
SDS	O
,	O
100	O
mM	O
NaHCO3	O
)	O
.	O

Both	O
input	O
and	O
ChIP	O
chromatin	O
were	O
then	O
treated	O
with	O
RNase	O
A	O
(	O
5	O
mug	O
total	O
)	O
for	O
1	O
h	O
at	O
37degreesC	O
,	O
followed	O
by	O
the	O
addition	O
of	O
proteinase	O
K	O
(	O
100	O
mug	O
total	O
)	O
and	O
overnight	O
incubation	O
at	O
65degreesC	O
to	O
reverse	O
cross	O
-	O
linking	O
.	O

DNA	O
was	O
then	O
purified	O
with	O
QIAquick	O
columns	O
(	O
Gel	O
Extraction	O
Kit	O
;	O
QIAGEN	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
and	O
resuspended	O
in	O
a	O
50	O
-	O
mul	O
volume	O
.	O

For	O
real	O
-	O
time	O
PCR	O
detection	O
of	O
immunoprecipitated	O
targets	O
using	O
the	O
SYBR	O
Green	O
PCR	O
Kit	O
,	O
a	O
standard	O
curve	O
was	O
obtained	O
with	O
serial	O
dilutions	O
of	O
input	O
DNA	O
for	O
each	O
sample	O
,	O
and	O
1	O
mul	O
ChIP	O
DNA	O
was	O
used	O
per	O
PCR	O
reaction	O
(	O
performed	O
in	O
duplicates	O
)	O
.	O

Melt	O
curves	O
and	O
agarose	O
gels	O
were	O
analyzed	O
to	O
ensure	O
amplification	O
of	O
specific	O
target	O
sequences	O
.	O

Refer	O
to	O
Table	O
S1	O
(	O
available	O
at	O
http	O
:	O
//www.jem.org/cgi/content/full/jem.20081242/DC1	O
)	O
for	O
a	O
list	O
of	O
primer	O
sets	O
.	O

The	O
data	O
are	O
presented	O
as	O
the	O
number	O
of	O
immunoprecipitated	O
target	O
sequences	O
relative	O
to	O
input	O
chromatin	O
,	O
assuming	O
two	O
copies	O
of	O
target	O
sequence	O
per	O
cell	O
equivalent	O
used	O
for	O
the	O
ChIP	O
.	O

Northern	O
and	O
Western	O
blot	O
analyses	O
.	O

RNA	O
isolation	O
and	O
Northern	O
blot	O
analysis	O
was	O
performed	O
as	O
previously	O
described	O
(	O
29	O
)	O
.	O

In	O
brief	O
,	O
10	O
mug	O
of	O
total	O
RNA	O
was	O
loaded	O
per	O
lane	O
and	O
transferred	O
to	O
positively	O
charged	O
nylon	O
membranes	O
(	O
Hybond	O
-	O
N+	O
;	O
GE	O
Healthcare	O
)	O
,	O
which	O
was	O
confirmed	O
by	O
ethidium	O
bromide	O
staining	O
of	O
ribosomal	O
RNA	O
species	O
on	O
the	O
membrane	O
.	O

Membranes	O
were	O
hybridized	O
with	O
1	O
ng/ml	O
alpha	O
-	O
[	O
32P	O
]	O
dCTP	O
-	O
labeled	O
trichloroacetic	O
acid	O
precipitable	O
probe	O
in	O
ExpressHyb	O
hybridization	O
buffer	O
(	O
Clontech	O
Laboratories	O
,	O
Inc.	O
)	O
.	O

All	O
cDNA	O
probes	O
were	O
confirmed	O
to	O
have	O
the	O
appropriate	O
single	O
-	O
copy	O
specificity	O
under	O
these	O
conditions	O
using	O
genomic	O
Southern	O
blot	O
analysis	O
.	O

Band	O
intensities	O
were	O
acquired	O
by	O
phosphorimaging	O
analysis	O
.	O

For	O
Western	O
analysis	O
,	O
whole	O
-	O
cell	O
protein	O
lysates	O
were	O
obtained	O
from	O
CD8+	O
T	O
cells	O
at	O
the	O
time	O
points	O
indicated	O
in	O
the	O
figures	O
during	O
clonal	O
expansion	O
in	O
100	O
U/ml	O
IL	O
-	O
2	O
with	O
lysis	O
buffer	O
(	O
50	O
mM	O
Tris	O
[	O
pH	O
7.5	O
]	O
,	O
150	O
mM	O
NaCl	O
,	O
10	O
%	O
glycerol	O
,	O
5	O
mM	O
EDTA	O
,	O
1	O
%	O
NP	O
-	O
40	O
)	O
by	O
resuspending	O
samples	O
in	O
10	O
mul	O
per	O
106	O
cells	O
and	O
incubating	O
on	O
ice	O
for	O
30	O
min	O
in	O
the	O
presence	O
of	O
protease	O
inhibitors	O
.	O

Immunoblot	O
analysis	O
was	O
performed	O
with	O
the	O
antibodies	O
indicated	O
in	O
the	O
figures	O
after	O
SDS	O
-	O
PAGE	O
(	O
10	O
-	O
30	O
mug	O
of	O
total	O
protein	O
was	O
loaded	O
per	O
well	O
)	O
.	O

Quantification	O
of	O
detected	O
protein	O
was	O
performed	O
with	O
an	O
Intelligent	O
Dark	O
Box	O
unit	O
(	O
LAS	O
-	O
3000	O
;	O
Fujifilm	O
)	O
and	O
normalized	O
for	O
loading	O
with	O
the	O
amount	O
of	O
RNA	O
Pol	O
-	O
II	O
detected	O
in	O
each	O
lane	O
.	O

Online	O
supplemental	O
material	O
.	O

Fig.	O
S1	O
shows	O
the	O
characterization	O
of	O
peripheral	O
CD8+	O
T	O
cells	O
from	O
Runx3-/	O
-	O
mice	O
.	O

Fig	O
.	O

S2	O
shows	O
effector	O
protein	O
expression	O
by	O
Runx3	O
WT	O
and	O
KO	O
cells	O
at	O
day	O
4	O
of	O
in	O
vitro	O
culture	O
.	O

Primer	O
sequences	O
used	O
for	O
ChIP	O
experiments	O
are	O
shown	O
in	O
Table	O
S1	O
.	O

Online	O
supplemental	O
material	O
is	O
available	O
at	O
http	O
:	O
//www.jem.org/cgi/content/full/jem.20081242/DC1	O
.	O

Supplementary	O
Material	O

[	O
Supplemental	O
Material	O
Index	O
]	O

Kinetics	O
of	O
gene	O
expression	O
during	O
CD8+	O
T	O
cell	O
differentiation	O
.	O

(	O
A	O
)	O
Kinetics	O
of	O
Prf1	O
,	O
Gzmb	O
,	O
Tbx21	O
(	O
T	O
-	O
bet	O
)	O
,	O
and	O
Eomes	O
mRNA	B-Transcription
expression	I-Transcription
in	O
differentiating	O
P14	O
CD8+	O
T	O
cells	O
analyzed	O
by	O
Northern	O
blotting	O
.	O

RNA	O
from	O
day	O
7	O
Th1	O
cells	O
was	O
used	O
as	O
a	O
control	O
.	O

Sizes	O
of	O
mRNA	O
transcripts	O
are	O
indicated	O
.	O

(	O
B	O
)	O
Quantification	O
of	O
relative	O
mRNA	O
amounts	O
by	O
phosphorimager	O
analysis	O
.	O

(	O
C	O
)	O
Kinetics	O
of	O
protein	O
expression	O
in	O
differentiating	O
P14	O
CD8+	O
T	O
cells	O
analyzed	O
by	O
immunoblotting	O
.	O

Sizes	O
of	O
protein	O
bands	O
are	O
indicated	O
.	O

(	O
D	O
)	O
Relative	O
protein	O
amounts	O
quantified	O
from	O
the	O
Western	O
blots	O
.	O

(	O
E	O
)	O
Intracellular	O
staining	B-Gene_expression
for	O
granzyme	O
B	O
,	O
IFN	O
-	O
gamma	O
,	O
and	O
TNF	O
.	O

Granzyme	O
B	O
staining	B-Gene_expression
was	O
specific	O
relative	O
to	O
an	O
isotype	O
control	O
(	O
not	O
depicted	O
)	O
.	O

Cells	O
were	O
restimulated	O
with	O
PMA	O
and	O
ionomycin	O
for	O
4	O
h	O
.	O

(	O
F	O
)	O
FACS	O
-	O
based	O
assay	O
to	O
measure	O
cytolytic	O
activity	O
of	O
P14	O
CD8+	O
T	O
cells	O
against	O
EL4	O
targets	O
loaded	O
with	O
0	O
(	O
-	O
)	O
or	O
1	O
(	O
+	O
)	O
muM	O
Gp33	O
peptide	O
(	O
effector-to	O
-	O
target	O
ratio	O
=	O
5	O
:	O
1	O
)	O
.	O

Percentage	O
of	O
Annexin	O
V+	O
(	O
apoptotic	O
)	O
target	O
cells	O
in	O
the	O
CD8	O
-	O
negative	O
EL4	O
target	O
population	O
(	O
dot	O
plots	O
)	O
was	O
determined	O
(	O
histograms	O
)	O
.	O

Cytolytic	O
activity	O
was	O
blocked	O
by	O
incubation	O
with	O
2	O
mM	O
EGTA	O
(	O
not	O
depicted	O
)	O
,	O
confirming	O
involvement	O
of	O
the	O
granule	O
exocytosis	O
(	O
perforin	O
-	O
granzyme	O
B	O
)	O
pathway	O
.	O

Data	O
are	O
representative	O
of	O
at	O
least	O
five	O
(	O
A	O
-	O
E	O
)	O
or	O
three	O
(	O
F	O
)	O
independent	O
experiments	O
.	O

Regulation	B-Regulation
of	O
perforin	O
,	O
granzyme	O
B	O
,	O
and	O
IFN	O
-	O
gamma	O
expression	B-Gene_expression
by	O
T	O
-	O
bet	O
and	O
Eomes	O
in	O
differentiating	O
CTLs	O
.	O

(	O
A	O
)	O
IFN	O
-	O
gamma	O
expression	B-Gene_expression
by	O
WT	O
(	O
Tbx21+/+	O
)	O
and	O
T-bet	O
-	O
deficient	B-Negative_regulation
(	O
Tbx21-/	O
-	O
)	O
T	O
cells	O
.	O

Naive	O
CD8+	O
T	O
cells	O
,	O
or	O
cells	O
activated	O
and	O
cultured	O
for	O
4	O
or	O
6	O
d	O
,	O
were	O
restimulated	O
with	O
PMA	O
and	O
ionomycin	O
for	O
6	O
h	O
,	O
and	O
IFN	O
-	O
gamma	O
expression	B-Gene_expression
was	O
assessed	O
by	O
intracellular	O
staining	O
.	O

Numbers	O
show	O
the	O
percentage	O
of	O
IFN	O
-	O
gamma+	O
cells	O
.	O

(	O
B	O
)	O
Northern	O
blot	O
analysis	O
of	O
Prf1	O
and	O
GzmB	O
mRNA	B-Transcription
expression	I-Transcription
in	O
WT	O
or	O
T-bet	O
-	O
deficient	B-Negative_regulation
CD8+	O
T	O
cells	O
activated	O
and	O
either	O
left	O
uninfected	O
(	O
uninf	O
)	O
or	O
transduced	O
with	O
retroviruses	O
expressing	B-Gene_expression
Eomes	O
-	O
VP16	O
(	O
Eo	O
-	O
VP16	O
)	O
or	O
an	O
empty	O
IRES	O
-	O
GFP	O
cassette	O
(	O
GFP	O
)	O
.	O

Total	O
cellular	O
RNA	O
was	O
analyzed	O
on	O
day	O
6	O
of	O
culture	O
.	O

The	O
frequency	O
of	O
transduced	O
cells	O
in	O
the	O
cultures	O
was	O
equivalent	O
for	O
both	O
constructs	O
(	O
approximately65	O
-	O
70	O
%	O
GFP+	O
cells	O
;	O
not	O
depicted	O
)	O
.	O

(	O
C	O
)	O
Granzyme	O
B	O
and	O
IFN	O
-	O
gamma	O
expression	B-Gene_expression
by	O
Tbx21+/+	O
and	O
Tbx21-/	O
-	O
T	O
cells	O
analyzed	O
in	O
restimulated	O
cells	O
that	O
had	O
been	O
cultured	O
for	O
5	O
d	O
.	O

(	O
D	O
)	O
IFN	O
-	O
gamma	O
production	B-Gene_expression
by	O
cells	O
transduced	O
with	O
Eo	O
-	O
VP16	O
or	O
control	O
(	O
GFP	O
)	O
retroviruses	O
(	O
RV	O
)	O
measured	O
on	O
day	O
4	O
after	O
6	O
h	O
of	O
restimulation	O
with	O
PMA	O
and	O
ionomycin	O
.	O

Numbers	O
show	O
the	O
percentage	O
of	O
GFP+	O
IFN	O
-	O
gamma+	O
cells	O
.	O

Results	O
are	O
representative	O
of	O
three	O
(	O
A	O
and	O
C	O
)	O
or	O
two	O
(	O
B	O
and	O
D	O
)	O
independent	O
experiments	O
.	O

Key	O
role	O
for	O
Runx3	O
in	O
effector	O
CTL	O
differentiation	O
.	O

(	O
A	O
)	O
Western	O
analysis	O
of	O
Runx3	O
,	O
Eomes	O
,	O
T	O
-	O
bet	O
,	O
and	O
perforin	O
expression	B-Gene_expression
in	O
Runx3+/+	O
versus	O
Runx3-/	O
-	O
CD8+	O
SP	O
T	O
cells	O
differentiated	O
for	O
6	O
d	O
.	O

beta	O
-	O
Actin	O
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

(	O
B	O
)	O
Northern	O
blot	O
analysis	O
of	O
Prf1	O
mRNA	B-Transcription
expression	I-Transcription
in	O
Runx3+/+	O
versus	O
Runx3-/	O
-	O
CD8+	O
T	O
cells	O
differentiated	O
for	O
6	O
d	O
.	O

beta	O
-	O
Actin	O
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

(	O
C	O
)	O
Expression	B-Gene_expression
of	O
granzyme	O
B	O
,	O
IFN	O
-	O
gamma	O
,	O
TNF	O
,	O
and	O
IL	O
-	O
2	O
by	O
resting	O
or	O
restimulated	O
(	O
6	O
h	O
)	O
Runx3+/+	O
versus	O
Runx3-/	O
-	O
CD8+	O
SP	O
T	O
cells	O
differentiated	O
for	O
6	O
d	O
.	O

The	O
vertical	O
gray	O
line	O
indicates	O
the	O
granzyme	O
B	O
MFI	O
for	O
WT	O
GFP+	O
cells	O
.	O

Results	O
in	O
A	O
-	O
C	O
are	O
representative	O
of	O
two	O
independent	O
experiments	O
.	O

(	O
D	O
)	O
ChIP	O
analysis	O
of	O
binding	B-Binding
of	O
endogenous	O
Runx3	O
and	O
Eomes	O
to	O
the	O
Prf1	O
locus	O
.	O

Enrichment	O
of	O
the	O
indicated	O
genomic	O
regions	O
was	O
evaluated	O
by	O
real	O
-	O
time	O
PCR	O
of	O
DNA	O
from	O
immunoprecipitated	O
and	O
input	O
chromatin	O
.	O

The	O
data	O
are	O
the	O
means	O
of	O
duplicate	O
measurements	O
from	O
two	O
chromatin	O
preparations	O
from	O
two	O
independent	O
CD8+	O
T	O
cell	O
differentiations	O
.	O

The	O
efficiency	O
of	O
recovery	O
of	O
input	O
for	O
the	O
-1	O
-	O
kb	O
region	O
of	O
Prf1	O
was	O
0.97	O
%	O
for	O
the	O
Runx3	O
ChIP	O
and	O
0.5	O
%	O
for	O
the	O
Eomes	O
ChIP	O
.	O

Runx3	O
controls	B-Regulation
Eomes	O
,	O
perforin	O
,	O
granzyme	O
B	O
,	O
and	O
IFN	O
-	O
gamma	O
expression	B-Gene_expression
in	O
effector	O
CTLs	O
.	O

Runx3+/+	O
or	O
Runx3-/	O
-	O
CD8+	O
T	O
cells	O
were	O
activated	O
and	O
transduced	O
with	O
retroviruses	O
bearing	O
an	O
empty	O
IRES	O
-	O
GFP	O
cassette	O
(	O
GFP	O
)	O
or	O
also	O
encoding	O
Eomes	O
-	O
VP16	O
(	O
Eo	O
-	O
VP16	O
)	O
or	O
Myc	O
-	O
Runx3	O
(	O
Runx3	O
)	O
.	O

The	O
frequency	O
of	O
transduced	O
cells	O
in	O
the	O
cultures	O
was	O
equivalent	O
for	O
all	O
constructs	O
(	O
approximately75	O
-	O
90	O
%	O
GFP+	O
cells	O
;	O
not	O
depicted	O
)	O
.	O

(	O
A	O
)	O
Protein	O
expression	O
in	O
whole	O
-	O
cell	O
extracts	O
(	O
day	O
6	O
)	O
was	O
analyzed	O
by	O
immunoblotting	O
.	O

Overexpression	B-Positive_regulation
of	O
Eomes	O
-	O
VP16	O
can	O
not	O
be	O
detected	O
with	O
the	O
Eomes	O
antibody	O
,	O
as	O
the	O
C	O
-	O
terminal	O
epitope	O
is	O
within	O
the	O
region	O
that	O
has	O
been	O
replaced	O
with	O
the	O
VP16	O
transactivation	O
domain	O
.	O

(	O
B	O
)	O
Expression	B-Gene_expression
of	O
granzyme	O
B	O
and	O
IFN	O
-	O
gamma	O
after	O
culture	O
for	O
6	O
d	O
and	O
restimulation	O
for	O
4	O
h	O
with	O
PMA	O
and	O
ionomycin	O
was	O
determined	O
by	O
intracellular	O
staining	O
.	O

The	O
percentage	O
of	O
positively	O
stained	O
cells	O
is	O
shown	O
above	O
the	O
gate	O
;	O
the	O
mean	O
fluorescence	O
intensity	O
(	O
MFI	O
)	O
of	O
granzyme	O
B	O
staining	B-Gene_expression
for	O
the	O
total	O
population	O
is	O
shown	O
below	O
the	O
gate	O
.	O

The	O
vertical	O
gray	O
lines	O
indicate	O
the	O
MFI	O
for	O
WT	O
GFP+	O
cells	O
.	O

Results	O
are	O
representative	O
of	O
at	O
least	O
two	O
independent	O
experiments	O
.	O

(	O
C	O
)	O
Schematic	O
diagram	O
of	O
the	O
transcriptional	O
network	O
involving	O
Runx3	O
and	O
T	O
-	O
box	O
factors	O
.	O

T	O
-	O
bet	O
is	O
induced	B-Positive_regulation
by	O
TCR	O
signals	O
and	O
is	O
essential	B-Positive_regulation
for	O
early	O
IFN	O
-	O
gamma	O
expression	B-Gene_expression
.	O

Runx3	O
is	O
present	B-Gene_expression
in	O
naive	O
CD8+	O
T	O
cells	O
and	O
represses	B-Negative_regulation
Runx1	O
and	O
induces	B-Positive_regulation
Eomes	O
,	O
perforin	O
,	O
granzyme	O
B	O
,	O
and	O
IFN	O
-	O
gamma	O
expression	B-Gene_expression
.	O

Eomes	O
may	O
participate	B-Regulation
in	O
sustaining	O
late	O
IFN	O
-	O
gamma	O
expression	B-Gene_expression
,	O
whereas	O
Runx3	O
and	O
Eomes	O
(	O
but	O
not	O
T	O
-	O
bet	O
)	O
may	O
cooperate	O
to	O
activate	B-Positive_regulation
perforin	O
expression	B-Gene_expression
.	O

The	O
dotted	O
line	O
indicates	O
the	O
partial	O
effect	B-Regulation
of	O
T	O
-	O
bet	O
deficiency	B-Negative_regulation
on	O
Gzmb	O
mRNA	O
but	O
not	O
granzyme	O
B	O
protein	O
expression	B-Gene_expression
.	O

[	O
Supplemental	O
Material	O
Index	O
]	O

Interleukin	O
-	O
10	O
Production	B-Gene_expression
by	O
Th1	O
Cells	O
Requires	B-Positive_regulation
Interleukin-12	O
-	O
Induced	B-Positive_regulation
STAT4	O
Transcription	O
Factor	O
and	O
ERK	O
MAP	O
Kinase	O
Activation	B-Positive_regulation
by	O
High	O
Antigen	O
Dose	O

Summary	O

CD4+	O
Tcells	O
producing	B-Gene_expression
interleukin	O
-	O
10	O
(	O
IL	O
-	O
10	O
)	O
and	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
are	O
reported	O
in	O
chronic	O
infections	O
.	O

However	O
,	O
the	O
signals	O
that	O
direct	O
the	O
development	O
of	O
IL-10	O
-	O
producing	B-Gene_expression
T	O
helper	O
1	O
(	O
Th1	O
)	O
cells	O
are	O
undefined	O
.	O

We	O
showed	O
that	O
development	O
of	O
IL-10	O
-	O
producing	B-Gene_expression
Th1	O
cells	O
required	O
high	O
Tcell	O
receptor	O
(	O
TCR	O
)	O
ligation	O
,	O
sustained	O
ERK1	O
and	O
ERK2	O
MAP	O
kinases	O
phosphorylation	B-Phosphorylation
,	O
and	O
IL-12	O
-	O
induced	B-Positive_regulation
STAT4	O
transcription	O
factor	O
activation	B-Positive_regulation
.	O

Repeated	O
TCR	O
triggering	O
led	O
to	O
enhanced	B-Positive_regulation
IL	O
-	O
10	O
production	B-Gene_expression
by	O
Th1	O
cells	O
,	O
and	O
continued	O
IL	O
-	O
12	O
action	O
and	O
high	O
-	O
dose	O
TCR	O
signaling	O
were	O
required	B-Positive_regulation
for	O
the	O
development	O
and	O
maintenance	O
of	O
IL-10	O
-	O
producing	B-Gene_expression
Th1	O
cells	O
.	O

Although	O
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
cells	O
require	O
the	O
activation	O
of	O
distinct	O
STATs	O
for	O
their	O
differentiation	O
,	O
activation	B-Positive_regulation
of	O
ERK1	O
and	O
ERK2	O
wasa	O
common	O
requirement	B-Positive_regulation
for	O
production	B-Gene_expression
of	O
IL	O
-	O
10	O
by	O
all	O
Th	O
cell	O
subsets	O
.	O

IL	O
-	O
10	O
expression	B-Gene_expression
also	O
correlated	O
with	O
c	O
-	O
maf	O
expression	B-Gene_expression
.	O

Despite	O
having	O
distinct	O
functions	O
in	O
protection	O
against	O
pathogens	O
,	O
all	O
Th	O
cells	O
share	O
the	O
important	O
task	O
of	O
controlling	O
overexuberant	O
immune	O
responses	O
by	O
means	O
of	O
IL	O
-	O
10	O
production	B-Gene_expression
.	O

Introduction	O

Interleukin	O
-	O
10	O
(	O
IL	O
-	O
10	O
)	O
is	O
a	O
cytokine	O
with	O
broad	O
anti	O
-	O
inflammatory	O
properties	O
that	O
inhibits	O
macrophage	O
and	O
dendritic	O
cell	O
(	O
DC	O
)	O
function	O
(	O
Moore	O
etal.	O
,	O
2001	O
)	O
.	O

IL	O
-	O
10	O
limits	O
the	O
immune	O
and	O
inflammatory	O
responses	O
to	O
pathogens	O
and	O
gut	O
flora	O
and	O
prevents	O
damage	O
to	O
the	O
host	O
(	O
Moore	O
etal.	O
,	O
2001	O
;	O
O'Garra	O
and	O
Vieira	O
,	O
2004	O
)	O
,	O
but	O
when	O
dysregulated	O
may	O
result	O
in	O
chronic	O
infection	O
(	O
Brooks	O
etal.	O
,	O
2006	O
;	O
Ejrnaes	O
etal.	O
,	O
2006	O
;	O
Moore	O
etal.	O
,	O
2001	O
)	O
.	O

IL	O
-	O
10	O
is	O
expressed	B-Gene_expression
by	O
T	O
helper	O
2	O
(	O
Th2	O
)	O
cells	O
,	O
B	O
cells	O
,	O
DCs	O
,	O
and	O
macrophages	O
(	O
Moore	O
etal.	O
,	O
2001	O
)	O
,	O
and	O
also	O
by	O
Th1	O
cells	O
(	O
Anderson	O
etal.	O
,	O
2007	O
;	O
Assenmacher	O
etal.	O
,	O
1994	O
;	O
Del	O
Prete	O
etal.	O
,	O
1993	O
;	O
Gerosa	O
etal.	O
,	O
1996	O
;	O
Jankovic	O
etal.	O
,	O
2007	O
;	O
Pohl	O
-	O
Koppe	O
etal.	O
,	O
1998	O
)	O
and	O
(	O
reviewed	O
in	O
O'Garra	O
and	O
Vieira	O
,	O
2007	O
;	O
Trinchieri	O
,	O
2007	O
)	O
,	O
certain	O
regulatory	O
(	O
Treg	O
)	O
Tcells	O
(	O
Moore	O
etal.	O
,	O
2001	O
;	O
O'Garra	O
and	O
Vieira	O
,	O
2004	O
;	O
Roncarolo	O
etal.	O
,	O
2006	O
)	O
,	O
and	O
Th17	O
cells	O
(	O
Awasthi	O
etal.	O
,	O
2007	O
;	O
Fitzgerald	O
etal.	O
,	O
2007	O
;	O
McGeachy	O
etal.	O
,	O
2007	O
;	O
Stumhofer	O
etal.	O
,	O
2007	O
)	O
.	O

In	O
vitro	O
human	O
CD4+	O
and	O
CD8+	O
Tcell	O
clones	O
,	O
or	O
mouse	O
CD4+	O
Tcells	O
that	O
produce	B-Gene_expression
both	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
and	O
IL	O
-	O
10	O
,	O
can	O
be	O
differentiated	O
by	O
Tcell	O
receptor	O
(	O
TCR	O
)	O
-	O
stimulation	O
in	O
the	O
presence	O
of	O
IL	O
-	O
12	O
(	O
Chang	O
etal.	O
,	O
2007	O
;	O
Gerosa	O
etal.	O
,	O
1996	O
;	O
Jeannin	O
etal.	O
,	O
1996	O
;	O
Meyaard	O
etal.	O
,	O
1996	O
;	O
Windhagen	O
etal.	O
,	O
1996	O
)	O
.	O

Furthermore	O
,	O
Th1	O
cell	O
clones	O
coproducing	B-Gene_expression
IFN	O
-	O
gamma	O
and	O
IL	O
-	O
10	O
have	O
been	O
isolated	O
from	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
of	O
active	O
pulmonary	O
tuberculosis	O
(	O
TB	O
)	O
patients	O
(	O
Gerosa	O
etal.	O
,	O
1999	O
)	O
.	O

IL	O
-	O
10	O
production	B-Gene_expression
by	O
Th1	O
cells	O
was	O
also	O
reported	O
in	O
animals	O
infected	O
with	O
Toxoplasma	O
gondii	O
(	O
Jankovic	O
etal.	O
,	O
2002	O
;	O
Shaw	O
etal.	O
,	O
2006	O
)	O
or	O
with	O
Leishmania	O
major	O
(	O
Anderson	O
etal.	O
,	O
2007	O
)	O
and	O
shown	O
to	O
be	O
required	O
for	O
regulation	O
of	O
the	O
immune	O
response	O
in	O
these	O
infections	O
(	O
Anderson	O
etal.	O
,	O
2007	O
;	O
Jankovic	O
etal.	O
,	O
2007	O
)	O
.	O

The	O
relative	O
amounts	O
of	O
IL	O
-	O
10	O
and	O
IFN	O
-	O
gamma	O
produced	B-Gene_expression
by	O
Th1	O
cells	O
may	O
influence	O
the	O
balance	O
between	O
clearance	O
and	O
persistent	O
infection	O
with	O
certain	O
pathogens	O
(	O
Moore	O
etal.	O
,	O
2001	O
;	O
Trinchieri	O
,	O
2007	O
)	O
,	O
thus	O
determining	O
whether	O
chronic	O
infection	O
or	O
immunopathology	O
ensues	O
.	O

Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
cell	O
responses	O
differentiate	O
along	O
distinct	O
signaling	O
pathways	O
(	O
Glimcher	O
and	O
Murphy	O
,	O
2000	O
;	O
Ivanov	O
etal.	O
,	O
2007	O
;	O
Stockinger	O
and	O
Veldhoen	O
,	O
2007	O
)	O
.	O

Th1	O
cell	O
development	O
requires	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
1activation	O
,	O
induced	B-Positive_regulation
by	O
type	O
I	O
IFN	O
or	O
IFN	O
-	O
gamma	O
,	O
the	O
transcription	O
factor	O
T	O
-	O
box	O
21	O
(	O
T	O
-	O
bet	O
)	O
,	O
and	O
IL-12	O
-	O
induced	O
STAT4	O
signaling	O
,	O
which	O
can	O
couple	O
with	O
IL-18	O
-	O
induced	B-Positive_regulation
IRAK	O
and	O
NF	O
-	O
kappaB	O
transcription	O
factors	O
to	O
drive	B-Positive_regulation
the	O
high	O
amounts	B-Gene_expression
of	O
IFN	O
-	O
gamma	O
required	O
to	O
eradicate	O
intracellular	O
pathogens	O
(	O
Glimcher	O
and	O
Murphy	O
,	O
2000	O
)	O
.	O

Th2	O
cell	O
development	O
,	O
with	O
expression	B-Gene_expression
of	O
IL	O
-	O
4	O
,	O
IL	O
-	O
5	O
,	O
and	O
IL	O
-	O
13	O
,	O
requires	B-Positive_regulation
IL	O
-	O
4	O
,	O
STAT6	O
,	O
and	O
the	O
transcription	O
factor	O
GATA	O
binding	O
protein	O
(	O
GATA	O
)	O
-	O
3	O
(	O
Glimcher	O
and	O
Murphy	O
,	O
2000	O
)	O
.	O

The	O
development	O
of	O
Th17	O
cells	O
requires	O
IL	O
-	O
6	O
,	O
TGF	O
-	O
beta	O
,	O
and	O
the	O
STAT3	O
-	O
dependent	B-Positive_regulation
expression	B-Gene_expression
of	O
the	O
transcription	O
factor	O
RORgammat	O
(	O
Ivanov	O
etal.	O
,	O
2007	O
;	O
Stockinger	O
and	O
Veldhoen	O
,	O
2007	O
)	O
.	O

Th1	O
and	O
Th2	O
cell	O
responses	O
can	O
also	O
be	O
induced	O
by	O
varying	O
the	O
dose	O
of	O
antigen	O
presented	O
to	O
the	O
naive	O
Tcell	O
by	O
the	O
antigen	O
-	O
presenting	O
cell	O
(	O
APC	O
)	O
.	O

Whereas	O
high	O
doses	O
of	O
antigen	O
,	O
with	O
sustained	O
TCR	O
signaling	O
and	O
extracellular	O
-	O
signal	O
regulated	O
(	O
ERK	O
)	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
phosphorylation	O
,	O
result	B-Positive_regulation
in	O
Th1	O
cells	O
producing	B-Gene_expression
IFN	O
-	O
gamma	O
via	O
an	O
IL-12	O
-	O
independent	B-Regulation
mechanism	O
,	O
low	O
doses	O
of	O
antigen	O
,	O
with	O
transient	O
ERK1	O
and	O
ERK2	O
activation	B-Positive_regulation
,	O
favor	B-Positive_regulation
Th2	O
responses	O
and	O
IL	O
-	O
4	O
secretion	B-Localization
(	O
Constant	O
etal.	O
,	O
1995	O
;	O
Hosken	O
etal.	O
,	O
1995	O
;	O
Jorritsma	O
etal.	O
,	O
2003	O
;	O
Yamane	O
etal.	O
,	O
2005	O
)	O
.	O

Because	O
Th1	O
and	O
Th2	O
cells	O
cross	O
regulate	O
each	O
other	O
's	O
development	O
and	O
function	O
and	O
can	O
suppress	O
Th17	O
cell	O
responses	O
,	O
and	O
all	O
differentiate	O
along	O
distinct	O
signaling	O
pathways	O
(	O
Glimcher	O
and	O
Murphy	O
,	O
2000	O
;	O
Stockinger	O
and	O
Veldhoen	O
,	O
2007	O
)	O
,	O
IL	O
-	O
10	O
produced	B-Gene_expression
by	O
all	O
these	O
Th	O
cells	O
may	O
thus	O
act	B-Regulation
as	I-Regulation
a	I-Regulation
feedback	I-Regulation
regulator	I-Regulation
to	O
control	O
the	O
pathology	O
associated	O
with	O
an	O
overexuberant	O
,	O
albeit	O
efficacious	O
,	O
inflammatory	O
response	O
.	O

Whether	O
IL	O
-	O
10	O
production	B-Gene_expression
by	O
these	O
different	O
Th	O
cell	O
subsets	O
is	O
induced	B-Positive_regulation
by	O
independent	O
and/or	O
common	O
mechanisms	O
is	O
unknown	O
.	O

Here	O
,	O
we	O
showed	O
that	O
invitro	O
differentiation	O
of	O
IL-10	O
-	O
producing	B-Gene_expression
Th1	O
cells	O
from	O
naive	O
CD4+	O
Tcells	O
required	O
IL-12	O
-	O
induced	O
STAT4	O
signaling	O
,	O
strong	O
TCR	O
activation	O
(	O
high	O
antigen	O
dose	O
)	O
,	O
and	O
sustained	O
ERK1	O
and	O
ERK2	O
phosphorylation	B-Phosphorylation
.	O

Furthermore	O
,	O
we	O
showed	O
that	O
activation	B-Positive_regulation
of	O
ERK1	O
and	O
ERK2	O
is	O
a	O
requirement	B-Positive_regulation
for	O
production	B-Gene_expression
of	O
IL	O
-	O
10	O
by	O
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
cell	O
subsets	O
.	O

This	O
common	O
but	O
highly	O
regulated	O
pathway	O
for	O
IL	O
-	O
10	O
induction	B-Positive_regulation
and	O
maintenance	O
ensures	O
its	O
function	O
as	O
a	O
feedback	O
loop	O
to	O
control	O
damage	O
to	O
the	O
host	O
and	O
also	O
allows	O
a	O
protective	O
response	O
to	O
ensue	O
as	O
opposed	O
to	O
chronic	O
infection	O
.	O

IL	O
-	O
12	O
and	O
High	O
Doses	O
of	O
Antigen	O
Induce	O
the	O
Development	O
of	O
Th1	O
Cells	O
Producing	B-Gene_expression
IL	O
-	O
10	O

To	O
study	O
the	O
differentiation	O
of	O
Th1	O
cells	O
coproducing	B-Gene_expression
IFN	O
-	O
gamma	O
and	O
IL	O
-	O
10	O
,	O
we	O
cultured	O
purified	O
TCR	O
-	O
transgenic	O
DO11.10	O
naive	O
CD4+	O
Tcells	O
with	O
purified	O
DCs	O
as	O
APCs	O
and	O
increasing	O
doses	O
of	O
ovalbumin	O
peptide	O
323	O
-	O
339	O
(	O
OVA	O
)	O
.	O

Culture	O
with	O
high	O
doses	O
of	O
antigen	O
for	O
7	O
days	O
gave	O
rise	B-Positive_regulation
to	O
Th1	O
cells	O
expressing	B-Gene_expression
IFN	O
-	O
gamma	O
upon	O
restimulation	O
(	O
Constant	O
etal.	O
,	O
1995	O
;	O
Hosken	O
etal.	O
,	O
1995	O
)	O
,	O
but	O
not	O
IL	O
-	O
10	O
(	O
FigureS1A	O
available	O
online	O
)	O
.	O

Culture	O
with	O
low	O
antigen	O
doses	O
under	O
the	O
same	O
conditions	O
led	O
to	O
the	O
differentiation	O
of	O
Th2	O
cells	O
,	O
which	O
expressed	B-Gene_expression
both	O
IL	O
-	O
4	O
and	O
IL	O
-	O
10	O
upon	O
restimulation	O
(	O
FigureS1A	O
)	O
.	O

Culture	O
of	O
naive	O
CD4+	O
Tcells	O
in	O
an	O
APC	O
-	O
free	O
system	O
by	O
stimulation	O
with	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	O
antibodies	O
in	O
the	O
presence	O
of	O
IL	O
-	O
12	O
resulted	B-Positive_regulation
in	O
IFN-gamma	O
-	O
producing	B-Gene_expression
Th1	O
cells	O
,	O
a	O
proportion	O
of	O
which	O
coproduced	B-Gene_expression
IL	O
-	O
10	O
,	O
as	O
did	O
Th2	O
cells	O
resulting	O
from	O
culture	O
in	O
IL	O
-	O
4	O
(	O
FigureS1B	O
)	O
.	O

To	O
investigate	O
whether	O
the	O
lack	B-Negative_regulation
of	O
IL	O
-	O
10	O
produced	B-Gene_expression
by	O
Th1	O
cells	O
resulted	B-Positive_regulation
from	O
inhibition	B-Negative_regulation
of	O
IL	O
-	O
10	O
production	B-Gene_expression
by	O
DCs	O
and	O
high	O
antigen	O
dose	O
or	O
alternatively	O
required	O
IL	O
-	O
12	O
,	O
we	O
cultured	O
naive	O
CD4+	O
Tcells	O
with	O
increasing	O
doses	O
of	O
antigen	O
presented	O
by	O
DC	O
in	O
the	O
presence	O
of	O
IL	O
-	O
12	O
.	O

At	O
low	O
doses	O
of	O
antigen	O
,	O
IL	O
-	O
12	O
abrogated	O
the	O
development	O
of	O
Th2	O
cells	O
and	O
induced	B-Positive_regulation
IFN	O
-	O
gamma	O
expression	B-Gene_expression
but	O
only	O
low	O
levels	O
of	O
IL	O
-	O
10	O
expression	B-Gene_expression
,	O
suggesting	O
that	O
IL	O
-	O
12	O
per	O
se	O
was	O
not	O
sufficient	O
to	O
induce	B-Positive_regulation
significant	O
IL	O
-	O
10	O
production	B-Gene_expression
in	O
Th1	O
cells	O
(	O
Figure1A	O
)	O
.	O

Strikingly	O
,	O
as	O
the	O
antigen	O
dose	O
was	O
increased	O
,	O
Th1	O
populations	O
driven	O
with	O
IL	O
-	O
12	O
now	O
contained	O
higher	O
numbers	O
of	O
IL-10	O
-	O
producing	B-Gene_expression
cells	O
(	O
Figure1A	O
)	O
and	O
produced	B-Gene_expression
more	B-Positive_regulation
IL	O
-	O
10	O
protein	O
upon	O
restimulation	O
(	O
Figures	O
1A	O
and	O
1B	O
)	O
.	O

Thus	O
,	O
the	O
development	O
of	O
Th1	O
cells	O
producing	B-Gene_expression
IL	O
-	O
10	O
required	B-Positive_regulation
both	O
IL	O
-	O
12	O
and	O
high	O
doses	O
of	O
antigen	O
.	O

Th1	O
cells	O
differentiated	O
to	O
produce	B-Gene_expression
large	O
amounts	O
of	O
IL	O
-	O
10	O
and	O
IFN	O
-	O
gamma	O
and	O
lost	B-Negative_regulation
theircapacity	O
to	O
produce	B-Gene_expression
IL	O
-	O
2	O
(	O
Figure1B	O
)	O
.	O

Because	O
the	O
presence	O
of	O
IL	O
-	O
12	O
reduced	O
the	O
proliferation	O
of	O
CD4+	O
Tcells	O
at	O
both	O
high	O
andlow	O
antigen	O
doses	O
(	O
Table	O
S1	O
)	O
,	O
and	O
only	O
the	O
former	O
showed	O
IL	O
-	O
10	O
production	B-Gene_expression
,	O
the	O
development	O
of	O
high	O
IL-10	O
-	O
producing	B-Gene_expression
cellsis	O
most	O
likely	O
not	O
related	O
to	O
limited	B-Negative_regulation
IL	O
-	O
2	O
.	O

Naive	O
CD4+	O
Tcells	O
from	O
DO11.10/recombination	O
-	O
activating	O
gene	O
1	O
(	O
Rag1	O
)	O
-	O
deficient	B-Negative_regulation
animals	O
,	O
cultured	O
with	O
high	O
doses	O
of	O
antigen	O
in	O
the	O
presence	O
of	O
IL	O
-	O
12	O
,	O
also	O
resulted	B-Positive_regulation
in	O
IL	O
-	O
10	O
expression	B-Gene_expression
by	O
Th1	O
cells	O
,	O
showing	O
that	O
this	O
expression	O
was	O
not	O
dependent	B-Positive_regulation
on	O
the	O
presence	O
of	O
effector	O
or	O
memory	O
Tcells	O
or	O
Treg	O
cells	O
(	O
FigureS2	O
)	O
.	O

Although	O
it	O
has	O
been	O
suggested	O
that	O
TGF	O
-	O
beta	O
can	O
induce	B-Positive_regulation
IL	O
-	O
10	O
in	O
CD4+	O
Tcells	O
(	O
Kitani	O
etal.	O
,	O
2003	O
;	O
Schiott	O
etal.	O
,	O
2000	O
)	O
,	O
we	O
found	O
that	O
in	O
developing	O
Th1	O
and	O
Th2	O
cells	O
this	O
was	O
not	O
the	O
case	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
fact	O
,	O
neutralization	B-Negative_regulation
of	O
TGF	O
-	O
beta	O
led	O
to	O
increased	B-Positive_regulation
IL	O
-	O
10	O
production	B-Gene_expression
by	O
both	O
Tcell	O
subsets	O
(	O
FigureS3	O
)	O
.	O

Thus	O
,	O
the	O
development	O
of	O
IL-10	O
-	O
producing	B-Gene_expression
Th1	O
cells	O
only	O
depended	B-Positive_regulation
on	O
the	O
presence	O
of	O
IL	O
-	O
12	O
together	O
with	O
high	O
antigen	O
dose	O
and	O
not	O
on	O
other	O
soluble	O
factors	O
such	O
as	O
IL	O
-	O
2	O
or	O
TGF	O
-	O
beta	O
or	O
on	O
the	O
presence	O
of	O
other	O
Tcell	O
types	O
.	O

IL	O
-	O
10	O
Production	B-Gene_expression
by	O
Th1	O
Cells	O
Is	O
Dependent	B-Positive_regulation
on	O
STAT4	O
but	O
Not	O
on	O
STAT6	O
,	O
IFN	O
-	O
gamma	O
,	O
or	O
IL	O
-	O
4	O
Signaling	O

To	O
further	O
elucidate	O
the	O
mechanisms	O
required	O
for	O
the	O
development	O
of	O
Th1	O
cells	O
producing	B-Gene_expression
IL	O
-	O
10	O
,	O
we	O
investigated	O
the	O
role	B-Regulation
of	O
STAT4	O
,	O
one	O
of	O
the	O
signaling	O
pathways	O
activated	B-Positive_regulation
by	O
IL	O
-	O
12	O
(	O
Murphy	O
etal.	O
,	O
2000	O
)	O
.	O

Naive	O
CD4+	O
D011.10	O
Tcells	O
deficient	B-Negative_regulation
in	O
STAT4	O
(	O
Ouyang	O
etal.	O
,	O
1998	O
)	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
IL	O
-	O
12	O
and	O
OVA	O
.	O

Again	O
,	O
IL-10	O
-	O
producing	B-Gene_expression
Th1	O
cells	O
were	O
differentiated	O
at	O
the	O
high	O
antigen	O
dose	O
in	O
the	O
presence	O
of	O
IL	O
-	O
12	O
in	O
DO11.10	O
Tcells	O
(	O
Figure2A	O
)	O
.	O

In	O
contrast	O
,	O
in	O
the	O
absence	B-Negative_regulation
of	O
STAT4	O
,	O
the	O
percentage	O
of	O
cells	O
expressing	B-Gene_expression
IFN	O
-	O
gamma	O
was	O
dramatically	O
diminished	B-Negative_regulation
as	O
expected	O
and	O
resulted	O
in	O
an	O
increase	B-Positive_regulation
in	O
the	O
percentage	O
of	O
cells	O
expressing	B-Gene_expression
IL	O
-	O
4	O
,	O
but	O
not	O
IL	O
-	O
10	O
(	O
Figure2A	O
)	O
,	O
suggesting	O
that	O
STAT4	O
contributes	B-Positive_regulation
to	O
IL	O
-	O
10	O
expression	B-Gene_expression
by	O
Th1	O
cells	O
.	O

Because	O
IL	O
-	O
10	O
expression	B-Gene_expression
is	O
associated	O
with	O
an	O
IL-4	O
-	O
induced	O
Th2	O
cell	O
phenotype	O
,	O
we	O
investigated	O
whether	O
the	O
differentiation	O
of	O
the	O
IL-10	O
-	O
producing	B-Gene_expression
Th1	O
cells	O
depended	O
on	O
signaling	O
through	O
the	O
IL	O
-	O
4	O
receptor	O
via	O
STAT6	O
activation	B-Positive_regulation
(	O
Glimcher	O
and	O
Murphy	O
,	O
2000	O
;	O
Murphy	O
etal.	O
,	O
2000	O
)	O
.	O

The	O
absence	B-Negative_regulation
of	O
STAT6	O
did	O
not	O
impair	O
the	O
differentiation	O
of	O
IL-10	O
-	O
producing	B-Gene_expression
Th1	O
cells	O
in	B-Positive_regulation
the	I-Positive_regulation
presence	I-Positive_regulation
of	I-Positive_regulation
IL	O
-	O
12	O
and	O
OVA	O
(	O
Figure2A	O
)	O
.	O

In	O
fact	O
,	O
a	O
higher	O
percentage	O
of	O
STAT6	O
-	O
deficient	B-Negative_regulation
cells	O
compared	O
with	O
WT	O
cells	O
produced	B-Gene_expression
both	O
IL	O
-	O
10	O
and	O
IFN	O
-	O
gamma	O
(	O
Figure2A	O
)	O
,	O
which	O
may	O
be	O
the	O
result	O
of	O
the	O
loss	O
of	O
Th2	O
cell	O
control	O
over	O
a	O
Th1	O
cell	O
response	O
.	O

As	O
expected	O
,	O
lack	B-Negative_regulation
of	O
STAT6	O
abrogated	B-Negative_regulation
both	O
IL	O
-	O
4	O
and	O
IL	O
-	O
10	O
production	B-Gene_expression
by	O
Tcells	O
developed	O
with	O
IL	O
-	O
4	O
or	O
with	O
low	O
antigen	O
dose	O
(	O
Figures	O
2B	O
and	O
2C	O
)	O
.	O

However	O
,	O
in	O
the	O
absence	O
of	O
STAT4	O
signaling	O
,	O
IL	O
-	O
10	O
and	O
IL	O
-	O
4	O
production	B-Gene_expression
by	O
Th2	O
cells	O
was	O
if	O
anything	O
increased	B-Positive_regulation
(	O
Figures	O
2B	O
and	O
2C	O
)	O
.	O

Thus	O
,	O
in	O
contrast	O
to	O
what	O
was	O
observed	O
under	O
Th1	O
conditions	O
,	O
IL	O
-	O
10	O
expression	B-Gene_expression
by	O
Th2	O
cells	O
depended	B-Positive_regulation
on	O
STAT6	O
,	O
but	O
not	O
on	O
STAT4	O
,	O
signaling	O
(	O
Figures	O
2B	O
and	O
2C	O
)	O
.	O

To	O
investigate	O
whether	O
the	O
inability	B-Negative_regulation
of	O
STAT4	O
-	O
deficient	B-Negative_regulation
Tcells	O
to	O
produce	B-Gene_expression
IL	O
-	O
10	O
might	O
be	O
due	B-Positive_regulation
to	O
the	O
absence	B-Negative_regulation
of	O
IFN	O
-	O
gamma	O
,	O
as	O
suggested	O
before	O
(	O
Shaw	O
etal.	O
,	O
2006	O
)	O
,	O
we	O
differentiated	O
DO11.10	O
or	O
DO11.10	O
IFN-gamma	O
-	O
deficient	B-Negative_regulation
naive	O
CD4+	O
Tcells	O
in	O
the	O
presence	O
of	O
IL	O
-	O
12	O
and	O
increasing	O
doses	O
of	O
OVA	O
.	O

The	O
secretion	B-Localization
of	O
IL	O
-	O
10	O
as	O
induced	B-Positive_regulation
by	O
high	O
antigen	O
dose	O
,	O
and	O
IL	O
-	O
12	O
was	O
not	O
affected	B-Regulation
by	O
an	O
absence	B-Negative_regulation
of	O
IFN	O
-	O
gamma	O
(	O
Figure2D	O
)	O
,	O
showing	O
that	O
the	O
expression	B-Gene_expression
ofIL	O
-	O
10	O
by	O
Th1	O
cells	O
is	O
independent	B-Regulation
of	O
IFN	O
-	O
gamma	O
.	O

In	O
the	O
absence	B-Negative_regulation
of	O
IFN	O
-	O
gamma	O
,	O
we	O
observed	O
an	O
increase	B-Positive_regulation
in	O
the	O
secreted	B-Localization
IL	O
-	O
4	O
as	O
expected	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
also	O
tested	O
for	O
any	O
potential	O
role	B-Regulation
of	O
IL	O
-	O
4	O
in	O
the	O
development	O
of	O
Th1	O
cells	O
producing	B-Gene_expression
IL	O
-	O
10	O
by	O
culturing	O
DO11.10	O
or	O
DO11.10	O
IL-4	O
-	O
deficient	B-Negative_regulation
naive	O
CD4+	O
Tcells	O
with	O
IL	O
-	O
12	O
and	O
increasing	O
doses	O
of	O
antigen	O
.	O

As	O
observed	O
in	O
the	O
absence	B-Negative_regulation
of	O
STAT6	O
(	O
Figure2A	O
)	O
,	O
IL	O
-	O
4	O
deficiency	B-Negative_regulation
had	O
no	O
effect	O
on	O
the	O
development	O
of	O
Th1	O
cells	O
producing	B-Gene_expression
IL	O
-	O
10	O
(	O
Figure2E	O
)	O
,	O
but	O
compromised	O
the	O
development	O
of	O
Th2	O
cells	O
producing	B-Gene_expression
IL	O
-	O
10	O
(	O
Figure2F	O
)	O
.	O

Thus	O
,	O
our	O
data	O
suggested	O
that	O
IL	O
-	O
10	O
production	B-Gene_expression
by	O
Th1	O
or	O
Th2	O
cells	O
was	O
dependent	O
on	O
the	O
specific	O
signaling	O
pathways	O
required	O
for	O
their	O
differentiation	O
,	O
given	O
that	O
STAT4	O
is	O
required	O
for	O
the	O
induction	B-Positive_regulation
of	O
IL	O
-	O
10	O
production	B-Gene_expression
by	O
Th1	O
cells	O
and	O
STAT6	O
for	O
Th2	O
cells	O
.	O

High	O
Antigen	O
Doses	O
and	O
STAT4	O
Are	O
Required	O
for	O
the	O
In	O
Vivo	O
Generation	O
of	O
IL-10	O
-	O
Producing	B-Gene_expression
Th1	O
Cells	O

To	O
address	O
the	O
mechanisms	O
regulating	B-Regulation
IL	O
-	O
10	O
production	B-Gene_expression
by	O
Th1	O
cells	O
invivo	O
,	O
we	O
transferred	O
DO11.10	O
cells	O
into	O
BALB/c	O
recipient	O
mice	O
and	O
immunized	O
the	O
recipients	O
with	O
very	O
high	O
doses	O
of	O
OVA	O
-	O
protein	O
with	O
or	O
without	O
added	O
lipopolysacharide	O
(	O
LPS	O
)	O
.	O

Tcells	O
were	O
recovered	O
from	O
the	O
inguinal	O
lymph	O
nodes	O
3	O
days	O
after	O
priming	O
and	O
restimulated	O
invitro	O
with	O
OVA	O
peptide	O
for	O
48	O
hr	O
.	O

This	O
invivo	O
immunization	O
induced	B-Positive_regulation
IL	O
-	O
10	O
and	O
IFN	O
-	O
gamma	O
production	B-Gene_expression
,	O
and	O
the	O
amount	O
of	O
IL	O
-	O
10	O
production	B-Gene_expression
was	O
enhanced	B-Positive_regulation
by	O
addition	O
of	O
LPS	O
in	O
the	O
immunization	O
(	O
Figure3A	O
)	O
and	O
with	O
higher	O
doses	O
of	O
OVA	O
(	O
3	O
muM	O
versus	O
1	O
muM	O
,	O
data	O
not	O
shown	O
)	O
.	O

To	O
test	O
the	O
role	O
of	O
STAT4	O
and	O
STAT6	O
signaling	O
in	O
the	O
invivo	O
development	O
of	O
IL-10	O
-	O
producing	B-Gene_expression
Th1	O
cells	O
,	O
we	O
transferred	O
STAT4	O
-	O
or	O
STAT6	O
-	O
deficient	B-Negative_regulation
or	O
WT	O
DO11.10	O
cells	O
into	O
recipient	O
BALB/c	O
mice	O
and	O
immunized	O
with	O
OVA	O
-	O
protein	O
plus	O
LPS	O
as	O
before	O
.	O

In	O
vivo	O
expression	B-Gene_expression
of	O
both	O
IL	O
-	O
10	O
and	O
IFN	O
-	O
gamma	O
was	O
markedly	O
reduced	B-Negative_regulation
but	O
not	O
completely	B-Negative_regulation
abrogated	I-Negative_regulation
in	O
the	O
absence	O
of	O
STAT4	O
signaling	O
(	O
Figures	O
3B	O
and	O
3C	O
)	O
,	O
suggesting	O
the	O
existence	O
of	O
compensatory	O
mechanisms	O
that	O
were	O
absent	O
in	O
the	O
invitro	O
system	O
.	O

Signaling	O
through	O
STAT6	O
had	O
no	O
effect	B-Regulation
on	O
IL	O
-	O
10	O
production	B-Gene_expression
by	O
Th1	O
cells	O
as	O
shown	O
by	O
intracellular	O
cytokine	O
staining	O
(	O
ICS	O
)	O
and	O
by	O
immunoassay	O
in	O
STAT6	O
-	O
deficient	B-Negative_regulation
Tcells	O
(	O
Figures	O
3B	O
and	O
3C	O
)	O
.	O

IL	O
-	O
10	O
Production	B-Gene_expression
Is	O
Maintained	B-Positive_regulation
by	O
High	O
TCR	O
Signal	O
Strength	O
and	O
IL	O
-	O
12	O

We	O
next	O
investigated	O
whether	O
repeated	O
strong	O
TCR	O
activation	O
is	O
a	O
compensatory	O
signal	O
for	O
IL-12	O
-	O
induced	O
STAT4	O
signaling	O
in	O
the	O
induction	B-Positive_regulation
of	O
IL	O
-	O
10	O
in	O
Th1	O
cells	O
.	O

For	O
this	O
,	O
CD4+	O
Tcells	O
were	O
differentiated	O
for	O
2	O
consecutive	O
weeks	O
with	O
high	O
antigen	O
doses	O
in	O
the	O
presence	O
or	O
absence	O
of	O
IL	O
-	O
12	O
throughout	O
(	O
Figures	O
4A	O
-	O
4D	O
)	O
.	O

High	O
antigen	O
dose	O
and	O
IL	O
-	O
12	O
cooperated	O
to	O
induce	B-Positive_regulation
maximal	O
IL	O
-	O
10	O
production	B-Gene_expression
(	O
Figures	O
4A	O
and	O
4B	O
)	O
,	O
given	O
that	O
this	O
combination	O
resulted	O
in	O
the	O
highest	O
numbers	O
of	O
IL-10	O
-	O
producing	B-Gene_expression
Th1	O
cells	O
.	O

Repeated	O
high	O
antigen	O
dose	O
stimulation	O
in	O
the	O
absence	O
of	O
exogenously	O
added	O
IL	O
-	O
12	O
resulted	B-Positive_regulation
in	O
the	O
production	B-Gene_expression
of	O
IL	O
-	O
10	O
by	O
Th1	O
cells	O
,	O
suggesting	O
that	O
repeated	O
strong	O
TCR	O
triggering	O
may	O
overcome	O
the	O
need	B-Positive_regulation
for	O
IL	O
-	O
12	O
for	O
IL	O
-	O
10	O
induction	B-Positive_regulation
(	O
Figures	O
4C	O
and	O
4D	O
)	O
.	O

However	O
,	O
IL	O
-	O
10	O
induction	B-Positive_regulation
under	O
these	O
conditions	O
was	O
abrogated	B-Negative_regulation
when	O
IL-12p40	O
-	O
deficient	B-Negative_regulation
DCs	O
were	O
used	O
as	O
APCs	O
(	O
Figure4E	O
)	O
.	O

Thus	O
,	O
IL	O
-	O
12	O
is	O
essential	B-Positive_regulation
during	O
both	O
primary	O
and	O
secondary	O
antigenic	O
stimulation	O
for	O
production	B-Gene_expression
of	O
IL	O
-	O
10	O
by	O
Th1	O
cells	O
.	O

To	O
determine	O
the	O
requirements	O
for	O
stability	O
of	O
the	O
IL-10	O
-	O
producing	B-Gene_expression
Th1	O
cells	O
,	O
we	O
differentiated	O
CD4+	O
Tcells	O
for	O
1	O
week	O
with	O
high	O
antigen	O
doses	O
with	O
or	O
without	O
IL	O
-	O
12	O
(	O
Figures	O
4A	O
and	O
4C	O
)	O
,	O
washed	O
them	O
,	O
and	O
then	O
restimulated	O
them	O
for	O
an	O
additional	O
week	O
with	O
a	O
low	O
antigen	O
dose	O
,	O
in	O
the	O
absence	O
or	O
presence	O
of	O
IL	O
-	O
12	O
(	O
Figure4F	O
)	O
.	O

Th1	O
cells	O
induced	B-Positive_regulation
in	O
the	O
first	O
week	O
to	O
produce	B-Gene_expression
IL	O
-	O
10	O
by	O
culture	O
with	O
high	O
antigen	O
doses	O
and	O
IL	O
-	O
12	O
lost	B-Negative_regulation
their	O
ability	O
to	O
express	B-Gene_expression
IL	O
-	O
10	O
when	O
recultured	O
with	O
low	O
doses	O
of	O
OVA	O
,	O
which	O
could	O
be	O
compensated	B-Negative_regulation
for	O
,	O
to	O
some	O
extent	O
,	O
by	O
addition	B-Positive_regulation
of	O
IL	O
-	O
12	O
to	O
the	O
secondary	O
cultures	O
(	O
Figure4F	O
)	O
,	O
again	O
suggesting	O
that	O
antigen	O
dose	O
and	O
IL	O
-	O
12	O
signals	O
cooperate	B-Positive_regulation
for	O
the	O
induction	B-Gene_expression
of	O
IL	O
-	O
10	O
.	O

Finally	O
,	O
DO11.10	O
CD4+	O
cells	O
that	O
were	O
exposed	O
to	O
low	O
doses	O
of	O
antigen	O
and	O
IL	O
-	O
12	O
during	O
the	O
primary	O
differentiation	O
phase	O
produced	B-Gene_expression
high	O
amounts	O
of	O
IFN	O
-	O
gamma	O
but	O
little	O
IL	O
-	O
10	O
,	O
but	O
they	O
could	O
be	O
induced	B-Positive_regulation
to	O
produce	B-Gene_expression
IL	O
-	O
10	O
when	O
both	O
high	O
antigen	O
dose	O
and	O
IL	O
-	O
12	O
were	O
present	O
during	O
the	O
recall	O
phase	O
(	O
FigureS4	O
)	O
.	O

Thus	O
,	O
high	O
antigen	O
dose	O
and	O
IL	O
-	O
12	O
are	O
required	O
for	O
sustaining	O
the	O
induction	B-Positive_regulation
of	O
IL	O
-	O
10	O
production	B-Gene_expression
by	O
Th1	O
cells	O
.	O

IL	O
-	O
10	O
Production	B-Gene_expression
by	O
Th1	O
Cells	O
Requires	B-Positive_regulation
ERK1	O
and	O
ERK2	O
Activation	B-Positive_regulation

Our	O
data	O
showed	O
that	O
the	O
maintenance	B-Positive_regulation
of	O
IL	O
-	O
10	O
induction	B-Gene_expression
in	O
Th1	O
cells	O
required	B-Positive_regulation
stimulation	O
with	O
high	O
antigen	O
dose	O
,	O
which	O
to	O
some	O
extent	O
could	O
be	O
compensated	O
for	O
by	O
the	O
addition	B-Positive_regulation
of	O
IL	O
-	O
12	O
.	O

Signaling	O
through	O
the	O
TCR	O
with	O
high	O
doses	O
of	O
antigen	O
induced	B-Positive_regulation
stronger	O
ERK1	O
and	O
ERK2	O
activation	B-Positive_regulation
than	O
that	O
induced	B-Positive_regulation
by	O
low	O
antigen	O
dose	O
,	O
not	O
only	O
in	O
naive	O
CD4+	O
Tcells	O
(	O
data	O
not	O
shown	O
)	O
as	O
previously	O
demonstrated	O
(	O
Jorritsma	O
etal.	O
,	O
2003	O
)	O
but	O
also	O
in	O
CD4+	O
Tcells	O
restimulated	O
with	O
the	O
same	O
high	O
and	O
low	O
antigen	O
doses	O
(	O
Figure5A	O
)	O
.	O

Although	O
the	O
apparent	O
peak	O
and	O
amount	O
of	O
ERK1	O
and	O
ERK2	O
activation	B-Positive_regulation
varied	O
slightly	O
between	O
experiments	O
,	O
a	O
consistent	O
finding	O
was	O
that	O
high	O
antigen	O
dose	O
differentiated	O
Th1	O
cells	O
always	O
showed	O
enhanced	B-Positive_regulation
and	O
prolonged	B-Positive_regulation
ERK1	O
and	O
ERK2	O
activation	B-Positive_regulation
in	O
the	O
presence	O
of	O
IL	O
-	O
12	O
,	O
regardless	O
of	O
whether	O
they	O
were	O
restimulated	O
with	O
high	O
or	O
low	O
antigen	O
dose	O
(	O
Figure5B	O
)	O
.	O

We	O
then	O
investigated	O
whether	O
ERK1	O
and	O
ERK2	O
activation	B-Positive_regulation
was	O
required	B-Positive_regulation
for	O
the	O
induction	B-Positive_regulation
of	O
IL	O
-	O
10	O
in	O
Th1	O
cells	O
by	O
using	O
U0126	O
(	O
Figure5C	O
)	O
,	O
a	O
compound	O
that	O
blocks	O
downstream	O
ERK	O
activation	O
.	O

To	O
ensure	O
that	O
only	O
Tcell	O
signaling	O
was	O
being	O
affected	O
by	O
U0126	O
,	O
we	O
used	O
an	O
APC	O
-	O
free	O
system	O
in	O
which	O
the	O
Tcells	O
were	O
differentiated	O
in	O
the	O
presence	O
of	O
increasing	O
doses	O
of	O
anti	O
-	O
CD3	O
and	O
a	O
constant	O
amount	O
of	O
IL	O
-	O
12	O
.	O

As	O
in	O
the	O
APC	O
-	O
driven	O
cultures	O
,	O
stronger	O
TCR	O
stimulation	O
together	O
with	O
IL	O
-	O
12	O
led	O
to	O
higher	O
percentages	O
of	O
cells	O
producing	B-Gene_expression
both	O
IL	O
-	O
10	O
and	O
IFN	O
-	O
gamma	O
after	O
1	O
week	O
of	O
culture	O
(	O
Figure5C	O
)	O
.	O

Addition	O
of	O
U0126	O
to	O
the	O
cultures	O
abrogated	B-Negative_regulation
the	O
production	B-Gene_expression
of	O
IL	O
-	O
10	O
at	O
all	O
doses	O
of	O
anti	O
-	O
CD3	O
(	O
Figure5C	O
)	O
.	O

Because	O
U0126	O
inhibits	B-Negative_regulation
the	O
MEK5	O
-	O
catalyzed	B-Positive_regulation
activation	B-Positive_regulation
of	O
ERK5	O
,	O
as	O
well	O
as	O
the	O
MEK1	O
-	O
and	O
MEK2	O
-	O
catalyzed	B-Positive_regulation
activation	B-Positive_regulation
of	O
ERK1	O
and	O
ERK2	O
(	O
Bain	O
etal.	O
,	O
2007	O
;	O
Mody	O
etal.	O
,	O
2001	O
)	O
,	O
we	O
also	O
used	O
the	O
more	O
specific	O
,	O
structurally	O
unrelated	O
MEK1	O
and	O
MEK2	O
inhibitor	B-Negative_regulation
PD184352	O
at	O
concentrations	O
in	O
which	O
it	O
inhibits	B-Negative_regulation
MEK1	O
and	O
MEK2	O
but	O
not	O
MEK5	O
(	O
Bain	O
etal.	O
,	O
2007	O
;	O
Mody	O
etal.	O
,	O
2001	O
)	O
.	O

PD184352	O
caused	O
a	O
similar	O
inhibition	B-Negative_regulation
of	O
IL	O
-	O
10	O
production	B-Gene_expression
by	O
Th1	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
(	O
Figure5D	O
and	O
FigureS5A	O
)	O
.	O

Upon	O
addition	O
of	O
inhibitors	O
to	O
othersignaling	O
pathways	O
,	O
including	O
a	O
p38	O
MAPK	O
inhibitor	B-Negative_regulation
,	O
SB203580	O
,	O
or	O
the	O
GSK3beta	O
inhibitor	B-Negative_regulation
,	O
CT99021	O
(	O
Bain	O
etal.	O
,	O
2007	O
)	O
,	O
no	O
effect	B-Regulation
on	O
IL	O
-	O
10	O
production	B-Gene_expression
was	O
observed	O
(	O
FigureS5B	O
)	O
.	O

Our	O
data	O
thus	O
suggested	O
that	O
IL	O
-	O
10	O
production	B-Gene_expression
by	O
Th1	O
cells	O
in	B-Positive_regulation
response	I-Positive_regulation
to	I-Positive_regulation
high	O
antigen	O
dose	O
and	O
IL	O
-	O
12	O
requires	B-Positive_regulation
ERK1	O
and	O
ERK2	O
signaling	O
,	O
but	O
not	O
the	O
activation	B-Positive_regulation
of	O
the	O
p38	O
or	O
the	O
GSK3beta	O
pathways	O
.	O

IL	O
-	O
10	O
Production	B-Gene_expression
by	O
Th2	O
and	O
Th17	O
Cells	O
Also	O
Requires	B-Positive_regulation
ERK1	O
and	O
ERK2	O
Activation	B-Positive_regulation

To	O
address	O
whether	O
IL	O
-	O
10	O
production	B-Gene_expression
by	O
Th2	O
and	O
Th17	O
cells	O
was	O
also	O
dependent	B-Positive_regulation
on	O
ERK1	O
and	O
ERK2	O
activation	B-Positive_regulation
,	O
we	O
differentiated	O
these	O
cells	O
with	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	O
in	O
the	O
absence	O
of	O
APCs	O
(	O
Shoemaker	O
etal.	O
,	O
2006	O
;	O
Veldhoen	O
etal.	O
,	O
2009	O
;	O
Veldhoen	O
etal.	O
,	O
2006	O
)	O
,	O
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
MEK	O
inhibitor	B-Negative_regulation
(	O
PD184352	O
)	O
.	O

We	O
showed	O
that	O
ERK1	O
and	O
ERK2	O
activation	B-Positive_regulation
is	O
a	O
common	O
pathway	O
required	B-Positive_regulation
for	O
induction	B-Gene_expression
of	O
IL	O
-	O
10	O
in	O
different	O
Th	O
cell	O
subsets	O
because	O
IL	O
-	O
10	O
production	B-Gene_expression
by	O
both	O
Th2	O
and	O
Th17	O
cells	O
was	O
markedly	O
inhibited	B-Negative_regulation
in	O
the	O
presence	O
of	O
the	O
MEK	O
inhibitor	B-Negative_regulation
(	O
PD184352	O
)	O
(	O
Figure5D	O
and	O
FigureS5B	O
)	O
.	O

In	O
contrast	O
,	O
inhibitors	B-Negative_regulation
of	O
p38	O
MAPK	O
or	O
of	O
GSK	O
-	O
3beta	O
activation	B-Positive_regulation
did	O
not	O
affect	B-Regulation
the	O
expression	B-Gene_expression
of	O
IL	O
-	O
10	O
by	O
these	O
subsets	O
(	O
FigureS5B	O
)	O
.	O

Activation	O
of	O
the	O
ERK1	O
and	O
ERK2	O
signaling	O
pathway	O
is	O
therefore	O
a	O
common	O
requirement	B-Positive_regulation
for	O
the	O
induction	B-Positive_regulation
of	O
IL	O
-	O
10	O
production	B-Gene_expression
by	O
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
cells	O
.	O

c	O
-	O
maf	O
Expression	B-Gene_expression
Correlates	O
with	O
IL	O
-	O
10	O
Production	B-Gene_expression
in	O
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
Cells	O

To	O
investigate	O
further	O
the	O
downstream	O
factors	O
involved	O
in	O
regulating	B-Regulation
IL	O
-	O
10	O
production	B-Gene_expression
,	O
we	O
differentiated	O
DO11.10	O
CD4+	O
Tcells	O
with	O
increasing	O
doses	O
of	O
OVA	O
,	O
in	O
the	O
presence	O
or	O
absence	O
of	O
IL	O
-	O
12	O
,	O
and	O
quantified	O
the	O
expression	O
of	O
cytokines	O
and	O
transcription	O
factors	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

Low	O
-	O
dose	O
antigen	O
resulted	B-Positive_regulation
in	O
transcription	B-Transcription
of	O
Il4	O
and	O
this	O
was	O
abrogated	B-Negative_regulation
by	O
both	O
high	O
antigen	O
doses	O
and	O
IL	O
-	O
12	O
(	O
Figure6A	O
)	O
.	O

A	O
low	O
amount	O
of	O
transcription	B-Transcription
of	O
Ifngamma	O
was	O
induced	B-Positive_regulation
by	O
IL	O
-	O
12	O
when	O
cells	O
were	O
differentiated	O
with	O
low	O
antigen	O
dose	O
,	O
but	O
this	B-Positive_regulation
effect	I-Positive_regulation
of	O
IL	O
-	O
12	O
was	O
markedly	O
upregulated	B-Positive_regulation
with	O
increasing	O
doses	O
of	O
antigen	O
(	O
Figure6A	O
)	O
.	O

A	O
low	O
amount	O
of	O
Il10	O
transcription	B-Transcription
was	O
observed	O
at	O
low	O
doses	O
of	O
antigen	O
accompanying	O
Il4	O
expression	B-Gene_expression
(	O
Th2	O
cell	O
response	O
)	O
,	O
and	O
this	O
was	O
abrogated	B-Negative_regulation
by	O
increased	O
doses	O
of	O
antigen	O
as	O
was	O
Il4	O
expression	B-Gene_expression
(	O
Figure6A	O
)	O
.	O

At	O
low	O
doses	O
of	O
antigen	O
,	O
IL	O
-	O
12	O
had	O
little	O
effect	B-Regulation
to	O
increase	B-Positive_regulation
IL	O
-	O
10	O
mRNA	B-Transcription
expression	I-Transcription
(	O
Figure6A	O
)	O
in	O
keeping	O
with	O
the	O
protein	O
data	O
(	O
Figure1A	O
)	O
.	O

However	O
,	O
IL	O
-	O
12	O
induced	B-Positive_regulation
a	O
high	O
amount	O
of	O
Il10	O
transcription	B-Transcription
as	O
well	O
as	O
Ifngamma	O
expression	B-Gene_expression
with	O
increased	O
antigen	O
doses	O
(	O
Figure6A	O
)	O
,	O
again	O
in	O
keeping	O
with	O
the	O
protein	O
data	O
(	O
Figure1A	O
)	O
.	O

CD4+	O
Tcells	O
differentiated	O
with	O
increasing	O
doses	O
of	O
antigen	O
did	O
not	O
express	B-Transcription
high	O
amounts	O
of	O
Tbx	O
-	O
21	O
(	O
T	O
-	O
bet	O
)	O
mRNA	O
,	O
unless	O
they	O
were	O
cocultured	O
with	O
IL	O
-	O
12	O
(	O
Figure6B	O
)	O
.	O

In	O
contrast	O
,	O
high	O
amounts	O
of	O
GATA	O
-	O
3	O
mRNA	B-Transcription
expression	I-Transcription
were	O
only	O
observed	O
under	O
Th2	O
cell	O
differentiation	O
conditions	O
(	O
low	O
-	O
dose	O
antigen	O
)	O
(	O
Figure6B	O
)	O
,	O
and	O
this	O
expression	O
was	O
markedly	O
downregulated	B-Negative_regulation
by	O
both	O
increasing	O
antigen	O
dose	O
and	O
coculture	O
in	O
IL	O
-	O
12	O
(	O
Figure6B	O
)	O
.	O

Differentiation	O
of	O
Tcells	O
under	O
low	O
antigen	O
dose	O
led	B-Positive_regulation
to	O
expression	B-Gene_expression
of	O
c	O
-	O
maf	O
,	O
in	O
keeping	O
with	O
the	O
Th2	O
cell	O
profile	O
(	O
Ho	O
etal.	O
,	O
1996	O
)	O
,	O
which	O
was	O
almost	O
completely	O
abrogated	B-Negative_regulation
by	O
increasing	O
doses	O
of	O
antigen	O
(	O
Figure6B	O
)	O
.	O

Interestingly	O
,	O
IL	O
-	O
12	O
sustained	B-Positive_regulation
the	O
high	O
expression	B-Transcription
of	O
c	O
-	O
Maf	O
mRNA	O
even	O
at	O
the	O
highest	O
antigen	O
dose	O
(	O
Figure6B	O
)	O
.	O

Moreover	O
,	O
IL	O
-	O
12	O
maintenance	B-Positive_regulation
of	O
c	O
-	O
maf	O
expression	B-Gene_expression
required	B-Positive_regulation
STAT4	O
activation	B-Positive_regulation
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
Th17	O
cells	O
that	O
expressed	B-Transcription
IL	O
-	O
17a	O
as	O
well	O
as	O
IL	O
-	O
10	O
mRNA	O
(	O
Figure6C	O
)	O
,	O
T	O
-	O
bet	O
and	O
GATA	O
-	O
3	O
mRNA	B-Transcription
were	O
undetectable	B-Negative_regulation
(	O
data	O
not	O
shown	O
)	O
,	O
whereas	O
that	O
of	O
ROR	O
-	O
gammat	O
was	O
high	B-Positive_regulation
(	O
Figure6C	O
)	O
(	O
Ivanov	O
etal.	O
,	O
2007	O
)	O
.	O

Th17	O
cells	O
also	O
expressed	B-Gene_expression
high	O
amounts	O
of	O
c	O
-	O
maf	O
(	O
Figure6C	O
)	O
,	O
confirming	O
a	O
recent	O
report	O
(	O
Bauquet	O
etal.	O
,	O
2009	O
)	O
.	O

c	O
-	O
Maf	O
is	O
therefore	O
expressed	B-Gene_expression
in	O
all	O
IL-10	O
-	O
expressing	B-Gene_expression
Tcell	O
populations	O
tested	O
(	O
Figures	O
6B	O
and	O
6C	O
)	O
and	O
may	O
not	O
be	O
just	O
a	O
Th2	O
cell	O
-	O
specific	O
transcription	O
factor	O
as	O
originally	O
thought	O
(	O
Ho	O
etal.	O
,	O
1996	O
)	O
.	O

We	O
showed	O
also	O
that	O
like	O
Il10	O
expression	B-Gene_expression
,	O
c	O
-	O
maf	O
expression	B-Gene_expression
was	O
inhibited	B-Negative_regulation
in	O
Th1	O
and	O
Th17	O
cells	O
in	O
the	O
presence	O
of	O
the	O
MEK1	O
and	O
MEK2	O
inhibitor	B-Negative_regulation
(	O
PD184352	O
)	O
,	O
whereas	O
T	O
-	O
bet	O
and	O
RORgammat	O
expression	B-Gene_expression
was	O
hardly	O
affected	B-Regulation
(	O
Figure6D	O
)	O
.	O

Discussion	O

IL	O
-	O
10	O
expression	B-Gene_expression
by	O
cells	O
of	O
the	O
innate	O
and	O
adaptive	O
immune	O
systems	O
reflects	O
the	O
importance	O
of	O
this	O
cytokine	O
in	O
the	O
tight	O
regulation	O
of	O
the	O
immune	O
response	O
,	O
to	O
minimize	O
pathology	O
during	O
infection	O
.	O

IL	O
-	O
10	O
expression	B-Gene_expression
by	O
Th1	O
cells	O
has	O
been	O
reported	O
to	O
regulate	O
the	O
immune	O
response	O
in	O
leishmaniasis	O
and	O
toxoplasmosis	O
.	O

However	O
,	O
in	O
many	O
situations	O
,	O
IL	O
-	O
10	O
is	O
not	O
produced	B-Gene_expression
by	O
Th1	O
cells	O
in	B-Positive_regulation
response	I-Positive_regulation
to	I-Positive_regulation
antigenic	O
stimulation	O
.	O

Our	O
goal	O
was	O
to	O
address	O
the	O
molecular	O
signals	O
that	O
determine	O
whether	O
Th1	O
cells	O
develop	O
to	O
produce	B-Gene_expression
IL	O
-	O
10	O
(	O
Trinchieri	O
,	O
2007	O
)	O
.	O

Here	O
,	O
we	O
showed	O
that	O
Th1	O
cells	O
required	B-Positive_regulation
high-antigen-dose	O
-	O
induced	O
ERK1	O
and	O
ERK2	O
phosphorylation	B-Phosphorylation
and	O
IL-12	O
-	O
induced	B-Positive_regulation
STAT	O
-	O
4	O
activation	B-Positive_regulation
to	O
produce	B-Gene_expression
IL	O
-	O
10	O
.	O

Our	O
findings	O
that	O
ERK1	O
and	O
ERK2	O
activation	B-Positive_regulation
was	O
a	O
common	O
pathway	O
required	B-Positive_regulation
for	O
the	O
production	B-Gene_expression
of	O
IL	O
-	O
10	O
by	O
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
cell	O
subsets	O
,	O
which	O
differentiate	O
along	O
distinct	O
pathways	O
,	O
such	O
that	O
IL	O
-	O
10	O
provides	B-Regulation
a	I-Regulation
highly	I-Regulation
regulated	I-Regulation
feedback	I-Regulation
loop	I-Regulation
to	O
avoid	O
the	O
extremes	O
of	O
excessive	O
inflammation	O
or	O
chronic	O
infections	O
and	O
also	O
allow	O
a	O
protective	O
response	O
to	O
diverse	O
pathogens	O
.	O

In	O
certain	O
viral	O
or	O
parasitic	O
infections	O
(	O
Anderson	O
etal.	O
,	O
2007	O
;	O
Brooks	O
etal.	O
,	O
2006	O
;	O
Ejrnaes	O
etal.	O
,	O
2006	O
)	O
,	O
high	O
amounts	O
of	O
stimulation	O
may	O
lead	O
to	O
the	O
chronic	O
nonhealing	O
infection	O
shown	O
to	O
be	O
regulated	O
by	O
IL	O
-	O
10	O
.	O

During	O
the	O
course	O
of	O
infection	O
,	O
after	O
initial	O
triggering	O
with	O
antigen	O
,	O
Tcells	O
migrate	O
to	O
the	O
tissue	O
encountering	O
high	O
doses	O
of	O
antigen	O
and	O
factors	O
produced	O
by	O
the	O
innate	O
immune	O
response	O
.	O

Under	O
these	O
conditions	O
,	O
we	O
speculate	O
that	O
Th1	O
cells	O
will	O
be	O
induced	B-Positive_regulation
to	O
express	B-Gene_expression
high	O
amounts	O
of	O
IL	O
-	O
10	O
,	O
in	O
keeping	O
with	O
reports	O
that	O
IL-10	O
-	O
producing	B-Gene_expression
Th1	O
cells	O
were	O
found	O
in	O
CD4+	O
clones	O
isolated	O
from	O
BAL	O
but	O
not	O
blood	O
of	O
TB	O
patients	O
(	O
Gerosa	O
etal.	O
,	O
1999	O
)	O
.	O

Similarly	O
,	O
the	O
immune	O
response	O
to	O
a	O
clinical	O
isolate	O
of	O
L.	O
major	O
,	O
which	O
produces	O
heavily	O
infected	O
nonhealing	O
lesions	O
,	O
was	O
found	O
to	O
be	O
regulated	O
by	O
IL	O
-	O
10	O
derived	O
from	O
Foxp3	O
-	O
Th1	O
cells	O
that	O
coproduce	B-Gene_expression
IL	O
-	O
10	O
and	O
IFN	O
-	O
gamma	O
(	O
Anderson	O
etal.	O
,	O
2007	O
)	O
,	O
and	O
the	O
immune	O
response	O
during	O
T.	O
gondii	O
infection	O
was	O
found	O
also	O
to	O
be	O
regulated	O
by	O
Foxp3	O
-	O
Th1	O
cells	O
(	O
Jankovic	O
etal.	O
,	O
2007	O
)	O
.	O

It	O
is	O
likely	O
that	O
IL	O
-	O
10	O
production	B-Gene_expression
by	O
Th1	O
cells	O
is	O
evoked	O
under	O
conditions	O
of	O
high	O
inflammation	O
and	O
antigenic	O
stimulation	O
,	O
whereas	O
regulatory	O
CD4+	O
Tcells	O
producing	B-Gene_expression
IL	O
-	O
10	O
may	O
operate	O
to	O
regulate	O
the	O
immune	O
response	O
under	O
conditions	O
in	O
which	O
the	O
pathogen	O
is	O
clinically	O
controlled	O
,	O
such	O
as	O
in	O
infection	O
with	O
L.	O
major	O
(	O
Friedlin	O
strain	O
)	O
(	O
Belkaid	O
etal.	O
,	O
2002	O
;	O
Suffia	O
etal.	O
,	O
2006	O
)	O
.	O

We	O
now	O
also	O
reported	O
that	O
CD4+	O
Tcells	O
cultured	O
with	O
high	O
antigen	O
dose	O
and	O
IL	O
-	O
12	O
differentiate	O
into	O
canonical	O
Th1	O
effector	O
cells	O
,	O
which	O
,	O
in	O
addition	O
to	O
expressing	B-Gene_expression
large	O
amounts	O
of	O
IFN	O
-	O
gamma	O
and	O
IL	O
-	O
10	O
,	O
lose	B-Negative_regulation
their	O
IL	O
-	O
2	O
expression	B-Gene_expression
as	O
described	O
before	O
in	O
certain	O
chronic	O
infection	O
models	O
(	O
Sallusto	O
etal.	O
,	O
2004	O
)	O
.	O

Our	O
demonstration	O
that	O
loss	B-Negative_regulation
of	O
IL	O
-	O
2	O
is	O
accompanied	O
by	O
production	B-Gene_expression
of	O
IL	O
-	O
10	O
offers	O
potential	O
additional	O
mechanisms	O
whereby	O
effector	O
Tcell	O
responses	O
may	O
be	O
dampened	O
during	O
chronic	O
disease	O
.	O

Using	O
an	O
invivo	O
transfer	O
model	O
of	O
DO11.10	O
TCR	O
transgenic	O
cells	O
(	O
Castro	O
etal.	O
,	O
2000	O
)	O
,	O
we	O
showed	O
that	O
IL-10	O
-	O
producing	O
Th1	O
cells	O
were	O
differentiated	O
in	O
the	O
presence	O
of	O
high	O
doses	O
of	O
OVA	O
protein	O
and	O
LPS	O
.	O

We	O
showed	O
here	O
that	O
this	O
induction	B-Positive_regulation
of	O
IL	O
-	O
10	O
inTh1	O
cells	O
invivo	O
was	O
markedly	O
,	O
but	O
not	O
totally	O
,	O
reduced	B-Negative_regulation
in	O
STAT4	O
-	O
deficient	B-Negative_regulation
Tcells	O
as	O
observed	O
during	O
T.	O
gondii	O
infection	O
(	O
Jankovic	O
etal.	O
,	O
2002	O
)	O
.	O

A	O
high	O
antigenic	O
activation	O
during	O
T.	O
gondii	O
infection	O
or	O
high	O
antigen	O
doses	O
delivered	O
in	O
the	O
presence	O
of	O
LPS	O
,	O
as	O
seen	O
in	O
our	O
system	O
,	O
may	O
compensate	O
for	O
an	O
absolute	O
requirement	B-Positive_regulation
for	O
IL	O
-	O
12	O
in	O
the	O
induction	B-Positive_regulation
of	O
IL	O
-	O
10	O
by	O
Th1	O
cells	O
.	O

In	O
our	O
invitro	O
system	O
,	O
repeated	O
stimulation	O
of	O
Th1	O
cells	O
with	O
high	O
antigen	O
doses	O
allowed	O
the	O
development	O
of	O
Th1	O
cells	O
producing	B-Gene_expression
IL	O
-	O
10	O
in	O
an	O
IL-12	O
-	O
dependent	O
manner	O
.	O

IL	O
-	O
10	O
production	B-Gene_expression
by	O
Th1	O
cells	O
induced	B-Positive_regulation
by	O
high	O
antigen	O
dose	O
and	O
IL	O
-	O
12	O
was	O
independent	B-Regulation
of	O
IFN	O
-	O
gamma	O
,	O
in	O
keeping	O
with	O
previous	O
findings	O
(	O
Jankovic	O
etal.	O
,	O
2002	O
)	O
.	O

However	O
,	O
a	O
role	O
for	O
IFN	O
-	O
gamma	O
in	O
mediating	B-Positive_regulation
IL	O
-	O
10	O
reactivation	B-Positive_regulation
by	O
Th1	O
cells	O
during	O
secondary	O
infection	O
with	O
T.	O
gondii	O
has	O
been	O
suggested	O
(	O
Shaw	O
etal.	O
,	O
2006	O
)	O
.	O

We	O
have	O
found	O
that	O
CD4+	O
Tcells	O
exposed	O
to	O
a	O
high	O
dose	O
of	O
antigen	O
do	O
not	O
express	B-Gene_expression
IL	O
-	O
10	O
upon	O
restimulation	O
,	O
but	O
can	O
be	O
induced	B-Positive_regulation
to	O
produce	B-Gene_expression
IL	O
-	O
10	O
upon	O
re	O
-	O
exposure	O
to	O
a	O
high	O
dose	O
of	O
antigen	O
in	O
the	O
recall	O
phase	O
in	O
the	O
absence	O
of	O
added	O
IL	O
-	O
12	O
.	O

However	O
,	O
this	O
is	O
dependent	B-Positive_regulation
on	O
the	O
induction	B-Positive_regulation
of	O
IL	O
-	O
12	O
by	O
antigen	O
-	O
presenting	O
DCs	O
.	O

The	O
combination	O
of	O
both	O
high	O
antigen	O
dose	O
and	O
IL	O
-	O
12	O
resulted	B-Positive_regulation
in	O
the	O
highest	O
levels	O
of	O
IL	O
-	O
10	O
production	B-Gene_expression
and	O
correlated	O
with	O
the	O
high	O
levels	O
of	O
ERK1	O
and	O
ERK2	O
activation	B-Positive_regulation
.	O

The	O
increased	B-Positive_regulation
expression	B-Gene_expression
of	O
IFN	O
-	O
gamma	O
observed	O
during	O
the	O
secondary	O
phase	O
will	O
induce	B-Positive_regulation
increased	B-Positive_regulation
IL	O
-	O
12	O
production	B-Gene_expression
by	O
DCs	O
and	O
suggests	O
that	O
repeated	O
high	O
-	O
level	O
TCR	O
activation	O
feeds	O
back	O
to	O
upregulate	B-Positive_regulation
IL	O
-	O
12	O
production	B-Gene_expression
by	O
DC	O
.	O

It	O
is	O
thus	O
likely	O
that	O
in	O
T.	O
gondii	O
infection	O
invivo	O
(	O
Shaw	O
etal.	O
,	O
2006	O
)	O
,	O
the	O
requirement	B-Positive_regulation
for	O
IFN	O
-	O
gamma	O
to	O
induce	B-Positive_regulation
IL	O
-	O
10	O
,	O
was	O
for	O
feedback	O
upregulation	B-Positive_regulation
of	O
IL	O
-	O
12	O
by	O
DCs	O
,	O
which	O
in	O
turn	O
induced	B-Positive_regulation
IL	O
-	O
10	O
in	O
the	O
Th1	O
cells	O
.	O

Although	O
IL	O
-	O
10	O
may	O
be	O
differentially	O
regulated	B-Regulation
in	O
Th1	O
and	O
Th2	O
cells	O
as	O
has	O
been	O
reported	O
(	O
Chang	O
etal.	O
,	O
2007	O
;	O
Wang	O
etal.	O
,	O
2005	O
)	O
,	O
some	O
studies	O
suggest	O
the	O
existence	O
of	O
common	O
pathways	O
,	O
but	O
the	O
molecular	O
basis	O
for	O
these	O
is	O
as	O
yet	O
unclear	O
.	O

Costimulatory	O
OX	O
-	O
40	O
signals	O
have	O
been	O
shown	O
to	O
negatively	B-Negative_regulation
regulate	I-Negative_regulation
IL	O
-	O
10	O
production	B-Gene_expression
(	O
Ito	O
etal.	O
,	O
2005	O
)	O
both	O
in	O
Th1	O
and	O
Th2	O
cells	O
,	O
whereas	O
ICOS	O
signaling	O
has	O
been	O
suggested	O
to	O
induce	B-Positive_regulation
IL	O
-	O
10	O
(	O
Ito	O
etal.	O
,	O
2007	O
;	O
Witsch	O
etal.	O
,	O
2002	O
)	O
in	O
both	O
Th1	O
and	O
Th2	O
cells	O
.	O

However	O
,	O
in	O
some	O
cases	O
,	O
ICOS	O
signaling	O
also	O
regulates	B-Regulation
IL	O
-	O
4	O
production	B-Gene_expression
and	O
Th2	O
responses	O
(	O
Greenwald	O
etal.	O
,	O
2005	O
)	O
.	O

We	O
now	O
provide	O
a	O
common	O
mechanism	O
of	O
ERK1	O
and	O
ERK2	O
activation	B-Positive_regulation
for	O
the	O
regulation	B-Regulation
of	O
IL	O
-	O
10	O
production	B-Gene_expression
in	O
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
cells	O
,	O
although	O
each	O
subset	O
differentiates	O
along	O
a	O
distinct	O
and	O
subset	O
-	O
specific	O
transcriptional	O
pathway	O
.	O

This	O
reinforces	O
the	O
fact	O
that	O
IL	O
-	O
10	O
is	O
not	O
a	O
Th	O
cell-subset	O
-	O
specific	O
cytokine	O
,	O
but	O
instead	O
is	O
produced	B-Gene_expression
in	O
a	O
tightly	O
regulated	B-Regulation
fashion	O
during	O
each	O
differentiation	O
pathway	O
.	O

Of	O
note	O
,	O
a	O
role	B-Regulation
for	O
ERK1	O
and	O
ERK2	O
activation	B-Positive_regulation
in	O
the	O
induction	B-Positive_regulation
of	O
IL	O
-	O
10	O
production	B-Gene_expression
has	O
already	O
been	O
described	O
for	O
macrophages	O
and	O
DC	O
(	O
Agrawal	O
etal.	O
,	O
2006	O
;	O
Hacker	O
etal.	O
,	O
1999	O
)	O
.	O

Differential	O
transcriptional	O
regulation	B-Regulation
of	O
IL	O
-	O
10	O
in	O
Th1	O
and	O
Th2	O
cells	O
has	O
been	O
suggested	O
(	O
Chang	O
etal.	O
,	O
2007	O
;	O
Wang	O
etal.	O
,	O
2005	O
)	O
,	O
and	O
extensive	O
histone	O
acetylation	O
of	O
the	O
IL	O
-	O
10	O
gene	O
is	O
detectable	O
in	O
fully	O
polarized	O
Th2	O
cells	O
,	O
but	O
not	O
Th1cells	O
(	O
Chang	O
etal.	O
,	O
2007	O
)	O
.	O

We	O
provide	O
evidence	O
that	O
IL	O
-	O
10	O
is	O
produced	B-Gene_expression
in	O
canonical	O
Th1	O
cells	O
and	O
that	O
its	O
expression	B-Gene_expression
correlates	O
with	O
the	O
expression	B-Gene_expression
of	O
T	O
-	O
bet	O
and	O
the	O
highest	O
IFN	O
-	O
gamma	O
production	B-Gene_expression
,	O
in	O
keeping	O
with	O
our	O
observations	O
that	O
high	O
-	O
dose	O
antigen	O
stimulation	O
and	O
IL	O
-	O
12	O
signaling	O
are	O
required	B-Positive_regulation
for	O
IL	O
-	O
10	O
and	O
IFN	O
-	O
gamma	O
expression	B-Gene_expression
.	O

It	O
has	O
also	O
been	O
shown	O
that	O
maintenance	B-Positive_regulation
of	O
IL	O
-	O
10	O
expression	B-Gene_expression
is	O
conditional	B-Positive_regulation
on	O
IL	O
-	O
12	O
or	O
IL	O
-	O
4	O
unless	O
the	O
IL	O
-	O
10	O
gene	O
is	O
imprinted	O
by	O
GATA	O
-	O
3	O
(	O
Chang	O
etal.	O
,	O
2007	O
)	O
,	O
which	O
can	O
remodel	O
the	O
IL	O
-	O
10	O
locus	O
,	O
thus	O
explaining	O
the	O
highest	O
amounts	O
of	O
IL	O
-	O
10	O
produced	B-Gene_expression
by	O
Th2	O
cells	O
(	O
Chang	O
etal.	O
,	O
2007	O
;	O
Shoemaker	O
etal.	O
,	O
2006	O
)	O
.	O

We	O
show	O
here	O
that	O
high	O
antigen	O
dose	O
and	O
IL	O
-	O
12	O
drastically	O
downregulate	B-Negative_regulation
Gata	O
-	O
3	O
expression	B-Gene_expression
,	O
suggesting	O
that	O
additional	O
factors	O
are	O
in	O
place	O
to	O
induce	B-Positive_regulation
IL	O
-	O
10	O
expression	B-Gene_expression
in	O
Th1	O
cells	O
,	O
albeit	O
transiently	O
.	O

Expression	B-Gene_expression
of	O
c	O
-	O
maf	O
was	O
greatly	O
diminished	B-Negative_regulation
by	O
high	O
antigen	O
doses	O
in	O
Tcells	O
and	O
yet	O
was	O
unexpectedly	O
maintained	B-Positive_regulation
by	O
IL	O
-	O
12	O
and	O
present	O
in	O
Th17	O
cells	O
.	O

That	O
c	O
-	O
maf	O
expression	B-Gene_expression
is	O
common	O
to	O
IL-10	O
-	O
producing	B-Gene_expression
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
cells	O
and	O
,	O
like	O
IL	O
-	O
10	O
,	O
is	O
dependent	B-Positive_regulation
on	O
ERK	O
activation	B-Positive_regulation
in	O
Th1	O
and	O
Th17	O
cells	O
for	O
its	O
expression	B-Gene_expression
is	O
of	O
interest	O
because	O
c	O
-	O
Maf	O
has	O
been	O
shown	O
to	O
be	O
an	O
essential	B-Positive_regulation
transcription	O
factor	O
for	O
IL	O
-	O
10	O
expression	B-Gene_expression
in	O
macrophages	O
(	O
Cao	O
etal.	O
,	O
2005	O
)	O
.	O

In	O
summary	O
,	O
we	O
show	O
that	O
although	O
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
CD4+	O
Tcell	O
subsets	O
differentiate	O
along	O
distinct	O
signaling	O
and	O
transcriptional	O
pathways	O
,	O
they	O
can	O
all	O
be	O
induced	B-Positive_regulation
to	O
make	B-Gene_expression
IL	O
-	O
10	O
.	O

ERK1	O
and	O
ERK2	O
activation	B-Positive_regulation
is	O
required	B-Positive_regulation
for	O
IL	O
-	O
10	O
production	B-Gene_expression
by	O
all	O
these	O
Th	O
cell	O
subsets	O
.	O

With	O
regard	O
to	O
the	O
expression	B-Gene_expression
of	O
IL	O
-	O
10	O
by	O
Th1	O
cells	O
,	O
our	O
data	O
provide	O
a	O
mechanism	O
for	O
how	O
IL	O
-	O
10	O
expression	B-Gene_expression
is	O
induced	B-Positive_regulation
and	O
then	O
amplified	B-Positive_regulation
and	O
regulated	B-Regulation
by	O
the	O
levels	O
of	O
antigen	O
and	O
IL	O
-	O
12	O
encountered	O
in	O
the	O
environment	O
.	O

This	O
provides	O
a	O
mechanism	O
whereby	O
a	O
Th1	O
cell	O
responds	O
to	O
extrinsic	O
signals	O
,	O
reflecting	O
increased	O
inflammation	O
in	O
the	O
tissue	O
,	O
to	O
tightly	O
regulate	B-Regulation
the	O
production	B-Gene_expression
of	O
IL	O
-	O
10	O
so	O
as	O
to	O
allow	O
a	O
protective	O
response	O
to	O
eradicate	O
a	O
pathogen	O
with	O
minimal	O
damage	O
to	O
the	O
host	O
and	O
also	O
prevent	O
chronic	O
infection	O
.	O

Moreover	O
,	O
our	O
findings	O
have	O
important	O
implications	O
for	O
the	O
regulation	B-Regulation
of	O
IL	O
-	O
10	O
production	B-Gene_expression
during	O
an	O
inflammatory	O
Th1	O
response	O
in	O
infection	O
and	O
may	O
be	O
of	O
relevance	O
for	O
the	O
design	O
of	O
vaccines	O
and	O
for	O
strategies	O
in	O
immunotherapy	O
in	O
infectious	O
diseases	O
.	O

Mice	O
,	O
Cytokines	O
,	O
Antibodies	O
,	O
and	O
Other	O
Reagents	O

BALB/c	O
DO11.10	O
mice	O
transgenic	O
for	O
OVA	O
-	O
specific	O
TCR	O
WT	O
or	O
crossed	O
back	O
with	O
Rag1	O
-	O
,	O
IL-4	O
-	O
,	O
IFN-gamma	O
-	O
,	O
STAT4	O
-	O
,	O
and	O
STAT6	O
-	O
deficient	B-Negative_regulation
mice	O
were	O
used	O
as	O
a	O
source	O
of	O
antigen	O
-	O
specific	O
Tcells	O
(	O
Murphy	O
etal.	O
,	O
1990	O
;	O
Ouyang	O
etal.	O
,	O
1998	O
;	O
Shoemaker	O
etal.	O
,	O
2006	O
)	O
and	O
were	O
bred	O
and	O
maintained	O
under	O
SPF	O
conditions	O
at	O
the	O
NIMR	O
,	O
London	O
,	O
Home	O
Office	O
,	O
UK	O
,	O
Animals	O
(	O
Scientific	O
Procedures	O
)	O
Act	O
1986	O
or	O
at	O
the	O
Washington	O
University	O
School	O
of	O
Medicine	O
.	O

Female	O
mice	O
were	O
used	O
at	O
8	O
-	O
12	O
weeks	O
old	O
,	O
and	O
animal	O
protocols	O
were	O
approved	O
according	O
to	O
the	O
Animals	O
(	O
Scientific	O
Procedures	O
)	O
Act	O
1986	O
,	O
Home	O
Office	O
,	O
UK	O
.	O

Reagents	O
,	O
including	O
antibodies	O
for	O
Tcell	O
and	O
DC	O
preparation	O
,	O
purification	O
and	O
culture	O
,	O
media	O
,	O
cytokines	O
,	O
and	O
cytokine	O
mAbs	O
have	O
been	O
described	O
(	O
Hosken	O
etal.	O
,	O
1995	O
;	O
Shoemaker	O
etal.	O
,	O
2006	O
;	O
Veldhoen	O
etal.	O
,	O
2009	O
;	O
Veldhoen	O
etal.	O
,	O
2006	O
)	O
.	O

LPS	O
(	O
S.	O
minnesota	O
)	O
was	O
from	O
Alexis	O
,	O
chicken	O
ovalbumin	O
protein	O
(	O
OVA	O
protein	O
)	O
was	O
from	O
from	O
Sigma	O
-	O
Aldrich	O
,	O
and	O
ovalbumin	O
peptide323	O
-	O
339	O
(	O
OVA	O
)	O
(	O
endotoxin	O
-	O
free	O
)	O
was	O
from	O
Biosynthesis	O
.	O

U0126	O
was	O
from	O
BioMol	O
International	O
.	O

PD184352	O
(	O
MEK	O
inhibitors	B-Negative_regulation
)	O
,	O
SB203580	O
(	O
p38	O
inhibitor	B-Negative_regulation
)	O
,	O
and	O
CT99021	O
(	O
GSK3beta	O
inhibitor	B-Negative_regulation
)	O
were	O
kind	O
gifts	O
from	O
P.	O
Cohen	O
and	O
N.Shpiro	O
,	O
University	O
of	O
Dundee	O
,	O
UK	O
.	O

Isolation	O
of	O
CD4+	O
T	O
Cells	O
and	O
of	O
Splenic	O
DC	O
and	O
Cell	O
Culture	O
for	O
T	O
Cell	O
Phenotype	O
Differentiation	O

T	O
cells	O
were	O
sorted	O
for	O
CD4+CD62Lhi	O
,	O
CD4+CD62LhiCD25	O
-	O
,	O
or	O
CD4+CD44loCD25	O
-	O
to	O
>	O
98	O
%	O
on	O
a	O
Moflo	O
cytometer	O
(	O
Cytomation	O
)	O
as	O
before	O
(	O
Shoemaker	O
etal.	O
,	O
2006	O
;	O
Veldhoen	O
etal.	O
,	O
2009	O
)	O
.	O

In	O
most	O
cases	O
,	O
experiments	O
were	O
reproduced	O
with	O
each	O
type	O
of	O
purified	O
CD4+	O
Tcell	O
population	O
with	O
similar	O
results	O
obtained	O
.	O

Splenic	O
DCs	O
were	O
prepared	O
as	O
described	O
(	O
Hosken	O
etal.	O
,	O
1995	O
)	O
,	O
and	O
sort	O
purified	O
CD11c+	O
cells	O
were	O
added	O
to	O
the	O
Tcell	O
culture	O
.	O

Purified	O
DO11.10	O
CD4+	O
Tcells	O
(	O
1	O
x	O
105	O
cells/ml	O
)	O
were	O
cultured	O
as	O
before	O
(	O
Hosken	O
etal.	O
,	O
1995	O
)	O
,	O
in	O
a	O
total	O
volume	O
of	O
1	O
ml	O
cRPMI	O
medium	O
in	O
a	O
48	O
-	O
well	O
plate	O
,	O
with	O
splenic	O
DCs	O
(	O
2	O
x	O
104	O
cells/ml	O
)	O
,	O
and	O
varying	O
amounts	O
of	O
OVA	O
and	O
of	O
IL	O
-	O
12	O
.	O

APC	O
-	O
independent	O
differentiation	O
of	O
naive	O
CD4+	O
Tcells	O
into	O
Th1	O
and	O
Th2	O
cells	O
used	O
stimulation	O
with	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	O
and	O
appropriate	O
cytokine	O
conditions	O
,	O
and	O
control	O
Th1	O
and	O
Th2	O
cells	O
were	O
cultured	O
as	O
described	O
before	O
(	O
Hosken	O
etal.	O
,	O
1995	O
;	O
Shoemaker	O
etal.	O
,	O
2006	O
)	O
.	O

Culture	O
conditions	O
for	O
Th17	O
cells	O
were	O
as	O
described	O
before	O
(	O
Veldhoen	O
etal.	O
,	O
2006	O
)	O
.	O

Importantly	O
,	O
Th1	O
and	O
Th2	O
cells	O
could	O
be	O
differentiated	O
in	O
cRPMI	O
or	O
IMDM	O
(	O
Hosken	O
etal.	O
,	O
1995	O
;	O
Shoemaker	O
etal.	O
,	O
2006	O
;	O
Veldhoen	O
etal.	O
,	O
2006	O
)	O
,	O
but	O
Th17	O
cells	O
were	O
only	O
differentiated	O
optimally	O
in	O
IMDM	O
(	O
Veldhoen	O
etal.	O
,	O
2009	O
)	O
.	O

When	O
indicated	O
,	O
U0126	O
or	O
PD184352	O
(	O
MEK	O
inhibitors	B-Negative_regulation
)	O
,	O
SB203580	O
(	O
p38	O
inhibitor	B-Negative_regulation
)	O
,	O
CT99021	O
(	O
GSK3beta	O
inhibitor	B-Negative_regulation
)	O
,	O
or	O
a	O
similar	O
amount	O
of	O
DMSO	O
were	O
present	O
in	O
the	O
culture	O
.	O

More	O
details	O
of	O
specific	O
culture	O
conditions	O
are	O
provided	O
in	O
Figures	O
S6	O
and	O
S7	O
.	O

Cytokine	O
Detection	O
by	O
ICS	O
and	O
ELISA	O

At	O
day	O
5	O
or	O
7	O
,	O
cells	O
were	O
restimulated	O
with	O
immobilized	O
anti	O
-	O
CD3	O
(	O
2	O
mug/ml	O
)	O
and	O
anti	O
-	O
CD28	O
(	O
2	O
mug/ml	O
)	O
(	O
4	O
hr	O
with	O
BrefeldinA	O
[	O
10	O
mug/ml	O
]	O
in	O
the	O
last	O
2	O
hr	O
)	O
or	O
with	O
PdBU	O
and	O
Ionomycin	O
(	O
5	O
hr	O
with	O
BrefeldinA	O
[	O
1	O
mug/ml	O
]	O
)	O
.	O

After	O
ICS	O
FACS	O
,	O
data	O
were	O
collected	O
on	O
a	O
FACSCalibur	O
(	O
Becton	O
Dickinson	O
)	O
and	O
analyzed	O
with	O
FlowJo	O
(	O
Tree	O
Star	O
)	O
.	O

For	O
ELISA	O
,	O
cells	O
were	O
similarly	O
restimulated	O
for	O
48	O
hr	O
and	O
supernatant	O
was	O
collected	O
and	O
analyzed	O
for	O
IL	O
-	O
4	O
,	O
IL	O
-	O
10	O
,	O
and	O
IFN	O
-	O
gamma	O
as	O
described	O
before	O
(	O
Shoemaker	O
etal.	O
,	O
2006	O
)	O
.	O

In	O
Vivo	O
Studies	O

BALB/c	O
mice	O
were	O
injected	O
intravenously	O
(	O
i.v.	O
)	O
with	O
a	O
red	O
blood	O
cell	O
-	O
depleted	O
single	O
-	O
cell	O
spleen	O
suspension	O
(	O
2.5	O
x	O
107	O
cells	O
)	O
(	O
Castro	O
etal.	O
,	O
2000	O
)	O
from	O
DO11.10	O
WT	O
or	O
STAT	O
-	O
deficient	B-Negative_regulation
mice	O
.	O

After	O
48	O
hr	O
,	O
they	O
were	O
injected	O
subcutaneously	O
with	O
PBS	O
or	O
with	O
OVA	O
protein	O
(	O
5	O
mg	O
)	O
plus	O
LPS	O
(	O
5	O
mug	O
)	O
.	O

The	O
inguinal	O
lymph	O
nodes	O
were	O
removed	O
48	O
hr	O
later	O
.	O

A	O
single	O
-	O
cell	O
suspension	O
(	O
1	O
x	O
106	O
cells	O
)	O
was	O
restimulated	O
for	O
24	O
or	O
48	O
hr	O
with	O
1	O
muM	O
or	O
3	O
muM	O
of	O
OVA	O
and	O
with	O
BrefeldinA	O
for	O
the	O
last	O
6	O
hr	O
.	O

Half	O
of	O
the	O
supernatant	O
was	O
removed	O
before	O
the	O
addition	O
of	O
BrefeldinA	O
for	O
use	O
in	O
an	O
ELISA	O
assay	O
.	O

The	O
cells	O
were	O
fixed	O
and	O
stained	O
as	O
before	O
.	O

Those	O
positive	O
for	O
KJ1-26	O
-	O
Bio	O
and	O
for	O
CD4	O
-	O
PerCP	O
were	O
gated	O
,	O
and	O
IFN	O
-	O
gamma	O
and	O
IL	O
-	O
10	O
staining	O
was	O
examined	O
for	O
this	O
population	O
and	O
analyzed	O
as	O
before	O
.	O

Real	O
-	O
Time	O
Quantitative	O
RT	O
-	O
PCR	O

Cells	O
were	O
harvested	O
and	O
restimulated	O
in	O
the	O
presence	O
of	O
immobilized	O
anti	O
-	O
CD3	O
(	O
2	O
mug/ml	O
)	O
plus	O
anti	O
-	O
CD28	O
(	O
2	O
mug/ml	O
)	O
for	O
3	O
hr	O
or	O
immediately	O
lysed	O
.	O

RNA	O
was	O
extracted	O
and	O
reverse	O
-	O
transcribed	O
and	O
cDNA	O
was	O
analyzed	O
for	O
the	O
expression	O
of	O
cytokines	O
and	O
transcription	O
factors	O
by	O
real	O
-	O
time	O
PCR	O
assay	O
as	O
before	O
(	O
Shoemaker	O
etal.	O
,	O
2006	O
)	O
.	O

Target	O
gene	O
mRNA	O
expression	O
was	O
quantified	O
either	O
with	O
SYBR	O
Green	O
(	O
Applied	O
Biosystems	O
)	O
or	O
with	O
Master	O
Mix	O
(	O
Applied	O
Biosystems	O
)	O
and	O
normalized	O
to	O
ubiquitin	O
or	O
HPRT	O
mRNA	B-Transcription
levels	I-Transcription
,	O
respectively	O
.	O

Immunoblotting	O

Differentiated	O
CD4+	O
Tcells	O
were	O
rested	O
for	O
5	O
hr	O
in	O
1	O
%	O
FCS	O
-	O
containing	O
medium	O
and	O
restimulated	O
as	O
described	O
for	O
specific	O
experiments	O
.	O

Cell	O
lysates	O
were	O
prepared	O
,	O
equal	O
amounts	O
of	O
protein	O
were	O
separated	O
by	O
SDS	O
-	O
PAGE	O
,	O
and	O
phosphorylated	O
or	O
total	O
ERK	O
and	O
actin	O
were	O
detected	O
as	O
described	O
before	O
(	O
Beinke	O
etal.	O
,	O
2004	O
)	O
.	O

Reactive	O
oxygen	O
intermediate	O
-	O
dependent	O
NF	O
-	O
kappaB	O
activation	O
by	O
interleukin	O
-	O
1beta	O
requires	O
5	O
-	O
lipoxygenase	O
or	O
NADPH	O
oxidase	O
activity	O
.	O

We	O
previously	O
reported	O
that	O
the	O
role	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROIs	O
)	O
in	O
NF	O
-	O
kappaB	O
activation	O
by	O
proinflammatory	O
cytokines	O
was	O
cell	O
specific	O
.	O

However	O
,	O
the	O
sources	O
for	O
ROIs	O
in	O
various	O
cell	O
types	O
are	O
yet	O
to	O
be	O
determined	O
and	O
might	O
include	O
5	O
-	O
lipoxygenase	O
(	O
5	O
-	O
LOX	O
)	O
and	O
NADPH	O
oxidase	O
.	O

5	O
-	O
LOX	O
and	O
5	O
-	O
LOX	O
activating	O
protein	O
(	O
FLAP	O
)	O
are	O
coexpressed	B-Gene_expression
in	O
lymphoid	O
cells	O
but	O
not	O
in	O
monocytic	O
or	O
epithelial	O
cells	O
.	O

Stimulation	O
of	O
lymphoid	O
cells	O
with	O
interleukin	O
-	O
1beta	O
(	O
IL	O
-	O
1beta	O
)	O
led	O
to	O
ROI	O
production	O
and	O
NF	O
-	O
kappaB	O
activation	O
,	O
which	O
could	O
both	O
be	O
blocked	O
by	O
antioxidants	O
or	O
FLAP	O
inhibitors	O
,	O
confirming	O
that	O
5	O
-	O
LOX	O
was	O
the	O
source	O
of	O
ROIs	O
and	O
was	O
required	O
for	O
NF	O
-	O
kappaB	O
activation	O
in	O
these	O
cells	O
.	O

IL	O
-	O
1beta	O
stimulation	O
of	O
epithelial	O
cells	O
did	O
not	O
generate	O
any	O
ROIs	O
and	O
NF	O
-	O
kappaB	O
induction	O
was	O
not	O
influenced	O
by	O
5	O
-	O
LOX	O
inhibitors	O
.	O

However	O
,	O
reintroduction	O
of	O
a	O
functional	O
5	O
-	O
LOX	O
system	O
in	O
these	O
cells	O
allowed	O
ROI	O
production	O
and	O
5-LOX	O
-	O
dependent	O
NF	O
-	O
kappaB	O
activation	O
.	O

In	O
monocytic	O
cells	O
,	O
IL	O
-	O
1beta	O
treatment	O
led	O
to	O
a	O
production	O
of	O
ROIs	O
which	O
is	O
independent	O
of	O
the	O
5	O
-	O
LOX	O
enzyme	O
but	O
requires	O
the	O
NADPH	O
oxidase	O
activity	O
.	O

This	O
pathway	O
involves	O
the	O
Rac1	O
and	O
Cdc42	O
GTPases	O
,	O
two	O
enzymes	O
which	O
are	O
not	O
required	O
for	O
NF	O
-	O
kappaB	O
activation	O
by	O
IL	O
-	O
1beta	O
in	O
epithelial	O
cells	O
.	O

In	O
conclusion	O
,	O
three	O
different	O
cell	O
-	O
specific	O
pathways	O
lead	O
to	O
NF	O
-	O
kappaB	O
activation	O
by	O
IL	O
-	O
1beta	O
:	O
a	O
pathway	O
dependent	O
on	O
ROI	O
production	O
by	O
5	O
-	O
LOX	O
in	O
lymphoid	O
cells	O
,	O
an	O
ROI	O
-	O
and	O
5-LOX	O
-	O
independent	O
pathway	O
in	O
epithelial	O
cells	O
,	O
and	O
a	O
pathway	O
requiring	O
ROI	O
production	O
by	O
NADPH	O
oxidase	O
in	O
monocytic	O
cells	O
.	O

Activation	O
-	O
dependent	B-Positive_regulation
transcriptional	O
regulation	B-Regulation
of	O
the	O
human	O
Fas	O
promoter	O
requires	B-Positive_regulation
NF	O
-	O
kappaB	O
p50	O
-	O
p65	O
recruitment	B-Positive_regulation
.	O

Fas	O
(	O
CD95	O
)	O
and	O
Fas	O
ligand	O
(	O
CD95L	O
)	O
are	O
an	O
interacting	B-Binding
receptor	I-Binding
-	I-Binding
ligand	I-Binding
pair	I-Binding
required	O
for	O
immune	O
homeostasis	O
.	O

Lymphocyte	O
activation	O
results	O
in	O
the	O
upregulation	B-Positive_regulation
of	O
Fas	O
expression	B-Gene_expression
and	O
the	O
acquisition	O
of	O
sensitivity	O
to	O
FasL	O
-	O
mediated	O
apoptosis	O
.	O

Although	O
Fas	O
upregulation	B-Positive_regulation
is	O
central	O
to	O
the	O
preservation	O
of	O
immunologic	O
tolerance	O
,	O
little	O
is	O
known	O
about	O
the	O
molecular	O
machinery	O
underlying	O
this	O
process	O
.	O

To	O
investigate	O
the	O
events	O
involved	O
in	O
activation	O
-	O
induced	B-Positive_regulation
Fas	O
upregulation	B-Positive_regulation
,	O
we	O
have	O
examined	O
mRNA	O
accumulation	O
,	O
fas	O
promoter	O
activity	O
,	O
and	O
protein	O
expression	B-Gene_expression
in	O
the	O
Jurkat	O
T	O
-	O
cell	O
line	O
treated	O
with	O
phorbol	O
myristate	O
acetate	O
and	O
ionomycin	O
(	O
P/I	O
)	O
,	O
pharmacological	O
mimics	O
of	O
T	O
-	O
cell	O
receptor	O
activation	O
.	O

Although	O
resting	O
Jurkat	O
cells	O
express	B-Gene_expression
Fas	O
,	O
Fas	O
mRNA	O
was	O
induced	B-Positive_regulation
approximately	O
10	O
-	O
fold	O
in	O
2	O
h	O
upon	O
P/I	O
stimulation	O
.	O

Using	O
sequential	O
deletion	O
mutants	O
of	O
the	O
human	O
fas	O
promoter	O
in	O
transient	O
transfection	O
assays	O
,	O
we	O
identified	O
a	O
47	O
-	O
bp	O
sequence	O
(	O
positions	O
-	O
306	O
to	O
-	O
260	O
relative	O
to	O
the	O
ATG	O
)	O
required	B-Positive_regulation
for	O
activation	O
-	O
driven	O
fas	O
upregulation	B-Positive_regulation
.	O

Sequence	O
analysis	O
revealed	O
the	O
presence	O
of	O
a	O
previously	O
unrecognized	O
composite	O
binding	O
site	O
for	O
both	O
the	O
Sp1	O
and	O
NF	O
-	O
kappaB	O
transcription	O
factors	O
at	O
positions	O
-	O
295	O
to	O
-	O
286	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
supershift	O
analyses	O
of	O
this	O
region	O
documented	O
constitutive	O
binding	B-Binding
of	O
Sp1	O
in	O
unactivated	O
nuclear	O
extracts	O
and	O
inducible	B-Positive_regulation
binding	B-Binding
of	O
p50	O
-	O
p65	O
NF	O
-	O
kappaB	O
heterodimers	O
after	O
P/I	O
activation	O
.	O

Sp1	O
and	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
binding	B-Binding
was	O
shown	O
to	O
be	O
mutually	B-Negative_regulation
exclusive	I-Negative_regulation
by	O
EMSA	O
displacement	O
studies	O
with	O
purified	O
recombinant	O
Sp1	O
and	O
recombinant	O
p50	O
.	O

The	O
functional	O
contribution	O
of	O
the	O
kappaB	O
-	O
Sp1	O
composite	O
site	O
in	O
P/I	O
-	O
inducible	O
fas	O
promoter	O
activation	B-Positive_regulation
was	O
verified	O
by	O
using	O
kappaB	O
-	O
Sp1	O
concatamers	O
(	O
-	O
295	O
to	O
-	O
286	O
)	O
in	O
a	O
thymidine	O
kinase	O
promoter	O
-	O
driven	O
reporter	O
construct	O
and	O
native	O
promoter	O
constructs	O
in	O
Jurkat	O
cells	O
overexpressing	O
IkappaB	O
-	O
alpha	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
critical	O
guanine	O
nucleotides	O
in	O
the	O
kappaB	O
-	O
Sp1	O
element	O
documented	O
the	O
essential	B-Positive_regulation
role	I-Positive_regulation
of	O
this	O
site	O
in	O
activation	O
-	O
dependent	O
fas	O
promoter	O
induction	B-Positive_regulation
.	O

RFLAT	O
-	O
1	O
:	O
a	O
new	O
zinc	O
finger	O
transcription	O
factor	O
that	O
activates	B-Positive_regulation
RANTES	O
gene	O
expression	B-Gene_expression
in	O
T	O
lymphocytes	O
.	O

RANTES	O
(	O
Regulated	O
upon	O
Activation	O
,	O
Normal	O
T	O
cell	O
Expressed	O
and	O
Secreted	O
)	O
is	O
a	O
chemoattractant	O
cytokine	O
(	O
chemokine	O
)	O
important	O
in	O
the	O
generation	O
of	O
inflammatory	O
infiltrate	O
and	O
human	O
immunodeficiency	O
virus	O
entry	O
into	O
immune	O
cells	O
.	O

RANTES	O
is	O
expressed	B-Gene_expression
late	O
(	O
3	O
-	O
5	O
days	O
)	O
after	O
activation	O
in	O
T	O
lymphocytes	O
.	O

Using	O
expression	O
cloning	O
,	O
we	O
identified	O
the	O
first	O
"	O
late	O
"	O
T	O
lymphocyte	O
associated	O
transcription	O
factor	O
and	O
named	O
it	O
"	O
RANTES	O
Factor	O
of	O
Late	O
Activated	O
T	O
Lymphocytes	O
-	O
1	O
"	O
(	O
RFLAT	O
-	O
1	O
)	O
.	O

RFLAT	O
-	O
1	O
is	O
a	O
novel	O
,	O
phosphorylated	B-Phosphorylation
,	O
zinc	O
finger	O
transcription	O
factor	O
that	O
is	O
expressed	B-Gene_expression
in	O
T	O
cells	O
3	O
days	O
after	O
activation	O
,	O
coincident	O
with	O
RANTES	O
expression	B-Gene_expression
.	O

While	O
Rel	O
proteins	O
play	O
the	O
dominant	B-Positive_regulation
role	I-Positive_regulation
in	O
RANTES	O
gene	O
expression	B-Gene_expression
in	O
fibroblasts	O
,	O
RFLAT	O
-	O
1	O
is	O
a	O
strong	O
transactivator	B-Positive_regulation
for	O
RANTES	O
in	O
T	O
cells	O
.	O

Interleukin	O
-	O
10	O
inhibits	O
expression	O
of	O
both	O
interferon	O
alpha	O
-	O
and	O
interferon	O
gamma	O
-	O
induced	O
genes	O
by	O
suppressing	B-Negative_regulation
tyrosine	O
phosphorylation	B-Phosphorylation
of	O
STAT1	O
.	O

Interleukin	O
-	O
10	O
(	O
IL	O
-	O
10	O
)	O
helps	O
maintain	O
polarized	O
T	O
-	O
helper	O
cells	O
in	O
a	O
T	O
-	O
helper	O
lymphocyte	O
2	O
(	O
Th2	O
)	O
phenotype	O
.	O

Part	O
of	O
this	O
process	O
involves	O
the	O
prevention	O
of	O
the	O
development	O
of	O
Th1	O
cells	O
,	O
which	O
are	O
a	O
primary	B-Gene_expression
source	I-Gene_expression
of	O
interferon	O
gamma	O
(	O
IFNgamma	O
)	O
,	O
a	O
potent	O
activator	O
of	O
monocytes	O
and	O
an	O
inhibitor	O
of	O
Th2	O
proliferation	O
.	O

Because	O
monocytes	O
and	O
macrophages	O
are	O
important	O
mediators	O
of	O
Th1	O
-	O
type	O
responses	O
,	O
such	O
as	O
delayed	O
-	O
type	O
hypersensitivity	O
,	O
we	O
sought	O
to	O
determine	O
if	O
IL	O
-	O
10	O
could	O
directly	O
mediate	O
inhibition	O
of	O
IFNgamma	O
-	O
and	O
IFNalpha	O
-	O
induced	O
gene	O
expression	O
in	O
these	O
cells	O
.	O

Highly	O
purified	O
monocytes	O
were	O
incubated	O
with	O
IL	O
-	O
10	O
for	O
60	O
to	O
90	O
minutes	O
before	O
the	O
addition	O
of	O
IFNgamma	O
or	O
IFNalpha	O
.	O

IL	O
-	O
10	O
preincubation	O
resulted	O
in	O
the	O
inhibition	B-Negative_regulation
of	O
gene	O
expression	B-Gene_expression
for	O
several	O
IFN	O
-	O
induced	B-Positive_regulation
genes	O
,	O
such	O
as	O
IP	O
-	O
10	O
,	O
ISG54	O
,	O
and	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
.	O

The	O
reduction	O
in	O
gene	O
expression	O
resulted	B-Positive_regulation
from	O
the	O
ability	O
of	O
IL	O
-	O
10	O
to	O
suppress	O
IFN	O
-	O
induced	O
assembly	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
factors	O
to	O
specific	O
promoter	O
motifs	O
on	O
IFNalpha	O
-	O
and	O
IFNgamma	O
-	O
inducible	O
genes	O
.	O

This	O
was	O
accomplished	B-Positive_regulation
by	O
preventing	B-Negative_regulation
the	O
IFN	O
-	O
induced	B-Positive_regulation
tyrosine	O
phosphorylation	B-Phosphorylation
of	O
STAT1	O
,	O
a	O
component	O
of	O
both	O
IFNalpha	O
-	O
and	O
IFNgamma	O
-	O
induced	B-Positive_regulation
DNA	O
binding	O
complexes	O
.	O

Therefore	O
,	O
IL	O
-	O
10	O
can	O
directly	O
inhibit	O
STAT	O
-	O
dependent	O
early	O
response	O
gene	O
expression	O
induced	O
by	O
both	O
IFNalpha	O
and	O
IFNgamma	O
in	O
monocytes	O
by	O
suppressing	B-Negative_regulation
the	O
tyrosine	O
phosphorylation	B-Phosphorylation
of	O
STAT1	O
.	O

This	O
may	O
occur	O
through	O
the	O
ability	O
of	O
IL	O
-	O
10	O
to	O
induce	B-Positive_regulation
expression	B-Gene_expression
of	O
the	O
gene	O
,	O
suppressor	O
of	O
cytokine	O
signaling	O
3	O
(	O
SOCS3	O
)	O
.	O

The	O
Megakaryocyte/Platelet	O
-	O
specific	O
enhancer	O
of	O
the	O
alpha2beta1	O
integrin	O
gene	O
:	O
two	O
tandem	O
AP1	O
sites	O
and	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
signaling	O
cascade	O
.	O

The	O
alpha2beta1	O
integrin	O
,	O
a	O
collagen	O
receptor	O
on	O
platelets	O
and	O
megakaryocytes	O
,	O
is	O
required	O
for	O
normal	O
platelet	O
function	O
.	O

Transcriptional	B-Regulation
regulation	I-Regulation
of	O
the	O
alpha2	O
integrin	O
gene	O
in	O
cells	O
undergoing	O
megakaryocytic	O
differentiation	O
requires	B-Positive_regulation
a	O
core	O
promoter	O
between	O
bp	O
-	O
30	O
and	O
-	O
92	O
,	O
a	O
silencer	O
between	O
bp	O
-	O
92	O
and	O
-	O
351	O
,	O
and	O
megakaryocytic	O
enhancers	O
in	O
the	O
distal	O
5	O
'	O
flank	O
.	O

We	O
have	O
now	O
identified	O
a	O
229	O
-	O
bp	O
region	O
of	O
the	O
distal	O
5	O
'	O
flank	O
of	O
the	O
alpha2	O
integrin	O
gene	O
required	O
for	O
high	O
-	O
level	O
enhancer	O
activity	O
in	O
cells	O
with	O
megakaryocytic	O
features	O
.	O

Two	O
tandem	O
AP1	O
binding	O
sites	O
with	O
dyad	O
symmetry	O
are	O
required	B-Positive_regulation
for	O
enhancer	O
activity	O
and	O
for	O
DNA	O
-	O
protein	O
complex	B-Binding
formation	I-Binding
with	O
members	O
of	O
the	O
c-fos/c	O
-	O
jun	O
family	O
.	O

The	O
requirement	B-Positive_regulation
for	O
AP1	O
activation	O
suggested	O
a	O
role	B-Positive_regulation
for	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
signaling	O
pathway	O
in	O
regulating	B-Regulation
alpha2	O
integrin	O
gene	O
expression	B-Gene_expression
.	O

Inhibition	O
of	O
the	O
MAP	O
kinase	O
cascade	O
with	O
PD98059	O
,	O
a	O
specific	O
inhibitor	B-Negative_regulation
of	O
MAPK	O
kinase	O
1	O
,	O
prevented	B-Negative_regulation
the	O
expression	B-Gene_expression
of	O
the	O
alpha2	O
integrin	O
subunit	O
in	O
cells	O
induced	O
to	O
become	O
megakaryocytic	O
.	O

We	O
provide	O
a	O
model	O
of	O
megakaryocytic	O
differentiation	O
in	O
which	O
expression	B-Gene_expression
of	O
the	O
alpha2	O
integrin	O
gene	O
requires	B-Positive_regulation
signaling	O
via	O
the	O
MAP	O
kinase	O
pathway	O
to	O
activate	O
two	O
tandem	O
AP1	O
binding	O
sites	O
in	O
the	O
alpha2	O
integrin	O
enhancer	O
.	O

Differential	O
expression	B-Gene_expression
and	O
phosphorylation	B-Phosphorylation
of	O
CTCF	O
,	O
a	O
c	O
-	O
myc	O
transcriptional	B-Regulation
regulator	I-Regulation
,	O
during	O
differentiation	O
of	O
human	O
myeloid	O
cells	O
.	O

CTCF	O
is	O
a	O
transcriptional	B-Negative_regulation
repressor	I-Negative_regulation
of	O
the	O
c	O
-	O
myc	O
gene	O
.	O

Although	O
CTCF	O
has	O
been	O
characterized	O
in	O
some	O
detail	O
,	O
there	O
is	O
very	O
little	O
information	O
about	O
the	O
regulation	B-Regulation
of	O
CTCF	O
activity	O
.	O

Therefore	O
we	O
investigated	O
CTCF	O
expression	B-Gene_expression
and	O
phosphorylation	B-Phosphorylation
during	O
induced	O
differentiation	O
of	O
human	O
myeloid	O
leukemia	O
cells	O
.	O

We	O
found	O
that	O
:	O
(	O
i	O
)	O
both	O
CTCF	O
mRNA	O
and	O
protein	O
are	O
down	B-Negative_regulation
-	I-Negative_regulation
regulated	I-Negative_regulation
during	O
terminal	O
differentiation	O
in	O
most	O
cell	O
lines	O
tested	O
;	O
(	O
ii	O
)	O
CTCF	O
down	B-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
is	O
retarded	O
and	O
less	O
pronounced	O
than	O
that	O
of	O
c	O
-	O
myc	O
;	O
(	O
iii	O
)	O
CTCF	O
protein	O
is	O
differentially	O
phosphorylated	B-Phosphorylation
and	O
the	O
phosphorylation	O
profiles	O
depend	B-Positive_regulation
on	O
the	O
differentiation	O
pathway	O
.	O

We	O
concluded	O
that	O
CTCF	O
expression	B-Gene_expression
and	O
activity	O
is	O
controlled	B-Regulation
at	I-Regulation
transcriptional	I-Regulation
and	I-Regulation
post	I-Regulation
-	I-Regulation
transcriptional	I-Regulation
levels	I-Regulation
.	O

T	O
-	O
cell	O
expression	B-Gene_expression
of	O
the	O
human	O
GATA	O
-	O
3	O
gene	O
is	O
regulated	B-Regulation
by	O
a	O
non-lineage	O
-	O
specific	O
silencer	O
.	O

The	O
GATA	O
-	O
3	O
transcription	O
factor	O
is	O
required	O
for	O
development	O
of	O
the	O
T	O
-	O
cell	O
lineage	O
and	O
Th2	O
cytokine	O
gene	O
expression	O
in	O
CD4	O
T	O
-	O
cells	O
.	O

We	O
have	O
mapped	O
the	O
DNase-I	O
-	O
hypersensitive	O
(	O
HS	O
)	O
regions	O
of	O
the	O
human	O
GATA	O
-	O
3	O
gene	O
in	O
T	O
-	O
cells	O
and	O
non-T	O
-	O
cells	O
and	O
studied	O
their	O
transcriptional	B-Transcription
activities	O
.	O

HS	O
I	O
-	O
III	O
,	O
located	O
5	O
'	O
from	O
the	O
transcriptional	O
initiation	O
site	O
,	O
were	O
found	O
in	O
hematopoietic	O
and	O
non	O
-	O
hematopoietic	O
cells	O
,	O
whereas	O
HS	O
IV	O
-	O
VII	O
,	O
located	O
3	O
'	O
from	O
the	O
transcriptional	O
start	O
site	O
,	O
were	O
exclusively	O
observed	O
in	O
T	O
-	O
cells	O
.	O

Among	O
these	O
hypersensitive	O
sites	O
,	O
two	O
transcriptional	O
control	O
elements	O
were	O
found	O
,	O
one	O
in	O
the	O
first	O
intron	O
of	O
the	O
GATA	O
-	O
3	O
gene	O
and	O
the	O
other	O
between	O
8.3	O
and	O
5.9	O
kilobases	O
5	O
'	O
from	O
the	O
GATA	O
-	O
3	O
transcriptional	O
initiation	O
site	O
.	O

The	O
first	O
intron	O
acted	O
as	O
a	O
strong	O
transcriptional	O
activator	O
in	O
a	O
position	O
-	O
dependent	O
manner	O
and	O
with	O
no	O
cell	O
-	O
type	O
specificity	O
.	O

The	O
upstream	O
regulatory	O
element	O
could	O
confer	B-Positive_regulation
T	O
-	O
cell	O
specificity	O
to	O
the	O
GATA	O
-	O
3	O
promoter	O
activity	O
,	O
and	O
analysis	O
of	O
this	O
region	O
revealed	O
a	O
707	O
-	O
base	O
pair	O
silencer	O
that	O
drastically	O
inhibited	B-Negative_regulation
GATA	O
-	O
3	O
promoter	O
activity	O
in	O
non-T	O
-	O
cells	O
.	O

Two	O
CAGGTG	O
E	O
-	O
boxes	O
,	O
located	O
at	O
the	O
5'	O
-	O
and	O
3'	O
-	O
ends	O
of	O
the	O
silencer	O
,	O
were	O
necessary	B-Positive_regulation
for	O
this	O
silencer	O
activity	O
.	O

The	O
3'	O
-	O
CAGGTG	O
E	O
-	O
box	O
could	O
bind	B-Binding
USF	O
proteins	O
,	O
the	O
ubiquitous	O
repressor	O
ZEB	O
,	O
or	O
the	O
basic	O
helix-loop	O
-	O
helix	O
proteins	O
E2A	O
and	O
HEB	O
,	O
and	O
we	O
showed	O
that	O
a	O
competition	B-Negative_regulation
between	O
ZEB	O
and	O
E2A/HEB	O
proteins	O
is	O
involved	B-Regulation
in	O
the	O
silencer	O
activity	O
.	O

AML	O
and	O
Ets	O
proteins	O
regulate	O
the	O
I	O
alpha1	O
germ	O
-	O
line	O
promoter	O
.	O

The	O
immunoglobulin	O
heavy	O
chain	O
(	O
IgH	O
)	O
class	O
switch	O
recombination	O
of	O
B	O
lymphocytes	O
preferentially	O
targets	O
unrearranged	O
IgH	O
genes	O
that	O
have	O
already	O
been	O
rendered	O
transcriptionally	O
active	O
.	O

Transcription	O
of	O
the	O
germ	O
-	O
line	O
IgH	O
genes	O
is	O
controlled	O
by	O
intervening	O
(	O
I	O
)	O
regions	O
upstream	O
of	O
their	O
switch	O
regions	O
.	O

The	O
I	O
alpha1	O
promoter	O
activates	O
transcription	O
of	O
the	O
human	O
germ	O
-	O
line	O
C	O
alpha1	O
gene	O
for	O
IgA1	O
and	O
mediates	O
the	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
-	O
beta1	O
responsiveness	O
of	O
this	O
locus	O
.	O

Here	O
we	O
show	O
that	O
the	O
I	O
alpha1	O
promoter	O
contains	O
several	O
binding	O
sites	O
for	O
the	O
AML/PEBP2/CBF	O
family	O
of	O
transcription	O
factors	O
and	O
that	O
AML	O
and	O
Ets	O
proteins	O
are	O
major	O
regulators	O
of	O
the	O
basal	O
and	O
TGF-beta	O
-	O
inducible	O
promoter	O
activity	O
.	O

Our	O
data	O
constitute	O
a	O
starting	O
point	O
for	O
studies	O
to	O
elucidate	O
the	O
molecular	O
mechanism	O
by	O
which	O
TGF	O
-	O
beta	O
regulates	O
IgA	O
production	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
isolated	O
from	O
patients	O
with	O
diabetic	O
nephropathy	O
show	O
increased	O
activation	O
of	O
the	O
oxidative	O
-	O
stress	O
sensitive	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

Increased	O
oxidative	O
stress	O
and	O
subsequent	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
has	O
been	O
linked	O
to	O
the	O
development	O
of	O
late	O
diabetic	O
complications	O
.	O

To	O
determine	O
whether	O
oxidative	O
stress	O
dependent	O
NF	O
-	O
kappaB	O
activation	O
is	O
evident	O
in	O
patients	O
with	O
diabetic	O
nephropathy	O
we	O
used	O
an	O
Electrophoretic	O
Mobility	O
Shift	O
Assay	O
based	O
semiquantitative	O
detection	O
system	O
which	O
enabled	O
us	O
to	O
determine	O
NF	O
-	O
kappaB	O
activation	O
in	O
ex	O
vivo	O
isolated	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

We	O
examined	O
33	O
patients	O
with	O
diabetes	O
mellitus	O
(	O
Type	O
I	O
and	O
Type	O
II	O
)	O
.	O

Patients	O
with	O
diabetic	O
nephropathy	O
showed	O
higher	O
NF	O
-	O
kappaB	O
binding	O
activity	O
in	O
Electrophoretic	O
Mobility	O
Shift	O
Assays	O
and	O
stronger	B-Positive_regulation
immunohistological	O
staining	O
for	O
activated	B-Positive_regulation
NF	O
-	O
kappaBp65	O
than	O
patients	O
without	O
renal	O
complications	O
.	O

NF	O
-	O
kappaB	O
binding	O
activity	O
correlated	O
with	O
the	O
degree	O
of	O
albuminuria	O
(	O
r	O
=	O
0.316	O
)	O
and	O
with	O
thrombomodulin	O
plasma	O
concentrations	O
(	O
r	O
=	O
0.33	O
)	O
,	O
indicative	O
for	O
albuminuria	O
associated	O
endothelial	O
dysfunction	O
.	O

In	O
a	O
3	O
day	O
intervention	O
study	O
in	O
which	O
600	O
mg	O
of	O
the	O
antioxidant	O
thioctic	O
acid	O
(	O
alpha	O
-	O
lipoic	O
acid	O
)	O
per	O
day	O
were	O
given	O
to	O
nine	O
patients	O
with	O
diabetic	O
nephropathy	O
oxidative	O
stress	O
in	O
plasma	O
samples	O
was	O
decreased	O
by	O
48	O
%	O
and	O
NF	O
-	O
kappaB	O
binding	O
activity	O
in	O
ex	O
vivo	O
isolated	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
38	O
%	O
.	O

In	O
conclusion	O
,	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
in	O
ex	O
vivo	O
isolated	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
patients	O
with	O
diabetes	O
mellitus	O
correlates	O
with	O
the	O
degree	O
of	O
diabetic	O
nephropathy	O
.	O

NF	O
-	O
kappaB	O
activation	O
is	O
at	O
least	O
in	O
part	O
dependent	O
on	O
oxidative	O
stress	O
since	O
thioctic	O
acid	O
(	O
alpha	O
-	O
lipoic	O
acid	O
)	O
reduced	O
NF	O
-	O
kappaB	O
binding	O
activity	O
.	O

Activation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
by	O
Gardnerella	O
vaginalis	O
.	O

Bacterial	O
vaginosis	O
(	O
BV	O
)	O
is	O
associated	O
with	O
an	O
increased	O
rate	O
of	O
sexual	O
transmission	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
type	O
1	O
,	O
and	O
Gardnerella	O
vaginalis	O
is	O
frequently	O
isolated	O
from	O
the	O
genital	O
tracts	O
of	O
women	O
with	O
BV	O
.	O

G.	O
vaginalis	O
lysates	O
were	O
found	O
to	O
significantly	O
stimulate	O
HIV	O
expression	O
in	O
monocytoid	O
cells	O
.	O

Stimulation	O
was	O
significantly	O
higher	O
when	O
lysates	O
were	O
heated	O
at	O
100	O
degrees	O
C	O
for	O
5	O
min	O
but	O
was	O
reduced	O
by	O
treatment	O
with	O
lysozyme	O
or	O
protease	O
.	O

G.	O
vaginalis	O
lysates	O
also	O
activated	O
HIV	O
expression	O
in	O
certain	O
T	O
cell	O
lines	O
.	O

G.	O
vaginalis	O
lysates	O
activated	O
HIV	O
long	O
-	O
terminal	O
repeat	O
transcription	O
in	O
HIV	O
-	O
infected	O
cells	O
and	O
increased	O
NF	O
-	O
kappaB	O
binding	O
activity	O
,	O
indicating	O
an	O
effect	O
by	O
G.	O
vaginalis	O
on	O
HIV	O
transcription	O
.	O

The	O
activation	O
of	O
HIV	O
production	O
by	O
G.	O
vaginalis	O
suggests	O
that	O
genital	O
tract	O
infection	O
with	O
G.	O
vaginalis	O
increases	O
the	O
risk	O
of	O
HIV	O
transmission	O
by	O
increasing	O
HIV	O
expression	O
in	O
the	O
genital	O
tract	O
.	O

This	O
may	O
explain	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
increased	O
rate	O
of	O
HIV	O
transmission	O
in	O
women	O
with	O
BV	O
.	O

Interferon	O
-	O
alpha	O
activates	O
multiple	O
STAT	O
proteins	O
and	O
upregulates	B-Positive_regulation
proliferation	O
-	O
associated	O
IL	O
-	O
2Ralpha	O
,	O
c	O
-	O
myc	O
,	O
and	O
pim	O
-	O
1	O
genes	O
in	O
human	O
T	O
cells	O
.	O

Interferon	O
-	O
alpha	O
(	O
IFN	O
-	O
alpha	O
)	O
is	O
a	O
pleiotropic	O
cytokine	O
that	O
has	O
antiviral	O
,	O
antiproliferative	O
,	O
and	O
immunoregulatory	O
functions	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
IFN	O
-	O
alpha	O
has	O
an	O
important	O
role	O
in	O
T	O
-	O
cell	O
biology	O
.	O

We	O
have	O
analyzed	O
the	O
expression	B-Gene_expression
of	O
IL	O
-	O
2Ralpha	O
,	O
c	O
-	O
myc	O
,	O
and	O
pim	O
-	O
1	O
genes	O
in	O
anti-CD3	O
-	O
activated	O
human	O
T	O
lymphocytes	O
.	O

The	O
induction	B-Positive_regulation
of	O
these	O
genes	O
is	O
associated	O
with	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
-	O
induced	O
T	O
-	O
cell	O
proliferation	O
.	O

Treatment	O
of	O
T	O
lymphocytes	O
with	O
IFN	O
-	O
alpha	O
,	O
IL	O
-	O
2	O
,	O
IL	O
-	O
12	O
,	O
and	O
IL	O
-	O
15	O
upregulated	B-Positive_regulation
IL	O
-	O
2Ralpha	O
,	O
c	O
-	O
myc	O
,	O
and	O
pim	O
-	O
1	O
gene	O
expression	B-Gene_expression
.	O

IFN	O
-	O
alpha	O
also	O
sensitized	O
T	O
cells	O
to	O
IL-2	O
-	O
induced	O
proliferation	O
,	O
further	O
suggesting	O
that	O
IFN	O
-	O
alpha	O
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
T	O
-	O
cell	O
mitogenesis	O
.	O

When	O
we	O
analyzed	O
the	O
nature	O
of	O
STAT	O
proteins	O
capable	O
of	O
binding	B-Binding
to	O
IL	O
-	O
2Ralpha	O
,	O
pim	O
-	O
1	O
,	O
and	O
IRF	O
-	O
1	O
GAS	O
elements	O
after	O
cytokine	O
stimulation	O
,	O
we	O
observed	O
IFN-alpha	O
-	O
induced	B-Positive_regulation
binding	B-Binding
of	O
STAT1	O
,	O
STAT3	O
,	O
and	O
STAT4	O
,	O
but	O
not	O
STAT5	O
to	O
all	O
of	O
these	O
elements	O
.	O

Yet	O
,	O
IFN	O
-	O
alpha	O
was	O
able	O
to	O
activate	O
binding	O
of	O
STAT5	O
to	O
the	O
high	O
-	O
affinity	O
IFP53	O
GAS	O
site	O
.	O

IFN	O
-	O
alpha	O
enhanced	B-Positive_regulation
tyrosine	O
phosphorylation	B-Phosphorylation
of	O
STAT1	O
,	O
STAT3	O
,	O
STAT4	O
,	O
STAT5a	O
,	O
and	O
STAT5b	O
.	O

IL	O
-	O
12	O
induced	B-Positive_regulation
STAT4	O
and	O
IL	O
-	O
2	O
and	O
IL	O
-	O
15	O
induced	O
STAT5	O
binding	B-Binding
to	O
the	O
GAS	O
elements	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
IFN	O
-	O
alpha	O
,	O
IL	O
-	O
2	O
,	O
IL	O
-	O
12	O
,	O
and	O
IL	O
-	O
15	O
have	O
overlapping	O
activities	O
on	O
human	O
T	O
cells	O
.	O

These	O
findings	O
thus	O
emphasize	O
the	O
importance	O
of	O
IFN	O
-	O
alpha	O
as	O
a	O
T	O
-	O
cell	O
regulatory	O
cytokine	O
.	O

Anti	O
-	O
rheumatic	O
compound	O
aurothioglucose	O
inhibits	O
tumor	O
necrosis	O
factor-alpha	O
-	O
induced	O
HIV	O
-	O
1	O
replication	O
in	O
latently	O
infected	O
OM10.1	O
and	O
Ach2	O
cells	O
.	O

NF	O
-	O
kappaB	O
is	O
a	O
potent	O
cellular	O
activator	O
of	O
HIV	O
-	O
1	O
gene	O
expression	O
.	O

Down	O
-	O
regulation	O
of	O
NF	O
-	O
kappaB	O
activation	O
is	O
known	O
to	O
inhibit	O
HIV	O
replication	O
from	O
the	O
latently	O
infected	O
cells	O
.	O

Gold	O
compounds	O
have	O
been	O
effectively	O
used	O
for	O
many	O
decades	O
in	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
.	O

We	O
previously	O
reported	O
that	O
gold	O
compounds	O
,	O
especially	O
aurothioglucose	O
(	O
AuTG	O
)	O
containing	O
monovalent	O
gold	O
ion	O
,	O
inhibited	O
the	O
DNA	O
-	O
binding	O
of	O
NF	O
-	O
kappaB	O
in	O
vitro	O
.	O

In	O
this	O
report	O
we	O
have	O
examined	O
the	O
efficacy	O
of	O
the	O
gold	O
compound	O
AuTG	O
as	O
an	O
inhibitor	O
of	O
HIV	O
replication	O
in	O
latently	O
infected	O
OM10.1	O
and	O
Ach2	O
cells	O
.	O

Tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-alpha	O
-	O
induced	O
HIV	O
-	O
1	O
replication	O
in	O
OM10.1	O
or	O
Ach2	O
cells	O
was	O
significantly	O
inhibited	O
by	O
non	O
-	O
cytotoxic	O
doses	O
of	O
AuTG	O
(	O
>	O
10	O
microM	O
in	O
OM10.1	O
cells	O
and	O
>	O
25	O
F.M	O
in	O
Ach2	O
cells	O
)	O
,	O
while	O
25	O
microM	O
of	O
the	O
counter	O
-	O
anion	O
thioglucose	O
(	O
TG	O
)	O
or	O
gold	O
compound	O
containing	O
divalent	O
gold	O
ion	O
,	O
HAuCl3	O
,	O
had	O
no	O
effect	O
.	O

The	O
effect	O
of	O
AuTG	O
on	O
NF-kappaB	O
-	O
dependent	O
gene	O
expression	O
was	O
confirmed	O
by	O
a	O
transient	O
CAT	O
assay	O
.	O

Specific	O
staining	O
as	O
well	O
as	O
electron	O
microscopic	O
examinations	O
revealed	O
the	O
accumulation	O
of	O
metal	O
gold	O
in	O
the	O
cells	O
,	O
supporting	O
our	O
previous	O
hypothesis	O
that	O
gold	O
ions	O
could	O
block	O
NF-kappaB	O
-	O
DNA	O
binding	O
by	O
a	O
redox	O
mechanism	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
monovalent	O
gold	O
compound	O
AuTG	O
is	O
a	O
potentially	O
useful	O
drug	O
for	O
the	O
treatment	O
of	O
patients	O
infected	O
with	O
HIV	O
.	O

Evidence	O
for	O
suppressed	B-Negative_regulation
activity	O
of	O
the	O
transcription	O
factor	O
NFAT1	O
at	O
its	O
proximal	O
binding	B-Binding
element	O
P0	O
in	O
the	O
IL	O
-	O
4	O
promoter	O
associated	O
with	O
enhanced	B-Positive_regulation
IL	O
-	O
4	O
gene	O
transcription	B-Transcription
in	O
T	O
cells	O
of	O
atopic	O
patients	O
.	O

Allergen	O
-	O
specific	O
T	O
cells	O
in	O
atopic	O
patients	O
are	O
polarized	O
IL-4	O
-	O
producing	B-Gene_expression
Th2	O
cells	O
,	O
promoting	B-Positive_regulation
IgE	O
synthesis	B-Gene_expression
by	O
B	O
cells	O
.	O

The	O
molecular	O
basis	O
for	O
increased	B-Positive_regulation
IL	O
-	O
4	O
gene	O
expression	B-Gene_expression
in	O
atopy	O
is	O
not	O
fully	O
understood	O
.	O

IL	O
-	O
4	O
gene	O
regulation	B-Regulation
in	O
general	O
involves	B-Regulation
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
family	O
of	O
transcription	O
factors	O
,	O
of	O
which	O
NFAT1	O
and	O
NFAT2	O
are	O
most	O
prominent	O
in	O
peripheral	O
T	O
cells	O
.	O

Recently	O
,	O
a	O
unique	O
inhibitory	B-Negative_regulation
role	I-Negative_regulation
of	O
NFAT1	O
in	O
IL	O
-	O
4	O
gene	O
control	B-Regulation
was	O
shown	O
in	O
the	O
mouse	O
.	O

In	O
a	O
series	O
of	O
electrophoretic	O
mobility	O
shift	O
assays	O
with	O
protein	O
extracts	O
of	O
highly	O
polarized	O
Th2	O
clones	O
from	O
atopics	O
and	O
Th1	O
clones	O
from	O
controls	O
we	O
compared	O
DNA	O
-	O
binding	O
activities	O
at	O
the	O
two	O
NFAT	O
-	O
binding	O
elements	O
P0	O
and	O
P1	O
of	O
the	O
crucial	O
proximal	O
human	O
IL	O
-	O
4	O
promoter	O
.	O

At	O
the	O
most	O
proximal	O
P0	O
site	O
,	O
NFAT	O
-	O
containing	O
complexes	B-Binding
devoid	O
of	O
NFAT2	O
were	O
readily	O
inducible	O
in	O
the	O
Th1	O
clones	O
,	O
but	O
hardly	O
or	O
not	O
in	O
the	O
Th2	O
clones	O
.	O

In	O
contrast	O
,	O
both	O
in	O
Th1	O
and	O
Th2	O
clones	O
NFAT	O
-	O
containing	O
complexes	B-Binding
were	O
strongly	O
inducible	B-Positive_regulation
at	O
the	O
P1	O
site	O
,	O
consisting	O
of	O
NFAT2	O
and	O
a	O
P0	O
-	O
compatible	O
NFAT	O
activity	O
,	O
without	O
apparent	O
differences	O
between	O
Th1	O
and	O
Th2	O
clones	O
.	O

Like	O
in	O
Th2	O
clones	O
,	O
suppressed	O
NFAT	O
-	O
P0	O
complex	O
formation	O
was	O
observed	O
also	O
at	O
the	O
polyclonal	O
level	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
of	O
three	O
of	O
five	O
severe	O
atopic	O
dermatitis	O
patients	O
with	O
strongly	O
elevated	B-Positive_regulation
serum	O
IgE	O
levels	B-Gene_expression
,	O
but	O
not	O
in	O
control	O
PBMC	O
.	O

These	O
findings	O
suggest	O
that	O
high	B-Positive_regulation
-	I-Positive_regulation
level	I-Positive_regulation
IL	O
-	O
4	O
production	B-Gene_expression
in	O
atopic	O
Th2	O
cells	O
is	O
associated	O
with	O
selective	O
reduction	O
of	O
suppressive	O
NFAT1	O
activity	O
at	O
the	O
IL	O
-	O
4	O
P0	O
element	O
and	O
that	O
some	O
patients	O
with	O
this	O
multifactorial	O
disease	O
may	O
have	O
a	O
putative	O
systemic	O
disorder	O
at	O
this	O
level	O
.	O

Nuclear	O
factor	O
-	O
kappa	O
B	O
activity	O
in	O
T	O
cells	O
from	O
patients	O
with	O
rheumatic	O
diseases	O
:	O
a	O
preliminary	O
report	O
.	O

OBJECTIVE	O
:	O
The	O
NF	O
-	O
kappa	O
B/Rel	O
family	O
of	O
transcription	O
factors	O
regulates	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
the	O
immune	O
or	O
inflammatory	O
response	O
at	O
the	O
transcriptional	O
level	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
distinctive	O
patterns	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
are	O
seen	O
in	O
different	O
forms	O
of	O
joint	O
disease	O
.	O

METHODS	O
:	O
The	O
DNA	O
binding	O
activity	O
of	O
these	O
nucleoproteins	O
was	O
examined	O
in	O
purified	O
synovial	O
and	O
peripheral	O
T	O
cells	O
from	O
patients	O
with	O
various	O
chronic	O
rheumatic	O
diseases	O
(	O
12	O
:	O
four	O
with	O
rheumatoid	O
arthritis	O
;	O
five	O
with	O
spondyloarthropathies	O
;	O
and	O
three	O
with	O
osteoarthritis	O
)	O
.	O

RESULTS	O
:	O
Electrophoretic	O
mobility	O
shift	O
assays	O
disclosed	O
two	O
specific	O
complexes	O
bound	O
to	O
a	O
NF	O
-	O
kappa	O
B	O
specific	O
32P	O
-	O
labelled	O
oligonucleotide	O
in	O
nucleoproteins	O
extracted	O
from	O
purified	O
T	O
cells	O
isolated	O
from	O
synovial	O
fluid	O
and	O
peripheral	O
blood	O
of	O
patients	O
with	O
rheumatoid	O
arthritis	O
.	O

The	O
complexes	O
consisted	O
of	O
p50/p50	O
homodimers	O
and	O
p50/p65	O
heterodimers	O
.	O

Increased	O
NF	O
-	O
kappa	O
B	O
binding	O
to	O
DNA	O
in	O
synovial	O
T	O
cells	O
was	O
observed	O
relative	O
to	O
peripheral	O
T	O
cells	O
.	O

In	O
non	O
-	O
rheumatoid	O
arthritis	O
,	O
binding	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
synovial	O
T	O
cells	O
was	O
exclusively	O
mediated	O
by	O
p50/p50	O
homodimers	O
.	O

CONCLUSION	O
:	O
Overall	O
,	O
the	O
results	O
suggest	O
that	O
NF	O
-	O
kappa	O
B	O
may	O
play	O
a	O
central	O
part	O
in	O
the	O
activation	O
of	O
infiltrating	O
T	O
cells	O
in	O
chronic	O
rheumatoid	O
arthritis	O
.	O

The	O
activation	O
of	O
this	O
nuclear	O
factor	O
is	O
qualitatively	O
different	O
in	O
rheumatoid	O
synovial	O
T	O
cells	O
to	O
that	O
in	O
other	O
forms	O
of	O
non	O
-	O
rheumatoid	O
arthritis	O
(	O
for	O
example	O
,	O
osteoarthritis	O
,	O
spondyloarthropathies	O
)	O
.	O

N-acetyl-L	O
-	O
cysteine	O
inhibits	O
primary	O
human	O
T	O
cell	O
responses	O
at	O
the	O
dendritic	O
cell	O
level	O
:	O
association	O
with	O
NF	O
-	O
kappaB	O
inhibition	O
.	O

N-acetyl-L	O
-	O
cysteine	O
(	O
NAC	O
)	O
is	O
an	O
antioxidant	O
molecule	O
endowed	O
with	O
immunomodulatory	O
properties	O
.	O

To	O
investigate	O
the	O
effect	O
of	O
NAC	O
on	O
the	O
induction	O
phase	O
of	O
T	O
cell	O
responses	O
,	O
we	O
analyzed	O
its	O
action	O
on	O
human	O
dendritic	O
cells	O
(	O
DC	O
)	O
derived	O
from	O
adherent	O
PBMC	O
cultured	O
with	O
IL	O
-	O
4	O
and	O
granulocyte	O
-	O
macrophage	O
CSF	O
.	O

We	O
first	O
found	O
that	O
NAC	O
inhibited	O
the	O
constitutive	O
as	O
well	O
as	O
the	O
LPS	O
-	O
induced	O
activity	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

In	O
parallel	O
,	O
NAC	O
was	O
shown	O
to	O
down	B-Negative_regulation
-	I-Negative_regulation
regulate	I-Negative_regulation
the	O
production	O
of	O
cytokines	O
by	O
DC	O
as	O
well	O
as	O
their	O
surface	O
expression	B-Gene_expression
of	O
HLA	O
-	O
DR	O
,	O
CD86	O
(	O
B7	O
-	O
2	O
)	O
,	O
and	O
CD40	O
molecules	O
both	O
at	O
the	O
basal	O
state	O
and	O
upon	O
LPS	O
activation	B-Positive_regulation
.	O

NAC	O
also	O
inhibited	O
DC	O
responses	O
induced	O
by	O
CD40	O
engagement	B-Binding
.	O

The	O
inhibitory	O
effects	O
of	O
NAC	O
were	O
not	O
due	O
to	O
nonspecific	O
toxicity	O
as	O
neither	O
the	O
viability	O
of	O
DC	O
nor	O
their	O
mannose	O
receptor	O
-	O
mediated	O
endocytosis	O
were	O
modified	O
by	O
NAC	O
.	O

Finally	O
,	O
we	O
found	O
that	O
the	O
addition	O
of	O
NAC	O
to	O
MLR	O
between	O
naive	O
T	O
cells	O
and	O
allogeneic	O
DC	O
resulted	O
in	O
a	O
profound	O
inhibition	O
of	O
alloreactive	O
responses	O
,	O
which	O
could	O
be	O
attributed	O
to	O
a	O
defect	O
of	O
DC	O
as	O
APC	O
-	O
independent	O
T	O
cell	O
responses	O
were	O
not	O
inhibited	O
by	O
NAC	O
.	O

Altogether	O
,	O
our	O
results	O
suggest	O
that	O
NAC	O
might	O
impair	O
the	O
generation	O
of	O
primary	O
immune	O
responses	O
in	O
humans	O
through	O
its	O
inhibitory	O
action	O
on	O
DC	O
.	O

Bacterial	O
lipopolysaccharide	O
activates	O
nuclear	O
factor	O
-	O
kappaB	O
through	O
interleukin	O
-	O
1	O
signaling	O
mediators	O
in	O
cultured	O
human	O
dermal	O
endothelial	O
cells	O
and	O
mononuclear	O
phagocytes	O
.	O

Bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
mediated	O
immune	O
responses	O
,	O
including	O
activation	O
of	O
monocytes	O
,	O
macrophages	O
,	O
and	O
endothelial	O
cells	O
,	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
Gram	O
-	O
negative	O
bacteria	O
-	O
induced	O
sepsis	O
syndrome	O
.	O

Activation	O
of	O
NF	O
-	O
kappaB	O
is	O
thought	O
to	O
be	O
required	O
for	O
cytokine	O
release	O
from	O
LPS	O
-	O
responsive	O
cells	O
,	O
a	O
critical	O
step	O
for	O
endotoxic	O
effects	O
.	O

Here	O
we	O
investigated	O
the	O
role	O
and	O
involvement	O
of	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
-	O
alpha	O
)	O
signal	O
transducer	O
molecules	O
in	O
LPS	O
signaling	O
in	O
human	O
dermal	O
microvessel	O
endothelial	O
cells	O
(	O
HDMEC	O
)	O
and	O
THP	O
-	O
1	O
monocytic	O
cells	O
.	O

LPS	O
stimulation	O
of	O
HDMEC	O
and	O
THP	O
-	O
1	O
cells	O
initiated	O
an	O
IL	O
-	O
1	O
receptor	O
-	O
like	O
NF	O
-	O
kappaB	O
signaling	O
cascade	O
.	O

In	O
transient	O
cotransfection	O
experiments	O
,	O
dominant	O
negative	O
mutants	O
of	O
the	O
IL	O
-	O
1	O
signaling	O
pathway	O
,	O
including	O
MyD88	O
,	O
IRAK	O
,	O
IRAK2	O
,	O
and	O
TRAF6	O
inhibited	O
both	O
IL-1	O
-	O
and	O
LPS	O
-	O
induced	O
NF-kappaB	O
-	O
luciferase	O
activity	O
.	O

LPS	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
was	O
not	O
inhibited	O
by	O
a	O
dominant	O
negative	O
mutant	O
of	O
TRAF2	O
that	O
is	O
involved	O
in	O
TNF	O
signaling	O
.	O

LPS	O
-	O
induced	O
activation	O
of	O
NF-kappaB	O
-	O
responsive	O
reporter	O
gene	O
was	O
not	O
inhibited	O
by	O
IL	O
-	O
1	O
receptor	O
antagonist	O
.	O

TLR2	O
and	O
TLR4	O
were	O
expressed	B-Gene_expression
on	O
the	O
cell	O
surface	O
of	O
HDMEC	O
and	O
THP	O
-	O
1	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
a	O
signal	O
transduction	O
molecule	O
in	O
the	O
LPS	O
receptor	O
complex	O
may	O
belong	O
to	O
the	O
IL	O
-	O
1	O
receptor/toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
super	O
family	O
,	O
and	O
the	O
LPS	O
signaling	O
cascade	O
uses	O
an	O
analogous	O
molecular	O
framework	O
for	O
signaling	O
as	O
IL	O
-	O
1	O
in	O
mononuclear	O
phagocytes	O
and	O
endothelial	O
cells	O
.	O

Selective	O
activation	O
and	O
functional	O
significance	O
of	O
p38alpha	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
in	O
lipopolysaccharide	O
-	O
stimulated	O
neutrophils	O
.	O

Activation	O
of	O
leukocytes	O
by	O
proinflammatory	O
stimuli	O
selectively	O
initiates	O
intracellular	O
signal	O
transduction	O
via	O
sequential	O
phosphorylation	O
of	O
kinases	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
stimulation	O
of	O
human	O
neutrophils	O
is	O
known	O
to	O
result	O
in	O
activation	O
of	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPk	O
)	O
;	O
however	O
,	O
the	O
upstream	O
activator	O
(	O
s	O
)	O
of	O
p38	O
MAPk	O
is	O
unknown	O
,	O
and	O
consequences	O
of	O
p38	O
MAPk	O
activation	O
remain	O
largely	O
undefined	O
.	O

We	O
investigated	O
the	O
MAPk	O
kinase	O
(	O
MKK	O
)	O
that	O
activates	O
p38	O
MAPk	O
in	O
response	O
to	O
LPS	O
,	O
the	O
p38	O
MAPk	O
isoforms	O
that	O
are	O
activated	O
as	O
part	O
of	O
this	O
pathway	O
,	O
and	O
the	O
functional	O
responses	O
affected	O
by	O
p38	O
MAPk	O
activation	O
.	O

Although	O
MKK3	O
,	O
MKK4	O
,	O
and	O
MKK6	O
all	O
activated	O
p38	O
MAPk	O
in	O
experimental	O
models	O
,	O
only	O
MKK3	O
was	O
found	O
to	O
activate	O
recombinant	O
p38	O
MAPk	O
in	O
LPS	O
-	O
treated	O
neutrophils	O
.	O

Of	O
p38	O
MAPk	O
isoforms	O
studied	O
,	O
only	O
p38alpha	O
and	O
p38delta	O
were	O
detected	B-Gene_expression
in	O
neutrophils	O
.	O

LPS	O
stimulation	O
selectively	O
activated	B-Positive_regulation
p38alpha	O
.	O

Specific	O
inhibitors	B-Negative_regulation
of	O
p38alpha	O
MAPk	O
blocked	B-Negative_regulation
LPS	O
-	O
induced	O
adhesion	O
,	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
activation	O
,	O
and	O
synthesis	B-Gene_expression
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
.	O

Inhibition	B-Negative_regulation
of	O
p38alpha	O
MAPk	O
resulted	O
in	O
a	O
transient	O
decrease	O
in	O
TNF	O
-	O
alpha	O
mRNA	O
accumulation	O
but	O
persistent	O
loss	B-Negative_regulation
of	O
TNF	O
-	O
alpha	O
synthesis	B-Gene_expression
.	O

These	O
findings	O
support	O
a	O
pathway	O
by	O
which	O
LPS	O
stimulation	O
of	O
neutrophils	O
results	B-Positive_regulation
in	O
activation	B-Positive_regulation
of	O
MKK3	O
,	O
which	O
in	O
turn	O
activates	B-Positive_regulation
p38alpha	O
MAPk	O
,	O
ultimately	O
regulating	O
adhesion	O
,	O
NF	O
-	O
kappaB	O
activation	O
,	O
enhanced	B-Positive_regulation
gene	O
expression	B-Gene_expression
of	O
TNF	O
-	O
alpha	O
,	O
and	O
regulation	B-Regulation
of	O
TNF	O
-	O
alpha	O
synthesis	B-Gene_expression
.	O

Inhibition	O
of	O
IL-4	O
-	O
inducible	O
gene	O
expression	O
in	O
human	O
monocytes	O
by	O
type	O
I	O
and	O
type	O
II	O
interferons	O
.	O

The	O
Th2	O
-	O
type	O
cytokines	O
,	O
interleukin	O
-	O
4	O
(	O
IL	O
-	O
4	O
)	O
and	O
interleukin	O
-	O
13	O
(	O
IL	O
-	O
13	O
)	O
,	O
induce	B-Positive_regulation
expression	B-Gene_expression
of	O
a	O
distinct	O
subset	O
of	O
genes	O
in	O
human	O
monocytes	O
,	O
including	O
FcepsilonRIIb	O
(	O
CD23	O
)	O
,	O
15	O
-	O
lipoxygenase	O
,	O
IL	O
-	O
1	O
receptor	O
antagonist	O
(	O
IL	O
-	O
1ra	O
)	O
,	O
and	O
type	O
I	O
and	O
type	O
II	O
IL	O
-	O
1	O
receptors	O
(	O
IL	O
-	O
1R	O
)	O
.	O

Type	O
I	O
interferons	O
(	O
IFN	O
-	O
alpha	O
and	O
IFN	O
-	O
beta	O
)	O
and	O
type	O
II	O
interferon	O
(	O
IFN	O
-	O
gamma	O
)	O
inhibit	B-Negative_regulation
induction	B-Positive_regulation
of	O
these	O
genes	O
by	O
IL	O
-	O
4	O
and	O
IL	O
-	O
13	O
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
IFNs	O
mediate	B-Positive_regulation
this	O
inhibition	O
has	O
not	O
been	O
defined	O
.	O

In	O
this	O
overview	O
,	O
we	O
discuss	O
the	O
role	O
of	O
the	O
transcription	O
factor	O
,	O
STAT6	O
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
-	O
6	O
)	O
in	O
mediating	O
IL-4	O
-	O
and	O
IL-13	O
-	O
induced	O
gene	O
expression	O
in	O
monocytes	O
.	O

We	O
also	O
discuss	O
our	O
recent	O
findings	O
that	O
type	O
I	O
and	O
type	O
II	O
IFNs	O
suppress	O
IL-4/IL-13	O
-	O
inducible	O
gene	O
expression	O
by	O
inhibiting	B-Negative_regulation
tyrosine	O
phosphorylation	B-Phosphorylation
and	O
nuclear	O
translocation	B-Localization
of	O
STAT6	O
.	O

The	O
ability	O
of	O
type	O
I	O
and	O
type	O
II	O
IFNs	O
to	O
inhibit	B-Negative_regulation
IL-4/IL-13	O
-	O
induced	B-Positive_regulation
STAT6	O
activity	O
is	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
,	O
and	O
is	O
not	O
unique	O
to	O
monocytes	O
because	O
IFNs	O
induce	O
the	O
same	O
effects	O
in	O
fibroblasts	O
.	O

Inhibition	B-Negative_regulation
of	O
STAT6	O
activity	O
is	O
not	O
evident	O
unless	O
cells	O
are	O
preincubated	O
with	O
IFN	O
for	O
at	O
least	O
1	O
h	O
before	O
IL	O
-	O
4	O
stimulation	O
.	O

Furthermore	O
,	O
inhibition	O
can	O
be	O
blocked	B-Negative_regulation
by	O
actinomycin	O
D	O
,	O
indicating	O
a	O
requirement	B-Positive_regulation
for	O
de	O
novo	O
transcription	O
.	O

We	O
propose	O
a	O
model	O
in	O
which	O
stimulation	O
of	O
monocytes	O
by	O
IFN	O
activates	O
de	O
novo	O
synthesis	O
of	O
an	O
inhibitory	O
factor	O
,	O
possibly	O
one	O
or	O
more	O
members	O
of	O
the	O
SOCS/	O
SSI/CIS	O
gene	O
family	O
,	O
capable	O
of	O
suppressing	B-Negative_regulation
activation	B-Positive_regulation
of	O
STAT6	O
by	O
IL	O
-	O
4	O
and	O
IL	O
-	O
13	O
.	O

Because	O
STAT6	O
activation	B-Positive_regulation
plays	O
an	O
essential	O
role	O
in	O
IL-4/IL-13	O
-	O
induced	O
gene	O
expression	O
,	O
the	O
ability	O
of	O
IFN	O
-	O
beta	O
and	O
IFN	O
-	O
gamma	O
to	O
inhibit	B-Negative_regulation
STAT6	O
activity	O
provides	O
an	O
explanation	O
for	O
how	O
IFNs	O
can	O
suppress	O
IL-4/IL-13	O
-	O
inducible	O
gene	O
expression	O
.	O

Involvement	B-Positive_regulation
of	O
NF	O
-	O
kappaB	O
p50/p65	O
heterodimer	O
in	O
activation	B-Positive_regulation
of	O
the	O
human	O
pro-interleukin	O
-	O
1beta	O
gene	O
at	O
two	O
subregions	O
of	O
the	O
upstream	O
enhancer	O
element	O
.	O

A	O
region	O
between	O
-	O
3134	O
and	O
-	O
2729	O
bp	O
upstream	O
from	O
the	O
transcription	O
site	O
of	O
the	O
human	O
pro	O
-	O
interleukin	O
1beta	O
(	O
proIL	O
-	O
1beta	O
)	O
gene	O
was	O
identified	O
as	O
an	O
LPS	O
-	O
responsive	O
enhancer	O
element	O
.	O

In	O
this	O
study	O
,	O
the	O
influence	B-Regulation
of	O
the	O
sequences	O
located	O
between	O
-	O
3134	O
and	O
-	O
2987	O
on	O
the	O
transcriptional	B-Transcription
activity	I-Transcription
of	O
the	O
proIL	O
-	O
1beta	O
gene	O
in	O
LPS	O
-	O
stimulated	O
Raw	O
264.7	O
cells	O
was	O
examined	O
in	O
detail	O
.	O

The	O
results	O
obtained	O
by	O
transient	O
transfection	O
of	O
fos	O
-	O
CAT	O
constructs	O
that	O
contained	O
serial	O
5'	O
-	O
deletion	O
mutations	O
showed	O
that	O
the	O
region	O
between	O
-	O
3134	O
and	O
-	O
3059	O
appears	O
to	O
be	O
required	O
for	O
the	O
induction	B-Positive_regulation
of	O
transcription	O
by	O
LPS	O
.	O

Gel	O
shift	O
assay	O
studies	O
with	O
synthetic	O
oligonucleotides	O
corresponding	O
to	O
partial	O
sequences	O
of	O
the	O
latter	O
region	O
and	O
nuclear	O
extracts	O
from	O
stimulated	O
cells	O
revealed	O
specific	O
protein	O
binding	O
sites	O
between	O
-	O
3110	O
and	O
-	O
3090	O
and	O
between	O
-	O
3079	O
and	O
-	O
3059	O
.	O

These	O
specific	O
bindings	O
were	O
time	O
and	O
LPS	O
dose	O
dependent	O
.	O

The	O
results	O
of	O
supershift	O
analysis	O
using	O
specific	O
antibodies	O
against	O
transcription	O
factors	O
suggested	O
that	O
both	O
binding	O
complexes	O
contained	O
the	O
NF	O
-	O
kappaB	O
components	O
p50	O
and	O
p65	O
,	O
and	O
did	O
not	O
contain	O
other	O
NF	O
-	O
kappaB	O
proteins	O
(	O
p52	O
,	O
c	O
-	O
Rel	O
,	O
Rel	O
B	O
)	O
,	O
AP	O
-	O
1	O
proteins	O
(	O
c	O
-	O
Fos	O
,	O
C	O
-	O
Jun	O
)	O
,	O
CREB	O
or	O
C/EBPbeta	O
(	O
NF	O
-	O
IL6	O
)	O
.	O

Mutation	O
of	O
either	O
of	O
the	O
putative	O
NF-kappaB	O
-	O
binding	O
sites	O
in	O
the	O
enhancer	O
element	O
decreased	B-Negative_regulation
the	O
LPS	O
-	O
stimulated	B-Positive_regulation
transcriptional	O
activity	O
.	O

These	O
data	O
indicated	O
that	O
two	O
NF-kappaB	O
-	O
binding	O
sites	O
,	O
which	O
are	O
located	O
between	O
-	O
3134	O
and	O
-	O
3059	O
,	O
are	O
critical	B-Positive_regulation
for	O
the	O
activation	B-Positive_regulation
of	O
proIL	O
-	O
1beta	O
gene	O
transcription	B-Transcription
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Phosphorylation	B-Phosphorylation
of	O
TRAF2	O
inhibits	B-Negative_regulation
binding	B-Binding
to	O
the	O
CD40	O
cytoplasmic	O
domain	O
.	O

TRAF2	O
is	O
a	O
signal	O
transducing	O
adaptor	O
molecule	O
which	O
binds	B-Binding
to	O
the	O
CD40	O
cytoplasmic	O
domain	O
.	O

We	O
have	O
found	O
that	O
it	O
is	O
phosphorylated	B-Phosphorylation
,	O
predominantly	O
on	O
serine	O
residues	O
,	O
when	B-Positive_regulation
transiently	O
overexpressed	B-Positive_regulation
in	O
293	O
cells	O
.	O

The	O
phosphorylation	O
appears	O
to	O
be	O
related	O
to	O
the	O
signaling	O
events	O
that	O
are	O
activated	O
by	O
TRAF2	O
under	O
these	O
circumstances	O
,	O
since	O
two	O
nonfunctional	O
mutants	O
were	O
found	O
to	O
be	O
phosphorylated	O
significantly	O
less	O
than	O
the	O
wild	O
-	O
type	O
protein	O
.	O

Furthermore	O
,	O
the	O
phosphorylation	B-Phosphorylation
status	O
of	O
TRAF2	O
had	O
significant	O
effects	B-Regulation
on	O
the	O
ability	O
of	O
the	O
protein	O
to	O
bind	B-Binding
to	O
CD40	O
,	O
as	O
evidenced	O
by	O
our	O
observations	O
that	O
the	O
CD40	O
cytoplasmic	O
domain	O
interacted	B-Binding
preferentially	O
with	O
underphosphorylated	B-Phosphorylation
TRAF2	O
and	O
that	O
phosphatase	O
treatment	O
significantly	O
enhanced	B-Positive_regulation
the	O
binding	B-Binding
of	O
TRAF2	O
to	O
CD40	O
.	O

We	O
conclude	O
from	O
these	O
studies	O
that	O
the	O
phosphorylation	B-Phosphorylation
of	O
TRAF2	O
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
regulating	O
signaling	O
by	O
virtue	O
of	O
its	O
ability	O
to	O
influence	B-Regulation
the	O
CD40	O
-	O
TRAF2	O
interaction	B-Binding
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Cobalt	O
chloride	O
-	O
induced	O
signaling	O
in	O
endothelium	O
leading	O
to	O
the	O
augmented	O
adherence	O
of	O
sickle	O
red	O
blood	O
cells	O
and	O
transendothelial	O
migration	O
of	O
monocyte	O
-	O
like	O
HL	O
-	O
60	O
cells	O
is	O
blocked	O
by	O
PAF	O
-	O
receptor	O
antagonist	O
.	O

In	O
response	O
to	O
hypoxia	O
,	O
sickle	O
red	O
blood	O
cells	O
(	O
SS	O
RBC	O
)	O
and	O
leukocytes	O
exhibit	O
increased	O
adherence	O
to	O
the	O
vascular	O
endothelium	O
,	O
while	O
diapedesis	O
of	O
leukocytes	O
through	O
the	O
blood	O
vessel	O
increases	O
.	O

However	O
,	O
the	O
cellular	O
signaling	O
pathway	O
(	O
s	O
)	O
caused	O
by	O
hypoxia	O
is	O
poorly	O
understood	O
.	O

We	O
utilized	O
CoCl2	O
as	O
a	O
mimetic	O
molecule	O
for	O
hypoxia	O
to	O
study	O
cellular	O
signaling	O
pathways	O
.	O

We	O
found	O
that	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
,	O
CoCl2	O
at	O
2	O
mM	O
concentration	O
induced	B-Positive_regulation
the	O
surface	O
expression	B-Gene_expression
of	O
a	O
subset	O
of	O
CAMs	O
(	O
VCAM	O
-	O
1	O
)	O
and	O
activation	O
of	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
in	O
the	O
nuclear	O
extracts	O
of	O
HUVEC	O
.	O

Furthermore	O
,	O
CoCl2	O
also	O
caused	B-Positive_regulation
time	O
-	O
dependent	O
tyrosine	O
phosphorylation	B-Phosphorylation
of	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
isoform	O
ERK2	O
without	O
significantly	O
affecting	B-Regulation
ERK1	O
,	O
indicating	O
ERK2	O
is	O
the	O
preferred	O
substrate	O
for	B-Positive_regulation
upstream	O
kinase	O
of	O
the	O
MAPK	O
pathway	O
.	O

Inhibitors	O
of	O
MAP	O
kinase	O
(	O
PD98059	O
)	O
or	O
platelet	O
-	O
activating	O
factor	O
(	O
PAF	O
)	O
-	O
receptor	O
antagonist	O
(	O
CV3988	O
)	O
inhibited	B-Negative_regulation
the	O
CoCl2	O
-	O
induced	B-Positive_regulation
NF	O
-	O
kappaB	O
activation	O
and	O
VCAM	O
-	O
1	O
expression	B-Gene_expression
.	O

Augmented	B-Positive_regulation
expression	B-Gene_expression
of	O
VCAM	O
-	O
1	O
led	O
to	O
increased	O
SS	O
RBC	O
adhesion	O
,	O
inhibitable	O
by	O
a	O
VCAM	O
-	O
1	O
antibody	O
.	O

Additionally	O
,	O
CoCl2	O
caused	B-Positive_regulation
a	O
two	O
-	O
to	O
threefold	O
increase	O
in	O
the	O
rate	O
of	O
transendothelial	O
migration	O
of	O
monocyte	O
-	O
like	O
HL	O
-	O
60	O
cells	O
and	O
a	O
twentyfold	O
increase	B-Positive_regulation
in	O
phosphorylation	B-Phosphorylation
of	O
platelet	O
endothelial	O
cell	O
adhesion	O
molecules	O
(	O
PECAM	O
-	O
1	O
)	O
.	O

The	O
transendothelial	O
migration	O
of	O
monocytes	O
was	O
inhibited	O
by	O
an	O
antibody	O
to	O
PECAM	O
-	O
1	O
.	O

Both	O
phosphorylation	B-Phosphorylation
of	O
PECAM	O
-	O
1	O
and	O
transendothelial	O
migration	O
of	O
monocytes	O
in	B-Positive_regulation
response	I-Positive_regulation
to	O
CoCl2	O
were	O
inhibited	B-Negative_regulation
by	O
protein	O
kinase	O
inhibitor	O
(	O
GF109203X	O
)	O
and	O
augmented	B-Positive_regulation
by	O
protein	O
phosphatase	O
inhibitor	O
(	O
Calyculin	O
A	O
)	O
.	O

Our	O
data	O
suggests	O
that	O
CoCl2	O
-	O
induced	B-Positive_regulation
cellular	O
signals	O
directing	B-Positive_regulation
increased	B-Positive_regulation
expression	B-Gene_expression
of	O
VCAM	O
-	O
1	O
in	O
HUVEC	O
involve	O
downstream	O
activation	O
of	O
MAP	O
kinase	O
and	O
NF	O
-	O
kappaB	O
,	O
while	O
the	O
phosphorylation	B-Phosphorylation
of	O
PECAM	O
-	O
1	O
occurs	B-Positive_regulation
as	O
a	O
result	O
of	O
activation	O
of	O
PKC	O
.	O

We	O
conclude	O
that	O
PAF	O
-	O
receptor	O
antagonist	O
inhibits	B-Negative_regulation
the	O
CoCl2	O
-	O
or	O
hypoxia	O
-	O
induced	O
increase	B-Positive_regulation
in	O
the	O
adhesion	O
of	O
SS	O
RBC	O
,	O
PECAM	O
-	O
1	O
phosphorylation	B-Phosphorylation
,	O
and	O
the	O
concomitant	O
transendothelial	O
migration	O
of	O
monocytes	O
.	O

Molecular	O
mechanisms	O
of	O
neutrophil	O
-	O
endothelial	O
cell	O
adhesion	O
induced	O
by	O
redox	O
imbalance	O
.	O

Previous	O
studies	O
have	O
implicated	O
a	O
role	O
for	O
intracellular	O
thiols	O
in	O
the	O
activation	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
and	O
transcriptional	O
regulation	O
of	O
endothelial	O
cell	O
adhesion	O
molecules	O
.	O

This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
changes	O
in	O
endothelial	O
cell	O
glutathione	O
(	O
GSH	O
)	O
or	O
oxidized	O
glutathione	O
(	O
GSSG	O
)	O
can	O
alter	O
neutrophil	O
adhesivity	O
and	O
to	O
define	O
the	O
molecular	O
mechanism	O
that	O
underlies	O
this	O
GSSG/GSH	O
-	O
induced	O
adhesion	O
response	O
.	O

Treatment	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cell	O
(	O
HUVEC	O
)	O
monolayers	O
for	O
6	O
hours	O
with	O
0.2	O
mmol/L	O
diamide	O
and	O
1	O
mmol/L	O
buthionine	O
sulfoximine	O
(	O
BSO	O
)	O
decreased	O
GSH	O
levels	O
and	O
increased	O
the	O
ratio	O
of	O
GSSG	O
to	O
GSH	O
without	O
cell	O
toxicity	O
.	O

These	O
redox	O
changes	O
are	O
similar	O
to	O
those	O
observed	O
with	O
anoxia/reoxygenation	O
.	O

Diamide	O
plus	O
BSO	O
-	O
induced	O
thiol/disulfide	O
imbalance	O
was	O
associated	O
with	O
a	O
biphasic	O
increase	O
in	O
neutrophil	O
adhesion	O
to	O
HUVECs	O
with	O
peak	O
responses	O
observed	O
at	O
15	O
minutes	O
(	O
phase	O
1	O
)	O
and	O
240	O
minutes	O
(	O
phase	O
2	O
)	O
.	O

N	O
-	O
Acetylcysteine	O
treatment	O
attenuated	O
neutrophil	O
adhesion	O
in	O
both	O
phases	O
,	O
which	O
indicated	O
a	O
role	O
for	O
GSH	O
in	O
the	O
adhesion	O
responses	O
.	O

Interestingly	O
,	O
phase	O
1	O
adhesion	O
was	O
inversely	O
correlated	O
with	O
GSH	O
levels	O
but	O
not	O
with	O
the	O
GSSG/GSH	O
ratio	O
,	O
whereas	O
phase	O
2	O
neutrophil	O
adhesion	O
was	O
positively	O
correlated	O
with	O
GSSG/GSH	O
ratio	O
but	O
not	O
with	O
GSH	O
levels	O
.	O

Intercellular	O
adhesion	O
molecule	O
-	O
1	O
and	O
P-selectin	O
-	O
specific	O
monoclonal	O
antibodies	O
attenuated	O
the	O
increased	O
neutrophil	O
adhesion	O
during	O
both	O
phases	O
,	O
whereas	O
an	O
anti-E	O
-	O
selectin	O
monoclonal	O
antibody	O
also	O
attenuated	O
the	O
phase	O
2	O
response	O
.	O

Pretreatment	O
with	O
actinomycin	O
D	O
and	O
cycloheximide	O
or	O
with	O
competing	O
ds	O
-	O
oligonucleotides	O
that	O
contained	O
nuclear	O
factor	O
-	O
kappaB	O
or	O
activator	O
protein	O
-	O
1	O
cognate	O
DNA	O
sequences	O
significantly	O
attenuated	O
the	O
phase	O
2	O
response	O
,	O
which	O
implicated	O
a	O
role	O
for	O
de	O
novo	O
protein	O
synthesis	O
.	O

Surface	O
expression	B-Gene_expression
of	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
,	O
P	O
-	O
selectin	O
,	O
and	O
E	O
-	O
selectin	O
on	O
HUVECs	O
correlated	O
with	O
the	O
phase	O
1	O
and	O
2	O
neutrophil	O
adhesion	O
responses	O
.	O

This	O
study	O
demonstrates	O
that	O
changes	O
in	O
endothelial	O
cell	O
GSSG/GSH	O
cause	O
transcription	O
-	O
independent	O
and	O
transcription	O
-	O
dependent	O
surface	O
expression	O
of	O
different	O
endothelial	O
cell	O
adhesion	O
molecules	O
,	O
which	O
leads	O
to	O
a	O
2	O
-	O
phase	O
neutrophil	O
-	O
endothelial	O
adhesion	O
response	O
.	O

Decreased	O
proteasome	O
-	O
mediated	O
degradation	O
in	O
T	O
cells	O
from	O
the	O
elderly	O
:	O
A	O
role	O
in	O
immune	O
senescence	O
.	O

Induction	O
of	O
NFkappaB	O
is	O
a	O
highly	O
regulated	O
process	O
requiring	O
phosphorylation	O
,	O
ubiquitination	O
,	O
and	O
proteasome	O
-	O
mediated	B-Positive_regulation
degradation	B-Protein_catabolism
of	O
the	O
cytosolic	O
inhibitor	O
IkappaBalpha	O
.	O

Analyses	O
of	O
the	O
regulation	B-Regulation
of	O
IkappaBalpha	O
in	O
TNF-alpha	O
-	O
treated	O
T	O
lymphocytes	O
from	O
young	O
and	O
elderly	O
donors	O
revealed	O
severely	O
compromised	O
degradation	B-Protein_catabolism
of	O
IkappaBalpha	O
in	O
T	O
cells	O
from	O
the	O
elderly	O
.	O

Examination	O
of	O
activation	O
-	O
induced	B-Positive_regulation
phosphorylation	B-Phosphorylation
and	O
ubiquitination	O
of	O
IkappaBalpha	O
did	O
not	O
demonstrate	O
any	O
significant	O
age	O
-	O
related	O
alterations	B-Regulation
.	O

However	O
,	O
examination	O
of	O
proteasome	O
activity	O
in	O
these	O
T	O
cells	O
using	O
fluorogenic	O
peptide	O
assays	O
revealed	O
a	O
significant	O
age	O
-	O
related	O
decline	O
in	O
chymotryptic	O
activity	O
.	O

These	O
results	O
suggest	O
that	O
a	O
decline	O
in	O
proteasome	O
activity	O
results	B-Positive_regulation
in	O
a	O
failure	O
to	O
fully	O
degrade	B-Protein_catabolism
IkappaBalpha	O
in	O
the	O
elderly	O
.	O

This	O
failure	O
to	O
degrade	B-Protein_catabolism
IkappaBalpha	O
may	O
underlie	O
both	O
the	O
observed	O
decrease	O
in	O
NFkappaB	O
induction	O
and	O
the	O
IL	O
-	O
2	O
receptor	O
expression	O
in	O
TNF	O
-	O
treated	O
T	O
cells	O
during	O
aging	O
.	O

Thus	O
,	O
decreased	O
proteasome	O
-	O
mediated	O
degradation	O
may	O
be	O
central	O
to	O
immune	O
dysfunction	O
that	O
accompanies	O
aging	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Identification	O
of	O
upstream	O
regulatory	O
elements	O
that	O
repress	O
expression	O
of	O
adult	O
beta	O
-	O
like	O
globin	O
genes	O
in	O
a	O
primitive	O
erythroid	O
environment	O
.	O

Our	O
investigations	O
have	O
focused	O
on	O
localizing	O
cis	O
-	O
elements	O
responsible	B-Regulation
for	O
the	O
down	B-Negative_regulation
regulation	I-Negative_regulation
of	O
the	O
adult	O
beta	O
-	O
like	O
globin	O
genes	O
(	O
delta	O
and	O
beta	O
)	O
in	O
immature	O
,	O
or	O
primitive	O
erythroid	O
tissues	O
.	O

We	O
studied	O
their	O
activity	O
after	O
transfection	O
into	O
K562	O
cells	O
,	O
an	O
erythroleukemia	O
cell	O
line	O
with	O
an	O
embryonic	O
-	O
fetal	O
phenotype	O
.	O

Analyzed	O
DNA	O
sequences	O
included	O
delta	O
and	O
beta	O
5	O
'	O
flanking	O
regions	O
extending	O
from	O
approximately	O
-	O
500	O
to	O
+50bp	O
(	O
promoter	O
regions	O
)	O
,	O
truncated	O
delta	O
and	O
beta	O
5	O
'	O
flanking	O
regions	O
extending	O
from	O
approximately	O
-	O
250	O
to	O
+50	O
bp	O
,	O
and	O
chimeric	O
promoter	O
constructions	O
,	O
which	O
consisted	O
of	O
a	O
distal	O
delta	O
or	O
beta	O
fragment	O
fused	O
to	O
a	O
proximal	O
beta	O
or	O
delta	O
sequence	O
.	O

In	O
CAT	O
reporter	O
constructions	O
no	O
appreciable	O
level	O
of	O
CAT	O
activity	O
was	O
supported	B-Positive_regulation
by	O
the	O
beta	O
globin	O
promoter	O
,	O
and	O
only	O
low	O
level	O
activity	O
by	O
the	O
delta	O
promoter	O
.	O

Truncation	O
of	O
the	O
beta	O
globin	O
promoter	O
led	O
to	O
a	O
2	O
-	O
3	O
fold	O
increase	B-Positive_regulation
in	O
promoter	O
activity	O
.	O

In	O
contrast	O
,	O
deletion	O
of	O
the	O
upstream	O
portion	O
of	O
the	O
delta	O
promoter	O
led	O
to	O
a	O
10	O
fold	O
decrease	B-Negative_regulation
in	O
expression	B-Gene_expression
.	O

Coupling	O
of	O
the	O
upstream	O
beta	O
globin	O
sequence	O
from	O
approximately	O
-	O
500	O
to	O
-	O
250	O
bp	O
to	O
the	O
truncated	O
delta	O
promoter	O
fragment	O
led	O
to	O
complete	O
extinction	O
of	O
transcription	O
activity	O
,	O
consistent	O
with	O
a	O
negative	O
regulatory	O
effect	O
of	O
the	O
beta	O
globin	O
gene	O
upstream	O
element	O
(	O
s	O
)	O
.	O

Fusion	O
of	O
the	O
upstream	O
portion	O
of	O
the	O
delta	O
promoter	O
to	O
the	O
truncated	O
beta	O
globin	O
promoter	O
yielded	O
a	O
modest	O
increase	B-Positive_regulation
in	O
promoter	O
strength	O
relative	O
to	O
the	O
truncated	O
beta	O
gene	O
promoter	O
,	O
indicating	O
the	O
presence	O
of	O
a	O
positive	O
transcriptional	O
element	O
(	O
s	O
)	O
in	O
the	O
upstream	O
delta	O
globin	O
regulatory	O
region	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
binding	O
sites	O
for	O
the	O
repressor	O
proteins	O
BP1	O
and	O
BP2	O
in	O
the	O
upstream	O
portion	O
of	O
the	O
beta	O
globin	O
gene	O
flanking	O
region	O
led	O
to	O
a	O
4	O
-	O
6	O
fold	O
increase	O
in	O
promoter	O
activity	O
.	O

DNase	O
I	O
footprinting	O
of	O
the	O
upstream	O
delta	O
-	O
globin	O
region	O
revealed	O
protected	O
sequences	O
corresponding	O
to	O
consensus	O
binding	O
sites	O
for	O
GATA	O
-	O
1	O
and	O
BP2	O
.	O

These	O
results	O
confirm	O
that	O
sequences	O
in	O
the	O
upstream	O
promoter	O
region	O
of	O
the	O
adult	O
beta	O
globin	O
gene	O
contribute	B-Positive_regulation
to	O
its	O
factor	O
-	O
mediated	O
suppression	B-Negative_regulation
early	O
in	O
development	O
and	O
then	O
may	O
modulate	B-Regulation
its	O
expression	B-Gene_expression
at	O
a	O
later	O
stage	O
.	O

Reduction	B-Negative_regulation
of	O
tumour	O
necrosis	O
factor	O
alpha	O
expression	B-Gene_expression
and	O
signalling	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
patients	O
with	O
thalassaemia	O
or	O
sickle	O
cell	O
anaemia	O
upon	O
treatment	O
with	O
desferrioxamine	O
.	O

Recent	O
evidence	O
indicates	O
that	O
the	O
rate	O
of	O
progression	O
of	O
the	O
HIV	O
-	O
1	O
disease	O
is	O
significantly	O
reduced	O
in	O
thalassaemia	O
major	O
patients	O
upon	O
treatment	O
with	O
high	O
doses	O
of	O
desferrioxamine	O
(	O
DFX	O
)	O
.	O

The	O
authors	O
have	O
previously	O
demonstrated	O
that	O
in	O
vitro	O
exposure	O
of	O
mononuclear	O
cells	O
to	O
DFX	O
decreases	B-Negative_regulation
the	O
bioavailability	O
of	O
tumour	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
which	O
has	O
a	O
stimulatory	O
effect	O
on	O
HIV	O
-	O
1	O
replication	O
.	O

In	O
this	O
study	O
,	O
therefore	O
,	O
TNF	O
-	O
alpha	O
bioavailability	O
from	O
mononuclear	O
cells	O
isolated	O
from	O
10	O
patients	O
with	O
thalassaemia	O
or	O
sickle	O
cell	O
anaemia	O
given	O
DFX	O
as	O
compared	O
to	O
10	O
untreated	O
subjects	O
has	O
been	O
evaluated	O
.	O

Evidence	O
is	O
presented	O
showing	O
that	O
DFX	O
treatment	O
reduces	B-Negative_regulation
TNF	O
-	O
alpha	O
bioavailability	O
(	O
P	O
<	O
0.05	O
)	O
by	O
inhibiting	O
its	O
steady	O
state	O
(	O
P	O
<	O
0.05	O
)	O
and	O
by	O
enhancing	B-Positive_regulation
its	O
inactivation	B-Negative_regulation
through	O
binding	B-Binding
to	O
soluble	O
TNF	O
-	O
alpha	O
receptor	O
type	O
II	O
(	O
P	O
<	O
0.05	O
)	O
.	O

We	O
also	O
show	O
that	O
DFX	O
treatment	O
limits	O
the	O
in	O
vivo	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
a	O
transcription	O
factor	O
involved	B-Positive_regulation
in	O
both	O
TNF	O
-	O
alpha	O
gene	O
transcription	B-Transcription
and	O
TNF	O
-	O
alpha	O
signalling	O
(	O
P	O
<	O
0.005	O
)	O
.	O

We	O
conclude	O
that	O
TNF	O
-	O
alpha	O
bioavailability	O
and	O
signalling	O
are	O
impaired	B-Negative_regulation
in	O
patients	O
upon	O
DFX	O
treatment	O
.	O

This	O
mechanism	O
may	O
contribute	O
to	O
delayed	O
progression	O
of	O
the	O
HIV	O
-	O
1	O
infection	O
in	O
vivo	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Inhibition	B-Negative_regulation
of	O
cyclooxygenase	O
-	O
2	O
expression	B-Gene_expression
by	O
4	O
-	O
trifluoromethyl	O
derivatives	O
of	O
salicylate	O
,	O
triflusal	O
,	O
and	O
its	O
deacetylated	O
metabolite	O
,	O
2-hydroxy-4	O
-	O
trifluoromethylbenzoic	O
acid	O
.	O

The	O
therapeutic	O
potential	O
of	O
drugs	O
that	O
block	O
the	O
induction	O
of	O
cyclooxygenase	O
-	O
2	O
has	O
been	O
emphasized	O
.	O

When	O
two	O
4	O
-	O
trifluoromethyl	O
salicylate	O
derivatives	O
[	O
2-acetoxy-4-trifluoromethyl	O
-	O
benzoic	O
acid	O
(	O
triflusal	O
)	O
and	O
its	O
deacetylated	O
metabolite	O
2-hydroxy-4	O
-	O
trifluoromethylbenzoic	O
acid	O
(	O
HTB	O
)	O
]	O
were	O
compared	O
with	O
aspirin	O
and	O
sodium	O
salicylate	O
as	O
cyclooxygenase	O
-	O
2	O
(	O
COX	O
-	O
2	O
)	O
inhibitors	O
,	O
we	O
observed	O
that	O
in	O
bacterial	O
lipopolysaccharide	O
-	O
activated	O
human	O
blood	O
,	O
triflusal	O
,	O
aspirin	O
,	O
and	O
HTB	O
,	O
but	O
not	O
sodium	O
salicylate	O
,	O
inhibited	O
COX-2	O
-	O
mediated	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
production	O
(	O
IC50	O
=	O
0.16	O
,	O
0.18	O
,	O
0.39	O
,	O
and	O
>	O
10	O
mM	O
,	O
respectively	O
)	O
.	O

However	O
,	O
only	O
triflusal	O
and	O
aspirin	O
inhibited	B-Negative_regulation
purified	O
COX	O
-	O
2	O
enzyme	O
.	O

To	O
test	O
this	O
apparent	O
discrepancy	O
,	O
we	O
realized	O
that	O
HTB	O
and	O
triflusal	O
(	O
but	O
neither	O
aspirin	O
nor	O
salicylate	O
)	O
produced	B-Positive_regulation
a	O
concentration	O
-	O
dependent	O
inhibition	B-Negative_regulation
of	O
COX	O
-	O
2	O
protein	O
expression	B-Gene_expression
in	O
peripheral	O
human	O
mononuclear	O
cells	O
.	O

This	O
observation	O
was	O
further	O
confirmed	O
in	O
a	O
rat	O
air	O
pouch	O
model	O
in	O
vivo	O
,	O
in	O
which	O
both	O
aspirin	O
and	O
triflusal	O
inhibited	O
PGE2	O
production	O
(	O
ID50	O
=	O
18.9	O
and	O
11.4	O
mg/kg	O
p.o.	O
,	O
respectively	O
)	O
but	O
only	O
triflusal	O
-	O
treated	O
animals	O
showed	O
a	O
decrease	B-Negative_regulation
in	O
COX	O
-	O
2	O
expression	B-Gene_expression
.	O

This	O
different	O
behavior	O
may	O
be	O
,	O
at	O
least	O
in	O
part	O
,	O
due	O
to	O
the	O
ability	O
of	O
HTB	O
and	O
triflusal	O
to	O
block	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappaB	O
to	O
a	O
higher	O
extent	O
than	O
aspirin	O
and	O
sodium	O
salicylate	O
.	O

Thus	O
,	O
in	O
addition	O
to	O
inhibiting	O
the	O
COX	O
-	O
2	O
activity	O
at	O
therapeutic	O
concentrations	O
,	O
triflusal	O
is	O
able	O
to	O
block	B-Negative_regulation
through	O
its	O
metabolite	O
HTB	O
the	O
expression	B-Gene_expression
of	O
new	O
enzyme	O
,	O
and	O
hence	O
the	O
resumption	O
of	O
PGE2	O
synthesis	O
.	O

Triflusal	O
and	O
HTB	O
may	O
exert	O
beneficial	O
effects	O
in	O
processes	O
in	O
which	O
de	O
novo	O
COX	O
-	O
2	O
expression	B-Gene_expression
is	O
involved	O
and	O
,	O
in	O
a	O
broader	O
sense	O
,	O
in	O
pathological	O
situations	O
in	O
which	O
genes	O
under	O
nuclear	O
factor	O
-	O
kappaB	O
control	O
are	O
up	O
-	O
regulated	O
.	O

Expression	B-Gene_expression
of	O
IkappaBalpha	O
in	O
the	O
nucleus	O
of	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
.	O

According	O
to	O
current	O
models	O
the	O
inhibitory	B-Negative_regulation
capacity	I-Negative_regulation
of	O
I	O
(	O
kappa	O
)	O
B	O
(	O
alpha	O
)	O
would	O
be	O
mediated	B-Positive_regulation
through	O
the	O
retention	O
of	O
Rel/NF	O
-	O
kappaB	O
proteins	O
in	O
the	O
cytosol	O
.	O

However	O
,	O
I	O
(	O
kappa	O
)	O
B	O
(	O
alpha	O
)	O
has	O
also	O
been	O
detected	B-Positive_regulation
in	O
the	O
nucleus	O
of	O
cell	O
lines	O
and	O
when	O
overexpressed	B-Positive_regulation
by	O
transient	O
transfection	O
.	O

To	O
gain	O
better	O
insight	O
into	O
the	O
potential	O
role	O
of	O
nuclear	O
I	O
(	O
kappa	O
)	O
B	O
(	O
alpha	O
)	O
in	O
a	O
physiological	O
context	O
we	O
have	O
analysed	O
its	O
presence	O
in	O
the	O
nucleus	O
of	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
(	O
PBL	O
)	O
.	O

We	O
demonstrate	O
the	O
nuclear	O
localization	B-Localization
of	O
I	O
(	O
kappa	O
)	O
B	O
(	O
alpha	O
)	O
in	O
PBL	O
by	O
different	O
techniques	O
:	O
Western	O
blot	O
,	O
indirect	O
immunofluorescence	O
and	O
electron	O
microscopy	O
.	O

Low	O
levels	O
of	O
nuclear	O
I	O
(	O
kappa	O
)	O
B	O
(	O
alpha	O
)	O
were	O
detected	B-Positive_regulation
in	O
resting	O
cells	O
whereas	O
a	O
superinduction	O
was	O
obtained	O
after	O
PMA	O
activation	O
.	O

The	O
nuclear	O
pool	O
of	O
I	O
(	O
kappa	O
)	O
B	O
(	O
alpha	O
)	O
showed	O
a	O
higher	B-Positive_regulation
stability	I-Positive_regulation
than	O
cytosolic	O
I	O
(	O
kappa	O
)	O
B	O
(	O
alpha	O
)	O
and	O
was	O
partially	O
independent	O
of	O
the	O
resynthesis	B-Gene_expression
of	O
the	O
protein	O
.	O

Unexpectedly	O
,	O
the	O
presence	B-Localization
of	O
nuclear	O
I	O
(	O
kappa	O
)	O
B	O
(	O
alpha	O
)	O
did	O
not	O
inhibit	O
NF	O
-	O
kappaB	O
binding	O
to	O
DNA	O
and	O
this	O
phenomenon	O
was	O
not	O
due	O
to	O
the	O
presence	B-Regulation
of	O
IkappaBbeta	O
at	O
the	O
nuclear	O
level	O
.	O

Immunoprecipitation	O
experiments	O
failed	O
to	O
demonstrate	O
an	O
association	O
between	O
nuclear	O
I	O
(	O
kappa	O
)	O
B	O
(	O
alpha	O
)	O
and	O
NF	O
-	O
kappaB	O
proteins	O
.	O

Our	O
results	O
demonstrate	O
that	O
in	O
resting	O
and	O
PMA	O
-	O
activated	O
human	O
PBL	O
,	O
I	O
(	O
kappa	O
)	O
B	O
(	O
alpha	O
)	O
is	O
present	B-Localization
in	O
the	O
nucleus	O
in	O
an	O
apparently	O
inactive	O
form	O
unable	O
to	O
disrupt	O
NF	O
-	O
kappaB	O
binding	O
from	O
DNA	O
.	O

PGG	O
-	O
glucan	O
,	O
a	O
soluble	O
beta	O
-	O
(	O
1	O
,	O
3	O
)	O
-	O
glucan	O
,	O
enhances	O
the	O
oxidative	O
burst	O
response	O
,	O
microbicidal	O
activity	O
,	O
and	O
activates	O
an	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
factor	O
in	O
human	O
PMN	O
:	O
evidence	O
for	O
a	O
glycosphingolipid	O
beta	O
-	O
(	O
1	O
,	O
3	O
)	O
-	O
glucan	O
receptor	O
.	O

PGG	O
-	O
Glucan	O
,	O
a	O
soluble	O
beta	O
-	O
(	O
1	O
,	O
6	O
)	O
-	O
branched	O
beta	O
-	O
(	O
1	O
,	O
3	O
)	O
-	O
linked	O
glucose	O
homopolymer	O
derived	O
from	O
the	O
cell	O
wall	O
of	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
,	O
is	O
an	O
immunomodulator	O
which	O
enhances	O
leukocyte	O
anti	O
-	O
infective	O
activity	O
and	O
enhances	O
myeloid	O
and	O
megakaryocyte	O
progenitor	O
proliferation	O
.	O

Incubation	O
of	O
human	O
whole	O
blood	O
with	O
PGG	O
-	O
Glucan	O
significantly	O
enhanced	O
the	O
oxidative	O
burst	O
response	O
of	O
subsequently	O
isolated	O
blood	O
leukocytes	O
to	O
both	O
soluble	O
and	O
particulate	O
activators	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
and	O
increased	O
leukocyte	O
microbicidal	O
activity	O
.	O

No	O
evidence	O
for	O
inflammatory	O
cytokine	O
production	O
was	O
obtained	O
under	O
these	O
conditions	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
PGG	O
-	O
Glucan	O
induced	O
the	O
activation	O
of	O
an	O
NF-kappaB	O
-	O
like	O
nuclear	O
transcription	O
factor	O
in	O
purified	O
human	O
neutrophils	O
.	O

The	O
binding	O
of	O
3H-PGG	O
-	O
Glucan	O
to	O
human	O
leukocyte	O
membranes	O
was	O
specific	O
,	O
concentration	O
-	O
dependent	O
,	O
saturable	O
,	O
and	O
high	O
affinity	O
(	O
Kd	O
approximately	O
6	O
nM	O
)	O
.	O

A	O
monoclonal	O
antibody	O
specific	O
to	O
the	O
glycosphingolipid	O
lactosylceramide	O
was	O
able	O
to	O
inhibit	O
activation	O
of	O
the	O
NF-kappaB	O
-	O
like	O
factor	O
by	O
PGG	O
-	O
Glucan	O
,	O
and	O
ligand	O
binding	O
data	O
,	O
including	O
polysaccharide	O
specificity	O
,	O
suggested	O
that	O
the	O
PGG	O
-	O
Glucan	O
binding	O
moiety	O
was	O
lactosylceramide	O
.	O

These	O
results	O
indicate	O
that	O
PGG	O
-	O
Glucan	O
enhances	O
neutrophil	O
anti	O
-	O
microbial	O
functions	O
and	O
that	O
interaction	O
between	O
this	O
beta	O
-	O
glucan	O
and	O
human	O
neutrophils	O
is	O
mediated	O
by	O
the	O
glycosphingolipid	O
lactosylceramide	O
present	O
at	O
the	O
cell	O
surface	O
.	O

[	O
Corticoids	O
and	O
allergy	O
]	O

Inflammation	O
is	O
constantly	O
observed	O
in	O
allergic	O
reactions	O
.	O

Corticosteroids	O
are	O
most	O
effective	O
in	O
preventing	O
the	O
late	O
phase	O
of	O
allergic	O
reaction	O
.	O

The	O
action	O
of	O
glucocorticosteroids	O
is	O
mediated	O
through	O
glucocorticoid	O
receptors	O
present	O
in	O
the	O
cellular	O
cytoplasm	O
.	O

When	O
activated	O
,	O
glucocorticoid	O
receptors	O
form	O
a	O
dimer	O
and	O
bind	O
to	O
DNA	O
after	O
migration	O
into	O
the	O
nucleus	O
.	O

Interaction	O
to	O
DNA	O
induces	O
changes	O
in	O
the	O
transcription	O
rate	O
,	O
leading	O
to	O
either	O
gene	O
induction	O
or	O
gene	O
repression	O
.	O

Glucocorticoid	O
receptors	O
are	O
also	O
able	O
to	O
interact	O
with	O
transcriptional	O
factors	O
such	O
as	O
AP	O
-	O
1	O
(	O
activator	O
protein	O
-	O
1	O
)	O
of	O
NF	O
-	O
kappa	O
B	O
(	O
nuclear	O
factor	O
-	O
kappa	O
B	O
)	O
.	O

Through	O
these	O
actions	O
glucocorticosteroids	O
are	O
susceptible	O
to	O
modify	O
functions	O
of	O
cells	O
involved	O
in	O
the	O
allergic	O
inflammatory	O
response	O
.	O

They	O
are	O
in	O
particular	O
able	O
to	O
inhibit	O
most	O
of	O
the	O
pro	O
-	O
inflammatory	O
functions	O
of	O
the	O
eosinophils	O
.	O

Activation	O
of	O
NF	O
-	O
kappaB	O
in	O
Mycobacterium	O
tuberculosis	O
-	O
induced	O
interleukin	O
-	O
2	O
receptor	O
expression	O
in	O
mononuclear	O
phagocytes	O
.	O

Soluble	O
interleukin	O
-	O
2	O
receptor	O
-	O
alpha	O
(	O
IL	O
-	O
2Ralpha	O
)	O
has	O
been	O
reported	O
to	O
be	O
increased	B-Positive_regulation
in	O
the	O
sera	O
of	O
patients	O
with	O
advanced	O
tuberculosis	O
,	O
and	O
levels	O
decline	B-Negative_regulation
after	O
therapy	O
in	O
accordance	O
with	O
improvement	O
of	O
radiologic	O
findings	O
.	O

We	O
investigated	O
expression	B-Gene_expression
of	O
the	O
IL	O
-	O
2Ralpha	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
cells	O
in	O
active	O
pulmonary	O
tuberculosis	O
,	O
and	O
evaluated	O
the	O
mechanism	O
Mycobacterium	O
tuberculosis	O
induces	B-Positive_regulation
in	O
the	O
IL	O
-	O
2Ralpha	O
using	O
the	O
THP	O
-	O
1	O
mononuclear	O
phagocyte	O
cell	O
line	O
.	O

We	O
found	O
IL	O
-	O
2Ralpha	O
expression	B-Gene_expression
to	O
be	O
increased	B-Positive_regulation
in	O
BAL	O
cells	O
from	O
involved	O
sites	O
of	O
active	O
pulmonary	O
tuberculosis	O
.	O

Expression	B-Gene_expression
of	O
the	O
alpha	O
-	O
chain	O
of	O
IL	O
-	O
2Ralpha	O
on	O
peripheral	O
blood	O
monocytes	O
(	O
PBM	O
)	O
was	O
induced	B-Positive_regulation
by	O
M.	O
tuberculosis	O
by	O
flow	O
cytometry	O
evaluation	O
.	O

Northern	O
analysis	O
demonstrated	O
increased	B-Positive_regulation
IL	O
-	O
2Ralpha	O
gene	O
expression	B-Gene_expression
after	O
stimulation	O
with	O
M.	O
tuberculosis	O
which	O
was	O
further	O
induced	B-Positive_regulation
by	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
.	O

The	O
IL	O
-	O
2Ralpha	O
promoter	O
containing	O
the	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
site	O
was	O
transcriptionally	O
induced	B-Positive_regulation
by	O
M.	O
tuberculosis	O
and	O
this	O
NF	O
-	O
kappaB	O
site	O
could	O
confer	O
inducibility	O
to	O
a	O
heterologous	O
herpes	O
thymidine	O
kinase	O
(	O
TK	O
)	O
promoter	O
by	O
M.	O
tuberculosis	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
revealed	O
specific	O
binding	O
of	O
nuclear	O
protein	O
to	O
the	O
NF	O
-	O
kappaB	O
site	O
upon	O
induction	O
with	O
M.	O
tuberculosis	O
.	O

Using	O
antibodies	O
against	O
the	O
p50	O
and	O
p65	O
subunits	O
of	O
NF	O
-	O
kappaB	O
in	O
EMSAs	O
,	O
the	O
involvement	O
of	O
both	O
p50	O
and	O
p65	O
proteins	O
was	O
further	O
demonstrated	O
.	O

Functional	O
expression	B-Gene_expression
of	O
the	O
IL	O
-	O
2Ralpha	O
on	O
mononuclear	O
phagocytes	O
in	O
M.	O
tuberculosis	O
infection	O
may	O
play	O
an	O
important	O
immunomodulatory	O
role	O
in	O
the	O
host	O
response	O
.	O

Regulation	B-Regulation
of	O
the	O
megakaryocytic	O
glycoprotein	O
IX	O
promoter	O
by	O
the	O
oncogenic	O
Ets	O
transcription	O
factor	O
Fli	O
-	O
1	O
.	O

Glycoprotein	O
(	O
GP	O
)	O
IX	O
is	O
a	O
subunit	O
of	O
the	O
von	O
Willebrand	O
receptor	O
,	O
GPIb-V	O
-	O
IX	O
,	O
which	O
mediates	O
adhesion	O
of	O
platelets	O
to	O
the	O
subendothelium	O
of	O
damaged	O
blood	O
vessels	O
.	O

Previous	O
characterization	O
of	O
the	O
GPIX	O
promoter	O
identified	O
a	O
functional	O
Ets	O
site	O
that	O
,	O
when	O
disrupted	O
,	O
reduced	B-Negative_regulation
promoter	O
activity	O
.	O

However	O
,	O
the	O
Ets	O
protein	O
(	O
s	O
)	O
that	O
regulated	B-Regulation
GPIX	O
promoter	O
expression	B-Gene_expression
was	O
unknown	O
.	O

In	O
this	O
study	O
,	O
transient	O
cotransfection	O
of	O
several	O
GPIX	O
promoter/reporter	O
constructs	O
into	O
293T	O
kidney	O
fibroblasts	O
with	O
a	O
Fli	O
-	O
1	O
expression	O
vector	O
shows	O
that	O
the	O
oncogenic	O
protein	O
Fli	O
-	O
1	O
can	O
transactivate	B-Positive_regulation
the	O
GPIX	O
promoter	O
when	O
an	O
intact	O
GPIX	O
Ets	O
site	O
is	O
present	O
.	O

In	O
addition	O
,	O
Fli	O
-	O
1	O
binding	B-Binding
of	O
the	O
GPIX	O
Ets	O
site	O
was	O
identified	O
in	O
antibody	O
supershift	O
experiments	O
in	O
nuclear	O
extracts	O
derived	O
from	O
hematopoietic	O
human	O
erythroleukemia	O
cells	O
.	O

Comparative	O
studies	O
showed	O
that	O
Fli	O
-	O
1	O
was	O
also	O
able	O
to	O
transactivate	B-Positive_regulation
the	O
GPIbalpha	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
the	O
GPIIb	O
promoter	O
.	O

Immunoblot	O
analysis	O
identified	B-Gene_expression
Fli	O
-	O
1	O
protein	O
in	O
lysates	O
derived	O
from	O
platelets	O
.	O

In	O
addition	O
,	O
expression	B-Gene_expression
of	O
Fli	O
-	O
1	O
was	O
identified	O
immunohistochemically	O
in	O
megakaryocytes	O
derived	O
from	O
CD34	O
(	O
+	O
)	O
cells	O
treated	O
with	O
the	O
megakaryocyte	O
differentiation	O
and	O
proliferation	O
factor	O
,	O
thrombopoietin	O
.	O

These	O
results	O
suggest	O
that	O
Fli	O
-	O
1	O
is	O
likely	O
to	O
regulate	O
lineage	O
-	O
specific	O
genes	O
during	O
megakaryocytopoiesis	O
.	O

Studies	O
into	O
the	O
effect	O
of	O
tyrosine	O
phosphatase	O
inhibitor	O
phenylarsine	O
oxide	O
on	O
NFkappaB	O
activation	O
in	O
T	O
lymphocytes	O
during	O
aging	O
:	O
evidence	O
for	O
altered	B-Regulation
IkappaB	O
-	O
alpha	O
phosphorylation	B-Phosphorylation
and	O
degradation	B-Protein_catabolism
.	O

Nuclear	O
Factor	O
kappa	O
B	O
(	O
NFkappaB	O
)	O
is	O
a	O
critical	O
regulator	O
of	O
several	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

Treatment	O
of	O
T	O
cells	O
with	O
a	O
variety	O
of	O
stimuli	O
,	O
including	O
TNF	O
-	O
alpha	O
,	O
leads	O
to	O
the	O
translocation	O
of	O
the	O
active	O
p65	O
-	O
50	O
heterodimer	O
to	O
the	O
nucleus	O
,	O
albeit	O
at	O
a	O
lower	O
level	O
in	O
T	O
cells	O
from	O
the	O
elderly	O
.	O

We	O
demonstrate	O
here	O
that	O
pretreatment	O
with	O
PAO	O
results	O
in	O
the	O
inhibition	O
of	O
NFkappaB	O
induction	O
in	O
TNF	O
-	O
alpha	O
treated	O
T	O
cells	O
,	O
suggesting	O
a	O
role	O
for	O
PAO	O
-	O
sensitive	O
phosphatase	O
in	O
the	O
activation	O
of	O
the	O
NFkappaB	O
via	O
this	O
pathway	O
in	O
human	O
T	O
cells	O
.	O

Furthermore	O
,	O
it	O
demonstrates	O
that	O
aging	O
does	O
not	O
influence	O
the	O
sensitivity	O
of	O
this	O
phosphatase	O
.	O

Treatment	O
with	O
DMP	O
prior	O
to	O
treatment	O
with	O
PAO	O
and	O
TNF	O
abolishes	O
the	O
inhibition	O
induced	O
by	O
PAO	O
,	O
in	O
T	O
cells	O
from	O
both	O
young	O
and	O
old	O
donors	O
,	O
alike	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
a	O
failure	O
to	O
degrade	B-Protein_catabolism
IkappaB	O
-	O
alpha	O
in	O
cytosols	O
of	O
TNF	O
-	O
treated	O
T	O
cells	O
pretreated	O
with	O
PAO	O
is	O
due	B-Positive_regulation
to	O
its	O
interference	B-Negative_regulation
with	O
the	O
phosphorylation	B-Phosphorylation
of	O
IkappaB	O
-	O
alpha	O
and	O
not	O
due	B-Regulation
to	O
its	O
inhibitory	O
effect	O
on	O
proteasomal	O
degradation	O
.	O

These	O
data	O
collectively	O
suggest	O
that	O
PAO	O
interferes	O
with	O
the	O
phosphorylation	B-Phosphorylation
and	O
the	O
regulated	O
degradation	B-Protein_catabolism
of	O
IkappaB	O
-	O
alpha	O
,	O
induced	O
by	O
TNF	O
,	O
without	O
affecting	O
the	O
chymotryptic	O
activity	O
of	O
the	O
proteasome	O
,	O
independent	O
of	O
age	O
.	O

A	O
novel	O
lipopolysaccharide	O
-	O
induced	O
transcription	O
factor	O
regulating	B-Regulation
tumor	O
necrosis	O
factor	O
alpha	O
gene	B-Gene_expression
expression	I-Gene_expression
:	O
molecular	O
cloning	O
,	O
sequencing	O
,	O
characterization	O
,	O
and	O
chromosomal	O
assignment	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
a	O
potent	O
stimulator	O
of	O
monocytes	O
and	O
macrophages	O
,	O
causing	B-Positive_regulation
secretion	B-Localization
of	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
other	O
inflammatory	O
mediators	O
.	O

Given	O
the	O
deleterious	O
effects	O
to	O
the	O
host	O
of	O
TNF	O
-	O
alpha	O
,	O
it	O
has	O
been	O
postulated	O
that	O
TNF	O
-	O
alpha	O
gene	B-Gene_expression
expression	I-Gene_expression
must	O
be	O
tightly	O
regulated	B-Regulation
.	O

The	O
nature	O
of	O
the	O
nuclear	O
factor	O
(	O
s	O
)	O
that	O
control	B-Regulation
TNF	O
-	O
alpha	O
gene	B-Transcription
transcription	I-Transcription
in	O
humans	O
remains	O
obscure	O
,	O
although	O
NF	O
-	O
kappaB	O
has	O
been	O
suggested	O
.	O

Our	O
previous	O
studies	O
pertaining	O
to	O
macrophage	O
response	O
to	O
LPS	O
identified	O
a	O
novel	O
DNA	O
-	O
binding	O
domain	O
located	O
from	O
-	O
550	O
to	O
-	O
487	O
in	O
the	O
human	O
TNF	O
-	O
alpha	O
promoter	O
that	O
contains	O
transcriptional	O
activity	O
,	O
but	O
lacks	O
any	O
known	O
NF-kappaB	O
-	O
binding	O
sites	O
.	O

We	O
have	O
used	O
this	O
DNA	O
fragment	O
to	O
isolate	O
and	O
purify	O
a	O
60	O
-	O
kDa	O
protein	O
binding	B-Binding
to	O
this	O
fragment	O
and	O
obtained	O
its	O
amino	O
-	O
terminal	O
sequence	O
,	O
which	O
was	O
used	O
to	O
design	O
degenerate	O
probes	O
to	O
screen	O
a	O
cDNA	O
library	O
from	O
THP	O
-	O
1	O
cells	O
.	O

A	O
novel	O
cDNA	O
clone	O
(	O
1.8	O
kb	O
)	O
was	O
isolated	O
and	O
fully	O
sequenced	O
.	O

Characterization	O
of	O
this	O
cDNA	O
clone	O
revealed	O
that	O
its	O
induction	B-Positive_regulation
was	O
dependent	B-Regulation
on	O
LPS	O
activation	O
of	O
THP	O
-	O
1	O
cells	O
;	O
hence	O
,	O
the	O
name	O
LPS	O
-	O
induced	O
TNF	O
-	O
alpha	O
factor	O
(	O
LITAF	O
)	O
.	O

Inhibition	B-Negative_regulation
of	O
LITAF	O
mRNA	O
expression	B-Transcription
in	O
THP	O
-	O
1	O
cells	O
resulted	B-Negative_regulation
in	I-Negative_regulation
a	I-Negative_regulation
reduction	I-Negative_regulation
of	O
TNF	O
-	O
alpha	O
transcripts	B-Transcription
.	O

In	O
addition	O
,	O
high	B-Positive_regulation
level	I-Positive_regulation
of	O
expression	B-Transcription
of	O
LITAF	O
mRNA	O
was	O
observed	O
predominantly	O
in	O
the	O
placenta	O
,	O
peripheral	O
blood	O
leukocytes	O
,	O
lymph	O
nodes	O
,	O
and	O
the	O
spleen	O
.	O

Finally	O
,	O
chromosomal	O
localization	O
using	O
fluorescence	O
in	O
situ	O
hybridization	O
revealed	O
that	O
LITAF	O
mapped	O
to	O
chromosome	O
16p12	O
-	O
16p13.3	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
LITAF	O
plays	O
an	O
important	O
role	B-Regulation
in	O
the	O
activation	B-Positive_regulation
of	O
the	O
human	O
TNF	O
-	O
alpha	O
gene	O
and	O
proposes	O
a	O
new	O
mechanism	O
to	O
control	B-Regulation
TNF	O
-	O
alpha	O
gene	B-Gene_expression
expression	I-Gene_expression
.	O

Engagement	O
of	O
natural	O
cytotoxicity	O
programs	O
regulates	O
AP	O
-	O
1	O
expression	O
in	O
the	O
NKL	O
human	O
NK	O
cell	O
line	O
.	O

NK	O
cell	O
cytotoxicity	O
is	O
a	O
fast	O
and	O
efficient	O
mechanism	O
of	O
target	O
cell	O
lysis	O
.	O

Using	O
transcription	O
analysis	O
,	O
such	O
as	O
multiplex	O
messenger	O
assays	O
,	O
we	O
show	O
here	O
that	O
natural	O
cytotoxicity	O
exerted	O
by	O
the	O
human	O
NKL	O
cell	O
line	O
correlates	O
with	O
mRNA	B-Positive_regulation
accumulation	I-Positive_regulation
of	O
very	O
early	O
activator	O
protein	O
(	O
AP	O
)	O
-	O
1	O
transcription	O
factor	O
genes	O
such	O
as	O
JunB	O
,	O
FosB	O
and	O
c	O
-	O
Fos	O
.	O

In	O
addition	O
,	O
DNA	O
-	O
binding	O
activities	O
of	O
Jun	O
-	O
Fos	O
heterodimers	O
were	O
observed	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
during	O
the	O
course	O
of	O
natural	O
cytotoxicity	O
.	O

Interaction	B-Binding
between	O
immunoglobulin	O
-	O
like	O
transcript	O
-	O
2/leukocyte	O
Ig	O
-	O
like	O
receptor	O
1	O
on	O
NKL	O
cells	O
and	O
HLA	O
-	O
B27	O
on	O
target	O
cells	O
leads	O
to	O
an	O
impairment	O
of	O
NKL	O
natural	O
cytotoxicity	O
,	O
which	O
correlates	O
with	O
an	O
absence	B-Negative_regulation
of	O
JunB	O
,	O
FosB	O
,	O
and	O
c	O
-	O
Fos	O
transcription	B-Transcription
,	O
as	O
well	O
as	O
an	O
absence	B-Negative_regulation
of	O
their	O
DNA	O
-	O
binding	B-Binding
activity	I-Binding
.	O

Our	O
studies	O
thus	O
indicate	O
that	O
,	O
despite	O
the	O
rapidity	O
of	O
NK	O
cell	O
-	O
mediated	O
lysis	O
,	O
AP	O
-	O
1	O
transcription	O
factor	O
is	O
activated	O
during	O
the	O
early	O
stage	O
of	O
NK	O
cell	O
cytolytic	O
programs	O
and	O
that	O
engagement	O
of	O
NK	O
cell	O
inhibitory	O
receptors	O
for	O
MHC	O
class	O
I	O
molecules	O
impairs	O
the	O
very	O
early	O
activation	O
of	O
AP	O
-	O
1	O
.	O

Human	O
cytomegalovirus	O
binding	O
to	O
human	O
monocytes	O
induces	O
immunoregulatory	O
gene	O
expression	O
.	O

To	O
continue	O
our	O
investigation	O
of	O
the	O
cellular	O
events	O
that	O
occur	O
following	O
human	O
CMV	O
(	O
HCMV	O
)	O
infection	O
,	O
we	O
focused	O
on	O
the	O
regulation	O
of	O
cellular	O
activation	O
following	O
viral	O
binding	O
to	O
human	O
monocytes	O
.	O

First	O
,	O
we	O
showed	O
that	O
viral	O
binding	O
induced	B-Positive_regulation
a	O
number	O
of	O
immunoregulatory	O
genes	O
(	O
IL	O
-	O
1beta	O
,	O
A20	O
,	O
NF-kappaB	O
-	O
p105/p50	O
,	O
and	O
IkappaBalpha	O
)	O
in	O
unactivated	O
monocytes	O
and	O
that	O
neutralizing	O
Abs	O
to	O
the	O
major	O
HCMV	O
glycoproteins	O
,	O
gB	O
(	O
UL55	O
)	O
and	O
gH	O
(	O
UL75	O
)	O
,	O
inhibited	B-Negative_regulation
the	O
induction	B-Positive_regulation
of	O
these	O
genes	O
.	O

Next	O
,	O
we	O
demonstrated	O
that	O
these	O
viral	O
ligands	O
directly	O
up	O
-	O
regulated	O
monocyte	O
gene	O
expression	O
upon	O
their	O
binding	O
to	O
their	O
appropriate	O
cellular	O
receptors	O
.	O

We	O
then	O
investigated	O
if	O
HCMV	O
binding	O
also	O
resulted	O
in	O
the	O
translation	O
and	O
secretion	O
of	O
cytokines	O
.	O

Our	O
results	O
showed	O
that	O
HCMV	O
binding	O
to	O
monocytes	O
resulted	B-Positive_regulation
in	O
the	O
production	B-Gene_expression
and	O
release	B-Localization
of	O
IL	O
-	O
1beta	O
protein	O
.	O

Because	O
these	O
induced	O
gene	O
products	O
have	O
NF	O
-	O
kappaB	O
sites	O
in	O
their	O
promoter	O
regions	O
,	O
we	O
next	O
examined	O
whether	O
there	O
was	O
an	O
up	O
-	O
regulation	O
of	O
nuclear	O
NF	O
-	O
kappaB	O
levels	O
.	O

These	O
experiments	O
showed	O
that	O
,	O
in	O
fact	O
,	O
NF	O
-	O
kappaB	O
was	O
translocated	O
to	O
the	O
nucleus	O
following	O
viral	O
binding	O
or	O
purified	O
viral	O
ligand	O
binding	O
.	O

Changes	B-Regulation
in	O
IkappaBalpha	O
levels	O
correlated	O
with	O
the	O
changes	O
in	O
NF	O
-	O
kappaB	O
translocation	O
.	O

Lastly	O
,	O
we	O
demonstrated	O
that	O
p38	O
kinase	O
activity	O
played	O
a	O
central	O
role	B-Positive_regulation
in	O
IL	O
-	O
1beta	O
production	B-Gene_expression
and	O
that	O
it	O
was	O
rapidly	O
up	O
-	O
regulated	O
following	O
infection	O
.	O

These	O
results	O
support	O
our	O
hypothesis	O
that	O
HCMV	O
initiates	O
a	O
signal	O
transduction	O
pathway	O
that	O
leads	O
to	O
monocyte	O
activation	O
and	O
pinpoints	O
a	O
potential	O
mechanism	O
whereby	O
HCMV	O
infection	O
of	O
monocytes	O
can	O
result	O
in	O
profound	O
pathogenesis	O
,	O
especially	O
in	O
chronic	O
inflammatory	O
-	O
type	O
conditions	O
.	O

Signal	O
transduction	O
pathways	O
activated	O
in	O
endothelial	O
cells	O
following	O
infection	O
with	O
Chlamydia	O
pneumoniae	O
.	O

Chlamydia	O
pneumoniae	O
is	O
an	O
important	O
respiratory	O
pathogen	O
.	O

Recently	O
,	O
its	O
presence	O
has	O
been	O
demonstrated	O
in	O
atherosclerotic	O
lesions	O
.	O

In	O
this	O
study	O
,	O
we	O
characterized	O
C.	O
pneumoniae	O
-	O
mediated	O
activation	O
of	O
endothelial	O
cells	O
and	O
demonstrated	O
an	O
enhanced	O
expression	O
of	O
endothelial	O
adhesion	O
molecules	O
followed	O
by	O
subsequent	O
rolling	O
,	O
adhesion	O
,	O
and	O
transmigration	O
of	O
leukocytes	O
(	O
monocytes	O
,	O
granulocytes	O
)	O
.	O

These	O
effects	O
were	O
blocked	O
by	O
mAbs	O
against	O
endothelial	O
and/or	O
leukocyte	O
adhesion	O
molecules	O
(	O
beta1	O
and	O
beta2	O
integrins	O
)	O
.	O

Additionally	O
,	O
activation	O
of	O
different	O
signal	O
transduction	O
pathways	O
in	O
C.	O
pneumoniae	O
-	O
infected	O
endothelial	O
cells	O
was	O
shown	O
:	O
protein	O
tyrosine	O
phosphorylation	O
,	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
phosphorylated	O
p42/p44	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
,	O
and	O
NF	O
-	O
kappaB	O
activation/translocation	O
occurred	B-Positive_regulation
within	O
10	O
-	O
15	O
min	O
.	O

Increased	B-Positive_regulation
mRNA	O
and	O
surface	O
expression	B-Transcription
of	O
E	O
-	O
selectin	O
,	O
ICAM	O
-	O
1	O
,	O
and	O
VCAM	O
-	O
1	O
were	O
noted	O
within	O
hours	O
.	O

Thus	O
,	O
C.	O
pneumoniae	O
triggers	O
a	O
cascade	O
of	O
events	O
that	O
could	O
lead	O
to	O
endothelial	O
activation	O
,	O
inflammation	O
,	O
and	O
thrombosis	O
,	O
which	O
in	O
turn	O
may	O
result	O
in	O
or	O
may	O
promote	O
atherosclerosis	O
.	O

Extracellular	O
-	O
regulated	O
kinase	O
1/2	O
,	O
Jun	O
N	O
-	O
terminal	O
kinase	O
,	O
and	O
c	O
-	O
Jun	O
are	O
involved	O
in	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	B-Positive_regulation
IL	O
-	O
6	O
expression	B-Gene_expression
in	O
human	O
monocytes	O
.	O

In	O
the	O
present	O
study	O
we	O
investigated	O
the	O
possible	O
involvement	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
family	O
members	O
extracellular	O
-	O
regulated	O
kinase	O
1/2	O
(	O
ERK1/2	O
)	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
in	O
mediating	B-Positive_regulation
IL	O
-	O
6	O
gene	O
expression	B-Gene_expression
in	O
human	O
monocytes	O
,	O
in	O
particular	O
their	O
role	O
in	O
enhancing	O
NF	O
-	O
kappa	O
B	O
activity	O
.	O

Freshly	O
isolated	O
monocytes	O
treated	O
with	O
the	O
protein	O
phosphatase	O
inhibitor	O
okadaic	O
acid	O
secreted	B-Gene_expression
high	B-Positive_regulation
levels	I-Positive_regulation
of	O
IL	O
-	O
6	O
protein	O
,	O
which	O
coincided	O
with	O
enhanced	O
binding	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
as	O
well	O
as	O
with	O
phosphorylation	B-Phosphorylation
and	O
activation	B-Positive_regulation
of	O
the	O
ERK1/2	O
and	O
JNK	O
proteins	O
.	O

The	O
ERK	O
pathway	O
-	O
specific	O
inhibitor	O
PD98059	O
inhibited	B-Negative_regulation
IL	O
-	O
6	O
secretion	B-Localization
from	O
monocytes	O
.	O

Transient	O
overexpression	O
of	O
inactive	O
mutants	O
of	O
either	O
Raf	O
-	O
1	O
or	O
JNK1	O
showed	O
that	O
both	O
pathways	O
were	O
involved	O
in	O
kappa	O
B	O
-	O
dependent	B-Regulation
IL	O
-	O
6	O
promoter	O
activity	O
.	O

By	O
using	O
PD98059	O
,	O
we	O
demonstrated	O
that	O
the	O
Raf1/MEK1/ERK1/2	O
pathway	O
did	O
not	O
affect	O
the	O
DNA	O
binding	O
of	O
NF	O
-	O
kappa	O
B	O
but	O
,	O
rather	O
,	O
acted	O
at	O
the	O
level	O
of	O
transcriptional	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Interestingly	O
,	O
it	O
was	O
shown	O
that	O
NF	O
-	O
kappa	O
B	O
-	O
mediated	O
gene	O
transcription	B-Transcription
,	O
both	O
in	O
the	O
context	O
of	O
the	O
IL	O
-	O
6	O
promoter	O
as	O
well	O
as	O
on	O
its	O
own	O
,	O
was	O
dependent	B-Positive_regulation
on	O
both	O
serine	O
kinase	O
activity	O
and	O
interaction	B-Binding
with	O
c	O
-	O
Jun	O
protein	O
.	O

We	O
conclude	O
that	O
okadaic	O
acid	O
-	O
induced	B-Positive_regulation
IL	O
-	O
6	O
gene	O
expression	B-Gene_expression
is	O
at	O
least	O
partly	O
mediated	B-Positive_regulation
through	O
the	O
ERK1/2	O
and	O
JNK	O
pathway	O
-	O
dependent	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
transcriptional	O
capacity	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
JNK	O
pathway	O
may	O
regulate	O
NF	O
-	O
kappa	O
B	O
-	O
mediated	O
gene	O
transcription	O
through	O
its	O
phosphorylation	B-Phosphorylation
and	O
activation	B-Positive_regulation
of	O
c	O
-	O
Jun	O
.	O

Differential	O
induction	B-Positive_regulation
of	O
interferon	O
(	O
IFN	O
)	O
-	O
inducible	O
protein	O
10	O
following	B-Positive_regulation
differentiation	O
of	O
a	O
monocyte	O
,	O
macrophage	O
cell	O
lineage	O
is	O
related	O
to	O
the	O
changes	O
of	O
nuclear	O
proteins	O
bound	O
to	O
IFN	O
stimulus	O
response	O
element	O
and	O
kappaB	O
sites	O
.	O

We	O
examined	O
chemokine	O
gene	O
expression	O
following	O
the	O
differentiation	O
of	O
a	O
monocyte	O
,	O
macrophage	O
cell	O
lineage	O
.	O

The	O
human	O
monoblastic	O
cell	O
line	O
,	O
U937	O
was	O
differentiated	O
to	O
macrophages	O
by	O
the	O
treatment	O
with	O
either	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
,	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
or	O
vitamin	O
D3	O
(	O
VitD3	O
)	O
.	O

The	O
gene	B-Gene_expression
expression	I-Gene_expression
of	O
interferon	O
(	O
IFN	O
)	O
-	O
inducible	O
protein	O
10	O
(	O
IP	O
-	O
10	O
)	O
(	O
a	O
CXC	O
chemokine	O
)	O
was	O
markedly	O
augmented	B-Positive_regulation
by	O
the	O
IFNgamma	O
treatment	O
in	O
PMA	O
-	O
or	O
RA	O
-	O
differentiated	O
U937	O
cells	O
,	O
but	O
only	O
marginally	O
in	O
undifferentiated	O
or	O
VitD3	O
-	O
treated	O
cells	O
.	O

In	O
contrast	O
,	O
another	O
inducible	O
gene	O
expression	B-Gene_expression
of	O
monocyte	O
chemotactic	O
protein	O
-	O
1	O
(	O
a	O
CC	O
chemokine	O
)	O
and	O
the	O
activation	O
of	O
the	O
transcriptional	O
factor	O
(	O
FcRFgamma	O
)	O
bound	O
to	O
the	O
gamma	O
response	O
region	O
were	O
similarly	O
or	O
less	O
abundantly	O
induced	B-Positive_regulation
by	O
IFNgamma	O
treatment	O
in	O
PMA	O
-	O
or	O
RA	O
-	O
differentiated	O
U937	O
cells	O
,	O
indicating	O
that	O
increased	B-Positive_regulation
IP	O
-	O
10	O
mRNA	O
induction	B-Positive_regulation
was	O
not	O
due	B-Positive_regulation
to	O
the	O
augmented	O
ability	O
of	O
the	O
cells	O
to	O
respond	O
to	O
the	O
presence	O
of	O
IFNgamma	O
.	O

Increased	B-Positive_regulation
expression	B-Transcription
of	O
IFNgamma	O
-	O
induced	B-Positive_regulation
IP	O
-	O
10	O
mRNA	O
following	O
the	O
differentiation	O
of	O
U937	O
cells	O
was	O
mediated	B-Positive_regulation
largely	O
by	O
augmented	B-Positive_regulation
transcriptional	B-Positive_regulation
activity	I-Positive_regulation
of	O
the	O
gene	O
and	O
was	O
related	O
to	O
differentiation	O
-	O
dependent	O
changes	O
of	O
the	O
proteins	O
bound	O
to	O
IFN	O
stimulus	O
response	O
element	O
(	O
ISRE	O
)	O
and	O
kB	O
sites	O
,	O
suggesting	O
that	O
these	O
nuclear	O
proteins	O
may	O
determine	B-Regulation
the	O
IP	O
-	O
10	O
mRNA	O
inducibility	B-Positive_regulation
by	O
IFNgamma	O
.	O

Fludarabine	O
-	O
induced	O
immunosuppression	O
is	O
associated	O
with	O
inhibition	O
of	O
STAT1	O
signaling	O
.	O

Fludarabine	O
is	O
a	O
nucleoside	O
analog	O
used	O
in	O
the	O
treatment	O
of	O
hematologic	O
malignancies	O
that	O
can	O
induce	O
severe	O
and	O
prolonged	O
immunosuppression	O
.	O

Although	O
it	O
can	O
be	O
incorporated	O
into	O
the	O
DNA	O
of	O
dividing	O
cells	O
,	O
fludarabine	O
is	O
also	O
a	O
potent	O
inhibitor	O
of	O
cells	O
with	O
a	O
low	O
growth	O
fraction	O
,	O
thus	O
it	O
must	O
have	O
other	O
mechanisms	O
of	O
action	O
.	O

STAT1	O
,	O
which	O
is	O
activated	B-Positive_regulation
in	O
response	O
to	O
many	O
lymphocyte	O
-	O
activating	O
cytokines	O
including	O
the	O
interferons	O
,	O
is	O
essential	O
for	O
cell	O
-	O
mediated	O
immunity	O
,	O
as	O
the	O
absence	B-Negative_regulation
of	O
this	O
protein	O
is	O
associated	O
with	O
prominent	O
defects	O
in	O
the	O
ability	O
to	O
control	O
viral	O
infections	O
.	O

Here	O
we	O
show	O
that	O
fludarabine	O
,	O
but	O
not	O
the	O
immunosuppressant	O
cyclosporine	O
A	O
,	O
inhibits	B-Negative_regulation
the	O
cytokine	O
-	O
induced	O
activation	B-Positive_regulation
of	O
STAT1	O
and	O
STAT1	O
-	O
dependent	O
gene	O
transcription	O
in	O
normal	O
resting	O
or	O
activated	O
lymphocytes	O
.	O

Fludarabine	O
caused	B-Positive_regulation
a	O
specific	O
depletion	B-Negative_regulation
of	O
STAT1	O
protein	O
(	O
and	O
mRNA	O
)	O
but	O
not	O
of	O
other	O
STATs	O
.	O

This	O
loss	B-Negative_regulation
of	O
STAT1	O
was	O
also	O
seen	O
in	O
cells	O
from	O
patients	O
treated	O
with	O
fludarabine	O
in	O
vivo	O
.	O

Brief	O
exposure	O
to	O
fludarabine	O
led	B-Positive_regulation
to	O
a	O
sustained	O
loss	B-Negative_regulation
of	O
STAT1	O
,	O
analogous	O
to	O
the	O
prolonged	O
period	O
of	O
immunosuppression	O
induced	O
by	O
exposure	O
to	O
the	O
drug	O
in	O
vivo	O
.	O

Thus	O
,	O
STAT1	O
may	O
be	O
a	O
useful	O
target	O
in	O
the	O
development	O
of	O
new	O
immunosuppressive	O
and	O
antineoplastic	O
agents	O
.	O

Suppressive	O
effects	O
of	O
anti	O
-	O
inflammatory	O
agents	O
on	O
human	O
endothelial	O
cell	O
activation	O
and	O
induction	O
of	O
heat	O
shock	O
proteins	O
.	O

BACKGROUND	O
:	O
Studies	O
from	O
our	O
laboratory	O
have	O
shown	O
that	O
the	O
earliest	O
stages	O
of	O
atherosclerosis	O
may	O
be	O
mediated	O
by	O
an	O
autoimmune	O
reaction	O
against	O
heat	O
shock	O
protein	O
60	O
(	O
Hsp60	O
)	O
.	O

The	O
interactions	O
of	O
Hsp60	O
-	O
specific	O
T	O
cells	O
with	O
arterial	O
endothelial	O
cells	O
(	O
EC	O
)	O
require	O
expression	B-Gene_expression
of	O
both	O
Hsp60	O
and	O
certain	O
adhesion	O
molecules	O
shown	O
to	O
be	O
induced	O
simultaneously	O
in	O
EC	O
by	O
mechanical	O
and	O
other	O
types	O
of	O
stress	O
.	O

Recently	O
,	O
it	O
was	O
shown	O
that	O
suppression	O
of	O
T	O
cell	O
-	O
mediated	O
immune	O
responses	O
by	O
cyclosporin	O
A	O
(	O
CyA	O
)	O
enhanced	O
atherosclerotic	O
lesion	O
formation	O
in	O
mice	O
.	O

In	O
contrast	O
,	O
aspirin	O
was	O
found	O
to	O
lower	O
the	O
risk	O
of	O
myocardial	O
infarction	O
in	O
men	O
.	O

These	O
conflicting	O
observations	O
may	O
be	O
due	O
to	O
different	O
effects	O
of	O
anti	O
-	O
inflammatory	O
agents	O
on	O
adhesion	O
molecule	O
and	O
Hsp	O
expression	O
in	O
EC	O
,	O
respectively	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
CyA	O
,	O
aspirin	O
,	O
and	O
indomethacin	O
on	O
T	O
cell	O
proliferation	O
using	O
a	O
proliferation	O
assay	O
.	O

To	O
explore	O
the	O
expression	B-Gene_expression
of	O
adhesion	O
molecules	O
,	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
(	O
MCP	O
-	O
1	O
)	O
,	O
and	O
Hsp60	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
,	O
Northern	O
blot	O
analyses	O
were	O
used	O
.	O

To	O
examine	O
the	O
activation	B-Positive_regulation
status	O
of	O
the	O
transcription	O
factors	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
and	O
heat	O
shock	O
factor	O
-	O
1	O
(	O
HSF	O
-	O
1	O
)	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
were	O
performed	O
.	O

RESULTS	O
:	O
With	O
the	O
exception	O
of	O
indomethacin	O
,	O
the	O
used	O
immunosuppressive	O
and	O
anti	O
-	O
inflammatory	O
agents	O
significantly	O
inhibited	O
T	O
cell	O
proliferation	O
in	O
response	O
to	O
influenza	O
virus	O
antigen	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Interestingly	O
,	O
CyA	O
and	O
indomethacin	O
did	O
not	O
suppress	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
-	O
induced	O
adhesion	O
molecule	O
expression	O
on	O
HUVECs	O
,	O
whereas	O
aspirin	O
had	O
an	O
inhibitory	O
effect	O
.	O

These	O
observations	O
correlated	O
with	O
the	O
modulation	O
of	O
NF	O
-	O
kappaB	O
activity	O
in	O
EC	O
.	O

All	O
agents	O
tested	O
induced	B-Positive_regulation
expression	B-Gene_expression
of	O
Hsp60	O
6	O
hr	O
after	O
application	O
.	O

In	O
addition	O
,	O
aspirin	O
and	O
indomethacin	O
,	O
but	O
not	O
CyA	O
,	O
induced	B-Positive_regulation
Hsp70	O
expression	B-Gene_expression
in	O
HUVECs	O
that	O
correlated	O
with	O
induction	B-Positive_regulation
of	O
HSF	O
-	O
1	O
activity	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
show	O
that	O
the	O
tested	O
agents	O
(	O
except	O
indomethacin	O
)	O
are	O
inhibitors	O
of	O
the	O
T	O
cell	O
-	O
mediated	O
immune	O
response	O
,	O
as	O
expected	O
,	O
that	O
aspirin	O
is	O
an	O
effective	O
suppressor	O
of	O
adhesion	O
molecule	O
expression	O
,	O
and	O
that	O
all	O
three	O
agents	O
can	O
induce	B-Positive_regulation
Hsp60	O
in	O
HUVECs	O
.	O

These	O
data	O
provide	O
the	O
molecular	O
basis	O
for	O
the	O
notion	O
that	O
(	O
1	O
)	O
part	O
of	O
the	O
anti	O
-	O
atherogenic	O
effect	O
of	O
aspirin	O
may	O
be	O
due	O
to	O
the	O
prevention	O
of	O
the	O
adhesion	O
of	O
sensitized	O
T	O
cells	O
to	O
stressed	O
EC	O
;	O
(	O
2	O
)	O
that	O
part	O
of	O
the	O
atherosclerosis	O
-	O
promoting	O
effect	O
of	O
CyA	O
may	O
be	O
due	O
to	O
its	O
potential	O
as	O
an	O
inducer	B-Positive_regulation
of	O
Hsp60	O
expression	B-Gene_expression
and	O
its	O
inability	O
to	O
down	O
-	O
regulate	O
adhesion	O
molecule	O
expression	O
on	O
EC	O
;	O
and	O
(	O
3	O
)	O
that	O
down	B-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
of	O
MCP	O
-	O
1	O
expression	B-Gene_expression
by	O
aspirin	O
may	O
result	O
in	O
decreased	O
recruitment	O
of	O
monocytes	O
into	O
the	O
arterial	O
intima	O
beneath	O
stressed	O
EC	O
.	O

Amelioration	O
of	O
rat	O
cerulein	O
pancreatitis	O
by	O
guamerin	O
-	O
derived	O
peptide	O
,	O
a	O
novel	O
elastase	O
inhibitor	O
.	O

Increased	O
activity	O
of	O
various	O
proteases	O
is	O
observed	O
in	O
both	O
human	O
and	O
experimental	O
pancreatitis	O
;	O
however	O
,	O
the	O
information	O
on	O
the	O
effects	O
of	O
specific	O
protease	O
inhibitors	O
on	O
the	O
disease	O
is	O
limited	O
.	O

In	O
this	O
study	O
we	O
show	O
that	O
a	O
novel	O
elastase	O
inhibitor	O
,	O
guamerin	O
-	O
derived	O
synthetic	O
peptide	O
(	O
GDSP	O
)	O
,	O
improves	O
the	O
parameters	O
of	O
cerulein	O
-	O
induced	O
acute	O
pancreatitis	O
in	O
the	O
rat	O
.	O

The	O
effects	O
of	O
GDSP	O
on	O
pancreatic	O
weight	O
,	O
serum	O
amylase	O
and	O
lipase	O
,	O
morphologic	O
changes	O
in	O
the	O
pancreas	O
,	O
neutrophil	O
infiltration	O
,	O
and	O
nuclear	O
factor	O
KB	O
(	O
NF	O
-	O
KB	O
)	O
activation	O
were	O
measured	O
in	O
rats	O
infused	O
with	O
supramaximal	O
dose	O
of	O
cerulein	O
(	O
5	O
(	O
g/kg/h	O
)	O
for	O
6	O
h	O
.	O

The	O
effects	O
of	O
GDSP	O
were	O
also	O
measured	O
on	O
superoxide	O
formation	O
by	O
activated	O
human	O
neutrophils	O
.	O

The	O
effects	O
of	O
GDSP	O
were	O
compared	O
with	O
those	O
of	O
another	O
elastase	O
inhibitor	O
,	O
elastatinal	O
.	O

GDSP	O
significantly	O
inhibited	O
edema	O
formation	O
,	O
neutrophil	O
infiltration	O
,	O
acinar	O
cell	O
damage	O
,	O
and	O
plasma	O
lipase	O
and	O
amylase	O
increases	O
caused	O
by	O
cerulein	O
.	O

GDSP	O
also	O
completely	O
inhibited	O
superoxide	O
formation	O
in	O
the	O
human	O
neutrophils	O
stimulated	O
by	O
N-formyl-methionine-leucine-phenyl	O
-	O
alanine	O
(	O
fMLP	O
)	O
or	O
12-O-tetradecanoylphorbol-13	O
-	O
acetate	O
(	O
TPA	O
)	O
.	O

Elastatinal	O
had	O
some	O
of	O
the	O
same	O
effects	O
as	O
GDSP	O
but	O
was	O
less	O
potent	O
and	O
effective	O
.	O

These	O
results	O
demonstrate	O
a	O
beneficial	O
effect	O
of	O
GDSP	O
,	O
a	O
novel	O
specific	O
elastase	O
inhibitor	O
,	O
on	O
the	O
development	O
of	O
rat	O
cerulein	O
pancreatitis	O
.	O

Inhibition	O
of	O
T	O
cell	O
signaling	O
by	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
-	O
targeted	O
hematopoietic	O
tyrosine	O
phosphatase	O
(	O
HePTP	O
)	O
.	O

Activation	O
of	O
T	O
lymphocytes	O
to	O
produce	O
cytokines	O
is	O
regulated	O
by	O
the	O
counterbalance	O
of	O
protein	O
-	O
tyrosine	O
kinases	O
and	O
protein	O
-	O
tyrosine	O
phosphatases	O
,	O
many	O
of	O
which	O
have	O
a	O
high	O
degree	O
of	O
substrate	O
specificity	O
because	O
of	O
physical	O
association	O
with	O
their	O
targets	O
.	O

Overexpression	B-Gene_expression
of	O
hematopoietic	O
protein	O
-	O
tyrosine	O
phosphatase	O
(	O
HePTP	O
)	O
results	O
in	O
suppression	O
of	O
T	O
lymphocyte	O
activation	O
as	O
measured	O
by	O
T	O
cell	O
antigen	O
receptor	O
-	O
induced	O
activation	B-Positive_regulation
of	O
transcription	O
factors	O
binding	B-Binding
to	O
the	O
5	O
'	O
promoter	O
of	O
the	O
interleukin	O
-	O
2	O
gene	O
.	O

Efforts	O
to	O
pinpoint	O
the	O
exact	O
site	O
of	O
action	O
and	O
specificity	O
of	O
HePTP	O
in	O
the	O
signaling	O
cascade	O
revealed	O
that	O
HePTP	O
acts	B-Regulation
directly	O
on	O
the	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinases	O
Erk1	O
and	O
2	O
and	O
consequently	O
reduces	B-Negative_regulation
the	O
magnitude	O
and	O
duration	O
of	O
their	O
catalytic	B-Positive_regulation
activation	I-Positive_regulation
in	O
intact	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
HePTP	O
had	O
no	O
effects	O
on	O
N	O
-	O
terminal	O
c	O
-	O
Jun	O
kinase	O
or	O
on	O
events	O
upstream	O
of	O
the	O
MAP	O
kinases	O
.	O

The	O
specificity	O
of	O
HePTP	O
correlated	O
with	O
its	O
physical	B-Binding
association	I-Binding
through	O
its	O
noncatalytic	O
N	O
terminus	O
with	O
Erk	O
and	O
another	O
MAP	O
kinase	O
,	O
p38	O
,	O
but	O
not	O
Jnk	O
or	O
other	O
proteins	O
.	O

We	O
propose	O
that	O
HePTP	O
plays	O
a	O
negative	O
role	O
in	O
antigen	O
receptor	O
signaling	O
by	O
specifically	O
regulating	O
MAP	O
kinases	O
in	O
the	O
cytosol	O
and	O
at	O
early	O
time	O
points	O
of	O
T	O
cell	O
activation	O
before	O
the	O
activation	O
-	O
induced	O
expression	O
of	O
nuclear	O
dual	O
-	O
specific	O
MAP	O
kinase	O
phosphatases	O
.	O

Angiotensin	O
II	O
activates	O
the	O
proinflammatory	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappaB	O
in	O
human	O
monocytes	O
.	O

The	O
renin	O
-	O
angiotensin	O
system	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
atherosclerosis	O
.	O

A	O
common	O
feature	O
of	O
all	O
stages	O
of	O
atherosclerosis	O
is	O
inflammation	O
of	O
the	O
vessel	O
wall	O
.	O

The	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
participates	O
in	O
most	O
signaling	O
pathways	O
involved	O
in	O
inflammation	O
.	O

This	O
study	O
therefore	O
examined	O
the	O
effect	O
of	O
angiotensin	O
(	O
ANG	O
)	O
II	O
on	O
NF	O
-	O
kappaB	O
activation	O
in	O
monocytic	O
cells	O
,	O
a	O
major	O
cellular	O
component	O
of	O
human	O
atheroma	O
,	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

ANG	O
II	O
,	O
like	O
TNFalpha	O
,	O
caused	O
rapid	O
activation	O
of	O
NF	O
-	O
kappaB	O
in	O
human	O
mononuclear	O
cells	O
isolated	O
from	O
peripheral	O
blood	O
by	O
Ficoll	O
density	O
gradient	O
.	O

This	O
ANG	O
II	O
effect	O
was	O
blocked	O
by	O
the	O
angiotensin	O
AT1	O
receptor	O
antagonist	O
losartan	O
.	O

Specificity	O
of	O
ANG	O
II	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
was	O
ascertained	O
by	O
supershift	O
and	O
competition	O
experiments	O
.	O

Moreover	O
,	O
ANG	O
II	O
stimulated	O
NF	O
-	O
kappaB	O
activation	O
in	O
human	O
monocytes	O
,	O
but	O
not	O
in	O
lymphocytes	O
from	O
the	O
same	O
preparation	O
.	O

Together	O
,	O
the	O
data	O
demonstrate	O
the	O
ability	O
of	O
the	O
vasoactive	O
peptide	O
ANG	O
II	O
to	O
activate	O
inflammatory	O
pathways	O
in	O
human	O
monocytes	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

SHP2	O
-	O
interacting	O
transmembrane	O
adaptor	O
protein	O
(	O
SIT	O
)	O
,	O
a	O
novel	O
disulfide	O
-	O
linked	O
dimer	O
regulating	O
human	O
T	O
cell	O
activation	O
.	O

T	O
lymphocytes	O
express	O
several	O
low	O
molecular	O
weight	O
transmembrane	O
adaptor	O
proteins	O
that	O
recruit	O
src	O
homology	O
(	O
SH	O
)	O
2	O
domain	O
-	O
containing	O
intracellular	O
molecules	O
to	O
the	O
cell	O
membrane	O
via	O
tyrosine	O
-	O
based	O
signaling	O
motifs	O
.	O

We	O
describe	O
here	O
a	O
novel	O
molecule	O
of	O
this	O
group	O
termed	O
SIT	O
(	O
SHP2	O
interacting	O
transmembrane	O
adaptor	O
protein	O
)	O
.	O

SIT	O
is	O
a	O
disulfide	O
-	O
linked	O
homodimeric	O
glycoprotein	O
that	O
is	O
expressed	B-Gene_expression
in	O
lymphocytes	O
.	O

After	O
tyrosine	O
phosphorylation	B-Phosphorylation
by	B-Positive_regulation
src	O
and	O
possibly	O
syk	O
protein	O
tyrosine	O
kinases	O
SIT	O
recruits	O
the	O
SH2	O
domain	O
-	O
containing	O
tyrosine	O
phosphatase	O
SHP2	O
via	O
an	O
immunoreceptor	O
tyrosine	O
-	O
based	O
inhibition	O
motif	O
.	O

Overexpression	B-Gene_expression
of	O
SIT	O
in	O
Jurkat	O
cells	O
downmodulates	O
T	O
cell	O
receptor	O
-	O
and	O
phytohemagglutinin	O
-	O
mediated	O
activation	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
by	O
interfering	O
with	O
signaling	O
processes	O
that	O
are	O
probably	O
located	O
upstream	O
of	O
activation	O
of	O
phospholipase	O
C	O
.	O

However	O
,	O
binding	B-Binding
of	O
SHP2	O
to	O
SIT	O
is	O
not	O
required	O
for	O
inhibition	O
of	O
NF	O
-	O
AT	O
induction	O
,	O
suggesting	O
that	O
SIT	O
not	O
only	O
regulates	O
NF	O
-	O
AT	O
activity	O
but	O
also	O
controls	O
NF	O
-	O
AT	O
unrelated	O
pathways	O
of	O
T	O
cell	O
activation	O
involving	O
SHP2	O
.	O

GrpL	O
,	O
a	O
Grb2	O
-	O
related	O
adaptor	O
protein	O
,	O
interacts	B-Binding
with	O
SLP	O
-	O
76	O
to	O
regulate	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
activation	O
.	O

Propagation	O
of	O
signals	O
from	O
the	O
T	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
involves	O
a	O
number	O
of	O
adaptor	O
molecules	O
.	O

SH2	O
domain	O
-	O
containing	O
protein	O
76	O
(	O
SLP	O
-	O
76	O
)	O
interacts	B-Binding
with	O
the	O
guanine	O
nucleotide	O
exchange	O
factor	O
Vav	O
to	O
activate	O
the	O
nuclear	O
factor	O
of	O
activated	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
,	O
and	O
its	O
expression	B-Gene_expression
is	O
required	O
for	O
normal	O
T	O
cell	O
development	O
.	O

We	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
novel	O
Grb2	O
-	O
like	O
adaptor	O
molecule	O
designated	O
as	O
Grb2	O
-	O
related	O
protein	O
of	O
the	O
lymphoid	O
system	O
(	O
GrpL	O
)	O
.	O

Expression	B-Gene_expression
of	O
GrpL	O
is	O
restricted	O
to	O
hematopoietic	O
tissues	O
,	O
and	O
it	O
is	O
distinguished	O
from	O
Grb2	O
by	O
having	O
a	O
proline	O
-	O
rich	O
region	O
.	O

GrpL	O
can	O
be	O
coimmunoprecipitated	B-Binding
with	O
SLP	O
-	O
76	O
but	O
not	O
with	O
Sos1	O
or	O
Sos2	O
from	O
Jurkat	O
cell	O
lysates	O
.	O

In	O
contrast	O
,	O
Grb2	O
can	O
be	O
coimmunoprecipitated	B-Binding
with	O
Sos1	O
and	O
Sos2	O
but	O
not	O
with	O
SLP	O
-	O
76	O
.	O

Moreover	O
,	O
tyrosine	O
-	O
phosphorylated	B-Phosphorylation
LAT/pp36/38	O
in	O
detergent	O
lysates	O
prepared	O
from	O
anti	O
-	O
CD3	O
stimulated	O
T	O
cells	O
associated	B-Binding
with	O
Grb2	O
but	O
not	O
GrpL	O
.	O

These	O
data	O
reveal	O
the	O
presence	O
of	O
distinct	O
complexes	O
involving	O
GrpL	O
and	O
Grb2	O
in	O
T	O
cells	O
.	O

A	O
functional	O
role	O
of	O
the	O
GrpL-SLP	O
-	O
76	O
complex	O
is	O
suggested	O
by	O
the	O
ability	O
of	O
GrpL	O
to	O
act	O
alone	O
or	O
in	O
concert	O
with	O
SLP	O
-	O
76	O
to	O
augment	O
NF	O
-	O
AT	O
activation	O
in	O
Jurkat	O
T	O
cells	O
.	O

Unexpected	O
and	O
coordinated	O
expression	B-Gene_expression
of	O
Spi	O
-	O
1	O
,	O
Fli	O
-	O
1	O
,	O
and	O
megakaryocytic	O
genes	O
in	O
four	O
Epo	O
-	O
dependent	O
cell	O
lines	O
established	O
from	O
transgenic	O
mice	O
displaying	O
erythroid	O
-	O
specific	O
expression	O
of	O
a	O
thermosensitive	O
SV40	O
T	O
antigen	O
.	O

Most	O
erythroleukemic	O
cell	O
lines	O
established	O
in	O
vitro	O
coexpress	O
erythrocytic	O
and	O
megakaryocytic	O
markers	O
that	O
often	O
are	O
associated	O
with	O
expression	B-Gene_expression
of	O
Spi	O
-	O
1	O
and/or	O
Fli	O
-	O
1	O
transcription	O
factors	O
known	O
as	O
transactivators	O
of	O
megakaryocyte	O
-	O
specific	O
promoters	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
possibility	O
of	O
establishing	O
new	O
cell	O
lines	O
keeping	O
strictly	O
erythroid	O
-	O
specific	O
properties	O
in	O
vitro	O
through	O
the	O
targeted	O
and	O
conditional	O
immortalization	O
of	O
erythrocytic	O
progenitors	O
.	O

For	O
that	O
purpose	O
,	O
we	O
established	O
several	O
lines	O
of	O
transgenic	O
mice	O
displaying	O
erythroid	O
-	O
specific	O
expression	O
of	O
a	O
thermosensitive	O
SV40	O
T	O
antigen	O
.	O

As	O
expected	O
,	O
these	O
transgenic	O
mice	O
developed	O
splenomegaly	O
due	O
to	O
the	O
massive	O
amplification	O
of	O
Ter	O
119	O
positive	O
erythroid	O
nucleated	O
cells	O
expressing	O
T	O
antigen	O
.	O

Despite	O
this	O
drastic	O
effect	O
in	O
vivo	O
,	O
the	O
in	O
vitro	O
immortalization	O
of	O
erythropoietin	O
-	O
dependent	O
erythroid	O
progenitors	O
unexpectedly	O
occurred	O
at	O
low	O
frequency	O
,	O
and	O
all	O
four	O
cell	O
lines	O
established	O
expressed	B-Gene_expression
both	O
erythrocytic	O
(	O
globins	O
)	O
and	O
megakaryocytic	O
markers	O
(	O
glycoprotein	O
IIb	O
,	O
platelet	O
factor	O
4	O
)	O
as	O
well	O
as	O
Spi	O
-	O
1	O
and	O
Fli	O
-	O
1	O
transcripts	O
at	O
permissive	O
temperature	O
.	O

Switching	O
the	O
cells	O
to	O
the	O
nonpermissive	O
temperature	O
led	O
to	O
a	O
marked	O
increase	O
in	O
globin	O
gene	O
expression	O
and	O
concomitant	O
decrease	B-Negative_regulation
in	O
expression	B-Gene_expression
of	O
Spi	O
-	O
1	O
,	O
Fli	O
-	O
1	O
,	O
and	O
megakaryocytic	O
genes	O
in	O
an	O
erythropoietin	O
-	O
dependent	B-Positive_regulation
manner	O
.	O

Interestingly	O
,	O
enhanced	O
expression	B-Gene_expression
of	O
Spi	O
-	O
1	O
and	O
Fli	O
-	O
1	O
genes	O
already	O
was	O
detected	O
in	O
the	O
Ter	O
119	O
positive	O
cell	O
population	O
of	O
transgenic	O
mice	O
spleen	O
in	O
vivo	O
.	O

However	O
,	O
like	O
normal	O
Ter	O
119	O
erythroid	O
cells	O
,	O
these	O
Ter	O
119	O
positive	O
cells	O
from	O
transgenic	O
mice	O
still	O
expressed	B-Transcription
high	O
levels	O
of	O
beta	O
-	O
globin	O
and	O
very	O
low	O
or	O
undetectable	O
glycoprotein	O
IIb	O
and	O
platelet	O
factor	O
4	O
megakaryocytic	O
transcripts	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
the	O
unexpected	O
expression	O
of	O
megakaryocytic	O
genes	O
is	O
a	O
specific	O
property	O
of	O
immortalized	O
cells	O
that	O
can	O
not	O
be	O
explained	O
only	O
by	O
enhanced	B-Positive_regulation
expression	B-Gene_expression
of	O
Spi	O
-	O
1	O
and/or	O
Fli	O
-	O
1	O
genes	O
.	O

LPS	O
-	O
Induced	B-Positive_regulation
NF	O
-	O
kappaB	O
activation	O
and	O
TNF	O
-	O
alpha	O
release	B-Localization
in	O
human	O
monocytes	O
are	O
protein	O
tyrosine	O
kinase	O
dependent	O
and	O
protein	O
kinase	O
C	O
independent	O
.	O

BACKGROUND	O
:	O
Tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
is	O
an	O
important	O
mediator	O
of	O
septic	O
shock	O
.	O

Endotoxin	O
(	O
LPS	O
)	O
signal	O
transduction	O
in	O
human	O
monocytes	O
leads	B-Positive_regulation
to	O
activation	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
and	O
TNF	O
-	O
alpha	O
release	B-Localization
.	O

Previous	O
studies	O
have	O
implicated	O
activation	O
of	O
both	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
and	O
protein	O
tyrosine	O
kinases	O
(	O
PTK	O
)	O
in	O
LPS	O
-	O
induced	B-Positive_regulation
NF	O
-	O
kappaB	O
activation	O
and	O
TNF	O
-	O
alpha	O
production	B-Gene_expression
.	O

We	O
hypothesized	O
that	O
inhibition	O
of	O
either	O
PKC	O
or	O
PTK	O
would	O
decrease	O
LPS	O
-	O
induced	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
and	O
TNF	O
-	O
alpha	O
release	O
in	O
human	O
monocytes	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Human	O
monocytes	O
were	O
stimulated	O
with	O
PMA	O
(	O
50	O
ng/ml	O
)	O
alone	O
or	O
LPS	O
(	O
100	O
ng/ml	O
)	O
with	O
and	O
without	O
a	O
nonspecific	O
serine/threonine	O
protein	O
kinase	O
inhibitor	O
staurosporine	O
(	O
Stauro	O
)	O
,	O
a	O
specific	O
pan	O
-	O
PKC	O
inhibitor	O
bisindolylmaleimide	O
(	O
Bis	O
)	O
,	O
or	O
an	O
inhibitor	O
of	O
PTK	O
genistein	O
(	O
Gen	O
)	O
.	O

TNF	O
-	O
alpha	O
release	O
in	O
culture	O
supernatants	O
was	O
measured	O
by	O
an	O
ELISA	O
.	O

NF	O
-	O
kappaB	O
DNA	O
binding	O
was	O
evaluated	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

RESULTS	O
:	O
LPS	O
increased	B-Positive_regulation
NF	O
-	O
kappaB	O
DNA	O
binding	O
and	O
TNF	O
-	O
alpha	O
release	B-Localization
in	O
human	O
monocytes	O
.	O

Nonspecific	O
protein	O
kinase	O
inhibition	O
inhibited	B-Negative_regulation
NF	O
-	O
kappaB	O
activation	O
and	O
TNF	O
-	O
alpha	O
release	B-Localization
,	O
while	O
specific	O
PKC	O
inhibition	O
with	O
Bis	O
had	O
no	O
effect	B-Regulation
on	O
LPS	O
-	O
induced	B-Positive_regulation
NF	O
-	O
kappaB	O
DNA	O
binding	O
or	O
TNF	O
-	O
alpha	O
release	B-Localization
.	O

PTK	O
inhibition	O
with	O
Gen	O
attenuated	B-Negative_regulation
both	O
LPS	O
-	O
induced	B-Positive_regulation
NF	O
-	O
kappaB	O
DNA	O
binding	O
and	O
TNF	O
-	O
alpha	O
production	B-Gene_expression
in	O
human	O
monocytes	O
.	O

Direct	O
activation	O
of	O
PKC	O
with	O
PMA	O
induced	B-Positive_regulation
both	O
NF	O
-	O
kappaB	O
activation	O
and	O
TNF	O
-	O
alpha	O
production	B-Gene_expression
by	O
human	O
monocytes	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
LPS	O
-	O
induced	B-Positive_regulation
NF	O
-	O
kappaB	O
activation	O
and	O
TNF	O
-	O
alpha	O
release	B-Localization
in	O
human	O
monocytes	O
are	O
independent	O
of	O
PKC	O
activity	O
.	O

Furthermore	O
,	O
our	O
results	O
provide	O
evidence	O
that	O
PTK	O
plays	O
a	O
role	O
in	O
LPS	O
-	O
induced	B-Positive_regulation
NF	O
-	O
kappaB	O
activation	O
and	O
TNF	O
-	O
alpha	O
release	B-Localization
in	O
human	O
monocytes	O
and	O
thus	O
could	O
be	O
a	O
potential	O
therapeutic	O
target	O
in	O
inflammatory	O
states	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Cellular	O
disposition	O
of	O
sulphamethoxazole	O
and	O
its	O
metabolites	O
:	O
implications	O
for	O
hypersensitivity	O
.	O

1.	O
Bioactivation	O
of	O
sulphamethoxazole	O
(	O
SMX	O
)	O
to	O
chemically	O
-	O
reactive	O
metabolites	O
and	O
subsequent	O
protein	O
conjugation	O
is	O
thought	O
to	O
be	O
involved	O
in	O
SMX	O
hypersensitivity	O
.	O

We	O
have	O
therefore	O
examined	O
the	O
cellular	O
metabolism	O
,	O
disposition	O
and	O
conjugation	O
of	O
SMX	O
and	O
its	O
metabolites	O
in	O
vitro	O
.	O

2	O
.	O

Flow	O
cytometry	O
revealed	O
binding	O
of	O
N	O
-	O
hydroxy	O
(	O
SMX	O
-	O
NHOH	O
)	O
and	O
nitroso	O
(	O
SMX	O
-	O
NO	O
)	O
metabolites	O
of	O
SMX	O
,	O
but	O
not	O
of	O
SMX	O
itself	O
,	O
to	O
the	O
surface	O
of	O
viable	O
white	O
blood	O
cells	O
.	O

Cellular	O
haptenation	O
by	O
SMX	O
-	O
NO	O
was	O
reduced	O
by	O
exogenous	O
glutathione	O
(	O
GSH	O
)	O
.	O

3	O
.	O

SMX	O
-	O
NHOH	O
and	O
SMX	O
-	O
NO	O
were	O
rapidly	O
reduced	O
back	O
to	O
the	O
parent	O
compound	O
by	O
cysteine	O
(	O
CYS	O
)	O
,	O
GSH	O
,	O
human	O
peripheral	O
blood	O
cells	O
and	O
plasma	O
,	O
suggesting	O
that	O
this	O
is	O
an	O
important	O
and	O
ubiquitous	O
bioinactivation	O
mechanism	O
.	O

4	O
.	O

Fluorescence	O
HPLC	O
showed	O
that	O
SMX	O
-	O
NHOH	O
and	O
SMX	O
-	O
NO	O
depleted	O
CYS	O
and	O
GSH	O
in	O
buffer	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
in	O
cells	O
and	O
plasma	O
.	O

5	O
.	O

Neutrophil	O
apoptosis	O
and	O
inhibition	O
of	O
neutrophil	O
function	O
were	O
induced	O
at	O
lower	O
concentrations	O
of	O
SMX	O
-	O
NHOH	O
and	O
SMX	O
-	O
NO	O
than	O
those	O
inducing	O
loss	O
of	O
membrane	O
viability	O
,	O
with	O
SMX	O
having	O
no	O
effect	O
.	O

Lymphocytes	O
were	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
more	O
sensitive	O
to	O
the	O
direct	O
cytotoxic	O
effects	O
of	O
SMX	O
-	O
NO	O
than	O
neutrophils	O
.	O

6	O
.	O

Partitioning	O
of	O
SMX	O
-	O
NHOH	O
into	O
red	O
blood	O
cells	O
was	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
lower	O
than	O
with	O
the	O
hydroxylamine	O
of	O
dapsone	O
.	O

7	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
balance	O
between	O
oxidation	O
of	O
SMX	O
to	O
its	O
toxic	O
metabolites	O
and	O
their	O
reduction	O
is	O
an	O
important	O
protective	O
cellular	O
mechanism	O
.	O

If	O
an	O
imbalance	O
exists	O
,	O
haptenation	O
of	O
the	O
toxic	O
metabolites	O
to	O
bodily	O
proteins	O
including	O
the	O
surface	O
of	O
viable	O
cells	O
can	O
occur	O
,	O
and	O
may	O
result	O
in	O
drug	O
hypersensitivity	O
.	O

Tcf-1	O
-	O
mediated	O
transcription	O
in	O
T	O
lymphocytes	O
:	O
differential	O
role	O
for	O
glycogen	O
synthase	O
kinase	O
-	O
3	O
in	O
fibroblasts	O
and	O
T	O
cells	O
.	O

Beta	O
-	O
catenin	O
is	O
the	O
vertebrate	O
homolog	O
of	O
the	O
Drosophila	O
segment	O
polarity	O
gene	O
Armadillo	O
and	O
plays	O
roles	O
in	O
both	O
cell	O
-	O
cell	O
adhesion	O
and	O
transduction	O
of	O
the	O
Wnt	O
signaling	O
cascade	O
.	O

Recently	O
,	O
members	O
of	O
the	O
Lef/Tcf	O
transcription	O
factor	O
family	O
have	O
been	O
identified	O
as	O
protein	O
partners	O
of	O
beta	O
-	O
catenin	O
,	O
explaining	O
how	O
beta	O
-	O
catenin	O
alters	O
gene	O
expression	O
.	O

Here	O
we	O
report	O
that	O
in	O
T	O
cells	O
,	O
Tcf	O
-	O
1	O
also	O
becomes	B-Positive_regulation
transcriptionally	I-Positive_regulation
active	I-Positive_regulation
through	O
interaction	B-Binding
with	O
beta	O
-	O
catenin	O
,	O
suggesting	O
that	O
the	O
Wnt	O
signal	O
transduction	O
pathway	O
is	O
operational	O
in	O
T	O
lymphocytes	O
as	O
well	O
.	O

However	O
,	O
although	O
Wnt	O
signals	O
are	O
known	O
to	O
inhibit	B-Negative_regulation
the	O
activity	O
of	O
the	O
negative	O
regulatory	O
protein	O
kinase	O
glycogen	O
synthase	O
kinase	O
-	O
3beta	O
(	O
GSK	O
-	O
3beta	O
)	O
,	O
resulting	O
in	O
increased	B-Positive_regulation
levels	I-Positive_regulation
of	O
beta	O
-	O
catenin	O
,	O
we	O
find	O
no	O
evidence	O
for	O
involvement	O
of	O
GSK	O
-	O
3beta	O
in	O
Tcf	O
-	O
mediated	O
transcription	O
in	O
T	O
cells	O
.	O

That	O
is	O
,	O
a	O
dominant	O
negative	O
GSK	O
-	O
3beta	O
does	O
not	O
specifically	O
activate	O
Tcf	O
transcription	O
and	O
stimuli	O
(	O
lithium	O
or	O
phytohemagglutinin	O
)	O
that	O
inhibit	B-Negative_regulation
GSK	O
-	O
3beta	O
activity	O
also	O
do	O
not	O
activate	O
Tcf	O
reporter	O
genes	O
.	O

Thus	O
,	O
inhibition	B-Negative_regulation
of	O
GSK	O
-	O
3beta	O
is	O
insufficient	O
to	O
activate	O
Tcf	O
-	O
dependent	O
transcription	O
in	O
T	O
lymphocytes	O
.	O

In	O
contrast	O
,	O
in	O
C57MG	O
fibroblast	O
cells	O
,	O
lithium	O
inactivates	B-Negative_regulation
GSK	O
-	O
3beta	O
and	O
induces	O
Tcf	O
-	O
controlled	O
transcription	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
that	O
lithium	O
can	O
alter	O
gene	O
expression	O
of	O
Tcf	O
-	O
responsive	O
genes	O
,	O
and	O
points	O
to	O
a	O
difference	O
in	O
regulation	O
of	O
Wnt	O
signaling	O
between	O
fibroblasts	O
and	O
lymphocytes	O
.	O

CIITA	O
-	O
induced	O
occupation	O
of	O
MHC	O
class	O
II	O
promoters	O
is	O
independent	O
of	O
the	O
cooperative	O
stabilization	O
of	O
the	O
promoter	O
-	O
bound	O
multi	O
-	O
protein	O
complexes	O
.	O

Precise	O
regulation	O
of	O
MHC	O
class	O
II	O
expression	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
control	O
of	O
the	O
immune	O
response	O
.	O

The	O
transactivator	O
CIITA	O
behaves	O
as	O
a	O
master	O
controller	O
of	O
constitutive	O
and	O
inducible	O
MHC	O
class	O
II	O
gene	O
activation	O
,	O
but	O
its	O
exact	O
mechanism	O
of	O
action	O
is	O
not	O
known	O
.	O

Activation	O
of	O
MHC	O
class	O
II	O
promoters	O
requires	O
binding	O
of	O
at	O
least	O
three	O
distinct	O
multi	O
-	O
protein	O
complexes	O
(	O
RFX	O
,	O
X2BP	O
and	O
NF	O
-	O
Y	O
)	O
.	O

It	O
is	O
known	O
that	O
the	O
stability	O
of	O
this	O
binding	O
results	O
from	O
cooperative	O
interactions	O
between	O
these	O
proteins	O
.	O

We	O
show	O
here	O
that	O
expression	B-Gene_expression
of	O
CIITA	O
in	O
MHC	O
class	O
II	O
-	O
cells	O
triggers	O
occupation	O
of	O
the	O
promoters	O
by	O
these	O
complexes	O
.	O

This	O
observation	O
raised	O
the	O
possibility	O
that	O
the	O
effect	O
of	O
CIITA	O
on	O
promoter	O
occupation	O
is	O
mediated	O
by	O
an	O
effect	O
on	O
the	O
cooperative	O
stabilization	O
of	O
the	O
DNA	O
-	O
bound	O
multi	O
-	O
protein	O
complexes	O
.	O

We	O
show	O
,	O
however	O
,	O
that	O
the	O
presence	O
of	O
CIITA	O
does	O
not	O
affect	O
the	O
stability	O
of	O
the	O
higher	O
-	O
order	O
protein	O
complex	O
formed	O
on	O
DNA	O
by	O
RFX	O
,	O
X2BP	O
and	O
NF	O
-	O
Y	O
.	O

This	O
suggests	O
other	O
mechanisms	O
for	O
CIITA	O
-	O
induced	O
promoter	O
occupancy	O
,	O
such	O
as	O
an	O
effect	O
on	O
chromatin	O
structure	O
leading	O
to	O
increased	O
accessibility	O
of	O
MHC	O
class	O
II	O
promoters	O
.	O

This	O
ability	O
of	O
CIITA	O
to	O
facilitate	O
promoter	O
occupation	O
is	O
undissociable	O
from	O
its	O
transactivation	O
potential	O
.	O

Finally	O
,	O
we	O
conclude	O
that	O
this	O
effect	O
of	O
CIITA	O
is	O
cell	O
-	O
type	O
specific	O
,	O
since	O
expression	B-Gene_expression
of	O
CIITA	O
is	O
not	O
required	O
for	O
normal	O
occupation	O
of	O
MHC	O
class	O
II	O
promoters	O
in	O
B	O
lymphocytes	O
.	O

Immunosuppressant	O
PG490	O
(	O
triptolide	O
)	O
inhibits	B-Negative_regulation
T	O
-	O
cell	O
interleukin	O
-	O
2	O
expression	B-Gene_expression
at	O
the	O
level	O
of	O
purine	O
-	O
box/nuclear	O
factor	O
of	O
activated	O
T	O
-	O
cells	O
and	O
NF	O
-	O
kappaB	O
transcriptional	O
activation	O
.	O

PG490	O
(	O
triptolide	O
)	O
is	O
a	O
diterpene	O
triepoxide	O
with	O
potent	O
immunosuppressive	O
and	O
antiinflammatory	O
properties	O
.	O

PG490	O
inhibits	B-Negative_regulation
interleukin	O
(	O
IL	O
)	O
-	O
2	O
expression	B-Gene_expression
by	O
normal	O
human	O
peripheral	O
blood	O
lymphocytes	O
stimulated	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
and	O
antibody	O
to	O
CD3	O
(	O
IC50	O
of	O
10	O
ng/ml	O
)	O
,	O
and	O
with	O
PMA	O
and	O
ionomycin	O
(	O
Iono	O
,	O
IC50	O
of	O
40	O
ng/ml	O
)	O
.	O

In	O
Jurkat	O
T	O
-	O
cells	O
,	O
PG490	B-Negative_regulation
inhibits	O
PMA/Iono	O
-	O
stimulated	B-Positive_regulation
IL	O
-	O
2	O
transcription	B-Transcription
.	O

PG490	O
inhibits	O
the	O
induction	O
of	O
DNA	O
binding	O
activity	O
at	O
the	O
purine	O
-	O
box/antigen	O
receptor	O
response	O
element	O
(	O
ARRE	O
)	O
/nuclear	O
factor	O
of	O
activated	O
T	O
-	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
target	O
sequence	O
but	O
not	O
at	O
the	O
NF	O
-	O
kappaB	O
site	O
.	O

PG490	O
can	O
completely	O
inhibit	O
transcriptional	O
activation	O
at	O
the	O
purine-box/ARRE/NF	O
-	O
AT	O
and	O
NF	O
-	O
kappaB	O
target	O
DNA	O
sequences	O
triggered	O
by	O
all	O
stimuli	O
examined	O
(	O
PMA	O
,	O
PMA/Iono	O
,	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
)	O
.	O

PG490	O
also	O
inhibits	O
PMA	O
-	O
stimulated	O
activation	O
of	O
a	O
chimeric	O
transcription	O
factor	O
in	O
which	O
the	O
C	O
-	O
terminal	O
TA1	O
transactivation	O
domain	O
of	O
NF	O
-	O
kappaB	O
p65	O
is	O
fused	O
to	O
the	O
DNA	O
binding	O
domain	O
of	O
GAL4	O
.	O

In	O
16HBE	O
human	O
bronchial	O
epithelial	O
cells	O
,	O
IL	O
-	O
8	O
expression	B-Gene_expression
is	O
regulated	B-Regulation
predominantly	O
by	O
NF	O
-	O
kappaB	O
,	O
and	O
PG490	O
but	O
not	O
cyclosporin	O
A	O
can	O
completely	O
inhibit	B-Negative_regulation
expression	B-Gene_expression
of	O
IL	O
-	O
8	O
.	O

The	O
mechanism	O
of	O
PG490	O
inhibition	O
of	O
cytokine	O
gene	O
expression	O
differs	O
from	O
cyclosporin	O
A	O
and	O
involves	O
nuclear	O
inhibition	O
of	O
transcriptional	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
the	O
purine	O
-	O
box	O
regulator	O
operating	O
at	O
the	O
ARRE/NF	O
-	O
AT	O
site	O
at	O
a	O
step	O
after	O
specific	O
DNA	O
binding	O
.	O

Activation	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
by	O
lipopolysaccharide	O
in	O
mononuclear	O
leukocytes	O
is	O
prevented	O
by	O
inhibitors	O
of	O
cytosolic	O
phospholipase	O
A2	O
.	O

In	O
monocytes	O
,	O
lipopolysaccharide	O
induces	O
synthesis	O
and	O
activity	O
of	O
the	O
85	O
-	O
kDa	O
cytosolic	O
phospholipase	O
A2	O
.	O

This	O
enzyme	O
releases	O
arachidonic	O
acid	O
and	O
lyso	O
-	O
phospholipids	O
from	O
membranes	O
which	O
are	O
metabolized	O
to	O
eicosanoids	O
and	O
platelet-activating	O
-	O
factor	O
.	O

These	O
lipid	O
mediators	O
increase	O
activity	O
of	O
transcription	O
factors	O
and	O
expression	O
of	O
cytokine	O
genes	O
indicating	O
a	O
function	O
for	O
cytosolic	O
phospholipase	O
A2	O
in	O
signal	O
transduction	O
and	O
inflammation	O
.	O

We	O
have	O
shown	O
previously	O
that	O
trifluoromethylketone	O
inhibitors	O
of	O
cytosolic	O
phospholipase	O
A2	O
suppressed	B-Negative_regulation
interleukin	O
-	O
1beta	O
protein	O
and	O
steady	O
-	O
state	O
mRNA	O
levels	O
in	O
human	O
lipopolysaccharide	O
-	O
stimulated	O
peripheral	O
blood	O
mononuclear	O
leukocytes	O
.	O

In	O
this	O
study	O
,	O
the	O
subcellular	O
mechanisms	O
were	O
analyzed	O
by	O
which	O
trifluoromethylketones	O
interfere	O
with	O
gene	O
expression	O
.	O

We	O
found	O
that	O
they	O
reduced	B-Negative_regulation
the	O
initial	O
interleukin	O
-	O
1beta	O
mRNA	O
transcription	B-Transcription
rate	O
through	O
prevention	O
of	O
degradation	B-Protein_catabolism
of	O
inhibitor	O
-	O
kappaB	O
alpha	O
.	O

Consequently	O
,	O
cytosolic	O
activation	O
,	O
nuclear	O
translocation	O
and	O
DNA	O
-	O
binding	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
were	O
decreased	O
.	O

Trifluoromethylketones	O
ameliorate	O
chronic	O
inflammation	O
in	O
vivo	O
.	O

Thus	O
,	O
this	O
therapeutic	O
potency	O
may	O
reside	O
in	O
retention	O
of	O
inactive	O
nuclear	O
factor	O
-	O
kappaB	O
in	O
the	O
cytosol	O
thereby	O
abrogating	B-Negative_regulation
interleukin	O
-	O
1beta	O
gene	O
transcription	B-Transcription
.	O

Molecular	O
regulation	O
of	O
cytokine	O
gene	O
expression	O
during	O
the	O
immune	O
response	O
.	O

Cytokine	O
expression	O
by	O
immune	O
system	O
cells	O
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
the	O
immune	O
response	O
.	O

On	O
first	O
encounter	O
with	O
antigen	O
,	O
naive	O
CD4+	O
T	O
helper	O
(	O
Th	O
)	O
cells	O
differentiate	O
into	O
cytokine	O
-	O
producing	O
effector	O
cells	O
.	O

Two	O
types	O
of	O
effector	O
cells	O
characterized	O
by	O
their	O
distinct	O
expression	O
of	O
cytokine	O
profiles	O
have	O
been	O
described	O
.	O

Th1	O
cells	O
produce	B-Gene_expression
IL	O
-	O
2	O
and	O
IFN	O
-	O
gamma	O
,	O
whereas	O
Th2	O
cells	O
produce	B-Gene_expression
IL	O
-	O
4	O
,	O
IL	O
-	O
5	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
10	O
,	O
and	O
IL	O
-	O
13	O
.	O

In	O
many	O
pathological	O
situations	O
,	O
the	O
balance	O
between	O
Th1	O
and	O
Th2	O
immune	O
responses	O
determines	O
the	O
outcome	O
of	O
diverse	O
immunologically	O
mediated	O
clinical	O
syndromes	O
including	O
infectious	O
,	O
autoimmune	O
,	O
and	O
allergic	O
diseases	O
.	O

However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
Th1/Th2	O
-	O
like	O
cytokines	O
has	O
remained	O
elusive	O
.	O

In	O
this	O
review	O
we	O
evaluate	O
the	O
possible	O
in	O
vivo	O
role	O
of	O
different	O
transcription	O
factors	O
and	O
transcriptional	O
mechanisms	O
in	O
T	O
cell	O
differentiation	O
and	O
the	O
immune	O
response	O
.	O

The	O
evolutionarily	O
conserved	O
sequence	O
upstream	O
of	O
the	O
human	O
Ig	O
heavy	O
chain	O
S	O
gamma	O
3	O
region	O
is	O
an	O
inducible	O
promoter	O
:	O
synergistic	O
activation	O
by	O
CD40	O
ligand	O
and	O
IL	O
-	O
4	O
via	O
cooperative	O
NF	O
-	O
kappa	O
B	O
and	O
STAT	O
-	O
6	O
binding	O
sites	O
.	O

Germline	O
C	O
gamma	O
gene	O
transcription	O
is	O
a	O
crucial	O
event	O
in	O
the	O
process	O
that	O
leads	O
to	O
switch	O
DNA	O
recombination	O
to	O
IgG	O
,	O
but	O
its	O
regulation	O
in	O
the	O
human	O
is	O
poorly	O
understood	O
.	O

We	O
took	O
advantage	O
of	O
our	O
monoclonal	O
model	O
of	O
germinal	O
center	O
B	O
cell	O
differentiation	O
,	O
IgM+	O
IgD+	O
CL	O
-	O
01	O
cells	O
,	O
to	O
define	O
the	O
role	B-Regulation
of	O
the	O
I	O
gamma	O
3	O
evolutionarily	O
conserved	O
sequence	O
(	O
ECS	O
)	O
in	O
the	O
germline	O
transcriptional	O
activation	B-Positive_regulation
of	O
the	O
human	O
C	O
gamma	O
3	O
gene	O
.	O

The	O
I	O
gamma	O
3	O
ECS	O
lies	O
upstream	O
of	O
the	O
major	O
I	O
gamma	O
3	O
transcription	O
initiation	O
site	O
and	O
displays	O
more	O
than	O
90	O
%	O
identity	O
with	O
the	O
corresponding	O
human	O
I	O
gamma	O
1	O
,	O
I	O
gamma	O
2	O
,	O
and	O
I	O
gamma	O
4	O
regions	O
.	O

Reporter	O
luciferase	O
gene	O
vectors	O
containing	O
the	O
human	O
gamma	O
3	O
ECS	O
were	O
used	O
to	O
transfect	O
CL	O
-	O
01	O
cells	O
,	O
which	O
have	O
been	O
shown	O
to	O
undergo	O
Smu	O
-	O
-	O
>	O
S	O
gamma	O
3	O
DNA	O
recombination	O
,	O
upon	O
engagement	B-Binding
of	O
CD40	O
by	O
CD40	O
ligand	O
(	O
CD40L	O
)	O
and	O
exposure	O
to	O
IL	O
-	O
4	O
.	O

In	O
these	O
transfected	O
CL	O
-	O
01	O
cells	O
,	O
CD40	O
:	O
CD40L	O
engagement	B-Binding
and	O
exposure	O
to	O
IL	O
-	O
4	O
synergistically	O
induced	O
gamma	O
3	O
ECS	O
-	O
dependent	O
luciferase	O
reporter	O
gene	O
activation	O
.	O

Targeted	O
mutational	O
analysis	O
demonstrated	O
that	O
a	O
tandem	O
NF	O
-	O
kappa	O
B/Rel	O
binding	O
motif	O
is	O
critical	O
for	O
the	O
gamma	O
3	O
ECS	O
responsiveness	O
to	O
both	O
CD40L	O
and	O
IL	O
-	O
4	O
,	O
while	O
a	O
STAT-6	O
-	O
binding	O
site	O
is	O
additionally	O
required	O
for	O
IL	O
-	O
4	O
inducibility	B-Positive_regulation
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
p50/p65/c	O
-	O
Rel	O
and	O
STAT	O
-	O
6	O
are	O
effectively	O
induced	B-Positive_regulation
by	O
CD40L	O
and	O
IL	O
-	O
4	O
,	O
respectively	O
,	O
and	O
bind	B-Binding
to	O
specific	O
DNA	O
motifs	O
within	O
the	O
ECS	O
.	O

These	O
partially	O
overlapping	O
CD40L	O
and	O
IL	O
-	O
4	O
responsive	O
elements	O
are	O
functionally	O
cooperative	O
as	O
the	O
disruption	O
of	O
one	O
of	O
them	O
prevents	O
synergistic	O
promoter	O
activation	O
.	O

Thus	O
,	O
the	O
gamma	O
3	O
ECS	O
is	O
an	O
inducible	O
promoter	O
containing	O
cis	O
elements	O
that	O
critically	O
mediate	O
CD40L	O
and	O
IL-4	O
-	O
triggered	O
transcriptional	O
activation	O
of	O
the	O
human	O
C	O
gamma	O
3	O
gene	O
.	O

Thrombin	O
-	O
induced	B-Positive_regulation
p65	O
homodimer	O
binding	B-Binding
to	O
downstream	O
NF	O
-	O
kappa	O
B	O
site	O
of	O
the	O
promoter	O
mediates	B-Positive_regulation
endothelial	O
ICAM	O
-	O
1	O
expression	B-Gene_expression
and	O
neutrophil	O
adhesion	O
.	O

We	O
investigated	O
the	O
mechanisms	O
by	O
which	O
proinflammatory	O
mediator	O
,	O
thrombin	O
,	O
released	B-Localization
during	O
intravascular	O
coagulation	O
and	O
tissue	O
injury	O
,	O
induces	B-Positive_regulation
ICAM	O
-	O
1	O
(	O
CD54	O
)	O
expression	B-Gene_expression
in	O
endothelial	O
cells	O
.	O

Stimulation	O
of	O
HUVEC	O
with	O
thrombin	O
resulted	O
in	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
increases	B-Positive_regulation
in	O
ICAM	O
-	O
1	O
mRNA	O
and	O
cell	O
surface	O
expression	B-Gene_expression
and	O
in	O
ICAM-1	O
-	O
dependent	O
endothelial	O
adhesivity	O
toward	O
polymorphonuclear	O
leukocytes	O
.	O

Transient	O
transfection	O
of	O
endothelial	O
cells	O
with	O
ICAM	O
-	O
1	O
promoter	O
luciferase	O
reporter	O
gene	O
(	O
ICAM	O
-	O
1LUC	O
)	O
constructs	O
indicated	O
that	O
deletion	O
of	O
upstream	O
NF	O
-	O
kappa	O
B	O
site	O
(	O
-	O
533	O
bases	O
from	O
translation	O
start	O
site	O
)	O
had	O
no	O
effect	O
on	O
thrombin	O
responsiveness	O
,	O
whereas	O
mutation/deletion	O
of	O
downstream	O
NF	O
-	O
kappa	O
B	O
site	O
(	O
-	O
223	O
bases	O
from	O
the	O
translation	O
start	O
site	O
)	O
prevented	B-Negative_regulation
the	O
activation	B-Positive_regulation
of	O
ICAM	O
-	O
1	O
promoter	O
,	O
indicating	O
that	O
the	O
downstream	O
NF	O
-	O
kappa	O
B	O
site	O
is	O
critical	O
for	O
thrombin	O
inducibility	O
.	O

NF	O
-	O
kappa	O
B	O
-	O
directed	O
luciferase	O
activity	O
increased	O
approximately	O
3	O
-	O
fold	O
when	O
cells	O
transfected	O
with	O
the	O
plasmid	O
pNF	O
-	O
kappa	O
BLUC	O
containing	O
five	O
copies	O
of	O
consensus	O
NF	O
-	O
kappa	O
B	O
site	O
linked	O
to	O
a	O
minimal	O
adenovirus	O
E1B	O
promoter	O
-	O
luciferase	O
gene	O
were	O
exposed	O
to	O
thrombin	O
,	O
indicating	O
that	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
was	O
essential	O
for	O
thrombin	O
response	O
.	O

Gel	O
supershift	O
assays	O
demonstrated	O
that	O
thrombin	O
induced	B-Positive_regulation
binding	B-Binding
of	O
NF	O
-	O
kappa	O
Bp65	O
(	O
Rel	O
A	O
)	O
to	O
downstream	O
NF	O
-	O
kappa	O
B	O
site	O
of	O
the	O
ICAM	O
-	O
1	O
promoter	O
.	O

Thrombin	O
receptor	O
activation	O
peptide	O
,	O
a	O
14-amino	O
-	O
acid	O
peptide	O
representing	O
the	O
new	O
NH2	O
terminus	O
of	O
proteolytically	O
activated	O
receptor	O
-	O
1	O
,	O
mimicked	O
thrombin	O
's	O
action	O
in	O
inducing	B-Positive_regulation
ICAM	O
-	O
1	O
expression	B-Gene_expression
.	O

These	O
data	O
indicate	O
that	O
thrombin	O
activates	B-Positive_regulation
endothelial	O
ICAM	O
-	O
1	O
expression	B-Gene_expression
and	O
polymorphonuclear	O
leukocyte	O
adhesion	O
by	O
NF	O
-	O
kappa	O
Bp65	O
binding	B-Binding
to	O
the	O
downstream	O
NF	O
-	O
kappa	O
B	O
site	O
of	O
ICAM	O
-	O
1	O
promoter	O
after	B-Positive_regulation
proteolytically	O
activated	O
receptor	O
-	O
1	O
activation	B-Positive_regulation
.	O

CTLA-4	O
-	O
Mediated	O
inhibition	O
of	O
early	O
events	O
of	O
T	O
cell	O
proliferation	O
.	O

CTLA	O
-	O
4	O
engagement	B-Binding
by	O
mAbs	O
inhibits	B-Negative_regulation
,	O
while	O
CD28	O
enhances	B-Positive_regulation
,	O
IL	O
-	O
2	O
production	B-Gene_expression
and	O
proliferation	O
upon	B-Positive_regulation
T	O
cell	O
activation	O
.	O

Here	O
,	O
we	O
have	O
analyzed	O
the	O
mechanisms	O
involved	O
in	O
CTLA-4	O
-	O
mediated	O
inhibition	O
of	O
T	O
cell	O
activation	O
of	O
naive	O
CD4+	O
T	O
cells	O
using	O
Ab	O
cross	O
-	O
linking	O
.	O

CTLA	O
-	O
4	O
ligation	B-Binding
inhibited	B-Negative_regulation
CD3/CD28	O
-	O
induced	O
IL	O
-	O
2	O
mRNA	O
accumulation	B-Positive_regulation
by	O
inhibiting	B-Negative_regulation
IL	O
-	O
2	O
transcription	B-Transcription
,	O
which	O
appears	O
to	O
be	O
mediated	B-Positive_regulation
in	O
part	O
through	O
decreasing	O
NF	O
-	O
AT	O
accumulation	O
in	O
the	O
nuclei	O
.	O

However	O
,	O
CTLA	O
-	O
4	O
ligation	B-Binding
did	O
not	O
appear	O
to	O
affect	B-Regulation
the	O
CD28	O
-	O
mediated	B-Positive_regulation
stabilization	B-Positive_regulation
of	O
IL	O
-	O
2	O
mRNA	O
.	O

Further	O
,	O
CTLA	O
-	O
4	O
engagement	B-Binding
inhibited	O
progression	O
through	O
the	O
cell	O
cycle	O
by	O
inhibiting	B-Negative_regulation
the	O
production	B-Gene_expression
of	O
cyclin	O
D3	O
,	O
cyclin	O
-	O
dependent	O
kinase	O
(	O
cdk	O
)	O
4	O
,	O
and	O
cdk6	O
when	B-Positive_regulation
the	O
T	O
cells	O
were	O
stimulated	O
with	O
anti	O
-	O
CD3/CD28	O
and	O
with	O
anti	O
-	O
CD3	O
alone	O
.	O

These	O
results	O
indicate	O
that	O
CTLA	O
-	O
4	O
signaling	O
inhibits	B-Negative_regulation
events	O
early	O
in	O
T	O
cell	O
activation	O
both	O
at	O
IL	O
-	O
2	O
transcription	B-Transcription
and	O
at	O
the	O
level	O
of	O
IL-2	O
-	O
independent	O
events	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
does	O
not	O
simply	O
oppose	O
CD28	O
-	O
mediated	O
costimulation	O
.	O

Fibroblast	O
growth	O
factor	O
-	O
1	O
(	O
FGF	O
-	O
1	O
)	O
enhances	B-Positive_regulation
IL	O
-	O
2	O
production	B-Gene_expression
and	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
in	O
FGF	O
receptor	O
-	O
bearing	O
Jurkat	O
T	O
cells	O
.	O

Fibroblast	O
growth	O
factors	O
(	O
FGFs	O
)	O
are	O
heparin	O
-	O
binding	O
proteins	O
crucial	O
to	O
embryogenesis	O
,	O
angiogenesis	O
,	O
and	O
wound	O
healing	O
.	O

FGF	O
-	O
1	O
is	O
abundantly	O
expressed	B-Gene_expression
in	O
the	O
synovium	O
in	O
rheumatoid	O
arthritis	O
and	O
in	O
rejecting	O
allografts	O
,	O
sites	O
of	O
chronic	O
immune	O
-	O
mediated	O
inflammation	O
.	O

The	O
frequency	O
of	O
FGF-1	O
-	O
responsive	O
T	O
cells	O
is	O
increased	O
in	O
the	O
peripheral	O
blood	O
of	O
these	O
disorders	O
,	O
and	O
a	O
high	O
percentage	O
of	O
infiltrating	O
T	O
cells	O
in	O
rheumatoid	O
arthritis	O
synovium	O
express	O
receptors	O
for	O
FGF	O
-	O
1	O
.	O

To	O
understand	O
the	O
action	O
of	O
FGF	O
-	O
1	O
in	O
T	O
cells	O
,	O
studies	O
were	O
initiated	O
in	O
Jurkat	O
T	O
cells	O
that	O
express	B-Gene_expression
the	O
signaling	O
isoform	O
of	O
FGF	O
receptor	O
-	O
1	O
.	O

These	O
experiments	O
show	O
that	O
FGF	O
-	O
1	O
stimulation	O
of	O
Jurkat	O
T	O
cells	O
provides	B-Positive_regulation
a	O
second	O
signal	O
that	O
augments	B-Positive_regulation
TCR	O
-	O
mediated	B-Positive_regulation
IL	O
-	O
2	O
production	B-Gene_expression
.	O

Analogous	O
to	O
costimulation	O
via	O
CD28	O
,	O
this	O
activity	O
is	O
mediated	B-Positive_regulation
through	O
activation	O
of	O
Rel/kappaB	O
,	O
a	O
family	O
of	O
transcription	O
factors	O
known	O
to	O
regulate	B-Regulation
IL	O
-	O
2	O
and	O
other	O
activation	O
-	O
inducible	O
proteins	O
.	O

FGF	O
-	O
1	O
alone	O
induces	O
modest	O
nuclear	O
translocation	O
of	O
kappaB	O
-	O
binding	O
proteins	O
,	O
and	O
this	O
translocation	O
is	O
enhanced	O
by	O
the	O
combination	O
of	O
anti	O
-	O
CD3	O
and	O
FGF	O
-	O
1	O
.	O

This	O
NF	O
-	O
kappaB	O
binding	O
complex	O
is	O
composed	B-Positive_regulation
of	O
transcriptionally	O
active	O
p65	O
(	O
RelA	O
)	O
/p50	O
heterodimers	O
and	O
results	B-Positive_regulation
primarily	O
from	O
the	O
targeted	O
degradation	B-Protein_catabolism
of	O
IkappaB	O
-	O
alpha	O
,	O
an	O
inhibitor	O
that	O
sequesters	O
Rel/kappaB	O
in	O
the	O
cytoplasm	O
.	O

These	O
data	O
are	O
the	O
first	O
to	O
show	O
a	O
connection	O
between	O
FGF	O
-	O
1	O
signaling	O
and	O
NF	O
-	O
kappaB	O
activation	O
outside	O
of	O
embryonic	O
development	O
.	O

The	O
signaling	O
events	O
that	O
link	O
FGF	O
receptor	O
-	O
1	O
engagement	B-Binding
and	O
NF	O
-	O
kappaB	O
activation	O
in	O
Jurkat	O
are	O
probably	O
distinct	O
from	O
the	O
CD28	O
costimulation	O
pathway	O
,	O
since	O
FGF-1	O
-	O
induced	B-Positive_regulation
Rel/kappaB	O
binding	O
proteins	O
do	O
not	O
contain	O
significant	O
levels	O
of	O
c	O
-	O
Rel	O
and	O
are	O
not	O
identical	O
with	O
the	O
CD28	O
response	O
complex	O
.	O

Signaling	O
through	O
the	O
lymphotoxin	O
-	O
beta	O
receptor	O
stimulates	O
HIV	O
-	O
1	O
replication	O
alone	O
and	O
in	O
cooperation	O
with	O
soluble	O
or	O
membrane	O
-	O
bound	O
TNF	O
-	O
alpha	O
.	O

The	O
level	O
of	O
ongoing	O
HIV	O
-	O
1	O
replication	O
within	O
an	O
individual	O
is	O
critical	O
to	O
HIV	O
-	O
1	O
pathogenesis	O
.	O

Among	O
host	O
immune	O
factors	O
,	O
the	O
cytokine	O
TNF	O
-	O
alpha	O
has	O
previously	O
been	O
shown	O
to	O
increase	O
HIV	O
-	O
1	O
replication	O
in	O
various	O
monocyte	O
and	O
T	O
cell	O
model	O
systems	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
signaling	O
through	O
the	O
TNF	O
receptor	O
family	O
member	O
,	O
the	O
lymphotoxin	O
-	O
beta	O
(	O
LT	O
-	O
beta	O
)	O
receptor	O
(	O
LT	O
-	O
betaR	O
)	O
,	O
also	O
regulates	O
HIV	O
-	O
1	O
replication	O
.	O

Furthermore	O
,	O
HIV	O
-	O
1	O
replication	O
is	O
cooperatively	O
stimulated	O
when	O
the	O
distinct	O
LT	O
-	O
betaR	O
and	O
TNF	O
receptor	O
systems	O
are	O
simultaneously	B-Binding
engaged	I-Binding
by	O
their	O
specific	O
ligands	O
.	O

Moreover	O
,	O
in	O
a	O
physiological	O
coculture	O
cellular	O
assay	O
system	O
,	O
we	O
show	O
that	O
membrane	O
-	O
bound	O
TNF	O
-	O
alpha	O
and	O
LT	O
-	O
alpha1beta2	O
act	O
virtually	O
identically	O
to	O
their	O
soluble	O
forms	O
in	O
the	O
regulation	O
of	O
HIV	O
-	O
1	O
replication	O
.	O

Thus	O
,	O
cosignaling	O
via	O
the	O
LT	O
-	O
beta	O
and	O
TNF	O
-	O
alpha	O
receptors	O
is	O
probably	O
involved	O
in	O
the	O
modulation	O
of	O
HIV	O
-	O
1	O
replication	O
and	O
the	O
subsequent	O
determination	O
of	O
HIV	O
-	O
1	O
viral	O
burden	O
in	O
monocytes	O
.	O

Intriguingly	O
,	O
surface	O
expression	O
of	O
LT	O
-	O
alpha1beta2	O
is	O
up	O
-	O
regulated	O
on	O
a	O
T	O
cell	O
line	O
acutely	O
infected	O
with	O
HIV	O
-	O
1	O
,	O
suggesting	O
a	O
positive	O
feedback	O
loop	O
between	O
HIV	O
-	O
1	O
infection	O
,	O
LT	O
-	O
alpha1beta2	O
expression	O
,	O
and	O
HIV	O
-	O
1	O
replication	O
.	O

Given	O
the	O
critical	O
role	O
that	O
LT	O
-	O
alpha1beta2	O
plays	O
in	O
lymphoid	O
architecture	O
,	O
we	O
speculate	O
that	O
LT	O
-	O
alpha1beta2	O
may	O
be	O
involved	O
in	O
HIV	O
-	O
associated	O
abnormalities	O
of	O
the	O
lymphoid	O
organs	O
.	O

Resistance	O
to	O
tumor	O
necrosis	O
factor	O
induced	O
apoptosis	O
in	O
vitro	O
correlates	O
with	O
high	O
metastatic	O
capacity	O
of	O
cells	O
in	O
vivo	O
.	O

TNF	O
is	O
one	O
of	O
the	O
cytokines	O
secreted	O
by	O
the	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Our	O
data	O
demonstrate	O
that	O
those	O
cell	O
lines	O
lacking	O
capability	O
to	O
form	O
metastatic	O
tumors	O
in	O
vivo	O
are	O
susceptible	O
to	O
TNF	O
induced	O
apoptosis	O
in	O
vitro	O
.	O

However	O
,	O
cell	O
lines	O
with	O
high	O
metastatic	O
potential	O
are	O
resistant	O
to	O
TNF	O
in	O
vitro	O
.	O

Furthermore	O
,	O
the	O
same	O
cell	O
lines	O
were	O
resistant	O
to	O
cytolytic	O
action	O
of	O
other	O
cytotoxic	O
proteins	O
secreted	O
by	O
LAK	O
cells	O
.	O

Our	O
data	O
showed	O
that	O
TNF	O
resistance	O
in	O
vitro	O
correlates	O
with	O
the	O
increased	O
level	O
of	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

This	O
finding	O
may	O
provide	O
a	O
tool	O
to	O
improve	O
current	O
protocols	O
of	O
immunotherapy	O
and	O
insights	O
to	O
how	O
tumor	O
cells	O
are	O
or	O
are	O
not	O
killed	O
by	O
LAK	O
cells	O
.	O

NF	O
-	O
kappaB	O
activation	O
is	O
required	O
for	O
C5a	O
-	O
induced	B-Positive_regulation
interleukin	O
-	O
8	O
gene	O
expression	B-Gene_expression
in	O
mononuclear	O
cells	O
.	O

C5a	O
,	O
a	O
potent	O
peptide	O
chemoattractant	O
,	O
stimulates	B-Positive_regulation
interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
)	O
secretion	B-Localization
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O

Experiments	O
were	O
conducted	O
to	O
understand	O
the	O
mechanisms	O
for	O
C5a	O
-	O
induced	B-Positive_regulation
IL	O
-	O
8	O
production	B-Gene_expression
,	O
which	O
was	O
14	O
-	O
fold	O
greater	O
than	O
that	O
in	O
unstimulated	O
cells	O
by	O
2	O
hours	O
.	O

IL	O
-	O
8	O
secretion	B-Localization
was	O
accompanied	O
by	O
accumulation	O
of	O
IL	O
-	O
8	O
mRNA	O
in	O
the	O
cytosol	O
and	O
by	O
nuclear	O
expression	O
of	O
a	O
kappaB	O
DNA	O
binding	O
activity	O
within	O
30	O
minutes	O
.	O

AP	O
-	O
1	O
but	O
not	O
NF-IL	O
-	O
6	O
DNA	O
binding	B-Binding
activity	O
was	O
also	O
detected	B-Positive_regulation
in	O
C5a	O
-	O
stimulated	O
PBMC	O
;	O
however	O
,	O
its	O
delayed	O
expression	O
(	O
maximal	O
at	O
4	O
hours	O
)	O
suggested	O
a	O
less	O
important	O
role	B-Regulation
in	O
the	O
rapid	O
production	B-Gene_expression
of	O
IL	O
-	O
8	O
.	O

The	O
correlation	O
between	O
C5a	O
-	O
induced	O
kappaB	O
binding	O
activity	O
and	O
IL	O
-	O
8	O
gene	O
expression	B-Gene_expression
was	O
examined	O
in	O
the	O
RAW264.7	O
macrophage	O
cells	O
using	O
reporter	O
genes	O
directed	O
by	O
the	O
kappaB	O
sequence	O
from	O
IkappaBalpha	O
and	O
IL	O
-	O
8	O
promoter	O
regions	O
.	O

C5a	O
-	O
induced	O
reporter	O
gene	O
expression	O
was	O
abolished	O
by	O
introducing	O
mutations	O
into	O
the	O
kappaB	O
sites	O
and	O
by	O
coexpression	B-Gene_expression
of	O
a	O
dominant	O
negative	O
IkappaBalpha	O
construct	O
resistant	O
to	O
agonist	O
-	O
induced	O
phosphorylation	O
.	O

Pertussis	O
toxin	O
,	O
which	O
ADP	O
-	O
ribosylates	O
the	O
Gi	O
proteins	O
known	O
to	O
couple	B-Binding
to	O
the	O
C5a	O
receptor	O
,	O
produced	O
minimal	O
inhibition	B-Negative_regulation
of	O
C5a	O
-	O
induced	B-Positive_regulation
IL	O
-	O
8	O
expression	B-Gene_expression
and	O
had	O
little	O
effect	O
on	O
C5a	O
-	O
induced	O
calcium	O
mobilization	O
in	O
RAW264.7	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
NF	O
-	O
kappaB	O
activation	O
is	O
required	O
for	O
C5a	O
-	O
induced	B-Positive_regulation
IL	O
-	O
8	O
gene	O
expression	B-Gene_expression
and	O
that	O
this	O
response	O
is	O
mediated	O
primarily	O
through	O
a	O
pertussis	O
toxin	O
-	O
insensitive	O
pathway	O
.	O

Transcriptional	O
targeting	O
of	O
retroviral	O
vectors	O
to	O
the	O
erythroblastic	O
progeny	O
of	O
transduced	O
hematopoietic	O
stem	O
cells	O
.	O

Targeted	O
expression	O
to	O
specific	O
tissues	O
or	O
cell	O
lineages	O
is	O
a	O
necessary	O
feature	O
of	O
a	O
gene	O
therapy	O
vector	O
for	O
many	O
clinical	O
applications	O
,	O
such	O
as	O
correction	O
of	O
hemoglobinopathies	O
or	O
thalassemias	O
by	O
transplantation	O
of	O
genetically	O
modified	O
hematopoietic	O
stem	O
cells	O
.	O

We	O
developed	O
retroviral	O
vectors	O
in	O
which	O
the	O
constitutive	O
viral	O
enhancer	O
in	O
the	O
U3	O
region	O
of	O
the	O
3	O
'	O
LTR	O
is	O
replaced	O
by	O
an	O
autoregulatory	O
enhancer	O
of	O
the	O
erythroid	O
-	O
specific	O
GATA	O
-	O
1	O
transcription	O
factor	O
gene	O
.	O

The	O
replaced	O
enhancer	O
is	O
propagated	O
to	O
the	O
5	O
'	O
LTR	O
upon	O
integration	O
into	O
the	O
target	O
cell	O
genome	O
.	O

The	O
modified	O
vectors	O
were	O
used	O
to	O
transduce	O
human	O
hematopoietic	O
cell	O
lines	O
,	O
cord	O
blood	O
-	O
derived	O
CD34	O
(	O
+	O
)	O
stem/progenitor	O
cells	O
,	O
and	O
murine	O
bone	O
marrow	O
repopulating	O
stem	O
cells	O
.	O

The	O
expression	B-Gene_expression
of	O
appropriate	O
reporter	O
genes	O
(	O
triangle	O
upLNGFR	O
,	O
EGFP	O
)	O
was	O
analyzed	O
in	O
the	O
differentiated	O
progeny	O
of	O
transduced	O
stem	O
cells	O
in	O
vitro	O
,	O
in	O
liquid	O
culture	O
as	O
well	O
as	O
in	O
clonogenic	O
assay	O
,	O
and	O
in	O
vivo	O
,	O
after	O
bone	O
marrow	O
transplantation	O
in	O
lethally	O
irradiated	O
mice	O
.	O

The	O
GATA	O
-	O
1	O
autoregulatory	O
enhancer	O
effectively	O
restricts	O
the	O
expression	O
of	O
the	O
LTR	O
-	O
driven	O
proviral	O
transcription	O
unit	O
to	O
the	O
erythroblastic	O
progeny	O
of	O
both	O
human	O
progenitors	O
and	O
mouse	O
-	O
repopulating	O
stem	O
cells	O
.	O

Packaging	O
of	O
viral	O
particles	O
,	O
integration	O
into	O
the	O
target	O
genome	O
,	O
and	O
stability	O
of	O
the	O
integrated	O
provirus	O
are	O
not	O
affected	O
by	O
the	O
LTR	O
modification	O
.	O

Enhancer	O
replacement	O
is	O
therefore	O
an	O
effective	O
strategy	O
to	O
target	O
expression	O
of	O
a	O
retroviral	O
transgene	O
to	O
a	O
specific	O
progeny	O
of	O
transduced	O
hematopoietic	O
stem	O
cells	O
.	O

An	O
essential	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
human	O
CD34	O
(	O
+	O
)	O
bone	O
marrow	O
cell	O
survival	O
.	O

The	O
transcription	O
factor	O
,	O
NF	O
-	O
kappaB	O
,	O
is	O
important	O
for	O
T	O
-	O
cell	O
activation	O
,	O
B	O
-	O
cell	O
maturation	O
,	O
and	O
human	O
immunodeficiency	O
virus	O
transcription	O
and	O
plays	O
a	O
role	O
in	O
alternatively	O
mediating	O
and	O
protecting	O
against	O
apoptosis	O
in	O
a	O
variety	O
of	O
cell	O
types	O
.	O

However	O
,	O
a	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
human	O
CD34	O
(	O
+	O
)	O
bone	O
marrow	O
cells	O
has	O
not	O
been	O
described	O
.	O

We	O
provide	O
evidence	O
here	O
that	O
virtually	O
all	O
human	O
CD34	O
(	O
+	O
)	O
bone	O
marrow	O
cells	O
express	B-Gene_expression
NF	O
-	O
kappaB	O
that	O
can	O
be	O
activated	O
by	O
exposure	O
to	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
and	O
a	O
variety	O
of	O
cytokines	O
,	O
eg	O
,	O
tumor	O
necrosis	O
factor	O
alpha	O
,	O
interleukin	O
-	O
3	O
,	O
and	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
NF	O
-	O
kappaB	O
may	O
be	O
required	O
for	O
human	O
CD34	O
(	O
+	O
)	O
bone	O
marrow	O
cell	O
clonogenic	O
function	O
and	O
survival	O
.	O

These	O
results	O
offer	O
insight	O
into	O
a	O
new	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
maintaining	O
survival	O
and	O
function	O
in	O
hematopoietic	O
stem	O
and	O
progenitor	O
cells	O
and	O
suggest	O
that	O
proposed	O
strategies	O
involving	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
as	O
an	O
adjunct	O
to	O
cancer	O
chemotherapy	O
should	O
be	O
approached	O
with	O
caution	O
.	O

Unicellular	O
-	O
unilineage	O
erythropoietic	O
cultures	O
:	O
molecular	O
analysis	O
of	O
regulatory	O
gene	O
expression	O
at	O
sibling	O
cell	O
level	O
.	O

In	O
vitro	O
studies	O
on	O
hematopoietic	O
control	O
mechanisms	O
have	O
been	O
hampered	O
by	O
the	O
heterogeneity	O
of	O
the	O
analyzed	O
cell	O
populations	O
,	O
ie	O
,	O
lack	O
of	O
lineage	O
specificity	O
and	O
developmental	O
stage	O
homogeneity	O
of	O
progenitor/precursor	O
cells	O
growing	O
in	O
culture	O
.	O

We	O
developed	O
unicellular	O
culture	O
systems	O
for	O
unilineage	O
differentiation	O
of	O
purified	O
hematopoietic	O
progenitor	O
cells	O
followed	O
by	O
daughter	O
cell	O
analysis	O
at	O
cellular	O
and	O
molecular	O
level	O
.	O

In	O
the	O
culture	O
system	O
reported	O
here	O
,	O
(	O
1	O
)	O
the	O
growth	O
factor	O
(	O
GF	O
)	O
stimulus	O
induces	O
cord	O
blood	O
(	O
CB	O
)	O
progenitor	O
cells	O
to	O
proliferate	O
and	O
differentiate/mature	O
exclusively	O
along	O
the	O
erythroid	O
lineage	O
;	O
(	O
2	O
)	O
this	O
erythropoietic	O
wave	O
is	O
characterized	O
by	O
less	O
than	O
4	O
%	O
apoptotic	O
cells	O
;	O
(	O
3	O
)	O
asymmetric	O
divisions	O
are	O
virtually	O
absent	O
,	O
ie	O
,	O
nonresponsive	O
hematopoietic	O
progenitors	O
with	O
no	O
erythropoietic	O
potential	O
are	O
forced	O
into	O
apoptosis	O
;	O
(	O
4	O
)	O
the	O
system	O
is	O
cell	O
division	O
controlled	O
(	O
cdc	O
)	O
,	O
ie	O
,	O
the	O
number	O
of	O
divisions	O
performed	O
by	O
each	O
cell	O
is	O
monitored	O
.	O

Single	O
-	O
cell	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analysis	O
was	O
applied	O
to	O
this	O
culture	O
system	O
to	O
investigate	O
gene	B-Gene_expression
expression	I-Gene_expression
of	O
diverse	O
receptors	O
,	O
markers	O
of	O
differentiation	O
,	O
and	O
transcription	O
factors	O
(	O
EKLF	O
,	O
GATA	O
-	O
1	O
,	O
GATA	O
-	O
2	O
,	O
p45	O
NF	O
-	O
E2	O
,	O
PU.1	O
,	O
and	O
SCL/Tal1	O
)	O
at	O
discrete	O
stages	O
of	O
erythropoietic	O
development	O
.	O

Freshly	O
isolated	O
CD34	O
(	O
+	O
)	O
cells	O
expressed	B-Gene_expression
CD34	O
,	O
c	O
-	O
kit	O
,	O
PU.1	O
,	O
and	O
GATA	O
-	O
2	O
but	O
did	O
not	O
express	B-Gene_expression
CD36	O
,	O
erythropoietin	O
receptor	O
(	O
EpoR	O
)	O
,	O
SCL/Tal1	O
,	O
EKLF	O
,	O
NF	O
-	O
E2	O
,	O
GATA	O
-	O
1	O
,	O
or	O
glyocophorin	O
A	O
(	O
GPA	O
)	O
.	O

In	O
early	O
to	O
intermediate	O
stages	O
of	O
erythroid	O
differentiation	O
we	O
monitored	O
the	O
induction	B-Positive_regulation
of	O
CD36	O
,	O
Tal1	O
,	O
EKLF	O
,	O
NF	O
-	O
E2	O
,	O
and	O
GATA	O
-	O
1	O
that	O
preceeded	O
expression	B-Gene_expression
of	O
EpoR	O
.	O

In	O
late	O
stages	O
of	O
erythroid	O
maturation	O
,	O
GPA	O
was	O
upregulated	B-Positive_regulation
,	O
whereas	O
CD34	O
,	O
c	O
-	O
kit	O
,	O
PU.1	O
,	O
and	O
GATA	O
-	O
2	O
were	O
barely	O
or	O
not	O
detected	B-Gene_expression
.	O

In	O
addition	O
,	O
competitive	O
single	O
-	O
cell	O
RT	O
-	O
PCR	O
was	O
used	O
to	O
assay	O
CD34	O
mRNA	B-Transcription
transcripts	I-Transcription
in	O
sibling	O
CD34	O
(	O
+	O
)	O
CD38	O
(	O
-	O
)	O
cells	O
differentiating	O
in	O
unilineage	O
erythroid	O
cultures	O
:	O
this	O
analysis	O
allowed	O
us	O
to	O
semiquantitate	O
the	O
gradual	O
downmodulation	B-Negative_regulation
of	O
CD34	O
mRNA	O
from	O
progenitor	O
cells	O
through	O
their	O
differentiating	O
erythroid	O
progeny	O
.	O

It	O
is	O
concluded	O
that	O
this	O
novel	O
culture	O
system	O
,	O
coupled	O
with	O
single	O
-	O
cell	O
RT	O
-	O
PCR	O
analysis	O
,	O
may	O
eliminate	O
the	O
ambiguities	O
intrinsic	O
to	O
molecular	O
studies	O
on	O
heterogeneous	O
populations	O
of	O
hematopoietic	O
progenitors/precursors	O
growing	O
in	O
culture	O
,	O
particularly	O
in	O
the	O
initial	O
stages	O
of	O
development	O
.	O

Control	O
of	O
cell	O
cycle	O
entry	O
and	O
apoptosis	O
in	O
B	O
lymphocytes	O
infected	O
by	O
Epstein	O
-	O
Barr	O
virus	O
.	O

Infection	O
of	O
human	O
B	O
cells	O
with	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
results	O
in	O
activation	O
of	O
the	O
cell	O
cycle	O
and	O
cell	O
growth	O
.	O

To	O
interpret	O
the	O
mechanisms	O
by	O
which	O
EBV	O
activates	O
the	O
cell	O
,	O
we	O
have	O
assayed	O
many	O
proteins	O
involved	O
in	O
control	O
of	O
the	O
G0	O
and	O
G1	O
phases	O
of	O
the	O
cell	O
cycle	O
and	O
regulation	O
of	O
apoptosis	O
.	O

In	O
EBV	O
infection	O
most	O
of	O
the	O
changes	O
,	O
including	O
the	O
early	O
induction	B-Positive_regulation
of	O
cyclin	O
D2	O
,	O
are	O
dependent	B-Positive_regulation
on	O
expression	O
of	O
EBV	O
genes	O
,	O
but	O
an	O
alteration	B-Regulation
in	O
the	O
E2F	O
-	O
4	O
profile	O
was	O
partly	O
independent	B-Regulation
of	O
viral	O
gene	O
expression	O
,	O
presumably	O
occurring	B-Positive_regulation
in	O
response	O
to	O
signal	O
transduction	O
activated	O
when	O
the	O
virus	O
binds	B-Binding
to	O
its	O
receptor	O
,	O
CD21	O
.	O

By	O
comparing	O
the	O
expression	O
of	O
genes	O
controlling	O
apoptosis	O
,	O
including	O
those	O
encoding	O
several	O
members	O
of	O
the	O
BCL	O
-	O
2	O
family	O
of	O
proteins	O
,	O
the	O
known	O
relative	O
resistance	O
of	O
EBV	O
-	O
immortalized	O
B	O
-	O
cell	O
lines	O
to	O
apoptosis	O
induced	O
by	O
low	O
serum	O
was	O
found	O
to	O
correlate	O
with	O
expression	B-Gene_expression
of	O
both	O
BCL	O
-	O
2	O
and	O
A20	O
.	O

A20	O
can	O
be	O
regulated	B-Regulation
by	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
,	O
which	O
is	O
known	O
to	O
be	O
activated	O
by	O
the	O
EBV	O
LMP	O
-	O
1	O
protein	O
.	O

Quantitative	O
assays	O
demonstrated	O
a	O
direct	O
temporal	O
relationship	O
between	O
LMP	O
-	O
1	O
protein	O
levels	O
and	O
active	O
NF	O
-	O
kappaB	O
during	O
the	O
time	O
course	O
of	O
infection	O
.	O

Immortalization	O
of	O
CD4	O
(	O
+	O
)	O
and	O
CD8	O
(	O
+	O
)	O
T	O
lymphocytes	O
by	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
Tax	O
mutants	O
expressed	B-Gene_expression
in	O
a	O
functional	O
molecular	O
clone	O
.	O

The	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
transcriptional	O
trans	O
-	O
activator	O
Tax	O
has	O
been	O
demonstrated	O
to	O
have	O
transforming	O
activity	O
in	O
multiple	O
cell	O
culture	O
and	O
transgenic	O
-	O
mouse	O
models	O
.	O

In	O
addition	O
to	O
activating	O
transcription	O
from	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
through	O
the	O
cyclic	O
AMP	O
response	O
element	O
binding	O
protein/activating	O
transcription	O
factor	O
(	O
CREB/ATF	O
)	O
family	O
of	O
transcription	O
factors	O
,	O
Tax	O
activates	O
the	O
expression	O
of	O
multiple	O
cellular	O
promoters	O
through	O
the	O
NF	O
-	O
kappaB	O
pathway	O
of	O
transcriptional	O
activation	O
.	O

The	O
Tax	O
mutants	O
M22	O
and	O
M47	O
have	O
previously	O
been	O
demonstrated	O
to	O
selectively	O
abrogate	O
the	O
ability	O
of	O
Tax	O
to	O
activate	O
transcription	O
through	O
the	O
NF	O
-	O
kappaB	O
or	O
CREB/ATF	O
pathway	O
,	O
respectively	O
.	O

These	O
mutations	O
were	O
introduced	O
in	O
the	O
tax	O
gene	O
of	O
the	O
ACH	O
functional	O
molecular	O
clone	O
of	O
HTLV	O
-	O
1	O
,	O
and	O
virus	O
produced	O
from	O
the	O
mutant	O
ACH	O
clones	O
was	O
examined	O
for	O
the	O
ability	O
to	O
replicate	O
and	O
immortalize	O
primary	O
human	O
lymphocytes	O
.	O

While	O
virus	O
derived	O
from	O
the	O
clone	O
containing	O
the	O
M47	O
mutation	O
retained	O
the	O
ability	O
to	O
immortalize	O
T	O
lymphocytes	O
,	O
the	O
M22	O
mutant	O
lost	O
the	O
ability	O
to	O
immortalize	O
infected	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
activation	O
of	O
the	O
CREB/ATF	O
pathway	O
by	O
Tax	O
is	O
dispensable	O
for	O
the	O
immortalization	O
of	O
T	O
cells	O
by	O
HTLV	O
-	O
1	O
,	O
whereas	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
may	O
be	O
critical	O
.	O

HIV	O
-	O
1	O
reactivation	O
in	O
resting	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
infected	O
adults	O
upon	O
in	O
vitro	O
CD4	O
cross	B-Binding
-	I-Binding
linking	I-Binding
by	O
ligands	O
of	O
the	O
CDR2	O
-	O
loop	O
in	O
extracellular	O
domain	O
1	O
.	O

HIV	O
-	O
1	O
infects	O
resting	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
but	O
remains	O
inactive	O
state	O
until	O
subsequent	O
cell	O
activation	O
.	O

We	O
have	O
demonstrated	O
that	O
the	O
cross	B-Binding
-	I-Binding
linking	I-Binding
of	O
cell	O
surface	O
CD4	O
by	O
gp120-anti	O
-	O
gp120	O
immune	O
complexes	O
or	O
heat	O
-	O
inactivated	O
HIV	O
-	O
1	O
(	O
iHIV	O
-	O
1	O
)	O
is	O
sufficient	O
to	O
trigger	O
activation	O
signals	O
leading	O
to	O
virus	O
reactivation	O
(	O
9	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
NF	O
-	O
kappaB	O
nuclear	O
translocation	O
and	O
stimulation	O
of	O
virus	O
production	O
by	O
iHIV	O
-	O
1	O
were	O
strictly	O
linked	O
to	O
the	O
concentrations	O
of	O
viral	O
proteins	O
used	O
as	O
exogenous	O
stimuli	O
.	O

Moreover	O
,	O
we	O
further	O
investigated	O
the	O
physiologic	O
relevance	O
of	O
these	O
observations	O
.	O

When	O
submitted	O
to	O
an	O
in	O
vitro	O
CD4	O
cross	B-Binding
-	I-Binding
linking	I-Binding
by	O
iHIV	O
-	O
1	O
,	O
PBMCs	O
from	O
HIV-1	O
-	O
infected	O
patients	O
were	O
found	O
to	O
produce	O
virus	O
.	O

This	O
viral	O
reactivation	O
was	O
associated	O
with	O
increased	O
NF	O
-	O
kappaB	O
nuclear	O
translocation	O
in	O
patients	O
'	O
PBMCs	O
.	O

Additionally	O
,	O
virus	O
reactivation	O
in	O
resting	O
PBMCs	O
infected	O
in	O
vitro	O
with	O
HIV	O
-	O
1	O
was	O
found	O
to	O
be	O
specifically	O
induced	O
by	O
ligands	O
of	O
the	O
CDR2	O
-	O
loop	O
in	O
domain	O
1	O
(	O
D1	O
)	O
of	O
CD4	O
(	O
virus	O
envelope	O
and	O
anti	O
-	O
CD4	O
monoclonal	O
antibodies	O
)	O
.	O

In	O
contrast	O
,	O
virus	O
reactivation	O
was	O
not	O
observed	O
following	O
CD4	O
oligomerization	B-Binding
by	O
antibodies	O
that	O
bind	O
other	O
epitopes	O
in	O
D1	O
,	O
including	O
the	O
D1/CDR3	O
-	O
loop	O
.	O

Finally	O
,	O
soluble	O
CD4	O
(	O
sCD4	O
)	O
prevented	O
virus	O
reactivation	O
by	O
D1/CDR2	O
-	O
loop	O
ligands	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
signaling	O
events	O
initiated	O
in	O
PBMCs	O
by	O
oligomerization	B-Binding
of	O
CD4	O
at	O
the	O
D1/CDR2	O
-	O
loop	O
can	O
trigger	O
HIV	O
-	O
1	O
upregulation	O
in	O
infected	O
individuals	O
.	O

Defining	O
therapeutic	O
targets	O
by	O
using	O
adenovirus	O
:	O
blocking	O
NF	O
-	O
kappaB	O
inhibits	O
both	O
inflammatory	O
and	O
destructive	O
mechanisms	O
in	O
rheumatoid	O
synovium	O
but	O
spares	O
anti	O
-	O
inflammatory	O
mediators	O
.	O

The	O
role	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
in	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
has	O
long	O
been	O
a	O
subject	O
of	O
controversy	O
.	O

We	O
used	O
an	O
adenoviral	O
technique	O
of	O
blocking	O
NF	O
-	O
kappaB	O
through	O
overexpression	B-Positive_regulation
of	O
the	O
inhibitory	O
subunit	O
IkappaBalpha	O
,	O
which	O
has	O
the	O
advantage	O
that	O
it	O
can	O
be	O
used	O
in	O
the	O
diseased	O
tissue	O
itself	O
,	O
with	O
>	O
90	O
%	O
of	O
the	O
synovial	O
macrophages	O
,	O
fibroblasts	O
,	O
and	O
T	O
cells	O
infected	O
.	O

We	O
found	O
that	O
the	O
spontaneous	O
production	B-Gene_expression
of	O
tumor	O
necrosis	O
factor	O
alpha	O
and	O
other	O
pro	O
-	O
inflammatory	O
cytokines	O
is	O
NF-kappaB	O
-	O
dependent	B-Regulation
in	O
rheumatoid	O
synovial	O
tissue	O
,	O
in	O
contrast	O
to	O
the	O
main	O
anti	O
-	O
inflammatory	O
mediators	O
,	O
like	O
IL	O
-	O
10	O
and	O
-	O
11	O
,	O
and	O
the	O
IL	O
-	O
1	O
receptor	O
antagonist	O
.	O

Of	O
even	O
more	O
interest	O
,	O
IkappaBalpha	O
overexpression	B-Gene_expression
inhibited	B-Negative_regulation
the	O
production	B-Gene_expression
of	O
matrix	O
metalloproteinases	O
1	O
and	O
3	O
while	O
not	O
affecting	B-Regulation
their	O
tissue	O
inhibitor	O
.	O

Blocking	O
NF	O
-	O
kappaB	O
in	O
the	O
rheumatoid	O
joint	O
thus	O
has	O
a	O
very	O
beneficial	O
profile	O
,	O
reducing	O
both	O
the	O
inflammatory	O
response	O
and	O
the	O
tissue	O
destruction	O
.	O

The	O
adenoviral	O
technique	O
described	O
here	O
has	O
widespread	O
applicability	O
,	O
allowing	O
rapid	O
testing	O
of	O
the	O
effects	O
of	O
blocking	O
a	O
potential	O
therapeutic	O
target	O
in	O
either	O
cultures	O
of	O
normal	O
cells	O
or	O
in	O
the	O
diseased	O
tissue	O
itself	O
.	O

Cell	O
growth	O
-	O
regulated	B-Regulation
expression	B-Gene_expression
of	O
mammalian	O
MCM5	O
and	O
MCM6	O
genes	O
mediated	B-Positive_regulation
by	O
the	O
transcription	O
factor	O
E2F	O
.	O

Initiation	O
of	O
DNA	O
replication	O
requires	O
the	O
function	O
of	O
MCM	O
gene	O
products	O
,	O
which	O
participate	O
in	O
ensuring	O
that	O
DNA	O
replication	O
occurs	O
only	O
once	O
in	O
the	O
cell	O
cycle	O
.	O

Expression	O
of	O
all	O
mammalian	O
genes	O
of	O
the	O
MCM	O
family	O
is	O
induced	O
by	O
growth	O
stimulation	O
,	O
unlike	O
yeast	O
,	O
and	O
the	O
mRNA	O
levels	O
peak	O
at	O
G1/S	O
boundary	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
transcriptional	O
activities	O
of	O
isolated	O
human	O
MCM	O
gene	O
promoters	O
.	O

Human	O
MCM5	O
and	O
MCM6	O
promoters	O
with	O
mutation	O
in	O
the	O
E2F	O
sites	O
failed	B-Negative_regulation
in	O
promoter	O
regulation	B-Regulation
following	O
serum	O
stimulation	O
and	O
exogenous	O
E2F	O
expression	O
.	O

In	O
addition	O
,	O
we	O
identified	O
a	O
novel	O
E2F	O
-	O
like	O
sequence	O
in	O
human	O
MCM6	O
promoter	O
which	O
cooperates	B-Regulation
with	O
the	O
authentic	O
E2F	O
sites	O
in	O
E2F	O
-	O
dependent	O
regulation	O
.	O

Forced	O
expression	B-Gene_expression
of	O
E2F1	O
could	O
induce	O
expression	O
of	O
all	O
members	O
of	O
the	O
endogenous	O
MCM	O
genes	O
in	O
rat	O
embryonal	O
fibroblast	O
REF52	O
cells	O
.	O

Our	O
results	O
demonstrated	O
that	O
the	O
growth	O
-	O
regulated	B-Regulation
expression	B-Gene_expression
of	O
mammalian	O
MCM5	O
and	O
MCM6	O
genes	O
,	O
and	O
presumably	O
other	O
MCM	O
members	O
,	O
is	O
primarily	O
regulated	B-Regulation
by	O
E2F	O
through	O
binding	B-Binding
to	O
multiple	O
E2F	O
sites	O
in	O
the	O
promoters	O
.	O

Non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
inhibit	O
the	O
expression	O
of	O
cytokines	O
and	O
induce	O
HSP70	O
in	O
human	O
monocytes	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
the	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
activate	B-Positive_regulation
heat	O
shock	O
transcription	O
factor	O
(	O
HSF1	O
)	O
from	O
a	O
latent	O
cytoplasmic	O
form	O
to	O
a	O
nuclear	O
,	O
DNA	O
binding	B-Binding
state	O
.	O

As	O
HSF1	O
can	O
function	O
as	O
both	O
an	O
activator	B-Positive_regulation
of	O
heat	O
shock	O
genes	O
and	O
a	O
repressor	B-Negative_regulation
of	O
non	O
-	O
heat	O
shock	O
genes	O
such	O
as	O
IL1B	O
and	O
c	O
-	O
fos	O
,	O
we	O
have	O
examined	O
the	O
potential	O
role	O
of	O
HSF1	O
in	O
the	O
effects	O
of	O
NSAIDs	O
on	O
gene	O
expression	O
in	O
a	O
human	O
monocytic	O
cell	O
line	O
THP	O
-	O
1	O
.	O

We	O
found	O
that	O
two	O
members	O
of	O
the	O
NSAIDs	O
,	O
sodium	O
salicylate	O
and	O
sulindac	O
repress	B-Negative_regulation
the	O
IL1B	O
promoter	O
to	O
similar	O
degree	O
to	O
heat	O
shock	O
or	O
HSF1	O
overexpression	O
.	O

In	O
addition	O
,	O
sodium	O
salicylate	O
and	O
additional	O
NSAIDs	O
used	O
at	O
concentrations	O
that	O
activate	B-Positive_regulation
HSF1	O
also	O
inhibited	B-Negative_regulation
the	O
expression	B-Gene_expression
of	O
other	O
monocytic	O
genes	O
(	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1beta	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
IL	O
-	O
10	O
,	O
ICAM	O
-	O
1	O
)	O
activated	B-Positive_regulation
by	O
exposure	O
to	O
a	O
pro	O
-	O
inflammatory	O
stimulus	O
(	O
lipopolysaccharide	O
,	O
LPS	O
)	O
.	O

At	O
least	O
in	O
the	O
case	O
of	O
the	O
IL1B	O
promoter	O
,	O
repression	B-Negative_regulation
did	O
not	O
seem	O
to	O
involve	O
another	O
factor	O
whose	O
activity	O
is	O
affected	O
by	O
the	O
NSAIDs	O
,	O
NFkappaB	O
as	O
the	O
IL1B	O
promoter	O
fragment	O
used	O
in	O
our	O
studies	O
is	O
not	O
NFkappaB	O
responsive	B-Regulation
and	O
binds	B-Binding
specifically	O
to	O
HSF1	O
.	O

Exposure	O
to	O
NSAIDs	O
had	O
a	O
complex	O
effect	O
on	O
HSP	O
gene	O
expression	O
and	O
while	O
sulindac	O
activated	B-Positive_regulation
the	O
stress	O
responsive	B-Positive_regulation
HSP70B	O
promoter	O
,	O
sodium	O
salicylate	O
did	O
not	O
.	O

In	O
addition	O
,	O
only	O
a	O
subset	O
of	O
the	O
NSAIDs	O
induced	B-Positive_regulation
HSP70	O
mRNA	O
species	O
.	O

These	O
findings	O
reflect	O
the	O
properties	O
of	O
HSF1	O
which	O
can	O
be	O
activated	B-Positive_regulation
to	O
at	O
least	O
two	O
DNA	O
binding	B-Binding
forms	O
only	O
one	O
of	O
which	O
activates	O
heat	O
shock	O
promoters	O
and	O
suggest	O
that	O
individual	O
NSAID	O
family	O
members	O
may	O
differentially	O
induce	O
one	O
or	O
other	O
of	O
these	O
forms	O
.	O

Overall	O
therefore	O
,	O
exposure	O
to	O
NSAIDs	O
leads	O
to	O
a	O
profound	O
switch	O
in	O
gene	O
expression	O
in	O
monocytic	O
cells	O
,	O
with	O
suppression	O
of	O
genes	O
involved	O
in	O
macrophage	O
activation	O
and	O
induction	O
of	O
stress	O
genes	O
and	O
HSF1	O
appears	O
to	O
play	O
a	O
regulatory	O
role	O
in	O
these	O
effects	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Disruption	O
of	O
alpha	O
beta	O
but	O
not	O
of	O
gamma	O
delta	O
T	O
cell	O
development	O
by	O
overexpression	B-Positive_regulation
of	O
the	O
helix-loop	O
-	O
helix	O
protein	O
Id3	O
in	O
committed	O
T	O
cell	O
progenitors	O
.	O

Enforced	B-Positive_regulation
expression	B-Gene_expression
of	O
Id3	O
,	O
which	O
has	O
the	O
capacity	O
to	O
inhibit	O
many	O
basic	O
helix-loop	O
-	O
helix	O
(	O
bHLH	O
)	O
transcription	O
factors	O
,	O
in	O
human	O
CD34	O
(	O
+	O
)	O
hematopoietic	O
progenitor	O
cells	O
that	O
have	O
not	O
undergone	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
gene	O
rearrangements	O
inhibits	O
development	O
of	O
the	O
transduced	O
cells	O
into	O
TCRalpha	O
beta	O
and	O
gamma	O
delta	O
cells	O
in	O
a	O
fetal	O
thymic	O
organ	O
culture	O
(	O
FTOC	O
)	O
.	O

Here	O
we	O
document	O
that	O
overexpression	B-Gene_expression
of	O
Id3	O
,	O
in	O
progenitors	O
that	O
have	O
initiated	O
TCR	O
gene	O
rearrangements	O
(	O
pre	O
-	O
T	O
cells	O
)	O
,	O
inhibits	O
development	O
into	O
TCRalpha	O
beta	O
but	O
not	O
into	O
TCRgamma	O
delta	O
T	O
cells	O
.	O

Furthermore	O
,	O
Id3	O
impedes	O
expression	O
of	O
recombination	O
activating	O
genes	O
and	O
downregulates	O
pre	O
-	O
Talpha	O
mRNA	O
.	O

These	O
observations	O
suggest	O
possible	O
mechanisms	O
by	O
which	O
Id3	O
overexpression	B-Gene_expression
can	O
differentially	O
affect	O
development	O
of	O
pre	O
-	O
T	O
cells	O
into	O
TCRalpha	O
beta	O
and	O
gamma	O
delta	O
cells	O
.	O

We	O
also	O
observed	O
that	O
cell	O
surface	O
CD4	O
(	O
-	O
)	O
CD8	O
(	O
-	O
)	O
CD3	O
(	O
-	O
)	O
cells	O
with	O
rearranged	O
TCR	O
genes	O
developed	O
from	O
Id3	O
-	O
transduced	O
but	O
not	O
from	O
control	O
-	O
transduced	O
pre	O
-	O
T	O
cells	O
in	O
an	O
FTOC	O
.	O

These	O
cells	O
had	O
properties	O
of	O
both	O
natural	O
killer	O
(	O
NK	O
)	O
and	O
pre	O
-	O
T	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
bHLH	O
factors	O
are	O
required	O
to	O
control	O
T	O
cell	O
development	O
after	O
the	O
T/NK	O
developmental	O
checkpoint	O
.	O

Rel/NF	O
-	O
kappaB	O
can	O
trigger	O
the	O
Notch	O
signaling	O
pathway	O
by	O
inducing	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
Jagged1	O
,	O
a	O
ligand	O
for	O
Notch	O
receptors	O
.	O

Jagged1	O
belongs	O
to	O
the	O
DSL	O
family	O
of	O
ligands	O
for	O
Notch	O
receptors	O
that	O
control	O
the	O
proliferation	O
and	O
differentiation	O
of	O
various	O
cell	O
lineages	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
transcription	O
factors	O
that	O
regulate	B-Regulation
its	O
expression	B-Gene_expression
.	O

Here	O
,	O
we	O
show	O
that	O
Jagged1	O
is	O
a	O
Rel/NF-kappaB	O
-	O
responsive	B-Regulation
gene	O
.	O

Both	O
c	O
-	O
Rel	O
and	O
RelA	O
induced	B-Positive_regulation
jagged1	O
gene	O
expression	B-Gene_expression
,	O
whereas	O
a	O
mutant	O
defective	O
for	O
transactivation	O
did	O
not	O
.	O

Importantly	O
,	O
jagged1	O
transcripts	O
were	O
also	O
upregulated	B-Positive_regulation
by	O
endogenous	O
NF	O
-	O
kappaB	O
activation	O
and	O
this	O
effect	O
was	O
inhibited	B-Negative_regulation
by	O
a	O
dominant	O
mutant	O
of	O
IkappaBalpha	O
,	O
a	O
physiological	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
.	O

Cell	O
surface	O
expression	B-Gene_expression
of	O
Jagged1	O
in	O
c-Rel	O
-	O
expressing	B-Gene_expression
cell	O
monolayers	O
led	O
to	O
a	O
functional	O
interaction	O
with	O
lymphocytes	O
expressing	B-Gene_expression
the	O
Notch1/TAN	O
-	O
1	O
receptor	O
.	O

This	O
correlated	O
with	O
the	O
initiation	O
of	O
signaling	O
downstream	O
of	O
Notch	O
,	O
as	O
evidenced	O
by	O
increased	B-Positive_regulation
levels	I-Positive_regulation
of	O
HES	O
-	O
1	O
transcripts	O
in	O
co	O
-	O
cultivated	O
T	O
cells	O
and	O
of	O
CD23	O
transcripts	O
in	O
co	O
-	O
cultivated	O
B	O
cells	O
.	O

Consistent	O
with	O
its	O
Rel/NF-kappaB	O
-	O
dependent	O
induction	B-Positive_regulation
,	O
Jagged1	O
was	O
found	O
to	O
be	O
highly	B-Positive_regulation
expressed	B-Gene_expression
in	O
splenic	O
B	O
cells	O
where	O
c	O
-	O
Rel	O
is	O
expressed	B-Gene_expression
constitutively	O
.	O

These	O
results	O
demonstrate	O
that	O
c	O
-	O
Rel	O
can	O
trigger	O
the	O
Notch	O
signaling	O
pathway	O
in	O
neighboring	O
cells	O
by	O
inducing	B-Positive_regulation
jagged1	O
gene	O
expression	B-Gene_expression
,	O
and	O
suggest	O
a	O
role	O
for	O
Jagged1	O
in	O
B	O
-	O
cell	O
activation	O
,	O
differentiation	O
or	O
function	O
.	O

These	O
findings	O
also	O
highlight	O
the	O
potential	O
for	O
an	O
interplay	O
between	O
the	O
Notch	O
and	O
NF	O
-	O
kappaB	O
signaling	O
pathways	O
in	O
the	O
immune	O
system	O
.	O

Transcriptional	B-Regulation
control	I-Regulation
of	O
the	O
IL	O
-	O
5	O
gene	O
by	O
human	O
helper	O
T	O
cells	O
:	O
IL	O
-	O
5	O
synthesis	B-Gene_expression
is	O
regulated	B-Regulation
independently	O
from	O
IL	O
-	O
2	O
or	O
IL	O
-	O
4	O
synthesis	B-Gene_expression
.	O

BACKGROUND	O
:	O
IL	O
-	O
5	O
is	O
fundamentally	O
involved	O
in	O
eosinophilic	O
inflammation	O
.	O

Control	B-Regulation
of	O
IL	O
-	O
5	O
production	B-Gene_expression
may	O
be	O
effective	O
for	O
the	O
management	O
of	O
allergic	O
diseases	O
.	O

OBJECTIVE	O
:	O
We	O
aimed	O
to	O
find	O
the	O
transcriptional	B-Transcription
mechanisms	O
that	O
regulate	B-Regulation
the	O
IL	O
-	O
5	O
gene	O
to	O
selectively	O
control	B-Regulation
IL	O
-	O
5	O
synthesis	B-Gene_expression
.	O

METHODS	O
:	O
Allergen	O
-	O
specific	O
T	O
-	O
cell	O
clones	O
and	O
T	O
-	O
cell	O
hybridomas	O
were	O
established	O
from	O
the	O
peripheral	O
blood	O
lymphocytes	O
of	O
patients	O
with	O
asthma	O
,	O
and	O
the	O
transcriptional	B-Transcription
regulation	I-Transcription
of	O
the	O
IL	O
-	O
5	O
gene	O
was	O
investigated	O
with	O
transient	O
transfection	O
and	O
electrophoretic	O
mobility	O
shift	O
analysis	O
.	O

RESULTS	O
:	O
A	O
human	O
IL	O
-	O
5	O
promoter/enhancer	O
-	O
luciferase	O
gene	O
construct	O
,	O
pIL	O
-	O
5	O
(	O
-	O
511	O
)	O
Luc	O
,	O
was	O
transcribed	O
on	O
activation	O
of	O
IL-5	O
-	O
producing	B-Gene_expression
T	O
-	O
cell	O
clones	O
,	O
but	O
not	O
IL-5	O
-	O
nonproducing	B-Gene_expression
clones	O
.	O

pIL	O
-	O
5	O
(	O
-	O
511	O
)	O
Luc	O
was	O
transcribed	O
by	O
T	O
-	O
cell	O
hybridomas	O
derived	O
from	O
fusion	O
between	O
IL-5	O
-	O
producing	B-Gene_expression
T	O
-	O
cell	O
clones	O
and	O
an	O
IL	O
-	O
5	O
gene	O
-	O
nonexpressing	B-Gene_expression
T	O
-	O
cell	O
line	O
,	O
but	O
not	O
by	O
hybridomas	O
derived	O
from	O
IL-5	O
-	O
nonproducing	B-Gene_expression
T	O
-	O
cell	O
clones	O
.	O

IL	O
-	O
5	O
synthesis	B-Gene_expression
was	O
not	O
only	O
induced	B-Positive_regulation
by	O
T	O
-	O
cell	O
receptor	O
stimulation	O
but	O
also	O
by	O
IL	O
-	O
2	O
receptor	O
stimulation	O
.	O

Binding	O
of	O
NF	O
-	O
AT	O
,	O
NF	O
-	O
kappaB	O
,	O
and	O
AP	O
-	O
1	O
was	O
induced	O
by	O
T	O
-	O
cell	O
receptor	O
(	O
TcR	O
)	O
stimulation	O
,	O
although	O
there	O
was	O
no	O
significant	O
upregulation	O
of	O
binding	O
by	O
IL	O
-	O
2	O
stimulation	O
.	O

CONCLUSION	O
:	O
IL	O
-	O
5	O
synthesis	B-Gene_expression
by	O
human	O
helper	O
T	O
cells	O
is	O
regulated	B-Regulation
at	O
the	O
transcriptional	O
level	O
.	O

A	O
unique	O
transcriptional	O
mechanism	O
distinct	O
from	O
those	O
regulating	B-Regulation
the	O
IL	O
-	O
2	O
or	O
IL	O
-	O
4	O
genes	O
seems	O
to	O
control	B-Regulation
the	O
IL	O
-	O
5	O
gene	O
.	O

Selective	O
regulation	B-Regulation
of	O
IL	O
-	O
5	O
gene	O
transcription	B-Transcription
may	O
be	O
useful	O
for	O
treating	O
eosinophlic	O
inflammation	O
.	O

Regulation	B-Regulation
of	O
low	O
shear	O
flow	O
-	O
induced	B-Positive_regulation
HAEC	O
VCAM	O
-	O
1	O
expression	B-Gene_expression
and	O
monocyte	O
adhesion	O
.	O

We	O
recently	O
reported	O
that	O
prolonged	O
exposure	O
of	O
human	O
aortic	O
endothelial	O
cells	O
(	O
HAEC	O
)	O
to	O
low	O
shear	O
stress	O
flow	O
patterns	O
is	O
associated	O
with	O
a	O
sustained	O
increase	O
in	O
the	O
activated	O
form	O
of	O
the	O
transcriptional	O
regulator	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
.	O

Here	O
we	O
investigate	O
the	O
hypothesis	O
that	O
low	O
shear	O
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
is	O
responsible	B-Positive_regulation
for	I-Positive_regulation
enhanced	I-Positive_regulation
expression	B-Gene_expression
of	O
vascular	O
cell	O
adhesion	O
molecule	O
(	O
VCAM	O
-	O
1	O
)	O
resulting	O
in	O
augmented	O
endothelial	O
cell	O
-	O
monocyte	O
(	O
EC	O
-	O
Mn	O
)	O
adhesion	O
and	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
intracellular	O
oxidant	O
activity	O
.	O

Before	O
exposure	O
to	O
low	O
shear	O
(	O
2	O
dyn/cm2	O
)	O
for	O
6	O
h	O
,	O
HAEC	O
were	O
preincubated	O
with	O
or	O
without	O
the	O
antioxidants	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
or	O
N-acetyl-L	O
-	O
cysteine	O
(	O
NAC	O
)	O
.	O

PDTC	O
strongly	O
inhibited	B-Negative_regulation
low	O
shear	O
-	O
induced	B-Positive_regulation
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
expression	B-Gene_expression
of	O
VCAM	O
-	O
1	O
,	O
and	O
EC	O
-	O
Mn	O
adhesion	O
.	O

Paradoxically	O
,	O
NAC	O
exerted	B-Positive_regulation
a	I-Positive_regulation
positive	I-Positive_regulation
effect	I-Positive_regulation
on	O
low	O
shear	O
-	O
induced	B-Positive_regulation
VCAM	O
-	O
1	O
expression	B-Gene_expression
and	O
EC	O
-	O
Mn	O
adhesion	O
and	O
only	O
slightly	O
downregulated	O
NF	O
-	O
kappaB	O
activation	O
.	O

However	O
,	O
cytokine	O
-	O
induced	B-Positive_regulation
NF	O
-	O
kappaB	O
activation	O
and	O
VCAM	O
-	O
1	O
expression	B-Gene_expression
are	O
blocked	B-Negative_regulation
by	O
both	O
PDTC	O
and	O
NAC	O
.	O

These	O
data	O
suggest	O
that	O
NF	O
-	O
kappaB	O
plays	O
a	O
key	O
role	O
in	O
low	O
shear	O
-	O
induced	B-Positive_regulation
VCAM	O
-	O
1	O
expression	B-Gene_expression
and	O
that	O
pathways	O
mediating	O
low	O
shear	O
-	O
and	O
cytokine	O
-	O
induced	O
EC	O
-	O
Mn	O
adhesion	O
may	O
be	O
differentially	O
regulated	O
.	O

Nuclear	O
localization	B-Localization
and	O
formation	O
of	O
beta-catenin	O
-	O
lymphoid	O
enhancer	O
factor	O
1	O
complexes	B-Binding
are	O
not	O
sufficient	O
for	O
activation	O
of	O
gene	O
expression	O
.	O

In	B-Positive_regulation
response	I-Positive_regulation
to	I-Positive_regulation
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
,	O
beta	O
-	O
catenin	O
accumulates	B-Localization
in	O
the	O
nucleus	O
,	O
where	O
it	O
cooperates	O
with	O
LEF/TCF	O
(	O
for	O
lymphoid	O
enhancer	O
factor	O
and	O
T	O
-	O
cell	O
factor	O
)	O
transcription	O
factors	O
to	O
activate	O
gene	O
expression	O
.	O

The	O
mechanisms	O
by	O
which	O
beta	O
-	O
catenin	O
undergoes	B-Positive_regulation
this	O
shift	O
in	O
location	O
and	O
participates	O
in	O
activation	O
of	O
gene	O
transcription	O
are	O
unknown	O
.	O

We	O
demonstrate	O
here	O
that	O
beta	O
-	O
catenin	O
can	O
be	O
imported	B-Localization
into	O
the	O
nucleus	O
independently	O
of	O
LEF/TCF	O
binding	B-Binding
,	O
and	O
it	O
may	O
also	O
be	O
exported	B-Localization
from	O
nuclei	O
.	O

We	O
have	O
introduced	O
a	O
small	O
deletion	O
within	O
beta	O
-	O
catenin	O
(	O
Delta19	O
)	O
that	O
disrupts	B-Negative_regulation
binding	B-Binding
to	O
LEF	O
-	O
1	O
,	O
E	O
-	O
cadherin	O
,	O
and	O
APC	O
but	O
not	O
axin	O
.	O

This	O
Delta19	O
beta	O
-	O
catenin	O
mutant	O
localizes	O
to	O
the	O
nucleus	O
because	O
it	O
may	O
not	O
be	O
efficiently	O
sequestered	O
in	O
the	O
cytoplasm	O
.	O

The	O
nuclear	O
localization	O
of	O
Delta19	O
definitively	O
demonstrates	O
that	O
the	O
mechanisms	O
by	O
which	O
beta	O
-	O
catenin	O
localizes	B-Localization
in	O
the	O
nucleus	O
are	O
completely	O
independent	O
of	O
LEF/TCF	O
factors	O
.	O

beta	O
-	O
Catenin	O
and	O
LEF	O
-	O
1	O
complexes	O
can	O
activate	O
reporter	O
gene	O
expression	O
in	O
a	O
transformed	O
T	O
-	O
lymphocyte	O
cell	O
line	O
(	O
Jurkat	O
)	O
but	O
not	O
in	O
normal	O
T	O
lymphocytes	O
,	O
even	O
though	O
both	O
factors	O
are	B-Localization
nuclear	O
.	O

Thus	O
,	O
localization	B-Localization
of	O
both	O
factors	O
to	O
the	O
nucleus	O
is	O
not	O
sufficient	O
for	O
activation	O
of	O
gene	O
expression	O
.	O

Excess	B-Positive_regulation
beta	O
-	O
catenin	O
can	O
squelch	O
reporter	O
gene	O
activation	O
by	O
LEF-1-beta	O
-	O
catenin	O
complexes	O
but	O
not	O
activation	O
by	O
the	O
transcription	O
factor	O
VP16	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
a	O
third	O
component	O
is	O
necessary	O
for	O
gene	O
activation	O
and	O
that	O
this	O
third	O
component	O
may	O
vary	O
with	O
cell	O
type	O
.	O

Paradoxical	O
priming	O
effects	O
of	O
IL	O
-	O
10	O
on	O
cytokine	O
production	O
.	O

IL	O
-	O
10	O
is	O
a	O
well	O
-	O
known	O
immunosuppressive	O
and/or	O
anti	O
-	O
inflammatory	O
cytokine	O
.	O

However	O
,	O
we	O
report	O
in	O
vitro	O
experimental	O
studies	O
in	O
which	O
IL	O
-	O
10	O
primed	O
leukocytes	O
and	O
led	B-Positive_regulation
to	I-Positive_regulation
an	I-Positive_regulation
enhanced	I-Positive_regulation
production	B-Gene_expression
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
upon	B-Positive_regulation
further	O
stimulation	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Monocytes	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
prepared	O
from	O
whole	O
blood	O
maintained	O
for	O
20	O
h	O
at	O
37	O
degrees	O
C	O
in	O
the	O
presence	O
of	O
recombinant	O
human	O
IL	O
-	O
10	O
had	O
an	O
enhanced	B-Positive_regulation
capacity	O
to	O
produce	B-Gene_expression
TNF	O
in	B-Positive_regulation
response	I-Positive_regulation
to	I-Positive_regulation
LPS	O
.	O

In	O
addition	O
to	O
TNF	O
,	O
LPS	O
-	O
induced	B-Positive_regulation
IL	O
-	O
6	O
and	O
spontaneous	O
IL	O
-	O
1ra	O
production	B-Gene_expression
were	O
also	O
enhanced	B-Positive_regulation
.	O

When	O
isolated	O
PBMC	O
were	O
first	O
cultured	O
for	O
20	O
h	O
in	O
the	O
presence	O
of	O
IL	O
-	O
10	O
on	O
Teflon	O
to	O
prevent	O
adherence	O
,	O
washed	O
to	O
remove	O
IL	O
-	O
10	O
and	O
then	O
further	O
cultured	O
in	O
plastic	O
dishes	O
for	O
an	O
additional	O
20	O
h	O
in	O
the	O
presence	O
of	O
LPS	O
or	O
IL	O
-	O
1beta	O
,	O
an	O
enhanced	B-Positive_regulation
release	B-Localization
of	O
TNF	O
was	O
observed	O
.	O

This	O
was	O
not	B-Positive_regulation
the	O
case	O
when	O
PBMC	O
were	O
pre	O
-	O
cultured	O
in	O
plastic	O
multidishes	O
in	O
the	O
presence	O
of	O
IL	O
-	O
10	O
.	O

TNF	O
mRNA	O
expression	O
induced	O
by	O
LPS	O
was	O
decreased	O
when	O
the	O
pre	O
-	O
treatment	O
of	O
PBMC	O
with	O
IL	O
-	O
10	O
was	O
performed	O
on	O
plastic	O
,	O
whereas	O
this	O
was	O
not	O
the	O
case	O
when	O
cells	O
were	O
pre	O
-	O
cultured	O
with	O
IL	O
-	O
10	O
on	O
Teflon	O
.	O

Furthermore	O
,	O
NFkappaB	O
translocation	O
following	O
LPS	O
activation	O
was	O
higher	O
after	O
IL	O
-	O
10	O
pre	O
-	O
treatment	O
on	O
Teflon	O
than	O
on	O
plastic	O
.	O

Interestingly	O
,	O
an	O
enhanced	O
frequency	O
of	O
CD16	O
and	O
CD68	O
(	O
+	O
)	O
cells	O
among	O
the	O
CD14	O
(	O
+	O
)	O
cells	O
was	O
observed	O
in	O
the	O
presence	O
of	O
IL	O
-	O
10	O
,	O
independently	O
of	O
the	O
pre	O
-	O
culture	O
conditions	O
of	O
the	O
PBMC	O
.	O

Altogether	O
,	O
these	O
results	O
indicate	O
that	O
the	O
IL-10	O
-	O
induced	O
up	O
-	O
regulation	O
of	O
cytokine	O
production	O
depends	O
on	O
the	O
prevention	O
of	O
monocyte	O
adherence	O
by	O
red	O
cells	O
in	O
the	O
whole	O
blood	O
assays	O
or	O
by	O
cultures	O
of	O
PBMC	O
on	O
Teflon	O
.	O

In	O
contrast	O
,	O
the	O
adherence	O
parameter	O
has	O
no	O
effect	O
on	O
the	O
IL-10	O
-	O
induced	O
modulation	O
of	O
some	O
monocyte	O
surface	O
markers	O
.	O

Different	O
sequence	O
requirements	B-Positive_regulation
for	O
expression	B-Gene_expression
in	O
erythroid	O
and	O
megakaryocytic	O
cells	O
within	O
a	O
regulatory	O
element	O
upstream	O
of	O
the	O
GATA	O
-	O
1	O
gene	O
.	O

The	O
lineage	O
-	O
restricted	O
transcription	O
factor	O
GATA	O
-	O
1	O
is	O
required	O
for	O
differentiation	O
of	O
erythroid	O
and	O
megakaryocytic	O
cells	O
.	O

We	O
have	O
localized	O
a	O
317	O
base	O
pair	O
cis	O
-	O
acting	O
regulatory	O
element	O
,	O
HS	O
I	O
,	O
associated	O
with	O
a	O
hematopoietic	O
-	O
specific	O
DNase	O
I	O
hypersensitive	O
site	O
,	O
which	O
lies	O
approx	O
.	O

3.7	O
kilobases	O
upstream	O
of	O
the	O
murine	O
hematopoietic	O
-	O
specific	O
GATA	O
-	O
1	O
IE	O
promoter	O
.	O

HS	O
I	O
directs	B-Positive_regulation
high	O
-	O
level	O
expression	B-Gene_expression
of	O
reporter	O
GATA	O
-	O
1/lacZ	O
genes	O
to	O
primitive	O
and	O
definitive	O
erythroid	O
cells	O
and	O
megakaryocytes	O
in	O
transgenic	O
mice	O
.	O

Comparative	O
sequence	O
analysis	O
of	O
HS	O
I	O
between	O
human	O
and	O
mouse	O
shows	O
approx	O
.	O

63	O
%	O
nucleotide	O
identity	O
with	O
a	O
more	O
conserved	O
core	O
of	O
169	O
base	O
pairs	O
(	O
86	O
%	O
identity	O
)	O
.	O

This	O
core	O
contains	O
a	O
GATA	O
site	O
separated	O
by	O
10	O
base	O
pairs	O
from	O
an	O
E	O
-	O
box	O
motif	O
.	O

The	O
composite	O
motif	O
binds	B-Binding
a	O
multi	O
-	O
protein	O
hematopoietic	O
-	O
specific	O
transcription	O
factor	O
complex	O
which	O
includes	O
GATA	O
-	O
1	O
,	O
SCL/tal	O
-	O
1	O
,	O
E2A	O
,	O
Lmo2	O
and	O
Ldb	O
-	O
1	O
.	O

Point	O
mutations	O
of	O
the	O
GATA	O
site	O
abolishes	O
HS	O
I	O
function	O
,	O
whereas	O
mutation	O
of	O
the	O
E	O
-	O
box	O
motif	O
still	O
allows	O
reporter	O
gene	O
expression	O
in	O
both	O
lineages	O
.	O

Strict	O
dependence	O
of	O
HS	O
I	O
activity	O
on	O
a	O
GATA	O
site	O
implies	O
that	O
assembly	B-Binding
of	I-Binding
a	I-Binding
protein	I-Binding
complex	I-Binding
containing	O
a	O
GATA	O
-	O
factor	O
,	O
presumably	O
GATA	O
-	O
1	O
or	O
GATA	O
-	O
2	O
,	O
is	O
critical	O
to	O
activating	O
or	O
maintaining	O
its	O
function	O
.	O

Further	O
dissection	O
of	O
the	O
317	O
base	O
pair	O
region	O
demonstrates	O
that	O
,	O
whereas	O
all	O
317	O
base	O
pairs	O
are	O
required	O
for	O
expression	O
in	O
megakaryocytes	O
,	O
only	O
the	O
5	O
'	O
62	O
base	O
pairs	O
are	O
needed	O
for	O
erythroid	O
-	O
specific	O
reporter	O
expression	O
.	O

These	O
findings	O
demonstrate	O
differential	O
lineage	O
requirements	O
for	O
expression	O
within	O
the	O
HS	O
I	O
element	O
.	O

Monocyte	O
arrest	O
and	O
transmigration	O
on	O
inflamed	O
endothelium	O
in	O
shear	O
flow	O
is	O
inhibited	O
by	O
adenovirus	O
-	O
mediated	O
gene	B-Gene_expression
transfer	I-Gene_expression
of	O
IkappaB	O
-	O
alpha	O
.	O

Mobilization	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
activates	O
transcription	O
of	O
genes	O
encoding	O
endothelial	O
adhesion	O
molecules	O
and	O
chemokines	O
that	O
contribute	O
to	O
monocyte	O
infiltration	O
critical	O
in	O
atherogenesis	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappaB	O
has	O
been	O
achieved	O
by	O
pharmacological	O
and	O
genetic	O
approaches	O
;	O
however	O
,	O
monocyte	O
interactions	O
with	O
activated	O
endothelium	O
in	O
shear	O
flow	O
following	B-Positive_regulation
gene	B-Gene_expression
transfer	I-Gene_expression
of	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
IkappaB	O
-	O
alpha	O
have	O
not	O
been	O
studied	O
.	O

We	O
found	O
that	O
overexpression	B-Gene_expression
of	O
IkappaB	O
-	O
alpha	O
in	O
endothelial	O
cells	O
using	O
a	O
recombinant	O
adenovirus	O
prevented	B-Negative_regulation
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
-	O
induced	B-Positive_regulation
degradation	B-Protein_catabolism
of	O
IkappaB	O
-	O
alpha	O
and	O
suppressed	B-Negative_regulation
the	O
upregulation	B-Positive_regulation
of	O
vascular	O
cell	O
adhesion	O
molecule	O
-	O
1	O
(	O
VCAM	O
-	O
1	O
)	O
,	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
,	O
and	O
E	O
-	O
selectin	O
mRNA	O
and	O
surface	O
protein	O
expression	B-Transcription
and	O
the	O
upregulation	B-Positive_regulation
of	O
transcripts	B-Transcription
for	O
the	O
chemokines	O
monocyte	O
chemoattractant	O
protein	O
1	O
(	O
MCP	O
-	O
1	O
)	O
and	O
growth	O
-	O
related	O
activity	O
-	O
alpha	O
(	O
GRO	O
-	O
alpha	O
)	O
by	O
TNF	O
-	O
alpha	O
.	O

This	O
was	O
associated	O
with	O
a	O
reduction	B-Negative_regulation
in	O
endothelial	O
MCP	O
-	O
1	O
secretion	B-Localization
and	O
GRO	O
-	O
alpha	O
immobilization	B-Localization
.	O

Adhesion	O
assays	O
under	O
physiological	O
shear	O
flow	O
conditions	O
showed	O
that	O
firm	O
arrest	O
,	O
spreading	O
,	O
and	O
transmigration	O
of	O
monocytes	O
on	O
TNF-alpha	O
-	O
activated	O
endothelium	O
was	O
markedly	O
inhibited	O
by	O
IkappaB	O
-	O
alpha	O
overexpression	B-Gene_expression
.	O

Inhibition	O
with	O
monoclonal	O
antibodies	O
and	O
peptide	O
antagonists	O
inferred	O
that	O
this	O
was	O
due	O
to	O
reduced	O
expression	O
of	O
Ig	O
integrin	O
ligand	O
as	O
well	O
as	O
of	O
chemokines	O
specifically	O
involved	O
in	O
these	O
events	O
.	O

In	O
contrast	O
,	O
rolling	O
of	O
monocytes	O
was	O
increased	O
by	O
IkappaB	O
-	O
alpha	O
transfer	B-Positive_regulation
and	O
was	O
partly	O
mediated	O
by	O
P	O
-	O
selectin	O
;	O
however	O
,	O
it	O
appeared	O
to	O
be	O
unaffected	O
by	O
the	O
inhibition	B-Negative_regulation
of	O
E	O
-	O
selectin	O
induction	B-Positive_regulation
.	O

Thus	O
,	O
our	O
data	O
provide	O
novel	O
evidence	O
that	O
selective	O
modulation	O
of	O
NF	O
-	O
kappaB	O
by	O
adenoviral	O
transfer	B-Gene_expression
of	O
IkappaB	O
-	O
alpha	O
impairs	O
the	O
expression	O
of	O
multiple	O
endothelial	O
gene	O
products	O
required	O
for	O
subsequent	O
monocyte	O
arrest	O
and	O
emigration	O
in	O
shear	O
flow	O
and	O
thus	O
for	O
monocyte	O
infiltration	O
in	O
atherosclerotic	O
plaques	O
.	O

SLP	O
-	O
76	O
and	O
Vav	O
function	O
in	O
separate	O
,	O
but	O
overlapping	O
pathways	O
to	O
augment	B-Positive_regulation
interleukin	O
-	O
2	O
promoter	O
activity	O
.	O

SLP	O
-	O
76	O
and	O
Vav	O
,	O
two	O
hematopoietic	O
cell	O
specific	O
molecules	O
,	O
are	O
critical	O
for	O
T	O
cell	O
development	O
and	O
activation	O
.	O

Following	B-Positive_regulation
T	O
cell	O
antigen	O
receptor	O
stimulation	O
,	O
SLP	O
-	O
76	O
and	O
Vav	O
both	O
undergo	O
tyrosine	O
phosphorylation	B-Phosphorylation
and	O
associate	B-Binding
with	O
each	O
other	O
via	O
the	O
SH2	O
domain	O
of	O
Vav	O
and	O
phosphorylated	B-Phosphorylation
tyrosines	O
of	O
SLP	O
-	O
76	O
.	O

Furthermore	O
,	O
SLP	O
-	O
76	O
and	O
Vav	O
have	O
a	O
synergistic	O
effect	B-Positive_regulation
on	O
interleukin	O
(	O
IL	O
)	O
-	O
2	O
promoter	O
activity	O
in	O
T	O
cells	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
two	O
tyrosines	O
,	O
Tyr	O
-	O
113	O
and	O
Tyr	O
-	O
128	O
,	O
of	O
SLP	O
-	O
76	O
are	O
required	B-Regulation
for	O
its	O
binding	B-Binding
to	O
Vav	O
,	O
both	O
in	O
vitro	O
and	O
in	O
intact	O
cells	O
.	O

Surprisingly	O
,	O
we	O
find	O
also	O
that	O
the	O
interaction	B-Binding
between	O
SLP	O
-	O
76	O
and	O
Vav	O
is	O
not	O
required	B-Positive_regulation
for	O
their	O
cooperation	O
in	O
augmenting	B-Positive_regulation
IL	O
-	O
2	O
promoter	O
activity	O
,	O
as	O
the	O
two	O
molecules	O
appear	O
to	O
function	O
in	O
different	O
signaling	O
pathways	O
upstream	B-Positive_regulation
of	O
IL	O
-	O
2	O
gene	B-Gene_expression
expression	I-Gene_expression
.	O

Overexpression	B-Positive_regulation
of	O
SLP	O
-	O
76	O
in	O
the	O
Jurkat	O
T	O
cell	O
line	O
potentiates	O
the	O
activities	O
of	O
both	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
and	O
AP	O
-	O
1	O
transcription	O
factors	O
.	O

In	O
contrast	O
,	O
overexpression	B-Positive_regulation
of	O
Vav	O
leads	O
to	O
enhanced	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
activity	O
without	O
affecting	O
AP	O
-	O
1	O
.	O

Additionally	O
,	O
overexpression	B-Gene_expression
of	O
Vav	O
,	O
but	O
not	O
SLP	O
-	O
76	O
,	O
augments	B-Positive_regulation
CD28	O
-	O
induced	B-Positive_regulation
IL	O
-	O
2	O
promoter	O
activity	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
synergy	O
between	O
SLP	O
-	O
76	O
and	O
Vav	O
in	O
regulating	B-Regulation
IL	O
-	O
2	O
gene	B-Gene_expression
expression	I-Gene_expression
reflects	O
the	O
cooperation	O
between	O
different	O
signaling	O
pathways	O
.	O

Targeted	O
remodeling	O
of	O
human	O
beta	O
-	O
globin	O
promoter	O
chromatin	O
structure	O
produces	O
increased	B-Positive_regulation
expression	B-Gene_expression
and	O
decreased	O
silencing	O
.	O

The	O
chromatin	O
structure	O
of	O
the	O
human	O
beta	O
-	O
globin	O
gene	O
locus	O
assumes	O
a	O
transcriptionally	B-Transcription
-	I-Transcription
active	I-Transcription
conformation	O
in	O
erythroid	O
cells	O
.	O

One	O
feature	O
of	O
this	O
chromatin	O
reorganization	O
is	O
the	O
formation	O
of	O
DNase	O
1	O
hypersensitive	O
sites	O
in	O
the	O
regions	O
of	O
active	O
globin	O
gene	O
promoters	O
.	O

This	O
reorganization	O
requires	O
the	O
globin	O
locus	O
control	O
region	O
and	O
is	O
associated	O
with	O
normal	O
expression	O
of	O
the	O
beta	O
-	O
like	O
globin	O
genes	O
.	O

To	O
determine	O
whether	O
it	O
is	O
possible	O
to	O
artificially	O
enhance	O
the	O
opening	O
of	O
the	O
chromatin	O
structure	O
of	O
a	O
minimal	O
beta	O
-	O
globin	O
promoter	O
,	O
we	O
placed	O
a	O
101bp	O
,	O
erythroid	O
-	O
specific	O
DNase	O
1	O
hypersensitive	O
site	O
-	O
forming	O
element	O
(	O
HSFE	O
)	O
immediately	O
upstream	O
of	O
the	O
beta	O
-	O
globin	O
promoter	O
and	O
gene	O
.	O

This	O
element	O
includes	O
binding	O
sites	O
for	O
NF	O
-	O
E2	O
,	O
AP	O
-	O
1	O
,	O
GATA	O
-	O
1	O
and	O
Sp	O
-	O
1	O
.	O

Constructs	O
were	O
stably	O
transfected	O
into	O
murine	O
erythroleukemia	O
cells	O
and	O
promoter	O
chromatin	O
structure	O
and	O
gene	O
expression	O
were	O
analyzed	O
.	O

The	O
HSFE	O
induced	O
an	O
area	O
of	O
enhanced	O
DNase	O
1	O
hypersensitivity	O
extending	O
from	O
the	O
transcriptional	O
start	O
site	O
to	O
-	O
300bp	O
of	O
the	O
artificial	O
promoter	O
and	O
significantly	O
increased	B-Positive_regulation
the	I-Positive_regulation
proportion	I-Positive_regulation
of	O
beta	O
-	O
globin	O
promoters	O
in	O
an	O
open	O
chromatin	O
configuration	O
.	O

This	O
remodeling	O
of	O
promoter	O
chromatin	O
structure	O
resulted	O
in	O
3	O
-	O
fold	O
increases	B-Positive_regulation
in	O
beta	O
-	O
globin	O
gene	O
transcription	B-Transcription
and	O
induction	B-Positive_regulation
,	O
and	O
inhibited	O
long	O
-	O
term	O
beta	O
-	O
globin	O
gene	O
silencing	O
.	O

These	O
results	O
indicate	O
that	O
a	O
relatively	O
small	O
cis	O
-	O
acting	O
element	O
is	O
able	O
to	O
enhance	O
remodeling	O
of	O
promoter	O
chromatin	O
structure	O
resulting	O
in	O
increased	B-Positive_regulation
beta	O
-	O
globin	O
gene	O
expression	B-Gene_expression
.	O

In	O
vivo	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
T	O
-	O
lineage	O
cells	O
leads	O
to	O
a	O
dramatic	O
decrease	O
in	O
cell	O
proliferation	O
and	O
cytokine	O
production	O
and	O
to	O
increased	O
cell	O
apoptosis	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
,	O
but	O
not	O
to	O
abnormal	O
thymopoiesis	O
.	O

To	O
understand	O
the	O
role	O
of	O
NF	O
-	O
kappa	O
B	O
complexes	O
in	O
T	O
cell	O
development	O
and	O
activation	O
,	O
we	O
have	O
generated	O
transgenic	O
mice	O
in	O
which	O
RelA	O
and	O
c	O
-	O
Rel	O
complexes	O
were	O
selectively	O
inhibited	B-Negative_regulation
in	O
the	O
T	O
-	O
lineage	O
cells	O
by	O
specific	O
expression	B-Gene_expression
of	O
a	O
trans	O
-	O
dominant	O
form	O
of	O
I	O
kappa	O
B	O
alpha	O
.	O

Transgene	O
expression	B-Gene_expression
did	O
not	O
affect	O
the	O
thymic	O
development	O
,	O
but	O
led	O
to	O
lowered	O
numbers	O
of	O
splenic	O
T	O
cells	O
and	O
to	O
a	O
dramatic	O
decrease	O
in	O
the	O
ex	O
vivo	O
proliferative	O
response	O
of	O
splenic	O
T	O
lymphocytes	O
.	O

Analysis	O
of	O
IL	O
-	O
2	O
and	O
IL	O
-	O
2R	O
alpha	O
expression	B-Gene_expression
demonstrated	O
that	O
the	O
perturbation	O
of	O
the	O
proliferation	O
response	O
was	O
not	O
attributable	O
to	O
an	O
abnormal	B-Negative_regulation
expression	B-Gene_expression
of	O
these	O
genes	O
.	O

In	O
contrast	O
,	O
expression	B-Gene_expression
of	O
IL	O
-	O
4	O
,	O
IL	O
-	O
10	O
,	O
and	O
IFN	O
-	O
gamma	O
was	O
strongly	O
inhibited	B-Negative_regulation
in	O
the	O
transgenic	O
T	O
cells	O
.	O

The	O
proliferative	O
deficiency	O
of	O
the	O
transgenic	O
T	O
cells	O
was	O
associated	O
with	O
an	O
increased	O
apoptosis	O
.	O

These	O
results	O
point	O
out	O
the	O
involvement	O
of	O
NF	O
-	O
kappa	O
B/Rel	O
family	O
proteins	O
in	O
growth	O
signaling	O
pathways	O
by	O
either	O
regulating	O
proteins	O
involved	O
in	O
the	O
IL	O
-	O
2	O
signaling	O
or	O
by	O
functionally	O
interfering	O
with	O
the	O
cell	O
cycle	O
progression	O
.	O

CD28	O
costimulation	B-Positive_regulation
augments	B-Positive_regulation
IL	O
-	O
2	O
secretion	B-Localization
of	O
activated	O
lamina	O
propria	O
T	O
cells	O
by	O
increasing	B-Positive_regulation
mRNA	O
stability	O
without	O
enhancing	B-Positive_regulation
IL	O
-	O
2	O
gene	O
transactivation	B-Positive_regulation
.	O

The	O
pathways	O
leading	O
to	O
activation	O
in	O
lamina	O
propria	O
(	O
LP	O
)	O
T	O
cells	O
are	O
different	O
from	O
peripheral	O
T	O
cells	O
.	O

LP	O
T	O
cells	O
exhibit	O
enhanced	B-Positive_regulation
IL	O
-	O
2	O
secretion	B-Localization
when	O
activated	O
through	O
the	O
CD2	O
pathway	O
.	O

Coligation	B-Binding
of	O
CD28	O
leads	B-Positive_regulation
to	I-Positive_regulation
synergistic	I-Positive_regulation
enhancement	I-Positive_regulation
of	O
IL	O
-	O
2	O
secretion	B-Localization
.	O

Previous	O
studies	O
have	O
characterized	O
the	O
CD28	O
augmentation	O
of	O
TCR	O
-	O
mediated	O
signaling	O
in	O
peripheral	O
blood	O
T	O
cells	O
through	O
transcriptional	O
activation	O
of	O
an	O
IL	O
-	O
2	O
promoter	O
CD28	O
response	O
element	O
(	O
CD28RE	O
)	O
,	O
along	O
with	O
enhanced	B-Positive_regulation
mRNA	O
stability	O
.	O

This	O
study	O
characterized	O
molecular	O
events	O
involved	B-Regulation
in	O
CD28	O
costimulation	B-Positive_regulation
of	O
IL	O
-	O
2	O
production	B-Gene_expression
in	O
LP	O
mononuclear	O
cells	O
(	O
LPMC	O
)	O
.	O

LPMC	O
exhibited	O
increased	O
IL	O
-	O
2	O
production	B-Gene_expression
in	B-Positive_regulation
response	I-Positive_regulation
to	I-Positive_regulation
CD28	O
costimulation	O
,	O
compared	O
with	O
cells	O
activated	O
through	O
CD2	O
alone	O
.	O

IL	O
-	O
2	O
secretion	B-Localization
was	O
paralleled	O
by	O
increased	B-Positive_regulation
expression	B-Transcription
of	O
IL	O
-	O
2	O
mRNA	O
,	O
resulting	B-Positive_regulation
from	O
enhanced	B-Positive_regulation
IL	O
-	O
2	O
mRNA	O
stability	O
.	O

In	O
contrast	O
to	O
transcriptional	O
activation	O
in	O
PBMC	O
,	O
EMSA	O
revealed	O
that	O
CD28	O
coligation	B-Binding
of	O
CD2	O
-	O
activated	O
LPMC	O
does	O
not	O
result	O
in	O
increased	O
binding	O
of	O
trans	O
-	O
factors	O
to	O
the	O
CD28RE	O
,	O
nor	O
did	O
Western	O
blots	O
detect	O
changes	B-Regulation
in	O
I	O
-	O
kappaBalpha	O
or	O
I	O
-	O
kappaBbeta	O
levels	B-Gene_expression
following	O
CD28	O
coligation	B-Binding
.	O

Furthermore	O
,	O
CD28	O
coligation	B-Binding
fails	O
to	O
enhance	O
IL	O
-	O
2	O
promoter	O
-	O
reporter	O
or	O
RE/AP	O
construct	O
expression	O
in	O
CD2	O
-	O
activated	O
LPMC	O
.	O

The	O
results	O
reported	O
herein	O
indicate	O
that	O
the	O
molecular	O
mechanisms	O
involved	B-Regulation
in	O
CD28	O
cosignaling	O
and	O
regulation	B-Regulation
of	O
IL	O
-	O
2	O
secretion	B-Localization
in	O
LP	O
T	O
cells	O
are	O
unique	O
to	O
that	O
compartment	O
and	O
differ	O
from	O
those	O
seen	O
in	O
peripheral	O
blood	O
T	O
cells	O
.	O

These	O
observations	O
suggest	O
a	O
biological	O
significance	O
for	O
different	O
mechanisms	O
of	O
IL	O
-	O
2	O
activation	O
in	O
initiation	O
and	O
maintenance	O
of	O
the	O
cytokine	O
repertoire	O
found	O
in	O
the	O
mucosa	O
.	O

Repression	O
by	O
Ikaros	O
and	O
Aiolos	O
is	O
mediated	O
through	O
histone	O
deacetylase	O
complexes	O
.	O

Here	O
we	O
show	O
that	O
the	O
lymphoid	O
lineage	O
-	O
determining	O
factors	O
Ikaros	O
and	O
Aiolos	O
can	O
function	O
as	O
strong	O
transcriptional	O
repressors	O
.	O

This	O
function	O
is	O
mediated	O
through	O
two	O
repression	O
domains	O
and	O
is	O
dependent	O
upon	O
the	O
promoter	O
context	O
and	O
cell	O
type	O
.	O

Repression	O
by	O
Ikaros	O
proteins	O
correlates	O
with	O
hypo	O
-	O
acetylation	O
of	O
core	O
histones	O
at	O
promoter	O
sites	O
and	O
is	O
relieved	O
by	O
histone	O
deacetylase	O
inhibitors	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
Ikaros	O
and	O
its	O
repression	O
domains	O
can	O
interact	B-Binding
in	O
vivo	O
and	O
in	O
vitro	O
with	O
the	O
mSin3	O
family	O
of	O
co	O
-	O
repressors	O
which	O
bind	O
to	O
histone	O
deacetylases	O
.	O

Based	O
on	O
these	O
and	O
our	O
recent	O
findings	O
of	O
associations	B-Binding
between	O
Ikaros	O
and	O
Mi-2	O
-	O
HDAC	O
,	O
we	O
propose	O
that	O
Ikaros	O
family	O
members	O
modulate	O
gene	O
expression	O
during	O
lymphocyte	O
development	O
by	O
recruiting	O
distinct	O
histone	O
deacetylase	O
complexes	O
to	O
specific	O
promoters	O
.	O

New	O
immunosuppressive	O
drug	O
PNU156804	O
blocks	O
IL-2	O
-	O
dependent	O
proliferation	O
and	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
activation	O
.	O

We	O
had	O
previously	O
shown	O
that	O
the	O
drug	O
undecylprodigiosin	O
(	O
UP	O
)	O
blocks	O
human	O
lymphocyte	O
proliferation	O
in	O
vitro	O
.	O

We	O
have	O
now	O
investigated	O
the	O
mechanism	O
of	O
action	O
of	O
a	O
new	O
analogue	O
of	O
UP	O
,	O
PNU156804	O
,	O
which	O
shows	O
a	O
more	O
favorable	O
activity	O
profile	O
than	O
UP	O
in	O
mice	O
.	O

We	O
demonstrate	O
here	O
that	O
the	O
biological	O
effect	O
of	O
PNU156804	O
in	O
vitro	O
is	O
indistinguishable	O
from	O
UP	O
:	O
PNU156804	O
blocks	O
human	O
T	O
cell	O
proliferation	O
in	O
mid	O
-	O
late	O
G1	O
,	O
as	O
determined	O
by	O
cell	O
cycle	O
analysis	O
,	O
expression	O
of	O
cyclins	O
,	O
and	O
cyclin	O
-	O
dependent	O
kinases	O
and	O
retinoblastoma	O
phosphorylation	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
PNU156804	O
does	O
not	O
block	B-Negative_regulation
significantly	O
the	O
induction	B-Positive_regulation
of	O
either	O
IL	O
-	O
2	O
or	O
IL	O
-	O
2R	O
alpha	O
-	O
and	O
gamma	O
-	O
chains	O
but	O
inhibits	O
IL-2	O
-	O
dependent	O
T	O
cell	O
proliferation	O
.	O

We	O
have	O
investigated	O
several	O
molecular	O
pathways	O
that	O
are	O
known	O
to	O
be	O
activated	O
by	O
IL	O
-	O
2	O
in	O
T	O
cells	O
.	O

We	O
show	O
that	O
PNU156804	O
does	O
not	O
inhibit	B-Negative_regulation
c	O
-	O
myc	O
and	O
bcl	O
-	O
2	O
mRNA	O
induction	B-Positive_regulation
.	O

On	O
the	O
other	O
hand	O
,	O
PNU156804	O
efficiently	O
inhibits	O
the	O
activation	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
transcription	O
factors	O
.	O

PNU156804	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
is	O
due	O
to	O
the	O
inhibition	B-Negative_regulation
of	O
the	O
degradation	B-Protein_catabolism
of	O
I	O
kappa	O
B	O
-	O
alpha	O
and	O
I	O
kappa	O
B	O
-	O
beta	O
.	O

PNU156804	O
action	O
is	O
restricted	O
to	O
some	O
signaling	O
pathways	O
;	O
it	O
does	O
not	O
affect	O
NF	O
-	O
kappa	O
B	O
activation	O
by	O
PMA	O
in	O
T	O
cells	O
but	O
blocks	O
that	O
induced	O
by	O
CD40	O
cross	B-Binding
-	I-Binding
linking	I-Binding
in	O
B	O
lymphocytes	O
.	O

We	O
conclude	O
that	O
the	O
prodigiosin	O
family	O
of	O
immunosuppressants	O
is	O
a	O
new	O
family	O
of	O
molecules	O
that	O
show	O
a	O
novel	O
target	O
specificity	O
clearly	O
distinct	O
from	O
that	O
of	O
other	O
immunosuppressive	O
drugs	O
such	O
as	O
cyclosporin	O
A	O
,	O
FK506	O
,	O
and	O
rapamycin	O
.	O

IL	O
-	O
12	O
induces	B-Positive_regulation
IFN	O
regulating	O
factor	O
-	O
1	O
(	O
IRF	O
-	O
1	O
)	O
gene	O
expression	B-Gene_expression
in	O
human	O
NK	O
and	O
T	O
cells	O
.	O

IL	O
-	O
12	O
is	O
a	O
critical	O
immunoregulatory	O
cytokine	O
that	O
promotes	O
cell	O
-	O
mediated	O
immune	O
responses	O
and	O
the	O
differentiation	O
of	O
naive	O
CD4+	O
cells	O
to	O
Th1	O
cells	O
;	O
however	O
,	O
relatively	O
few	O
IL	O
-	O
12	O
target	O
genes	O
have	O
been	O
identified	O
.	O

To	O
better	O
clarify	O
the	O
molecular	O
basis	O
of	O
IL	O
-	O
12	O
action	O
,	O
we	O
set	O
out	O
to	O
characterize	O
genes	O
up	O
-	O
regulated	O
by	O
IL	O
-	O
12	O
,	O
first	O
by	O
contrasting	O
IL-12	O
-	O
and	O
IFN-alpha	O
-	O
inducible	O
genes	O
.	O

We	O
identified	O
several	O
genes	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
by	O
IL	O
-	O
12	O
,	O
namely	O
,	O
MIP	O
-	O
1alpha	O
,	O
MIP	O
-	O
1beta	O
,	O
IL	O
-	O
1RA	O
,	O
and	O
IFN	O
regulatory	O
factor	O
-	O
1	O
(	O
IRF	O
-	O
1	O
)	O
.	O

IRF	O
-	O
1	O
is	O
a	O
transcription	O
factor	O
regulated	B-Regulation
by	O
IFNs	O
that	O
is	O
also	O
essential	O
for	O
Th1	O
responses	O
.	O

We	O
demonstrated	O
that	O
IL	O
-	O
12	O
directly	O
up	B-Positive_regulation
-	I-Positive_regulation
regulates	I-Positive_regulation
IRF	O
-	O
1	O
to	O
the	O
same	O
extent	O
as	O
IFN	O
-	O
alpha	O
in	O
normal	O
human	O
T	O
cells	O
and	O
in	O
NK	O
cells	O
.	O

We	O
showed	O
that	O
IL	O
-	O
12	O
had	O
a	O
direct	O
effect	B-Regulation
on	O
IRF	O
-	O
1	O
,	O
an	O
effect	O
not	O
mediated	B-Positive_regulation
indirectly	O
by	O
the	O
induction	B-Positive_regulation
of	O
IFN	O
-	O
gamma	O
production	B-Gene_expression
.	O

Furthermore	O
,	O
IL	O
-	O
2	O
and	O
IL	O
-	O
12	O
synergistically	B-Positive_regulation
induced	I-Positive_regulation
IRF	O
-	O
1	O
,	O
whereas	O
IFN	O
-	O
alpha	O
and	O
IL	O
-	O
12	O
did	O
not	O
.	O

The	O
participation	B-Regulation
of	O
STAT4	O
in	O
the	O
regulation	B-Regulation
of	O
IRF	O
-	O
1	O
was	O
demonstrated	O
in	O
two	O
ways	O
.	O

First	O
,	O
STAT4	O
was	O
required	O
for	O
the	O
IL-12	O
-	O
dependent	O
transactivation	O
of	O
an	O
IRF	O
-	O
1	O
reporter	O
construct	O
,	O
and	O
second	O
,	O
STAT4	O
binding	B-Binding
to	O
the	O
IRF	O
-	O
1	O
promoter	O
was	O
shown	O
using	O
EMSA	O
.	O

In	O
contrast	O
to	O
IL	O
-	O
12	O
,	O
no	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
IRF	O
-	O
1	O
was	O
found	O
in	O
IL-4	O
-	O
stimulated	O
cells	O
,	O
and	O
IL	O
-	O
4	O
did	O
not	O
block	B-Negative_regulation
IL-12	O
-	O
dependent	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
IRF	O
-	O
1	O
.	O

Therefore	O
,	O
IRF	O
-	O
1	O
may	O
be	O
an	O
important	O
contributor	O
to	O
IL	O
-	O
12	O
signaling	O
,	O
and	O
we	O
speculate	O
that	O
the	O
defective	O
IL	O
-	O
12	O
responses	O
seen	O
in	O
IRF-1-/	O
-	O
mice	O
might	O
be	O
attributable	O
,	O
in	O
part	O
,	O
to	O
the	O
absence	B-Positive_regulation
of	O
this	O
transcription	O
factor	O
.	O

Transcriptional	O
regulation	O
of	O
T	O
lymphocyte	O
development	O
and	O
function	O
.	O

The	O
development	O
and	O
function	O
of	O
T	O
lymphocytes	O
are	O
regulated	O
tightly	O
by	O
signal	O
transduction	O
pathways	O
that	O
include	O
specific	O
cell	O
-	O
surface	O
receptors	O
,	O
intracellular	O
signaling	O
molecules	O
,	O
and	O
nuclear	O
transcription	O
factors	O
.	O

Since	O
1988	O
,	O
several	O
families	O
of	O
functionally	O
important	O
T	O
cell	O
transcription	O
factors	O
have	O
been	O
identified	O
.	O

These	O
include	O
the	O
Ikaros	O
,	O
LKLF	O
,	O
and	O
GATA3	O
zinc	O
-	O
finger	O
proteins	O
;	O
the	O
Ets	O
,	O
CREB/ATF	O
,	O
and	O
NF	O
-	O
kappa	O
B/Rel/NFAT	O
transcription	O
factors	O
;	O
the	O
Stat	O
proteins	O
;	O
and	O
HMG	O
box	O
transcription	O
factors	O
such	O
as	O
LEF1	O
,	O
TCF1	O
,	O
and	O
Sox4	O
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
our	O
current	O
understanding	O
of	O
the	O
transcriptional	O
regulation	O
of	O
T	O
cell	O
development	O
and	O
function	O
with	O
particular	O
emphasis	O
on	O
the	O
results	O
of	O
recent	O
gene	O
targeting	O
and	O
transgenic	O
experiments	O
.	O

In	O
addition	O
to	O
increasing	O
our	O
understanding	O
of	O
the	O
molecular	O
pathways	O
that	O
regulate	O
T	O
cell	O
development	O
and	O
function	O
,	O
these	O
results	O
have	O
suggested	O
novel	O
targets	O
for	O
genetic	O
and	O
pharmacological	O
manipulation	O
of	O
T	O
cell	O
immunity	O
.	O

Binding	B-Binding
of	O
YY1	O
and	O
Oct1	O
to	O
a	O
novel	O
element	O
that	O
downregulates	B-Negative_regulation
expression	B-Gene_expression
of	O
IL	O
-	O
5	O
in	O
human	O
T	O
cells	O
.	O

BACKGROUND	O
:	O
IL	O
-	O
5	O
controls	O
development	O
of	O
eosinophilia	O
and	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
allergic	O
diseases	O
.	O

In	O
both	O
atopic	O
and	O
nonatopic	O
asthma	O
,	O
elevated	B-Positive_regulation
IL	O
-	O
5	O
has	O
been	O
detected	O
in	O
peripheral	O
blood	O
and	O
the	O
airways	O
.	O

IL	O
-	O
5	O
is	O
produced	B-Gene_expression
mainly	O
by	O
activated	O
T	O
cells	O
,	O
and	O
its	O
expression	O
is	O
regulated	B-Regulation
at	O
the	O
transcriptional	O
level	O
.	O

OBJECTIVE	O
:	O
This	O
study	O
focuses	O
on	O
the	O
functional	O
analysis	O
of	O
the	O
human	O
IL	O
-	O
5	O
(	O
hIL	O
-	O
5	O
)	O
promoter	O
and	O
characterization	O
of	O
cis	O
-	O
regulatory	O
elements	O
and	O
transcription	O
factors	O
involved	B-Regulation
in	O
the	O
suppression	B-Negative_regulation
of	O
IL	O
-	O
5	O
transcription	B-Transcription
in	O
T	O
cells	O
.	O

METHODS	O
:	O
Methods	O
used	O
in	O
this	O
study	O
include	O
DNase	O
I	O
footprint	O
assays	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
and	O
functional	O
analysis	O
by	O
mammalian	O
cell	O
transfection	O
involving	O
deletion	O
analysis	O
and	O
site	O
-	O
directed	O
mutagenesis	O
.	O

RESULTS	O
:	O
We	O
identified	O
5	O
protein	O
binding	O
regions	O
(	O
BRs	O
)	O
located	O
within	O
the	O
proximal	O
hIL	O
-	O
5	O
promoter	O
.	O

Functional	O
analysis	O
indicates	O
that	O
the	O
BRs	O
are	O
involved	O
in	O
control	B-Regulation
of	O
hIL	O
-	O
5	O
promoter	O
activity	O
.	O

Two	O
of	O
these	O
regions	O
,	O
BR3	O
and	O
BR4	O
located	O
at	O
positions	O
-	O
102	O
to	O
-	O
73	O
,	O
have	O
not	O
previously	O
been	O
described	O
as	O
regulators	B-Regulation
of	O
IL	O
-	O
5	O
expression	B-Gene_expression
in	O
T	O
cells	O
.	O

We	O
show	O
that	O
the	O
BR3	O
sequence	O
contains	O
a	O
novel	O
negative	B-Negative_regulation
regulatory	I-Negative_regulation
element	O
located	O
at	O
positions	O
-	O
90	O
to	O
-	O
79	O
of	O
the	O
hIL	O
-	O
5	O
promoter	O
,	O
which	O
binds	B-Binding
Oct1	O
,	O
octamer	O
-	O
like	O
,	O
and	O
YY1	O
nuclear	O
factors	O
.	O

Substitution	O
mutations	O
,	O
which	O
abolished	B-Negative_regulation
binding	B-Binding
of	O
these	O
proteins	O
to	O
the	O
BR3	O
sequence	O
,	O
significantly	O
increased	B-Positive_regulation
hIL	O
-	O
5	O
promoter	O
activity	O
in	O
activated	O
T	O
cells	O
.	O

CONCLUSION	O
:	O
We	O
suggest	O
that	O
Oct1	O
,	O
YY1	O
,	O
and	O
octamer	O
-	O
like	O
factors	O
binding	B-Binding
to	O
the	O
-90/	O
-	O
79	O
sequence	O
within	O
the	O
proximal	O
IL	O
-	O
5	O
promoter	O
are	O
involved	B-Regulation
in	O
suppression	B-Negative_regulation
of	O
IL	O
-	O
5	O
transcription	B-Transcription
in	O
T	O
cells	O
.	O

Direct	O
interaction	B-Binding
of	O
hematopoietic	O
transcription	O
factors	O
PU.1	O
and	O
GATA	O
-	O
1	O
:	O
functional	O
antagonism	O
in	O
erythroid	O
cells	O
.	O

Malignant	O
transformation	O
usually	O
inhibits	O
terminal	O
cell	O
differentiation	O
but	O
the	O
precise	O
mechanisms	O
involved	O
are	O
not	O
understood	O
.	O

PU.1	O
is	O
a	O
hematopoietic	O
-	O
specific	O
Ets	O
family	O
transcription	O
factor	O
that	O
is	O
required	O
for	O
development	O
of	O
some	O
lymphoid	O
and	O
myeloid	O
lineages	O
.	O

PU.1	O
can	O
also	O
act	O
as	O
an	O
oncoprotein	O
as	O
activation	B-Positive_regulation
of	O
its	O
expression	B-Gene_expression
in	O
erythroid	O
precursors	O
by	O
proviral	O
insertion	O
or	O
transgenesis	O
causes	O
erythroleukemias	O
in	O
mice	O
.	O

Restoration	O
of	O
terminal	O
differentiation	O
in	O
the	O
mouse	O
erythroleukemia	O
(	O
MEL	O
)	O
cells	O
requires	O
a	O
decline	B-Negative_regulation
in	I-Negative_regulation
the	I-Negative_regulation
level	I-Negative_regulation
of	O
PU.1	O
,	O
indicating	O
that	O
PU.1	O
can	O
block	O
erythroid	O
differentiation	O
.	O

Here	O
we	O
investigate	O
the	O
mechanism	O
by	O
which	O
PU.1	O
interferes	O
with	O
erythroid	O
differentiation	O
.	O

We	O
find	O
that	O
PU.1	O
interacts	B-Binding
directly	O
with	O
GATA	O
-	O
1	O
,	O
a	O
zinc	O
finger	O
transcription	O
factor	O
required	O
for	O
erythroid	O
differentiation	O
.	O

Interaction	B-Binding
between	O
PU.1	O
and	O
GATA	O
-	O
1	O
requires	B-Positive_regulation
intact	O
DNA	O
-	O
binding	O
domains	O
in	O
both	O
proteins	O
.	O

PU.1	O
represses	O
GATA-1	O
-	O
mediated	O
transcriptional	O
activation	O
.	O

Both	O
the	O
DNA	O
binding	O
and	O
transactivation	O
domains	O
of	O
PU.1	O
are	O
required	O
for	O
repression	O
and	O
both	O
domains	O
are	O
also	O
needed	O
to	O
block	O
terminal	O
differentiation	O
in	O
MEL	O
cells	O
.	O

We	O
also	O
show	O
that	O
ectopic	O
expression	B-Gene_expression
of	O
PU.1	O
in	O
Xenopus	O
embryos	O
is	O
sufficient	O
to	O
block	O
erythropoiesis	O
during	O
normal	O
development	O
.	O

Furthermore	O
,	O
introduction	O
of	O
exogenous	O
GATA	O
-	O
1	O
in	O
both	O
MEL	O
cells	O
and	O
Xenopus	O
embryos	O
and	O
explants	O
relieves	O
the	O
block	O
to	O
erythroid	O
differentiation	O
imposed	O
by	O
PU.1	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
stoichiometry	O
of	O
directly	O
interacting	B-Binding
but	O
opposing	B-Negative_regulation
transcription	O
factors	O
may	O
be	O
a	O
crucial	O
determinant	O
governing	O
processes	O
of	O
normal	O
differentiation	O
and	O
malignant	O
transformation	O
.	O

Potent	O
and	O
stable	O
attenuation	O
of	O
live-HIV	O
-	O
1	O
by	O
gain	O
of	O
a	O
proteolysis	B-Protein_catabolism
-	O
resistant	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
(	O
IkappaB	O
-	O
alphaS32/36A	O
)	O
and	O
the	O
implications	O
for	O
vaccine	O
development	O
.	O

Live	O
-	O
attenuated	O
human	O
immunodeficiency	O
viruses	O
(	O
HIVs	O
)	O
are	O
candidates	O
for	O
Acquired	O
Immunodeficiency	O
Syndrome	O
(	O
AIDS	O
)	O
vaccine	O
.	O

Based	O
on	O
the	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
model	O
for	O
AIDS	O
,	O
loss-of	O
-	O
function	O
(	O
e.g.	O
deletion	O
of	O
accessory	O
genes	O
such	O
as	O
nef	O
)	O
has	O
been	O
forwarded	O
as	O
a	O
primary	O
approach	O
for	O
creating	O
enfeebled	O
,	O
but	O
replication	O
-	O
competent	O
,	O
HIV	O
-	O
1/SIV	O
.	O

Regrettably	O
,	O
recent	O
evidence	O
suggests	O
that	O
loss-of	O
-	O
function	O
alone	O
is	O
not	O
always	O
sufficient	O
to	O
prevent	O
the	O
emergence	O
of	O
virulent	O
mutants	O
.	O

New	O
strategies	O
that	O
attenuate	O
via	O
mechanisms	O
distinct	O
from	O
loss-of	O
-	O
function	O
are	O
needed	O
for	O
enhancing	O
the	O
safety	O
phenotype	O
of	O
viral	O
genome	O
.	O

Here	O
,	O
we	O
propose	O
gain-of	O
-	O
function	O
to	O
be	O
used	O
simultaneously	O
with	O
loss-of	O
-	O
function	O
as	O
a	O
novel	O
approach	O
for	O
attenuating	O
HIV	O
-	O
1	O
.	O

We	O
have	O
constructed	O
an	O
HIV	O
-	O
1	O
genome	O
carrying	O
the	O
cDNA	O
of	O
a	O
proteolysis	B-Protein_catabolism
-	O
resistant	B-Negative_regulation
nuclear	O
factor	O
-	O
kappaB	O
inhibitor	O
(	O
IkappaB	O
-	O
alphaS32/36A	O
)	O
in	O
the	O
nef	O
region	O
.	O

HIV	O
-	O
1	O
expressing	B-Gene_expression
IkappaB	O
-	O
alphaS32/36A	O
down	O
-	O
regulates	O
viral	O
expression	O
and	O
is	O
highly	O
attenuated	B-Negative_regulation
in	O
both	O
Jurkat	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

We	O
provide	O
formal	O
proof	O
that	O
the	O
phenotypic	O
and	O
attenuating	O
characteristics	O
of	O
IkappaB	O
-	O
alphaS32/36A	O
permit	O
its	O
stable	O
maintenance	B-Positive_regulation
in	O
a	O
live	O
,	O
replicating	O
HIV	O
-	O
1	O
despite	O
180	O
days	O
of	O
forced	O
ex	O
vivo	O
passaging	O
in	O
tissue	O
culture	O
.	O

As	O
compared	O
with	O
other	O
open	O
-	O
reading	O
frames	O
embedded	O
into	O
HIV/SIV	O
genome	O
,	O
this	O
degree	O
of	O
stability	O
is	O
unprecedented	O
.	O

Thus	O
,	O
IkappaB	O
-	O
alphaS32/36A	O
offers	O
proof-of	O
-	O
principle	O
that	O
artifactually	O
gained	O
functions	O
,	O
when	O
used	O
to	O
attenuate	O
the	O
replication	O
of	O
live	O
HIV	O
-	O
1	O
,	O
can	O
be	O
stable	O
.	O

These	O
findings	O
illustrate	O
gain-of	O
-	O
function	O
as	O
a	O
feasible	O
strategy	O
for	O
developing	O
safer	O
live	O
-	O
attenuated	O
HIVs	O
to	O
be	O
tested	O
as	O
candidates	O
for	O
AIDS	O
vaccine	O
.	O

Human	O
alveolar	O
macrophages	O
are	O
markedly	O
deficient	B-Negative_regulation
in	O
REF	O
-	O
1	O
and	O
AP	O
-	O
1	O
DNA	O
binding	B-Binding
activity	I-Binding
.	O

Although	O
many	O
functions	O
of	O
human	O
alveolar	O
macrophages	O
are	O
altered	O
compared	O
with	O
their	O
precursor	O
cell	O
,	O
the	O
blood	O
monocyte	O
(	O
monocyte	O
)	O
,	O
the	O
reason	O
(	O
s	O
)	O
for	O
these	O
functional	O
changes	O
have	O
not	O
been	O
determined	O
.	O

We	O
recently	O
reported	O
that	O
human	O
alveolar	O
macrophages	O
do	O
not	O
express	O
AP	O
-	O
1	O
DNA	O
binding	O
activity	O
(	O
Monick	O
,	O
M.	O
M.	O
,	O
Carter	O
,	O
A	O
.	O

B.	O
,	O
Gudmundsson	O
,	O
G.	O
,	O
Geist	O
,	O
L.	O
J.	O
,	O
and	O
Hunninghake	O
,	O
G	O
.	O

W	O
.	O

(	O
1998	O
)	O
Am	O
.	O

J	O
.	O

Physiol	O
.	O

275	O
,	O
L389	O
-	O
L397	O
)	O
.	O

To	O
determine	O
why	O
alveolar	O
macrophages	O
do	O
not	O
express	O
AP	O
-	O
1	O
DNA	O
binding	O
activity	O
,	O
we	O
first	O
showed	O
that	O
there	O
was	O
not	O
a	O
decrease	O
in	O
expression	O
of	O
the	O
FOS	O
and	O
JUN	O
proteins	O
that	O
make	O
up	O
the	O
AP	O
-	O
1	O
complex	O
.	O

There	O
was	O
,	O
however	O
,	O
a	O
significant	O
difference	O
in	B-Gene_expression
the	I-Gene_expression
amounts	I-Gene_expression
of	O
the	O
nuclear	O
protein	O
,	O
REF	O
-	O
1	O
(	O
which	O
regulates	O
AP	O
-	O
1	O
DNA	O
binding	O
by	O
altering	O
the	O
redox	O
status	O
of	O
FOS	O
and	O
JUN	O
proteins	O
)	O
,	O
in	O
alveolar	O
macrophages	O
compared	O
with	O
monocytes	O
.	O

In	O
addition	O
,	O
in	O
vitro	O
differentiation	O
of	O
monocytes	O
to	O
a	O
macrophage	O
-	O
like	O
cell	O
resulted	O
in	O
decreased	B-Negative_regulation
amounts	O
of	O
REF	O
-	O
1	O
.	O

Finally	O
,	O
addition	O
of	O
REF	O
-	O
1	O
from	O
activated	O
monocytes	O
to	O
alveolar	O
macrophage	O
nuclear	O
proteins	O
resulted	O
in	O
a	O
marked	O
increase	O
in	O
AP	O
-	O
1	O
DNA	O
binding	O
.	O

These	O
studies	O
strongly	O
suggest	O
that	O
the	O
process	O
of	O
differentiation	O
of	O
monocytes	O
into	O
alveolar	O
macrophages	O
is	O
associated	O
with	O
a	O
loss	B-Negative_regulation
of	O
REF	O
-	O
1	O
and	O
AP	O
-	O
1	O
activity	O
.	O

This	O
observation	O
may	O
explain	O
,	O
in	O
part	O
,	O
some	O
of	O
the	O
functional	O
differences	O
observed	O
for	O
alveolar	O
macrophages	O
compared	O
with	O
monocytes	O
.	O

A	O
polymorphism	O
that	O
affects	B-Regulation
OCT	O
-	O
1	O
binding	B-Binding
to	O
the	O
TNF	O
promoter	O
region	O
is	O
associated	O
with	O
severe	O
malaria	O
[	O
see	O
comments	O
]	O

Genetic	O
variation	O
in	O
cytokine	O
promoter	O
regions	O
is	O
postulated	O
to	O
influence	O
susceptibility	O
to	O
infection	O
,	O
but	O
the	O
molecular	O
mechanisms	O
by	O
which	O
such	O
polymorphisms	O
might	O
affect	O
gene	O
regulation	O
are	O
unknown	O
.	O

Through	O
systematic	O
DNA	O
footprinting	O
of	O
the	O
TNF	O
(	O
encoding	O
tumour	O
necrosis	O
factor	O
,	O
TNF	O
)	O
promoter	O
region	O
,	O
we	O
have	O
identified	O
a	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
that	O
causes	B-Positive_regulation
the	O
helix-turn	O
-	O
helix	O
transcription	O
factor	O
OCT	O
-	O
1	O
to	O
bind	B-Binding
to	O
a	O
novel	O
region	O
of	O
complex	O
protein	O
-	O
DNA	O
interactions	O
and	O
alters	B-Regulation
gene	O
expression	B-Gene_expression
in	O
human	O
monocytes	O
.	O

The	O
OCT-1	O
-	O
binding	B-Binding
genotype	I-Binding
,	O
found	O
in	O
approximately	O
5	O
%	O
of	O
Africans	O
,	O
is	O
associated	O
with	O
fourfold	O
increased	O
susceptibility	O
to	O
cerebral	O
malaria	O
in	O
large	O
case	O
-	O
control	O
studies	O
of	O
West	O
African	O
and	O
East	O
African	O
populations	O
,	O
after	O
correction	O
for	O
other	O
known	O
TNF	O
polymorphisms	O
and	O
linked	O
HLA	O
alleles	O
.	O

Novel	O
therapies	O
for	O
inflammatory	O
bowel	O
disease	O
.	O

Looking	O
back	O
at	O
successes	O
and	O
failures	O
in	O
newer	O
approaches	O
to	O
treating	O
IBD	O
,	O
it	O
is	O
tempting	O
-	O
-	O
although	O
still	O
difficult	O
-	O
-	O
to	O
draw	O
conclusions	O
about	O
pathogenesis	O
.	O

When	O
a	O
therapy	O
proves	O
effective	O
,	O
do	O
clinicians	O
truly	O
know	O
how	O
it	O
works	O
?	O
Even	O
with	O
a	O
therapy	O
as	O
specific	O
as	O
anti	O
-	O
TNF	O
antibody	O
,	O
it	O
is	O
not	O
clear	O
if	O
the	O
benefit	O
is	O
attributable	O
to	O
simple	O
binding	B-Binding
and	O
clearance	O
of	O
TNF	O
-	O
alpha	O
or	O
to	O
binding	O
on	O
the	O
cell	O
surface	O
and	O
subsequent	O
deletion	O
of	O
the	O
activated	O
macrophage	O
.	O

When	O
a	O
drug	O
appears	O
to	O
be	O
less	O
effective	O
than	O
preclinical	O
models	O
suggest	O
,	O
can	O
failures	O
in	O
effectiveness	O
from	O
delivery	O
or	O
dosing	O
be	O
differentiated	O
?	O

The	O
disappointing	O
results	O
of	O
clinical	O
trials	O
with	O
IL	O
-	O
10	O
-	O
-	O
so	O
at	O
odds	O
with	O
the	O
prediction	O
of	O
benefit	O
from	O
animal	O
models	O
-	O
-	O
bring	O
into	O
question	O
the	O
validity	O
of	O
those	O
models	O
as	O
well	O
as	O
the	O
soundness	O
of	O
design	O
of	O
the	O
clinical	O
trials	O
on	O
which	O
efficacy	O
of	O
IL	O
-	O
10	O
is	O
judged	O
.	O

The	O
variability	O
of	O
response	O
even	O
to	O
the	O
most	O
narrowly	O
targeted	O
agents	O
suggests	O
that	O
these	O
diseases	O
are	O
far	O
more	O
heterogeneous	O
in	O
humans	O
than	O
in	O
their	O
murine	O
counterparts	O
.	O

Clinicians	O
are	O
only	O
just	O
beginning	O
to	O
recognize	O
subclinical	O
markers	O
of	O
response	O
,	O
and	O
it	O
may	O
soon	O
be	O
possible	O
to	O
predict	O
response	O
on	O
the	O
basis	O
of	O
genetic	O
composition	O
.	O

For	O
the	O
moment	O
,	O
however	O
,	O
the	O
field	O
of	O
pharmacogenetics	O
is	O
embryonic	O
.	O

Challenges	O
in	O
developing	O
new	O
therapeutic	O
strategies	O
include	O
not	O
only	O
identifying	O
novel	O
agents	O
,	O
but	O
also	O
improving	O
the	O
definitions	O
of	O
clinical	O
endpoints	O
and	O
defining	O
efficacy	O
at	O
the	O
biologic	O
level	O
.	O

Only	O
through	O
considered	O
evaluation	O
of	O
clinical	O
evidence	O
may	O
clinicians	O
determine	O
which	O
therapies	O
should	O
remain	O
novelties	O
and	O
which	O
should	O
become	O
an	O
accepted	O
part	O
of	O
the	O
armamentarium	O
.	O

PPARalpha	O
activators	O
inhibit	B-Negative_regulation
cytokine	O
-	O
induced	B-Positive_regulation
vascular	O
cell	O
adhesion	O
molecule	O
-	O
1	O
expression	B-Gene_expression
in	O
human	O
endothelial	O
cells	O
.	O

BACKGROUND	O
:	O
Adhesion	O
molecule	O
expression	O
on	O
the	O
endothelial	O
cell	O
(	O
EC	O
)	O
surface	O
is	O
critical	O
for	O
leukocyte	O
recruitment	O
to	O
atherosclerotic	O
lesions	O
.	O

Better	O
understanding	O
of	O
transcriptional	O
regulation	O
of	O
adhesion	O
molecules	O
in	O
ECs	O
may	O
provide	O
important	O
insight	O
into	O
plaque	O
formation	O
.	O

Peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
-	O
alpha	O
(	O
PPARalpha	O
)	O
,	O
a	O
member	O
of	O
the	O
nuclear	O
receptor	O
family	O
,	O
regulates	O
gene	O
expression	O
in	B-Regulation
response	I-Regulation
to	I-Regulation
certain	O
fatty	O
acids	O
and	O
fibric	O
acid	O
derivatives	O
.	O

The	O
present	O
study	O
investigated	O
PPARalpha	O
expression	B-Gene_expression
in	O
human	O
ECs	O
and	O
their	O
regulation	B-Regulation
of	O
vascular	O
cell	O
adhesion	O
molecule	O
-	O
1	O
(	O
VCAM	O
-	O
1	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Immunohistochemistry	O
revealed	O
that	O
human	O
carotid	O
artery	O
ECs	O
express	B-Gene_expression
PPARalpha	O
.	O

Pretreatment	O
of	O
cultured	O
human	O
ECs	O
with	O
the	O
PPARalpha	O
activators	B-Positive_regulation
fenofibrate	O
or	O
WY14643	O
inhibited	B-Negative_regulation
TNF-alpha	O
-	O
induced	B-Positive_regulation
VCAM	O
-	O
1	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
,	O
an	O
effect	O
not	O
seen	O
with	O
PPARgamma	O
activators	O
.	O

Both	O
PPARalpha	O
activators	O
decreased	B-Negative_regulation
cytokine	O
-	O
induced	B-Positive_regulation
VCAM	O
-	O
1	O
mRNA	B-Transcription
expression	I-Transcription
without	O
altering	B-Regulation
its	O
mRNA	O
half	O
-	O
life	O
.	O

Transient	O
transfection	O
of	O
deletional	O
VCAM	O
-	O
1	O
promoter	O
constructs	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggest	O
that	O
fenofibrate	O
inhibits	O
VCAM	O
-	O
1	O
transcription	B-Transcription
in	O
part	O
by	O
inhibiting	O
NF	O
-	O
kappaB	O
.	O

Finally	O
,	O
PPARalpha	O
activators	O
significantly	O
reduced	O
adhesion	O
of	O
U937	O
cells	O
to	O
cultured	O
human	O
ECs	O
.	O

CONCLUSIONS	O
:	O
Human	O
ECs	O
express	B-Gene_expression
PPARalpha	O
,	O
a	O
potentially	O
important	O
regulator	O
of	O
atherogenesis	O
through	O
its	O
transcriptional	B-Regulation
control	I-Regulation
of	O
VCAM	O
-	O
1	O
gene	O
expression	B-Gene_expression
.	O

Such	O
findings	O
also	O
have	O
implications	O
regarding	O
the	O
clinical	O
use	O
of	O
lipid	O
-	O
lowering	O
agents	O
,	O
like	O
fibric	O
acids	O
,	O
which	O
can	O
activate	B-Positive_regulation
PPARalpha	O
.	O

The	O
intracellular	O
parasite	O
Theileria	O
parva	O
protects	O
infected	O
T	O
cells	O
from	O
apoptosis	O
.	O

Parasites	O
have	O
evolved	O
a	O
plethora	O
of	O
strategies	O
to	O
ensure	O
their	O
survival	O
.	O

The	O
intracellular	O
parasite	O
Theileria	O
parva	O
secures	O
its	O
propagation	O
and	O
spreads	O
through	O
the	O
infected	O
animal	O
by	O
infecting	O
and	O
transforming	O
T	O
cells	O
,	O
inducing	O
their	O
continuous	O
proliferation	O
and	O
rendering	O
them	O
metastatic	O
.	O

In	O
previous	O
work	O
,	O
we	O
have	O
shown	O
that	O
the	O
parasite	O
induces	O
constitutive	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
by	O
inducing	O
the	O
constitutive	O
degradation	O
of	O
its	O
cytoplasmic	O
inhibitors	O
.	O

The	O
biological	O
significance	O
of	O
NF	O
-	O
kappaB	O
activation	O
in	O
T.	O
parva	O
-	O
infected	O
cells	O
,	O
however	O
,	O
has	O
not	O
yet	O
been	O
defined	O
.	O

Cells	O
that	O
have	O
been	O
transformed	O
by	O
viruses	O
or	O
oncogenes	O
can	O
persist	O
only	O
if	O
they	O
manage	O
to	O
avoid	O
destruction	O
by	O
the	O
apoptotic	O
mechanisms	O
that	O
are	O
activated	O
on	O
transformation	O
and	O
that	O
contribute	O
to	O
maintain	O
cellular	O
homeostasis	O
.	O

We	O
now	O
demonstrate	O
that	O
parasite	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
survival	O
of	O
T.	O
parva	O
-	O
transformed	O
T	O
cells	O
by	O
conveying	O
protection	O
against	O
an	O
apoptotic	O
signal	O
that	O
accompanies	O
parasite	O
-	O
mediated	O
transformation	O
.	O

Consequently	O
,	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
nuclear	O
translocation	O
and	O
the	O
expression	O
of	O
dominant	O
negative	O
mutant	O
forms	O
of	O
components	O
of	O
the	O
NF	O
-	O
kappaB	O
activation	O
pathway	O
,	O
such	O
as	O
IkappaBalpha	O
or	O
p65	O
,	O
prompt	O
rapid	O
apoptosis	O
of	O
T.	O
parva	O
-	O
transformed	O
T	O
cells	O
.	O

Our	O
findings	O
offer	O
important	O
insights	O
into	O
parasite	O
survival	O
strategies	O
and	O
demonstrate	O
that	O
parasite	O
-	O
induced	O
constitutive	O
NF	O
-	O
kappaB	O
activation	O
is	O
an	O
essential	O
step	O
in	O
maintaining	O
the	O
transformed	O
phenotype	O
of	O
the	O
infected	O
cells	O
.	O

Downregulation	B-Negative_regulation
of	O
Wilms	O
'	O
tumor	O
gene	O
(	O
WT1	O
)	O
is	O
not	O
a	O
prerequisite	O
for	O
erythroid	O
or	O
megakaryocytic	O
differentiation	O
of	O
the	O
leukemic	O
cell	O
line	O
K562	O
.	O

The	O
Wilms	O
'	O
tumor	O
gene	O
(	O
WT1	O
)	O
encodes	O
a	O
transcription	O
factor	O
of	O
the	O
zinc	O
finger	O
type	O
.	O

A	O
high	B-Positive_regulation
expression	I-Positive_regulation
of	O
WT1	O
has	O
been	O
detected	O
in	O
a	O
range	O
of	O
acute	O
leukemias	O
,	O
and	O
WT1	O
is	O
downregulated	B-Negative_regulation
during	O
induced	O
differentiation	O
of	O
some	O
leukemic	O
cell	O
lines	O
.	O

Overexpression	B-Gene_expression
of	O
WT1	O
in	O
some	O
myeloid	O
cell	O
lines	O
confers	O
resistance	O
to	O
differentiation	O
induction	O
.	O

These	O
observations	O
suggest	O
that	O
a	O
high	B-Positive_regulation
WT1	O
expression	B-Gene_expression
in	O
hematopoietic	O
cells	O
is	O
incompatible	O
with	O
differentiation	O
.	O

In	O
this	O
study	O
,	O
each	O
of	O
the	O
four	O
different	O
isoforms	O
of	O
WT1	O
was	O
constitutively	O
overexpressed	B-Gene_expression
in	O
the	O
leukemic	O
cell	O
line	O
K562	O
.	O

K562	O
cells	O
express	B-Gene_expression
endogenous	O
WT1	O
,	O
which	O
is	O
downregulated	B-Negative_regulation
as	O
a	O
response	O
to	O
induced	O
differentiation	O
along	O
the	O
erythroid	O
and	O
megakaryocytic	O
pathways	O
.	O

We	O
now	O
demonstrate	O
that	O
a	O
forced	B-Positive_regulation
exogenous	O
expression	B-Gene_expression
of	O
the	O
four	O
different	O
isoforms	O
of	O
WT1	O
in	O
K562	O
does	O
not	O
affect	O
the	O
differentiation	O
response	O
,	O
as	O
judged	O
by	O
accumulation	O
of	O
hemoglobin	O
in	O
response	O
to	O
hemin	O
or	O
the	O
expression	O
of	O
megakaryocytic	O
cell	O
surface	O
markers	O
in	O
response	O
to	O
12-O-tetradecanoylphorbol-13	O
-	O
acetate	O
(	O
TPA	O
)	O
.	O

We	O
conclude	O
that	O
downregulation	B-Negative_regulation
of	O
WT1	O
during	O
induced	O
differentiation	O
of	O
K562	O
cells	O
is	O
not	O
a	O
prerequisite	O
for	O
erythroid	O
or	O
megakaryocytic	O
differentiation	O
of	O
these	O
cells	O
.	O

GATA	O
-	O
1	O
and	O
erythropoietin	O
cooperate	O
to	O
promote	O
erythroid	O
cell	O
survival	O
by	O
regulating	B-Regulation
bcl	O
-	O
xL	O
expression	B-Gene_expression
.	O

The	O
transcription	O
factor	O
GATA	O
-	O
1	O
is	O
essential	O
for	O
normal	O
erythropoiesis	O
.	O

By	O
examining	O
in	O
vitro	O
-	O
differentiated	O
embryonic	O
stem	O
cells	O
,	O
we	O
showed	O
previously	O
that	O
in	O
the	O
absence	O
of	O
GATA	O
-	O
1	O
,	O
committed	O
erythroid	O
precursors	O
fail	O
to	O
complete	O
maturation	O
and	O
instead	O
undergo	O
apoptosis	O
.	O

The	O
mechanisms	O
by	O
which	O
GATA	O
-	O
1	O
controls	O
cell	O
survival	O
are	O
unknown	O
.	O

Here	O
we	O
report	O
that	O
in	O
erythroid	O
cells	O
,	O
GATA	O
-	O
1	O
strongly	O
induces	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
the	O
anti	O
-	O
apoptotic	O
protein	O
bcl	O
-	O
xL	O
,	O
but	O
not	O
the	O
related	O
proteins	O
bcl	O
-	O
2	O
and	O
mcl	O
-	O
1	O
.	O

Consistent	O
with	O
a	O
role	O
for	O
bcl	O
-	O
xL	O
in	O
mediating	O
GATA-1	O
-	O
induced	O
erythroid	O
cell	O
survival	O
,	O
in	O
vitro	O
-	O
differentiated	O
bcl-xL-/	O
-	O
embryonic	O
stem	O
cells	O
fail	O
to	O
generate	O
viable	O
mature	O
definitive	O
erythroid	O
cells	O
,	O
a	O
phenotype	O
resembling	O
that	O
of	O
GATA	O
-	O
1	O
gene	O
disruption	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
erythropoietin	O
,	O
which	O
is	O
also	O
required	O
for	O
erythroid	O
cell	O
survival	O
,	O
cooperates	O
with	O
GATA	O
-	O
1	O
to	O
stimulate	B-Positive_regulation
bcl	O
-	O
xL	O
gene	O
expression	B-Gene_expression
and	O
to	O
maintain	O
erythroid	O
cell	O
viability	O
during	O
terminal	O
maturation	O
.	O

Together	O
,	O
our	O
data	O
show	O
that	O
bcl	O
-	O
xL	O
is	O
essential	O
for	O
normal	O
erythroid	O
development	O
and	O
suggest	O
a	O
regulatory	O
hierarchy	O
in	O
which	O
bcl	O
-	O
xL	O
is	O
a	O
critical	O
downstream	B-Regulation
effector	I-Regulation
of	O
GATA	O
-	O
1	O
and	O
erythropoietin	O
-	O
mediated	O
signals	O
.	O

NF	O
-	O
kappaB	O
functions	O
as	O
both	O
a	O
proapoptotic	O
and	O
antiapoptotic	O
regulatory	O
factor	O
within	O
a	O
single	O
cell	O
type	O
.	O

Recently	O
NF	O
-	O
kappaB	O
has	O
been	O
shown	O
to	O
have	O
both	O
proapoptotic	O
and	O
antiapoptotic	O
functions	O
.	O

In	O
T	O
cell	O
hybridomas	O
,	O
both	O
T	O
cell	O
activators	O
and	O
glucocorticoids	O
induce	O
apoptosis	O
.	O

Here	O
we	O
show	O
that	O
blockade	O
of	O
NF	O
-	O
kappaB	O
activity	O
,	O
using	O
a	O
dominant	O
negative	O
IkappaBalpha	O
,	O
has	O
opposite	O
effects	O
on	O
these	O
two	O
apoptotic	O
signals	O
.	O

Treatment	O
with	O
PMA	O
plus	O
ionomycin	O
(	O
P/I	O
)	O
results	O
in	O
the	O
upregulation	B-Positive_regulation
of	O
Fas	O
Ligand	O
(	O
FasL	O
)	O
and	O
induction	O
of	O
apoptosis	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
inhibits	B-Negative_regulation
the	O
P/I	O
mediated	B-Positive_regulation
induction	B-Transcription
of	O
FasL	O
mRNA	O
and	O
decreases	O
the	O
level	O
of	O
apoptosis	O
in	O
these	O
cultures	O
,	O
thus	O
establishing	O
NF	O
-	O
kappaB	O
as	O
a	O
proapoptotic	O
factor	O
in	O
this	O
context	O
.	O

Conversely	O
,	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
confers	O
a	O
tenfold	O
increase	O
in	O
glucocorticoid	O
mediated	O
apoptosis	O
,	O
establishing	O
that	O
NF	O
-	O
kappaB	O
also	O
functions	O
as	O
an	O
antiapoptotic	O
factor	O
.	O

We	O
conclude	O
that	O
NF	O
-	O
kappaB	O
is	O
a	O
context	O
-	O
dependent	O
apoptosis	O
regulator	O
.	O

Our	O
data	O
suggests	O
that	O
NF	O
-	O
kappaB	O
may	O
function	O
as	O
an	O
antiapoptotic	O
factor	O
in	O
thymocytes	O
while	O
functioning	O
as	O
a	O
proapoptotic	O
factor	O
in	O
mature	O
peripheral	O
T	O
cells	O
.	O

3	O
-	O
deazaadenosine	O
,	O
a	O
S	O
-	O
adenosylhomocysteine	O
hydrolase	O
inhibitor	B-Negative_regulation
,	O
has	O
dual	O
effects	O
on	O
NF	O
-	O
kappaB	O
regulation	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
and	O
promotion	B-Positive_regulation
of	O
IkappaBalpha	O
degradation	B-Protein_catabolism
.	O

Previously	O
we	O
reported	O
that	O
3	O
-	O
deazaadenosine	O
(	O
DZA	O
)	O
,	O
a	O
potent	O
inhibitor	O
and	O
substrate	O
for	O
S	O
-	O
adenosylhomocysteine	O
hydrolase	O
inhibits	B-Negative_regulation
bacterial	O
lipopolysaccharide	O
-	O
induced	B-Positive_regulation
transcription	B-Transcription
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
and	O
interleukin	O
-	O
1beta	O
in	O
mouse	O
macrophage	O
RAW	O
264.7	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
the	O
effects	O
of	O
DZA	O
on	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
regulation	O
.	O

DZA	O
inhibits	O
the	O
transcriptional	O
activity	O
of	O
NF	O
-	O
kappaB	O
through	O
the	O
hindrance	B-Negative_regulation
of	O
p65	O
(	O
Rel	O
-	O
A	O
)	O
phosphorylation	B-Phosphorylation
without	O
reduction	O
of	O
its	O
nuclear	O
translocation	O
and	O
DNA	O
binding	O
activity	O
.	O

The	O
inhibitory	O
effect	O
of	O
DZA	O
on	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
is	O
potentiated	O
by	O
the	O
addition	O
of	O
homocysteine	O
.	O

Taken	O
together	O
,	O
DZA	O
promotes	B-Positive_regulation
the	O
proteolytic	B-Protein_catabolism
degradation	I-Protein_catabolism
of	O
IkappaBalpha	O
,	O
but	O
not	O
IkappaBbeta	O
,	O
resulting	O
in	O
an	O
increase	O
of	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
in	O
the	O
nucleus	O
in	O
the	O
absence	O
of	O
its	O
transcriptional	O
activity	O
in	O
RAW	O
264.7	O
cells	O
.	O

The	O
reduction	B-Negative_regulation
of	O
IkappaBalpha	O
by	O
DZA	O
is	O
neither	O
involved	O
in	O
IkappaB	O
kinase	O
complex	O
activation	O
nor	O
modulated	B-Regulation
by	O
the	O
addition	O
of	O
homocysteine	O
.	O

This	O
study	O
strongly	O
suggests	O
that	O
DZA	O
may	O
be	O
a	O
potent	O
drug	O
for	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
NF	O
-	O
kappaB	O
plays	O
a	O
central	O
pathogenic	O
role	O
,	O
as	O
well	O
as	O
a	O
useful	O
tool	O
for	O
studying	O
the	O
regulation	O
and	O
physiological	O
functions	O
of	O
NF	O
-	O
kappaB	O
.	O

STAT1	O
activation	B-Positive_regulation
during	O
monocyte	O
to	O
macrophage	O
maturation	O
:	O
role	B-Positive_regulation
of	O
adhesion	O
molecules	O
.	O

Human	O
monocytes	O
isolated	O
from	O
peripheral	O
blood	O
of	O
healthy	O
donors	O
show	O
a	O
time	O
-	O
dependent	O
differentiation	O
into	O
macrophages	O
upon	O
in	O
vitro	O
cultivation	O
,	O
closely	O
mimicking	O
their	O
in	O
vivo	O
migration	O
and	O
maturation	O
into	O
extravascular	O
tissues	O
.	O

The	O
mediator	O
(	O
s	O
)	O
of	O
this	O
maturation	O
process	O
has	O
not	O
been	O
yet	O
defined	O
.	O

We	O
investigated	O
the	O
involvement	O
of	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
factors	O
in	O
this	O
phenomenon	O
and	O
reported	O
the	O
specific	O
,	O
time	O
-	O
dependent	O
,	O
activation	B-Positive_regulation
of	O
STAT1	O
protein	O
starting	O
at	O
day	O
0/1	O
of	O
cultivation	O
and	O
maximally	B-Positive_regulation
expressed	I-Positive_regulation
at	O
day	O
5	O
.	O

STAT1	O
activity	O
was	O
evident	O
on	O
the	O
STAT	O
binding	B-Binding
sequences	O
(	O
SBE	O
)	O
present	O
in	O
the	O
promoters	O
of	O
genes	O
which	O
are	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
during	O
monocyte	O
to	O
macrophage	O
maturation	O
such	O
as	O
FcgammaRI	O
and	O
ICAM	O
-	O
1	O
,	O
and	O
in	O
the	O
promoter	O
of	O
the	O
transcription	O
factor	O
IFN	O
regulatory	O
factor	O
-	O
1	O
.	O

Moreover	O
,	O
the	O
effect	O
of	O
cell	O
adhesion	O
to	O
fibronectin	O
or	O
laminin	O
was	O
studied	O
to	O
investigate	O
mechanisms	O
involved	O
in	O
STAT1	O
activation	B-Positive_regulation
.	O

Compared	O
with	O
monocytes	O
adherent	O
on	O
plastic	O
surfaces	O
,	O
freshly	O
isolated	O
cells	O
allowed	O
to	O
adhere	O
either	O
to	O
fibronectin	O
-	O
or	O
laminin	O
-	O
coated	O
flasks	O
exhibited	O
an	O
increased	B-Positive_regulation
STAT1	O
binding	B-Binding
activity	I-Binding
both	O
in	O
control	O
and	O
in	O
IFN-gamma	O
-	O
treated	O
cells	O
.	O

The	O
molecular	O
events	O
leading	O
to	O
enhanced	B-Positive_regulation
STAT1	O
activation	B-Positive_regulation
and	O
cytokine	O
responsiveness	O
concerned	O
both	O
Y701	O
and	O
S727	O
STAT1	O
phosphorylation	B-Phosphorylation
.	O

Exogenous	O
addition	O
of	O
transforming	O
growth	O
factor	O
-	O
beta	O
,	O
which	O
exerts	O
an	O
inhibitory	O
effect	O
on	O
some	O
monocytic	O
differentiation	O
markers	O
,	O
inhibited	B-Negative_regulation
macrophage	O
maturation	O
,	O
integrin	O
expression	O
and	O
STAT1	O
binding	B-Binding
activity	I-Binding
.	O

Taken	O
together	O
these	O
results	O
indicate	O
that	O
STAT1	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
differentiation/maturation	O
process	O
of	O
monocytes	O
as	O
an	O
early	O
transcription	O
factor	O
initially	O
activated	B-Positive_regulation
by	O
adherence	O
and	O
then	O
able	O
to	O
modulate	B-Regulation
the	O
expression	B-Gene_expression
of	O
functional	O
genes	O
,	O
such	O
as	O
ICAM	O
-	O
1	O
and	O
FcgammaRI	O
.	O

Stimulation	O
of	O
neutrophil	O
interleukin	O
-	O
8	O
production	B-Gene_expression
by	O
eosinophil	O
granule	O
major	O
basic	O
protein	O
.	O

We	O
evaluated	O
the	O
ability	O
of	O
eosinophil	O
granule	O
major	O
basic	O
protein	O
(	O
MBP	O
)	O
to	O
stimulate	B-Positive_regulation
interleukin	O
(	O
IL	O
)	O
-	O
8	O
production	B-Gene_expression
by	O
neutrophils	O
.	O

MBP	O
over	O
the	O
concentration	O
range	O
of	O
0.1	O
to	O
10	O
microM	O
stimulated	B-Positive_regulation
the	O
release	B-Localization
of	O
up	O
to	O
approximately	O
8	O
ng/ml	O
IL	O
-	O
8	O
.	O

Incubation	O
with	O
2	O
microM	O
MBP	O
showed	O
that	O
,	O
after	O
a	O
1	O
h	O
lag	O
,	O
the	O
level	O
of	O
IL	O
-	O
8	O
release	B-Localization
increased	B-Positive_regulation
with	O
time	O
for	O
approximately	O
10	O
h	O
.	O

At	O
the	O
2	O
microM	O
concentration	O
,	O
eosinophil	O
cationic	O
protein	O
,	O
eosinophil	O
-	O
derived	O
neurotoxin	O
,	O
and	O
eosinophil	O
peroxidase	O
did	O
not	O
stimulate	O
significant	O
levels	O
of	O
IL	O
-	O
8	O
production	B-Gene_expression
.	O

MBP	O
stimulated	B-Positive_regulation
2	O
-	O
fold	O
increases	B-Positive_regulation
in	O
IL	O
-	O
8	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
after	O
1	O
and	O
3	O
h	O
of	O
incubation	O
,	O
which	O
were	O
blocked	B-Negative_regulation
by	O
pretreatment	O
with	O
actinomycin	O
D	O
.	O

However	O
,	O
stimulation	O
with	O
MBP	O
did	O
not	O
produce	O
an	O
increase	O
in	O
the	O
binding	O
activity	O
of	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
or	O
activator	O
protein	O
-	O
1	O
.	O

No	O
NF-IL	O
-	O
6	O
binding	O
activity	O
was	O
detected	O
in	O
the	O
same	O
nuclear	O
extracts	O
.	O

In	O
addition	O
,	O
stimulation	O
with	O
MBP	O
prolonged	B-Positive_regulation
the	I-Positive_regulation
stability	I-Positive_regulation
of	O
IL	O
-	O
8	O
mRNA	O
.	O

MBP	O
also	O
induced	O
transient	O
increases	B-Positive_regulation
in	O
mRNA	O
for	O
macrophage	O
inflammatory	O
protein	O
(	O
MIP	O
)	O
-	O
1alpha	O
and	O
MIP	O
-	O
1beta	O
,	O
but	O
did	O
not	O
stimulate	B-Positive_regulation
the	O
release	B-Localization
of	O
either	O
chemokine	O
.	O

These	O
findings	O
indicate	O
that	O
MBP	O
is	O
selective	O
among	O
the	O
eosinophil	O
granule	O
proteins	O
as	O
a	O
stimulus	O
for	O
neutrophil	O
IL	O
-	O
8	O
release	B-Localization
and	O
,	O
further	O
,	O
that	O
stimulation	O
of	O
neutrophil	O
IL	O
-	O
8	O
release	B-Localization
by	O
MBP	O
involves	O
both	O
transcriptional	O
and	O
posttranscriptional	O
regulation	O
.	O

We	O
postulate	O
that	O
MBP	O
-	O
induced	B-Positive_regulation
release	B-Localization
of	O
IL	O
-	O
8	O
by	O
neutrophils	O
may	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
acute	O
asthma	O
and	O
other	O
inflammatory	O
lung	O
diseases	O
.	O

PPARgamma	O
activation	B-Positive_regulation
induces	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
the	O
adipocyte	O
fatty	O
acid	O
binding	O
protein	O
gene	O
in	O
human	O
monocytes	O
.	O

The	O
peroxisome	O
-	O
proliferator	O
activated	O
receptor	O
gamma	O
(	O
PPARgamma	O
)	O
,	O
a	O
member	O
of	O
the	O
nuclear	O
receptor	O
superfamily	O
of	O
ligand	O
activated	O
transcription	O
factors	O
,	O
plays	O
a	O
key	O
role	O
in	O
the	O
anti	O
-	O
diabetic	O
actions	O
of	O
the	O
thiazolidinediones	O
(	O
TZDs	O
)	O
.	O

PPARgamma	O
induces	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
many	O
genes	O
involved	O
in	O
lipid	O
anabolism	O
,	O
including	O
the	O
adipocyte	O
fatty	O
acid	O
binding	O
protein	O
(	O
aP2	O
)	O
,	O
and	O
is	O
a	O
key	O
regulator	O
of	O
adipocyte	O
differentiation	O
.	O

PPARgamma	O
is	O
also	O
expressed	B-Gene_expression
in	O
hematopoietic	O
cells	O
and	O
is	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
in	O
activated	O
monocytes/macrophages	O
.	O

Activation	B-Positive_regulation
of	O
PPARgamma	O
may	O
play	O
a	O
role	O
in	O
the	O
induction	O
of	O
differentiation	O
of	O
macrophages	O
to	O
foam	O
cells	O
that	O
are	O
associated	O
with	O
atherosclerotic	O
lesions	O
.	O

We	O
report	O
that	O
both	O
natural	O
and	O
synthetic	O
PPARgamma	O
agonists	O
induce	B-Positive_regulation
time	O
-	O
and	O
dose	O
-	O
dependent	O
increases	B-Positive_regulation
in	O
aP2	O
mRNA	O
in	O
both	O
primary	O
human	O
monocytes	O
and	O
the	O
monocytic	O
cell	O
line	O
,	O
THP	O
-	O
1	O
.	O

These	O
data	O
suggest	O
that	O
PPARgamma	O
activation	B-Positive_regulation
may	O
play	O
a	O
role	O
in	O
monocyte	O
differentiation	O
and	O
function	O
analogous	O
to	O
its	O
well	O
-	O
characterized	O
role	O
in	O
adipocytes	O
.	O

Reactive	O
oxygen	O
intermediate	O
-	O
release	O
of	O
fibre	O
-	O
exposed	O
monocytes	O
increases	O
inflammatory	O
cytokine	O
-	O
mRNA	O
level	O
,	O
protein	O
tyrosine	O
kinase	O
and	O
NF	O
-	O
kappaB	O
activity	O
in	O
co	O
-	O
cultured	O
bronchial	O
epithelial	O
cells	O
(	O
BEAS	O
-	O
2B	O
)	O
.	O

Some	O
pulmonary	O
diseases	O
like	O
bronchitis	O
or	O
asthma	O
bronchiale	O
are	O
mediated	O
by	O
inflammatory	O
mechanisms	O
in	O
bronchial	O
epithelial	O
cells	O
.	O

Alveolar	O
macrophages	O
are	O
located	O
directly	O
in	O
the	O
surrounding	O
of	O
these	O
cells	O
,	O
so	O
that	O
we	O
suppose	O
an	O
interaction	O
between	O
epithelial	O
cells	O
and	O
macrophages	O
regarding	O
to	O
the	O
release	O
of	O
inflammatory	O
mediators	O
.	O

For	O
measuring	O
the	O
contribution	O
of	O
macrophages	O
to	O
the	O
release	O
of	O
inflammatory	O
mediators	O
by	O
bronchial	O
epithelial	O
cells	O
,	O
we	O
established	O
an	O
in	O
vitro	O
model	O
of	O
co	O
-	O
cultured	O
blood	O
monocytes	O
(	O
BM	O
)	O
and	O
BEAS	O
-	O
2B	O
cells	O
in	O
a	O
transwell	O
system	O
(	O
Costar	O
)	O
.	O

BM	O
were	O
exposed	O
to	O
Chrysotile	O
B	O
and	O
soot	O
particle	O
FR	O
101	O
in	O
a	O
concentration	O
of	O
100	O
microg/10	O
(	O
6	O
)	O
cells	O
.	O

After	O
up	O
to	O
90	O
min	O
exposure	O
time	O
ELISA	O
,	O
EMSA	O
(	O
electromobility	O
shift	O
assay	O
)	O
and	O
RT	O
-	O
PCR	O
were	O
used	O
to	O
measure	O
protein	O
tyrosine	O
kinase	O
activity	O
,	O
protein	O
activity	O
of	O
NF	O
-	O
kappaB	O
and	O
cytokine	O
(	O
IL	O
-	O
1beta	O
,	O
IL	O
-	O
6	O
,	O
TNF	O
-	O
alpha	O
)	O
specific	O
mRNA	O
levels	O
in	O
BEAS	O
-	O
2B	O
cells	O
.	O

We	O
observed	O
an	O
increase	O
in	O
protein	O
tyrosine	O
kinase	O
activity	O
(	O
up	O
to	O
1.8	O
+/	O
-	O
0.5	O
-	O
fold	O
)	O
and	O
NF	O
-	O
kappaB	O
protein	O
activity	O
in	O
BEAS	O
-	O
2B	O
cells	O
after	O
particle	O
or	O
fibre	O
exposure	O
of	O
co	O
-	O
cultured	O
BM	O
.	O

Consecutive	O
IL-1beta	O
-	O
,	O
IL-6	O
-	O
and	O
TNF-alpha	O
-	O
mRNA	O
were	O
elevated	B-Positive_regulation
(	O
up	O
to	O
1.9	O
+/	O
-	O
0.58	O
-	O
fold	O
)	O
.	O

Protein	O
tyrosine	O
kinase	O
activity	O
,	O
NF	O
-	O
kappaB	O
activity	O
,	O
and	O
the	O
synthesis	O
of	O
cytokine	O
-	O
specific	O
mRNA	O
were	O
inhibited	O
by	O
antioxidants	O
.	O

These	O
data	O
suggest	O
a	O
ROI	O
-	O
dependent	O
NF	O
-	O
kappaB	O
mediated	O
transcription	O
of	O
inflammatory	O
cytokines	O
in	O
bronchial	O
epithelial	O
cells	O
.	O

Host	O
defense	O
mechanisms	O
triggered	O
by	O
microbial	O
lipoproteins	O
through	O
toll	O
-	O
like	O
receptors	O
.	O

The	O
generation	O
of	O
cell	O
-	O
mediated	O
immunity	O
against	O
many	O
infectious	O
pathogens	O
involves	O
the	O
production	B-Gene_expression
of	O
interleukin	O
-	O
12	O
(	O
IL	O
-	O
12	O
)	O
,	O
a	O
key	O
signal	O
of	O
the	O
innate	O
immune	O
system	O
.	O

Yet	O
,	O
for	O
many	O
pathogens	O
,	O
the	O
molecules	O
that	O
induce	B-Positive_regulation
IL	O
-	O
12	O
production	B-Gene_expression
by	O
macrophages	O
and	O
the	O
mechanisms	O
by	O
which	O
they	O
do	O
so	O
remain	O
undefined	O
.	O

Here	O
it	O
is	O
shown	O
that	O
microbial	O
lipoproteins	O
are	O
potent	O
stimulators	O
of	O
IL	O
-	O
12	O
production	B-Gene_expression
by	O
human	O
macrophages	O
,	O
and	O
that	O
induction	O
is	O
mediated	O
by	O
Toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
.	O

Several	O
lipoproteins	O
stimulated	B-Positive_regulation
TLR	O
-	O
dependent	B-Regulation
transcription	B-Transcription
of	O
inducible	B-Positive_regulation
nitric	O
oxide	O
synthase	O
and	O
the	O
production	O
of	O
nitric	O
oxide	O
,	O
a	O
powerful	O
microbicidal	O
pathway	O
.	O

Activation	O
of	O
TLRs	O
by	O
microbial	O
lipoproteins	O
may	O
initiate	O
innate	O
defense	O
mechanisms	O
against	O
infectious	O
pathogens	O
.	O

Cell	O
activation	O
and	O
apoptosis	O
by	O
bacterial	O
lipoproteins	O
through	O
toll	O
-	O
like	O
receptor	O
-	O
2	O
.	O

Apoptosis	O
is	O
implicated	O
in	O
the	O
generation	O
and	O
resolution	O
of	O
inflammation	O
in	O
response	O
to	O
bacterial	O
pathogens	O
.	O

All	O
bacterial	O
pathogens	O
produce	O
lipoproteins	O
(	O
BLPs	O
)	O
,	O
which	O
trigger	O
the	O
innate	O
immune	O
response	O
.	O

BLPs	O
were	O
found	O
to	O
induce	O
apoptosis	O
in	O
THP	O
-	O
1	O
monocytic	O
cells	O
through	O
human	O
Toll	O
-	O
like	O
receptor	O
-	O
2	O
(	O
hTLR2	O
)	O
.	O

BLPs	O
also	O
initiated	O
apoptosis	O
in	O
an	O
epithelial	O
cell	O
line	O
transfected	B-Positive_regulation
with	O
hTLR2	O
.	O

In	O
addition	O
,	O
BLPs	O
stimulated	O
nuclear	O
factor	O
-	O
kappaB	O
,	O
a	O
transcriptional	O
activator	O
of	O
multiple	O
host	O
defense	O
genes	O
,	O
and	O
activated	O
the	O
respiratory	O
burst	O
through	O
hTLR2	O
.	O

Thus	O
,	O
hTLR2	O
is	O
a	O
molecular	O
link	O
between	O
microbial	O
products	O
,	O
apoptosis	O
,	O
and	O
host	O
defense	O
mechanisms	O
.	O

Tissue	O
-	O
specific	O
regulation	B-Regulation
of	O
the	O
ecto-5'	O
-	O
nucleotidase	O
promoter	O
.	O

Role	B-Regulation
of	O
the	O
camp	O
response	O
element	O
site	O
in	O
mediating	B-Positive_regulation
repression	B-Negative_regulation
by	O
the	O
upstream	O
regulatory	O
region	O
.	O

We	O
have	O
isolated	O
the	O
5	O
'	O
region	O
of	O
the	O
ecto-5'	O
-	O
nucleotidase	O
(	O
low	O
K	O
(	O
m	O
)	O
5'	O
-	O
NT	O
)	O
gene	O
and	O
established	O
that	O
a	O
969	O
-	O
base	O
pair	O
(	O
bp	O
)	O
fragment	O
confers	O
cell	O
-	O
specific	O
expression	O
of	O
a	O
CAT	O
reporter	O
gene	O
that	O
correlates	O
with	O
the	O
expression	B-Transcription
of	O
endogenous	O
ecto-5'	O
-	O
NT	O
mRNA	O
and	O
enzymatic	O
activity	O
.	O

A	O
768	O
-	O
bp	O
upstream	O
negative	O
regulatory	O
region	O
has	O
been	O
identified	O
that	O
conferred	O
lymphocyte	O
-	O
specific	O
negative	O
regulation	O
in	O
a	O
heterologous	O
system	O
with	O
a	O
244	O
-	O
bp	O
deoxycytidine	O
kinase	O
core	O
promoter	O
.	O

DNase	O
I	O
footprinting	O
identified	O
several	O
protected	O
areas	O
including	O
Sp1	O
,	O
Sp1/AP	O
-	O
2	O
,	O
and	O
cAMP	O
response	O
element	O
(	O
CRE	O
)	O
binding	O
sites	O
within	O
the	O
201	O
-	O
bp	O
core	O
promoter	O
region	O
and	O
Sp1	O
,	O
NRE	O
-	O
2a	O
,	O
TCF-1/LEF	O
-	O
1	O
,	O
and	O
Sp1/NF	O
-	O
AT	O
binding	O
sites	O
in	O
the	O
upstream	O
regulatory	O
region	O
.	O

Whereas	O
the	O
CRE	O
site	O
was	O
essential	O
in	O
mediating	O
the	O
negative	O
activity	O
of	O
the	O
upstream	O
regulatory	O
region	O
in	O
Jurkat	O
but	O
not	O
in	O
HeLa	O
cells	O
,	O
mutation	O
of	O
the	O
Sp1/AP	O
-	O
2	O
site	O
decreased	O
promoter	O
activity	O
in	O
both	O
cell	O
lines	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
analysis	O
of	O
proteins	O
binding	B-Binding
to	O
the	O
CRE	O
site	O
identified	O
both	O
ATF	O
-	O
1	O
and	O
ATF	O
-	O
2	O
in	O
Jurkat	O
cells	O
.	O

Finally	O
,	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
increased	O
the	O
activity	O
of	O
both	O
the	O
core	O
and	O
the	O
969	O
-	O
bp	O
promoter	O
fragments	O
,	O
and	O
this	O
increase	O
was	O
abrogated	O
by	O
mutations	O
at	O
the	O
CRE	O
site	O
.	O

In	O
summary	O
,	O
we	O
have	O
identified	O
a	O
tissue	O
-	O
specific	O
regulatory	O
region	O
5	O
'	O
of	O
the	O
ecto-5'	O
-	O
NT	O
core	O
promoter	O
that	O
requires	O
the	O
presence	O
of	O
a	O
functional	O
CRE	O
site	O
within	O
the	O
basal	O
promoter	O
for	O
its	O
suppressive	O
activity	O
.	O

NF-kappaB	O
-	O
mediated	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
Bcl	O
-	O
x	O
and	O
Bfl	O
-	O
1/A1	O
is	O
required	O
for	O
CD40	O
survival	O
signaling	O
in	O
B	O
lymphocytes	O
.	O

Activation	B-Positive_regulation
of	O
CD40	O
is	O
essential	O
for	O
thymus	O
-	O
dependent	O
humoral	O
immune	O
responses	O
and	O
rescuing	O
B	O
cells	O
from	O
apoptosis	O
.	O

Many	O
of	O
the	O
effects	O
of	O
CD40	O
are	O
believed	O
to	O
be	O
achieved	O
through	O
altered	O
gene	O
expression	O
.	O

In	O
addition	O
to	O
Bcl	O
-	O
x	O
,	O
a	O
known	O
CD40	O
-	O
regulated	B-Regulation
antiapoptotic	O
molecule	O
,	O
we	O
identified	O
a	O
related	O
antiapoptotic	O
molecule	O
,	O
A1/Bfl	O
-	O
1	O
,	O
as	O
a	O
CD40	O
-	O
inducible	B-Positive_regulation
gene	O
.	O

Inhibition	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
by	O
overexpression	O
of	O
a	O
dominant	O
-	O
active	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
abolished	B-Negative_regulation
CD40	O
-	O
induced	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
both	O
the	O
Bfl	O
-	O
1	O
and	O
Bcl	O
-	O
x	O
genes	O
and	O
also	O
eliminated	O
the	O
ability	O
of	O
CD40	O
to	O
rescue	O
Fas	O
-	O
induced	O
cell	O
death	O
.	O

Within	O
the	O
upstream	O
promoter	O
region	O
of	O
Bcl	O
-	O
x	O
,	O
a	O
potential	O
NF-kappaB	O
-	O
binding	O
sequence	O
was	O
found	O
to	O
support	O
NF-kappaB	O
-	O
dependent	O
transcriptional	O
activation	O
.	O

Furthermore	O
,	O
expression	B-Gene_expression
of	O
physiological	O
levels	O
of	O
Bcl	O
-	O
x	O
protected	O
B	O
cells	O
from	O
Fas	O
-	O
mediated	O
apoptosis	O
in	O
the	O
absence	O
of	O
NF	O
-	O
kappaB	O
signaling	O
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
CD40	O
-	O
mediated	O
cell	O
survival	O
proceeds	O
through	O
NF-kappaB	O
-	O
dependent	O
up	O
-	O
regulation	O
of	O
Bcl	O
-	O
2	O
family	O
members	O
.	O

Distinctive	O
gene	O
expression	O
patterns	O
in	O
human	O
mammary	O
epithelial	O
cells	O
and	O
breast	O
cancers	O
.	O

cDNA	O
microarrays	O
and	O
a	O
clustering	O
algorithm	O
were	O
used	O
to	O
identify	O
patterns	O
of	O
gene	O
expression	O
in	O
human	O
mammary	O
epithelial	O
cells	O
growing	O
in	O
culture	O
and	O
in	O
primary	O
human	O
breast	O
tumors	O
.	O

Clusters	O
of	O
coexpressed	O
genes	O
identified	O
through	O
manipulations	O
of	O
mammary	O
epithelial	O
cells	O
in	O
vitro	O
also	O
showed	O
consistent	O
patterns	O
of	O
variation	O
in	O
expression	O
among	O
breast	O
tumor	O
samples	O
.	O

By	O
using	O
immunohistochemistry	O
with	O
antibodies	O
against	O
proteins	O
encoded	O
by	O
a	O
particular	O
gene	O
in	O
a	O
cluster	O
,	O
the	O
identity	O
of	O
the	O
cell	O
type	O
within	O
the	O
tumor	O
specimen	O
that	O
contributed	O
the	O
observed	O
gene	O
expression	O
pattern	O
could	O
be	O
determined	O
.	O

Clusters	O
of	O
genes	O
with	O
coherent	O
expression	O
patterns	O
in	O
cultured	O
cells	O
and	O
in	O
the	O
breast	O
tumors	O
samples	O
could	O
be	O
related	O
to	O
specific	O
features	O
of	O
biological	O
variation	O
among	O
the	O
samples	O
.	O

Two	O
such	O
clusters	O
were	O
found	O
to	O
have	O
patterns	O
that	O
correlated	O
with	O
variation	O
in	O
cell	O
proliferation	O
rates	O
and	O
with	O
activation	O
of	O
the	O
IFN	O
-	O
regulated	O
signal	O
transduction	O
pathway	O
,	O
respectively	O
.	O

Clusters	O
of	O
genes	O
expressed	O
by	O
stromal	O
cells	O
and	O
lymphocytes	O
in	O
the	O
breast	O
tumors	O
also	O
were	O
identified	O
in	O
this	O
analysis	O
.	O

These	O
results	O
support	O
the	O
feasibility	O
and	O
usefulness	O
of	O
this	O
systematic	O
approach	O
to	O
studying	O
variation	O
in	O
gene	O
expression	O
patterns	O
in	O
human	O
cancers	O
as	O
a	O
means	O
to	O
dissect	O
and	O
classify	O
solid	O
tumors	O
.	O

Bcl-2	O
-	O
mediated	O
drug	O
resistance	O
:	O
inhibition	O
of	O
apoptosis	O
by	O
blocking	B-Negative_regulation
nuclear	O
factor	O
of	O
activated	O
T	O
lymphocytes	O
(	O
NFAT	O
)	O
-	O
induced	B-Positive_regulation
Fas	O
ligand	O
transcription	B-Transcription
.	O

Bcl	O
-	O
2	O
inhibits	O
apoptosis	O
induced	O
by	O
a	O
variety	O
of	O
stimuli	O
,	O
including	O
chemotherapy	O
drugs	O
and	O
glucocorticoids	O
.	O

It	O
is	O
generally	O
accepted	O
that	O
Bcl	O
-	O
2	O
exerts	O
its	O
antiapoptotic	O
effects	O
mainly	O
by	O
dimerizing	B-Binding
with	O
proapoptotic	O
members	O
of	O
the	O
Bcl	O
-	O
2	O
family	O
such	O
as	O
Bax	O
and	O
Bad	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
the	O
antiapoptotic	O
effects	O
is	O
unclear	O
.	O

Paclitaxel	O
and	O
other	O
drugs	O
that	O
disturb	O
microtubule	O
dynamics	O
kill	O
cells	O
in	O
a	O
Fas/Fas	O
ligand	O
(	O
FasL	O
)	O
-	O
dependent	O
manner	O
;	O
antibody	O
to	O
FasL	O
inhibits	O
paclitaxel	O
-	O
induced	O
apoptosis	O
.	O

We	O
have	O
found	O
that	O
Bcl	O
-	O
2	O
overexpression	B-Positive_regulation
leads	B-Negative_regulation
to	I-Negative_regulation
the	I-Negative_regulation
prevention	I-Negative_regulation
of	O
chemotherapy	O
(	O
paclitaxel	O
)	O
-	O
induced	B-Positive_regulation
expression	B-Gene_expression
of	O
FasL	O
and	O
blocks	O
paclitaxel	O
-	O
induced	O
apoptosis	O
.	O

The	O
mechanism	O
of	O
this	O
effect	O
is	O
that	O
Bcl	O
-	O
2	O
prevents	O
the	O
nuclear	O
translocation	O
of	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
lymphocytes	O
,	O
a	O
transcription	O
factor	O
activated	O
by	O
microtubule	O
damage	O
)	O
by	O
binding	B-Binding
and	O
sequestering	O
calcineurin	O
,	O
a	O
calcium	O
-	O
dependent	O
phosphatase	O
that	O
must	O
dephosphorylate	O
NFAT	O
to	O
move	O
to	O
the	O
nucleus	O
.	O

Without	B-Positive_regulation
NFAT	O
nuclear	O
translocation	O
,	O
the	O
FasL	O
gene	O
is	O
not	O
transcribed	B-Transcription
.	O

Thus	O
,	O
it	O
appears	O
that	O
paclitaxel	O
and	O
other	O
drugs	O
that	O
disturb	O
microtubule	O
function	O
kill	O
cells	O
at	O
least	O
in	O
part	O
through	O
the	O
induction	B-Positive_regulation
of	O
FasL	O
.	O

Furthermore	O
,	O
Bcl	O
-	O
2	O
antagonizes	O
drug	O
-	O
induced	O
apoptosis	O
by	O
inhibiting	O
calcineurin	O
activation	O
,	O
blocking	O
NFAT	O
nuclear	O
translocation	O
,	O
and	O
preventing	B-Negative_regulation
FasL	O
expression	B-Gene_expression
.	O

The	O
effects	O
of	O
Bcl	O
-	O
2	O
can	O
be	O
overcome	O
,	O
at	O
least	O
partially	O
,	O
through	O
phosphorylation	B-Phosphorylation
of	O
Bcl	O
-	O
2	O
.	O

Phosphorylated	B-Phosphorylation
Bcl	O
-	O
2	O
can	B-Negative_regulation
not	I-Negative_regulation
bind	B-Binding
calcineurin	O
,	O
and	O
NFAT	O
activation	O
,	O
FasL	O
expression	B-Gene_expression
,	O
and	O
apoptosis	O
can	O
occur	O
after	B-Positive_regulation
Bcl	O
-	O
2	O
phosphorylation	B-Phosphorylation
.	O

Retinoblastoma	O
protein	O
expression	B-Gene_expression
leads	O
to	O
reduced	B-Negative_regulation
Oct	O
-	O
1	O
DNA	O
binding	B-Binding
activity	I-Binding
and	O
enhances	B-Positive_regulation
interleukin	O
-	O
8	O
expression	B-Gene_expression
.	O

Tumor	O
cell	O
lines	O
with	O
a	O
defective	B-Negative_regulation
retinoblastoma	O
gene	O
are	O
unable	O
to	O
transcribe	O
the	O
HLA	O
class	O
II	O
genes	O
in	O
response	O
to	O
IFN	O
-	O
gamma	O
treatment	O
,	O
and	O
reconstitution	O
of	O
functional	O
Rb	O
rescues	O
IFN-gamma	O
-	O
induced	O
class	O
II	O
gene	O
expression	O
.	O

However	O
,	O
the	O
molecular	O
mechanism	O
of	O
Rb	O
rescue	O
of	O
the	O
class	O
II	O
genes	O
is	O
unknown	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
Rb	O
expression	B-Gene_expression
on	O
the	O
activation	O
of	O
the	O
promoter	O
for	O
HLA	O
-	O
DRA	O
,	O
the	O
prototype	O
class	O
II	O
gene	O
.	O

Oct	O
-	O
1	O
,	O
a	O
POU	O
domain	O
transcription	O
factor	O
,	O
was	O
identified	O
as	O
a	O
repressor	O
of	O
HLA	O
-	O
DRA	O
promoter	O
activity	O
in	O
the	O
Rb	O
-	O
defective	B-Negative_regulation
cells	O
.	O

Rb	O
expression	B-Gene_expression
led	B-Positive_regulation
to	O
phosphorylation	B-Phosphorylation
of	O
Oct	O
-	O
1	O
,	O
thus	O
relieving	O
its	O
repressive	O
effect	O
.	O

Oct	O
-	O
1	O
has	O
also	O
been	O
shown	O
to	O
repress	B-Negative_regulation
interleukin	O
8	O
promoter	O
activity	O
.	O

Consistent	O
with	O
reduced	B-Negative_regulation
levels	I-Negative_regulation
of	O
Oct	O
-	O
1	O
DNA	O
binding	B-Binding
activity	I-Binding
in	O
the	O
Rb	O
-	O
transformed	O
cell	O
lines	O
,	O
interleukin	O
8	O
expression	B-Gene_expression
is	O
higher	B-Positive_regulation
in	O
these	O
cell	O
lines	O
.	O

Protein	O
kinase	O
C	O
and	O
calcineurin	O
synergize	O
to	O
activate	O
IkappaB	O
kinase	O
and	O
NF	O
-	O
kappaB	O
in	O
T	O
lymphocytes	O
.	O

The	O
nuclear	O
factor	O
of	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
is	O
a	O
ubiquitous	O
transcription	O
factor	O
that	O
is	O
key	O
in	O
the	O
regulation	O
of	O
the	O
immune	O
response	O
and	O
inflammation	O
.	O

T	O
cell	O
receptor	O
(	O
TCR	O
)	O
cross	O
-	O
linking	O
is	O
in	O
part	O
required	O
for	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
which	O
is	O
dependent	O
on	O
the	O
phosphorylation	B-Phosphorylation
and	O
degradation	B-Protein_catabolism
of	O
IkappaBalpha	O
.	O

By	O
using	O
Jurkat	O
and	O
primary	O
human	O
T	O
lymphocytes	O
,	O
we	O
demonstrate	O
that	O
the	O
simultaneous	O
activation	O
of	O
two	O
second	O
messengers	O
of	O
the	O
TCR	O
-	O
initiated	O
signal	O
transduction	O
,	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
and	O
calcineurin	O
,	O
results	O
in	O
the	O
synergistic	B-Positive_regulation
activation	I-Positive_regulation
of	O
the	O
IkappaBalpha	O
kinase	O
(	O
IKK	O
)	O
complex	O
but	O
not	O
of	O
another	O
putative	O
IkappaBalpha	O
kinase	O
,	O
p90	O
(	O
rsk	O
)	O
.	O

We	O
also	O
demonstrate	O
that	O
the	O
IKK	O
complex	O
,	O
but	O
not	O
p90	O
(	O
rsk	O
)	O
,	O
is	O
responsible	B-Regulation
for	O
the	O
in	O
vivo	O
phosphorylation	B-Phosphorylation
of	O
IkappaBalpha	O
mediated	B-Positive_regulation
by	O
the	O
co	O
-	O
activation	O
of	O
PKC	O
and	O
calcineurin	O
.	O

Each	O
second	O
messenger	O
is	O
necessary	O
,	O
as	O
inhibition	O
of	O
either	O
one	O
reverses	B-Negative_regulation
the	O
activation	O
of	O
the	O
IKK	O
complex	O
and	O
IkappaBalpha	O
phosphorylation	B-Phosphorylation
in	O
vivo	O
.	O

Overexpression	O
of	O
dominant	O
negative	O
forms	O
of	O
IKKalpha	O
and	O
-	O
beta	O
demonstrates	O
that	O
only	O
IKKbeta	O
is	O
the	O
target	B-Regulation
for	O
PKC	O
and	O
calcineurin	O
.	O

These	O
results	O
indicate	O
that	O
within	O
the	O
TCR/CD3	O
signal	O
transduction	O
pathway	O
both	O
PKC	O
and	O
calcineurin	O
are	O
required	O
for	O
the	O
effective	O
activation	O
of	O
the	O
IKK	O
complex	O
and	O
NF	O
-	O
kappaB	O
in	O
T	O
lymphocytes	O
.	O

C/EBPbeta	O
and	O
GATA	O
-	O
1	O
synergistically	O
regulate	B-Regulation
activity	O
of	O
the	O
eosinophil	O
granule	O
major	O
basic	O
protein	O
promoter	O
:	O
implication	O
for	O
C/EBPbeta	O
activity	O
in	O
eosinophil	O
gene	O
expression	O
.	O

Eosinophil	O
granule	O
major	O
basic	O
protein	O
(	O
MBP	O
)	O
is	O
expressed	B-Gene_expression
exclusively	O
in	O
eosinophils	O
and	O
basophils	O
in	O
hematopoietic	O
cells	O
.	O

In	O
our	O
previous	O
study	O
,	O
we	O
demonstrated	O
a	O
major	O
positive	B-Positive_regulation
regulatory	I-Positive_regulation
role	I-Positive_regulation
for	O
GATA	O
-	O
1	O
and	O
a	O
negative	B-Negative_regulation
regulatory	I-Negative_regulation
role	I-Negative_regulation
for	O
GATA	O
-	O
2	O
in	O
MBP	O
gene	O
transcription	B-Transcription
.	O

Further	O
analysis	O
of	O
the	O
MBP	O
promoter	O
region	O
identified	O
a	O
C/EBP	O
(	O
CCAAT/enhancer	O
-	O
binding	O
protein	O
)	O
consensus	O
binding	O
site	O
6	O
bp	O
upstream	O
of	O
the	O
functional	O
GATA	O
-	O
binding	O
site	O
in	O
the	O
MBP	O
gene	O
.	O

In	O
the	O
cell	O
line	O
HT93A	O
,	O
which	O
is	O
capable	O
of	O
differentiating	O
towards	O
both	O
the	O
eosinophil	O
and	O
neutrophil	O
lineages	O
in	O
response	O
to	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
C/EBPalpha	O
mRNA	O
expression	B-Transcription
decreased	B-Negative_regulation
significantly	O
concomitant	O
with	O
eosinophilic	O
and	O
neutrophilic	O
differentiation	O
,	O
whereas	O
C/EBPbeta	O
expression	B-Gene_expression
was	O
markedly	O
increased	B-Positive_regulation
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
showed	O
that	O
recombinant	O
C/EBPbeta	O
protein	O
could	O
bind	B-Binding
to	O
the	O
potential	O
C/EBP	O
-	O
binding	O
site	O
(	O
bp	O
-	O
90	O
to	O
-	O
82	O
)	O
in	O
the	O
MBP	O
promoter	O
.	O

Furthermore	O
,	O
we	O
have	O
demonstrated	O
that	O
both	O
C/EBPbeta	O
and	O
GATA	O
-	O
1	O
can	O
bind	B-Binding
simultaneously	O
to	O
the	O
C/EBP	O
-	O
and	O
GATA	O
-	O
binding	O
sites	O
in	O
the	O
MBP	O
promoter	O
.	O

To	O
determine	O
the	O
functionality	O
of	O
both	O
the	O
C/EBP	O
-	O
and	O
GATA	O
-	O
binding	O
sites	O
,	O
we	O
analyzed	O
whether	O
C/EBPbeta	O
and	O
GATA	O
-	O
1	O
can	O
stimulate	B-Positive_regulation
the	O
MBP	O
promoter	O
in	O
the	O
C/EBPbeta	O
and	O
GATA	O
-	O
1	O
negative	B-Gene_expression
Jurkat	O
T	O
-	O
cell	O
line	O
.	O

Cotransfection	B-Positive_regulation
with	O
C/EBPbeta	O
and	O
GATA	O
-	O
1	O
expression	O
vectors	O
produced	O
a	O
5	O
-	O
fold	O
increase	B-Positive_regulation
compared	O
with	O
cotransfection	B-Positive_regulation
with	O
the	O
C/EBPbeta	O
or	O
GATA	O
-	O
1	O
expression	O
vectors	O
individually	O
.	O

In	O
addition	O
,	O
GST	O
pull	O
-	O
down	O
experiments	O
demonstrated	O
a	O
physical	B-Binding
interaction	I-Binding
between	O
human	O
GATA	O
-	O
1	O
and	O
C/EBPbeta	O
.	O

Expression	O
of	O
FOG	O
(	O
riend	O
ATA	O
)	O
,	O
which	O
binds	B-Binding
to	O
GATA	O
-	O
1	O
and	O
acts	O
as	O
a	O
cofactor	O
for	O
GATA	O
-	O
binding	O
proteins	O
,	O
decreased	B-Negative_regulation
transactivation	B-Positive_regulation
activity	O
of	O
GATA	O
-	O
1	O
for	O
the	O
MBP	O
promoter	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Our	O
results	O
provide	O
the	O
first	O
evidence	O
that	O
both	O
GATA	O
-	O
1	O
and	O
C/EBPbeta	O
synergistically	O
transactivate	O
the	O
promoter	O
of	O
an	O
eosinophil	O
-	O
specific	O
granule	O
protein	O
gene	O
and	O
that	O
FOG	O
may	O
act	O
as	O
a	O
negative	O
cofactor	O
for	O
the	O
eosinophil	O
lineage	O
,	O
unlike	O
its	O
positively	O
regulatory	O
function	O
for	O
the	O
erythroid	O
and	O
megakaryocyte	O
lineages	O
.	O

Thymocyte	O
-	O
thymic	O
epithelial	O
cell	O
interaction	O
leads	O
to	O
high	O
-	O
level	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
exclusively	O
in	O
mature	O
CD4	O
(	O
+	O
)	O
CD8	O
(	O
-	O
)	O
CD3	O
(	O
+	O
)	O
thymocytes	O
:	O
a	O
critical	O
role	O
for	O
tumor	O
necrosis	O
factor	O
and	O
interleukin	O
-	O
7	O
.	O

This	O
work	O
aims	O
at	O
identifying	O
the	O
thymocyte	O
subpopulation	O
able	O
to	O
support	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
replication	O
under	O
the	O
biological	O
stimuli	O
of	O
the	O
thymic	O
microenvironment	O
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
interaction	O
with	O
thymic	O
epithelial	O
cells	O
(	O
TEC	O
)	O
induces	O
a	O
high	O
-	O
level	O
replication	O
of	O
the	O
T	O
-	O
tropic	O
primary	O
isolate	O
HIV	O
-	O
1	O
(	O
B	O
-	O
LAIp	O
)	O
exclusively	O
in	O
the	O
mature	O
CD4	O
(	O
+	O
)	O
CD8	O
(	O
-	O
)	O
CD3	O
(	O
+	O
)	O
thymocytes	O
.	O

Tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
and	O
interleukin	O
-	O
7	O
(	O
IL	O
-	O
7	O
)	O
,	O
secreted	B-Localization
during	O
this	O
interaction	O
,	O
are	O
critical	O
cytokines	O
for	O
HIV	O
long	O
terminal	O
repeat	O
transactivation	O
through	O
NF-kappaB	O
-	O
dependent	O
activation	O
.	O

TNF	O
is	O
the	O
major	O
inducer	B-Positive_regulation
of	O
NF	O
-	O
kappaB	O
and	O
particularly	O
of	O
the	O
p50	O
-	O
p65	O
complex	O
,	O
whereas	O
IL	O
-	O
7	O
acts	B-Positive_regulation
as	I-Positive_regulation
a	I-Positive_regulation
cofactor	I-Positive_regulation
by	I-Positive_regulation
sustaining	I-Positive_regulation
the	O
expression	B-Gene_expression
of	O
the	O
p75	O
TNF	O
receptor	O
.	O

The	O
requirement	O
for	O
TNF	O
is	O
further	O
confirmed	O
by	O
the	O
observation	O
that	O
the	O
inability	O
of	O
the	O
intermediate	O
CD4	O
(	O
+	O
)	O
CD8	O
(	O
-	O
)	O
CD3	O
(	O
-	O
)	O
thymocytes	O
to	O
replicate	O
the	O
virus	O
is	O
associated	O
with	O
a	O
defect	O
in	O
TNF	O
production	B-Gene_expression
during	O
their	O
interaction	O
with	O
TEC	O
and	O
correlates	O
with	O
the	O
absence	O
of	O
nuclear	O
NF	O
-	O
kappaB	O
activity	O
in	O
these	O
freshly	O
isolated	O
thymocytes	O
.	O

Addition	O
of	O
exogenous	O
TNF	O
to	O
the	O
intermediate	O
thymocyte	O
cultures	O
induces	O
NF	O
-	O
kappaB	O
activity	O
and	O
is	O
sufficient	O
to	O
promote	O
HIV	O
replication	O
in	O
the	O
cocultures	O
with	O
TEC	O
.	O

The	O
other	O
major	O
subpopulation	O
expressing	B-Gene_expression
the	O
CD4	O
receptor	O
,	O
namely	O
,	O
the	O
double	O
-	O
positive	O
(	O
DP	O
)	O
CD4	O
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
CD3	O
(	O
+/	O
-	O
)	O
thymocytes	O
,	O
despite	O
the	O
entry	O
of	O
the	O
virus	O
,	O
do	O
not	O
produce	O
a	O
significant	O
level	O
of	O
virus	O
,	O
presumably	O
because	O
they	O
are	O
unresponsive	O
to	O
TNF	O
and	O
IL	O
-	O
7	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
in	O
vivo	O
,	O
despite	O
an	O
efficient	O
entry	O
of	O
the	O
virus	O
in	O
all	O
the	O
CD4	O
(	O
+	O
)	O
subpopulations	O
,	O
a	O
high	O
viral	O
load	O
may	O
be	O
generated	O
exclusively	O
within	O
the	O
mature	O
CD4	O
(	O
+	O
)	O
CD8	O
(	O
-	O
)	O
CD3	O
(	O
+	O
)	O
subset	O
of	O
thymocytes	O
.	O

However	O
,	O
under	O
conditions	O
of	O
inflammatory	O
response	O
after	O
infection	O
,	O
TNF	O
might	O
also	O
be	O
present	B-Gene_expression
in	O
the	O
intermediate	O
thymocyte	O
compartment	O
,	O
leading	O
to	O
efficient	O
HIV	O
replication	O
in	O
these	O
cells	O
.	O

IL-2	O
-	O
independent	O
activation	O
and	O
proliferation	O
in	O
human	O
T	O
cells	O
induced	O
by	O
CD28	O
.	O

Although	O
the	O
role	O
of	O
CD28	O
in	O
T	O
cell	O
costimulation	O
is	O
firmly	O
established	O
,	O
the	O
mechanisms	O
by	O
which	O
it	O
exerts	O
its	O
costimulatory	O
actions	O
are	O
less	O
clear	O
.	O

In	O
many	O
circumstances	O
it	O
is	O
difficult	O
to	O
distinguish	O
the	O
effects	O
of	O
CD28	O
from	O
subsequent	O
actions	O
of	O
cytokines	O
,	O
such	O
as	O
IL	O
-	O
2	O
,	O
on	O
T	O
cell	O
proliferation	O
.	O

Here	O
,	O
we	O
report	O
a	O
model	O
of	O
CD28	O
costimulation	O
using	O
PMA	O
plus	O
the	O
natural	O
ligand	O
CD80	O
that	O
resulted	B-Negative_regulation
in	I-Negative_regulation
very	I-Negative_regulation
limited	I-Negative_regulation
stimulation	B-Positive_regulation
of	O
IL	O
-	O
2	O
,	O
as	O
evidenced	O
by	O
both	O
cytokine	O
production	O
and	O
IL	O
-	O
2	O
promoter	O
stimulation	B-Positive_regulation
.	O

Promoter	O
assays	O
revealed	O
CD28	O
-	O
dependent	O
effects	B-Regulation
on	O
both	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
,	O
but	O
not	O
on	O
NF	O
-	O
AT	O
or	O
the	O
intact	O
IL	O
-	O
2	O
promoter	O
.	O

In	O
addition	O
,	O
T	O
cell	O
proliferation	O
was	O
completely	O
resistant	O
to	O
the	O
actions	O
of	O
the	O
immunosuppressant	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

Moreover	O
T	O
cell	O
proliferation	O
was	O
unaffected	O
by	O
the	O
addition	O
of	O
blocking	B-Negative_regulation
Abs	O
to	O
both	O
IL	O
-	O
2	O
and	O
the	O
IL	O
-	O
2	O
receptor	O
,	O
demonstrating	O
that	O
this	O
form	O
of	O
costimulation	O
by	O
CD28	O
was	O
independent	O
of	O
IL	O
-	O
2	O
.	O

We	O
also	O
investigated	O
the	O
effects	O
of	O
stimulating	O
T	O
cell	O
blasts	O
with	O
CD80	O
alone	O
and	O
found	O
that	O
there	O
was	O
a	O
limited	O
requirement	O
for	O
IL	O
-	O
2	O
in	O
this	O
system	O
.	O

We	O
conclude	O
that	O
CD28	O
costimulation	O
can	O
cause	O
substantial	O
T	O
cell	O
proliferation	O
in	O
the	O
absence	O
of	O
IL	O
-	O
2	O
,	O
which	O
is	O
driven	O
by	O
a	O
soluble	O
factor	O
independent	O
of	O
NF	O
-	O
AT	O
transactivation	O
.	O

Suppression	O
of	O
TNFalpha	O
-	O
mediated	O
NFkappaB	O
activity	O
by	O
myricetin	O
and	O
other	O
flavonoids	O
through	O
downregulating	O
the	O
activity	O
of	O
IKK	O
in	O
ECV304	O
cells	O
.	O

Flavonoids	O
are	O
a	O
group	O
of	O
naturally	O
-	O
occurring	O
phenolic	O
compounds	O
in	O
the	O
plant	O
kingdom	O
,	O
and	O
many	O
flavonoids	O
are	O
found	O
with	O
vascular	O
protective	O
properties	O
.	O

Nevertheless	O
how	O
the	O
protective	O
response	O
is	O
exerted	O
by	O
flavonoids	O
is	O
not	O
well	O
characterized	O
.	O

In	O
view	O
of	O
the	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NFkappaB	O
)	O
may	O
play	O
a	O
central	O
role	O
in	O
the	O
initiation	O
of	O
atherosclerosis	O
,	O
prevention	O
of	O
the	O
activation	O
of	O
NFkappaB	O
represents	O
an	O
important	O
role	O
in	O
protecting	O
vascular	O
injury	O
.	O

In	O
this	O
study	O
,	O
the	O
effects	O
of	O
flavonoids	O
on	O
NFkappaB/inhibitor	O
-	O
kappaB	O
(	O
IkappaB	O
)	O
system	O
in	O
ECV304	O
cells	O
activated	O
with	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNFalpha	O
)	O
were	O
examined	O
.	O

We	O
investigated	O
the	O
inhibitory	O
action	O
of	O
six	O
flavonoids	O
on	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
activity	O
,	O
an	O
enzyme	O
recently	O
found	O
to	O
phosphorylate	O
critical	O
serine	O
residues	O
of	O
IkappaB	O
for	O
degradation	O
.	O

Of	O
six	O
flavonoids	O
tested	O
,	O
myricetin	O
was	O
found	O
to	O
strongly	O
inhibit	O
IKK	O
kinase	O
activity	O
,	O
and	O
prevent	B-Negative_regulation
the	O
degradation	B-Protein_catabolism
of	O
IkappaBalpha	O
and	O
IkappaBbeta	O
in	O
activated	O
endothelial	O
cells	O
.	O

Furthermore	O
,	O
myricetin	O
was	O
also	O
found	O
to	O
inhibit	O
NFkappaB	O
activity	O
correlated	O
with	O
suppression	O
of	O
monocyte	O
adhesion	O
to	O
ECV304	O
cells	O
.	O

Therefore	O
we	O
conclude	O
that	O
flavonoids	O
may	O
be	O
of	O
therapeutic	O
value	O
for	O
vascular	O
disease	O
through	O
down	O
regulation	O
of	O
NFkappaB/IkappaB	O
system	O
.	O

Copyright	O
1999	O
Wiley	O
-	O
Liss	O
,	O
Inc	O
.	O

Induction	B-Positive_regulation
of	O
a	O
functional	O
vitamin	O
D	O
receptor	O
in	O
all-trans	O
-	O
retinoic	O
acid	O
-	O
induced	O
monocytic	O
differentiation	O
of	O
M2	O
-	O
type	O
leukemic	O
blast	O
cells	O
.	O

Different	O
types	O
of	O
acute	O
myeloid	O
leukemia	O
blast	O
cells	O
were	O
induced	O
to	O
differentiate	O
in	O
vitro	O
with	O
all-trans	O
-	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
and	O
vitamin	O
D3	O
(	O
VD	O
)	O
.	O

M0/M1	O
leukemic	O
cells	O
are	O
not	O
sensitive	O
to	O
differentiating	O
agents	O
,	O
whereas	O
M3	O
leukemic	O
cells	O
are	O
induced	O
to	O
undergo	O
granulocytic	O
differentiation	O
after	O
ATRA	O
treatment	O
but	O
are	O
not	O
sensitive	O
to	O
VD	O
.	O

M2	O
leukemic	O
blast	O
cells	O
behave	O
differently	O
because	O
they	O
undergo	O
monocytic	O
differentiation	O
with	O
both	O
the	O
differentiation	O
inducers	O
.	O

To	O
gain	O
some	O
insight	O
into	O
the	O
maturation	O
of	O
M2	O
-	O
type	O
leukemic	O
cells	O
,	O
we	O
studied	O
the	O
molecular	O
mechanisms	O
underlying	O
monocytic	O
differentiation	O
induced	O
by	O
ATRA	O
and	O
VD	O
in	O
spontaneous	O
M2	O
blast	O
cells	O
as	O
well	O
as	O
in	O
Kasumi	O
-	O
1	O
cells	O
(	O
an	O
acute	O
myeloid	O
leukemia	O
M2	O
-	O
type	O
cell	O
line	O
)	O
.	O

Our	O
results	O
indicate	O
that	O
ATRA	O
as	O
well	O
as	O
VD	O
efficiently	O
increases	B-Positive_regulation
the	O
nuclear	O
abundance	B-Localization
of	O
VD	O
receptor	O
(	O
VDR	O
)	O
and	O
promotes	O
monocytic	O
differentiation	O
.	O

VDR	O
is	O
functionally	O
active	B-Positive_regulation
in	O
ATRA	O
-	O
treated	O
Kasumi	O
-	O
1	O
cells	O
because	O
it	O
efficiently	O
heterodimerizes	B-Binding
with	O
retinoid	O
X	O
receptor	O
,	O
binds	B-Binding
to	O
a	O
DR3	O
-	O
type	O
vitamin	O
D	O
-	O
responsive	O
element	O
,	O
and	O
activates	O
the	O
transcription	O
of	O
a	O
vitamin	O
D	O
-	O
responsive	O
element	O
-	O
regulated	O
reporter	O
gene	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
VD	O
-	O
responsive	O
genes	O
are	O
induced	O
by	O
ATRA	O
treatment	O
of	O
Kasumi	O
-	O
1	O
cells	O
,	O
suggesting	O
that	O
the	O
genetic	O
program	O
underlying	O
monocytic	O
differentiation	O
is	O
activated	O
.	O

The	O
molecular	O
mechanism	O
by	O
which	O
ATRA	O
increases	B-Positive_regulation
the	O
nuclear	O
abundance	B-Localization
of	O
a	O
functional	O
VDR	O
is	O
still	O
unknown	O
,	O
but	O
our	O
data	O
clearly	O
indicate	O
that	O
the	O
M2	O
leukemic	O
cell	O
context	O
is	O
only	O
permissive	O
of	O
monocytic	O
differentiation	O
.	O

Signal	O
transduction	O
pathways	O
triggered	O
by	O
the	O
FcepsilonRIIb	O
receptor	O
(	O
CD23	O
)	O
in	O
human	O
monocytes	O
lead	O
to	O
nuclear	O
factor	O
-	O
kappaB	O
activation	O
.	O

BACKGROUND	O
:	O
Alveolar	O
macrophages	O
play	O
a	O
key	O
role	O
in	O
the	O
initiation	O
of	O
the	O
inflammatory	O
reaction	O
of	O
allergic	O
asthma	O
.	O

Alveolar	O
macrophages	O
and	O
peripheral	O
blood	O
monocytes	O
are	O
activated	O
when	O
IgE/allergen	O
immune	O
complexes	O
bind	B-Binding
to	O
the	O
CD23	O
receptor	O
,	O
which	O
leads	O
to	O
the	O
production	O
of	O
inflammatory	O
cytokines	O
.	O

OBJECTIVE	O
:	O
We	O
sought	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
regulating	O
this	O
early	O
inflammatory	O
response	O
.	O

We	O
have	O
focused	O
on	O
the	O
study	O
of	O
the	O
signal	O
transduction	O
pathways	O
triggered	O
by	O
CD23	O
in	O
human	O
monocytes	O
and	O
the	O
promonocytic	O
cell	O
line	O
U937	O
.	O

METHODS	O
:	O
CD23	O
was	O
cross	B-Binding
-	I-Binding
linked	I-Binding
in	O
human	O
monocytes	O
and	O
U937	O
cells	O
with	O
IgE	O
immune	O
complexes	O
.	O

Surface	O
expression	B-Gene_expression
of	O
CD23	O
was	O
determined	O
by	O
FACS	O
analysis	O
.	O

Transcription	O
factor	O
activation	O
and	O
gene	O
transcription	O
were	O
studied	O
by	O
gel	O
-	O
shift	O
assays	O
and	O
Northern	O
blot	O
analysis	O
,	O
respectively	O
.	O

IkappaBalpha	O
phosphorylation	B-Phosphorylation
and	O
degradation	B-Protein_catabolism
was	O
analyzed	O
by	O
Western	O
blot	O
.	O

RESULTS	O
:	O
Nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
is	O
the	O
main	O
transcription	O
factor	O
involved	O
in	O
the	O
gene	O
activation	O
that	O
follows	O
CD23	O
cross	B-Binding
-	I-Binding
linking	I-Binding
in	O
monocytes	O
.	O

CD23	O
-	O
induced	B-Positive_regulation
NF	O
-	O
kappaB	O
is	O
a	O
heterodimer	O
composed	O
of	O
p65/p50	O
subunits	O
.	O

NF	O
-	O
kappaB	O
nuclear	O
translocation	O
is	O
secondary	O
to	O
the	O
phosphorylation	B-Phosphorylation
and	O
subsequent	O
degradation	B-Protein_catabolism
of	O
the	O
NF	O
-	O
kappaB	O
inhibitory	O
molecule	O
IkappaBalpha	O
.	O

Tyrosine	O
kinase	O
-	O
dependent	O
,	O
and	O
not	O
protein	O
kinase	O
C	O
-	O
dependent	O
,	O
pathways	O
mediate	O
CD23	O
-	O
triggered	O
NF	O
-	O
kappaB	O
activation	O
but	O
do	O
not	O
participate	B-Regulation
in	O
the	O
direct	O
phosphorylation	B-Phosphorylation
of	O
IkappaBalpha	O
.	O

IkappaBalpha	O
degradation	B-Protein_catabolism
and	O
NF	O
-	O
kappaB	O
nuclear	O
translocation	O
correlate	O
with	O
transcriptional	B-Positive_regulation
activation	I-Positive_regulation
of	O
the	O
inflammatory	O
cytokines	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
1beta	O
.	O

CONCLUSIONS	O
:	O
NF	O
-	O
kappaB	O
is	O
the	O
main	O
transcription	O
factor	O
involved	O
in	O
the	O
signal	O
transduction	O
pathway	O
of	O
CD23	O
in	O
monocytes	O
.	O

Dopamine	O
stimulates	O
expression	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
via	O
NF	O
-	O
kappaB	O
in	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Recent	O
studies	O
have	O
reported	O
that	O
lymphocytes	O
produce	O
,	O
transport	O
and	O
bind	O
dopamine	O
present	O
in	O
plasma	O
.	O

However	O
,	O
the	O
action	O
of	O
dopamine	O
on	O
HIV	O
-	O
1	O
gene	O
expression	O
in	O
cells	O
of	O
the	O
immune	O
system	O
has	O
not	O
yet	O
been	O
examined	O
.	O

Here	O
,	O
we	O
have	O
investigated	O
the	O
regulation	O
of	O
HIV	O
-	O
1	O
expression	O
by	O
dopamine	O
in	O
Jurkat	O
T	O
cells	O
and	O
in	O
primary	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O

HIV	O
-	O
1	O
replication	O
was	O
increased	O
by	O
dopamine	O
,	O
which	O
correlated	O
with	O
the	O
increased	O
levels	O
of	O
HIV	O
-	O
1	O
transactivation	O
.	O

Our	O
transient	O
expression	O
data	O
revealed	O
that	O
dopamine	O
stimulated	O
transcription	O
through	O
the	O
NF	O
-	O
kappaB	O
element	O
present	O
in	O
the	O
long	O
terminal	O
repeat	O
.	O

The	O
importance	O
of	O
NF	O
-	O
kappaB	O
sites	O
was	O
confirmed	O
by	O
using	O
vectors	O
containing	O
wild	O
-	O
type	O
or	O
mutant	O
kappaB	O
sites	O
in	O
a	O
heterologous	O
promoter	O
.	O

Consistent	O
with	O
the	O
role	O
of	O
NF	O
-	O
kappaB	O
in	O
mediating	O
dopamine	O
responsiveness	O
,	O
the	O
proteasome	O
inhibitor	O
MG132	O
abolished	O
dopamine	O
-	O
induced	O
transcriptional	O
activation	O
.	O

We	O
further	O
explored	O
the	O
effect	O
of	O
dopamine	O
in	O
the	O
presence	O
of	O
phorbol	O
esters	O
or	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
known	O
to	O
activate	O
NF	O
-	O
kappaB	O
.	O

The	O
combination	O
of	O
dopamine	O
and	O
TNF	O
-	O
alpha	O
led	O
to	O
a	O
stimulation	O
of	O
HIV	O
-	O
1	O
transcription	O
and	O
replication	O
.	O

However	O
,	O
in	O
contrast	O
with	O
TNF	O
-	O
alpha	O
,	O
dopamine	O
treatment	O
did	O
not	O
affect	B-Regulation
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
nor	O
the	O
concentrations	B-Regulation
of	O
p50	O
,	O
p65	O
and	O
IkappaB	O
-	O
alpha	O
proteins	O
,	O
which	O
suggests	O
a	O
distinct	O
NF	O
-	O
kappaB	O
activation	O
mechanism	O
.	O

These	O
results	O
reveal	O
a	O
new	O
link	O
between	O
the	O
dopamine	O
system	O
,	O
cytokine	O
signaling	O
pathway	O
and	O
regulation	O
of	O
gene	O
expression	O
via	O
the	O
involvement	O
of	O
NF	O
-	O
kappaB	O
in	O
T	O
cells	O
and	O
PBMC	O
.	O

AML1	O
(	O
CBFalpha2	O
)	O
cooperates	O
with	O
B	O
cell	O
-	O
specific	O
activating	O
protein	O
(	O
BSAP/PAX5	O
)	O
in	O
activation	B-Positive_regulation
of	O
the	O
B	O
cell	O
-	O
specific	O
BLK	O
gene	O
promoter	O
.	O

AML1	O
plays	O
a	O
critical	O
role	O
during	O
hematopoiesis	O
and	O
chromosomal	O
translocations	O
involving	O
AML1	O
are	O
commonly	O
associated	O
with	O
different	O
forms	O
of	O
leukemia	O
,	O
including	O
pre	O
-	O
B	O
acute	O
lymphoblastic	O
leukemia	O
.	O

To	O
understand	O
the	O
function	O
of	O
AML1	O
during	O
B	O
cell	O
differentiation	O
,	O
we	O
analyzed	O
regulatory	O
regions	O
of	O
B	O
cell	O
-	O
specific	O
genes	O
for	O
potential	O
AML1	O
-	O
binding	B-Binding
sites	I-Binding
and	O
have	O
identified	O
a	O
putative	O
AML1	O
-	O
binding	O
site	O
in	O
the	O
promoter	O
of	O
the	O
B	O
cell	O
-	O
specific	O
tyrosine	O
kinase	O
gene	O
,	O
blk	O
.	O

Gel	O
mobility	O
shift	O
assays	O
and	O
transient	O
transfection	O
assays	O
demonstrate	O
that	O
AML1	O
binds	B-Binding
specifically	O
to	O
this	O
site	O
in	O
the	O
blk	O
promoter	O
and	O
this	O
binding	O
site	O
is	O
important	B-Positive_regulation
for	O
blk	O
promoter	O
activity	O
.	O

Furthermore	O
,	O
in	O
vitro	O
binding	O
analysis	O
revealed	O
that	O
the	O
AML1	O
runt	O
DNA	O
-	O
binding	O
domain	O
physically	B-Binding
interacts	I-Binding
with	O
the	O
paired	O
DNA	O
-	O
binding	O
domain	O
of	O
BSAP	O
,	O
a	O
B	O
cell	O
-	O
specific	O
transcription	O
factor	O
.	O

BSAP	O
has	O
been	O
shown	O
previously	O
to	O
be	O
important	B-Positive_regulation
for	O
B	O
cell	O
-	O
specific	O
regulation	B-Regulation
of	O
the	O
blk	O
gene	O
.	O

Physical	B-Binding
interaction	I-Binding
of	O
AML1	O
with	O
BSAP	O
correlates	O
with	O
functional	O
cooperativity	O
in	O
transfection	O
studies	O
where	O
AML1	O
and	O
BSAP	O
synergistically	O
activate	B-Positive_regulation
blk	O
promoter	O
transcription	B-Transcription
by	O
more	O
than	O
50	O
-	O
fold	O
.	O

These	O
results	O
demonstrate	O
physical	O
and	O
functional	O
interactions	B-Binding
between	O
AML1	O
and	O
BSAP	O
and	O
suggest	O
that	O
AML1	O
is	O
an	O
important	B-Positive_regulation
factor	I-Positive_regulation
for	O
regulating	B-Regulation
a	O
critical	O
B	O
cell	O
-	O
specific	O
gene	O
,	O
blk	O
.	O

c	O
-	O
Maf	O
induces	O
monocytic	O
differentiation	O
and	O
apoptosis	O
in	O
bipotent	O
myeloid	O
progenitors	O
.	O

The	O
transcriptional	O
mechanisms	O
that	O
drive	O
colony	O
-	O
forming	O
unit	O
granulocyte	O
-	O
macrophage	O
(	O
CFU	O
-	O
GM	O
)	O
myeloid	O
progenitors	O
to	O
differentiate	O
into	O
cells	O
of	O
either	O
the	O
granulocytic	O
or	O
monocytic	O
lineage	O
are	O
not	O
fully	O
understood	O
.	O

We	O
have	O
shown	O
that	O
the	O
c	O
-	O
Maf	O
and	O
c	O
-	O
Myb	O
transcription	O
factors	O
physically	B-Binding
interact	I-Binding
in	O
myeloid	O
cells	O
to	O
form	O
inhibitory	O
complexes	O
that	O
hinder	O
transactivation	O
of	O
c	O
-	O
Myb	O
target	O
genes	O
through	O
direct	O
binding	O
to	O
Myb	O
consensus	O
sites	O
.	O

These	O
complexes	O
arise	O
in	O
a	O
developmentally	O
regulated	O
pattern	O
,	O
peaking	O
at	O
the	O
promyelocyte	O
stage	O
,	O
or	O
in	O
cell	O
model	O
systems	O
,	O
appearing	O
soon	O
after	O
the	O
induction	O
of	O
monocytic	O
differentiation	O
.	O

We	O
wished	O
to	O
determine	O
if	O
this	O
developmentally	O
related	O
interaction	O
is	O
a	O
consequence	O
of	O
myeloid	O
differentiation	O
or	O
an	O
intrinsic	O
differentiating	O
stimulus	O
.	O

Because	O
the	O
elevated	O
Myb	O
:	O
Maf	O
status	O
seen	O
in	O
differentiating	O
cells	O
can	O
be	O
recapitulated	O
by	O
overexpression	B-Positive_regulation
of	O
c	O
-	O
Maf	O
in	O
myeloid	O
cell	O
lines	O
,	O
we	O
inducibly	O
expressed	O
the	O
c	O
-	O
Maf	O
cDNA	O
in	O
2	O
bipotent	O
human	O
myeloid	O
progenitor	O
cells	O
.	O

Elevated	B-Positive_regulation
levels	I-Positive_regulation
of	O
c	O
-	O
Maf	O
protein	O
led	O
to	O
marked	O
increases	O
in	O
Myb	O
:	O
Maf	O
complexes	O
and	O
the	O
accumulation	O
of	O
monocyte/macrophage	O
cells	O
,	O
followed	O
by	O
eventual	O
programmed	O
cell	O
death	O
.	O

Analysis	O
of	O
targets	O
that	O
could	O
mediate	O
these	O
phenotypic	O
changes	O
indicated	O
that	O
c	O
-	O
Maf	O
likely	O
plays	O
a	O
key	O
role	O
in	O
myeloid	O
cell	O
development	O
through	O
dual	O
mechanisms	O
;	O
inhibition	B-Negative_regulation
of	O
a	O
select	O
set	O
of	O
c	O
-	O
Myb	O
regulated	B-Regulation
targets	O
,	O
such	O
as	O
Bcl	O
-	O
2	O
and	O
CD13/APN	O
,	O
coupled	O
with	O
the	O
activation	O
of	O
as	O
yet	O
undefined	O
differentiation	O
-	O
promoting	O
genes	O
.	O

Nuclear	O
factor-kappaB	O
-	O
dependent	B-Regulation
induction	B-Positive_regulation
of	O
interleukin	O
-	O
8	O
gene	B-Gene_expression
expression	I-Gene_expression
by	O
tumor	O
necrosis	O
factor	O
alpha	O
:	O
evidence	O
for	O
an	O
antioxidant	O
sensitive	B-Regulation
activating	B-Positive_regulation
pathway	I-Positive_regulation
distinct	O
from	O
nuclear	O
translocation	B-Localization
.	O

Tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNFalpha	O
)	O
is	O
a	O
pluripotent	O
activator	O
of	O
inflammation	O
by	O
inducing	O
a	O
proinflammatory	O
cytokine	O
cascade	O
.	O

This	O
phenomenon	O
is	O
mediated	O
,	O
in	O
part	O
,	O
through	O
inducible	B-Positive_regulation
expression	B-Gene_expression
of	O
the	O
CXC	O
chemokine	O
,	O
interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
investigate	O
the	O
role	B-Regulation
of	O
TNFalpha	O
-	O
inducible	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
IL	O
-	O
8	O
expression	B-Gene_expression
by	O
"	O
monocyte	O
-	O
like	O
"	O
U937	O
histiocytic	O
lymphoma	O
cells	O
.	O

TNFalpha	O
is	O
a	O
rapid	O
activator	B-Positive_regulation
of	O
IL	O
-	O
8	O
gene	B-Gene_expression
expression	I-Gene_expression
by	O
U937	O
,	O
producing	B-Positive_regulation
a	O
50	O
-	O
fold	O
induction	B-Transcription
of	O
mRNA	O
within	O
1	O
hour	O
of	O
treatment	O
.	O

In	O
gene	O
transfection	O
assays	O
,	O
the	O
effect	O
of	O
TNFalpha	O
requires	O
the	O
presence	O
of	O
an	O
inducible	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
(	O
Rel	O
A	O
)	O
binding	O
site	O
in	O
the	O
IL	O
-	O
8	O
promoter	O
.	O

TNFalpha	O
treatment	O
induces	B-Positive_regulation
a	O
rapid	O
translocation	B-Localization
of	O
the	O
65	O
kD	O
transcriptional	O
activator	O
NF	O
-	O
kappaB	O
subunit	O
,	O
Rel	O
A	O
,	O
whose	O
binding	B-Binding
in	O
the	O
nucleus	O
occurs	O
before	O
changes	O
in	O
intracellular	O
ROS	O
.	O

Pretreatment	O
(	O
or	O
up	O
to	O
15	O
minutes	O
posttreatment	O
)	O
relative	O
to	O
TNFalpha	O
with	O
the	O
antioxidant	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
)	O
(	O
2	O
%	O
[	O
vol/vol	O
]	O
)	O
blocks	O
80	O
%	O
of	O
NF-kappaB	O
-	O
dependent	O
transcription	O
.	O

Surprisingly	O
,	O
however	O
,	O
DMSO	O
has	O
no	O
effect	B-Regulation
on	O
inducible	O
Rel	O
A	O
binding	B-Binding
.	O

Similar	O
selective	O
effects	O
on	O
NF	O
-	O
kappaB	O
transcription	O
are	O
seen	O
with	O
the	O
unrelated	O
antioxidants	O
,	O
N	O
-	O
acetylcysteine	O
(	O
NAC	O
)	O
and	O
vitamin	O
C	O
.	O

These	O
data	O
indicate	O
that	O
TNFalpha	O
induces	O
a	O
delayed	O
ROS	O
-	O
dependent	O
signalling	O
pathway	O
that	O
is	O
required	O
for	O
NF	O
-	O
kappaB	O
transcriptional	O
activation	O
and	O
is	O
separable	O
from	O
that	O
required	O
for	O
its	O
nuclear	O
translocation	O
.	O

Further	O
definition	O
of	O
this	O
pathway	O
will	O
yield	O
new	O
insights	O
into	O
inflammation	O
initiated	O
by	O
TNFalpha	O
signalling	O
.	O

Neutrophil	O
maturation	O
and	O
the	O
role	O
of	O
retinoic	O
acid	O
.	O

Neutrophil	O
maturation	O
occurs	O
in	O
well	O
defined	O
morphological	O
stages	O
that	O
correlate	O
with	O
the	O
acquisition	O
of	O
molecular	O
markers	O
associated	O
with	O
neutrophil	O
function	O
.	O

A	O
variety	O
of	O
factors	O
are	O
known	O
to	O
play	O
a	O
role	O
in	O
terminal	O
neutrophil	O
maturation	O
,	O
including	O
the	O
vitamin	O
A	O
derivative	O
,	O
retinoic	O
acid	O
.	O

Retinoic	O
acid	O
can	O
directly	O
modulate	O
gene	O
expression	O
via	O
binding	O
to	O
its	O
nuclear	O
receptors	O
,	O
which	O
can	O
,	O
in	O
turn	O
,	O
activate	O
transcription	O
of	O
target	O
genes	O
.	O

A	O
role	O
for	O
retinoic	O
acid	O
during	O
neutrophil	O
maturation	O
has	O
been	O
suggested	O
from	O
a	O
variety	O
of	O
sources	O
.	O

Here	O
we	O
present	O
a	O
review	O
of	O
the	O
mechanism	O
of	O
retinoic	O
acid	O
receptor	O
action	O
and	O
the	O
major	O
evidence	O
showing	O
that	O
normal	O
retinoid	O
signaling	O
is	O
required	O
for	O
neutrophil	O
maturation	O
.	O

Induction	B-Positive_regulation
of	O
Bcl	O
-	O
x	O
(	O
L	O
)	O
expression	B-Gene_expression
by	B-Positive_regulation
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
Tax	O
through	O
NF	O
-	O
kappaB	O
in	O
apoptosis	O
-	O
resistant	O
T	O
-	O
cell	O
transfectants	B-Gene_expression
with	O
Tax	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
Tax	O
is	O
thought	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
immortalization	O
of	O
T	O
cells	O
.	O

We	O
have	O
recently	O
shown	O
that	O
the	O
expression	B-Gene_expression
of	O
Tax	O
protected	O
the	O
mouse	O
T	O
-	O
cell	O
line	O
CTLL	O
-	O
2	O
against	O
apoptosis	O
induced	O
by	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
deprivation	B-Negative_regulation
and	O
converted	O
its	O
growth	O
from	O
being	O
IL	O
-	O
2	O
dependent	O
to	O
being	O
IL	O
-	O
2	O
independent	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
constitutive	O
expression	B-Gene_expression
of	O
bcl	O
-	O
xl	O
but	O
not	O
bcl	O
-	O
2	O
,	O
bcl	O
-	O
xs	O
,	O
bak	O
,	O
bad	O
,	O
or	O
bax	O
was	O
associated	O
with	O
apoptosis	O
resistance	O
after	O
IL	O
-	O
2	O
deprivation	B-Negative_regulation
in	O
CTLL	O
-	O
2	O
cells	O
that	O
expressed	B-Gene_expression
Tax	O
.	O

Transient	O
-	O
transfection	O
assays	O
showed	O
that	O
bcl	O
-	O
x	O
promoter	O
was	O
transactivated	B-Positive_regulation
by	O
wild	O
-	O
type	O
Tax	O
.	O

Similar	O
effects	B-Positive_regulation
were	O
observed	O
in	O
mutant	O
Tax	O
retaining	O
transactivating	O
ability	O
through	O
NF	O
-	O
kappaB	O
.	O

Deletion	O
or	O
substitution	O
of	O
a	O
putative	O
NF	O
-	O
kappaB	O
binding	O
site	O
identified	O
in	O
the	O
bcl	O
-	O
x	O
promoter	O
significantly	O
decreased	O
Tax	O
-	O
induced	O
transactivation	O
.	O

This	O
NF-kappaB	O
-	O
like	O
element	O
was	O
able	O
to	O
form	O
a	O
complex	O
with	O
NF	O
-	O
kappaB	O
family	O
proteins	O
in	O
vitro	O
.	O

Furthermore	O
,	O
Tax	O
-	O
induced	O
transactivation	B-Positive_regulation
of	O
the	O
bcl	O
-	O
x	O
promoter	O
was	O
also	O
diminished	B-Negative_regulation
by	O
the	O
mutant	O
IkappaBalpha	O
,	O
which	O
specifically	O
inhibits	O
NF	O
-	O
kappaB	O
activity	O
.	O

Our	O
findings	O
suggest	O
that	O
constitutive	O
expression	B-Gene_expression
of	O
Bcl	O
-	O
x	O
(	O
L	O
)	O
induced	B-Positive_regulation
by	B-Positive_regulation
Tax	O
through	O
the	O
NF	O
-	O
kappaB	O
pathway	O
contributes	O
to	O
the	O
inhibition	O
of	O
apoptosis	O
in	O
CTLL	O
-	O
2	O
cells	O
after	O
IL	O
-	O
2	O
deprivation	B-Negative_regulation
.	O

Interferons	O
inhibit	B-Negative_regulation
activation	B-Positive_regulation
of	O
STAT6	O
by	O
interleukin	O
4	O
in	O
human	O
monocytes	O
by	O
inducing	B-Positive_regulation
SOCS	O
-	O
1	O
gene	O
expression	B-Gene_expression
.	O

Interferons	O
(	O
IFNs	O
)	O
inhibit	O
induction	O
by	O
IL	O
-	O
4	O
of	O
multiple	O
genes	O
in	O
human	O
monocytes	O
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
IFNs	O
mediate	O
this	O
inhibition	O
has	O
not	O
been	O
defined	O
.	O

IL	O
-	O
4	O
activates	O
gene	O
expression	O
by	O
inducing	B-Positive_regulation
tyrosine	O
phosphorylation	B-Phosphorylation
,	O
homodimerization	B-Binding
,	O
and	O
nuclear	O
translocation	B-Localization
of	O
the	O
latent	O
transcription	O
factor	O
,	O
STAT6	O
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
-	O
6	O
)	O
.	O

STAT6	O
-	O
responsive	O
elements	O
are	O
characteristically	O
present	O
in	O
the	O
promoters	O
of	O
IL-4	O
-	O
inducible	O
genes	O
.	O

Because	O
STAT6	O
activation	B-Positive_regulation
is	O
essential	O
for	O
IL-4	O
-	O
induced	O
gene	O
expression	O
,	O
we	O
examined	O
the	O
ability	O
of	O
type	O
I	O
and	O
type	O
II	O
IFNs	O
to	O
regulate	B-Regulation
activation	B-Positive_regulation
of	O
STAT6	O
by	O
IL	O
-	O
4	O
in	O
primary	O
human	O
monocytes	O
.	O

Pretreatment	O
of	O
monocytes	O
with	O
IFN	O
-	O
beta	O
or	O
IFN	O
-	O
gamma	O
,	O
but	O
not	O
IL	O
-	O
1	O
,	O
IL	O
-	O
2	O
,	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
,	O
granulocyte/macrophage	O
colony	O
-	O
stimulating	O
factor	O
,	O
IL	O
-	O
6	O
,	O
or	O
transforming	O
growth	O
factor	O
beta	O
suppressed	B-Negative_regulation
activation	B-Positive_regulation
of	O
STAT6	O
by	O
IL	O
-	O
4	O
.	O

This	O
inhibition	O
was	O
associated	O
with	O
decreased	B-Negative_regulation
tyrosine	O
phosphorylation	B-Phosphorylation
and	O
nuclear	O
translocation	B-Localization
of	O
STAT6	O
and	O
was	O
not	O
evident	O
unless	O
the	O
cells	O
were	O
preincubated	O
with	O
IFN	O
for	O
at	O
least	O
1	O
hr	O
before	O
IL	O
-	O
4	O
stimulation	O
.	O

Furthermore	O
,	O
inhibition	O
by	O
IFN	O
could	O
be	O
blocked	O
by	O
cotreatment	O
with	O
actinomycin	O
D	O
and	O
correlated	O
temporally	O
with	O
induction	B-Positive_regulation
of	O
the	O
JAK/STAT	O
inhibitory	O
gene	O
,	O
SOCS	O
-	O
1	O
.	O

Forced	O
expression	B-Gene_expression
of	O
SOCS	O
-	O
1	O
in	O
a	O
macrophage	O
cell	O
line	O
,	O
RAW264	O
,	O
markedly	O
suppressed	O
trans	O
-	O
activation	O
of	O
an	O
IL-4	O
-	O
inducible	O
reporter	O
as	O
well	O
as	O
IL-6	O
-	O
and	O
IFN-gamma	O
-	O
induced	O
reporter	O
gene	O
activity	O
.	O

These	O
findings	O
demonstrate	O
that	O
IFNs	O
inhibit	B-Negative_regulation
IL-4	O
-	O
induced	O
activation	B-Positive_regulation
of	O
STAT6	O
and	O
STAT6	O
-	O
dependent	O
gene	O
expression	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
inducing	B-Positive_regulation
expression	B-Gene_expression
of	O
SOCS	O
-	O
1	O
.	O

Increased	O
IkappaB	O
expression	O
and	O
diminished	O
nuclear	O
NF	O
-	O
kappaB	O
in	O
human	O
mononuclear	O
cells	O
following	O
hydrocortisone	O
injection	O
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
hydrocortisone	O
and	O
other	O
glucocorticoids	O
inhibit	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
generation	O
by	O
mononuclear	O
(	O
MNC	O
)	O
and	O
polymorphonuclear	O
leucocytes	O
(	O
PMNL	O
)	O
.	O

Since	O
NF	O
-	O
kappaB/IkappaB	O
system	O
regulates	O
the	O
transcription	O
of	O
proinflammatory	O
genes	O
,	O
including	O
those	O
responsible	O
for	O
ROS	O
generation	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
hydrocortisone	O
may	O
stimulate	O
IkappaB	O
production	O
thus	O
inhibiting	O
NF	O
-	O
kappaB	O
translocation	O
from	O
the	O
cytosol	O
into	O
the	O
nucleus	O
in	O
MNC	O
,	O
in	O
vivo	O
.	O

One	O
hundred	O
milligram	O
of	O
hydrocortisone	O
was	O
injected	O
intravenously	O
into	O
4	O
normal	O
subjects	O
.	O

Blood	O
samples	O
were	O
obtained	O
prior	O
to	O
the	O
injection	O
and	O
at	O
1	O
,	O
2	O
,	O
4	O
,	O
8	O
and	O
24	O
hr	O
after	O
the	O
injection	O
.	O

Nuclear	O
extracts	O
and	O
total	O
cell	O
lysates	O
were	O
prepared	O
from	O
MNC	O
by	O
standard	O
techniques	O
.	O

IkappaB	O
levels	O
in	O
MNC	O
homogenates	O
increased	O
at	O
1	O
hr	O
,	O
peaked	O
at	O
2	O
-	O
4	O
hr	O
,	O
started	O
to	O
decrease	O
at	O
8	O
hr	O
,	O
and	O
returned	O
to	O
baseline	O
levels	O
at	O
24	O
hr	O
.	O

NF	O
-	O
kappaB	O
in	O
MNC	O
nuclear	O
extracts	O
decreased	O
at	O
1	O
hr	O
,	O
reached	O
a	O
nadir	O
at	O
4	O
hr	O
,	O
gradually	O
increased	O
at	O
8	O
hr	O
and	O
returned	O
back	O
to	O
baseline	O
levels	O
at	O
24	O
hr	O
.	O

The	O
total	O
protein	O
content	O
of	O
NF	O
-	O
kappaB	O
subunit	O
(	O
P65	O
)	O
in	O
MNC	O
lysates	O
also	O
showed	O
a	O
decrease	B-Negative_regulation
following	O
hydrocortisone	O
injection	O
.	O

This	O
decrease	O
was	O
observed	O
at	O
2	O
hr	O
,	O
reached	O
a	O
nadir	O
at	O
4	O
hr	O
,	O
and	O
returned	B-Negative_regulation
to	I-Negative_regulation
baseline	I-Negative_regulation
levels	I-Negative_regulation
at	O
24	O
hr	O
.	O

ROS	O
generation	O
inhibition	O
paralleled	O
NF	O
-	O
kappaB	O
levels	O
in	O
the	O
nucleus	O
.	O

It	O
was	O
inhibited	O
at	O
1	O
hr	O
,	O
reached	O
a	O
nadir	O
at	O
2	O
-	O
4	O
hr	O
,	O
started	O
to	O
increase	O
at	O
8	O
hr	O
,	O
and	O
returned	O
to	O
basal	O
levels	O
at	O
24	O
hr	O
.	O

Our	O
data	O
demonstrate	O
that	O
hydrocortisone	O
induces	O
IkappaB	O
and	O
suppresses	O
NF	O
-	O
kappaB	O
expression	O
in	O
MNC	O
in	O
parallel	O
.	O

IkappaB	O
further	O
reduces	O
the	O
translocation	O
of	O
NF	O
-	O
kappaB	O
into	O
the	O
nucleus	O
thus	O
preventing	O
the	O
expression	O
of	O
proinflammatory	O
genes	O
.	O

Renal	O
cell	O
carcinoma	O
-	O
derived	O
gangliosides	O
suppress	O
nuclear	O
factor	O
-	O
kappaB	O
activation	O
in	O
T	O
cells	O
.	O

Activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NFkappaB	O
)	O
is	O
impaired	O
in	O
T	O
cells	O
from	O
patients	O
with	O
renal	O
cell	O
carcinomas	O
(	O
RCCs	O
)	O
.	O

In	O
circulating	O
T	O
cells	O
from	O
a	O
subset	O
of	O
patients	O
with	O
RCCs	O
,	O
the	O
suppression	O
of	O
NFkappaB	O
binding	O
activity	O
is	O
downstream	O
from	O
the	O
stimulus	O
-	O
induced	B-Positive_regulation
degradation	B-Protein_catabolism
of	O
the	O
cytoplasmic	O
factor	O
IkappaBalpha	O
.	O

Tumor	O
-	O
derived	O
soluble	O
products	O
from	O
cultured	O
RCC	O
explants	O
inhibit	O
NFkappaB	O
activity	O
in	O
T	O
cells	O
from	O
healthy	O
volunteers	O
,	O
despite	O
a	O
normal	B-Negative_regulation
level	I-Negative_regulation
of	O
stimulus	O
-	O
induced	B-Positive_regulation
IkappaBalpha	O
degradation	B-Protein_catabolism
in	O
these	O
cells	O
.	O

The	O
inhibitory	O
agent	O
has	O
several	O
features	O
characteristic	O
of	O
a	O
ganglioside	O
,	O
including	O
sensitivity	O
to	O
neuraminidase	O
but	O
not	O
protease	O
treatment	O
;	O
hydrophobicity	O
;	O
and	O
molecular	O
weight	O
less	O
than	O
3	O
kDa	O
.	O

Indeed	O
,	O
we	O
detected	O
gangliosides	O
in	O
supernatants	O
from	O
RCC	O
explants	O
and	O
not	O
from	O
adjacent	O
normal	O
kidney	O
tissue	O
.	O

Gangliosides	O
prepared	O
from	O
RCC	O
supernatants	O
,	O
as	O
well	O
as	O
the	O
purified	O
bovine	O
gangliosides	O
G	O
(	O
m1	O
)	O
and	O
G	O
(	O
d1a	O
)	O
,	O
suppressed	O
NFkappaB	O
binding	O
activity	O
in	O
T	O
cells	O
and	O
reduced	B-Negative_regulation
expression	B-Gene_expression
of	O
the	O
cytokines	O
IL	O
-	O
2	O
and	O
IFN	O
-	O
gamma	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
tumor	O
-	O
derived	O
gangliosides	O
may	O
blunt	O
antitumor	O
immune	O
responses	O
in	O
patients	O
with	O
RCCs	O
.	O

Affinity	O
-	O
driven	O
peptide	O
selection	O
of	O
an	O
NFAT	O
inhibitor	O
more	O
selective	O
than	O
cyclosporin	O
A	O
[	O
see	O
comments	O
]	O

The	O
flow	O
of	O
information	O
from	O
calcium	O
-	O
mobilizing	O
receptors	O
to	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
-	O
dependent	O
genes	O
is	O
critically	O
dependent	O
on	O
interaction	O
between	O
the	O
phosphatase	O
calcineurin	O
and	O
the	O
transcription	O
factor	O
NFAT	O
.	O

A	O
high	O
-	O
affinity	O
calcineurin	O
-	O
binding	O
peptide	O
was	O
selected	O
from	O
combinatorial	O
peptide	O
libraries	O
based	O
on	O
the	O
calcineurin	O
docking	O
motif	O
of	O
NFAT	O
.	O

This	O
peptide	O
potently	O
inhibited	O
NFAT	O
activation	O
and	O
NFAT	O
-	O
dependent	O
expression	O
of	O
endogenous	O
cytokine	O
genes	O
in	O
T	O
cells	O
,	O
without	O
affecting	O
the	O
expression	O
of	O
other	O
cytokines	O
that	O
require	O
calcineurin	O
but	O
not	O
NFAT	O
.	O

Substitution	O
of	O
the	O
optimized	O
peptide	O
sequence	O
into	O
the	O
natural	O
calcineurin	O
docking	O
site	O
increased	O
the	O
calcineurin	O
responsiveness	O
of	O
NFAT	O
.	O

Compounds	O
that	O
interfere	O
selectively	O
with	O
the	O
calcineurin	O
-	O
NFAT	O
interaction	O
without	O
affecting	O
calcineurin	O
phosphatase	O
activity	O
may	O
be	O
useful	O
as	O
therapeutic	O
agents	O
that	O
are	O
less	O
toxic	O
than	O
current	O
drugs	O
.	O

Leukotriene	O
B4	O
stimulates	B-Positive_regulation
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
gene	O
transcription	B-Transcription
and	O
AP	O
-	O
1	O
binding	O
activity	O
in	O
human	O
monocytes	O
.	O

We	O
have	O
examined	O
the	O
effect	B-Regulation
of	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
,	O
a	O
potent	O
lipid	O
proinflammatory	O
mediator	O
,	O
on	O
the	O
expression	B-Gene_expression
of	O
the	O
proto	O
-	O
oncogenes	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
.	O

In	O
addition	O
,	O
we	O
looked	O
at	O
the	O
modulation	O
of	O
nuclear	O
factors	O
binding	O
specifically	O
to	O
the	O
AP	O
-	O
1	O
element	O
after	O
LTB4	O
stimulation	O
.	O

LTB4	O
increased	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
the	O
c	O
-	O
fos	O
gene	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
.	O

The	O
c	O
-	O
jun	O
mRNA	O
,	O
which	O
is	O
constitutively	O
expressed	B-Transcription
in	O
human	O
peripheral	O
-	O
blood	O
monocytes	O
at	O
relatively	O
high	B-Positive_regulation
levels	I-Positive_regulation
,	O
was	O
also	O
slightly	O
augmented	B-Positive_regulation
by	O
LTB4	O
,	O
although	O
to	O
a	O
much	O
lower	O
extent	O
than	O
c	O
-	O
fos	O
.	O

The	O
kinetics	O
of	O
expression	B-Gene_expression
of	O
the	O
two	O
genes	O
were	O
also	O
slightly	O
different	O
,	O
with	O
c	O
-	O
fos	O
mRNA	O
reaching	B-Positive_regulation
a	I-Positive_regulation
peak	I-Positive_regulation
at	O
15	O
min	O
after	O
stimulation	O
and	O
c	O
-	O
jun	O
at	O
30	O
min	O
.	O

Both	O
messages	O
rapidly	O
declined	B-Negative_regulation
thereafter	O
.	O

Stability	O
of	O
the	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
mRNA	O
was	O
not	O
affected	B-Regulation
by	O
LTB4	O
,	O
as	O
assessed	O
after	O
actinomycin	O
D	O
treatment	O
.	O

Nuclear	O
transcription	O
studies	O
in	O
vitro	O
showed	O
that	O
LTB4	O
increased	B-Positive_regulation
the	O
transcription	B-Transcription
of	O
the	O
c	O
-	O
fos	O
gene	O
7	O
-	O
fold	O
and	O
the	O
c	O
-	O
jun	O
gene	O
1.4	O
-	O
fold	O
.	O

Resting	O
monocytes	O
contained	O
nuclear	O
factors	O
binding	O
to	O
the	O
AP	O
-	O
1	O
element	O
,	O
but	O
stimulation	O
of	O
monocytes	O
with	O
LTB4	O
induced	O
greater	O
AP-1	O
-	O
binding	O
activity	O
of	O
nuclear	O
proteins	O
.	O

These	O
results	O
indicate	O
that	O
LTB4	O
may	O
regulate	O
the	O
production	O
of	O
different	O
cytokines	O
by	O
modulating	O
the	O
yield	O
and/or	O
the	O
function	O
of	O
transcription	O
factors	O
such	O
as	O
AP-1	O
-	O
binding	O
proto	O
-	O
oncogene	O
products	O
.	O

Transcription	O
factor	O
activation	O
and	O
functional	O
stimulation	O
of	O
human	O
monocytes	O
.	O

Activation	B-Positive_regulation
of	O
expression	B-Gene_expression
of	O
genes	O
encoding	O
transcription	O
factors	O
:	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
and	O
formation	O
of	O
AP1	O
transcriptional	O
complex	O
in	O
human	O
monocytes	O
was	O
investigated	O
.	O

It	O
was	O
found	O
that	O
lipopolysaccharide	O
induced	B-Positive_regulation
strongly	O
both	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
expression	B-Gene_expression
as	O
well	O
as	O
AP1	O
formation	O
.	O

Interferon	O
gamma	O
activated	B-Positive_regulation
strongly	O
c	O
-	O
fos	O
and	O
weakly	O
c	O
-	O
jun	O
and	O
AP1	O
.	O

Tumor	O
necrosis	O
factor	O
induced	B-Positive_regulation
slightly	O
c	O
-	O
fos	O
and	O
had	O
almost	O
no	O
effect	B-Regulation
on	O
c	O
-	O
jun	O
and	O
AP1	O
.	O

The	O
data	O
suggest	O
that	O
differences	O
in	O
functional	O
responses	O
elicited	O
in	O
monocytes	O
by	O
all	O
three	O
factors	O
may	O
be	O
dependent	B-Positive_regulation
on	O
different	O
routes	O
on	O
nuclear	O
signalling	O
employed	O
by	O
the	O
factors	O
.	O

Interferon	O
-	O
gamma	O
potentiates	O
the	O
antiviral	O
activity	O
and	O
the	O
expression	O
of	O
interferon	O
-	O
stimulated	O
genes	O
induced	O
by	O
interferon	O
-	O
alpha	O
in	O
U937	O
cells	O
.	O

Binding	O
of	O
type	O
I	O
interferon	O
(	O
IFN	O
-	O
alpha/beta	O
)	O
to	O
specific	O
receptors	O
results	O
in	O
the	O
rapid	O
transcriptional	O
activation	O
,	O
independent	O
of	O
protein	O
synthesis	O
,	O
of	O
IFN-alpha	O
-	O
stimulated	O
genes	O
(	O
ISGs	O
)	O
in	O
human	O
fibroblasts	O
and	O
HeLa	O
and	O
Daudi	O
cell	O
lines	O
.	O

The	O
binding	O
of	O
ISGF3	O
(	O
IFN	O
-	O
stimulated	O
gene	O
factor	O
3	O
)	O
to	O
the	O
conserved	O
IFN	O
-	O
stimulated	O
response	O
element	O
(	O
ISRE	O
)	O
results	O
in	O
transcriptional	O
activation	O
.	O

This	O
factor	O
is	O
composed	O
of	O
a	O
DNA	O
-	O
binding	O
protein	O
(	O
ISGF3	O
gamma	O
)	O
,	O
which	O
normally	O
is	O
present	B-Localization
in	O
the	O
cytoplasm	O
,	O
and	O
other	O
IFN-alpha	O
-	O
activated	O
proteins	O
which	O
preexist	O
as	O
latent	O
cytoplasmic	O
precursors	O
(	O
ISGF3	O
alpha	O
)	O
.	O

We	O
have	O
found	O
that	O
ISG	O
expression	O
in	O
the	O
monocytic	O
U937	O
cell	O
line	O
differs	O
from	O
most	O
cell	O
lines	O
previously	O
examined	O
.	O

U937	O
cells	O
express	O
both	O
type	O
I	O
and	O
type	O
II	O
IFN	O
receptors	O
,	O
but	O
only	O
IFN	O
-	O
alpha	O
is	O
capable	O
of	O
inducing	O
antiviral	O
protection	O
in	O
these	O
cells	O
.	O

Pretreatment	O
with	O
IFN	O
-	O
gamma	O
potentiates	O
the	O
IFN-alpha	O
-	O
induced	O
protection	O
,	O
but	O
IFN	O
-	O
gamma	O
alone	O
does	O
not	O
have	O
any	O
antiviral	O
activity	O
.	O

ISG15	O
mRNA	O
accumulation	B-Positive_regulation
in	O
U937	O
cells	O
is	O
not	O
detectable	B-Positive_regulation
before	O
6	O
h	O
of	O
IFN	O
-	O
alpha	O
treatment	O
,	O
peaks	O
at	O
24	O
h	O
,	O
and	O
requires	B-Positive_regulation
protein	O
synthesis	O
.	O

Although	O
IFN	O
-	O
gamma	O
alone	O
does	O
not	O
induce	O
ISG	O
expression	O
,	O
IFN	O
-	O
gamma	O
pretreatment	O
markedly	O
increases	O
and	O
hastens	O
ISG	O
expression	O
and	O
transcriptional	O
induction	O
.	O

Nuclear	O
extracts	O
assayed	O
for	O
the	O
presence	O
of	O
ISRE	O
binding	O
factors	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
show	O
that	O
ISGF3	O
is	O
induced	O
by	O
IFN	O
-	O
alpha	O
within	O
6	O
h	O
from	O
undetectable	O
basal	O
levels	O
in	O
untreated	O
U937	O
cells	O
.	O

Activation	O
of	O
ISGF3	O
alpha	O
,	O
the	O
latent	O
component	O
of	O
ISGF3	O
,	O
occurs	O
rapidly	O
.	O

However	O
,	O
the	O
increase	O
in	O
ISGF3	O
activity	O
ultimately	O
correlates	O
with	O
the	O
accumulation	B-Positive_regulation
of	O
ISGF3	O
gamma	O
induced	O
by	O
IFN	O
-	O
alpha	O
or	O
IFN	O
-	O
gamma	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

A	O
lymphoid	O
cell	O
-	O
specific	O
nuclear	O
factor	O
containing	O
c-Rel	O
-	O
like	O
proteins	O
preferentially	O
interacts	O
with	O
interleukin	O
-	O
6	O
kappa	O
B	O
-	O
related	O
motifs	O
whose	O
activities	O
are	O
repressed	O
in	O
lymphoid	O
cells	O
.	O

The	O
proto	O
-	O
oncoprotein	O
c	O
-	O
Rel	O
is	O
a	O
member	O
of	O
the	O
nuclear	O
factor	O
kappa	O
B	O
transcription	O
factor	O
family	O
,	O
which	O
includes	O
the	O
p50	O
and	O
p65	O
subunits	O
of	O
nuclear	O
factor	O
kappa	O
B	O
.	O

We	O
show	O
here	O
that	O
c	O
-	O
Rel	O
binds	B-Binding
to	O
kappa	O
B	O
sites	O
as	O
homodimers	B-Binding
as	O
well	O
as	O
heterodimers	B-Binding
with	O
p50	O
.	O

These	O
homodimers	O
and	O
heterodimers	O
show	O
distinct	O
DNA	O
-	O
binding	B-Binding
specificities	I-Binding
and	O
affinities	B-Binding
for	O
various	O
kappa	O
B	O
motifs	O
.	O

In	O
particular	O
,	O
the	O
c	O
-	O
Rel	O
homodimer	O
has	O
a	O
high	B-Binding
affinity	I-Binding
for	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
and	O
beta	O
interferon	O
kappa	O
B	O
sites	O
.	O

In	O
spite	O
of	O
its	O
association	B-Binding
with	O
p50	O
in	O
vitro	O
,	O
however	O
,	O
we	O
found	O
a	O
lymphoid	O
cell	O
-	O
specific	O
nuclear	O
factor	O
in	O
vivo	O
that	O
contains	O
c	O
-	O
Rel	O
but	O
not	O
p50	O
epitopes	O
;	O
this	O
factor	O
,	O
termed	O
IL	O
-	O
6	O
kappa	O
B	O
binding	O
factor	O
II	O
,	O
appears	O
to	O
contain	O
the	O
c	O
-	O
Rel	O
homodimer	O
and	O
preferentially	O
recognizes	B-Binding
several	O
IL	O
-	O
6	O
kappa	O
B	O
-	O
related	O
kappa	O
B	O
motifs	O
.	O

Although	O
it	O
has	O
been	O
previously	O
shown	O
that	O
the	O
IL	O
-	O
6	O
kappa	O
B	O
motif	O
functions	O
as	O
a	O
potent	O
IL	O
-	O
1/tumor	O
necrosis	O
factor	O
-	O
responsive	O
element	O
in	O
nonlymphoid	O
cells	O
,	O
its	O
activity	O
was	O
found	O
to	O
be	O
repressed	O
in	O
lymphoid	O
cells	O
such	O
as	O
a	O
Jurkat	O
T	O
-	O
cell	O
line	O
.	O

We	O
also	O
present	O
evidence	O
that	O
IL	O
-	O
6	O
kappa	O
B	O
binding	O
factor	O
II	O
functions	O
as	O
a	O
repressor	O
specific	O
for	O
IL	O
-	O
6	O
kappa	O
B	O
-	O
related	O
kappa	O
B	O
motifs	O
in	O
lymphoid	O
cells	O
.	O

The	O
promoter	O
of	O
the	O
CD19	O
gene	O
is	O
a	O
target	B-Binding
for	O
the	O
B-cell	O
-	O
specific	O
transcription	O
factor	O
BSAP	O
.	O

The	O
CD19	O
protein	O
is	O
expressed	B-Gene_expression
on	O
the	O
surface	O
of	O
all	O
B	O
-	O
lymphoid	O
cells	O
with	O
the	O
exception	O
of	O
terminally	O
differentiated	O
plasma	O
cells	O
and	O
has	O
been	O
implicated	O
as	O
a	O
signal	O
-	O
transducing	O
receptor	O
in	O
the	O
control	O
of	O
proliferation	O
and	O
differentiation	O
.	O

Here	O
we	O
demonstrate	O
complete	O
correlation	O
between	O
the	O
expression	B-Gene_expression
pattern	O
of	O
the	O
CD19	O
gene	O
and	O
the	O
B-cell	O
-	O
specific	O
transcription	O
factor	O
BSAP	O
in	O
a	O
large	O
panel	O
of	O
B	O
-	O
lymphoid	O
cell	O
lines	O
.	O

The	O
human	O
CD19	O
gene	O
has	O
been	O
cloned	O
,	O
and	O
several	O
BSAP	O
-	O
binding	O
sites	O
have	O
been	O
mapped	O
by	O
in	O
vitro	O
protein	O
-	O
DNA	O
binding	O
studies	O
.	O

In	O
particular	O
,	O
a	O
high	O
-	O
affinity	O
BSAP	O
-	O
binding	O
site	O
instead	O
of	O
a	O
TATA	O
sequence	O
is	O
located	O
in	O
the	O
-	O
30	O
promoter	O
region	O
upstream	O
of	O
a	O
cluster	O
of	O
heterogeneous	O
transcription	O
start	O
sites	O
.	O

Moreover	O
,	O
this	O
site	O
is	O
occupied	B-Binding
by	O
BSAP	O
in	O
vivo	O
in	O
a	O
CD19	O
-	O
expressing	O
B	O
-	O
cell	O
line	O
but	O
not	O
in	O
plasma	O
or	O
HeLa	O
cells	O
.	O

This	O
high	O
-	O
affinity	O
site	O
has	O
been	O
conserved	O
in	O
the	O
promoters	O
of	O
both	O
human	O
and	O
mouse	O
CD19	O
genes	O
and	O
was	O
furthermore	O
shown	O
to	O
confer	O
B	O
-	O
cell	O
specificity	O
to	O
a	O
beta	O
-	O
globin	O
reporter	O
gene	O
in	O
transient	O
transfection	O
experiments	O
.	O

In	O
addition	O
,	O
BSAP	O
was	O
found	O
to	O
be	O
the	O
only	O
abundant	O
DNA	O
-	O
binding	B-Binding
activity	O
of	O
B	O
-	O
cell	O
nuclear	O
extracts	O
that	O
interacts	B-Binding
with	O
the	O
CD19	O
promoter	O
.	O

Together	O
,	O
this	O
evidence	O
strongly	O
implicates	O
BSAP	O
in	O
the	O
regulation	B-Regulation
of	O
the	O
CD19	O
gene	O
.	O

SRC	O
-	O
related	O
proto	O
-	O
oncogenes	O
and	O
transcription	O
factors	O
in	O
primary	O
human	O
T	O
cells	O
:	O
modulation	O
by	O
cyclosporin	O
A	O
and	O
FK506	O
.	O

Activation	O
of	O
T	O
lymphocytes	O
induces	O
transcription	O
of	O
genes	O
encoding	O
for	O
lymphokines	O
.	O

Interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
gene	O
expression	O
is	O
controlled	B-Regulation
transcriptionally	B-Transcription
by	O
the	O
cooperative	O
activity	O
of	O
specific	O
trans	O
-	O
activating	O
factors	O
that	O
bind	B-Binding
to	O
the	O
IL	O
-	O
2	O
enhancer	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
inhibit	B-Negative_regulation
the	O
production	O
of	O
IL	O
-	O
2	O
in	O
T	O
lymphocytes	O
at	O
the	O
level	O
of	O
gene	B-Transcription
transcription	I-Transcription
.	O

A	O
member	O
of	O
the	O
src	O
gene	O
family	O
,	O
the	O
lymphocyte	O
-	O
specific	O
protein	O
tyrosine	O
kinase	O
,	O
p56lck	O
,	O
has	O
been	O
implicated	B-Regulation
in	O
IL	O
-	O
2	O
production	B-Gene_expression
.	O

CsA	O
was	O
found	O
not	O
to	O
inhibit	B-Negative_regulation
lck	O
gene	O
expression	B-Gene_expression
,	O
nor	O
the	O
activity	O
of	O
the	O
lck	O
gene	O
product	O
.	O

However	O
,	O
CsA	O
and	O
FK506	O
inhibit	O
the	O
appearance	O
of	O
DNA	O
binding	O
activity	O
of	O
factors	O
that	O
bind	O
to	O
the	O
NF	O
-	O
AT	O
and	O
AP	O
-	O
1	O
sites	O
in	O
the	O
IL	O
-	O
2	O
enhancer	O
.	O

Since	O
the	O
induction	O
of	O
NF	O
-	O
AT	O
and	O
AP	O
-	O
1	O
is	O
induced	O
by	O
the	O
same	O
stimuli	O
that	O
stimulate	B-Positive_regulation
IL	O
-	O
2	O
production	B-Gene_expression
,	O
these	O
results	O
indicate	O
that	O
the	O
immunosuppressant	O
action	O
of	O
CsA	O
and	O
FK506	O
is	O
exerted	O
at	O
the	O
level	O
of	O
these	O
trans	O
-	O
activating	O
factors	O
.	O

The	O
development	O
of	O
functionally	O
responsive	O
T	O
cells	O
.	O

The	O
work	O
reviewed	O
in	O
this	O
article	O
separates	O
T	O
cell	O
development	O
into	O
four	O
phases	O
.	O

First	O
is	O
an	O
expansion	O
phase	O
prior	O
to	O
TCR	O
rearrangement	O
,	O
which	O
appears	O
to	O
be	O
correlated	O
with	O
programming	O
of	O
at	O
least	O
some	O
response	O
genes	O
for	O
inducibility	O
.	O

This	O
phase	O
can	O
occur	O
to	O
some	O
extent	O
outside	O
of	O
the	O
thymus	O
.	O

However	O
,	O
the	O
profound	O
T	O
cell	O
deficit	O
of	O
nude	O
mice	O
indicates	O
that	O
the	O
thymus	O
is	O
by	O
far	O
the	O
most	O
potent	O
site	O
for	O
inducing	O
the	O
expansion	O
per	O
se	O
,	O
even	O
if	O
other	O
sites	O
can	O
induce	O
some	O
response	O
acquisition	O
.	O

Second	O
is	O
a	O
controlled	O
phase	O
of	O
TCR	O
gene	O
rearrangement	O
.	O

The	O
details	O
of	O
the	O
regulatory	O
mechanism	O
that	O
selects	O
particular	O
loci	O
for	O
rearrangement	O
are	O
still	O
not	O
known	O
.	O

It	O
seems	O
that	O
the	O
rearrangement	O
of	O
the	O
TCR	O
gamma	O
loci	O
in	O
the	O
gamma	O
delta	O
lineage	O
may	O
not	O
always	O
take	O
place	O
at	O
a	O
developmental	O
stage	O
strictly	O
equivalent	O
to	O
the	O
rearrangement	O
of	O
TCR	O
beta	O
in	O
the	O
alpha	O
beta	O
lineage	O
,	O
and	O
it	O
is	O
not	O
clear	O
just	O
how	O
early	O
the	O
two	O
lineages	O
diverge	O
.	O

In	O
the	O
TCR	O
alpha	O
beta	O
lineage	O
,	O
however	O
,	O
the	O
final	O
gene	O
rearrangement	O
events	O
are	O
accompanied	O
by	O
rapid	O
proliferation	O
and	O
an	O
interruption	O
in	O
cellular	O
response	O
gene	O
inducibility	O
.	O

The	O
loss	O
of	O
conventional	O
responsiveness	O
is	O
probably	O
caused	O
by	O
alterations	O
at	O
the	O
level	O
of	O
signaling	O
,	O
and	O
may	O
be	O
a	O
manifestation	O
of	O
the	O
physiological	O
state	O
that	O
is	O
a	O
precondition	O
for	O
selection	O
.	O

Third	O
is	O
the	O
complex	O
process	O
of	O
selection	O
.	O

Whereas	O
peripheral	O
T	O
cells	O
can	O
undergo	O
forms	O
of	O
positive	O
selection	O
(	O
by	O
antigen	O
-	O
driven	O
clonal	O
expansion	O
)	O
and	O
negative	O
selection	O
(	O
by	O
abortive	O
stimulation	O
leading	O
to	O
anergy	O
or	O
death	O
)	O
,	O
neither	O
is	O
exactly	O
the	O
same	O
phenomenon	O
that	O
occurs	O
in	O
the	O
thymic	O
cortex	O
.	O

Negative	O
selection	O
in	O
the	O
cortex	O
appears	O
to	O
be	O
a	O
suicidal	O
inversion	B-Negative_regulation
of	O
antigen	O
responsiveness	B-Positive_regulation
:	O
instead	O
of	O
turning	B-Positive_regulation
on	O
IL	O
-	O
2	O
expression	B-Gene_expression
,	O
the	O
activated	O
cell	O
destroys	O
its	O
own	O
chromatin	O
.	O

The	O
genes	O
that	O
need	O
to	O
be	O
induced	O
for	O
this	O
response	O
are	O
not	O
yet	O
identified	O
,	O
but	O
it	O
is	O
unquestionably	O
a	O
form	O
of	O
activation	O
.	O

It	O
is	O
interesting	O
that	O
in	O
humans	O
and	O
rats	O
,	O
cortical	O
thymocytes	O
undergoing	O
negative	O
selection	O
can	O
still	O
induce	B-Positive_regulation
IL	O
-	O
2R	O
alpha	O
expression	B-Gene_expression
and	O
even	O
be	O
rescued	O
in	O
vitro	O
,	O
if	O
exogenous	O
IL	O
-	O
2	O
is	O
provided	O
.	O

Perhaps	O
murine	O
thymocytes	O
are	O
denied	O
this	O
form	O
of	O
rescue	O
because	O
they	O
shut	O
off	O
IL	O
-	O
2R	O
beta	O
chain	O
expression	B-Gene_expression
at	O
an	O
earlier	O
stage	O
or	O
because	O
they	O
may	O
be	O
uncommonly	O
Bcl	O
-	O
2	O
deficient	B-Negative_regulation
(	O
cf	O
.	O

Sentman	O
et	O
al.	O
,	O
1991	O
;	O
Strasser	O
et	O
al.	O
,	O
1991	O
)	O
.	O

Even	O
so	O
,	O
medullary	O
thymocytes	O
remain	O
at	O
least	O
partially	O
susceptible	O
to	O
negative	O
selection	O
even	O
as	O
they	O
continue	O
to	O
mature	O
.	O

Regulation	B-Regulation
of	O
c	O
-	O
jun	O
expression	B-Gene_expression
during	O
induction	O
of	O
monocytic	O
differentiation	O
by	O
okadaic	O
acid	O
.	O

The	O
present	O
work	O
has	O
examined	O
the	O
effects	B-Regulation
of	O
okadaic	O
acid	O
,	O
an	O
inhibitor	B-Negative_regulation
of	O
type	O
1	O
and	O
2A	O
protein	O
phosphatases	O
,	O
on	O
the	O
regulation	B-Regulation
of	O
c	O
-	O
jun	O
expression	B-Gene_expression
during	O
monocytic	O
differentiation	O
of	O
U	O
-	O
937	O
leukemia	O
cells	O
.	O

The	O
results	O
demonstrate	O
that	O
okadaic	O
acid	O
treatment	O
is	O
associated	O
with	O
induction	B-Positive_regulation
of	O
a	O
differentiated	O
monocyte	O
phenotype	O
characterized	O
by	O
:	O
(	O
a	O
)	O
growth	O
arrest	O
;	O
(	O
b	O
)	O
increases	B-Positive_regulation
in	O
Mac	O
-	O
1	O
cell	O
surface	O
antigen	O
expression	B-Gene_expression
;	O
(	O
c	O
)	O
down	B-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
of	O
c	O
-	O
myc	O
transcripts	B-Transcription
;	O
and	O
(	O
d	O
)	O
induction	O
of	O
tumor	O
necrosis	O
factor	O
gene	O
expression	O
.	O

This	O
induction	O
of	O
monocytic	O
differentiation	O
was	O
associated	O
with	O
transient	O
increases	B-Positive_regulation
in	O
c	O
-	O
jun	O
mRNA	O
levels	B-Transcription
,	O
which	O
were	O
maximal	O
at	O
6	O
h	O
.	O

Similar	B-Positive_regulation
effects	I-Positive_regulation
were	O
obtained	O
for	O
the	O
c	O
-	O
fos	O
gene	O
.	O

Run	O
-	O
on	O
analysis	O
demonstrated	O
detectable	O
levels	O
of	O
c	O
-	O
jun	O
transcription	B-Transcription
in	O
U	O
-	O
937	O
cells	O
and	O
that	O
this	O
rate	O
is	O
increased	B-Positive_regulation
approximately	O
40	O
-	O
fold	O
following	O
okadaic	O
acid	O
exposure	O
.	O

c	O
-	O
jun	O
mRNA	O
levels	B-Transcription
were	O
superinduced	B-Positive_regulation
in	O
cells	O
treated	O
with	O
both	O
okadaic	O
acid	O
and	O
cycloheximide	O
,	O
whereas	O
inhibition	O
of	O
protein	O
synthesis	O
had	B-Regulation
little	I-Regulation
,	I-Regulation
if	I-Regulation
any	I-Regulation
,	I-Regulation
effect	I-Regulation
on	O
okadaic	O
acid	O
-	O
induced	B-Positive_regulation
c	O
-	O
jun	O
transcription	B-Transcription
.	O

The	O
half	O
-	O
life	O
of	O
c	O
-	O
jun	O
mRNA	O
was	O
similar	O
(	O
45	O
-	O
50	O
min	O
)	O
in	O
both	O
untreated	O
and	O
okadaic	O
acid	O
-	O
induced	O
cells	O
.	O

In	O
contrast	O
,	O
treatment	O
with	O
both	O
okadaic	O
acid	O
and	O
cycloheximide	O
was	O
associated	O
with	O
stabilization	B-Positive_regulation
(	O
t	O
1/2	O
=	O
90	O
min	O
)	O
of	O
c	O
-	O
jun	O
transcripts	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
indicate	O
that	O
the	O
induction	B-Positive_regulation
of	O
c	O
-	O
jun	O
transcription	B-Transcription
by	O
okadaic	O
acid	O
is	O
controlled	B-Regulation
primarily	O
by	O
a	O
transcriptional	O
mechanism	O
.	O

Since	O
previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
c	O
-	O
jun	O
gene	O
is	O
autoinduced	B-Positive_regulation
by	O
Jun/AP	O
-	O
1	O
,	O
we	O
also	O
studied	O
transcription	O
of	O
c	O
-	O
jun	O
promoter	O
(	O
positions	O
-	O
132/+170	O
)	O
-	O
reporter	O
gene	O
constructs	O
with	O
and	O
without	O
a	O
mutated	O
AP	O
-	O
1	O
element	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Activation	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
interleukin	O
2	O
in	O
human	O
blood	O
monocytes	O
.	O

We	O
report	O
here	O
that	O
interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
acts	O
on	O
human	O
blood	O
monocytes	O
by	O
enhancing	B-Positive_regulation
binding	B-Binding
activity	I-Binding
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
to	O
its	O
consensus	O
sequence	O
in	O
the	O
5	O
'	O
regulatory	O
enhancer	O
region	O
of	O
the	O
IL	O
-	O
2	O
receptor	O
alpha	O
chain	O
(	O
p55	O
)	O
.	O

Similarly	O
,	O
IL	O
-	O
2	O
activates	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
human	O
monocytic	O
cell	O
line	O
U	O
937	O
,	O
but	O
not	O
in	O
resting	O
human	O
T	O
-	O
cells	O
.	O

This	O
effect	O
is	O
detectable	O
within	O
15	O
min	O
and	O
peaks	O
1	O
h	O
after	O
exposure	O
to	O
IL	O
-	O
2	O
.	O

Enhanced	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
is	O
followed	O
by	O
functional	O
activation	O
in	O
that	O
inducibility	B-Positive_regulation
of	O
the	O
IL	O
-	O
2	O
receptor	O
alpha	O
chain	O
is	O
mediated	B-Positive_regulation
by	O
enhanced	O
NF	O
-	O
kappa	O
B	O
binding	O
and	O
that	O
a	O
heterologous	O
promoter	O
containing	O
the	O
NF	O
-	O
kappa	O
B	O
consensus	O
sequence	O
(	O
-	O
291	O
to	O
-	O
245	O
)	O
of	O
the	O
IL	O
-	O
2	O
receptor	O
alpha	O
chain	O
gene	O
is	O
activated	B-Positive_regulation
.	O

In	O
addition	O
,	O
IL	O
-	O
2	O
is	O
capable	O
of	O
increasing	B-Positive_regulation
transcript	B-Transcription
levels	I-Transcription
of	O
the	O
p50	O
gene	O
coding	O
for	O
the	O
p50	O
subunit	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
,	O
whereas	O
mRNA	B-Transcription
levels	I-Transcription
of	O
the	O
p65	O
NF	O
-	O
kappa	O
B	O
gene	O
remained	O
unchanged	B-Positive_regulation
.	O

The	O
regulation	B-Regulation
of	O
the	O
human	O
tumor	O
necrosis	O
factor	O
alpha	O
promoter	O
region	O
in	O
macrophage	O
,	O
T	O
cell	O
,	O
and	O
B	O
cell	O
lines	O
.	O

The	O
1311	O
-	O
base	O
pair	O
human	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
alpha	O
promoter	O
region	O
was	O
fused	O
to	O
the	O
luciferase	O
(	O
Luc	O
)	O
reporter	O
gene	O
and	O
studied	O
in	O
a	O
transient	O
transfection	O
system	O
in	O
three	O
TNF	O
producing	O
cell	O
lines	O
,	O
the	O
U937	O
macrophage	O
cell	O
line	O
,	O
the	O
MLA	O
144	O
T	O
cell	O
line	O
,	O
and	O
the	O
729	O
-	O
6	O
B	O
cell	O
line	O
.	O

This	O
full	O
length	O
promoter	O
construct	O
can	O
be	O
induced	B-Positive_regulation
by	O
phorbol	O
13	O
-	O
myristate	O
acetate	O
(	O
PMA	O
)	O
in	O
each	O
of	O
these	O
cell	O
types	O
.	O

Analysis	O
of	O
a	O
series	O
of	O
5'	O
-	O
truncations	O
showed	O
several	O
peaks	O
of	O
basal	O
and	O
PMA	O
induced	O
activity	O
suggesting	O
the	O
presence	O
of	O
several	O
positive	O
and	O
negative	O
regulatory	O
elements	O
.	O

A	O
PMA	O
responsive	O
element	O
was	O
localized	O
to	O
a	O
region	O
between	O
-	O
95	O
and	O
-	O
36	O
bp	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
.	O

Within	O
this	O
region	O
,	O
single	O
AP-2	O
-	O
and	O
AP-1	O
-	O
like	O
consensus	O
sequences	O
were	O
noted	O
.	O

These	O
AP	O
-	O
2	O
and	O
AP	O
-	O
1	O
sites	O
were	O
each	O
modified	O
with	O
a	O
double	O
point	O
mutation	O
.	O

A	O
modest	O
(	O
20	O
-	O
50	O
%	O
)	O
reduction	B-Negative_regulation
in	O
TNF	O
promoter	O
activity	O
was	O
observed	O
with	O
the	O
AP	O
-	O
2	O
site	O
mutation	O
.	O

However	O
,	O
mutation	O
of	O
the	O
AP	O
-	O
1	O
site	O
markedly	O
diminished	B-Negative_regulation
both	O
the	O
basal	O
and	O
PMA	O
-	O
activated	B-Positive_regulation
promoter	O
activity	O
.	O

Also	O
co	B-Gene_expression
-	I-Gene_expression
transfections	I-Gene_expression
of	O
the	O
wild	O
-	O
type	O
promoter	O
construct	O
with	O
an	O
AP-1/c	O
-	O
jun	O
expression	O
vector	O
resulted	O
in	O
augmented	B-Positive_regulation
basal	O
and	O
PMA	O
-	O
induced	B-Positive_regulation
promoter	O
activity	O
.	O

Redox	O
status	O
of	O
cells	O
influences	O
constitutive	O
or	O
induced	O
NF	O
-	O
kappa	O
B	O
translocation	O
and	O
HIV	O
long	O
terminal	O
repeat	O
activity	O
in	O
human	O
T	O
and	O
monocytic	O
cell	O
lines	O
.	O

We	O
have	O
tested	O
the	O
hypothesis	O
that	O
cellular	O
activation	O
events	O
occurring	O
in	O
T	O
lymphocytes	O
and	O
monocytes	O
and	O
mediated	O
through	O
translocation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
are	O
dependent	O
upon	O
the	O
constitutive	O
redox	O
status	O
of	O
these	O
cells	O
.	O

We	O
used	O
phenolic	O
,	O
lipid	O
-	O
soluble	O
,	O
chain	O
-	O
breaking	O
antioxidants	O
(	O
butylated	O
hydroxyanisole	O
(	O
BHA	O
)	O
,	O
nordihydroquairetic	O
acid	O
,	O
or	O
alpha	O
-	O
tocopherol	O
(	O
vitamin	O
E	O
)	O
to	O
show	O
that	O
peroxyl	O
radical	O
scavenging	O
in	O
unstimulated	O
and	O
PMA	O
-	O
or	O
TNF	O
-	O
stimulated	O
cells	O
blocks	O
the	O
functions	O
depending	O
on	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

BHA	O
was	O
found	O
to	O
suppress	O
not	O
only	O
PMA	O
-	O
or	O
TNF	O
-	O
induced	O
,	O
but	O
also	O
constitutive	O
,	O
HIV	O
-	O
enhancer	O
activity	O
concomitant	O
to	O
an	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
in	O
both	O
lymphoblastoid	O
T	O
(	O
J.Jhan	O
)	O
and	O
monocytic	O
(	O
U937	O
)	O
cell	O
lines	O
.	O

This	O
was	O
also	O
true	O
for	O
KBF	O
(	O
p50	O
homodimer	O
)	O
binding	B-Binding
activity	I-Binding
in	O
U937	O
cells	O
.	O

Secretion	O
of	O
TNF	O
,	O
the	O
product	O
of	O
another	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
gene	O
,	O
was	O
abolished	O
by	O
BHA	O
in	O
PMA	O
-	O
stimulated	O
U937	O
cells	O
.	O

The	O
anti	O
-	O
oxidative	O
effect	O
of	O
BHA	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
thiol	O
,	O
but	O
not	O
glutathione	O
,	O
content	O
in	O
stimulated	O
and	O
unstimulated	O
T	O
cell	O
,	O
whereas	O
TNF	O
stimulation	O
itself	O
barely	O
modified	O
the	O
cellular	O
thiol	O
level	O
.	O

Oxidative	O
stress	O
obtained	O
by	O
the	O
addition	O
of	O
H2O2	O
to	O
the	O
culture	O
medium	O
of	O
J.Jhan	O
or	O
U937	O
cells	O
could	O
not	O
by	O
itself	O
induce	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

These	O
observations	O
suggest	O
that	O
TNF	O
and	O
PMA	O
do	O
not	O
lead	O
to	O
NF	O
-	O
kappa	O
B	O
activation	O
through	O
induction	O
of	O
changes	O
in	O
the	O
cell	O
redox	O
status	O
.	O

Rather	O
,	O
TNF	O
and	O
PMA	O
can	O
exert	O
their	O
effect	O
only	O
if	O
cells	O
are	O
in	O
an	O
appropriate	O
redox	O
status	O
,	O
because	O
prior	O
modification	O
toward	O
reduction	O
with	O
BHA	O
treatment	O
prevents	O
this	O
activation	O
.	O

It	O
appears	O
that	O
a	O
basal	O
redox	O
equilibrium	O
tending	O
toward	O
oxidation	O
is	O
a	O
prerequisite	O
for	O
full	O
activation	O
of	O
transduction	O
pathways	O
regulating	O
the	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
genes	O
.	O

Natural	O
variants	O
of	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
:	O
analysis	O
of	O
promoters	O
with	O
duplicated	O
DNA	O
regulatory	O
motifs	O
.	O

Sequence	O
variation	O
in	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
region	O
of	O
HIV	O
-	O
1	O
was	O
analyzed	O
in	O
viral	O
isolates	O
of	O
17	O
infected	O
individuals	O
.	O

Two	O
classes	O
of	O
LTR	O
size	O
variants	O
were	O
found	O
.	O

One	O
HIV	O
-	O
1	O
variant	O
was	O
detected	O
containing	O
an	O
additional	O
binding	O
site	O
for	O
the	O
transcription	O
factor	O
Sp1	O
.	O

Another	O
LTR	O
size	O
variation	O
was	O
observed	O
in	O
four	O
patients	O
in	O
a	O
region	O
just	O
upstream	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
enhancer	O
.	O

This	O
variation	O
was	O
the	O
result	O
of	O
a	O
duplication	O
of	O
a	O
short	O
DNA	O
sequence	O
(	O
CTG	O
-	O
motif	O
)	O
.	O

Cell	O
culture	O
experiments	O
demonstrated	O
that	O
the	O
natural	O
variant	O
with	O
four	O
Sp1	O
sites	O
had	O
a	O
slightly	O
higher	O
promoter	O
activity	O
and	O
viral	O
replication	O
rate	O
than	O
the	O
isogenic	O
control	O
LTR	O
with	O
three	O
Sp1	O
sites	O
.	O

No	O
positive	O
effect	O
of	O
the	O
duplicated	O
CTG	O
-	O
motif	O
could	O
be	O
detected	O
.	O

In	O
order	O
to	O
measure	O
small	O
differences	O
in	O
virus	O
production	O
more	O
accurately	O
,	O
equal	O
amounts	O
of	O
a	O
size	O
variant	O
and	O
the	O
wild	O
-	O
type	O
plasmid	O
were	O
cotransfected	O
into	O
T	O
-	O
cells	O
.	O

The	O
virus	O
with	O
four	O
Sp1	O
sites	O
did	O
outgrow	O
the	O
three	O
Sp1	O
virus	O
in	O
35	O
days	O
of	O
culture	O
and	O
CTG	O
-	O
monomer	O
virus	O
outcompeted	O
the	O
CTG	O
-	O
dimer	O
virus	O
in	O
42	O
days	O
.	O

Based	O
on	O
these	O
results	O
we	O
estimate	O
a	O
5	O
-	O
10	O
%	O
difference	O
in	O
virus	O
production	O
of	O
the	O
LTR	O
variants	O
when	O
compared	O
to	O
that	O
of	O
wild	O
-	O
type	O
.	O

Transcription	O
of	O
the	O
hypersensitive	O
site	O
HS2	O
enhancer	O
in	O
erythroid	O
cells	O
.	O

In	O
the	O
human	O
genome	O
,	O
the	O
erythroid	O
-	O
specific	O
hypersensitive	O
site	O
HS2	O
enhancer	O
regulates	B-Regulation
the	O
transcription	B-Transcription
of	O
the	O
downstream	O
beta	O
-	O
like	O
globin	O
genes	O
10	O
-	O
50	O
kilobases	O
away	O
.	O

The	O
mechanism	O
of	O
HS2	O
enhancer	O
function	O
is	O
not	O
known	O
.	O

The	O
present	O
study	O
employs	O
RNA	O
protection	O
assays	O
to	O
analyze	O
the	O
transcriptional	O
status	O
of	O
the	O
HS2	O
enhancer	O
in	O
transfected	O
recombinant	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
plasmids	O
.	O

In	O
erythroid	O
K562	O
cells	O
in	O
which	O
the	O
HS2	O
enhancer	O
is	O
active	O
,	O
the	O
HS2	O
sequence	O
directs	O
the	O
synthesis	O
of	O
long	O
enhancer	O
transcripts	O
that	O
are	O
initiated	O
apparently	O
from	O
within	O
the	O
enhancer	O
and	O
elongated	O
through	O
the	O
intervening	O
DNA	O
into	O
the	O
cis	O
-	O
linked	O
CAT	O
gene	O
.	O

In	O
nonerythroid	O
HL	O
-	O
60	O
cells	O
in	O
which	O
the	O
HS2	O
enhancer	O
is	O
inactive	O
,	O
long	O
enhancer	O
transcripts	O
are	O
not	O
detectable	O
.	O

Splitting	O
the	O
HS2	O
enhancer	O
between	O
two	O
tandem	O
Ap1	O
sites	O
abolishes	O
the	O
synthesis	O
of	O
a	O
group	O
of	O
long	O
enhancer	O
transcripts	O
and	O
results	O
in	O
loss	O
of	O
enhancer	O
function	O
and	O
transcriptional	O
silencing	O
of	O
the	O
cis	O
-	O
linked	O
CAT	O
gene	O
.	O

In	O
directing	O
the	O
synthesis	O
of	O
RNA	O
through	O
the	O
intervening	O
DNA	O
and	O
the	O
gene	O
by	O
a	O
tracking	O
and	O
transcription	O
mechanism	O
,	O
the	O
HS2	O
enhancer	O
may	O
(	O
i	O
)	O
open	O
up	O
the	O
chromatin	O
structure	O
of	O
a	O
gene	O
domain	O
and	O
(	O
ii	O
)	O
deliver	O
enhancer	O
binding	O
proteins	O
to	O
the	O
promoter	O
sequence	O
where	O
they	O
may	O
stimulate	O
the	O
transcription	O
of	O
the	O
gene	O
at	O
the	O
cap	O
site	O
.	O

Phorbol	O
ester	O
reduces	O
constitutive	O
nuclear	O
NF	O
kappa	O
B	O
and	O
inhibits	O
HIV	O
-	O
1	O
production	O
in	O
mature	O
human	O
monocytic	O
cells	O
.	O

NF	O
kappa	O
B	O
is	O
a	O
potent	O
mediator	O
of	O
specific	O
gene	O
expression	O
in	O
human	O
monocytes	O
and	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
transcription	O
of	O
the	O
HIV	O
-	O
1	O
genome	O
in	O
promonocytic	O
leukemias	O
.	O

There	O
is	O
little	O
information	O
available	O
on	O
the	O
response	O
of	O
NF	O
kappa	O
B	O
to	O
cytokines	O
in	O
normal	O
human	O
monocytes	O
.	O

We	O
have	O
used	O
a	O
32P	O
-	O
labeled	O
oligonucleotide	O
derived	O
from	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
-	O
1	O
)	O
long	O
terminal	O
repeat	O
,	O
which	O
contains	O
a	O
tandem	O
repeat	O
of	O
the	O
NF	O
kappa	O
B	O
binding	O
sequence	O
,	O
as	O
a	O
probe	O
in	O
a	O
gel	O
retardation	O
assay	O
to	O
study	O
this	O
transcription	O
factor	O
.	O

Using	O
this	O
assay	O
,	O
we	O
have	O
detected	O
NF	O
kappa	O
B	O
in	O
extracts	O
of	O
nuclei	O
from	O
normal	O
human	O
monocytes	O
.	O

Treatment	O
of	O
normal	O
monocytes	O
with	O
12-0	O
-	O
tetradecanoyl	O
phorbol-13	O
-	O
acetate	O
(	O
TPA	O
)	O
for	O
4	O
-	O
24	O
h	O
caused	O
the	O
complete	O
disappearance	O
of	O
NF	O
kappa	O
B	O
from	O
nuclear	O
extracts	O
of	O
monocytes	O
.	O

A	O
similar	O
result	O
was	O
obtained	O
with	O
the	O
mature	O
monocytic	O
leukemia	O
cell	O
line	O
THP	O
-	O
1	O
.	O

The	O
constitutive	O
transcription	O
factor	O
SP1	O
was	O
unaffected	B-Negative_regulation
by	O
addition	O
of	O
TPA	O
.	O

The	O
disappearance	O
of	O
NF	O
kappa	O
B	O
from	O
the	O
nucleus	O
was	O
concentration	O
dependent	O
between	O
10	O
and	O
50	O
ng/ml	O
of	O
phorbol	O
ester	O
.	O

In	O
THP	O
-	O
1	O
cells	O
,	O
TPA	O
also	O
induced	O
a	O
new	O
,	O
faster	O
-	O
migrating	O
NF	O
kappa	O
B	O
species	O
not	O
induced	O
in	O
monocytes	O
.	O

Protein	O
kinase	O
C	O
inhibitor	O
staurosporine	O
,	O
but	O
not	O
cyclic	O
nucleotide	O
-	O
dependent	O
protein	O
kinase	O
inhibitor	O
HA	O
-	O
1004	O
,	O
also	O
dramatically	O
reduced	O
constitutive	O
levels	O
of	O
nuclear	O
NF	O
kappa	O
B	O
.	O

Finally	O
,	O
TPA	O
addition	O
to	O
monocytes	O
infected	O
with	O
HIV	O
-	O
1	O
inhibited	O
HIV	O
-	O
1	O
replication	O
,	O
as	O
determined	O
by	O
reverse	O
transcriptase	O
assays	O
,	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

These	O
results	O
are	O
in	O
striking	O
contrast	O
to	O
the	O
increase	O
in	O
nuclear	O
NF	O
kappa	O
B	O
and	O
HIV	O
-	O
1	O
replication	O
induced	O
by	O
phorbol	O
esters	O
in	O
promonocytic	O
leukemia	O
cells	O
U937	O
and	O
HL	O
-	O
60	O
,	O
and	O
emphasize	O
the	O
importance	O
of	O
studying	O
cytokine	O
regulation	O
of	O
HIV	O
-	O
1	O
in	O
normal	O
monocytes	O
.	O

Targeted	B-Positive_regulation
degradation	B-Protein_catabolism
of	O
c	O
-	O
Fos	O
,	O
but	O
not	O
v	O
-	O
Fos	O
,	O
by	O
a	O
phosphorylation	O
-	O
dependent	O
signal	O
on	O
c	O
-	O
Jun	O
.	O

The	O
proto	O
-	O
oncogene	O
products	O
c	O
-	O
Fos	O
and	O
c	O
-	O
Jun	O
heterodimerize	B-Binding
through	B-Positive_regulation
their	O
leucine	O
zippers	O
to	O
form	O
the	O
AP	O
-	O
1	O
transcription	O
factor	O
.	O

The	O
transcriptional	O
activity	O
of	O
the	O
heterodimer	O
is	O
regulated	O
by	O
signal	O
-	O
dependent	O
phosphorylation	O
and	O
dephosphorylation	O
events	O
.	O

The	O
stability	B-Protein_catabolism
of	O
c	O
-	O
Fos	O
was	O
found	O
to	O
also	O
be	O
controlled	B-Regulation
by	O
intracellular	O
signal	O
transduction	O
.	O

In	O
transient	O
expression	O
and	O
in	O
vitro	O
degradation	O
experiments	O
,	O
the	O
stability	O
of	O
c	O
-	O
Fos	O
was	O
decreased	B-Negative_regulation
when	B-Positive_regulation
the	O
protein	O
was	O
dimerized	B-Binding
with	O
phosphorylated	B-Phosphorylation
c	O
-	O
Jun.	O
c	O
-	O
Jun	O
protein	O
isolated	O
from	O
phorbol	O
ester	O
-	O
induced	O
cells	O
did	O
not	O
target	B-Positive_regulation
c	O
-	O
Fos	O
for	O
degradation	B-Protein_catabolism
,	O
which	O
suggests	O
that	O
c	O
-	O
Fos	O
is	O
transiently	O
stabilized	B-Protein_catabolism
after	B-Positive_regulation
stimulation	O
of	O
cell	O
growth	O
.	O

v	O
-	O
Fos	O
protein	O
,	O
the	O
retroviral	O
counterpart	O
of	O
c	O
-	O
Fos	O
,	O
was	O
not	O
susceptible	B-Positive_regulation
to	O
degradation	B-Protein_catabolism
targeted	B-Binding
by	O
c	O
-	O
Jun	O
.	O

Alpha	O
-	O
lipoic	O
acid	O
is	O
a	O
potent	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
human	O
T	O
cells	O
.	O

Acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
results	O
from	O
infection	O
with	O
a	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O

The	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
region	O
of	O
HIV	O
proviral	O
DNA	O
contains	O
binding	O
sites	O
for	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
,	O
and	O
this	O
transcriptional	O
activator	O
appears	O
to	O
regulate	O
HIV	O
activation	O
.	O

Recent	O
findings	O
suggest	O
an	O
involvement	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
signal	O
transduction	O
pathways	O
leading	O
to	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

The	O
present	O
study	O
was	O
based	O
on	O
reports	O
that	O
antioxidants	O
which	O
eliminate	O
ROS	O
should	O
block	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
subsequently	O
HIV	O
transcription	O
,	O
and	O
thus	O
antioxidants	O
can	O
be	O
used	O
as	O
therapeutic	O
agents	O
for	O
AIDS	O
.	O

Incubation	O
of	O
Jurkat	O
T	O
cells	O
(	O
1	O
x	O
10	O
(	O
6	O
)	O
cells/ml	O
)	O
with	O
a	O
natural	O
thiol	O
antioxidant	O
,	O
alpha	O
-	O
lipoic	O
acid	O
,	O
prior	O
to	O
the	O
stimulation	O
of	O
cells	O
was	O
found	O
to	O
inhibit	O
NF	O
-	O
kappa	O
B	O
activation	O
induced	O
by	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
25	O
ng/ml	O
)	O
or	O
by	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
50	O
ng/ml	O
)	O
.	O

The	O
inhibitory	O
action	O
of	O
alpha	O
-	O
lipoic	O
acid	O
was	O
found	O
to	O
be	O
very	O
potent	O
as	O
only	O
4	O
mM	O
was	O
needed	O
for	O
a	O
complete	O
inhibition	O
,	O
whereas	O
20	O
mM	O
was	O
required	O
for	O
N	O
-	O
acetylcysteine	O
.	O

These	O
results	O
indicate	O
that	O
alpha	O
-	O
lipoic	O
acid	O
may	O
be	O
effective	O
in	O
AIDS	O
therapeutics	O
.	O

Activation	O
of	O
lymphokine	O
genes	O
in	O
T	O
cells	O
:	O
role	O
of	O
cis	O
-	O
acting	O
DNA	O
elements	O
that	O
respond	O
to	O
T	O
cell	O
activation	O
signals	O
.	O

Activation	O
of	O
T	O
cells	O
is	O
initiated	O
by	O
the	O
recognition	O
of	O
antigen	O
on	O
antigen	O
presenting	O
cells	O
to	O
exert	O
the	O
effector	O
functions	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

Two	O
types	O
of	O
helper	O
T	O
cell	O
(	O
Th	O
)	O
clones	O
(	O
Th1	O
and	O
Th2	O
)	O
are	O
defined	O
on	O
the	O
basis	O
of	O
different	O
patterns	O
of	O
cytokine	O
(	O
lymphokine	O
)	O
secretion	O
.	O

They	O
determine	O
the	O
outcome	O
of	O
an	O
antigenic	O
response	O
toward	O
humoral	O
or	O
cell	O
-	O
mediated	O
immunity	O
.	O

Although	O
lymphokine	O
genes	O
are	O
coordinately	O
regulated	O
upon	O
antigen	O
stimulation	O
,	O
they	O
are	O
regulated	O
by	O
the	O
mechanisms	O
common	O
to	O
all	O
as	O
well	O
as	O
those	O
which	O
are	O
unique	O
to	O
each	O
gene	O
.	O

For	O
most	O
lymphokine	O
genes	O
,	O
a	O
combination	O
of	O
phorbol	O
esters	O
(	O
phorbol	O
12	O
-	O
myristate	O
13	O
acetate	O
,	O
PMA	O
)	O
and	O
calcium	O
ionophores	O
(	O
A23187	O
)	O
is	O
required	O
for	O
their	O
maximal	O
induction	O
.	O

Yet	O
phorbol	O
ester	O
alone	O
or	O
calcium	O
ionophore	O
alone	O
produce	O
several	O
lymphokines	O
.	O

The	O
production	B-Gene_expression
of	O
the	O
granulocyte	O
-	O
macrophage	O
colony	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
is	O
completely	O
dependent	B-Positive_regulation
on	O
the	O
two	O
signals	O
.	O

We	O
have	O
previously	O
found	O
a	O
cis	O
-	O
acting	O
region	O
spanning	O
the	O
GM	O
-	O
CSF	O
promoter	O
region	O
(	O
positions	O
-	O
95	O
to	O
+27	O
)	O
that	O
confers	O
inducibility	O
to	O
reporter	O
genes	O
in	O
transient	O
transfection	O
assays	O
.	O

Further	O
analysis	O
identified	O
three	O
elements	O
required	O
for	O
efficient	O
induction	O
,	O
referred	O
to	O
as	O
GM2	O
,	O
GC	O
-	O
box	O
and	O
conserved	O
lymphokine	O
element	O
(	O
CLE0	O
)	O
.	O

GM2	O
defines	O
a	O
binding	O
site	O
for	O
protein	O
(	O
s	O
)	O
whose	O
binding	O
is	O
inducible	O
by	O
PMA	O
.	O

One	O
protein	O
,	O
NF	O
-	O
GM2	O
is	O
similar	O
to	O
the	O
transcription	O
factor	O
NF	O
-	O
kB	O
.	O

GC	O
-	O
box	O
is	O
a	O
binding	O
site	O
for	O
constitutively	O
bound	O
proteins	O
.	O

CLEO	O
defines	O
a	O
binding	O
site	O
for	O
protein	O
(	O
s	O
)	O
whose	O
optimum	O
binding	O
is	O
stimulated	O
by	O
PMA	O
and	O
A23187	O
.	O

Viral	O
trans	O
-	O
activators	O
such	O
as	O
Tax	O
(	O
human	O
T	O
cell	O
leukemia	O
virus	O
-	O
1	O
,	O
HTLV	O
-	O
1	O
)	O
and	O
E2	O
(	O
bovine	O
papilloma	O
virus	O
,	O
BPV	O
)	O
proteins	O
are	O
other	O
agents	O
which	O
activate	O
lymphokine	O
gene	O
expression	O
by	O
bypassing	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
mediated	O
signaling	O
.	O

The	O
trans	O
-	O
activation	O
domain	O
of	O
E2	O
and	O
Tax	O
is	O
interchangeable	O
although	O
they	O
have	O
no	O
obvious	O
sequence	O
homology	O
between	O
them	O
.	O

The	O
viral	O
trans	O
-	O
activators	O
appear	O
to	O
target	B-Binding
specific	O
DNA	O
binding	O
protein	O
such	O
as	O
NF	O
-	O
kB	O
and	O
Sp1	O
to	O
cis	O
-	O
acting	O
DNA	O
site	O
and	O
promote	O
lymphokine	O
gene	O
expression	O
without	O
TCR	O
-	O
mediated	O
stimulation	O
.	O

I	O
kappa	O
B/MAD	O
-	O
3	O
masks	B-Negative_regulation
the	O
nuclear	O
localization	O
signal	O
of	O
NF	O
-	O
kappa	O
B	O
p65	O
and	O
requires	O
the	O
transactivation	O
domain	O
to	O
inhibit	B-Negative_regulation
NF	O
-	O
kappa	O
B	O
p65	O
DNA	O
binding	B-Binding
.	O

The	O
active	O
nuclear	O
form	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
complex	B-Binding
is	O
composed	O
of	O
two	O
DNA	O
binding	B-Binding
subunits	O
,	O
NF	O
-	O
kappa	O
B	O
p65	O
and	O
NF	O
-	O
kappa	O
B	O
p50	O
,	O
both	O
of	O
which	O
share	O
extensive	O
N	O
-	O
terminal	O
sequence	O
homology	O
with	O
the	O
v	O
-	O
rel	O
oncogene	O
product	O
.	O

The	O
NF	O
-	O
kappa	O
B	O
p65	O
subunit	O
provides	O
the	O
transactivation	O
activity	O
in	O
this	O
complex	O
and	O
serves	O
as	O
an	O
intracellular	O
receptor	B-Binding
for	O
a	O
cytoplasmic	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
termed	O
I	O
kappa	O
B	O
.	O

In	O
contrast	O
,	O
NF	O
-	O
kappa	O
B	O
p50	O
alone	O
fails	O
to	O
stimulate	O
kappa	O
B	O
-	O
directed	O
transcription	O
,	O
and	O
based	O
on	O
prior	O
in	O
vitro	O
studies	O
,	O
is	O
not	O
directly	O
regulated	B-Regulation
by	O
I	O
kappa	O
B	O
.	O

To	O
investigate	O
the	O
molecular	O
basis	O
for	O
the	O
critical	O
regulatory	O
interaction	O
between	O
NF	O
-	O
kappa	O
B	O
and	O
I	O
kappa	O
B/MAD	O
-	O
3	O
,	O
a	O
series	O
of	O
human	O
NF	O
-	O
kappa	O
B	O
p65	O
mutants	O
was	O
identified	O
that	O
functionally	O
segregated	O
DNA	O
binding	O
,	O
I	O
kappa	O
B	O
-	O
mediated	O
inhibition	O
,	O
and	O
I	O
kappa	O
B	O
-	O
induced	O
nuclear	O
exclusion	O
of	O
this	O
transcription	O
factor	O
.	O

Results	O
from	O
in	O
vivo	O
expression	O
studies	O
performed	O
with	O
these	O
NF	O
-	O
kappa	O
B	O
p65	O
mutants	O
revealed	O
the	O
following	O
:	O
1	O
)	O
I	O
kappa	O
B/MAD	O
-	O
3	O
completely	O
inhibits	O
NF	O
-	O
kappa	O
B	O
p65	O
-	O
dependent	O
transcriptional	O
activation	O
mediated	O
through	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
kappa	O
B	O
enhancer	O
in	O
human	O
T	O
lymphocytes	O
,	O
2	O
)	O
the	O
binding	B-Binding
of	O
I	O
kappa	O
B/MAD	O
-	O
3	O
to	O
NF	O
-	O
kappa	O
B	O
p65	O
is	O
sufficient	B-Positive_regulation
to	O
retarget	B-Localization
NF	O
-	O
kappa	O
B	O
p65	O
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
,	O
3	O
)	O
selective	O
deletion	B-Negative_regulation
of	O
the	O
functional	O
nuclear	O
localization	O
signal	O
present	O
in	O
the	O
Rel	O
homology	O
domain	O
of	O
NF	O
-	O
kappa	O
B	O
p65	O
disrupts	B-Negative_regulation
its	O
ability	O
to	O
engage	B-Binding
I	O
kappa	O
B/MAD	O
-	O
3	O
,	O
and	O
4	O
)	O
the	O
unique	O
C	O
-	O
terminus	O
of	O
NF	O
-	O
kappa	O
B	O
p65	O
attenuates	B-Negative_regulation
its	O
own	O
nuclear	O
localization	B-Localization
and	O
contains	O
sequences	O
that	O
are	O
required	B-Positive_regulation
for	O
I	O
kappa	O
B	O
-	O
mediated	O
inhibition	B-Negative_regulation
of	O
NF	O
-	O
kappa	O
B	O
p65	O
DNA	O
binding	B-Binding
activity	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
the	O
nuclear	O
localization	O
signal	O
and	O
transactivation	O
domain	O
of	O
NF	O
-	O
kappa	O
B	O
p65	O
constitute	O
a	O
bipartite	O
system	O
that	O
is	O
critically	O
involved	O
in	O
the	O
inhibitory	O
function	O
of	O
I	O
kappa	O
B/MAD	O
-	O
3	O
.	O

Unexpectedly	O
,	O
our	O
in	O
vivo	O
studies	O
also	O
demonstrate	O
that	O
I	O
kappa	O
B/MAD	O
-	O
3	O
binds	B-Binding
directly	O
to	O
NF	O
-	O
kappa	O
B	O
p50	O
.	O

This	O
interaction	O
is	O
functional	O
as	O
it	O
leads	B-Positive_regulation
to	O
retargeting	B-Localization
of	O
NF	O
-	O
kappa	O
B	O
p50	O
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
.	O

However	O
,	O
no	O
loss	O
of	O
DNA	O
binding	O
activity	O
is	O
observed	O
,	O
presumably	O
reflecting	O
the	O
unique	O
C	O
-	O
terminal	O
domain	O
that	O
is	O
distinct	O
from	O
that	O
present	O
in	O
NF	O
-	O
kappa	O
B	O
p65	O
.	O

Simple	O
derivation	O
of	O
TFIID	O
-	O
dependent	O
RNA	O
polymerase	O
II	O
transcription	O
systems	O
from	O
Schizosaccharomyces	O
pombe	O
and	O
other	O
organisms	O
,	O
and	O
factors	O
required	O
for	O
transcriptional	O
activation	O
.	O

Resolution	O
of	O
whole	O
cell	O
extract	O
through	O
two	O
chromatographic	O
steps	O
yields	O
a	O
single	O
protein	O
fraction	O
requiring	O
only	O
the	O
addition	O
of	O
TFIID	O
for	O
the	O
initiation	O
of	O
transcription	O
at	O
RNA	O
polymerase	O
II	O
promoters	O
.	O

This	O
approach	O
allows	O
the	O
convenient	O
generation	O
of	O
RNA	O
polymerase	O
II	O
transcription	O
systems	O
from	O
Saccharomyces	O
cerevisiae	O
,	O
human	O
lymphocytes	O
,	O
and	O
Schizosaccharomyces	O
pombe	O
.	O

TFIIDs	O
from	O
all	O
three	O
organisms	O
are	O
interchangeable	O
among	O
all	O
three	O
systems	O
.	O

The	O
S.	O
cerevisiae	O
and	O
Sch.	O
pombe	O
systems	O
support	O
effects	O
of	O
acidic	O
activator	O
proteins	O
,	O
provided	O
a	O
further	O
protein	O
fraction	O
from	O
S.	O
cerevisiae	O
is	O
supplied	O
.	O

This	O
further	O
fraction	O
is	O
distinct	O
from	O
the	O
mediator	O
of	O
transcriptional	O
activation	O
described	O
previously	O
and	O
represents	O
a	O
second	O
component	O
in	O
addition	O
to	O
general	O
initiation	O
factors	O
that	O
may	O
facilitate	O
a	O
response	O
to	O
acidic	O
activators	O
.	O

NF	O
-	O
kappa	O
B	O
-	O
dependent	O
induction	B-Positive_regulation
of	O
the	O
NF	O
-	O
kappa	O
B	O
p50	O
subunit	O
gene	O
promoter	O
underlies	B-Regulation
self	O
-	O
perpetuation	B-Positive_regulation
of	O
human	O
immunodeficiency	O
virus	O
transcription	B-Transcription
in	O
monocytic	O
cells	O
.	O

The	O
molecular	O
mechanisms	O
underlying	O
the	O
sustained	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
observed	O
in	O
U937	O
monocytic	O
cells	O
chronically	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
were	O
studied	O
.	O

The	O
activity	O
of	O
the	O
promoter	O
regulating	B-Regulation
the	O
synthesis	B-Gene_expression
of	O
the	O
p105	O
precursor	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
p50	O
subunit	O
was	O
enhanced	B-Positive_regulation
in	O
these	O
cells	O
.	O

Deletions	O
in	O
this	O
promoter	O
indicated	O
that	O
this	O
upregulation	O
was	O
mediated	B-Regulation
through	O
the	O
NF	O
-	O
kappa	O
B	O
-	O
but	O
not	O
the	O
AP-1	O
-	O
binding	O
motif	O
,	O
by	O
bona	O
fide	O
p50/p65	O
heterodimers	O
.	O

Analysis	O
of	O
cytosolic	O
extracts	O
indicated	O
that	O
NF	O
-	O
kappa	O
B	O
levels	O
were	O
increased	O
in	O
HIV	O
-	O
infected	O
cells	O
.	O

In	O
contrast	O
to	O
the	O
transient	O
NF	O
-	O
kappa	O
B	O
activation	O
induced	O
by	O
phorbol	O
ester	O
,	O
the	O
permanent	O
NF	O
-	O
kappa	O
B	O
translocation	O
induced	O
by	O
HIV	O
infection	O
was	O
not	O
dependent	O
on	O
PKC	O
isoenzymes	O
alpha	O
and	O
beta	O
as	O
shown	O
by	O
the	O
use	O
of	O
a	O
specific	O
inhibitor	B-Negative_regulation
(	O
GF	O
109203X	O
)	O
.	O

These	O
observations	O
indicate	O
that	O
during	O
chronic	O
HIV	O
infection	O
of	O
U937	O
cells	O
,	O
continuous	O
NF	O
-	O
kappa	O
B	O
(	O
p50/p65	O
)	O
translocation	B-Localization
results	B-Positive_regulation
in	O
p105	O
promoter	O
upregulation	B-Positive_regulation
with	O
subsequent	O
cytosolic	O
NF	O
-	O
kappa	O
B	O
accumulation	O
,	O
ready	O
for	O
further	O
translocation	O
.	O

This	O
HIV	O
-	O
mediated	O
mechanism	O
results	O
in	O
a	O
self	O
-	O
perpetuating	O
loop	O
of	O
NF	O
-	O
kappa	O
B	O
production	O
.	O

TAR	O
-	O
independent	O
transactivation	O
by	O
Tat	O
in	O
cells	O
derived	O
from	O
the	O
CNS	O
:	O
a	O
novel	O
mechanism	O
of	O
HIV	O
-	O
1	O
gene	O
regulation	O
.	O

The	O
Tat	O
protein	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
is	O
essential	O
for	O
productive	O
infection	O
and	O
is	O
a	O
potential	O
target	O
for	O
antiviral	O
therapy	O
.	O

Tat	O
,	O
a	O
potent	O
activator	O
of	O
HIV	O
-	O
1	O
gene	O
expression	O
,	O
serves	O
to	O
greatly	O
increase	O
the	O
rate	O
of	O
transcription	O
directed	O
by	O
the	O
viral	O
promoter	O
.	O

This	O
induction	O
,	O
which	O
seems	O
to	O
be	O
an	O
important	O
component	O
in	O
the	O
progression	O
of	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
AIDS	O
)	O
,	O
may	O
be	O
due	O
to	O
increased	O
transcriptional	O
initiation	O
,	O
increased	O
transcriptional	O
elongation	O
,	O
or	O
a	O
combination	O
of	O
these	O
processes	O
.	O

Much	O
attention	O
has	O
been	O
focused	O
on	O
the	O
interaction	B-Binding
of	O
Tat	O
with	O
a	O
specific	O
RNA	O
target	O
termed	O
TAR	O
(	O
transactivation	O
responsive	O
)	O
which	O
is	O
present	O
in	O
the	O
leader	O
sequence	O
of	O
all	O
HIV	O
-	O
1	O
mRNAs	O
.	O

This	O
interaction	O
is	O
believed	O
to	O
be	O
an	O
important	O
component	O
of	O
the	O
mechanism	O
of	O
transactivation	O
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
in	O
certain	O
CNS	O
-	O
derived	O
cells	O
Tat	O
is	O
capable	O
of	O
activating	O
HIV	O
-	O
1	O
through	O
a	O
TAR	O
-	O
independent	O
pathway	O
.	O

A	O
Tat	O
-	O
responsive	O
element	O
is	O
found	O
upstream	O
within	O
the	O
viral	O
promoter	O
that	O
in	O
glial	O
-	O
derived	O
cell	O
lines	O
allows	O
transactivation	O
in	O
the	O
absence	O
of	O
TAR	O
.	O

Deletion	O
mapping	O
and	O
hybrid	O
promoter	O
constructs	O
demonstrate	O
that	O
the	O
newly	O
identified	O
Tat	O
-	O
responsive	O
element	O
corresponds	O
to	O
a	O
sequence	O
within	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
previously	O
identified	O
as	O
the	O
HIV	O
-	O
1	O
enhancer	O
,	O
or	O
NF	O
-	O
kappa	O
B	O
domain	O
.	O

DNA	O
band	O
-	O
shift	O
analysis	O
reveals	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
in	O
glial	O
cells	O
that	O
differs	O
from	O
that	O
present	O
in	O
T	O
lymphoid	O
cells	O
.	O

Further	O
,	O
we	O
observe	O
that	O
TAR	O
-	O
deleted	O
mutants	O
of	O
HIV	O
-	O
1	O
demonstrate	O
normal	O
late	O
gene	O
expression	O
in	O
glial	O
cells	O
as	O
evidenced	O
by	O
syncytia	O
formation	O
and	O
production	B-Gene_expression
of	O
viral	O
p24	O
antigen	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Mitogen	O
stimulation	O
of	O
T	O
-	O
cells	O
increases	B-Positive_regulation
c	O
-	O
Fos	O
and	O
c	O
-	O
Jun	O
protein	O
levels	O
,	O
AP	O
-	O
1	O
binding	O
and	O
AP	O
-	O
1	O
transcriptional	O
activity	O
.	O

We	O
have	O
analysed	O
the	O
effect	B-Regulation
of	O
mitogenic	O
lectins	O
on	O
c	O
-	O
Fos	O
and	O
c	O
-	O
Jun	O
protein	O
levels	O
as	O
well	O
as	O
on	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
binding	O
and	O
enhancer	O
activity	O
in	O
Jurkat	O
T	O
-	O
cells	O
.	O

Both	O
c	O
-	O
Fos	O
and	O
c	O
-	O
Jun	O
protein	O
levels	O
were	O
increased	B-Positive_regulation
after	O
Con	O
A	O
and	O
PHA	O
stimulation	O
.	O

Since	O
T	O
-	O
cell	O
stimulation	O
increases	O
both	O
intracellular	O
Ca2+	O
and	O
cAMP	O
levels	O
and	O
activates	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
the	O
possible	O
involvement	B-Regulation
of	O
these	O
intracellular	O
messengers	O
in	O
c	O
-	O
Fos	O
and	O
c	O
-	O
Jun	O
induction	B-Positive_regulation
was	O
tested	O
.	O

PMA	O
,	O
which	O
directly	O
activates	B-Positive_regulation
PKC	O
,	O
mimicked	B-Positive_regulation
the	I-Positive_regulation
effect	I-Positive_regulation
of	I-Positive_regulation
the	I-Positive_regulation
lectins	I-Positive_regulation
on	O
c	O
-	O
Fos	O
and	O
c	O
-	O
Jun	O
,	O
but	O
elevation	O
of	O
either	O
intracellular	O
Ca2+	O
or	O
cAMP	O
levels	O
had	O
little	O
or	O
no	O
effect	B-Regulation
.	O

The	O
mitogen	O
-	O
induced	O
increase	B-Positive_regulation
of	O
c	O
-	O
Fos	O
and	O
c	O
-	O
Jun	O
immunoreactivity	B-Regulation
was	O
inhibited	B-Negative_regulation
by	O
H	O
-	O
7	O
,	O
a	O
kinase	O
inhibitor	B-Negative_regulation
with	O
relatively	O
high	O
specificity	O
for	O
PKC	O
,	O
and	O
less	O
efficiently	O
by	O
H	O
-	O
8	O
,	O
a	O
structurally	O
related	O
kinase	O
inhibitor	B-Negative_regulation
less	O
active	O
on	O
PKC	O
,	O
but	O
more	O
active	O
on	O
cyclic	O
nucleotide	O
-	O
dependent	O
kinases	O
.	O

Con	O
A	O
stimulation	O
was	O
found	O
to	O
increase	O
both	O
binding	O
of	O
AP	O
-	O
1	O
to	O
the	O
AP	O
-	O
1	O
consensus	O
sequence	O
,	O
TRE	O
,	O
and	O
AP	O
-	O
1	O
enhancer	O
activity	O
,	O
in	O
Jurkat	O
cells	O
.	O

PMA	O
was	O
also	O
found	O
to	O
increase	O
the	O
AP	O
-	O
1	O
enhancer	O
activity	O
,	O
whereas	O
elevation	O
of	O
Ca2+	O
or	O
cAMP	O
had	O
only	O
minor	O
effects	O
.	O

We	O
conclude	O
that	O
stimulation	O
with	O
mitogenic	O
lectins	O
is	O
sufficient	O
to	O
increase	B-Positive_regulation
both	O
c	O
-	O
Fos	O
and	O
c	O
-	O
Jun	O
protein	O
levels	O
,	O
AP	O
-	O
1	O
binding	O
and	O
AP	O
-	O
1	O
enhancer	O
activity	O
in	O
Jurkat	O
cells	O
and	O
that	O
they	O
act	O
via	O
mechanisms	O
that	O
could	O
involve	B-Regulation
the	O
activation	B-Positive_regulation
of	O
PKC	O
.	O

Okadaic	O
acid	O
is	O
a	O
potent	O
inducer	B-Positive_regulation
of	O
AP	O
-	O
1	O
,	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
in	O
human	O
B	O
lymphocytes	O
.	O

Treatment	O
of	O
human	O
B	O
lymphocytes	O
with	O
an	O
optimal	O
concentration	O
of	O
okadaic	O
acid	O
,	O
an	O
inhibitor	B-Negative_regulation
of	O
phosphatases	O
1	O
and	O
2A	O
,	O
resulted	O
in	O
the	O
induction	O
of	O
the	O
transcription	O
factor	O
,	O
AP	O
-	O
1	O
and	O
a	O
marked	O
increase	O
in	O
NF	O
-	O
kappa	O
B	O
levels	O
.	O

In	O
contrast	O
,	O
no	O
effect	B-Positive_regulation
on	O
the	O
levels	O
of	O
the	O
octamer	O
binding	O
proteins	O
,	O
Oct	O
-	O
1	O
or	O
Oct	O
-	O
2	O
,	O
were	O
found	O
.	O

Since	O
both	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
have	O
been	O
reported	O
to	O
be	O
important	B-Regulation
in	O
the	O
induction	B-Gene_expression
of	O
the	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
gene	O
we	O
examined	O
the	O
effects	B-Regulation
of	O
okadaic	O
acid	O
on	O
TNF	O
-	O
alpha	O
mRNA	O
levels	O
.	O

Treatment	O
with	O
okadaic	O
acid	O
resulted	O
in	O
a	O
striking	O
increase	B-Positive_regulation
in	O
TNF	O
-	O
alpha	O
mRNA	O
transcripts	O
within	O
1	O
h	O
of	O
stimulation	O
and	O
large	B-Positive_regulation
amounts	I-Positive_regulation
of	O
TNF	O
-	O
alpha	O
were	O
released	B-Localization
into	O
the	O
culture	O
media	O
.	O

Although	O
okadaic	O
acid	O
provides	O
a	O
potent	O
inductive	O
signal	O
for	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
it	O
did	O
not	O
induce	O
either	O
B	O
cell	O
proliferation	O
or	O
immunoglobulin	O
secretion	O
.	O

A	O
novel	O
Ets	O
-	O
related	O
transcription	O
factor	O
,	O
Elf	O
-	O
1	O
,	O
binds	B-Binding
to	O
human	O
immunodeficiency	O
virus	O
type	O
2	O
regulatory	O
elements	O
that	O
are	O
required	O
for	O
inducible	O
trans	O
activation	O
in	O
T	O
cells	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
and	O
HIV	O
-	O
2	O
are	O
structurally	O
related	O
retroviruses	O
which	O
both	O
cause	O
AIDS	O
in	O
humans	O
.	O

Although	O
both	O
viruses	O
establish	O
latency	O
in	O
quiescent	O
human-peripheral	O
-	O
blood	O
T	O
cells	O
,	O
the	O
asymptomatic	O
phase	O
of	O
HIV	O
-	O
2	O
infection	O
may	O
be	O
more	O
prolonged	O
than	O
that	O
of	O
HIV	O
-	O
1	O
.	O

The	O
latent	O
phases	O
of	O
both	O
HIV	O
-	O
1	O
and	O
HIV	O
-	O
2	O
infection	O
have	O
been	O
shown	O
to	O
be	O
disrupted	O
by	O
T	O
-	O
cell	O
activation	O
,	O
a	O
process	O
that	O
requires	O
host	O
cell	O
transcription	O
factors	O
.	O

In	O
the	O
case	O
of	O
HIV	O
-	O
1	O
,	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
is	O
sufficient	O
for	O
inducible	O
transcriptional	O
activation	O
.	O

In	O
contrast	O
,	O
factors	O
in	O
addition	O
to	O
NF	O
-	O
kappa	O
B	O
are	O
required	O
to	O
activate	O
HIV	O
-	O
2	O
transcription	O
in	O
infected	O
T	O
cells	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
a	O
novel	O
Ets	O
-	O
related	O
transcription	O
factor	O
,	O
Elf	O
-	O
1	O
,	O
binds	B-Binding
specifically	O
to	O
two	O
purine	O
-	O
rich	O
motifs	O
in	O
the	O
HIV	O
-	O
2	O
enhancer	O
.	O

Mutagenesis	O
experiments	O
demonstrated	O
that	O
these	O
Elf	O
-	O
1	O
binding	O
sites	O
are	O
required	O
for	O
induction	O
of	O
HIV	O
-	O
2	O
transcription	O
following	O
T-cell-receptor	O
-	O
mediated	O
T	O
-	O
cell	O
activation	O
.	O

Moreover	O
,	O
Elf	O
-	O
1	O
is	O
the	O
only	O
factor	O
present	O
in	O
activated	O
T	O
-	O
cell	O
nuclear	O
extracts	O
that	O
binds	B-Binding
to	O
these	O
sites	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

Thus	O
,	O
Elf	O
-	O
1	O
is	O
a	O
novel	O
transcription	O
factor	O
that	O
appears	O
to	O
be	O
required	O
for	O
the	O
T-cell-receptor	O
-	O
mediated	O
trans	O
activation	O
of	O
HIV	O
-	O
2	O
gene	O
expression	O
.	O

These	O
results	O
may	O
explain	O
differences	O
in	O
the	O
clinical	O
spectra	O
of	O
diseases	O
caused	O
by	O
HIV	O
-	O
1	O
and	O
HIV	O
-	O
2	O
and	O
may	O
also	O
have	O
implications	O
for	O
the	O
design	O
of	O
therapeutic	O
approaches	O
to	O
HIV	O
-	O
2	O
infection	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
Nef	O
protein	O
inhibits	O
NF	O
-	O
kappa	O
B	O
induction	O
in	O
human	O
T	O
cells	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
can	O
establish	O
a	O
persistent	O
and	O
latent	O
infection	O
in	O
CD4+	O
T	O
lymphocytes	O
(	O
W.C.Greene	O
,	O
N.Engl.J	O
.	O

Med.324	O
:	O
308	O
-	O
317	O
,	O
1991	O
;	O
S.M.Schnittman	O
,	O
M.C.Psallidopoulos	O
,	O
H.C	O
.	O

Lane	O
,	O
L.Thompson	O
,	O
M.Baseler	O
,	O
F.Massari	O
,	O
C.H.Fox	O
,	O
N.P.Salzman	O
,	O
and	O
A.S.Fauci	O
,	O
Science	O
245	O
:	O
305	O
-	O
308	O
,	O
1989	O
)	O
.	O

Production	O
of	O
HIV	O
-	O
1	O
from	O
latently	O
infected	O
cells	O
requires	O
host	O
cell	O
activation	O
by	O
T	O
-	O
cell	O
mitogens	O
(	O
T.Folks	O
,	O
D.M.Powell	O
,	O
M.M.Lightfoote	O
,	O
S.Benn	O
,	O
M.A	O
.	O

Martin	O
,	O
and	O
A.S.Fauci	O
,	O
Science	O
231	O
:	O
600	O
-	O
602	O
,	O
1986	O
;	O
D.Zagury	O
,	O
J.	O
Bernard	O
,	O
R.Leonard	O
,	O
R.Cheynier	O
,	O
M.Feldman	O
,	O
P.S.Sarin	O
,	O
and	O
R.C	O
.	O

Gallo	O
,	O
Science	O
231	O
:	O
850	O
-	O
853	O
,	O
1986	O
)	O
.	O

This	O
activation	O
is	O
mediated	O
by	O
the	O
host	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
[	O
G.Nabel	O
and	O
D.Baltimore	O
,	O
Nature	O
(	O
London	O
)	O
326	O
:	O
711	O
-	O
717	O
,	O
1987	O
]	O
.	O

We	O
report	O
here	O
that	O
the	O
HIV-1	O
-	O
encoded	O
Nef	O
protein	O
inhibits	O
the	O
induction	O
of	O
NF	O
-	O
kappa	O
B	O
DNA	O
-	O
binding	O
activity	O
by	O
T	O
-	O
cell	O
mitogens	O
.	O

However	O
,	O
Nef	O
does	O
not	O
affect	B-Regulation
the	O
DNA	O
-	O
binding	B-Binding
activity	O
of	O
other	O
transcription	O
factors	O
implicated	O
in	O
HIV	O
-	O
1	O
regulation	O
,	O
including	O
SP	O
-	O
1	O
,	O
USF	O
,	O
URS	O
,	O
and	O
NF	O
-	O
AT	O
.	O

Additionally	O
,	O
Nef	O
inhibits	O
the	O
induction	O
of	O
HIV-1	O
-	O
and	O
interleukin	O
2	O
-	O
directed	O
gene	O
expression	O
,	O
and	O
the	O
effect	O
on	O
HIV	O
-	O
1	O
transcription	O
depends	O
on	O
an	O
intact	O
NF	O
-	O
kappa	O
B	O
-	O
binding	O
site	O
.	O

These	O
results	O
indicate	O
that	O
defective	O
recruitment	O
of	O
NF	O
-	O
kappa	O
B	O
may	O
underlie	B-Positive_regulation
Nef	O
's	O
negative	B-Negative_regulation
transcriptional	I-Negative_regulation
effects	I-Negative_regulation
on	O
the	O
HIV	O
-	O
1	O
and	O
interleukin	O
2	O
promoters	O
.	O

Further	O
evidence	O
suggests	O
that	O
Nef	O
inhibits	O
NF	O
-	O
kappa	O
B	O
induction	O
by	O
interfering	O
with	O
a	O
signal	O
derived	O
from	O
the	O
T	O
-	O
cell	O
receptor	O
complex	O
.	O

A	O
novel	O
mitogen	O
-	O
inducible	O
gene	O
product	O
related	O
to	O
p50/p105-NF	O
-	O
kappa	O
B	O
participates	O
in	O
transactivation	O
through	O
a	O
kappa	O
B	O
site	O
.	O

A	O
Rel	O
-	O
related	O
,	O
mitogen	O
-	O
inducible	O
,	O
kappa	O
B	O
-	O
binding	O
protein	O
has	O
been	O
cloned	O
as	O
an	O
immediate	O
-	O
early	O
activation	O
gene	O
of	O
human	O
peripheral	O
blood	O
T	O
cells	O
.	O

The	O
cDNA	O
has	O
an	O
open	O
reading	O
frame	O
of	O
900	O
amino	O
acids	O
capable	O
of	O
encoding	O
a	O
97	O
-	O
kDa	O
protein	O
.	O

This	O
protein	O
is	O
most	O
similar	O
to	O
the	O
105	O
-	O
kDa	O
precursor	O
polypeptide	O
of	O
p50-NF	O
-	O
kappa	O
B	O
.	O

Like	O
the	O
105	O
-	O
kDa	O
precursor	O
,	O
it	O
contains	O
an	O
amino	O
-	O
terminal	O
Rel	O
-	O
related	O
domain	O
of	O
about	O
300	O
amino	O
acids	O
and	O
a	O
carboxy	O
-	O
terminal	O
domain	O
containing	O
six	O
full	O
cell	O
cycle	O
or	O
ankyrin	O
repeats	O
.	O

In	O
vitro	O
-	O
translated	O
proteins	O
,	O
truncated	O
downstream	O
of	O
the	O
Rel	O
domain	O
and	O
excluding	O
the	O
repeats	O
,	O
bind	O
kappa	O
B	O
sites	O
.	O

We	O
refer	O
to	O
the	O
kappa	O
B	O
-	O
binding	B-Binding
,	O
truncated	O
protein	O
as	O
p50B	O
by	O
analogy	O
with	O
p50-NF	O
-	O
kappa	O
B	O
and	O
to	O
the	O
full	O
-	O
length	O
protein	O
as	O
p97	O
.	O

p50B	O
is	O
able	O
to	O
form	O
heteromeric	O
kappa	O
B	O
-	O
binding	B-Binding
complexes	B-Binding
with	O
RelB	O
,	O
as	O
well	O
as	O
with	O
p65	O
and	O
p50	O
,	O
the	O
two	O
subunits	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Transient	O
-	O
transfection	O
experiments	O
in	O
embryonal	O
carcinoma	O
cells	O
demonstrate	O
a	O
functional	O
cooperation	O
between	O
p50B	O
and	O
RelB	O
or	O
p65	O
in	O
transactivation	O
of	O
a	O
reporter	O
plasmid	O
dependent	O
on	O
a	O
kappa	O
B	O
site	O
.	O

The	O
data	O
imply	O
the	O
existence	O
of	O
a	O
complex	O
family	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
transcription	O
factors	O
.	O

Transcriptional	B-Transcription
regulation	B-Regulation
during	O
T	O
-	O
cell	O
development	O
:	O
the	O
alpha	O
TCR	O
gene	O
as	O
a	O
molecular	O
model	O
.	O

The	O
regulation	O
of	O
gene	O
expression	O
during	O
lymphocyte	O
differentiation	O
is	O
a	O
complex	O
process	O
involving	O
interactions	O
between	O
multiple	O
positive	O
and	O
negative	O
transcriptional	O
regulatory	O
elements	O
.	O

In	O
this	O
article	O
,	O
transcriptional	B-Regulation
regulation	I-Regulation
of	O
the	O
archetypal	O
T-cell	O
-	O
specific	O
gene	O
,	O
alpha	O
TCR	O
,	O
is	O
discussed	O
.	O

Major	O
recent	O
developments	O
,	O
including	O
the	O
identification	O
of	O
novel	O
families	O
of	O
transcription	O
factors	O
that	O
regulate	O
multiple	O
T	O
-	O
cell	O
genes	O
during	O
thymocyte	O
ontogeny	O
and	O
T	O
-	O
cell	O
activation	O
,	O
are	O
described	O
.	O

An	O
11-base	O
-	O
pair	O
DNA	O
sequence	O
motif	O
apparently	O
unique	O
to	O
the	O
human	O
interleukin	O
4	O
gene	O
confers	O
responsiveness	O
to	O
T	O
-	O
cell	O
activation	O
signals	O
.	O

We	O
have	O
identified	O
a	O
DNA	O
segment	O
that	O
confers	B-Positive_regulation
responsiveness	B-Regulation
to	O
antigen	O
stimulation	O
signals	O
on	O
the	O
human	O
interleukin	O
(	O
IL	O
)	O
4	O
gene	O
in	O
Jurkat	O
cells	O
.	O

The	O
human	O
IL	O
-	O
4	O
gene	O
,	O
of	O
10	O
kilobases	O
,	O
is	O
composed	O
of	O
four	O
exons	O
and	O
three	O
introns	O
.	O

A	O
cis	O
-	O
acting	O
element	O
(	O
P	O
sequence	O
)	O
resides	O
in	O
the	O
5	O
'	O
upstream	O
region	O
;	O
no	O
additional	O
DNA	O
segments	O
with	O
enhancer	O
activity	O
were	O
identified	O
in	O
the	O
human	O
IL	O
-	O
4	O
gene	O
.	O

For	O
further	O
mapping	O
purposes	O
,	O
a	O
fusion	O
promoter	O
was	O
constructed	O
with	O
the	O
granulocyte/macrophage	O
colony	O
-	O
stimulating	O
factor	O
basic	O
promoter	O
containing	O
60	O
base	O
pairs	O
of	O
sequence	O
upstream	O
from	O
the	O
cap	O
site	O
of	O
the	O
mouse	O
granulocyte/macrophage	O
colony	O
-	O
stimulating	O
factor	O
gene	O
and	O
various	O
lengths	O
of	O
the	O
5	O
'	O
upstream	O
sequence	O
of	O
the	O
IL	O
-	O
4	O
gene	O
.	O

The	O
P	O
sequence	O
was	O
located	O
between	O
positions	O
-	O
79	O
and	O
-	O
69	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
of	O
the	O
human	O
IL	O
-	O
4	O
gene	O
,	O
and	O
this	O
location	O
was	O
confirmed	O
by	O
base	O
-	O
substitution	O
mutations	O
.	O

The	O
plasmids	O
carrying	O
multiple	O
copies	O
of	O
the	O
P	O
sequence	O
showed	O
higher	O
responsiveness	O
to	O
the	O
stimulation	O
.	O

The	O
binding	O
protein	O
(	O
s	O
)	O
that	O
recognize	B-Binding
the	O
P	O
sequence	O
of	O
the	O
IL	O
-	O
4	O
gene	O
were	O
identified	O
by	O
DNA-mobility	O
-	O
shift	O
assays	O
.	O

The	O
binding	O
of	O
NF	O
(	O
P	O
)	O
(	O
a	O
DNA	O
binding	O
protein	O
that	O
specifically	O
recognizes	O
the	O
P	O
sequence	O
)	O
to	O
the	O
P	O
sequence	O
was	O
abolished	O
when	O
oligonucleotides	O
carrying	O
base	O
substitutions	O
were	O
used	O
,	O
indicating	O
that	O
the	O
NF	O
(	O
P	O
)	O
interaction	O
is	O
sequence	O
-	O
specific	O
and	O
that	O
binding	O
specificity	O
of	O
the	O
protein	O
paralleled	O
the	O
sequence	O
requirements	B-Positive_regulation
for	O
IL	O
-	O
4	O
expression	B-Gene_expression
in	O
vivo	O
.	O

The	O
P	O
sequence	O
does	O
not	O
share	O
homology	O
with	O
the	O
5	O
'	O
upstream	O
sequence	O
of	O
the	O
IL	O
-	O
2	O
gene	O
,	O
even	O
though	O
surrounding	O
sequences	O
of	O
the	O
IL	O
-	O
4	O
gene	O
share	O
high	O
homology	O
with	O
the	O
IL	O
-	O
2	O
gene	O
.	O

We	O
conclude	O
that	O
a	O
different	O
set	O
of	O
proteins	O
recognize	B-Binding
IL	O
-	O
2	O
and	O
IL	O
-	O
4	O
genes	O
.	O

Activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
enhancer	O
is	O
not	O
dependent	O
on	O
NFAT	O
-	O
1	O
.	O

The	O
function	O
of	O
a	O
putative	O
NFAT	O
-	O
1	O
site	O
in	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
enhancer	O
has	O
been	O
analyzed	O
.	O

Activation	O
by	O
the	O
T	O
-	O
cell	O
antigen	O
receptor	O
is	O
minimal	O
in	O
Jurkat	O
cells	O
and	O
is	O
mediated	O
by	O
the	O
kappa	O
B	O
sites	O
.	O

The	O
putative	O
NFAT	O
-	O
1	O
region	O
is	O
not	O
required	O
for	O
the	O
response	O
to	O
anti	O
-	O
CD3	O
or	O
to	O
mitogens	O
in	O
T	O
-	O
cell	O
,	O
B	O
-	O
cell	O
,	O
or	O
monocyte/macrophage	O
leukemia	O
lines	O
,	O
nor	O
is	O
it	O
a	O
cis	O
-	O
acting	O
negative	O
regulatory	O
element	O
.	O

Interleukin	O
6	O
-	O
induced	O
differentiation	O
of	O
a	O
human	O
B	O
cell	O
line	O
into	O
IgM	O
-	O
secreting	O
plasma	O
cells	O
is	O
mediated	O
by	O
c	O
-	O
fos	O
.	O

The	O
role	O
of	O
the	O
protooncogene	O
c	O
-	O
fos	O
in	O
interleukin	O
(	O
IL	O
)	O
6	O
-	O
induced	O
B	O
cell	O
differentiation	O
was	O
assessed	O
.	O

Treatment	O
of	O
SKW	O
6.4	O
cells	O
with	O
IL	O
6	O
induced	O
a	O
transient	O
and	O
early	O
stimulation	B-Positive_regulation
of	O
c	O
-	O
fos	O
sense	O
mRNA	O
expression	B-Transcription
.	O

The	O
effect	O
appeared	B-Positive_regulation
within	O
30	O
min	O
and	O
returned	B-Negative_regulation
to	O
basal	O
levels	O
after	O
2	O
h	O
.	O

The	O
addition	O
of	O
antisense	O
oligonucleotides	O
to	O
c	O
-	O
fos	O
significantly	O
inhibited	O
IL	O
6	O
-	O
induced	O
IgM	O
production	O
by	O
SKW	O
6.4	O
cells	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
whereas	O
control	O
oligonucleotides	O
had	O
no	O
inhibitory	O
effect	O
.	O

These	O
results	O
indicate	O
that	O
activation	B-Positive_regulation
of	O
c	O
-	O
fos	O
is	O
involved	O
in	O
IL	O
6	O
-	O
induced	O
differentiation	O
of	O
SKW	O
6.4	O
cells	O
into	O
IgM	O
-	O
secreting	O
cells	O
.	O

Binding	O
of	O
erythroid	O
and	O
non	O
-	O
erythroid	O
nuclear	O
proteins	O
to	O
the	O
silencer	O
of	O
the	O
human	O
epsilon-globin	O
-	O
encoding	O
gene	O
.	O

To	O
clarify	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
developmental	O
control	O
of	O
hemoglobin	O
-	O
encoding	O
genes	O
we	O
have	O
been	O
studying	O
the	O
expression	O
of	O
these	O
genes	O
in	O
human	O
cells	O
in	O
continuous	O
culture	O
.	O

We	O
have	O
previously	O
reported	O
the	O
presence	O
of	O
a	O
transcriptional	O
control	O
element	O
with	O
the	O
properties	O
of	O
a	O
silencer	O
extending	O
from	O
-	O
392	O
to	O
-	O
177	O
bp	O
relative	O
to	O
the	O
cap	O
site	O
of	O
the	O
human	O
epsilon-globin	O
-	O
encoding	O
gene	O
[	O
Cao	O
et	O
al.	O
,	O
Proc.Natl.Acad.Sci.USA	O
86	O
(	O
1989	O
)	O
5306	O
-	O
5309	O
]	O
.	O

We	O
also	O
showed	O
that	O
this	O
silencer	O
has	O
stronger	O
inhibitory	O
activity	O
in	O
HeLa	O
cells	O
,	O
as	O
compared	O
to	O
K562	O
human	O
erythroleukemia	O
cells	O
.	O

Using	O
deletion	O
mutants	O
and	O
cis	O
-	O
cloned	O
synthetic	O
oligodeoxyribonucleotides	O
in	O
transient	O
expression	O
assays	O
,	O
nucleotide	O
sequences	O
responsible	O
for	O
this	O
effect	O
have	O
now	O
been	O
further	O
delimited	O
to	O
44	O
bp	O
located	O
from	O
-	O
294	O
to	O
-	O
251	O
bp	O
.	O

Gel	O
electrophoresis	O
mobility	O
shift	O
assays	O
and	O
DNaseI	O
footprinting	O
assays	O
demonstrate	O
that	O
these	O
negative	O
regulatory	O
sequences	O
are	O
recognized	O
differently	O
by	O
proteins	O
present	O
in	O
nuclear	O
extracts	O
obtained	O
from	O
HeLa	O
and	O
K562	O
cells	O
.	O

Two	O
binding	O
proteins	O
are	O
detected	O
in	O
K562	O
nuclear	O
extracts	O
,	O
while	O
only	O
one	O
is	O
found	O
in	O
extracts	O
from	O
HeLa	O
cells	O
.	O

Possible	O
mechanisms	O
by	O
which	O
these	O
proteins	O
may	O
regulate	B-Regulation
transcription	B-Transcription
of	O
the	O
epsilon-globin	O
-	O
encoding	O
gene	O
in	O
erythroid	O
and	O
non	O
-	O
erythroid	O
cells	O
are	O
discussed	O
.	O

T	O
cell	O
-	O
specific	O
negative	B-Negative_regulation
regulation	I-Negative_regulation
of	O
transcription	B-Transcription
of	O
the	O
human	O
cytokine	O
IL	O
-	O
4	O
.	O

IL	O
-	O
4	O
secreted	B-Localization
by	O
activated	O
T	O
cells	O
is	O
a	O
pleiotropic	O
cytokine	O
affecting	O
growth	O
and	O
differentiation	O
of	O
diverse	O
cell	O
types	O
such	O
as	O
T	O
cells	O
,	O
B	O
cells	O
,	O
and	O
mast	O
cells	O
.	O

We	O
investigated	O
the	O
upstream	O
regulatory	O
elements	O
of	O
the	O
human	O
IL	O
-	O
4	O
promoter	O
.	O

A	O
novel	O
T	O
cell	O
-	O
specific	O
negative	O
regulatory	O
element	O
(	O
NRE	O
)	O
composed	O
of	O
two	O
protein	O
-	O
binding	O
sites	O
were	O
mapped	O
in	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
IL	O
-	O
4	O
gene	O
:	O
-311CTCCCTTCT	O
-	O
303	O
(	O
NRE	O
-	O
I	O
)	O
and	O
-288CTTTTTGCTT-TGC	O
-	O
300	O
(	O
NRE	O
-	O
II	O
)	O
.	O

A	O
T	O
cell	O
-	O
specific	O
protein	O
Neg	O
-	O
1	O
and	O
a	O
ubiquitous	O
protein	O
Neg	O
-	O
2	O
binding	B-Binding
to	O
NRE	O
-	O
I	O
and	O
NRE	O
-	O
II	O
,	O
respectively	O
,	O
were	O
identified	O
.	O

Furthermore	O
,	O
a	O
positive	O
regulatory	O
element	O
was	O
found	O
45	O
bp	O
downstream	O
of	O
the	O
NRE	O
.	O

The	O
enhancer	O
activity	O
of	O
the	O
PRE	O
was	O
completely	O
suppressed	O
when	O
the	O
NRE	O
was	O
present	O
.	O

These	O
data	O
suggest	O
that	O
IL	O
-	O
4	O
promoter	O
activity	O
is	O
normally	O
down	B-Negative_regulation
-	I-Negative_regulation
regulated	I-Negative_regulation
by	O
an	O
NRE	O
via	O
repression	O
of	O
the	O
enhancer	O
positive	O
regulatory	O
element	O
.	O

These	O
data	O
may	O
have	O
implications	O
for	O
the	O
stringent	O
control	B-Regulation
of	O
IL	O
-	O
4	O
expression	B-Gene_expression
in	O
T	O
cells	O
.	O

Human	O
T	O
cell	O
activation	O
through	O
the	O
activation	O
-	O
inducer	O
molecule/CD69	O
enhances	O
the	O
activity	O
of	O
transcription	O
factor	O
AP	O
-	O
1	O
.	O

The	O
induction	O
of	O
the	O
AP	O
-	O
1	O
transcription	O
factor	O
has	O
been	O
ascribed	O
to	O
the	O
early	O
events	O
leading	O
to	O
T	O
cell	O
differentiation	O
and	O
activation	O
.	O

We	O
have	O
studied	O
the	O
regulation	O
of	O
AP	O
-	O
1	O
activity	O
in	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
stimulated	O
through	O
the	O
activation	O
inducer	O
molecule	O
(	O
AIM	O
)	O
/CD69	O
activation	O
pathway	O
.	O

Phorbol	O
esters	O
are	O
required	B-Positive_regulation
to	I-Positive_regulation
induce	I-Positive_regulation
AIM/CD69	O
cell	O
-	O
surface	O
expression	B-Localization
as	O
well	O
as	O
for	O
triggering	O
the	O
proliferation	O
of	O
T	O
cells	O
in	O
conjunction	O
with	O
anti	O
-	O
AIM	O
mAb	O
.	O

Mobility	O
shift	O
assays	O
showed	O
that	O
addition	O
of	O
anti	O
-	O
AIM	O
mAb	O
to	O
PMA	O
-	O
treated	O
T	O
lymphocytes	O
markedly	O
enhanced	O
the	O
binding	O
activity	O
of	O
AP	O
-	O
1	O
to	O
its	O
cognate	O
sequence	O
,	O
the	O
phorbol	O
ester	O
response	O
element	O
.	O

In	O
contrast	O
,	O
anti	O
-	O
AIM	O
mAb	O
did	O
not	O
induce	O
any	O
change	O
in	O
the	O
binding	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
a	O
transcription	O
factor	O
whose	O
activity	O
is	O
also	O
regulated	O
by	O
protein	O
kinase	O
C	O
.	O

The	O
increase	O
in	O
AP-1	O
-	O
binding	O
activity	O
was	O
accompanied	O
by	O
the	O
marked	O
stimulation	B-Positive_regulation
of	O
the	O
transcription	B-Transcription
of	O
c	O
-	O
fos	O
but	O
not	O
that	O
of	O
c	O
-	O
jun	O
.	O

Blockade	O
of	O
the	O
DNA	O
-	O
binding	O
complexes	O
with	O
an	O
anti	O
-	O
Fos	O
mAb	O
demonstrated	O
a	O
direct	O
participation	B-Binding
of	O
c	O
-	O
Fos	O
in	O
the	O
AP	O
-	O
1	O
complexes	O
induced	B-Positive_regulation
by	O
anti	O
-	O
AIM	O
mAb	O
.	O

Most	O
of	O
the	O
AP	O
-	O
1	O
activity	O
could	O
be	O
eliminated	O
when	O
the	O
anti	O
-	O
AIM	O
mAb	O
was	O
added	O
to	O
the	O
culture	O
medium	O
in	O
the	O
presence	O
of	O
cycloheximide	O
,	O
suggesting	O
that	O
de	O
novo	O
protein	O
synthesis	O
is	O
crucial	O
for	O
the	O
induction	O
of	O
AP-1	O
-	O
binding	O
activity	O
.	O

These	O
data	O
provide	O
the	O
evidence	O
that	O
activation	O
of	O
human	O
peripheral	O
blood	O
T	O
cells	O
through	O
the	O
AIM	O
activation	O
pathway	O
regulate	O
the	O
activity	O
of	O
AP	O
-	O
1	O
.	O

Therefore	O
,	O
this	O
pathway	O
appears	O
as	O
a	O
crucial	O
step	O
in	O
the	O
initiation	O
of	O
early	O
T	O
cell	O
activation	O
events	O
.	O

The	O
B	O
cell	O
-	O
specific	O
nuclear	O
factor	O
OTF	O
-	O
2	O
positively	B-Positive_regulation
regulates	I-Positive_regulation
transcription	B-Transcription
of	O
the	O
human	O
class	O
II	O
transplantation	O
gene	O
,	O
DRA	O
.	O

The	O
promoter	O
of	O
the	O
major	O
histocompatibility	O
class	O
II	O
gene	O
DRA	O
contains	O
an	O
octamer	O
element	O
(	O
ATTTGCAT	O
)	O
that	O
is	O
required	B-Positive_regulation
for	O
efficient	O
DRA	O
expression	B-Gene_expression
in	O
B	O
cells	O
.	O

Several	O
DNA	O
-	O
binding	O
proteins	O
are	O
known	O
to	O
bind	B-Binding
this	O
sequence	O
.	O

The	O
best	O
characterized	O
are	O
the	O
B	O
cell	O
-	O
specific	O
OTF	O
-	O
2	O
and	O
the	O
ubiquitous	O
OTF	O
-	O
1	O
.	O

This	O
report	O
directly	O
demonstrates	O
that	O
OTF	O
-	O
2	O
but	O
not	O
OTF	O
-	O
1	O
regulates	B-Regulation
the	O
DRA	O
gene	O
.	O

In	O
vitro	O
transcription	O
analysis	O
using	O
protein	O
fractions	O
enriched	O
for	O
the	O
octamer	O
-	O
binding	O
protein	O
OTF	O
-	O
2	O
demonstrate	O
a	O
positive	O
functional	O
role	B-Positive_regulation
for	O
OTF	O
-	O
2	O
in	O
DRA	O
gene	O
transcription	B-Transcription
.	O

In	O
contrast	O
,	O
OTF-1	O
-	O
enriched	O
protein	O
fractions	O
did	O
not	O
affect	B-Regulation
DRA	O
gene	O
transcription	B-Transcription
although	O
it	O
functionally	O
enhanced	O
the	O
transcription	O
of	O
another	O
gene	O
.	O

Recombinant	O
OTF	O
-	O
2	O
protein	O
produced	O
by	O
in	O
vitro	O
transcription/translation	O
could	O
also	O
enhance	B-Positive_regulation
DRA	O
gene	O
transcription	B-Transcription
in	O
vitro	O
.	O

In	O
vivo	O
transient	O
transfection	O
studies	O
utilizing	O
an	O
OTF	O
-	O
2	O
expression	O
vector	O
resulted	O
in	O
similar	O
findings	O
:	O
that	O
OTF	O
-	O
2	O
protein	O
enhanced	B-Positive_regulation
DRA	O
gene	O
transcription	B-Transcription
,	O
and	O
that	O
this	O
effect	O
requires	B-Positive_regulation
an	O
intact	O
octamer	O
element	O
.	O

Together	O
these	O
results	O
constitute	O
the	O
first	O
direct	O
evidence	O
of	O
a	O
positive	B-Positive_regulation
role	I-Positive_regulation
for	O
the	O
lymphoid	O
-	O
specific	O
octamer	O
-	O
binding	O
factor	O
in	O
DRA	O
gene	O
transcription	B-Transcription
.	O

Specific	O
NF	O
-	O
kappa	O
B	O
subunits	O
act	O
in	O
concert	O
with	O
Tat	O
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
a	O
protein	O
complex	O
which	O
functions	O
in	O
concert	O
with	O
the	O
tat	O
-	O
I	O
gene	O
product	O
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
transcription	O
.	O

To	O
determine	O
whether	O
specific	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
family	O
contribute	O
to	O
this	O
effect	O
,	O
we	O
have	O
examined	O
the	O
abilities	O
of	O
different	O
NF	O
-	O
kappa	O
B	O
subunits	O
to	O
act	O
with	O
Tat	O
-	O
I	O
to	O
stimulate	O
transcription	O
of	O
HIV	O
in	O
Jurkat	O
T	O
-	O
leukemia	O
cells	O
.	O

We	O
have	O
found	O
that	O
the	O
p49	O
(	O
100	O
)	O
DNA	O
binding	B-Binding
subunit	I-Binding
,	O
together	O
with	O
p65	O
,	O
can	O
act	O
in	O
concert	O
with	O
Tat	O
-	O
I	O
to	O
stimulate	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
HIV	O
-	O
CAT	O
plasmid	O
.	O

Little	O
effect	B-Positive_regulation
was	O
observed	O
with	O
50	O
-	O
kDa	O
forms	O
of	O
p105	O
NF	O
-	O
kappa	O
B	O
or	O
rel	O
,	O
in	O
combination	O
with	O
p65	O
or	O
full	O
-	O
length	O
c	O
-	O
rel	O
,	O
which	O
do	O
not	O
stimulate	O
the	O
HIV	O
enhancer	O
in	O
these	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
combination	O
of	O
p49	O
(	O
100	O
)	O
and	O
p65	O
NF	O
-	O
kappa	O
B	O
can	O
act	O
in	O
concert	O
with	O
the	O
tat	O
-	O
I	O
gene	O
product	O
to	O
stimulate	O
the	O
synthesis	O
of	O
HIV	O
RNA	O
.	O

Heterodimerization	O
and	O
transcriptional	O
activation	O
in	O
vitro	O
by	O
NF	O
-	O
kappa	O
B	O
proteins	O
.	O

The	O
NF	O
-	O
kappa	O
B	O
family	O
of	O
transcription	O
proteins	O
represents	O
multiple	O
DNA	O
binding	O
,	O
rel	O
related	O
polypeptides	O
that	O
contribute	O
to	O
regulation	O
of	O
genes	O
involved	O
in	O
immune	O
responsiveness	O
and	O
inflammation	O
,	O
as	O
well	O
as	O
activation	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
.	O

In	O
this	O
study	O
multiple	O
NF	O
-	O
kappa	O
B	O
related	O
polypeptides	O
ranging	O
from	O
85	O
to	O
45	O
kDa	O
were	O
examined	O
for	O
their	O
capacity	O
to	O
interact	O
with	O
the	O
PRDII	O
regulatory	O
element	O
of	O
interferon	O
beta	O
and	O
were	O
shown	O
to	O
possess	O
distinct	O
intrinsic	O
DNA	O
binding	O
affinities	O
for	O
this	O
NF	O
-	O
kappa	O
B	O
site	O
and	O
form	O
multiple	O
DNA	O
binding	O
homo	O
-	O
and	O
heterodimer	O
complexes	O
in	O
co	O
-	O
renaturation	O
experiments	O
.	O

Furthermore	O
,	O
using	O
DNA	O
templates	O
containing	O
two	O
copies	O
of	O
the	O
PRDII	O
domain	O
linked	O
to	O
the	O
rabbit	O
beta	O
globin	O
gene	O
,	O
the	O
purified	O
polypeptides	O
specifically	O
stimulated	O
NF	O
-	O
kappa	O
B	O
dependent	O
transcription	O
in	O
an	O
in	O
vitro	O
reconstitution	O
assay	O
as	O
heterodimers	O
but	O
not	O
as	O
p50	O
homodimers	O
.	O

These	O
experiments	O
emphasize	O
the	O
role	O
of	O
NF	O
-	O
kappa	O
B	O
dimerization	O
as	O
a	O
distinct	O
level	O
of	O
transcriptional	O
control	O
that	O
may	O
permit	O
functional	O
diversification	O
of	O
a	O
limited	O
number	O
of	O
regulatory	O
proteins	O
.	O

Oct2	O
transactivation	O
from	O
a	O
remote	O
enhancer	O
position	O
requires	O
a	O
B-cell	O
-	O
restricted	O
activity	O
.	O

Previous	O
cotransfection	O
experiments	O
had	O
demonstrated	O
that	O
ectopic	O
expression	B-Gene_expression
of	O
the	O
lymphocyte	O
-	O
specific	O
transcription	O
factor	O
Oct2	O
could	O
efficiently	O
activate	O
a	O
promoter	O
containing	O
an	O
octamer	O
motif	O
.	O

Oct2	O
expression	B-Gene_expression
was	O
unable	O
to	O
stimulate	O
a	O
multimerized	O
octamer	O
enhancer	O
element	O
in	O
HeLa	O
cells	O
,	O
however	O
.	O

We	O
have	O
tested	O
a	O
variety	O
of	O
Oct2	O
isoforms	O
generated	B-Positive_regulation
by	O
alternative	O
splicing	O
for	O
the	O
capability	O
to	O
activate	O
an	O
octamer	O
enhancer	O
in	O
nonlymphoid	O
cells	O
and	O
a	O
B	O
-	O
cell	O
line	O
.	O

Our	O
analyses	O
show	O
that	O
several	O
Oct2	O
isoforms	O
can	O
stimulate	O
from	O
a	O
remote	O
position	O
but	O
that	O
this	O
stimulation	O
is	O
restricted	O
to	O
B	O
cells	O
.	O

This	O
result	O
indicates	O
the	O
involvement	O
of	O
either	O
a	O
B-cell	O
-	O
specific	O
cofactor	O
or	O
a	O
specific	O
modification	O
of	O
a	O
cofactor	O
or	O
the	O
Oct2	O
protein	O
in	O
Oct2	O
-	O
mediated	O
enhancer	O
activation	O
.	O

Mutational	O
analyses	O
indicate	O
that	O
the	O
carboxy	O
-	O
terminal	O
domain	O
of	O
Oct2	O
is	O
critical	O
for	O
enhancer	O
activation	O
.	O

Moreover	O
,	O
this	O
domain	O
conferred	O
enhancing	O
activity	O
when	O
fused	O
to	O
the	O
Oct1	O
protein	O
,	O
which	O
by	O
itself	O
was	O
unable	O
to	O
stimulate	O
from	O
a	O
remote	O
position	O
.	O

The	O
glutamine	O
-	O
rich	O
activation	O
domain	O
present	O
in	O
the	O
amino	O
-	O
terminal	O
portion	O
of	O
Oct2	O
and	O
the	O
POU	O
domain	O
contribute	O
only	O
marginally	O
to	O
the	O
transactivation	O
function	O
from	O
a	O
distal	O
position	O
.	O

Transcription	O
factor	O
AP	O
-	O
2	O
activates	O
gene	O
expression	O
of	O
HTLV	O
-	O
I	O
.	O

The	O
HTLV	O
-	O
I	O
LTR	O
contains	O
three	O
conserved	O
regulatory	O
elements	O
known	O
as	O
21	O
base	O
pair	O
repeats	O
which	O
are	O
required	O
for	O
stimulation	O
of	O
gene	O
expression	O
by	O
the	O
transactivator	O
protein	O
tax	O
.	O

Mutagenesis	O
indicates	O
that	O
the	O
21	O
bp	O
repeats	O
can	O
be	O
subdivided	O
into	O
three	O
motifs	O
,	O
A	O
,	O
B	O
and	O
C	O
,	O
each	O
of	O
which	O
influences	B-Regulation
the	I-Regulation
level	I-Regulation
of	O
tax	O
activation	B-Positive_regulation
.	O

The	O
A	O
site	O
in	O
the	O
21	O
bp	O
repeat	O
has	O
strong	O
homology	O
with	O
previously	O
described	O
binding	O
sites	O
for	O
the	O
transcription	O
factor	O
AP	O
-	O
2	O
.	O

We	O
demonstrated	O
that	O
AP	O
-	O
2	O
mRNA	O
was	O
present	O
in	O
T	O
-	O
lymphocytes	O
and	O
that	O
cellular	O
factors	O
from	O
both	O
non	O
-	O
transformed	O
and	O
transformed	O
T	O
-	O
lymphocytes	O
specifically	O
bound	O
to	O
the	O
consensus	O
motif	O
for	O
AP	O
-	O
2	O
in	O
each	O
21	O
bp	O
.	O

To	O
determine	O
the	O
role	O
of	O
AP	O
-	O
2	O
in	O
the	O
regulation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
gene	O
expression	O
,	O
we	O
used	O
an	O
AP	O
-	O
2	O
cDNA	O
in	O
DNA	O
binding	O
and	O
transient	O
expression	O
assays	O
.	O

Gel	O
retardation	O
and	O
methylation	O
interference	O
studies	O
revealed	O
that	O
bacterially	O
produced	O
AP	O
-	O
2	O
bound	O
specifically	O
and	O
with	O
high	O
affinity	O
to	O
all	O
three	O
21	O
bp	O
repeats	O
,	O
and	O
that	O
it	O
required	O
the	O
core	O
sequence	O
AGGC	O
for	O
specific	O
binding	O
.	O

Binding	O
of	O
AP	O
-	O
2	O
prevented	O
the	O
subsequent	O
binding	O
of	O
members	O
of	O
the	O
CREB/ATF	O
family	O
to	O
an	O
adjacent	O
regulatory	O
motif	O
in	O
the	O
21	O
bp	O
repeat	O
.	O

Transfection	O
of	O
an	O
AP	O
-	O
2	O
expression	O
construct	O
into	O
T	O
-	O
lymphocytes	O
activated	O
gene	O
expression	O
from	O
the	O
HTLV	O
-	O
I	O
LTR	O
.	O

At	O
least	O
two	O
21	O
bp	O
repeats	O
were	O
required	O
for	O
high	O
levels	O
of	O
AP	O
-	O
2	O
activation	O
and	O
mutagenesis	O
of	O
the	O
AP	O
-	O
2	O
consensus	O
binding	O
sequences	O
in	O
the	O
21	O
bp	O
repeats	O
eliminate	O
this	O
activation	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
human	O
myelomonocytic	O
cell	O
line	O
U	O
-	O
937	O
as	O
a	O
model	O
for	O
studying	O
alterations	O
in	O
steroid	O
-	O
induced	O
monokine	O
gene	O
expression	O
:	O
marked	O
enhancement	B-Positive_regulation
of	O
lipopolysaccharide	O
-	O
stimulated	B-Positive_regulation
interleukin	O
-	O
1	O
beta	O
messenger	O
RNA	O
levels	B-Transcription
by	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
.	O

The	O
active	O
metabolite	O
of	O
vitamin	O
D	O
,	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
]	O
,	O
is	O
a	O
potent	O
regulator	O
of	O
human	O
monocyte/macrophage	O
function	O
in	O
vitro	O
.	O

To	O
establish	O
a	O
model	O
for	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
regulation	O
of	O
human	O
monocyte	O
monokine	O
synthesis	O
,	O
three	O
human	O
cell	O
lines	O
(	O
U	O
-	O
937	O
,	O
THP	O
-	O
1	O
,	O
and	O
HL	O
-	O
60	O
)	O
were	O
examined	O
for	O
:	O
1	O
)	O
the	O
presence	O
of	O
functional	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
receptors	O
;	O
2	O
)	O
the	O
accumulation	B-Positive_regulation
of	O
interleukin	O
-	O
1	O
beta	O
(	O
IL	O
-	O
1	O
beta	O
)	O
mRNA	O
and	O
IL	O
-	O
1	O
beta	O
protein	O
in	O
response	O
to	O
lipopolysaccharide	O
(	O
LPS	O
)	O
;	O
and	O
3	O
)	O
the	O
regulation	B-Regulation
of	O
this	O
response	O
by	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
.	O

All	O
three	O
cell	O
lines	O
expressed	B-Gene_expression
vitamin	O
D	O
receptor	O
and	O
had	O
increased	B-Positive_regulation
levels	O
of	O
IL	O
-	O
1	O
beta	O
mRNA	O
in	O
response	O
to	O
LPS	O
.	O

Preincubation	O
of	O
cells	O
with	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
augmented	B-Positive_regulation
IL	O
-	O
1	O
beta	O
mRNA	O
levels	O
only	O
in	O
U	O
-	O
937	O
and	O
HL	O
-	O
60	O
cells	O
.	O

From	O
these	O
data	O
,	O
and	O
taking	O
into	O
consideration	O
their	O
state	O
of	O
differentiation	O
and	O
relative	O
ease	O
of	O
culture	O
,	O
U	O
-	O
937	O
was	O
chosen	O
over	O
HL	O
-	O
60	O
and	O
THP	O
-	O
1	O
as	O
the	O
cell	O
line	O
we	O
further	O
characterized	O
.	O

In	O
U	O
-	O
937	O
cells	O
,	O
optimum	O
time	O
and	O
dose	O
of	O
pretreatment	O
with	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
were	O
determined	O
to	O
be	O
12	O
-	O
24	O
h	O
at	O
a	O
receptor	O
saturating	O
concentration	O
of	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
(	O
10	O
nM	O
)	O
.	O

Preincubation	O
of	O
cells	O
with	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
had	O
no	O
effect	B-Regulation
on	O
the	O
time	O
course	O
of	O
IL	O
-	O
1	O
beta	O
mRNA	O
appearance	B-Transcription
in	B-Positive_regulation
response	I-Positive_regulation
to	I-Positive_regulation
LPS	O
.	O

However	O
,	O
exposure	O
of	O
U	O
-	O
937	O
cells	O
to	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
increased	B-Positive_regulation
by	O
200	O
%	O
the	O
level	O
of	O
IL	O
-	O
1	O
beta	O
mRNA	O
detected	O
and	O
decreased	O
by	O
three	O
orders	O
of	O
magnitude	O
the	O
concentration	O
of	O
LPS	O
required	O
to	O
achieve	O
steady	O
state	O
mRNA	O
levels	O
equivalent	O
to	O
those	O
observed	O
in	O
U	O
-	O
937	O
cells	O
not	O
preincubated	O
with	O
the	O
hormone.2+o	O

NF	O
-	O
kappa	O
B	O
activation	O
by	O
tumor	O
necrosis	O
factor	O
alpha	O
in	O
the	O
Jurkat	O
T	O
cell	O
line	O
is	O
independent	O
of	O
protein	O
kinase	O
A	O
,	O
protein	O
kinase	O
C	O
,	O
and	O
Ca	O
(	O
2+	O
)	O
-	O
regulated	O
kinases	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
a	O
DNA	O
-	O
binding	O
regulatory	O
factor	O
able	O
to	O
control	O
transcription	O
of	O
a	O
number	O
of	O
genes	O
,	O
including	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
genes	O
.	O

In	O
T	O
cells	O
,	O
NF	O
-	O
kappa	O
B	O
is	O
activated	O
upon	O
cellular	O
treatment	O
by	O
phorbol	O
esters	O
and	O
the	O
cytokine	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
investigated	O
the	O
molecular	O
events	O
leading	O
to	O
NF	O
-	O
kappa	O
B	O
activation	O
by	O
TNF	O
alpha	O
in	O
a	O
human	O
T	O
cell	O
line	O
(	O
Jurkat	O
)	O
and	O
its	O
subclone	O
JCT6	O
,	O
which	O
presents	O
a	O
deficiency	O
in	O
the	O
PKA	O
transduction	O
pathway	O
.	O

We	O
found	O
that	O
in	O
both	O
cell	O
lines	O
,	O
both	O
phorbol	O
ester	O
and	O
TNF	O
alpha	O
were	O
able	O
to	O
activate	O
NF	O
-	O
kappa	O
B	O
.	O

Phorbol	O
activation	O
was	O
positively	O
modulated	O
by	O
Ca2+	O
influx	O
while	O
TNF	O
alpha	O
activation	O
was	O
not	O
.	O

Furthermore	O
,	O
while	O
PMA	O
activation	O
was	O
inhibited	O
by	O
the	O
PKC	O
inhibitor	O
staurosporin	O
,	O
the	O
TNF	O
alpha	O
effect	O
was	O
unchanged	O
.	O

TNF	O
alpha	O
did	O
not	O
activate	O
cAMP	O
production	O
and	O
its	O
signal	O
was	O
not	O
modulated	O
by	O
cAMP	O
activators	O
.	O

Moreover	O
,	O
cAMP	O
activators	O
did	O
not	O
activate	O
NF	O
-	O
kappa	O
B	O
in	O
Jurkat	O
cells	O
.	O

Thus	O
,	O
TNF	O
alpha	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
was	O
found	O
to	O
be	O
mediated	O
by	O
none	O
of	O
the	O
major	O
signal	O
-	O
mediating	O
kinases	O
such	O
as	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
protein	O
kinase	O
A	O
,	O
or	O
Ca	O
(	O
2+	O
)	O
-	O
regulated	O
kinases	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
cytoplasmic	O
acidification	O
facilitated	O
NF	O
-	O
kappa	O
B	O
activation	O
by	O
both	O
TNF	O
alpha	O
and	O
PKC	O
,	O
by	O
a	O
mechanism	O
that	O
increases	O
NF	O
-	O
kappa	O
B/I	O
kappa	O
B	O
dissociation	O
without	O
affecting	O
the	O
NF	O
-	O
kappa	O
B	O
translocation	O
step	O
.	O

USF	O
-	O
related	O
transcription	O
factor	O
,	O
HIV	O
-	O
TF1	O
,	O
stimulates	O
transcription	O
of	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
.	O

The	O
transcription	O
factor	O
HIV	O
-	O
TF1	O
,	O
which	O
binds	B-Binding
to	O
a	O
region	O
about	O
60	O
bp	O
upstream	O
from	O
the	O
enhancer	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
(	O
HIV	O
-	O
1	O
)	O
,	O
was	O
purified	O
from	O
human	O
B	O
cells	O
.	O

HIV	O
-	O
TF1	O
had	O
a	O
molecular	O
weight	O
of	O
39	O
,	O
000	O
.	O

Binding	B-Binding
of	O
HIV	O
-	O
TF1	O
to	O
the	O
HIV	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
activated	O
transcription	O
from	O
the	O
HIV	O
promoter	O
in	O
vitro	O
.	O

The	O
HIV-TF1	O
-	O
binding	O
site	O
in	O
HIV	O
LTR	O
was	O
similar	O
to	O
the	O
site	O
recognized	B-Binding
by	O
upstream	O
stimulatory	O
factor	O
(	O
USF	O
)	O
in	O
the	O
adenovirus	O
major	O
late	O
promoter	O
.	O

DNA	O
-	O
binding	B-Binding
properties	O
of	O
HIV	O
-	O
TF1	O
suggested	O
that	O
HIV	O
-	O
TF1	O
might	O
be	O
identical	O
or	O
related	O
to	O
USF	O
.	O

Interestingly	O
,	O
treatment	O
of	O
purified	O
HIV	O
-	O
TF1	O
by	O
phosphatase	O
greatly	O
reduced	B-Negative_regulation
its	O
DNA	O
-	O
binding	B-Binding
activity	O
,	O
suggesting	O
that	O
phosphorylation	B-Phosphorylation
of	O
HIV	O
-	O
TF1	O
was	O
essential	B-Positive_regulation
for	O
DNA	O
binding	B-Binding
.	O

The	O
disruption	O
of	O
HIV-TF1	O
-	O
binding	O
site	O
induced	O
a	O
60	O
%	O
decrease	O
in	O
the	O
level	O
of	O
transcription	O
from	O
the	O
HIV	O
promoter	O
in	O
vivo	O
.	O

These	O
results	O
suggest	O
that	O
HIV	O
-	O
TF1	O
is	O
involved	O
in	O
transcriptional	O
regulation	O
of	O
HIV	O
-	O
1	O
.	O

Nuclear	O
transcription	O
factors	O
that	O
bind	B-Binding
to	O
elements	O
of	O
the	O
IL	O
-	O
2	O
promoter	O
.	O

Induction	O
requirements	O
in	O
primary	O
human	O
T	O
cells	O
.	O

Prior	O
studies	O
have	O
identified	O
several	O
elements	O
that	O
contribute	B-Regulation
to	O
the	O
activity	O
of	O
the	O
IL	O
-	O
2	O
promoter	O
in	O
the	O
stimulated	O
T	O
cell	O
line	O
,	O
Jurkat	O
.	O

The	O
sites	O
and	O
their	O
corresponding	O
nuclear	O
binding	O
factors	O
include	O
:	O
NF	O
-	O
kappa	O
B	O
,	O
AP	O
-	O
1	O
,	O
AP	O
-	O
3	O
,	O
OCT	O
-	O
1	O
,	O
and	O
NF	O
-	O
AT	O
.	O

The	O
latter	O
"	O
nuclear	O
factor	O
for	O
activated	O
T	O
cells	O
"	O
likely	O
contributes	B-Regulation
to	O
the	O
tissue	O
specificity	B-Regulation
of	O
IL	O
-	O
2	O
gene	O
expression	B-Gene_expression
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
have	O
studied	O
these	O
transcription	O
factors	O
in	O
primary	O
T	O
cells	O
from	O
human	O
blood	O
to	O
verify	O
their	O
presence	O
in	O
a	O
physiologic	O
setting	O
and	O
to	O
identify	O
the	O
signals	O
that	O
stimulate	B-Positive_regulation
factor	O
activity	O
.	O

All	O
factors	O
are	O
induced	B-Positive_regulation
in	O
the	O
nuclei	O
of	O
T	O
cells	O
upon	O
activation	O
with	O
mitogens	O
but	O
not	O
with	O
exogenous	O
IL	O
-	O
2	O
growth	O
factor	O
.	O

However	O
,	O
the	O
signaling	O
requirements	B-Positive_regulation
and	O
sensitivity	O
to	O
protein	O
synthesis	O
inhibitors	O
differ	O
considerably	O
.	O

Only	O
the	O
activities	O
for	O
NF	O
-	O
AT	O
and	O
AP	O
-	O
1	O
sites	O
require	O
two	O
signals	O
for	O
optimal	O
induction	O
,	O
i.e.	O
,	O
PMA	O
plus	O
either	O
lectin	O
or	O
antibody	O
to	O
the	O
CD3	O
or	O
CD28	O
surface	O
molecules	O
.	O

Other	O
factors	O
are	O
induced	B-Positive_regulation
by	O
lectin	O
,	O
antibody	O
,	O
and/or	O
PMA	O
alone	O
.	O

After	O
appropriate	O
stimulation	O
,	O
both	O
NF	O
-	O
AT	O
and	O
AP	O
-	O
1	O
are	O
peculiarly	O
sensitive	O
to	O
the	O
protein	O
synthesis	O
inhibitor	O
anisomycin	O
.	O

Our	O
data	O
correlate	O
the	O
activity	O
of	O
NF	O
-	O
AT	O
and	O
AP	O
-	O
1	O
in	O
gel	O
shift	O
assays	O
with	O
the	O
two	O
signals	O
requirements	B-Positive_regulation
for	O
IL	O
-	O
2	O
gene	O
expression	B-Gene_expression
.	O

An	O
erythroid	O
specific	O
enhancer	O
upstream	O
to	O
the	O
gene	O
encoding	O
the	O
cell	O
-	O
type	O
specific	O
transcription	O
factor	O
GATA	O
-	O
1	O
.	O

The	O
transcription	O
factor	O
GATA	O
-	O
1	O
is	O
expressed	B-Gene_expression
in	O
a	O
subset	O
of	O
hemopoietic	O
cells	O
,	O
where	O
it	O
mediates	O
the	O
cell	O
-	O
type	O
specific	O
expression	O
of	O
several	O
genes	O
.	O

We	O
have	O
cloned	O
the	O
mouse	O
and	O
human	O
GATA	O
-	O
1	O
genes	O
.	O

A	O
region	O
upstream	O
to	O
the	O
first	O
exon	O
,	O
and	O
highly	O
conserved	O
between	O
mouse	O
and	O
man	O
,	O
acts	O
as	O
an	O
erythroid	O
specific	O
enhancer	O
in	O
transient	O
assays	O
,	O
if	O
linked	O
to	O
the	O
GATA	O
-	O
1	O
or	O
to	O
the	O
SV40	O
promoter	O
.	O

The	O
activity	O
of	O
the	O
enhancer	O
is	O
almost	O
completely	O
dependent	O
on	O
the	O
integrity	O
of	O
a	O
dimeric	O
GATA	O
-	O
1	O
binding	O
site	O
.	O

Clone	O
pAT	O
133	O
identifies	O
a	O
gene	O
that	O
encodes	O
another	O
human	O
member	O
of	O
a	O
class	O
of	O
growth	O
factor	O
-	O
induced	O
genes	O
with	O
almost	O
identical	O
zinc	O
-	O
finger	O
domains	O
.	O

We	O
report	O
the	O
structure	O
and	O
regulation	O
of	O
a	O
gene	O
represented	O
by	O
clone	O
pAT	O
133	O
,	O
which	O
is	O
induced	O
upon	O
transition	O
from	O
a	O
resting	O
state	O
(	O
G0	O
)	O
through	O
the	O
early	O
phase	O
of	O
the	O
cell	O
cycle	O
(	O
G1	O
)	O
.	O

The	O
pAT	O
133	O
gene	O
is	O
immediately	O
induced	O
,	O
with	O
FOS	O
-	O
like	O
kinetics	O
,	O
in	O
human	O
T	O
cells	O
and	O
in	O
fibroblasts	O
.	O

Primary	O
structure	O
analysis	O
showed	O
that	O
the	O
encoded	O
protein	O
contains	O
three	O
tandem	O
zinc	O
-	O
finger	O
sequences	O
of	O
the	O
type	O
Cys2-Xaa12	O
-	O
His2	O
.	O

This	O
zinc	O
-	O
finger	O
region	O
,	O
which	O
is	O
thought	O
to	O
bind	O
DNA	O
in	O
a	O
sequence	O
-	O
specific	O
manner	O
,	O
is	O
similar	O
(	O
greater	O
than	O
80	O
%	O
on	O
the	O
amino	O
acid	O
level	O
)	O
to	O
two	O
previously	O
described	O
transcription	O
factors	O
pAT	O
225/EGR1	O
and	O
pAT	O
591/EGR2	O
.	O

Except	O
for	O
the	O
conserved	O
zinc	O
-	O
finger	O
domains	O
,	O
the	O
amino	O
acid	O
sequences	O
of	O
the	O
three	O
proteins	O
are	O
distinct	O
.	O

This	O
structural	O
similarity	O
suggests	O
that	O
the	O
pAT	O
133	O
gene	O
encodes	O
a	O
transcription	O
factor	O
with	O
a	O
specific	O
biological	O
function	O
.	O

Comparing	O
the	O
regulation	B-Regulation
of	O
these	O
related	O
zinc-finger	O
-	O
encoding	O
genes	O
showed	O
coordinate	O
induction	O
upon	O
mitogenic	O
stimulation	O
of	O
resting	O
T	O
lymphocytes	O
and	O
of	O
resting	O
fibroblasts	O
.	O

However	O
,	O
upon	O
transition	O
from	O
a	O
proliferating	O
(	O
G1	O
)	O
to	O
a	O
resting	O
state	O
of	O
the	O
cell	O
cycle	O
the	O
three	O
genes	O
were	O
differently	O
regulated	B-Regulation
.	O

In	O
human	O
histiocytic	O
U937	O
cells	O
mRNA	O
of	O
clone	O
pAT	O
133	O
was	O
constitutively	O
expressed	O
,	O
whereas	O
mRNA	O
of	O
pAT	O
225/EGR1	O
was	O
induced	B-Positive_regulation
upon	O
induction	O
of	O
terminal	O
differentiation	O
.	O

In	O
contrast	O
mRNA	O
representing	O
pAT	O
591/EGR2	O
was	O
not	O
expressed	B-Transcription
in	O
these	O
cells	O
.	O

This	O
difference	O
in	O
gene	O
regulation	O
suggests	O
distinct	O
biological	O
roles	O
in	O
the	O
control	O
of	O
cell	O
proliferation	O
for	O
the	O
respective	O
proteins	O
.	O

Every	O
enhancer	O
works	O
with	O
every	O
promoter	O
for	O
all	O
the	O
combinations	O
tested	O
:	O
could	O
new	O
regulatory	O
pathways	O
evolve	O
by	O
enhancer	O
shuffling	O
?	O

The	O
promoters	O
and	O
enhancers	O
of	O
cell	O
type	O
-	O
specific	O
genes	O
are	O
often	O
conserved	O
in	O
evolution	O
,	O
and	O
hence	O
one	O
might	O
expect	O
that	O
a	O
given	O
enhancer	O
has	O
evolved	O
to	O
work	O
best	O
with	O
its	O
own	O
promoter	O
.	O

While	O
this	O
expectation	O
may	O
be	O
realized	O
in	O
some	O
cases	O
,	O
we	O
have	O
not	O
found	O
evidence	O
for	O
it	O
.	O

A	O
total	O
of	O
27	O
combinations	O
of	O
different	O
promoters	O
and	O
enhancers	O
were	O
tested	O
by	O
transfection	O
into	O
cultured	O
cells	O
.	O

We	O
found	O
that	O
the	O
relative	O
efficiency	O
of	O
the	O
enhancers	O
is	O
approximately	O
the	O
same	O
,	O
irrespective	O
of	O
the	O
type	O
of	O
promoter	O
used	O
,	O
i.e.	O
,	O
there	O
was	O
no	O
strong	O
preference	O
for	O
any	O
given	O
enhancer/promoter	O
combination	O
.	O

Notably	O
,	O
we	O
do	O
not	O
see	O
particularly	O
strong	O
transcription	O
when	O
the	O
immunoglobulin	O
kappa	O
enhancer	O
(	O
or	O
the	O
immunoglobulin	O
heavy	O
chain	O
enhancer	O
)	O
is	O
used	O
to	O
activate	O
a	O
kappa	O
gene	O
promoter	O
.	O

We	O
propose	O
that	O
a	O
generally	O
permissive	O
enhancer/promoter	O
interaction	O
is	O
of	O
evolutionary	O
benefit	O
for	O
higher	O
eukaryotes	O
:	O
by	O
enhancer	O
shuffling	O
,	O
genes	O
could	O
be	O
easily	O
brought	O
under	O
a	O
new	O
type	O
of	O
inducibility/cell	O
type	O
specificity	O
.	O

Towards	O
a	O
molecular	O
understanding	O
of	O
T	O
-	O
cell	O
differentiation	O
.	O

Lymphoid	O
differentiation	O
is	O
one	O
of	O
the	O
best	O
studied	O
examples	O
of	O
mammalian	O
development	O
.	O

Here	O
Hans	O
Clevers	O
and	O
Michael	O
Owen	O
describe	O
how	O
the	O
cloning	O
of	O
the	O
genes	O
that	O
encode	O
T-cell	O
-	O
specific	O
membrane	O
proteins	O
allows	O
the	O
identification	O
of	O
transcription	O
factors	O
that	O
control	O
the	O
expression	O
of	O
these	O
T	O
-	O
cell	O
genes	O
.	O

Such	O
transcription	O
factors	O
play	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
the	O
mature	O
T	O
-	O
cell	O
phenotype	O
by	O
functioning	O
as	O
'master	O
regulators	O
of	O
T	O
-	O
cell	O
differentiation	O
'	O
.	O

Transcription	O
factor	O
requirements	O
for	O
U2	O
snRNA	O
-	O
encoding	O
gene	O
activation	O
in	O
B	O
lymphoid	O
cells	O
.	O

Transcription	O
of	O
a	O
human	O
U2	O
small	O
nuclear	O
RNA	O
(	O
snRNA	O
)	O
-	O
encoding	O
gene	O
in	O
HeLa	O
cells	O
requires	O
a	O
distal	O
enhancer	O
element	O
,	O
which	O
is	O
composed	O
of	O
one	O
octamer	O
motif	O
(	O
Oct	O
)	O
and	O
three	O
Sp	O
1	O
-	O
binding	O
sites	O
.	O

To	O
study	O
the	O
transcription	O
factor	O
requirement	O
in	O
B	O
-	O
cells	O
,	O
different	O
U2	O
enhancer	O
constructions	O
were	O
transfected	O
into	O
the	O
lymphoid	O
cell	O
line	O
,	O
BJA	O
-	O
B	O
.	O

The	O
results	O
showed	O
that	O
the	O
activation	O
of	O
U2	O
snRNA	O
transcription	O
in	O
B	O
-	O
cells	O
also	O
requires	O
an	O
enhancer	O
comprising	O
both	O
the	O
Oct	O
and	O
at	O
least	O
one	O
Sp	O
1	O
-	O
binding	O
site	O
.	O

Deletion	O
of	O
all	O
the	O
Sp	O
1	O
-	O
binding	O
sites	O
from	O
the	O
enhancer	O
reduces	O
transcription	O
by	O
80	O
-	O
90	O
%	O
in	O
HeLa	O
,	O
as	O
well	O
as	O
in	O
BJA	O
-	O
B	O
cells	O
,	O
whereas	O
the	O
removal	O
of	O
the	O
octamer	O
-	O
binding	O
site	O
reduces	O
transcription	O
to	O
levels	O
below	O
detection	O
in	O
both	O
cell	O
types	O
.	O

Enhancers	O
containing	O
a	O
single	O
Oct	O
have	O
,	O
nevertheless	O
,	O
the	O
capacity	O
to	O
partially	O
activate	O
U2	O
snRNA	O
transcription	O
in	O
both	O
HeLa	O
cells	O
,	O
in	O
which	O
only	O
OTF	O
-	O
1	O
is	O
expressed	B-Gene_expression
,	O
and	O
in	O
BJA	O
-	O
B	O
cells	O
in	O
which	O
OTF	O
-	O
2	O
is	O
the	O
predominantly	O
expressed	B-Gene_expression
octamer	O
-	O
binding	O
factor	O
.	O

The	O
most	O
likely	O
interpretation	O
of	O
our	O
results	O
is	O
that	O
both	O
the	O
ubiquitous	O
transcription	O
factor	O
,	O
OTF	O
-	O
1	O
,	O
and	O
the	O
B-cell	O
-	O
specific	O
transcription	O
factor	O
,	O
OTF	O
-	O
2	O
,	O
can	O
activate	O
U2	O
snRNA	O
transcription	O
.	O

The	O
results	O
also	O
revealed	O
a	O
similar	O
functional	O
cooperation	O
between	O
the	O
transcription	O
factors	O
which	O
bind	O
to	O
the	O
Oct	O
and	O
the	O
adjacent	O
Sp	O
1	O
-	O
binding	O
site	O
in	O
BJA	O
-	O
B	O
cells	O
,	O
as	O
has	O
been	O
observed	O
in	O
HeLa	O
cells	O
,	O
since	O
a	O
template	O
which	O
contains	O
a	O
weak	O
binding	O
site	O
for	O
OTFs	O
expresses	O
wild	O
-	O
type	O
levels	O
of	O
U2	O
snRNA	O
in	O
both	O
cell	O
types	O
when	O
the	O
weak	O
octamer	O
-	O
binding	O
site	O
is	O
combined	O
with	O
a	O
Sp	O
1	O
-	O
binding	O
site	O
.	O

Kappa	O
B	O
-	O
specific	O
DNA	O
binding	O
proteins	O
are	O
differentially	O
inhibited	O
by	O
enhancer	O
mutations	O
and	O
biological	O
oxidation	O
.	O

Kappa	O
B	O
(	O
kappa	O
B	O
)	O
enhancer	O
binding	O
proteins	O
isolated	O
from	O
the	O
nuclei	O
of	O
activated	O
human	O
T	O
cells	O
produce	O
two	O
distinct	O
nucleoprotein	O
complexes	O
when	O
incubated	O
with	O
the	O
kappa	O
B	O
element	O
from	O
the	O
interleukin	O
-	O
2	O
receptor	O
-	O
alpha	O
(	O
IL	O
-	O
2R	O
alpha	O
)	O
gene	O
.	O

These	O
two	O
DNA	O
-	O
protein	O
complexes	O
are	O
composed	O
of	O
at	O
least	O
four	O
host	O
proteins	O
(	O
p50	O
,	O
p55	O
,	O
p75	O
,	O
p85	O
)	O
,	O
each	O
of	O
which	O
shares	O
structural	O
similarity	O
with	O
the	O
v	O
-	O
rel	O
oncogene	O
product	O
.	O

Nuclear	O
expression	B-Gene_expression
of	O
these	O
proteins	O
is	O
induced	B-Positive_regulation
with	O
distinctly	O
biphasic	O
kinetics	O
following	O
phorbol	O
ester	O
activation	O
of	O
T	O
cells	O
(	O
p55/p75	O
early	O
and	O
p50/p85	O
late	O
)	O
.	O

DNA	O
-	O
protein	O
crosslinking	O
studies	O
have	O
revealed	O
that	O
the	O
more	O
rapidly	O
migrating	B-Localization
B2	O
complex	O
contains	O
both	O
p50	O
and	O
p55	O
while	O
the	O
more	O
slowly	O
migrating	B-Localization
B1	O
complex	O
is	O
composed	O
of	O
p50	O
,	O
p55	O
,	O
p75	O
,	O
and	O
p85	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
wild	O
-	O
type	O
IL	O
-	O
2R	O
alpha	O
kappa	O
B	O
enhancer	O
(	O
GGGGAATCTCCC	O
)	O
has	O
revealed	O
that	O
the	O
binding	B-Binding
of	O
p50	O
and	O
p55	O
(	O
B2	O
complex	O
)	O
is	O
particularly	O
sensitive	B-Regulation
to	O
alteration	O
of	O
the	O
5	O
'	O
triplet	O
of	O
deoxyguanosine	O
residues	O
.	O

In	O
contrast	O
,	O
formation	O
of	O
the	O
B1	O
complex	O
,	O
reflecting	O
the	O
binding	B-Binding
of	O
p75	O
and	O
p85	O
,	O
critically	O
depends	B-Positive_regulation
upon	O
the	O
more	O
3	O
'	O
sequences	O
of	O
this	O
enhancer	O
element	O
.	O

DNA	O
binding	B-Binding
by	O
all	O
four	O
of	O
these	O
Rel	O
-	O
related	O
factors	O
is	O
blocked	B-Negative_regulation
by	O
selective	O
chemical	O
modification	O
of	O
lysine	O
and	O
arginine	O
residues	O
,	O
suggesting	O
that	O
both	O
of	O
these	O
basic	O
amino	O
acids	O
are	O
required	O
for	O
binding	O
to	O
the	O
kappa	O
B	O
element	O
.	O

Similarly	O
,	O
covalent	O
modification	O
of	O
free	O
sulfhydryl	O
groups	O
with	O
diamide	O
(	O
reversible	O
)	O
or	O
N	O
-	O
ethylmaleimide	O
(	O
irreversible	O
)	O
results	O
in	O
a	O
complete	O
loss	B-Negative_regulation
of	O
DNA	O
binding	O
activity	O
.	O

In	O
contrast	O
,	O
mild	O
oxidation	O
with	O
glucose	O
oxidase	O
selectively	O
inhibits	B-Negative_regulation
p75	O
and	O
p85	O
binding	B-Binding
while	O
not	O
blocking	B-Negative_regulation
p50	O
and	O
p55	O
interactions	B-Binding
.	O

These	O
findings	O
suggest	O
that	O
reduced	O
cysteine	O
thiols	O
play	O
an	O
important	O
role	O
in	O
the	O
DNA	O
binding	O
activity	O
of	O
this	O
family	O
of	O
Rel	O
-	O
related	O
transcription	O
factors	O
.	O

Activity	O
of	O
the	O
kappa	O
B	O
enhancer	O
of	O
the	O
interleukin	O
-	O
2	O
receptor	O
alpha	O
chain	O
in	O
somatic	O
cell	O
hybrids	O
is	O
accompanied	O
by	O
the	O
nuclear	O
localization	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
two	O
nuclear	O
proteins	O
NF	O
-	O
kappa	O
B	O
(	O
consisting	O
of	O
subunits	O
p50	O
and	O
p65	O
)	O
and	O
the	O
DNA	O
-	O
binding	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
(	O
p50	O
)	O
by	O
itself	O
,	O
also	O
called	O
KBF1	O
,	O
are	O
constitutively	O
expressed	B-Gene_expression
and	O
localized	B-Localization
in	O
the	O
nucleus	O
of	O
the	O
human	O
T	O
-	O
cell	O
line	O
IARC	O
301.5	O
.	O

In	O
order	O
to	O
define	O
the	O
roles	O
of	O
these	O
two	O
factors	O
,	O
which	O
bind	B-Binding
to	O
the	O
same	O
kappa	O
B	O
enhancers	O
,	O
in	O
transcription	O
activation	O
we	O
have	O
prepared	O
somatic	O
cell	O
hybrids	O
between	O
IARC	O
301.5	O
and	O
a	O
murine	O
myeloma	O
.	O

Most	O
hybrids	O
express	B-Gene_expression
both	O
KBF1	O
and	O
NF	O
-	O
kappa	O
B	O
in	O
their	O
nuclei	O
,	O
but	O
one	O
hybrid	O
expresses	B-Gene_expression
only	O
KBF1	O
.	O

The	O
kappa	O
B	O
enhancer	O
of	O
the	O
gene	O
encoding	O
the	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
receptor	O
alpha	O
chain	O
(	O
IL	O
-	O
2R	O
alpha	O
)	O
is	O
functional	O
only	O
in	O
the	O
hybrids	O
expressing	O
nuclear	O
NF	O
-	O
kappa	O
B	O
.	O

These	O
findings	O
show	O
that	O
nuclear	O
NF	O
-	O
kappa	O
B	O
is	O
necessary	O
to	O
activate	O
the	O
kappa	O
B	O
enhancer	O
,	O
while	O
KBF1	O
by	O
itself	O
is	O
not	O
sufficient	O
.	O

We	O
propose	O
that	O
KBF1	O
is	O
a	O
competitive	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
discuss	O
how	O
these	O
factors	O
may	O
be	O
involved	O
in	O
the	O
transient	O
expression	B-Gene_expression
of	O
IL	O
-	O
2	O
and	O
IL	O
-	O
2R	O
alpha	O
genes	O
during	O
the	O
immune	O
response	O
.	O

Stimulation	B-Positive_regulation
of	O
interferon	O
beta	O
gene	O
transcription	B-Transcription
in	O
vitro	O
by	O
purified	O
NF	O
-	O
kappa	O
B	O
and	O
a	O
novel	O
TH	O
protein	O
.	O

The	O
human	O
interferon	O
beta	O
(	O
IFN	O
-	O
beta	O
)	O
regulatory	O
element	O
consists	O
of	O
multiple	O
enhanson	O
domains	O
which	O
are	O
targets	B-Regulation
for	O
transcription	O
factors	O
involved	O
in	O
inducible	B-Positive_regulation
expression	B-Gene_expression
of	O
the	O
promoter	O
.	O

To	O
further	O
characterize	O
the	O
protein	O
-	O
DNA	O
interactions	O
mediating	B-Positive_regulation
IFN	O
-	O
beta	O
induction	B-Positive_regulation
,	O
positive	O
regulatory	O
domain	O
(	O
PRD	O
)	O
II	O
binding	O
proteins	O
were	O
purified	O
from	O
phorbol	O
ester	O
induced	O
Jurkat	O
T	O
-	O
cells	O
and	O
from	O
IFN	O
primed	O
,	O
cycloheximide/polyinosinic	O
-	O
polycytidylic	O
acid	O
treated	O
HeLa	O
S3	O
cells	O
.	O

From	O
HeLa	O
cells	O
,	O
two	O
major	O
proteins	O
of	O
52	O
and	O
45	O
kilodaltons	O
(	O
kD	O
)	O
copurified	O
with	O
DNA	O
binding	O
activity	O
,	O
whereas	O
from	O
T	O
-	O
cells	O
,	O
four	O
proteins	O
-	O
-	O
a	O
major	O
protein	O
of	O
52	O
kD	O
and	O
three	O
minor	O
proteins	O
of	O
82	O
,	O
67	O
,	O
and	O
43	O
-	O
47	O
kD	O
-	O
-	O
were	O
purified	O
.	O

Also	O
,	O
an	O
induction	O
specific	O
DNA	O
binding	O
protein	O
was	O
purified	O
from	O
HeLa	O
cells	O
that	O
interacted	O
with	O
the	O
(	O
AAGTGA	O
)	O
4	O
tetrahexamer	O
sequence	O
and	O
the	O
PRDI	O
domain	O
.	O

This	O
protein	O
is	O
immunologically	O
distinct	O
from	O
IRF	O
-	O
1/ISGF2	O
.	O

Uninduced	O
or	O
Sendai	O
virus	O
induced	O
HeLa	O
extracts	O
were	O
used	O
to	O
examine	O
transcription	O
in	O
vitro	O
using	O
a	O
series	O
of	O
IFN	O
beta	O
promoter	O
deletions	O
.	O

Deletions	O
upstream	O
of	O
the	O
PRDII	O
element	O
increased	B-Positive_regulation
transcription	O
in	O
the	O
uninduced	O
extract	O
,	O
indicating	O
predominantly	O
negative	O
regulation	O
of	O
the	O
promoter	O
.	O

A	O
2-4	O
-	O
fold	O
increase	B-Positive_regulation
in	O
IFN	O
-	O
beta	O
promoter	O
transcription	B-Transcription
was	O
observed	O
in	O
Sendai	O
virus	O
induced	O
extracts	O
,	O
and	O
deletion	O
of	O
PRDI	O
and	O
PRDII	O
elements	O
decreased	B-Negative_regulation
this	O
induced	O
level	O
of	O
transcription	O
.	O

When	O
purified	O
PRDII	O
and	O
tetrahexamer	O
binding	O
proteins	O
were	O
added	O
to	O
the	O
induced	O
extract	O
,	O
a	O
4	O
-	O
fold	O
increase	B-Positive_regulation
in	O
transcription	O
was	O
observed	O
.	O

These	O
experiments	O
demonstrate	O
that	O
it	O
is	O
possible	O
to	O
modulate	O
IFN	O
-	O
beta	O
transcription	O
in	O
vitro	O
but	O
indicate	O
that	O
additional	O
proteins	O
may	O
be	O
required	O
to	O
fully	O
activate	B-Positive_regulation
IFN	O
-	O
beta	O
transcription	B-Transcription
.	O

Characterization	O
of	O
an	O
immediate	O
-	O
early	O
gene	O
induced	O
in	O
adherent	O
monocytes	O
that	O
encodes	O
I	O
kappa	O
B	O
-	O
like	O
activity	O
.	O

We	O
have	O
cloned	O
a	O
group	O
of	O
cDNAs	O
representing	O
mRNAs	O
that	O
are	O
rapidly	O
induced	O
following	O
adherence	O
of	O
human	O
monocytes	O
.	O

One	O
of	O
the	O
induced	B-Positive_regulation
transcripts	O
(	O
MAD	O
-	O
3	O
)	O
encodes	O
a	O
protein	O
of	O
317	O
amino	O
acids	O
with	O
one	O
domain	O
containing	O
five	O
tandem	O
repeats	O
of	O
the	O
cdc10/ankyrin	O
motif	O
,	O
which	O
is	O
60	O
%	O
similar	O
(	O
46	O
%	O
identical	O
)	O
to	O
the	O
ankyrin	O
repeat	O
region	O
of	O
the	O
precursor	O
of	O
NF	O
-	O
kappa	O
B/KBF1	O
p50	O
.	O

The	O
C	O
-	O
terminus	O
has	O
a	O
putative	O
protein	O
kinase	O
C	O
phosphorylation	O
site	O
.	O

In	O
vitro	O
translated	O
MAD	O
-	O
3	O
protein	O
was	O
found	O
to	O
specifically	O
inhibit	B-Negative_regulation
the	O
DNA	O
-	O
binding	B-Binding
activity	I-Binding
of	O
the	O
p50/p65	O
NF	O
-	O
kappa	O
B	O
complex	O
but	O
not	O
that	O
of	O
the	O
p50/p50	O
KBF1	O
factor	O
or	O
of	O
other	O
DNA	O
-	O
binding	O
proteins	O
.	O

The	O
MAD	O
-	O
3	O
cDNA	O
encodes	O
an	O
I	O
kappa	O
B	O
-	O
like	O
protein	O
that	O
is	O
likely	O
to	O
be	O
involved	O
in	O
regulation	O
of	O
transcriptional	O
responses	O
to	O
NF	O
-	O
kappa	O
B	O
,	O
including	O
adhesion	O
-	O
dependent	O
pathways	O
of	O
monocyte	O
activation	O
.	O

Platelet	O
-	O
activating	O
factor	O
induces	O
phospholipid	O
turnover	O
,	O
calcium	O
flux	O
,	O
arachidonic	O
acid	O
liberation	O
,	O
eicosanoid	O
generation	O
,	O
and	O
oncogene	O
expression	O
in	O
a	O
human	O
B	O
cell	O
line	O
.	O

Platelet	O
-	O
activating	O
factor	O
is	O
a	O
potent	O
mediator	O
of	O
the	O
inflammatory	O
response	O
.	O

Studies	O
of	O
the	O
actions	O
of	O
platelet	O
-	O
activating	O
factor	O
have	O
centered	O
mainly	O
around	O
neutrophils	O
,	O
monocytes	O
,	O
and	O
platelets	O
.	O

In	O
this	O
report	O
we	O
begin	O
to	O
uncover	O
the	O
influence	O
of	O
platelet	O
-	O
activating	O
factor	O
on	O
B	O
lymphocytes	O
.	O

Employing	O
the	O
EBV	O
-	O
transformed	O
human	O
B	O
cell	O
line	O
SKW6.4	O
,	O
we	O
demonstrate	O
that	O
platelet	O
-	O
activating	O
factor	O
significantly	O
alters	O
membrane	O
phospholipid	O
metabolism	O
indicated	O
by	O
the	O
incorporation	O
of	O
32P	O
into	O
phosphatidylcholine	O
,	O
phosphatidylinositol	O
,	O
and	O
phosphatidic	O
acid	O
but	O
not	O
significantly	O
into	O
phosphatidylethanolamine	O
at	O
concentrations	O
ranging	O
from	O
10	O
(	O
-	O
9	O
)	O
to	O
10	O
(	O
-	O
6	O
)	O
M	O
.	O

The	O
inactive	O
precursor	O
,	O
lyso-platelet	O
-	O
activating	O
factor	O
,	O
at	O
a	O
concentration	O
as	O
high	O
as	O
10	O
(	O
-	O
7	O
)	O
M	O
had	O
no	O
effect	O
on	O
any	O
of	O
the	O
membrane	O
phospholipids	O
.	O

We	O
also	O
show	O
that	O
platelet	O
-	O
activating	O
factor	O
from	O
10	O
(	O
-	O
12	O
)	O
to	O
10	O
(	O
-	O
6	O
)	O
M	O
induced	O
rapid	O
and	O
significant	O
elevation	O
in	O
intracellular	O
calcium	O
levels	O
,	O
whereas	O
lyso-platelet	O
-	O
activating	O
factor	O
was	O
again	O
ineffective	O
.	O

We	O
further	O
demonstrate	O
the	O
impact	O
of	O
platelet	O
-	O
activating	O
factor	O
binding	O
to	O
B	O
cells	O
by	O
measuring	O
platelet	O
-	O
activating	O
factor	O
induced	O
arachidonic	O
acid	O
release	O
and	O
5	O
-	O
hydroxyeicosatetraenoic	O
acid	O
production	O
.	O

Moreover	O
,	O
platelet	O
-	O
activating	O
factor	O
was	O
capable	O
of	O
inducing	B-Positive_regulation
transcription	B-Transcription
of	O
the	O
nuclear	O
proto	O
-	O
oncogenes	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
.	O

Finally	O
we	O
explored	O
the	O
possible	O
role	O
of	O
5	O
-	O
hydroxyeicosatetraenoic	O
acid	O
as	O
a	O
regulator	O
of	O
arachidonic	O
acid	O
liberation	O
demonstrating	O
that	O
endogenous	O
5	O
-	O
lipoxygenase	O
activity	O
modulates	O
platelet	O
-	O
activating	O
factor	O
induced	O
arachidonic	O
acid	O
release	O
perhaps	O
acting	O
at	O
the	O
level	O
of	O
phospholipase	O
A2	O
.	O

In	O
summary	O
,	O
platelet	O
-	O
activating	O
factor	O
is	O
shown	O
here	O
to	O
have	O
a	O
direct	O
and	O
profound	O
effect	O
on	O
a	O
pure	O
B	O
cell	O
line	O
.	O

Inhibition	O
of	O
protein	O
phosphatases	O
by	O
okadaic	O
acid	O
induces	O
AP1	O
in	O
human	O
T	O
cells	O
.	O

To	O
examine	O
the	O
role	O
of	O
protein	O
phosphatases	O
in	O
T	O
cell	O
activation	O
,	O
Jurkat	O
cells	O
were	O
treated	O
with	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
type	O
1	O
and	O
2A	O
phosphatases	O
,	O
and	O
nuclear	O
extracts	O
were	O
examined	O
for	O
the	O
presence	O
of	O
AP1	O
as	O
a	O
measure	O
of	O
early	O
T	O
cell	O
activation	O
.	O

Okadaic	O
acid	O
was	O
found	O
to	O
be	O
a	O
potent	O
inducer	O
of	O
AP1	O
.	O

In	O
contrast	O
to	O
phorbol	O
esters	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
the	O
induction	O
of	O
AP1	O
by	O
okadaic	O
acid	O
occurs	O
predominantly	O
by	O
transcriptional	O
activation	O
of	O
the	O
jun	O
and	O
fos	O
family	O
of	O
proto	O
-	O
oncogenes	O
.	O

Surprisingly	O
,	O
while	O
the	O
addition	O
of	O
phytohemagglutinin	O
further	O
enhanced	O
the	O
induction	O
of	O
AP1	O
,	O
the	O
addition	O
of	O
PMA	O
inhibited	O
it	O
.	O

Okadaic	O
acid	O
treatment	O
was	O
found	O
to	O
dramatically	O
increase	B-Positive_regulation
mRNA	B-Transcription
transcripts	I-Transcription
of	O
the	O
jun	O
family	O
of	O
proto	O
-	O
oncogenes	O
including	O
c	O
-	O
jun	O
,	O
junD	O
,	O
and	O
junB	O
and	O
to	O
a	O
lesser	O
extent	O
the	O
fos	O
family	O
including	O
c	O
-	O
fos	O
and	O
fra	O
-	O
1	O
.	O

By	O
comparison	O
,	O
PMA	O
is	O
a	O
very	O
inefficient	O
inducer	O
of	O
the	O
jun	O
gene	O
family	O
in	O
Jurkat	O
cells	O
.	O

Similar	O
to	O
its	O
effect	O
on	O
the	O
induction	O
of	O
AP1	O
by	O
okadaic	O
acid	O
,	O
PMA	O
inhibits	B-Negative_regulation
the	O
induction	B-Positive_regulation
of	O
c	O
-	O
jun	O
mRNA	O
by	O
okadaic	O
acid	O
.	O

Transfection	O
of	O
c	O
-	O
jun	O
promoter	O
constructs	O
confirmed	O
the	O
marked	O
difference	O
between	O
PMA	O
and	O
okadaic	O
acid	O
in	O
inducing	B-Positive_regulation
c	O
-	O
jun	O
transcription	B-Transcription
.	O

The	O
induction	O
of	O
AP1	O
by	O
okadaic	O
acid	O
suggests	O
that	O
protein	O
phosphatases	O
1	O
and	O
2A	O
(	O
PP1	O
and	O
PP2A	O
)	O
may	O
be	O
involved	O
in	O
T	O
cell	O
activation	O
as	O
important	O
negative	O
regulators	O
of	O
the	O
transcription	O
factor	O
AP1	O
.	O

Transactivation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
promoter	O
by	O
human	O
herpesvirus	O
6	O
(	O
HHV	O
-	O
6	O
)	O
strains	O
GS	O
and	O
Z	O
-	O
29	O
in	O
primary	O
human	O
T	O
lymphocytes	O
and	O
identification	O
of	O
transactivating	O
HHV	O
-	O
6	O
(	O
GS	O
)	O
gene	O
fragments	O
.	O

Human	O
herpesvirus	O
6	O
(	O
HHV	O
-	O
6	O
)	O
can	O
activate	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
promoter	O
and	O
accelerate	O
cytopathic	O
effects	O
in	O
HIV	O
-	O
infected	O
human	O
T	O
cells	O
.	O

This	O
study	O
examines	O
the	O
regions	O
of	O
the	O
HIV	O
promoter	O
required	O
for	O
HHV	O
-	O
6	O
transactivation	O
in	O
a	O
heterogeneous	O
population	O
of	O
primary	O
human	O
T	O
lymphocytes	O
with	O
or	O
without	O
antigenic	O
stimulation	O
.	O

Two	O
different	O
strains	O
of	O
HHV	O
-	O
6	O
,	O
GS	O
and	O
Z29	O
,	O
transactivated	O
the	O
HIV	O
promoter	O
.	O

The	O
GS	O
strain	O
transactivated	O
the	O
promoter	O
in	O
both	O
stimulated	O
and	O
resting	O
T	O
cells	O
,	O
while	O
the	O
Z29	O
strain	O
increased	O
HIV	O
promoter	O
activity	O
only	O
in	O
stimulated	O
T	O
cells	O
.	O

Three	O
DNA	O
clones	O
containing	O
HHV	O
-	O
6	O
(	O
GS	O
)	O
genomic	O
fragments	O
transactivated	O
the	O
HIV	O
promoter	O
in	O
cotransfected	O
T	O
cells	O
.	O

A	O
21.4	O
-	O
kb	O
DNA	O
clone	O
,	O
pZVB70	O
,	O
showed	O
the	O
highest	O
transactivating	O
ability	O
,	O
while	O
two	O
other	O
DNA	O
fragments	O
,	O
pZVB10	O
(	O
6.2	O
kb	O
)	O
and	O
pZVH14	O
(	O
8.7	O
kb	O
)	O
,	O
showed	O
lower	O
activity	O
.	O

One	O
of	O
these	O
clones	O
,	O
pZVH14	O
,	O
activated	O
the	O
HIV	O
promoter	O
construct	O
containing	O
a	O
mutation	O
in	O
the	O
NF	O
kappa	O
B	O
site	O
.	O

However	O
,	O
this	O
mutated	O
NF	O
kappa	O
B	O
promoter	O
was	O
not	O
transactivated	O
during	O
HHV	O
-	O
6	O
(	O
GS	O
)	O
infection	O
or	O
after	O
cotransfection	O
with	O
pZVB70	O
or	O
pZVB10	O
.	O

These	O
data	O
indicate	O
that	O
the	O
NF	O
kappa	O
B	O
sites	O
of	O
the	O
HIV	O
promoter	O
are	O
essential	O
for	O
its	O
transactivation	O
during	O
HHV	O
-	O
6	O
(	O
GS	O
)	O
infection	O
.	O

By	O
increasing	O
HIV	O
promoter	O
activity	O
in	O
primary	O
T	O
lymphocytes	O
,	O
HHV	O
-	O
6	O
may	O
consequently	O
increase	O
HIV	O
replication	O
,	O
leading	O
to	O
an	O
increase	O
in	O
the	O
cytopathic	O
effect	O
on	O
coinfected	O
human	O
T	O
cells	O
.	O

Regulation	B-Regulation
of	O
M	O
-	O
CSF	O
expression	B-Gene_expression
by	O
M	O
-	O
CSF	O
:	O
role	O
of	O
protein	O
kinase	O
C	O
and	O
transcription	O
factor	O
NF	O
kappa	O
B	O
.	O

Macrophage-colony	O
-	O
stimulating	O
factor	O
(	O
M	O
-	O
CSF	O
)	O
,	O
also	O
referred	O
to	O
as	O
CSF	O
-	O
1	O
,	O
regulates	O
the	O
survival	O
,	O
growth	O
,	O
differentiation	O
and	O
functional	O
activity	O
of	O
monocytes	O
by	O
binding	B-Binding
to	O
a	O
single	O
class	O
of	O
high	O
-	O
affinity	O
cell	O
surface	O
receptors	O
,	O
known	O
to	O
be	O
the	O
product	O
of	O
the	O
c	O
-	O
fms	O
protooncogene	O
.	O

The	O
detection	O
of	O
both	O
M	O
-	O
CSF	O
and	O
c	O
-	O
fms	O
expression	B-Gene_expression
by	O
cells	O
of	O
the	O
monocyte	O
lineage	O
has	O
suggested	O
that	O
M	O
-	O
CSF	O
may	O
act	B-Positive_regulation
by	O
an	O
autocrine	O
mechanism	O
.	O

Interestingly	O
,	O
it	O
has	O
been	O
shown	O
that	O
M	O
-	O
CSF	O
can	O
induce	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
its	O
own	O
gene	O
.	O

Although	O
sensitivity	O
to	O
M	O
-	O
CSF	O
can	O
be	O
modulated	O
by	O
regulation	O
of	O
receptor	O
expression	O
and	O
function	O
,	O
M	O
-	O
CSF	O
responsiveness	O
is	O
largely	O
determined	O
at	O
a	O
postreceptor	O
level	O
.	O

To	O
date	O
,	O
little	O
is	O
known	O
about	O
the	O
intracellular	O
pathway	O
of	O
M	O
-	O
CSF	O
signal	O
transduction	O
.	O

We	O
have	O
therefore	O
investigated	O
the	O
changes	O
in	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activity	O
upon	O
exposure	O
of	O
monocytes	O
to	O
M	O
-	O
CSF	O
.	O

We	O
show	O
that	O
M	O
-	O
CSF	O
activates	O
and	O
translocates	O
PKC	O
.	O

Inhibition	O
of	O
PKC	O
by	O
the	O
isoquinoline	O
derivative	O
H7	O
abolishes	B-Negative_regulation
induction	B-Positive_regulation
of	O
M	O
-	O
CSF	O
by	O
M	O
-	O
CSF	O
.	O

Furthermore	O
,	O
activation	O
of	O
PKC	O
was	O
pertussis-toxin	O
-	O
sensitive	O
and	O
was	O
associated	O
with	O
the	O
detection	O
of	O
an	O
NF	O
kappa	O
B	O
protein	O
in	O
nuclear	O
extracts	O
of	O
M-CSF	O
-	O
induced	O
blood	O
monocytes	O
but	O
not	O
in	O
monocytes	O
exposed	O
to	O
medium	O
treatment	O
only	O
.	O

The	O
results	O
suggest	O
that	O
M	O
-	O
CSF	O
induction	B-Positive_regulation
of	O
M	O
-	O
CSF	O
involves	O
G	O
proteins	O
,	O
PKC	O
and	O
NF	O
kappa	O
B	O
.	O

HIV1	O
infection	O
of	O
human	O
monocytes	O
and	O
macrophages	O
promotes	O
induction	O
or	O
translocation	O
of	O
NF-KB	O
-	O
related	O
factors	O
.	O

In	O
1991	O
,	O
we	O
demonstrated	O
,	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
that	O
3	O
different	O
factors	O
(	O
termed	O
B1	O
,	O
B2	O
and	O
B3	O
)	O
with	O
affinity	O
for	O
the	O
KB	O
-	O
enhancer	O
target	O
sequence	O
were	O
specifically	O
detected	O
in	O
nuclear	O
extracts	O
from	O
HIV1	O
-	O
infected	O
monocytes	O
and	O
macrophages	O
.	O

The	O
B2	O
factor	O
was	O
induced	O
in	O
the	O
nuclei	O
of	O
these	O
cells	O
only	O
upon	O
HIV1	O
infection	O
.	O

The	O
B3	O
factor	O
was	O
only	O
slightly	O
evident	O
in	O
nuclei	O
of	O
uninfected	O
cells	O
but	O
was	O
readily	O
detectable	O
in	O
nuclei	O
of	O
infected	O
monocytes	O
.	O

Its	O
expression	O
remained	O
very	O
low	O
in	O
nuclei	O
of	O
HIV1	O
-	O
infected	O
macrophages	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
the	O
B2	O
factor	O
is	O
expressed	O
in	O
the	O
cytosol	O
of	O
monocytes	O
and	O
macrophages	O
as	O
a	O
DNA	O
-	O
binding	O
protein	O
,	O
indicating	O
that	O
it	O
is	O
not	O
associated	O
with	O
an	O
inhibitor	O
(	O
IKB	O
)	O
.	O

This	O
factor	O
remained	O
clustered	O
in	O
the	O
cytosol	O
and	O
was	O
translocated	O
to	O
the	O
nuclei	O
only	O
after	O
HIV1	O
infection	O
.	O

The	O
B3	O
factor	O
is	O
detected	O
in	O
the	O
cytosol	O
only	O
when	O
cells	O
are	O
HIV1	O
-	O
infected	O
.	O

The	O
role	O
of	O
HIV1	O
infection	O
in	O
the	O
expression	O
and	O
the	O
translocation	O
of	O
these	O
factors	O
is	O
discussed	O
.	O

Induction	O
of	O
NF	O
-	O
kappa	O
B	O
during	O
monocyte	O
differentiation	O
is	O
associated	O
with	O
activation	O
of	O
HIV	O
-	O
gene	O
expression	O
.	O

Cells	O
of	O
the	O
monocyte	O
-	O
macrophage	O
lineage	O
are	O
important	O
targets	O
of	O
HIV	O
infection	O
.	O

We	O
report	O
here	O
that	O
the	O
phenotypic	O
differentiation	O
of	O
monocyte	O
cell	O
lines	O
induced	O
by	O
phorbol	O
esters	O
or	O
tumour	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
is	O
associated	O
with	O
expression	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
.	O

In	O
parallel	O
with	O
such	O
differentiation	O
,	O
HIV	O
transcription	O
,	O
monitored	O
using	O
an	O
HIV	O
long	O
terminal	O
repeat	O
reporter	O
gene	O
construct	O
,	O
is	O
activated	O
in	O
such	O
cells	O
under	O
the	O
influence	O
of	O
enhanced	O
NF	O
-	O
kappa	O
B	O
expression	O
.	O

Also	O
,	O
in	O
a	O
promonocyte	O
cell	O
line	O
chronically	O
infected	O
with	O
HIV	O
,	O
NF	O
-	O
kappa	O
B	O
expression	O
and	O
HIV	O
transcription	O
were	O
enhanced	O
on	O
stimulation	O
with	O
phorbol	O
ester	O
or	O
TNF	O
alpha	O
.	O

Thus	O
,	O
stimulation	O
of	O
monocyte	O
cell	O
lines	O
by	O
phorbol	O
esters	O
or	O
TNF	O
alpha	O
induces	O
cell	O
differentiation	O
and	O
activates	O
HIV	O
transcription	O
.	O

Such	O
a	O
process	O
may	O
have	O
fundamental	O
implications	O
in	O
AIDS	O
pathogenesis	O
in	O
vivo	O
and	O
may	O
be	O
important	O
in	O
disease	O
progression	O
induced	O
by	O
opportunistic	O
infections	O
directly	O
or	O
indirectly	O
involving	O
macrophages	O
.	O

Expression	B-Gene_expression
of	O
c	O
-	O
jun	O
,	O
jun	O
B	O
and	O
jun	O
D	O
proto	O
-	O
oncogenes	O
in	O
human	O
peripheral	O
-	O
blood	O
granulocytes	O
.	O

We	O
have	O
found	O
that	O
purified	O
human	O
peripheral	O
-	O
blood	O
granulocytes	O
express	B-Transcription
constitutively	O
significant	O
levels	O
of	O
proto	O
-	O
oncogenes	O
c	O
-	O
jun	O
,	O
jun	O
B	O
and	O
jun	O
D	O
mRNA	O
.	O

Upon	O
functional	O
activation	O
of	O
granulocytes	O
by	O
4	O
beta	O
-	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
,	O
the	O
levels	B-Transcription
of	O
c	O
-	O
jun	O
,	O
jun	O
B	O
and	O
jun	O
D	O
transcripts	O
were	O
increased	B-Positive_regulation
.	O

The	O
three	O
jun	O
genes	O
showed	O
a	O
similar	O
time	O
course	O
in	O
their	O
induction	B-Positive_regulation
by	O
PMA	O
,	O
maximal	O
mRNA	B-Transcription
levels	I-Transcription
being	O
reached	O
after	O
60	O
min	O
of	O
induction	O
.	O

These	O
results	O
suggest	O
that	O
expression	B-Gene_expression
of	O
c	O
-	O
jun	O
,	O
jun	O
B	O
and	O
jun	O
D	O
genes	O
might	O
be	O
involved	O
in	O
terminal	O
granulocyte	O
differentiation	O
or	O
in	O
regulating	O
granulocyte	O
functionality	O
.	O

Transforming	O
growth	O
factor	O
-	O
beta	O
suppresses	O
human	O
B	O
lymphocyte	O
Ig	O
production	O
by	O
inhibiting	O
synthesis	O
and	O
the	O
switch	O
from	O
the	O
membrane	O
form	O
to	O
the	O
secreted	O
form	O
of	O
Ig	O
mRNA	O
.	O

Transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
inhibits	O
B	O
cell	O
Ig	O
secretion	O
and	O
reduces	O
B	O
cell	O
membrane	O
Ig	O
expression	O
.	O

The	O
addition	O
of	O
TGF	O
-	O
beta	O
to	O
human	O
B	O
lymphocyte	O
cultures	O
stimulated	O
with	O
Staphylococcus	O
aureus	O
Cowan	O
strain	O
I	O
and	O
IL	O
-	O
2	O
completely	O
inhibited	O
B	O
cell	O
Ig	O
secretion	O
(	O
greater	O
than	O
90	O
%	O
)	O
and	O
decreased	B-Negative_regulation
B	O
cell	O
surface	O
IgM	O
,	O
IgD	O
,	O
kappa	O
L	O
chain	O
,	O
and	O
lambda	O
L	O
chain	O
expression	B-Gene_expression
.	O

In	O
contrast	O
,	O
TGF	O
-	O
beta	O
had	O
only	O
minimal	O
effects	B-Regulation
on	O
two	O
other	O
B	O
cell	O
membrane	O
proteins	O
,	O
HLA	O
-	O
DR	O
and	O
CD20	O
.	O

Internal	O
labeling	O
with	O
[	O
35S	O
]	O
methionine	O
and	O
immunoprecipitation	O
with	O
anti	O
-	O
IgM	O
,	O
anti	O
-	O
kappa	O
,	O
and	O
anti	O
-	O
lambda	O
antibodies	O
revealed	O
a	O
striking	O
reduction	B-Negative_regulation
in	O
kappa	O
L	O
chain	O
in	O
the	O
presence	O
of	O
TGF	O
-	O
beta	O
.	O

A	O
less	O
pronounced	O
reduction	B-Negative_regulation
in	O
lambda	O
L	O
chain	O
and	O
microH	O
chain	O
was	O
also	O
noted	O
.	O

Northern	O
blot	O
analysis	O
of	O
RNA	O
purified	O
from	O
B	O
cells	O
treated	O
with	O
TGF	O
-	O
beta	O
for	O
varying	O
time	O
intervals	O
revealed	O
a	O
significant	O
decrease	O
in	O
steady	O
state	O
kappa	O
and	O
lambda	O
L	O
chain	O
mRNA	O
levels	B-Negative_regulation
.	O

Furthermore	O
,	O
a	O
significant	O
decrease	O
in	O
the	O
switch	O
from	O
the	O
membrane	O
forms	O
of	O
mu	O
and	O
gamma	O
to	O
their	O
respective	O
secreted	O
forms	O
was	O
noted	O
in	O
the	O
presence	O
of	O
TGF	O
-	O
beta	O
.	O

Nuclear	O
run	O
-	O
on	O
experiments	O
demonstrated	O
decreased	B-Negative_regulation
transcription	B-Transcription
of	O
kappa	O
L	O
chain	O
.	O

The	O
effects	B-Regulation
of	O
TGF	O
-	O
beta	O
on	O
two	O
transcriptional	O
regulatory	O
factors	O
,	O
Oct	O
-	O
2	O
and	O
nuclear	O
factor	O
(	O
NF	O
)	O
kappa	O
B	O
,	O
known	O
to	O
be	O
important	O
in	O
Ig	O
gene	O
transcription	O
were	O
examined	O
.	O

Oct	O
-	O
2	O
mRNA	O
levels	O
and	O
both	O
Oct	O
-	O
2	O
and	O
NF	O
-	O
kappa	O
B	O
proteins	O
in	O
nuclear	O
extracts	O
were	O
not	O
altered	B-Regulation
by	O
treatment	O
with	O
TGF	O
-	O
beta	O
.	O

In	O
contrast	O
,	O
levels	O
of	O
the	O
transcriptional	O
factor	O
AP	O
-	O
1	O
,	O
which	O
is	O
not	O
known	O
to	O
be	O
important	O
in	O
B	O
cell	O
Ig	O
production	O
,	O
were	O
reduced	O
by	O
TGF	O
-	O
beta	O
.	O

These	O
findings	O
demonstrate	O
that	O
TGF	O
-	O
beta	O
decreases	O
B	O
lymphocyte	O
Ig	O
secretion	O
by	O
inhibiting	O
the	O
synthesis	O
of	O
Ig	O
mRNA	O
and	O
inhibiting	O
the	O
switch	O
from	O
the	O
membrane	O
form	O
to	O
the	O
secreted	O
forms	O
of	O
mu	O
and	O
gamma	O
mRNA	O
.	O

The	O
mechanism	O
by	O
which	O
TGF	O
-	O
beta	O
inhibits	O
Ig	O
chain	O
synthesis	O
is	O
unclear	O
although	O
it	O
does	O
not	O
involve	O
inhibition	B-Negative_regulation
of	O
the	O
binding	B-Binding
of	O
NF	O
-	O
kappa	O
B	O
or	O
Oct	O
-	O
2	O
to	O
their	O
respective	O
target	O
sequences	O
.	O

Inhibition	O
of	O
HIV	O
-	O
1	O
replication	O
and	O
NF	O
-	O
kappa	O
B	O
activity	O
by	O
cysteine	O
and	O
cysteine	O
derivatives	O
.	O

HIV	O
-	O
1	O
proviral	O
DNA	O
contains	O
two	O
binding	O
sites	O
for	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
.	O

HIV-1	O
-	O
infected	O
individuals	O
have	O
,	O
on	O
average	O
,	O
abnormally	O
high	B-Positive_regulation
levels	I-Positive_regulation
of	O
tumour	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
and	O
abnormally	O
low	O
plasma	O
cysteine	O
levels	O
.	O

We	O
therefore	O
investigated	O
the	O
effects	O
of	O
cysteine	O
and	O
related	O
thiols	O
on	O
HIV	O
-	O
1	O
replication	O
and	O
NF	O
-	O
kappa	O
B	O
expression	O
.	O

The	O
experiments	O
in	O
this	O
report	O
show	O
that	O
cysteine	O
or	O
N	O
-	O
acetylcysteine	O
(	O
NAC	O
)	O
raise	O
the	O
intracellular	O
glutathione	O
(	O
GSH	O
)	O
level	O
and	O
inhibit	O
HIV	O
-	O
1	O
replication	O
in	O
persistently	O
infected	O
Molt	O
-	O
4	O
and	O
U937	O
cells	O
.	O

However	O
,	O
inhibition	O
of	O
HIV	O
-	O
1	O
replication	O
appears	O
not	O
to	O
be	O
directly	O
correlated	O
with	O
GSH	O
levels	O
.	O

Cysteine	O
and	O
NAC	O
also	O
inhibit	B-Negative_regulation
NF	O
-	O
kappa	O
B	O
activity	O
as	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
chloramphenicol	O
acetyl	O
-	O
transferase	O
(	O
CAT	O
)	O
gene	O
expression	B-Gene_expression
under	O
control	B-Regulation
of	O
NF	O
-	O
kappa	O
B	O
binding	O
sites	O
in	O
uninfected	O
cells	O
.	O

This	O
suggests	O
that	O
the	O
cysteine	O
deficiency	O
in	O
HIV-1	O
-	O
infected	O
individuals	O
may	O
cause	O
an	O
over	O
-	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
genes	O
and	O
enhance	O
HIV	O
-	O
1	O
replication	O
.	O

NAC	O
may	O
be	O
considered	O
for	O
the	O
treatment	O
of	O
HIV-1	O
-	O
infected	O
individuals	O
.	O

A	O
nuclear	O
factor	O
NF	O
-	O
GM2	O
that	O
interacts	O
with	O
a	O
regulatory	O
region	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
essential	B-Positive_regulation
for	O
its	O
induction	B-Gene_expression
in	O
responses	B-Regulation
to	O
T	O
-	O
cell	O
activation	O
:	O
purification	O
from	O
human	O
T	O
-	O
cell	O
leukemia	O
line	O
Jurkat	O
cells	O
and	O
similarity	O
to	O
NF	O
-	O
kappa	O
B	O
.	O

Activation	O
of	O
T	O
cells	O
by	O
antigen	O
,	O
lectin	O
,	O
or	O
a	O
combination	O
of	O
phorbol-12	O
-	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
leads	B-Positive_regulation
to	O
the	O
induction	B-Gene_expression
of	O
genes	O
for	O
a	O
set	O
of	O
lymphokines	O
,	O
including	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
.	O

We	O
demonstrated	O
in	O
earlier	O
studies	O
that	O
the	O
upstream	O
region	O
of	O
the	O
mouse	O
GM	O
-	O
CSF	O
promoter	O
at	O
positions	O
between	O
-	O
95	O
and	O
-	O
73	O
is	O
essential	B-Positive_regulation
for	O
transcriptional	B-Positive_regulation
activation	I-Positive_regulation
in	O
response	O
to	O
PMA/A23187	O
.	O

This	O
region	O
contains	O
two	O
DNA	O
-	O
binding	O
motifs	O
,	O
GM2	O
and	O
GC	O
-	O
box	O
.	O

The	O
GM2	O
sequence	O
(	O
GGTAGTTCCC	O
)	O
is	O
recognized	O
by	O
an	O
inducible	O
factor	O
NF	O
-	O
GM2	O
;	O
the	O
other	O
(	O
CCGCCC	O
)	O
by	O
constitutive	O
factors	O
A1	O
,	O
A2	O
,	O
and	O
B	O
.	O

To	O
elucidate	O
the	O
mechanism	O
of	O
GM	O
-	O
CSF	O
gene	O
activation	B-Positive_regulation
,	O
we	O
have	O
purified	O
the	O
inducible	O
factor	O
NF	O
-	O
GM2	O
from	O
the	O
nuclear	O
extract	O
of	O
stimulated	O
Jurkat	O
cells	O
on	O
the	O
basis	O
of	O
specific	O
DNA	O
-	O
binding	O
activity	O
.	O

The	O
purified	O
NF	O
-	O
GM2	O
consists	O
of	O
50	O
(	O
p50	O
)	O
and	O
65	O
kDa	O
(	O
p65	O
)	O
polypeptides	O
and	O
has	O
a	O
binding	B-Binding
activity	I-Binding
specific	O
for	O
both	O
the	O
GM	O
-	O
CSF	O
and	O
immunoglobulin	O
kappa	O
(	O
GGAAAGTCCC	O
)	O
enhancers	O
.	O

Electrophoretically	O
purified	O
p50	O
alone	O
can	O
form	O
a	O
protein	O
-	O
DNA	O
complex	B-Binding
,	O
but	O
in	O
the	O
mixture	O
,	O
p50	O
associates	B-Binding
preferentially	O
with	O
p65	O
to	O
form	O
the	O
NF	O
-	O
GM2	O
complex	O
.	O

In	O
addition	O
,	O
p65	O
gave	O
per	O
se	O
,	O
with	O
low	O
affinity	O
,	O
a	O
protein	O
-	O
DNA	O
complex	B-Binding
that	O
migrated	O
more	O
slowly	O
than	O
native	O
NF	O
-	O
GM2	O
complex	O
.	O

Furthermore	O
,	O
an	O
antiserum	O
against	O
KBF1	O
(	O
identical	O
to	O
50	O
kDa	O
NF	O
-	O
kappa	O
B	O
protein	O
)	O
reacted	B-Binding
with	O
the	O
p50	O
of	O
NF	O
-	O
GM2	O
,	O
indicating	O
that	O
the	O
NF	O
-	O
GM2	O
polypeptide	O
can	O
not	O
be	O
immunologically	O
differentiated	O
from	O
the	O
50	O
kDa	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
purified	O
NF	O
-	O
GM2	O
activated	O
in	O
vitro	O
transcription	O
from	O
the	O
kappa	O
B	O
enhancer	O
,	O
while	O
it	O
failed	O
to	O
stimulate	B-Positive_regulation
transcription	B-Transcription
from	O
the	O
GM	O
-	O
CSF	O
promoter	O
harboring	O
the	O
GM2	O
sequence	O
.	O

This	O
suggests	O
that	O
the	O
activation	B-Gene_expression
mechanism	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
through	B-Positive_regulation
the	O
GM2/GC	O
-	O
box	O
sequence	O
is	O
different	O
from	O
that	O
of	O
genes	O
carrying	O
the	O
kappa	O
B	O
enhancer	O
alone	O
.	O

Synergism	O
between	O
two	O
distinct	O
elements	O
of	O
the	O
HTLV	O
-	O
I	O
enhancer	O
during	O
activation	O
by	O
the	O
trans	O
-	O
activator	O
of	O
HTLV	O
-	O
I	O
.	O

We	O
have	O
conducted	O
functional	O
studies	O
of	O
the	O
enhancer	O
elements	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
using	O
the	O
human	O
T	O
-	O
cell	O
lines	O
Jurkat	O
and	O
MOLT	O
4	O
,	O
which	O
are	O
negative	O
for	O
HTLV	O
-	O
I	O
,	O
and	O
MT	O
-	O
2	O
and	O
TL	O
-	O
Mor	O
,	O
which	O
carry	O
the	O
proviral	O
genome	O
of	O
HTLV	O
-	O
I	O
.	O

Two	O
distinct	O
elements	O
have	O
been	O
implicated	O
in	O
function	O
of	O
the	O
HTLV	O
-	O
I	O
enhancer	O
.	O

One	O
is	O
the	O
21-base	O
-	O
pair	O
(	O
bp	O
)	O
core	O
element	O
that	O
is	O
responsible	O
for	O
trans	O
-	O
activation	O
by	O
the	O
HTLV	O
-	O
I	O
trans	O
-	O
activator	O
p40tax	O
and	O
that	O
has	O
the	O
ability	O
to	O
bind	B-Binding
to	O
cyclic	O
-	O
AMP	O
responsive	O
element	O
binding	O
factor	O
(	O
CREB	O
)	O
-	O
like	O
factor	O
(	O
s	O
)	O
.	O

The	O
other	O
is	O
a	O
region	O
interposed	O
between	O
the	O
21	O
-	O
bp	O
elements	O
.	O

In	O
this	O
study	O
we	O
demonstrate	O
that	O
a	O
subfragment	O
(	O
C26	O
)	O
in	O
the	O
region	O
between	O
the	O
21	O
-	O
bp	O
elements	O
is	O
involved	O
in	O
trans	O
-	O
activation	O
by	O
p40tax	O
,	O
possibly	O
through	O
binding	O
to	O
an	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
nuclear	O
factor	O
or	O
factors	O
.	O

Formation	O
of	O
the	O
protein	O
-	O
DNA	O
complex	O
with	O
the	O
C26	O
subfragment	O
was	O
positively	O
affected	O
by	O
p40tax	O
.	O

The	O
C26	O
element	O
conferred	O
partial	O
responsiveness	O
to	O
p40tax	O
when	O
linked	O
to	O
one	O
copy	O
of	O
the	O
21	O
-	O
bp	O
element	O
that	O
,	O
by	O
itself	O
,	O
showed	O
little	O
activation	O
in	O
response	O
to	O
p40tax	O
.	O

However	O
,	O
the	O
C26	O
element	O
alone	O
,	O
even	O
when	O
repeated	O
,	O
could	O
not	O
be	O
activated	O
by	O
p40tax	O
,	O
unlike	O
other	O
NF	O
-	O
kappa	O
B	O
-	O
binding	O
elements	O
.	O

In	O
contrast	O
,	O
the	O
C26	O
element	O
itself	O
was	O
profoundly	O
activated	O
upon	O
stimulation	O
with	O
12-O-tetradecanoylphorbol-13	O
-	O
acetate	O
.	O

These	O
findings	O
therefore	O
suggest	O
that	O
the	O
HTLV	O
-	O
I	O
enhancer	O
contains	O
multiple	O
functional	O
elements	O
,	O
including	O
binding	O
sites	O
for	O
at	O
least	O
CREB	O
-	O
and	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
factors	O
,	O
which	O
synergistically	O
cooperate	O
in	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
enhancer	O
in	O
response	O
to	O
p40tax	O
.	O

Our	O
results	O
also	O
demonstrate	O
that	O
TPA	O
-	O
dependent	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
enhancer	O
may	O
be	O
mediated	O
through	O
the	O
C26	O
element	O
.	O

Inhibition	O
of	O
phorbol	O
ester	O
-	O
induced	O
monocytic	O
differentiation	O
by	O
dexamethasone	O
is	O
associated	O
with	O
down	B-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
of	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
(	O
AP	O
-	O
1	O
)	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
treatment	O
of	O
human	O
myeloid	O
leukemia	O
cells	O
with	O
12-O-tetradecanoylphorbol-13	O
-	O
acetate	O
(	O
TPA	O
)	O
is	O
associated	O
with	O
induction	O
of	O
monocytic	O
differentiation	O
and	O
expression	O
of	O
the	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
early	O
response	O
genes	O
.	O

The	O
present	O
work	O
demonstrates	O
that	O
the	O
glucocorticoid	O
dexamethasone	O
inhibits	B-Negative_regulation
TPA	O
-	O
induced	O
increases	B-Positive_regulation
in	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
mRNA	O
levels	O
in	O
U	O
-	O
937	O
leukemia	O
cells	O
.	O

These	O
findings	O
were	O
associated	O
with	O
a	O
block	O
in	O
appearance	O
of	O
the	O
monocytic	O
phenotype	O
,	O
including	O
inhibition	B-Negative_regulation
of	O
TPA	O
-	O
induced	O
increases	B-Positive_regulation
in	O
lamin	O
A	O
,	O
lamin	O
C	O
,	O
and	O
vimentin	O
transcripts	O
.	O

Other	O
studies	O
have	O
demonstrated	O
that	O
TPA	O
-	O
induced	O
monocytic	O
differentiation	O
and	O
expression	B-Gene_expression
of	O
the	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
genes	O
in	O
myeloid	O
leukemia	O
cells	O
are	O
regulated	B-Regulation
by	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
.	O

The	O
finding	O
that	O
dexamethasone	O
has	O
no	O
effect	B-Regulation
on	O
TPA	O
-	O
induced	O
activation	B-Positive_regulation
of	O
PKC	O
suggests	O
that	O
this	O
glucocorticoid	O
inhibits	O
signals	O
downstream	O
or	O
parallel	O
to	O
this	O
enzyme	O
.	O

Nuclear	O
run	O
-	O
on	O
assays	O
demonstrate	O
that	O
:	O
(	O
1	O
)	O
induction	B-Positive_regulation
of	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
expression	B-Gene_expression
by	O
TPA	O
is	O
regulated	B-Regulation
by	O
transcriptional	O
mechanisms	O
,	O
(	O
2	O
)	O
TPA	O
-	O
induced	B-Positive_regulation
expression	B-Gene_expression
of	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
does	O
not	O
require	B-Positive_regulation
protein	O
synthesis	O
,	O
and	O
(	O
3	O
)	O
TPA	O
-	O
induced	B-Positive_regulation
expression	O
of	O
both	O
genes	O
is	O
inhibited	B-Negative_regulation
at	B-Transcription
the	I-Transcription
transcriptional	I-Transcription
level	I-Transcription
by	O
dexamethasone	O
.	O

To	O
further	O
define	O
the	O
effects	O
of	O
dexamethasone	O
at	O
the	O
molecular	O
level	O
,	O
we	O
prepared	O
a	O
series	O
of	O
deleted	O
c	O
-	O
jun	O
promoter	O
fragments	O
linked	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
gene	O
.	O

Increases	B-Positive_regulation
in	O
CAT	O
activity	O
during	O
transient	O
expression	O
of	O
these	O
constructs	O
in	O
TPA	O
-	O
treated	O
U	O
-	O
937	O
cells	O
could	O
be	O
assigned	O
to	O
the	O
region	O
(	O
-	O
97	O
to	O
-	O
20	O
)	O
of	O
the	O
promoter	O
that	O
contains	O
the	O
AP	O
-	O
1	O
binding	O
site	O
.	O

This	O
induction	B-Positive_regulation
of	O
CAT	O
activity	O
was	O
sensitive	B-Regulation
to	O
dexamethasone	O
.	O

These	O
findings	O
suggest	O
that	O
dexamethasone	O
down	B-Negative_regulation
-	I-Negative_regulation
regulates	I-Negative_regulation
TPA	O
-	O
induced	B-Positive_regulation
transcription	B-Transcription
of	O
the	O
c	O
-	O
jun	O
gene	O
during	O
monocytic	O
differentiation	O
by	O
inhibiting	O
activation	O
of	O
the	O
AP	O
-	O
1	O
site	O
.	O

Evaluation	O
of	O
the	O
role	O
of	O
ligand	O
and	O
thermal	O
activation	O
of	O
specific	O
DNA	O
binding	O
by	O
in	O
vitro	O
synthesized	O
human	O
glucocorticoid	O
receptor	O
.	O

We	O
have	O
used	O
a	O
DNA	O
-	O
binding/immunoprecipitation	O
assay	O
to	O
analyze	O
the	O
capacity	O
of	O
human	O
glucocorticoid	O
receptor	O
(	O
hGR	O
)	O
,	O
generated	O
in	O
rabbit	O
reticulocyte	O
lysates	O
,	O
to	O
bind	O
DNA	O
.	O

In	O
vitro	O
translated	O
hGR	O
was	O
indistinguishable	O
from	O
native	O
hGR	O
,	O
as	O
determined	O
by	O
migration	O
on	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gels	O
,	O
sedimentation	O
on	O
sucrose	O
density	O
gradients	O
,	O
and	O
reactivity	O
with	O
antipeptide	O
antibodies	O
generated	O
against	O
hGR	O
.	O

In	O
addition	O
,	O
cell	O
-	O
free	O
synthesized	O
hGR	O
was	O
capable	O
of	O
specific	O
binding	O
to	O
glucocorticoid	O
response	O
element	O
(	O
GRE	O
)	O
-	O
containing	O
DNA	O
fragments	O
.	O

Using	O
this	O
assay	O
system	O
,	O
we	O
have	O
evaluated	O
the	O
contributions	O
of	O
ligand	O
binding	O
and	O
heat	O
activation	O
to	O
DNA	O
binding	O
by	O
these	O
glucocorticoid	O
receptors	O
.	O

In	O
vitro	O
translated	O
hGR	O
was	O
capable	O
of	O
selective	O
DNA	O
binding	O
even	O
in	O
the	O
absence	O
of	O
glucocorticoid	O
.	O

Treatment	O
with	O
dexamethasone	O
or	O
the	O
antiglucocorticoid	O
RU486	O
had	O
no	O
additional	O
effect	O
on	O
the	O
DNA	O
-	O
binding	O
capacity	O
when	O
receptor	O
preparations	O
were	O
maintained	O
at	O
0	O
C	O
(	O
no	O
activation	O
)	O
.	O

In	O
contrast	O
,	O
addition	O
of	O
either	O
ligand	O
or	O
antagonist	O
in	O
combination	O
with	O
a	O
heat	O
activation	O
step	O
promoted	O
DNA	O
binding	O
by	O
approximately	O
3	O
-	O
fold	O
over	O
that	O
of	O
heat	O
-	O
activated	O
unliganded	O
receptors	O
.	O

Agonist	O
(	O
dexamethasone	O
)	O
was	O
slightly	O
more	O
effective	O
in	O
supporting	O
specific	O
DNA	O
binding	O
than	O
antagonist	O
(	O
RU486	O
)	O
.	O

DNA	O
binding	O
by	O
in	O
vitro	O
synthesized	O
GR	O
was	O
blocked	O
by	O
the	O
addition	O
of	O
sodium	O
molybdate	O
to	O
the	O
receptor	O
preparations	O
before	O
steroid	O
addition	O
and	O
thermal	O
activation	O
.	O

Addition	O
of	O
KCl	O
resulted	O
in	O
less	O
DNA	O
binding	O
either	O
due	O
to	O
blockage	O
of	O
DNA	O
-	O
receptor	O
complex	O
formation	O
or	O
disruption	O
of	O
the	O
complexes	O
.	O

The	O
specificity	O
of	O
DNA	O
binding	O
by	O
cell	O
-	O
free	O
synthesized	O
hGR	O
was	O
analyzed	O
further	O
by	O
examining	O
the	O
abilities	O
of	O
various	O
DNAs	O
to	O
compete	O
for	O
binding	O
to	O
a	O
naturally	O
occurring	O
GRE	O
found	O
in	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
-	O
long	O
terminal	O
repeat	O
.	O

Oligonucleotides	O
containing	O
the	O
consensus	O
GRE	O
were	O
the	O
most	O
efficient	O
competitors	O
,	O
and	O
fragments	O
containing	O
regulatory	O
sequences	O
from	O
glucocorticoid	O
-	O
repressible	O
genes	O
were	O
somewhat	O
competitive	O
,	O
whereas	O
single	O
stranded	O
oligonucleotides	O
were	O
unable	O
to	O
compete	O
for	O
mouse	O
mammary	O
tumor	O
virus	O
-	O
long	O
terminal	O
repeat	O
DNA	O
binding	O
,	O
except	O
when	O
competitor	O
was	O
present	O
at	O
extremely	O
high	O
concentrations	O
.	O

Together	O
these	O
studies	O
indicate	O
that	O
hGR	O
synthesized	O
in	O
rabbit	O
reticulocyte	O
lysates	O
displays	O
many	O
of	O
the	O
same	O
properties	O
,	O
including	O
GRE	O
-	O
specific	O
DNA	O
binding	O
,	O
observed	O
for	O
glucocorticoid	O
receptor	O
present	O
in	O
cytosolic	O
extracts	O
of	O
mammalian	O
cells	O
and	O
tissues	O
.	O

Similarities	O
between	O
the	O
effects	O
of	O
dexamethasone	O
and	O
RU486	O
suggest	O
that	O
the	O
antiglucocorticoid	O
properties	O
of	O
RU486	O
do	O
not	O
occur	O
at	O
the	O
level	O
of	O
specific	O
DNA	O
binding	O
.	O

One	O
base	O
pair	O
change	O
abolishes	O
the	O
T	O
cell	O
-	O
restricted	O
activity	O
of	O
a	O
kB	O
-	O
like	O
proto	O
-	O
enhancer	O
element	O
from	O
the	O
interleukin	O
2	O
promoter	O
.	O

The	O
inducible	O
,	O
T	O
cell	O
-	O
specific	O
enhancers	O
of	O
murine	O
and	O
human	O
Interleukin	O
2	O
(	O
Il	O
-	O
2	O
)	O
genes	O
contain	O
the	O
kB	O
-	O
like	O
sequence	O
GGGATTTCACC	O
as	O
an	O
essential	O
cis	O
-	O
acting	O
enhancer	O
motif	O
.	O

When	O
cloned	O
in	O
multiple	O
copies	O
this	O
so	O
-	O
called	O
TCEd	O
(	O
distal	O
T	O
cell	O
element	O
)	O
acts	O
as	O
an	O
inducible	O
proto	O
-	O
enhancer	O
element	O
in	O
E14	O
T	O
lymphoma	O
cells	O
,	O
but	O
not	O
in	O
HeLa	O
cells	O
.	O

In	O
extracts	O
of	O
induced	O
,	O
Il	O
-	O
2	O
secreting	B-Localization
El4	O
cells	O
three	O
individual	O
protein	O
factors	O
bind	O
to	O
TCEd	O
DNA	O
.	O

The	O
binding	B-Binding
of	O
the	O
most	O
prominent	O
factor	O
,	O
named	O
TCF	O
-	O
1	O
(	O
T	O
cell	O
factor	O
1	O
)	O
,	O
is	O
correlated	O
with	O
the	O
proto	O
-	O
enhancer	O
activity	O
of	O
TCEd	O
.	O

TCF	O
-	O
1	O
consists	O
of	O
two	O
polypeptides	O
of	O
about	O
50	O
kD	O
and	O
105	O
kD	O
;	O
the	O
former	O
seems	O
to	O
be	O
related	O
to	O
the	O
50	O
kD	O
polypeptide	O
of	O
NF	O
-	O
kB	O
.	O

Purified	O
NF	O
-	O
kB	O
is	O
also	O
able	O
to	O
bind	O
to	O
the	O
TCEd	O
,	O
but	O
TCF	O
-	O
1	O
binds	B-Binding
stronger	O
than	O
NF	O
-	O
kB	O
to	O
TCEd	O
DNA	O
.	O

The	O
conversion	O
of	O
the	O
TCEd	O
to	O
a	O
'perfect	O
'	O
NF	O
-	O
kB	O
binding	O
site	O
leads	O
to	O
a	O
tighter	O
binding	O
of	O
NF	O
-	O
kB	O
to	O
TCEd	O
DNA	O
and	O
,	O
as	O
a	O
functional	O
consequence	O
,	O
to	O
the	O
activity	O
of	O
the	O
'converted	O
'	O
TCEd	O
motifs	O
in	O
HeLa	O
cells	O
.	O

Thus	O
,	O
the	O
substitution	O
of	O
the	O
underlined	O
A	O
residue	O
to	O
a	O
C	O
within	O
the	O
GGGATTTCACC	O
motif	O
abolishes	O
its	O
T	O
cell	O
-	O
restricted	O
activity	O
and	O
leads	O
to	O
its	O
functioning	O
in	O
both	O
El4	O
cells	O
and	O
HeLa	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
lymphocyte	O
-	O
specific	O
factors	O
binding	O
to	O
the	O
TCEd	O
are	O
involved	O
in	O
the	O
control	B-Regulation
of	O
T	O
cell	O
specific	O
-	O
transcription	B-Transcription
of	O
the	O
Il	O
-	O
2	O
gene	O
.	O

Negative	O
regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
in	O
monocytes	O
:	O
role	O
of	O
the	O
65	O
-	O
kDa	O
plus	O
50	O
-	O
kDa	O
NF	O
-	O
kappa	O
B	O
dimer	O
.	O

Although	O
monocytic	O
cells	O
can	O
provide	O
a	O
reservoir	O
for	O
viral	O
production	O
in	O
vivo	O
,	O
their	O
regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
transcription	O
can	O
be	O
either	O
latent	O
,	O
restricted	O
,	O
or	O
productive	O
.	O

These	O
differences	O
in	O
gene	O
expression	O
have	O
not	O
been	O
molecularly	O
defined	O
.	O

In	O
THP	O
-	O
1	O
cells	O
with	O
restricted	O
HIV	O
expression	O
,	O
there	O
is	O
an	O
absence	O
of	O
DNA	O
-	O
protein	O
binding	O
complex	O
formation	O
with	O
the	O
HIV	O
-	O
1	O
promoter	O
-	O
enhancer	O
associated	O
with	O
markedly	O
less	O
viral	O
RNA	O
production	O
.	O

This	O
absence	O
of	O
binding	O
was	O
localized	O
to	O
the	O
NF	O
-	O
kappa	O
B	O
region	O
of	O
the	O
HIV	O
-	O
1	O
enhancer	O
;	O
the	O
65	O
-	O
kDa	O
plus	O
50	O
-	O
kDa	O
NF	O
-	O
kappa	O
B	O
heterodimer	B-Binding
was	O
preferentially	O
lost	B-Negative_regulation
.	O

Adding	O
purified	O
NF	O
-	O
kappa	O
B	O
protein	O
to	O
nuclear	O
extracts	O
from	O
cells	O
with	O
restricted	O
expression	O
overcomes	B-Negative_regulation
this	O
lack	O
of	O
binding	O
.	O

In	O
addition	O
,	O
treatment	O
of	O
these	O
nuclear	O
extracts	O
with	O
sodium	O
deoxycholate	O
restored	B-Positive_regulation
their	O
ability	O
to	O
form	O
the	O
heterodimer	O
,	O
suggesting	O
the	O
presence	O
of	O
an	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
.	O

Furthermore	O
,	O
treatment	O
of	O
nuclear	O
extracts	O
from	O
these	O
cells	O
that	O
had	O
restricted	O
expression	O
with	O
lipopolysaccharide	O
increased	O
viral	O
production	O
and	O
NF	O
-	O
kappa	O
B	O
activity	O
.	O

Antiserum	O
specific	O
for	O
NF	O
-	O
kappa	O
B	O
binding	O
proteins	O
,	O
but	O
not	O
c-rel	O
-	O
specific	O
antiserum	O
,	O
disrupted	B-Negative_regulation
heterodimer	O
complex	O
formation	O
.	O

Thus	O
,	O
both	O
NF	O
-	O
kappa	O
B	O
-	O
binding	O
complexes	O
are	O
needed	O
for	O
optimal	O
viral	O
transcription	O
.	O

Binding	B-Binding
of	O
the	O
65	O
-	O
kDa	O
plus	O
50	O
-	O
kDa	O
heterodimer	B-Binding
to	O
the	O
HIV	O
-	O
1	O
enhancer	O
can	O
be	O
negatively	B-Negative_regulation
regulated	I-Negative_regulation
in	O
monocytes	O
,	O
providing	O
one	O
mechanism	O
restricting	O
HIV	O
-	O
1	O
gene	O
expression	O
.	O

Isolation	O
of	O
a	O
candidate	O
repressor/activator	O
,	O
NF	O
-	O
E1	O
(	O
YY	O
-	O
1	O
,	O
delta	O
)	O
,	O
that	O
binds	B-Binding
to	O
the	O
immunoglobulin	O
kappa	O
3	O
'	O
enhancer	O
and	O
the	O
immunoglobulin	O
heavy	O
-	O
chain	O
mu	O
E1	O
site	O
.	O

We	O
have	O
determined	O
that	O
the	O
developmental	O
control	O
of	O
immunoglobulin	O
kappa	O
3	O
'	O
enhancer	O
(	O
kappa	O
E3	O
'	O
)	O
activity	O
is	O
the	O
result	O
of	O
the	O
combined	O
influence	O
of	O
positive	O
-	O
and	O
negative	O
-	O
acting	O
elements	O
.	O

We	O
show	O
that	O
a	O
central	O
core	O
in	O
the	O
kappa	O
E3	O
'	O
enhancer	O
is	O
active	O
at	O
the	O
pre-B	O
-	O
cell	O
stage	O
but	O
is	O
repressed	O
by	O
flanking	O
negative	O
-	O
acting	O
elements	O
.	O

The	O
negative	O
-	O
acting	O
sequences	O
repress	O
enhancer	O
activity	O
in	O
a	O
position	O
-	O
and	O
orientation	O
-	O
independent	O
manner	O
at	O
the	O
pre-B	O
-	O
cell	O
stage	O
.	O

We	O
have	O
isolated	O
a	O
human	O
cDNA	O
clone	O
encoding	O
a	O
zinc	O
finger	O
protein	O
(	O
NF	O
-	O
E1	O
)	O
that	O
binds	B-Binding
to	O
the	O
negative	O
-	O
acting	O
segment	O
of	O
the	O
kappa	O
E3	O
'	O
enhancer	O
.	O

This	O
protein	O
also	O
binds	B-Binding
to	O
the	O
immunoglobulin	O
heavy	O
-	O
chain	O
enhancer	O
mu	O
E1	O
site	O
.	O

NF	O
-	O
E1	O
is	O
encoded	O
by	O
the	O
same	O
gene	O
as	O
the	O
YY	O
-	O
1	O
protein	O
,	O
which	O
binds	B-Binding
to	O
the	O
adeno	O
-	O
associated	O
virus	O
P5	O
promoter	O
.	O

NF	O
-	O
E1	O
is	O
also	O
the	O
human	O
homologue	O
of	O
the	O
mouse	O
delta	O
protein	O
,	O
which	O
binds	B-Binding
to	O
ribosomal	O
protein	O
gene	O
promoters	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
this	O
protein	O
contains	O
features	O
characteristic	O
of	O
transcriptional	O
activators	O
as	O
well	O
as	O
transcriptional	O
repressors	O
.	O

Cotransfection	O
studies	O
with	O
this	O
cDNA	O
indicate	O
that	O
it	O
can	O
repress	O
basal	O
promoter	O
activity	O
.	O

The	O
apparent	O
dual	O
function	O
of	O
this	O
protein	O
is	O
discussed	O
.	O

Regulation	B-Regulation
of	O
interleukin	O
-	O
1	O
beta	O
production	B-Gene_expression
by	O
glucocorticoids	O
in	O
human	O
monocytes	O
:	O
the	O
mechanism	O
of	O
action	O
depends	B-Regulation
on	O
the	O
activation	O
signal	O
.	O

Glucocorticoids	O
are	O
known	O
to	O
downregulate	B-Negative_regulation
interleukin	O
-	O
1	O
beta	O
production	B-Gene_expression
in	O
monocytic	O
cells	O
by	O
two	O
different	O
mechanims	O
:	O
direct	O
inhibition	O
of	O
the	O
gene	O
transcription	O
and	O
destabilization	B-Negative_regulation
of	O
the	O
preformed	B-Transcription
interleukin	O
-	O
1	O
beta	O
mRNA	O
.	O

Now	O
we	O
have	O
examined	O
the	O
effect	B-Regulation
of	O
the	O
nature	O
of	O
the	O
monocyte	O
activating	O
signal	O
on	O
these	O
two	O
inhibitory	O
mechanims	O
.	O

When	O
human	O
monocytes	O
were	O
preincubated	O
with	O
dexamethasone	O
for	O
1	O
hour	O
and	O
then	O
stimulated	O
either	O
with	O
bacterial	O
lipopolysaccharide	O
or	O
phorbol	O
myristate	O
,	O
it	O
was	O
found	O
that	O
dexamethasone	O
inhibited	B-Negative_regulation
the	O
lipopolysaccharide	O
-	O
induced	B-Positive_regulation
interleukin	O
-	O
1	O
beta	O
protein	O
production	B-Gene_expression
,	O
but	O
the	O
phorbol	O
myristate	O
-	O
induced	B-Positive_regulation
production	O
was	O
increased	B-Positive_regulation
3	O
-	O
10	O
fold	O
.	O

This	O
difference	O
was	O
also	O
seen	O
at	O
the	O
mRNA	O
level	O
.	O

When	O
dexamethasone	O
was	O
added	O
to	O
the	O
cultures	O
3	O
hours	O
after	O
the	O
stimulators	O
,	O
it	O
clearly	O
decreased	B-Negative_regulation
the	O
interleukin	O
-	O
1	O
beta	O
mRNA	O
levels	B-Transcription
regardless	B-Regulation
of	I-Regulation
the	O
stimulator	O
used	O
(	O
although	O
the	O
effect	O
was	O
clearly	O
weaker	O
on	O
the	O
PMA	O
-	O
induced	B-Positive_regulation
mRNA	O
)	O
.	O

Thus	O
these	O
data	O
suggest	O
that	O
the	O
phorbol	O
myristate	O
-	O
induced	B-Positive_regulation
signal	O
(	O
prolonged	O
protein	O
kinase	O
C	O
activation	O
?	O
)	O
can	O
not	O
be	O
inhibited	B-Negative_regulation
by	O
prior	O
incubation	O
with	O
dexamethasone	O
and	O
it	O
also	O
protects	O
the	O
induced	O
mRNA	O
for	O
the	O
degradative	O
action	O
of	O
dexamethasone	O
.	O

Identification	O
of	O
transcriptional	O
suppressor	O
proteins	O
that	O
bind	O
to	O
the	O
negative	O
regulatory	O
element	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

Two	O
different	O
proteins	O
which	O
independently	O
bound	O
to	O
neighboring	O
sequences	O
within	O
the	O
negative	O
regulatory	O
element	O
(	O
NRE	O
)	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
were	O
detected	O
in	O
the	O
nuclear	O
extract	O
of	O
a	O
virus	O
-	O
infected	O
human	O
T	O
cell	O
line	O
.	O

One	O
of	O
the	O
factors	O
bound	O
to	O
a	O
novel	O
dyad	O
symmetrical	O
sequence	O
.	O

This	O
sequence	O
is	O
well	O
conserved	O
in	O
various	O
HIV	O
-	O
1	O
isolates	O
and	O
partial	O
homology	O
was	O
found	O
with	O
the	O
promoter	O
region	O
of	O
the	O
human	O
retinoblastoma	O
gene	O
.	O

Similar	O
DNA	O
binding	O
activity	O
was	O
detected	O
in	O
a	O
variety	O
of	O
virus	O
-	O
uninfected	O
human	O
T	O
cell	O
lines	O
and	O
HeLa	O
cells	O
by	O
means	O
of	O
a	O
gel	O
mobility	O
shift	O
assay	O
.	O

The	O
other	O
factor	O
bound	O
to	O
a	O
putative	O
AP	O
-	O
1	O
recognition	O
sequence	O
predicted	O
for	O
the	O
HIV	O
-	O
1	O
NRE	O
.	O

However	O
,	O
this	O
factor	O
did	O
not	O
bind	O
to	O
a	O
typical	O
AP	O
-	O
1	O
site	O
.	O

The	O
insertion	O
of	O
multiple	O
copies	O
of	O
the	O
binding	O
site	O
for	O
the	O
former	O
or	O
latter	O
factor	O
into	O
a	O
heterologous	O
promoter	O
reduced	O
the	O
promoter	O
activity	O
to	O
one	O
-	O
tenth	O
or	O
one	O
-	O
third	O
,	O
respectively	O
.	O

Thus	O
,	O
each	O
factor	O
may	O
function	O
as	O
a	O
novel	O
negative	O
regulator	O
of	O
transcription	O
.	O

Constitutive	O
activation	O
of	O
NF	O
-	O
kB	O
in	O
human	O
thymocytes	O
.	O

NF	O
-	O
kB	O
is	O
a	O
eukaryotic	O
transcription	O
regulatory	O
factor	O
.	O

In	O
T	O
cells	O
and	O
T	O
cell	O
lines	O
,	O
NF	O
-	O
kB	O
is	O
bound	O
to	O
a	O
cytoplasmic	O
proteic	O
inhibitor	O
,	O
the	O
IkB	O
.	O

Treatment	O
of	O
T	O
cells	O
with	O
mitogens	O
(	O
phorbol	O
esters	O
)	O
or	O
cytokines	O
(	O
TNF	O
alpha	O
)	O
induces	O
NF	O
-	O
kB	O
nuclear	O
translocation	O
and	O
the	O
subsequent	O
expression	O
of	O
NF	O
-	O
kB	O
dependent	O
T	O
cell	O
genes	O
.	O

Here	O
we	O
examined	O
the	O
activation	O
of	O
NF	O
-	O
kB	O
in	O
human	O
T	O
cell	O
thymic	O
progenitors	O
.	O

We	O
report	O
differences	O
in	O
(	O
Ca2+	O
)	O
i	O
requirement	O
for	O
NF	O
-	O
kB	O
activation	O
in	O
thymocytes	O
as	O
compared	O
to	O
mature	O
T	O
cells	O
.	O

Furthermore	O
,	O
our	O
results	O
indicated	O
that	O
thymocytes	O
have	O
a	O
constitutively	O
active	O
form	O
of	O
NF	O
-	O
kB	O
,	O
suggesting	O
that	O
they	O
are	O
activated	O
in	O
vivo	O
.	O

Suppression	O
of	O
signals	O
required	O
for	O
activation	O
of	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
in	O
cells	O
constitutively	O
expressing	B-Gene_expression
the	O
HTLV	O
-	O
I	O
Tax	O
protein	O
.	O

Transient	O
short	O
-	O
term	O
expression	B-Gene_expression
of	O
the	O
Tax	O
protein	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
-	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
leads	O
to	O
activation	O
of	O
the	O
pleiotropic	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
.	O

Consistent	O
with	O
findings	O
obtained	O
with	O
transient	O
expression	O
assays	O
,	O
we	O
observed	O
marked	O
accumulation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
nucleus	O
of	O
Namalwa	O
B	O
lymphoid	O
cells	O
,	O
which	O
constitutively	O
express	B-Gene_expression
Tax	O
.	O

In	O
contrast	O
,	O
NF	O
-	O
kappa	O
B	O
activity	O
was	O
not	O
detected	O
in	O
the	O
nucleus	O
following	O
long	O
-	O
term	O
expression	B-Gene_expression
of	O
Tax	O
in	O
Jurkat	O
T	O
lymphocytes	O
.	O

The	O
ability	O
of	O
both	O
mitogens	O
and	O
cytokines	O
to	O
activate	O
NF	O
-	O
kappa	O
B	O
was	O
also	O
blocked	O
in	O
Jurkat	O
cells	O
constitutively	O
expressing	B-Gene_expression
Tax	O
.	O

However	O
,	O
the	O
activation	B-Positive_regulation
of	O
other	O
mitogen	O
-	O
inducible	O
transcription	O
factors	O
,	O
such	O
as	O
Fos	O
and	O
Jun	O
,	O
was	O
unaffected	B-Negative_regulation
.	O

Thus	O
,	O
depending	B-Regulation
on	O
the	O
cellular	O
environment	O
,	O
the	O
short	O
-	O
and	O
long	O
-	O
term	O
effects	O
of	O
Tax	O
expression	B-Gene_expression
can	O
be	O
quite	O
different	O
.	O

Consequently	O
,	O
one	O
function	O
of	O
Tax	O
in	O
cells	O
infected	O
with	O
HTLV	O
-	O
I	O
might	O
involve	O
cell-type	O
-	O
specific	O
suppression	O
,	O
as	O
opposed	O
to	O
activation	O
,	O
of	O
distinct	O
signal	O
pathways	O
.	O

The	O
cells	O
lines	O
described	O
here	O
should	O
be	O
useful	O
for	O
the	O
delineation	O
of	O
signaling	O
pathways	O
utilized	O
in	O
the	O
selective	O
regulation	O
of	O
gene	O
expression	O
.	O

Stimulation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
2	O
(	O
HIV	O
-	O
2	O
)	O
gene	O
expression	O
by	O
the	O
cytomegalovirus	O
and	O
HIV	O
-	O
2	O
transactivator	O
gene	O
.	O

Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
often	O
causes	O
latent	O
infection	O
.	O

Transactivation	O
by	O
some	O
DNA	O
viruses	O
has	O
been	O
implicated	O
in	O
inducing	O
HIV	O
-	O
1	O
replication	O
and	O
pathogenesis	O
.	O

The	O
transactivator	O
(	O
IE	O
-	O
2	O
)	O
gene	O
of	O
the	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
can	O
enhance	O
HIV	O
-	O
2	O
as	O
well	O
as	O
HIV	O
-	O
1	O
gene	O
expression	O
in	O
vitro	O
.	O

This	O
inducer	O
can	O
act	O
in	O
concert	O
with	O
the	O
HIV	O
-	O
2	O
tat	O
gene	O
and	O
T	O
-	O
cell	O
activation	O
in	O
enhancing	O
gene	O
expression	O
in	O
human	O
CD4+	O
lymphocytes	O
.	O

While	O
the	O
HIV	O
-	O
2	O
and	O
HIV	O
-	O
1	O
tat	O
genes	O
and	O
T	O
-	O
cell	O
activators	O
apparently	O
employ	O
independent	O
modes	O
of	O
action	O
,	O
the	O
CMV	O
transactivator	O
in	O
combination	O
with	O
the	O
HIV	O
-	O
2	O
tat	O
or	O
T	O
-	O
cell	O
activators	O
may	O
employ	O
a	O
gene	O
activation	O
pathway	O
with	O
some	O
common	O
and	O
some	O
distinct	O
components	O
.	O

Both	O
HIV	O
-	O
2	O
and	O
CMV	O
transactivators	O
enhance	O
HIV	O
-	O
2	O
gene	O
expression	O
by	O
transcriptional	O
activation	O
involving	O
transcript	O
initiation	O
as	O
well	O
as	O
elongation	O
,	O
with	O
CMV	O
transactivator	O
affecting	O
elongation	O
more	O
than	O
the	O
initiation	O
.	O

A	O
significant	O
proportion	O
of	O
transcripts	O
appear	O
to	O
terminate	O
prematurely	O
in	O
the	O
absence	O
of	O
transactivators	O
.	O

Deletion	O
mutation	O
analysis	O
of	O
the	O
HIV	O
-	O
2	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
suggests	O
that	O
the	O
element	O
that	O
responds	O
to	O
CMV	O
transactivation	O
in	O
human	O
CD4+	O
lymphocytes	O
is	O
either	O
a	O
diffuse	O
one	O
or	O
located	O
downstream	O
of	O
the	O
HIV	O
-	O
2	O
enhancer	O
element	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
-	O
2	O
gene	O
expression	O
:	O
two	O
enhancers	O
and	O
their	O
activation	O
by	O
T	O
-	O
cell	O
activators	O
.	O

The	O
human	O
immunodeficiency	O
viruses	O
(	O
HIVs	O
)	O
may	O
include	O
a	O
spectrum	O
of	O
retroviruses	O
with	O
varying	O
potential	O
to	O
infect	O
their	O
host	O
,	O
undergo	O
long	O
periods	O
of	O
latent	O
infection	O
,	O
and	O
induce	O
pathology	O
.	O

Since	O
expression	O
of	O
the	O
viruses	O
is	O
in	O
large	O
part	O
regulated	O
by	O
the	O
sequence	O
elements	O
in	O
their	O
long	O
terminal	O
repeats	O
(	O
LTRs	O
)	O
,	O
this	O
study	O
was	O
directed	O
to	O
an	O
analysis	O
of	O
the	O
regulatory	O
elements	O
in	O
the	O
HIV	O
-	O
2	O
LTR	O
.	O

The	O
HIV	O
-	O
2	O
LTR	O
was	O
found	O
to	O
contain	O
two	O
enhancers	O
.	O

One	O
of	O
these	O
enhancers	O
is	O
,	O
in	O
part	O
,	O
identical	O
to	O
the	O
HIV	O
-	O
1	O
enhancer	O
.	O

This	O
enhancer	O
in	O
HIV	O
-	O
1	O
is	O
the	O
T	O
-	O
cell	O
activation	O
response	O
element	O
;	O
in	O
HIV	O
-	O
2	O
,	O
however	O
,	O
it	O
is	O
the	O
second	O
enhancer	O
that	O
is	O
mainly	O
responsible	O
for	O
activation	O
in	O
response	O
to	O
T	O
-	O
cell	O
activators	O
.	O

The	O
second	O
enhancer	O
interacts	O
with	O
two	O
nuclear	O
binding	O
proteins	O
(	O
85	O
kD	O
and	O
27	O
kD	O
mobility	O
)	O
that	O
appear	O
to	O
be	O
required	O
for	O
optimal	O
enhancer	O
function	O
and	O
activation	O
.	O

Observations	O
such	O
as	O
these	O
encourage	O
the	O
speculation	O
that	O
there	O
may	O
be	O
subtle	O
differences	O
in	O
the	O
regulation	O
of	O
HIV	O
-	O
1	O
and	O
HIV	O
-	O
2	O
expression	O
that	O
may	O
be	O
relevant	O
to	O
the	O
possible	O
longer	O
latency	O
and	O
reduced	O
pathogenicity	O
of	O
HIV	O
-	O
2	O
.	O

Induction	O
of	O
NF	O
-	O
KB	O
during	O
monocyte	O
differentiation	O
by	O
HIV	O
type	O
1	O
infection	O
.	O

The	O
production	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
progeny	O
was	O
followed	O
in	O
the	O
U937	O
promonocytic	O
cell	O
line	O
after	O
stimulation	O
either	O
with	O
retinoic	O
acid	O
or	O
PMA	O
,	O
and	O
in	O
purified	O
human	O
monocytes	O
and	O
macrophages	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
Southwestern	O
blotting	O
experiments	O
were	O
used	O
to	O
detect	O
the	O
binding	O
of	O
cellular	O
transactivation	O
factor	O
NF	O
-	O
KB	O
to	O
the	O
double	O
repeat	O
-	O
KB	O
enhancer	O
sequence	O
located	O
in	O
the	O
long	O
terminal	O
repeat	O
.	O

PMA	O
treatment	O
,	O
and	O
not	O
retinoic	O
acid	O
treatment	O
of	O
the	O
U937	O
cells	O
acts	O
in	O
inducing	O
NF	O
-	O
KB	O
expression	O
in	O
the	O
nuclei	O
.	O

In	O
nuclear	O
extracts	O
from	O
monocytes	O
or	O
macrophages	O
,	O
induction	O
of	O
NF	O
-	O
KB	O
occurred	O
only	O
if	O
the	O
cells	O
were	O
previously	O
infected	O
with	O
HIV	O
-	O
1	O
.	O

When	O
U937	O
cells	O
were	O
infected	O
with	O
HIV	O
-	O
1	O
,	O
no	O
induction	O
of	O
NF	O
-	O
KB	O
factor	O
was	O
detected	O
,	O
whereas	O
high	O
level	O
of	O
progeny	O
virions	O
was	O
produced	O
,	O
suggesting	O
that	O
this	O
factor	O
was	O
not	O
required	O
for	O
viral	O
replication	O
.	O

These	O
results	O
indicate	O
that	O
in	O
monocytic	O
cell	O
lineage	O
,	O
HIV	O
-	O
1	O
could	O
mimic	O
some	O
differentiation/activation	O
stimuli	O
allowing	O
nuclear	O
NF	O
-	O
KB	O
expression	O
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
immunoglobulin	O
gene	O
expression	O
by	O
a	O
novel	O
B-cell	O
-	O
specific	O
enhancer	O
element	O
.	O

A	O
new	O
B-cell	O
-	O
specific	O
enhancer	O
element	O
has	O
been	O
identified	O
3	O
'	O
of	O
E4	O
and	O
the	O
octamerlike	O
motifs	O
in	O
the	O
human	O
immunoglobulin	O
heavy	O
-	O
chain	O
gene	O
enhancer	O
.	O

Tandem	O
copies	O
of	O
this	O
67	O
-	O
bp	O
MnlI	O
-	O
AluI	O
fragment	O
,	O
when	O
fused	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
gene	O
driven	O
by	O
the	O
conalbumin	O
promoter	O
,	O
stimulated	O
transcription	O
in	O
B	O
cells	O
but	O
not	O
in	O
Jurkat	O
T	O
cells	O
or	O
HeLa	O
cells	O
.	O

Footprinting	O
analysis	O
revealed	O
that	O
the	O
identical	O
sequence	O
CCGAAACTGAAAAGG	O
,	O
designated	O
E6	O
,	O
was	O
protected	O
by	O
nuclear	O
extracts	O
from	O
B	O
cells	O
,	O
T	O
cells	O
,	O
or	O
HeLa	O
cells	O
.	O

Gel	O
mobility	O
shift	O
assays	O
using	O
a	O
synthetic	O
E6	O
motif	O
detected	O
a	O
B-cell	O
-	O
specific	O
complex	O
in	O
addition	O
to	O
a	O
ubiquitous	O
band	O
found	O
also	O
in	O
T	O
cells	O
and	O
HeLa	O
cells	O
.	O

In	O
agreement	O
with	O
the	O
results	O
of	O
gel	O
retardation	O
assays	O
,	O
tandem	O
copies	O
of	O
the	O
E6	O
motif	O
stimulated	O
transcription	O
in	O
ARH77	O
and	O
Raji	O
cells	O
but	O
not	O
in	O
Jurkat	O
or	O
HeLa	O
cells	O
.	O

Furthermore	O
,	O
a	O
mutant	O
E6	O
motif	O
lost	O
both	O
in	O
vitro	O
binding	O
activity	O
and	O
in	O
vivo	O
enhancer	O
activity	O
.	O

In	O
striking	O
contrast	O
to	O
the	O
mouse	O
Ig	O
heavy	O
-	O
chain	O
enhancer	O
,	O
in	O
which	O
the	O
octamer	O
motif	O
acts	O
as	O
a	O
B-cell	O
-	O
specific	O
enhancer	O
element	O
,	O
the	O
human	O
enhancer	O
contains	O
an	O
octamerlike	O
sequence	O
with	O
one	O
base	O
substitution	O
which	O
bound	O
octamer	O
-	O
binding	O
proteins	O
with	O
only	O
very	O
low	O
affinity	O
and	O
showed	O
no	O
enhancer	O
activity	O
of	O
its	O
own	O
.	O

Interestingly	O
,	O
the	O
MnlI	O
-	O
AluI	O
fragment	O
could	O
suppress	O
the	O
basal	O
-	O
level	O
activity	O
of	O
the	O
conalbumin	O
promoter	O
in	O
both	O
Jurkat	O
and	O
HeLa	O
cells	O
.	O

Moreover	O
,	O
simian	O
virus	O
40	O
enhancer	O
activity	O
was	O
blocked	O
by	O
the	O
MnlI	O
-	O
AluI	O
fragment	O
in	O
HeLa	O
cells	O
but	O
not	O
in	O
B	O
cells	O
.	O

Thus	O
,	O
the	O
novel	O
enhancer	O
element	O
identified	O
in	O
this	O
study	O
is	O
probably	O
a	O
target	O
site	O
for	O
both	O
positive	O
and	O
negative	O
factors	O
.	O

The	O
NF	O
kappa	O
B	O
independent	O
cis	O
-	O
acting	O
sequences	O
in	O
HIV	O
-	O
1	O
LTR	O
responsive	O
to	O
T	O
-	O
cell	O
activation	O
.	O

The	O
rate	O
of	O
transcription	O
initiation	O
directed	O
by	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
HIV	O
-	O
1	O
increases	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
of	O
T	O
cells	O
.	O

Here	O
we	O
show	O
that	O
the	O
response	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
may	O
be	O
governed	O
by	O
two	O
independent	O
sequences	O
located	O
5	O
'	O
to	O
the	O
site	O
of	O
transcription	O
initiation	O
sequences	O
that	O
bind	B-Binding
either	O
NFAT	O
-	O
1	O
or	O
NF	O
kappa	O
B	O
.	O

The	O
rate	O
of	O
LTR	O
-	O
directed	O
gene	O
expression	O
increased	O
in	O
response	O
to	O
treatment	O
with	O
either	O
a	O
phorbol	O
ester	O
or	O
tumor	O
necrosis	O
factor	O
alpha	O
if	O
either	O
the	O
NFAT	O
-	O
1	O
or	O
NF	O
kappa	O
B	O
binding	O
sites	O
were	O
deleted	O
,	O
but	O
failed	O
to	O
respond	O
to	O
these	O
mitogenic	O
stimuli	O
if	O
both	O
sequences	O
were	O
absent	O
.	O

The	O
HIV	O
-	O
1	O
mutant	O
virus	O
containing	O
both	O
NF	O
kappa	O
B	O
and	O
NFAT	O
-	O
1	O
deletion	O
was	O
able	O
to	O
replicate	O
although	O
at	O
a	O
much	O
decreased	O
growth	O
rate	O
,	O
while	O
the	O
deletion	O
of	O
NFAT	O
-	O
1	O
alone	O
increased	O
the	O
viral	O
growth	O
rate	O
in	O
Jurkat	O
cells	O
.	O

Neither	O
deletion	O
of	O
NF	O
kappa	O
B	O
nor	O
deletion	O
of	O
NFAT	O
-	O
1	O
decreased	O
activation	O
of	O
viral	O
replication	O
by	O
phorbol	O
ester	O
.	O

Comparison	O
of	O
constitutive	O
and	O
inducible	O
transcriptional	O
enhancement	O
mediated	O
by	O
kappa	O
B	O
-	O
related	O
sequences	O
:	O
modulation	O
of	O
activity	O
in	O
B	O
cells	O
by	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
tax	O
gene	O
.	O

The	O
kappa	O
B	O
sequence	O
(	O
GGGACTTTCC	O
)	O
binds	O
a	O
factor	O
,	O
NF	O
-	O
kappa	O
B	O
,	O
that	O
is	O
constitutively	O
found	O
in	O
its	O
functional	O
,	O
DNA	O
binding	O
form	O
only	O
in	O
B	O
lymphocytes	O
.	O

A	O
factor	O
with	O
apparently	O
indistinguishable	O
sequence	O
specificity	O
can	O
be	O
induced	O
in	O
many	O
other	O
cell	O
types	O
,	O
where	O
it	O
is	O
used	O
to	O
regulate	O
inducible	O
gene	O
expression	O
.	O

For	O
example	O
,	O
kappa	O
B	O
-	O
related	O
sequences	O
have	O
been	O
shown	O
to	O
be	O
important	O
for	O
the	O
transcription	B-Transcription
of	O
a	O
few	O
inducible	O
genes	O
,	O
such	O
as	O
the	O
interleukin	O
2	O
receptor	O
alpha	O
-	O
chain	O
gene	O
and	O
the	O
beta	O
-	O
interferon	O
gene	O
.	O

However	O
,	O
these	O
genes	O
are	O
not	O
constitutively	O
active	B-Positive_regulation
in	O
B	O
lymphocytes	O
,	O
suggesting	O
that	O
other	O
regulatory	O
mechanisms	O
must	O
play	O
a	O
role	O
in	O
determining	O
the	O
patterns	O
of	O
expression	O
.	O

We	O
have	O
investigated	O
the	O
constitutive	O
and	O
inducible	O
transcriptional	O
activity	O
mediated	O
by	O
five	O
kappa	O
B	O
-	O
related	O
sequence	O
elements	O
in	O
two	O
different	O
cell	O
types	O
.	O

We	O
show	O
that	O
in	O
S194	O
plasma	O
cells	O
the	O
activity	O
of	O
each	O
element	O
correlates	O
well	O
with	O
the	O
relative	O
affinity	O
of	O
B-cell	O
-	O
derived	O
NF	O
-	O
kappa	O
B	O
for	O
that	O
element	O
.	O

This	O
leads	O
to	O
significantly	O
lower	O
transcription	O
enhancement	O
by	O
sites	O
derived	O
from	O
the	O
interleukin	O
2	O
receptor	O
or	O
T	O
-	O
cell	O
receptor	O
genes	O
in	O
S194	O
cells	O
.	O

However	O
,	O
in	O
either	O
EL	O
-	O
4	O
(	O
T	O
)	O
cells	O
or	O
S194	O
cells	O
,	O
both	O
lower	O
-	O
affinity	O
sites	O
can	O
be	O
significantly	O
induced	O
by	O
the	O
tax	O
gene	O
product	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
,	O
showing	O
that	O
NF	O
-	O
kappa	O
B	O
activity	O
can	O
be	O
modulated	O
even	O
in	O
a	O
B	O
-	O
cell	O
line	O
that	O
constitutively	O
expresses	O
this	O
factor	O
.	O

Isolation	O
of	O
a	O
rel	O
-	O
related	O
human	O
cDNA	O
that	O
potentially	O
encodes	O
the	O
65	O
-	O
kD	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
[	O
published	O
erratum	O
appears	O
in	O
Science	O
1991	O
Oct	O
4	O
;	O
254	O
(	O
5028	O
)	O
:	O
11	O
]	O

A	O
DNA	O
probe	O
that	O
spanned	O
a	O
domain	O
conserved	O
among	O
the	O
proto	O
-	O
oncogene	O
c	O
-	O
rel	O
,	O
the	O
Drosophila	O
morphogen	O
dorsal	O
,	O
and	O
the	O
p50	O
DNA	O
binding	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
was	O
generated	O
from	O
Jurkat	O
T	O
cell	O
complementary	O
DNA	O
with	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
degenerate	O
oligonucleotides	O
.	O

This	O
probe	O
was	O
used	O
to	O
identify	O
a	O
rel	O
-	O
related	O
complementary	O
DNA	O
that	O
hybridized	O
to	O
a	O
2.6	O
-	O
kilobase	O
messenger	O
RNA	O
present	O
in	O
human	O
T	O
and	O
B	O
lymphocytes	O
.	O

In	O
vitro	O
transcription	O
and	O
translation	O
of	O
the	O
complementary	O
DNA	O
resulted	O
in	O
the	O
synthesis	O
of	O
a	O
protein	O
with	O
an	O
apparent	O
molecular	O
size	O
of	O
65	O
kilodaltons	O
(	O
kD	O
)	O
.	O

The	O
translated	O
protein	O
showed	O
weak	O
DNA	O
binding	O
with	O
a	O
specificity	O
for	O
the	O
kappa	O
B	O
binding	O
motif	O
.	O

This	O
protein	O
-	O
DNA	O
complex	O
comigrated	O
with	O
the	O
complex	O
obtained	O
with	O
the	O
purified	O
human	O
p65	O
NF	O
-	O
kappa	O
B	O
subunit	O
and	O
binding	O
was	O
inhibited	O
by	O
I	O
kappa	O
B	O
-	O
alpha	O
and	O
-	O
beta	O
proteins	O
.	O

In	O
addition	O
,	O
the	O
65	O
-	O
kD	O
protein	O
associated	B-Binding
with	O
the	O
p50	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
the	O
kappa	O
B	O
probe	O
to	O
form	O
a	O
complex	O
with	O
the	O
same	O
electrophoretic	O
mobility	O
as	O
the	O
NF	O
-	O
kappa	O
B	O
-	O
DNA	O
complex	O
.	O

Therefore	O
the	O
rel	O
-	O
related	O
65	O
-	O
kD	O
protein	O
may	O
represent	O
the	O
p65	O
subunit	O
of	O
the	O
active	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
complex	O
.	O

Murine	O
and	O
human	O
T	O
-	O
lymphocyte	O
GATA	O
-	O
3	O
factors	O
mediate	O
transcription	O
through	B-Binding
a	O
cis	O
-	O
regulatory	O
element	O
within	O
the	O
human	O
T	O
-	O
cell	O
receptor	O
delta	O
gene	O
enhancer	O
.	O

A	O
family	O
of	O
transcriptional	O
activators	O
has	O
recently	O
been	O
identified	O
in	O
chickens	O
;	O
these	O
transcriptional	O
activators	O
recognize	O
a	O
common	O
consensus	O
motif	O
(	O
WGATAR	O
)	O
through	O
a	O
conserved	O
C4	O
zinc	O
finger	O
DNA	O
-	O
binding	O
domain	O
.	O

One	O
of	O
the	O
members	O
of	O
this	O
multigene	O
family	O
,	O
cGATA	O
-	O
3	O
,	O
is	O
most	O
abundantly	O
expressed	B-Gene_expression
in	O
the	O
T	O
-	O
lymphocyte	O
cell	O
lineage	O
.	O

Analysis	O
of	O
human	O
and	O
murine	O
GATA	O
-	O
3	O
factors	O
shows	O
a	O
striking	O
degree	O
of	O
amino	O
acid	O
sequence	O
identity	O
and	O
similar	O
patterns	O
of	O
tissue	O
specificity	O
of	O
expression	B-Gene_expression
in	O
these	O
three	O
organisms	O
.	O

The	O
murine	O
and	O
human	O
factors	O
are	O
abundantly	O
expressed	B-Gene_expression
in	O
a	O
variety	O
of	O
human	O
and	O
murine	O
T	O
-	O
cell	O
lines	O
and	O
can	O
activate	O
transcription	O
through	O
a	O
tissue	O
-	O
specific	O
GATA	O
-	O
binding	O
site	O
identified	O
within	O
the	O
human	O
T	O
-	O
cell	O
receptor	O
delta	O
gene	O
enhancer	O
.	O

We	O
infer	O
that	O
the	O
murine	O
and	O
human	O
GATA	O
-	O
3	O
proteins	O
play	O
a	O
central	O
and	O
highly	O
conserved	O
role	O
in	O
vertebrate	O
T-cell	O
-	O
specific	O
transcriptional	O
regulation	O
.	O

Processing	O
of	O
the	O
precursor	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
the	O
HIV	O
-	O
1	O
protease	O
during	O
acute	O
infection	O
.	O

Transcription	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
-	O
1	O
(	O
HIV	O
-	O
1	O
)	O
genome	O
is	O
regulated	O
in	O
part	O
by	O
cellular	O
factors	O
and	O
is	O
stimulated	O
by	O
activation	O
of	O
latently	O
infected	O
T	O
cells	O
.	O

T	O
-	O
cell	O
activation	O
also	O
correlates	O
with	O
the	O
induction	O
of	O
the	O
factor	O
NF	O
-	O
kappa	O
B	O
which	O
binds	O
to	O
two	O
adjacent	O
sites	O
in	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
.	O

This	O
factor	O
consists	O
of	O
two	O
DNA	O
-	O
binding	O
subunits	O
of	O
relative	O
molecular	O
mass	O
50	O
,	O
000	O
(	O
50K	O
)	O
associated	O
with	O
two	O
65K	O
subunits	O
.	O

It	O
is	O
located	O
in	O
the	O
nucleus	O
in	O
mature	O
B	O
cells	O
,	O
but	O
is	O
present	O
in	O
other	O
cell	O
types	O
as	O
an	O
inactive	O
cytoplasmic	O
complex	O
.	O

External	O
stimuli	O
,	O
including	O
those	O
that	O
activate	O
T	O
cells	O
,	O
result	O
in	O
nuclear	O
translocation	O
of	O
active	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
cloning	O
of	O
the	O
complementary	O
DNA	O
for	O
the	O
50K	O
subunit	O
helped	O
to	O
identify	O
an	O
exclusively	O
cytoplasmic	O
105K	O
precursor	O
(	O
p105	O
)	O
(	O
V.B.	O
,	O
P.K.	O
and	O
A.I.	O
,	O
manuscript	O
submitted	O
)	O
.	O

The	O
expression	O
of	O
active	O
NF	O
-	O
kappa	O
B	O
might	O
therefore	O
also	O
be	O
regulated	O
by	O
the	O
extent	O
of	O
processing	O
of	O
p105	O
.	O

Because	O
HIV	O
-	O
1	O
requires	O
active	O
NF	O
-	O
kappa	O
B	O
for	O
efficient	O
transcription	O
,	O
we	O
tested	O
the	O
effect	O
of	O
HIV	O
-	O
1	O
infection	O
on	O
the	O
processing	O
of	O
the	O
human	O
105K	O
precursor	O
.	O

We	O
show	O
here	O
that	O
the	O
HIV	O
-	O
1	O
protease	O
can	O
process	B-Protein_catabolism
p105	O
and	O
increases	O
levels	O
of	O
active	O
nuclear	O
NF	O
-	O
kappa	O
B	O
complex	O
.	O

HIV	O
enhancer	O
activity	O
perpetuated	O
by	O
NF	O
-	O
kappa	O
B	O
induction	O
on	O
infection	O
of	O
monocytes	O
[	O
see	O
comments	O
]	O

Permissiveness	O
to	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
differs	O
in	O
T	O
lymphocytes	O
and	O
macrophages	O
.	O

In	O
T	O
cells	O
,	O
HIV	O
transcription	O
is	O
poorly	O
detected	O
in	O
vivo	O
.	O

Cloned	O
,	O
normal	O
T	O
lymphocytes	O
show	O
very	O
little	O
,	O
if	O
any	O
,	O
basal	O
activity	O
of	O
the	O
HIV	O
enhancer	O
and	O
low	O
nuclear	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
a	O
potent	O
transcriptional	O
activator	O
of	O
the	O
HIV	O
enhancer	O
.	O

In	O
contrast	O
,	O
fixed	O
tissue	O
macrophages	O
express	O
detectable	O
HIV	O
proteins	O
,	O
indicating	O
permanent	O
virus	O
transcription	O
.	O

One	O
explanation	O
for	O
the	O
perpetuation	O
of	O
virus	O
infection	O
in	O
macrophages	O
could	O
be	O
sustained	O
nuclear	O
NF	O
-	O
kappa	O
B	O
expression	O
.	O

However	O
,	O
the	O
U937	O
monocytic	O
cell	O
line	O
,	O
which	O
is	O
fully	O
permissive	O
to	O
HIV	O
replication	O
,	O
is	O
known	O
to	O
express	O
only	O
low	O
levels	O
of	O
nuclear	O
NF	O
-	O
kappa	O
B	O
.	O

We	O
show	O
here	O
that	O
chronic	O
HIV	O
infection	O
results	O
in	O
both	O
induction	O
of	O
a	O
nuclear	O
factor	O
with	O
antigenic	O
properties	O
indistinguishable	O
from	O
those	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
permanently	O
increased	O
HIV	O
enhancer	O
activity	O
.	O

This	O
phenomenon	O
,	O
which	O
is	O
independent	O
of	O
tumour	O
necrosis	O
factor	O
,	O
is	O
associated	O
with	O
HIV	O
replication	O
,	O
and	O
is	O
thus	O
likely	O
to	O
explain	O
at	O
least	O
in	O
part	O
the	O
perpetuation	O
of	O
HIV	O
infection	O
in	O
monocytes	O
.	O

Tissue	O
-	O
specific	O
expression	B-Gene_expression
of	O
the	O
platelet	O
GPIIb	O
gene	O
.	O

One	O
of	O
the	O
major	O
objectives	O
in	O
the	O
study	O
of	O
thrombogenesis	O
is	O
to	O
determine	O
the	O
mechanisms	O
by	O
which	O
a	O
hematopoietic	O
progenitor	O
is	O
activated	O
and	O
committed	O
to	O
the	O
megakaryocytic	O
lineage	O
.	O

Recent	O
development	O
of	O
primary	O
cultures	O
of	O
human	O
megakaryocytes	O
and	O
the	O
molecular	O
cloning	O
of	O
genes	O
that	O
are	O
specific	O
to	O
this	O
lineage	O
offer	O
the	O
possibility	O
of	O
getting	O
some	O
insights	O
into	O
the	O
genetic	O
mechanisms	O
that	O
control	O
megakaryocytopoiesis	O
.	O

One	O
gene	O
of	O
interest	O
is	O
the	O
glycoprotein	O
IIb	O
(	O
GPIIb	O
)	O
gene	O
;	O
GPIIb	O
,	O
the	O
alpha	O
subunit	O
of	O
the	O
platelet	O
cytoadhesin	O
GPIIb	O
-	O
IIIa	O
,	O
is	O
produced	B-Gene_expression
in	O
megakaryocytes	O
at	O
an	O
early	O
stage	O
of	O
the	O
differentiation	O
,	O
whereas	O
the	O
other	O
subunit	O
of	O
this	O
complex	O
,	O
GPIIIa	O
,	O
is	O
expressed	B-Gene_expression
in	O
other	O
cells	O
.	O

For	O
these	O
reasons	O
,	O
the	O
5'	O
-	O
flanking	O
region	O
of	O
the	O
GPIIb	O
gene	O
was	O
used	O
to	O
identify	O
the	O
regions	O
that	O
interact	B-Binding
with	O
DNA	O
-	O
binding	O
nuclear	O
factors	O
.	O

A	O
fragment	O
extending	O
from	O
-	O
643	O
to	O
+33	O
is	O
capable	B-Regulation
of	I-Regulation
controlling	I-Regulation
the	O
tissue	O
-	O
specific	O
expression	B-Gene_expression
of	O
the	O
CAT	O
gene	O
in	O
transfection	O
experiments	O
.	O

Within	O
this	O
region	O
,	O
we	O
have	O
identified	O
several	O
sequences	O
that	O
are	O
implicated	O
in	O
DNA	O
protein	O
interactions	O
as	O
shown	O
in	O
DNAse	O
I	O
footprints	O
and	O
gel	O
mobility	O
shift	O
assays	O
.	O

One	O
region	O
,	O
centered	O
at	O
-	O
54	O
,	O
is	O
similar	O
to	O
a	O
nuclear	O
factor	O
E1	O
-	O
binding	O
site	O
,	O
and	O
a	O
region	O
located	O
at	O
position	O
-	O
233	O
contains	O
a	O
CCAAT	O
motif	O
.	O

Two	O
domains	O
centered	O
at	O
positions	O
-	O
345	O
and	O
-	O
540	O
,	O
respectively	O
,	O
bind	O
proteins	O
that	O
are	O
present	O
in	O
megakaryocytic	O
cells	O
and	O
nonrelated	O
cells	O
as	O
well	O
.	O

Finally	O
,	O
two	O
other	O
domains	O
,	O
located	O
at	O
positions	O
-	O
460	O
and	O
-	O
510	O
,	O
interact	O
with	O
proteins	O
that	O
are	O
only	O
present	O
in	O
megakaryocytic	O
cells	O
.	O

In	O
addition	O
,	O
deletion	O
of	O
the	O
region	O
containing	O
these	O
two	O
domains	O
results	O
in	O
a	O
significant	O
decrease	O
of	O
the	O
promoter	O
activity	O
.	O

It	O
is	O
very	O
likely	O
that	O
these	O
domains	O
bind	O
megakaryocyte	O
-	O
specific	O
nuclear	O
proteins	O
acting	O
as	O
positive	O
transcription	O
factors	O
.	O

Cortivazol	O
mediated	O
induction	B-Positive_regulation
of	O
glucocorticoid	O
receptor	O
messenger	O
ribonucleic	O
acid	O
in	O
wild	O
-	O
type	O
and	O
dexamethasone	O
-	O
resistant	O
human	O
leukemic	O
(	O
CEM	O
)	O
cells	O
.	O

Cortivazol	O
is	O
a	O
phenylpyrazolo	O
glucocorticoid	O
of	O
high	O
potency	O
and	O
unusual	O
structure	O
.	O

In	O
both	O
wild	O
-	O
type	O
and	O
highly	O
dexamethasone	O
(	O
dex	O
)	O
-	O
resistant	O
clones	O
of	O
the	O
human	O
leukemic	O
cell	O
line	O
CEM	O
,	O
exposure	O
to	O
cortivazol	O
leads	O
to	O
cell	O
death	O
.	O

It	O
has	O
been	O
shown	O
recently	O
that	O
in	O
wild	O
-	O
type	O
CEM	O
cells	O
but	O
not	O
in	O
a	O
dex	O
-	O
resistant	O
,	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
-	O
defective	O
clone	O
ICR	O
-	O
27	O
TK	O
-	O
3	O
,	O
dex	O
induces	B-Positive_regulation
GR	O
mRNA	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
cortivazol	O
acts	O
in	O
dex	O
-	O
resistant	O
cells	O
by	O
making	O
use	O
of	O
the	O
residual	O
GR	O
found	O
there	O
,	O
wild	O
-	O
type	O
and	O
dex	O
-	O
resistant	O
clones	O
were	O
treated	O
with	O
various	O
concentrations	O
of	O
cortivazol	O
and	O
induction	B-Positive_regulation
of	O
GR	O
mRNA	O
was	O
studied	O
.	O

Cortivazol	O
significantly	O
induced	B-Positive_regulation
GR	O
mRNA	O
in	O
the	O
normal	O
CEM	O
-	O
C7	O
as	O
well	O
as	O
in	O
two	O
classes	O
of	O
dex	O
-	O
resistant	O
clones	O
,	O
although	O
the	O
dex	O
-	O
resistant	O
clones	O
needed	O
at	O
least	O
10	O
times	O
more	O
cortivazol	O
than	O
the	O
normal	O
cells	O
for	O
significant	O
GR	O
mRNA	O
induction	B-Positive_regulation
.	O

Increased	B-Positive_regulation
levels	B-Transcription
of	O
GR	O
mRNA	O
were	O
noticed	O
as	O
early	O
as	O
3	O
h	O
after	O
treatment	O
.	O

A	O
general	O
correlation	O
between	O
induction	B-Positive_regulation
of	O
GR	O
mRNA	O
and	O
lysis	O
of	O
the	O
normal	O
and	O
dex	O
-	O
resistant	O
cells	O
was	O
found	O
.	O

Positive	B-Positive_regulation
induction	I-Positive_regulation
of	O
GR	O
mRNA	O
might	O
be	O
one	O
of	O
the	O
earliest	O
crucial	O
steps	O
in	O
the	O
lysis	O
of	O
normal	O
and	O
dex	O
-	O
resistant	O
CEM	O
cells	O
,	O
or	O
might	O
serve	O
as	O
a	O
marker	O
for	O
the	O
process	O
.	O

However	O
,	O
the	O
lysis	O
pathway	O
in	O
the	O
dex	O
-	O
resistant	O
cells	O
is	O
defective	O
in	O
that	O
dex	O
-	O
resistant	O
clones	O
needed	O
significantly	O
more	O
cortivazol	O
than	O
the	O
normal	O
cells	O
for	O
lysis	O
of	O
the	O
cells	O
.	O

Human	O
tumor	O
necrosis	O
factor	O
alpha	O
gene	O
regulation	B-Regulation
in	O
phorbol	O
ester	O
stimulated	O
T	O
and	O
B	O
cell	O
lines	O
.	O

The	O
minimal	O
region	O
of	O
the	O
human	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
gene	O
promoter	O
necessary	B-Positive_regulation
for	O
its	O
transcriptional	B-Positive_regulation
induction	I-Positive_regulation
by	O
phorbol	O
esters	O
(	O
PMA	O
)	O
in	O
human	O
T	O
and	O
B	O
lymphocyte	O
cell	O
lines	O
has	O
been	O
localized	O
between	O
-	O
52	O
and	O
+89	O
nucleotides	O
(	O
nt	O
)	O
relative	O
to	O
the	O
gene	O
's	O
transcriptional	O
start	O
site	O
.	O

Comparison	O
of	O
these	O
sequences	O
to	O
those	O
required	O
to	O
mediate	B-Positive_regulation
virus	O
or	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induction	B-Positive_regulation
of	O
the	O
gene	O
reveal	O
significant	O
differences	O
,	O
and	O
thus	O
,	O
the	O
sequence	O
requirements	B-Positive_regulation
for	O
PMA	O
induction	O
are	O
distinct	O
from	O
those	O
that	O
mediate	B-Positive_regulation
induction	B-Positive_regulation
by	O
virus	O
or	O
LPS	O
.	O

Although	O
three	O
sites	O
in	O
the	O
TNF	O
-	O
alpha	O
promoter	O
(	O
kappa	O
1	O
,	O
kappa	O
2	O
,	O
and	O
kappa	O
3	O
)	O
specifically	O
bind	B-Binding
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
in	O
lymphoid	O
nuclear	O
extracts	O
,	O
TNF	O
-	O
alpha	O
mRNA	O
induction	B-Positive_regulation
by	O
PMA	O
does	O
not	O
correlate	O
with	O
NF	O
-	O
kappa	O
B	O
binding	O
activities	O
displayed	O
by	O
different	O
T	O
and	O
B	O
cell	O
lines	O
.	O

Moreover	O
,	O
kappa	O
1	O
-	O
kappa	O
3	O
can	O
each	O
be	O
deleted	O
from	O
the	O
TNF	O
-	O
alpha	O
promoter	O
with	O
little	O
effect	O
on	O
the	O
gene	O
's	O
inducibility	B-Positive_regulation
by	O
PMA	O
.	O

Therefore	O
,	O
TNF	O
-	O
alpha	O
mRNA	O
induction	B-Positive_regulation
by	O
PMA	O
,	O
like	O
its	O
induction	B-Positive_regulation
by	O
virus	O
and	O
LPS	O
,	O
is	O
not	O
primarily	O
mediated	B-Positive_regulation
by	O
NF	O
-	O
kappa	O
B	O
,	O
but	O
rather	O
is	O
mediated	O
through	O
other	O
sequences	O
and	O
protein	O
factors	O
.	O

Surprisingly	O
,	O
multimers	O
of	O
kappa	O
1	O
-	O
kappa	O
3	O
can	O
confer	O
PMA	O
inducibility	O
on	O
a	O
heterologous	O
promoter	O
in	O
a	O
B	O
(	O
Raji	O
)	O
,	O
but	O
not	O
a	O
T	O
(	O
HUT78	O
)	O
cell	O
line	O
.	O

However	O
they	O
are	O
not	O
functional	O
on	O
a	O
truncated	O
TNF	O
-	O
alpha	O
promoter	O
,	O
indicating	O
that	O
promoter	O
context	O
and	O
cell	O
type	O
specificity	O
influence	O
the	O
PMA	O
inducible	O
function	O
of	O
these	O
NF	O
-	O
kappa	O
B	O
binding	O
sites	O
.	O

Reactive	O
oxygen	O
intermediates	O
as	O
apparently	O
widely	O
used	O
messengers	O
in	O
the	O
activation	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
and	O
HIV	O
-	O
1	O
.	O

Hydrogen	O
peroxide	O
and	O
oxygen	O
radicals	O
are	O
agents	O
commonly	O
produced	O
during	O
inflammatory	O
processes	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
micromolar	O
concentrations	O
of	O
H2O2	O
can	O
induce	O
the	O
expression	O
and	O
replication	O
of	O
HIV	O
-	O
1	O
in	O
a	O
human	O
T	O
cell	O
line	O
.	O

The	O
effect	O
is	O
mediated	O
by	O
the	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
which	O
is	O
potently	O
and	O
rapidly	O
activated	O
by	O
an	O
H2O2	O
treatment	O
of	O
cells	O
from	O
its	O
inactive	O
cytoplasmic	O
form	O
.	O

N-acetyl-L	O
-	O
cysteine	O
(	O
NAC	O
)	O
,	O
a	O
well	O
characterized	O
antioxidant	O
which	O
counteracts	O
the	O
effects	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
in	O
living	O
cells	O
,	O
prevented	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
H2O2	O
.	O

NAC	O
and	O
other	O
thiol	O
compounds	O
also	O
blocked	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
cycloheximide	O
,	O
double	O
-	O
stranded	O
RNA	O
,	O
calcium	O
ionophore	O
,	O
TNF	O
-	O
alpha	O
,	O
active	O
phorbol	O
ester	O
,	O
interleukin	O
-	O
1	O
,	O
lipopolysaccharide	O
and	O
lectin	O
.	O

This	O
suggests	O
that	O
diverse	O
agents	O
thought	O
to	O
activate	O
NF	O
-	O
kappa	O
B	O
by	O
distinct	O
intracellular	O
pathways	O
might	O
all	O
act	O
through	O
a	O
common	O
mechanism	O
involving	O
the	O
synthesis	O
of	O
ROI	O
.	O

ROI	O
appear	O
to	O
serve	O
as	O
messengers	O
mediating	O
directly	O
or	O
indirectly	O
the	O
release	O
of	O
the	O
inhibitory	O
subunit	O
I	O
kappa	O
B	O
from	O
NF	O
-	O
kappa	O
B	O
.	O

Contribution	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
Sp1	O
binding	O
motifs	O
to	O
the	O
replicative	O
capacity	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
:	O
distinct	O
patterns	O
of	O
viral	O
growth	O
are	O
determined	O
by	O
T	O
-	O
cell	O
types	O
.	O

Starting	O
with	O
a	O
replication	O
-	O
incompetent	O
molecular	O
clone	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
lacking	O
all	O
the	O
NF	O
-	O
kappa	O
B	O
and	O
Sp1	O
binding	O
sites	O
present	O
in	O
the	O
native	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
,	O
proviruses	O
containing	O
reconstructed	O
LTRs	O
with	O
individual	O
or	O
combinations	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
Sp1	O
elements	O
were	O
generated	O
and	O
evaluated	O
for	O
their	O
capacity	O
to	O
produce	O
virus	O
progeny	O
following	O
transfection	O
-	O
cocultivation	O
.	O

Virus	O
stocks	O
obtained	O
from	O
these	O
experiments	O
exhibited	O
a	O
continuum	O
of	O
replicative	O
capacities	O
in	O
different	O
human	O
T	O
-	O
cell	O
types	O
depending	O
on	O
which	O
element	O
(	O
s	O
)	O
was	O
present	O
in	O
the	O
LTR	O
.	O

For	O
example	O
,	O
in	O
experiments	O
involving	O
proviral	O
clones	O
with	O
LTRs	O
containing	O
one	O
or	O
two	O
NF	O
-	O
kappa	O
B	O
elements	O
(	O
and	O
no	O
Sp1	O
binding	O
sites	O
)	O
,	O
a	O
hierarchy	O
of	O
cellular	O
permissivity	O
to	O
virus	O
replication	O
(	O
peripheral	O
blood	O
lymphocytes	O
=	O
MT4	O
greater	O
than	O
H9	O
greater	O
than	O
CEM	O
greater	O
than	O
Jurkat	O
)	O
was	O
observed	O
.	O

Of	O
note	O
was	O
the	O
associated	O
emergence	O
of	O
second	O
-	O
site	O
LTR	O
revertants	O
which	O
involved	O
an	O
alteration	O
of	O
the	O
TATA	O
box	O
.	O

These	O
results	O
suggest	O
that	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
LTR	O
possesses	O
functional	O
redundancy	O
which	O
ensures	O
virus	O
replication	O
in	O
different	O
T	O
-	O
cell	O
types	O
and	O
is	O
capable	O
of	O
changing	O
depending	O
on	O
the	O
particular	O
combination	O
of	O
transcriptional	O
factors	O
present	O
.	O

Purification	O
of	O
TCF	O
-	O
1	O
alpha	O
,	O
a	O
T-cell	O
-	O
specific	O
transcription	O
factor	O
that	O
activates	B-Positive_regulation
the	O
T	O
-	O
cell	O
receptor	O
C	O
alpha	O
gene	O
enhancer	O
in	O
a	O
context	O
-	O
dependent	O
manner	O
.	O

The	O
differentiation	O
of	O
T	O
cells	O
into	O
functionally	O
diverse	O
subpopulations	O
is	O
controlled	O
in	O
part	O
,	O
by	O
transcriptional	O
activation	O
and	O
silencing	O
;	O
however	O
,	O
little	O
is	O
known	O
in	O
detail	O
about	O
the	O
proteins	O
that	O
influence	O
this	O
developmental	O
process	O
.	O

We	O
have	O
purified	O
a	O
new	O
T-cell	O
-	O
specific	O
factor	O
,	O
TCF	O
-	O
1	O
alpha	O
,	O
that	O
is	O
implicated	O
in	O
the	O
activation	O
of	O
genes	O
encoding	O
a	O
major	O
component	O
of	O
the	O
human	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
.	O

TCF	O
-	O
1	O
alpha	O
,	O
originally	O
identified	O
and	O
purified	O
through	O
its	O
binding	O
sites	O
on	O
the	O
HIV	O
-	O
1	O
promoter	O
,	O
was	O
found	O
to	O
bind	B-Binding
to	O
the	O
TCR	O
alpha	O
enhancer	O
and	O
to	O
promoters	B-Positive_regulation
for	O
several	O
genes	O
expressed	B-Gene_expression
at	O
significantly	O
earlier	O
stages	O
of	O
T	O
-	O
cell	O
development	O
than	O
the	O
TCR	O
alpha	O
gene	O
(	O
e.g.	O
,	O
p56lck	O
and	O
CD3	O
delta	O
)	O
.	O

Sequences	O
related	O
to	O
the	O
TCF	O
-	O
1	O
alpha	O
binding	O
motif	O
(	O
5'-GGCACCCTTTGA	O
-	O
3	O
'	O
)	O
are	O
also	O
found	O
in	O
the	O
human	O
TCR	O
delta	O
(	O
and	O
possibly	O
TCR	O
beta	O
)	O
enhancers	O
.	O

Southwestern	O
and	O
gel	O
renaturation	O
experiments	O
with	O
the	O
use	O
of	O
purified	O
protein	O
fractions	O
revealed	O
that	O
TCF	O
-	O
1	O
alpha	O
activity	O
is	O
derived	B-Positive_regulation
from	O
a	O
family	O
of	O
57	O
-	O
to	O
53	O
-	O
kD	O
proteins	O
that	O
are	O
abundantly	O
expressed	O
in	O
mature	O
and	O
immature	O
T	O
-	O
cell	O
lines	O
(	O
Jurkat	O
,	O
CCRF	O
-	O
CEM	O
)	O
and	O
not	O
in	O
mature	O
B	O
cells	O
(	O
JY	O
,	O
Namalwa	O
)	O
or	O
nonlymphoid	O
(	O
HeLa	O
)	O
cell	O
lines	O
.	O

A	O
small	O
95	O
-	O
bp	O
fragment	O
of	O
the	O
TCR	O
alpha	O
control	O
region	O
that	O
contains	O
the	O
TCF	O
-	O
1	O
alpha	O
binding	O
site	O
juxtaposed	O
between	O
a	O
cAMP	O
-	O
response	O
element	O
(	O
the	O
CRE	O
or	O
T	O
alpha	O
1	O
motif	O
)	O
and	O
the	O
binding	O
site	O
for	O
a	O
distinct	O
lymphoid	O
-	O
specific	O
protein	O
(	O
TCF	O
-	O
2	O
alpha	O
)	O
behaved	O
as	O
a	O
potent	O
T-cell	O
-	O
specific	O
enhancer	O
in	O
vivo	O
.	O

Tandem	O
copies	O
of	O
this	O
enhancer	O
functioned	O
synergistically	O
in	O
mature	O
(	O
Jurkat	O
)	O
T	O
-	O
cell	O
lines	O
as	O
well	O
as	O
resting	O
and	O
activated	O
immature	O
(	O
CCRF	O
-	O
CEM	O
)	O
T	O
-	O
cell	O
lines	O
.	O

Mutation	O
of	O
the	O
TCF	O
-	O
1	O
alpha	O
binding	O
site	O
diminished	O
enhancer	O
activity	O
and	O
disrupted	O
the	O
synergism	O
observed	O
in	O
vivo	O
between	O
tandem	O
enhancer	O
repeats	O
.	O

The	O
TCF	O
-	O
1	O
alpha	O
binding	O
site	O
was	O
also	O
required	B-Positive_regulation
for	O
TCR	O
alpha	O
enhancer	O
activity	O
in	O
transcriptionally	O
active	O
extracts	O
from	O
Jurkat	O
but	O
not	O
HeLa	O
cells	O
,	O
confirming	O
that	O
TCF	O
-	O
1	O
alpha	O
is	O
a	O
T-cell	O
-	O
specific	O
transcription	O
factor	O
.	O

Curiously	O
,	O
the	O
TCF	O
-	O
1	O
alpha	O
binding	O
element	O
was	O
inactive	O
in	O
vivo	O
when	O
removed	O
from	O
its	O
neighboring	O
elements	O
on	O
the	O
TCR	O
alpha	O
enhancer	O
and	O
positioned	O
in	O
one	O
or	O
more	O
copies	O
upstream	O
of	O
a	O
heterologous	O
promoter	O
.	O

Thus	O
,	O
the	O
transcriptional	B-Transcription
activity	I-Transcription
of	O
TCF	O
-	O
1	O
alpha	O
appears	O
to	O
depend	B-Positive_regulation
on	O
the	O
TCF	O
-	O
2	O
alpha	O
and	O
T	O
alpha	O
1	O
(	O
CREB	O
)	O
transcription	O
factors	O
and	O
the	O
context	O
of	O
its	O
binding	O
site	O
within	O
the	O
TCR	O
alpha	O
enhancer	O
.	O

A	O
novel	O
T	O
-	O
cell	O
trans	O
-	O
activator	O
that	O
recognizes	B-Binding
a	O
phorbol	O
ester	O
-	O
inducible	O
element	O
of	O
the	O
interleukin	O
-	O
2	O
promoter	O
.	O

The	O
interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
gene	O
promoter	O
is	O
recognized	B-Binding
by	O
several	O
cell-type	O
-	O
specific	O
and	O
ubiquitous	O
transcriptional	O
regulators	O
that	O
integrate	O
information	O
transmitted	O
by	O
various	O
signaling	O
systems	O
leading	B-Positive_regulation
to	O
IL	O
-	O
2	O
production	B-Gene_expression
and	O
T	O
-	O
cell	O
activation	O
.	O

Using	O
a	O
combination	O
of	O
transfection	O
,	O
protein	O
-	O
DNA	O
binding	O
,	O
and	O
in	O
vitro	O
transcription	O
methods	O
,	O
we	O
have	O
discovered	O
the	O
novel	O
T-cell	O
-	O
specific	O
transcriptional	O
activator	O
TCF	O
-	O
1	O
(	O
for	O
T	O
-	O
Cell	O
Factor	O
-	O
1	O
)	O
,	O
which	O
recognizes	B-Binding
a	O
T-cell	O
-	O
specific	O
response	O
element	O
(	O
TCE	O
)	O
located	O
within	O
the	O
IL	O
-	O
2	O
promoter	O
.	O

Although	O
the	O
TCE	O
is	O
similar	O
in	O
sequence	O
to	O
a	O
consensus	O
NF	O
kappa	O
B	O
site	O
,	O
several	O
criteria	O
indicate	O
that	O
TCF	O
-	O
1	O
is	O
distinct	O
from	O
NF	O
kappa	O
B	O
.	O

However	O
,	O
like	O
NF	O
kappa	O
B	O
,	O
TCF	O
-	O
1	O
activity	O
is	O
induced	B-Positive_regulation
by	O
phorbol	O
esters	O
and	O
other	O
T	O
-	O
cell	O
activators	O
.	O

Two	O
distinct	O
transcription	O
factors	O
that	O
bind	O
the	O
immunoglobulin	O
enhancer	O
microE5/kappa	O
2	O
motif	O
.	O

Activity	O
of	O
the	O
immunoglobulin	O
heavy	O
and	O
kappa	O
light	O
chain	O
gene	O
enhancers	O
depends	O
on	O
a	O
complex	O
interplay	O
of	O
ubiquitous	O
and	O
developmentally	O
regulated	O
proteins	O
.	O

Two	O
complementary	O
DNAs	O
were	O
isolated	O
that	O
encode	O
proteins	O
,	O
denoted	O
ITF	O
-	O
1	O
and	O
ITF	O
-	O
2	O
,	O
that	O
are	O
expressed	B-Gene_expression
in	O
a	O
variety	O
of	O
cell	O
types	O
and	O
bind	B-Binding
the	O
microE5/kappa	O
2	O
motif	O
found	O
in	O
both	O
heavy	O
and	O
kappa	O
light	O
chain	O
enhancers	O
.	O

The	O
complementary	O
DNAs	O
are	O
the	O
products	O
of	O
distinct	O
genes	O
,	O
yet	O
both	O
ITF	O
-	O
1	O
and	O
ITF	O
-	O
2	O
are	O
structurally	O
and	O
functionally	O
similar	O
.	O

The	O
two	O
proteins	O
interact	B-Binding
with	O
one	O
another	O
through	O
their	O
putative	O
helix-loop	O
-	O
helix	O
motifs	O
and	O
each	O
possesses	O
a	O
distinct	O
domain	O
that	O
dictates	O
transcription	O
activation	O
.	O

A	O
factor	O
known	O
to	O
bind	O
to	O
endogenous	O
Ig	O
heavy	O
chain	O
enhancer	O
only	O
in	O
lymphocytes	O
is	O
a	O
ubiquitously	O
active	O
transcription	O
factor	O
.	O

The	O
transcriptional	O
enhancer	O
located	O
in	O
the	O
first	O
intron	O
of	O
the	O
immunoglobulin	O
heavy	O
chain	O
constant	O
region	O
is	O
a	O
major	O
determinant	O
of	O
B-cell	O
-	O
specific	O
expression	O
of	O
immunoglobulin	O
genes	O
.	O

Like	O
other	O
enhancers	O
,	O
the	O
Ig	O
heavy	O
chain	O
enhancer	O
contains	O
several	O
short	O
sequence	O
motifs	O
that	O
bind	O
specific	O
transcription	O
factors	O
.	O

Each	O
binding	O
site	O
contributes	O
to	O
the	O
overall	O
activity	O
of	O
the	O
enhancer	O
,	O
however	O
no	O
single	O
element	O
seems	O
absolutely	O
required	O
for	O
activity	O
.	O

For	O
a	O
better	O
understanding	O
of	O
the	O
Ig	O
heavy	O
chain	O
enhancer	O
components	O
,	O
we	O
have	O
cloned	O
and	O
analyzed	O
individual	O
sequence	O
elements	O
.	O

We	O
find	O
that	O
the	O
factor	O
that	O
binds	O
to	O
the	O
E3	O
enhancer	O
motif	O
,	O
CATGTGGC	O
,	O
is	O
a	O
ubiquitous	O
transcription	O
factor	O
.	O

It	O
is	O
present	O
in	O
an	O
active	O
form	O
in	O
both	O
B	O
cells	O
and	O
non	O
-	O
B	O
cells	O
,	O
where	O
it	O
can	O
mediate	O
transcriptional	O
activation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

However	O
,	O
despite	O
its	O
ability	O
to	O
activate	O
transcription	O
of	O
a	O
transfected	O
reporter	O
gene	O
,	O
the	O
factor	O
is	O
apparently	O
unable	O
to	O
bind	O
to	O
the	O
endogenous	O
Ig	O
heavy	O
chain	O
enhancer	O
in	O
non	O
-	O
lymphoid	O
cells	O
:	O
In	O
previous	O
experiments	O
by	O
others	O
,	O
the	O
characteristic	O
in	O
vivo	O
footprint	O
of	O
this	O
factor	O
,	O
designated	O
NF	O
-	O
muE3	O
,	O
was	O
detected	O
in	O
B	O
cells	O
but	O
not	O
in	O
non	O
-	O
B	O
cells	O
.	O

From	O
this	O
and	O
other	O
findings	O
the	O
picture	O
emerges	O
that	O
there	O
are	O
at	O
least	O
three	O
categories	O
of	O
factors	O
which	O
mediate	O
cell-type	O
-	O
specific	O
transcription	O
in	O
B	O
lymphocytes	O
:	O
(	O
a	O
)	O
cell	O
-	O
specific	O
factors	O
such	O
as	O
Oct	O
-	O
2A	O
and	O
Oct	O
-	O
2B	O
that	O
are	O
not	O
expressed	B-Gene_expression
in	O
most	O
other	O
cell	O
types	O
:	O
(	O
b	O
)	O
ubiquitous	O
factors	O
such	O
as	O
NF	O
-	O
kappa	O
B	O
that	O
are	O
constitutively	O
active	O
in	O
B	O
cells	O
but	O
are	O
sequestered	O
in	O
an	O
inactive	O
form	O
in	O
other	O
cells	O
;	O
(	O
c	O
)	O
ubiquitously	O
active	O
factors	O
,	O
exemplified	O
by	O
the	O
one	O
binding	O
to	O
the	O
E3	O
sequence	O
motif	O
.	O

This	O
factor	O
is	O
present	O
in	O
an	O
active	B-Positive_regulation
form	O
in	O
a	O
variety	O
of	O
cell	O
types	O
but	O
is	O
apparently	O
unable	O
to	O
bind	B-Binding
to	O
the	O
endogenous	O
Ig	O
heavy	O
chain	O
enhancer	O
in	O
non	O
-	O
B	O
cells	O
,	O
perhaps	O
due	O
to	O
a	O
non	O
-	O
permissive	O
chromatin	O
structure	O
of	O
the	O
Ig	O
heavy	O
chain	O
locus	O
.	O

Transcriptional	O
and	O
post	O
-	O
transcriptional	O
regulation	O
of	O
c	O
-	O
jun	O
expression	B-Gene_expression
during	O
monocytic	O
differentiation	O
of	O
human	O
myeloid	O
leukemic	O
cells	O
.	O

AP	O
-	O
1	O
,	O
the	O
polypeptide	O
product	O
of	O
c	O
-	O
jun	O
,	O
recognizes	B-Binding
and	O
binds	B-Binding
to	O
specific	O
DNA	O
sequences	O
and	O
stimulates	O
transcription	O
of	O
genes	O
responsive	O
to	O
certain	O
growth	O
factors	O
and	O
phorbol	O
esters	O
such	O
as	O
12-O-tetradecanoylphorbol-13	O
-	O
acetate	O
(	O
TPA	O
)	O
.	O

We	O
studied	O
the	O
effects	B-Regulation
of	O
TPA	O
on	O
the	O
regulation	B-Regulation
of	O
c	O
-	O
jun	O
gene	O
expression	B-Gene_expression
in	O
HL	O
-	O
60	O
cells	O
during	O
monocytic	O
differentiation	O
.	O

Low	O
levels	O
of	O
c	O
-	O
jun	O
transcripts	B-Transcription
were	O
detectable	O
in	O
untreated	O
HL	O
-	O
60	O
leukemic	O
cells	O
,	O
increased	B-Positive_regulation
significantly	O
by	O
6	O
h	O
,	O
and	O
reached	O
near	O
maximal	O
levels	O
by	O
24	O
h	O
of	O
exposure	O
to	O
32	O
nM	O
TPA	O
.	O

Similar	O
kinetics	O
of	O
c	O
-	O
jun	O
induction	B-Positive_regulation
by	O
TPA	O
were	O
observed	O
in	O
human	O
U	O
-	O
937	O
and	O
THP	O
-	O
1	O
monocytic	O
leukemia	O
cells	O
.	O

Similar	O
findings	O
were	O
obtained	O
with	O
bryostatin	O
1	O
(	O
10	O
nM	O
)	O
,	O
another	O
activator	O
of	O
protein	O
kinase	O
C	O
and	O
inducer	O
of	O
monocytic	O
differentiation	O
.	O

Furthermore	O
,	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
(	O
0.5	O
microM	O
)	O
,	O
a	O
structurally	O
distinct	O
agent	O
which	O
also	O
induces	O
HL	O
-	O
60	O
monocytic	O
differentiation	O
,	O
increased	B-Positive_regulation
c	O
-	O
jun	O
expression	B-Gene_expression
.	O

TPA	O
treatment	O
of	O
HL	O
-	O
60	O
cells	O
in	O
the	O
presence	O
of	O
cycloheximide	O
was	O
associated	B-Positive_regulation
with	I-Positive_regulation
superinduction	I-Positive_regulation
of	O
c	O
-	O
jun	O
transcripts	B-Transcription
.	O

Run	O
-	O
on	O
analysis	O
demonstrated	O
detectable	O
levels	O
of	O
c	O
-	O
jun	O
gene	O
transcription	B-Transcription
in	O
untreated	O
HL	O
-	O
60	O
cells	O
,	O
and	O
that	O
exposure	O
to	O
TPA	O
increases	B-Positive_regulation
this	O
rate	O
3.3	O
-	O
fold	O
.	O

Treatment	O
of	O
HL	O
-	O
60	O
cells	O
with	O
both	O
TPA	O
and	O
cycloheximide	O
had	O
no	O
effect	B-Positive_regulation
on	O
the	O
rates	O
of	O
c	O
-	O
jun	O
transcription	B-Transcription
.	O

The	O
half	O
-	O
life	O
of	O
c	O
-	O
jun	O
RNA	O
as	O
determined	O
by	O
treating	O
HL	O
-	O
60	O
cells	O
with	O
TPA	O
and	O
actinomycin	O
D	O
was	O
30	O
min	O
.	O

In	O
contrast	O
,	O
the	O
half	O
-	O
life	O
of	O
c	O
-	O
jun	O
RNA	O
in	O
TPA	O
-	O
treated	O
HL	O
-	O
60	O
cells	O
exposed	O
to	O
cycloheximide	O
and	O
actinomycin	O
D	O
was	O
greater	O
than	O
2	O
h	O
.	O

These	O
findings	O
suggested	O
that	O
the	O
increase	B-Positive_regulation
in	O
c	O
-	O
jun	O
RNA	O
observed	O
during	O
TPA	O
-	O
induced	O
monocytic	O
differentiation	O
is	O
mediated	B-Positive_regulation
by	O
both	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
mechanisms	O
.	O

Identification	O
of	O
a	O
novel	O
factor	O
that	O
interacts	O
with	O
an	O
immunoglobulin	O
heavy	O
-	O
chain	O
promoter	O
and	O
stimulates	O
transcription	O
in	O
conjunction	O
with	O
the	O
lymphoid	O
cell	O
-	O
specific	O
factor	O
OTF2	O
.	O

The	O
tissue	O
-	O
specific	O
expression	O
of	O
the	O
MOPC	O
141	O
immunoglobulin	O
heavy	O
-	O
chain	O
gene	O
was	O
studied	O
by	O
using	O
in	O
vitro	O
transcription	O
.	O

B-cell	O
-	O
specific	O
transcription	O
of	O
this	O
gene	O
was	O
dependent	O
on	O
the	O
octamer	O
element	O
5'-ATGCAAAG	O
-	O
3	O
'	O
,	O
located	O
in	O
the	O
upstream	O
region	O
of	O
this	O
promoter	O
and	O
in	O
the	O
promoters	O
of	O
all	O
other	O
immunoglobulin	O
heavy	O
-	O
and	O
light	O
-	O
chain	O
genes	O
.	O

The	O
interaction	O
of	O
purified	O
octamer	O
transcription	O
factors	O
1	O
and	O
2	O
(	O
OTF1	O
and	O
OTF2	O
)	O
with	O
the	O
MOPC	O
141	O
promoter	O
was	O
studied	O
by	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
DNase	O
I	O
footprinting	O
.	O

Purified	O
OTF1	O
from	O
HeLa	O
cells	O
and	O
OTF1	O
and	O
OTF2	O
from	O
B	O
cells	O
bound	B-Binding
to	O
identical	O
sequences	O
within	O
the	O
heavy	O
-	O
chain	O
promoter	O
.	O

The	O
OTF	O
interactions	O
we	O
observed	O
extended	O
over	O
the	O
heptamer	O
element	O
5'-CTCAGGA	O
-	O
3	O
'	O
,	O
and	O
it	O
seems	O
likely	O
that	O
the	O
binding	B-Binding
of	O
the	O
purified	O
factors	O
involves	B-Regulation
cooperation	O
between	O
octamer	O
and	O
heptamer	O
sites	O
in	O
this	O
promoter	O
.	O

In	O
addition	O
to	O
these	O
elements	O
,	O
we	O
identified	O
a	O
second	O
regulatory	O
element	O
,	O
the	O
N	O
element	O
with	O
the	O
sequence	O
5'-GGAACCTCCCCC	O
-	O
3	O
'	O
.	O

The	O
N	O
element	O
could	O
independently	O
mediate	O
low	O
levels	O
of	O
transcription	O
in	O
both	O
B	O
-	O
cell	O
and	O
HeLa	O
-	O
cell	O
extracts	O
,	O
and	O
,	O
in	O
conjunction	O
with	O
the	O
octamer	O
element	O
,	O
it	O
can	O
promote	O
high	O
levels	O
of	O
transcription	O
in	O
B	O
-	O
cell	O
extracts	O
.	O

The	O
N	O
element	O
bound	O
a	O
transcription	O
factor	O
,	O
NTF	O
,	O
that	O
is	O
ubiquitous	O
in	O
cell	O
-	O
type	O
distribution	O
,	O
and	O
NTF	O
was	O
distinct	O
from	O
any	O
of	O
the	O
previously	O
described	O
proteins	O
that	O
bind	O
to	O
similar	O
sequences	O
.	O

Based	O
on	O
these	O
results	O
,	O
we	O
propose	O
that	O
NTF	O
and	O
OTF2	O
interactions	O
(	O
both	O
with	O
their	O
cognate	O
DNA	O
elements	O
and	O
possibly	O
at	O
the	O
protein	O
-	O
protein	O
level	O
)	O
may	O
be	O
critical	O
to	O
B-cell	O
-	O
specific	O
expression	O
and	O
that	O
these	O
interactions	O
provide	O
additional	O
pathways	O
for	O
regulating	O
gene	O
expression	O
.	O

Involvement	O
of	O
a	O
second	O
lymphoid	O
-	O
specific	O
enhancer	O
element	O
in	O
the	O
regulation	O
of	O
immunoglobulin	O
heavy	O
-	O
chain	O
gene	O
expression	O
.	O

To	O
determine	O
whether	O
enhancer	O
elements	O
in	O
addition	O
to	O
the	O
highly	O
conserved	O
octamer	O
(	O
OCTA	O
)	O
-	O
nucleotide	O
motif	O
are	O
important	O
for	O
lymphoid	O
-	O
specific	O
expression	O
of	O
the	O
immunoglobulin	O
heavy	O
-	O
chain	O
(	O
IgH	O
)	O
gene	O
,	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
mutating	O
the	O
binding	B-Binding
site	O
for	O
a	O
putative	O
additional	O
lymphoid	O
-	O
specific	O
transcription	O
factor	O
,	O
designated	O
NF	O
-	O
microB	O
,	O
in	O
the	O
murine	O
IgH	O
enhancer	O
.	O

We	O
demonstrate	O
that	O
the	O
NF-microB	O
-	O
binding	O
site	O
plays	O
a	O
critical	O
role	O
in	O
the	O
IgH	O
enhancer	O
,	O
because	O
mutation	O
of	O
the	O
microB	O
DNA	O
motif	O
decreased	O
transcriptional	O
activity	O
of	O
the	O
IgH	O
enhancer	O
in	O
cells	O
of	O
the	O
B	O
-	O
cell	O
lineage	O
but	O
not	O
in	O
nonlymphoid	O
cells	O
.	O

This	O
effect	O
was	O
comparable	O
to	O
or	O
even	O
stronger	O
than	O
the	O
effect	O
of	O
a	O
mutation	O
in	O
the	O
OCTA	O
site	O
.	O

Moreover	O
,	O
combined	O
mutation	O
of	O
both	O
microB	O
and	O
OCTA	O
sites	O
further	O
reduced	O
enhancer	O
activity	O
in	O
lymphoid	O
cells	O
.	O

Interestingly	O
,	O
alteration	O
of	O
either	O
the	O
microB	O
or	O
E3	O
site	O
in	O
a	O
70-base	O
-	O
pair	O
fragment	O
of	O
the	O
IgH	O
enhancer	O
that	O
lacks	O
the	O
binding	O
site	O
for	O
OCTA	O
abolished	O
enhancer	O
activity	O
in	O
lymphoid	O
cells	O
completely	O
.	O

Nevertheless	O
,	O
a	O
multimer	O
of	O
the	O
microB	O
motif	O
alone	O
showed	O
no	O
enhancer	O
activity	O
.	O

DNase	O
footprinting	O
analysis	O
corroborated	O
the	O
functional	O
data	O
showing	O
that	O
a	O
lymphoid	O
-	O
specific	O
protein	O
binds	O
to	O
the	O
microB	O
DNA	O
motif	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
microB	O
element	O
is	O
a	O
new	O
crucial	O
element	O
important	O
for	O
lymphoid	O
-	O
specific	O
expression	O
of	O
the	O
IgH	O
gene	O
but	O
that	O
interaction	O
with	O
another	O
enhancer	O
element	O
is	O
essential	O
for	O
its	O
activity	O
.	O

The	O
expression	B-Gene_expression
of	O
c	O
-	O
fos	O
,	O
c	O
-	O
jun	O
,	O
and	O
c	O
-	O
myc	O
genes	O
is	O
regulated	B-Regulation
by	O
heat	O
shock	O
in	O
human	O
lymphoid	O
cells	O
.	O

The	O
effect	B-Regulation
of	O
heat	O
shock	O
on	O
the	O
expression	B-Gene_expression
of	O
the	O
nuclear	O
protooncogenes	O
c	O
-	O
fos	O
,	O
c	O
-	O
jun	O
,	O
and	O
c	O
-	O
myc	O
was	O
studied	O
in	O
human	O
lymphoid	O
cells	O
.	O

Heat	O
shock	O
caused	O
an	O
increase	B-Positive_regulation
in	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
mRNA	O
levels	B-Transcription
and	O
a	O
decrease	B-Negative_regulation
in	O
c	O
-	O
myc	O
mRNA	O
levels	B-Transcription
in	O
pre	O
-	O
B	O
(	O
Hyon	O
)	O
and	O
T	O
(	O
DND	O
-	O
41	O
)	O
cell	O
lines	O
as	O
well	O
as	O
in	O
freshly	O
isolated	O
normal	O
human	O
thymocytes	O
.	O

The	O
changes	B-Regulation
in	O
the	O
mRNA	O
levels	O
of	O
these	O
protooncogenes	O
in	O
Hyon	O
cells	O
were	O
most	O
pronounced	O
at	O
42	O
and	O
43	O
degrees	O
C	O
;	O
kinetic	O
analysis	O
demonstrated	O
that	O
the	O
changes	O
could	O
be	O
detected	B-Positive_regulation
within	O
30	O
min	O
of	O
heat	O
shock	O
.	O

Altered	B-Regulation
transcription	B-Transcription
of	O
c	O
-	O
fos	O
and	O
c	O
-	O
myc	O
genes	O
was	O
the	O
primary	O
effect	O
of	O
heat	O
shock	O
.	O

Secondarily	O
,	O
heat	O
shock	O
of	O
Hyon	O
cells	O
stabilized	O
the	O
c	O
-	O
myc	O
mRNA	O
level	O
by	O
increasing	B-Positive_regulation
its	O
half	O
-	O
life	O
from	O
24	O
to	O
45	O
min	O
.	O

The	O
overall	O
effect	B-Regulation
of	O
heat	O
shock	O
on	O
c	O
-	O
myc	O
mRNA	O
level	B-Transcription
,	O
however	O
,	O
was	O
a	O
marked	O
inhibition	B-Negative_regulation
of	O
its	O
transcription	B-Transcription
.	O

These	O
results	O
demonstrate	O
that	O
the	O
transcription	O
of	O
nuclear	O
protooncogenes	O
is	O
regulated	O
by	O
heat	O
shock	O
indicating	O
a	O
role	O
for	O
nuclear	O
protooncogenes	O
in	O
the	O
stress	O
response	O
of	O
lymphoid	O
cells	O
.	O

Tandem	O
AP-1	O
-	O
binding	O
sites	O
within	O
the	O
human	O
beta	O
-	O
globin	O
dominant	O
control	O
region	O
function	O
as	O
an	O
inducible	O
enhancer	O
in	O
erythroid	O
cells	O
.	O

A	O
powerful	O
enhancer	O
has	O
been	O
mapped	O
to	O
an	O
18	O
-	O
bp	O
DNA	O
segment	O
located	O
11	O
kb	O
5	O
'	O
to	O
the	O
human	O
epsilon	O
-	O
globin	O
gene	O
within	O
the	O
dominant	O
control	O
or	O
locus	O
-	O
activating	O
region	O
.	O

This	O
enhancer	O
is	O
inducible	O
in	O
K562	O
human	O
erythroleukemia	O
cells	O
,	O
increasing	B-Positive_regulation
linked	O
gamma	O
-	O
globin	O
promoter/luciferase	O
gene	O
expression	B-Gene_expression
to	O
170	O
-	O
fold	O
over	O
an	O
enhancerless	O
construct	O
.	O

The	O
enhancer	O
consists	O
of	O
tandem	O
AP-1	O
-	O
binding	O
sites	O
,	O
phased	O
10	O
bp	O
apart	O
,	O
which	O
are	O
both	O
required	B-Positive_regulation
for	O
full	O
activity	O
.	O

DNA	O
-	O
protein	O
binding	O
assays	O
with	O
nuclear	O
extracts	O
from	O
induced	O
cells	O
demonstrate	O
a	O
high	O
molecular	O
weight	O
complex	O
on	O
the	O
enhancer	O
.	O

The	O
formation	O
of	O
this	O
complex	O
also	O
requires	O
both	O
AP	O
-	O
1	O
sites	O
and	O
correlates	O
with	O
maximal	O
enhancer	O
activity	O
.	O

Induction	O
of	O
the	O
enhancer	O
may	O
have	O
a	O
role	O
in	O
the	O
increase	O
in	O
globin	O
gene	O
transcription	O
that	O
characterizes	O
erythroid	O
maturation	O
.	O

Enhancer	O
activity	O
appears	O
to	O
be	O
mediated	O
by	O
the	O
binding	O
of	O
a	O
complex	O
of	O
proteins	O
from	O
the	O
jun	O
and	O
fos	O
families	O
to	O
tandem	O
AP	O
-	O
1	O
consensus	O
sequences	O
.	O

Adherence	O
-	O
dependent	O
increase	B-Positive_regulation
in	O
human	O
monocyte	O
PDGF	O
(	O
B	O
)	O
mRNA	O
is	O
associated	O
with	O
increases	B-Positive_regulation
in	O
c	O
-	O
fos	O
,	O
c	O
-	O
jun	O
,	O
and	O
EGR2	O
mRNA	O
.	O

Adherence	O
is	O
an	O
important	O
initial	O
step	O
in	O
the	O
transition	O
of	O
a	O
circulating	O
monocyte	O
to	O
a	O
tissue	O
macrophage	O
.	O

This	O
differentiation	O
is	O
accompanied	O
by	O
an	O
augmented	O
capacity	O
to	O
generate	O
growth	O
factors	O
.	O

We	O
hypothesized	O
that	O
adherence	O
itself	O
might	O
be	O
an	O
important	O
trigger	O
for	O
a	O
sequence	O
of	O
gene	O
activation	O
culminating	B-Positive_regulation
in	O
cells	O
with	O
increased	B-Positive_regulation
mRNA	O
encoding	O
profibrotic	O
growth	O
factors	O
such	O
as	O
platelet	O
-	O
derived	O
growth	O
factor	O
B	O
subunit	O
(	O
PDGF	O
[	O
B	O
]	O
)	O
and	O
transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
.	O

After	O
in	O
vitro	O
adherence	O
,	O
human	O
monocytes	O
had	O
a	O
biphasic	O
increase	B-Positive_regulation
in	O
PDGF	O
(	O
B	O
)	O
mRNA	O
with	O
peaks	O
at	O
6	O
h	O
and	O
13	O
d	O
.	O

No	O
increase	B-Positive_regulation
in	O
TGF	O
-	O
beta	O
mRNA	O
was	O
observed	O
.	O

The	O
6	O
-	O
h	O
increase	B-Positive_regulation
in	O
PDGF	O
(	O
B	O
)	O
mRNA	O
was	O
adherence	O
dependent	B-Regulation
,	O
and	O
in	O
addition	O
,	O
was	O
abrogated	B-Negative_regulation
when	O
the	O
cytoskeletal	O
integrity	O
was	O
compromised	O
by	O
cytochalasin	O
D	O
.	O

The	O
6	O
-	O
h	O
increase	B-Positive_regulation
in	O
PDGF	O
(	O
B	O
)	O
mRNA	O
was	O
unaltered	B-Regulation
by	O
adherence	O
in	B-Positive_regulation
the	I-Positive_regulation
presence	I-Positive_regulation
of	I-Positive_regulation
the	O
monocyte	O
stimulus	O
lipopolysaccharide	O
.	O

Adherence	O
to	O
either	O
fibronectin	O
or	O
collagen	O
-	O
coated	O
plastic	O
had	O
little	O
consistent	O
effect	B-Regulation
on	O
PDGF	O
(	O
B	O
)	O
mRNA	O
accumulation	B-Positive_regulation
.	O

The	O
increased	B-Positive_regulation
PDGF	O
(	O
B	O
)	O
mRNA	O
observed	O
in	O
adherent	O
monocytes	O
was	O
accompanied	O
by	O
increases	B-Positive_regulation
in	O
mRNAs	O
of	O
the	O
early	O
growth	O
response	O
genes	O
c	O
-	O
fos	O
(	O
maximal	O
at	O
20	O
min	O
)	O
,	O
c	O
-	O
jun	O
,	O
and	O
EGR2	O
(	O
maximal	O
at	O
6	O
-	O
24	O
h	O
)	O
.	O

The	O
increase	B-Positive_regulation
in	O
c	O
-	O
jun	O
and	O
EGR2	O
,	O
but	O
not	O
c	O
-	O
fos	O
,	O
mRNA	O
was	O
also	O
abrogated	B-Negative_regulation
by	O
cytochalasin	O
D	O
.	O

These	O
observations	O
suggest	O
that	O
adherence	O
results	B-Positive_regulation
in	I-Positive_regulation
increases	I-Positive_regulation
of	O
c	O
-	O
fos	O
,	O
c	O
-	O
jun	O
,	O
EGR2	O
,	O
and	O
PDGF	O
(	O
B	O
)	O
mRNA	O
.	O

In	O
addition	O
,	O
the	O
increases	B-Positive_regulation
in	O
c	O
-	O
jun	O
,	O
EGR2	O
,	O
and	O
PDGF	O
(	O
B	O
)	O
may	O
depend	B-Regulation
on	O
cytoskeletal	O
rearrangement	O
.	O

Modulation	B-Regulation
of	O
these	O
events	O
at	O
the	O
time	O
of	O
adherence	O
offers	O
a	O
mechanism	O
by	O
which	O
differential	O
priming	O
of	O
the	O
cells	O
may	O
be	O
accomplished	O
.	O

Interferon	O
-	O
gamma	O
and	O
the	O
sexual	O
dimorphism	O
of	O
autoimmunity	O
.	O

The	O
sexual	O
difference	O
in	O
the	O
incidence	O
of	O
autoimmune	O
diseases	O
has	O
remained	O
an	O
enigma	O
for	O
many	O
years	O
.	O

In	O
the	O
examination	O
of	O
the	O
induction	O
of	O
autoimmunity	O
in	O
transgenic	O
mice	O
,	O
evidence	O
has	O
been	O
obtained	O
further	O
implicating	O
the	O
lymphokine	O
interferon	O
-	O
gamma	O
in	O
the	O
etiology	O
of	O
autoimmunity	O
.	O

Sex	O
steroid	O
regulation	B-Regulation
of	O
the	O
production	B-Gene_expression
of	O
this	O
molecule	O
,	O
as	O
well	O
as	O
other	O
cytokines	O
,	O
may	O
help	O
explain	O
the	O
gender	O
-	O
specific	O
differences	O
in	O
the	O
immune	O
system	O
,	O
including	O
autoimmunity	O
.	O

Single	O
cell	O
assay	O
of	O
a	O
transcription	O
factor	O
reveals	O
a	O
threshold	O
in	O
transcription	O
activated	O
by	O
signals	O
emanating	O
from	O
the	O
T	O
-	O
cell	O
antigen	O
receptor	O
.	O

Stimulation	O
of	O
T	O
lymphocytes	O
through	O
their	O
antigen	O
receptor	O
leads	O
to	O
the	O
appearance	O
of	O
several	O
transcription	O
factors	O
,	O
including	O
NF	O
-	O
AT	O
and	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
are	O
involved	O
in	O
regulating	O
genes	O
required	O
for	O
immunologic	O
activation	O
.	O

To	O
investigate	O
the	O
activity	O
of	O
a	O
single	O
transcription	O
factor	O
in	O
individual	O
viable	O
cells	O
,	O
we	O
have	O
applied	O
an	O
assay	O
that	O
uses	O
the	O
fluorescence	O
-	O
activated	O
cell	O
sorter	O
to	O
quantitate	O
beta	O
-	O
galactosidase	O
(	O
beta	O
-	O
gal	O
)	O
.	O

We	O
have	O
analyzed	O
the	O
distribution	O
of	O
NF	O
-	O
AT	O
transcriptional	O
activity	O
among	O
T	O
cells	O
undergoing	O
activation	O
by	O
using	O
a	O
construct	O
in	O
which	O
three	O
tandem	O
copies	O
of	O
the	O
NF-AT	O
-	O
binding	O
site	O
directs	B-Regulation
transcription	B-Transcription
of	O
the	O
lacZ	O
gene	O
.	O

Unexpectedly	O
,	O
stimulation	O
of	O
cloned	O
stably	O
transfected	O
Jurkat	O
T	O
cells	O
leads	B-Positive_regulation
to	O
a	O
bimodal	O
pattern	O
of	O
beta	O
-	O
gal	O
expression	B-Gene_expression
in	O
which	O
some	O
cells	O
express	B-Gene_expression
no	O
beta	O
-	O
gal	O
and	O
others	O
express	B-Gene_expression
high	B-Positive_regulation
levels	I-Positive_regulation
.	O

This	O
expression	O
pattern	O
can	O
not	O
be	O
accounted	B-Regulation
for	O
by	O
cell	O
-	O
cycle	O
position	O
or	O
heritable	O
variation	O
.	O

Further	O
results	O
,	O
in	O
which	O
beta	O
-	O
gal	O
activity	O
is	O
correlated	O
with	O
NF-AT	O
-	O
binding	O
activity	O
,	O
indicate	O
that	O
the	O
concentration	O
of	O
NF	O
-	O
AT	O
must	O
exceed	O
a	O
critical	O
threshold	O
before	O
transcription	O
initiates	O
.	O

This	O
threshold	O
likely	O
reflects	O
the	O
NF	O
-	O
AT	O
concentration	O
-	O
dependent	O
assembly	O
of	O
transcription	O
complexes	O
at	O
the	O
promoter	O
.	O

Similar	O
constructs	O
controlled	O
by	O
NF	O
-	O
kappa	O
B	O
or	O
the	O
entire	O
interleukin	O
-	O
2	O
enhancer	O
show	B-Regulation
bimodal	O
expression	B-Gene_expression
patterns	O
during	O
induction	B-Positive_regulation
,	O
suggesting	O
that	O
thresholds	O
set	O
by	O
the	O
concentration	O
of	O
transcription	O
factors	O
may	O
be	O
a	O
common	O
property	O
of	O
inducible	O
genes	O
.	O

Two	O
distinct	O
signal	O
transmission	O
pathways	O
in	O
T	O
lymphocytes	O
are	O
inhibited	O
by	O
complexes	O
formed	O
between	O
an	O
immunophilin	O
and	O
either	O
FK506	O
or	O
rapamycin	O
.	O

Proliferation	O
and	O
immunologic	O
function	O
of	O
T	O
lymphocytes	O
are	O
initiated	O
by	O
signals	O
from	O
the	O
antigen	O
receptor	O
that	O
are	O
inhibited	O
by	O
the	O
immunosuppressant	O
FK506	O
but	O
not	O
by	O
its	O
structural	O
analog	O
,	O
rapamycin	O
.	O

On	O
the	O
other	O
hand	O
,	O
interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
-	O
induced	O
signals	O
are	O
blocked	O
by	O
rapamycin	O
but	O
not	O
by	O
FK506	O
.	O

Remarkably	O
,	O
these	O
two	O
drugs	O
inhibit	O
each	O
other	O
's	O
actions	O
,	O
raising	O
the	O
possibility	O
that	O
both	O
act	O
by	O
means	O
of	O
a	O
common	O
immunophilin	O
(	O
immunosuppressant	O
binding	O
protein	O
)	O
.	O

We	O
find	O
that	O
the	O
dissociation	O
constant	O
of	O
rapamycin	O
to	O
the	O
FK506	O
binding	O
protein	O
FKBP	O
(	O
Kd	O
=	O
0.2	O
nM	O
)	O
is	O
close	O
to	O
the	O
dissociation	O
constant	O
of	O
FK506	O
to	O
FKBP	O
(	O
Kd	O
=	O
0.4	O
nM	O
)	O
and	O
to	O
their	O
effective	O
biologic	O
inhibitory	O
concentrations	O
.	O

However	O
,	O
an	O
excess	O
of	O
rapamycin	O
is	O
needed	B-Negative_regulation
to	I-Negative_regulation
revert	I-Negative_regulation
FK506	O
-	O
mediated	O
inhibition	B-Negative_regulation
of	O
IL	O
-	O
2	O
production	B-Gene_expression
,	O
apoptosis	O
,	O
and	O
transcriptional	O
activation	O
of	O
NF	O
-	O
AT	O
,	O
a	O
T-cell	O
-	O
specific	O
transcription	O
factor	O
necessary	B-Positive_regulation
for	O
IL	O
-	O
2	O
gene	O
activation	B-Positive_regulation
.	O

Similarly	O
,	O
an	O
excess	O
of	O
FK506	O
is	O
needed	O
to	O
revert	O
rapamycin	O
-	O
mediated	O
inhibition	O
of	O
IL-2	O
-	O
induced	O
proliferation	O
.	O

The	O
drug	O
concentrations	O
required	O
for	O
antagonism	O
may	O
be	O
explained	O
by	O
the	O
relative	O
affinity	O
of	O
the	O
drugs	O
to	O
,	O
and	O
by	O
the	O
abundance	O
of	O
,	O
the	O
immunophilin	O
FKBP	O
.	O

FKBP	O
has	O
been	O
shown	O
to	O
catalyze	O
the	O
interconversion	O
of	O
the	O
cis	O
-	O
and	O
trans	O
-	O
rotamers	O
of	O
the	O
peptidyl	O
-	O
prolyl	O
amide	O
bond	O
of	O
peptide	O
substrates	O
;	O
here	O
we	O
show	O
that	O
rapamycin	O
,	O
like	O
FK506	O
,	O
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
rotamase	O
activity	O
of	O
FKBP	O
(	O
Ki	O
=	O
0.2	O
nM	O
)	O
.	O

Neither	O
FKBP	O
binding	O
nor	O
inhibition	O
of	O
rotamase	O
activity	O
of	O
FKBP	O
alone	O
is	O
sufficient	O
to	O
explain	O
the	O
biologic	O
actions	O
of	O
these	O
drugs	O
.	O

Rather	O
,	O
these	O
findings	O
suggest	O
that	O
immunophilin	O
bound	O
to	O
FK506	O
interferes	O
with	O
antigen	O
receptor	O
-	O
induced	O
signals	O
,	O
while	O
rapamycin	O
bound	O
to	O
the	O
immunophilin	O
interferes	O
with	O
IL-2	O
-	O
induced	O
signals	O
.	O

Transcriptional	O
down	B-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
of	O
c	O
-	O
myc	O
expression	B-Gene_expression
by	O
protein	O
synthesis	O
-	O
dependent	O
and	O
-	O
independent	O
pathways	O
in	O
a	O
human	O
T	O
lymphoblastic	O
tumor	O
cell	O
line	O
.	O

We	O
show	O
that	O
in	O
the	O
human	O
T	O
lymphoblastic	O
tumor	O
cell	O
line	O
Molt4	O
c	O
-	O
myc	O
mRNA	O
and	O
protein	O
expression	B-Transcription
is	O
down	B-Negative_regulation
-	I-Negative_regulation
regulated	I-Negative_regulation
after	O
exposure	O
to	O
dimethyl	O
sulfoxide	O
,	O
to	O
phorbol	O
myristate	O
acetate	O
,	O
or	O
to	O
the	O
calcium	O
ionophore	O
A23187	O
,	O
which	O
raises	O
the	O
intracellular	O
calcium	O
concentration	O
.	O

A	O
block	O
to	O
RNA	O
elongation	O
is	O
largely	O
responsible	B-Regulation
for	O
decreased	B-Negative_regulation
c	O
-	O
myc	O
transcription	B-Transcription
.	O

Although	O
negative	B-Negative_regulation
regulation	I-Negative_regulation
by	O
dimethyl	O
sulfoxide	O
takes	O
place	O
even	O
when	B-Positive_regulation
protein	O
synthesis	O
is	O
inhibited	O
by	O
cycloheximide	O
,	O
the	O
phorbol	O
myristate	O
acetate	O
effect	B-Negative_regulation
is	O
blocked	B-Negative_regulation
to	O
some	O
extent	O
only	O
by	O
cycloheximide	O
.	O

The	O
calcium	O
ionophore	O
-	O
induced	O
c	O
-	O
myc	O
suppression	B-Negative_regulation
,	O
however	O
,	O
strictly	O
requires	B-Positive_regulation
de	O
novo	O
protein	O
synthesis	O
.	O

Therefore	O
,	O
two	O
different	O
negative	O
regulatory	O
pathways	O
are	O
involved	O
in	O
c	O
-	O
myc	O
regulation	B-Regulation
:	O
one	O
which	O
is	O
independent	O
and	O
one	O
which	O
depends	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O

The	O
latter	O
one	O
appears	O
to	O
be	O
mediated	O
by	O
a	O
rapidly	O
calcium	O
-	O
dependent	O
induced	O
gene	O
product	O
.	O

Induction	O
of	O
immediate	O
early	O
response	O
genes	O
by	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
in	O
normal	O
human	O
monocytes	O
.	O

A	O
group	O
of	O
coordinately	O
induced	O
protooncogenes	O
,	O
cytoskeletal	O
,	O
and	O
extracellular	O
matrix	O
genes	O
have	O
been	O
termed	O
immediate	O
early	O
response	O
genes	O
,	O
and	O
their	O
induction	O
has	O
been	O
associated	O
with	O
growth	O
factor	O
-	O
stimulated	O
cell	O
proliferation	O
.	O

We	O
have	O
investigated	O
the	O
induction	O
of	O
these	O
genes	O
by	O
macrophage	O
-	O
CSF	O
(	O
M	O
-	O
CSF	O
)	O
in	O
human	O
monocytes	O
that	O
do	O
not	O
proliferate	O
in	O
response	O
to	O
M	O
-	O
CSF	O
but	O
require	O
the	O
factor	O
for	O
optimal	O
cell	O
differentiation	O
.	O

Normal	O
human	O
monocytes	O
were	O
isolated	O
,	O
carefully	O
washed	O
,	O
and	O
incubated	O
for	O
36	O
to	O
48	O
h	O
in	O
fetal	O
bovine	O
serum	O
-	O
containing	O
medium	O
.	O

At	O
the	O
end	O
of	O
this	O
incubation	O
the	O
resting	O
cells	O
were	O
stimulated	O
with	O
M	O
-	O
CSF	O
,	O
and	O
RNA	O
was	O
isolated	O
for	O
analysis	O
by	O
Northern	O
blotting	O
.	O

RNA	O
from	O
control	O
resting	O
cells	O
contained	O
low	O
to	O
undetectable	O
levels	B-Transcription
of	O
c	O
-	O
jun	O
,	O
fibronectin	O
receptor	O
,	O
and	O
actin	O
mRNA	O
.	O

Within	O
15	O
to	O
30	O
min	O
of	O
addition	O
of	O
M	O
-	O
CSF	O
,	O
however	O
,	O
there	O
was	O
a	O
dramatic	O
coordinate	O
induction	B-Positive_regulation
of	O
these	O
genes	O
.	O

The	O
c	O
-	O
jun	O
gene	O
expression	B-Gene_expression
was	O
very	O
transient	O
and	O
was	O
not	O
detectable	O
by	O
60	O
min	O
after	B-Positive_regulation
M	O
-	O
CSF	O
addition	O
.	O

In	O
contrast	O
,	O
the	O
expression	O
of	O
actin	O
and	O
fibronectin	O
receptor	O
mRNA	O
was	O
more	O
sustained	O
,	O
and	O
the	O
expression	O
of	O
these	O
genes	O
remained	O
elevated	O
at	O
24	O
to	O
48	O
h	O
after	O
M	O
-	O
CSF	O
addition	O
.	O

We	O
also	O
observed	O
the	O
induction	B-Positive_regulation
of	O
the	O
myelomonocytic	O
specific	O
tyrosine	O
kinase	O
hck	O
gene	O
simultaneously	O
with	O
the	O
other	O
immediate	O
early	O
response	O
genes	O
.	O

The	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
did	O
not	O
block	O
the	O
induction	O
of	O
any	O
of	O
these	O
genes	O
,	O
and	O
in	O
fact	O
,	O
super	B-Positive_regulation
-	I-Positive_regulation
induced	I-Positive_regulation
the	O
expression	B-Gene_expression
of	O
c	O
-	O
jun	O
and	O
hck	O
.	O

Nuclear	O
run	O
on	O
transcription	B-Transcription
of	O
the	O
c	O
-	O
jun	O
,	O
hck	O
,	O
and	O
actin	O
genes	O
.	O

Therefore	O
,	O
in	O
normal	O
human	O
monocytes	O
M	O
-	O
CSF	O
induces	O
immediate	O
early	O
response	O
genes	O
without	O
inducing	O
cell	O
proliferation	O
.	O

These	O
genes	O
may	O
then	O
play	O
a	O
role	O
in	O
altering	O
the	O
physiologic	O
status	O
of	O
the	O
cells	O
in	O
response	O
to	O
CSF	O
.	O

Stimulation	O
of	O
a	O
human	O
T	O
-	O
cell	O
clone	O
with	O
anti	O
-	O
CD3	O
or	O
tumor	O
necrosis	O
factor	O
induces	O
NF	O
-	O
kappa	O
B	O
translocation	O
but	O
not	O
human	O
immunodeficiency	O
virus	O
1	O
enhancer	O
-	O
dependent	O
transcription	O
.	O

The	O
expression	O
of	O
transiently	O
transfected	O
expression	O
vectors	O
under	O
the	O
control	O
of	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
or	O
its	O
enhancer	O
sequence	O
and	O
the	O
translocation	O
of	O
the	O
HIV	O
enhancer	O
-	O
binding	O
protein	O
NF	O
-	O
kappa	O
B	O
were	O
analyzed	O
in	O
two	O
human	O
T	O
-	O
cell	O
clones	O
stimulated	O
through	O
their	O
T	O
-	O
cell	O
receptor	O
complex	O
or	O
by	O
tumor	O
necrosis	O
factor	O
or	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
.	O

We	O
found	O
a	O
dissociation	O
of	O
NF	O
-	O
kappa	O
B	O
translocation	O
from	O
transactivation	O
of	O
either	O
the	O
HIV	O
LTR	O
or	O
the	O
HIV	O
enhancer	O
.	O

Interleukin	O
2	O
induced	O
proliferation	O
but	O
not	O
NF	O
-	O
kappa	O
B	O
translocation	O
or	O
LTR	O
transactivation	O
.	O

Phorbol	O
ester	O
or	O
specific	O
antigen	O
recognition	O
induced	O
HIV	O
LTR	O
transactivation	O
,	O
whereas	O
stimulation	O
with	O
tumor	O
necrosis	O
factor	O
or	O
antibody	O
to	O
CD3	O
did	O
not	O
.	O

The	O
two	O
latter	O
signals	O
were	O
nevertheless	O
able	O
to	O
induce	O
NF	O
-	O
kappa	O
B	O
translocation	O
with	O
a	O
pattern	O
in	O
the	O
band	O
-	O
shift	O
assay	O
indistinguishable	O
from	O
that	O
observed	O
using	O
phorbol	O
ester	O
.	O

Our	O
finding	O
that	O
induction	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
tumor	O
necrosis	O
factor	O
or	O
antibody	O
to	O
CD3	O
is	O
not	O
sufficient	O
to	O
induce	O
HIV	O
enhancer	O
-	O
dependent	O
transcription	O
in	O
cloned	O
T	O
cells	O
contrasts	O
with	O
results	O
obtained	O
in	O
most	O
lymphoblastoid	O
T	O
-	O
cell	O
lines	O
and	O
indicates	O
that	O
normal	O
T	O
lymphocytes	O
differ	O
from	O
tumoral	O
T	O
cells	O
in	O
terms	O
of	O
requirements	O
for	O
HIV	O
LTR	O
activation	O
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
events	O
linked	O
to	O
T	O
-	O
cell	O
activation	O
,	O
in	O
addition	O
to	O
NF	O
-	O
kappa	O
B	O
translocation	O
per	O
se	O
,	O
induce	O
functional	O
interactions	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
with	O
the	O
HIV	O
enhancer	O
.	O

Lymphoid	O
specific	O
gene	O
expression	O
of	O
the	O
adenovirus	O
early	O
region	O
3	O
promoter	O
is	O
mediated	O
by	O
NF	O
-	O
kappa	O
B	O
binding	O
motifs	O
.	O

A	O
primary	O
site	O
of	O
infection	O
by	O
human	O
adenoviruses	O
is	O
lymphoid	O
cells	O
.	O

However	O
,	O
analysis	O
of	O
the	O
viral	O
control	O
elements	O
and	O
the	O
cellular	O
factors	O
that	O
regulate	O
adenoviral	O
gene	O
expression	O
in	O
lymphocytes	O
has	O
not	O
been	O
reported	O
.	O

The	O
adenovirus	O
early	O
region	O
3	O
(	O
ES	O
)	O
gene	O
products	O
are	O
involved	O
in	O
the	O
maintenance	O
of	O
viral	O
persistence	O
by	O
complexing	O
with	O
the	O
class	O
I	O
MHC	O
antigens	O
,	O
thus	O
preventing	O
their	O
cell	O
surface	O
expression	O
with	O
a	O
resultant	O
decrease	O
in	O
host	O
immunologic	O
destruction	O
.	O

To	O
determine	O
whether	O
different	O
cellular	O
factors	O
were	O
involved	O
in	O
E3	O
regulation	O
in	O
lymphocytes	O
as	O
compared	O
with	O
HeLa	O
cells	O
,	O
both	O
DNA	O
binding	O
and	O
transfection	O
analysis	O
with	O
the	O
E3	O
promoter	O
in	O
both	O
cell	O
types	O
were	O
performed	O
.	O

These	O
studies	O
detected	O
two	O
novel	O
domains	O
referred	O
to	O
as	O
L1	O
and	O
L2	O
with	O
a	O
variety	O
of	O
lymphoid	O
but	O
not	O
HeLa	O
extracts	O
.	O

Each	O
of	O
these	O
domains	O
possessed	O
strong	O
homology	O
to	O
motifs	O
previously	O
found	O
to	O
bind	O
the	O
cellular	O
factor	O
NF	O
-	O
kappa	O
B	O
.	O

Transfections	O
of	O
E3	O
constructs	O
linked	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
gene	O
revealed	O
that	O
mutagenesis	O
of	O
the	O
distal	O
NF	O
-	O
kappa	O
B	O
motif	O
(	O
L2	O
)	O
had	O
minimal	O
effects	O
on	O
promoter	O
expression	O
in	O
HeLa	O
cells	O
,	O
but	O
resulted	O
in	O
dramatic	O
decreases	O
in	O
expression	O
by	O
lymphoid	O
cells	O
.	O

In	O
contrast	O
,	O
mutagenesis	O
of	O
proximal	O
NF	O
-	O
kappa	O
B	O
motif	O
(	O
L1	O
)	O
had	O
minimal	O
effects	O
on	O
gene	O
expression	O
in	O
both	O
HeLa	O
cells	O
and	O
lymphoid	O
cells	O
but	O
resulted	O
in	O
a	O
small	O
,	O
but	O
reproducible	O
,	O
increase	O
in	O
gene	O
expression	O
in	O
lymphoid	O
cells	O
when	O
coupled	O
to	O
the	O
L2	O
mutation	O
.	O

Reversing	O
the	O
position	O
and	O
subsequent	O
mutagenesis	O
of	O
the	O
L1	O
and	O
L2	O
domains	O
indicated	O
that	O
the	O
primary	O
sequence	O
of	O
these	O
motifs	O
rather	O
than	O
their	O
position	O
in	O
the	O
E3	O
promoter	O
was	O
critical	O
for	O
regulating	O
gene	O
expression	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Characterization	O
of	O
defensin	O
resistance	O
phenotypes	O
associated	O
with	O
mutations	O
in	O
the	O
phoP	O
virulence	O
regulon	O
of	O
Salmonella	O
typhimurium	O
.	O

The	O
defensin	O
sensitivities	O
of	O
Salmonella	O
typhimurium	O
strains	O
with	O
mutations	O
in	O
the	O
phoP/phoQ	O
two	O
-	O
component	O
virulence	O
regulon	O
were	O
tested	O
by	O
using	O
purified	O
defensins	O
NP	O
-	O
1	O
and	O
NP	O
-	O
2	O
.	O

Strains	O
with	O
mutations	O
in	O
either	O
gene	O
of	O
the	O
regulatory	O
pair	O
(	O
phoP	O
[	O
transcriptional	O
activator	O
]	O
or	O
phoQ	O
[	O
membrane	O
sensor	O
kinase	O
]	O
)	O
had	O
increased	O
sensitivities	O
to	O
defensin	O
.	O

The	O
predicted	O
periplasmic	O
domain	O
of	O
the	O
PhoQ	O
protein	O
contained	O
a	O
markedly	O
anionic	O
domain	O
that	O
could	O
interact	O
with	O
cationic	O
proteins	O
and	O
that	O
could	O
be	O
responsible	O
for	O
resistance	O
to	O
defensin	O
.	O

Because	O
insertion	O
mutations	O
in	O
phoP	O
are	O
polar	O
on	O
phoQ	O
,	O
we	O
constructed	O
strains	O
that	O
expressed	B-Gene_expression
the	O
PhoQ	O
protein	O
in	O
the	O
absence	O
of	O
PhoP	O
to	O
test	O
whether	O
resistance	O
to	O
defensin	O
requires	O
only	O
the	O
phoQ	O
gene	O
product	O
.	O

We	O
found	O
that	O
resistance	O
to	O
defensin	O
requires	O
the	O
function	O
of	O
both	O
components	O
of	O
this	O
regulatory	O
system	O
,	O
because	O
strains	O
expressing	B-Gene_expression
PhoQ	O
without	O
PhoP	O
were	O
still	O
markedly	O
sensitive	O
to	O
defensins	O
.	O

This	O
implied	O
that	O
a	O
pag	O
(	O
phoP	O
-	O
activated	O
gene	O
)	O
product	O
is	O
responsible	O
for	O
defensin	O
resistance	O
.	O

We	O
also	O
tested	O
for	O
the	O
ability	O
of	O
defensins	O
NP	O
-	O
1	O
,	O
NP	O
-	O
5	O
,	O
and	O
HNP	O
-	O
1	O
to	O
activate	O
pag	O
expression	O
and	O
found	O
that	O
these	O
peptides	O
have	O
no	O
effect	O
.	O

Defensin	O
resistance	O
is	O
not	O
the	O
only	O
virulence	O
characteristic	O
controlled	O
by	O
the	O
PhoP	O
-	O
PhoQ	O
regulon	O
because	O
mutations	O
in	O
pagC	O
,	O
as	O
well	O
as	O
ones	O
in	O
the	O
phoP	O
locus	O
that	O
resulted	O
in	O
constitutive	O
pag	O
activation	O
(	O
phenotype	O
PhoPc	O
)	O
,	O
had	O
no	O
effect	O
on	O
defensin	O
resistance	O
,	O
even	O
though	O
they	O
rendered	O
the	O
organism	O
avirulent	O
and	O
deficient	O
in	O
survival	O
within	O
macrophages	O
.	O

The	O
virulence	O
defect	O
conferred	O
by	O
mutations	O
in	O
the	O
phoP	O
-	O
phoQ	O
two	O
-	O
component	O
regulatory	O
system	O
is	O
not	O
completely	O
explained	O
by	O
alterations	O
in	O
resistance	O
to	O
cationic	O
proteins	O
and	O
involves	O
the	O
control	O
of	O
other	O
proteins	O
necessary	O
for	O
S.	O
typhimurium	O
survival	O
within	O
macrophages	O
.	O

Involvement	O
of	O
cyclic	O
AMP	O
-	O
dependent	O
protein	O
kinases	O
in	O
the	O
signal	O
transduction	O
pathway	O
for	O
interleukin	O
-	O
1	O
.	O

Expression	O
of	O
a	O
highly	O
specific	O
protein	O
inhibitor	O
for	O
cyclic	O
AMP	O
-	O
dependent	O
protein	O
kinases	O
in	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
-	O
responsive	O
cells	O
blocked	O
IL-1	O
-	O
induced	O
gene	O
transcription	O
that	O
was	O
driven	O
by	O
the	O
kappa	O
immunoglobulin	O
enhancer	O
or	O
the	O
human	O
immunodeficiency	O
virus	O
long	O
terminal	O
repeat	O
.	O

This	O
inhibitor	O
did	O
not	O
affect	O
protein	O
kinase	O
C	O
-	O
mediated	O
gene	O
transcription	O
,	O
suggesting	O
that	O
cyclic	O
AMP	O
-	O
dependent	O
protein	O
kinases	O
are	O
involved	O
in	O
the	O
signal	O
transduction	O
pathway	O
for	O
IL	O
-	O
1	O
in	O
a	O
number	O
of	O
responsive	O
cell	O
types	O
.	O

Lipopolysaccharide	O
is	O
a	O
potent	O
monocyte/macrophage	O
-	O
specific	O
stimulator	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
potently	O
stimulates	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
-	O
long	O
terminal	O
repeat	O
(	O
HIV-1	O
-	O
LTR	O
)	O
CAT	O
constructs	O
transfected	O
into	O
monocyte/macrophage	O
-	O
like	O
cell	O
lines	O
but	O
not	O
a	O
T	O
cell	O
line	O
.	O

This	O
effect	O
appears	O
to	O
be	O
mediated	O
through	O
the	O
induction	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrate	O
that	O
LPS	O
induces	O
a	O
DNA	O
binding	O
activity	O
indistinguishable	O
from	O
NF	O
-	O
kappa	O
B	O
in	O
U937	O
and	O
THP	O
-	O
1	O
cells	O
.	O

LPS	O
is	O
also	O
shown	O
to	O
dramatically	O
increase	O
HIV	O
-	O
1	O
production	O
from	O
a	O
chronically	O
infected	O
monocyte/macrophage	O
-	O
like	O
cloned	O
cell	O
line	O
,	O
U1	O
,	O
which	O
produces	O
very	O
low	O
levels	O
of	O
HIV	O
-	O
1	O
at	O
baseline	O
.	O

The	O
stimulation	O
of	O
viral	O
production	O
from	O
this	O
cell	O
line	O
occurs	O
only	O
if	O
these	O
cells	O
are	O
treated	O
with	O
granulocyte/macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
before	O
treatment	O
with	O
LPS	O
.	O

This	O
stimulation	O
of	O
HIV	O
-	O
1	O
production	O
is	O
correlated	O
with	O
an	O
increase	O
in	O
the	O
level	O
of	O
HIV	O
-	O
1	O
RNA	O
and	O
and	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

LPS	O
is	O
not	O
able	O
to	O
induce	O
HIV	O
-	O
1	O
production	O
in	O
a	O
cloned	O
T	O
cell	O
line	O
.	O

The	O
effect	O
of	O
LPS	O
on	O
HIV	O
-	O
1	O
replication	O
occurs	O
at	O
picogram	O
per	O
milliliter	O
concentrations	O
and	O
may	O
be	O
clinically	O
significant	O
in	O
understanding	O
the	O
variability	O
of	O
the	O
natural	O
history	O
of	O
HIV	O
-	O
1	O
infection	O
.	O

Inducible	O
nuclear	O
factor	O
binding	O
to	O
the	O
kappa	O
B	O
elements	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
enhancer	O
in	O
T	O
cells	O
can	O
be	O
blocked	O
by	O
cyclosporin	O
A	O
in	O
a	O
signal	O
-	O
dependent	O
manner	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
is	O
thought	O
to	O
exert	O
its	O
immunosuppressive	O
effects	O
by	O
inhibiting	B-Negative_regulation
the	O
expression	B-Gene_expression
of	O
a	O
distinct	O
set	O
of	O
lymphokine	O
genes	O
which	O
are	O
induced	O
upon	O
T	O
-	O
cell	O
activation	O
,	O
among	O
them	O
the	O
gene	O
coding	O
for	O
interleukin	O
-	O
2	O
.	O

In	O
addition	O
,	O
the	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
partially	O
suppressed	O
.	O

To	O
better	O
understand	O
the	O
molecular	O
mechanisms	O
underlying	O
suppression	O
by	O
CsA	O
,	O
we	O
have	O
investigated	O
the	O
effects	O
of	O
this	O
drug	O
on	O
transcription	O
factors	O
in	O
T	O
cells	O
.	O

Here	O
we	O
report	O
that	O
the	O
formation	B-Binding
of	O
two	O
distinct	O
mitogen	O
-	O
inducible	O
DNA	O
-	O
binding	O
complexes	O
,	O
the	O
kappa	O
B	O
complex	O
within	O
the	O
HIV	O
enhancer	O
and	O
the	O
NFAT	O
-	O
1	O
complex	O
within	O
the	O
interleukin	O
-	O
2	O
enhancer	O
,	O
is	O
inhibited	B-Negative_regulation
in	O
the	O
presence	O
of	O
CsA	O
.	O

The	O
kappa	O
B	O
-	O
binding	O
activity	O
with	O
the	O
HIV	O
enhancer	O
is	O
inhibited	O
only	O
if	O
it	O
is	O
activated	O
via	O
the	O
mitogen	O
phytohemagglutinin	O
whereas	O
phorbol	O
myristate	O
acetate	O
-	O
mediated	O
activation	O
is	O
completely	O
insensitive	O
to	O
the	O
drug	O
.	O

This	O
suggests	O
a	O
model	O
in	O
which	O
functionally	O
indistinguishable	O
kappa	O
B	O
complexes	O
can	O
be	O
activated	O
via	O
two	O
separate	O
pathways	O
of	O
signal	O
transduction	O
distinguishable	O
by	O
CsA	O
.	O

Cell	O
-	O
specific	O
differences	O
in	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
regulatory	O
elements	O
of	O
human	O
immunodeficiency	O
virus	O
and	O
beta	O
interferon	O
promoters	O
by	O
tumor	O
necrosis	O
factor	O
.	O

Three	O
aspects	O
of	O
the	O
involvement	O
of	O
tumor	O
necrosis	O
factor	O
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
pathogenesis	O
were	O
examined	O
.	O

Tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
mRNA	O
production	B-Transcription
was	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
in	O
monocytic	O
U937	O
cells	O
and	O
in	O
a	O
chronically	O
HIV	O
infected	O
U937	O
cell	O
line	O
(	O
U9	O
-	O
IIIB	O
)	O
.	O

TNF	O
-	O
alpha	O
RNA	O
was	O
undetectable	B-Transcription
in	O
U937	O
cells	O
,	O
whereas	O
a	O
low	O
constitutive	O
level	O
was	O
detected	B-Transcription
in	O
U9	O
-	O
IIIB	O
cells	O
.	O

Paramyxovirus	O
infection	O
induced	B-Positive_regulation
a	O
5	O
-	O
to	O
10	O
-	O
fold	O
increase	B-Positive_regulation
in	O
the	O
steady	O
-	O
state	O
level	O
of	O
TNF	O
-	O
alpha	O
RNA	O
in	O
U9	O
-	O
IIIB	O
cells	O
compared	O
with	O
U937	O
cells	O
,	O
suggesting	O
that	O
HIV	O
-	O
infected	O
monocytic	O
cells	O
produced	B-Gene_expression
higher	B-Positive_regulation
levels	I-Positive_regulation
of	O
TNF	O
-	O
alpha	O
than	O
did	O
normal	O
cells	O
after	O
a	O
secondary	O
virus	O
infection	O
.	O

The	O
effects	O
of	O
TNF	O
-	O
alpha	O
on	O
gene	O
expression	O
were	O
examined	O
by	O
transient	O
expression	O
assays	O
using	O
reporter	O
chloramphenicol	O
acetyltransferase	O
plasmids	O
linked	O
to	O
regulatory	O
elements	O
from	O
the	O
HIV	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
and	O
the	O
beta	O
interferon	O
promoter	O
.	O

In	O
U937	O
and	O
Jurkat	O
T	O
lymphoid	O
cells	O
,	O
the	O
inducibility	O
of	O
the	O
different	O
hybrid	O
promoters	O
by	O
TNF	O
-	O
alpha	O
or	O
phorbol	O
ester	O
varied	O
in	O
a	O
cell	O
type	O
-	O
and	O
promoter	O
context	O
-	O
specific	O
manner	O
;	O
the	O
levels	O
of	O
gene	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
containing	O
plasmids	O
correlated	O
directly	O
with	O
induction	O
of	O
NF	O
-	O
kappa	O
B	O
DNA	O
-	O
binding	O
activity	O
.	O

Although	O
the	O
intact	O
beta	O
interferon	O
promoter	O
was	O
only	O
weakly	O
stimulated	B-Positive_regulation
by	O
phorbol	O
ester	O
or	O
TNF	O
-	O
alpha	O
,	O
multimers	O
of	O
the	O
PRDII	O
NF	O
-	O
kappa	O
B	O
-	O
binding	O
domain	O
were	O
inducible	O
by	O
both	O
agents	O
.	O

TNF	O
-	O
alpha	O
was	O
able	O
to	O
increase	O
expression	O
of	O
the	O
HIV	O
LTR	O
in	O
T	O
cells	O
,	O
but	O
in	O
monocytic	O
cells	O
,	O
TNF	O
-	O
alpha	O
did	O
not	O
induce	O
the	O
HIV	O
LTR	O
above	O
a	O
constitutive	O
level	O
of	O
activity	O
.	O

This	O
level	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
independent	O
activity	O
appears	O
to	O
be	O
sufficient	O
for	O
virus	O
multiplication	O
,	O
since	O
TNF	O
-	O
alpha	O
treatment	O
had	O
no	O
effect	O
on	O
the	O
kinetics	O
of	O
de	O
novo	O
HIV	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
infection	O
and	O
viral	O
RNA	O
production	O
in	O
U937	O
cells	O
.	O

However	O
,	O
in	O
Jurkat	O
cells	O
,	O
TNF	O
-	O
alpha	O
dramatically	O
enhanced	O
the	O
spread	O
of	O
HIV	O
-	O
1	O
through	O
the	O
cell	O
population	O
and	O
increased	O
viral	O
RNA	O
synthesis	O
,	O
indicating	O
that	O
in	O
T	O
cells	O
HIV	O
-	O
1	O
multiplication	O
was	O
stimulated	O
by	O
TNF	O
-	O
alpha	O
treatment	O
.	O

Astrocytes	O
and	O
glioblastoma	O
cells	O
express	O
novel	O
octamer	O
-	O
DNA	O
binding	O
proteins	O
distinct	O
from	O
the	O
ubiquitous	O
Oct	O
-	O
1	O
and	O
B	O
cell	O
type	O
Oct	O
-	O
2	O
proteins	O
.	O

The	O
'octamer	O
'	O
sequence	O
,	O
ATGCAAAT	O
or	O
its	O
complement	O
ATTTGCAT	O
,	O
is	O
a	O
key	O
element	O
for	O
the	O
transcriptional	O
regulation	O
of	O
immunoglobulin	O
genes	O
in	O
B	O
-	O
lymphocytes	O
as	O
well	O
as	O
a	O
number	O
of	O
housekeeping	O
genes	O
in	O
all	O
cell	O
types	O
.	O

In	O
lymphocytes	O
,	O
the	O
octamer	O
-	O
binding	O
protein	O
Oct	O
-	O
2A	O
and	O
variants	O
thereof	O
are	O
thought	O
to	O
contribute	O
to	O
the	O
B	O
-	O
cell	O
specific	O
gene	O
expression	O
,	O
while	O
the	O
ubiquitous	O
protein	O
Oct	O
-	O
1	O
seems	O
to	O
control	O
general	O
octamer	O
site	O
-	O
dependent	O
transcription	O
.	O

Various	O
other	O
genes	O
,	O
for	O
example	O
interleukin	O
-	O
1	O
and	O
MHC	O
class	O
II	O
genes	O
,	O
contain	O
an	O
octamer	O
sequence	O
in	O
the	O
promoter	O
and	O
are	O
expressed	O
in	O
cells	O
of	O
both	O
the	O
immune	O
and	O
nervous	O
systems	O
.	O

This	O
prompted	O
us	O
to	O
analyze	O
the	O
octamer	O
-	O
binding	O
proteins	O
in	O
the	O
latter	O
cells	O
.	O

Using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
at	O
least	O
six	O
novel	O
octamer	O
binding	O
proteins	O
were	O
detected	O
in	O
nuclear	O
extracts	O
of	O
cultured	O
mouse	O
astrocytes	O
.	O

These	O
proteins	O
are	O
differentially	O
expressed	O
in	O
human	O
glioblastoma	O
and	O
neuroblastoma	O
cell	O
lines	O
.	O

The	O
nervous	O
system	O
-	O
derived	O
(	O
N	O
-	O
Oct	O
)	O
proteins	O
bound	O
to	O
the	O
octamer	O
DNA	O
sequence	O
in	O
a	O
manner	O
which	O
is	O
indistinguishable	O
from	O
the	O
Oct	O
-	O
1	O
and	O
Oct	O
-	O
2A	O
proteins	O
.	O

The	O
relationship	O
of	O
the	O
N	O
-	O
Oct	O
proteins	O
to	O
Oct	O
-	O
1	O
and	O
Oct	O
-	O
2A	O
was	O
analyzed	O
by	O
proteolytic	O
clipping	O
bandshift	O
assays	O
and	O
by	O
their	O
reactivity	O
towards	O
antisera	O
raised	O
against	O
recombinant	O
Oct	O
-	O
1	O
and	O
Oct	O
-	O
2A	O
proteins	O
.	O

On	O
the	O
basis	O
of	O
these	O
assays	O
,	O
all	O
N-Oct	O
-	O
factors	O
were	O
found	O
to	O
be	O
distinct	O
from	O
the	O
ubiquitous	O
Oct	O
-	O
1	O
and	O
the	O
lymphoid	O
-	O
specific	O
Oct	O
-	O
2A	O
proteins	O
.	O

In	O
melanoma	O
cells	O
that	O
contain	O
the	O
N-Oct	O
-	O
3	O
factor	O
,	O
a	O
transfected	O
lymphocyte	O
-	O
specific	O
promoter	O
was	O
neither	O
activated	O
nor	O
was	O
it	O
repressed	O
upon	O
contransfection	O
with	O
an	O
Oct	O
-	O
2A	O
expression	O
vector	O
.	O

We	O
therefore	O
speculate	O
that	O
N-Oct	O
-	O
3	O
and	O
other	O
N	O
-	O
Oct	O
factors	O
have	O
a	O
specific	O
role	O
in	O
gene	O
expression	O
in	O
cells	O
of	O
the	O
nervous	O
system	O
.	O

Cloning	O
of	O
a	O
mitogen	O
-	O
inducible	O
gene	O
encoding	O
a	O
kappa	O
B	O
DNA	O
-	O
binding	O
protein	O
with	O
homology	O
to	O
the	O
rel	O
oncogene	O
and	O
to	O
cell	O
-	O
cycle	O
motifs	O
.	O

We	O
have	O
cloned	O
and	O
characterized	O
a	O
mitogen	O
-	O
inducible	O
gene	O
isolated	O
from	O
human	O
T	O
cells	O
that	O
predicts	O
a	O
protein	O
of	O
968	O
amino	O
acids	O
.	O

The	O
amino	O
-	O
terminal	O
domain	O
has	O
regions	O
homologous	O
to	O
the	O
oncogene	O
rel	O
and	O
to	O
the	O
developmentally	O
important	O
gene	O
dorsal	O
of	O
Drosophila	O
.	O

The	O
carboxy	O
-	O
terminal	O
domain	O
contains	O
repeat	O
structures	O
found	O
in	O
a	O
variety	O
of	O
proteins	O
that	O
are	O
involved	O
in	O
cell	O
-	O
cycle	O
control	O
of	O
yeast	O
and	O
in	O
tissue	O
differentiation	O
in	O
Drosophila	O
and	O
Ceanorhabditis	O
elegans	O
,	O
as	O
well	O
as	O
in	O
the	O
putative	O
human	O
oncogene	O
bcl	O
-	O
3	O
and	O
in	O
the	O
ankyrin	O
protein	O
.	O

A	O
truncated	O
form	O
of	O
the	O
product	O
of	O
this	O
gene	O
translated	O
in	O
vitro	O
is	O
a	O
DNA	O
-	O
binding	O
protein	O
which	O
interacts	O
specifically	O
with	O
the	O
kappa	O
B	O
binding	O
site	O
found	O
in	O
many	O
inducible	O
genes	O
,	O
including	O
the	O
enhancer	O
in	O
human	O
immunodeficiency	O
virus	O
.	O

This	O
gene	O
is	O
yet	O
another	O
in	O
a	O
growing	O
list	O
of	O
important	O
regulatory	O
molecules	O
whose	O
expression	O
is	O
transcriptionally	O
induced	O
upon	O
cellular	O
activation	O
.	O

Regulation	O
of	O
gene	O
expression	O
with	O
double	O
-	O
stranded	O
phosphorothioate	O
oligonucleotides	O
.	O

Alteration	O
of	O
gene	O
transcription	O
by	O
inhibition	O
of	O
specific	O
transcriptional	O
regulatory	O
proteins	O
is	O
necessary	O
for	O
determining	O
how	O
these	O
factors	O
participate	O
in	O
cellular	O
differentiation	O
.	O

The	O
functions	O
of	O
these	O
proteins	O
can	O
be	O
antagonized	O
by	O
several	O
methods	O
,	O
each	O
with	O
specific	O
limitations	O
.	O

Inhibition	O
of	O
sequence	O
-	O
specific	O
DNA	O
-	O
binding	O
proteins	O
was	O
achieved	O
with	O
double	O
-	O
stranded	O
(	O
ds	O
)	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
octamer	O
or	O
kappa	O
B	O
consensus	O
sequences	O
.	O

The	O
phosphorothioate	O
oligonucleotides	O
specifically	O
bound	O
either	O
octamer	O
transcription	O
factor	O
or	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
.	O

The	O
modified	O
oligonucleotides	O
accumulated	O
in	O
cells	O
more	O
effectively	O
than	O
standard	O
ds	O
oligonucleotides	O
and	O
modulated	O
gene	O
expression	O
in	O
a	O
specific	O
manner	O
.	O

Octamer	O
-	O
dependent	O
activation	O
of	O
a	O
reporter	O
plasmid	O
or	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
enhancer	O
was	O
inhibited	O
when	O
the	O
appropriate	O
phosphorothioate	O
oligonucleotide	O
was	O
added	O
to	O
a	O
transiently	O
transfected	O
B	O
cell	O
line	O
.	O

Addition	O
of	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
the	O
octamer	O
consensus	O
to	O
Jurkat	O
T	O
leukemia	O
cells	O
inhibited	B-Negative_regulation
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
secretion	B-Localization
to	O
a	O
degree	O
similar	O
to	O
that	O
observed	O
with	O
a	O
mutated	O
octamer	O
site	O
in	O
the	O
IL	O
-	O
2	O
enhancer	O
.	O

The	O
ds	O
phosphorothioate	O
oligonucleotides	O
probably	O
compete	O
for	O
binding	O
of	O
specific	O
transcription	O
factors	O
and	O
may	O
provide	O
anti	O
-	O
viral	O
,	O
immunosuppressive	O
,	O
or	O
other	O
therapeutic	O
effects	O
.	O

Differences	O
in	O
transcriptional	O
enhancers	O
of	O
HIV	O
-	O
1	O
and	O
HIV	O
-	O
2	O
.	O

Response	O
to	O
T	O
cell	O
activation	O
signals	O
.	O

T	O
cell	O
activation	O
results	O
in	O
high	O
levels	O
of	O
HIV	O
replication	O
and	O
is	O
thought	O
to	O
be	O
one	O
mechanism	O
leading	O
to	O
the	O
conversion	O
from	O
latent	O
to	O
active	O
viral	O
infection	O
.	O

In	O
HIV	O
-	O
1	O
,	O
the	O
sequences	O
that	O
respond	O
to	O
these	O
signaling	O
events	O
are	O
found	O
in	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
and	O
comprise	O
the	O
transcriptional	O
enhancer	O
,	O
which	O
contains	O
two	O
conserved	O
binding	O
sites	O
for	O
the	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
kappa	O
B	O
)	O
.	O

The	O
corresponding	O
region	O
in	O
the	O
second	O
AIDS	O
retrovirus	O
,	O
HIV	O
-	O
2	O
,	O
contains	O
a	O
conserved	O
and	O
a	O
divergent	O
NF	O
kappa	O
B	O
binding	O
site	O
.	O

We	O
demonstrate	O
that	O
the	O
HIV	O
-	O
1	O
LTR	O
responds	O
better	O
than	O
the	O
HIV	O
-	O
2	O
LTR	O
to	O
T	O
cell	O
activation	O
signals	O
.	O

These	O
qualitative	O
differences	O
in	O
the	O
response	O
to	O
T	O
cell	O
activation	O
are	O
reproduced	O
not	O
only	O
when	O
HIV	O
-	O
1	O
or	O
HIV	O
-	O
2	O
enhancers	O
are	O
placed	O
upstream	O
of	O
a	O
heterologous	O
promoter	O
but	O
also	O
when	O
these	O
enhancers	O
are	O
switched	O
between	O
their	O
respective	O
LTR	O
.	O

In	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
NF	O
kappa	O
B	O
binds	O
to	O
both	O
conserved	O
sites	O
in	O
the	O
HIV	O
-	O
1	O
transcriptional	O
enhancer	O
and	O
only	O
to	O
the	O
single	O
conserved	O
site	O
in	O
the	O
HIV	O
-	O
2	O
transcriptional	O
enhancer	O
.	O

Instead	O
of	O
NF	O
kappa	O
B	O
,	O
the	O
activator	O
protein	O
3	O
binds	B-Binding
to	O
the	O
divergent	O
site	O
in	O
HIV	O
-	O
2	O
.	O

In	O
conclusion	O
,	O
HIV	O
-	O
1	O
and	O
HIV	O
-	O
2	O
are	O
differentially	O
regulated	O
by	O
T	O
cell	O
activation	O
signals	O
,	O
and	O
this	O
difference	O
may	O
account	O
for	O
the	O
longer	O
period	O
of	O
viral	O
latency	O
observed	O
with	O
HIV	O
-	O
2	O
than	O
with	O
HIV	O
-	O
1	O
infection	O
.	O

An	O
in	O
vitro	O
globin	O
gene	O
switching	O
model	O
based	O
on	O
differentiated	O
embryonic	O
stem	O
cells	O
.	O

We	O
used	O
mouse	O
embryonic	O
stem	O
(	O
ES	O
)	O
cells	O
to	O
study	O
globin	O
gene	O
expression	O
and	O
switching	O
in	O
vitro	O
.	O

We	O
show	O
that	O
ES	O
-	O
derived	O
embryoid	O
bodies	O
express	O
the	O
full	O
complement	O
of	O
mouse	O
embryonic	O
globin	O
genes	O
in	O
the	O
correct	O
temporal	O
order	O
and	O
that	O
on	O
further	O
differentiation	O
,	O
a	O
switch	O
occurs	O
to	O
the	O
fetal/adult	O
genes	O
.	O

In	O
addition	O
,	O
the	O
erythroid	O
-	O
specific	O
transcription	O
factor	O
NF	O
-	O
E1	O
was	O
shown	O
to	O
be	O
expressed	B-Gene_expression
coordinately	O
with	O
that	O
of	O
globin	O
in	O
embryoid	O
bodies	O
.	O

We	O
conclude	O
from	O
these	O
experiments	O
that	O
the	O
ES	O
cell	O
system	O
provides	O
a	O
good	O
model	O
to	O
study	O
hematopoietic	O
development	O
.	O

When	O
the	O
human	O
epsilon	O
-	O
or	O
beta	O
-	O
globin	O
genes	O
driven	O
by	O
the	O
dominant	O
control	O
region	O
(	O
DCR	O
)	O
are	O
introduced	O
into	O
this	O
system	O
,	O
the	O
human	O
epsilon	O
-	O
globin	O
gene	O
,	O
in	O
contrast	O
to	O
the	O
beta	O
-	O
globin	O
gene	O
,	O
is	O
not	O
deregulated	B-Regulation
by	O
the	O
presence	O
of	O
the	O
DCR	O
and	O
is	O
expressed	B-Gene_expression
strictly	O
as	O
an	O
embryonic	O
gene	O
.	O

We	O
conclude	O
from	O
this	O
that	O
the	O
epsilon	O
-	O
globin	O
gene	O
is	O
not	O
regulated	B-Regulation
by	O
competition	O
with	O
other	O
genes	O
in	O
the	O
human	O
beta	O
-	O
globin	O
locus	O
.	O

Functional	O
analysis	O
of	O
cis	O
-	O
linked	O
regulatory	O
sequences	O
in	O
the	O
HLA	O
DRA	O
promoter	O
by	O
transcription	O
in	O
vitro	O
.	O

Two	O
consensus	O
sequences	O
,	O
called	O
X	O
and	O
Y	O
boxes	O
,	O
capable	O
of	O
binding	O
nuclear	O
proteins	O
and	O
regulating	O
expression	O
in	O
B	O
cells	O
have	O
been	O
defined	O
within	O
the	O
immediate	O
upstream	O
region	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
promoters	O
.	O

Unlike	O
other	O
class	O
II	O
promoters	O
,	O
the	O
HLA	O
-	O
DR	O
alpha	O
(	O
DRA	O
)	O
promoter	O
also	O
contains	O
one	O
element	O
identical	O
to	O
the	O
"	O
octamer	O
"	O
motif	O
of	O
immunoglobulin	O
variable	O
region	O
promoters	O
that	O
is	O
responsible	O
for	O
B	O
cell	O
-	O
specific	O
transcription	O
.	O

This	O
"	O
octamer	O
"	O
in	O
the	O
context	O
of	O
DRA	O
appears	O
capable	O
of	O
binding	B-Binding
both	O
the	O
ubiquitous	O
(	O
OTF	O
-	O
1	O
)	O
and	O
lymphoid	O
-	O
specific	O
(	O
OTF	O
-	O
2	O
)	O
"	O
octamer	O
"	O
binding	O
proteins	O
,	O
but	O
at	O
least	O
one	O
other	O
distinct	O
"	O
octamer	O
"	O
complex	O
was	O
found	O
.	O

In	O
order	O
to	O
characterize	O
the	O
function	O
of	O
cis	O
-	O
acting	O
elements	O
,	O
we	O
have	O
developed	O
an	O
in	O
vitro	O
system	O
in	O
which	O
a	O
DRA	O
promoter	O
construct	O
is	O
transcribed	O
more	O
efficiently	O
in	O
extracts	O
from	O
B	O
cells	O
than	O
in	O
extracts	O
from	O
class	O
II	O
-	O
negative	O
HeLa	O
cells	O
.	O

5	O
'	O
deletion	O
constructs	O
which	O
lacked	O
the	O
Y	O
box	O
,	O
but	O
retained	O
the	O
"	O
octamer	O
"	O
motif	O
and	O
TATA	O
box	O
were	O
completely	O
inactive	O
,	O
and	O
internal	O
deletion	O
of	O
the	O
Y	O
box	O
reduced	O
transcription	O
by	O
95	O
%	O
.	O

Using	O
supercoiled	O
,	O
but	O
not	O
linear	O
templates	O
,	O
we	O
observed	O
differences	O
in	O
transcription	O
efficiencies	O
from	O
templates	O
lacking	O
or	O
disrupting	O
the	O
X	O
consensus	O
element	O
that	O
reflect	O
effects	O
of	O
random	O
replacement	O
of	O
X	O
box	O
sequences	O
in	O
transient	O
expression	O
assays	O
.	O

Demonstration	O
of	O
the	O
complete	O
dependence	O
on	O
the	O
Y	O
box	O
in	O
this	O
system	O
suggests	O
that	O
,	O
despite	O
its	O
demonstrated	O
importance	O
in	O
the	O
DRA	O
promoter	O
,	O
the	O
DRA	O
"	O
octamer	O
"	O
does	O
not	O
utilize	B-Regulation
OTF	O
-	O
2	O
in	O
a	O
manner	O
analogous	O
to	O
immunoglobulin	O
promoters	O
in	O
B	O
cells	O
.	O

Characterization	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
enhancer	O
-	O
binding	O
proteins	O
from	O
the	O
human	O
T	O
-	O
cell	O
line	O
Jurkat	O
.	O

The	O
transcription	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
is	O
under	O
the	O
control	O
of	O
cellular	O
proteins	O
that	O
bind	O
to	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

Among	O
the	O
protein	O
-	O
binding	O
regions	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
is	O
the	O
transcription	O
-	O
enhancer	O
region	O
.	O

We	O
show	O
that	O
at	O
least	O
one	O
inducible	O
,	O
C1	O
,	O
and	O
one	O
constitutive	O
,	O
C2	O
,	O
protein	O
can	O
bind	B-Binding
to	O
the	O
HIV	O
enhancer	O
in	O
Jurkat	O
cells	O
.	O

The	O
two	O
proteins	O
differ	O
in	O
their	O
surface	O
charge	O
,	O
since	O
they	O
are	O
separable	O
by	O
anion	O
-	O
exchange	O
chromatography	O
.	O

Bivalent	O
cations	O
such	O
as	O
Mg2+	O
and	O
Zn2+	O
differentially	O
affect	B-Regulation
their	O
binding	B-Binding
to	O
oligonucleotides	O
which	O
contain	O
the	O
HIV	O
-	O
enhancer	O
domain	O
.	O

Both	O
C1	O
and	O
C2	O
proteins	O
also	O
bind	B-Binding
to	O
a	O
similar	O
sequence	O
found	O
in	O
the	O
interleukin-2	O
-	O
receptor	O
alpha	O
-	O
subunit	O
enhancer	O
.	O

The	O
inducible	O
C1	O
protein	O
was	O
partially	O
purified	O
by	O
three	O
chromatographic	O
steps	O
and	O
characterized	O
by	O
u.v	O
.	O

cross	O
-	O
linking	O
as	O
a	O
47	O
kDa	O
protein	O
.	O

The	O
ubiquitous	O
octamer	O
-	O
binding	O
protein	O
(	O
s	O
)	O
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	O
genes	O
.	O

All	O
immunoglobulin	O
genes	O
contain	O
a	O
conserved	O
octanucleotide	O
promoter	O
element	O
,	O
ATGCAAAT	O
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
required	O
for	O
their	O
normal	O
B-cell	O
-	O
specific	O
transcription	O
.	O

Proteins	O
that	O
bind	O
this	O
octamer	O
have	O
been	O
purified	O
,	O
and	O
cDNAs	O
encoding	O
octamer	O
-	O
binding	O
proteins	O
have	O
been	O
cloned	O
.	O

Some	O
of	O
these	O
proteins	O
(	O
referred	O
to	O
as	O
OTF	O
-	O
2	O
)	O
are	O
lymphoid	O
specific	O
,	O
whereas	O
at	O
least	O
one	O
other	O
,	O
and	O
possibly	O
more	O
(	O
referred	O
to	O
as	O
OTF	O
-	O
1	O
)	O
,	O
is	O
found	O
ubiquitously	O
in	O
all	O
cell	O
types	O
.	O

The	O
exact	O
role	O
of	O
these	O
different	O
proteins	O
in	O
directing	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
immunoglobulin	O
genes	O
is	O
unclear	O
.	O

We	O
have	O
identified	O
two	O
human	O
pre-B	O
-	O
cell	O
lines	O
that	O
contain	O
extremely	O
low	O
levels	O
of	O
OTF	O
-	O
2	O
yet	O
still	O
express	O
high	O
levels	O
of	O
steady	O
-	O
state	O
immunoglobulin	O
heavy	O
-	O
chain	O
mRNA	O
in	O
vivo	O
and	O
efficiently	O
transcribe	O
an	O
immunoglobulin	O
gene	O
in	O
vitro	O
.	O

Addition	O
of	O
a	O
highly	O
enriched	O
preparation	O
of	O
OTF	O
-	O
1	O
made	B-Gene_expression
from	O
one	O
of	O
these	O
pre	O
-	O
B	O
cells	O
or	O
from	O
HeLa	O
cells	O
specifically	O
stimulated	O
in	O
vitro	O
transcription	O
of	O
an	O
immunoglobulin	O
gene	O
.	O

Furthermore	O
,	O
OFT	O
-	O
1	O
appeared	O
to	O
have	O
approximately	O
the	O
same	O
transactivation	B-Positive_regulation
ability	O
as	O
OTF	O
-	O
2	O
when	O
normalized	O
for	O
binding	O
activity	O
.	O

These	O
results	O
suggest	O
that	O
OTF	O
-	O
1	O
,	O
without	O
OTF	O
-	O
2	O
,	O
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	O
genes	O
and	O
that	O
OTF	O
-	O
2	O
alone	O
is	O
not	O
responsible	O
for	O
the	O
B-cell	O
-	O
specific	O
regulation	O
of	O
immunoglobulin	O
gene	O
expression	O
.	O

Tax	O
-	O
independent	O
binding	O
of	O
multiple	O
cellular	O
factors	O
to	O
Tax	O
-	O
response	O
element	O
DNA	O
of	O
HTLV	O
-	O
I	O
.	O

The	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
promoter	O
contains	O
three	O
copies	O
of	O
imperfect	O
repeats	O
of	O
a	O
21	O
-	O
base	O
pair	O
sequence	O
designated	O
here	O
as	O
TRE	O
(	O
Tax	O
-	O
response	O
element	O
)	O
that	O
is	O
responsive	O
to	O
the	O
virally	O
encoded	O
transactivator	O
protein	O
Tax	O
.	O

We	O
have	O
identified	O
and	O
separated	O
four	O
nuclear	O
proteins	O
from	O
C81-66	O
-	O
45	O
cells	O
,	O
an	O
HTLV	O
-	O
I	O
immortalized	O
Tax	O
-	O
expressing	B-Gene_expression
human	O
T	O
-	O
lymphocyte	O
line	O
(	O
Salahuddin	O
et	O
al.	O
,	O
1983	O
)	O
,	O
that	O
interact	O
with	O
the	O
TRE	O
-	O
DNA	O
,	O
none	O
of	O
which	O
are	O
identical	O
with	O
the	O
Tax	O
-	O
protein	O
.	O

The	O
proteins	O
identified	O
have	O
molecular	O
weights	O
of	O
about	O
32	O
,	O
36	O
to	O
42	O
,	O
50	O
and	O
110	O
kD	O
.	O

Four	O
different	O
methods	O
were	O
used	O
to	O
identify	O
the	O
proteins	O
.	O

First	O
,	O
from	O
different	O
cell	O
lines	O
three	O
or	O
all	O
four	O
of	O
the	O
nuclear	O
proteins	O
were	O
specifically	O
cross	O
-	O
linked	O
by	O
UV	O
irradiation	O
to	O
the	O
radioactively	O
labeled	O
TRE	O
-	O
DNA	O
fragment	O
.	O

Second	O
,	O
TRE	O
-	O
DNA	O
binding	O
proteins	O
sedimented	O
through	O
a	O
glycerol	O
density	O
gradient	O
at	O
rates	O
corresponding	O
to	O
proteins	O
of	O
native	O
molecular	O
weights	O
of	O
35	O
to	O
50	O
kD	O
and	O
110	O
kD	O
.	O

Third	O
,	O
only	O
the	O
50	O
kD	O
protein	O
was	O
retained	O
on	O
a	O
biotinylated	O
DNA	O
-	O
streptavidin	O
matrix	O
when	O
the	O
DNA	O
fragment	O
contained	O
the	O
TRE	O
-	O
DNA	O
.	O

Fourth	O
,	O
extensive	O
purification	O
by	O
several	O
cycles	O
of	O
TRE	O
-	O
DNA	O
affinity	O
chromatography	O
resulted	O
in	O
the	O
32	O
,	O
36	O
to	O
42	O
and	O
110	O
kD	O
proteins	O
and	O
to	O
less	O
extent	O
the	O
50	O
kD	O
factor	O
.	O

Two	O
abundant	O
proteins	O
of	O
75	O
and	O
80	O
kD	O
were	O
competed	O
out	O
by	O
poly	O
[	O
d	O
(	O
I	O
-	O
C	O
)	O
]	O
in	O
all	O
reactions	O
.	O

The	O
cAMP	O
-	O
response	O
element	O
CRE	O
,	O
TGACGTCA	O
,	O
present	O
in	O
the	O
21	O
base	O
-	O
pair	O
sequence	O
,	O
appears	O
to	O
be	O
essential	O
for	O
specific	O
protein-TRE	O
-	O
DNA	O
interactions	O
because	O
mutation	O
of	O
the	O
two	O
G	O
's	O
destroys	O
this	O
complex	O
.	O

This	O
result	O
suggests	O
that	O
the	O
cAMP	O
response	O
element	O
binding	O
protein	O
,	O
CREB	O
,	O
is	O
involved	B-Regulation
in	O
the	O
protein-TRE	O
-	O
DNA	O
complex	O
and	O
in	O
mediating	B-Regulation
the	O
Tax	O
response	B-Regulation
.	O

Cell	O
type	O
specificity	O
and	O
activation	O
requirements	O
for	O
NFAT	O
-	O
1	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
-	O
cells	O
)	O
transcriptional	O
activity	O
determined	O
by	O
a	O
new	O
method	O
using	O
transgenic	O
mice	O
to	O
assay	O
transcriptional	O
activity	O
of	O
an	O
individual	O
nuclear	O
factor	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
-	O
cells	O
(	O
NFAT	O
-	O
1	O
)	O
is	O
a	O
transcription	O
factor	O
which	O
is	O
considered	O
to	O
be	O
an	O
important	O
regulator	O
in	O
early	O
T	O
-	O
cell	O
activation	O
.	O

We	O
have	O
developed	O
a	O
system	O
to	O
monitor	O
the	O
transcriptional	O
activity	O
of	O
NFAT	O
-	O
1	O
at	O
the	O
single	O
cell	O
level	O
in	O
whole	O
animals	O
.	O

The	O
system	O
is	O
based	O
on	O
the	O
use	O
of	O
an	O
oligomerized	O
NFAT	O
-	O
1	O
binding	O
motif	O
that	O
directs	O
transcription	O
of	O
SV40	O
T	O
-	O
antigen	O
in	O
transgenic	O
mice	O
.	O

This	O
report	O
represents	O
the	O
first	O
demonstration	O
that	O
a	O
multimerized	O
short	O
binding	O
motif	O
can	O
function	O
appropriately	O
in	O
transgenic	O
mice	O
.	O

NFAT	O
-	O
1	O
activity	O
had	O
previously	O
been	O
thought	O
to	O
be	O
confined	O
to	O
activated	O
T	O
-	O
lymphocytes	O
upon	O
release	O
of	O
intracellular	O
calcium	O
.	O

By	O
targeting	O
NFAT-1	O
-	O
dependent	O
gene	O
expression	O
in	O
transgenic	O
mice	O
we	O
discovered	O
new	O
sites	O
of	O
NFAT	O
-	O
1	O
activity	O
.	O

Besides	O
in	O
T	O
-	O
lymphocytes	O
NFAT	O
-	O
1	O
activity	O
could	O
also	O
be	O
induced	B-Positive_regulation
in	O
T-lymphocyte	O
-	O
depleted	O
spleen	O
cells	O
and	O
purified	O
B	O
-	O
lymphocytes	O
and	O
requires	B-Positive_regulation
agents	O
that	O
both	O
release	O
intracellular	O
calcium	O
and	O
activate	O
protein	O
kinase	O
C	O
.	O

A	O
difference	O
in	O
the	O
time	O
course	O
of	O
appearance	B-Positive_regulation
of	O
NFAT	O
-	O
1	O
activity	O
between	O
T	O
-	O
lymphocytes	O
and	O
non-T	O
-	O
lymphocytes	O
was	O
revealed	O
.	O

Constitutive	O
expression	O
was	O
observed	O
in	O
a	O
small	O
population	O
of	O
cells	O
in	O
the	O
dermis	O
and	O
some	O
mice	O
have	O
developed	O
skin	O
lesions	O
.	O

Interestingly	O
,	O
the	O
tissue	O
pattern	O
of	O
expression	B-Localization
of	O
the	O
NFAT	O
-	O
1	O
activity	O
resembles	O
the	O
expression	B-Localization
pattern	O
described	O
for	O
HIV	O
-	O
LTR/tat	O
transgenic	O
mice	O
(	O
Vogel	O
,	O
J.	O
,	O
Hinrichs	O
,	O
S.	O
H.	O
,	O
Reynolds	O
,	O
R	O
.	O

K.	O
,	O
Luciw	O
,	O
P.	O
A.	O
,	O
and	O
Jay	O
,	O
G	O
.	O

(	O
1988	O
)	O
Nature	O
335	O
,	O
606	O
-	O
611	O
)	O
.	O

This	O
similarity	O
in	O
expression	O
and	O
the	O
fact	O
that	O
NFAT	O
-	O
1	O
has	O
been	O
shown	O
to	O
bind	B-Binding
functional	O
sequences	O
in	O
HIV	O
-	O
LTR	O
suggest	O
a	O
role	O
for	O
NFAT	O
-	O
1	O
in	O
dermal	O
activation	O
of	O
the	O
HIV	O
-	O
LTR	O
.	O

Octamer	O
transcription	O
factors	O
and	O
the	O
cell	O
type	O
-	O
specificity	O
of	O
immunoglobulin	O
gene	O
expression	O
.	O

Antibodies	O
are	O
produced	O
exclusively	O
in	O
B	O
lymphocytes	O
.	O

The	O
expression	O
of	O
the	O
antibody	O
-	O
encoding	O
genes	O
,	O
the	O
immunoglobulin	O
(	O
Ig	O
)	O
genes	O
,	O
is	O
also	O
restricted	O
to	O
B	O
cells	O
.	O

The	O
octamer	O
sequence	O
ATGCAAAT	O
is	O
present	O
in	O
the	O
promoter	O
and	O
the	O
enhancer	O
of	O
Ig	O
genes	O
,	O
and	O
plays	O
an	O
important	O
role	O
in	O
its	O
tissue	O
-	O
specific	O
expression	O
.	O

This	O
sequence	O
motif	O
is	O
a	O
binding	O
site	O
for	O
nuclear	O
proteins	O
,	O
the	O
so	O
-	O
called	O
octamer	O
transcription	O
factors	O
(	O
Oct	O
or	O
OTF	O
factors	O
)	O
.	O

The	O
Oct	O
-	O
1	O
protein	O
is	O
present	B-Gene_expression
in	O
all	O
cell	O
types	O
analyzed	O
so	O
far	O
,	O
whereas	O
Oct	O
-	O
2A	O
and	O
Oct	O
-	O
2B	O
are	O
found	B-Gene_expression
mainly	O
in	O
B	O
lymphocytes	O
.	O

All	O
three	O
proteins	O
show	O
the	O
same	O
sequence	O
specificity	O
and	O
binding	O
affinity	O
.	O

It	O
appears	O
that	O
the	O
B	O
cell	O
-	O
specific	O
expression	O
of	O
Ig	O
genes	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
cell	O
type	O
-	O
specific	O
Oct	O
factors	O
,	O
and	O
that	O
there	O
are	O
both	O
quantitative	O
and	O
qualitative	O
differences	O
between	O
Oct	O
-	O
1	O
and	O
Oct	O
-	O
2	O
factors	O
.	O

Recently	O
,	O
a	O
number	O
of	O
other	O
octamer	O
factor	O
variants	O
were	O
identified	O
.	O

Many	O
of	O
these	O
may	O
be	O
created	O
by	O
alternative	O
splicing	O
of	O
a	O
primary	O
transcript	O
of	O
one	O
Oct	O
factor	O
gene	O
and	O
may	O
serve	O
a	O
specific	O
function	O
in	O
the	O
fine	O
tuning	O
of	O
gene	O
expression	O
.	O

Thrombin	O
and	O
thrombin	O
receptor	O
agonist	O
peptide	O
induce	O
early	O
events	O
of	O
T	O
cell	O
activation	O
and	O
synergize	B-Positive_regulation
with	O
TCR	O
cross	O
-	O
linking	O
for	O
CD69	O
expression	B-Gene_expression
and	O
interleukin	O
2	O
production	B-Gene_expression
.	O

Thrombin	O
stimulation	O
of	O
the	O
T	O
leukemic	O
cell	O
line	O
Jurkat	O
induced	O
a	O
transient	O
increase	O
in	O
[	O
Ca2+	O
]	O
i	O
.	O

Proteolytic	O
activity	O
of	O
the	O
enzyme	O
was	O
required	O
for	O
this	O
effect	O
since	O
diisopropyl	O
fluorophosphate	O
-	O
thrombin	O
failed	O
to	O
increase	O
[	O
Ca2+	O
]	O
i	O
.	O

Furthermore	O
,	O
hirudin	O
and	O
anti	O
-	O
thrombin	O
III	O
inhibited	O
the	O
thrombin	O
-	O
induced	O
[	O
Ca2+	O
]	O
i	O
rise	O
in	O
Jurkat	O
T	O
cells	O
.	O

A	O
synthetic	O
thrombin	O
receptor	O
agonist	O
peptide	O
(	O
TRP	O
)	O
of	O
7	O
residues	O
(	O
SFLLRNP	O
)	O
was	O
found	O
to	O
be	O
as	O
effective	O
as	O
thrombin	O
for	O
[	O
Ca2+	O
]	O
i	O
mobilization	O
,	O
and	O
both	O
agonists	O
induced	O
Ca2+	O
release	O
exclusively	O
from	O
internal	O
stores	O
.	O

Thrombin	O
stimulated	O
tyrosine	O
phosphorylation	O
of	O
several	O
proteins	O
of	O
molecular	O
mass	O
40	O
,	O
42	O
,	O
70	O
,	O
120	O
,	O
and	O
130	O
kDa	O
.	O

There	O
was	O
a	O
good	O
correlation	O
between	O
thrombin	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
latter	O
three	O
proteins	O
and	O
Ca2+	O
mobilization	O
.	O

Thrombin	O
and	O
TRP	O
also	O
caused	O
translocation	O
of	O
protein	O
kinase	O
C	O
from	O
the	O
cytosol	O
to	O
the	O
plasma	O
membrane	O
.	O

As	O
a	O
likely	O
consequence	O
of	O
these	O
events	O
,	O
thrombin	O
activated	O
the	O
nuclear	O
factor	O
NF	O
-	O
kB	O
.	O

Several	O
cell	O
lines	O
of	O
hematopoietic	O
origin	O
including	O
the	O
leukemic	O
T	O
cell	O
line	O
HPB.ALL	O
and	O
the	O
erythroleukemic	O
cell	O
line	O
K562	O
were	O
responsive	O
to	O
thrombin	O
,	O
whereas	O
others	O
such	O
as	O
THP1	O
,	O
a	O
myelomonocytic	O
cell	O
line	O
,	O
and	O
BL2	O
,	O
a	O
Burkitt	O
lymphoma	O
were	O
refractory	O
to	O
thrombin	O
or	O
TRP	O
stimulation	O
.	O

The	O
magnitude	O
of	O
the	O
thrombin	O
response	O
in	O
the	O
different	O
cell	O
types	O
paralleled	O
the	O
expression	B-Transcription
of	O
the	O
thrombin	O
receptor	O
mRNA	O
.	O

We	O
found	O
that	O
activation	O
of	O
Jurkat	O
T	O
cells	O
by	O
a	O
combination	O
of	O
phytohemagglutinin	O
and	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
led	O
to	O
a	O
dramatic	O
inhibition	B-Negative_regulation
of	O
thrombin	O
receptor	O
mRNA	O
expression	B-Transcription
and	O
to	O
a	O
concomitant	O
loss	O
of	O
the	O
thrombin	O
response	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
thrombin	O
and	O
TRP	O
enhanced	B-Positive_regulation
CD69	O
expression	B-Gene_expression
and	O
interleukin	O
2	O
production	B-Gene_expression
induced	B-Positive_regulation
by	O
T	O
cell	O
receptor	O
cross	O
-	O
linking	O
in	O
both	O
Jurkat	O
T	O
cells	O
and	O
peripheral	O
blood	O
lymphocytes	O
.	O

These	O
findings	O
highlight	O
the	O
role	O
of	O
thrombin	O
as	O
a	O
potential	O
regulator	O
of	O
T	O
lymphocyte	O
activation	O
.	O

Sp1	O
is	O
a	O
critical	B-Regulation
factor	O
for	O
the	O
monocytic	O
specific	O
expression	B-Gene_expression
of	O
human	O
CD14	O
.	O

CD14	O
is	O
a	O
membrane	O
glycoprotein	O
expressed	B-Gene_expression
specifically	O
on	O
monocytes	O
and	O
macrophages	O
,	O
and	O
its	O
expression	O
is	O
markedly	O
increased	B-Positive_regulation
during	O
the	O
process	O
of	O
monocyte	O
differentiation	O
.	O

In	O
order	O
to	O
study	O
CD14	O
gene	O
regulation	B-Regulation
,	O
the	O
human	O
CD14	O
gene	O
was	O
cloned	O
from	O
a	O
partial	O
EcoRI	O
digested	O
chromosome	O
5	O
library	O
.	O

A	O
5.5	O
-	O
kilobase	O
genomic	O
clone	O
contained	O
the	O
full	O
-	O
length	O
CD14	O
coding	O
sequence	O
and	O
4.2	O
kilobases	O
of	O
5'	O
-	O
upstream	O
sequence	O
.	O

One	O
major	O
and	O
one	O
minor	O
transcription	O
start	O
site	O
were	O
identified	O
101	O
and	O
130	O
base	O
pairs	O
(	O
bp	O
)	O
upstream	O
,	O
respectively	O
,	O
from	O
the	O
protein	O
translation	O
start	O
ATG	O
.	O

A	O
DNA	O
fragment	O
containing	O
128	O
bp	O
of	O
upstream	O
sequence	O
had	O
strong	O
,	O
monocyte	O
-	O
specific	O
promoter	O
activity	O
in	O
the	O
CD14	O
positive	O
monocytic	O
cell	O
line	O
Mono	O
Mac	O
6	O
as	O
compared	O
to	O
the	O
nonmonocytic	O
cell	O
lines	O
HeLa	O
and	O
REX	O
.	O

Four	O
regions	O
in	O
this	O
DNA	O
fragment	O
interact	O
with	O
nuclear	O
proteins	O
isolated	O
from	O
monocytic	O
cells	O
.	O

The	O
Sp1	O
transcription	O
factor	O
bound	B-Binding
to	O
three	O
different	O
regions	O
in	O
the	O
CD14	O
promoter	O
.	O

Mutation	O
of	O
the	O
major	O
Sp1	O
binding	O
site	O
(	O
-	O
110	O
bp	O
)	O
decreased	O
tissue	O
-	O
specific	O
promoter	O
activity	O
,	O
and	O
these	O
results	O
,	O
together	O
with	O
transactivation	O
experiments	O
,	O
demonstrate	O
that	O
Sp1	O
plays	O
a	O
critical	O
role	B-Regulation
in	O
the	O
tissue	O
-	O
specific	O
expression	B-Gene_expression
of	O
CD14	O
in	O
monocytic	O
cells	O
.	O

CD14	O
Sp1	O
site	O
oligonucleotides	O
bound	B-Binding
preferentially	O
to	O
a	O
105	O
-	O
kDa	O
Sp1	O
species	O
,	O
which	O
is	O
present	O
in	O
higher	O
relative	O
levels	O
in	O
monocytic	O
than	O
non	O
-	O
monocytic	O
cells	O
,	O
suggesting	O
that	O
modification	O
of	O
Sp1	O
,	O
such	O
as	O
phosphorylation	B-Phosphorylation
,	O
may	O
explain	O
how	O
the	O
Sp1	O
site	O
mediates	O
monocytic	O
specific	O
promoter	O
activity	O
.	O

Tolerance	O
to	O
lipopolysaccharide	O
involves	O
mobilization	B-Localization
of	O
nuclear	O
factor	O
kappa	O
B	O
with	O
predominance	O
of	O
p50	O
homodimers	O
.	O

Stimulation	O
of	O
the	O
human	O
monocytic	O
cell	O
line	O
Mono	O
Mac	O
6	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
leads	O
to	O
rapid	O
and	O
transient	O
expression	O
of	O
cytokines	O
like	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
.	O

When	O
such	O
cells	O
are	O
precultured	O
for	O
2	O
days	O
with	O
a	O
low	O
dose	O
of	O
LPS	O
(	O
20	O
ng/ml	O
)	O
followed	O
by	O
stimulation	O
with	O
a	O
high	O
dose	O
of	O
LPS	O
(	O
1	O
microgram/ml	O
)	O
,	O
expression	O
of	O
the	O
TNF	O
gene	O
is	O
minimal	O
,	O
i.e.	O
the	O
cells	O
are	O
tolerant	O
.	O

In	O
nuclear	O
run	O
-	O
on	O
analysis	O
,	O
such	O
tolerant	O
cells	O
show	O
only	O
a	O
low	O
degree	O
of	O
transcription	O
,	O
indicating	O
that	O
tolerance	O
operates	O
at	O
or	O
upstream	O
of	O
the	O
transcription	O
level	O
.	O

The	O
CD14	O
LPS	O
receptor	O
is	O
,	O
however	O
,	O
up	O
-	O
regulated	O
(	O
not	O
down	O
-	O
regulated	O
)	O
in	O
tolerant	O
cells	O
,	O
and	O
LPS	O
can	O
,	O
in	O
fact	O
,	O
still	O
lead	O
to	O
activation	O
of	O
tolerant	O
cells	O
as	O
evidenced	O
by	O
mobilization	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
.	O

Resolution	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
in	O
gel	O
shift	O
analysis	O
shows	O
that	O
the	O
binding	O
protein	O
,	O
mobilized	B-Localization
in	O
naive	O
Mono	O
Mac	O
6	O
cells	O
,	O
consists	O
mainly	O
of	O
p50	O
-	O
p65	O
heterodimers	O
,	O
while	O
in	O
tolerant	O
cells	O
,	O
the	O
p50	O
homodimer	O
is	O
predominant	O
.	O

This	O
increase	B-Positive_regulation
in	O
p50	O
homodimers	O
coincides	O
with	O
an	O
increase	B-Positive_regulation
in	O
p105	O
mRNA	O
,	O
suggestive	O
of	O
a	O
transcriptional	B-Positive_regulation
up	I-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
p50	O
.	O

Reporter	O
gene	O
analysis	O
reveals	O
that	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
mobilized	O
in	O
tolerant	O
cells	O
is	O
functionally	O
inactive	O
in	O
that	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
luciferase	O
constructs	O
containing	O
the	O
human	O
immunodeficiency	O
virus	O
long	O
terminal	O
repeat	O
or	O
the	O
TNF	O
5'	O
-	O
region	O
show	O
only	O
minimal	O
transactivation	O
after	O
LPS	O
stimulation	O
.	O

Similar	O
to	O
Mono	O
Mac	O
6	O
cells	O
,	O
primary	O
blood	O
monocytes	O
,	O
when	O
precultured	O
with	O
a	O
low	O
dose	O
of	O
LPS	O
,	O
also	O
become	O
tolerant	O
and	O
produce	O
little	O
TNF	O
after	O
LPS	O
stimulation	O
.	O

The	O
tolerant	O
blood	O
monocytes	O
also	O
up	B-Positive_regulation
-	I-Positive_regulation
regulate	I-Positive_regulation
CD14	O
,	O
and	O
they	O
mobilize	O
NF	O
-	O
kappa	O
B	O
with	O
a	O
predominance	O
of	O
p50	O
homodimers	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
tolerance	O
to	O
LPS	O
is	O
determined	O
by	O
post	O
-	O
receptor	O
mechanisms	O
that	O
involve	O
an	O
altered	O
composition	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
.	O

Evidence	O
for	O
a	O
trans	O
-	O
acting	O
activator	O
function	O
regulating	B-Regulation
the	O
expression	B-Gene_expression
of	O
the	O
human	O
CD5	O
antigen	O
.	O

Interspecies	O
somatic	O
cell	O
hybrids	O
were	O
generated	O
by	O
fusing	O
the	O
mouse	O
T	O
-	O
lymphoma	O
cell	O
line	O
,	O
BW5147	O
,	O
with	O
normal	O
human	O
T	O
lymphocytes	O
at	O
different	O
stages	O
of	O
differentiation	O
.	O

Thymocytes	O
,	O
activated	O
peripheral	O
T	O
lymphocytes	O
,	O
or	O
an	O
activated	O
T	O
-	O
cell	O
clone	O
were	O
used	O
as	O
human	O
partners	O
,	O
respectively	O
,	O
in	O
three	O
independent	O
fusions	O
.	O

Irrespective	O
of	O
the	O
human	O
cell	O
partner	O
used	O
for	O
fusion	O
,	O
a	O
certain	O
number	O
of	O
hybrids	O
lost	B-Negative_regulation
CD5	O
surface	O
expression	B-Gene_expression
over	O
a	O
period	O
of	O
time	O
in	O
culture	O
.	O

Analysis	O
at	O
the	O
phenotype	O
and	O
genetic	O
level	O
showed	O
that	O
lack	O
of	O
CD5	O
expression	B-Gene_expression
was	O
due	B-Positive_regulation
neither	O
to	O
segregation	O
of	O
human	O
autosome	O
11	O
,	O
on	O
which	O
the	O
CD5	O
gene	O
has	O
been	O
mapped	O
,	O
nor	O
to	O
deletion	O
of	O
the	O
CD5	O
structural	O
gene	O
.	O

Furthermore	O
,	O
loss	B-Negative_regulation
of	O
CD5	O
surface	O
expression	B-Gene_expression
correlated	O
with	O
the	O
absence	B-Transcription
of	O
specific	O
mRNA	O
.	O

Since	O
these	O
hybrids	O
preferentially	O
segregate	O
human	O
chromosomes	O
,	O
these	O
results	O
indicate	O
the	O
existence	O
of	O
a	O
non	O
-	O
syntenic	O
trans	O
-	O
active	O
locus	O
,	O
or	O
loci	O
,	O
positively	B-Positive_regulation
controlling	I-Positive_regulation
the	O
expression	B-Gene_expression
of	O
the	O
human	O
CD5	O
gene	O
.	O

Alpha	O
-	O
tocopherol	O
inhibits	O
agonist	O
-	O
induced	O
monocytic	O
cell	O
adhesion	O
to	O
cultured	O
human	O
endothelial	O
cells	O
.	O

Antioxidants	O
have	O
been	O
proposed	O
to	O
be	O
anti	O
-	O
atherosclerotic	O
agents	O
;	O
however	O
,	O
the	O
mechanisms	O
underlying	O
their	O
beneficial	O
effects	O
are	O
poorly	O
understood	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
tcp	O
)	O
on	O
one	O
cellular	O
event	O
in	O
atherosclerotic	O
plaque	O
development	O
,	O
monocyte	O
adhesion	O
to	O
stimulated	O
endothelial	O
cells	O
(	O
ECs	O
)	O
.	O

Human	O
umbilical	O
vein	O
ECs	O
were	O
pretreated	O
with	O
alpha	O
-	O
tcp	O
before	O
stimulation	O
with	O
known	O
agonists	O
of	O
monocyte	O
adhesion	O
:	O
IL	O
-	O
1	O
(	O
10	O
ng/ml	O
)	O
,	O
LPS	O
(	O
10	O
ng/ml	O
)	O
,	O
thrombin	O
(	O
30	O
U/ml	O
)	O
,	O
or	O
PMA	O
(	O
10	O
nM	O
)	O
.	O

Agonist	O
-	O
induced	O
monocytic	O
cell	O
adhesion	O
,	O
but	O
not	O
basal	O
adhesion	O
,	O
was	O
inhibited	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
by	O
alpha	O
-	O
tcp	O
.	O

The	O
IC50	O
of	O
alpha	O
-	O
tcp	O
on	O
an	O
IL-1	O
-	O
induced	O
response	O
was	O
45	O
microM	O
.	O

The	O
inhibition	O
correlated	O
with	O
a	O
decrease	B-Negative_regulation
in	O
steady	O
state	O
levels	O
of	O
E	O
-	O
selectin	O
mRNA	O
and	O
cell	O
surface	O
expression	B-Gene_expression
of	O
E	O
-	O
selectin	O
which	O
is	O
consistent	O
with	O
the	O
ability	O
of	O
a	O
monoclonal	O
antibody	O
to	O
E	O
-	O
selectin	O
to	O
inhibit	O
monocytic	O
cell	O
adhesion	O
in	O
this	O
system	O
.	O

Probucol	O
(	O
50	O
microM	O
)	O
and	O
N	O
-	O
acetylcysteine	O
(	O
20	O
mM	O
)	O
also	O
inhibited	O
agonist	O
-	O
induced	O
monocytic	O
cell	O
adhesion	O
;	O
whereas	O
,	O
several	O
other	O
antioxidants	O
had	O
no	O
significant	O
effect	O
.	O

Protein	O
kinase	O
C	O
(	O
PKC	O
)	O
does	O
not	O
appear	O
to	O
play	O
a	O
role	O
in	O
the	O
alpha	O
-	O
tcp	O
effect	O
since	O
no	O
suppression	O
of	O
phosphorylation	O
of	O
PKC	O
substrates	O
was	O
observed	O
.	O

Activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
is	O
reported	O
to	O
be	O
necessary	B-Positive_regulation
but	O
not	O
sufficient	O
for	O
E	O
-	O
selectin	O
expression	B-Gene_expression
in	O
EC	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
failed	O
to	O
show	O
an	O
alpha-tcp	O
-	O
induced	O
decrease	O
in	O
activation	O
of	O
this	O
transcription	O
factor	O
after	O
cytokine	O
stimulation	O
.	O

It	O
has	O
been	O
hypothesized	O
that	O
alpha	O
-	O
tcp	O
acts	O
as	O
an	O
anti	O
-	O
atherosclerotic	O
molecule	O
by	O
inhibiting	O
generation	O
of	O
oxidized	O
LDL	O
-	O
-	O
a	O
putative	O
triggering	O
molecule	O
in	O
the	O
atherosclerotic	O
process	O
.	O

Our	O
results	O
point	O
to	O
a	O
novel	O
alternative	O
mechanism	O
of	O
action	O
of	O
alpha	O
-	O
tcp	O
.	O

Upregulation	B-Positive_regulation
of	O
bcl	O
-	O
2	O
by	O
the	O
Epstein	O
-	O
Barr	O
virus	O
latent	O
membrane	O
protein	O
LMP1	O
:	O
a	O
B-cell	O
-	O
specific	O
response	O
that	O
is	O
delayed	O
relative	O
to	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
to	O
induction	O
of	O
cell	O
surface	O
markers	O
.	O

An	O
ability	O
of	O
the	O
Epstein	O
-	O
Barr	O
virus	O
latent	O
membrane	O
protein	O
LMP1	O
to	O
enhance	O
the	O
survival	O
of	O
infected	O
B	O
cells	O
through	O
upregulation	B-Positive_regulation
of	O
the	O
bcl	O
-	O
2	O
oncogene	O
was	O
first	O
suggested	O
by	O
experiments	O
involving	O
gene	O
transfection	O
and	O
the	O
selection	O
of	O
stable	O
LMP1+	O
clones	O
(	O
S.Henderson	O
,	O
M.	O
Rowe	O
,	O
C.Gregory	O
,	O
F.Wang	O
,	O
E.Kieff	O
,	O
and	O
A.Rickinson	O
,	O
Cell	O
65	O
:	O
1107	O
-	O
1115	O
,	O
1991	O
)	O
.	O

However	O
,	O
it	O
was	O
not	O
possible	O
to	O
ascertain	O
whether	O
Bcl	O
-	O
2	O
upregulation	B-Positive_regulation
was	O
a	O
specific	O
consequence	O
of	O
LMP1	O
expression	B-Gene_expression
or	O
an	O
artifact	O
of	O
the	O
selection	O
procedure	O
whereby	O
rare	O
Bcl	O
-	O
2+	O
cells	O
already	O
present	O
in	O
the	O
starting	O
population	O
might	O
best	O
be	O
able	O
to	O
tolerate	O
the	O
potentially	O
toxic	O
effects	O
of	O
LMP1	O
.	O

We	O
therefore	O
reexamined	O
this	O
issue	O
by	O
using	O
two	O
different	O
experimental	O
approaches	O
that	O
allowed	O
LMP1	O
-	O
induced	B-Positive_regulation
effects	O
to	O
be	O
monitored	O
immediately	O
following	O
expression	B-Gene_expression
of	O
the	O
viral	O
protein	O
and	O
in	O
the	O
absence	O
of	O
selective	O
pressures	O
;	O
activation	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
and	O
upregulation	B-Positive_regulation
of	O
the	O
cell	O
adhesion	O
molecule	O
ICAM	O
-	O
1	O
were	O
used	O
as	O
early	O
indices	O
of	O
LMP1	O
function	O
.	O

In	O
the	O
first	O
approach	O
,	O
stable	O
clones	O
of	O
two	O
B	O
-	O
cell	O
lines	O
carrying	O
an	O
LMP1	O
gene	O
under	O
the	O
control	O
of	O
an	O
inducible	O
metallothionein	O
promoter	O
were	O
induced	B-Positive_regulation
to	O
express	B-Gene_expression
LMP1	O
in	O
all	O
cells	O
.	O

Activation	O
of	O
NK	O
-	O
kappa	O
B	O
and	O
upregulation	B-Positive_regulation
of	O
ICAM	O
-	O
1	O
occurred	O
within	O
24	O
h	O
and	O
were	O
followed	O
at	O
48	O
to	O
72	O
h	O
by	O
upregulation	B-Positive_regulation
of	O
Bcl	O
-	O
2	O
.	O

In	O
the	O
second	O
approach	O
,	O
we	O
tested	O
the	O
generality	O
of	O
this	O
phenomenon	O
by	O
transiently	O
expressing	B-Gene_expression
LMP1	O
from	O
a	O
strong	O
constitutively	O
active	O
promoter	O
in	O
a	O
range	O
of	O
different	O
cell	O
types	O
.	O

All	O
six	O
B	O
-	O
cell	O
lines	O
tested	O
showed	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
response	O
to	O
LMP1	O
expression	B-Gene_expression
,	O
and	O
this	O
was	O
followed	O
in	O
five	O
of	O
six	O
lines	O
by	O
expression	B-Gene_expression
of	O
ICAM	O
-	O
1	O
and	O
Bcl	O
-	O
2	O
.	O

In	O
the	O
same	O
experiments	O
,	O
all	O
three	O
non-B	O
-	O
cell	O
lines	O
showed	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
ICAM	O
-	O
1	O
upregulation	B-Positive_regulation
but	O
never	O
any	O
effect	B-Positive_regulation
upon	O
Bcl	O
-	O
2	O
.	O

We	O
therefore	O
conclude	O
that	O
Bcl	O
-	O
2	O
upregulation	B-Positive_regulation
is	O
part	O
of	O
the	O
panoply	O
of	O
cellular	O
changes	O
induced	O
by	O
LMP1	O
but	O
that	O
the	O
effect	O
is	O
cell	O
type	O
specific	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
whilst	O
NF	O
-	O
kappa	O
B	O
may	O
be	O
an	O
essential	O
component	O
of	O
LMP1	O
signal	O
transduction	O
,	O
other	O
cell	O
-	O
specific	O
factors	O
may	O
be	O
required	O
to	O
effect	O
some	O
functions	O
of	O
the	O
viral	O
protein	O
.	O

CD14	O
-	O
mediated	O
translocation	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
induced	O
by	O
lipopolysaccharide	O
does	O
not	O
require	O
tyrosine	O
kinase	O
activity	O
.	O

During	O
the	O
course	O
of	O
serious	O
bacterial	O
infections	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
believed	O
to	O
interact	O
with	O
macrophage	O
receptors	O
,	O
resulting	O
in	O
the	O
generation	O
of	O
inflammatory	O
mediators	O
and	O
systemic	O
symptoms	O
including	O
hemodynamic	O
instability	O
and	O
shock	O
.	O

CD14	O
,	O
a	O
glycosylphosphatidylinositol	O
-	O
linked	O
antigen	O
,	O
functions	O
as	O
an	O
LPS	O
signaling	O
receptor	B-Regulation
.	O

A	O
critical	O
issue	O
concerns	O
the	O
mechanism	O
by	O
which	O
CD14	O
,	O
which	O
has	O
no	O
transmembrane	O
domain	O
,	O
transduces	O
its	O
signal	O
following	O
LPS	O
binding	B-Binding
.	O

Recently	O
,	O
investigators	O
have	O
hypothesized	O
that	O
CD14	O
-	O
mediated	O
signaling	O
is	O
effected	O
through	O
a	O
receptor	O
-	O
associated	O
tyrosine	O
kinase	O
(	O
TK	O
)	O
,	O
suggesting	O
a	O
multicomponent	O
receptor	O
model	O
of	O
LPS	O
signaling	O
.	O

Wild	O
-	O
type	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
-	O
K1	O
cells	O
can	O
be	O
activated	O
by	O
endotoxin	O
to	O
release	O
arachidonate	O
following	O
transfection	B-Gene_expression
with	O
human	O
CD14	O
(	O
CHO/CD14	O
)	O
.	O

Nuclear	O
translocation	O
of	O
cytosolic	O
NF	O
-	O
kappa	O
B	O
is	O
correlated	O
with	O
a	O
number	O
of	O
LPS	O
-	O
inducible	O
responses	O
.	O

We	O
sought	O
to	O
determine	O
if	O
this	O
pathway	O
were	O
present	O
in	O
CHO/CD14	O
cells	O
and	O
to	O
elucidate	O
the	O
relationship	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
to	O
the	O
CD14	O
receptor	O
system	O
.	O

LPS	O
-	O
stimulated	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
CHO/CD14	O
cells	O
resembled	O
the	O
same	O
response	O
in	O
the	O
murine	O
macrophage	O
-	O
like	O
cell	O
line	O
RAW	O
264.7	O
.	O

Protein	O
synthesis	O
inhibitors	O
and	O
corticosteroids	O
,	O
which	O
suppress	O
arachidonate	O
release	O
and	O
the	O
synthesis	O
of	O
proinflammatory	O
cytokines	O
,	O
had	O
no	O
effect	O
on	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
CHO/CD14	O
or	O
RAW	O
264.7	O
cells	O
,	O
demonstrating	O
that	O
NF	O
-	O
kappa	O
B	O
translocation	O
is	O
an	O
early	O
event	O
.	O

Although	O
TK	O
activity	O
was	O
consistently	O
observed	O
by	O
immunoblotting	O
extracts	O
from	O
activated	O
RAW	O
264.7	O
cells	O
,	O
LPS	O
-	O
induced	O
phosphotyrosine	O
residues	O
were	O
not	O
observed	O
from	O
similarly	O
treated	O
CHO/CD14	O
cells	O
.	O

Furthermore	O
,	O
the	O
TK	O
inhibitors	O
herbimycin	O
A	O
and	O
genistein	O
failed	O
to	O
inhibit	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
CHO/CD14	O
or	O
RAW	O
264.7	O
cells	O
,	O
although	O
both	O
of	O
these	O
agents	O
inhibited	O
LPS	O
-	O
induced	O
TK	O
activity	O
in	O
RAW	O
264.7	O
cells	O
.	O

These	O
results	O
imply	O
that	O
TK	O
activity	O
is	O
not	O
obligatory	O
for	O
CD14	O
-	O
mediated	O
signal	O
transduction	O
to	O
occur	O
in	O
response	O
to	O
LPS	O
.	O

Regulation	B-Regulation
of	O
CD14	O
expression	B-Gene_expression
during	O
monocytic	O
differentiation	O
induced	O
with	O
1	O
alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
.	O

CD14	O
,	O
a	O
monocyte/macrophage	O
receptor	O
for	O
the	O
complex	O
of	O
LPS	O
and	O
LPS	O
binding	O
protein	O
,	O
is	O
a	O
differentiation	O
marker	O
for	O
the	O
monocyte/macrophage	O
lineage	O
.	O

We	O
have	O
analyzed	O
the	O
regulation	B-Regulation
of	O
CD14	O
expression	B-Gene_expression
during	O
1	O
alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
(	O
VitD3	O
)	O
-	O
induced	O
monocytic	O
differentiation	O
.	O

Using	O
FACS	O
,	O
Northern	O
blotting	O
,	O
and	O
nuclear	O
run	O
-	O
on	O
analyses	O
,	O
we	O
demonstrate	O
that	O
the	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
CD14	O
expression	B-Gene_expression
during	O
monocytic	O
cell	O
maturation	O
is	O
regulated	B-Regulation
mainly	O
at	O
the	O
level	B-Positive_regulation
of	O
gene	O
transcription	B-Transcription
,	O
and	O
that	O
new	O
protein	O
synthesis	O
is	O
required	B-Positive_regulation
for	O
CD14	O
induction	B-Positive_regulation
.	O

We	O
have	O
recently	O
cloned	O
the	O
CD14	O
5	O
'	O
upstream	O
sequence	O
and	O
demonstrated	O
its	O
tissue	O
-	O
specific	O
promoter	O
activity	O
.	O

Using	O
stable	O
transfection	O
of	O
the	O
monocytoid	O
U937	O
cell	O
line	O
with	O
a	O
series	O
of	O
deletion	O
mutants	O
of	O
the	O
CD14	O
5	O
'	O
upstream	O
sequence	O
coupled	O
to	O
a	O
reporter	O
gene	O
construct	O
,	O
we	O
show	O
that	O
bp	O
-	O
128	O
to	O
-	O
70	O
is	O
the	O
critical	O
region	O
for	O
the	O
induction	B-Positive_regulation
of	O
CD14	O
expression	B-Gene_expression
.	O

This	O
region	O
contains	O
two	O
binding	B-Binding
sites	O
for	O
the	O
Sp1	O
transcription	O
factor	O
.	O

A	O
3	O
-	O
bp	O
mutation	O
at	O
the	O
distal	O
Sp1	O
-	O
binding	O
site	O
not	O
only	O
eliminates	B-Negative_regulation
Sp1	O
interaction	B-Binding
,	O
but	O
also	O
abolishes	B-Negative_regulation
most	O
of	O
the	O
VitD3	O
induction	B-Positive_regulation
of	O
CD14	O
expression	B-Gene_expression
.	O

Electrophoretic	O
mobility	O
shift	O
analysis	O
does	O
not	O
detect	O
a	O
direct	O
interaction	B-Binding
of	O
the	O
CD14	O
distal	O
Sp1	O
-	O
binding	O
site	O
with	O
the	O
vitamin	O
D3	O
receptor	O
and	O
its	O
partner	O
,	O
the	O
retinoid	O
X	O
receptor	O
.	O

These	O
data	O
demonstrate	O
that	O
VitD3	O
induces	O
CD14	O
indirectly	O
through	B-Positive_regulation
some	O
intermediary	O
factor	O
,	O
and	O
suggest	O
a	O
critical	B-Positive_regulation
role	I-Positive_regulation
for	O
Sp1	O
in	O
this	O
process	O
.	O

Calcium	O
signalling	O
in	O
T	O
cells	O
stimulated	O
by	O
a	O
cyclophilin	O
B	O
-	O
binding	O
protein	O
.	O

The	O
immunosuppressant	O
drug	O
cyclosporin	O
A	O
blocks	O
a	O
calcium	O
-	O
dependent	O
signal	O
from	O
the	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
that	O
normally	O
leads	O
to	O
T	O
-	O
cell	O
activation	O
.	O

When	O
bound	O
to	O
cyclophilin	O
,	O
cyclosporin	O
A	O
binds	O
and	O
inactivates	O
the	O
key	O
signalling	O
intermediate	O
calcineurin	O
.	O

To	O
identify	O
potential	O
cellular	O
homologues	O
of	O
cyclosporin	O
A	O
that	O
might	O
regulate	O
calcium	O
signalling	O
,	O
we	O
have	O
cloned	O
human	O
genes	O
encoding	O
cyclophilin	O
B-binding	O
-	O
proteins	O
using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
.	O

One	O
gene	O
product	O
,	O
when	O
overexpressed	O
in	O
Jurkat	O
T	O
cells	O
,	O
specifically	O
induced	B-Positive_regulation
transcription	B-Transcription
from	O
the	O
interleukin	O
-	O
2	O
enhancer	O
,	O
by	O
activating	O
the	O
T-cell	O
-	O
specific	O
transcription	O
factors	O
NF	O
-	O
AT	O
and	O
NF	O
-	O
IL2A	O
.	O

This	O
protein	O
,	O
termed	O
calcium	O
-	O
signal	O
modulating	O
cyclophilin	O
ligand	O
(	O
CAML	O
)	O
,	O
acts	O
downstream	O
of	O
the	O
TCR	O
and	O
upstream	O
of	O
calcineurin	O
by	O
causing	O
an	O
influx	O
of	O
calcium	O
.	O

CAML	O
appears	O
to	O
be	O
a	O
new	O
participant	O
in	O
the	O
calcium	O
-	O
signal	O
transduction	O
pathway	O
,	O
implicating	O
cyclophilin	O
B	O
in	O
calcium	O
signalling	O
,	O
even	O
in	O
the	O
absence	O
of	O
cyclosporin	O
.	O

Antioxidants	O
inhibit	O
monocyte	O
adhesion	O
by	O
suppressing	B-Negative_regulation
nuclear	O
factor	O
-	O
kappa	O
B	O
mobilization	O
and	O
induction	B-Positive_regulation
of	O
vascular	O
cell	O
adhesion	O
molecule	O
-	O
1	O
in	O
endothelial	O
cells	O
stimulated	O
to	O
generate	O
radicals	O
.	O

Cell	O
adhesion	O
to	O
endothelial	O
cells	O
stimulated	O
by	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
)	O
is	O
due	O
to	O
induction	B-Positive_regulation
of	O
surface	O
receptors	O
,	O
such	O
as	O
vascular	O
cell	O
adhesion	O
molecule	O
-	O
1	O
(	O
VCAM	O
-	O
1	O
)	O
.	O

The	O
antioxidant	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
specifically	O
inhibits	O
activation	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
.	O

Since	O
kappa	O
B	O
motifs	O
are	O
present	O
in	O
VCAM	O
-	O
1	O
and	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
promoters	O
,	O
we	O
used	O
PDTC	O
to	O
study	O
the	O
regulatory	B-Regulation
mechanisms	O
of	O
VCAM	O
-	O
1	O
and	O
ICAM	O
-	O
1	O
induction	B-Positive_regulation
and	O
subsequent	O
monocyte	O
adhesion	O
in	O
TNF	O
-	O
treated	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
.	O

PDTC	O
or	O
N	O
-	O
acetylcysteine	O
dose	O
dependently	O
reduced	B-Negative_regulation
TNF	O
-	O
induced	B-Positive_regulation
VCAM	O
-	O
1	O
but	O
not	O
ICAM	O
-	O
1	O
surface	O
protein	O
(	O
also	O
in	O
human	O
umbilical	O
arterial	O
endothelial	O
cells	O
)	O
and	O
mRNA	O
expression	B-Transcription
(	O
by	O
70	O
%	O
at	O
100	O
mumol/L	O
PDTC	O
)	O
in	O
HUVECs	O
as	O
assessed	O
by	O
flow	O
cytometry	O
and	O
polymerase	O
chain	O
reaction	O
.	O

Gel	O
-	O
shift	O
analysis	O
in	O
HUVECs	O
demonstrated	O
that	O
PDTC	O
prevented	O
NF	O
-	O
kappa	O
B	O
mobilization	O
by	O
TNF	O
,	O
suggesting	O
that	O
only	O
VCAM	O
-	O
1	O
induction	B-Positive_regulation
was	O
controlled	B-Regulation
by	O
NF	O
-	O
kappa	O
B	O
.	O

Since	O
HUVECs	O
released	O
superoxide	O
anions	O
in	O
response	O
to	O
TNF	O
,	O
and	O
H2O2	O
induces	B-Positive_regulation
VCAM	O
-	O
1	O
,	O
PDTC	O
may	O
act	O
as	O
a	O
radical	O
scavenger	O
.	O

Although	O
ICAM	O
-	O
1	O
induction	B-Positive_regulation
was	O
unaffected	B-Negative_regulation
,	O
inhibitors	O
of	O
NADPH	O
oxidase	O
(	O
apocynin	O
)	O
or	O
cytochrome	O
P	O
-	O
450	O
(	O
SKF525a	O
)	O
suppressed	B-Negative_regulation
VCAM	O
-	O
1	O
induction	B-Positive_regulation
by	O
TNF	O
,	O
revealing	O
that	O
several	O
radical	O
-	O
generating	O
systems	O
are	O
involved	O
in	O
its	O
regulation	B-Regulation
.	O

PDTC	O
,	O
apocynin	O
,	O
or	O
SKF525a	O
decreased	O
adhesion	O
of	O
monocytic	O
U937	O
cells	O
to	O
TNF	O
-	O
treated	O
HUVECs	O
(	O
by	O
75	O
%	O
at	O
100	O
mumol/L	O
PDTC	O
)	O
.	O

Inhibition	O
by	O
anti-VCAM	O
-	O
1	O
monoclonal	O
antibody	O
1G11	O
indicated	O
that	O
U937	O
adhesion	O
was	O
VCAM	O
-	O
1	O
dependent	O
and	O
suppression	O
by	O
antioxidants	O
was	O
due	O
to	O
reduced	B-Negative_regulation
VCAM	O
-	O
1	O
induction	B-Positive_regulation
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Inducible	O
binding	O
to	O
the	O
c	O
-	O
fos	O
serum	O
response	O
element	O
during	O
T	O
cell	O
activation	O
is	O
regulated	O
by	O
a	O
phosphotyrosine	O
-	O
containing	O
protein	O
.	O

The	O
proto	O
-	O
oncogene	O
c	O
-	O
fos	O
is	O
an	O
immediate	O
-	O
early	O
gene	O
,	O
and	O
one	O
of	O
the	O
first	O
genes	O
transcribed	B-Transcription
after	B-Positive_regulation
stimulation	O
of	O
most	O
cells	O
with	O
a	O
variety	O
of	O
ligands	O
.	O

Fos	O
expression	B-Gene_expression
may	O
be	O
a	O
pivotal	O
event	O
in	O
converting	O
ligand	O
-	O
receptor	O
interactions	O
at	O
the	O
membrane	O
into	O
functional	O
modulation	O
of	O
cell	O
phenotype	O
.	O

The	O
serum	O
response	O
element	O
(	O
SRE	O
)	O
in	O
the	O
c	O
-	O
fos	O
regulatory	O
region	O
participates	O
in	O
induction	O
of	O
transcription	O
by	O
various	O
growth	O
factors	O
and	O
by	O
phorbol	O
esters	O
and	O
subsequent	O
squelching	O
of	O
transcription	O
.	O

We	O
show	O
that	O
an	O
inducible	O
protein	O
complex	O
(	O
Band	O
A	O
)	O
binds	O
to	O
SRE	O
DNA	O
within	O
10	O
min	O
after	O
mitogenic	O
stimulation	O
of	O
human	O
PBL	O
-	O
T	O
,	O
and	O
becomes	O
nondetectable	O
by	O
60	O
min	O
.	O

Band	O
A	O
contains	O
the	O
serum	O
response	O
factor	O
plus	O
additional	O
factor	O
(	O
s	O
)	O
.	O

A	O
protein	O
that	O
is	O
phosphorylated	O
on	O
a	O
tyrosine	O
residue	O
in	O
resting	O
PBL	O
-	O
T	O
suppresses	O
binding	O
of	O
a	O
component	O
of	O
Band	O
A	O
to	O
the	O
SRE	O
motif	O
.	O

Upon	O
stimulation	O
of	O
the	O
cells	O
,	O
this	O
protein	O
no	O
longer	O
prevents	O
binding	O
of	O
DNA	O
by	O
Band	O
A	O
,	O
and	O
suppression	O
of	O
binding	O
is	O
restored	O
within	O
30	O
min	O
.	O

The	O
phosphorylated	O
tyrosine	O
residue	O
itself	O
is	O
important	O
for	O
the	O
protein	O
-	O
protein	O
interaction	O
.	O

Steel	O
factor	O
affects	B-Regulation
SCL	O
expression	B-Gene_expression
during	O
normal	O
erythroid	O
differentiation	O
.	O

Steel	O
factor	O
is	O
one	O
of	O
the	O
growth	O
factors	O
that	O
controls	O
the	O
proliferation	O
and	O
differentiation	O
of	O
hematopoietic	O
cells	O
and	O
SCL	O
,	O
also	O
known	O
as	O
Tcl	O
-	O
5	O
or	O
Tal	O
-	O
1	O
,	O
is	O
a	O
transcription	O
factor	O
involved	O
in	O
erythropoiesis	O
.	O

In	O
this	O
report	O
,	O
we	O
studied	O
the	O
role	O
of	O
SCL	O
in	O
the	O
proliferation	O
of	O
human	O
peripheral	O
blood	O
burst	O
-	O
forming	O
unit	O
-	O
erythroid	O
(	O
BFU	O
-	O
E	O
)	O
and	O
the	O
effects	B-Regulation
of	O
Steel	O
factor	O
on	O
SCL	O
expression	B-Gene_expression
in	O
proliferating	O
erythroid	O
cells	O
.	O

BFU-E	O
-	O
derived	O
colonies	O
increase	O
progressively	O
in	O
size	O
,	O
as	O
determined	O
by	O
cell	O
number	O
,	O
from	O
day	O
7	O
to	O
day	O
14	O
of	O
culture	O
,	O
with	O
the	O
greatest	O
increase	O
in	O
colony	O
size	O
(	O
10	O
-	O
fold	O
expansion	O
)	O
occurring	O
between	O
day	O
7	O
and	O
day	O
10	O
.	O

SCL	O
protein	O
levels	O
in	O
BFU-E	O
-	O
derived	O
cells	O
were	O
highest	O
in	O
day	O
7	O
cells	O
and	O
decreased	B-Negative_regulation
progressively	O
from	O
day	O
7	O
to	O
day	O
14	O
of	O
culture	O
,	O
suggesting	O
an	O
association	O
of	O
SCL	O
with	O
erythroid	O
proliferation	O
.	O

In	O
contrast	O
,	O
SCL	O
mRNA	O
levels	O
did	O
not	O
decrease	B-Negative_regulation
significantly	O
between	O
day	O
7	O
and	O
day	O
14	O
cells	O
,	O
suggesting	O
that	O
posttranscriptional	O
mechanisms	O
are	O
largely	O
responsible	B-Regulation
for	O
the	O
decrease	B-Negative_regulation
in	O
SCL	O
protein	O
observed	O
.	O

The	O
role	O
of	O
SCL	O
in	O
Steel	O
factor	O
-	O
induced	O
erythroid	O
proliferation	O
was	O
then	O
examined	O
.	O

In	O
BFU-E	O
-	O
derived	O
colonies	O
cultured	O
with	O
Steel	O
factor	O
,	O
colony	O
size	O
was	O
significantly	O
increased	O
compared	O
to	O
control	O
.	O

In	O
day	O
7	O
and	O
day	O
10	O
erythroid	O
precursors	O
cultured	O
with	O
Steel	O
factor	O
,	O
SCL	O
protein	O
was	O
increased	B-Positive_regulation
significantly	O
compared	O
to	O
control	O
.	O

The	O
increase	B-Positive_regulation
in	O
SCL	O
protein	O
levels	O
in	O
early	O
erythroid	O
precursors	O
stimulated	O
with	O
Steel	O
factor	O
suggests	O
one	O
mechanism	O
through	O
which	O
Steel	O
factor	O
may	O
enhance	O
normal	O
erythroid	O
proliferation	O
.	O

SCL	O
mRNA	O
levels	B-Transcription
assessed	O
by	O
Northern	O
blot	O
in	O
day	O
7	O
cells	O
did	O
not	O
increase	B-Positive_regulation
significantly	O
in	O
response	O
to	O
Steel	O
factor	O
stimulation	O
,	O
suggesting	O
that	O
posttranscriptional	O
mechanisms	O
may	O
also	O
be	O
important	B-Regulation
in	O
the	O
increase	B-Positive_regulation
in	O
SCL	O
protein	O
observed	O
in	O
response	O
to	O
Steel	O
.	O

Cross	B-Binding
-	I-Binding
linking	I-Binding
CD40	O
on	O
B	O
cells	O
rapidly	O
activates	O
nuclear	O
factor	O
-	O
kappa	O
B	O
.	O

The	O
B	O
cell	O
-	O
associated	O
surface	O
molecule	O
CD40	O
functions	O
to	O
regulate	O
B	O
cell	O
responses	O
.	O

Cross	B-Binding
-	I-Binding
linking	I-Binding
CD40	O
on	O
B	O
cells	O
can	O
lead	B-Positive_regulation
to	O
homotypic	O
cell	O
adhesion	O
,	O
IL	O
-	O
6	O
production	B-Gene_expression
,	O
and	O
,	O
in	O
combination	O
with	O
cytokines	O
,	O
to	O
Ig	O
isotype	O
switching	O
.	O

Tyrosine	O
kinase	O
activity	O
is	O
increased	O
shortly	O
after	O
engagement	B-Binding
of	O
this	O
receptor	O
.	O

Little	O
is	O
known	O
about	O
how	O
the	O
very	O
early	O
events	O
induced	O
by	O
CD40	O
cross	B-Binding
-	I-Binding
linking	I-Binding
link	O
to	O
cellular	O
responses	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
and	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
transcription	O
factors	O
are	O
activated	O
after	O
cross	B-Binding
-	I-Binding
linking	I-Binding
CD40	O
on	O
resting	O
human	O
tonsillar	O
B	O
cells	O
and	O
on	O
B	O
cell	O
lines	O
.	O

The	O
activation	O
is	O
rapid	O
and	O
is	O
mediated	O
through	O
a	O
tyrosine	O
kinase	O
-	O
dependent	O
pathway	O
.	O

The	O
complexes	O
detected	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
contain	O
p50	O
,	O
p65	O
(	O
RelA	O
)	O
,	O
c	O
-	O
Rel	O
,	O
and	O
most	O
likely	O
other	O
components	O
.	O

By	O
using	O
transient	O
transfection	O
assays	O
,	O
we	O
found	O
that	O
cross	B-Binding
-	I-Binding
linking	I-Binding
CD40	O
supports	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
gene	O
expression	O
.	O

Our	O
results	O
define	O
the	O
NF	O
-	O
kappa	O
B	O
system	O
as	O
an	O
intermediate	O
event	O
in	O
CD40	O
signaling	O
and	O
suggest	O
that	O
the	O
CD40	O
pathway	O
can	O
influence	O
the	O
expression	O
of	O
B	O
cell	O
-	O
associated	O
genes	O
with	O
NF	O
-	O
kappa	O
B	O
consensus	O
sites	O
.	O

Separation	O
of	O
oxidant	O
-	O
initiated	O
and	O
redox	O
-	O
regulated	O
steps	O
in	O
the	O
NF	O
-	O
kappa	O
B	O
signal	O
transduction	O
pathway	O
.	O

Studies	O
presented	O
here	O
show	O
that	O
overall	O
NF	O
-	O
kappa	O
B	O
signal	O
transduction	O
begins	O
with	O
a	O
parallel	O
series	O
of	O
stimuli	O
-	O
specific	O
pathways	O
through	O
which	O
cytokines	O
(	O
tumor	O
necrosis	O
factor	O
alpha	O
)	O
,	O
oxidants	O
(	O
hydrogen	O
peroxide	O
and	O
mitomycin	O
C	O
)	O
,	O
and	O
phorbol	O
ester	O
(	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
)	O
individually	O
initiate	O
signaling	O
.	O

These	O
initial	O
pathways	O
culminate	O
in	O
a	O
common	O
pathway	O
through	O
which	O
all	O
of	O
the	O
stimulating	O
agents	O
ultimately	O
signal	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

We	O
distinguish	O
the	O
stimuli	O
-	O
specific	O
pathways	O
by	O
showing	O
that	O
the	O
oxidative	O
stimuli	O
trigger	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
only	O
one	O
of	O
two	O
human	O
T	O
-	O
cell	O
lines	O
(	O
Wurzburg	O
but	O
not	O
Jurkat	O
)	O
,	O
whereas	O
tumor	O
necrosis	O
factor	O
alpha	O
and	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
readily	O
stimulate	O
in	O
both	O
lines	O
.	O

We	O
propose	O
the	O
common	O
pathway	O
as	O
the	O
simplest	O
way	O
of	O
accounting	O
for	O
the	O
common	O
requirements	O
and	O
properties	O
of	O
the	O
signaling	O
pathway	O
.	O

We	O
include	O
a	O
redox	O
-	O
regulatory	O
mechanism	O
(	O
s	O
)	O
in	O
this	O
common	O
pathway	O
to	O
account	O
for	O
the	O
previously	O
demonstrated	O
redox	O
regulation	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
Jurkat	O
cells	O
(	O
in	O
which	O
oxidants	O
do	O
n't	O
activate	O
NF	O
-	O
kappa	O
B	O
)	O
;	O
we	O
put	O
tyrosine	O
phosphorylation	O
in	O
the	O
common	O
pathway	O
by	O
showing	O
that	O
kinase	O
activity	O
(	O
inhibitable	O
by	O
herbimycin	O
A	O
and	O
tyrphostin	O
47	O
)	O
is	O
required	O
for	O
NF	O
-	O
kappa	O
B	O
activation	O
by	O
all	O
stimuli	O
tested	O
in	O
both	O
cell	O
lines	O
.	O

Since	O
internal	O
sites	O
of	O
oxidant	O
production	O
have	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
cytokine	O
-	O
stimulated	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
since	O
tyrosine	O
kinase	O
and	O
phosphatase	O
activities	O
are	O
known	O
to	O
be	O
altered	O
by	O
oxidants	O
,	O
these	O
findings	O
suggest	O
that	O
intracellular	O
redox	O
status	O
controls	O
NF	O
-	O
kappa	O
B	O
activation	O
by	O
regulating	O
tyrosine	O
phosphorylation	O
event	O
(	O
s	O
)	O
within	O
the	O
common	O
step	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
signal	O
transduction	O
pathway	O
.	O

Transcription	O
-	O
independent	O
turnover	O
of	O
I	O
kappa	O
B	O
alpha	O
during	O
monocyte	O
adherence	O
:	O
implications	O
for	O
a	O
translational	O
component	O
regulating	B-Regulation
I	O
kappa	O
B	O
alpha/MAD	O
-	O
3	O
mRNA	O
levels	O
.	O

We	O
identified	O
I	O
kappa	O
B	O
alpha/MAD	O
-	O
3	O
as	O
an	O
immediate	O
-	O
early	O
gene	O
in	O
human	O
monocytes	O
that	O
is	O
expressed	B-Gene_expression
in	B-Positive_regulation
response	I-Positive_regulation
to	I-Positive_regulation
a	O
variety	O
of	O
signals	O
,	O
including	O
adhesion	O
,	O
lipopolysaccharide	O
,	O
and	O
phorbol	O
myristate	O
acetate	O
.	O

Within	O
5	O
min	O
of	O
monocyte	O
adhesion	O
,	O
the	O
level	O
of	O
the	O
I	O
kappa	O
B	O
alpha	O
protein	O
is	O
markedly	O
diminished	B-Negative_regulation
but	O
is	O
rapidly	O
replaced	B-Negative_regulation
in	O
a	O
cycloheximide	O
-	O
sensitive	B-Regulation
manner	O
within	O
20	O
min	O
.	O

Accompanying	O
the	O
rapid	O
turnover	O
of	O
the	O
I	O
kappa	O
B	O
alpha	O
protein	O
is	O
simultaneous	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
related	O
transcription	O
factors	O
to	O
nuclei	O
of	O
adhered	O
monocytes	O
.	O

The	O
demonstration	O
that	O
NF	O
-	O
kappa	O
B	O
can	O
regulate	B-Regulation
I	O
kappa	O
B	O
alpha/MAD	O
-	O
3	O
gene	O
transcription	B-Transcription
in	O
other	O
cell	O
types	O
suggested	O
that	O
the	O
rapid	O
increase	B-Positive_regulation
in	O
steady	O
-	O
state	O
I	O
kappa	O
B	O
alpha/MAD	O
-	O
3	O
mRNA	O
levels	O
we	O
observed	O
within	O
30	O
min	O
of	O
monocyte	O
adherence	O
would	O
result	O
from	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
transcriptional	B-Positive_regulation
stimulation	I-Positive_regulation
of	O
the	O
I	O
kappa	O
B	O
alpha/MAD	O
-	O
3	O
gene	O
.	O

Nuclear	O
run	O
-	O
on	O
analyses	O
indicated	O
that	O
,	O
instead	O
,	O
while	O
several	O
immediate	O
-	O
early	O
cytokine	O
genes	O
,	O
such	O
as	O
the	O
interleukin	O
1	O
beta	O
(	O
IL	O
-	O
1	O
beta	O
)	O
gene	O
,	O
were	O
transcriptionally	B-Positive_regulation
activated	I-Positive_regulation
during	O
monocyte	O
adhesion	O
,	O
the	O
rate	O
of	O
I	O
kappa	O
B	O
alpha/MAD	O
-	O
3	O
gene	O
transcription	B-Transcription
remained	B-Positive_regulation
constant	I-Positive_regulation
.	O

The	O
adherence	O
-	O
dependent	O
increase	B-Positive_regulation
in	O
I	O
kappa	O
B	O
alpha/MAD	O
-	O
3	O
mRNA	O
levels	O
was	O
also	O
not	O
a	O
consequence	B-Positive_regulation
of	O
mRNA	O
stabilization	B-Positive_regulation
events	O
.	O

Interestingly	O
,	O
while	O
increases	B-Positive_regulation
in	O
both	O
IL	O
-	O
1	O
beta	O
and	O
I	O
kappa	O
B	O
alpha/MAD	O
-	O
3	O
mRNA	O
levels	O
were	O
detected	O
in	O
nuclei	O
of	O
adherent	O
monocytes	O
,	O
cytoplasmic	O
levels	O
of	O
IL	O
-	O
1	O
beta	O
mRNA	O
increased	B-Positive_regulation
during	O
adherence	O
whereas	O
those	O
of	O
I	O
kappa	O
B	O
alpha/MAD	O
-	O
3	O
mRNA	O
did	O
not	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
two	O
interactive	O
mechanisms	O
regulate	B-Regulation
monocytic	O
I	O
kappa	O
B	O
alpha/MAD	O
-	O
3	O
mRNA	O
levels	O
.	O

We	O
propose	O
that	O
adherent	O
monocytes	O
regulate	O
nuclear	O
processing	O
(	O
or	O
decay	O
)	O
of	O
I	O
kappa	O
B	O
alpha/MAD	O
-	O
3	O
mRNA	O
,	O
thereby	O
increasing	B-Positive_regulation
mRNA	O
levels	O
without	B-Positive_regulation
stimulating	I-Positive_regulation
I	O
kappa	O
B	O
alpha/MAD	O
-	O
3	O
gene	O
transcription	B-Transcription
.	O

Moreover	O
,	O
since	O
inhibition	O
of	O
protein	O
synthesis	O
leads	B-Positive_regulation
to	O
accumulation	B-Positive_regulation
of	O
I	O
kappa	O
B	O
alpha/MAD	O
-	O
3	O
mRNA	O
without	O
stimulating	B-Positive_regulation
I	O
kappa	O
B	O
alpha/MAD	O
-	O
3	O
gene	O
transcription	B-Transcription
,	O
we	O
suggest	O
that	O
low	O
cytoplasmic	O
levels	O
of	O
I	O
kappa	O
B	O
alpha/MAD	O
-	O
3	O
mRNA	O
are	O
maintained	B-Negative_regulation
by	O
a	O
translation	O
-	O
dependent	O
degradation	O
mechanism	O
.	O

E2F	O
-	O
1	O
and	O
a	O
cyclin	O
-	O
like	O
DNA	O
repair	O
enzyme	O
,	O
uracil	O
-	O
DNA	O
glycosylase	O
,	O
provide	O
evidence	O
for	O
an	O
autoregulatory	O
mechanism	O
for	O
transcription	O
.	O

The	O
cell	O
cycle	O
-	O
dependent	O
transcription	O
factor	O
,	O
E2F	O
-	O
1	O
,	O
regulates	B-Regulation
the	O
cyclin	O
-	O
like	O
species	O
of	O
the	O
DNA	O
repair	O
enzyme	O
uracil	O
-	O
DNA	O
glycosylase	O
(	O
UDG	O
)	O
gene	O
in	O
human	O
osteosarcoma	O
(	O
Saos	O
-	O
2	O
)	O
cells	O
.	O

We	O
demonstrate	O
,	O
through	O
the	O
deletion	O
of	O
the	O
human	O
UDG	O
promoter	O
sequences	O
,	O
that	O
expression	B-Gene_expression
of	O
E2F	O
-	O
1	O
activates	B-Positive_regulation
the	O
UDG	O
promoter	O
through	B-Positive_regulation
several	O
E2F	O
sites	O
.	O

The	O
major	O
putative	O
downstream	O
site	O
for	O
E2F	O
,	O
located	O
in	O
the	O
first	O
exon	O
,	O
serves	O
as	O
a	O
target	B-Binding
for	O
E2F	O
-	O
1/DP1	O
complex	B-Binding
binding	I-Binding
in	O
vitro	O
.	O

We	O
also	O
provide	O
evidence	O
for	O
the	O
functional	O
relationship	O
between	O
the	O
cyclin	O
-	O
like	O
UDG	O
gene	O
product	B-Gene_expression
and	O
E2F	O
.	O

High	B-Positive_regulation
levels	I-Positive_regulation
of	O
UDG	O
expression	B-Gene_expression
in	O
a	O
transient	O
transfection	O
assay	O
result	O
in	O
the	O
down	O
-	O
regulation	O
of	O
transcriptional	O
activity	O
through	O
elements	O
specific	O
for	O
E2F	O
-	O
mediated	O
transcription	O
.	O

Overexpression	B-Gene_expression
of	O
UDG	O
in	O
Saos	O
2	O
cells	O
was	O
observed	O
to	O
delay	O
growth	O
late	O
in	O
G1	O
phase	O
and	O
transiently	O
arrest	O
these	O
cells	O
from	O
progressing	O
into	O
the	O
S	O
phase	O
.	O

This	O
hypothetical	O
model	O
integrates	O
one	O
mechanism	O
of	O
DNA	O
repair	O
with	O
the	O
cell	O
cycle	O
control	O
of	O
gene	O
transcription	O
,	O
likely	O
through	O
E2F	O
.	O

This	O
implicates	O
E2F	O
as	O
a	O
multifunctional	O
target	O
for	O
proteins	O
and	O
enzymes	O
,	O
possibly	O
,	O
responsive	O
to	O
DNA	O
damage	O
through	O
the	O
negative	O
effect	O
of	O
UDG	O
on	O
E2F	O
-	O
mediated	O
transcriptional	O
activity	O
.	O

Aspirin	O
inhibits	O
nuclear	O
factor	O
-	O
kappa	O
B	O
mobilization	O
and	O
monocyte	O
adhesion	O
in	O
stimulated	O
human	O
endothelial	O
cells	O
.	O

BACKGROUND	O
:	O
The	O
induction	B-Positive_regulation
of	O
vascular	O
cell	O
adhesion	O
molecule	O
-	O
1	O
(	O
VCAM	O
-	O
1	O
)	O
and	O
E	O
-	O
selectin	O
by	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
)	O
is	O
mediated	B-Positive_regulation
by	O
mobilization	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
.	O

Since	O
salicylates	O
have	O
been	O
reported	O
to	O
inhibit	O
NF	O
-	O
kappa	O
B	O
activation	O
by	O
preventing	O
the	O
degradation	O
of	O
its	O
inhibitor	O
I	O
kappa	O
B	O
,	O
we	O
studied	O
a	O
potential	O
inhibition	O
of	O
this	O
pathway	O
by	O
acetylsalicylate	O
(	O
aspirin	O
)	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Gel	O
-	O
shift	O
analyses	O
demonstrated	O
dose	O
-	O
dependent	O
inhibition	O
of	O
TNF	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
mobilization	O
by	O
aspirin	O
at	O
concentrations	O
ranging	O
from	O
1	O
to	O
10	O
mmol/L	O
.	O

Induction	B-Positive_regulation
of	O
VCAM	O
-	O
1	O
and	O
E	O
-	O
selectin	O
surface	O
expression	B-Localization
by	O
TNF	O
was	O
dose	O
-	O
dependently	O
reduced	B-Negative_regulation
by	O
aspirin	O
over	O
the	O
same	O
range	O
,	O
while	O
induction	B-Positive_regulation
of	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
was	O
hardly	O
affected	B-Regulation
.	O

Aspirin	O
appeared	O
to	O
prevent	B-Negative_regulation
VCAM	O
-	O
1	O
transcription	B-Transcription
,	O
since	O
it	O
dose	O
-	O
dependently	O
inhibited	B-Negative_regulation
induction	B-Positive_regulation
of	O
VCAM	O
-	O
1	O
mRNA	O
by	O
TNF	O
.	O

As	O
a	O
functional	O
consequence	O
,	O
adhesion	O
of	O
U937	O
monocytes	O
to	O
TNF	O
-	O
stimulated	O
HUVECs	O
was	O
markedly	O
reduced	O
by	O
aspirin	O
due	O
to	O
suppression	B-Negative_regulation
of	O
VCAM	O
-	O
1	O
and	O
E	O
-	O
selectin	O
upregulation	B-Positive_regulation
.	O

These	O
effects	O
of	O
aspirin	O
were	O
not	O
related	O
to	O
the	O
inhibition	O
of	O
cyclooxygenase	O
activity	O
,	O
since	O
indomethacin	O
was	O
ineffective	B-Regulation
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
aspirin	O
inhibits	B-Negative_regulation
NF	O
-	O
kappa	O
B	O
mobilization	O
,	O
induction	B-Positive_regulation
of	O
VCAM	O
-	O
1	O
and	O
E	O
-	O
selectin	O
,	O
and	O
subsequent	O
monocyte	O
adhesion	O
in	O
endothelial	O
cells	O
stimulated	O
by	O
TNF	O
,	O
thereby	O
providing	O
an	O
additional	O
mechanism	O
for	O
therapeutic	O
effects	O
of	O
aspirin	O
.	O

Danazol	O
decreases	B-Negative_regulation
transcription	B-Transcription
of	O
estrogen	O
receptor	O
gene	O
in	O
human	O
monocytes	O
.	O

1.	O
Administration	O
of	O
danazol	O
for	O
over	O
one	O
month	O
reduced	B-Negative_regulation
the	I-Negative_regulation
levels	I-Negative_regulation
of	O
estrogen	O
receptor	O
(	O
ER	O
)	O
and	O
its	O
mRNA	O
to	O
approximately	O
50	O
and	O
20	O
%	O
,	O
respectively	O
in	O
monocytes	O
.	O

2	O
.	O

Danazol	O
did	O
not	O
alter	B-Regulation
the	O
degradation	B-Protein_catabolism
rate	O
of	O
ER	O
mRNA	O
in	O
monocytes	O
.	O

3	O
.	O

Danazol	O
decreased	B-Negative_regulation
the	O
transcription	B-Transcription
rate	O
of	O
ER	O
gene	O
to	O
approximately	O
50	O
%	O
in	O
monocytes	O
in	O
a	O
run	O
-	O
on	O
assay	O
.	O

4	O
.	O

Danazol	O
may	O
release	O
estrogen	O
predominance	O
via	O
the	O
reduction	B-Negative_regulation
of	O
transcription	B-Transcription
for	O
ER	O
gene	O
,	O
which	O
leads	B-Positive_regulation
to	O
the	O
reduction	B-Negative_regulation
of	O
ER	O
mRNA	O
and	O
ER	O
expressions	B-Gene_expression
in	O
monocytes	O
.	O

Cross	B-Binding
-	I-Binding
linking	I-Binding
of	O
CD30	O
induces	O
HIV	O
expression	O
in	O
chronically	O
infected	O
T	O
cells	O
.	O

CD30	O
,	O
a	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
receptor	O
family	O
,	O
is	O
expressed	B-Gene_expression
constitutively	O
on	O
the	O
surface	O
of	O
the	O
human	O
T	O
cell	O
line	O
ACH	O
-	O
2	O
,	O
which	O
is	O
chronically	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
type	O
-	O
1	O
(	O
HIV	O
)	O
-	O
1	O
.	O

We	O
demonstrate	O
that	O
cross	B-Binding
-	I-Binding
linking	I-Binding
CD30	O
with	O
an	O
anti-CD30	O
-	O
specific	O
monoclonal	O
antibody	O
,	O
which	O
mimics	O
the	O
described	O
biological	O
activities	O
of	O
the	O
CD30	O
ligand	O
(	O
CD30L	O
)	O
,	O
results	O
in	O
HIV	O
expression	O
.	O

CD30	O
cross	B-Binding
-	I-Binding
linking	I-Binding
does	O
not	O
alter	O
proliferation	O
of	O
ACH	O
-	O
2	O
cells	O
and	O
the	O
induction	O
of	O
HIV	O
expression	O
is	O
not	O
mediated	O
by	O
endogenous	O
TNF	O
alpha/beta	O
.	O

Furthermore	O
,	O
cross	B-Binding
-	I-Binding
linking	I-Binding
of	O
CD30	O
leads	O
to	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
enhanced	O
HIV	O
transcription	O
.	O

Thus	O
,	O
CD30	O
-	O
CD30L	O
interactions	B-Binding
mediate	O
the	O
induction	O
of	O
HIV	O
expression	O
by	O
a	O
kappa	O
B	O
-	O
dependent	O
pathway	O
that	O
is	O
independent	O
of	O
TNF	O
.	O

This	O
mechanism	O
may	O
be	O
important	O
in	O
the	O
activation	O
of	O
HIV	O
expression	O
from	O
latently	O
infected	O
CD4+	O
T	O
cells	O
,	O
especially	O
in	O
lymphoid	O
organs	O
where	O
cell	O
to	O
cell	O
contact	O
is	O
conducive	O
to	O
receptor	O
-	O
ligand	O
interactions	B-Binding
.	O

Integrin	O
-	O
mediated	O
tyrosine	O
phosphorylation	O
and	O
cytokine	O
message	O
induction	O
in	O
monocytic	O
cells	O
.	O

A	O
possible	O
signaling	B-Positive_regulation
role	I-Positive_regulation
for	O
the	O
Syk	O
tyrosine	O
kinase	O
.	O

Activation	O
of	O
cytoplasmic	O
tyrosine	O
kinases	O
is	O
an	O
important	O
aspect	O
of	O
signal	O
transduction	O
mediated	O
by	O
integrins	O
.	O

In	O
the	O
human	O
monocytic	O
cell	O
line	O
THP	O
-	O
1	O
,	O
either	O
integrin	O
-	O
dependent	O
cell	O
adhesion	O
to	O
fibronectin	O
or	O
ligation	B-Binding
of	O
beta	O
1	O
integrins	O
with	O
antibodies	O
causes	O
a	O
rapid	O
and	O
intense	O
tyrosine	O
phosphorylation	O
of	O
two	O
sets	O
of	O
proteins	O
of	O
about	O
65	O
-	O
75	O
and	O
120	O
-	O
125	O
kDa	O
.	O

In	O
addition	O
,	O
integrin	O
ligation	O
leads	B-Positive_regulation
to	O
nuclear	O
translocation	B-Localization
of	O
the	O
p50	O
and	O
p65	O
subunits	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
,	O
to	O
activation	O
of	O
a	O
reporter	O
gene	O
driven	O
by	O
a	O
promoter	O
containing	O
NF	O
-	O
kappa	O
B	O
sites	O
,	O
and	O
to	O
increased	B-Positive_regulation
levels	O
of	O
mRNAs	O
for	O
immediate	O
-	O
early	O
genes	O
,	O
including	O
the	O
cytokine	O
interleukin	O
(	O
IL	O
)	O
-	O
1	O
beta	O
.	O

The	O
tyrosine	O
kinase	O
inhibitors	O
genistein	O
and	O
herbimycin	O
A	O
block	B-Negative_regulation
both	O
integrin	O
-	O
mediated	O
tyrosine	O
phosphorylation	O
and	O
increases	B-Positive_regulation
in	O
IL	O
-	O
1	O
beta	O
message	O
levels	O
,	O
indicating	O
a	O
causal	O
relationship	O
between	O
the	O
two	O
events	O
.	O

The	O
components	O
tyrosine	O
phosphorylated	B-Phosphorylation
subsequent	B-Positive_regulation
to	I-Positive_regulation
cell	O
adhesion	O
include	O
paxillin	O
,	O
pp125FAK	O
,	O
and	O
the	O
SH2	O
domain	O
containing	O
tyrosine	O
kinase	O
Syk	O
.	O

In	O
contrast	O
,	O
integrin	O
ligation	O
with	O
antibodies	O
induces	B-Positive_regulation
tyrosine	O
phosphorylation	B-Phosphorylation
of	O
Syk	O
but	O
not	O
of	O
FAK	O
or	O
paxillin	O
.	O

In	O
adhering	O
cells	O
,	O
pre	O
-	O
treatment	O
with	O
cytochalasin	O
D	O
suppresses	B-Negative_regulation
tyrosine	O
phosphorylation	B-Phosphorylation
of	O
FAK	O
and	O
paxillin	O
but	O
not	O
of	O
Syk	O
,	O
while	O
IL	O
-	O
1	O
beta	O
message	O
induction	B-Positive_regulation
is	O
unaffected	B-Regulation
.	O

These	O
observations	O
indicate	O
that	O
the	O
Syk	O
tyrosine	O
kinase	O
may	O
be	O
an	O
important	O
component	O
of	O
an	O
integrin	O
signaling	O
pathway	O
in	O
monocytic	O
cells	O
,	O
leading	O
to	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
to	O
increased	O
levels	O
of	O
cytokine	O
messages	O
.	O

Nitric	O
oxide	O
decreases	O
cytokine	O
-	O
induced	O
endothelial	O
activation	O
.	O

Nitric	O
oxide	O
selectively	O
reduces	O
endothelial	O
expression	O
of	O
adhesion	O
molecules	O
and	O
proinflammatory	O
cytokines	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
nitric	O
oxide	O
(	O
NO	O
)	O
limits	O
endothelial	O
activation	O
,	O
we	O
treated	O
cytokine	O
-	O
stimulated	O
human	O
saphenous	O
vein	O
endothelial	O
cells	O
with	O
several	O
NO	O
donors	O
and	O
assessed	O
their	O
effects	B-Regulation
on	O
the	O
inducible	B-Positive_regulation
expression	B-Gene_expression
of	O
vascular	O
cell	O
adhesion	O
molecule	O
-	O
1	O
(	O
VCAM	O
-	O
1	O
)	O
.	O

In	O
a	O
concentration	O
-	O
dependent	O
manner	O
,	O
NO	O
inhibited	B-Negative_regulation
interleukin	O
(	O
IL	O
)	O
-	O
1	O
alpha	O
-	O
stimulated	B-Positive_regulation
VCAM	O
-	O
1	O
expression	B-Gene_expression
by	O
35	O
-	O
55	O
%	O
as	O
determined	O
by	O
cell	O
surface	O
enzyme	O
immunoassays	O
and	O
flow	O
cytometry	O
.	O

This	O
inhibition	B-Negative_regulation
was	O
paralleled	O
by	O
reduced	O
monocyte	O
adhesion	O
to	O
endothelial	O
monolayers	O
in	O
nonstatic	O
assays	O
,	O
was	O
unaffected	B-Regulation
by	O
cGMP	O
analogues	O
,	O
and	O
was	O
quantitatively	O
similar	O
after	O
stimulation	B-Positive_regulation
by	O
either	O
IL	O
-	O
1	O
alpha	O
,	O
IL	O
-	O
1	O
beta	O
,	O
IL	O
-	O
4	O
,	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
alpha	O
)	O
,	O
or	O
bacterial	O
lipopolysaccharide	O
.	O

NO	O
also	O
decreased	B-Negative_regulation
the	O
endothelial	O
expression	B-Gene_expression
of	O
other	O
leukocyte	O
adhesion	O
molecules	O
(	O
E	O
-	O
selectin	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
)	O
and	O
secretable	O
cytokines	O
(	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
)	O
.	O

Inhibition	O
of	O
endogenous	O
NO	O
production	O
by	O
L-N-monomethyl	O
-	O
arginine	O
also	O
induced	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
VCAM	O
-	O
1	O
,	O
but	O
did	O
not	O
augment	B-Positive_regulation
cytokine	O
-	O
induced	B-Positive_regulation
VCAM	O
-	O
1	O
expression	B-Gene_expression
.	O

Nuclear	O
run	O
-	O
on	O
assays	O
,	O
transfection	O
studies	O
using	O
various	O
VCAM	O
-	O
1	O
promoter	O
reporter	O
gene	O
constructs	O
,	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
indicated	O
that	O
NO	O
represses	B-Negative_regulation
VCAM	O
-	O
1	O
gene	O
transcription	B-Transcription
,	O
in	O
part	O
,	O
by	O
inhibiting	O
NF	O
-	O
kappa	O
B	O
.	O

We	O
propose	O
that	O
NO	O
's	O
ability	O
to	O
limit	O
endothelial	O
activation	O
and	O
inhibit	O
monocyte	O
adhesion	O
may	O
contribute	O
to	O
some	O
of	O
its	O
antiatherogenic	O
and	O
antiinflammatory	O
properties	O
within	O
the	O
vessel	O
wall	O
.	O

Distinct	O
signaling	O
properties	O
identify	O
functionally	O
different	O
CD4	O
epitopes	O
.	O

The	O
CD4	O
coreceptor	O
interacts	B-Binding
with	O
non	O
-	O
polymorphic	O
regions	O
of	O
major	O
histocompatibility	O
complex	O
class	O
II	O
molecules	O
on	O
antigen	O
-	O
presenting	O
cells	O
and	O
contributes	O
to	O
T	O
cell	O
activation	O
.	O

We	O
have	O
investigated	O
the	O
effect	O
of	O
CD4	O
triggering	B-Positive_regulation
on	O
T	O
cell	O
activating	O
signals	O
in	O
a	O
lymphoma	O
model	O
using	O
monoclonal	O
antibodies	O
(	O
mAb	O
)	O
which	O
recognize	B-Binding
different	O
CD4	O
epitopes	O
.	O

We	O
demonstrate	O
that	O
CD4	O
triggering	B-Positive_regulation
delivers	O
signals	O
capable	O
of	O
activating	O
the	O
NF	O
-	O
AT	O
transcription	O
factor	O
which	O
is	O
required	B-Positive_regulation
for	O
interleukin	O
-	O
2	O
gene	O
expression	B-Gene_expression
.	O

Whereas	O
different	O
anti	O
-	O
CD4	O
mAb	O
or	O
HIV	O
-	O
1	O
gp120	O
could	O
all	O
trigger	B-Positive_regulation
activation	B-Positive_regulation
of	O
the	O
protein	O
tyrosine	O
kinases	O
p56lck	O
and	O
p59fyn	O
and	O
phosphorylation	O
of	O
the	O
Shc	O
adaptor	O
protein	O
,	O
which	O
mediates	O
signals	O
to	O
Ras	O
,	O
they	O
differed	O
significantly	O
in	O
their	O
ability	O
to	O
activate	O
NF	O
-	O
AT	O
.	O

Lack	O
of	O
full	O
activation	O
of	O
NF	O
-	O
AT	O
could	O
be	O
correlated	O
to	O
a	O
dramatically	O
reduced	O
capacity	O
to	O
induce	O
calcium	O
flux	O
and	O
could	O
be	O
complemented	O
with	O
a	O
calcium	O
ionophore	O
.	O

The	O
results	O
identify	O
functionally	O
distinct	O
epitopes	O
on	O
the	O
CD4	O
coreceptor	O
involved	O
in	O
activation	O
of	O
the	O
Ras/protein	O
kinase	O
C	O
and	O
calcium	O
pathways	O
.	O

Lipopolysaccharide	O
-	O
induced	B-Positive_regulation
E	O
-	O
selectin	O
expression	B-Gene_expression
requires	B-Positive_regulation
continuous	O
presence	O
of	O
LPS	O
and	O
is	O
inhibited	B-Negative_regulation
by	O
bactericidal/permeability	O
-	O
increasing	O
protein	O
.	O

Endothelial	O
cells	O
stimulated	O
by	O
LPS	O
express	B-Gene_expression
E	O
-	O
selectin	O
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
mediating	O
neutrophil	O
adhesion	O
during	O
inflammation	O
.	O

E	O
-	O
selectin	O
is	O
induced	B-Positive_regulation
within	O
1	O
-	O
2	O
h	O
,	O
peaks	O
at	O
4	O
-	O
6	O
h	O
,	O
and	O
gradually	O
returns	O
to	O
basal	O
level	O
by	O
24	O
h	O
.	O

rBPI21	O
,	O
a	O
recombinant	O
N	O
-	O
terminal	O
fragment	O
of	O
human	O
bactericidal/permeability	O
-	O
increasing	O
protein	O
(	O
BPI	O
)	O
,	O
inhibited	B-Negative_regulation
LPS	O
-	O
induced	B-Positive_regulation
E	O
-	O
selectin	O
expression	B-Gene_expression
when	O
added	O
at	O
the	O
same	O
time	O
as	O
,	O
and	O
up	O
to	O
6	O
h	O
after	O
,	O
LPS	O
.	O

Delayed	O
administration	O
of	O
rBPI21	O
also	O
affected	O
LPS	O
-	O
mediated	O
activation	O
of	O
the	O
nuclear	O
factor	O
,	O
NF	O
-	O
kappa	O
B	O
.	O

Two	O
to	O
4	O
h	O
following	O
LPS	O
addition	O
to	O
endothelial	O
cells	O
,	O
when	O
NF	O
-	O
kappa	O
B	O
was	O
already	O
activated	O
,	O
addition	O
of	O
rBPI21	O
resulted	O
in	O
marked	O
reduction	O
of	O
NF	O
-	O
kappa	O
B	O
detectable	O
at	O
4	O
or	O
6	O
h	O
.	O

These	O
results	O
indicate	O
that	O
endothelial	O
activation	O
requires	O
continuous	O
presence	O
of	O
LPS	O
,	O
and	O
rBPI21	O
acts	O
to	O
reverse	O
LPS	O
-	O
mediated	O
endothelial	O
activation	O
by	O
interrupting	O
the	O
on	O
-	O
going	O
LPS	O
signal	O
.	O

Costimulation	O
of	O
human	O
CD4+	O
T	O
cells	O
with	O
LFA	O
-	O
3	O
and	O
B7	O
induce	O
distinct	O
effects	O
on	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
.	O

We	O
have	O
earlier	O
shown	O
that	O
stimulation	O
of	O
human	O
CD4+	O
T	O
cells	O
with	O
SEA	O
presented	O
on	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
-	O
DR	O
transfectants	O
coexpressing	B-Gene_expression
either	O
B7	O
or	O
LFA	O
-	O
3	O
resulted	O
in	O
distinct	O
cytokine	O
profiles	O
.	O

We	O
now	O
demonstrate	O
that	O
B7	O
,	O
but	O
not	O
LFA	O
-	O
3	O
,	O
strongly	O
costimulated	B-Positive_regulation
IL	O
-	O
2	O
transcription	B-Transcription
and	O
mRNA	B-Transcription
expression	I-Transcription
in	O
CD4+	O
T	O
cells	O
.	O

Maximal	O
increase	B-Positive_regulation
in	O
IL	O
-	O
2	O
transcription	B-Transcription
was	O
recorded	O
with	O
CHO-DR/B7/LFA	O
-	O
3	O
,	O
suggesting	O
a	O
cooperative	O
effect	B-Regulation
of	O
B7	O
and	O
LFA	O
-	O
3	O
at	O
the	O
transcriptional	O
level	O
.	O

Gel	O
-	O
shift	O
analysis	O
demonstrated	O
that	O
stimulation	O
of	O
CD4+	O
T	O
cells	O
with	O
CHO	O
-	O
DR	O
and	O
staphylococcal	O
enterotoxin	O
A	O
was	O
sufficient	O
to	O
induce	O
significant	O
amounts	O
of	O
NF	O
-	O
kappa	O
B	O
binding	O
proteins	O
,	O
whereas	O
induction	O
of	O
AP	O
-	O
1	O
binding	O
proteins	O
required	O
costimulation	O
.	O

LFA	O
-	O
3	O
induced	O
moderate	O
levels	O
of	O
AP	O
-	O
1	O
,	O
but	O
did	O
not	O
influence	O
the	O
levels	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
while	O
B7	O
costimulation	O
strongly	O
induced	O
both	O
AP	O
-	O
1	O
and	O
substantially	O
enhanced	O
NF	O
-	O
kappa	O
B	O
binding	O
proteins	O
.	O

The	O
CHO-DR/B7/LFA	O
-	O
3	O
triple	O
transfectant	O
induced	O
a	O
further	O
increase	O
in	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
binding	O
proteins	O
compared	O
with	O
the	O
double	O
transfectants	O
.	O

The	O
level	O
of	O
Oct	O
-	O
1	O
binding	O
proteins	O
remained	O
similar	O
in	O
all	O
samples	O
.	O

Super	O
-	O
shift	O
analysis	O
revealed	O
that	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
of	O
costimulated	O
CD4+	O
T	O
cells	O
contained	O
large	O
amounts	O
of	O
p50	O
,	O
substantial	O
amounts	O
of	O
p65	O
,	O
and	O
marginal	O
levels	O
of	O
c	O
-	O
Rel	O
proteins	O
.	O

The	O
AP	O
-	O
1	O
binding	O
proteins	O
contained	O
c	O
-	O
Jun	O
,	O
Jun	O
-	O
D	O
,	O
and	O
Fra	O
-	O
1	O
,	O
but	O
marginal	O
amounts	O
of	O
Jun	O
-	O
B	O
and	O
c	O
-	O
Fos	O
.	O

Our	O
results	O
indicate	O
distinct	O
effects	O
of	O
B7	O
and	O
LFA	O
-	O
3	O
costimulation	O
on	O
the	O
activity	O
of	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
.	O

These	O
may	O
partly	O
account	O
for	O
the	O
differential	O
effects	B-Regulation
of	O
B7	O
and	O
LFA	O
-	O
3	O
costimulation	O
on	O
IL	O
-	O
2	O
expression	B-Gene_expression
.	O

Regulation	B-Regulation
of	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
and	O
E	O
-	O
selectin	O
expression	B-Gene_expression
in	O
endothelial	O
cells	O
by	O
cyclosporin	O
A	O
and	O
the	O
T	O
-	O
cell	O
transcription	O
factor	O
NFAT	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
was	O
originally	O
described	O
as	O
a	O
T-cell	O
-	O
specific	O
transcription	O
factor	O
athat	O
supported	O
the	O
activation	O
of	O
cytokine	O
gene	O
expression	O
and	O
mediated	O
the	O
immunoregulatory	O
effects	O
of	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

As	O
we	O
observed	O
that	O
activated	O
endothelial	O
cells	O
also	O
expressed	O
NFAT	O
,	O
we	O
tested	O
the	O
antiinflammatory	O
properties	O
of	O
CsA	O
in	O
endothelial	O
cells	O
.	O

Significantly	O
,	O
CsA	O
completely	O
suppressed	O
the	O
induction	O
of	O
NFAT	O
in	O
endothelial	O
cells	O
and	O
inhibited	O
the	O
activity	O
of	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
gene	O
regulatory	O
elements	O
that	O
use	O
NFAT	O
by	O
60	O
%	O
.	O

CsA	O
similarly	O
mediated	B-Negative_regulation
a	I-Negative_regulation
reduction	I-Negative_regulation
of	O
up	O
to	O
65	O
%	O
in	O
GM	O
-	O
CSF	O
mRNA	O
and	O
protein	O
expression	B-Transcription
in	O
activated	O
endothelial	O
cells	O
.	O

CsA	O
also	O
suppressed	B-Negative_regulation
E	O
-	O
selectin	O
,	O
but	O
not	O
vascular	O
cell	O
adhesion	O
molecule	O
-	O
1	O
(	O
VCAM	O
-	O
1	O
)	O
expression	B-Gene_expression
in	O
endothelial	O
cells	O
,	O
even	O
though	O
the	O
E	O
-	O
selectin	O
promoter	O
is	O
activated	B-Positive_regulation
by	O
NF	O
-	O
kappa	O
B	O
rather	O
than	O
NFAT	O
.	O

Hence	O
,	O
induction	B-Positive_regulation
of	O
cell	O
surface	O
expression	B-Gene_expression
of	O
this	O
leukocyte	O
adhesion	O
molecule	O
by	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
alpha	O
was	O
reduced	B-Negative_regulation
by	O
40	O
%	O
in	O
the	O
presence	O
of	O
CsA	O
,	O
and	O
this	O
was	O
reflected	O
by	O
a	O
29	O
%	O
decrease	O
in	O
neutrophil	O
adhesion	O
.	O

The	O
effects	O
of	O
CsA	O
on	O
endothelial	O
cells	O
were	O
also	O
detected	O
at	O
the	O
chromatin	O
structure	O
level	O
,	O
as	O
DNasel	O
hypersensitive	O
sites	O
within	O
both	O
the	O
GM	O
-	O
CSF	O
enhancer	O
and	O
the	O
E	O
-	O
selectin	O
promoter	O
were	O
suppressed	O
by	O
CsA	O
.	O

This	O
represents	O
the	O
first	O
report	O
of	O
NFAT	O
in	O
endothelial	O
cells	O
and	O
suggests	O
mechanisms	O
by	O
which	O
CsA	O
could	O
function	O
as	O
an	O
antiinflammatory	O
agent	O
.	O

Signalling	O
via	O
CD28	O
of	O
human	O
naive	O
neonatal	O
T	O
lymphocytes	O
.	O

Accessory	O
molecules	O
play	O
a	O
crucial	O
role	O
in	O
the	O
development	O
of	O
the	O
T	O
cell	O
response	O
to	O
antigenic	O
challenge	O
.	O

We	O
have	O
examined	O
the	O
role	O
of	O
CD28	O
in	O
modulating	O
the	O
'naive	O
'	O
neonatal	O
T	O
cell	O
response	O
to	O
anti-CD2	O
-	O
mediated	O
activation	O
.	O

To	O
compare	O
the	O
role	O
of	O
CD28	O
,	O
neonatal	O
and	O
adult	O
T	O
cells	O
were	O
stimulated	O
with	O
a	O
pair	O
of	O
mitogenic	O
anti	O
-	O
CD2	O
antibodies	O
in	O
the	O
presence	O
or	O
absence	O
of	O
anti	O
-	O
CD28	O
MoAb	O
.	O

With	B-Positive_regulation
anti	O
-	O
CD2	O
alone	O
,	O
neonatal	O
T	O
cells	O
proliferated	O
slightly	O
but	O
produced	B-Gene_expression
no	O
detectable	O
IL	O
-	O
2	O
,	O
whereas	O
adult	O
T	O
cells	O
proliferated	O
vigorously	O
,	O
with	O
significant	O
IL	O
-	O
2	O
production	B-Gene_expression
.	O

Costimulation	O
with	O
anti	O
-	O
CD28	O
MoAb	O
greatly	O
enhanced	O
the	O
proliferative	O
response	O
of	O
neonatal	O
T	O
cells	O
to	O
levels	O
equivalent	O
to	O
those	O
of	O
adult	O
T	O
cells	O
,	O
whereas	O
adult	O
T	O
cells	O
showed	O
only	O
slight	O
increases	O
.	O

Although	O
IL	O
-	O
2	O
secretion	B-Localization
was	O
increased	B-Positive_regulation
in	O
the	O
presence	O
of	O
anti	O
-	O
CD28	O
MoAb	O
,	O
neonatal	O
T	O
cell	O
IL	O
-	O
2	O
production	B-Gene_expression
remained	O
lower	O
than	O
in	O
adults	O
.	O

In	O
contrast	O
,	O
enhancement	B-Positive_regulation
of	O
IL	O
-	O
2	O
mRNA	O
expression	B-Transcription
in	O
neonates	O
was	O
similar	O
to	O
adult	O
levels	O
.	O

Anti	O
-	O
CD28	O
MoAb	O
costimulation	O
increased	O
NF	O
kappa	O
B	O
levels	O
in	O
neonates	O
,	O
albeit	O
to	O
levels	O
lower	O
than	O
that	O
of	O
adults	O
.	O

The	O
cellular	O
mechanism	O
governing	O
the	O
diminished	O
proliferative	O
response	O
of	O
neonatal	O
T	O
lymphocytes	O
to	O
anti	O
-	O
CD2	O
may	O
therefore	O
be	O
due	O
to	O
decreased	O
NF	O
kappa	O
B	O
induction	O
,	O
reduced	B-Negative_regulation
IL	O
-	O
2	O
mRNA	O
expression	B-Transcription
and	O
deficient	B-Negative_regulation
IL	O
-	O
2	O
production	B-Gene_expression
.	O

Although	O
anti	O
-	O
CD28	O
MoAb	O
costimulation	O
enhances	B-Positive_regulation
all	O
of	O
the	O
above	O
signals	O
,	O
NF	O
kappa	O
B	O
and	O
IL	O
-	O
2	O
levels	O
remain	O
lower	O
than	O
in	O
adults	O
,	O
suggesting	O
the	O
need	O
for	O
further	O
activation	O
requirements	O
in	O
the	O
neonate	O
.	O

N	O
-	O
and	O
C	O
-	O
terminal	O
sequences	O
control	B-Regulation
degradation	B-Protein_catabolism
of	O
MAD3/I	O
kappa	O
B	O
alpha	O
in	B-Positive_regulation
response	I-Positive_regulation
to	I-Positive_regulation
inducers	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
.	O

The	O
proteolytic	B-Protein_catabolism
degradation	I-Protein_catabolism
of	O
the	O
inhibitory	O
protein	O
MAD3/I	O
kappa	O
B	O
alpha	O
in	B-Positive_regulation
response	I-Positive_regulation
to	I-Positive_regulation
extracellular	O
stimulation	O
is	O
a	O
prerequisite	O
step	O
in	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
.	O

Analysis	O
of	O
the	O
expression	B-Gene_expression
of	O
human	O
I	O
kappa	O
B	O
alpha	O
protein	O
in	O
stable	O
transfectants	O
of	O
mouse	O
70Z/3	O
cells	O
shows	O
that	O
,	O
as	O
for	O
the	O
endogenous	O
murine	O
protein	O
,	O
exogenous	O
I	O
kappa	O
B	O
alpha	O
is	O
degraded	B-Protein_catabolism
in	B-Positive_regulation
response	I-Positive_regulation
to	I-Positive_regulation
inducers	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
,	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
or	O
lipopolysaccharide	O
.	O

In	O
addition	O
,	O
pretreatment	O
of	O
the	O
cells	O
with	O
the	O
proteasome	O
inhibitor	O
N-Ac-Leu-Leu	O
-	O
norleucinal	O
inhibits	O
this	O
ligand	O
-	O
induced	O
degradation	O
and	O
,	O
in	O
agreement	O
with	O
previous	O
studies	O
,	O
stabilizes	B-Positive_regulation
a	O
hyperphosphorylated	B-Phosphorylation
form	O
of	O
the	O
human	O
I	O
kappa	O
B	O
alpha	O
protein	O
.	O

By	O
expressing	O
mutant	O
forms	O
of	O
the	O
human	O
protein	O
in	O
this	O
cell	O
line	O
,	O
we	O
have	O
been	O
able	O
to	O
delineate	O
the	O
sequences	O
responsible	O
for	O
both	O
the	O
ligand	O
-	O
induced	B-Positive_regulation
phosphorylation	B-Phosphorylation
and	O
the	O
degradation	B-Protein_catabolism
of	O
I	O
kappa	O
B	O
alpha	O
.	O

Our	O
results	O
show	O
that	O
deletion	O
of	O
the	O
C	O
terminus	O
of	O
the	O
I	O
kappa	O
B	O
alpha	O
molecule	O
up	O
to	O
amino	O
acid	O
279	O
abolishes	O
constitutive	O
but	O
not	O
ligand	O
-	O
inducible	O
phosphorylation	O
and	O
inhibits	O
ligand	O
-	O
inducible	O
degradation	O
.	O

Further	O
analysis	O
reveals	O
that	O
the	O
inducible	B-Positive_regulation
phosphorylation	B-Phosphorylation
of	O
I	O
kappa	O
B	O
alpha	O
maps	O
to	O
two	O
serines	O
in	O
the	O
N	O
terminus	O
of	O
the	O
protein	O
(	O
residues	O
32	O
and	O
36	O
)	O
and	O
that	O
the	O
mutation	O
of	O
either	O
residue	O
is	O
sufficient	O
to	O
abolish	B-Negative_regulation
ligand	O
-	O
induced	B-Positive_regulation
degradation	B-Protein_catabolism
,	O
whereas	O
both	O
residues	O
must	O
be	O
mutated	O
to	O
abolish	B-Negative_regulation
inducible	B-Positive_regulation
phosphorylation	B-Phosphorylation
of	O
the	O
protein	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Transcriptional	B-Negative_regulation
repression	I-Negative_regulation
of	O
the	O
interleukin	O
-	O
2	O
gene	O
by	O
vitamin	O
D3	O
:	O
direct	O
inhibition	B-Negative_regulation
of	O
NFATp/AP	O
-	O
1	O
complex	B-Binding
formation	I-Binding
by	O
a	O
nuclear	O
hormone	O
receptor	O
.	O

T	O
-	O
lymphocyte	O
proliferation	O
is	O
suppressed	O
by	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
]	O
,	O
the	O
active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
and	O
is	O
associated	O
with	O
a	O
decrease	B-Negative_regulation
in	O
interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
,	O
gamma	O
interferon	O
,	O
and	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
mRNA	O
levels	O
.	O

We	O
report	O
here	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
-	O
mediated	O
repression	O
in	O
Jurkat	O
cells	O
is	O
cycloheximide	O
resistant	O
,	O
suggesting	O
that	O
it	O
is	O
a	O
direct	O
transcriptional	O
repressive	B-Negative_regulation
effect	I-Negative_regulation
on	O
IL	O
-	O
2	O
expression	B-Transcription
by	O
the	O
vitamin	O
D3	O
receptor	O
(	O
VDR	O
)	O
.	O

We	O
therefore	O
examined	O
vitamin	O
D3	O
-	O
mediated	O
repression	B-Negative_regulation
of	O
activated	B-Positive_regulation
IL	O
-	O
2	O
expression	B-Gene_expression
by	O
cotransfecting	B-Gene_expression
Jurkat	O
cells	O
with	O
IL	O
-	O
2	O
promoter/reporter	O
constructs	O
and	O
a	O
VDR	O
overexpression	O
vector	O
and	O
by	O
DNA	O
binding	O
.	O

We	O
delineated	O
an	O
element	O
conferring	B-Regulation
both	O
DNA	O
binding	B-Binding
by	O
the	O
receptor	O
in	O
vitro	O
and	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
-	O
mediated	O
repression	O
in	O
vivo	O
to	O
a	O
short	O
40	O
-	O
bp	O
region	O
encompassing	O
an	O
important	O
positive	O
regulatory	O
element	O
,	O
NF-AT	O
-	O
1	O
,	O
which	O
is	O
bound	B-Binding
by	O
a	O
T-cell	O
-	O
specific	O
transcription	O
factor	O
,	O
NFATp	O
,	O
as	O
well	O
as	O
by	O
AP	O
-	O
1	O
.	O

VDR	O
DNA	O
-	O
binding	B-Binding
mutants	I-Binding
were	O
unable	O
to	O
either	O
bind	O
to	O
this	O
element	O
in	O
vitro	O
or	O
repress	B-Negative_regulation
in	O
vivo	O
;	O
the	O
VDR	O
DNA	O
-	O
binding	O
domain	O
alone	O
,	O
however	O
,	O
bound	O
the	O
element	O
but	O
also	O
could	O
not	O
repress	B-Negative_regulation
IL	O
-	O
2	O
expression	B-Gene_expression
.	O

These	O
results	O
indicate	O
that	O
DNA	O
binding	B-Binding
by	O
VDR	O
is	O
necessary	B-Positive_regulation
but	I-Positive_regulation
not	I-Positive_regulation
sufficient	I-Positive_regulation
to	I-Positive_regulation
mediate	I-Positive_regulation
IL	O
-	O
2	O
repression	B-Negative_regulation
.	O

By	O
combining	O
partially	O
purified	O
proteins	O
in	O
vitro	O
,	O
we	O
observed	O
the	O
loss	B-Negative_regulation
of	O
the	O
bound	B-Binding
NFATp/AP-1	O
-	O
DNA	O
complex	O
upon	O
inclusion	O
of	O
VDR	O
or	O
VDR	O
-	O
retinoid	O
X	O
receptor	O
.	O

Order	O
of	O
addition	O
and	O
off	O
-	O
rate	O
experiments	O
indicate	O
that	O
the	O
VDR	O
-	O
retinoid	O
X	O
receptor	O
heterodimer	O
blocks	B-Negative_regulation
NFATp/AP	O
-	O
1	O
complex	B-Binding
formation	I-Binding
and	O
then	O
stably	O
associates	B-Binding
with	O
the	O
NF-AT	O
-	O
1	O
element	O
.	O

This	O
direct	O
inhibition	O
by	O
a	O
nuclear	O
hormone	O
receptor	O
of	O
transcriptional	B-Positive_regulation
activators	I-Positive_regulation
of	O
the	O
IL	O
-	O
2	O
gene	O
may	O
provide	O
a	O
mechanistic	O
explanation	O
of	O
how	O
vitamin	O
derivatives	O
can	O
act	O
as	O
potent	O
immunosuppressive	O
agents	O
.	O

An	O
interferon	O
-	O
gamma	O
activation	O
sequence	O
mediates	B-Positive_regulation
the	O
transcriptional	B-Regulation
regulation	I-Regulation
of	O
the	O
IgG	O
Fc	O
receptor	O
type	O
IC	O
gene	O
by	O
interferon	O
-	O
gamma	O
.	O

Expression	B-Gene_expression
of	O
the	O
IgG	O
Fc	O
receptor	O
type	O
I	O
(	O
Fc	O
gamma	O
RI	O
)	O
on	O
myeloid	O
cells	O
is	O
dramatically	O
increased	B-Positive_regulation
by	O
treatment	O
with	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
.	O

We	O
observed	O
that	O
Fc	O
gamma	O
RI	O
transcript	O
levels	O
in	O
monoblast	O
-	O
like	O
U937	O
cells	O
were	O
elevated	B-Positive_regulation
within	O
3	O
hr	O
and	O
peaked	O
12	O
hr	O
after	O
exposure	O
to	O
IFN	O
-	O
gamma	O
.	O

Treatment	O
of	O
U937	O
with	O
IFN	O
-	O
gamma	O
for	O
9	O
hr	O
in	O
the	O
presence	O
of	O
cycloheximide	O
led	B-Positive_regulation
to	O
super	B-Positive_regulation
-	O
induction	B-Positive_regulation
of	O
Fc	O
gamma	O
RI	O
expression	B-Gene_expression
.	O

Nuclear	O
run	O
-	O
on	O
analysis	O
revealed	O
that	O
the	O
rate	O
of	O
Fc	O
gamma	O
RI	O
transcription	B-Transcription
was	O
increased	B-Positive_regulation
by	O
IFN	O
-	O
gamma	O
.	O

Genomic	O
sequence	O
upstream	O
of	O
the	O
Fc	O
gamma	O
RIC	O
gene	O
was	O
cloned	O
and	O
subjected	O
to	O
primer	O
extension	O
analysis	O
,	O
which	O
demonstrated	O
a	O
single	O
transcription	O
initiation	O
site	O
without	O
a	O
TATA	O
box	O
.	O

Transient	O
transfections	O
of	O
CAT	O
reporter	O
gene	O
constructs	O
containing	O
various	O
Fc	O
gamma	O
RIC	O
promoter	O
sequences	O
into	O
U937	O
cells	O
revealed	O
that	O
a	O
20	O
-	O
bp	O
region	O
surrounding	O
the	O
transcription	O
start	O
site	O
(	O
-	O
7	O
to	O
+13	O
)	O
was	O
capable	O
of	O
mediating	O
transcription	O
initiation	O
and	O
that	O
an	O
IFN	O
-	O
gamma	O
responsive	O
element	O
(	O
GIRE	O
)	O
was	O
present	O
within	O
74	O
bp	O
upstream	O
of	O
the	O
transcription	O
initiation	O
site	O
.	O

A	O
17	O
-	O
bp	O
sequence	O
between	O
positions	O
-	O
51	O
and	O
-	O
35	O
conferred	O
IFN	O
-	O
gamma	O
responsiveness	O
on	O
a	O
heterologous	O
promoter	O
.	O

Double	O
-	O
stranded	O
GIRE	O
sequence	O
,	O
but	O
not	O
a	O
scrambled	O
sequence	O
,	O
was	O
specifically	O
bound	O
by	O
nuclear	O
proteins	O
from	O
IFN	O
-	O
gamma	O
treated	O
U937	O
cells	O
.	O

Gel	O
shift	O
experiments	O
further	O
showed	O
that	O
the	O
STAT1	O
alpha	O
protein	O
bound	B-Binding
to	O
the	O
Fc	O
gamma	O
RIC	O
GIRE	O
in	B-Positive_regulation
response	I-Positive_regulation
to	I-Positive_regulation
IFN	O
-	O
gamma	O
treatment	O
of	O
U937	O
cells	O
.	O

The	O
Fc	O
gamma	O
RIC	O
GIRE	O
is	O
homologous	O
to	O
the	O
IFN	O
-	O
gamma	O
activation	O
sequence	O
(	O
GAS	O
)	O
of	O
the	O
guanylate	O
binding	O
protein	O
and	O
to	O
X	O
box	O
elements	O
of	O
class	O
II	O
MHC	O
genes	O
.	O

Our	O
results	O
demonstrate	O
that	O
transcriptional	B-Regulation
regulation	I-Regulation
of	O
the	O
Fc	O
gamma	O
RIC	O
gene	O
by	O
IFN	O
-	O
gamma	O
involves	B-Regulation
the	O
binding	B-Binding
of	O
STAT1	O
alpha	O
to	O
a	O
17	O
-	O
bp	O
GAS	O
homology	O
in	O
the	O
proximal	O
promoter	O
.	O

Immunosuppression	O
by	O
glucocorticoids	O
:	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
through	O
induction	O
of	O
I	O
kappa	O
B	O
synthesis	O
[	O
see	O
comments	O
]	O

Glucocorticoids	O
are	O
among	O
the	O
most	O
potent	O
anti	O
-	O
inflammatory	O
and	O
immunosuppressive	O
agents	O
.	O

They	O
inhibit	O
synthesis	O
of	O
almost	O
all	O
known	O
cytokines	O
and	O
of	O
several	O
cell	O
surface	O
molecules	O
required	O
for	O
immune	O
function	O
,	O
but	O
the	O
mechanism	O
underlying	O
this	O
activity	O
has	O
been	O
unclear	O
.	O

Here	O
it	O
is	O
shown	O
that	O
glucocorticoids	O
are	O
potent	O
inhibitors	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
activation	O
in	O
mice	O
and	O
cultured	O
cells	O
.	O

This	O
inhibition	O
is	O
mediated	O
by	O
induction	O
of	O
the	O
I	O
kappa	O
B	O
alpha	O
inhibitory	O
protein	O
,	O
which	O
traps	O
activated	O
NF	O
-	O
kappa	O
B	O
in	O
inactive	O
cytoplasmic	O
complexes	O
.	O

Because	O
NF	O
-	O
kappa	O
B	O
activates	O
many	O
immunoregulatory	O
genes	O
in	O
response	O
to	O
pro	O
-	O
inflammatory	O
stimuli	O
,	O
the	O
inhibition	O
of	O
its	O
activity	O
can	O
be	O
a	O
major	O
component	O
of	O
the	O
anti	O
-	O
inflammatory	O
activity	O
of	O
glucocorticoids	O
.	O

IFN	O
-	O
gamma	O
priming	O
of	O
monocytes	O
enhances	O
LPS	O
-	O
induced	O
TNF	O
production	O
by	O
augmenting	O
both	O
transcription	O
and	O
MRNA	O
stability	O
.	O

The	O
induction	O
of	O
cytokine	O
expression	O
in	O
monocytes/macrophages	O
by	O
bacterial	O
endotoxin	O
or	O
lipopolysaccharide	O
is	O
a	O
critical	O
,	O
highly	O
regulated	O
host	O
defence	O
response	O
.	O

The	O
augmentation	O
of	O
LPS	O
responses	O
by	O
interferon	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
,	O
referred	O
to	O
as	O
priming	O
,	O
is	O
well	O
established	O
.	O

However	O
,	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
priming	O
occurs	O
is	O
poorly	O
defined	O
.	O

Using	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)	O
induction	O
as	O
a	O
model	O
,	O
experiments	O
were	O
designed	O
to	O
analyse	O
in	O
detail	O
the	O
priming	O
effect	O
on	O
the	O
LPS	O
response	O
in	O
human	O
monocytes	O
.	O

Priming	O
by	O
IFN	O
-	O
gamma	O
was	O
primarily	O
manifested	O
at	O
the	O
level	O
of	O
TNF	O
mRNA	O
accumulation	O
.	O

IFN	O
-	O
gamma	O
pre	O
-	O
treatment	O
affected	O
the	O
magnitude	O
rather	O
than	O
the	O
sensitivity	O
of	O
the	O
LPS	O
response	O
.	O

Priming	O
occurred	O
after	O
several	O
hours	O
of	O
treatment	O
,	O
and	O
the	O
primed	O
state	O
was	O
induced	O
by	O
either	O
IFN	O
-	O
gamma	O
or	O
GM	O
-	O
CSF	O
,	O
but	O
not	O
M	O
-	O
CSF	O
.	O

Primed	O
monocytes	O
transcribed	O
TNF	O
mRNA	O
at	O
a	O
higher	O
rate	O
than	O
freshly	O
isolated	O
monocytes	O
upon	O
activation	O
with	O
LPS	O
.	O

The	O
increased	O
transcriptional	O
rate	O
correlated	O
with	O
a	O
marked	O
increase	O
in	O
nuclear	O
factor	O
-	O
kappa	O
B	O
activity	O
in	O
these	O
cells	O
as	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
consensus	O
NF	O
-	O
kappa	O
B	O
oligonucleotide	O
.	O

An	O
additional	O
significant	O
finding	O
was	O
than	O
TNF	O
mRNA	O
induced	O
in	O
primed	O
cells	O
was	O
much	O
more	O
stable	O
than	O
in	O
unprimed	O
cells	O
(	O
T1/2	O
increased	O
6-8	O
-	O
fold	O
)	O
.	O

Consistent	O
with	O
the	O
increased	O
mRNA	O
stability	O
,	O
the	O
duration	O
of	O
mRNA	O
accumulation	O
was	O
longer	O
following	O
LPS	O
stimulation	O
in	O
primed	O
monocytes	O
,	O
in	O
addition	O
to	O
being	O
of	O
greater	O
magnitude	O
.	O

Finally	O
,	O
primed	O
and	O
unprimed	O
cells	O
possessed	O
a	O
differential	O
sensitivity	O
to	O
the	O
kinase	O
inhibitor	O
H	O
-	O
89	O
.	O

H	O
-	O
89	O
substantially	O
suppressed	O
LPS	O
-	O
induced	O
TNF	O
mRNA	O
accumulation	O
in	O
unprimed	O
cells	O
,	O
but	O
had	O
no	O
effect	O
on	O
primed	O
monocytes	O
following	O
LPS	O
stimulation	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
myeloid	O
zinc	O
finger	O
gene	O
,	O
MZF	O
-	O
1	O
,	O
regulates	B-Regulation
the	O
CD34	O
promoter	O
in	O
vitro	O
.	O

MZF	O
-	O
1	O
is	O
a	O
C2H2	O
zinc	O
finger	O
gene	O
encoding	O
a	O
putative	O
transcriptional	O
regulator	O
of	O
myeloid	O
differentiation	O
.	O

The	O
MZF	O
-	O
1	O
protein	O
contains	O
13	O
C2H2	O
zinc	O
fingers	O
arranged	O
in	O
bipartite	O
DNA	O
binding	O
domains	O
containing	O
zinc	O
fingers	O
through	O
4	O
and	O
,	O
in	O
the	O
carboxy	O
-	O
terminus	O
,	O
5	O
through	O
13	O
.	O

We	O
previously	O
identified	O
the	O
DNA	O
consensus	O
binding	O
site	O
recognized	O
by	O
the	O
two	O
DNA	O
binding	O
domains	O
.	O

To	O
assess	O
the	O
transcription	O
regulatory	O
function	O
of	O
MZF	O
-	O
1	O
,	O
the	O
full	O
-	O
length	O
MZF	O
-	O
1	O
coding	O
region	O
was	O
fused	O
to	O
the	O
DNA	O
binding	O
domain	O
of	O
the	O
yeast	O
transactivator	O
GAL4	O
.	O

The	O
expression	O
vector	O
was	O
cotransfected	B-Gene_expression
with	O
the	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
reporter	O
gene	O
regulated	B-Regulation
by	O
the	O
thymidine	O
kinase	O
promoter	O
containing	O
GAL4	O
DNA	O
binding	O
sites	O
into	O
NIH	O
3T3	O
,	O
293	O
,	O
K562	O
,	O
and	O
Jurkat	O
cell	O
lines	O
.	O

MZF	O
-	O
1	O
represses	B-Negative_regulation
CAT	O
reporter	O
gene	O
expression	B-Gene_expression
via	B-Positive_regulation
GAL4	O
binding	O
sites	O
in	O
the	O
nonhematopoietic	O
cell	O
lines	O
NIH	O
3T3	O
and	O
293	O
.	O

In	O
contrast	O
,	O
MZF	O
-	O
1	O
activates	B-Positive_regulation
CAT	O
reporter	O
gene	O
expression	B-Gene_expression
in	O
the	O
hematopoietic	O
cell	O
lines	O
K562	O
and	O
Jurkat	O
.	O

The	O
MZF	O
-	O
1	O
binding	O
sites	O
are	O
present	O
in	O
the	O
promoters	O
of	O
several	O
genes	O
expressed	B-Gene_expression
during	O
myeloid	O
differentiation	O
,	O
including	O
the	O
CD34	O
promoter	O
.	O

MZF	O
-	O
1	O
transcriptional	B-Regulation
regulation	I-Regulation
of	O
this	O
physiologically	O
relevant	O
promoter	O
was	O
assessed	O
in	O
both	O
hematopoietic	O
and	O
nonhematopoietic	O
cell	O
lines	O
.	O

Recombinant	O
MZF	O
-	O
1	O
protein	O
specifically	O
binds	B-Binding
to	O
the	O
consensus	O
binding	O
sites	O
in	O
the	O
CD34	O
promoter	O
in	O
mobility	O
shift	O
assays	O
.	O

MZF	O
-	O
1	O
expression	O
vectors	O
were	O
cotransfected	O
with	O
the	O
luciferase	O
reporter	O
plasmids	O
regulated	O
by	O
the	O
CD34	O
promoter	O
into	O
both	O
nonhematopoietic	O
and	O
hematopoietic	O
cell	O
lines	O
.	O

As	O
with	O
the	O
heterologous	O
DNA	O
binding	O
domain	O
,	O
MZF	O
-	O
1	O
represses	O
reporter	O
gene	O
expression	O
in	O
nonhematopoietic	O
cell	O
lines	O
and	O
activates	O
expression	O
in	O
hematopoietic	O
cell	O
lines	O
.	O

Activation	B-Positive_regulation
of	O
CD34	O
expression	B-Gene_expression
in	O
hematopoietic	O
cell	O
lines	O
is	O
dependent	B-Positive_regulation
on	O
the	O
presence	O
of	O
intact	O
MZF	O
-	O
1	O
binding	O
sites	O
.	O

The	O
cell	O
type	O
-	O
specific	O
regulation	B-Regulation
of	O
the	O
CD34	O
promoter	O
by	O
MZF	O
-	O
1	O
suggests	O
the	O
presence	O
of	O
tissue	O
-	O
specific	O
regulators/adapters	O
or	O
differential	O
MZF	O
-	O
1	O
modifications	O
that	O
determine	B-Regulation
MZF	O
-	O
1	O
transcriptional	O
regulatory	O
function	O
.	O

The	O
normal	O
cell	O
cycle	O
activation	O
program	O
is	O
exploited	O
during	O
the	O
infection	O
of	O
quiescent	O
B	O
lymphocytes	O
by	O
Epstein	O
-	O
Barr	O
virus	O
.	O

B	O
lymphocytes	O
in	O
the	O
peripheral	O
circulation	O
are	O
maintained	O
in	O
a	O
non	O
-	O
proliferative	O
state	O
.	O

Antigen	O
recognition	O
stimulates	O
limited	O
proliferation	O
,	O
whereas	O
infection	O
with	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
results	O
in	O
continual	O
proliferation	O
and	O
the	O
outgrowth	O
of	O
immortal	O
cell	O
lines	O
.	O

Because	O
it	O
is	O
not	O
clear	O
at	O
which	O
point	O
in	O
cell	O
cycle	O
the	O
peripheral	O
B	O
lymphocytes	O
are	O
arrested	O
,	O
we	O
characterized	O
the	O
expression	O
of	O
several	O
cell	O
cycle	O
-	O
associated	O
genes	O
in	O
quiescent	O
and	O
stimulated	O
cells	O
.	O

We	O
show	O
that	O
the	O
expression	B-Gene_expression
of	O
four	O
cell	O
genes	O
,	O
cdc	O
-	O
2	O
,	O
cyclin	O
E	O
,	O
CD23	O
,	O
and	O
cyclin	O
D2	O
,	O
are	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
approximately	O
100	O
-	O
fold	O
as	O
a	O
result	O
of	O
EBV	O
-	O
mediated	O
immortalization	O
.	O

Because	O
these	O
genes	O
play	O
a	O
positive	O
role	O
in	O
cell	O
proliferation	O
,	O
we	O
suggest	O
that	O
this	O
regulatory	O
switch	O
contributes	O
to	O
controlling	O
entry	O
into	O
the	O
cell	O
cycle	O
.	O

Transient	O
stimulation	O
of	O
quiescent	O
B	O
lymphocytes	O
with	O
either	O
a	O
cocktail	O
of	O
anti	O
-	O
CD40	O
,	O
anti	O
-	O
IgM	O
,	O
and	O
IL4	O
,	O
or	O
EBV	O
results	B-Positive_regulation
in	O
the	O
rapid	O
expression	B-Gene_expression
of	O
the	O
same	O
four	O
genes	O
,	O
suggesting	O
that	O
,	O
after	O
infection	O
,	O
EBV	O
exploits	O
the	O
normal	O
program	O
of	O
B	O
-	O
lymphocyte	O
cell	O
cycle	O
activation	O
.	O

CD30	O
ligation	B-Binding
induces	O
nuclear	O
factor	O
-	O
kappa	O
B	O
activation	O
in	O
human	O
T	O
cell	O
lines	O
.	O

CD30	O
is	O
a	O
recently	O
described	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor/nerve	O
growth	O
factor	O
receptor	O
superfamily	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
following	O
incubation	O
of	O
L540	O
cells	O
(	O
Hodgkin	O
's	O
disease	O
-	O
derived	O
,	O
T	O
cell	O
-	O
like	O
,	O
CD30+	O
cells	O
)	O
with	O
the	O
agonistic	O
anti	O
-	O
CD30	O
monoclonal	O
antibodies	O
(	O
mAb	O
)	O
M44	O
and	O
M67	O
,	O
two	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
DNA	O
binding	O
activities	O
were	O
induced	O
in	O
nuclear	O
extracts	O
,	O
as	O
determined	O
in	O
gel	O
retardation	O
assays	O
.	O

The	O
effect	O
of	O
the	O
mAb	O
towards	O
NF	O
-	O
kappa	O
B	O
activation	O
was	O
rapid	O
,	O
as	O
it	O
occurred	O
within	O
20	O
min	O
,	O
and	O
was	O
sustained	O
for	O
up	O
to	O
6	O
h	O
.	O

By	O
comparison	O
,	O
an	O
isotype	O
-	O
matched	O
antibody	O
had	O
no	O
effect	O
on	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

Moreover	O
,	O
in	O
human	O
T	O
helper	O
(	O
Th	O
)	O
clones	O
functionally	O
characterized	O
as	O
being	O
of	O
the	O
type	O
0	O
,	O
type	O
1	O
and	O
type	O
2	O
(	O
28	O
%	O
,	O
<	O
1	O
%	O
und	O
93	O
%	O
CD30+	O
,	O
respectively	O
)	O
,	O
the	O
extent	O
of	O
CD30	O
-	O
mediated	O
NF	O
-	O
kappa	O
B	O
activation	O
correlated	O
with	O
the	O
proportion	O
of	O
CD30+	O
cells	O
.	O

In	O
all	O
cell	O
lines	O
investigated	O
,	O
the	O
NF	O
-	O
kappa	O
B	O
complexes	O
induced	O
following	O
CD30	O
engagement	B-Binding
were	O
shown	O
to	O
contain	O
p50	O
NF	O
-	O
kappa	O
B1	O
,	O
p65	O
RelA	O
,	O
and	O
possibly	O
other	O
transcription	O
factors	O
.	O

Collectively	O
,	O
our	O
results	O
demonstrate	O
that	O
nuclear	O
translocation	O
and	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
rank	O
among	O
the	O
short	O
-	O
term	O
cellular	O
responses	O
elicited	O
following	O
CD30	O
ligation	B-Binding
.	O

Constitutive	O
NF	O
-	O
kappa	O
B	O
activation	O
,	O
enhanced	O
granulopoiesis	O
,	O
and	O
neonatal	O
lethality	O
in	O
I	O
kappa	O
B	O
alpha	O
-	O
deficient	B-Gene_expression
mice	O
.	O

Transcription	O
factors	O
belonging	O
to	O
the	O
NF	O
-	O
kappa	O
B	O
family	O
are	O
controlled	O
by	O
inhibitory	O
I	O
kappa	O
B	O
proteins	O
,	O
mainly	O
I	O
kappa	O
B	O
alpha	O
and	O
I	O
kappa	O
B	O
beta	O
.	O

Apparently	O
normal	O
at	O
birth	O
,	O
I	O
kappa	O
B	O
alpha-/	O
-	O
mice	O
exhibit	O
severe	O
runting	O
,	O
skin	O
defects	O
,	O
and	O
extensive	O
granulopoiesis	O
postnatally	O
,	O
typically	O
dying	O
by	O
8	O
days	O
.	O

Hematopoietic	O
tissues	O
from	O
these	O
mice	O
display	O
elevated	O
levels	O
of	O
both	O
nuclear	O
NF	O
-	O
kappa	O
B	O
and	O
mRNAs	O
of	O
some	O
,	O
but	O
not	O
all	O
,	O
genes	O
thought	O
to	O
be	O
regulated	O
by	O
NF	O
-	O
kappa	O
B	O
.	O

NF	O
-	O
kappa	O
B	O
elevation	O
results	O
in	O
these	O
phenotypic	O
abnormalities	O
because	O
mice	O
lacking	B-Negative_regulation
both	O
I	O
kappa	O
B	O
alpha	O
and	O
the	O
p50	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
show	O
a	O
dramatically	O
delayed	O
onset	O
of	O
abnormalities	O
.	O

In	O
contrast	O
to	O
hematopoietic	O
cells	O
,	O
I	O
kappa	O
B	O
alpha-/	O
-	O
embryonic	O
fibroblasts	O
show	O
minimal	O
constitutive	O
NF	O
-	O
kappa	O
B	O
,	O
as	O
well	O
as	O
normal	O
signal	O
-	O
dependent	O
NF	O
-	O
kappa	O
B	O
activation	O
that	O
is	O
concomitant	O
with	O
I	O
kappa	O
B	O
beta	O
degradation	B-Protein_catabolism
.	O

Our	O
results	O
indicate	O
that	O
I	O
kappa	O
b	O
beta	O
,	O
but	O
not	O
I	O
kappa	O
B	O
alpha	O
,	O
is	O
required	O
for	O
the	O
signal	O
-	O
dependent	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
fibroblasts	O
.	O

However	O
,	O
I	O
kappa	O
B	O
alpha	O
is	O
required	O
for	O
the	O
postinduction	O
repression	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
fibroblasts	O
.	O

These	O
results	O
define	O
distinct	O
roles	O
for	O
the	O
two	O
forms	O
of	O
I	O
kappa	O
B	O
and	O
demonstrate	O
the	O
necessity	O
for	O
stringent	O
control	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Vitamin	O
E	O
therapy	O
of	O
acute	O
CCl4	O
-	O
induced	O
hepatic	O
injury	O
in	O
mice	O
is	O
associated	O
with	O
inhibition	O
of	O
nuclear	O
factor	O
kappa	O
B	O
binding	O
.	O

Oxidative	O
stress	O
,	O
with	O
reactive	O
oxygen	O
intermediate	O
formation	O
,	O
may	O
represent	O
a	O
common	O
mechanism	O
by	O
which	O
liver	O
injury	O
is	O
induced	O
by	O
diverse	O
etiologies	O
.	O

Oxidative	O
stress	O
enhances	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
activity	O
,	O
and	O
NF	O
-	O
kappa	O
B	O
activity	O
has	O
been	O
shown	O
to	O
enhance	O
the	O
expression	O
of	O
cytotoxic	O
cytokines	O
.	O

Acute	O
hepatic	O
injury	O
caused	O
by	O
reactive	O
oxygen	O
intermediate	O
production	O
was	O
induced	O
by	O
an	O
intraperitoneal	O
injection	O
of	O
CCl4	O
in	O
mice	O
.	O

This	O
injury	O
was	O
significantly	O
inhibited	O
by	O
intravenous	O
pretreatment	O
of	O
the	O
mice	O
with	O
a	O
water	O
-	O
soluble	O
emulsion	O
of	O
alpha	O
-	O
tocopherol	O
.	O

Alpha	O
-	O
tocopherol	O
treatment	O
of	O
the	O
mice	O
given	O
the	O
CCl4	O
also	O
reduced	O
the	O
NF	O
-	O
kappa	O
B	O
binding	O
to	O
levels	O
approaching	O
those	O
found	O
in	O
normal	O
mice	O
.	O

In	O
vitro	O
treatment	O
of	O
a	O
monocyte/macrophage	O
cell	O
line	O
with	O
CCl4	O
led	O
to	O
enhanced	O
NF	O
-	O
kappa	O
B	O
binding	O
and	O
an	O
increase	B-Positive_regulation
in	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
messenger	O
RNA	O
levels	O
.	O

Liver	O
specimens	O
taken	O
from	O
patients	O
with	O
acute	O
fulminant	O
hepatitis	O
had	O
markedly	O
increased	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
in	O
comparison	O
with	O
the	O
binding	O
of	O
normal	O
livers	O
.	O

These	O
data	O
demonstrate	O
that	O
abolishing	O
acute	O
hepatic	O
injury	O
with	O
alpha	O
-	O
tocopherol	O
,	O
a	O
free	O
radical	O
scavenger	O
,	O
also	O
eliminated	O
increased	O
NF	O
-	O
kappa	O
B	O
binding	O
.	O

It	O
is	O
tempting	O
to	O
speculate	O
that	O
enhanced	O
NF	O
-	O
kappa	O
B	O
expression	O
caused	O
by	O
free	O
radical	O
production/oxidative	O
stress	O
may	O
modulate	O
liver	O
injury	O
,	O
perhaps	O
through	O
an	O
effect	O
on	O
cytotoxic	O
cytokine	O
synthesis	O
.	O

Activation	O
of	O
the	O
signal	O
transducer	O
and	O
transcription	O
(	O
STAT	O
)	O
signaling	O
pathway	O
in	O
a	O
primary	O
T	O
cell	O
response	O
.	O

Critical	O
role	O
for	O
IL	O
-	O
6	O
.	O

The	O
T	O
cell	O
activation	O
is	O
initiated	O
by	O
interaction	B-Binding
of	O
specific	O
Ags	O
with	O
TCR	O
,	O
followed	B-Regulation
by	O
activation	O
of	O
intracellular	O
biochemical	O
events	O
leading	O
to	O
activation	O
of	O
several	O
genes	O
.	O

The	O
activation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
proteins	O
in	O
a	O
primary	O
TCR	O
-	O
mediated	O
activation	O
of	O
T	O
cells	O
have	O
been	O
explored	O
.	O

In	O
purified	O
human	O
peripheral	O
blood	O
T	O
cells	O
,	O
nuclear	O
STAT	O
proteins	O
were	O
activated	O
approximately	O
3	O
h	O
after	O
activation	O
by	O
cross	O
-	O
linked	O
anti	O
-	O
CD3	O
Abs	O
.	O

These	O
STAT	O
proteins	O
were	O
detected	O
by	O
using	O
the	O
IFN-gamma	O
-	O
activated	O
sequence	O
(	O
GAS	O
)	O
and	O
related	O
oligonucleotides	O
as	O
probes	O
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Analysis	O
of	O
the	O
nuclear	O
extracts	O
with	O
anti	O
-	O
STAT	O
Abs	O
indicated	O
that	O
they	O
contained	O
STAT	O
-	O
3	O
and	O
additional	O
proteins	O
crossreactive	O
with	O
the	O
STAT	O
family	O
.	O

The	O
induction	O
of	O
STAT	O
activity	O
was	O
inhibited	O
completely	O
by	O
pretreatment	O
with	O
either	O
cycloheximide	O
or	O
cyclosporin	O
A	O
,	O
thus	O
indicating	O
that	O
the	O
induction	O
was	O
due	O
to	O
a	O
secondary	O
factor	O
produced	O
by	O
the	O
activated	O
T	O
cells	O
.	O

As	O
neutralizing	O
anti-IL	O
-	O
6	O
Abs	O
effectively	O
down	O
-	O
regulated	O
the	O
early	O
induction	O
of	O
STAT	O
proteins	O
and	O
as	O
exogenously	O
added	O
IL	O
-	O
6	O
rapidly	O
activated	B-Positive_regulation
DNA	O
binding	O
similar	O
to	O
TCR	O
-	O
mediated	O
bindings	O
,	O
it	O
can	O
be	O
concluded	O
that	O
IL	O
-	O
6	O
is	O
the	O
factor	O
responsible	O
for	O
the	O
activation	O
of	O
STAT	O
proteins	O
in	O
a	O
primary	O
T	O
cell	O
response	O
.	O

Regulation	B-Regulation
of	O
IkB	O
alpha	O
phosphorylation	B-Phosphorylation
by	O
PKC	O
-	O
and	O
Ca	O
(	O
2+	O
)	O
-	O
dependent	O
signal	O
transduction	O
pathways	O
.	O

The	O
Ca	O
(	O
2+	O
)	O
-	O
dependent	O
phosphatase	O
calcineurin	O
,	O
a	O
target	O
of	O
FK506	O
and	O
CsA	O
,	O
synergizes	O
with	O
PKC	O
-	O
induced	O
activation	O
of	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
in	O
T	O
cell	O
lines	O
.	O

We	O
have	O
investigated	O
whether	O
this	O
synergy	O
is	O
present	O
in	O
other	O
cell	O
types	O
and	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
these	O
two	O
pathways	O
lead	O
to	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

While	O
this	O
synergy	O
is	O
present	O
in	O
other	O
cell	O
types	O
,	O
in	O
the	O
monocytic	O
cell	O
line	O
U937	O
calcineurin	O
is	O
also	O
sufficient	O
to	O
activate	O
NF	O
-	O
kappa	O
B	O
.	O

Having	O
previously	O
shown	O
that	O
Ca	O
(	O
2+	O
)	O
-	O
and	O
PKC	O
-	O
dependent	O
pathways	B-Positive_regulation
synergize	I-Positive_regulation
by	O
accelerating	B-Positive_regulation
the	O
degradation	B-Protein_catabolism
of	O
IkB	O
alpha	O
,	O
we	O
focused	O
on	O
the	O
regulation	B-Regulation
of	O
IkB	O
alpha	O
phosphorylation	B-Phosphorylation
.	O

While	O
PKC	O
-	O
dependent	O
pathways	O
sequentially	O
result	B-Positive_regulation
in	O
the	O
phosphorylation	B-Phosphorylation
and	O
in	O
an	O
incomplete	O
degradation	B-Protein_catabolism
of	O
IkB	O
alpha	O
in	O
T	O
cell	O
lines	O
,	O
co	O
-	O
activation	O
of	O
Ca	O
(	O
2+	O
)	O
-	O
dependent	O
pathways	O
accelerates	B-Positive_regulation
the	O
rate	O
of	O
IkB	O
alpha	O
phosphorylation	B-Phosphorylation
and	O
results	B-Negative_regulation
in	O
its	O
complete	B-Protein_catabolism
degradation	I-Protein_catabolism
.	O

Activation	O
of	O
Ca	O
(	O
2+	O
)	O
-	O
dependent	O
pathways	O
alone	O
do	O
not	O
result	B-Positive_regulation
in	O
the	O
phosphorylation	B-Phosphorylation
and/or	O
degradation	B-Protein_catabolism
of	O
IkB	O
alpha	O
in	O
Jurkat	O
T	O
or	O
in	O
U937	O
cells	O
.	O

Treatment	O
of	O
T	O
cells	O
with	O
the	O
selective	O
PKC	O
inhibitor	O
GF109203X	O
abrogates	B-Negative_regulation
the	O
PMA	O
-	O
induced	B-Positive_regulation
IkB	O
alpha	O
phosphorylation/degradation	O
irrespective	O
of	O
activation	O
of	O
Ca	O
(	O
2+	O
)	O
-	O
dependent	O
pathways	O
,	O
but	O
not	O
the	O
phosphorylation	B-Phosphorylation
and	O
degradation	B-Protein_catabolism
of	O
IkB	O
alpha	O
induced	B-Positive_regulation
by	O
TNF	O
-	O
alpha	O
,	O
a	O
PKC	O
-	O
independent	O
stimulus	O
.	O

Contrary	O
to	O
the	O
interaction	O
with	O
PKC	O
,	O
Ca	O
(	O
2+	O
)	O
-	O
dependent	O
pathways	O
synergize	B-Positive_regulation
with	O
TNF	O
-	O
alpha	O
not	O
at	O
the	O
level	O
of	O
IkB	O
alpha	O
phosphorylation	B-Phosphorylation
,	O
but	O
at	O
the	O
level	O
of	O
its	O
degradation	B-Protein_catabolism
.	O

These	O
results	O
indicate	O
that	O
Ca	O
(	O
2+	O
)	O
-	O
dependent	O
pathways	O
,	O
including	O
the	O
phosphatase	O
calcineurin	O
,	O
participate	O
in	O
the	O
regulation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
a	O
cell	O
specific	O
fashion	O
and	O
synergize	B-Positive_regulation
with	O
PKC	O
-	O
dependent	O
and	O
-	O
independent	O
pathways	O
at	O
the	O
level	O
of	O
IkB	O
alpha	O
phosphorylation	B-Phosphorylation
and	O
degradation	B-Protein_catabolism
.	O

Triggering	B-Positive_regulation
of	O
complement	O
receptors	O
CR1	O
(	O
CD35	O
)	O
and	O
CR3	O
(	O
CD11b/CD18	O
)	O
induces	B-Positive_regulation
nuclear	O
translocation	B-Localization
of	O
NF	O
-	O
kappa	O
B	O
(	O
p50/p65	O
)	O
in	O
human	O
monocytes	O
and	O
enhances	O
viral	O
replication	O
in	O
HIV	O
-	O
infected	O
monocytic	O
cells	O
.	O

Monocyte/macrophages	O
may	O
harbor	O
HIV	O
in	O
a	O
nonproductive	O
fashion	O
for	O
prolonged	O
periods	O
of	O
time	O
.	O

Viral	O
gene	O
expression	O
may	O
be	O
reactivated	O
by	O
stimulation	O
of	O
the	O
cells	O
with	O
LPS	O
or	O
cytokines	O
such	O
as	O
TNF	O
-	O
alpha	O
in	O
vitro	O
.	O

The	O
effect	O
of	O
LPS	O
and	O
TNF	O
-	O
alpha	O
is	O
mediated	O
by	O
their	O
ability	O
to	O
induce	B-Positive_regulation
nuclear	O
translocation	B-Localization
of	O
the	O
DNA	O
-	O
binding	O
heterodimer	O
NF	O
-	O
kappa	O
B	O
(	O
p50/p65	O
)	O
,	O
which	O
binds	B-Binding
to	O
a	O
specific	O
sequence	O
in	O
the	O
HIV	O
-	O
long	O
terminal	O
repeat	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
triggering	B-Positive_regulation
of	O
complement	O
receptors	O
CR1	O
(	O
CD35	O
)	O
and	O
CR3	O
(	O
CD11b/CD18	O
)	O
enhances	O
viral	O
replication	O
in	O
HIV	O
-	O
infected	O
human	O
monocytic	O
cells	O
.	O

Monocytic	O
cell	O
lines	O
and	O
normal	O
peripheral	O
blood	O
monocytes	O
were	O
infected	O
with	O
HIV	O
-	O
1	O
in	O
vitro	O
and	O
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
F	O
(	O
ab	O
'	O
)	O
2	O
fragments	O
of	O
monoclonal	O
anti	O
-	O
CR1	O
or	O
anti	O
-	O
CR3	O
Abs	O
or	O
with	O
C3	O
fragments	O
.	O

Stimulation	B-Positive_regulation
of	O
CR1	O
or	O
CR3	O
induces	O
a	O
two	O
-	O
to	O
fourfold	O
increase	B-Positive_regulation
in	O
the	O
amount	O
of	O
cell	O
-	O
associated	O
and	O
released	O
p24	O
Ag	O
in	O
cell	O
cultures	O
that	O
was	O
equivalent	O
to	O
that	O
observed	O
in	O
control	O
cultures	O
triggered	O
with	O
LPS	O
.	O

We	O
further	O
observed	O
that	O
stimulation	B-Positive_regulation
of	O
CR1	O
or	O
CR3	O
induces	B-Positive_regulation
the	O
nuclear	O
translocation	B-Localization
of	O
NF	O
-	O
kappa	O
B	O
p50/p65	O
in	O
infected	O
cells	O
.	O

Translocation	B-Localization
of	O
NF	O
-	O
kappa	O
B	O
p50/p65	O
was	O
also	O
observed	B-Positive_regulation
following	O
stimulation	B-Positive_regulation
of	O
CR1	O
or	O
CR3	O
of	O
uninfected	O
peripheral	O
blood	O
monocytes	O
from	O
HIV	O
-	O
seronegative	O
donors	O
.	O

The	O
amount	O
of	O
protein	O
translocated	B-Localization
was	O
similar	O
to	O
that	O
observed	B-Positive_regulation
when	O
cells	O
were	O
stimulated	O
with	O
rhTNF	O
-	O
alpha	O
.	O

TNF	O
-	O
alpha	O
did	O
not	O
mediate	B-Positive_regulation
the	O
translocation	B-Localization
of	O
NF	O
-	O
kappa	O
B	O
p50/p65	O
induced	B-Positive_regulation
by	O
triggering	O
of	O
complement	O
receptors	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
HIV	O
gene	O
expression	O
may	O
be	O
activated	O
in	O
infected	O
monocytes	O
through	O
interaction	O
of	O
the	O
cells	O
with	O
complement	O
-	O
opsonized	O
particles	O
and	O
that	O
enhanced	O
viral	O
replication	O
is	O
associated	O
with	O
C3	O
receptor	O
-	O
mediated	O
nuclear	O
translocation	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
.	O

Nuclear	O
factor	O
-	O
IL6	O
activates	B-Positive_regulation
the	O
human	O
IL	O
-	O
4	O
promoter	O
in	O
T	O
cells	O
.	O

Positive	O
regulatory	O
element	O
I	O
(	O
PRE	O
-	O
I	O
)	O
is	O
a	O
strong	O
enhancer	O
element	O
essential	B-Positive_regulation
for	O
expression	B-Gene_expression
of	O
the	O
human	O
IL	O
-	O
4	O
gene	O
.	O

To	O
identify	O
transcription	O
factors	O
binding	O
to	O
PRE	O
-	O
I	O
,	O
we	O
screened	O
a	O
cDNA	O
expression	O
library	O
from	O
Jurkat	O
T	O
cells	O
and	O
isolated	O
a	O
cDNA	O
encoding	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
IL6	O
(	O
also	O
known	O
as	O
C/EBP	O
beta	O
)	O
.	O

NF	O
-	O
IL6	O
mRNA	O
was	O
found	B-Transcription
in	O
human	O
Jurkat	O
T	O
cells	O
and	O
in	O
the	O
mouse	O
Th2	O
clone	O
D10	O
,	O
but	O
not	O
in	O
Th1	O
clone	O
29	O
.	O

rNF	O
-	O
IL6	O
expressed	B-Gene_expression
in	O
bacteria	O
was	O
shown	O
to	O
specifically	O
bind	B-Binding
to	O
PRE	O
-	O
I	O
.	O

PRE	O
-	O
I	O
forms	O
multiple	O
DNA	O
-	O
protein	O
complexes	O
with	O
nuclear	O
extracts	O
from	O
Jurkat	O
cells	O
.	O

Some	O
of	O
these	O
complexes	B-Binding
were	O
demonstrated	O
to	O
contain	O
NF	O
-	O
IL6	O
by	O
using	O
anti	O
-	O
C/EBP	O
beta	O
Abs	O
.	O

Overexpression	B-Gene_expression
of	O
NF	O
-	O
IL6	O
enhanced	B-Positive_regulation
expression	B-Gene_expression
of	O
the	O
chloramphenicol	O
acetyl	O
transferase	O
reporter	O
gene	O
linked	O
to	O
the	O
PRE-I	O
-	O
thymidine	O
kinase	O
or	O
the	O
human	O
IL	O
-	O
4	O
promoter	O
more	O
than	O
10	O
-	O
fold	O
in	O
Jurkat	O
cells	O
.	O

Promoter	O
deletion	O
studies	O
revealed	O
two	O
additional	O
NF	O
-	O
IL6	O
binding	O
sites	O
located	O
at	O
positions	O
-	O
44	O
to	O
-	O
36	O
(	O
C/EBP	O
proximal	O
)	O
and	O
-	O
87	O
to	O
-	O
79	O
(	O
C/EBP	O
medial	O
)	O
,	O
respectively	O
.	O

Our	O
results	O
demonstrate	O
that	O
NF	O
-	O
IL6	O
is	O
involved	B-Regulation
in	O
transcriptional	B-Positive_regulation
activation	I-Positive_regulation
of	O
the	O
human	O
IL	O
-	O
4	O
promoter	O
in	O
T	O
cells	O
.	O

The	O
peri	O
-	O
kappa	O
B	O
site	O
mediates	O
human	O
immunodeficiency	O
virus	O
type	O
2	O
enhancer	O
activation	O
in	O
monocytes	O
but	O
not	O
in	O
T	O
cells	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
2	O
(	O
HIV	O
-	O
2	O
)	O
,	O
like	O
HIV	O
-	O
1	O
,	O
causes	O
AIDS	O
and	O
is	O
associated	O
with	O
AIDS	O
cases	O
primarily	O
in	O
West	O
Africa	O
.	O

HIV	O
-	O
1	O
and	O
HIV	O
-	O
2	O
display	O
significant	O
differences	O
in	O
nucleic	O
acid	O
sequence	O
and	O
in	O
the	O
natural	O
history	O
of	O
clinical	O
disease	O
.	O

Consistent	O
with	O
these	O
differences	O
,	O
we	O
have	O
previously	O
demonstrated	O
that	O
the	O
enhancer/promoter	O
region	O
of	O
HIV	O
-	O
2	O
functions	O
quite	O
differently	O
from	O
that	O
of	O
HIV	O
-	O
1	O
.	O

Whereas	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
enhancer	O
following	O
T	O
-	O
cell	O
stimulation	O
is	O
mediated	O
largely	O
through	O
binding	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
to	O
two	O
adjacent	O
kappa	O
B	O
sites	O
in	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
,	O
activation	O
of	O
the	O
HIV	O
-	O
2	O
enhancer	O
in	O
monocytes	O
and	O
T	O
cells	O
is	O
dependent	O
on	O
four	O
cis	O
-	O
acting	O
elements	O
:	O
a	O
single	O
kappa	O
B	O
site	O
,	O
two	O
purine	O
-	O
rich	O
binding	O
sites	O
,	O
PuB1	O
and	O
PuB2	O
,	O
and	O
a	O
pets	O
site	O
.	O

We	O
have	O
now	O
identified	O
a	O
novel	O
cis	O
-	O
acting	O
element	O
within	O
the	O
HIV	O
-	O
2	O
enhancer	O
,	O
immediately	O
upstream	O
of	O
the	O
kappa	O
B	O
site	O
,	O
designated	O
peri	O
-	O
kappa	O
B	O
.	O

This	O
site	O
is	O
conserved	O
among	O
isolates	O
of	O
HIV	O
-	O
2	O
and	O
the	O
closely	O
related	O
simian	O
immunodeficiency	O
virus	O
,	O
and	O
transfection	O
assays	O
show	O
this	O
site	O
to	O
mediate	O
HIV	O
-	O
2	O
enhancer	O
activation	O
following	O
stimulation	O
of	O
monocytic	O
but	O
not	O
T	O
-	O
cell	O
lines	O
.	O

This	O
is	O
the	O
first	O
description	O
of	O
an	O
HIV	O
-	O
2	O
enhancer	O
element	O
which	O
displays	O
such	O
monocyte	O
specificity	O
,	O
and	O
no	O
comparable	O
enhancer	O
element	O
has	O
been	O
clearly	O
defined	O
for	O
HIV	O
-	O
1	O
.	O

While	O
a	O
nuclear	O
factor	O
(	O
s	O
)	O
from	O
both	O
peripheral	O
blood	O
monocytes	O
and	O
T	O
cells	O
binds	O
the	O
peri	O
-	O
kappa	O
B	O
site	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggest	O
that	O
either	O
a	O
different	O
protein	O
binds	O
to	O
this	O
site	O
in	O
monocytes	O
versus	O
T	O
cells	O
or	O
that	O
the	O
protein	O
recognizing	O
this	O
enhancer	O
element	O
undergoes	O
differential	O
modification	O
in	O
monocytes	O
and	O
T	O
cells	O
,	O
thus	O
supporting	O
the	O
transfection	O
data	O
.	O

Further	O
,	O
while	O
specific	O
constitutive	O
binding	O
to	O
the	O
peri	O
-	O
kappa	O
B	O
site	O
is	O
seen	O
in	O
monocytes	O
,	O
stimulation	O
with	O
phorbol	O
esters	O
induces	O
additional	O
,	O
specific	O
binding	O
.	O

Understanding	O
the	O
monocyte	O
-	O
specific	O
function	O
of	O
the	O
peri	O
-	O
kappa	O
B	O
factor	O
may	O
ultimately	O
provide	O
insight	O
into	O
the	O
different	O
role	O
monocytes	O
and	O
T	O
cells	O
play	O
in	O
HIV	O
pathogenesis	O
.	O

Thapsigargin	O
induces	B-Positive_regulation
IL	O
-	O
2	O
receptor	O
alpha	O
-	O
chain	O
in	O
human	O
peripheral	O
and	O
Jurkat	O
T	O
cells	O
via	O
a	O
protein	O
kinase	O
C	O
-	O
independent	O
mechanism	O
.	O

Thapsigargin	O
(	O
TG	O
)	O
,	O
an	O
inhibitor	O
of	O
Ca	O
(	O
2+	O
)	O
-	O
ATPase	O
,	O
depletes	O
intracellular	O
Ca2+	O
stores	O
and	O
induces	O
a	O
sustained	O
Ca2+	O
influx	O
without	O
altering	O
phosphatidyl	O
inositol	O
levels	O
.	O

TG	O
plus	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
but	O
not	O
TG	O
alone	O
induced	B-Positive_regulation
IL	O
-	O
2	O
in	O
Jurkat	O
T	O
cells	O
,	O
suggesting	O
that	O
TG	O
had	O
no	O
effect	O
on	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
.	O

However	O
,	O
TG	O
induced	O
increases	B-Positive_regulation
in	O
IL	O
-	O
2R	O
alpha	O
protein	O
as	O
well	O
as	O
IL	O
-	O
2R	O
alpha	O
mRNA	O
in	O
Jurkat	O
T	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

A	O
similar	O
increase	B-Positive_regulation
in	O
IL	O
-	O
2R	O
alpha	O
by	O
TG	O
was	O
also	O
observed	O
in	O
human	O
peripheral	O
T	O
cells	O
.	O

Further	O
,	O
like	O
PMA	O
,	O
TG	O
markedly	O
induced	O
NF	O
kappa	O
B	O
in	O
Jurkat	O
T	O
cells	O
.	O

However	O
,	O
TG	O
and	O
PMA	O
exhibited	O
a	O
synergistic	B-Regulation
action	I-Regulation
on	O
IL	O
-	O
2R	O
alpha	O
expression	B-Gene_expression
,	O
suggesting	O
that	O
TG	O
and	O
PMA	O
induce	B-Positive_regulation
IL	O
-	O
2R	O
alpha	O
through	O
distinct	O
pathways	O
.	O

PMA	O
-	O
but	O
not	O
TG	O
-	O
induced	B-Positive_regulation
IL	O
-	O
2R	O
alpha	O
is	O
inhibited	B-Negative_regulation
by	O
the	O
PKC	O
inhibitor	O
H7	O
,	O
whereas	O
TG	O
-	O
but	O
not	O
PMA	O
-	O
induced	B-Positive_regulation
IL	O
-	O
2R	O
alpha	O
was	O
inhibited	B-Negative_regulation
by	O
cholera	O
toxin	O
,	O
forskolin	O
and	O
1	O
,	O
9	O
-	O
dideoxy	O
forskolin	O
.	O

In	O
toto	O
,	O
these	O
results	O
suggest	O
that	O
TG	O
induces	B-Positive_regulation
IL	O
-	O
2R	O
alpha	O
in	O
human	O
T	O
cells	O
through	O
a	O
PKC	O
-	O
independent	O
pathway	O
.	O

A	O
functional	O
T	O
-	O
cell	O
receptor	O
signaling	O
pathway	O
is	O
required	B-Positive_regulation
for	O
p95vav	O
activity	O
.	O

Stimulation	O
of	O
the	O
T	O
-	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
induces	O
activation	O
of	O
multiple	O
tyrosine	O
kinases	O
,	O
resulting	O
in	O
phosphorylation	O
of	O
numerous	O
intracellular	O
substrates	O
.	O

One	O
substrate	O
is	O
p95vav	O
,	O
which	O
is	O
expressed	B-Gene_expression
exclusively	O
in	O
hematopoietic	O
and	O
trophoblast	O
cells	O
.	O

It	O
contains	O
a	O
number	O
of	O
structural	O
motifs	O
,	O
including	O
Src	O
homology	O
2	O
,	O
Src	O
homology	O
3	O
,	O
and	O
pleckstrin	O
homology	O
domains	O
and	O
a	O
putative	O
guanine	O
nucleotide	O
exchange	O
domain	O
.	O

The	O
role	O
of	O
p95vav	O
in	O
TCR	O
-	O
mediated	O
signaling	O
processes	O
is	O
unclear	O
.	O

Here	O
,	O
we	O
show	O
that	O
overexpression	B-Positive_regulation
of	O
p95vav	O
alone	O
in	O
Jurkat	O
T	O
cells	O
leads	O
to	O
activation	O
of	O
the	O
nuclear	O
factors	O
,	O
including	O
NFAT	O
,	O
involved	B-Regulation
in	O
interleukin	O
-	O
2	O
expression	B-Gene_expression
.	O

Furthermore	O
,	O
p95vav	O
synergizes	O
with	O
TCR	O
stimulation	O
in	O
inducing	O
NFAT	O
-	O
and	O
interleukin-2	O
-	O
dependent	O
transcription	O
.	O

In	O
contrast	O
,	O
NFAT	O
activation	O
by	O
a	O
G-protein	O
-	O
coupled	O
receptor	O
is	O
not	O
modulated	O
by	O
p95vav	O
overexpression	B-Positive_regulation
,	O
suggesting	O
that	O
the	O
effect	O
is	O
specific	O
to	O
the	O
TCR	O
signaling	O
pathways	O
.	O

Although	O
removal	O
of	O
the	O
first	O
67	O
amino	O
acids	O
of	O
p95vav	O
activates	O
its	O
transforming	O
potential	O
in	O
NIH	O
3T3	O
cells	O
,	O
this	O
region	O
appears	O
to	O
be	O
required	O
for	O
its	O
function	O
in	O
T	O
cells	O
.	O

We	O
further	O
demonstrate	O
that	O
the	O
p95vav	O
-	O
induced	O
NFAT	O
activation	O
is	O
not	O
mimicked	O
by	O
Ras	O
activation	O
,	O
though	O
its	O
function	O
is	O
dependent	O
upon	O
Ras	O
and	O
Raf	O
.	O

Furthermore	O
,	O
the	O
activating	O
function	O
of	O
p95vav	O
is	O
blocked	O
by	O
FK506	O
,	O
suggesting	O
that	O
its	O
activity	O
also	O
depends	O
on	O
calcineurin	O
.	O

To	O
further	O
dissect	O
p95vav	O
involvement	O
in	O
TCR	O
signaling	O
,	O
we	O
analyzed	O
various	O
Jurkat	O
mutants	O
deficient	O
in	O
TCR	O
signaling	O
function	O
or	O
TCR	O
expression	O
and	O
showed	O
that	O
an	O
intact	O
TCR	O
signaling	O
pathway	O
is	O
required	O
for	O
p95vav	O
to	O
function	O
.	O

However	O
,	O
overexpression	B-Positive_regulation
of	O
p95vav	O
does	O
not	O
appear	O
to	O
influence	O
TCR	O
-	O
induced	O
protein	O
tyrosine	O
phosphorylation	O
or	O
increases	O
in	O
cytoplasmic	O
free	O
calcium	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
p95vav	O
plays	O
an	O
important	O
role	O
at	O
an	O
yet	O
unidentified	O
proximal	O
position	O
in	O
the	O
TCR	O
signaling	O
cascade	O
.	O

Activation	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
phosphatase	O
inhibitors	O
involves	O
the	O
phosphorylation	B-Phosphorylation
of	O
I	O
kappa	O
B	O
alpha	O
at	O
phosphatase	O
2A	O
-	O
sensitive	O
sites	O
.	O

Activation	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
various	O
cellular	O
stimuli	O
involves	O
the	O
phosphorylation	B-Phosphorylation
and	O
subsequent	O
degradation	B-Protein_catabolism
of	O
its	O
inhibitor	O
,	O
I	O
kappa	O
B	O
alpha	O
,	O
although	O
the	O
underlying	O
mechanism	O
remains	O
unclear	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
role	O
of	O
serine/threonine	O
phosphatases	O
in	O
the	O
regulation	B-Regulation
of	O
I	O
kappa	O
B	O
alpha	O
phosphorylation	B-Phosphorylation
was	O
investigated	O
.	O

Our	O
studies	O
demonstrate	O
that	O
incubation	O
of	O
human	O
T	O
cells	O
with	O
low	O
concentrations	O
(	O
approximately	O
1	O
-	O
5	O
nM	O
)	O
of	O
calyculin	O
A	O
or	O
okadaic	O
acid	O
,	O
potent	O
inhibitors	O
of	O
protein	O
phosphatase	O
type	O
1	O
(	O
PP	O
-	O
1	O
)	O
and	O
type	O
2A	O
(	O
PP	O
-	O
2A	O
)	O
,	O
induces	B-Positive_regulation
the	O
phosphorylation	B-Phosphorylation
of	O
I	O
kappa	O
B	O
alpha	O
even	O
in	O
the	O
absence	B-Regulation
of	O
any	O
cellular	O
stimulus	O
.	O

This	O
action	O
of	O
the	O
phosphatase	O
inhibitors	O
,	O
which	O
is	O
associated	O
with	O
the	O
activation	B-Positive_regulation
of	O
the	O
RelA.p50	O
NF	O
-	O
kappa	O
B	O
heterodimer	O
,	O
is	O
not	O
affected	B-Regulation
by	O
agents	O
that	O
block	B-Negative_regulation
the	O
induction	B-Positive_regulation
of	O
I	O
kappa	O
B	O
alpha	O
phosphorylation	B-Phosphorylation
by	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
.	O

Furthermore	O
,	O
the	O
phosphorylated	B-Phosphorylation
I	O
kappa	O
B	O
alpha	O
from	O
calyculin	O
A	O
-	O
treated	O
cells	O
,	O
but	O
not	O
that	O
from	O
TNF-alpha	O
-	O
stimulated	O
cells	O
,	O
is	O
sensitive	O
to	O
PP	O
-	O
2A	O
in	O
vitro	O
,	O
suggesting	O
the	O
existence	O
of	O
fundamental	O
differences	O
in	O
the	O
phosphorylation	B-Phosphorylation
of	O
I	O
kappa	O
B	O
alpha	O
induced	B-Positive_regulation
by	O
the	O
two	O
different	O
NF	O
-	O
kappa	O
B	O
inducers	O
.	O

However	O
,	O
induction	B-Positive_regulation
of	O
I	O
kappa	O
B	O
alpha	O
phosphorylation	B-Phosphorylation
by	O
both	O
TNF	O
-	O
alpha	O
and	O
the	O
phosphatase	O
inhibitors	O
is	O
associated	O
with	O
the	O
subsequent	O
degradation	B-Protein_catabolism
of	O
I	O
kappa	O
B	O
alpha	O
.	O

We	O
further	O
demonstrate	O
that	O
TNF-alpha	O
-	O
and	O
calyculin	O
A	O
-	O
induced	B-Positive_regulation
I	O
kappa	O
B	O
alpha	O
degradation	B-Protein_catabolism
exhibits	O
similar	O
but	O
not	O
identical	O
sensitivities	O
to	O
a	O
proteasome	O
inhibitor	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
phosphorylation	B-Phosphorylation
of	O
I	O
kappa	O
B	O
alpha	O
,	O
mediated	B-Positive_regulation
through	O
both	O
the	O
TNF-alpha	O
-	O
inducible	O
and	O
the	O
PP-2A	O
-	O
opposing	O
kinases	O
,	O
may	O
serve	B-Regulation
to	I-Regulation
target	I-Regulation
I	O
kappa	O
B	O
alpha	O
for	O
proteasome	O
-	O
mediated	B-Positive_regulation
degradation	B-Protein_catabolism
.	O

Functional	O
roles	O
of	O
the	O
transcription	O
factor	O
Oct	O
-	O
2A	O
and	O
the	O
high	O
mobility	O
group	O
protein	O
I/Y	O
in	O
HLA	O
-	O
DRA	O
gene	O
expression	O
.	O

The	O
class	O
II	O
major	O
histocompatibility	O
complex	O
gene	O
HLA	O
-	O
DRA	O
is	O
expressed	O
in	O
B	O
cells	O
,	O
activated	O
T	O
lymphocytes	O
,	O
and	O
in	O
antigen	O
-	O
presenting	O
cells	O
.	O

In	O
addition	O
,	O
HLA	O
-	O
DRA	O
gene	O
expression	O
is	O
inducible	O
in	O
a	O
variety	O
of	O
cell	O
types	O
by	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
.	O

Here	O
we	O
show	O
that	O
the	O
lymphoid	O
-	O
specific	O
transcription	O
factor	O
Oct	O
-	O
2A	O
plays	O
a	O
critical	O
role	O
in	O
HLA	O
-	O
DRA	O
gene	O
expression	O
in	O
class	O
II	O
-	O
positive	O
B	O
cell	O
lines	O
,	O
and	O
that	O
the	O
high	O
mobility	O
group	O
protein	O
(	O
HMG	O
)	O
I/Y	O
binds	B-Binding
to	O
multiple	O
sites	O
within	O
the	O
DRA	O
promoter	O
,	O
including	O
the	O
Oct	O
-	O
2A	O
binding	O
site	O
.	O

Coexpression	B-Gene_expression
of	O
HMG	O
I/Y	O
and	O
Oct	O
-	O
2	O
in	O
cell	O
lines	O
lacking	O
Oct	O
-	O
2	O
results	O
in	O
high	O
levels	O
of	O
HLA	O
-	O
DRA	O
gene	O
expression	O
,	O
and	O
in	O
vitro	O
DNA	O
-	O
binding	O
studies	O
reveal	O
that	O
HMG	O
I/Y	O
stimulates	B-Positive_regulation
Oct	O
-	O
2A	O
binding	B-Binding
to	O
the	O
HLA	O
-	O
DRA	O
promoter	O
.	O

Thus	O
,	O
Oct	O
-	O
2A	O
and	O
HMG	O
I/Y	O
may	O
synergize	O
to	O
activate	O
HLA	O
-	O
DRA	O
expression	O
in	O
B	O
cells	O
.	O

By	O
contrast	O
,	O
Oct	O
-	O
2A	O
is	O
not	O
involved	O
in	O
the	O
IFN	O
-	O
gamma	O
induction	O
of	O
the	O
HLA	O
-	O
DRA	O
gene	O
in	O
HeLa	O
cells	O
,	O
but	O
antisense	O
HMG	O
I/Y	O
dramatically	O
decreases	O
the	O
level	O
of	O
induction	O
.	O

We	O
conclude	O
that	O
distinct	O
sets	O
of	O
transcription	O
factors	O
are	O
involved	O
in	O
the	O
two	O
modes	O
of	O
HLA	O
-	O
DRA	O
expression	O
,	O
and	O
that	O
HMG	O
I/Y	O
may	O
be	O
important	O
for	O
B	O
cell	O
-	O
specific	O
expression	O
,	O
and	O
is	O
essential	O
for	O
IFN	O
-	O
gamma	O
induction	O
.	O

Interleukin	O
4	O
activates	O
a	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
Stat	O
)	O
protein	O
which	O
interacts	O
with	O
an	O
interferon	O
-	O
gamma	O
activation	O
site	O
-	O
like	O
sequence	O
upstream	O
of	O
the	O
I	O
epsilon	O
exon	O
in	O
a	O
human	O
B	O
cell	O
line	O
.	O

Evidence	O
for	O
the	O
involvement	O
of	O
Janus	O
kinase	O
3	O
and	O
interleukin	O
-	O
4	O
Stat	O
.	O

Germ	O
line	O
C	O
transcripts	O
can	O
be	O
induced	O
by	O
IL	O
-	O
4	O
in	O
the	O
human	O
B	O
cell	O
line	O
,	O
BL	O
-	O
2	O
.	O

Utilizing	O
a	O
IFN	O
-	O
gamma	O
activation	O
site	O
-	O
like	O
DNA	O
sequence	O
element	O
located	O
upstream	O
of	O
the	O
I	O
epsilon	O
exon	O
,	O
we	O
demonstrated	O
by	O
gel	O
mobility	O
shift	O
assays	O
that	O
IL	O
-	O
4	O
induced	O
a	O
binding	O
activity	O
in	O
the	O
cytosol	O
and	O
nucleus	O
of	O
BL	O
-	O
2	O
cells	O
.	O

This	O
factor	O
was	O
designated	O
IL	O
-	O
4	O
NAF	O
(	O
IL-4	O
-	O
induced	O
nuclear	O
-	O
activating	O
factors	O
)	O
and	O
was	O
identified	O
as	O
a	O
tyrosine	O
phosphoprotein	O
,	O
which	O
translocates	O
from	O
the	O
cytosol	O
to	O
the	O
nucleus	O
upon	O
IL	O
-	O
4	O
treatment	O
.	O

Because	O
these	O
are	O
the	O
characteristics	O
of	O
a	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
Stat	O
)	O
protein	O
,	O
we	O
determined	O
whether	O
antibodies	O
to	O
Stat	O
proteins	O
will	O
interfere	O
with	O
gel	O
mobility	O
shift	O
and	O
found	O
that	O
antibodies	O
to	O
IL	O
-	O
4	O
Stat	O
,	O
also	O
known	O
as	O
Stat6	O
,	O
but	O
not	O
antibodies	O
to	O
other	O
Stat	O
proteins	O
,	O
interfere	O
with	O
the	O
formation	O
of	O
the	O
IL	O
-	O
4	O
NAF	O
complex	O
.	O

Congruous	O
with	O
the	O
involvement	O
of	O
a	O
Stat	O
protein	O
,	O
IL	O
-	O
4	O
induced	B-Positive_regulation
robust	O
Janus	O
kinase	O
3	O
(	O
JAK3	O
)	O
activity	O
in	O
BL	O
-	O
2	O
cells	O
.	O

Cotransfection	B-Positive_regulation
of	O
JAK3	O
with	O
IL	O
-	O
4	O
Stat	O
into	O
COS	O
-	O
7	O
cells	O
produced	O
an	O
intracellular	O
activity	O
which	O
bound	O
the	O
same	O
IFN	O
-	O
gamma	O
activation	O
site	O
-	O
like	O
sequence	O
and	O
comigrated	B-Binding
with	O
IL	O
-	O
4	O
NAF	O
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

These	O
results	O
show	O
that	O
IL	O
-	O
4	O
NAF	O
is	O
IL	O
-	O
4	O
Stat	O
,	O
which	O
is	O
activated	B-Positive_regulation
by	O
JAK3	O
in	B-Positive_regulation
response	I-Positive_regulation
to	I-Positive_regulation
IL	O
-	O
4	O
receptor	O
engagement	O
.	O

An	O
IRF-1	O
-	O
dependent	O
pathway	O
of	O
DNA	O
damage	O
-	O
induced	O
apoptosis	O
in	O
mitogen	O
-	O
activated	O
T	O
lymphocytes	O
.	O

Lymphocytes	O
are	O
particularly	O
susceptible	O
to	O
DNA	O
damage	O
-	O
induced	O
apoptosis	O
,	O
a	O
response	O
which	O
may	O
serve	O
as	O
a	O
form	O
of	O
'altruistic	O
suicide	O
'	O
to	O
counter	O
their	O
intrinsic	O
high	O
potential	O
for	O
mutation	O
and	O
clonal	O
expansion	O
.	O

The	O
tumour	O
suppressor	O
p53	O
has	O
been	O
shown	O
to	O
regulate	O
this	O
type	O
of	O
apoptosis	O
in	O
thymocytes	O
,	O
but	O
an	O
as	O
yet	O
unknown	O
,	O
p53	O
-	O
independent	O
pathway	O
(	O
s	O
)	O
appears	O
to	O
mediate	O
the	O
same	O
event	O
in	O
mitogen	O
-	O
activated	O
mature	O
T	O
lymphocytes	O
.	O

Here	O
we	O
show	O
DNA	O
damage	O
-	O
induced	O
apoptosis	O
in	O
these	O
T	O
lymphocytes	O
is	O
dependent	O
on	O
the	O
antioncogenic	O
transcription	O
factor	O
interferon	O
regulatory	O
factor	O
(	O
IRF	O
)	O
-	O
1	O
.	O

Thus	O
two	O
different	O
anti-onco	O
-	O
genic	O
transcription	O
factors	O
,	O
p53	O
and	O
IRF	O
-	O
1	O
,	O
are	O
required	O
for	O
distinct	O
apoptotic	O
pathways	O
in	O
T	O
lymphocytes	O
.	O

We	O
also	O
show	O
that	O
mitogen	O
induction	B-Positive_regulation
of	O
the	O
interleukin	O
-	O
1	O
beta	O
converting	O
enzyme	O
(	O
ICE	O
)	O
gene	O
,	O
a	O
mammalian	O
homologue	O
of	O
the	O
Caenorhabditis	O
elegans	O
cell	O
death	O
gene	O
ced	O
-	O
3	O
,	O
is	O
IRF-1	O
-	O
dependent	B-Regulation
.	O

Ectopic	O
overexpression	B-Gene_expression
of	O
IRF	O
-	O
1	O
results	B-Positive_regulation
in	O
the	O
activation	B-Positive_regulation
of	O
the	O
endogenous	O
gene	O
for	O
ICE	O
and	O
enhances	O
the	O
sensitivity	O
of	O
cells	O
to	O
radiation	O
-	O
induced	O
apoptosis	O
.	O

Regulation	B-Regulation
of	O
c	O
-	O
jun	O
mRNA	O
expression	B-Transcription
by	O
hydroxyurea	O
in	O
human	O
K562	O
cells	O
during	O
erythroid	O
differentiation	O
[	O
published	O
erratum	O
appears	O
in	O
Biochim	O
Biophys	O
Acta	O
1995	O
Dec	O
27	O
;	O
1264	O
(	O
3	O
)	O
:	O
409	O
]	O

Hydroxyurea	O
(	O
HU	O
)	O
is	O
an	O
antitumor	O
agent	O
which	O
also	O
induces	O
hemoglobinization	O
during	O
erythroid	O
differentiation	O
.	O

In	O
addition	O
,	O
HU	O
stimulates	O
the	O
synthesis	O
of	O
fetal	O
hemoglobin	O
in	O
sickle	O
cell	O
anemia	O
patients	O
.	O

To	O
further	O
understand	O
its	O
mechanism	O
of	O
action	O
,	O
we	O
investigated	O
the	O
effects	B-Regulation
of	O
HU	O
on	O
regulation	B-Regulation
of	O
c	O
-	O
jun	O
expression	B-Gene_expression
prior	O
to	O
the	O
onset	O
of	O
erythroid	O
differentiation	O
of	O
K562	O
cells	O
.	O

HU	O
induced	B-Positive_regulation
a	O
dose	O
-	O
dependent	O
stimulation	B-Positive_regulation
of	O
c	O
-	O
jun	O
synthesis	B-Gene_expression
.	O

The	O
levels	O
of	O
c	O
-	O
jun	O
mRNA	O
was	O
elevated	B-Positive_regulation
4	O
to	O
7.5	O
-	O
fold	O
by	O
HU	O
within	O
2	O
h	O
.	O

This	O
was	O
followed	O
by	O
a	O
gradual	O
decline	B-Negative_regulation
to	O
the	O
basal	O
level	O
by	O
24	O
h	O
.	O

Both	O
nuclear	O
run	O
-	O
on	O
and	O
actinomycin	O
D	O
pulse	O
experiments	O
strongly	O
indicate	O
that	O
HU	O
regulates	B-Regulation
c	O
-	O
jun	O
mRNA	O
expression	B-Transcription
by	O
increasing	B-Positive_regulation
the	O
rate	O
of	O
synthesis	B-Transcription
as	O
well	O
as	O
stabilizing	B-Positive_regulation
the	O
c	O
-	O
jun	O
mRNA	O
.	O

In	O
addition	O
,	O
the	O
level	O
of	O
jun	O
protein	O
was	O
elevated	O
by	O
2	O
to	O
5	O
-	O
fold	O
within	O
4	O
h	O
in	O
HU	O
treated	O
cells	O
.	O

Furthermore	O
,	O
concentrations	O
of	O
HU	O
below	O
250	O
microM	O
slightly	O
increased	O
the	O
5X	O
AP	O
-	O
1/CAT	O
activity	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
HU	O
induces	B-Positive_regulation
both	O
transcriptional	B-Transcription
and	O
post	B-Gene_expression
-	I-Gene_expression
transcription	I-Gene_expression
regulation	B-Regulation
of	O
c	O
-	O
jun	O
during	O
erythroid	O
differentiation	O
.	O

Characterization	O
of	O
5	O
'	O
end	O
of	O
human	O
thromboxane	O
receptor	O
gene	O
.	O

Organizational	O
analysis	O
and	O
mapping	O
of	O
protein	O
kinase	O
C	O
-	O
-	O
responsive	O
elements	O
regulating	B-Regulation
expression	B-Gene_expression
in	O
platelets	O
.	O

Platelet	O
thromboxane	O
receptors	O
are	O
acutely	O
and	O
reversibly	O
upregulated	B-Positive_regulation
after	O
acute	O
myocardial	O
infarction	O
.	O

To	O
determine	O
if	O
platelet	O
thromboxane	O
receptors	O
are	O
under	B-Regulation
transcriptional	I-Regulation
control	I-Regulation
,	O
we	O
isolated	O
and	O
characterized	O
human	O
genomic	O
DNA	O
clones	O
containing	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
thromboxane	O
receptor	O
gene	O
.	O

The	O
exon	O
-	O
intron	O
structure	O
of	O
the	O
5	O
'	O
portion	O
of	O
the	O
thromboxane	O
receptor	O
gene	O
was	O
determined	O
initially	O
by	O
comparing	O
the	O
nucleotide	O
sequence	O
of	O
the	O
5	O
'	O
flanking	O
genomic	O
clone	O
with	O
that	O
of	O
a	O
novel	O
human	O
uterine	O
thromboxane	O
receptor	O
cDNA	O
that	O
extended	O
the	O
mRNA	B-Transcription
141	O
bp	O
further	O
upstream	O
than	O
the	O
previously	O
identified	O
human	O
placental	O
cDNA	O
.	O

A	O
major	O
transcription	O
initiation	O
site	O
was	O
located	O
in	O
three	O
human	O
tissues	O
approximately	O
560	O
bp	O
upstream	O
from	O
the	O
translation	O
initiation	O
codon	O
and	O
380	O
bp	O
upstream	O
from	O
any	O
previously	O
identified	O
transcription	O
initiation	O
site	O
.	O

The	O
thromboxane	O
receptor	O
gene	O
has	O
neither	O
a	O
TATA	O
nor	O
a	O
CAAT	O
consensus	O
site	O
.	O

Promoter	B-Positive_regulation
function	I-Positive_regulation
of	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
thromboxane	O
receptor	O
gene	O
was	O
evaluated	O
by	O
transfection	O
of	O
thromboxane	O
receptor	O
gene	O
promoter/chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
chimera	O
plasmids	O
into	O
platelet	O
-	O
like	O
K562	O
cells	O
.	O

Thromboxane	O
receptor	O
promoter	O
activity	O
,	O
as	O
assessed	O
by	O
CAT	O
expression	B-Gene_expression
,	O
was	O
relatively	O
weak	O
but	O
was	O
significantly	O
enhanced	B-Positive_regulation
by	O
phorbol	O
ester	O
treatment	O
.	O

Functional	O
analysis	O
of	O
5	O
'	O
deletion	O
constructs	O
in	O
transfected	O
K562	O
cells	O
and	O
gel	O
mobility	O
shift	O
localized	O
the	O
major	O
phorbol	O
ester	O
-	O
responsive	O
motifs	O
in	O
the	O
thromboxane	O
receptor	O
gene	O
promoter	O
to	O
a	O
cluster	O
of	O
activator	O
protein	O
-	O
2	O
(	O
AP	O
-	O
2	O
)	O
binding	O
consensus	O
sites	O
located	O
approximately	O
1.8	O
kb	O
5	O
'	O
from	O
the	O
transcription	O
initiation	O
site	O
.	O

These	O
studies	O
are	O
the	O
first	O
to	O
determine	O
the	O
structure	O
and	O
organization	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
thromboxane	O
receptor	O
gene	O
and	O
demonstrate	O
that	O
thromboxane	O
receptor	O
gene	O
expression	B-Gene_expression
can	O
be	O
regulated	B-Regulation
by	O
activation	O
of	O
protein	O
kinase	O
C	O
via	O
induction	O
of	O
an	O
AP-2	O
-	O
like	O
nuclear	O
factor	O
binding	O
to	O
upstream	O
promoter	O
elements	O
.	O

These	O
findings	O
strongly	O
suggest	O
that	O
the	O
mechanism	B-Positive_regulation
for	O
previously	O
described	O
upregulation	B-Positive_regulation
of	O
platelet	O
thromboxane	O
receptors	O
after	O
acute	O
myocardial	O
infarction	O
is	O
increased	B-Positive_regulation
thromboxane	O
receptor	O
gene	O
transcription	B-Transcription
in	O
platelet	O
-	O
progenitor	O
cells	O
.	O

IL	O
-	O
2	O
gene	O
expression	B-Gene_expression
and	O
NF	O
-	O
kappa	O
B	O
activation	B-Positive_regulation
through	O
CD28	O
requires	B-Positive_regulation
reactive	O
oxygen	O
production	O
by	O
5	O
-	O
lipoxygenase	O
.	O

Activation	O
of	O
the	O
CD28	O
surface	O
receptor	O
provides	O
a	O
major	O
costimulatory	O
signal	O
for	O
T	O
cell	O
activation	O
resulting	O
in	O
enhanced	B-Positive_regulation
production	B-Gene_expression
of	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
and	O
cell	O
proliferation	O
.	O

In	O
primary	O
T	O
lymphocytes	O
we	O
show	O
that	O
CD28	O
ligation	O
leads	O
to	O
the	O
rapid	O
intracellular	O
formation	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROIs	O
)	O
which	O
are	O
required	B-Positive_regulation
for	O
CD28	O
-	O
mediated	O
activation	B-Positive_regulation
of	O
the	O
NF	O
-	O
kappa	O
B/CD28	O
-	O
responsive	O
complex	O
and	O
IL	O
-	O
2	O
expression	B-Gene_expression
.	O

Delineation	O
of	O
the	O
CD28	O
signaling	O
cascade	O
was	O
found	O
to	O
involve	O
protein	O
tyrosine	O
kinase	O
activity	O
,	O
followed	O
by	O
the	O
activation	O
of	O
phospholipase	O
A2	O
and	O
5	O
-	O
lipoxygenase	O
.	O

Our	O
data	O
suggest	O
that	O
lipoxygenase	O
metabolites	O
activate	O
ROI	O
formation	O
which	O
then	O
induce	B-Positive_regulation
IL	O
-	O
2	O
expression	B-Gene_expression
via	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

These	O
findings	O
should	O
be	O
useful	O
for	O
therapeutic	O
strategies	O
and	O
the	O
development	O
of	O
immunosuppressants	O
targeting	O
the	O
CD28	O
costimulatory	O
pathway	O
.	O

Infection	O
and	O
replication	O
of	O
Tat	O
-	O
human	O
immunodeficiency	O
viruses	O
:	O
genetic	O
analyses	O
of	O
LTR	O
and	O
tat	O
mutations	O
in	O
primary	O
and	O
long	O
-	O
term	O
human	O
lymphoid	O
cells	O
.	O

Tat	O
is	O
an	O
essential	O
regulatory	O
protein	O
for	O
the	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O

Mutations	O
in	O
the	O
tat	O
gene	O
have	O
been	O
shown	O
to	O
block	O
HIV	O
replication	O
in	O
human	O
T	O
cells	O
.	O

Several	O
studies	O
have	O
established	O
that	O
Tat	O
releases	O
an	O
elongation	O
block	O
to	O
the	O
transcription	O
of	O
HIV	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
;	O
however	O
,	O
it	O
is	O
not	O
known	O
whether	O
this	O
mechanism	O
alone	O
is	O
sufficient	O
to	O
explain	O
the	O
block	O
to	O
HIV	O
replication	O
in	O
human	O
T	O
cells	O
when	O
Tat	O
is	O
absent	B-Negative_regulation
.	O

It	O
is	O
possible	O
that	O
Tat	O
is	O
also	O
needed	O
for	O
other	O
functions	O
during	O
HIV	O
replication	O
.	O

To	O
test	O
these	O
hypotheses	O
,	O
we	O
studied	O
several	O
tat	O
mutants	O
,	O
including	O
two	O
stop	O
codon	O
mutants	O
and	O
one	O
deletion	O
mutant	O
using	O
replication	O
-	O
competent	O
HIV	O
-	O
1	O
constructs	O
carrying	O
wild	O
-	O
type	O
or	O
mutant	O
LTRs	O
with	O
modifications	O
in	O
the	O
NF	O
-	O
kappa	O
B	O
and/or	O
Sp1	O
binding	O
sites	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
Tat	O
-	O
HIV	O
-	O
1	O
with	O
wild	O
-	O
type	O
LTRs	O
can	O
replicate	O
in	O
HeLa	O
cells	O
,	O
and	O
the	O
virus	O
produced	O
from	O
HeLa	O
cells	O
can	O
infect	O
primary	O
peripheral	O
blood	O
lymphocytes	O
and	O
macrophages	O
.	O

It	O
was	O
found	O
that	O
the	O
propagation	O
of	O
the	O
Tat	O
mutants	O
containing	O
wild	O
-	O
type	O
LTRs	O
was	O
less	O
efficient	O
than	O
that	O
of	O
the	O
LTR	O
-	O
modified	O
Tat	O
mutants	O
.	O

Large	O
amounts	O
of	O
viral	O
RNA	O
and	O
particles	O
were	O
synthesized	O
in	O
infections	O
established	O
using	O
the	O
tat	O
mutants	O
that	O
contain	O
modified	O
LTRs	O
.	O

However	O
,	O
this	O
efficient	O
propagation	O
of	O
the	O
LTR	O
-	O
modified	O
tat	O
mutants	O
was	O
restricted	O
to	O
some	O
lymphoid	O
cell	O
lines	O
that	O
have	O
been	O
transformed	O
with	O
other	O
viruses	O
.	O

Thus	O
,	O
despite	O
its	O
essential	O
role	O
for	O
releasing	O
an	O
elongation	O
block	O
,	O
Tat	O
is	O
not	O
otherwise	O
absolutely	O
required	O
for	O
synthesis	O
of	O
full	O
-	O
length	O
HIV	O
transcripts	O
and	O
assembly	O
of	O
virus	O
particles	O
.	O

Direct	O
sequencing	O
of	O
the	O
viral	O
genomes	O
and	O
reinfection	O
kinetics	O
showed	O
no	O
evidence	O
of	O
wild	O
-	O
type	O
reversion	O
even	O
after	O
prolonged	O
infection	O
with	O
the	O
Tat	O
-	O
virus	O
.	O

The	O
implications	O
for	O
in	O
vivo	O
HIV	O
-	O
1	O
replication	O
and	O
potential	O
application	O
of	O
this	O
system	O
to	O
the	O
study	O
of	O
alternative	O
Tat	O
function	O
are	O
discussed	O
.	O

Activation	B-Positive_regulation
and	O
expression	B-Gene_expression
of	O
the	O
nuclear	O
factors	O
of	O
activated	O
T	O
cells	O
,	O
NFATp	O
and	O
NFATc	O
,	O
in	O
human	O
natural	O
killer	O
cells	O
:	O
regulation	B-Regulation
upon	O
CD16	O
ligand	O
binding	O
.	O

The	O
putative	O
factors	O
that	O
couple	O
the	O
signal	O
transduction	O
from	O
surface	O
receptors	O
to	O
the	O
activation	O
of	O
cytokine	O
synthesis	O
in	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
have	O
not	O
been	O
elucidated	O
.	O

We	O
report	O
here	O
that	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFATp	O
)	O
,	O
a	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
-	O
sensitive	B-Regulation
factor	O
that	O
regulates	O
the	O
transcription	O
of	O
several	O
cytokines	O
,	O
mediates	O
CD16	O
-	O
induced	O
activation	O
of	O
cytokine	O
genes	O
in	O
human	O
NK	O
cells	O
.	O

CD16	O
(	O
Fc	O
gamma	O
RIIIA	O
)	O
-	O
induced	O
expression	O
of	O
cytokine	O
mRNA	O
in	O
NK	O
cells	O
occurs	O
via	O
a	O
CsA	O
-	O
sensitive	O
and	O
Ca	O
(	O
2+	O
)	O
-	O
dependent	O
mechanism	O
.	O

Stimulation	O
of	O
NK	O
cells	O
with	O
CD16	O
ligands	O
induces	O
NFAT	O
-	O
like	O
DNA	O
binding	O
activity	O
in	O
the	O
nuclear	O
extracts	O
from	O
these	O
cells	O
,	O
as	O
detected	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

This	O
occurs	O
with	O
fast	O
kinetics	O
after	O
stimulation	O
,	O
via	O
a	O
CsA	O
-	O
sensitive	O
and	O
Ca	O
(	O
2+	O
)	O
-	O
dependent	O
mechanism	O
that	O
does	O
not	O
require	O
de	O
novo	O
protein	O
synthesis	O
.	O

NK	O
cell	O
NFAT	O
is	O
present	O
in	O
the	O
cytosol	O
of	O
nonstimulated	O
cells	O
,	O
migrates	O
to	O
the	O
nucleus	O
upon	O
stimulation	O
,	O
and	O
can	O
associate	O
with	O
AP	O
-	O
1	O
.	O

Two	O
distinct	O
molecules	O
,	O
NFATp	O
and	O
NFATc	O
,	O
have	O
been	O
reported	O
to	O
mediate	O
NFAT	O
activity	O
.	O

The	O
results	O
of	O
supershift	O
assays	O
using	O
NFATp	O
-	O
and	O
NFATc	O
-	O
specific	O
antibodies	O
indicate	O
that	O
NK	O
cell	O
activation	O
early	O
after	O
CD16	O
ligand	O
binding	O
involves	O
primarily	O
,	O
if	O
not	O
exclusively	O
,	O
NFATp	O
,	O
and	O
Western	O
blot	O
analysis	O
shows	O
that	O
this	O
has	O
the	O
same	O
electrophoretic	O
mobility	O
(	O
approximately	O
120	O
kD	O
)	O
as	O
that	O
of	O
T	O
lymphocytes	O
.	O

NK	O
cells	O
do	O
not	O
express	B-Gene_expression
NFATc	O
constitutively	O
,	O
but	O
NFATc	O
mRNA	O
accumulation	B-Positive_regulation
is	O
induced	B-Positive_regulation
in	O
these	O
cells	O
within	O
2	O
h	O
of	O
stimulation	O
with	O
CD16	O
ligands	O
.	O

However	O
,	O
supershift	O
assays	O
using	O
the	O
available	O
mAb	O
recognizing	O
the	O
T	O
cell	O
NFATc	O
revealed	O
no	O
detectable	B-Gene_expression
NFATc	O
protein	O
in	O
nuclear	O
and	O
cytoplasmic	O
extracts	O
from	O
CD16	O
-	O
or	O
phorbol	O
ester	O
-	O
stimulated	O
cells	O
at	O
any	O
time	O
tested	O
,	O
up	O
to	O
4	O
h	O
.	O

These	O
results	O
provide	O
the	O
first	O
direct	O
evidence	O
that	O
both	O
CsA	O
-	O
sensitive	B-Regulation
transcription	O
factors	O
,	O
NFATp	O
and	O
NFATc	O
,	O
are	O
expressed	B-Gene_expression
in	O
human	O
NK	O
cells	O
,	O
and	O
that	O
their	O
activation	B-Positive_regulation
and/or	O
expression	B-Gene_expression
can	O
be	O
regulated	B-Regulation
in	O
primary	O
cells	O
by	O
a	O
single	O
stimulus	O
,	O
that	O
,	O
in	O
the	O
case	O
of	O
CD16	O
in	O
NK	O
cells	O
,	O
results	B-Positive_regulation
in	O
early	O
activation	B-Positive_regulation
of	O
NFATp	O
and	O
subsequently	O
induced	B-Positive_regulation
expression	B-Transcription
of	O
NFATc	O
mRNA	O
.	O

Constitutive	O
activation	O
of	O
different	O
Jak	O
tyrosine	O
kinases	O
in	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
tax	O
protein	O
or	O
virus	O
-	O
transformed	O
cells	O
.	O

HTLV	O
-	O
1	O
infection	O
causes	O
an	O
adult	O
T	O
cell	O
leukemia	O
in	O
humans	O
.	O

The	O
viral	O
encoded	O
protein	O
tax	O
,	O
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
oncogenesis	O
.	O

Our	O
previous	O
data	O
obtained	O
from	O
a	O
tax	O
transgenic	O
mouse	O
model	O
revealed	O
that	O
tax	O
transforms	O
mouse	O
fibroblasts	O
but	O
not	O
thymocytes	O
,	O
despite	O
comparable	O
levels	O
of	O
tax	O
expression	B-Gene_expression
in	O
both	O
tissues	O
.	O

Constitutive	O
tyrosine	O
phosphorylation	O
of	O
a	O
130	O
-	O
kD	O
protein	O
(	O
s	O
)	O
was	O
observed	O
in	O
the	O
tax	O
transformed	O
fibroblast	O
B	O
line	O
and	O
in	O
HTLV	O
-	O
1	O
transformed	O
human	O
lymphoid	O
lines	O
,	O
but	O
not	O
in	O
thymocytes	O
from	O
Thy	O
-	O
tax	O
transgenic	O
mice	O
.	O

Phosphotyrosine	O
immunoprecipitation	O
followed	O
by	O
Western	O
blot	O
analysis	O
with	O
a	O
set	O
of	O
Jak	O
kinase	O
specific	O
antibodies	O
,	O
identified	O
p130	O
as	O
Jak2	O
in	O
the	O
tax	O
transformed	O
mouse	O
fibroblastic	O
cell	O
line	O
and	O
Jak3	O
in	O
HTLV	O
-	O
1	O
transformed	O
human	O
T	O
cell	O
lines	O
.	O

Phosphorylation	B-Phosphorylation
of	O
Jak2	O
in	O
tax	O
transformed	O
cells	O
resulted	B-Positive_regulation
from	O
high	B-Positive_regulation
expression	B-Gene_expression
of	O
IL	O
-	O
6	O
.	O

Tyrosine	O
phosphorylation	B-Phosphorylation
of	O
this	O
protein	O
could	O
also	O
be	O
induced	B-Positive_regulation
in	O
Balb/c3T3	O
cells	O
using	O
a	O
supernatant	O
from	O
the	O
B	O
line	O
,	O
which	O
was	O
associated	O
with	O
induction	O
of	O
cell	O
proliferation	O
.	O

Both	O
phosphorylation	O
and	O
proliferation	O
were	O
inhibited	B-Negative_regulation
by	O
IL	O
-	O
6	O
neutralizing	O
antibodies	O
.	O

Constitutive	O
phosphorylation	O
of	O
Jak	O
kinases	O
may	O
facilitate	O
tumor	O
growth	O
in	O
both	O
HTLV	O
-	O
1	O
infected	O
human	O
T	O
cells	O
and	O
the	O
transgenic	O
mouse	O
model	O
.	O

Regulation	B-Regulation
of	O
transcription	B-Transcription
of	O
the	O
human	O
erythropoietin	O
receptor	O
gene	O
by	O
proteins	O
binding	O
to	O
GATA	O
-	O
1	O
and	O
Sp1	O
motifs	O
.	O

Erythropoietin	O
(	O
Epo	O
)	O
,	O
the	O
primary	O
regulator	O
of	O
the	O
production	O
of	O
erythroid	O
cells	O
,	O
acts	O
by	O
binding	B-Binding
to	O
a	O
cell	O
surface	O
receptor	O
(	O
EpoR	O
)	O
on	O
erythroid	O
progenitors	O
.	O

We	O
used	O
deletion	O
analysis	O
and	O
transfection	O
assays	O
with	O
reporter	O
gene	O
constructs	O
to	O
examine	O
the	O
transcription	O
control	O
elements	O
in	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
human	O
EpoR	O
gene	O
.	O

In	O
erythroid	O
cells	O
most	O
of	O
the	O
transcription	O
activity	O
was	O
contained	O
in	O
a	O
150	O
bp	O
promoter	O
fragment	O
with	O
binding	O
sites	O
for	O
transcription	O
factors	O
AP2	O
,	O
Sp1	O
and	O
the	O
erythroid	O
-	O
specific	O
GATA	O
-	O
1	O
.	O

The	O
150	O
bp	O
hEpoR	O
promoter	O
exhibited	O
high	O
and	O
low	O
activity	O
in	O
erythroid	O
OCIM1	O
and	O
K562	O
cells	O
,	O
respectively	O
,	O
reflecting	O
the	O
high	O
and	O
low	O
levels	O
of	O
constitutive	O
hEpoR	O
expression	B-Gene_expression
.	O

The	O
GATA	O
-	O
1	O
and	O
Sp1	O
binding	O
sites	O
in	O
this	O
promoter	O
lacking	O
a	O
TATA	O
sequence	O
were	O
necessary	O
for	O
a	O
high	O
level	O
of	O
transcription	O
activation	O
.	O

Protein	O
-	O
DNA	O
binding	O
studies	O
suggested	O
that	O
Sp1	O
and	O
two	O
other	O
CCGCCC	O
binding	O
proteins	O
from	O
erythroid	O
and	O
non	O
-	O
erythroid	O
cells	O
could	O
bind	B-Binding
to	O
the	O
Sp1	O
binding	O
motif	O
.	O

By	O
increasing	B-Positive_regulation
GATA	O
-	O
1	O
levels	O
via	O
co	O
-	O
transfection	O
,	O
we	O
were	O
able	O
to	O
transactivate	B-Positive_regulation
the	O
hEpoR	O
promoter	O
in	O
K562	O
cells	O
and	O
non	O
-	O
erythroid	O
cells	O
,	O
but	O
not	O
in	O
the	O
highly	O
active	O
OCIM1	O
cells	O
,	O
although	O
GATA	O
-	O
1	O
mRNA	O
levels	O
were	O
comparable	O
in	O
OCIM1	O
and	O
K562	O
.	O

Interestingly	O
,	O
when	O
we	O
mutated	O
the	O
Sp1	O
site	O
,	O
resulting	B-Positive_regulation
in	O
a	O
marked	O
decrease	B-Negative_regulation
in	O
hEpoR	O
promoter	O
activity	O
,	O
we	O
could	O
restore	B-Positive_regulation
transactivation	O
by	O
increasing	O
GATA	O
-	O
1	O
levels	O
in	O
OCIM1	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
while	O
GATA	O
-	O
1	O
can	O
transactivate	B-Positive_regulation
the	O
EpoR	O
promoter	O
,	O
the	O
level	O
of	O
hEpoR	O
gene	O
expression	B-Gene_expression
does	O
not	O
depend	B-Positive_regulation
on	O
GATA	O
-	O
1	O
alone	O
.	O

Rather	O
,	O
hEpoR	O
transcription	B-Transcription
activity	O
depends	B-Positive_regulation
on	O
coordination	O
between	O
Sp1	O
and	O
GATA	O
-	O
1	O
with	O
other	O
cell	O
-	O
specific	O
factors	O
,	O
including	O
possibly	O
other	O
Sp1	O
-	O
like	O
binding	O
proteins	O
,	O
to	O
provide	B-Positive_regulation
high	I-Positive_regulation
level	I-Positive_regulation
,	O
tissue	O
-	O
specific	O
expression	O
.	O

TCL1	O
oncogene	O
activation	B-Positive_regulation
in	O
preleukemic	O
T	O
cells	O
from	O
a	O
case	O
of	O
ataxia	O
-	O
telangiectasia	O
.	O

The	O
TCL1	O
oncogene	O
on	O
human	O
chromosome	O
14q32.1	O
is	O
involved	O
in	O
chromosome	O
translocations	O
[	O
t	O
(	O
14	O
;	O
14	O
)	O
(	O
q11	O
;	O
q32.1	O
)	O
and	O
t	O
(	O
7	O
;	O
14	O
)	O
(	O
q35	O
;	O
q32.1	O
)	O
]	O
and	O
inversions	O
[	O
inv14	O
(	O
q11	O
;	O
q32.1	O
)	O
]	O
with	O
TCR	O
alpha/beta	O
loci	O
in	O
T	O
-	O
cell	O
leukemias	O
,	O
such	O
as	O
T	O
-	O
prolymphocytic	O
(	O
T	O
-	O
PLL	O
)	O
.	O

It	O
is	O
also	O
involved	O
in	O
T	O
-	O
acute	O
and	O
-	O
chronic	O
leukemias	O
arising	O
in	O
cases	O
of	O
ataxia	O
-	O
telangiectasia	O
(	O
AT	O
)	O
,	O
an	O
immunodeficiency	O
syndrome	O
.	O

Similar	O
chromosomal	O
rearrangements	O
occur	O
also	O
in	O
the	O
clonally	O
expanded	O
T	O
cells	O
in	O
AT	O
patients	O
before	O
the	O
appearance	O
of	O
the	O
overt	O
leukemia	O
.	O

We	O
have	O
analyzed	O
the	O
expression	B-Gene_expression
of	O
TCL1	O
mRNA	O
and	O
protein	O
in	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBLs	O
)	O
from	O
four	O
AT	O
cases	O
and	O
from	O
healthy	O
controls	O
.	O

We	O
found	O
that	O
the	O
TCL1	O
gene	O
was	O
overexpressed	B-Positive_regulation
in	O
the	O
PBLs	O
of	O
an	O
AT	O
patient	O
with	O
a	O
large	O
clonal	O
T	O
-	O
cell	O
population	O
exhibiting	O
the	O
t	O
(	O
14	O
;	O
14	O
)	O
translocation	O
but	O
not	O
in	O
the	O
lymphocytes	O
of	O
the	O
other	O
cases	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
of	O
the	O
TCL1	O
genomic	O
locus	O
to	O
lymphocyte	O
metaphases	O
from	O
the	O
AT	O
patient	O
with	O
the	O
T	O
-	O
cell	O
clonal	O
expansion	O
showed	O
that	O
the	O
breakpoint	O
of	O
the	O
t	O
(	O
14	O
;	O
14	O
)	O
translocation	O
lies	O
within	O
the	O
TCL1	O
locus	O
and	O
is	O
accompanied	O
by	O
an	O
inverted	O
duplication	O
of	O
the	O
distal	O
part	O
of	O
chromosome	O
14	O
.	O

These	O
data	O
indicate	O
that	O
TCL1	O
is	O
activated	B-Positive_regulation
in	O
preleukemic	O
clonal	O
cells	O
as	B-Positive_regulation
a	I-Positive_regulation
consequence	I-Positive_regulation
of	I-Positive_regulation
chromosome	O
translocation	O
involving	O
sequences	O
from	O
the	O
TCR	O
locus	O
at	O
14q11	O
.	O

Deregulation	B-Negative_regulation
of	O
TCL1	O
is	O
the	O
first	O
event	O
in	O
the	O
initiation	O
of	O
malignancy	O
in	O
these	O
types	O
of	O
leukemias	O
and	O
represents	O
a	O
potential	O
tool	O
for	O
clinical	O
evaluation	O
.	O

Interleukin	O
-	O
2	O
promoter	O
activity	O
in	O
Epstein	O
-	O
Barr	O
virus	O
-	O
transformed	O
B	O
lymphocytes	O
is	O
controlled	O
by	O
nuclear	O
factor	O
-	O
chi	O
B	O
.	O

The	O
regulation	B-Regulation
of	O
interleukin	O
(	O
IL	O
)	O
-	O
2	O
gene	O
expression	B-Gene_expression
has	O
been	O
investigated	O
mainly	O
in	O
T	O
lymphocytes	O
,	O
the	O
predominant	O
producers	B-Gene_expression
of	O
IL	O
-	O
2	O
.	O

However	O
,	O
B	O
cells	O
can	O
also	O
synthesize	B-Gene_expression
IL	O
-	O
2	O
.	O

In	O
the	O
present	O
study	O
we	O
analyzed	O
the	O
control	O
of	O
IL	O
-	O
2	O
promoter	O
activity	O
in	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
-	O
transformed	O
B	O
cell	O
clones	O
which	O
are	O
capable	O
of	O
secreting	B-Localization
IL	O
-	O
2	O
at	O
a	O
low	O
level	O
after	B-Positive_regulation
stimulation	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
and	O
the	O
Ca2+	O
ionophore	O
ionomycin	O
.	O

Transient	O
transfections	O
using	O
reporter	O
constructs	O
with	O
multiples	O
of	O
transcription	O
factor	O
binding	O
sites	O
from	O
the	O
IL	O
-	O
2	O
promoter	O
[	O
distal	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
AT	O
,	O
proximal	O
NF	O
-	O
AT	O
,	O
AP	O
-	O
1/Octamer	O
(	O
UPS	O
)	O
or	O
NF	O
-	O
chi	O
B	O
(	O
TCEd	O
)	O
sites	O
]	O
were	O
performed	O
.	O

In	O
EBV	O
-	O
transformed	O
B	O
clones	O
,	O
the	O
chi	O
B	O
site	O
exerted	O
the	O
strongest	O
inducible	O
activity	O
;	O
the	O
NF	O
-	O
AT	O
binding	O
sites	O
showed	O
either	O
no	O
or	O
only	O
weak	O
activity	O
compared	O
to	O
Jurkat	O
T	O
cells	O
.	O

An	O
IL	O
-	O
2	O
promoter	O
bearing	O
a	O
defective	O
NF	O
-	O
chi	O
B	O
site	O
was	O
completely	O
inactive	O
in	O
EBV	O
-	O
transformed	O
B	O
cells	O
,	O
while	O
it	O
still	O
had	O
activity	O
in	O
Jurkat	O
T	O
cells	O
.	O

In	O
seven	O
EBV	O
-	O
B	O
cell	O
clones	O
or	O
lines	O
differing	O
in	O
their	O
capacity	O
to	O
secrete	B-Localization
IL	O
-	O
2	O
,	O
the	O
activity	B-Positive_regulation
of	O
the	O
IL	O
-	O
2	O
promoter	O
correlated	O
well	O
with	O
the	O
status	O
of	O
IL	O
-	O
2	O
secretion	B-Localization
.	O

Similarly	O
,	O
a	O
human	O
immunodeficiency	O
virus	O
promoter	O
,	O
whose	O
activity	O
is	O
controlled	O
through	O
chi	O
B	O
factors	O
,	O
was	O
found	O
to	O
be	O
active	O
in	O
the	O
IL	O
-	O
2	O
producing	B-Gene_expression
EBV	O
-	O
B	O
cells	O
,	O
but	O
inactive	O
in	O
the	O
non-IL-2	O
-	O
producing	B-Gene_expression
cells	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
using	O
protein	O
extracts	O
from	O
EBV	O
-	O
B	O
cells	O
and	O
the	O
IL	O
-	O
2	O
NF	O
-	O
chi	O
B	O
probe	O
revealed	O
the	O
constitutive	O
generation	B-Positive_regulation
of	O
chi	O
B	O
complexes	O
in	O
IL-2	O
-	O
secreting	B-Localization
cells	O
consisting	O
mainly	O
of	O
heterodimeric	O
p50/p65	O
complexes	O
.	O

A	O
weaker	O
chi	O
B	O
complex	O
formation	O
and	O
faster	O
-	O
migrating	O
complexes	O
were	O
detected	O
in	O
non-IL-2	O
-	O
secreting	B-Localization
cells	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
IL	O
-	O
2	O
NF	O
-	O
chi	O
B	O
site	O
is	O
indispensable	B-Positive_regulation
for	I-Positive_regulation
the	I-Positive_regulation
activity	I-Positive_regulation
of	O
the	O
IL	O
-	O
2	O
promoter	O
in	O
EBV	O
-	O
transformed	O
B	O
cells	O
,	O
whereas	O
other	O
transcription	O
factors	O
appear	O
to	O
be	O
less	B-Regulation
important	I-Regulation
for	O
IL	O
-	O
2	O
expression	B-Gene_expression
in	O
these	O
cells	O
.	O

Ubiquitin	O
-	O
mediated	O
processing	O
of	O
NF	O
-	O
kappa	O
B	O
transcriptional	O
activator	O
precursor	O
p105	O
.	O

Reconstitution	O
of	O
a	O
cell	O
-	O
free	O
system	O
and	O
identification	O
of	O
the	O
ubiquitin	O
-	O
carrier	O
protein	O
,	O
E2	O
,	O
and	O
a	O
novel	O
ubiquitin	O
-	O
protein	O
ligase	O
,	O
E3	O
,	O
involved	O
in	O
conjugation	O
.	O

In	O
most	O
cases	O
,	O
the	O
transcriptional	O
factor	O
NF	O
-	O
kappa	O
B	O
is	O
a	O
heterodimer	B-Binding
consisting	O
of	O
two	O
subunits	O
,	O
p50	O
and	O
p65	O
,	O
which	O
are	O
encoded	O
by	O
two	O
distinct	O
genes	O
of	O
the	O
Rel	O
family	O
.	O

p50	O
is	O
translated	O
as	O
a	O
precursor	O
of	O
105	O
kDa	O
.	O

The	O
C	O
-	O
terminal	O
domain	O
of	O
the	O
precursor	O
is	O
rapidly	O
degraded	B-Protein_catabolism
,	O
forming	B-Positive_regulation
the	O
mature	O
p50	O
subunit	O
consisted	O
of	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
molecule	O
.	O

The	O
mechanism	O
of	O
generation	B-Gene_expression
of	O
p50	O
is	O
not	O
known	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
ubiquitin	O
-	O
proteasome	O
system	O
is	O
involved	O
in	O
the	O
process	O
;	O
however	O
,	O
the	O
specific	O
enzymes	O
involved	O
and	O
the	O
mechanism	O
of	O
limited	O
proteolysis	O
,	O
in	O
which	O
half	O
of	O
the	O
molecule	O
is	O
spared	O
,	O
have	O
been	O
obscure	O
.	O

Palombella	O
and	O
colleagues	O
(	O
Palombella	O
,	O
V.J.	O
,	O
Rando	O
,	O
O.J.	O
,	O
Goldberg	O
,	O
A.L.	O
,	O
and	O
Maniatis	O
,	O
T.	O
(	O
1994	O
)	O
Cell	O
78	O
,	O
773	O
-	O
785	O
)	O
have	O
shown	O
that	O
ubiquitin	O
is	O
required	O
for	O
the	O
processing	O
in	O
a	O
cell	O
-	O
free	O
system	O
of	O
a	O
truncated	O
,	O
artificially	O
constructed	O
,	O
60	O
-	O
kDa	O
precursor	O
.	O

They	O
have	O
also	O
shown	O
that	O
proteasome	O
inhibitors	O
block	O
the	O
processing	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
reconstitution	O
of	O
a	O
cell	O
-	O
free	O
processing	O
system	O
and	O
demonstrate	O
directly	O
that	O
:	O
(	O
a	O
)	O
the	O
ubiquitin	O
-	O
proteasome	O
system	O
is	O
involved	O
in	O
processing	O
of	O
the	O
intact	O
p105	O
precursor	O
,	O
(	O
b	O
)	O
conjugation	O
of	O
ubiquitin	O
to	O
the	O
precursor	O
is	O
an	O
essential	O
intermediate	O
step	O
in	O
the	O
processing	O
,	O
(	O
c	O
)	O
the	O
recently	O
discovered	O
novel	O
species	O
of	O
the	O
ubiquitin	O
-	O
carrier	O
protein	O
,	O
E2	O
-	O
F1	O
,	O
that	O
is	O
involved	O
in	O
the	O
conjugation	B-Binding
and	O
degradation	B-Protein_catabolism
of	O
p53	O
,	O
is	O
also	O
required	O
for	O
the	O
limited	O
processing	O
of	O
the	O
p105	O
precursor	O
,	O
and	O
(	O
d	O
)	O
a	O
novel	O
,	O
approximately	O
320	O
-	O
kDa	O
species	O
of	O
ubiquitin	O
-	O
protein	O
ligase	O
,	O
is	O
involved	O
in	O
the	O
process	O
.	O

This	O
novel	O
enzyme	O
is	O
distinct	O
from	O
E6	O
-	O
AP	O
,	O
the	O
p53	O
-	O
conjugating	O
ligase	O
,	O
and	O
from	O
E3	O
alpha	O
,	O
the	O
"	O
N	O
-	O
end	O
rule	O
"	O
ligase	O
.	O

The	O
hematopoietic	O
transcription	O
factor	O
PU.1	O
is	O
downregulated	B-Negative_regulation
in	O
human	O
multiple	O
myeloma	O
cell	O
lines	O
.	O

PU.1	O
is	O
a	O
hematopoietic	O
transcription	O
factor	O
belonging	O
to	O
the	O
Ets	O
-	O
family	O
.	O

It	O
is	O
identical	O
to	O
the	O
Spi	O
-	O
1	O
oncogene	O
,	O
which	O
is	O
implicated	O
in	O
spleen	O
focus	O
-	O
forming	O
virus	O
-	O
induced	O
murine	O
erythroleukemias	O
.	O

PU.1	O
seems	O
to	O
be	O
required	O
for	O
early	O
development	O
of	O
multiple	O
hematopoietic	O
lineages	O
,	O
but	O
its	O
expression	B-Gene_expression
in	O
mature	O
cells	O
is	O
preferentially	O
observed	O
in	O
cells	O
of	O
the	O
B-cell	O
-	O
and	O
monocyte/macrophage	O
-	O
differentiation	O
lineage	O
.	O

It	O
binds	B-Binding
the	O
so	O
-	O
called	O
Pu	O
box	O
,	O
an	O
important	O
tissue	O
-	O
specific	O
regulatory	O
DNA	O
element	O
present	O
in	O
a	O
number	O
of	O
genes	O
expressed	O
in	O
these	O
cell	O
lineages	O
.	O

We	O
have	O
analyzed	O
the	O
expression	B-Gene_expression
and	O
activity	B-Positive_regulation
of	O
PU.1	O
during	O
human	O
B	O
-	O
cell	O
development	O
using	O
a	O
panel	O
of	O
B	O
-	O
cell	O
lines	O
representing	O
different	O
stages	O
of	O
maturation	O
,	O
from	O
early	O
precursors	O
to	O
differentiated	O
plasma	O
cells	O
.	O

PU.1	O
mRNA	O
expression	B-Transcription
and	O
PU.1	O
DNA	O
binding	B-Binding
activity	I-Binding
,	O
as	O
measured	O
by	O
Northern	O
blot	O
analysis	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
respectively	O
,	O
were	O
evident	O
in	O
cell	O
lines	O
representing	O
pro	O
-	O
B	O
,	O
pre	O
-	O
B	O
,	O
and	O
mature	O
B	O
cells	O
.	O

We	O
could	O
also	O
show	O
Pu	O
box	O
-	O
dependent	O
transactivation	O
of	O
a	O
reporter	O
gene	O
in	O
transient	O
transfections	O
in	O
these	O
cell	O
lines	O
.	O

In	O
contrast	O
,	O
in	O
a	O
number	O
of	O
multiple	O
myeloma	O
cell	O
lines	O
,	O
representing	O
differentiated	O
,	O
plasma	O
cell	O
-	O
like	O
B	O
cells	O
,	O
PU.1	O
DNA	O
binding	O
activity	O
,	O
mRNA	O
expression	O
,	O
and	O
Pu	O
box	O
-	O
dependent	O
transactivation	O
were	O
absent	B-Negative_regulation
or	I-Negative_regulation
detectable	I-Negative_regulation
at	I-Negative_regulation
a	I-Negative_regulation
very	I-Negative_regulation
low	I-Negative_regulation
level	I-Negative_regulation
.	O

In	O
lymphoblastoid	O
cell	O
lines	O
,	O
which	O
exemplify	O
an	O
intermediate	O
stage	O
of	O
B	O
-	O
cell	O
differentiation	O
,	O
a	O
reduced	B-Negative_regulation
expression	B-Gene_expression
and	O
activity	B-Positive_regulation
were	O
observed	O
.	O

The	O
findings	O
in	O
the	O
human	O
multiple	O
myeloma	O
cell	O
lines	O
represent	O
the	O
first	O
examples	O
of	O
B	O
cells	O
with	O
downregulated	B-Negative_regulation
PU.1	O
expression	B-Gene_expression
and	O
apparently	O
contradict	O
observations	O
in	O
the	O
murine	O
system	O
in	O
which	O
PU.1	O
is	O
expressed	B-Gene_expression
and	O
active	B-Positive_regulation
in	O
plasmacytoma	O
cell	O
lines	O
.	O

At	O
present	O
,	O
it	O
is	O
unclear	O
whether	O
the	O
lack	B-Negative_regulation
of	O
PU.1	O
expression	B-Gene_expression
and	O
activity	B-Positive_regulation
in	O
human	O
multiple	O
myeloma	O
cell	O
lines	O
represents	O
a	O
malignancy	O
-	O
associated	B-Regulation
defect	O
in	O
these	O
cells	O
or	O
exemplifies	O
a	O
normal	O
developmental	B-Regulation
regulation	I-Regulation
in	O
terminally	O
differentiated	O
B	O
cells	O
.	O

A	O
regulatory	O
element	O
in	O
the	O
human	O
interleukin	O
2	O
gene	O
promoter	O
is	O
a	O
binding	B-Binding
site	O
for	O
the	O
zinc	O
finger	O
proteins	O
Sp1	O
and	O
EGR	O
-	O
1	O
.	O

Activation	B-Positive_regulation
of	O
the	O
interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
gene	O
after	O
antigen	O
recognition	O
is	O
a	O
critical	O
event	O
for	O
T	O
cell	O
proliferation	O
and	O
effector	O
function	O
.	O

Prior	O
studies	O
have	O
identified	O
several	O
transcription	O
factors	O
that	O
contribute	B-Positive_regulation
to	O
the	O
activity	O
of	O
the	O
IL	O
-	O
2	O
promoter	O
in	O
stimulated	O
T	O
lymphocytes	O
.	O

Here	O
we	O
describe	O
a	O
novel	O
regulatory	O
element	O
within	O
the	O
IL	O
-	O
2	O
promoter	O
located	O
immediately	O
upstream	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
(	O
NFAT	O
)	O
domain	O
.	O

This	O
region	O
(	O
termed	O
the	O
zinc	O
finger	O
protein	O
binding	O
region	O
(	O
ZIP	O
)	O
)	O
serves	O
as	O
binding	B-Binding
site	O
for	O
two	O
differently	O
regulated	O
zinc	O
finger	O
proteins	O
:	O
the	O
constitutively	O
expressed	B-Gene_expression
transcription	O
factor	O
Sp1	O
and	O
the	O
inducible	B-Positive_regulation
early	O
growth	O
response	O
protein	O
EGR	O
-	O
1	O
.	O

In	O
unstimulated	O
cells	O
which	O
do	O
not	O
secrete	B-Localization
IL	O
-	O
2	O
,	O
only	O
Sp1	O
binds	B-Binding
to	O
this	O
region	O
,	O
while	O
in	O
stimulated	B-Positive_regulation
IL	O
-	O
2	O
secreting	B-Localization
cells	O
the	O
inducible	B-Positive_regulation
EGR	O
-	O
1	O
protein	O
recognizes	O
this	O
element	O
.	O

In	O
Jurkat	O
T	O
cells	O
,	O
the	O
ZIP	O
site	O
serves	O
as	O
an	O
activator	B-Positive_regulation
for	O
IL	O
-	O
2	O
gene	O
expression	B-Gene_expression
,	O
and	O
a	O
combination	O
of	O
ZIP	O
and	O
NFAT	O
binding	O
sites	O
is	O
required	B-Positive_regulation
for	O
maximal	O
IL	O
-	O
2	O
promoter	O
activity	O
.	O

These	O
results	O
suggest	O
a	O
critical	O
role	B-Regulation
of	O
the	O
ZIP	O
site	O
for	O
IL	O
-	O
2	O
promoter	O
activity	O
.	O

Functional	O
antagonism	O
between	O
vitamin	O
D3	O
and	O
retinoic	O
acid	O
in	O
the	O
regulation	B-Regulation
of	O
CD14	O
and	O
CD23	O
expression	B-Gene_expression
during	O
monocytic	O
differentiation	O
of	O
U	O
-	O
937	O
cells	O
.	O

1	O
,	O
25	O
alpha	O
-	O
Dihydroxicholecalciferol	O
(	O
VitD3	O
)	O
and	O
retinoic	O
acid	O
(	O
RA	O
)	O
are	O
important	O
regulators	O
of	O
the	O
proliferation	O
and	O
differentiation	O
of	O
several	O
cell	O
types	O
.	O

This	O
paper	O
describes	O
how	O
the	O
expression	B-Gene_expression
of	O
the	O
monocyte	O
-	O
macrophage	O
Ag	O
,	O
CD14	O
,	O
and	O
the	O
low	O
affinity	O
Fc	O
receptor	O
for	O
IgE	O
,	O
CD23	O
,	O
were	O
inversely	O
regulated	B-Regulation
during	O
VitD3	O
-	O
and	O
RA	O
-	O
induced	O
monocytic	O
differentiation	O
of	O
human	O
U	O
-	O
937	O
monoblasts	O
.	O

PMA	O
induced	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
both	O
CD14	O
and	O
CD23	O
mRNA	O
and	O
protein	O
.	O

Exposure	O
to	O
VitD3	O
rapidly	O
induced	B-Positive_regulation
the	O
de	O
novo	O
expression	B-Gene_expression
of	O
CD14	O
mRNA	O
and	O
protein	O
.	O

The	O
addition	O
of	O
cycloheximide	O
completely	O
blocked	B-Negative_regulation
the	O
VitD3	O
induction	B-Positive_regulation
of	O
CD14	O
mRNA	O
expression	B-Transcription
,	O
indicating	O
that	O
the	O
induction	O
was	O
dependent	B-Regulation
on	O
ongoing	O
protein	O
synthesis	O
.	O

While	O
inducing	B-Positive_regulation
CD14	O
expression	B-Gene_expression
,	O
VitD3	O
concomitantly	O
suppressed	B-Negative_regulation
the	O
basal	O
,	O
PMA	O
-	O
,	O
and	O
RA	O
-	O
inducible	B-Positive_regulation
CD23	O
expression	B-Gene_expression
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

In	O
contrast	O
,	O
U	O
-	O
937	O
cells	O
induced	O
by	O
RA	O
strongly	O
increased	B-Positive_regulation
their	O
expression	B-Transcription
of	O
CD23	O
mRNA	O
and	O
protein	O
,	O
whereas	O
they	O
completely	O
lacked	O
detectable	O
CD14	O
cell	O
surface	O
or	O
mRNA	O
expression	B-Gene_expression
.	O

Furthermore	O
,	O
the	O
VitD3	O
-	O
and	O
the	O
PMA	O
-	O
induced	B-Positive_regulation
CD14	O
expression	B-Gene_expression
was	O
inhibited	B-Negative_regulation
as	B-Positive_regulation
a	I-Positive_regulation
temporal	I-Positive_regulation
consequence	I-Positive_regulation
of	I-Positive_regulation
the	O
RA	O
-	O
induced	O
differentiation	O
.	O

The	O
results	O
suggest	O
that	O
there	O
exists	O
a	O
functional	O
antagonism	O
between	O
VitD3	O
and	O
RA	O
that	O
may	O
have	O
important	O
implications	O
for	O
the	O
regulation	O
of	O
certain	O
immune	O
and	O
inflammatory	O
responses	O
through	O
their	O
inverse	O
effects	B-Regulation
on	O
CD14	O
and	O
CD23	O
gene	B-Gene_expression
expression	I-Gene_expression
.	O

Cytokine	O
modulation	O
of	O
HIV	O
expression	O
.	O

Cytokines	O
,	O
the	O
peptide	O
hormones	O
which	O
control	O
the	O
homeostasis	O
of	O
the	O
immune	O
system	O
and	O
also	O
play	O
a	O
fundamental	O
role	O
in	O
inflammatory	O
and	O
immune	O
mediated	O
reactions	O
,	O
have	O
been	O
involved	O
at	O
multiple	O
levels	O
in	O
the	O
pathogenesis	O
of	O
the	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
AIDS	O
)	O
.	O

Infection	O
with	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
has	O
been	O
shown	O
to	O
induce	O
production	O
of	O
several	O
cytokines	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Conversely	O
,	O
several	O
cytokines	O
modulate	O
the	O
levels	O
of	O
HIV	O
expression	O
in	O
infected	O
cells	O
of	O
both	O
T	O
lymphocytic	O
and	O
mononuclear	O
phagocytic	O
lineage	O
.	O

Activated	O
mononuclear	O
cells	O
,	O
particularly	O
B	O
cells	O
which	O
are	O
in	O
a	O
state	O
of	O
chronic	O
activation	O
in	O
HIV	O
infected	O
individuals	O
,	O
release	O
HIV	O
-	O
inductive	O
cytokines	O
and	O
thus	O
play	O
a	O
potentially	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
HIV	O
infection	O
.	O

Inhibition	O
of	O
HIV	O
-	O
1	O
latency	O
reactivation	O
by	O
dehydroepiandrosterone	O
(	O
DHEA	O
)	O
and	O
an	O
analog	O
of	O
DHEA	O
.	O

The	O
initial	O
infection	O
with	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
in	O
most	O
individuals	O
usually	O
results	O
in	O
the	O
establishment	O
of	O
a	O
latent	O
or	O
chronic	O
infection	O
before	O
eventual	O
progression	O
toward	O
acquired	O
immunodeficiency	O
syndrome	O
.	O

HIV	O
-	O
1	O
can	O
also	O
establish	O
a	O
latent	O
or	O
persistent	O
infection	O
in	O
some	O
T	O
cell	O
lines	O
that	O
show	O
minimal	O
constitutive	O
virus	O
expression	O
.	O

However	O
,	O
activation	O
of	O
the	O
T	O
cell	O
lines	O
leading	O
to	O
enhanced	O
HIV	O
-	O
1	O
replication	O
can	O
be	O
induced	O
by	O
antigens	O
,	O
mitogens	O
,	O
and	O
cytokines	O
(	O
tumor	O
necrosis	O
factor	O
alpha	O
[	O
TNF	O
-	O
alpha	O
]	O
,	O
interleukin	O
1	O
,	O
and	O
interleukin	O
-	O
2	O
)	O
.	O

Various	O
gene	O
products	O
from	O
other	O
viruses	O
(	O
HTLV	O
-	O
1	O
,	O
HSV	O
,	O
EBV	O
,	O
CMV	O
,	O
HBV	O
,	O
and	O
HHV	O
-	O
6	O
)	O
can	O
also	O
enhance	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
-	O
driven	O
reporter	O
gene	O
activity	O
.	O

On	O
the	O
basis	O
of	O
these	O
observations	O
,	O
it	O
has	O
been	O
proposed	O
that	O
reactivation	O
of	O
latent	O
HIV	O
-	O
1	O
harbored	O
in	O
chronically	O
infected	O
T	O
lymphocytes	O
,	O
monocytes	O
,	O
or	O
macrophages	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
AIDS	O
.	O

So	O
far	O
,	O
there	O
are	O
no	O
drugs	O
or	O
therapy	O
available	O
that	O
can	O
provide	O
protection	O
against	O
HIV	O
-	O
1	O
latency	O
reactivation	O
.	O

ACH	O
-	O
2	O
,	O
derived	O
from	O
a	O
human	O
T	O
cell	O
line	O
(	O
CEM	O
)	O
,	O
is	O
chronically	O
infected	O
with	O
HIV	O
-	O
1	O
,	O
with	O
low	O
levels	O
of	O
constitutive	O
virus	O
expression	O
.	O

ACH	O
-	O
2	O
can	O
be	O
converted	O
to	O
productive	O
infection	O
by	O
stimulation	O
of	O
the	O
cells	O
with	O
12-O-tetradecanoylphorbol-13	O
-	O
acetate	O
(	O
TPA	O
)	O
,	O
mitogen	O
or	O
cytokines	O
(	O
TNF	O
-	O
alpha	O
)	O
,	O
or	O
infection	O
with	O
HSV	O
.	O

Therefore	O
the	O
ACH	O
-	O
2	O
cell	O
line	O
is	O
a	O
good	O
candidate	O
for	O
studying	O
the	O
effects	O
of	O
drugs	O
on	O
HIV	O
-	O
1	O
activation	O
.	O

Previously	O
,	O
we	O
have	O
reported	O
that	O
DHEA	O
and	O
synthetic	O
analogs	O
of	O
DHEA	O
can	O
be	O
modest	O
inhibitors	O
of	O
HIV	O
-	O
1	O
IIIB	O
replication	O
in	O
phytohemagglutinin	O
-	O
stimulated	O
peripheral	O
blood	O
lymphocyte	O
cultures	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Nitric	O
oxide	O
-	O
stimulated	O
guanine	O
nucleotide	O
exchange	O
on	O
p21ras	O
.	O

The	O
protooncogene	O
p21ras	O
,	O
a	O
monomeric	O
G	O
protein	O
family	O
member	O
,	O
plays	O
a	O
critical	O
role	O
in	O
converting	O
extracellular	O
signals	O
into	O
intracellular	O
biochemical	O
events	O
.	O

Here	O
,	O
we	O
report	O
that	O
nitric	O
oxide	O
(	O
NO	O
)	O
activates	B-Positive_regulation
p21ras	O
in	O
human	O
T	O
cells	O
as	O
evidenced	O
by	O
an	O
increase	B-Positive_regulation
in	O
GTP	O
-	O
bound	O
p21ras	O
.	O

In	O
vitro	O
studies	O
using	O
pure	O
recombinant	O
p21ras	O
demonstrate	O
that	O
the	O
activation	O
is	O
direct	O
and	O
reversible	O
.	O

Circular	O
dichroism	O
analysis	O
reveals	O
that	O
NO	O
induces	O
a	O
profound	O
conformational	O
change	O
in	O
p21ras	O
in	O
association	O
with	O
GDP/GTP	O
exchange	O
.	O

The	O
mechanism	O
of	O
activation	O
is	O
due	O
to	O
S	O
-	O
nitrosylation	O
of	O
a	O
critical	O
cysteine	O
residue	O
which	O
stimulates	O
guanine	O
nucleotide	O
exchange	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
p21ras	O
is	O
essential	O
for	O
NO	O
-	O
induced	O
downstream	O
signaling	O
,	O
such	O
as	O
NF	O
-	O
kappa	O
B	O
activation	O
,	O
and	O
that	O
endogenous	O
NO	O
can	O
activate	B-Positive_regulation
p21ras	O
in	O
the	O
same	O
cell	O
.	O

These	O
studies	O
identify	O
p21ras	O
as	O
a	O
target	O
of	O
the	O
same	O
cell	O
.	O

These	O
studies	O
identify	O
p21ras	O
as	O
a	O
target	B-Regulation
of	O
NO	O
in	O
T	O
cells	O
and	O
suggest	O
that	O
NO	O
activates	B-Positive_regulation
p21ras	O
by	O
an	O
action	O
which	O
mimics	O
that	O
of	O
guanine	O
nucleotide	O
exchange	O
factors	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
vacuolar	O
H	O
(	O
+	O
)	O
-	O
ATPase	O
B2	O
subunit	O
gene	O
in	O
differentiating	O
THP	O
-	O
1	O
cells	O
.	O

Monocyte	O
-	O
macrophage	O
differentiation	O
was	O
used	O
as	O
a	O
model	O
system	O
for	O
studying	O
gene	O
regulation	O
of	O
the	O
human	O
vacuolar	O
H	O
(	O
+	O
)	O
-	O
ATPase	O
(	O
V	O
-	O
ATPase	O
)	O
.	O

We	O
examined	O
mRNA	O
levels	O
of	O
various	O
V	O
-	O
ATPase	O
subunits	O
during	O
differentiation	O
of	O
both	O
native	O
monocytes	O
and	O
the	O
cell	O
line	O
THP	O
-	O
1	O
,	O
and	O
found	O
that	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
mechanisms	O
could	O
account	O
for	O
increases	O
in	O
cell	O
V	O
-	O
ATPase	O
content	O
.	O

From	O
nuclear	O
runoff	O
experiments	O
,	O
we	O
found	O
that	O
one	O
subunit	O
in	O
particular	O
,	O
the	O
B2	O
isoform	O
(	O
Mr	O
=	O
56	O
,	O
000	O
)	O
,	O
was	O
amplified	B-Positive_regulation
primarily	O
by	O
transcriptional	O
means	O
.	O

We	O
have	O
begun	O
to	O
examine	O
the	O
structure	O
of	O
the	O
B2	O
subunit	O
promoter	O
region	O
.	O

Isolation	O
and	O
sequencing	O
of	O
the	O
first	O
exon	O
and	O
5'	O
-	O
flanking	O
region	O
of	O
this	O
gene	O
reveal	O
a	O
TATA	O
-	O
less	O
promoter	O
with	O
a	O
high	O
G	O
+	O
C	O
content	O
.	O

Primer	O
extension	O
and	O
ribonuclease	O
protection	O
analyses	O
indicate	O
a	O
single	O
major	O
transcriptional	O
start	O
site	O
.	O

We	O
transfected	O
promoter	O
-	O
luciferase	O
reporter	O
plasmids	O
into	O
THP	O
-	O
1	O
cells	O
to	O
define	O
sequences	O
that	O
mediate	O
transcriptional	O
control	O
during	O
monocyte	O
differentiation	O
.	O

We	O
found	O
that	O
sequences	O
downstream	O
from	O
the	O
transcriptional	O
start	O
site	O
were	O
sufficient	O
to	O
confer	O
increased	O
expression	O
during	O
THP	O
-	O
1	O
differentiation	O
.	O

DNase	O
I	O
footprinting	O
and	O
sequence	O
analysis	O
revealed	O
the	O
existence	O
of	O
multiple	O
AP2	O
and	O
Sp1	O
binding	B-Binding
sites	O
in	O
the	O
5'	O
-	O
untranslated	O
and	O
proximal	O
coding	O
regions	O
.	O

Functional	O
characterization	O
of	O
novel	O
IL	O
-	O
2	O
transcriptional	B-Negative_regulation
inhibitors	I-Negative_regulation
.	O

IL-2	O
-	O
mediated	O
T	O
cell	O
proliferation	O
is	O
a	O
critical	O
early	O
event	O
in	O
the	O
inflammatory	O
process	O
.	O

Formation	O
of	O
the	O
NFAT	O
-	O
1	O
transcriptional	O
complex	B-Binding
on	O
the	O
IL	O
-	O
2	O
promoter	O
is	O
essential	B-Positive_regulation
for	O
IL	O
-	O
2	O
transcription	B-Transcription
.	O

Using	O
a	O
cell	O
line	O
that	O
is	O
stably	O
transfected	O
with	O
a	O
trimer	O
of	O
the	O
NFAT	O
-	O
1	O
regulatory	O
element	O
linked	O
to	O
a	O
lac	O
-	O
Z	O
reporter	O
gene	O
,	O
we	O
screened	B-Positive_regulation
for	O
inhibitors	B-Negative_regulation
of	O
NFAT-1	O
-	O
mediated	B-Positive_regulation
beta	O
-	O
galactosidase	O
activity	O
.	O

WIN	O
61058	O
and	O
WIN	O
53071	O
were	O
identified	O
as	O
microM	O
inhibitors	B-Negative_regulation
.	O

These	O
compounds	O
also	O
inhibited	B-Negative_regulation
beta	O
-	O
galactosidase	O
mRNA	O
levels	B-Transcription
.	O

Similar	O
inhibition	O
of	O
NFAT-1	O
-	O
mediated	O
gene	O
expression	O
was	O
observed	O
in	O
a	O
second	O
cell	O
line	O
,	O
which	O
is	O
stably	O
transfected	B-Gene_expression
with	O
NFAT	O
-	O
1	O
regulatory	O
elements	O
linked	O
to	O
the	O
reporter	O
gene	O
for	O
sCD8	O
.	O

At	O
10	O
microM	O
,	O
both	O
compounds	O
inhibited	B-Negative_regulation
IL	O
-	O
2	O
mRNA	O
and	O
protein	O
levels	B-Transcription
in	O
the	O
NFAT-1	O
-	O
linked	O
lac	O
-	O
Z	O
transfectants	O
,	O
and	O
in	O
human	O
lymphocytes	O
.	O

Both	O
compounds	O
inhibited	O
the	O
mixed	O
lymphocyte	O
reaction	O
,	O
and	O
this	O
inhibition	O
was	O
reversed	O
by	O
exogenous	O
IL	O
-	O
2	O
.	O

WIN	O
53071	O
inhibited	B-Negative_regulation
IL	O
-	O
2	O
production	B-Gene_expression
induced	B-Positive_regulation
in	O
the	O
calcium	O
-	O
dependent	O
PMA	O
and	O
ionomycin	O
pathway	O
.	O

Conversely	O
,	O
calcium	O
-	O
independent	O
anti	O
-	O
CD28	O
Ab	O
and	O
PMA	O
-	O
induced	B-Positive_regulation
IL	O
-	O
2	O
production	B-Gene_expression
was	O
resistant	O
.	O

Both	O
compounds	O
altered	B-Regulation
the	O
NFAT	O
-	O
1	O
transcriptional	B-Binding
complex	I-Binding
,	O
causing	O
its	O
retarded	O
mobility	O
on	O
gels	O
.	O

By	O
these	O
functional	O
criteria	O
,	O
we	O
believe	O
we	O
have	O
identified	O
two	O
structurally	O
distinct	O
,	O
novel	O
inhibitors	O
of	O
NFAT-1	O
-	O
mediated	O
transcription	O
.	O

cDNA	O
cloning	O
of	O
a	O
NGFI-B/nur77	O
-	O
related	O
transcription	O
factor	O
from	O
an	O
apoptotic	O
human	O
T	O
cell	O
line	O
.	O

A	O
human	O
T	O
lymphoid	O
cell	O
line	O
,	O
PEER	O
,	O
dies	O
by	O
apoptosis	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
calcium	O
ionophore	O
.	O

A	O
new	O
gene	O
,	O
TINUR	O
,	O
was	O
cloned	O
from	O
apoptotic	O
PEER	O
cells	O
.	O

The	O
expression	B-Gene_expression
of	O
the	O
TINUR	O
gene	O
is	O
induced	B-Positive_regulation
within	O
1	O
h	O
after	O
the	O
cross	O
-	O
linking	O
of	O
the	O
T	O
cell	O
Ag	O
receptor	O
complex	O
.	O

TINUR	O
belongs	O
to	O
the	O
NGFI	O
-	O
B/nur77	O
family	O
of	O
the	O
steroid	O
receptor	O
superfamily	O
and	O
is	O
an	O
orphan	O
receptor	O
.	O

TINUR	O
binds	B-Binding
to	O
the	O
same	O
DNA	O
sequence	O
as	O
NGFI	O
-	O
B/nur77	O
.	O

We	O
also	O
propose	O
that	O
the	O
NGFI	O
-	O
B/nur77	O
family	O
can	O
be	O
classified	O
into	O
two	O
subtypes	O
.	O

Platelet	O
-	O
activating	O
factor	O
stimulates	B-Positive_regulation
transcription	B-Transcription
of	O
the	O
heparin	O
-	O
binding	O
epidermal	O
growth	O
factor	O
-	O
like	O
growth	O
factor	O
in	O
monocytes	O
.	O

Correlation	O
with	O
an	O
increased	O
kappa	O
B	O
binding	O
activity	O
.	O

Human	O
peripheral	O
blood	O
monocytes	O
responded	O
to	O
stimulation	O
of	O
platelet	O
-	O
activating	O
factor	O
(	O
PAF	O
)	O
with	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
the	O
transcript	O
for	O
heparin	O
-	O
binding	O
epidermal	O
growth	O
factor	O
-	O
like	O
growth	O
factor	O
(	O
HB	O
-	O
EGF	O
)	O
,	O
a	O
potent	O
mitogen	O
for	O
vascular	O
smooth	O
muscle	O
cells	O
.	O

This	O
function	O
of	O
PAF	O
was	O
observed	O
at	O
nanomolar	O
concentrations	O
of	O
the	O
ligand	O
,	O
starting	O
at	O
30	O
min	O
after	O
stimulation	O
.	O

The	O
PAF	O
-	O
induced	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
HB	O
-	O
EGF	O
mRNA	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
kappa	O
B	O
binding	O
activity	O
.	O

These	O
functions	O
of	O
PAF	O
appeared	O
to	O
be	O
mediated	B-Positive_regulation
through	O
the	O
cell	O
surface	O
PAF	O
receptors	O
,	O
as	O
two	O
PAF	O
receptor	O
antagonists	O
,	O
WEB	O
2086	O
and	O
L	O
-	O
659	O
,	O
989	O
,	O
blocked	B-Negative_regulation
both	O
the	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
HB	O
-	O
EGF	O
mRNA	O
and	O
kappa	O
B	O
binding	O
activity	O
induced	O
by	O
PAF	O
.	O

The	O
antagonists	O
,	O
however	O
,	O
had	O
no	O
effect	B-Regulation
on	O
phorbol	O
ester	O
-	O
induced	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
HB	O
-	O
EGF	O
mRNA	O
and	O
kappa	O
B	O
binding	O
activity	O
.	O

Pretreatment	O
of	O
monocytes	O
with	O
pertussis	O
toxin	O
inhibited	B-Negative_regulation
these	O
functions	O
of	O
PAF	O
,	O
whereas	O
cholera	O
toxin	O
had	O
no	O
inhibitory	B-Negative_regulation
effect	I-Negative_regulation
.	O

Pyrrolidine	O
dithiocarbamate	O
,	O
an	O
inhibitor	O
for	O
NF	O
-	O
kappa	O
B	O
activation	O
,	O
markedly	O
reduced	B-Negative_regulation
PAF	O
-	O
stimulated	O
kappa	O
B	O
binding	O
activity	O
as	O
well	O
as	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
HB	O
-	O
EGF	O
mRNA	O
.	O

These	O
results	O
suggest	O
a	O
potential	B-Positive_regulation
role	I-Positive_regulation
of	O
PAF	O
in	O
HB	O
-	O
EGF	O
expression	B-Gene_expression
and	O
provide	O
evidence	O
that	O
this	O
stimulation	O
may	O
occur	B-Positive_regulation
through	O
increased	O
kappa	O
B	O
binding	O
activity	O
.	O

IL	O
-	O
1	O
receptor	O
and	O
TCR	O
signals	O
synergize	O
to	O
activate	O
NF	O
-	O
kappa	O
B	O
-	O
mediated	O
gene	O
transcription	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
IL	O
-	O
1	O
receptor	O
(	O
IL	O
-	O
1R	O
)	O
-	O
and	O
TCR	O
-	O
initiated	O
signals	O
can	O
interact	O
synergistically	O
to	O
increase	O
the	O
rate	O
of	O
transcription	O
of	O
several	O
lymphokine	O
and	O
lymphokine	O
receptor	O
genes	O
during	O
the	O
competence	O
phase	O
of	O
the	O
activation	O
program	O
in	O
T	O
helper	O
lymphocytes	O
.	O

In	O
this	O
report	O
we	O
describe	O
how	O
signals	O
initiated	O
through	O
the	O
type	O
I	O
IL	O
-	O
1R	O
interact	O
with	O
signals	O
from	O
the	O
antigen	O
receptor	O
to	O
synergistically	O
augment	O
the	O
transactivating	O
properties	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
synergistic	O
antigen	O
receptor	O
initiated	O
signals	O
are	O
mediated	O
through	O
protein	O
kinase	O
C	O
because	O
they	O
can	O
be	O
mimicked	O
by	O
the	O
phorbol	O
ester	O
,	O
12-O-tetradecanoylphorbol-13	O
-	O
acetate	O
,	O
but	O
not	O
with	O
calcium	O
ionophores	O
;	O
and	O
are	O
staurosporine	O
sensitive	O
but	O
cyclosporine	O
resistant	O
.	O

Gel	O
shift	O
analyses	O
demonstrate	O
that	O
NF	O
-	O
kappa	O
B	O
nuclear	O
translocation	O
is	O
stimulated	O
primarily	O
by	O
IL	O
-	O
1	O
rather	O
than	O
by	O
antigen	O
receptor	O
signals	O
.	O

Western	O
blot	O
and	O
phosphorylation	O
analyses	O
demonstrate	O
that	O
the	O
synergistic	O
effect	O
on	O
NF	O
-	O
kappa	O
B	O
functional	O
activity	O
is	O
independent	O
of	O
I	O
kappa	O
B	O
alpha	O
(	O
MAD3	O
)	O
-NF	O
-	O
kappa	O
B	O
dissociation	O
in	O
the	O
cytosol	O
and	O
is	O
not	O
associated	O
with	O
I	O
kappa	O
B	O
nuclear	O
translocation	O
.	O

The	O
IL-1	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
DNA	O
nuclear	O
localization	O
is	O
transient	O
and	O
can	O
be	O
prolonged	O
either	O
by	O
an	O
antigen	O
receptor	O
-	O
initiated	O
signal	O
or	O
by	O
inhibiting	O
protein	O
synthesis	O
.	O

These	O
results	O
suggest	O
that	O
IL	O
-	O
1	O
induces	O
both	O
NF	O
-	O
kappa	O
B	O
nuclear	O
translocation	O
and	O
the	O
synthesis	O
of	O
a	O
protein	O
(	O
s	O
)	O
responsible	O
for	O
terminating	O
NF	O
-	O
kappa	O
B	O
-	O
DNA	O
interaction	O
in	O
the	O
nucleus	O
.	O

Antigen	O
receptor	O
signals	O
prolong	O
NF	O
-	O
kappa	O
B	O
-	O
DNA	O
interaction	O
,	O
probably	O
by	O
functionally	O
antagonizing	O
the	O
IL-1	O
-	O
induced	O
synthesis	O
of	O
a	O
protein	O
(	O
s	O
)	O
responsible	O
for	O
the	O
transient	O
NF	O
-	O
kappa	O
B	O
-	O
DNA	O
interaction	O
and	O
consequently	O
synergistically	O
enhance	O
IL-1	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
gene	O
transcription	O
.	O

Induction	O
of	O
transcription	O
factors	O
in	O
human	O
T	O
lymphocytes	O
by	O
aspirin	O
-	O
like	O
drugs	O
.	O

Aspirin	O
-	O
like	O
drugs	O
(	O
ALD	O
)	O
induce	O
calcium	O
mobilization	O
,	O
an	O
essential	O
component	O
of	O
T	O
cell	O
activation	O
,	O
but	O
do	O
not	O
induce	B-Positive_regulation
the	O
biosynthesis	B-Gene_expression
of	O
IL	O
-	O
2	O
.	O

To	O
understand	O
the	O
extent	O
to	O
which	O
ALD	O
may	O
mimic	O
mitogenic	O
stimulation	O
,	O
we	O
studied	O
cytoplasmic	O
and	O
nuclear	O
signaling	O
steps	O
in	O
ALD	O
-	O
treated	O
T	O
cells	O
.	O

We	O
found	O
that	O
ALD	O
induce	O
a	O
transient	O
activation	O
of	O
protein	O
kinase	O
(	O
PKC	O
)	O
but	O
have	O
no	O
effect	B-Regulation
(	O
in	O
comparison	O
to	O
anti	O
-	O
CD3	O
antibodies	O
)	O
on	O
protein	O
tyrosine	O
phosphorylation	O
nor	O
on	O
PCL	O
gamma	O
1	O
tyrosine	O
phosphorylation	B-Phosphorylation
.	O

ALD	O
-	O
induced	O
calcium	O
mobilization	O
and	O
PKC	O
activation	O
are	O
independent	O
of	O
tyrosine	O
protein	O
kinase	O
activity	O
as	O
shown	O
by	O
the	O
lack	O
of	O
effect	O
of	O
herbimycin	O
,	O
a	O
tyrosine	O
-	O
protein	O
kinase	O
-	O
specific	O
inhibitor	O
.	O

Although	O
we	O
detected	B-Transcription
no	O
IL	O
-	O
2	O
mRNA	O
in	O
ALD	O
-	O
treated	O
cells	O
,	O
the	O
nuclei	O
of	O
these	O
cells	O
contain	O
proteins	O
capable	O
of	O
binding	B-Binding
to	O
three	O
regulatory	O
sequences	O
in	O
the	O
IL	O
-	O
2	O
promoter	O
region	O
:	O
NFAT	O
,	O
NF	O
kappa	O
B	O
,	O
and	O
AP	O
-	O
1	O
.	O

These	O
binding	O
activities	O
are	O
expressed	B-Positive_regulation
only	O
in	O
activated	O
T	O
cells	O
.	O

The	O
expression	O
of	O
AP	O
-	O
1	O
depended	O
on	O
calcium	O
mobilization	O
and	O
PKC	O
activation	O
.	O

These	O
data	O
suggest	O
that	O
ALD	O
cause	O
transient	O
but	O
significant	O
changes	O
in	O
T	O
cell	O
transmembrane	O
signaling	O
,	O
although	O
some	O
events	O
induced	O
by	O
stimulation	O
with	O
anti	O
-	O
CD3	O
antibodies	O
are	O
not	O
induced	O
by	O
ALD	O
.	O

The	O
signal	O
is	O
transmitted	O
to	O
the	O
nucleus	O
and	O
induces	O
DNA	O
-	O
binding	O
activity	O
by	O
several	O
transcription	O
factors	O
.	O

However	O
,	O
the	O
ALD	O
stimulus	O
is	O
not	O
capable	O
of	O
causing	O
complete	O
T	O
cell	O
activation	O
.	O

Interleukin	O
(	O
IL	O
)	O
-	O
10	O
inhibits	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
kappa	O
B	O
)	O
activation	O
in	O
human	O
monocytes	O
.	O

IL	O
-	O
10	O
and	O
IL	O
-	O
4	O
suppress	O
cytokine	O
synthesis	O
by	O
different	O
mechanisms	O
.	O

Our	O
previous	O
studies	O
in	O
human	O
monocytes	O
have	O
demonstrated	O
that	O
interleukin	O
(	O
IL	O
)	O
-	O
10	O
inhibits	B-Negative_regulation
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
stimulated	B-Positive_regulation
production	B-Gene_expression
of	O
inflammatory	O
cytokines	O
,	O
IL	O
-	O
1	O
beta	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
alpha	O
by	O
blocking	O
gene	O
transcription	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
,	O
we	O
now	O
show	O
that	O
,	O
in	O
monocytes	O
stimulated	O
with	O
LPS	O
or	O
TNF	O
alpha	O
,	O
IL	O
-	O
10	O
inhibits	O
nuclear	O
stimulation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
kappa	O
B	O
)	O
,	O
a	O
transcription	O
factor	O
involved	O
in	O
the	O
expression	O
of	O
inflammatory	O
cytokine	O
genes	O
.	O

Several	O
other	O
transcription	O
factors	O
including	O
NF-IL	O
-	O
6	O
,	O
AP	O
-	O
1	O
,	O
AP	O
-	O
2	O
,	O
GR	O
,	O
CREB	O
,	O
Oct	O
-	O
1	O
,	O
and	O
Sp	O
-	O
1	O
are	O
not	O
affected	B-Regulation
by	O
IL	O
-	O
10	O
.	O

This	O
selective	O
inhibition	O
by	O
IL	O
-	O
10	O
of	O
NF	O
kappa	O
B	O
activation	O
occurs	O
rapidly	O
and	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
correlates	O
well	O
with	O
IL	O
-	O
10	O
's	O
cytokine	O
synthesis	O
inhibitory	O
activity	O
in	O
terms	O
of	O
both	O
kinetics	O
and	O
dose	O
responsiveness	O
.	O

Furthermore	O
,	O
compounds	O
such	O
as	O
tosylphenylalanyl	O
chloromethyl	O
ketone	O
and	O
pyrrolidinedithiocarbamate	O
that	O
are	O
known	O
to	O
selectively	O
inhibit	O
NF	O
kappa	O
B	O
activation	O
block	O
cytokine	O
gene	O
transcription	O
in	O
LPS	O
-	O
stimulated	O
monocytes	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
inhibition	O
of	O
NF	O
kappa	O
B	O
activation	O
may	O
be	O
an	O
important	O
mechanism	O
for	O
IL	O
-	O
10	O
suppression	O
of	O
cytokine	O
gene	O
transcription	O
in	O
human	O
monocytes	O
.	O

IL	O
-	O
4	O
,	O
another	O
cytokine	O
that	O
inhibits	O
cytokine	O
mRNA	O
accumulation	O
in	O
monocytes	O
,	O
shows	O
little	O
inhibitory	O
effect	O
on	O
LPS	O
-	O
induced	O
NF	O
kappa	O
B	O
activation	O
.	O

Further	O
examination	O
reveals	O
that	O
,	O
unlike	O
IL	O
-	O
10	O
,	O
IL	O
-	O
4	O
enhances	O
mRNA	O
degradation	O
and	O
does	O
not	O
suppress	O
cytokine	O
gene	O
transcription	O
.	O

These	O
data	O
indicate	O
that	O
IL	O
-	O
10	O
and	O
IL	O
-	O
4	O
inhibit	O
cytokine	O
production	O
by	O
different	O
mechanisms	O
.	O

Activation	O
of	O
transcription	O
by	O
binding	B-Binding
of	O
NF	O
-	O
E1	O
(	O
YY1	O
)	O
to	O
a	O
newly	O
identified	O
element	O
in	O
the	O
first	O
exon	O
of	O
the	O
human	O
DR	O
alpha	O
gene	O
.	O

A	O
previously	O
unrecognized	O
element	O
,	O
located	O
downstream	O
of	O
the	O
start	O
site	O
of	O
transcription	O
in	O
the	O
first	O
exon	O
of	O
the	O
DR	O
alpha	O
gene	O
,	O
has	O
been	O
defined	O
that	O
enhances	O
promoter	O
activity	O
up	O
to	O
eightfold	O
in	O
a	O
position	O
-	O
dependent	O
manner	O
.	O

Mutations	O
in	O
this	O
DNA	O
-	O
binding	O
site	O
abolished	O
binding	O
of	O
a	O
nuclear	O
factor	O
in	O
human	O
B	O
cell	O
nuclear	O
extract	O
and	O
decreased	B-Negative_regulation
the	O
activity	O
of	O
the	O
DR	O
alpha	O
promoter	O
to	O
a	O
basal	O
level	O
.	O

Significant	O
sequence	O
homology	O
of	O
this	O
element	O
was	O
found	O
in	O
the	O
DNA	O
of	O
the	O
DR	O
beta	O
,	O
DP	O
alpha	O
and	O
-	O
beta	O
,	O
and	O
DQ	O
alpha	O
genes	O
,	O
always	O
located	O
downstream	O
of	O
the	O
transcriptional	O
start	O
site	O
.	O

The	O
nuclear	O
factor	O
binds	B-Binding
to	O
the	O
DR	O
alpha	O
and	O
DP	O
alpha	O
element	O
but	O
not	O
to	O
the	O
element	O
in	O
the	O
DQ	O
alpha	O
gene	O
.	O

It	O
was	O
identified	O
as	O
NF	O
-	O
E1	O
(	O
YY1	O
)	O
.	O

This	O
protein	O
,	O
previously	O
identified	O
by	O
its	O
binding	B-Binding
to	O
the	O
Ig	O
kappa	O
3	O
'	O
enhancer	O
and	O
the	O
Ig	O
heavy	O
chain	O
mu	O
E1	O
site	O
,	O
thus	O
also	O
appears	O
to	O
be	O
quite	O
important	O
in	O
the	O
regulation	O
of	O
MHC	O
class	O
II	O
gene	O
expression	O
.	O

Coupling	O
of	O
a	O
signal	O
response	O
domain	O
in	O
I	O
kappa	O
B	O
alpha	O
to	O
multiple	O
pathways	O
for	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

The	O
eukaryotic	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
plays	O
a	O
central	O
role	O
in	O
the	O
induced	O
expression	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
and	O
in	O
many	O
aspects	O
of	O
the	O
genetic	O
program	O
mediating	O
normal	O
T	O
-	O
cell	O
activation	O
and	O
growth	O
.	O

The	O
nuclear	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
is	O
tightly	O
regulated	O
from	O
the	O
cytoplasmic	O
compartment	O
by	O
an	O
inhibitory	O
subunit	O
called	O
I	O
kappa	O
B	O
alpha	O
.	O

This	O
cytoplasmic	O
inhibitor	O
is	O
rapidly	O
phosphorylated	B-Phosphorylation
and	O
degraded	B-Protein_catabolism
in	B-Positive_regulation
response	I-Positive_regulation
to	I-Positive_regulation
a	O
diverse	O
set	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
inducing	O
agents	O
,	O
including	O
T	O
-	O
cell	O
mitogens	O
,	O
proinflammatory	O
cytokines	O
,	O
and	O
viral	O
transactivators	O
such	O
as	O
the	O
Tax	O
protein	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
.	O

To	O
explore	O
these	O
I	O
kappa	O
B	O
alpha	O
-	O
dependent	O
mechanisms	O
for	O
NF	O
-	O
kappa	O
B	O
induction	O
,	O
we	O
identified	O
novel	O
mutants	O
of	O
I	O
kappa	O
B	O
alpha	O
that	O
uncouple	O
its	O
inhibitory	O
and	O
signal	O
-	O
transducing	O
functions	O
in	O
human	O
T	O
lymphocytes	O
.	O

Specifically	O
,	O
removal	O
of	O
the	O
N	O
-	O
terminal	O
36	O
amino	O
acids	O
of	O
I	O
kappa	O
B	O
alpha	O
failed	O
to	O
disrupt	O
its	O
ability	O
to	O
form	O
latent	O
complexes	O
with	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
cytoplasm	O
.	O

However	O
,	O
this	O
deletion	O
mutation	O
prevented	B-Negative_regulation
the	O
induced	B-Positive_regulation
phosphorylation	B-Phosphorylation
,	O
degradative	B-Protein_catabolism
loss	I-Protein_catabolism
,	O
and	O
functional	O
release	O
of	O
I	O
kappa	O
B	O
alpha	O
from	O
NF	O
-	O
kappa	O
B	O
in	O
Tax	O
-	O
expressing	O
cells	O
.	O

Alanine	O
substitutions	O
introduced	O
at	O
two	O
serine	O
residues	O
positioned	O
within	O
this	O
N	O
-	O
terminal	O
regulatory	O
region	O
of	O
I	O
kappa	O
B	O
alpha	O
also	O
yielded	O
constitutive	O
repressors	O
that	O
escaped	O
from	O
Tax	O
-	O
induced	O
turnover	O
and	O
that	O
potently	O
inhibited	O
immune	O
activation	O
pathways	O
for	O
NF	O
-	O
kappa	O
B	O
induction	O
,	O
including	O
those	O
initiated	O
from	O
antigen	O
and	O
cytokine	O
receptors	O
.	O

In	O
contrast	O
,	O
introduction	O
of	O
a	O
phosphoserine	O
mimetic	O
at	O
these	O
sites	O
rectified	O
this	O
functional	O
defect	O
,	O
a	O
finding	O
consistent	O
with	O
a	O
causal	O
linkage	O
between	O
the	O
phosphorylation	B-Phosphorylation
status	O
and	O
proteolytic	B-Protein_catabolism
stability	O
of	O
this	O
cytoplasmic	O
inhibitor	O
.	O

Together	O
,	O
these	O
in	O
vivo	O
studies	O
define	O
a	O
critical	O
signal	O
response	O
domain	O
in	O
I	O
kappa	O
B	O
alpha	O
that	O
coordinately	O
controls	B-Regulation
the	O
biologic	O
activities	O
of	O
I	O
kappa	O
B	O
alpha	O
and	O
NF	O
-	O
kappa	O
B	O
in	B-Positive_regulation
response	I-Positive_regulation
to	I-Positive_regulation
viral	O
and	O
immune	O
stimuli	O
.	O

HIV	O
type	O
1	O
protease	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
within	O
T	O
lymphoid	O
cells	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
a	O
nuclear	O
protein	O
of	O
the	O
rel	O
oncogene	O
family	O
capable	O
of	O
enhancing	B-Positive_regulation
transcription	B-Transcription
of	O
several	O
cellular	O
genes	O
,	O
including	O
IL	O
-	O
2	O
and	O
the	O
IL	O
-	O
2	O
receptor	O
,	O
and	O
viral	O
genes	O
transcribed	O
from	O
the	O
HIV	O
-	O
1	O
LTR	O
.	O

It	O
has	O
been	O
reported	O
that	O
HIV	O
-	O
1	O
protease	O
may	O
cleave	O
the	O
NF	O
-	O
kappa	O
B	O
precursor	O
to	O
its	O
active	O
form	O
in	O
vitro	O
.	O

In	O
this	O
study	O
the	O
effects	O
of	O
HIV	O
protease	O
on	O
NF	O
-	O
kappa	O
B	O
precursor	O
activation	O
were	O
examined	O
in	O
Jurkat	O
T	O
cells	O
by	O
introducing	B-Positive_regulation
a	O
protease	O
expression	B-Gene_expression
vector	O
into	O
the	O
cells	O
.	O

Increased	O
NF	O
-	O
kappa	O
B	O
activity	O
was	O
observed	O
and	O
this	O
increased	O
activity	O
was	O
blocked	O
by	O
a	O
specific	O
inhibitor	B-Negative_regulation
of	O
the	O
viral	O
protease	O
.	O

Viral	O
transcription	O
,	O
as	O
measured	O
using	O
LTR	O
-	O
CAT	O
assays	O
,	O
was	O
only	O
slightly	O
enhanced	O
in	O
the	O
HIV	O
-	O
protease	O
expressing	B-Gene_expression
cells	O
,	O
while	O
secretion	B-Localization
of	O
IL	O
-	O
2	O
and	O
expression	O
of	O
the	O
IL	O
-	O
2	O
receptor	O
were	O
not	O
affected	B-Regulation
.	O

The	O
limited	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
HIV	O
protease	O
appears	O
unlikely	O
to	O
have	O
a	O
significant	O
effect	O
on	O
virus	O
expression	O
or	O
T	O
cell	O
function	O
.	O

Expression	B-Gene_expression
of	O
Ah	O
receptor	O
(	O
TCDD	O
receptor	O
)	O
during	O
human	O
monocytic	O
differentiation	O
.	O

We	O
have	O
previously	O
found	O
a	O
high	O
expression	B-Transcription
of	O
human	O
Ah	O
receptor	O
(	O
TCDD	O
receptor	O
)	O
mRNA	O
in	O
peripheral	O
blood	O
cells	O
of	O
individuals	O
.	O

In	O
this	O
paper	O
,	O
the	O
expression	B-Gene_expression
of	O
this	O
gene	O
in	O
blood	O
cells	O
was	O
first	O
investigated	O
in	O
fractions	O
of	O
nucleated	O
cells	O
,	O
revealing	O
predominant	O
expression	B-Gene_expression
of	O
the	O
Ah	O
receptor	O
gene	O
in	O
the	O
monocyte	O
fraction	O
.	O

Then	O
the	O
expression	B-Gene_expression
levels	O
of	O
AhR	O
mRNA	O
in	O
various	O
hematopoietic	O
cell	O
lines	O
were	O
examined	O
together	O
with	O
those	O
of	O
Arnt	O
and	O
P450IA1	O
.	O

AhR	O
was	O
expressed	B-Gene_expression
at	O
high	O
levels	O
in	O
monocytoid	O
U937	O
,	O
THP1	O
,	O
and	O
HEL/S	O
cells	O
,	O
and	O
at	O
moderate	O
levels	O
in	O
promyelocytic	O
HL60	O
cells	O
and	O
erythroblastic	O
HEL	O
cells	O
.	O

However	O
,	O
it	O
was	O
not	O
detected	B-Gene_expression
in	O
lymphoid	O
cells	O
MOLT4	O
(	O
T	O
cell	O
)	O
and	O
BALL1	O
(	O
B	O
cell	O
)	O
,	O
nor	O
in	O
K562	O
erythroblasts	O
.	O

Furthermore	O
,	O
a	O
specific	O
induction	B-Positive_regulation
of	O
AhR	O
during	O
monocytic	O
differentiation	O
was	O
investigated	O
in	O
HL60	O
and	O
HEL	O
cells	O
.	O

HL60	O
cells	O
were	O
induced	O
to	O
differentiate	O
toward	O
monocytes	O
-	O
macrophages	O
by	O
incubation	O
with	O
phorbol	O
ester	O
,	O
showing	O
a	O
5	O
-	O
to	O
2	O
-	O
fold	O
increase	B-Positive_regulation
of	O
AhR	O
mRNA	O
.	O

The	O
incubation	O
with	O
transforming	O
growth	O
factor	O
beta	O
1	O
and	O
1	O
alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
resulted	O
in	O
a	O
5	O
-	O
to	O
7	O
-	O
fold	O
increase	B-Positive_regulation
of	O
AhR	O
mRNA	O
.	O

The	O
HEL	O
cells	O
also	O
exhibited	O
a	O
similar	O
elevation	B-Positive_regulation
of	O
AhR	O
mRNA	O
level	O
,	O
when	O
they	O
had	O
differentiated	O
toward	O
monocyte	O
-	O
macrophage	O
cells	O
by	O
these	O
combined	O
inducers	O
,	O
but	O
little	O
change	B-Regulation
in	O
the	O
mRNA	O
level	O
was	O
observed	O
when	O
the	O
cells	O
were	O
induced	O
to	O
differentiate	O
into	O
other	O
cell	O
types	O
.	O

Treatment	O
of	O
the	O
differentiated	O
HL60	O
cells	O
with	O
3	O
-	O
methylcholanthrene	O
,	O
a	O
ligand	B-Binding
of	O
AhR	O
,	O
induced	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
the	O
P450IA1	O
gene	O
.	O

These	O
results	O
indicated	O
that	O
expression	B-Transcription
of	O
AhR	O
mRNA	O
was	O
significantly	O
induced	B-Positive_regulation
during	O
monocytic	O
differentiation	O
and	O
that	O
the	O
differentiated	O
cells	O
were	O
responsive	O
to	O
xenobiotics	O
.	O

Our	O
results	O
suggest	O
that	O
AhR	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
function	O
of	O
monocytes	O
and	O
also	O
in	O
the	O
eventual	O
activation	O
of	O
environmental	O
carcinogens	O
.	O

Platelet	O
-	O
activating	O
factor	O
(	O
PAF	O
)	O
positively	O
auto	O
-	O
regulates	O
the	O
expression	B-Positive_regulation
of	O
human	O
PAF	O
receptor	O
transcript	O
1	O
(	O
leukocyte	O
-	O
type	O
)	O
through	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
human	O
platelet	O
-	O
activating	O
factor	O
receptor	O
(	O
PAFR	O
)	O
gene	O
is	O
transcribed	B-Transcription
by	B-Positive_regulation
two	O
distinct	O
promoters	O
(	O
promoter	O
1	O
and	O
promoter	O
2	O
)	O
to	O
generate	O
two	O
transcripts	O
(	O
designated	O
as	O
PAFR	O
transcript	O
1	O
and	O
PAFR	O
transcript	O
2	O
)	O
,	O
though	O
their	O
open	O
reading	O
frames	O
are	O
identical	O
.	O

By	O
primer	O
extension	O
analysis	O
to	O
discriminate	O
two	O
transcripts	O
,	O
we	O
found	O
that	O
the	O
levels	O
of	O
PAFR	O
transcript	O
1	O
(	O
leukocyte	O
-	O
type	O
)	O
,	O
but	O
not	O
PAFR	O
transcript	O
2	O
(	O
tissue	O
-	O
type	O
)	O
,	O
are	O
upregulated	B-Positive_regulation
by	O
PAF	O
as	O
well	O
as	O
by	O
12-O-tetradecanoylphorbol-13	O
-	O
acetate	O
(	O
TPA	O
)	O
in	O
the	O
human	O
stomach	O
cancer	O
cell	O
line	O
(	O
JR	O
-	O
St	O
cells	O
)	O
which	O
expresses	B-Gene_expression
both	O
functional	O
PAFR	O
transcript	O
1	O
and	O
PAFR	O
transcript	O
2	O
endogenously	O
.	O

Functional	O
analysis	O
of	O
the	O
promoter	O
1	O
with	O
a	O
transient	O
expression	O
assay	O
using	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
gene	O
as	O
a	O
reporter	O
showed	O
that	O
both	O
PAF	O
and	O
TPA	O
activated	O
the	O
promoter	O
1	O
but	O
not	O
the	O
deleted	O
promoter	O
lacking	O
the	O
three	O
consensus	O
binding	O
sites	O
for	O
NF	O
-	O
kappa	O
B	O
located	O
from	O
-	O
571	O
bp	O
to	O
-	O
459	O
bp	O
.	O

These	O
findings	O
suggest	O
a	O
molecular	O
mechanism	O
of	O
positive	B-Positive_regulation
regulation	I-Positive_regulation
of	O
PAFR	O
gene	O
expression	B-Gene_expression
by	O
PAF	O
through	O
NF	O
-	O
kappa	O
B	O
,	O
possibly	O
by	O
a	O
phosphorylation	O
reaction	O
involving	O
protein	O
kinase	O
C	O
by	O
PAF	O
.	O

Distinct	O
roles	O
of	O
the	O
molecular	O
chaperone	O
hsp90	O
in	O
modulating	O
dioxin	O
receptor	O
function	O
via	O
the	O
basic	O
helix-loop	O
-	O
helix	O
and	O
PAS	O
domains	O
.	O

The	O
intracellular	O
dioxin	O
receptor	O
mediates	O
signal	O
transduction	O
by	O
dioxin	O
and	O
functions	O
as	O
a	O
ligand	O
-	O
activated	O
transcription	O
factor	O
.	O

It	O
contains	O
a	O
basic	O
helix-loop	O
-	O
helix	O
(	O
bHLH	O
)	O
motif	O
contiguous	O
with	O
a	O
Per-Arnt	O
-	O
Sim	O
(	O
PAS	O
)	O
homology	O
region	O
.	O

In	O
extracts	O
from	O
nonstimulated	O
cells	O
the	O
receptor	O
is	O
recovered	O
in	O
an	O
inducible	O
cytoplasmic	O
form	O
associated	O
with	O
the	O
90	O
-	O
kDa	O
heat	O
shock	O
protein	O
(	O
hsp90	O
)	O
,	O
a	O
molecular	O
chaperone	O
.	O

We	O
have	O
reconstituted	O
ligand	O
-	O
dependent	O
activation	O
of	O
the	O
receptor	O
to	O
a	O
DNA	O
-	O
binding	O
form	O
by	O
using	O
the	O
dioxin	O
receptor	O
and	O
its	O
bHLH	O
-	O
PAS	O
partner	O
factor	O
Arnt	O
expressed	O
by	O
in	O
vitro	O
translation	O
in	O
reticulocyte	O
lysate	O
.	O

Deletion	O
of	O
the	O
PAS	O
domain	O
of	O
the	O
receptor	O
resulted	O
in	O
constitutive	O
dimerization	O
with	O
Arnt	O
.	O

In	O
contrast	O
,	O
this	O
receptor	O
mutant	O
showed	O
low	O
levels	O
of	O
xenobiotic	O
response	O
element	O
-	O
binding	O
activity	O
,	O
indicating	O
that	O
the	O
PAS	O
domain	O
may	O
be	O
important	O
for	O
DNA	O
-	O
binding	O
affinity	O
and/or	O
specificity	O
of	O
the	O
receptor	O
.	O

It	O
was	O
not	O
possible	O
to	O
reconstitute	O
dioxin	O
receptor	O
function	O
with	O
proteins	O
expressed	O
in	O
wheat	O
germ	O
lysate	O
.	O

In	O
line	O
with	O
these	O
observations	O
,	O
reticulocyte	O
lysate	O
but	O
not	O
wheat	O
germ	O
lysate	O
promoted	O
the	O
association	O
of	O
de	O
novo	O
synthesized	O
dioxin	O
receptor	O
with	O
hsp90	O
.	O

At	O
least	O
two	O
distinct	O
domains	O
of	O
the	O
receptor	O
mediated	O
interaction	O
with	O
hsp90	O
:	O
the	O
ligand	O
-	O
binding	O
domain	O
located	O
within	O
the	O
PAS	O
region	O
and	O
,	O
surprisingly	O
,	O
the	O
bHLH	O
domain	O
.	O

Whereas	O
ligand	O
-	O
binding	O
activity	O
correlated	O
with	O
association	O
with	O
hsp90	O
,	O
bHLH	O
-	O
hsp90	O
interaction	O
appeared	O
to	O
be	O
important	O
for	O
DNA	O
-	O
binding	O
activity	O
but	O
not	O
for	O
dimerization	O
of	O
the	O
receptor	O
.	O

Several	O
distinct	O
roles	O
for	O
hsp90	O
in	O
modulating	O
dioxin	O
receptor	O
function	O
are	O
therefore	O
likely	O
:	O
correct	O
folding	O
of	O
the	O
ligand	O
-	O
binding	O
domain	O
,	O
interference	O
with	O
Arnt	O
heterodimerization	O
,	O
and	O
folding	O
of	O
a	O
DNA	O
-	O
binding	O
conformation	O
of	O
the	O
bHLH	O
domain	O
.	O

Thus	O
,	O
the	O
dioxin	O
receptor	O
system	O
provides	O
a	O
complex	O
and	O
interesting	O
model	O
of	O
the	O
regulation	O
of	O
transcription	O
factors	O
by	O
hsp90	O
.	O

T	O
-	O
cell	O
functional	O
regions	O
of	O
the	O
human	O
IL	O
-	O
3	O
proximal	O
promoter	O
.	O

The	O
human	O
interleukin	O
-	O
3	O
(	O
IL	O
-	O
3	O
)	O
gene	O
is	O
expressed	B-Gene_expression
almost	O
exclusively	O
in	O
activated	O
T	O
cells	O
.	O

Its	O
expression	B-Gene_expression
is	O
regulated	B-Regulation
at	O
both	O
the	O
transcriptional	B-Transcription
and	O
post	O
-	O
transcriptional	O
level	O
.	O

We	O
have	O
previously	O
shown	O
that	O
treatment	O
of	O
Jurkat	O
T	O
cells	O
with	O
phytohemaglutinin	O
(	O
PHA	O
)	O
and	O
the	O
phorbol	O
ester	O
,	O
PMA	O
,	O
activated	B-Positive_regulation
transcription	B-Transcription
initiation	I-Transcription
from	O
the	O
IL	O
-	O
3	O
gene	O
.	O

To	O
define	O
the	O
regions	O
of	O
the	O
gene	O
required	B-Positive_regulation
for	O
transcription	O
activation	O
,	O
we	O
generated	O
a	O
series	O
of	O
reporter	O
constructs	O
containing	O
different	O
regions	O
of	O
the	O
IL	O
-	O
3	O
gene	O
5	O
'	O
and	O
3	O
'	O
flanking	O
sequences	O
.	O

Both	O
positive	O
and	O
negative	O
regulatory	O
elements	O
were	O
identified	O
in	O
the	O
proximal	O
5	O
'	O
flanking	O
region	O
of	O
the	O
IL	O
-	O
3	O
gene	O
.	O

The	O
promoter	O
region	O
between	O
-	O
173	O
and	O
-	O
60	O
contained	O
the	O
strongest	O
activating	O
elements	O
.	O

The	O
transcription	O
factor	O
AP	O
-	O
1	O
could	O
bind	O
to	O
this	O
positive	O
activator	O
region	O
of	O
the	O
promoter	O
.	O

We	O
also	O
examined	O
the	O
function	O
of	O
the	O
IL	O
-	O
3	O
CK-1/CK	O
-	O
2	O
elements	O
that	O
are	O
present	O
in	O
many	O
cytokine	O
genes	O
and	O
found	O
that	O
they	O
acted	O
as	O
a	O
repressor	O
of	O
basal	O
level	O
expression	O
when	O
cloned	O
upstream	O
of	O
a	O
heterologous	O
promoter	O
but	O
were	O
also	O
inducible	O
by	O
PMA/PHA	O
.	O

Two	O
distinct	O
signalling	O
pathways	O
are	O
involved	O
in	O
the	O
control	B-Regulation
of	O
the	O
biphasic	O
junB	O
transcription	B-Transcription
induced	B-Positive_regulation
by	O
interleukin	O
-	O
6	O
in	O
the	O
B	O
cell	O
hybridoma	O
7TD1	O
.	O

We	O
have	O
measured	O
the	O
level	B-Transcription
of	O
junB	O
mRNA	O
in	O
the	O
B	O
hybridoma	O
cell	O
line	O
7TD1	O
,	O
under	B-Regulation
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
stimulation	O
.	O

IL	O
-	O
6	O
increases	B-Positive_regulation
junB	O
mRNA	O
in	O
a	O
biphasic	O
fashion	O
.	O

The	O
first	O
early	O
-	O
induced	O
peak	O
was	O
transient	O
and	O
likely	O
corresponds	O
to	O
the	O
well	O
documented	O
typical	O
junB	O
mRNA	O
,	O
stimulated	B-Positive_regulation
in	O
response	O
to	O
numerous	O
growth	O
factors	O
,	O
including	O
IL	O
-	O
6	O
.	O

At	O
variance	O
,	O
the	O
second	O
peak	O
which	O
has	O
never	O
been	O
reported	O
previously	O
,	O
lasted	O
several	O
hours	O
.	O

As	O
a	O
consequence	O
of	O
its	O
effect	B-Regulation
on	O
junB	O
mRNA	O
,	O
IL	O
-	O
6	O
stimulated	B-Positive_regulation
,	O
in	O
a	O
biphasic	O
fashion	O
,	O
the	O
nuclear	O
accumulation	B-Localization
of	O
the	O
JunB	O
protein	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
IL	O
-	O
6	O
regulation	O
occurred	O
exclusively	O
at	O
the	O
transcriptional	O
level	O
and	O
that	O
the	O
bimodal	O
increase	B-Positive_regulation
of	O
junB	O
mRNA	O
and	O
JunB	O
protein	O
can	O
be	O
accounted	O
for	O
by	O
a	O
biphasic	O
stimulation	B-Positive_regulation
of	O
junB	O
transcription	B-Transcription
.	O

Furthermore	O
,	O
our	O
data	O
point	O
to	O
two	O
major	O
differences	O
between	O
the	O
mechanism	O
of	O
control	B-Regulation
of	O
the	O
early	O
and	O
the	O
late	O
IL-6	O
-	O
induced	B-Positive_regulation
junB	O
transcription	B-Transcription
waves	O
.	O

First	O
,	O
cycloheximide	O
strongly	O
potentiated	O
the	O
transcription	O
of	O
the	O
second	O
wave	O
,	O
whereas	O
it	O
failed	O
to	O
affect	O
the	O
early	O
-	O
induced	O
burst	O
.	O

Second	O
,	O
tyrphostin	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
impaired	B-Negative_regulation
the	O
expression	B-Transcription
of	O
the	O
first	O
but	O
not	O
the	O
second	O
junB	O
mRNA	O
peak	O
.	O

Conversely	O
,	O
genistein	O
,	O
another	O
tyrosine	O
kinase	O
inhibitor	O
,	O
totally	O
abolished	B-Negative_regulation
the	O
expression	B-Transcription
of	O
the	O
second	O
peak	O
of	O
junB	O
mRNA	O
whereas	O
it	O
did	O
not	O
affect	B-Regulation
the	O
expression	O
of	O
the	O
first	O
peak	O
.	O

Altogether	O
these	O
data	O
indicate	O
that	O
,	O
in	O
7TD1	O
cells	O
,	O
IL	O
-	O
6	O
controls	B-Regulation
junB	O
transcription	B-Transcription
in	O
a	O
biphasic	O
fashion	O
by	B-Positive_regulation
means	I-Positive_regulation
of	I-Positive_regulation
two	O
separate	O
transduction	O
pathways	O
.	O

Biphasic	O
control	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
activation	O
by	O
the	O
T	O
cell	O
receptor	O
complex	O
:	O
role	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
.	O

The	O
regulation	O
of	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
activation	O
by	O
the	O
T	O
cell	O
receptor	O
(	O
TcR	O
)	O
/CD3	O
complex	O
in	O
primary	O
human	O
T	O
cells	O
has	O
been	O
studied	O
at	O
various	O
times	O
after	O
activation	O
.	O

Only	O
p50	O
NF	O
-	O
kappa	O
B	O
protein	O
bound	B-Binding
the	O
kappa	O
B	O
element	O
of	O
interleukin	O
-	O
2	O
receptor	O
(	O
IL	O
-	O
2R	O
)	O
alpha	O
chain	O
promoter	O
on	O
resting	O
T	O
cells	O
.	O

However	O
,	O
immediately	O
after	B-Positive_regulation
TcR/CD3	O
cross	O
-	O
linking	O
(	O
after	O
approximately	O
1	O
h	O
;	O
immediate	O
)	O
binding	B-Binding
of	O
p50.p65	O
heterodimers	B-Binding
was	O
observed	O
.	O

p50.c	O
-	O
rel	O
heterodimers	B-Binding
were	O
also	O
detected	O
bound	B-Binding
to	O
this	O
sequence	O
at	O
early	O
time	O
points	O
(	O
7	O
-	O
16	O
h	O
;	O
early	O
)	O
,	O
and	O
both	O
remained	O
active	O
at	O
later	O
time	O
points	O
(	O
40	O
h	O
;	O
late	O
)	O
after	O
activation	O
.	O

This	O
regulation	O
takes	O
place	O
mainly	O
at	O
the	O
level	O
of	O
nuclear	O
translocation	B-Localization
of	O
p65	O
and	O
c	O
-	O
rel	O
,	O
at	O
immediate	O
and	O
early	O
time	O
points	O
.	O

Activation	O
also	O
induced	B-Positive_regulation
c	O
-	O
rel	O
and	O
p105/p50	O
mRNA	O
synthesis	B-Transcription
,	O
but	O
not	O
p65	O
mRNA	O
whose	O
expression	O
was	O
constitutive	O
.	O

Interestingly	O
,	O
all	O
those	O
early	O
and	O
late	O
events	O
,	O
but	O
not	O
the	O
immediate	O
ones	O
,	O
were	O
inhibited	B-Negative_regulation
by	O
a	O
neutralizing	O
anti	O
-	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
monoclonal	O
antibody	O
.	O

Similarly	O
,	O
cycloheximide	O
prevented	B-Negative_regulation
the	O
p65	O
and	O
c	O
-	O
rel	O
translocation	B-Localization
and	O
consequent	O
formation	O
of	O
active	O
binding	O
heterodimers	B-Binding
,	O
at	O
early	O
and	O
late	O
times	O
.	O

Cyclosporin	O
A	O
impaired	B-Negative_regulation
not	O
only	O
early	O
and	O
late	O
,	O
but	O
also	O
immediate	O
events	O
;	O
however	O
,	O
addition	O
of	O
TNF	O
-	O
alpha	O
prevented	B-Negative_regulation
all	O
inhibition	O
.	O

These	O
results	O
indicate	O
that	O
the	O
regulation	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
during	O
T	O
cell	O
activation	O
by	O
TcR/CD3	O
signals	O
is	O
biphasic	O
:	O
TcR/CD3	O
triggers	O
its	O
immediate	O
translocation	O
,	O
which	O
is	O
transient	O
if	O
no	O
TNF	O
-	O
alpha	O
is	O
present	O
.	O

TNF	O
-	O
alpha	O
,	O
therefore	O
,	O
emerges	O
as	O
the	O
main	O
factor	O
responsible	O
for	O
a	O
second	O
phase	O
of	O
NF	O
-	O
kappa	O
B	O
regulation	O
,	O
controlling	B-Regulation
both	O
translocation	B-Localization
of	O
p65	O
and	O
c	O
-	O
rel	O
,	O
and	O
new	O
mRNA	B-Transcription
synthesis	I-Transcription
for	O
c	O
-	O
rel	O
and	O
p105/p50	O
.	O

Protein	O
kinase	O
C	O
is	O
not	O
a	O
downstream	O
effector	O
of	O
p21ras	O
in	O
activated	O
T	O
cells	O
.	O

The	O
aim	O
of	O
this	O
present	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
downstream	O
of	O
p21ras	O
,	O
in	O
activating	B-Positive_regulation
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
gene	O
expression	B-Gene_expression
.	O

It	O
has	O
been	O
reported	O
that	O
PKC	O
is	O
an	O
effector	O
of	O
p21ras	O
in	O
T	O
cells	O
.	O

Data	O
is	O
presented	O
,	O
using	O
the	O
potent	O
and	O
selective	O
PKC	O
inhibitor	O
Ro	O
31	O
-	O
8425	O
and	O
transient	O
expression	O
of	O
a	O
constitutively	O
active	O
ras	O
mutant	O
,	O
which	O
clearly	O
shows	O
that	O
PKC	O
is	O
not	O
downstream	O
of	O
p21ras	O
in	O
the	O
induction	O
of	O
NF	O
-	O
AT	O
and	O
AP	O
-	O
1	O
transcriptional	O
activity	O
and	O
in	O
the	O
expression	B-Gene_expression
of	O
IL	O
-	O
2	O
in	O
human	O
Jurkat	O
T	O
cells	O
.	O

Reporter	O
gene	O
experiments	O
demonstrated	O
that	O
NF	O
-	O
kappa	O
B	O
transcriptional	O
activity	O
is	O
not	O
affected	O
by	O
expression	O
of	O
activated	B-Positive_regulation
p21ras	O
.	O

The	O
signaling	O
pathways	O
involving	O
PKC	O
activation	O
,	O
calcium	O
mobilization	O
and	O
ras	O
activation	O
combine	O
to	O
provide	O
the	O
necessary	O
components	O
for	O
production	B-Gene_expression
of	O
IL	O
-	O
2	O
during	B-Positive_regulation
T	O
cell	O
activation	O
.	O

Association	O
of	O
alterations	O
in	O
NF	O
-	O
kappa	O
B	O
moieties	O
with	O
HIV	O
type	O
1	O
proviral	O
latency	O
in	O
certain	O
monocytic	O
cells	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
replication	O
is	O
controlled	O
by	O
a	O
complex	O
array	O
of	O
virally	O
encoded	O
and	O
cellular	O
proteins	O
.	O

A	O
wide	O
spectrum	O
of	O
levels	O
of	O
HIV	O
-	O
1	O
expression	O
have	O
been	O
demonstrated	O
in	O
various	O
cells	O
,	O
both	O
in	O
cell	O
culture	O
and	O
in	O
vivo	O
.	O

Molecular	O
mechanisms	O
leading	O
to	O
restricted	O
HIV	O
-	O
1	O
replication	O
may	O
differ	O
between	O
certain	O
cell	O
types	O
.	O

It	O
is	O
now	O
demonstrated	O
that	O
HIV	O
-	O
1	O
proviral	O
latency	O
in	O
the	O
monocytic	O
cell	O
line	O
U1	O
,	O
in	O
which	O
only	O
extremely	O
low	O
levels	O
of	O
HIV	O
-	O
1	O
expression	O
are	O
detected	O
in	O
the	O
baseline	O
unstimulated	O
state	O
,	O
is	O
associated	O
with	O
alterations	O
in	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
moieties	O
demonstrated	O
in	O
these	O
cells	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
and	O
in	O
situ	O
UV	O
cross	O
-	O
linking	O
studies	O
.	O

A	O
predominance	O
of	O
p50	O
NF	O
-	O
kappa	O
B	O
moieties	O
and	O
possibly	O
p50	O
homodimers	B-Binding
or	O
closely	O
related	O
species	O
,	O
rather	O
than	O
the	O
p50	O
-	O
p56	O
heterodimer	B-Binding
of	O
NF	O
-	O
kappa	O
B	O
that	O
is	O
the	O
predominant	O
NF	O
-	O
kappa	O
B	O
species	O
in	O
most	O
T	O
lymphocytic	O
and	O
monocytic	O
cells	O
,	O
is	O
demonstrated	O
in	O
the	O
nuclei	O
of	O
U1	O
cells	O
.	O

This	O
pattern	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
related	O
moieties	O
differs	O
from	O
the	O
latently	O
infected	O
T	O
lymphocytic	O
cell	O
line	O
ACH	O
-	O
2	O
,	O
and	O
from	O
the	O
U937	O
monocytic	O
line	O
,	O
the	O
parental	O
cell	O
line	O
of	O
the	O
U1	O
cellular	O
clone	O
.	O

As	O
such	O
,	O
these	O
data	O
suggest	O
that	O
different	O
proximal	O
mechanisms	O
may	O
lead	O
to	O
restricted	O
HIV	O
-	O
1	O
replication	O
in	O
various	O
cell	O
types	O
.	O

Overexpression	B-Positive_regulation
of	O
protein	O
kinase	O
C	O
-	O
zeta	O
stimulates	O
leukemic	O
cell	O
differentiation	O
.	O

A	O
function	O
for	O
protein	O
kinase	O
C	O
-	O
zeta	O
(	O
PKC	O
-	O
zeta	O
)	O
,	O
a	O
member	O
of	O
the	O
phorbol	O
ester	O
nonresponsive	B-Regulation
atypical	O
protein	O
kinase	O
C	O
subfamily	O
,	O
in	O
modulating	O
differentiation	O
was	O
examined	O
in	O
the	O
leukemic	O
U937	O
cell	O
.	O

Transfected	O
U937	O
cells	O
stably	O
overexpressing	B-Gene_expression
PKC	O
-	O
zeta	O
displayed	O
a	O
longer	O
doubling	O
time	O
,	O
lower	O
saturation	O
density	O
at	O
confluency	O
,	O
and	O
an	O
increase	O
in	O
adherence	O
to	O
plastic	O
as	O
compared	O
to	O
control	O
cells	O
.	O

PKC	O
-	O
zeta	O
cells	O
expressed	O
a	O
more	O
differentiated	O
phenotype	O
as	O
assessed	O
by	O
changes	O
in	O
morphology	O
,	O
surface	O
antigen	O
expression	O
,	O
and	O
lysosomal	O
enzyme	O
activities	O
and	O
were	O
distinct	O
from	O
parental	O
U937	O
cells	O
stimulated	O
to	O
differentiate	O
by	O
exposure	O
to	O
phorbol	O
esters	O
.	O

In	O
contrast	O
to	O
parental	O
U937	O
cells	O
,	O
PKC	O
-	O
zeta	O
cells	O
constitutively	O
expressed	B-Transcription
mRNA	O
transcripts	O
for	O
c	O
-	O
jun	O
and	O
a	O
low	O
mobility	O
AP	O
-	O
1	O
binding	O
activity	O
.	O

Thus	O
,	O
PKC	O
-	O
zeta	O
overexpression	B-Gene_expression
stimulates	O
a	O
type	O
of	O
phenotypic	O
differentiation	O
that	O
differs	O
significantly	O
from	O
maturation	O
occurring	O
upon	O
activation	O
of	O
other	O
PKC	O
subfamilies	O
induced	O
by	O
phorbol	O
ester	O
treatment	O
.	O

Increased	B-Positive_regulation
expression	B-Gene_expression
of	O
the	O
c	O
-	O
jun	O
protooncogene	O
and	O
an	O
increase	O
in	O
AP	O
-	O
1	O
binding	O
activity	O
in	O
PKC	O
-	O
zeta	O
cells	O
provides	O
a	O
potential	O
mechanism	O
for	O
explaining	O
the	O
altered	O
differentiation	O
status	O
of	O
this	O
cell	O
.	O

Posttranscriptional	B-Regulation
regulation	I-Regulation
of	O
macrophage	O
tissue	O
factor	O
expression	B-Gene_expression
by	O
antioxidants	O
.	O

Tissue	O
factor	O
(	O
TF	O
)	O
expression	B-Gene_expression
by	O
cells	O
of	O
monocyte/macrophage	O
lineage	O
represents	O
an	O
important	O
mechanism	O
underlying	O
the	O
initiation	O
of	O
fibrin	O
deposition	O
at	O
sites	O
of	O
extravascular	O
inflammation	O
.	O

Recent	O
evidence	O
suggests	O
a	O
role	O
for	O
oxidant	O
stress	O
in	O
the	O
signalling	O
pathway	O
of	O
various	O
cell	O
types	O
by	O
virtue	O
of	O
its	O
ability	O
to	O
induce	O
DNA	O
binding	O
of	O
various	O
transcription	O
factors	O
,	O
including	O
nuclear	O
factor	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
.	O

The	O
effect	B-Regulation
of	O
antioxidant	O
treatment	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
induced	B-Positive_regulation
TF	O
expression	B-Gene_expression
was	O
examined	O
in	O
murine	O
peritoneal	O
macrophages	O
and	O
human	O
monocytes	O
.	O

Both	O
pyrrolidine	O
dithiocarbamate	O
,	O
an	O
oxidant	O
scavenger	O
,	O
and	O
N-acetyl	O
-	O
cysteine	O
,	O
a	O
precursor	O
of	O
the	O
endogenous	O
antioxidant	O
glutathione	O
,	O
inhibited	O
stimulation	O
of	O
macrophage	O
procoagulant	O
activity	O
by	O
LPS	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
neither	O
of	O
these	O
agents	O
reduced	B-Negative_regulation
LPS	O
-	O
stimulated	B-Positive_regulation
TF	O
mRNA	O
accumulation	B-Positive_regulation
,	O
thereby	O
suggesting	O
a	O
posttranscriptional	O
mechanism	O
for	O
the	O
effect	O
.	O

Immunofluorescence	O
studies	O
of	O
human	O
monocytes	O
using	O
polyclonal	O
anti	O
-	O
TF	O
antibody	O
showed	O
that	O
N-acetyl	O
-	O
cysteine	O
treatment	O
prevented	B-Negative_regulation
the	O
characteristic	O
plasmalemmal	O
localization	B-Localization
of	O
TF	O
antigen	O
that	O
occurs	B-Positive_regulation
in	O
response	O
to	O
LPS	O
.	O

Western	O
blot	O
analysis	O
showed	O
that	O
N-acetyl	O
-	O
cysteine	O
reduced	O
the	O
accumulation	O
of	O
the	O
47	O
-	O
kD	O
mature	O
glycoprotein	O
in	O
LPS	O
-	O
treated	O
cells	O
,	O
a	O
finding	O
consistent	O
with	O
the	O
results	O
of	O
the	O
immunofluorescence	O
studies	O
.	O

Furthermore	O
,	O
these	O
conditions	O
did	O
not	O
result	B-Positive_regulation
in	O
an	O
accumulation	B-Positive_regulation
of	O
the	O
less	O
mature	O
forms	O
of	O
TF	O
.	O

When	O
considered	O
together	O
,	O
these	O
data	O
suggest	O
that	O
antioxidants	O
exert	O
their	O
effects	O
by	O
impairing	O
translation	O
and/or	O
by	O
causing	O
degradation	O
of	O
newly	O
translated	O
protein	O
.	O

The	O
effect	O
of	O
antioxidants	O
on	O
tumor	O
necrosis	O
factor	O
appeared	O
to	O
be	O
species	O
specific	O
,	O
with	O
no	O
effect	O
on	O
LPS	O
-	O
induced	O
tumor	O
necrosis	O
factor	O
in	O
murine	O
cells	O
,	O
but	O
with	O
inhibition	O
in	O
human	O
monocytes	O
.	O

The	O
posttranscriptional	B-Regulation
effect	I-Regulation
of	O
antioxidants	O
on	O
TF	O
expression	B-Gene_expression
data	O
suggests	O
a	O
novel	O
mechanism	O
whereby	O
these	O
agents	O
might	O
modulate	O
monocyte/macrophage	O
activation	O
.	O

Regulation	B-Regulation
of	O
I	O
kappa	O
B	O
alpha	O
and	O
p105	O
in	O
monocytes	O
and	O
macrophages	O
persistently	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
.	O

The	O
mechanisms	O
regulating	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
persistence	O
in	O
human	O
monocytes/macrophages	O
are	O
partially	O
understood	O
.	O

Persistent	O
HIV	O
infection	O
of	O
U937	O
monocytic	O
cells	O
results	O
in	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

Whether	O
virus	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
is	O
a	O
mechanism	O
that	O
favors	O
continuous	O
viral	O
replication	O
in	O
macrophages	O
remains	O
unknown	O
.	O

To	O
further	O
delineate	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
HIV	O
-	O
infected	O
monocytes	O
and	O
macrophages	O
,	O
we	O
have	O
focused	O
on	O
the	O
regulation	O
of	O
the	O
I	O
kappa	O
B	O
molecules	O
.	O

First	O
,	O
we	O
show	O
that	O
persistent	O
HIV	O
infection	O
results	O
in	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
not	O
only	O
in	O
monocytic	O
cells	O
but	O
also	O
in	O
macrophages	O
.	O

In	O
HIV	O
-	O
infected	O
cells	O
,	O
I	O
kappa	O
B	O
alpha	O
protein	O
levels	O
are	O
decreased	B-Negative_regulation
secondary	O
to	O
enhanced	O
protein	O
degradation	O
.	O

This	O
parallels	O
the	O
increased	O
I	O
kappa	O
B	O
alpha	O
synthesis	O
secondary	O
to	O
increased	B-Positive_regulation
I	O
kappa	O
B	O
alpha	O
gene	O
transcription	B-Transcription
,	O
i.e.	O
,	O
increased	B-Positive_regulation
RNA	O
and	O
transcriptional	B-Transcription
activity	I-Transcription
of	O
its	O
promoter	O
-	O
enhancer	O
.	O

Another	O
protein	O
with	O
I	O
kappa	O
B	O
function	O
,	O
p105	O
,	O
is	O
also	O
modified	B-Regulation
in	O
HIV	O
-	O
infected	O
cells	O
:	O
p105	O
and	O
p50	O
steady	O
-	O
state	O
protein	O
levels	O
are	O
increased	B-Positive_regulation
as	O
a	O
result	O
of	O
increased	O
synthesis	O
and	O
proteolytic	O
processing	O
of	O
p105	O
.	O

Transcriptional	B-Transcription
activity	I-Transcription
of	O
p105	O
is	O
also	O
increased	B-Positive_regulation
in	O
infected	O
cells	O
and	O
is	O
also	O
mediated	B-Positive_regulation
by	O
NF	O
-	O
kappa	O
B	O
through	O
a	O
specific	O
kappa	O
B	O
motif	O
.	O

These	O
results	O
demonstrate	O
the	O
existence	O
of	O
a	O
triple	B-Regulation
autoregulatory	I-Regulation
loop	I-Regulation
in	O
monocytes	O
and	O
macrophages	O
involving	O
HIV	O
,	O
p105	O
and	O
p50	O
,	O
and	O
MAD3	O
,	O
with	O
the	O
end	O
result	O
of	O
persistent	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
viral	O
persistence	O
.	O

Furthermore	O
,	O
persistent	O
HIV	O
infection	O
of	O
monocytes	O
and	O
macrophages	O
provides	O
a	O
useful	O
model	O
with	O
which	O
to	O
study	O
concomitant	O
modifications	O
of	O
different	O
I	O
kappa	O
B	O
molecules	O
.	O

Expression	B-Gene_expression
and	O
genomic	O
configuration	O
of	O
GM	O
-	O
CSF	O
,	O
IL	O
-	O
3	O
,	O
M	O
-	O
CSF	O
receptor	O
(	O
C	O
-	O
FMS	O
)	O
,	O
early	O
growth	O
response	O
gene	O
-	O
1	O
(	O
EGR	O
-	O
1	O
)	O
and	O
M	O
-	O
CSF	O
genes	O
in	O
primary	O
myelodysplastic	O
syndromes	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
from	O
seventeen	O
patients	O
with	O
primary	O
myelodysplastic	O
syndromes	O
(	O
MDS	O
)	O
in	O
advanced	O
stage	O
were	O
enriched	O
for	O
blasts	O
and	O
tested	O
for	O
(	O
1	O
)	O
karyotype	O
,	O
(	O
2	O
)	O
genomic	O
configuration	O
and	O
(	O
3	O
)	O
expression	B-Gene_expression
of	O
IL	O
-	O
3	O
,	O
GM	O
-	O
CSF	O
,	O
FMS	O
and	O
EGR	O
-	O
1	O
genes	O
which	O
are	O
all	O
located	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
5	O
.	O

The	O
expression	B-Gene_expression
of	O
the	O
M	O
-	O
CSF	O
gene	O
,	O
that	O
has	O
been	O
recently	O
reassigned	O
to	O
the	O
short	O
arm	O
of	O
chromosome	O
1	O
(	O
lp	O
)	O
,	O
was	O
also	O
investigated	O
.	O

Aims	O
of	O
the	O
study	O
were	O
to	O
(	O
1	O
)	O
assess	O
the	O
potential	O
role	O
of	O
the	O
expression	B-Gene_expression
of	O
these	O
genes	O
in	O
the	O
maintenance	O
and	O
expansion	O
of	O
the	O
neoplastic	O
clones	O
and	O
(	O
2	O
)	O
search	O
for	O
constitutional	O
losses	O
or	O
rearrangements	O
of	O
one	O
allele	O
followed	O
by	O
a	O
deletion	O
of	O
the	O
second	O
allele	O
of	O
the	O
same	O
genes	O
in	O
the	O
leukemic	O
cells	O
.	O

The	O
latter	O
issue	O
was	O
investigated	O
by	O
comparing	O
,	O
in	O
8	O
cases	O
,	O
constitutive	O
DNA	O
from	O
skin	O
fibroblasts	O
with	O
leukemic	O
DNA	O
.	O

Eleven	O
of	O
the	O
17	O
patients	O
had	O
abnormal	O
karyotypes	O
.	O

The	O
M	O
-	O
CSF	O
gene	O
was	O
expressed	B-Gene_expression
in	O
6	O
cases	O
and	O
the	O
FMS	O
and	O
the	O
EGR	O
-	O
1	O
genes	O
were	O
expressed	B-Gene_expression
in	O
2	O
of	O
the	O
latter	O
cases	O
.	O

An	O
autocrine	O
mechanism	O
of	O
growth	O
could	O
be	O
hypothesized	O
only	O
for	O
the	O
2	O
patients	O
whose	O
cells	O
expressed	B-Gene_expression
both	O
the	O
M	O
-	O
CSF	O
and	O
FMS	O
genes	O
.	O

No	O
germline	O
changes	B-Regulation
or	O
rearrangements	O
were	O
observed	O
in	O
any	O
of	O
the	O
genes	O
studied	O
.	O

Thus	O
,	O
deregulation	O
of	O
genes	O
encoding	O
for	O
certain	O
hemopoietic	O
growth	O
factors	O
or	O
receptors	O
does	O
not	O
seem	O
to	O
represent	O
a	O
major	O
mechanism	O
of	O
MDS	O
progression	O
.	O

OBF	O
-	O
1	O
,	O
a	O
novel	O
B	O
cell	O
-	O
specific	O
coactivator	O
that	O
stimulates	O
immunoglobulin	O
promoter	O
activity	O
through	O
association	B-Binding
with	O
octamer	O
-	O
binding	O
proteins	O
.	O

Recent	O
biochemical	O
and	O
genetic	O
studies	O
indicate	O
that	O
in	O
addition	O
to	O
the	O
octamer	O
-	O
binding	O
proteins	O
Oct	O
-	O
1	O
and	O
Oct	O
-	O
2	O
,	O
other	O
B	O
cell	O
components	O
are	O
required	O
for	O
lymphoid	O
-	O
restricted	O
,	O
octamer	O
site	O
-	O
mediated	O
immunoglobulin	O
gene	O
promoter	O
activity	O
.	O

Using	O
a	O
genetic	O
screen	O
in	O
yeast	O
,	O
we	O
have	O
isolated	O
B	O
cell	O
-	O
derived	O
cDNAs	O
encoding	O
Oct	O
-	O
binding	O
factor	O
1	O
(	O
OBF	O
-	O
1	O
)	O
,	O
a	O
novel	O
protein	O
that	O
specifically	O
associates	B-Binding
with	O
Oct	O
-	O
1	O
and	O
Oct	O
-	O
2	O
.	O

Biochemical	O
studies	O
demonstrate	O
that	O
OBF	O
-	O
1	O
has	O
no	O
intrinsic	O
DNA	O
-	O
binding	B-Binding
activity	O
and	O
recognizes	B-Binding
the	O
POU	O
domains	O
of	O
Oct	O
-	O
1	O
and	O
Oct	O
-	O
2	O
,	O
but	O
not	O
those	O
of	O
Oct	O
-	O
4	O
and	O
Oct	O
-	O
6	O
.	O

The	O
OBF	O
-	O
1	O
mRNA	O
is	O
expressed	B-Transcription
in	O
a	O
highly	O
cell	O
-	O
specific	O
manner	O
,	O
being	O
most	O
abundant	O
in	O
B	O
cells	O
and	O
essentially	O
absent	O
in	O
most	O
of	O
the	O
other	O
cells	O
or	O
tissues	O
tested	O
.	O

Furthermore	O
,	O
expression	B-Gene_expression
of	O
OBF	O
-	O
1	O
in	O
HeLa	O
cells	O
selectively	O
stimulates	O
the	O
activity	O
of	O
a	O
natural	O
immunoglobulin	O
promoter	O
in	O
an	O
octamer	O
site	O
-	O
dependent	O
manner	O
.	O

Thus	O
,	O
OBF	O
-	O
1	O
has	O
all	O
the	O
properties	O
expected	O
for	O
a	O
B	O
cell	O
-	O
specific	O
transcriptional	O
coactivator	O
protein	O
.	O

Glucocorticoid	O
-	O
induced	O
apoptosis	O
of	O
human	O
leukemic	O
cells	O
is	O
caused	O
by	O
the	O
repressive	O
function	O
of	O
the	O
glucocorticoid	O
receptor	O
.	O

Induction	O
of	O
apoptosis	O
in	O
lymphocytes	O
,	O
which	O
may	O
account	O
for	O
the	O
therapeutic	O
effects	O
of	O
glucocorticoids	O
in	O
various	O
diseases	O
including	O
leukemia	O
,	O
depends	O
on	O
the	O
glucocorticoid	O
receptor	O
.	O

However	O
,	O
the	O
events	O
leading	O
from	O
the	O
activated	B-Positive_regulation
receptor	O
to	O
cell	O
lysis	O
are	O
not	O
understood	O
.	O

A	O
prevailing	O
hypothesis	O
postulates	O
induction	O
of	O
so	O
-	O
called	O
'lysis	O
genes	O
'	O
by	O
the	O
activated	B-Positive_regulation
receptor	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
an	O
activation	O
-	O
deficient	O
glucocorticoid	O
receptor	O
mutant	O
is	O
as	O
effective	O
as	O
the	O
wild	O
-	O
type	O
receptor	O
in	O
repression	O
of	O
AP	O
-	O
1	O
activity	O
,	O
inhibition	B-Negative_regulation
of	O
interleukin	O
-	O
2	O
production	B-Gene_expression
,	O
inhibition	B-Negative_regulation
of	O
c	O
-	O
myc	O
expression	B-Gene_expression
and	O
induction	O
of	O
apoptosis	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
retinoic	O
acid	O
can	O
also	O
induce	O
apoptosis	O
in	O
these	O
cells	O
through	O
the	O
retinoic	O
acid	O
receptor	O
,	O
whose	O
repressive	O
functions	O
but	O
not	O
target	O
site	O
specificity	O
,	O
are	O
similar	O
to	O
those	O
of	O
the	O
glucocorticoid	O
receptor	O
.	O

Therefore	O
,	O
the	O
primary	O
effect	O
of	O
the	O
receptor	O
in	O
glucocorticoid	O
-	O
mediated	O
apoptosis	O
correlates	O
with	O
transcriptional	O
repression	O
rather	O
than	O
activation	O
and	O
could	O
be	O
mediated	O
by	O
interference	O
with	O
other	O
transcription	O
factors	O
required	O
for	O
cell	O
survival	O
.	O

HIV	O
-	O
1	O
Tat	O
potentiates	O
TNF	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
cytotoxicity	O
by	O
altering	O
the	O
cellular	O
redox	O
state	O
.	O

This	O
study	O
demonstrates	O
that	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
Tat	O
protein	O
amplifies	O
the	O
activity	O
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
,	O
a	O
cytokine	O
that	O
stimulates	O
HIV	O
-	O
1	O
replication	O
through	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

In	O
HeLa	O
cells	O
stably	O
transfected	O
with	O
the	O
HIV	O
-	O
1	O
tat	O
gene	O
(	O
HeLa	O
-	O
tat	O
cells	O
)	O
,	O
expression	B-Gene_expression
of	O
the	O
Tat	O
protein	O
enhanced	O
both	O
TNF	O
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
TNF	O
-	O
mediated	O
cytotoxicity	O
.	O

A	O
similar	O
potentiation	O
of	O
TNF	O
effects	O
was	O
observed	O
in	O
Jurkat	O
T	O
cells	O
and	O
HeLa	O
cells	O
treated	O
with	O
soluble	O
Tat	O
protein	O
.	O

TNF	O
-	O
mediated	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
cytotoxicity	O
involves	O
the	O
intracellular	O
formation	O
of	O
reactive	O
oxygen	O
intermediates	O
.	O

Therefore	O
,	O
Tat	O
-	O
mediated	O
effects	O
on	O
the	O
cellular	O
redox	O
state	O
were	O
analyzed	O
.	O

In	O
both	O
T	O
cells	O
and	O
HeLa	O
cells	O
HIV	O
-	O
1	O
Tat	O
suppressed	B-Negative_regulation
the	O
expression	B-Gene_expression
of	O
Mn	O
-	O
dependent	O
superoxide	O
dismutase	O
(	O
Mn	O
-	O
SOD	O
)	O
,	O
a	O
mitochondrial	O
enzyme	O
that	O
is	O
part	O
of	O
the	O
cellular	O
defense	O
system	O
against	O
oxidative	O
stress	O
.	O

Thus	O
,	O
Mn	O
-	O
SOD	O
RNA	B-Transcription
protein	B-Gene_expression
levels	I-Gene_expression
and	O
activity	O
were	O
markedly	O
reduced	B-Negative_regulation
in	O
the	O
presence	O
of	O
Tat	O
.	O

Decreased	B-Negative_regulation
Mn	O
-	O
SOD	O
expression	B-Gene_expression
was	O
associated	O
with	O
decreased	O
levels	O
of	O
glutathione	O
and	O
a	O
lower	O
ratio	O
of	O
reduced	O
:	O
oxidized	O
glutathione	O
.	O

A	O
truncated	O
Tat	O
protein	O
(	O
Tat1	O
-	O
72	O
)	O
,	O
known	O
to	O
transactivate	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
,	O
no	O
longer	O
affected	B-Regulation
Mn	O
-	O
SOD	O
expression	B-Gene_expression
,	O
the	O
cellular	O
redox	O
state	O
or	O
TNF	O
-	O
mediated	O
cytotoxicity	O
.	O

Thus	O
,	O
our	O
experiments	O
demonstrate	O
that	O
the	O
C	O
-	O
terminal	O
region	O
of	O
HIV	O
-	O
1	O
Tat	O
is	O
required	O
to	O
suppress	B-Negative_regulation
Mn	O
-	O
SOD	O
expression	B-Gene_expression
and	O
to	O
induce	O
pro	O
-	O
oxidative	O
conditions	O
reflected	O
by	O
a	O
drop	O
in	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
and	O
the	O
GSH	O
:	O
oxidized	O
GSH	O
(	O
GSSG	O
)	O
ratio	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Expression	O
of	O
the	O
Runt	O
domain	O
-	O
encoding	O
PEBP2	O
alpha	O
genes	O
in	O
T	O
cells	O
during	O
thymic	O
development	O
.	O

The	O
PEBP2	O
alpha	O
A	O
and	O
PEBP2	O
alpha	O
B	O
genes	O
encode	O
the	O
DNA	O
-	O
binding	O
subunit	O
of	O
a	O
murine	O
transcription	O
factor	O
,	O
PEBP2	O
,	O
which	O
is	O
implicated	O
as	O
a	O
T-cell	O
-	O
specific	O
transcriptional	O
regulator	O
.	O

These	O
two	O
related	O
genes	O
share	O
the	O
evolutionarily	O
conserved	O
region	O
encoding	O
the	O
Runt	O
domain	O
.	O

PEBP2	O
alpha	O
B	O
is	O
the	O
murine	O
counterpart	O
of	O
human	O
AML1	O
,	O
which	O
is	O
located	O
at	O
the	O
breakpoints	O
of	O
the	O
8	O
;	O
21	O
and	O
3	O
;	O
21	O
chromosome	O
translocations	O
associated	O
with	O
acute	O
myeloid	O
leukemia	O
.	O

Northern	O
(	O
RNA	O
)	O
blots	O
of	O
various	O
adult	O
mouse	O
tissues	O
revealed	O
that	O
the	O
levels	O
of	O
expression	B-Gene_expression
of	O
both	O
genes	O
were	O
most	O
prominent	B-Positive_regulation
in	O
the	O
thymus	O
.	O

Furthermore	O
,	O
transcripts	O
of	O
PEBP2	O
alpha	O
A	O
and	O
mouse	O
AML1/PEBP2	O
alpha	O
B	O
were	O
detected	B-Transcription
in	O
T	O
lymphocytes	O
in	O
the	O
thymuses	O
from	O
day	O
16	O
embryos	O
and	O
newborns	O
,	O
as	O
well	O
as	O
4-week	O
-	O
old	O
adult	O
mice	O
,	O
by	O
in	O
situ	O
hybridization	O
.	O

The	O
expression	B-Gene_expression
of	O
the	O
genes	O
persisted	B-Positive_regulation
in	O
peripheral	O
lymph	O
nodes	O
of	O
adult	O
mice	O
.	O

The	O
transcripts	O
were	O
detected	B-Transcription
in	O
all	O
the	O
CD4	O
-	O
CD8	O
-	O
,	O
CD4+	O
CD8+	O
,	O
CD4+	O
CD8	O
-	O
,	O
and	O
CD4	O
-	O
CD8+	O
cell	O
populations	O
.	O

The	O
results	O
indicated	O
that	O
both	O
genes	O
are	O
expressed	B-Gene_expression
in	O
T	O
cells	O
throughout	O
their	O
development	O
,	O
supporting	O
the	O
notion	O
that	O
PEBP2	O
is	O
a	O
T-cell	O
-	O
specific	O
transcription	O
factor	O
.	O

Transcripts	O
of	O
mouse	O
AML1/PEBP2	O
alpha	O
B	O
were	O
also	O
detected	B-Transcription
in	O
day	O
12	O
fetal	O
hematopoietic	O
liver	O
and	O
in	O
the	O
bone	O
marrow	O
cells	O
of	O
newborn	O
mice	O
.	O

The	O
implication	O
of	O
mouse	O
AML1/PEBP2	O
alpha	O
B	O
expression	B-Gene_expression
in	O
hematopoietic	O
cells	O
other	O
than	O
those	O
of	O
T	O
-	O
cell	O
lineage	O
is	O
discussed	O
in	O
relation	O
to	O
myeloid	O
leukemogenesis	O
.	O

Regulation	B-Regulation
of	O
cell-type	O
-	O
specific	O
interleukin	O
-	O
2	O
receptor	O
alpha	O
-	O
chain	O
gene	O
expression	B-Gene_expression
:	O
potential	O
role	O
of	O
physical	O
interactions	B-Binding
between	O
Elf	O
-	O
1	O
,	O
HMG	O
-	O
I	O
(	O
Y	O
)	O
,	O
and	O
NF	O
-	O
kappa	O
B	O
family	O
proteins	O
.	O

The	O
interleukin	O
2	O
receptor	O
alpha	O
-	O
chain	O
(	O
IL	O
-	O
2R	O
alpha	O
)	O
gene	O
is	O
rapidly	O
and	O
potently	O
induced	B-Gene_expression
in	O
T	O
cells	O
in	O
response	B-Positive_regulation
to	O
mitogenic	O
stimuli	O
.	O

Previously	O
,	O
an	O
inducible	O
enhancer	O
between	O
nucleotides	O
-	O
299	O
and	O
-	O
228	O
that	O
contains	O
NF	O
-	O
kappa	O
B	O
and	O
CArG	O
motifs	O
was	O
identified	O
.	O

We	O
now	O
report	O
the	O
characterization	O
of	O
a	O
second	O
essential	O
positive	O
regulatory	O
element	O
located	O
between	O
nucleotides	O
-	O
137	O
and	O
-	O
64	O
that	O
binds	B-Binding
Elf	O
-	O
1	O
and	O
HMG	O
-	O
I	O
(	O
Y	O
)	O
.	O

This	O
element	O
had	O
maximal	O
activity	O
in	O
lymphoid	O
cells	O
,	O
paralleling	O
the	O
cell	O
type	O
specificity	O
of	O
Elf	O
-	O
1	O
expression	B-Gene_expression
.	O

Transcription	B-Transcription
from	B-Positive_regulation
the	O
IL	O
-	O
2R	O
alpha	O
promoter	O
was	O
inhibited	B-Negative_regulation
when	O
either	O
the	O
Elf	O
-	O
1	O
or	O
the	O
HMG	O
-	O
I	O
(	O
Y	O
)	O
binding	O
site	O
was	O
mutated	O
.	O

Coexpression	B-Gene_expression
of	O
both	O
proteins	O
activated	O
transcription	O
of	O
the	O
-	O
137	O
to	O
-	O
64	O
element	O
in	O
COS	O
-	O
7	O
cells	O
.	O

Elf	O
-	O
1	O
physically	O
associated	B-Binding
with	O
HMG	O
-	O
I	O
and	O
with	O
NF	O
-	O
kappa	O
B	O
p50	O
and	O
c	O
-	O
Rel	O
in	O
vitro	O
,	O
suggesting	O
that	O
protein	O
-	O
protein	O
interactions	O
might	O
functionally	O
coordinate	O
the	O
actions	O
of	O
the	O
upstream	O
and	O
downstream	O
positive	O
regulatory	O
elements	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
physical	O
interaction	O
between	O
an	O
Ets	O
family	O
member	O
and	O
NF	O
-	O
kappa	O
B	O
family	O
proteins	O
.	O

These	O
findings	O
provide	O
significant	O
new	O
insights	O
into	O
the	O
protein	O
-	O
protein	O
and	O
protein	O
-	O
DNA	O
interactions	O
that	O
regulate	B-Regulation
cell-type	O
-	O
specific	O
and	O
inducible	O
IL	O
-	O
2R	O
alpha	O
gene	O
expression	B-Gene_expression
and	O
also	O
have	O
implications	O
for	O
other	O
genes	O
regulated	O
by	O
Elf	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
family	O
proteins	O
.	O

Effects	O
of	O
glucocorticoids	O
on	O
transcription	O
factor	O
activation	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Glucocorticoids	O
have	O
an	O
inhibitory	O
effect	O
on	O
inflammatory	O
and	O
immune	O
responses	O
,	O
and	O
this	O
may	O
be	O
through	O
the	O
modulation	O
of	O
transcription	O
factor	O
binding	O
to	O
DNA	O
.	O

The	O
interaction	B-Binding
of	O
the	O
transcription	O
factors	O
,	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
,	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
kappa	O
B	O
)	O
,	O
and	O
cAMP	O
-	O
responsive	O
element	O
binding	O
protein	O
(	O
CREB	O
)	O
with	O
DNA	O
and	O
glucocorticoid	O
receptors	O
(	O
GR	O
)	O
was	O
analyzed	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
gel	O
mobility	O
shift	O
assays	O
.	O

TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1	O
beta	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
treatment	O
increased	O
AP	O
-	O
1	O
and	O
NF	O
kappa	O
B	O
DNA	O
binding	O
by	O
up	O
to	O
200	O
%	O
but	O
decreased	O
CREB	O
binding	O
(	O
38	O
%	O
)	O
over	O
a	O
60	O
-	O
min	O
time	O
course	O
.	O

Dexamethasone	O
produced	O
a	O
rapid	O
and	O
sustained	O
increase	O
in	O
glucocorticoid	O
response	O
element	O
binding	O
and	O
a	O
concomitant	O
40	O
-	O
50	O
%	O
decrease	O
in	O
AP	O
-	O
1	O
,	O
NF	O
kappa	O
B	O
,	O
and	O
CREB	O
DNA	O
binding	O
that	O
was	O
blocked	O
by	O
combined	O
dexamethasone	O
and	O
cytokine	O
or	O
PMA	O
treatment	O
.	O

These	O
latter	O
effects	O
were	O
due	O
to	O
increases	O
in	O
the	O
nuclear	O
localization	B-Localization
of	O
GR	O
,	O
not	O
to	O
reduced	O
amounts	O
of	O
the	O
other	O
transcription	O
factors	O
.	O

This	O
suggests	O
that	O
in	O
these	O
cells	O
GR	O
within	O
the	O
nucleus	O
interacts	B-Binding
with	O
cytokine	O
-	O
stimulated	O
transcription	O
factors	O
by	O
the	O
process	O
of	O
cross	O
coupling	O
.	O

This	O
may	O
be	O
an	O
important	O
molecular	O
site	O
of	O
steroid	O
action	O
.	O

Isolation	O
of	O
cDNA	O
clones	O
for	O
42	O
different	O
Kruppel	O
-	O
related	O
zinc	O
finger	O
proteins	O
expressed	O
in	O
the	O
human	O
monoblast	O
cell	O
line	O
U	O
-	O
937	O
.	O

To	O
study	O
the	O
complexity	O
and	O
structural	O
characteristics	O
of	O
zinc	O
finger	O
proteins	O
expressed	O
during	O
human	O
hematopoiesis	O
and	O
to	O
isolate	O
novel	O
regulators	O
of	O
blood	O
cell	O
development	O
,	O
a	O
degenerate	O
oligonucleotide	O
probe	O
specific	O
for	O
a	O
consensus	O
zinc	O
finger	O
peptide	O
domain	O
was	O
used	O
to	O
isolate	O
63	O
cDNA	O
clones	O
for	O
Kruppel	O
-	O
related	O
zinc	O
finger	O
genes	O
from	O
the	O
human	O
monoblast	O
cell	O
line	O
U	O
-	O
937	O
.	O

By	O
extensive	O
nucleotide	O
sequence	O
and	O
Northern	O
blot	O
analysis	O
,	O
these	O
cDNA	O
clones	O
were	O
found	O
to	O
originate	O
from	O
approximately	O
42	O
different	O
genes	O
(	O
HZF	O
1	O
-	O
42	O
)	O
of	O
which	O
only	O
8	O
have	O
previously	O
been	O
described	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
a	O
majority	O
of	O
these	O
genes	O
were	O
expressed	B-Gene_expression
at	O
comparable	O
levels	O
in	O
U	O
-	O
937	O
and	O
HeLa	O
cells	O
.	O

The	O
large	O
number	O
of	O
individual	O
genes	O
represented	O
among	O
the	O
63	O
clones	O
and	O
their	O
apparent	O
non-cell-type	O
-	O
specific	O
expression	B-Gene_expression
suggest	O
that	O
the	O
majority	O
of	O
the	O
Kruppel	O
-	O
related	O
zinc	O
finger	O
genes	O
are	O
likely	O
to	O
be	O
expressed	O
in	O
most	O
human	O
tissues	O
.	O

In	O
contrast	O
,	O
some	O
of	O
the	O
genes	O
displayed	O
a	O
restricted	O
expression	B-Gene_expression
pattern	O
,	O
indicating	O
that	O
they	O
represent	O
potential	O
regulators	O
of	O
monocyte	O
differentiation	O
or	O
proliferation	O
.	O

Detailed	O
structural	O
analysis	O
of	O
the	O
first	O
12	O
cDNAs	O
(	O
HZF	O
1	O
-	O
10	O
)	O
and	O
a	O
partial	O
characterization	O
of	O
HZF	O
11	O
-	O
42	O
revealed	O
that	O
a	O
common	O
feature	O
of	O
human	O
Kruppel	O
-	O
related	O
zinc	O
finger	O
proteins	O
is	O
the	O
presence	O
of	O
tandem	O
arrays	O
of	O
zinc	O
fingers	O
ranging	O
in	O
number	O
from	O
3	O
to	O
over	O
20	O
that	O
are	O
preferentially	O
located	O
in	O
the	O
carboxy	O
-	O
terminal	O
regions	O
of	O
the	O
proteins	O
.	O

In	O
addition	O
,	O
several	O
novel	O
KRAB	O
-	O
containing	O
zinc	O
finger	O
genes	O
and	O
a	O
novel	O
conserved	O
sequence	O
element	O
were	O
identified	O
.	O

Calcium/calmodulin	O
-	O
dependent	O
protein	O
kinase	O
II	O
downregulates	O
both	O
calcineurin	O
and	O
protein	O
kinase	O
C	O
-	O
mediated	O
pathways	O
for	O
cytokine	O
gene	O
transcription	O
in	O
human	O
T	O
cells	O
.	O

Engagement	O
of	O
the	O
T	O
cell	O
receptor	O
for	O
antigen	O
activates	O
phospholipase	O
C	O
resulting	O
in	O
an	O
increase	O
in	O
intracellular	O
free	O
calcium	O
concentration	O
(	O
[	O
Ca2+	O
]	O
i	O
)	O
and	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
.	O

Increased	O
[	O
Ca2+	O
]	O
i	O
activates	O
Ca2+/calmodulin	O
-	O
dependent	O
kinases	O
including	O
the	O
multifunctional	O
Ca2+/calmodulin	O
-	O
dependent	O
protein	O
kinase	O
II	O
(	O
CaM	O
-	O
K	O
II	O
)	O
,	O
as	O
well	O
as	O
calcineurin	O
,	O
a	O
type	O
2B	O
protein	O
phosphatase	O
.	O

Recent	O
studies	O
have	O
identified	O
calcineurin	O
as	O
a	O
key	B-Positive_regulation
enzyme	I-Positive_regulation
for	O
interleukin	O
(	O
IL	O
)	O
-	O
2	O
and	O
IL	O
-	O
4	O
promoter	O
activation	B-Positive_regulation
.	O

However	O
,	O
the	O
role	O
of	O
CaM	O
-	O
K	O
II	O
remains	O
unknown	O
.	O

We	O
have	O
used	O
mutants	O
of	O
these	O
kinases	O
and	O
phosphatases	O
(	O
gamma	O
B*CaM	O
-	O
K	O
and	O
delta	O
CaM	O
-	O
AI	O
,	O
respectively	O
)	O
to	O
explore	O
their	O
relative	O
role	O
in	O
cytokine	O
gene	O
transcription	O
and	O
their	O
interactions	O
with	O
PKC	O
-	O
dependent	O
signaling	O
systems	O
.	O

gamma	O
B*CaM	O
-	O
K	O
and	O
delta	O
CaM	O
-	O
AI	O
,	O
known	O
to	O
exhibit	O
constitutive	O
Ca	O
(	O
2+	O
)	O
-	O
independent	O
activity	O
,	O
were	O
cotransfected	O
(	O
alone	O
or	O
in	O
combination	O
)	O
in	O
Jurkat	O
T	O
cells	O
with	O
a	O
plasmid	O
containing	O
the	O
intact	O
IL	O
-	O
2	O
promoter	O
driving	O
the	O
expression	O
of	O
the	O
chloramphenicol	O
acetyltransferase	O
reporter	O
gene	O
.	O

Cotransfection	O
of	O
gamma	O
B*CaM	O
-	O
K	O
with	O
the	O
IL	O
-	O
2	O
promoter	O
construct	O
downregulated	O
its	O
transcription	O
in	O
response	O
to	O
stimulation	O
with	O
ionomycin	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
.	O

The	O
inhibitory	B-Negative_regulation
effect	I-Negative_regulation
of	O
CaM	O
-	O
K	O
II	O
on	O
IL	O
-	O
2	O
promoter	O
was	O
associated	O
with	O
decreased	B-Negative_regulation
transcription	B-Transcription
of	O
its	O
AP	O
-	O
1	O
and	O
NF	O
-	O
AT	O
transactivating	B-Positive_regulation
pathways	I-Positive_regulation
.	O

Under	O
the	O
same	O
conditions	O
,	O
delta	O
CaM	O
-	O
AI	O
superinduced	B-Positive_regulation
IL	O
-	O
2	O
promoter	O
activity	O
(	O
approximately	O
twofold	O
increase	O
)	O
.	O

When	O
both	O
mutants	O
were	O
used	O
in	O
combination	O
,	O
gamma	O
B*CaM	O
-	O
K	O
inhibited	B-Negative_regulation
the	O
induction	B-Positive_regulation
of	O
the	O
IL	O
-	O
2	O
promoter	O
by	O
delta	O
CaM	O
-	O
AI	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
a	O
construct	O
containing	O
the	O
IL	O
-	O
4	O
promoter	O
also	O
was	O
used	O
.	O

gamma	O
B*CaM	O
-	O
K	O
also	O
downregulated	O
the	O
activation	O
of	O
AP	O
-	O
1	O
in	O
response	O
to	O
transfection	O
with	O
a	O
constitutively	O
active	O
mutant	O
of	O
PKC	O
or	O
stimulation	O
with	O
PMA	O
.	O

These	O
results	O
suggest	O
that	O
CaM	O
-	O
K	O
II	O
may	O
exert	O
negative	O
influences	O
on	O
cytokine	O
gene	O
transcription	O
in	O
human	O
T	O
cells	O
,	O
and	O
provide	O
preliminary	O
evidence	O
for	O
negative	O
cross	O
-	O
talk	O
with	O
the	O
calcineurin	O
-	O
and	O
PKC	O
-	O
dependent	O
signaling	O
systems	O
.	O

Control	B-Regulation
of	O
I	O
kappa	O
B	O
-	O
alpha	O
proteolysis	B-Protein_catabolism
by	O
site	O
-	O
specific	O
,	O
signal	O
-	O
induced	O
phosphorylation	B-Phosphorylation
.	O

I	O
kappa	O
B	O
-	O
alpha	O
inhibits	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
by	O
retaining	O
it	O
in	O
the	O
cytoplasm	O
.	O

Various	O
stimuli	O
,	O
typically	O
those	O
associated	O
with	O
stress	O
or	O
pathogens	O
,	O
rapidly	O
inactivate	B-Negative_regulation
I	O
kappa	O
B	O
-	O
alpha	O
.	O

This	O
liberates	O
NF	O
-	O
kappa	O
B	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
initiate	O
transcription	O
of	O
genes	O
important	O
for	O
the	O
defense	O
of	O
the	O
organism	O
.	O

Activation	O
of	O
NF	O
-	O
kappa	O
B	O
correlates	O
with	O
phosphorylation	B-Phosphorylation
of	O
I	O
kappa	O
B	O
-	O
alpha	O
and	O
requires	B-Regulation
the	O
proteolysis	B-Protein_catabolism
of	O
this	O
inhibitor	O
.	O

When	O
either	O
serine	O
-	O
32	O
or	O
serine	O
-	O
36	O
of	O
I	O
kappa	O
B	O
-	O
alpha	O
was	O
mutated	O
,	O
the	O
protein	O
did	O
not	O
undergo	O
signal	O
-	O
induced	O
phosphorylation	B-Phosphorylation
or	O
degradation	B-Protein_catabolism
,	O
and	O
NF	O
-	O
kappa	O
B	O
could	O
not	O
be	O
activated	O
.	O

These	O
results	O
suggest	O
that	O
phosphorylation	B-Phosphorylation
at	O
one	O
or	O
both	O
of	O
these	O
residues	O
is	O
critical	O
for	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

HIV	O
-	O
1	O
Nef	O
leads	O
to	O
inhibition	O
or	O
activation	O
of	O
T	O
cells	O
depending	O
on	O
its	O
intracellular	O
localization	B-Localization
.	O

Nef	O
of	O
primate	O
lentiviruses	O
is	O
required	O
for	O
viremia	O
and	O
progression	O
to	O
AIDS	O
in	O
monkeys	O
.	O

Negative	O
,	O
positive	O
,	O
and	O
no	O
effects	O
of	O
Nef	O
have	O
also	O
been	O
reported	O
on	O
viral	O
replication	O
in	O
cells	O
.	O

To	O
reconcile	O
these	O
observations	O
,	O
we	O
expressed	O
a	O
hybrid	O
CD8	O
-	O
Nef	O
protein	O
in	O
Jurkat	O
cells	O
.	O

Two	O
opposite	O
phenotypes	O
were	O
found	O
,	O
which	O
depended	O
on	O
the	O
intracellular	O
localization	B-Localization
of	O
Nef	O
.	O

Expressed	O
in	O
the	O
cytoplasm	O
or	O
on	O
the	O
cell	O
surface	O
,	O
the	O
chimera	O
inhibited	O
or	O
activated	O
early	O
signaling	O
events	O
from	O
the	O
T	O
cell	O
antigen	O
receptor	O
.	O

Activated	O
Jurkat	O
cells	O
died	O
by	O
apoptosis	O
,	O
and	O
only	O
cells	O
with	O
mutated	O
nef	O
genes	O
expressing	B-Gene_expression
truncated	O
Nefs	O
survived	O
,	O
which	O
rendered	O
Nef	O
nonfunctional	O
.	O

These	O
mutations	O
paralleled	O
those	O
in	O
other	O
viral	O
strains	O
passaged	O
in	O
vitro	O
.	O

Not	O
only	O
do	O
these	O
positional	O
effects	O
of	O
Nef	O
reconcile	O
diverse	O
phenotypes	O
of	O
Nef	O
and	O
suggest	O
a	O
role	O
for	O
its	O
N	O
-	O
terminal	O
myristylation	O
,	O
but	O
they	O
also	O
explain	O
effects	O
of	O
Nef	O
in	O
HIV	O
infection	O
and	O
progression	O
to	O
AIDS	O
.	O

LMP	O
-	O
1	O
activates	O
NF	O
-	O
kappa	O
B	O
by	O
targeting	B-Regulation
the	O
inhibitory	O
molecule	O
I	O
kappa	O
B	O
alpha	O
.	O

LMP	O
-	O
1	O
,	O
an	O
Epstein	O
-	O
Barr	O
virus	O
membrane	O
protein	O
expressed	B-Gene_expression
during	O
latent	O
infection	O
,	O
has	O
oncogenic	O
properties	O
,	O
as	O
judged	O
from	O
its	O
ability	O
to	O
transform	O
B	O
lymphocytes	O
and	O
rodent	O
fibroblasts	O
.	O

LMP	O
-	O
1	O
induces	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
bcl2	O
,	O
an	O
oncogene	O
which	O
protects	O
cells	O
from	O
apoptosis	O
,	O
as	O
well	O
as	O
of	O
genes	O
encoding	O
other	O
proteins	O
involved	O
in	O
cell	O
regulation	O
and	O
growth	O
control	O
.	O

The	O
mechanisms	O
by	O
which	O
LMP	O
-	O
1	O
upregulates	B-Positive_regulation
these	O
proteins	O
is	O
unknown	O
,	O
but	O
it	O
is	O
plausible	O
that	O
LMP	O
-	O
1	O
modifies	O
signal	O
transduction	O
pathways	O
that	O
result	O
in	O
the	O
activation	O
of	O
one	O
or	O
more	O
transcription	O
factors	O
that	O
ultimately	O
regulate	O
transcription	O
of	O
oncogenic	O
genes	O
.	O

NF	O
-	O
kappa	O
B	O
,	O
a	O
transcription	O
factor	O
controlling	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
cell	O
activation	O
and	O
growth	O
control	O
,	O
has	O
been	O
shown	O
to	O
be	O
activated	O
by	O
LMP	O
-	O
1	O
.	O

The	O
mechanism	O
(	O
s	O
)	O
regulating	O
this	O
activation	O
remains	O
unknown	O
.	O

Our	O
data	O
indicate	O
that	O
increased	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
and	O
functional	O
activity	O
are	O
present	O
in	O
B	O
-	O
lymphoid	O
cells	O
stably	O
or	O
transiently	O
expressing	B-Gene_expression
LMP	O
-	O
1	O
.	O

I	O
kappa	O
B	O
alpha	O
is	O
selectively	O
modified	O
in	O
LMP-1	O
-	O
expressing	B-Gene_expression
B	O
cells	O
.	O

A	O
phosphorylated	B-Phosphorylation
form	I-Phosphorylation
of	O
I	O
kappa	O
B	O
alpha	O
and	O
increased	O
protein	O
turnover	O
-	O
degradation	O
correlate	O
with	O
increased	O
NF	O
-	O
kappa	O
B	O
nuclear	O
translocation	O
.	O

This	O
results	O
in	O
increased	B-Positive_regulation
transcription	B-Transcription
of	O
NF	O
-	O
kappa	O
B-dependent	O
-	O
genes	O
,	O
including	O
those	O
encoding	O
p105	O
and	O
I	O
kappa	O
B	O
alpha	O
(	O
MAD3	O
)	O
.	O

These	O
results	O
indicate	O
that	O
LMP	O
-	O
1	O
activates	O
NF	O
-	O
kappa	O
B	O
in	O
B	O
-	O
cell	O
lines	O
by	O
targeting	B-Regulation
I	O
kappa	O
B	O
alpha	O
.	O

Identification	O
of	O
the	O
pathways	O
activated	O
by	O
LMP	O
-	O
1	O
to	O
result	O
in	O
posttranslational	O
modifications	O
of	O
I	O
kappa	O
B	O
alpha	O
will	O
aid	O
in	O
determining	O
the	O
role	O
of	O
this	O
virus	O
-	O
host	O
cell	O
protein	O
interaction	O
in	O
Epstein	O
-	O
Barr	O
virus	O
-	O
mediated	O
oncogenesis	O
.	O

The	O
regulation	O
of	O
HIV	O
by	O
retinoic	O
acid	O
correlates	O
with	O
cellular	O
expression	O
of	O
the	O
retinoic	O
acid	O
receptors	O
.	O

OBJECTIVES	O
:	O
To	O
analyze	O
the	O
effect	O
of	O
retinoic	O
acids	O
(	O
RA	O
)	O
on	O
HIV	O
-	O
1	O
expression	O
and	O
correlate	O
this	O
effect	O
with	O
expression	O
levels	O
of	O
RA	O
receptors	O
(	O
RARs	O
)	O
in	O
T	O
-	O
lymphoid	O
and	O
monocytoid	O
cell	O
lines	O
.	O

DESIGN	O
AND	O
METHODS	O
:	O
The	O
effect	O
of	O
all	O
-	O
trans	O
and	O
9	O
-	O
cis	O
RA	O
on	O
HIV	O
-	O
1	O
production	O
in	O
T	O
-	O
lymphoid	O
(	O
H9	O
,	O
CEM	O
)	O
and	O
monocytoid	O
(	O
U937	O
,	O
THP	O
-	O
1	O
)	O
cell	O
lines	O
was	O
measured	O
during	O
acute	O
and	O
chronic	O
infection	O
.	O

The	O
expression	B-Gene_expression
levels	O
of	O
human	O
RAR	O
alpha	O
(	O
hRAR	O
alpha	O
,	O
receptor	B-Binding
for	O
all	O
-	O
trans	O
RA	O
)	O
and	O
the	O
human	O
retinoid	O
-	O
X	O
receptor	O
alpha	O
(	O
hRXR	O
alpha	O
receptor	B-Binding
for	O
9	O
-	O
cis	O
RA	O
)	O
were	O
determined	O
by	O
Northern	O
blot	O
analysis	O
.	O

RESULTS	O
:	O
Both	O
all	O
-	O
trans	O
and	O
9	O
-	O
cis	O
RA	O
inhibited	O
virus	O
replication	O
in	O
HIV	O
-	O
1	O
IIIB	O
-	O
infected	O
monocytoid	O
cells	O
,	O
in	O
the	O
presence	O
and	O
absence	O
of	O
the	O
co	O
-	O
stimulatory	O
agent	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
.	O

The	O
retinoids	O
had	O
weak	O
or	O
no	O
stimulatory	O
effects	O
on	O
HIV	O
production	O
by	O
T	O
-	O
cell	O
lines	O
.	O

HIV	O
production	O
by	O
PMA	O
-	O
stimulated	O
T	O
-	O
cell	O
lines	O
was	O
inhibited	O
by	O
these	O
retinoids	O
.	O

The	O
9	O
-	O
cis	O
RA	O
was	O
generally	O
more	O
effective	O
than	O
all	O
-	O
trans	O
RA	O
in	O
inhibiting	O
HIV	O
production	O
and	O
in	O
combination	O
generally	O
more	O
effective	O
than	O
the	O
single	O
agents	O
alone	O
.	O

Human	O
RAR	O
alpha	O
was	O
expressed	O
in	O
H9	O
,	O
U937	O
and	O
THP	O
-	O
1	O
cells	O
,	O
but	O
almost	O
undetectable	O
in	O
CEM	O
cells	O
.	O

Human	O
RXR	O
alpha	O
was	O
significantly	O
expressed	B-Gene_expression
in	O
U937	O
and	O
THP	O
-	O
1	O
cells	O
,	O
weakly	O
expressed	B-Gene_expression
in	O
H9	O
cells	O
and	O
not	O
detectable	B-Gene_expression
in	O
CEM	O
cells	O
.	O

After	O
stimulation	O
by	O
PMA	O
,	O
RXR	O
alpha	O
expression	B-Gene_expression
increased	B-Positive_regulation
in	O
H9	O
and	O
U937	O
cells	O
but	O
not	O
in	O
CEM	O
cells	O
.	O

Human	O
RAR	O
alpha	O
expression	B-Gene_expression
was	O
unchanged	B-Regulation
in	O
H9	O
and	O
CEM	O
cells	O
,	O
and	O
elevated	B-Positive_regulation
in	O
U937	O
cells	O
,	O
after	O
PMA	O
stimulation	O
.	O

CONCLUSION	O
:	O
The	O
effect	O
of	O
RA	O
on	O
HIV	O
-	O
1	O
expression	O
was	O
cell-type	O
-	O
dependent	O
and	O
partially	O
correlated	O
with	O
cellular	O
expression	O
of	O
RARs	O
.	O

Endogenous	O
or	O
exogenously	O
administered	O
RA	O
may	O
have	O
a	O
significant	O
role	O
in	O
HIV	O
regulation	O
.	O

Identification	O
of	O
human	O
TR2	O
orphan	O
receptor	O
response	O
element	O
in	O
the	O
transcriptional	O
initiation	O
site	O
of	O
the	O
simian	O
virus	O
40	O
major	O
late	O
promoter	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1995	O
Nov	O
3	O
;	O
270	O
(	O
44	O
)	O
:	O
26721	O
]	O

A	O
DNA	O
response	O
element	O
(	O
TR2RE	O
-	O
SV40	O
)	O
for	O
the	O
TR2	O
orphan	O
receptor	O
,	O
a	O
member	O
of	O
the	O
steroid	O
-	O
thyroid	O
hormone	O
receptor	O
superfamily	O
,	O
has	O
been	O
identified	O
in	O
the	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
+55	O
region	O
(	O
nucleotide	O
numbers	O
368	O
-	O
389	O
,	O
5'-GTTAAGGTTCGTAGGTCATGGA	O
-	O
3	O
'	O
)	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
,	O
using	O
in	O
vitro	O
translated	O
TR2	O
orphan	O
receptor	O
with	O
a	O
molecular	O
mass	O
of	O
67	O
kilodaltons	O
,	O
showed	O
a	O
specific	O
binding	O
with	O
high	O
affinity	O
(	O
dissociation	O
constant	O
=	O
9	O
nM	O
)	O
for	O
this	O
DNA	O
sequence	O
.	O

DNA	O
-	O
swap	O
experiments	O
using	O
chloramphenicol	O
acetyl	O
-	O
transferase	O
assay	O
demonstrated	O
that	O
androgen	O
can	O
suppress	O
the	O
transcriptional	O
activities	O
of	O
SV40	O
early	O
promoter	O
via	O
the	O
interaction	O
between	O
this	O
TR2RE	O
-	O
SV40	O
and	O
the	O
chimeric	O
receptor	O
AR/TR2/AR	O
with	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
TR2	O
orphan	O
receptor	O
flanked	O
by	O
the	O
N	O
-	O
terminal	O
and	O
androgen	O
-	O
binding	O
domains	O
of	O
the	O
androgen	O
receptor	O
.	O

In	O
addition	O
,	O
this	O
TR2RE	O
-	O
SV40	O
can	O
function	O
as	O
a	O
repressor	O
to	O
suppress	O
the	O
transcriptional	O
activities	O
of	O
both	O
SV40	O
early	O
and	O
late	O
promoters	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
the	O
TR2RE	O
-	O
SV40	O
may	O
represent	O
the	O
first	O
identified	O
natural	O
DNA	O
response	O
element	O
for	O
the	O
TR2	O
orphan	O
receptor	O
that	O
may	O
function	O
as	O
a	O
repressor	O
for	O
the	O
SV40	O
gene	O
expression	O
.	O

Mapping	O
of	O
the	O
interaction	O
site	O
of	O
the	O
defective	O
transcription	O
factor	O
in	O
the	O
class	O
II	O
major	O
histocompatibility	O
complex	O
mutant	O
cell	O
line	O
clone	O
-	O
13	O
to	O
the	O
divergent	O
X2	O
-	O
box	O
.	O

We	O
have	O
previously	O
described	O
a	O
mutant	O
B	O
lymphoblastoid	O
cell	O
line	O
,	O
Clone	O
-	O
13	O
,	O
that	O
expresses	O
HLA	O
-	O
DQ	O
in	O
the	O
absence	O
of	O
HLA	O
-	O
DR	O
and	O
-	O
DP	O
.	O

Several	O
criteria	O
indicated	O
that	O
the	O
defect	O
in	O
this	O
cell	O
line	O
influences	O
the	O
activity	O
of	O
an	O
isotype	O
-	O
specific	O
transcription	O
factor	O
.	O

Indeed	O
,	O
transient	O
transfection	O
of	O
HLA	O
-	O
DRA	O
and	O
DQB	O
reporter	O
constructs	O
indicated	O
that	O
the	O
affected	O
factor	O
operates	O
via	O
cis	O
-	O
elements	O
located	O
between	O
-	O
141	O
base	O
pairs	O
and	O
the	O
transcription	O
initiation	O
site	O
.	O

A	O
series	O
of	O
hybrid	O
DRA/DQB	O
reporter	O
constructs	O
was	O
generated	O
to	O
further	O
map	O
the	O
relevant	O
cis	O
-	O
elements	O
in	O
this	O
system	O
.	O

Insertion	O
of	O
oligonucleotides	O
spanning	O
the	O
DQB	O
X	O
-	O
box	O
(	O
but	O
not	O
the	O
DQB	O
-	O
W	O
region	O
or	O
the	O
DQB	O
Y	O
-	O
box	O
)	O
upstream	O
of	O
-	O
141	O
in	O
a	O
DRA	O
reporter	O
plasmid	O
rescued	O
expression	O
to	O
nearly	O
wild	O
-	O
type	O
levels	O
.	O

Substitution	O
promoters	O
were	O
then	O
generated	O
where	O
the	O
entire	O
X	O
-	O
box	O
,	O
or	O
only	O
the	O
X1	O
-	O
or	O
X2	O
-	O
boxes	O
of	O
HLA	O
-	O
DRA	O
were	O
replaced	O
with	O
the	O
analogous	O
regions	O
of	O
HLA	O
-	O
DQB	O
.	O

The	O
DQB	O
X2	O
-	O
box	O
was	O
able	O
to	O
restore	O
expression	O
to	O
the	O
silent	O
DRA	O
reporter	O
construct	O
.	O

Moreover	O
,	O
replacement	O
of	O
the	O
DQB	O
X2	O
-	O
box	O
with	O
the	O
DRA	O
X2	O
-	O
box	O
markedly	O
diminished	O
the	O
activity	O
of	O
the	O
DQB	O
promoter	O
in	O
the	O
mutant	O
cell	O
.	O

None	O
of	O
the	O
hybrid	O
reporter	O
constructs	O
were	O
defective	O
when	O
transfected	O
into	O
the	O
wild	O
-	O
type	O
,	O
HLA-DR/	O
-	O
DQ	O
positive	O
parental	O
cell	O
line	O
,	O
Jijoye	O
.	O

These	O
studies	O
suggest	O
that	O
the	O
divergent	O
X2	O
-	O
box	O
of	O
the	O
class	O
II	O
major	O
histocompatibility	O
complex	O
promoters	O
plays	O
an	O
important	O
role	O
in	O
influencing	O
differential	O
expression	O
of	O
the	O
human	O
class	O
II	O
isotypes	O
.	O

[	O
Regulation	B-Regulation
of	O
transcription	B-Transcription
of	O
the	O
interleukin	O
-	O
2	O
gene	O
in	O
B	O
-	O
lymphocytes	O
]	O

Since	O
most	O
B	O
cell	O
clones	O
immortalized	O
with	O
EBV	O
virus	O
can	O
be	O
induced	B-Positive_regulation
to	O
produce	B-Gene_expression
interleukin	O
-	O
2	O
,	O
a	O
typical	O
T	O
cell	O
cytokine	O
,	O
we	O
studied	O
the	O
role	O
of	O
different	O
elements	O
of	O
the	O
IL	O
-	O
2	O
promoter	O
in	O
such	O
clones	O
by	O
transfection	O
.	O

It	O
was	O
found	O
,	O
in	O
particular	O
,	O
that	O
the	O
element	O
TCEd	O
,	O
which	O
binds	O
the	O
transcription	O
factor	O
NF	O
-	O
kB	O
,	O
is	O
very	O
active	O
in	O
all	O
three	O
B	O
clones	O
tested	O
.	O

This	O
element	O
has	O
no	O
activity	O
in	O
T	O
cells	O
of	O
the	O
Jurkat	O
line	O
.	O

The	O
NFATd	O
element	O
,	O
which	O
binds	B-Binding
the	O
transcription	O
factor	O
NFAT	O
-	O
1	O
and	O
is	O
very	O
active	O
in	O
T	O
cells	O
,	O
is	O
only	O
weakly	O
active	O
in	O
one	O
B	O
clone	O
and	O
not	O
at	O
all	O
in	O
another	O
.	O

Different	O
elements	O
thus	O
contribute	O
to	O
IL	O
-	O
2	O
promoter	O
activity	O
in	O
different	O
cells	O
.	O

Effects	O
of	O
CD45	O
on	O
NF	O
-	O
kappa	O
B	O
.	O

Implications	O
for	O
replication	O
of	O
HIV	O
-	O
1	O
.	O

Increased	O
levels	O
of	O
replication	O
of	O
the	O
HIV	O
type	O
1	O
are	O
observed	O
after	O
the	O
activation	O
of	O
infected	O
T	O
cells	O
through	O
the	O
TCR	O
.	O

However	O
,	O
anti	O
-	O
CD45	O
antibodies	O
inhibit	O
these	O
effects	O
in	O
cells	O
from	O
infected	O
individuals	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
interrelationships	O
between	O
CD45	O
and	O
HIV	O
-	O
1	O
further	O
.	O

We	O
measured	O
effects	O
on	O
the	O
HIV	O
-	O
1	O
LTR	O
in	O
T	O
cell	O
lines	O
that	O
were	O
stimulated	O
with	O
antibodies	O
against	O
CD45	O
and	O
in	O
those	O
that	O
lacked	O
the	O
expression	B-Gene_expression
of	O
CD45	O
on	O
their	O
surfaces	O
.	O

First	O
,	O
anti	O
-	O
CD45	O
antibodies	O
did	O
not	O
affect	O
basal	O
but	O
decreased	O
activated	O
levels	O
of	O
expression	O
from	O
the	O
HIV	O
-	O
1	O
LTR	O
.	O

Second	O
,	O
T	O
cells	O
,	O
which	O
lack	B-Negative_regulation
CD45	O
and	O
can	O
not	O
signal	O
via	O
the	O
TCR	O
,	O
supported	O
higher	O
levels	O
of	O
viral	O
replication	O
and	O
gene	O
expression	O
.	O

This	O
was	O
due	O
to	O
the	O
presence	O
of	O
active	O
NF	O
-	O
kappa	O
B	O
complexes	O
in	O
the	O
nucleus	O
of	O
CD45	O
-	O
T	O
cells	O
.	O

Additionally	O
,	O
infected	O
T	O
cells	O
displayed	B-Negative_regulation
lower	I-Negative_regulation
levels	I-Negative_regulation
of	O
CD45	O
on	O
their	O
surfaces	O
.	O

Thus	O
,	O
CD45	O
plays	O
an	O
active	O
role	O
in	O
the	O
physiology	O
of	O
T	O
cells	O
and	O
in	O
the	O
replication	O
of	O
HIV	O
-	O
1	O
.	O

ERP	O
,	O
a	O
new	O
member	O
of	O
the	O
ets	O
transcription	O
factor/oncoprotein	O
family	O
:	O
cloning	O
,	O
characterization	O
,	O
and	O
differential	O
expression	B-Gene_expression
during	O
B	O
-	O
lymphocyte	O
development	O
.	O

The	O
ets	O
gene	O
family	O
encodes	O
a	O
group	O
of	O
proteins	O
which	O
function	O
as	O
transcription	O
factors	O
under	O
physiological	O
conditions	O
and	O
,	O
if	O
aberrantly	O
expressed	O
,	O
can	O
cause	O
cellular	O
transformation	O
.	O

We	O
have	O
recently	O
identified	O
two	O
regulatory	O
elements	O
in	O
the	O
murine	O
immunoglobulin	O
heavy	O
-	O
chain	O
(	O
IgH	O
)	O
enhancer	O
,	O
pi	O
and	O
microB	O
,	O
which	O
exhibit	O
striking	O
similarity	O
to	O
binding	O
sites	O
for	O
ets	O
-	O
related	O
proteins	O
.	O

To	O
identify	O
ets	O
-	O
related	O
transcriptional	O
regulators	O
expressed	O
in	O
pre	O
-	O
B	O
lymphocytes	O
that	O
may	O
interact	O
with	O
either	O
the	O
pi	O
or	O
the	O
microB	O
site	O
,	O
we	O
have	O
used	O
a	O
PCR	O
approach	O
with	O
degenerate	O
oligonucleotides	O
encoding	O
conserved	O
sequences	O
in	O
all	O
members	O
of	O
the	O
ets	O
family	O
.	O

We	O
have	O
cloned	O
the	O
gene	O
for	O
a	O
new	O
ets	O
-	O
related	O
transcription	O
factor	O
,	O
ERP	O
(	O
ets	O
-	O
related	O
protein	O
)	O
,	O
from	O
the	O
murine	O
pre	O
-	O
B	O
cell	O
line	O
BASC	O
6C2	O
and	O
from	O
mouse	O
lung	O
tissue	O
.	O

The	O
ERP	O
protein	O
contains	O
a	O
region	O
of	O
high	O
homology	O
with	O
the	O
ETS	O
DNA	O
-	O
binding	O
domain	O
common	O
to	O
all	O
members	O
of	O
the	O
ets	O
transcription	O
factor/oncoprotein	O
family	O
.	O

Three	O
additional	O
smaller	O
regions	O
show	O
homology	O
to	O
the	O
ELK	O
-	O
1	O
and	O
SAP	O
-	O
1	O
genes	O
,	O
a	O
subgroup	O
of	O
the	O
ets	O
gene	O
family	O
that	O
interacts	B-Binding
with	O
the	O
serum	O
response	O
factor	O
.	O

Full	O
-	O
length	O
ERP	O
expresses	O
only	O
negligible	O
DNA	O
-	O
binding	B-Binding
activity	I-Binding
by	O
itself	O
.	O

Removal	O
of	O
the	O
carboxy	O
terminus	O
enables	B-Positive_regulation
ERP	O
to	O
interact	B-Binding
with	O
a	O
variety	O
of	O
ets	O
-	O
binding	O
sites	O
including	O
the	O
E74	O
site	O
,	O
the	O
IgH	O
enhancer	O
pi	O
site	O
,	O
and	O
the	O
lck	O
promoter	O
ets	O
site	O
,	O
suggesting	O
a	O
carboxy	O
-	O
terminal	O
negative	O
regulatory	O
domain	O
.	O

At	O
least	O
three	O
ERP	O
-	O
related	O
transcripts	O
are	O
expressed	O
in	O
a	O
variety	O
of	O
tissues	O
.	O

However	O
,	O
within	O
the	O
B	O
-	O
cell	O
lineage	O
,	O
ERP	O
is	O
highly	O
expressed	B-Gene_expression
primarily	O
at	O
early	O
stages	O
of	O
B	O
-	O
lymphocyte	O
development	O
,	O
and	O
expression	O
declines	B-Negative_regulation
drastically	O
upon	O
B	O
-	O
cell	O
maturation	O
,	O
correlating	O
with	O
the	O
enhancer	O
activity	O
of	O
the	O
IgH	O
pi	O
site	O
.	O

These	O
data	O
suggest	O
that	O
ERP	O
might	O
play	O
a	O
role	O
in	O
B	O
-	O
cell	O
development	O
and	O
in	O
IgH	O
gene	O
regulation	O
.	O

Pentoxifylline	O
for	O
the	O
treatment	O
of	O
infection	O
with	O
human	O
immunodeficiency	O
virus	O
.	O

Cytokine	O
dysregulation	O
in	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
infection	O
has	O
been	O
documented	O
in	O
numerous	O
studies	O
and	O
has	O
been	O
cited	O
as	O
an	O
important	O
component	O
in	O
the	O
pathogenesis	O
of	O
this	O
retroviral	O
infection	O
.	O

Pharmacological	O
modification	O
of	O
cytokine	O
dysregulation	O
,	O
therefore	O
,	O
has	O
been	O
suggested	O
as	O
a	O
therapeutic	O
modality	O
for	O
HIV	O
-	O
1	O
infection	O
.	O

Dr	O
.	O

Dezube	O
of	O
Beth	O
Israel	O
Hospital	O
(	O
Boston	O
)	O
concisely	O
reviews	O
the	O
state	O
of	O
our	O
knowledge	O
regarding	O
the	O
effects	B-Regulation
of	O
pentoxifylline	O
on	O
expression	B-Gene_expression
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
,	O
a	O
cytokine	O
known	O
to	O
influence	O
HIV	O
-	O
1	O
replication	O
and	O
to	O
play	O
a	O
possible	O
role	O
in	O
the	O
clinical	O
manifestations	O
of	O
advanced	O
infection	O
with	O
this	O
virus	O
.	O

Pentoxifylline	O
,	O
a	O
trisubstituted	O
xanthine	O
derivative	O
,	O
has	O
been	O
used	O
to	O
decrease	O
blood	O
viscosity	O
and	O
is	O
reasonably	O
well	O
tolerated	O
by	O
most	O
recipients	O
of	O
the	O
drug	O
.	O

Results	O
of	O
preliminary	O
studies	O
,	O
many	O
of	O
which	O
were	O
conducted	O
by	O
Dr.	O
Dezube	O
,	O
suggest	O
that	O
use	O
of	O
this	O
agent	O
in	O
combination	O
with	O
antiretroviral	O
compounds	O
may	O
prove	O
useful	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
HIV	O
-	O
1	O
infection	O
.	O

Signals	O
transduced	O
through	O
the	O
CD4	O
molecule	O
on	O
T	O
lymphocytes	O
activate	O
NF	O
-	O
kappa	O
B	O
.	O

We	O
have	O
demonstrated	O
that	O
native	O
envelope	O
glycoproteins	O
of	O
HIV	O
-	O
1	O
,	O
gp160	O
can	O
induce	O
activation	O
of	O
the	O
transcription	O
factor	O
,	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
stimulatory	O
effects	O
of	O
gp160	O
are	O
mediated	O
through	O
the	O
CD4	O
molecule	O
,	O
since	O
pretreatment	O
with	O
soluble	O
CD4	O
abrogates	O
its	O
activity	O
.	O

The	O
gp160	O
-	O
induced	B-Positive_regulation
NF	O
-	O
kappa	O
B	O
complex	B-Binding
consists	O
of	O
p65	O
,	O
p50	O
and	O
c	O
-	O
rel	O
proteins	O
.	O

The	O
stimulatory	O
effect	O
of	O
gp160	O
on	O
NF	O
-	O
kappa	O
B	O
activation	O
is	O
protein	O
synthesis	O
independent	O
,	O
is	O
dependent	O
upon	O
protein	O
tyrosine	O
phosphorylation	O
,	O
and	O
abrogated	O
by	O
inhibitors	O
of	O
protein	O
kinase	O
C	O
.	O

The	O
gp160	O
-	O
mediated	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
CD4	O
positive	O
T	O
cells	O
may	O
be	O
involved	O
in	O
biological	O
effects	O
,	O
e.g.	O
,	O
enhanced	O
HIV	O
replication	O
,	O
hypergammaglobulinemia	O
,	O
increased	O
cytokine	O
secretion	O
,	O
hypercellularity	O
in	O
bone	O
marrow	O
and	O
apoptosis	O
.	O

Role	O
of	O
HIV	O
-	O
1	O
Nef	O
expression	B-Gene_expression
in	O
activation	O
pathways	O
in	O
CD4+	O
T	O
cells	O
.	O

The	O
role	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
-	O
1	O
)	O
Nef	O
protein	O
in	O
T	O
cell	O
activation	O
pathways	O
was	O
investigated	O
using	O
a	O
Jurkat	O
CD4+	O
cell	O
line	O
stably	O
transfected	B-Positive_regulation
with	O
a	O
Nef	O
expression	B-Gene_expression
vector	O
.	O

Secretion	B-Localization
of	O
IL	O
-	O
2	O
and	O
TNF	O
-	O
alpha	O
,	O
surface	O
expression	O
of	O
IL	O
-	O
2R	O
,	O
and	O
DNA	O
-	O
binding	B-Binding
activity	I-Binding
of	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
(	O
Fos/Jun	O
)	O
complex	O
in	O
response	B-Positive_regulation
to	O
phorbol	O
myristate	O
acetate	O
,	O
TNF	O
-	O
alpha	O
,	O
or	O
immobilized	O
antibodies	O
to	O
CD3	O
were	O
monitored	O
.	O

These	O
parameters	O
were	O
not	O
modified	B-Regulation
by	O
Nef	O
expression	B-Gene_expression
in	O
Jurkat	O
cells	O
,	O
whereas	O
stimulation	O
with	O
the	O
same	O
stimuli	O
resulted	O
in	O
partial	O
inhibition	O
of	O
LTR	O
activation	O
in	O
Nef+	O
Jurkat	O
cells	O
.	O

This	O
inhibition	O
was	O
not	O
mediated	O
through	O
Nef	O
phosphorylation	B-Phosphorylation
on	O
Thr	O
-	O
15	O
or	O
GTP	O
-	O
binding	B-Binding
activity	I-Binding
because	O
mutations	O
in	O
critical	O
sites	O
did	O
not	O
alter	O
this	O
inhibition	O
.	O

Analysis	O
of	O
truncated	O
LTRs	O
confirmed	O
that	O
inhibition	O
of	O
LTR	O
activation	O
was	O
not	O
mediated	O
through	O
NF	O
-	O
kappa	O
B	O
-	O
binding	O
activity	O
but	O
through	O
the	O
region	O
containing	O
the	O
negative	O
responding	O
elements	O
(	O
NREs	O
)	O
.	O

These	O
results	O
suggest	O
that	O
Nef	O
downmodulates	O
LTR	O
activation	O
without	O
significantly	O
inhibiting	O
the	O
capacity	O
of	O
T	O
cells	O
to	O
respond	O
to	O
immunological	O
activations	O
.	O

A	O
low	O
NM23.H1	O
gene	O
expression	B-Gene_expression
identifying	O
high	O
malignancy	O
human	O
melanomas	O
.	O

The	O
NM23	O
gene	O
has	O
been	O
proposed	O
as	O
a	O
metastasis	O
-	O
suppressor	O
gene	O
,	O
and	O
its	O
use	O
has	O
been	O
suggested	O
as	O
prognostic	O
factor	O
.	O

NM23	O
was	O
identified	O
in	O
a	O
system	O
of	O
murine	O
melanoma	O
cell	O
lines	O
,	O
in	O
which	O
an	O
inverse	O
relationship	O
was	O
found	O
between	O
NM23	O
expression	O
and	O
metastatic	O
ability	O
.	O

In	O
a	O
human	O
malignant	O
melanoma	O
study	O
NM23	O
expression	O
was	O
found	O
to	O
be	O
significantly	O
lower	O
in	O
metastases	O
that	O
developed	O
less	O
than	O
24	O
months	O
after	O
diagnosis	O
of	O
the	O
primary	O
tumours	O
.	O

The	O
present	O
paper	O
studies	O
the	O
expression	B-Gene_expression
of	O
the	O
NM23.H1	O
gene	O
in	O
cell	O
lines	O
which	O
derive	O
from	O
primary	O
or	O
metastatic	O
human	O
malignant	O
melanomas	O
in	O
relation	O
to	O
staging	O
,	O
infiltration	O
degree	O
,	O
lymphocytic	O
infiltration	O
,	O
cell	O
morphology	O
,	O
cell	O
pigmentation	O
,	O
karyotype	O
,	O
and	O
disease	O
-	O
free	O
survival	O
.	O

The	O
level	O
of	O
mRNA	O
expression	O
of	O
the	O
NM23	O
gene	O
is	O
significantly	O
lower	O
in	O
cell	O
lines	O
that	O
derive	O
from	O
more	O
infiltrating	O
primary	O
melanomas	O
than	O
in	O
cell	O
lines	O
obtained	O
from	O
less	O
infiltrating	O
tumours	O
.	O

Moreover	O
,	O
cell	O
lines	O
derived	O
from	O
tumours	O
of	O
patients	O
with	O
a	O
disease	O
-	O
free	O
survival	O
of	O
more	O
than	O
24	O
months	O
(	O
24	O
-	O
58	O
months	O
)	O
express	O
the	O
NM23	O
gene	O
at	O
higher	O
levels	O
than	O
cell	O
lines	O
obtained	O
from	O
melanomas	O
of	O
patients	O
with	O
a	O
disease	O
-	O
free	O
survival	O
of	O
less	O
than	O
24	O
months	O
(	O
6	O
-	O
15	O
months	O
)	O
.	O

T	O
cells	O
from	O
renal	O
cell	O
carcinoma	O
patients	O
exhibit	O
an	O
abnormal	O
pattern	O
of	O
kappa	O
B	O
-	O
specific	O
DNA	O
-	O
binding	O
activity	O
:	O
a	O
preliminary	O
report	O
.	O

Recent	O
data	O
suggest	O
that	O
the	O
poor	O
induction	O
of	O
a	O
T	O
-	O
cell	O
response	O
to	O
human	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
may	O
be	O
related	O
to	O
alterations	O
in	O
signal	O
transduction	O
pathways	O
.	O

We	O
report	O
that	O
T	O
cells	O
from	O
RCC	O
patients	O
have	O
two	O
alterations	O
in	O
kappa	O
B	O
motif	O
-	O
specific	O
DNA	O
-	O
binding	O
activity	O
.	O

The	O
first	O
alteration	O
involves	O
the	O
constitutive	O
expression	O
of	O
substantial	O
kappa	O
B	O
-	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
,	O
which	O
was	O
observed	O
in	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

The	O
magnitude	O
of	O
kappa	O
B	O
activity	O
in	O
unstimulated	O
patient	O
T	O
cells	O
was	O
similar	O
to	O
that	O
observed	O
in	O
T	O
cells	O
from	O
normal	O
individuals	O
that	O
had	O
been	O
activated	O
in	O
vitro	O
.	O

On	O
the	O
basis	O
of	O
Western	O
blotting	O
experiments	O
using	O
antibodies	O
to	O
kappa	O
B/Rel	O
family	O
proteins	O
,	O
the	O
kappa	O
B	O
-	O
binding	B-Binding
activity	I-Binding
constitutively	O
expressed	O
in	O
T	O
cells	O
from	O
RCC	O
patients	O
is	O
composed	O
mostly	O
of	O
the	O
NF	O
-	O
kappa	O
B1	O
(	O
p50	O
)	O
subunit	O
.	O

The	O
second	O
abnormality	O
in	O
kappa	O
B	O
-	O
binding	O
activity	O
in	O
T	O
cells	O
from	O
these	O
patients	O
is	O
that	O
RelA	O
,	O
a	O
member	O
of	O
the	O
Rel	O
homology	O
family	O
which	O
is	O
part	O
of	O
the	O
normal	O
NF	O
-	O
kappa	O
B	O
complex	O
,	O
was	O
not	O
induced	B-Positive_regulation
in	O
the	O
nucleus	O
following	O
activation	O
.	O

Western	O
blotting	O
analysis	O
did	O
not	O
detect	B-Localization
any	O
RelA	O
in	O
nuclear	O
extracts	O
either	O
before	O
or	O
after	O
stimulation	O
of	O
T	O
cells	O
.	O

The	O
altered	O
kappa	O
B	O
-	O
binding	O
activity	O
in	O
T	O
cells	O
from	O
RCC	O
patients	O
may	O
impair	O
their	O
capacity	O
to	O
respond	O
normally	O
to	O
various	O
stimuli	O
.	O

Activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
vivo	O
is	O
regulated	O
by	O
multiple	O
phosphorylations	O
.	O

The	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
in	O
intact	O
cells	O
is	O
mechanistically	O
not	O
well	O
understood	O
.	O

Therefore	O
we	O
investigated	O
the	O
modifications	O
imposed	O
on	O
NF	O
-	O
kappa	O
B/I	O
kappa	O
B	O
components	O
following	O
stimulation	O
and	O
show	O
that	O
the	O
final	O
step	O
of	O
NF	O
-	O
kappa	O
B	O
induction	O
in	O
vivo	O
involves	O
phosphorylation	O
of	O
several	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B/I	O
kappa	O
B	O
protein	O
families	O
.	O

In	O
HeLa	O
cells	O
as	O
well	O
as	O
in	O
B	O
cells	O
,	O
TNF	O
-	O
alpha	O
rapidly	O
induced	B-Positive_regulation
nuclear	O
translocation	B-Localization
primarily	O
of	O
p50	O
-	O
p65	O
,	O
but	O
not	O
of	O
c	O
-	O
rel	O
.	O

Both	O
NF	O
-	O
kappa	O
B	O
precursors	O
and	O
I	O
kappa	O
B	O
alpha	O
became	O
strongly	O
phosphorylated	B-Phosphorylation
with	O
the	O
same	O
kinetics	O
.	O

In	O
addition	O
to	O
the	O
inducible	O
phosphorylation	O
after	O
stimulation	O
,	O
B	O
lymphocytes	O
containing	O
constitutive	O
nuclear	O
NF	O
-	O
kappa	O
B	O
revealed	O
constitutively	O
phosphorylated	B-Phosphorylation
p65	O
and	O
I	O
kappa	O
B	O
alpha	O
.	O

Phosphorylation	O
was	O
accompanied	O
by	O
induced	O
processing	O
of	O
the	O
precursors	O
p100	O
and	O
p105	O
and	O
by	O
degradation	B-Protein_catabolism
of	O
I	O
kappa	O
B	O
alpha	O
.	O

As	O
an	O
in	O
vitro	O
model	O
we	O
show	O
that	O
phosphorylation	B-Phosphorylation
of	O
p105	O
impedes	B-Negative_regulation
its	O
ability	O
to	O
interact	B-Binding
with	O
NF	O
-	O
kappa	O
B	O
,	O
as	O
has	O
been	O
shown	O
before	O
for	O
I	O
kappa	O
B	O
alpha	O
.	O

Surprisingly	O
,	O
even	O
p65	O
,	O
but	O
not	O
c	O
-	O
rel	O
,	O
was	O
phosphorylated	B-Phosphorylation
after	O
induction	B-Positive_regulation
in	O
vivo	O
,	O
suggesting	O
that	O
TNF	O
-	O
alpha	O
selectively	O
activates	O
only	O
specific	O
NF	O
-	O
kappa	O
B	O
heteromers	O
and	O
that	O
modifications	O
regulate	O
not	O
only	O
I	O
kappa	O
B	O
molecules	O
but	O
also	O
NF	O
-	O
kappa	O
B	O
molecules	O
.	O

In	O
fact	O
,	O
cellular	O
NF	O
-	O
kappa	O
B	O
activity	O
was	O
phosphorylation	O
-	O
dependent	O
and	O
the	O
DNA	O
binding	B-Binding
activity	I-Binding
of	O
p65	O
-	O
containing	O
NF	O
-	O
kappa	O
B	O
was	O
enhanced	B-Positive_regulation
by	O
phosphorylation	O
in	O
vitro	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
induction	O
by	O
hydrogen	O
peroxide	O
of	O
NF	O
-	O
kappa	O
B	O
translocation	O
to	O
the	O
nucleus	O
,	O
which	O
is	O
assumed	O
to	O
be	O
triggered	O
by	O
reactive	O
oxygen	O
intermediates	O
,	O
also	O
coincided	O
with	O
incorporation	O
of	O
phosphate	O
into	O
the	O
same	O
subunits	O
that	O
were	O
modified	O
after	O
stimulation	O
by	O
TNF	O
-	O
alpha	O
.	O

Thus	O
,	O
phosphorylation	O
appears	O
to	O
be	O
a	O
general	O
mechanism	O
for	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
vivo	O
.	O

An	O
active	O
v	O
-	O
abl	O
protein	O
tyrosine	O
kinase	O
blocks	O
immunoglobulin	O
light	O
-	O
chain	O
gene	O
rearrangement	O
.	O

Lymphoid	O
cells	O
transformed	O
by	O
Abelson	O
murine	O
leukemia	O
virus	O
have	O
provided	O
one	O
of	O
the	O
classic	O
models	O
for	O
study	O
of	O
early	O
B	O
-	O
cell	O
development	O
and	O
immunoglobulin	O
rearrangement	O
.	O

Most	O
of	O
these	O
cells	O
have	O
rearranged	O
their	O
heavy	O
-	O
chain	O
locus	O
but	O
not	O
their	O
light	O
chain	O
genes	O
,	O
suggesting	O
that	O
an	O
active	O
v	O
-	O
abl	O
protein	O
interferes	O
with	O
this	O
differentiation	O
step	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
light	O
-	O
chain	O
gene	O
structure	O
was	O
examined	O
in	O
pre	O
-	O
B	O
cells	O
transformed	O
by	O
temperature	O
-	O
sensitive	O
mutants	O
of	O
the	O
Abelson	O
virus	O
and	O
in	O
derivatives	O
that	O
survive	O
at	O
the	O
nonpermissive	O
temperature	O
because	O
they	O
express	B-Gene_expression
a	O
human	O
BCL	O
-	O
2	O
gene	O
.	O

Our	O
studies	O
reveal	O
that	O
inactivation	B-Negative_regulation
of	O
the	O
v	O
-	O
abl	O
protein	O
tyrosine	O
kinase	O
triggers	O
high	O
-	O
frequency	O
rearrangement	O
of	O
kappa	O
and	O
lambda	O
light	O
-	O
chain	O
genes	O
.	O

These	O
events	O
are	O
accompanied	O
by	O
marked	O
increases	B-Positive_regulation
in	O
the	O
expression	B-Transcription
of	O
RAG	O
-	O
1	O
and	O
RAG	O
-	O
2	O
RNAs	O
.	O

These	O
increases	O
occur	O
in	O
the	O
absence	O
of	O
protein	O
synthesis	O
but	O
are	O
dependent	B-Positive_regulation
on	O
inactivation	B-Negative_regulation
of	O
the	O
v	O
-	O
abl	O
protein	O
tyrosine	O
kinase	O
.	O

As	O
documented	O
in	O
the	O
accompanying	O
paper	O
(	O
Klug	O
et	O
al.	O
,	O
this	O
issue	O
)	O
,	O
an	O
active	O
v	O
-	O
abl	O
protein	O
also	O
suppresses	O
the	O
activity	O
of	O
NF	O
-	O
kappa	O
B/rel	O
and	O
expression	O
controlled	O
by	O
the	O
kappa	O
intron	O
enhancer	O
.	O

Together	O
these	O
data	O
demonstrate	O
that	O
the	O
v	O
-	O
abl	O
protein	O
specifically	O
interferes	O
with	O
light	O
-	O
chain	O
gene	O
rearrangement	O
by	O
suppressing	O
at	O
least	O
two	O
pathways	O
essential	O
for	O
this	O
stage	O
of	O
B	O
-	O
cell	O
differentiation	O
and	O
suggest	O
that	O
tyrosine	O
phosphorylation	O
is	O
important	O
in	O
regulating	O
RAG	O
gene	O
expression	O
.	O

[	O
An	O
overexpression	B-Positive_regulation
of	O
retinoic	O
acid	O
receptor	O
alpha	O
blocks	O
myeloid	O
cell	O
differentiation	O
at	O
the	O
promyelocyte	O
stage	O
]	O

Retinoic	O
acid	O
(	O
RA	O
)	O
,	O
a	O
vitamin	O
A	O
derivative	O
,	O
exerts	O
a	O
wide	O
range	O
of	O
biological	O
effects	O
related	O
to	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

The	O
pleiotropic	O
effects	O
of	O
RA	O
are	O
thought	O
to	O
be	O
mediated	O
through	O
specific	O
nuclear	O
RA	O
receptors	O
(	O
RARs	O
)	O
.	O

RARs	O
are	O
members	O
of	O
the	O
steroid/thyroid	O
hormone	O
receptor	O
superfamily	O
and	O
exhibit	O
a	O
molecular	O
structure	O
that	O
possess	O
discrete	O
DNA	O
-	O
binding	O
and	O
RA	O
(	O
ligand	O
)	O
-	O
binding	O
domains	O
.	O

In	O
hematopoietic	O
system	O
,	O
RA	O
and	O
RARs	O
,	O
predominantly	O
RAR	O
alpha	O
may	O
play	O
key	O
roles	O
for	O
the	O
proliferation	O
and	O
differentiation	O
of	O
hematopoietic	O
progenitors	O
.	O

However	O
,	O
it	O
is	O
currently	O
unknown	O
how	O
RA	O
and	O
RARs	O
are	O
involved	O
in	O
regulating	O
normal	O
hematopoietic	O
differentiation	O
.	O

To	O
make	O
clear	O
the	O
roles	O
of	O
RA	O
and	O
RAR	O
alpha	O
in	O
the	O
normal	O
hematopoiesis	O
,	O
I	O
have	O
introduced	O
the	O
construct	O
of	O
human	O
RAR	O
alpha	O
(	O
hRAR	O
alpha	O
)	O
into	O
murine	O
bone	O
marrow	O
cells	O
with	O
retroviral	O
vector	O
,	O
and	O
selected	O
infected	O
cells	O
with	O
drug	O
resistant	O
marker	O
(	O
Neo	O
(	O
r	O
)	O
)	O
cultured	O
on	O
the	O
stroma	O
cell	O
line	O
(	O
PA6	O
-	O
neo	O
)	O
,	O
and	O
analyzed	O
the	O
behavior	O
of	O
infected	O
cells	O
.	O

All	O
of	O
procedure	O
were	O
done	O
in	O
vitro	O
.	O

Most	O
cells	O
infected	O
with	O
hRAR	O
alpha	O
exhibited	O
promyelocytic	O
morphology	O
and	O
were	O
thought	O
to	O
be	O
blocked	O
at	O
the	O
promyelocytic	O
stage	O
in	O
their	O
myeloid	O
differentiation	O
.	O

Furthermore	O
,	O
these	O
immature	O
cells	O
differentiated	O
terminally	O
into	O
mature	O
granulocytes	O
by	O
adding	O
with	O
RA	O
(	O
10	O
(	O
-	O
6	O
)	O
M	O
)	O
.	O

RAR	O
alpha	O
infected	O
cells	O
were	O
also	O
able	O
to	O
differentiate	O
into	O
mature	O
macrophages	O
in	O
the	O
both	O
of	O
long	O
term	O
culture	O
and	O
IL3	O
colony	O
.	O

These	O
observations	O
suggest	O
that	O
an	O
overexpression	B-Gene_expression
of	O
RAR	O
alpha	O
alone	O
is	O
effective	O
to	O
suppress	O
myeloid	O
cell	O
differentiation	O
and	O
RAR	O
alpha	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
terminal	O
differentiation	O
of	O
myeloid	O
precursors	O
.	O

The	O
system	O
described	O
here	O
may	O
serve	O
as	O
a	O
model	O
for	O
studying	O
the	O
the	O
essential	O
genes	O
for	O
differentiation	O
of	O
normal	O
bone	O
marrow	O
cells	O
.	O

Regulation	B-Regulation
of	O
interleukin	O
-	O
2	O
receptor	O
alpha	O
chain	O
expression	B-Gene_expression
and	O
nuclear	O
factor.kappa	O
B	O
activation	O
by	O
protein	O
kinase	O
C	O
in	O
T	O
lymphocytes	O
.	O

Autocrine	O
role	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
.	O

The	O
regulation	B-Regulation
of	O
interleukin	O
-	O
2	O
receptor	O
alpha	O
chain	O
(	O
IL	O
-	O
2R	O
alpha	O
)	O
expression	B-Gene_expression
and	O
nuclear	O
factor	O
(	O
NF	O
)	O
activation	O
by	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
in	O
resting	O
T	O
cells	O
,	O
has	O
been	O
studied	O
.	O

Treatment	O
of	O
human	O
resting	O
T	O
cells	O
with	O
phorbol	O
esters	O
strongly	O
induced	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
IL	O
-	O
2R	O
alpha	O
and	O
the	O
activation	O
of	O
NF.kappa	O
B	O
.	O

This	O
activation	O
was	O
due	O
to	O
the	O
translocation	B-Localization
of	O
p65	O
and	O
c	O
-	O
Rel	O
NF.kappa	O
B	O
proteins	O
from	O
cytoplasmic	O
stores	O
to	O
the	O
nucleus	O
,	O
where	O
they	O
bound	B-Binding
the	O
kappa	O
B	O
sequence	O
of	O
the	O
IL	O
-	O
2R	O
alpha	O
promoter	O
either	O
as	O
p50.p65	O
or	O
as	O
p50.c	O
-	O
Rel	O
heterodimers	B-Binding
.	O

Interestingly	O
,	O
all	O
of	O
those	O
events	O
were	O
largely	O
indirect	O
and	O
mediated	B-Positive_regulation
by	O
endogenously	O
secreted	B-Localization
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
,	O
as	O
they	O
were	O
strongly	O
inhibited	B-Negative_regulation
by	O
a	O
neutralizing	O
anti	O
-	O
TNF	O
alpha	O
monoclonal	O
antibody	O
.	O

Furthermore	O
,	O
cyclosporin	O
A	O
,	O
which	O
blocked	B-Negative_regulation
TNF	O
alpha	O
production	B-Gene_expression
induced	B-Positive_regulation
by	O
PKC	O
,	O
strongly	O
inhibited	B-Negative_regulation
IL	O
-	O
2R	O
alpha	O
and	O
NF.kappa	O
B	O
activation	B-Positive_regulation
.	O

The	O
addition	O
of	O
either	O
TNF	O
alpha	O
or	O
IL	O
-	O
2	O
partially	O
recovered	B-Negative_regulation
cyclosporin	O
A	O
-	O
induced	O
IL	O
-	O
2R	O
alpha	O
inhibition	B-Negative_regulation
,	O
but	O
only	O
TNF	O
alpha	O
completely	O
recovered	O
NF.kappa	O
B	O
activation	O
.	O

Those	O
results	O
indicate	O
that	O
,	O
in	O
resting	O
T	O
cells	O
,	O
PKC	O
activation	O
has	O
only	O
a	O
triggering	O
role	O
,	O
whereas	O
the	O
endogenously	O
secreted	B-Localization
TNF	O
alpha	O
plays	O
an	O
essential	O
role	O
in	O
the	O
quantitative	O
control	B-Regulation
of	O
the	O
expression	B-Gene_expression
of	O
IL	O
-	O
2R	O
alpha	O
chain	O
or	O
NF.kappa	O
B	O
activation	O
.	O

Protease	O
inhibitors	O
block	O
lipopolysaccharide	O
induction	O
of	O
tissue	O
factor	O
gene	O
expression	O
in	O
human	O
monocytic	O
cells	O
by	O
preventing	B-Negative_regulation
activation	B-Positive_regulation
of	O
c	O
-	O
Rel/p65	O
heterodimers	O
.	O

Tissue	O
factor	O
(	O
TF	O
)	O
is	O
expressed	B-Gene_expression
rapidly	O
by	O
human	O
monocytes	O
exposed	B-Positive_regulation
to	I-Positive_regulation
bacterial	O
endotoxin	O
(	O
lipopolysaccharide	O
,	O
or	O
LPS	O
)	O
.	O

Transcriptional	O
regulation	O
is	O
mediated	O
by	O
binding	B-Binding
of	O
c	O
-	O
Rel/p65	O
heterodimers	O
to	O
a	O
kappa	O
B	O
-	O
like	O
site	O
in	O
the	O
TF	O
promoter	O
.	O

Nuclear	O
translocation	B-Localization
of	O
cytosolic	O
c	O
-	O
Rel/p65	O
heterodimers	O
and	O
other	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B/Rel	O
family	O
requires	B-Positive_regulation
dissociation	O
and	O
proteolytic	B-Protein_catabolism
degradation	I-Protein_catabolism
of	O
the	O
inhibitor	O
protein	O
,	O
I	O
kappa	O
B	O
alpha	O
.	O

The	O
protease	O
inhibitors	O
N	O
alpha	O
-	O
tosylphenylalanyl	O
chloromethyl	O
ketone	O
(	O
TPCK	O
)	O
and	O
N	O
alpha-tosyl-L	O
-	O
lysine	O
chloromethyl	O
ketone	O
(	O
TLCK	O
)	O
block	O
activation	O
of	O
NF	O
-	O
kappa	O
B/Rel	O
proteins	O
by	O
preventing	B-Negative_regulation
degradation	B-Protein_catabolism
of	O
I	O
kappa	O
B	O
alpha	O
.	O

To	O
determine	O
if	O
TPCK	O
and	O
TLCK	O
inhibited	B-Negative_regulation
LPS	O
induction	B-Positive_regulation
of	O
TF	O
expression	B-Gene_expression
,	O
freshly	O
isolated	O
human	O
monocytes	O
and	O
monocytic	O
THP	O
-	O
1	O
cells	O
were	O
pretreated	O
with	O
these	O
inhibitors	O
for	O
30	O
min	O
before	O
LPS	O
stimulation	O
.	O

Both	O
TPCK	O
and	O
TLCK	O
inhibited	B-Negative_regulation
LPS	O
induction	B-Positive_regulation
of	O
TF	O
protein	O
,	O
TF	O
mRNA	O
and	O
TF	O
promoter	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

These	O
inhibitors	O
specifically	O
prevented	B-Negative_regulation
degradation	B-Protein_catabolism
of	O
I	O
kappa	O
B	O
alpha	O
and	O
nuclear	O
translocation	B-Localization
of	O
c	O
-	O
Rel/p65	O
heterodimers	O
.	O

In	O
contrast	O
,	O
TPCK	O
and	O
TLCK	O
did	O
not	O
block	B-Negative_regulation
induction	B-Positive_regulation
of	O
an	O
immediate	O
-	O
early	O
gene	O
encoding	O
the	O
transcription	O
factor	O
,	O
Egr	O
-	O
1	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicated	O
that	O
inhibiting	B-Negative_regulation
nuclear	O
translocation	B-Localization
of	O
c	O
-	O
Rel/p65	O
heterodimers	O
prevented	B-Negative_regulation
LPS	O
induction	B-Positive_regulation
of	O
TF	O
gene	O
transcription	B-Transcription
in	O
monocytic	O
cells	O
.	O

A	O
family	O
of	O
serine	O
proteases	O
expressed	O
exclusively	O
in	O
myelo	O
-	O
monocytic	O
cells	O
specifically	O
processes	O
the	O
nuclear	O
factor	O
-	O
kappa	O
B	O
subunit	O
p65	O
in	O
vitro	O
and	O
may	O
impair	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
these	O
cells	O
.	O

Two	O
groups	O
of	O
U937	O
promonocytic	O
cells	O
were	O
obtained	O
by	O
limiting	O
dilution	O
cloning	O
which	O
differed	O
strikingly	O
in	O
their	O
ability	O
to	O
support	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV	O
-	O
1	O
)	O
replication	O
.	O

"	O
Plus	O
"	O
clones	O
replicated	O
the	O
virus	O
efficiently	O
,	O
whereas	O
"	O
minus	O
"	O
clones	O
did	O
not	O
.	O

We	O
examined	O
these	O
clones	O
for	O
differences	O
in	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
activity	O
which	O
might	O
account	O
for	O
the	O
observed	O
phenomenon	O
.	O

Stimulation	O
of	O
plus	O
clones	O
liberated	B-Localization
the	O
classical	O
p50	O
-	O
p65	O
complex	O
from	O
cytoplasmic	O
pools	O
,	O
whereas	O
minus	O
clones	O
produced	O
an	O
apparently	O
novel	O
,	O
faster	O
-	O
migrating	O
complex	O
,	O
as	O
judged	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

It	O
is	O
surprising	O
that	O
the	O
faster	O
-	O
migrating	O
complex	O
was	O
composed	O
also	O
of	O
p50	O
and	O
p65	O
.	O

However	O
,	O
the	O
p65	O
subunit	O
was	O
COOH	O
-	O
terminally	O
truncated	O
,	O
as	O
shown	O
by	O
immunoprecipitation	O
.	O

The	O
truncation	O
resulted	O
from	O
limited	O
proteolysis	O
of	O
p65	O
during	O
cellular	O
extraction	O
which	O
released	O
particular	O
lysosomal	O
serine	O
proteases	O
,	O
such	O
as	O
elastase	O
,	O
cathepsin	O
G	O
,	O
and	O
proteinase	O
3	O
.	O

These	O
specific	O
proteases	O
are	O
coordinately	O
expressed	B-Gene_expression
and	O
were	O
present	O
exclusively	O
in	O
the	O
minus	O
U937	O
clones	O
,	O
but	O
not	O
in	O
the	O
plus	O
clones	O
,	O
as	O
demonstrated	O
in	O
the	O
case	O
of	O
cathepsin	O
G	O
.	O

In	O
addition	O
,	O
these	O
proteases	O
were	O
detected	B-Gene_expression
in	O
certain	O
subclones	O
of	O
THP	O
-	O
1	O
and	O
HL	O
-	O
60	O
cells	O
and	O
in	O
primary	O
monocytes	O
,	O
in	O
each	O
case	O
correlating	O
with	O
the	O
truncated	O
from	O
of	O
p65	O
.	O

We	O
demonstrate	O
in	O
vitro	O
cleavage	O
of	O
p65	O
by	O
purified	O
elastase	O
and	O
cathepsin	O
G	O
.	O

It	O
is	O
possible	O
that	O
particular	O
serine	O
proteases	O
may	O
have	O
inhibiting	O
effects	O
on	O
the	O
replication	O
of	O
HIV	O
-	O
1	O
in	O
myelo	O
-	O
monocytic	O
cells	O
.	O

The	O
data	O
also	O
demonstrate	O
that	O
special	O
precautions	O
must	O
be	O
taken	O
when	O
making	O
extracts	O
from	O
myelo	O
-	O
monocytic	O
cells	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
Tax	O
activation	O
of	O
NF	O
-	O
kappa	O
B/Rel	O
involves	O
phosphorylation	B-Phosphorylation
and	O
degradation	B-Protein_catabolism
of	O
I	O
kappa	O
B	O
alpha	O
and	O
RelA	O
(	O
p65	O
)	O
-	O
mediated	O
induction	O
of	O
the	O
c	O
-	O
rel	O
gene	O
.	O

The	O
tax	O
gene	O
product	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
a	O
potent	O
transcriptional	O
activator	O
that	O
both	O
stimulates	O
viral	O
gene	O
expression	O
and	O
activates	O
an	O
array	O
of	O
cellular	O
genes	O
involved	O
in	O
T	O
-	O
cell	O
growth	O
.	O

Tax	O
acts	O
indirectly	O
by	O
inducing	O
or	O
modifying	O
the	O
action	O
of	O
various	O
host	O
transcription	O
factors	O
,	O
including	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B/Rel	O
family	O
of	O
enhancer	O
-	O
binding	O
proteins	O
.	O

In	O
resting	O
T	O
cells	O
,	O
many	O
of	O
these	O
NF	O
-	O
kappa	O
B/Rel	O
factors	O
are	O
sequestered	O
in	O
the	O
cytoplasm	O
by	O
various	O
ankyrin	O
-	O
rich	O
inhibitory	O
proteins	O
,	O
including	O
I	O
kappa	O
B	O
alpha	O
.	O

HTLV	O
-	O
I	O
Tax	O
expression	B-Gene_expression
leads	B-Positive_regulation
to	O
the	O
constitutive	O
nuclear	O
expression	B-Gene_expression
of	O
biologically	O
active	O
NF	O
-	O
kappa	O
B	O
and	O
c	O
-	O
Rel	O
complexes	O
;	O
however	O
,	O
the	O
biochemical	O
mechanism	O
(	O
s	O
)	O
underlying	O
this	O
response	O
remains	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
Tax	O
-	O
stimulated	O
nuclear	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
both	O
HTLV-I	O
-	O
infected	O
and	O
Tax	O
-	O
transfected	O
human	O
T	O
cells	O
is	O
associated	O
with	O
the	O
phosphorylation	B-Phosphorylation
and	O
rapid	O
proteolytic	O
degradation	B-Protein_catabolism
of	O
I	O
kappa	O
B	O
alpha	O
.	O

In	O
contrast	O
to	O
prior	O
in	O
vitro	O
studies	O
,	O
at	O
least	O
a	O
fraction	O
of	O
the	O
phosphorylated	O
form	O
of	O
I	O
kappa	O
B	O
alpha	O
remains	O
physically	O
associated	B-Binding
with	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
in	O
vivo	O
but	O
is	O
subject	O
to	O
rapid	O
degradation	B-Protein_catabolism
,	O
thereby	O
promoting	O
the	O
nuclear	O
translocation	O
of	O
the	O
active	O
NF	O
-	O
kappa	O
B	O
complex	O
.	O

We	O
further	O
demonstrate	O
that	O
Tax	O
induction	B-Positive_regulation
of	O
nuclear	O
c	O
-	O
Rel	O
expression	B-Gene_expression
is	O
activated	B-Positive_regulation
by	O
the	O
RelA	O
(	O
p65	O
)	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
activates	B-Positive_regulation
transcription	B-Transcription
of	O
the	O
c	O
-	O
rel	O
gene	O
through	O
an	O
intrinsic	O
kappa	O
B	O
enhancer	O
element	O
.	O

In	O
normal	O
cells	O
,	O
the	O
subsequent	O
accumulation	B-Positive_regulation
of	O
nuclear	O
c	O
-	O
Rel	O
acts	O
to	O
inhibit	B-Negative_regulation
its	O
own	O
continued	O
production	B-Gene_expression
,	O
indicating	O
the	O
presence	O
of	O
an	O
autoregulatory	O
loop	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Arrested	O
development	O
:	O
understanding	O
v	O
-	O
abl	O
.	O

The	O
protein	O
tyrosine	O
kinase	O
activity	O
of	O
the	O
v	O
-	O
abl	O
oncogene	O
has	O
been	O
demonstrated	O
to	O
subvert	O
the	O
normal	O
second	O
messenger	O
systems	O
used	O
by	O
lymphoid	O
cells	O
for	O
growth	O
and	O
differentiation	O
.	O

Transformation	O
of	O
bone	O
marrow	O
with	O
the	O
Abelson	O
murine	O
leukemia	O
virus	O
results	O
in	O
the	O
appearance	O
of	O
B	O
cell	O
lineage	O
cells	O
arrested	O
at	O
the	O
pre	O
-	O
B	O
cell	O
stage	O
.	O

Recent	O
reports	O
have	O
characterized	O
these	O
cells	O
expressing	O
high	O
v	O
-	O
abl	O
kinase	O
activity	O
as	O
deficient	O
in	O
detectable	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
and	O
low	O
level	O
RAG	O
gene	O
expression	O
.	O

These	O
observations	O
suggest	O
that	O
v	O
-	O
abl	O
may	O
be	O
inhibiting	O
the	O
differentiation	O
of	O
B	O
cells	O
by	O
blocking	O
these	O
two	O
crucial	O
elements	O
in	O
the	O
maturation	O
pathway	O
.	O

Distinct	O
DNase	O
-	O
I	O
hypersensitive	O
sites	O
are	O
associated	O
with	O
TAL	O
-	O
1	O
transcription	B-Transcription
in	O
erythroid	O
and	O
T	O
-	O
cell	O
lines	O
.	O

The	O
tal	O
-	O
1	O
gene	O
,	O
frequently	O
activated	B-Positive_regulation
in	O
human	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T	O
-	O
ALL	O
)	O
,	O
is	O
expressed	B-Gene_expression
in	O
the	O
erythroid	O
,	O
megakaryocytic	O
,	O
and	O
mast	O
cell	O
lineages	O
during	O
normal	O
hematopoiesis	O
.	O

To	O
gain	O
further	O
insight	O
into	O
the	O
molecular	O
mechanisms	O
that	O
control	B-Regulation
tal	O
-	O
1	O
expression	B-Gene_expression
,	O
we	O
investigated	O
tal	O
-	O
1	O
chromatin	O
structure	O
in	O
erythroid/megakaryocytic	O
cell	O
lines	O
and	O
in	O
T	O
-	O
cell	O
lines	O
either	O
with	O
or	O
without	O
tal	O
-	O
1	O
rearrangements	O
.	O

Tal	O
-	O
1	O
transcription	B-Transcription
was	O
shown	O
to	O
be	O
monoallelic	O
in	O
Jurkat	O
,	O
a	O
T	O
-	O
cell	O
line	O
that	O
expresses	B-Gene_expression
tal	O
-	O
1	O
in	O
the	O
absence	O
of	O
apparent	O
genomic	O
alteration	O
of	O
the	O
locus	O
.	O

Methylation	O
studies	O
indicated	O
that	O
the	O
tal	O
-	O
15	O
'	O
GC	O
-	O
rich	O
region	O
behaves	O
like	O
a	O
CpG	O
island	O
,	O
hypomethylated	O
in	O
normal	O
cells	O
,	O
and	O
methylated	O
de	O
novo	O
on	O
transcriptionally	O
inactive	O
alleles	O
in	O
established	O
cell	O
lines	O
.	O

Five	O
major	O
DNase	O
-	O
I	O
hypersensitive	O
sites	O
(	O
HS	O
)	O
were	O
mapped	O
in	O
the	O
tal	O
-	O
1	O
locus	O
.	O

HS	O
I	O
,	O
IV	O
,	O
and	O
V	O
were	O
exclusively	O
observed	O
in	O
the	O
erythroid/megakaryocytic	O
cell	O
lines	O
that	O
express	B-Gene_expression
tal	O
-	O
1	O
from	B-Positive_regulation
the	O
promoters	O
1a	O
and	O
1b	O
.	O

HS	O
II	O
was	O
weak	O
in	O
hematopoietic	O
cell	O
lines	O
,	O
absent	O
in	O
Hela	O
,	O
and	O
greatly	O
enhanced	O
in	O
Jurkat	O
,	O
suggesting	O
that	O
this	O
region	O
might	O
be	O
implicated	O
in	O
the	O
cis	B-Positive_regulation
-	I-Positive_regulation
activation	I-Positive_regulation
of	O
tal	O
-	O
1	O
promoter	O
1b	O
in	O
this	O
cell	O
line	O
.	O

HS	O
III	O
was	O
weak	O
in	O
HEL	O
and	O
Jurkat	O
,	O
and	O
greatly	O
enhanced	O
in	O
DU528	O
,	O
a	O
T	O
-	O
cell	O
line	O
that	O
bears	O
a	O
t	O
(	O
1	O
;	O
14	O
)	O
and	O
initiates	O
tal	O
-	O
1	O
transcription	B-Transcription
within	O
exon	O
4	O
.	O

These	O
results	O
suggest	O
that	O
distinct	O
regulatory	O
elements	O
are	O
associated	O
with	O
the	O
use	O
of	O
the	O
different	O
tal	O
-	O
1	O
promoters	O
.	O

Functions	O
of	O
glutathione	O
and	O
glutathione	O
disulfide	O
in	O
immunology	O
and	O
immunopathology	O
.	O

Even	O
a	O
moderate	O
increase	O
in	O
the	O
cellular	O
cysteine	O
supply	O
elevates	O
the	O
intracellular	O
glutathione	O
(	O
GSH	O
)	O
and	O
glutathione	O
disulfide	O
(	O
GSSG	O
)	O
levels	O
and	O
potentiates	O
immunological	O
functions	O
of	O
lymphocytes	O
in	O
vitro	O
.	O

At	O
low	O
GSSG	O
levels	O
,	O
T	O
cells	O
can	O
not	O
optimally	O
activate	O
the	O
immunologically	O
important	O
transcription	O
factor	O
NF	O
kappa	O
B	O
,	O
whereas	O
high	O
GSSG	O
levels	O
inhibit	O
the	O
DNA	O
binding	O
activity	O
of	O
NF	O
kappa	O
B	O
.	O

The	O
effects	O
of	O
GSSG	O
are	O
antagonized	O
by	O
reduced	O
thioredoxin	O
(	O
TRX	O
)	O
.	O

As	O
the	O
protein	O
tyrosine	O
kinase	O
activities	O
p56lck	O
and	O
p59fyn	O
are	O
activated	B-Positive_regulation
in	O
intact	O
cells	O
by	O
hydrogen	O
peroxide	O
,	O
they	O
are	O
likely	O
targets	B-Regulation
for	O
GSSG	O
action	O
.	O

These	O
redox	O
-	O
regulated	O
enzymes	O
trigger	B-Positive_regulation
signal	I-Positive_regulation
cascades	I-Positive_regulation
for	O
NF	O
kappa	O
B	O
activation	O
and	O
transduce	O
signals	O
from	O
the	O
T	O
cell	O
antigen	O
receptor	O
,	O
from	O
CD4	O
and	O
CD8	O
molecules	O
,	O
and	O
from	O
the	O
IL	O
-	O
2	O
receptor	O
beta	O
-	O
chain	O
.	O

The	O
effector	O
phase	O
of	O
cytotoxic	O
T	O
cell	O
responses	O
and	O
IL-2	O
-	O
dependent	O
functions	O
are	O
inhibited	O
even	O
by	O
a	O
partial	O
depletion	O
of	O
the	O
intracellular	O
GSH	O
pool	O
.	O

As	O
signal	O
transduction	O
is	O
facilitated	O
by	O
prooxidant	O
conditions	O
,	O
we	O
propose	O
that	O
the	O
well	O
-	O
known	O
immunological	O
consequences	O
of	O
GSH	O
depletion	O
ultimately	O
may	O
be	O
results	O
of	O
the	O
accompanying	O
GSSG	O
deficiency	O
.	O

As	O
HIV	O
-	O
infected	O
patients	O
and	O
SIV	O
-	O
infected	O
rhesus	O
macaques	O
have	O
,	O
on	O
the	O
average	O
,	O
significantly	O
decreased	O
plasma	O
cyst	O
(	O
e	O
)	O
ine	O
and	O
intracellular	O
GSH	O
levels	O
,	O
we	O
also	O
hypothesize	O
that	O
AIDS	O
may	O
be	O
the	O
consequence	O
of	O
a	O
GSSG	O
deficiency	O
as	O
well	O
.	O

Erythropoietin	O
-	O
dependent	O
induction	O
of	O
hemoglobin	O
synthesis	O
in	O
a	O
cytokine	O
-	O
dependent	O
cell	O
line	O
M	O
-	O
TAT	O
.	O

M	O
-	O
TAT	O
is	O
a	O
cytokine	O
-	O
dependent	O
cell	O
line	O
with	O
the	O
potential	O
to	O
differentiate	O
along	O
the	O
erythroid	O
and	O
megakaryocytic	O
lineages	O
.	O

We	O
cultured	O
M	O
-	O
TAT	O
cells	O
long	O
term	O
(	O
>	O
1	O
year	O
)	O
in	O
the	O
continuous	O
presence	O
of	O
erythropoietin	O
(	O
EPO	O
)	O
,	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
,	O
or	O
stem	O
cell	O
factor	O
(	O
SCF	O
)	O
.	O

These	O
long	O
term	O
cultures	O
are	O
referred	O
to	O
as	O
M	O
-	O
TAT/EPO	O
,	O
M-TAT/GM	O
-	O
CSF	O
,	O
and	O
M	O
-	O
TAT/SCF	O
cells	O
,	O
respectively	O
.	O

Hemoglobin	O
concentration	O
and	O
gamma	O
-	O
globin	O
and	O
erythroid	O
delta	O
-	O
aminolevulinate	O
synthase	O
mRNA	B-Transcription
levels	I-Transcription
were	O
significantly	O
higher	O
in	O
M	O
-	O
TAT/EPO	O
cells	O
than	O
in	O
M-TAT/GM	O
-	O
CSF	O
cells	O
.	O

When	O
the	O
supplemented	O
cytokine	O
was	O
switched	O
from	O
GM	O
-	O
CSF	O
to	O
EPO	O
,	O
hemoglobin	O
synthesis	O
in	O
M-TAT/GM	O
-	O
CSF	O
cells	O
increased	O
rapidly	O
(	O
within	O
5	O
h	O
)	O
,	O
and	O
the	O
level	O
of	O
GATA	O
-	O
1	O
mRNA	O
increased	B-Positive_regulation
.	O

In	O
contrast	O
,	O
the	O
addition	O
of	O
GM	O
-	O
CSF	O
to	O
the	O
M	O
-	O
TAT/EPO	O
cell	O
culture	O
decreased	O
the	O
amount	O
of	O
hemoglobin	O
,	O
even	O
in	O
the	O
presence	O
of	O
EPO	O
,	O
indicating	O
that	O
the	O
EPO	O
signal	O
for	O
erythroid	O
differentiation	O
is	O
suppressed	O
by	O
GM	O
-	O
CSF	O
.	O

Thus	O
,	O
erythroid	O
development	O
of	O
M	O
-	O
TAT	O
cells	O
is	O
promoted	O
by	O
EPO	O
and	O
suppressed	O
by	O
GM	O
-	O
CSF	O
.	O

These	O
results	O
support	O
the	O
hypothesis	O
that	O
EPO	O
actively	O
influences	O
the	O
programming	O
of	O
gene	O
expression	O
required	O
for	O
erythroid	O
progenitor	O
cell	O
differentiation	O
.	O

One	O
gene	O
,	O
two	O
transcripts	O
:	O
isolation	O
of	O
an	O
alternative	O
transcript	O
encoding	O
for	O
the	O
autoantigen	O
La/SS	O
-	O
B	O
from	O
a	O
cDNA	O
library	O
of	O
a	O
patient	O
with	O
primary	O
Sjogrens	O
'	O
syndrome	O
.	O

A	O
cDNA	O
library	O
was	O
prepared	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
an	O
autoimmune	O
patient	O
with	O
primary	O
Sjogrens	O
'	O
syndrome	O
.	O

The	O
cDNA	O
library	O
was	O
screened	O
with	O
the	O
patients	O
own	O
autoimmune	O
serum	O
being	O
monospecific	O
for	O
the	O
nuclear	O
autoantigen	O
La/SS	O
-	O
B	O
.	O

Thereby	O
an	O
alternative	O
type	O
of	O
La	O
mRNA	O
was	O
identified	O
that	O
differed	O
from	O
the	O
known	O
La	O
mRNA	O
due	O
to	O
an	O
exchange	O
of	O
the	O
exon	O
1	O
.	O

Sequencing	O
of	O
the	O
genomic	O
region	O
between	O
the	O
exons	O
1	O
and	O
2	O
showed	O
that	O
the	O
alternative	O
5'	O
-	O
end	O
is	O
a	O
part	O
of	O
the	O
intron	O
.	O

In	O
addition	O
,	O
the	O
presence	O
of	O
an	O
alternative	O
promoter	O
site	O
,	O
which	O
exists	O
within	O
the	O
intron	O
downstream	O
of	O
the	O
exon	O
1	O
,	O
became	O
evident	O
.	O

In	O
consequence	O
,	O
the	O
alternative	O
La	O
mRNA	O
is	O
the	O
result	B-Positive_regulation
of	O
a	O
promoter	O
switching	O
combined	O
with	O
an	O
alternative	O
splicing	O
mechanism	O
.	O

In	O
the	O
intron	O
,	O
further	O
transcription	O
factor	O
binding	O
sites	O
,	O
including	O
a	O
NF	O
-	O
kappa	O
B	O
element	O
,	O
were	O
identified	O
leading	O
to	O
the	O
suggestion	O
that	O
the	O
expression	B-Gene_expression
of	O
the	O
gene	O
encoding	O
for	O
the	O
nuclear	O
autoantigen	O
La/SS	O
-	O
B	O
alters	B-Regulation
in	O
dependence	O
on	O
disease	O
conditions	O
.	O

Functional	O
Myc	O
-	O
Max	O
heterodimer	O
is	O
required	O
for	O
activation	O
-	O
induced	O
apoptosis	O
in	O
T	O
cell	O
hybridomas	O
.	O

T	O
cell	O
hybridomas	O
respond	O
to	O
activation	O
signals	O
by	O
undergoing	O
apoptotic	O
cell	O
death	O
,	O
and	O
this	O
is	O
likely	O
to	O
represent	O
comparable	O
events	O
related	O
to	O
tolerance	O
induction	O
in	O
immature	O
and	O
mature	O
T	O
cells	O
in	O
vivo	O
.	O

Previous	O
studies	O
using	O
antisense	O
oligonucleotides	O
implicated	O
the	O
c	O
-	O
Myc	O
protein	O
in	O
the	O
phenomenon	O
of	O
activation	O
-	O
induced	O
apoptosis	O
.	O

This	O
role	O
for	O
c	O
-	O
Myc	O
in	O
apoptosis	O
is	O
now	O
confirmed	O
in	O
studies	O
using	O
a	O
dominant	O
negative	O
form	O
of	O
its	O
heterodimeric	O
binding	B-Binding
partner	I-Binding
,	O
Max	O
,	O
which	O
we	O
show	O
here	O
inhibits	O
activation	O
-	O
induced	O
apoptosis	O
.	O

Further	O
,	O
coexpression	B-Gene_expression
of	O
a	O
reciprocally	O
mutant	O
Myc	O
protein	O
capable	B-Binding
of	I-Binding
forming	I-Binding
functional	I-Binding
heterodimers	I-Binding
with	O
the	O
mutant	O
Max	O
can	O
compensate	O
for	O
the	O
dominant	O
negative	O
activity	O
and	O
restore	O
activation	O
-	O
induced	O
apoptosis	O
.	O

These	O
results	O
imply	O
that	O
Myc	O
promotes	O
activation	O
-	O
induced	O
apoptosis	O
by	O
obligatory	O
heterodimerization	B-Binding
with	O
Max	O
,	O
and	O
therefore	O
,	O
by	O
regulating	O
gene	O
transcription	O
.	O

DNA	O
-	O
binding	B-Binding
studies	O
of	O
the	O
Epstein	O
-	O
Barr	O
virus	O
nuclear	O
antigen	O
2	O
(	O
EBNA	O
-	O
2	O
)	O
:	O
evidence	O
for	O
complex	O
formation	O
by	O
latent	O
membrane	O
protein	O
gene	O
promoter	O
-	O
binding	O
proteins	O
in	O
EBNA-2	O
-	O
positive	O
cell	O
lines	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
nuclear	O
antigen	O
2	O
(	O
EBNA	O
-	O
2	O
)	O
protein	O
is	O
essential	O
for	O
the	O
immortalization	O
of	O
human	O
primary	O
B	O
cells	O
by	O
EBV	O
.	O

EBNA	O
-	O
2	O
trans	B-Positive_regulation
-	I-Positive_regulation
activates	I-Positive_regulation
cellular	O
and	O
viral	O
genes	O
like	O
CD23	O
,	O
c	O
-	O
fgr	O
,	O
latent	O
membrane	O
protein	O
1	O
(	O
LMP1	O
)	O
and	O
terminal	O
protein	O
1	O
(	O
TP1	O
)	O
.	O

Trans	B-Positive_regulation
-	I-Positive_regulation
activation	I-Positive_regulation
of	O
the	O
TP1	O
promoter	O
and	O
of	O
the	O
BamHI	O
C	O
promoter	O
has	O
already	O
been	O
investigated	O
in	O
detail	O
and	O
appears	O
to	O
be	O
mediated	B-Positive_regulation
via	O
protein	O
-	O
protein	O
interactions	O
and	O
not	O
by	O
direct	O
binding	O
of	O
EBNA	O
-	O
2	O
type	O
A	O
(	O
of	O
EBV	O
type	O
1	O
)	O
to	O
the	O
DNA	O
.	O

EBNA	O
-	O
2	O
is	O
able	O
to	O
trans	B-Positive_regulation
-	I-Positive_regulation
activate	I-Positive_regulation
the	O
expression	B-Gene_expression
of	O
the	O
LMP	O
gene	O
in	O
several	O
cell	O
lines	O
.	O

Various	O
reports	O
have	O
delineated	O
the	O
cis	O
-	O
acting	O
elements	O
of	O
the	O
LMP	O
promoter	O
through	O
which	O
EBNA	O
-	O
2	O
mediates	B-Positive_regulation
trans	O
-	O
activation	O
.	O

To	O
determine	O
whether	O
EBNA	O
-	O
2	O
also	O
trans	B-Positive_regulation
-	I-Positive_regulation
activates	I-Positive_regulation
the	O
LMP	O
promoter	O
by	O
protein	O
-	O
protein	O
interactions	B-Binding
,	O
we	O
performed	O
a	O
series	O
of	O
gel	O
retardation	O
assays	O
and	O
competition	O
experiments	O
with	O
LMP	O
promoter	O
fragments	O
of	O
different	O
sizes	O
.	O

We	O
determined	O
that	O
the	O
protein	O
-	O
binding	B-Binding
region	O
on	O
the	O
LMP	O
promoter	O
was	O
within	O
a	O
42	O
bp	O
fragment	O
encompassing	O
nucleotides	O
-	O
135	O
to	O
-	O
176	O
relative	O
to	O
the	O
LMP	O
transcriptional	O
start	O
site	O
.	O

None	O
of	O
the	O
DNA	O
fragments	O
investigated	O
indicated	O
interaction	B-Binding
of	O
EBNA	O
-	O
2	O
with	O
the	O
DNA	O
via	O
protein	O
-	O
protein	O
interactions	B-Binding
.	O

No	O
significant	O
differences	O
between	O
EBNA-2	O
-	O
positive	O
and	O
EBNA-2	O
-	O
negative	O
nuclear	O
extracts	O
could	O
be	O
seen	O
in	O
the	O
gel	O
retardation	O
assay	O
under	O
conditions	O
that	O
clearly	O
showed	O
binding	B-Binding
of	O
EBNA	O
-	O
2A	O
to	O
the	O
TP1	O
promoter	O
.	O

However	O
,	O
analysis	O
of	O
sucrose	O
gradient	O
fractions	O
in	O
the	O
gel	O
retardation	O
assay	O
provided	O
evidence	O
that	O
the	O
LMP	O
promoter	O
-	O
binding	B-Binding
proteins	O
form	O
a	O
complex	O
of	O
higher	O
M	O
(	O
r	O
)	O
in	O
EBNA-2	O
-	O
positive	O
cell	O
extracts	O
.	O

These	O
complexes	O
were	O
destroyed	O
by	O
detergent	O
.	O

We	O
deduce	O
from	O
these	O
results	O
that	O
EBNA-2	O
-	O
positive	O
cells	O
might	O
indeed	O
contain	O
specific	O
complexes	O
bound	B-Binding
to	O
the	O
LMP	O
promoter	O
which	O
are	O
,	O
however	O
,	O
too	O
labile	O
to	O
be	O
detected	O
in	O
a	O
standard	O
gel	O
retardation	O
assay	O
.	O

Enhanced	O
responsiveness	O
to	O
nuclear	O
factor	O
kappa	O
B	O
contributes	O
to	O
the	O
unique	O
phenotype	O
of	O
simian	O
immunodeficiency	O
virus	O
variant	O
SIVsmmPBj14	O
.	O

Infection	O
with	O
a	O
variant	O
of	O
simian	O
immunodeficiency	O
virus	O
,	O
SIVsmmPBj14	O
,	O
leads	O
to	O
severe	O
acute	O
disease	O
in	O
macaques	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
functional	O
significance	O
of	O
previously	O
described	O
mutations	O
in	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
and	O
to	O
elucidate	O
their	O
contribution	O
to	O
the	O
unique	O
phenotype	O
of	O
SIVsmmPBj14	O
.	O

LTR	O
-	O
directed	O
transcription	O
was	O
measured	O
by	O
using	O
luciferase	O
reporter	O
constructs	O
that	O
were	O
transiently	O
transfected	O
into	O
cultured	O
cells	O
.	O

In	O
a	O
wide	O
range	O
of	O
cell	O
types	O
,	O
the	O
basal	O
transcriptional	O
activity	O
of	O
the	O
LTR	O
from	O
SIVsmmPBj14	O
was	O
found	O
to	O
be	O
2	O
-	O
to	O
4.5	O
-	O
fold	O
higher	O
than	O
that	O
of	O
an	O
LTR	O
from	O
a	O
non	O
-	O
acutely	O
pathogenic	O
strain	O
.	O

These	O
LTRs	O
differ	O
by	O
five	O
point	O
mutations	O
and	O
a	O
22	O
-	O
bp	O
duplication	O
in	O
SIVsmmPBj14	O
,	O
which	O
includes	O
a	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
kappa	O
B	O
)	O
site	O
.	O

Transcriptional	O
differences	O
between	O
these	O
LTRs	O
were	O
further	O
enhanced	O
by	O
two	O
-	O
to	O
threefold	O
upon	O
treatment	O
of	O
cells	O
with	O
phorbol	O
ester	O
or	O
tumor	O
necrosis	O
factor	O
alpha	O
or	O
by	O
cotransfection	O
with	O
plasmids	O
expressing	O
NF	O
kappa	O
B	O
subunits	O
.	O

Mutagenesis	O
studies	O
,	O
and	O
the	O
use	O
of	O
a	O
reporter	O
construct	O
containing	O
an	O
enhancerless	O
promoter	O
,	O
indicate	O
that	O
these	O
transcriptional	O
effects	O
are	O
due	O
principally	O
to	O
the	O
22	O
-	O
bp	O
sequence	O
duplication	O
and	O
the	O
NF	O
kappa	O
B	O
site	O
contained	O
within	O
it	O
.	O

Finally	O
,	O
infectious	O
virus	O
stocks	O
that	O
were	O
isogenic	O
except	O
for	O
the	O
LTR	O
were	O
generated	O
.	O

The	O
LTR	O
from	O
SIVsmmPBj14	O
was	O
found	O
to	O
confer	O
an	O
increase	O
in	O
the	O
kinetics	O
of	O
virus	O
replication	O
in	O
cultured	O
cells	O
.	O

Inclusion	O
of	O
this	O
LTR	O
in	O
recombinant	O
SIVs	O
also	O
resulted	O
in	O
a	O
two	O
-	O
to	O
threefold	O
rise	O
in	O
the	O
extent	O
of	O
cellular	O
proliferation	O
that	O
was	O
induced	O
in	O
quiescent	O
simian	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

These	O
studies	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
LTR	O
mutations	O
assist	O
SIVsmmPBj14	O
in	O
responding	O
efficiently	O
to	O
cellular	O
stimulation	O
and	O
allow	O
it	O
to	O
replicate	O
to	O
high	O
titers	O
during	O
the	O
acute	O
phase	O
of	O
viral	O
infection	O
.	O

Identification	O
of	O
a	O
region	O
which	O
directs	B-Regulation
the	O
monocytic	O
activity	O
of	O
the	O
colony	O
-	O
stimulating	O
factor	O
1	O
(	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
)	O
receptor	O
promoter	O
and	O
binds	B-Binding
PEBP2/CBF	O
(	O
AML1	O
)	O
.	O

The	O
receptor	O
for	O
the	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
or	O
colony	O
-	O
stimulating	O
factor	O
1	O
[	O
CSF	O
-	O
1	O
]	O
)	O
is	O
expressed	O
from	O
different	O
promoters	O
in	O
monocytic	O
cells	O
and	O
placental	O
trophoblasts	O
.	O

We	O
have	O
demonstrated	O
that	O
the	O
monocyte	O
-	O
specific	O
expression	B-Gene_expression
of	O
the	O
CSF	O
-	O
1	O
receptor	O
is	O
regulated	B-Regulation
at	O
the	O
level	O
of	O
transcription	O
by	O
a	O
tissue	O
-	O
specific	O
promoter	O
whose	O
activity	O
is	O
stimulated	O
by	O
the	O
monocyte/B-cell	O
-	O
specific	O
transcription	O
factor	O
PU.1	O
(	O
D.	O
-	O
E.Zhang	O
,	O
C.J.Hetherington	O
,	O
H.	O
-	O
M.Chen	O
,	O
and	O
D.G.Tenen	O
,	O
Mol.Cell	O
.	O

Biol.14	O
:	O
373	O
-	O
381	O
,	O
1994	O
)	O
.	O

Here	O
we	O
report	O
that	O
the	O
tissue	O
specificity	O
of	O
this	O
promoter	O
is	O
also	O
mediated	O
by	O
sequences	O
in	O
a	O
region	O
II	O
(	O
bp	O
-	O
88	O
to	O
-	O
59	O
)	O
,	O
which	O
lies	O
10	O
bp	O
upstream	O
from	O
the	O
PU.1	O
-	O
binding	O
site	O
.	O

When	O
analyzed	O
by	O
DNase	O
footprinting	O
,	O
region	O
II	O
was	O
protected	O
preferentially	O
in	O
monocytic	O
cells	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
confirmed	O
that	O
region	O
II	O
interacts	O
specifically	O
with	O
nuclear	O
proteins	O
from	O
monocytic	O
cells	O
.	O

Two	O
gel	O
shift	O
complexes	O
(	O
Mono	O
A	O
and	O
Mono	O
B	O
)	O
were	O
formed	O
with	O
separate	O
sequence	O
elements	O
within	O
this	O
region	O
.	O

Competition	O
and	O
supershift	O
experiments	O
indicate	O
that	O
Mono	O
B	O
contains	B-Binding
a	O
member	O
of	O
the	O
polyomavirus	O
enhancer	O
-	O
binding	O
protein	O
2/core	O
-	O
binding	O
factor	O
(	O
PEBP2/CBF	O
)	O
family	O
,	O
which	O
includes	O
the	O
AML1	O
gene	O
product	O
,	O
while	O
Mono	O
A	O
is	O
a	O
distinct	O
complex	O
preferentially	O
expressed	O
in	O
monocytic	O
cells	O
.	O

Promoter	O
constructs	O
with	O
mutations	O
in	O
these	O
sequence	O
elements	O
were	O
no	O
longer	O
expressed	O
specifically	O
in	O
monocytes	O
.	O

Furthermore	O
,	O
multimerized	O
region	O
II	O
sequence	O
elements	O
enhanced	O
the	O
activity	O
of	O
a	O
heterologous	O
thymidine	O
kinase	O
promoter	O
in	O
monocytic	O
cells	O
but	O
not	O
other	O
cell	O
types	O
tested	O
.	O

These	O
results	O
indicate	O
that	O
the	O
monocyte/B-cell	O
-	O
specific	O
transcription	O
factor	O
PU.1	O
and	O
the	O
Mono	O
A	O
and	O
Mono	O
B	O
protein	O
complexes	O
act	O
in	B-Regulation
concert	I-Regulation
to	I-Regulation
regulate	I-Regulation
monocyte	O
-	O
specific	O
transcription	B-Transcription
of	O
the	O
CSF	O
-	O
1	O
receptor	O
.	O

A	O
factor	O
that	O
regulates	B-Regulation
the	O
class	O
II	O
major	O
histocompatibility	O
complex	O
gene	O
DPA	O
is	O
a	O
member	O
of	O
a	O
subfamily	O
of	O
zinc	O
finger	O
proteins	O
that	O
includes	O
a	O
Drosophila	O
developmental	O
control	O
protein	O
.	O

A	O
novel	O
DNA	O
sequence	O
element	O
termed	O
the	O
J	O
element	O
involved	O
in	O
the	O
regulated	O
expression	O
of	O
class	O
II	O
major	O
histocompatibility	O
complex	O
genes	O
was	O
recently	O
described	O
.	O

To	O
study	O
this	O
element	O
and	O
its	O
role	O
in	O
class	O
II	O
gene	O
regulation	O
further	O
,	O
a	O
cDNA	O
library	O
was	O
screened	O
with	O
oligonucleotide	O
probes	O
containing	O
both	O
the	O
S	O
element	O
and	O
the	O
nearby	O
J	O
element	O
of	O
the	O
human	O
DPA	O
gene	O
.	O

Several	O
DNA	O
clones	O
were	O
obtained	O
by	O
this	O
procedure	O
,	O
one	O
of	O
which	O
,	O
clone	O
18	O
,	O
is	O
reported	O
and	O
characterized	O
here	O
.	O

It	O
encodes	O
a	O
protein	O
predicted	O
to	O
contain	O
688	O
amino	O
acid	O
residues	O
,	O
including	O
11	O
zinc	O
finger	O
motifs	O
of	O
the	O
C2H2	O
type	O
in	O
the	O
C	O
-	O
terminal	O
region	O
,	O
that	O
are	O
Kruppel	O
-	O
like	O
in	O
the	O
conservation	O
of	O
the	O
H/C	O
link	O
sequence	O
connecting	O
them	O
.	O

The	O
160	O
N	O
-	O
terminal	O
amino	O
acids	O
in	O
the	O
nonfinger	O
region	O
of	O
clone	O
18	O
are	O
highly	O
homologous	O
with	O
similar	O
regions	O
of	O
several	O
other	O
human	O
,	O
mouse	O
,	O
and	O
Drosophila	O
sequences	O
,	O
defining	O
a	O
subfamily	O
of	O
Kruppel	O
-	O
like	O
zinc	O
finger	O
proteins	O
termed	O
TAB	O
(	O
tramtrack	O
[	O
ttk	O
]	O
-	O
associated	O
box	O
)	O
here	O
.	O

One	O
of	O
the	O
Drosophila	O
sequences	O
,	O
ttk	O
,	O
is	O
a	O
developmental	O
control	O
gene	O
,	O
while	O
a	O
second	O
does	O
not	O
contain	O
a	O
zinc	O
finger	O
region	O
but	O
encodes	O
a	O
structure	O
important	O
in	O
oocyte	O
development	O
.	O

An	O
acidic	O
activation	O
domain	O
is	O
located	O
between	O
the	O
N	O
-	O
terminal	O
conserved	O
region	O
of	O
clone	O
18	O
and	O
its	O
zinc	O
fingers	O
.	O

This	O
protein	O
appears	O
to	O
require	O
both	O
the	O
S	O
and	O
J	O
elements	O
,	O
which	O
are	O
separated	O
by	O
10	O
bp	O
for	O
optimal	O
binding	O
.	O

Antisense	O
cDNA	O
to	O
clone	O
18	O
inhibited	O
the	O
expression	O
of	O
a	O
reporter	O
construct	O
containing	O
the	O
DPA	O
promoter	O
,	O
indicating	O
its	O
functional	O
importance	B-Positive_regulation
in	O
the	O
expression	B-Gene_expression
of	O
this	O
class	O
II	O
gene	O
.	O

Glucocorticoid	O
-	O
induced	O
apoptosis	O
of	O
lymphoid	O
cells	O
.	O

The	O
induction	O
of	O
cell	O
death	O
in	O
lymphoid	O
cells	O
by	O
glucocorticoids	O
is	O
one	O
of	O
the	O
earliest	O
and	O
most	O
thoroughly	O
studied	O
models	O
of	O
apoptosis	O
.	O

Although	O
the	O
exact	O
mechanism	O
by	O
which	O
apoptosis	O
occurs	O
in	O
lymphocytes	O
is	O
unknown	O
many	O
biochemical	O
and	O
molecular	O
changes	O
have	O
been	O
shown	O
to	O
occur	O
in	O
these	O
cells	O
in	O
response	O
to	O
glucocorticoids	O
.	O

The	O
role	O
of	O
chromatin	O
degradation	O
and	O
endonucleases	O
in	O
the	O
apoptotic	O
process	O
has	O
been	O
closely	O
studied	O
,	O
as	O
well	O
as	O
the	O
involvement	O
of	O
several	O
oncogenes	O
in	O
glucocorticoid	O
-	O
induced	O
cell	O
lysis	O
.	O

In	O
addition	O
,	O
the	O
clinical	O
importance	O
of	O
glucocorticoid	O
-	O
induced	O
apoptosis	O
in	O
the	O
treatment	O
of	O
lymphoid	O
neoplasms	O
has	O
recently	O
received	O
increased	O
attention	O
.	O

Inhibition	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
replication	O
by	O
a	O
Tat	O
-	O
activated	O
,	O
transduced	O
interferon	O
gene	O
:	O
targeted	O
expression	O
to	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
-	O
infected	O
cells	O
.	O

We	O
have	O
examined	O
the	O
feasibility	O
of	O
using	O
interferon	O
(	O
IFN	O
)	O
gene	O
transfer	O
as	O
a	O
novel	O
approach	O
to	O
anti	O
-	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
therapy	O
in	O
this	O
study	O
.	O

To	O
limit	O
expression	O
of	O
a	O
transduced	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
-	O
IFNA2	O
(	O
the	O
new	O
approved	O
nomenclature	O
for	O
IFN	O
genes	O
is	O
used	O
throughout	O
this	O
article	O
)	O
hybrid	O
gene	O
to	O
the	O
HIV-1	O
-	O
infected	O
cells	O
,	O
HIV	O
-	O
1	O
LTR	O
was	O
modified	O
.	O

Deletion	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
elements	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
significantly	O
inhibited	O
Tat	O
-	O
mediated	O
transactivation	O
in	O
T	O
-	O
cell	O
lines	O
,	O
as	O
well	O
as	O
in	O
a	O
monocyte	O
line	O
,	O
U937	O
.	O

Replacement	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
elements	O
in	O
the	O
HIV	O
-	O
1	O
LTR	O
by	O
a	O
DNA	O
fragment	O
derived	O
from	O
the	O
5'	O
-	O
flanking	O
region	O
of	O
IFN	O
-	O
stimulated	O
gene	O
15	O
(	O
ISG15	O
)	O
,	O
containing	O
the	O
IFN	O
-	O
stimulated	O
response	O
element	O
,	O
partially	O
restored	O
Tat	O
-	O
mediated	O
activation	O
of	O
LTR	O
in	O
T	O
cells	O
as	O
well	O
as	O
in	O
monocytes	O
.	O

Insertion	O
of	O
this	O
chimeric	O
promoter	O
(	O
ISG15	O
LTR	O
)	O
upstream	O
of	O
the	O
human	O
IFNA2	O
gene	O
directed	O
high	O
levels	O
of	O
IFN	O
synthesis	O
in	O
Tat	O
-	O
expressing	B-Gene_expression
cells	O
,	O
while	O
this	O
promoter	O
was	O
not	O
responsive	O
to	O
tumor	O
necrosis	O
factor	O
alpha	O
-	O
mediated	O
activation	O
.	O

ISG15-LTR	O
-	O
IFN	O
hybrid	O
gene	O
inserted	O
into	O
the	O
retrovirus	O
vector	O
was	O
transduced	O
into	O
Jurkat	O
and	O
U937	O
cells	O
.	O

Selected	O
transfected	O
clones	O
produced	B-Gene_expression
low	O
levels	O
of	O
IFN	O
A	O
(	O
IFNA	O
)	O
constitutively	O
,	O
and	O
their	O
abilities	O
to	O
express	B-Gene_expression
interleukin	O
-	O
2	O
and	O
interleukin	O
-	O
2	O
receptor	O
upon	O
stimulation	B-Positive_regulation
with	O
phytohemagglutinin	O
and	O
phorbol	O
myristate	O
acetate	O
were	O
retained	O
.	O

Enhancement	B-Positive_regulation
of	O
IFNA	O
synthesis	B-Gene_expression
observed	O
upon	O
HIV	O
-	O
1	O
infection	O
resulted	O
in	O
significant	O
inhibition	O
of	O
HIV	O
-	O
1	O
replication	O
for	O
a	O
period	O
of	O
at	O
least	O
30	O
days	O
.	O

Virus	O
isolated	O
from	O
IFNA	O
-	O
producing	B-Gene_expression
cells	O
was	O
able	O
to	O
replicate	O
in	O
the	O
U937	O
cells	O
but	O
did	O
not	O
replicate	O
efficiently	O
in	O
U937	O
cells	O
transduced	O
with	O
the	O
IFNA	O
gene	O
.	O

These	O
results	O
suggest	O
that	O
targeting	O
IFN	O
synthesis	O
to	O
HIV-1	O
-	O
infected	O
cells	O
is	O
an	O
attainable	O
goal	O
and	O
that	O
autocrine	O
IFN	O
synthesis	O
results	O
in	O
a	O
long	O
-	O
lasting	O
and	O
permanent	O
suppression	O
of	O
HIV	O
-	O
1	O
replication	O
.	O

Pyrrolidine	O
dithiocarbamate	O
,	O
a	O
potent	O
inhibitor	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
activation	O
,	O
prevents	O
apoptosis	O
in	O
human	O
promyelocytic	O
leukemia	O
HL	O
-	O
60	O
cells	O
and	O
thymocytes	O
.	O

We	O
examined	O
the	O
effect	O
of	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
which	O
potently	O
blocks	O
the	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
,	O
on	O
the	O
induction	O
of	O
apoptosis	O
by	O
a	O
variety	O
of	O
agents	O
.	O

Treatment	O
of	O
a	O
human	O
promyelocytic	O
leukemia	O
cell	O
line	O
,	O
HL	O
-	O
60	O
,	O
with	O
10	O
micrograms/mL	O
etoposide	O
or	O
2	O
microM	O
1-beta-D	O
-	O
arabinofuranosylcytosine	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
within	O
1	O
hr	O
and	O
subsequently	O
caused	O
apoptosis	O
within	O
3	O
-	O
4	O
hr	O
.	O

The	O
simultaneous	O
addition	O
of	O
50	O
-	O
500	O
microM	O
PDTC	O
with	O
these	O
agents	O
blocked	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
completely	O
abrogated	O
both	O
morphologically	O
apoptotic	O
changes	O
and	O
internucleosomal	O
DNA	O
fragmentation	O
for	O
up	O
to	O
6	O
hr	O
.	O

However	O
,	O
PDTC	O
failed	O
to	O
inhibit	O
the	O
endonuclease	O
activity	O
contained	O
in	O
the	O
whole	O
cell	O
lysates	O
.	O

The	O
inhibitory	O
effect	O
of	O
PDTC	O
was	O
also	O
observed	O
in	O
etoposide	O
-	O
and	O
dexamethasone	O
-	O
induced	O
apoptosis	O
in	O
human	O
thymocytes	O
at	O
a	O
concentration	O
of	O
1	O
-	O
10	O
microM	O
.	O

Since	O
PDTC	O
has	O
both	O
antioxidant	O
and	O
metal	O
-	O
ion	O
chelating	O
activities	O
,	O
we	O
tested	O
the	O
effects	O
of	O
N-acetyl-L	O
-	O
cysteine	O
(	O
NAC	O
)	O
(	O
antioxidant	O
)	O
or	O
o	O
-	O
phenanthroline	O
(	O
OP	O
)	O
(	O
metal	O
-	O
ion	O
chelator	O
)	O
on	O
the	O
induction	O
of	O
apoptosis	O
.	O

Pretreatment	O
of	O
HL	O
-	O
60	O
cells	O
or	O
thymocytes	O
with	O
100	O
-	O
500	O
microM	O
OP	O
for	O
2	O
hr	O
,	O
but	O
not	O
10	O
-	O
60	O
mM	O
NAC	O
,	O
suppressed	O
subsequent	O
occurrence	O
of	O
apoptosis	O
induced	O
by	O
etoposide	O
.	O

These	O
results	O
suggest	O
that	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
plays	O
an	O
important	O
role	O
in	O
the	O
apoptotic	O
process	O
of	O
human	O
hematopoietic	O
cells	O
.	O

Differential	O
regulation	B-Regulation
of	O
proto	O
-	O
oncogenes	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
in	O
T	O
lymphocytes	O
activated	O
through	O
CD28	O
.	O

The	O
T	O
cell	O
surface	O
molecule	O
CD28	O
binds	B-Binding
to	O
ligands	O
on	O
accessory	O
cells	O
and	O
APCs	O
,	O
playing	O
an	O
important	O
costimulatory	O
role	O
in	O
the	O
response	O
of	O
T	O
cells	O
to	O
Ags	O
.	O

Our	O
knowledge	O
of	O
the	O
intracellular	O
signaling	O
pathways	O
coupled	O
to	O
this	O
receptor	O
is	O
incomplete	O
.	O

In	O
addition	O
to	O
activation	B-Positive_regulation
of	O
phospholipase	O
C	O
gamma	O
1	O
,	O
ligation	B-Binding
of	O
this	O
receptor	O
also	O
seems	O
to	O
activate	O
a	O
calcium	O
-	O
independent	O
,	O
CD28	O
-	O
specific	O
pathway	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
that	O
cross	B-Binding
-	I-Binding
linking	I-Binding
of	O
CD28	O
(	O
but	O
not	O
CD2	O
,	O
CD5	O
,	O
LFA	O
-	O
1	O
,	O
or	O
CD7	O
)	O
leads	B-Positive_regulation
to	O
an	O
elevation	B-Positive_regulation
of	O
c	O
-	O
jun	O
mRNA	O
,	O
with	O
only	O
minimal	O
activation	B-Positive_regulation
of	O
c	O
-	O
fos	O
expression	B-Gene_expression
.	O

CD28	O
-	O
dependent	O
induction	B-Positive_regulation
of	O
c	O
-	O
jun	O
expression	B-Gene_expression
requires	B-Positive_regulation
protein	O
tyrosine	O
kinase	O
activity	O
,	O
but	O
does	O
not	O
depend	B-Regulation
on	O
activation	O
of	O
a	O
phorbol	O
ester	O
-	O
responsive	O
protein	O
kinase	O
C	O
or	O
elevation	O
of	O
cytosolic	O
calcium	O
.	O

Furthermore	O
,	O
CD28	O
-	O
dependent	O
elevation	B-Positive_regulation
of	O
c	O
-	O
jun	O
mRNA	O
does	O
not	O
appear	O
to	O
be	O
mediated	B-Positive_regulation
at	O
the	O
level	O
of	O
mRNA	O
stability	B-Regulation
.	O

A	O
mechanism	O
is	O
suggested	O
whereby	O
expression	B-Gene_expression
of	O
c	O
-	O
jun	O
and	O
junB	O
,	O
in	O
the	O
absence	O
of	O
members	O
of	O
the	O
fos	O
family	O
,	O
can	O
prevent	O
inappropriate	O
activation	O
of	O
T	O
cells	O
caused	O
by	O
ligation	B-Binding
of	O
CD28	O
in	O
the	O
absence	O
of	O
a	O
specific	O
antigenic	O
stimulus	O
.	O

Constitutive	O
nuclear	O
NF	O
-	O
kappa	O
B	O
in	O
cells	O
of	O
the	O
monocyte	O
lineage	O
.	O

In	O
monocytes	O
,	O
the	O
nuclear	O
factor	O
NF	O
-	O
kappa	O
B	O
has	O
been	O
invoked	O
as	O
an	O
important	O
transcription	O
factor	O
in	O
the	O
expression	O
of	O
cytokine	O
genes	O
,	O
of	O
cell	O
-	O
surface	O
receptors	O
and	O
in	O
the	O
expression	O
of	O
human	O
immunodeficiency	O
virus	O
.	O

In	O
such	O
cells	O
,	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
can	O
be	O
detected	O
without	O
intentional	O
stimulation	O
.	O

In	O
our	O
studies	O
,	O
cells	O
of	O
the	O
human	O
monocytic	O
line	O
Mono	O
Mac	O
6	O
,	O
cultured	O
in	O
medium	O
containing	O
fetal	O
-	O
calf	O
serum	O
and	O
low	O
levels	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
also	O
exhibit	O
such	O
'constitutive	O
'	O
NF	O
-	O
kappa	O
B	O
,	O
as	O
demonstrated	O
by	O
mobility	O
-	O
shift	O
analysis	O
of	O
nuclear	O
extracts	O
.	O

This	O
nuclear	O
NF	O
-	O
kappa	O
B	O
was	O
still	O
present	O
when	O
contaminant	O
LPS	O
was	O
removed	O
by	O
ultrafiltration	O
and	O
when	O
serum	O
was	O
omitted	O
.	O

Protein	O
-	O
DNA	O
complexes	O
of	O
constitutive	O
NF	O
-	O
kappa	O
B	O
are	O
similar	O
in	O
mobility	O
to	O
the	O
LPS	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
and	O
both	O
are	O
recognized	O
by	O
an	O
antibody	O
specific	O
to	O
the	O
p50	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

By	O
contrast	O
,	O
treatment	O
of	O
cells	O
with	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
will	O
only	O
block	O
LPS	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
,	O
but	O
not	O
the	O
constitutive	O
binding	O
protein	O
.	O

Using	O
LPS	O
-	O
free	O
and	O
serum	O
-	O
free	O
conditions	O
,	O
constitutive	O
NF	O
-	O
kappa	O
B	O
can	O
be	O
detected	O
in	O
different	O
cell	O
lines	O
of	O
the	O
monocytic	O
lineage	O
(	O
HL60	O
,	O
U937	O
,	O
THP	O
-	O
1	O
,	O
Mono	O
Mac	O
1	O
and	O
Mono	O
Mac	O
6	O
)	O
,	O
but	O
not	O
in	O
Molt	O
4	O
T	O
cells	O
or	O
K562	O
stem	O
cells	O
.	O

When	O
ordered	O
according	O
to	O
stage	O
of	O
maturation	O
,	O
the	O
amount	O
of	O
constitutive	O
NF	O
-	O
kappa	O
B	O
was	O
not	O
increased	O
in	O
more	O
mature	O
cell	O
lines	O
.	O

Furthermore	O
,	O
when	O
inducing	O
differentiation	O
in	O
Mono	O
Mac	O
6	O
cells	O
,	O
with	O
vitamin	O
D3	O
,	O
no	O
change	O
in	O
constitutive	O
or	O
inducible	O
NF	O
-	O
kappa	O
B	O
can	O
be	O
detected	O
.	O

Analysis	O
of	O
primary	O
cells	O
revealed	O
substantial	O
constitutive	O
NF	O
-	O
kappa	O
B	O
-	O
binding	O
activity	O
in	O
blood	O
monocytes	O
,	O
pleural	O
macrophages	O
and	O
alveolar	O
macrophages	O
.	O

The	O
constitutive	O
NF	O
-	O
kappa	O
B	O
appears	O
to	O
be	O
functionally	O
active	O
,	O
since	O
a	O
low	O
level	O
of	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)	O
transcript	O
is	O
detectable	O
in	O
monocytes	O
,	O
and	O
this	O
level	O
can	O
be	O
increased	O
by	O
blocking	O
transcript	O
degradation	O
using	O
cycloheximide	O
.	O

The	O
level	O
of	O
constitutive	O
NF	O
-	O
kappa	O
B	O
in	O
these	O
cells	O
is	O
variable	O
and	O
is	O
frequently	O
found	O
to	O
be	O
lower	O
in	O
the	O
more	O
mature	O
macrophages	O
.	O

Constitutive	O
NF	O
-	O
kappa	O
B	O
was	O
not	O
maintained	O
by	O
autocrine	O
action	O
of	O
cytokines	O
TNF	O
,	O
interleukin	O
6	O
,	O
interleukin	O
10	O
,	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
or	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
,	O
since	O
neutralizing	O
antibodies	O
did	O
not	O
reduce	O
constitutive	O
DNA	O
-	O
binding	O
activity	O
.	O

Furthermore	O
,	O
blockade	O
of	O
prostaglandin	O
or	O
leukotriene	O
biosynthesis	O
did	O
not	O
affect	O
constitutive	O
NF	O
-	O
kappa	O
B	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Function	O
and	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
immune	O
system	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
a	O
ubiquitous	O
transcription	O
factor	O
.	O

Nevertheless	O
,	O
its	O
properties	O
seem	O
to	O
be	O
most	O
extensively	O
exploited	O
in	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Among	O
these	O
properties	O
are	O
NF	O
-	O
kappa	O
B	O
's	O
rapid	O
posttranslational	O
activation	O
in	O
response	O
to	O
many	O
pathogenic	O
signals	O
,	O
its	O
direct	O
participation	O
in	O
cytoplasmic/nuclear	O
signaling	O
,	O
and	O
its	O
potency	O
to	O
activate	O
transcription	O
of	O
a	O
great	O
variety	O
of	O
genes	O
encoding	O
immunologically	O
relevant	O
proteins	O
.	O

In	O
vertebrates	O
,	O
five	O
distinct	O
DNA	O
binding	O
subunits	O
are	O
currently	O
known	O
which	O
might	O
extensively	O
heterodimerize	O
,	O
thereby	O
forming	O
complexes	O
with	O
distinct	O
transcriptional	O
activity	O
,	O
DNA	O
sequence	O
specificity	O
,	O
and	O
cell	O
type	O
-	O
and	O
cell	O
stage	O
-	O
specific	O
distribution	O
.	O

The	O
activity	O
of	O
DNA	O
binding	O
NF	O
-	O
kappa	O
B	O
dimers	O
is	O
tightly	O
controlled	O
by	O
accessory	O
proteins	O
called	O
I	O
kappa	O
B	O
subunits	O
of	O
which	O
there	O
are	O
also	O
five	O
different	O
species	O
currently	O
known	O
in	O
vertebrates	O
.	O

I	O
kappa	O
B	O
proteins	O
inhibit	O
DNA	O
binding	O
and	O
prevent	O
nuclear	O
uptake	O
of	O
NF	O
-	O
kappa	O
B	O
complexes	O
.	O

An	O
exception	O
is	O
the	O
Bcl	O
-	O
3	O
protein	O
which	O
in	O
addition	O
can	O
function	O
as	O
a	O
transcription	O
activating	O
subunit	O
in	O
th	O
nucleus	O
.	O

Other	O
I	O
kappa	O
B	O
proteins	O
are	O
rather	O
involved	O
in	O
terminating	O
NF	O
-	O
kappa	O
B	O
's	O
activity	O
in	O
the	O
nucleus	O
.	O

The	O
intracellular	O
events	O
that	O
lead	O
to	O
the	O
inactivation	O
of	O
I	O
kappa	O
B	O
,	O
i.e.	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
are	O
complex	O
.	O

They	O
involve	O
phosphorylation	O
and	O
proteolytic	O
reactions	O
and	O
seem	O
to	O
be	O
controlled	O
by	O
the	O
cells	O
'	O
redox	O
status	O
.	O

Interference	O
with	O
the	O
activation	O
or	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
may	O
be	O
beneficial	O
in	O
suppressing	O
toxic/septic	O
shock	O
,	O
graft-vs	O
-	O
host	O
reactions	O
,	O
acute	O
inflammatory	O
reactions	O
,	O
acute	O
phase	O
response	O
,	O
and	O
radiation	O
damage	O
.	O

The	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
by	O
antioxidants	O
and	O
specific	O
protease	O
inhibitors	O
may	O
provide	O
a	O
pharmacological	O
basis	O
for	O
interfering	O
with	O
these	O
acute	O
processes	O
.	O

Increased	B-Positive_regulation
interleukin	O
2	O
transcription	B-Transcription
in	O
murine	O
lymphocytes	O
by	O
ciprofloxacin	O
.	O

The	O
fluoroquinolone	O
antibiotic	O
,	O
ciprofloxacin	O
(	O
cipro	O
)	O
,	O
induces	B-Positive_regulation
hyperproduction	O
of	O
interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
and	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
in	O
stimulated	O
human	O
peripheral	O
blood	O
lymphocytes	O
.	O

In	O
this	O
investigation	O
an	O
enhanced	B-Positive_regulation
and	I-Positive_regulation
prolonged	I-Positive_regulation
IL	O
-	O
2	O
and	O
IL	O
-	O
2	O
mRNA	O
response	B-Regulation
was	O
also	O
detected	O
in	O
both	O
stimulated	O
(	O
T	O
cell	O
mitogens	O
or	O
alloantigens	O
)	O
murine	O
splenocytes	O
and	O
in	O
the	O
stimulated	O
murine	O
T	O
cell	O
line	O
EL	O
-	O
4	O
in	O
the	O
presence	O
of	O
ciprofloxacin	O
(	O
5	O
-	O
80	O
micrograms/ml	O
)	O
as	O
compared	O
to	O
control	O
cells	O
without	O
antibiotics	O
.	O

However	O
,	O
in	O
contrast	O
to	O
human	O
lymphocytes	O
,	O
IFN	O
-	O
gamma	O
production	B-Gene_expression
was	O
inhibited	B-Negative_regulation
and	O
IFN	O
-	O
gamma	O
mRNA	O
levels	O
were	O
unaffected	B-Regulation
at	O
24	O
h	O
and	O
only	O
slightly	O
upregulated	B-Positive_regulation
at	O
48	O
and	O
72	O
h	O
of	O
culture	O
in	O
murine	O
splenocytes	O
incubated	O
with	O
cipro	O
(	O
20	O
micrograms/ml	O
)	O
.	O

EL	O
-	O
4	O
cells	O
were	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
IL	O
-	O
2	O
promoter	O
and	O
enhancer	O
region	O
linked	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
reporter	O
gene	O
.	O

Analysis	O
of	O
CAT	O
activity	O
revealed	O
that	O
cipro	O
enhanced	B-Positive_regulation
IL	O
-	O
2	O
gene	O
induction	B-Gene_expression
.	O

In	O
addition	O
,	O
EL	O
-	O
4	O
cells	O
incubated	O
with	O
ciprofloxacin	O
showed	B-Positive_regulation
an	I-Positive_regulation
early	I-Positive_regulation
peak	I-Positive_regulation
and	I-Positive_regulation
more	I-Positive_regulation
activated	I-Positive_regulation
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
-	O
1	O
)	O
as	O
compared	O
to	O
control	O
cells	O
without	O
antibiotics	O
.	O

Cipro	O
did	O
not	O
affect	B-Regulation
the	O
nuclear	O
transcription	O
factors	O
AP	O
-	O
1	O
or	O
NFIL	O
-	O
2A	O
.	O

Taken	O
together	O
,	O
cipro	O
inhibited	B-Negative_regulation
IFN	O
-	O
gamma	O
synthesis	B-Gene_expression
,	O
but	O
enhanced	B-Positive_regulation
IL	O
-	O
2	O
production	B-Gene_expression
in	O
murine	O
lymphocytes	O
by	O
means	O
of	O
influencing	B-Regulation
NFAT	O
-	O
1	O
and	O
causing	B-Positive_regulation
an	I-Positive_regulation
increased	I-Positive_regulation
IL	O
-	O
2	O
transcription	B-Transcription
.	O

Multiple	O
prolactin	O
-	O
responsive	O
elements	O
mediate	B-Positive_regulation
G1	O
and	O
S	O
phase	O
expression	B-Gene_expression
of	O
the	O
interferon	O
regulatory	O
factor	O
-	O
1	O
gene	O
.	O

The	O
interferon	O
regulatory	O
factor	O
-	O
1	O
(	O
IRF	O
-	O
1	O
)	O
gene	O
is	O
both	O
an	O
immediate	O
-	O
early	O
G1	O
phase	O
gene	O
and	O
an	O
S	O
phase	O
gene	O
inducible	B-Positive_regulation
by	O
PRL	O
in	O
rat	O
Nb2	O
T	O
lymphocytes	O
.	O

To	O
understand	O
the	O
mechanism	O
by	O
which	O
PRL	O
regulates	B-Regulation
the	O
biphasic	O
expression	B-Gene_expression
of	O
IRF	O
-	O
1	O
,	O
we	O
cloned	O
the	O
rat	O
IRF	O
-	O
1	O
gene	O
and	O
functionally	O
characterized	O
the	O
IRF	O
-	O
1	O
promoter	O
.	O

Upon	O
transfection	O
into	O
Nb2	O
T	O
cells	O
,	O
1.7	O
kilobases	O
(	O
kb	O
)	O
of	O
IRF	O
-	O
1	O
5'	O
-	O
flanking	O
DNA	O
linked	O
to	O
a	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
reporter	O
gene	O
mediated	B-Positive_regulation
a	O
30	O
-	O
fold	O
induction	B-Positive_regulation
of	O
CAT	O
enzyme	O
activity	O
in	O
response	O
to	O
24	O
h	O
of	O
PRL	O
stimulation	O
.	O

Deletion	O
mutants	O
containing	O
1.3	O
,	O
0.6	O
,	O
and	O
0.2	O
kb	O
5'	O
-	O
flanking	O
DNA	O
were	O
incrementally	O
less	O
transcriptionally	O
active	O
,	O
although	O
0.2	O
kb	O
still	O
mediated	O
a	O
12	O
-	O
fold	O
induction	O
by	O
PRL	O
.	O

The	O
sequence	O
between	O
-	O
1.7	O
and	O
-	O
0.2	O
kb	O
linked	O
to	O
a	O
heterologous	O
thymidine	O
kinase	O
promoter	O
failed	O
to	O
respond	O
to	O
PRL	O
stimulation	O
,	O
suggesting	O
that	O
the	O
activity	O
of	O
upstream	O
PRL	O
response	O
elements	O
may	O
require	O
an	O
interaction	O
with	O
promoter	O
-	O
proximal	O
elements	O
.	O

By	O
assaying	O
CAT	O
enzyme	O
activity	O
across	O
a	O
24	O
-	O
h	O
PRL	O
induction	O
time	O
course	O
,	O
we	O
were	O
able	O
to	O
assign	O
G1	O
vs.	O
S	O
phase	O
PRL	O
responses	B-Regulation
of	O
the	O
IRF	O
-	O
1	O
gene	O
to	O
different	O
regions	O
of	O
the	O
IRF	O
-	O
1	O
5'	O
-	O
flanking	O
and	O
promoter	O
DNA	O
.	O

The	O
0.2	O
-	O
kb	O
IRF	O
-	O
CAT	O
construct	O
was	O
induced	O
by	O
PRL	O
stimulation	O
during	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

In	O
contrast	O
,	O
the	O
1.7	O
-	O
kb	O
IRF	O
-	O
CAT	O
construct	O
was	O
inducible	O
by	O
PRL	O
during	O
both	O
G1	O
and	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Hence	O
,	O
the	O
PRL	O
-	O
induced	B-Positive_regulation
biphasic	O
expression	B-Gene_expression
of	O
the	O
IRF	O
-	O
1	O
gene	O
appears	O
to	O
be	O
controlled	B-Regulation
by	O
separate	O
PRL	O
-	O
responsive	O
elements	O
:	O
elements	O
in	O
the	O
first	O
0.2	O
kb	O
of	O
the	O
IRF	O
-	O
1	O
promoter	O
region	O
act	B-Positive_regulation
during	O
early	O
activation	O
,	O
and	O
elements	O
between	O
0.2	O
and	O
1.7	O
kb	O
act	O
in	O
concert	O
with	O
the	O
proximal	O
0.2	O
-	O
kb	O
region	O
during	O
S	O
phase	O
progression	O
.	O

Nonpituitary	O
human	O
prolactin	O
gene	O
transcription	B-Transcription
is	O
independent	B-Regulation
of	O
Pit	O
-	O
1	O
and	O
differentially	O
controlled	B-Regulation
in	O
lymphocytes	O
and	O
in	O
endometrial	O
stroma	O
.	O

Expression	B-Gene_expression
of	O
the	O
human	O
PRL	O
(	O
hPRL	O
)	O
gene	O
in	O
extrapituitary	O
sites	O
such	O
as	O
the	O
uterus	O
(	O
decidualized	O
endometrial	O
stroma	O
and	O
myometrium	O
)	O
and	O
cells	O
of	O
the	O
hematopoietic	O
lineage	O
is	O
directed	B-Positive_regulation
by	O
an	O
alternative	O
promoter	O
which	O
is	O
located	O
approximately	O
6	O
kilobases	O
(	O
kb	O
)	O
upstream	O
of	O
the	O
pituitary	O
-	O
specific	O
start	O
site	O
.	O

In	O
order	O
to	O
delineate	O
the	O
tissue	O
-	O
specific	O
mechanisms	O
governing	O
the	O
control	B-Regulation
of	O
nonpituitary	O
PRL	O
gene	O
expression	B-Gene_expression
,	O
we	O
have	O
cloned	O
and	O
sequenced	O
3	O
kb	O
5'	O
-	O
flanking	O
DNA	O
of	O
the	O
upstream	O
decidual/lymphoid	O
(	O
dPRL	O
)	O
promoter	O
.	O

Based	O
on	O
sequence	O
homology	O
we	O
identified	O
two	O
binding	O
motifs	O
for	O
Pit	O
-	O
1	O
and	O
seven	O
half	O
-	O
sites	O
for	O
glucocorticoid	O
receptor/progesterone	O
receptor	O
(	O
PR	O
)	O
binding	O
.	O

We	O
focused	O
our	O
studies	O
on	O
the	O
role	O
of	O
Pit	O
-	O
1	O
and	O
of	O
PR	O
as	O
potential	O
transcriptional	O
regulators	O
,	O
since	O
the	O
POU	O
domain	O
protein	O
Pit	O
-	O
1	O
is	O
essential	B-Regulation
in	I-Regulation
the	I-Regulation
control	I-Regulation
of	O
pituitary	O
PRL	O
expression	B-Gene_expression
,	O
and	O
progesterone	O
induces	O
decidual	O
transformation	O
of	O
the	O
endometrial	O
stroma	O
,	O
a	O
differentiation	O
process	O
during	O
which	O
the	O
decidual	O
PRL	O
gene	O
is	O
activated	B-Positive_regulation
.	O

We	O
demonstrate	O
in	O
a	O
variety	O
of	O
cell	O
types	O
,	O
including	O
lymphocytes	O
and	O
endometrial	O
stroma	O
,	O
that	O
Pit	O
-	O
1	O
is	O
not	O
involved	O
in	O
the	O
regulation	O
of	O
dPRL	O
promoter/reporter	O
gene	O
constructs	O
carrying	O
3	O
kb	O
5'	O
-	O
flanking	O
DNA	O
.	O

Our	O
experiments	O
also	O
show	O
that	O
activated	B-Positive_regulation
PR	O
does	O
not	O
confer	B-Regulation
direct	I-Regulation
transcriptional	I-Regulation
control	I-Regulation
on	O
the	O
dPRL	O
promoter	O
.	O

When	O
we	O
compared	O
the	O
activity	O
of	O
the	O
transfected	O
dPRL	O
promoter	O
in	O
PRL	O
-	O
secreting	B-Gene_expression
and	O
nonsecreting	B-Gene_expression
lymphoid	O
cells	O
,	O
we	O
found	O
that	O
the	O
3	O
kb	O
5'	O
-	O
flanking	O
region	O
of	O
the	O
dPRL	O
promoter	O
did	O
not	O
contain	O
elements	O
restricting	B-Positive_regulation
expression	B-Gene_expression
to	O
only	O
those	O
lymphocytes	O
that	O
produce	B-Gene_expression
PRL	O
but	O
allowed	O
expression	O
of	O
fusion	O
reporter	O
genes	O
irrespective	O
of	O
the	O
status	O
of	O
the	O
endogenous	O
PRL	O
gene	O
.	O

This	O
was	O
in	O
sharp	O
contrast	O
to	O
endometrial	O
cells	O
where	O
3	O
kb	O
5'	O
-	O
flanking	O
DNA	O
conferred	B-Positive_regulation
strong	I-Positive_regulation
transcriptional	I-Positive_regulation
activation	I-Positive_regulation
on	O
the	O
dPRL	O
promoter	O
in	O
decidualized	O
endometrial	O
stromal	O
cells	O
actively	O
secreting	B-Gene_expression
PRL	O
,	O
but	O
did	O
not	O
allow	B-Positive_regulation
transcription	B-Transcription
in	O
undifferentiated	O
non-PRL	O
-	O
secreting	B-Gene_expression
endometrial	O
stromal	O
cells	O
.	O

Activation	O
of	O
the	O
dPRL	O
promoter	O
construct	O
in	O
these	O
undifferentiated	O
cells	O
could	O
however	O
be	O
induced	O
by	O
the	O
addition	O
of	O
cAMP	O
,	O
in	O
the	O
absence	O
of	O
progesterone	O
,	O
suggesting	O
that	O
a	O
signal	O
transduced	O
through	O
the	O
cAMP	O
signaling	O
pathway	O
is	O
a	O
primary	O
inducer	B-Positive_regulation
of	O
decidual	O
PRL	O
gene	O
expression	B-Gene_expression
.	O

Activation	B-Positive_regulation
of	O
early	O
growth	O
response	O
1	O
gene	O
transcription	B-Transcription
and	O
pp90rsk	O
during	O
induction	O
of	O
monocytic	O
differentiation	O
.	O

The	O
present	O
work	O
has	O
studied	O
mechanisms	O
responsible	O
for	O
induction	B-Positive_regulation
of	O
early	O
growth	O
response	O
1	O
(	O
EGR	O
-	O
1	O
)	O
gene	O
expression	B-Gene_expression
during	O
monocytic	O
differentiation	O
of	O
U	O
-	O
937	O
myeloid	O
leukemia	O
cells	O
.	O

Differentiation	O
of	O
U	O
-	O
937	O
cells	O
with	O
12-O-tetradecanoylphorbol-13	O
-	O
acetate	O
(	O
TPA	O
)	O
,	O
an	O
activator	O
of	O
the	O
serine/threonine	O
protein	O
kinase	O
C	O
,	O
was	O
associated	O
with	O
transcriptional	O
activation	O
of	O
EGR	O
-	O
1	O
promoter	O
-	O
reporter	O
constructs	O
.	O

The	O
EGR	O
-	O
1	O
promoter	O
contains	O
six	O
CC	O
(	O
A/T	O
)	O
6GG	O
(	O
CArG	O
)	O
motifs	O
.	O

The	O
two	O
5'	O
-	O
most	O
distal	O
CArG	O
sequences	O
conferred	O
TPA	O
inducibility	O
.	O

In	O
contrast	O
,	O
there	O
was	O
little	O
effect	B-Regulation
of	O
TPA	O
on	O
EGR	O
-	O
1	O
transcription	B-Transcription
in	O
a	O
TPA	O
-	O
resistant	O
U	O
-	O
937	O
cell	O
variant	O
,	O
designated	O
TUR	O
.	O

Treatment	O
of	O
both	O
U	O
-	O
937	O
and	O
TUR	O
cells	O
with	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
serine/threonine	O
protein	O
phosphatases	O
1	O
and	O
2A	O
,	O
was	O
associated	O
with	O
induction	B-Positive_regulation
of	O
monocytic	O
differentiation	O
and	O
EGR	O
-	O
1	O
transcription	B-Transcription
through	O
the	O
5'	O
-	O
most	O
CArG	O
element	O
.	O

Since	O
these	O
findings	O
supported	O
the	O
involvement	O
of	O
serine/threonine	O
protein	O
phosphorylation	O
in	O
the	O
regulation	B-Regulation
of	O
EGR	O
-	O
1	O
expression	B-Gene_expression
,	O
we	O
studied	O
activation	O
of	O
the	O
40S	O
ribosomal	O
protein	O
S6	O
serine/threonine	O
kinases	O
,	O
pp70S6K	O
and	O
pp90rsk	O
.	O

Although	O
both	O
kinases	O
participate	O
in	O
regulating	O
cell	O
growth	O
,	O
there	O
was	O
no	O
detectable	O
activation	O
of	O
pp70S6K	O
during	O
TPA	O
-	O
or	O
okadaic	O
acid	O
-	O
induced	O
monocytic	O
differentiation	O
.	O

Moreover	O
,	O
rapamycin	O
,	O
an	O
inhibitor	O
of	O
pp70S6K	O
activation	O
,	O
had	O
no	O
effect	B-Regulation
on	O
induction	B-Positive_regulation
of	O
EGR	O
-	O
1	O
expression	B-Gene_expression
.	O

In	O
contrast	O
,	O
analysis	O
of	O
pp90rsk	O
activity	O
by	O
phosphorylation	O
of	O
a	O
peptide	O
derived	O
from	O
S6	O
protein	O
demonstrated	O
stimulation	O
of	O
this	O
kinase	O
in	O
TPA	O
-	O
treated	O
U	O
-	O
937	O
,	O
and	O
not	O
TUR	O
,	O
cells	O
.	O

Okadaic	O
acid	O
treatment	O
of	O
both	O
cell	O
types	O
was	O
associated	O
with	O
activation	O
of	O
pp90rsk	O
.	O

Effects	O
of	O
prostaglandin	O
E2	O
on	O
Th0	O
-	O
type	O
human	O
T	O
cell	O
clones	O
:	O
modulation	O
of	O
functions	O
of	O
nuclear	O
proteins	O
involved	O
in	O
cytokine	O
production	O
.	O

The	O
effects	O
of	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
on	O
cytokine	O
production	O
and	O
proliferation	O
of	O
the	O
CD4+	O
human	O
helper	O
T	O
cell	O
clone	O
SP	O
-	O
B21	O
were	O
investigated	O
.	O

In	O
cells	O
stimulated	O
with	O
anti	O
-	O
CD3	O
mAb	O
,	O
PGE2	O
inhibited	O
cell	O
proliferation	O
and	O
the	O
production	O
of	O
all	O
the	O
cytokines	O
examined	O
.	O

Addition	O
of	O
rIL	O
-	O
2	O
fully	O
restored	O
the	O
proliferative	O
response	O
and	O
partially	O
restored	B-Positive_regulation
the	O
production	B-Gene_expression
of	O
IL	O
-	O
4	O
and	O
IL	O
-	O
5	O
,	O
but	O
not	O
that	O
of	O
other	O
cytokines	O
.	O

In	O
contrast	O
,	O
in	O
cells	O
stimulated	O
with	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
/A23187	O
,	O
PGE2	O
enhanced	B-Positive_regulation
the	O
production	B-Gene_expression
of	O
IL	O
-	O
4	O
and	O
IL	O
-	O
5	O
,	O
and	O
only	O
partially	O
inhibited	O
the	O
production	O
of	O
other	O
cytokines	O
.	O

Therefore	O
,	O
the	O
effects	O
of	O
PGE2	O
vary	O
depending	O
on	O
the	O
mode	O
of	O
T	O
cell	O
activation	O
,	O
and	O
the	O
IL	O
-	O
4	O
and	O
IL	O
-	O
5	O
are	O
regulated	B-Regulation
differently	O
from	O
other	O
cytokines	O
.	O

In	O
a	O
mobility	O
shift	O
assay	O
,	O
only	O
the	O
NF	O
-	O
kappa	O
B	O
(	O
p50/p50	O
)	O
homodimer	O
was	O
observed	O
in	O
a	O
complex	B-Binding
formed	I-Binding
with	O
the	O
kappa	O
B	O
sequence	O
in	O
unstimulated	O
SP	O
-	O
B21	O
cells	O
.	O

When	O
cells	O
were	O
stimulated	O
with	O
anti	O
-	O
CD3	O
mAb	O
or	O
PMA/A23187	O
,	O
a	O
complex	B-Binding
formation	I-Binding
of	O
NF	O
-	O
kappa	O
B	O
(	O
p50/p65	O
)	O
heterodimer	O
with	O
the	O
kappa	O
B	O
sequence	O
was	O
induced	B-Positive_regulation
.	O

Interestingly	O
,	O
PGE2	O
or	O
di	O
-	O
butyryl	O
(	O
Bt2	O
)	O
cAMP	O
abolished	B-Negative_regulation
the	O
binding	B-Binding
of	O
NF	O
-	O
kappa	O
B	O
(	O
p50/p65	O
)	O
heterodimer	O
to	O
the	O
kappa	O
B	O
sequence	O
in	O
cells	O
stimulated	O
with	O
anti	O
-	O
CD3	O
mAb	O
but	O
not	O
with	O
PMA/A23187	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
target	O
of	O
PGE2	O
action	O
is	O
a	O
component	O
in	O
the	O
signal	O
transduction	O
pathway	O
leading	O
to	O
the	O
activation	O
of	O
protein	O
kinase	O
C	O
.	O

However	O
,	O
the	O
inhibition	O
of	O
the	O
T	O
cell	O
activation	O
signals	O
by	O
PGE2	O
is	O
selective	O
.	O

PGE2	O
enhanced	O
the	O
complex	O
formation	O
with	O
NF	O
-	O
AT	O
,	O
AP	O
-	O
1	O
and	O
CLE0	O
sequences	O
when	O
the	O
cells	O
were	O
activated	O
by	O
either	O
anti	O
-	O
CD3	O
mAb	O
or	O
PMA/A23187	O
stimulation	O
.	O

It	O
seems	O
therefore	O
that	O
PGE2	O
,	O
by	O
elevating	O
cAMP	O
levels	O
,	O
interferes	O
with	O
the	O
activation	O
pathway	O
for	O
NF	O
-	O
kappa	O
B	O
but	O
not	O
for	O
NF	O
-	O
AT	O
,	O
AP	O
-	O
1	O
or	O
CLE0	O
binding	O
protein	O
.	O

IL	O
-	O
4	O
down	O
-	O
regulates	O
IL-2	O
-	O
,	O
IL-3	O
-	O
,	O
and	O
GM-CSF	O
-	O
induced	O
cytokine	O
gene	O
expression	O
in	O
peripheral	O
blood	O
monocytes	O
.	O

IL	O
-	O
4	O
,	O
a	O
product	B-Gene_expression
of	O
the	O
T	O
-	O
helper	O
0	O
(	O
Th0	O
)	O
and	O
2	O
(	O
Th2	O
)	O
subset	O
,	O
was	O
originally	O
described	O
as	O
a	O
B	O
-	O
cell	O
stimulatory	O
factor	O
and	O
has	O
subsequently	O
been	O
found	O
to	O
suppress	B-Negative_regulation
IL	O
-	O
1	O
alpha	O
,	O
IL	O
-	O
1	O
beta	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
and	O
TNF	O
-	O
alpha	O
gene	O
expression	B-Gene_expression
in	O
monocytes	O
stimulated	B-Positive_regulation
with	O
LPS	O
,	O
and	O
to	O
upregulate	B-Positive_regulation
IL	O
-	O
1	O
receptor	O
antagonist	O
(	O
IL1	O
-	O
RA	O
)	O
gene	O
expression	B-Gene_expression
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
effect	O
of	O
IL	O
-	O
4	O
on	O
the	O
expression	O
of	O
cytokine	O
genes	O
in	O
monocytes	O
evoked	O
by	O
other	O
T	O
-	O
helper	O
cell	O
cytokines	O
:	O
IL	O
-	O
2	O
,	O
IL	O
-	O
3	O
,	O
and	O
GM	O
-	O
CSF	O
.	O

IL	O
-	O
4	O
down	B-Negative_regulation
-	I-Negative_regulation
regulated	I-Negative_regulation
mRNA	B-Positive_regulation
accumulation	I-Positive_regulation
of	O
the	O
proinflammatory	O
cytokines	O
IL	O
-	O
1	O
beta	O
,	O
IL	O
-	O
8	O
,	O
and	O
TNF	O
-	O
alpha	O
in	O
monocytes	O
stimulated	O
with	O
IL	O
-	O
2	O
,	O
IL	O
-	O
3	O
,	O
and	O
GM	O
-	O
CSF	O
.	O

IL	O
-	O
4	O
also	O
suppressed	B-Negative_regulation
the	O
IL-2	O
-	O
induced	B-Positive_regulation
IL	O
-	O
6	O
mRNA	O
expression	B-Transcription
.	O

Temporal	O
analysis	O
of	O
the	O
IL	O
-	O
4	O
down	O
-	O
regulatory	O
effect	O
on	O
the	O
IL-2	O
-	O
,	O
IL-3	O
-	O
,	O
or	O
GM-CSF	O
-	O
induced	O
proinflammatory	O
cytokine	O
gene	O
expression	O
in	O
monocytes	O
provided	O
evidence	O
that	O
IL	O
-	O
4	O
acts	O
predominantly	O
on	O
the	O
post	O
-	O
transcriptional	O
level	O
.	O

This	O
was	O
supported	O
by	O
the	O
observation	O
that	O
the	O
down	O
-	O
regulatory	O
capacity	O
of	O
IL	O
-	O
4	O
appeared	O
to	O
be	O
dependent	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O

IL	O
-	O
4	O
did	O
not	O
exert	O
significant	O
influence	B-Regulation
on	O
the	O
induction	B-Positive_regulation
of	O
expression	B-Gene_expression
of	O
IL-1	O
-	O
RA	O
or	O
various	O
CSFs	O
by	O
IL	O
-	O
2	O
,	O
IL	O
-	O
3	O
,	O
and	O
GM	O
-	O
CSF	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Long	O
-	O
term	O
inositol	O
phosphate	O
release	O
,	O
but	O
not	O
tyrosine	O
kinase	O
activity	O
,	O
correlates	O
with	O
IL	O
-	O
2	O
secretion	B-Localization
and	O
NF	O
-	O
AT	O
induction	O
in	O
anti-CD3	O
-	O
activated	O
peripheral	O
human	O
T	O
lymphocytes	O
.	O

The	O
cascade	O
of	O
events	O
within	O
the	O
first	O
few	O
minutes	O
of	O
T	O
cell	O
stimulation	O
has	O
been	O
well	O
characterized	O
.	O

Although	O
many	O
second	O
messengers	O
have	O
been	O
shown	O
to	O
be	O
necessary	O
and	O
sufficient	O
for	O
T	O
cell	O
activation	O
in	O
a	O
number	O
of	O
model	O
systems	O
,	O
the	O
rate	O
-	O
limiting	O
step	O
in	O
peripheral	O
T	O
cells	O
has	O
not	O
been	O
demonstrated	O
.	O

To	O
model	O
effective	O
versus	O
ineffective	O
CD3	O
-	O
mediated	O
stimulation	O
in	O
peripheral	O
T	O
cells	O
,	O
we	O
used	O
two	O
anti	O
-	O
CD3	O
mAbs	O
that	O
differ	O
in	O
their	O
ability	O
to	O
stimulate	O
purified	O
T	O
cells	O
:	O
OKT3	O
,	O
which	O
causes	O
early	O
second	O
messenger	O
generation	O
but	O
is	O
unable	O
to	O
activate	O
T	O
cells	O
without	O
a	O
second	O
signal	O
,	O
and	O
64.1	O
,	O
which	O
stimulates	O
T	O
cell	O
proliferation	O
on	O
its	O
own	O
.	O

We	O
found	O
that	O
tyrosine	O
kinase	O
activity	O
was	O
similar	O
for	O
both	O
mAbs	O
over	O
a	O
period	O
of	O
hours	O
.	O

However	O
,	O
the	O
inositol	O
phosphate	O
response	O
was	O
stronger	O
for	O
64.1	O
than	O
for	O
OKT3	O
.	O

To	O
tie	O
these	O
events	O
to	O
gene	O
activation	O
,	O
we	O
measured	O
NF	O
-	O
kappa	O
B	O
and	O
NF	O
-	O
AT	O
activity	O
in	O
the	O
nucleus	O
after	O
anti	O
-	O
CD3	O
stimulation	O
.	O

Both	O
stimuli	O
induced	B-Positive_regulation
the	O
appearance	B-Localization
of	O
the	O
NF	O
-	O
kappa	O
B	O
components	O
(	O
c	O
-	O
Rel	O
,	O
p65	O
(	O
RelA	O
)	O
,	O
and	O
p50	O
(	O
NF	O
-	O
kappa	O
B1	O
)	O
)	O
and	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
activity	O
in	O
the	O
nucleus	O
.	O

However	O
,	O
only	O
64.1	O
induced	O
NF	O
-	O
AT	O
in	O
the	O
nucleus	O
,	O
correlating	O
with	O
its	O
ability	O
to	O
activate	O
T	O
cells	O
.	O

Thus	O
,	O
NF	O
-	O
AT	O
induction	O
and	O
IL	O
-	O
2	O
secretion	B-Localization
were	O
correlated	O
with	O
the	O
levels	O
of	O
inositol	O
phosphate	O
release	O
but	O
not	O
with	O
gross	O
levels	O
of	O
tyrosine	O
kinase	O
activity	O
induced	O
late	O
following	O
the	O
response	O
.	O

On	O
the	O
other	O
hand	O
,	O
NF	O
-	O
kappa	O
B	O
induction	O
and	O
IL	O
-	O
2	O
receptor	O
expression	O
occurred	O
even	O
with	O
the	O
smaller	O
second	O
messenger	O
response	O
generated	O
by	O
OKT3	O
.	O

ZAP	O
-	O
70	O
tyrosine	O
kinase	O
,	O
CD45	O
,	O
and	O
T	O
cell	O
receptor	O
involvement	O
in	O
UV	O
-	O
and	O
H2O2	O
-	O
induced	O
T	O
cell	O
signal	O
transduction	O
.	O

Several	O
mammalian	O
responses	O
to	O
UV	O
irradiation	O
,	O
including	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
are	O
believed	O
to	O
involve	O
tyrosine	O
phosphorylation	O
.	O

UV	O
irradiation	O
and	O
H2O2	O
treatment	O
of	O
T	O
lymphocytes	O
induce	O
protein	O
tyrosine	O
phosphorylation	O
and	O
Ca2+	O
signals	O
similar	O
to	O
those	O
observed	O
following	O
biological	O
stimulation	O
.	O

We	O
have	O
examined	O
the	O
role	O
of	O
cell	O
surface	O
molecules	O
in	O
these	O
responses	O
.	O

Normal	O
T	O
lymphocytes	O
whose	O
surface	O
expression	O
of	O
CD3	O
was	O
depleted	O
showed	O
impaired	O
UV	O
-	O
induced	O
tyrosine	O
phosphorylation	O
and	O
Ca2+	O
signals	O
.	O

Similarly	O
,	O
Jurkat	O
T	O
cell	O
lines	O
deficient	B-Negative_regulation
in	O
CD3	O
or	O
CD45	O
expression	B-Gene_expression
also	O
gave	O
impaired	O
UV	O
responses	O
.	O

However	O
,	O
all	O
these	O
cell	O
types	O
still	O
gave	O
strong	O
Ca2+	O
and	O
tyrosine	O
phosphorylation	O
responses	O
to	O
H2O2	O
.	O

The	O
T	O
cell	O
tyrosine	O
kinase	O
ZAP	O
-	O
70	O
was	O
found	O
to	O
be	O
highly	O
responsive	B-Regulation
to	O
UV	O
and	O
H2O2	O
treatment	O
.	O

ZAP	O
-	O
70	O
responsiveness	B-Regulation
to	O
UV	O
required	O
expression	B-Gene_expression
of	O
both	O
CD3	O
and	O
CD45	O
,	O
whereas	O
only	O
CD3	O
was	O
required	O
for	O
the	O
response	B-Regulation
to	O
H2O2	O
.	O

UV	O
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
was	O
blocked	O
by	O
CD3	O
depletion	O
,	O
indicating	O
the	O
importance	O
of	O
such	O
cell	O
surface	O
molecules	O
in	O
biological	O
responses	O
to	O
UV	O
.	O

In	O
nonlymphoid	O
cells	O
,	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
displayed	O
increased	B-Positive_regulation
tyrosine	O
phosphorylation	B-Phosphorylation
within	O
seconds	O
of	O
UV	O
irradiation	O
.	O

These	O
results	O
suggest	O
that	O
UV	O
-	O
induced	O
signal	O
transduction	O
is	O
mediated	O
via	O
cell	O
surface	O
receptors	O
that	O
normally	O
respond	O
to	O
biological	O
stimulation	O
,	O
whereas	O
H2O2	O
is	O
able	O
to	O
partially	O
bypass	O
this	O
requirement	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
sodium	O
salicylate	O
and	O
aspirin	O
[	O
see	O
comments	O
]	O

The	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
is	O
critical	O
for	O
the	O
inducible	O
expression	O
of	O
multiple	O
cellular	O
and	O
viral	O
genes	O
involved	O
in	O
inflammation	O
and	O
infection	O
including	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
,	O
IL	O
-	O
6	O
,	O
and	O
adhesion	O
molecules	O
.	O

The	O
anti	O
-	O
inflammatory	O
drugs	O
sodium	O
salicylate	O
and	O
aspirin	O
inhibited	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
further	O
explains	O
the	O
mechanism	O
of	O
action	O
of	O
these	O
drugs	O
.	O

This	O
inhibition	O
prevented	O
the	O
degradation	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
inhibitor	O
,	O
I	O
kappa	O
B	O
,	O
and	O
therefore	O
NF	O
-	O
kappa	O
B	O
was	O
retained	O
in	O
the	O
cytosol	O
.	O

Sodium	O
salicylate	O
and	O
aspirin	O
also	O
inhibited	B-Negative_regulation
NF	O
-	O
kappa	O
B	O
-	O
dependent	B-Positive_regulation
transcription	B-Transcription
from	O
the	O
Ig	O
kappa	O
enhancer	O
and	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
in	O
transfected	O
T	O
cells	O
.	O

Positive	B-Positive_regulation
and	O
negative	B-Negative_regulation
regulation	I-Negative_regulation
of	O
IL	O
-	O
2	O
gene	O
expression	B-Gene_expression
:	O
role	B-Regulation
of	O
multiple	O
regulatory	O
sites	O
.	O

Interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
is	O
an	O
important	O
lymphokine	O
required	O
in	O
the	O
process	O
of	O
T	O
cell	O
activation	O
,	O
proliferation	O
,	O
clonal	O
expansion	O
and	O
differentiation	O
.	O

The	O
IL	O
-	O
2	O
gene	O
displays	O
both	O
T	O
cell	O
specific	O
and	O
inducible	B-Positive_regulation
expression	B-Gene_expression
:	O
it	O
is	O
only	O
expressed	B-Positive_regulation
in	O
CD4+	O
T	O
cells	O
after	O
antigenic	O
or	O
mitogenic	O
stimulation	O
.	O

Several	O
cis	O
-	O
acting	O
regulatory	O
sites	O
are	O
required	B-Positive_regulation
for	O
induction	B-Positive_regulation
of	O
the	O
IL	O
-	O
2	O
gene	O
after	O
stimulation	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
analysed	O
the	O
function	O
of	O
these	O
cis	O
-	O
acting	O
regulatory	O
sites	O
in	O
the	O
context	O
of	O
the	O
native	O
IL	O
-	O
2	O
enhancer	O
and	O
promoter	O
sequence	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
NFAT	O
(	O
-	O
276	O
to	O
-	O
261	O
)	O
,	O
the	O
distal	O
octamer	O
(	O
-	O
256	O
to	O
-	O
248	O
)	O
and	O
the	O
proximal	O
octamer	O
(	O
-	O
75	O
to	O
-	O
66	O
)	O
sites	O
not	O
only	O
act	B-Positive_regulation
as	I-Positive_regulation
enhancers	I-Positive_regulation
of	O
IL	O
-	O
2	O
gene	O
transcription	B-Transcription
in	B-Positive_regulation
the	I-Positive_regulation
presence	I-Positive_regulation
of	I-Positive_regulation
cellular	O
stimulation	O
,	O
but	O
also	O
have	B-Negative_regulation
a	I-Negative_regulation
silencing	I-Negative_regulation
effect	I-Negative_regulation
on	O
IL	O
-	O
2	O
gene	O
expression	B-Gene_expression
in	O
resting	O
cells	O
.	O

Two	O
other	O
sites	O
display	B-Regulation
disparate	I-Regulation
effects	I-Regulation
on	O
IL	O
-	O
2	O
gene	O
expression	B-Gene_expression
in	O
different	O
T	O
leukemia	O
cell	O
lines	O
:	O
the	O
distal	O
purine	O
box	O
(	O
-	O
291	O
to	O
-	O
277	O
)	O
and	O
the	O
proximal	O
purine	O
box	O
sites	O
(	O
-	O
145	O
to	O
-	O
128	O
)	O
.	O

Finally	O
,	O
the	O
AP	O
-	O
1	O
(	O
-	O
186	O
to	O
-	O
176	O
)	O
and	O
the	O
kappa	O
B	O
sites	O
(	O
-	O
206	O
to	O
-	O
195	O
)	O
respond	O
to	O
different	O
cellular	O
activation	O
in	O
EL4	O
cells	O
.	O

The	O
AP	O
-	O
1	O
site	O
mediated	O
the	O
response	O
to	O
PMA	O
stimulation	O
while	O
the	O
kappa	O
B	O
site	O
responded	O
to	O
IL	O
-	O
1	O
stimulation	O
.	O

These	O
data	O
suggest	O
that	O
the	O
regulation	B-Regulation
of	O
IL	O
-	O
2	O
gene	O
expression	B-Gene_expression
is	O
a	O
complex	O
process	O
and	O
multiple	O
cis	O
-	O
acting	O
regulatory	O
sites	O
interact	B-Regulation
to	I-Regulation
exert	I-Regulation
different	I-Regulation
effects	I-Regulation
in	O
T	O
cells	O
representative	O
of	O
alternative	O
stages	O
of	O
differentiation	O
.	O

Superantigens	O
activate	O
HIV	O
-	O
1	O
gene	O
expression	O
in	O
monocytic	O
cells	O
.	O

Binding	O
of	O
superantigens	O
to	O
MHC	O
class	O
II	O
molecules	O
results	O
in	O
transduction	O
of	O
biochemical	O
signals	O
leading	O
to	O
cellular	O
activation	O
and	O
gene	O
expression	O
.	O

We	O
demonstrate	O
that	O
the	O
staphylococcal	O
superantigens	O
toxic	O
shock	O
syndrome	O
toxin	O
-	O
1	O
(	O
TSST	O
-	O
1	O
)	O
and	O
staphylococcal	O
enterotoxin	O
A	O
(	O
SEA	O
)	O
activate	B-Positive_regulation
HIV-1-LTR	O
-	O
driven	B-Positive_regulation
transcription	B-Transcription
of	O
chloramphenicol	O
acetyl	O
transferase	O
in	O
the	O
human	O
monocytic	O
cell	O
line	O
THP	O
-	O
1	O
.	O

Induction	O
of	O
HIV-1-LTR	O
-	O
driven	O
transcription	O
in	O
THP	O
-	O
1	O
cells	O
by	O
superantigens	O
was	O
associated	O
with	O
the	O
induction	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
DNA	O
-	O
binding	O
activity	O
.	O

Superantigens	O
also	O
increased	O
viral	O
protein	O
secretion	O
from	O
the	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
-	O
pretreated	O
chronically	O
infected	O
human	O
monocytic	O
cell	O
line	O
U1	O
.	O

Induction	O
of	O
HIV	O
-	O
1	O
gene	O
expression	O
in	O
monocytic	O
cells	O
by	O
superantigens	O
occurred	O
via	O
tumor	O
necrosis	O
factor-alpha	O
-	O
dependent	O
and	O
-	O
independent	O
mechanisms	O
.	O

Our	O
results	O
suggest	O
that	O
superantigens	O
and	O
other	O
MHC	O
class	O
II	O
ligands	O
may	O
activate	O
HIV	O
-	O
1	O
gene	O
expression	O
in	O
monocytes/macrophages	O
.	O

Inhibition	O
of	O
activation	O
of	O
transcription	O
factor	O
AP	O
-	O
1	O
by	O
CD28	O
signalling	O
in	O
human	O
T	O
-	O
cells	O
.	O

Co	O
-	O
stimulation	O
of	O
T	O
-	O
lymphocytes	O
by	O
T	O
-	O
cell	O
receptor	O
(	O
TcR	O
)	O
occupancy	O
and	O
activation	B-Positive_regulation
of	O
the	O
CD28	O
surface	O
molecule	O
results	O
in	O
enhanced	O
proliferation	O
and	O
interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
production	B-Gene_expression
.	O

The	O
increase	B-Positive_regulation
in	O
IL	O
-	O
2	O
gene	O
expression	B-Gene_expression
triggered	O
by	O
CD28	O
involves	O
a	O
kappa	O
B	O
-	O
like	O
sequence	O
in	O
the	O
5'	O
-	O
regulatory	O
region	O
of	O
the	O
IL	O
-	O
2	O
promoter	O
,	O
called	O
CD28	O
-	O
responsive	O
element	O
.	O

Stimulation	O
of	O
T	O
-	O
cells	O
by	O
agonistic	O
anti	O
-	O
CD28	O
antibodies	O
in	O
conjunction	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
-	O
or	O
TcR	O
-	O
derived	O
signals	O
induces	O
the	O
enhanced	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
.	O

Here	O
we	O
report	O
that	O
CD28	O
engagement	B-Binding
,	O
however	O
,	O
exerts	O
opposite	O
effects	O
on	O
the	O
transcription	O
factor	O
AP	O
-	O
1	O
.	O

Whereas	O
anti	O
-	O
CD28	O
together	O
with	O
PMA	O
increased	O
the	O
DNA	O
binding	O
and	O
trans	O
-	O
activation	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
PMA	O
-	O
induced	O
activation	O
of	O
AP	O
-	O
1	O
was	O
significantly	O
suppressed	O
.	O

The	O
inhibitory	O
effect	O
exerted	O
by	O
anti	O
-	O
CD28	O
was	O
observed	O
at	O
the	O
level	O
of	O
DNA	O
binding	O
as	O
well	O
as	O
in	O
functional	O
reporter	O
-	O
gene	O
assays	O
.	O

These	O
results	O
suggest	O
that	O
the	O
two	O
transcription	O
factors	O
are	O
independently	O
regulated	O
and	O
may	O
perform	O
different	O
functions	O
during	O
T	O
-	O
cell	O
activation	O
.	O

Induction	B-Positive_regulation
of	O
IL	O
-	O
8	O
expression	B-Gene_expression
in	O
T	O
cells	O
uses	B-Positive_regulation
the	O
CD28	O
costimulatory	O
pathway	O
.	O

IL	O
-	O
8	O
,	O
a	O
potent	O
chemotactic	O
factor	O
for	O
neutrophil	O
granulocytes	O
and	O
lymphocytes	O
,	O
is	O
a	O
proinflammatory	O
cytokine	O
secreted	B-Localization
by	O
a	O
variety	O
of	O
cell	O
types	O
,	O
including	O
T	O
cells	O
.	O

Stimulation	B-Positive_regulation
of	O
the	O
CD28	O
cell	O
surface	O
molecule	O
delivers	O
costimulatory	O
signals	O
essential	O
for	O
lymphokine	O
production	O
in	O
activated	O
T	O
cells	O
via	O
a	O
conserved	O
sequence	O
element	O
found	O
in	O
the	O
promoter	O
of	O
several	O
lymphokine	O
genes	O
.	O

Anti-CD28	O
-	O
stimulated	O
T	O
cells	O
produced	B-Gene_expression
significant	O
amounts	O
of	O
IL	O
-	O
8	O
;	O
additionally	O
,	O
costimulation	O
with	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	O
Abs	O
resulted	B-Positive_regulation
in	O
a	O
synergistic	B-Positive_regulation
induction	I-Positive_regulation
of	O
IL	O
-	O
8	O
secretion	B-Localization
.	O

Sequence	O
homology	O
,	O
single	O
nucleotide	O
mutations	O
,	O
and	O
anti	O
-	O
CD28	O
Ab	O
stimulation	O
studies	O
established	O
that	O
the	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
sequence	O
in	O
the	O
promoter	O
of	O
the	O
IL	O
-	O
8	O
gene	O
functioned	O
as	O
a	O
CD28	O
response	B-Regulation
element	O
.	O

Furthermore	O
,	O
cyclosporin	O
A	O
,	O
but	O
not	O
rapamycin	O
,	O
blocked	B-Negative_regulation
the	O
synergistic	B-Positive_regulation
induction	I-Positive_regulation
of	O
IL	O
-	O
8	O
expression	B-Gene_expression
achieved	O
with	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	O
costimulation	O
.	O

The	O
involvement	B-Positive_regulation
of	O
a	O
CD28	O
response	O
element	O
in	O
the	O
induction	B-Positive_regulation
of	O
IL	O
-	O
8	O
expression	B-Gene_expression
in	O
activated	O
T	O
cells	O
may	O
provide	O
new	O
insights	O
into	O
the	O
pathogenesis	O
and	O
persistence	O
of	O
immune	O
disorders	O
characterized	O
by	O
increased	B-Positive_regulation
levels	B-Gene_expression
of	O
IL	O
-	O
8	O
,	O
such	O
as	O
psoriasis	O
and	O
rheumatoid	O
arthritis	O
.	O

The	O
severe	O
phenotype	O
of	O
females	O
with	O
tiny	O
ring	O
X	O
chromosomes	O
is	O
associated	O
with	O
inability	O
of	O
these	O
chromosomes	O
to	O
undergo	O
X	O
inactivation	O
.	O

Mental	O
retardation	O
and	O
a	O
constellation	O
of	O
congenital	O
malformations	O
not	O
usually	O
associated	O
with	O
Turner	O
syndrome	O
are	O
seen	O
in	O
some	O
females	O
with	O
a	O
mosaic	O
45	O
,	O
X/46	O
,	O
X	O
,	O
r	O
(	O
X	O
)	O
karyotype	O
.	O

Studies	O
of	O
these	O
females	O
show	O
that	O
the	O
XIST	O
locus	O
on	O
their	O
tiny	O
ring	O
X	O
chromosomes	O
is	O
either	O
not	O
present	B-Negative_regulation
or	O
not	O
expressed	B-Gene_expression
.	O

As	O
XIST	O
transcription	B-Transcription
is	O
well	O
correlated	O
with	O
inactivation	O
of	O
the	O
X	O
chromosome	O
in	O
female	O
somatic	O
cells	O
and	O
spermatogonia	O
,	O
nonexpression	B-Gene_expression
of	O
the	O
locus	O
even	O
when	O
it	O
is	O
present	O
suggests	O
that	O
these	O
chromosomes	O
are	O
transcriptionally	O
active	O
.	O

We	O
examined	O
the	O
transcriptional	O
activity	O
of	O
ring	O
X	O
chromosomes	O
lacking	O
XIST	O
expression	B-Gene_expression
(	O
XISTE	O
-	O
)	O
,	O
from	O
three	O
females	O
with	O
severe	O
phenotypes	O
.	O

The	O
two	O
tiny	O
ring	O
X	O
chromosomes	O
studied	O
with	O
an	O
antibody	O
specific	O
for	O
the	O
acetylated	O
isoforms	O
of	O
histone	O
H4	O
marking	O
transcribed	O
chromatin	O
domains	O
were	O
labeled	O
at	O
a	O
level	O
consistent	O
with	O
their	O
being	O
active	O
.	O

We	O
also	O
examined	O
tow	O
of	O
the	O
XISTE	O
-	O
ring	O
chromosomes	O
to	O
determine	O
whether	O
genes	O
that	O
are	O
normally	O
silent	O
on	O
an	O
inactive	O
X	O
are	O
expressed	O
from	O
these	O
chromosomes	O
.	O

Analyses	O
of	O
hybrid	O
cells	O
show	O
that	O
TIMP	O
,	O
ZXDA	O
,	O
and	O
ZXDB	O
loci	O
on	O
the	O
proximal	O
short	O
arm	O
,	O
and	O
AR	O
and	O
PHKA1	O
loci	O
on	O
the	O
long	O
arm	O
,	O
are	O
well	O
expressed	B-Gene_expression
from	O
the	O
tiny	O
ring	O
X	O
chromosome	O
lacking	B-Negative_regulation
XIST	O
DNA	O
.	O

Studies	O
of	O
the	O
ring	O
chromosome	O
that	O
has	O
XIST	O
DNA	O
but	O
does	O
not	O
transcribe	B-Transcription
it	O
show	O
that	O
its	O
AR	O
allele	O
is	O
transcribed	O
along	O
with	O
the	O
one	O
on	O
the	O
normal	O
X	O
allele	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Signals	O
and	O
nuclear	O
factors	O
that	O
regulate	B-Regulation
the	O
expression	B-Gene_expression
of	O
interleukin	O
-	O
4	O
and	O
interleukin	O
-	O
5	O
genes	O
in	O
helper	O
T	O
cells	O
.	O

Mouse	O
thymoma	O
line	O
EL	O
-	O
4	O
cells	O
produce	B-Gene_expression
cytokines	O
such	O
as	O
interleukin	O
(	O
IL	O
)	O
-	O
2	O
,	O
IL	O
-	O
3	O
,	O
IL	O
-	O
4	O
,	O
IL	O
-	O
10	O
,	O
and	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
in	B-Positive_regulation
response	I-Positive_regulation
to	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
.	O

EL	O
-	O
4	O
cells	O
also	O
produce	B-Gene_expression
low	O
levels	O
of	O
IL	O
-	O
5	O
when	B-Positive_regulation
stimulated	O
by	O
PMA	O
alone	O
;	O
however	O
,	O
cAMP	O
greatly	O
augments	B-Positive_regulation
PMA	O
-	O
dependent	B-Positive_regulation
IL	O
-	O
5	O
production	B-Gene_expression
.	O

A	O
transient	O
transfection	O
assay	O
revealed	O
that	O
two	O
signals	O
,	O
PMA	O
and	O
cAMP	O
,	O
are	O
required	B-Positive_regulation
for	O
optimal	O
activation	B-Positive_regulation
of	O
the	O
IL	O
-	O
5	O
promoter	O
.	O

In	O
contrast	O
,	O
cAMP	O
almost	O
completely	O
inhibited	B-Negative_regulation
the	O
PMA	O
-	O
dependent	O
activation	B-Positive_regulation
of	O
the	O
endogenous	O
IL	O
-	O
2	O
gene	O
,	O
as	O
well	O
as	O
the	O
transfected	O
IL	O
-	O
2	O
promoter	O
.	O

These	O
results	O
indicate	O
that	O
the	O
IL	O
-	O
5	O
gene	O
is	O
positively	B-Positive_regulation
regulated	I-Positive_regulation
by	O
cAMP	O
in	O
a	O
manner	O
opposite	B-Negative_regulation
to	O
that	O
for	O
the	O
IL	O
-	O
2	O
gene	O
.	O

One	O
of	O
the	O
nuclear	O
factors	O
(	O
NFs	O
)	O
that	O
regulates	B-Regulation
the	O
response	B-Regulation
of	O
the	O
IL	O
-	O
5	O
promoter	O
to	O
cAMP	O
and	O
PMA	O
has	O
properties	O
similar	O
to	O
NF	O
for	O
activated	O
t	O
cell	O
.	O

The	O
P	O
sequence	O
of	O
the	O
IL	O
-	O
4	O
gene	O
,	O
defined	B-Regulation
as	I-Regulation
a	I-Regulation
responsive	I-Regulation
element	I-Regulation
for	O
PMA	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
,	O
shares	O
sequence	O
similarity	O
with	O
the	O
NF	O
kappa	O
B	O
and	O
the	O
NF	O
-	O
activated	O
T	O
cell	O
binding	O
sites	O
.	O

We	O
attempted	O
to	O
determine	O
whether	O
NF	O
(	O
P	O
)	O
,	O
a	O
nuclear	O
factor	O
specific	O
for	O
the	O
P	O
sequence	O
,	O
is	O
related	O
to	O
NF	O
-	O
kappa	O
B	O
and	O
nuclear	O
factor	O
for	O
activated	O
T	O
cell	O
(	O
NF	O
-	O
AT	O
)	O
.	O

In	O
electromobility	O
shift	O
assays	O
both	O
NF	O
-	O
kappa	O
B	O
(	O
P65	O
or	O
P65/P50	O
heterodimer	O
)	O
and	O
NF	O
-	O
AT	O
bound	B-Binding
to	O
the	O
P	O
sequence	O
.	O

However	O
,	O
sequence	O
specificity	O
of	O
NF	O
-	O
AT	O
was	O
more	O
similar	O
to	O
that	O
of	O
NF	O
(	O
P	O
)	O
,	O
and	O
only	O
a	O
small	O
amount	O
of	O
P65	O
was	O
detected	O
in	O
NF	O
(	O
P	O
)	O
.	O

These	O
results	O
indicate	O
that	O
a	O
component	O
or	O
components	O
of	O
NF	O
-	O
AT	O
have	O
the	O
potential	O
to	O
reconstitute	O
NF	O
(	O
P	O
)	O
,	O
whereas	O
NF	O
-	O
kappa	O
B	O
alone	O
does	O
not	O
account	O
for	O
NF	O
(	O
P	O
)	O
in	O
Jurkat	O
crude	O
extract	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
NF-AT	O
-	O
like	O
factors	O
are	O
involved	O
in	O
the	O
regulation	B-Regulation
of	O
IL	O
-	O
4	O
and	O
IL	O
-	O
5	O
genes	O
.	O

Structure	O
and	O
expression	B-Gene_expression
of	O
the	O
human	O
GATA3	O
gene	O
.	O

GATA3	O
,	O
a	O
member	O
of	O
the	O
GATA	O
family	O
that	O
is	O
abundantly	O
expressed	B-Gene_expression
in	O
the	O
T	O
-	O
lymphocyte	O
lineage	O
,	O
is	O
thought	O
to	O
participate	O
in	O
T	O
-	O
cell	O
receptor	O
gene	O
activation	O
through	O
binding	B-Binding
to	O
enhancers	O
.	O

To	O
understand	O
GATA3	O
gene	O
regulation	B-Regulation
,	O
we	O
cloned	O
the	O
human	O
gene	O
and	O
the	O
5	O
'	O
end	O
of	O
the	O
mouse	O
GATA3	O
gene	O
.	O

We	O
show	O
that	O
the	O
human	O
GATA3	O
gene	O
contains	O
six	O
exons	O
distributed	O
over	O
17	O
kb	O
of	O
DNA	O
.	O

The	O
two	O
human	O
GATA3	O
zinc	O
fingers	O
are	O
encoded	O
by	O
two	O
separate	O
exons	O
highly	O
conserved	O
with	O
those	O
of	O
GATA1	O
,	O
but	O
no	O
other	O
structural	O
homologies	O
between	O
these	O
two	O
genes	O
can	O
be	O
found	O
.	O

The	O
human	O
and	O
mouse	O
GATA3	O
transcription	O
units	O
start	O
at	O
a	O
major	O
initiation	O
site	O
.	O

The	O
promoter	O
sequence	O
analysis	O
of	O
these	O
two	O
genes	O
revealed	O
that	O
they	O
are	O
embedded	O
within	O
a	O
CpG	O
island	O
and	O
share	O
structural	O
features	O
often	O
found	O
in	O
the	O
promoters	O
of	O
housekeeping	O
genes	O
.	O

Finally	O
,	O
we	O
show	O
that	O
a	O
DNA	O
fragment	O
containing	O
the	O
human	O
GATA3	O
transcription	O
unit	O
,	O
3	O
kb	O
upstream	O
from	O
the	O
initiation	O
site	O
and	O
4	O
kb	O
downstream	O
from	O
the	O
polyadenylation	O
site	O
,	O
displays	O
T	O
-	O
cell	O
specificity	O
.	O

Characterization	O
of	O
NF	O
(	O
P	O
)	O
,	O
the	O
nuclear	O
factor	O
that	O
interacts	B-Binding
with	O
the	O
regulatory	O
P	O
sequence	O
(	O
5'-CGAAAATTTCC	O
-	O
3	O
'	O
)	O
of	O
the	O
human	O
interleukin	O
-	O
4	O
gene	O
:	O
relationship	O
to	O
NF	O
-	O
kappa	O
B	O
and	O
NF	O
-	O
AT	O
.	O

The	O
P	O
sequence	O
of	O
the	O
human	O
interleukin	O
-	O
4	O
(	O
IL	O
-	O
4	O
)	O
gene	O
,	O
which	O
was	O
defined	O
as	O
a	O
responsive	B-Regulation
element	I-Regulation
for	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
in	O
Jurkat	O
T	O
cells	O
,	O
shares	O
sequence	O
similarity	O
with	O
the	O
NF	O
-	O
kappa	O
B	O
and	O
the	O
NF	O
-	O
AT	O
binding	O
sites	O
.	O

We	O
examined	O
whether	O
NF	O
(	O
P	O
)	O
,	O
a	O
nuclear	O
factor	O
specific	O
for	O
the	O
P	O
sequence	O
,	O
is	O
related	O
to	O
NF	O
-	O
kappa	O
B	O
and	O
NF	O
-	O
AT	O
.	O

NF	O
-	O
kappa	O
B	O
(	O
P65	O
or	O
P65/P50	O
heterodimer	O
)	O
bound	B-Binding
to	O
the	O
P	O
sequence	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
and	O
activated	O
transcription	O
through	O
the	O
P	O
sequence	O
when	O
expression	O
plasmids	O
were	O
cotransfected	O
with	O
P	O
sequence	O
-	O
driven	O
reporter	O
plasmids	O
in	O
Jurkat	O
T	O
cells	O
.	O

In	O
EMSAs	O
,	O
NF	O
(	O
P	O
)	O
binding	O
was	O
inhibited	O
by	O
the	O
unlabeled	O
NF	O
-	O
AT	O
binding	O
site	O
but	O
not	O
by	O
the	O
unlabeled	O
AP1	O
binding	O
site	O
and	O
purified	O
NF	O
-	O
AT	O
contained	O
an	O
activity	O
that	O
bound	O
to	O
the	O
P	O
sequence	O
.	O

Both	O
mobility	O
shift	O
and	O
sequence	O
specificity	O
of	O
NF	O
-	O
AT	O
were	O
similar	O
to	O
those	O
of	O
NF	O
(	O
P	O
)	O
and	O
only	O
a	O
small	O
amount	O
of	O
P65	O
was	O
detected	B-Binding
in	O
NF	O
(	O
P	O
)	O
in	O
crude	O
nuclear	O
extracts	O
.	O

These	O
results	O
indicate	O
that	O
the	O
component	O
(	O
s	O
)	O
of	O
NF	O
-	O
AT	O
has	O
the	O
potential	O
to	O
reconstitute	O
NF	O
(	O
P	O
)	O
whereas	O
NF	O
-	O
kappa	O
B	O
alone	O
can	O
not	O
account	O
for	O
NF	O
(	O
P	O
)	O
in	O
crude	O
extracts	O
.	O

Unlike	O
NF	O
-	O
AT	O
,	O
NF	O
(	O
P	O
)	O
does	O
not	O
contain	O
AP1	O
as	O
its	O
DNA	O
binding	O
component	O
.	O

Hypoxia	O
causes	B-Positive_regulation
the	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
through	O
the	O
phosphorylation	B-Phosphorylation
of	O
I	O
kappa	O
B	O
alpha	O
on	O
tyrosine	O
residues	O
.	O

The	O
response	O
of	O
mammalian	O
cells	O
to	O
stress	O
is	O
controlled	O
by	O
transcriptional	O
regulatory	O
proteins	O
such	O
as	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
to	O
induce	O
a	O
wide	O
variety	O
of	O
early	O
response	O
genes	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
exposure	O
of	O
cells	O
to	O
hypoxia	O
(	O
0.02	O
%	O
O2	O
)	O
results	B-Positive_regulation
in	O
I	O
kappa	O
B	O
alpha	O
degradation	B-Protein_catabolism
,	O
increased	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
activity	O
,	O
and	O
transactivation	O
of	O
a	O
reporter	O
gene	O
construct	O
containing	O
two	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
sites	O
.	O

Pretreatment	O
of	O
cells	O
with	O
protein	O
tyrosine	O
kinase	O
inhibitors	O
and	O
the	O
dominant	O
negative	O
allele	O
of	O
c-Raf	O
-	O
1	O
(	O
Raf	O
301	O
)	O
inhibited	B-Negative_regulation
I	O
kappa	O
B	O
alpha	O
degradation	B-Protein_catabolism
,	O
NF	O
-	O
kappa	O
B	O
binding	O
,	O
and	O
transactivation	O
of	O
kappa	O
B	O
reporter	O
constructs	O
by	B-Positive_regulation
hypoxia	O
.	O

To	O
demonstrate	O
a	O
direct	O
link	O
between	O
changes	O
in	O
the	O
phosphorylation	B-Phosphorylation
pattern	O
of	O
I	O
kappa	O
B	O
alpha	O
with	O
NF	O
-	O
kappa	O
B	O
activation	O
,	O
we	O
immunoprecipitated	O
I	O
kappa	O
B	O
alpha	O
after	O
varying	O
times	O
of	O
hypoxic	O
exposure	O
and	O
found	O
that	O
its	O
tyrosine	O
phosphorylation	B-Phosphorylation
status	O
increased	B-Positive_regulation
during	O
hypoxic	O
exposure	O
.	O

Inhibition	B-Negative_regulation
of	O
the	O
transfer	B-Phosphorylation
of	I-Phosphorylation
tyrosine	I-Phosphorylation
phosphoryl	I-Phosphorylation
groups	I-Phosphorylation
onto	O
I	O
kappa	O
B	O
alpha	O
prevented	B-Negative_regulation
I	O
kappa	O
B	O
alpha	O
degradation	B-Protein_catabolism
and	O
NF	O
-	O
kappa	O
B	O
binding	O
.	O

In	O
comparison	O
to	O
other	O
activators	O
of	O
NF	O
-	O
kappa	O
B	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
or	O
tumor	O
necrosis	O
factor	O
,	O
we	O
did	O
not	O
detect	O
changes	B-Regulation
in	O
the	O
tyrosine	O
phosphorylation	B-Phosphorylation
status	O
of	O
I	O
kappa	O
B	O
alpha	O
following	O
treatment	O
with	O
either	O
of	O
these	O
agents	O
.	O

These	O
results	O
suggest	O
that	O
tyrosine	O
phosphorylation	B-Phosphorylation
of	O
I	O
kappa	O
B	O
alpha	O
during	B-Positive_regulation
hypoxia	O
is	O
an	O
important	O
proximal	O
step	O
which	O
precedes	B-Positive_regulation
its	O
dissociation	O
and	O
degradation	B-Protein_catabolism
from	O
NF	O
-	O
kappa	O
B	O
.	O

A	O
transcriptional	O
regulatory	O
element	O
is	O
associated	O
with	O
a	O
nuclease	O
-	O
hypersensitive	O
site	O
in	O
the	O
pol	O
gene	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

Analysis	O
of	O
the	O
chromatin	O
organization	O
of	O
the	O
integrated	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
genome	O
has	O
previously	O
revealed	O
a	O
major	O
constitutive	O
DNase	O
I	O
-	O
hypersensitive	O
site	O
associated	O
with	O
the	O
pol	O
gene	O
(	O
E	O
.	O

Verdin	O
,	O
J.	O
Virol	O
.	O

65	O
:	O
6790	O
-	O
6799	O
,	O
1991	O
)	O
.	O

In	O
the	O
present	O
report	O
,	O
high	O
-	O
resolution	O
mapping	O
of	O
this	O
site	O
with	O
DNase	O
I	O
and	O
micrococcal	O
nuclease	O
identified	O
a	O
nucleosome	O
-	O
free	O
region	O
centered	O
around	O
nucleotides	O
(	O
nt	O
)	O
4490	O
to	O
4766	O
.	O

A	O
500	O
-	O
bp	O
fragment	O
encompassing	O
this	O
hypersensitive	O
site	O
(	O
nt	O
4481	O
to	O
4982	O
)	O
exhibited	O
transcription	O
-	O
enhancing	O
activity	O
(	O
two	O
-	O
to	O
threefold	O
)	O
when	O
it	O
was	O
cloned	O
in	O
its	O
natural	O
position	O
with	O
respect	O
to	O
the	O
HIV	O
-	O
1	O
promoter	O
after	O
transient	O
transfection	O
in	O
U937	O
and	O
CEM	O
cells	O
.	O

Using	O
in	O
vitro	O
footprinting	O
and	O
gel	O
shift	O
assays	O
,	O
we	O
have	O
identified	O
four	O
distinct	O
binding	O
sites	O
for	O
nuclear	O
proteins	O
within	O
this	O
positive	O
regulatory	O
element	O
.	O

Site	O
B	O
(	O
nt	O
4519	O
to	O
4545	O
)	O
specifically	O
bound	B-Binding
four	O
distinct	O
nuclear	O
protein	O
complexes	O
:	O
a	O
ubiquitous	O
factor	O
,	O
a	O
T-cell	O
-	O
specific	O
factor	O
,	O
a	O
B-cell	O
-	O
specific	O
factor	O
,	O
and	O
the	O
monocyte/macrophage	O
-	O
and	O
B-cell	O
-	O
specific	O
transcription	O
factor	O
PU.1/Spi	O
-	O
1	O
.	O

In	O
most	O
HIV	O
-	O
1	O
isolates	O
in	O
which	O
this	O
PU	O
box	O
was	O
not	O
conserved	O
,	O
it	O
was	O
replaced	O
by	O
a	O
binding	B-Binding
site	O
for	O
the	O
related	O
factor	O
Ets1	O
.	O

Factors	O
binding	O
to	O
site	O
C	O
(	O
nt	O
4681	O
to	O
4701	O
)	O
had	O
a	O
DNA	O
-	O
binding	O
specificity	O
similar	O
to	O
that	O
of	O
factors	O
binding	O
to	O
site	O
B	O
,	O
except	O
for	O
PU.1/Spi	O
-	O
1	O
.	O

A	O
GC	O
box	O
containing	B-Binding
a	I-Binding
binding	I-Binding
site	I-Binding
for	O
Sp1	O
was	O
identified	O
(	O
nt	O
4623	O
to	O
4631	O
)	O
.	O

Site	O
D	O
(	O
nt	O
4816	O
to	O
4851	O
)	O
specifically	O
bound	O
a	O
ubiquitously	O
expressed	O
factor	O
.	O

These	O
results	O
identify	O
a	O
transcriptional	O
regulatory	O
element	O
associated	O
with	O
a	O
nuclease	O
-	O
hypersensitive	O
site	O
in	O
the	O
pol	O
gene	O
of	O
HIV	O
-	O
1	O
and	O
suggest	O
that	O
its	O
activity	O
may	O
be	O
controlled	O
by	O
a	O
complex	O
interplay	O
of	O
cis	O
-	O
regulatory	O
elements	O
.	O

Expression	B-Gene_expression
of	O
v	O
-	O
src	O
in	O
T	O
cells	O
correlates	O
with	O
nuclear	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
a	O
rapidly	O
inducible	O
transcriptional	O
activator	O
that	O
responds	O
to	O
a	O
variety	O
of	O
signals	O
and	O
influences	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
the	O
immune	O
response	O
.	O

Protein	O
tyrosine	O
kinases	O
transmit	O
signals	O
from	O
cytokine	O
and	O
immune	O
receptors	O
.	O

Very	O
little	O
information	O
exists	O
linking	O
these	O
two	O
important	O
classes	O
of	O
signaling	O
molecules	O
.	O

We	O
now	O
demonstrate	O
that	O
v	O
-	O
src	O
expression	B-Gene_expression
correlates	O
with	O
nuclear	O
expression	O
of	O
a	O
kappa	O
B	O
binding	O
complex	O
similar	O
to	O
that	O
induced	O
by	O
phorbol	O
ester	O
and	O
ionomycin	O
,	O
as	O
detected	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
variety	O
of	O
kappa	O
B	O
sites	O
.	O

This	O
complex	O
was	O
blocked	O
by	O
the	O
tyrosine	O
kinase	O
inhibitor	O
,	O
herbimycin	O
A	O
.	O

The	O
v-src	O
-	O
induced	B-Binding
complex	I-Binding
comprised	O
the	O
p50	O
and	O
p65	O
components	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
as	O
determined	O
by	O
supershift	O
and	O
immunoblot	O
analysis	O
.	O

As	O
a	O
functional	O
correlate	O
of	O
this	O
finding	O
,	O
transient	O
co	O
-	O
transfection	O
of	O
HIV	O
-	O
1	O
LTR	O
reporter	O
constructs	O
in	O
a	O
different	O
T	O
cell	O
line	O
demonstrated	O
that	O
v	O
-	O
src	O
activated	O
this	O
promoter	O
in	O
a	O
kappa	O
B	O
-	O
dependent	O
manner	O
.	O

We	O
found	O
that	O
transactivation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
by	O
v	O
-	O
src	O
was	O
more	O
sensitive	O
to	O
mutations	O
of	O
the	O
proximal	O
,	O
rather	O
than	O
the	O
distal	O
,	O
kappa	O
B	O
element	O
.	O

The	O
implications	O
for	O
T	O
cell	O
receptor	O
signaling	O
and	O
HIV	O
-	O
1	O
gene	O
expression	O
are	O
considered	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
Nef	O
protein	O
down	O
-	O
regulates	O
transcription	O
factors	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
in	O
human	O
T	O
cells	O
in	O
vitro	O
after	O
T	O
-	O
cell	O
receptor	O
stimulation	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
negative	O
factor	O
(	O
Nef	O
)	O
has	O
been	O
shown	O
to	O
down	O
-	O
regulate	O
the	O
transcription	O
factors	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
in	O
vitro	O
.	O

To	O
define	O
the	O
mechanism	O
of	O
action	O
of	O
the	O
Nef	O
protein	O
,	O
the	O
signal	O
transduction	O
pathways	O
which	O
may	O
be	O
affected	O
in	O
T	O
cells	O
by	O
constitutive	O
expression	B-Gene_expression
of	O
the	O
nef	O
gene	O
were	O
examined	O
.	O

Stimulation	O
of	O
T	O
cells	O
with	O
tumor	O
necrosis	O
factor	O
,	O
interleukin	O
-	O
1	O
,	O
or	O
lipopolysaccharide	O
resulted	O
in	O
the	O
recruitment	O
of	O
transcriptional	O
factors	O
to	O
a	O
similar	O
level	O
whether	O
or	O
not	O
the	O
cells	O
expressed	O
the	O
nef	O
gene	O
.	O

On	O
the	O
other	O
hand	O
,	O
stimulation	O
of	O
T	O
cells	O
by	O
mitogens	O
or	O
antibodies	O
to	O
the	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
-	O
CD3	O
complex	O
resulted	O
in	O
the	O
down	O
-	O
regulation	O
of	O
transcriptional	O
factors	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
in	O
cells	O
expressing	B-Gene_expression
the	O
nef	O
gene	O
compared	O
with	O
cells	O
not	O
expressing	O
the	O
nef	O
gene	O
.	O

Because	O
the	O
Nef	O
protein	O
does	O
not	O
affect	O
the	O
surface	O
expression	O
of	O
the	O
CD3	O
-	O
TCR	O
complex	O
,	O
we	O
conclude	O
that	O
the	O
Nef	O
protein	O
down	O
-	O
regulates	O
the	O
transcriptional	O
factors	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
in	O
T	O
cells	O
in	O
vitro	O
through	O
an	O
effect	O
on	O
the	O
TCR	O
-	O
dependent	O
signal	O
transduction	O
pathway	O
.	O

Activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
in	O
human	O
neuroblastoma	O
cell	O
lines	O
.	O

The	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
is	O
a	O
eukaryotic	O
transcription	O
factor	O
.	O

In	O
B	O
cells	O
and	O
macrophages	O
it	O
is	O
constitutively	O
present	O
in	O
cell	O
nuclei	O
,	O
whereas	O
in	O
many	O
other	O
cell	O
types	O
,	O
NF	O
-	O
kappa	O
B	O
translocates	O
from	O
cytosol	O
to	O
nucleus	O
as	O
a	O
result	O
of	O
transduction	O
by	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
,	O
phorbol	O
ester	O
,	O
and	O
other	O
polyclonal	O
signals	O
.	O

Using	O
neuroblastoma	O
cell	O
lines	O
as	O
models	O
,	O
we	O
have	O
shown	O
that	O
in	O
neural	O
cells	O
NF	O
-	O
kappa	O
B	O
was	O
present	O
in	O
the	O
cytosol	O
and	O
translocated	O
into	O
nuclei	O
as	O
a	O
result	O
of	O
TNF	O
alpha	O
treatment	O
.	O

The	O
TNF	O
alpha	O
-	O
activated	O
NF	O
-	O
kappa	O
B	O
was	O
transcriptionally	O
functional	O
.	O

NF	O
-	O
kappa	O
B	O
activation	O
by	O
TNF	O
alpha	O
was	O
not	O
correlated	O
with	O
cell	O
differentiation	O
or	O
proliferation	O
.	O

However	O
,	O
reagents	O
such	O
as	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
and	O
the	O
phorbol	O
ester	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
,	O
which	O
induce	O
phenotypical	O
differentiation	O
of	O
the	O
SH	O
-	O
SY5Y	O
neuroblastoma	O
cell	O
line	O
,	O
activated	O
NF	O
-	O
kappa	O
B	O
,	O
but	O
only	O
in	O
that	O
particular	O
cell	O
line	O
.	O

In	O
a	O
NGF	O
-	O
responsive	O
rat	O
pheochromocytoma	O
cell	O
line	O
,	O
PC12	O
,	O
PMA	O
activated	O
NF	O
-	O
kappa	O
B	O
,	O
whereas	O
NGF	O
did	O
not	O
.	O

In	O
other	O
neuroblastoma	O
cell	O
lines	O
,	O
such	O
as	O
SK-N	O
-	O
Be	O
(	O
2	O
)	O
,	O
the	O
lack	O
of	O
PMA	O
induction	O
of	O
differentiation	O
was	O
correlated	O
with	O
the	O
lack	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

We	O
found	O
,	O
moreover	O
,	O
that	O
in	O
SK-N	O
-	O
Be	O
(	O
2	O
)	O
cells	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
enzymatic	O
activity	O
was	O
much	O
lower	O
compared	O
with	O
that	O
in	O
a	O
control	O
cell	O
line	O
and	O
that	O
the	O
low	O
PKC	O
enzymatic	O
activity	O
was	O
due	O
to	O
low	O
PKC	O
protein	O
expression	O
.	O

NF	O
-	O
kappa	O
B	O
was	O
not	O
activated	O
by	O
retinoic	O
acid	O
,	O
which	O
induced	O
morphological	O
differentiation	O
of	O
all	O
the	O
neuroblastoma	O
cell	O
lines	O
used	O
in	O
the	O
present	O
study	O
.	O

Thus	O
,	O
NF	O
-	O
kappa	O
B	O
activation	O
was	O
not	O
required	O
for	O
neuroblastoma	O
cell	O
differentiation	O
.	O

Furthermore	O
,	O
the	O
results	O
obtained	O
with	O
TNF	O
alpha	O
proved	O
that	O
NF	O
-	O
kappa	O
B	O
activation	O
was	O
not	O
sufficient	O
for	O
induction	O
of	O
neuroblastoma	O
differentiation	O
.	O

Genes	O
encoding	O
general	O
initiation	O
factors	O
for	O
RNA	O
polymerase	O
II	O
transcription	O
are	O
dispersed	O
in	O
the	O
human	O
genome	O
.	O

General	O
transcription	O
factors	O
are	O
required	O
for	O
accurate	O
initiation	O
of	O
transcription	O
by	O
RNA	O
polymerase	O
II	O
.	O

Human	O
cDNAs	O
encoding	O
subunits	O
of	O
these	O
factors	O
have	O
been	O
cloned	O
and	O
sequenced	O
.	O

Using	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
,	O
we	O
show	O
here	O
that	O
the	O
genes	O
encoding	O
the	O
TATA	O
-	O
box	O
binding	O
protein	O
(	O
TBP	O
)	O
,	O
TFIIB	O
,	O
TFIIE	O
alpha	O
,	O
TFIIE	O
beta	O
,	O
RAP30	O
,	O
RAP74	O
and	O
the	O
62	O
kDa	O
subunit	O
,	O
of	O
TFIIH	O
are	O
located	O
at	O
the	O
human	O
chromosomal	O
bands	O
6q26	O
-	O
27	O
,	O
1p21	O
-	O
22	O
,	O
3q21	O
-	O
24	O
,	O
8p12	O
,	O
13q14	O
,	O
19p13.3	O
and	O
11p14	O
-	O
15.1	O
,	O
respectively	O
.	O

This	O
dispersed	O
localization	O
of	O
a	O
group	O
of	O
functionally	O
related	O
gene	O
provides	O
insights	O
into	O
the	O
molecular	O
mechanism	O
of	O
human	O
genome	O
evolution	O
and	O
their	O
possible	O
involvement	O
in	O
human	O
diseases	O
.	O

A	O
novel	O
heterodimerization	O
partner	O
for	O
thyroid	O
hormone	O
receptor	O
.	O

Peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
.	O

Retinoid	O
-	O
like	O
receptors	O
play	O
a	O
central	O
role	O
in	O
hormonal	O
responses	O
by	O
forming	O
heterodimers	O
with	O
other	O
nuclear	O
hormone	O
receptors	O
.	O

In	O
this	O
study	O
we	O
have	O
identified	O
the	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
(	O
PPAR	O
)	O
as	O
a	O
new	O
thyroid	O
hormone	O
receptor	O
(	O
THR	O
)	O
auxiliary	O
nuclear	O
protein	O
,	O
heterodimerizing	O
with	O
THR	O
in	O
solution	O
.	O

Although	O
these	O
heterodimers	O
do	O
not	O
recognize	O
a	O
classical	O
thyroid	O
hormone	O
response	O
element	O
(	O
TRE	O
)	O
characterized	O
by	O
direct	O
repeat	O
separated	O
by	O
four	O
nucleotides	O
(	O
DR+4	O
)	O
,	O
PPAR	O
behaves	O
as	O
a	O
dominant	O
negative	O
regulator	O
of	O
thyroid	O
hormone	O
(	O
TH	O
)	O
action	O
.	O

However	O
,	O
a	O
TH	O
-	O
dependent	O
positive	O
effect	O
is	O
elicited	O
by	O
selective	O
interaction	O
of	O
the	O
THR	O
beta	O
-	O
PPAR	O
but	O
not	O
the	O
THR	O
alpha	O
-	O
PPAR	O
heterodimer	O
with	O
a	O
novel	O
TRE	O
(	O
DR+2	O
)	O
.	O

The	O
critical	O
region	O
of	O
THR	O
beta	O
was	O
mapped	O
to	O
3	O
amino	O
acids	O
in	O
the	O
distal	O
box	O
of	O
the	O
DNA	O
binding	O
domain	O
.	O

Hence	O
,	O
PPAR	O
can	O
positively	O
or	O
negatively	O
influence	O
TH	O
action	O
depending	O
on	O
TRE	O
structure	O
and	O
THR	O
isotype	O
.	O

Hypoxic	O
induction	B-Positive_regulation
of	O
interleukin	O
-	O
8	O
gene	O
expression	B-Gene_expression
in	O
human	O
endothelial	O
cells	O
.	O

Because	O
leukocyte	O
-	O
mediated	O
tissue	O
damage	O
is	O
an	O
important	O
component	O
of	O
the	O
pathologic	O
picture	O
in	O
ischemia/reperfusion	O
,	O
we	O
have	O
sought	O
mechanisms	O
by	O
which	O
PMNs	O
are	O
directed	O
into	O
hypoxic	O
tissue	O
.	O

Incubation	O
of	O
human	O
endothelial	O
cells	O
(	O
ECs	O
)	O
in	O
hypoxia	O
,	O
PO2	O
approximately	O
14	O
-	O
18	O
Torr	O
,	O
led	B-Positive_regulation
to	O
time	O
-	O
dependent	O
release	B-Localization
of	O
IL	O
-	O
8	O
antigen	O
into	O
the	O
conditioned	O
medium	O
;	O
this	O
was	O
accompanied	O
by	O
increased	O
chemotactic	O
activity	O
for	O
PMNs	O
,	O
blocked	O
by	O
antibody	O
to	O
IL	O
-	O
8	O
.	O

Production	B-Positive_regulation
of	O
IL	O
-	O
8	O
by	O
hypoxic	O
ECs	O
occurred	O
concomitantly	O
with	O
both	O
increased	B-Positive_regulation
levels	O
of	O
IL	O
-	O
8	O
mRNA	O
,	O
based	O
on	O
polymerase	O
chain	O
reaction	O
analysis	O
,	O
and	O
increased	B-Positive_regulation
IL	O
-	O
8	O
transcription	B-Transcription
,	O
based	O
on	O
nuclear	O
run	O
-	O
on	O
assays	O
.	O

Northern	O
analysis	O
of	O
mRNA	O
from	O
hypoxic	O
ECs	O
also	O
demonstrated	O
increased	B-Positive_regulation
levels	O
of	O
mRNA	O
for	O
macrophage	O
chemotactic	O
protein	O
-	O
1	O
,	O
another	O
member	O
of	O
the	O
chemokine	O
superfamily	O
of	O
proinflammatory	O
cytokines	O
.	O

IL	O
-	O
8	O
gene	O
induction	B-Positive_regulation
was	O
associated	O
with	O
the	O
presence	O
of	O
increased	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
from	O
hypoxic	O
ECs	O
for	O
the	O
NF	O
-	O
kB	O
site	O
.	O

Studies	O
with	O
human	O
umbilical	O
vein	O
segments	O
exposed	O
to	O
hypoxia	O
also	O
demonstrated	O
increased	B-Positive_regulation
elaboration	O
of	O
IL	O
-	O
8	O
antigen	O
compared	O
with	O
normoxic	O
controls	O
.	O

In	O
mice	O
exposed	O
to	O
hypoxia	O
(	O
PO2	O
approximately	O
30	O
-	O
40	O
Torr	O
)	O
,	O
there	O
was	O
increased	O
pulmonary	O
leukostasis	O
,	O
as	O
evidenced	O
by	O
increased	O
myeloperoxidase	O
activity	O
in	O
tissue	O
homogenates	O
.	O

In	O
parallel	O
,	O
increased	B-Positive_regulation
levels	O
of	O
transcripts	O
for	O
IP	O
-	O
10	O
,	O
a	O
murine	O
homologue	O
in	O
the	O
chemokine	O
family	O
related	O
to	O
IL	O
-	O
8	O
,	O
were	O
observed	O
in	O
hypoxic	O
lung	O
tissue	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
hypoxia	O
constitutes	O
a	O
stimulus	O
for	O
leukocyte	O
chemotaxis	O
and	O
tissue	O
leukostasis	O
.	O

Function	B-Regulation
of	O
NF	O
-	O
kappa	O
B/Rel	O
binding	O
sites	O
in	O
the	O
major	O
histocompatibility	O
complex	O
class	O
II	O
invariant	O
chain	O
promoter	O
is	O
dependent	B-Regulation
on	O
cell	O
-	O
specific	O
binding	O
of	O
different	O
NF	O
-	O
kappa	O
B/Rel	O
subunits	O
.	O

The	O
promoter	O
of	O
the	O
human	O
major	O
histocompatibility	O
complex	O
class	O
II	O
-	O
associated	O
invariant	O
-	O
chain	O
gene	O
(	O
Ii	O
)	O
contains	O
two	O
NF	O
-	O
kappa	O
B/Rel	O
binding	O
sites	O
located	O
at	O
-	O
109	O
to	O
-	O
118	O
(	O
Ii	O
kappa	O
B	O
-	O
1	O
)	O
and	O
-	O
163	O
to	O
-	O
172	O
(	O
Ii	O
kappa	O
B	O
-	O
2	O
)	O
from	O
the	O
transcription	O
start	O
site	O
.	O

We	O
report	O
here	O
that	O
the	O
differential	O
function	O
of	O
each	O
of	O
these	O
NF	O
-	O
kappa	O
B/Rel	O
sites	O
in	O
several	O
distinct	O
cell	O
types	O
depends	O
on	O
cell	O
-	O
specific	O
binding	O
of	O
NF	O
-	O
kappa	O
B/Rel	O
transcription	O
factors	O
.	O

Ii	O
kappa	O
B	O
-	O
1	O
is	O
a	O
positive	O
regulatory	O
element	O
in	O
B	O
-	O
cell	O
lines	O
and	O
in	O
the	O
Ii	O
-	O
expressing	O
T	O
-	O
cell	O
line	O
,	O
H9	O
,	O
but	O
acts	O
as	O
a	O
negative	O
regulatory	O
element	O
in	O
myelomonocytic	O
and	O
glia	O
cell	O
lines	O
.	O

In	O
vivo	O
protein	O
-	O
DNA	O
contacts	O
are	O
detectable	O
at	O
Ii	O
kappa	O
B	O
-	O
1	O
in	O
cell	O
lines	O
in	O
which	O
this	O
site	O
is	O
functional	O
as	O
either	O
a	O
positive	O
or	O
negative	O
regulator	O
.	O

Electrophoretic	O
mobility	O
supershift	O
assays	O
determine	O
that	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B/Rel	O
family	O
of	O
transcription	O
factors	O
can	O
bind	O
to	O
this	O
site	O
in	O
vitro	O
and	O
that	O
DNA	O
-	O
binding	B-Binding
complexes	I-Binding
that	O
contain	O
p50	O
,	O
p52	O
,	O
p65	O
,	O
and	O
cRel	O
correlate	O
with	O
positive	O
regulation	O
whereas	O
the	O
presence	B-Binding
of	O
p50	O
correlates	O
with	O
negative	O
regulation	O
.	O

Ii	O
kappa	O
B	O
-	O
2	O
is	O
a	O
site	O
of	O
positive	O
regulation	O
in	O
B	O
-	O
cell	O
lines	O
and	O
a	O
site	O
of	O
negative	O
regulation	O
in	O
H9	O
T	O
cells	O
,	O
myelomonocytic	O
,	O
and	O
glial	O
cell	O
lines	O
.	O

In	O
vivo	O
occupancy	O
of	O
this	O
site	O
is	O
observed	O
only	O
in	O
the	O
H9	O
T	O
-	O
cell	O
line	O
.	O

Again	O
,	O
in	O
vitro	O
supershift	O
studies	O
indicate	O
that	O
the	O
presence	B-Binding
of	O
p50	O
,	O
p52	O
,	O
p65	O
,	O
and	O
cRel	O
correlates	O
with	O
positive	O
function	O
whereas	O
the	O
presence	B-Binding
of	O
only	O
p50	O
and	O
p52	O
correlates	O
with	O
negative	O
function	O
.	O

This	O
differential	O
binding	O
of	O
specific	O
NF	O
-	O
kappa	O
B/Rel	O
subunits	O
is	O
likely	O
to	O
mediate	O
the	O
disparate	O
functions	O
of	O
these	O
two	O
NF	O
-	O
kappa	O
B/Rel	O
binding	O
sites	O
.	O

Positive	B-Positive_regulation
regulators	I-Positive_regulation
of	O
the	O
lineage	O
-	O
specific	O
transcription	O
factor	O
GATA	O
-	O
1	O
in	O
differentiating	O
erythroid	O
cells	O
.	O

The	O
zinc	O
finger	O
transcription	O
factor	O
GATA	O
-	O
1	O
is	O
a	O
major	O
regulator	O
of	O
gene	O
expression	O
in	O
erythroid	O
,	O
megakaryocyte	O
,	O
and	O
mast	O
cell	O
lineages	O
.	O

GATA	O
-	O
1	O
binds	B-Binding
to	O
WGATAR	O
consensus	O
motifs	O
in	O
the	O
regulatory	O
regions	O
of	O
virtually	O
all	O
erythroid	O
cell	O
-	O
specific	O
genes	O
.	O

Analyses	O
with	O
cultured	O
cells	O
and	O
cell	O
-	O
free	O
systems	O
have	O
provided	O
strong	O
evidence	O
that	O
GATA	O
-	O
1	O
is	O
involved	O
in	O
control	O
of	O
globin	O
gene	O
expression	O
during	O
erythroid	O
differentiation	O
.	O

Targeted	O
mutagenesis	O
of	O
the	O
GATA	O
-	O
1	O
gene	O
in	O
embryonic	O
stem	O
cells	O
has	O
demonstrated	O
its	O
requirement	O
in	O
normal	O
erythroid	O
development	O
.	O

Efficient	O
rescue	O
of	O
the	O
defect	O
requires	O
an	O
intact	O
GATA	O
element	O
in	O
the	O
distal	O
promoter	O
,	O
suggesting	O
autoregulatory	B-Regulation
control	I-Regulation
of	O
GATA	O
-	O
1	O
transcription	B-Transcription
.	O

To	O
examine	O
whether	O
GATA	O
-	O
1	O
expression	B-Gene_expression
involves	O
additional	O
regulatory	O
factors	O
or	O
is	O
maintained	B-Positive_regulation
entirely	O
by	O
an	O
autoregulatory	O
loop	O
,	O
we	O
have	O
used	O
a	O
transient	O
heterokaryon	O
system	O
to	O
test	O
the	O
ability	O
of	O
erythroid	O
factors	O
to	O
activate	B-Positive_regulation
the	O
GATA	O
-	O
1	O
gene	O
in	O
nonerythroid	O
nuclei	O
.	O

We	O
show	O
here	O
that	O
proerythroblasts	O
and	O
mature	O
erythroid	O
cells	O
contain	O
a	O
diffusible	O
activity	O
(	O
TAG	O
)	O
capable	O
of	O
transcriptional	B-Positive_regulation
activation	I-Positive_regulation
of	O
GATA	O
-	O
1	O
and	O
that	O
this	O
activity	O
decreases	B-Negative_regulation
during	O
the	O
terminal	O
differentiation	O
of	O
erythroid	O
cells	O
.	O

Nuclei	O
from	O
GATA-1	O
-	O
mutant	O
embryonic	O
stem	O
cells	O
can	O
still	O
be	O
reprogrammed	O
to	O
express	O
their	O
globin	O
genes	O
in	O
erythroid	O
heterokaryons	O
,	O
indicating	O
that	O
de	O
novo	O
induction	B-Positive_regulation
of	O
GATA	O
-	O
1	O
is	O
not	O
required	O
for	O
globin	O
gene	O
activation	O
following	O
cell	O
fusion	O
.	O

Patterns	O
of	O
Pan	O
expression	O
and	O
role	O
of	O
Pan	O
proteins	O
in	O
endocrine	O
cell	O
type	O
-	O
specific	O
complex	O
formation	O
.	O

The	O
Pan	O
gene	O
encodes	O
at	O
least	O
two	O
distinct	O
transcripts	O
,	O
Pan	O
-	O
1	O
and	O
Pan	O
-	O
2	O
(	O
also	O
known	O
as	O
E47	O
and	O
E12	O
,	O
respectively	O
)	O
,	O
by	O
the	O
mechanism	O
of	O
alternative	O
RNA	O
splicing	O
.	O

Northern	O
blot	O
analyses	O
performed	O
on	O
rat	O
and	O
mouse	O
tissues	O
have	O
detected	O
ubiquitously	O
expressed	B-Transcription
Pan	O
transcripts	O
,	O
but	O
the	O
abundance	O
,	O
distribution	O
,	O
and	O
form	O
of	O
Pan	O
proteins	O
have	O
not	O
been	O
clearly	O
defined	O
.	O

Studies	O
of	O
cell	O
lines	O
representing	O
endocrine	O
,	O
fibroblast	O
,	O
and	O
lymphoid	O
lineages	O
using	O
polyclonal	O
antisera	O
to	O
detect	O
E2A	O
proteins	O
have	O
suggested	O
that	O
significant	O
E2A	O
protein	O
expression	B-Gene_expression
is	O
restricted	O
to	O
B	O
-	O
lymphocytes	O
.	O

We	O
have	O
developed	O
a	O
monoclonal	O
antibody	O
,	O
Yae	O
,	O
which	O
is	O
specific	O
for	O
Pan/E2A	O
proteins	O
,	O
and	O
have	O
used	O
the	O
Yae	O
antibody	O
to	O
examine	O
a	O
variety	O
of	O
endocrine	O
and	O
nonendocrine	O
cell	O
lineages	O
for	O
differences	O
in	O
Pan/E2A	O
protein	O
expression	B-Gene_expression
,	O
subcellular	O
localization	O
,	O
and	O
heteromeric	B-Binding
complex	I-Binding
formation	I-Binding
.	O

In	O
contrast	O
to	O
previous	O
results	O
obtained	O
using	O
polyclonal	O
antiseras	O
to	O
detect	O
Pan/E2A	O
proteins	O
,	O
we	O
report	O
comparable	B-Gene_expression
levels	I-Gene_expression
of	O
Pan	O
proteins	O
in	O
GH/PRL	O
-	O
and	O
insulin	O
-	O
producing	B-Gene_expression
,	O
B	O
-	O
and	O
T	O
-	O
lymphocyte	O
cells	O
.	O

IEF	O
-	O
1	O
,	O
a	O
pancreatic	O
beta	O
-	O
cell	O
type	O
-	O
specific	O
complex	O
believed	O
to	O
regulate	B-Regulation
insulin	O
expression	B-Gene_expression
,	O
is	O
demonstrated	O
to	O
consist	O
of	O
at	O
least	O
two	O
distinct	O
species	O
,	O
one	O
of	O
which	O
does	O
not	O
contain	O
Pan	O
molecules	O
.	O

Although	O
it	O
has	O
been	O
postulated	O
that	O
pituitary	O
endocrine	O
cells	O
and	O
pancreatic	O
endocrine	O
beta	O
-	O
cells	O
share	O
identical	O
Pan/E2A	O
complexes	O
,	O
native	O
-	O
Western	O
analyses	O
of	O
pituitary	O
and	O
endocrine	O
beta	O
-	O
cells	O
detect	B-Gene_expression
Pan	O
proteins	O
in	O
distinct	O
cell	O
type	O
-	O
specific	O
complexes	O
.	O

Functional	O
block	O
for	O
1	O
alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
-	O
mediated	O
gene	O
regulation	O
in	O
human	O
B	O
lymphocytes	O
.	O

Elements	O
necessary	O
for	O
the	O
steroid	O
hormone	O
1	O
alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
(	O
1	O
alpha	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
)	O
to	O
induce	O
a	O
biological	O
response	O
include	O
the	O
presence	O
of	O
specific	O
intracellular	O
receptors	O
(	O
vitamin	O
D3	O
receptors	O
(	O
VDR	O
)	O
)	O
and	O
modulation	O
of	O
gene	O
expression	O
via	O
hormone	O
-	O
activated	B-Positive_regulation
receptor	O
binding	O
to	O
regulatory	O
regions	O
of	O
target	O
genes	O
.	O

These	O
parameters	O
were	O
examined	O
in	O
normal	O
and	O
Epstein	O
-	O
Barr	O
virus	O
-	O
immortalized	O
human	O
B	O
cells	O
and	O
compared	O
with	O
1	O
alpha	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
-	O
responsive	O
cells	O
of	O
the	O
T	O
and	O
monocytic	O
lineages	O
.	O

Although	O
resting	O
tonsillar	O
B	O
cells	O
did	O
not	O
express	B-Transcription
VDR	O
mRNA	O
,	O
activation	O
of	O
these	O
cells	O
with	O
interleukin	O
-	O
4	O
induced	B-Positive_regulation
VDR	O
in	O
the	O
absence	O
of	O
exogenously	O
supplemented	O
1	O
alpha	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
.	O

As	O
indicators	O
of	O
hormone	O
-	O
mediated	O
gene	O
regulation	O
we	O
analyzed	O
modulation	B-Regulation
of	O
CD23	O
,	O
a	O
common	O
B	O
cell/monocyte	O
surface	O
antigen	O
,	O
and	O
24	O
-	O
hydroxylase	O
.	O

1	O
alpha	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
inhibited	B-Negative_regulation
CD23	O
expression	B-Gene_expression
in	O
U937	O
cells	O
,	O
yet	O
failed	O
to	O
modulate	B-Regulation
CD23	O
expression	B-Gene_expression
in	O
B	O
cells	O
.	O

Furthermore	O
,	O
1	O
alpha	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
induced	B-Positive_regulation
24	O
-	O
hydroxylase	O
mRNA	O
expression	B-Transcription
and	O
metabolic	O
activity	O
in	O
both	O
U937	O
cells	O
and	O
lectin	O
-	O
activated	O
T	O
cells	O
,	O
yet	O
failed	O
to	O
induce	B-Positive_regulation
24	O
-	O
hydroxylase	O
mRNA	O
or	O
its	O
metabolic	O
activity	O
in	O
B	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
although	O
human	O
B	O
lymphocytes	O
can	O
express	B-Transcription
VDR	O
mRNA	O
and	O
protein	O
,	O
they	O
exhibit	O
a	O
functional	O
block	O
for	O
vitamin	O
D	O
-	O
dependent	O
gene	O
regulation	O
.	O

Effects	B-Regulation
of	O
alpha	O
-	O
lipoic	O
acid	O
and	O
dihydrolipoic	O
acid	O
on	O
expression	B-Gene_expression
of	O
proto	O
-	O
oncogene	O
c	O
-	O
fos	O
.	O

The	O
transcription	O
factor	O
AP	O
-	O
1	O
is	O
an	O
important	O
human	O
mediator	O
of	O
the	O
cellular	O
response	O
to	O
serum	O
,	O
growth	O
factors	O
,	O
and	O
phorbol	O
esters	O
such	O
as	O
12-O-tetradecanoyl-phorbol	O
-	O
13	O
acetate	O
(	O
TPA	O
)	O
.	O

The	O
AP	O
-	O
1	O
complex	O
consists	O
of	O
distinct	O
protein	O
heterodimers	O
encoded	O
by	O
the	O
proto	O
-	O
oncogene	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
mRNA	O
whose	O
gene	B-Transcription
expression	I-Transcription
can	O
be	O
induced	B-Positive_regulation
by	O
TPA	O
,	O
cyclic	O
AMP	O
and	O
growth	O
factors	O
.	O

Recent	O
findings	O
suggest	O
an	O
involvement	B-Regulation
of	O
reactive	O
oxygen	O
species	O
in	O
the	O
pathway	O
of	O
TPA	O
and	O
protein	O
kinase	O
C	O
leading	B-Positive_regulation
to	O
expression	B-Transcription
of	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
mRNA	O
.	O

To	O
investigate	O
the	O
role	B-Regulation
of	O
reactive	O
oxygen	O
species	O
we	O
studied	O
the	O
effects	B-Regulation
of	O
alpha	O
-	O
lipoic	O
acid	O
and	O
dihydrolipoic	O
acid	O
(	O
natural	O
thiol	O
antioxidants	O
)	O
on	O
the	O
expression	B-Transcription
of	O
c	O
-	O
fos	O
mRNA	O
in	O
human	O
Jurkat	O
T	O
cells	O
.	O

When	B-Positive_regulation
cells	O
were	O
preincubated	O
with	O
dihydrolipoic	O
acid	O
(	O
0.2	O
mM	O
)	O
the	O
expression	B-Transcription
of	O
c	O
-	O
fos	O
mRNA	O
was	O
suppressed	B-Negative_regulation
at	O
30	O
min	O
after	O
stimulation	O
of	O
TPA	O
(	O
0.5	O
microM	O
)	O
whereas	O
in	B-Positive_regulation
the	I-Positive_regulation
case	I-Positive_regulation
of	I-Positive_regulation
preincubation	O
of	O
alpha	O
-	O
lipoic	O
acid	O
(	O
0.2	O
microM	O
)	O
,	O
the	O
expression	O
was	O
enhanced	B-Positive_regulation
at	O
30	O
min	O
.	O

These	O
studies	O
support	O
the	O
idea	O
that	O
superoxide	O
anion	O
radical	O
plays	B-Regulation
a	I-Regulation
role	I-Regulation
in	O
the	O
expression	B-Transcription
of	O
c	O
-	O
fos	O
mRNA	O
.	O

Alternative	O
splicing	O
of	O
RNA	O
transcripts	O
encoded	O
by	O
the	O
murine	O
p105	O
NF	O
-	O
kappa	O
B	O
gene	O
generates	B-Gene_expression
I	O
kappa	O
B	O
gamma	O
isoforms	O
with	O
different	O
inhibitory	O
activities	O
.	O

The	O
gene	O
encoding	O
the	O
105	O
-	O
kDa	O
protein	O
(	O
p105	O
)	O
precursor	O
of	O
the	O
p50	O
subunit	O
of	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
also	O
encodes	O
a	O
p70	O
I	O
kappa	O
B	O
protein	O
,	O
I	O
kappa	O
B	O
gamma	O
,	O
which	O
is	O
identical	O
to	O
the	O
C	O
-	O
terminal	O
607	O
amino	O
acids	O
of	O
p105	O
.	O

Here	O
we	O
show	O
that	O
alternative	O
RNA	O
splicing	O
generates	B-Gene_expression
I	O
kappa	O
B	O
gamma	O
isoforms	O
with	O
properties	O
different	O
from	O
those	O
of	O
p70	O
.	O

One	O
63	O
-	O
kDa	O
isoform	O
,	O
termed	O
I	O
kappa	O
B	O
gamma	O
-	O
1	O
,	O
which	O
lacks	O
59	O
amino	O
acids	O
C	O
-	O
terminal	O
to	O
ankyrin	O
repeat	O
7	O
,	O
has	O
a	O
novel	O
35	O
-	O
amino	O
acid	O
C	O
terminus	O
encoded	O
by	O
an	O
alternative	O
reading	O
frame	O
of	O
the	O
p105	O
gene	O
.	O

A	O
55	O
-	O
kDa	O
isoform	O
,	O
I	O
kappa	O
B	O
gamma	O
-	O
2	O
,	O
lacks	O
the	O
190	O
C	O
-	O
terminal	O
amino	O
acids	O
of	O
p70I	O
kappa	O
B	O
gamma	O
.	O

In	O
contrast	O
to	O
p70I	O
kappa	O
B	O
gamma	O
,	O
which	O
is	O
a	O
cytoplasmic	O
protein	O
,	O
I	O
kappa	O
B	O
gamma	O
-	O
1	O
is	O
found	B-Localization
in	O
both	O
the	O
cytoplasm	O
and	O
nucleus	O
,	O
whereas	O
I	O
kappa	O
B	O
gamma	O
-	O
2	O
is	O
predominantly	O
nuclear	O
.	O

The	O
I	O
kappa	O
B	O
gamma	O
isoforms	O
also	O
display	O
differences	O
in	O
specificity	O
and	O
affinity	O
for	O
Rel/NF	O
-	O
kappa	O
B	O
proteins	O
.	O

While	O
p70I	O
kappa	O
B	O
gamma	O
inhibits	O
p50	O
-	O
,	O
p65	O
-	O
,	O
and	O
c-Rel	O
-	O
mediated	O
transactivation	O
and/or	O
DNA	O
binding	O
,	O
both	O
I	O
kappa	O
B	O
gamma	O
-	O
1	O
and	O
I	O
kappa	O
B	O
gamma	O
-	O
2	O
are	O
specific	B-Binding
for	O
p50	O
and	O
have	O
different	O
affinities	O
for	O
this	O
subunit	O
.	O

The	O
absence	O
in	O
I	O
kappa	O
B	O
gamma	O
-	O
1	O
and	O
I	O
kappa	O
B	O
gamma	O
-	O
2	O
of	O
a	O
protein	O
kinase	O
A	O
site	O
whose	O
phosphorylation	O
modulates	O
p70I	O
kappa	O
B	O
gamma	O
inhibitory	O
activity	O
suggests	O
that	O
alternative	O
RNA	O
splicing	O
may	O
be	O
used	O
to	O
generate	B-Positive_regulation
I	O
kappa	O
B	O
gamma	O
isoforms	O
that	O
respond	B-Regulation
differently	O
to	O
intracellular	O
signals	O
.	O

Activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
in	O
human	O
lymphoblastoid	O
cells	O
by	O
low	O
-	O
dose	O
ionizing	O
radiation	O
.	O

Nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
is	O
a	O
pleiotropic	O
transcription	O
factor	O
which	O
is	O
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
several	O
specific	O
genes	O
.	O

Recent	O
reports	O
demonstrated	O
that	O
ionizing	O
radiation	O
in	O
the	O
dose	O
range	O
of	O
2	O
-	O
50	O
Gy	O
results	O
in	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
human	O
KG	O
-	O
1	O
myeloid	O
leukemia	O
cells	O
and	O
human	O
B	O
-	O
lymphocyte	O
precursor	O
cells	O
;	O
the	O
precise	O
mechanism	O
involved	O
and	O
the	O
significance	O
are	O
not	O
yet	O
known	O
.	O

The	O
present	O
report	O
demonstrates	O
that	O
even	O
lower	O
doses	O
of	O
ionizing	O
radiation	O
,	O
0.25	O
-	O
2.0	O
Gy	O
,	O
are	O
capable	O
of	O
inducing	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
EBV	O
-	O
transformed	O
244B	O
human	O
lymphoblastoid	O
cells	O
.	O

These	O
results	O
are	O
in	O
a	O
dose	O
range	O
where	O
the	O
viability	O
of	O
the	O
cells	O
remains	O
very	O
high	O
.	O

After	O
exposure	O
to	O
137Cs	O
gamma	O
rays	O
at	O
a	O
dose	O
rate	O
of	O
1.17	O
Gy/min	O
,	O
a	O
maximum	O
in	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
was	O
seen	O
at	O
8	O
h	O
after	O
a	O
0.5	O
-	O
Gy	O
exposure	O
.	O

Time	O
-	O
course	O
studies	O
revealed	O
a	O
biphasic	O
time	O
-	O
dependent	O
expression	O
after	O
0.5	O
-	O
,	O
1	O
-	O
and	O
2	O
-	O
Gy	O
exposures	O
.	O

However	O
,	O
for	O
each	O
time	O
examined	O
,	O
the	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
was	O
maximum	O
after	O
the	O
0.5	O
-	O
Gy	O
exposure	O
.	O

The	O
expression	B-Gene_expression
of	O
the	O
p50	O
and	O
p65	O
NF	O
-	O
kappa	O
B	O
subunits	O
was	O
also	O
shown	O
to	O
be	O
regulated	B-Regulation
differentially	O
after	O
exposures	O
to	O
1.0	O
and	O
2.0	O
Gy	O
.	O

Some	O
antioxidants	O
inhibit	B-Negative_regulation
,	O
in	O
a	O
co	O
-	O
ordinate	O
fashion	O
,	O
the	O
production	B-Gene_expression
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
,	O
IL	O
-	O
beta	O
,	O
and	O
IL	O
-	O
6	O
by	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Some	O
antioxidants	O
,	O
including	O
butylated	O
hydroxyanisole	O
(	O
BHA	O
)	O
,	O
tetrahydropapaveroline	O
(	O
THP	O
)	O
,	O
nordihydroguiauretic	O
acid	O
,	O
and	O
10	O
,	O
11	O
-	O
dihydroxyaporphine	O
(	O
DHA	O
)	O
,	O
were	O
found	O
to	O
be	O
potent	O
inhibitors	B-Negative_regulation
of	O
the	O
production	B-Gene_expression
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
alpha	O
,	O
IL	O
-	O
1	O
beta	O
,	O
and	O
IL	O
-	O
6	O
by	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
stimulated	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
(	O
IC50s	O
in	O
the	O
low	O
micromolar	O
range	O
)	O
.	O

Inhibition	O
of	O
cytokine	O
production	O
was	O
gene	O
selective	O
and	O
not	O
due	O
to	O
general	O
effects	O
on	O
protein	O
synthesis	O
.	O

Inhibition	O
of	O
cytokine	O
production	O
by	O
PBMC	O
was	O
observed	O
also	O
when	O
other	O
inducers	O
were	O
used	O
(	O
staphylococci	O
,	O
silica	O
,	O
zymosan	O
)	O
.	O

Much	O
higher	O
concentrations	O
of	O
other	O
antioxidants	O
-	O
-	O
including	O
ascorbic	O
acid	O
,	O
trolox	O
,	O
alpha	O
-	O
tocopherol	O
,	O
butylated	O
hydroxytoluene	O
,	O
and	O
the	O
5	O
-	O
lipoxygenase	O
inhibitor	O
zileuton	O
-	O
-	O
did	O
not	O
affect	B-Regulation
the	O
production	B-Gene_expression
of	O
these	O
cytokines	O
.	O

The	O
active	O
compounds	O
did	O
not	O
inhibit	B-Negative_regulation
IL-1	O
-	O
induced	B-Positive_regulation
production	B-Gene_expression
of	O
IL	O
-	O
6	O
in	O
fibroblasts	O
,	O
showing	O
the	O
cell	O
selectivity	O
of	O
the	O
effect	O
.	O

Antioxidant	O
-	O
mediated	O
inhibition	O
of	O
cytokine	O
production	O
was	O
correlated	O
with	O
low	O
levels	O
of	O
the	O
corresponding	O
messenger	O
RNAs	O
.	O

Nuclear	O
run	O
-	O
on	O
experiments	O
showed	O
that	O
THP	O
inhibited	B-Negative_regulation
transcription	B-Transcription
of	O
the	O
IL	O
-	O
1	O
beta	O
gene	O
.	O

THP	O
decreased	O
the	O
concentration	O
of	O
the	O
transcription	O
factors	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
detected	O
in	O
nuclear	O
extracts	O
of	O
PBMC	O
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
LPS	O
.	O

THP	O
and	O
DHA	O
markedly	O
decreased	B-Negative_regulation
the	O
levels	B-Gene_expression
of	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
1	O
beta	O
in	O
the	O
circulation	O
of	O
mice	O
following	O
LPS	O
injection	O
.	O

Thus	O
antioxidants	O
vary	O
widely	O
in	O
potency	O
as	O
inhibitors	O
of	O
the	O
activation	O
of	O
transcription	O
factors	O
and	O
of	O
the	O
transcription	O
of	O
genes	O
for	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

Coordinate	O
inhibition	O
of	O
the	O
transcription	O
of	O
genes	O
for	O
inflammatory	O
cytokines	O
could	O
provide	O
a	O
strategy	O
for	O
therapy	O
of	O
diseases	O
with	O
inflammatory	O
pathogenesis	O
and	O
for	O
septic	O
shock	O
.	O

Calcineurin	O
potentiates	B-Positive_regulation
activation	B-Positive_regulation
of	O
the	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
gene	O
in	O
T	O
cells	O
:	O
involvement	O
of	O
the	O
conserved	O
lymphokine	O
element	O
0	O
.	O

Granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
and	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
are	O
produced	B-Gene_expression
by	B-Positive_regulation
stimulation	I-Positive_regulation
with	I-Positive_regulation
phorbol-12	O
-	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
in	O
human	O
T	O
cell	O
leukemia	O
Jurkat	O
cells	O
.	O

The	O
expression	B-Gene_expression
of	O
GM	O
-	O
CSF	O
and	O
IL	O
-	O
2	O
is	O
inhibited	B-Negative_regulation
by	O
immunosuppressive	O
drugs	O
such	O
as	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
.	O

Earlier	O
studies	O
on	O
the	O
IL	O
-	O
2	O
gene	O
expression	B-Gene_expression
showed	O
that	O
overexpression	O
of	O
calcineurin	O
(	O
CN	O
)	O
,	O
a	O
Ca2+/calmodulin	O
-	O
dependent	O
protein	O
phosphatase	O
,	O
can	O
stimulate	B-Positive_regulation
transcription	B-Transcription
from	O
the	O
IL	O
-	O
2	O
promoter	O
through	O
the	O
NF-AT	O
-	O
binding	O
site	O
.	O

In	O
this	O
study	O
,	O
we	O
obtained	O
evidence	O
that	O
transfection	B-Positive_regulation
of	O
the	O
cDNAs	O
for	O
CN	O
A	O
(	O
catalytic	O
)	O
and	O
CN	O
B	O
(	O
regulatory	O
)	O
subunits	O
also	O
augments	B-Positive_regulation
transcription	B-Transcription
from	O
the	O
GM	O
-	O
CSF	O
promoter	O
and	O
recovers	B-Negative_regulation
the	O
transcription	O
inhibited	B-Negative_regulation
by	O
CsA	O
.	O

The	O
constitutively	O
active	O
type	O
of	O
the	O
CN	O
A	O
subunit	O
,	O
which	O
lacks	O
the	O
auto	O
-	O
inhibitory	O
and	O
calmodulin	O
-	O
binding	O
domains	O
,	O
acts	O
in	O
synergy	O
with	O
PMA	O
to	O
activate	B-Positive_regulation
transcription	B-Transcription
from	O
the	O
GM	O
-	O
CSF	O
promoter	O
.	O

We	O
also	O
found	O
that	O
the	O
active	O
CN	O
partially	O
replaces	O
calcium	O
ionophore	O
in	O
synergy	O
with	O
PMA	O
to	B-Positive_regulation
induce	I-Positive_regulation
expression	B-Gene_expression
of	O
endogenous	O
GM	O
-	O
CSF	O
and	O
IL	O
-	O
2	O
.	O

By	O
multimerizing	O
the	O
regulatory	O
elements	O
of	O
the	O
GM	O
-	O
CSF	O
promoter	O
,	O
we	O
found	O
that	O
one	O
of	O
the	O
target	O
sites	O
for	O
the	O
CN	O
action	O
is	O
the	O
conserved	O
lymphokine	O
element	O
0	O
(	O
CLE0	O
)	O
,	O
located	O
at	O
positions	O
between	O
-	O
54	O
and	O
-	O
40	O
.	O

Mobility	O
shift	O
assays	O
showed	O
that	O
the	O
CLE0	O
sequence	O
has	O
an	O
AP1	O
-	O
binding	O
site	O
and	O
is	O
associated	B-Binding
with	O
an	O
NF-AT	O
-	O
like	O
factor	O
,	O
termed	O
NF	O
-	O
CLE0	O
gamma	O
.	O

NF	O
-	O
CLE0	O
gamma	O
binding	B-Binding
is	O
induced	B-Positive_regulation
by	O
PMA/A23187	O
and	O
is	O
inhibited	B-Negative_regulation
by	O
treatment	O
with	O
CsA	O
.	O

These	O
results	O
suggest	O
that	O
CN	O
is	O
involved	O
in	O
the	O
coordinated	O
induction	B-Positive_regulation
of	O
the	O
GM	O
-	O
CSF	O
and	O
IL	O
-	O
2	O
genes	O
and	O
that	O
the	O
CLE0	O
sequence	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
is	O
a	O
functional	O
analogue	O
of	O
the	O
NF-AT	O
-	O
binding	O
site	O
in	O
the	O
IL	O
-	O
2	O
promoter	O
,	O
which	O
mediates	O
signals	O
downstream	O
of	O
T	O
cell	O
activation	O
.	O

Central	O
nervous	O
system	O
-	O
derived	O
cells	O
express	O
a	O
kappa	O
B	O
-	O
binding	O
activity	O
that	O
enhances	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
in	O
vitro	O
and	O
facilitates	O
TAR	O
-	O
independent	O
transactivation	O
by	O
Tat	O
.	O

The	O
Tat	O
protein	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
is	O
a	O
potent	O
activator	O
of	O
long	O
terminal	O
repeat	O
-	O
directed	O
transcription	O
.	O

While	O
in	O
most	O
cell	O
types	O
,	O
activation	O
requires	O
interaction	B-Binding
of	O
Tat	O
with	O
the	O
unusual	O
transcription	O
element	O
TAR	O
,	O
astrocytic	O
glial	O
cells	O
support	O
TAR	O
-	O
independent	O
transactivation	O
of	O
HIV	O
-	O
1	O
transcription	O
by	O
Tat	O
.	O

This	O
alternative	O
pathway	O
of	O
Tat	O
activation	O
is	O
mediated	O
by	O
the	O
viral	O
enhancer	O
,	O
a	O
kappa	O
B	O
domain	O
capable	O
of	O
binding	O
the	O
prototypical	O
form	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
present	O
in	O
many	O
cell	O
types	O
,	O
including	O
T	O
lymphocytes	O
.	O

Tat	O
transactivation	O
mediated	O
by	O
the	O
kappa	O
B	O
domain	O
is	O
sufficient	O
to	O
allow	O
replication	O
of	O
TAR	O
-	O
deleted	O
mutant	O
HIV	O
-	O
1	O
in	O
astrocytes	O
.	O

The	O
present	O
study	O
demonstrates	O
the	O
existence	O
of	O
kappa	O
B	O
-	O
specific	O
binding	O
factors	O
present	O
in	O
human	O
glial	O
astrocytes	O
that	O
differ	O
from	O
prototypical	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
novel	O
astrocyte	O
-	O
derived	O
kappa	O
B	O
-	O
binding	O
activity	O
is	O
retained	O
on	O
an	O
HIV	O
-	O
1	O
Tat	O
affinity	O
column	O
,	O
while	O
prototypical	O
NF	O
-	O
kappa	O
B	O
from	O
Jurkat	O
T	O
cells	O
is	O
not	O
.	O

In	O
vitro	O
transcription	O
studies	O
demonstrate	O
that	O
astrocyte	O
-	O
derived	O
kappa	O
B	O
-	O
binding	O
factors	O
activate	O
transcription	O
of	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
and	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
the	O
kappa	O
B	O
domain	O
.	O

Moreover	O
,	O
TAR	O
-	O
independent	O
transactivation	O
of	O
HIV	O
-	O
1	O
transcription	O
is	O
reproduced	O
in	O
vitro	O
in	O
an	O
astrocyte	O
factor	O
-	O
dependent	O
manner	O
which	O
correlates	O
with	O
kappa	O
B	O
-	O
binding	O
activity	O
.	O

The	O
importance	O
of	O
the	O
central	O
nervous	O
system	O
-	O
enriched	O
kappa	O
B	O
transcription	O
factor	O
in	O
the	O
regulation	O
of	O
HIV	O
-	O
1	O
expression	O
is	O
discussed	O
.	O

An	O
intricate	O
arrangement	O
of	O
binding	O
sites	O
for	O
the	O
Ets	O
family	O
of	O
transcription	O
factors	O
regulates	B-Regulation
activity	O
of	O
the	O
alpha	O
4	O
integrin	O
gene	O
promoter	O
.	O

alpha	O
4	O
integrins	O
mediate	O
cell	O
-	O
cell	O
and	O
cell	O
-	O
extracellular	O
matrix	O
interactions	O
that	O
are	O
critical	O
for	O
maturation	O
and	O
function	O
of	O
the	O
immune	O
system	O
as	O
well	O
as	O
differentiation	O
of	O
skeletal	O
muscle	O
.	O

Here	O
we	O
examine	O
molecular	O
mechanisms	O
controlling	B-Regulation
the	O
pattern	O
of	O
alpha	O
4	O
expression	B-Gene_expression
.	O

The	O
activity	O
of	O
constructs	O
containing	O
5	O
'	O
deletion	O
mutants	O
of	O
the	O
alpha	O
4	O
gene	O
promoter	O
was	O
compared	O
in	O
transfection	O
assays	O
into	O
cell	O
lines	O
that	O
express	B-Gene_expression
alpha	O
4	O
and	O
cell	O
lines	O
that	O
do	O
not	O
.	O

The	O
sequence	O
between	O
position	O
-	O
42	O
and	O
-	O
76	O
base	O
pairs	O
(	O
bp	O
)	O
was	O
required	B-Positive_regulation
for	O
efficient	O
transcription	B-Transcription
in	O
cells	O
that	O
express	B-Gene_expression
alpha	O
4	O
,	O
but	O
it	O
showed	O
no	O
activity	B-Positive_regulation
in	O
HeLa	O
cells	O
,	O
which	O
do	O
not	O
express	B-Gene_expression
alpha	O
4	O
.	O

Three	O
binding	O
sites	O
for	O
the	O
Ets	O
family	O
of	O
transcription	O
factors	O
are	O
found	O
in	O
this	O
region	O
:	O
two	O
adjacent	O
sites	O
at	O
positions	O
-	O
50	O
and	O
-	O
54	O
bp	O
and	O
a	O
more	O
5	O
'	O
site	O
at	O
position	O
-	O
67	O
bp	O
.	O

Using	O
a	O
series	O
of	O
constructs	O
containing	O
deletions	O
and	O
mutations	O
in	O
this	O
region	O
,	O
we	O
found	O
that	O
the	O
3'	O
-	O
most	O
site	O
alone	O
was	O
sufficient	B-Positive_regulation
for	I-Binding
binding	I-Binding
GA	O
-	O
binding	O
protein	O
alpha	O
(	O
GABP	O
alpha	O
)	O
/GABP	O
beta	O
and	O
for	O
a	O
low	O
level	O
of	O
transcriptional	B-Positive_regulation
activation	I-Positive_regulation
.	O

When	O
all	O
three	O
sites	O
were	O
present	O
,	O
a	O
second	O
complex	O
"	O
a	O
"	O
was	O
detected	O
,	O
which	O
contains	O
an	O
unknown	O
member	O
of	O
the	O
Ets	O
family	O
.	O

Formation	O
of	O
complex	O
a	O
was	O
cell	O
-	O
type	O
specific	O
and	O
correlated	O
with	O
a	O
high	B-Positive_regulation
level	I-Positive_regulation
of	O
transcription	B-Transcription
.	O

Deletion	O
of	O
the	O
5'	O
-	O
most	O
Ets	O
site	O
had	O
no	O
effect	B-Regulation
on	O
binding	B-Binding
to	O
GABP	O
alpha/GABP	O
beta	O
,	O
but	O
it	O
eliminated	O
a	O
.	O

Concomitant	O
with	O
this	O
loss	O
of	O
a	O
,	O
a	O
new	O
Ets-1	O
-	O
containing	O
complex	O
"	O
c	O
"	O
appeared	O
.	O

Complex	O
c	O
substituted	O
efficiently	O
for	O
complex	O
a	O
in	B-Positive_regulation
transcriptional	I-Positive_regulation
activation	I-Positive_regulation
.	O

We	O
conclude	O
that	O
although	O
neither	O
of	O
the	O
two	O
5'	O
-	O
most	O
Ets	O
sites	O
alone	O
binds	O
nuclear	O
protein	O
,	O
they	O
appear	O
to	O
act	O
as	O
modulators	O
which	O
control	O
the	O
pattern	O
of	O
Ets	O
proteins	O
that	O
bind	B-Binding
the	O
alpha	O
4	O
gene	O
promoter	O
.	O

This	O
arrangement	O
of	O
Ets	O
sites	O
,	O
coupled	O
with	O
the	O
tissue	O
-	O
and	O
developmental	O
-	O
specific	O
expression	O
of	O
Ets	O
members	O
,	O
likely	O
play	B-Regulation
a	I-Regulation
key	I-Regulation
role	I-Regulation
in	I-Regulation
defining	I-Regulation
the	O
pattern	B-Gene_expression
of	O
alpha	O
4	O
integrin	O
.	O

Lipopolysaccharide	O
induction	O
of	O
tissue	O
factor	O
gene	O
expression	O
in	O
monocytic	O
cells	O
is	O
mediated	O
by	O
binding	B-Binding
of	O
c	O
-	O
Rel/p65	O
heterodimers	O
to	O
a	O
kappa	O
B	O
-	O
like	O
site	O
.	O

Exposure	O
of	O
monocytic	O
cells	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
activates	O
the	O
NF	O
-	O
kappa	O
B/Rel	O
family	O
of	O
proteins	O
and	O
leads	O
to	O
the	O
rapid	O
induction	B-Positive_regulation
of	O
inflammatory	O
gene	O
products	O
,	O
including	O
tissue	O
factor	O
(	O
TF	O
)	O
.	O

TF	O
is	O
the	O
primary	O
cellular	O
initiator	O
of	O
the	O
coagulation	O
protease	O
cascades	O
.	O

Here	O
we	O
report	O
the	O
characterization	O
of	O
a	O
nuclear	O
complex	O
from	O
human	O
monocytic	O
cells	O
that	O
bound	B-Binding
to	O
a	O
kappa	O
B	O
-	O
like	O
site	O
,	O
5'-CGGAGTTTCC	O
-	O
3	O
'	O
,	O
in	O
the	O
5'	O
-	O
flanking	O
region	O
of	O
the	O
human	O
TF	O
gene	O
.	O

This	O
nuclear	O
complex	O
was	O
activated	O
by	O
LPS	O
with	O
kinetics	O
that	O
preceded	O
induction	B-Positive_regulation
of	O
the	O
TF	O
gene	O
.	O

In	O
vitro	O
binding	O
studies	O
demonstrated	O
that	O
the	O
TF	O
site	O
bound	B-Binding
translated	O
c	O
-	O
Rel	O
and	O
p65	O
homodimers	O
but	O
not	O
p50/p65	O
heterodimers	O
or	O
p50	O
homodimers	O
.	O

Base	O
-	O
pair	O
substitutions	O
in	O
the	O
TF	O
site	O
indicated	O
that	O
the	O
presence	O
of	O
a	O
cytosine	O
at	O
position	O
1	O
precluded	O
binding	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

In	O
fact	O
,	O
under	O
low-ionic	O
-	O
strength	O
conditions	O
,	O
the	O
TF	O
complex	O
did	O
not	O
migrate	B-Binding
with	O
translated	O
p50/p65	O
dimers	O
but	O
instead	O
comigrated	B-Binding
with	O
c	O
-	O
Rel/p65	O
dimers	O
.	O

Antibodies	O
against	O
the	O
NF	O
-	O
kappa	O
B	O
and	O
Rel	O
proteins	O
and	O
UV	O
cross	O
-	O
linking	O
studies	O
revealed	O
the	O
presence	B-Binding
of	O
c	O
-	O
Rel	O
and	O
p65	O
and	O
the	O
absence	B-Binding
of	O
p50	O
in	O
the	O
TF	O
complex	O
and	O
further	O
showed	O
that	O
c	O
-	O
Rel/p65	O
heterodimers	O
selectively	O
bound	B-Binding
to	O
the	O
TF	O
kappa	O
B	O
-	O
like	O
site	O
.	O

Functional	O
studies	O
indicated	O
that	O
the	O
TF	O
site	O
conferred	O
LPS	O
inducibility	O
on	O
a	O
heterologous	O
promoter	O
and	O
was	O
transactivated	O
by	O
c	O
-	O
Rel	O
or	O
p65	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrated	O
that	O
binding	B-Binding
of	O
c	O
-	O
Rel/p65	O
heterodimers	O
to	O
a	O
novel	O
kappa	O
B	O
-	O
like	O
site	O
mediated	B-Positive_regulation
LPS	O
induction	B-Positive_regulation
of	O
TF	O
gene	O
expression	B-Gene_expression
in	O
monocytic	O
cells	O
.	O

Stimulation	O
of	O
HIV	O
replication	O
in	O
mononuclear	O
phagocytes	O
by	O
leukemia	O
inhibitory	O
factor	O
.	O

This	O
study	O
examined	O
the	O
effects	O
of	O
leukemia	O
inhibitory	O
factor	O
(	O
LIF	O
)	O
on	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
replication	O
in	O
mononuclear	O
phagocytes	O
(	O
MNP	O
)	O
.	O

LIF	O
induced	O
a	O
dose	O
-	O
dependent	O
increase	B-Positive_regulation
in	O
p24	O
antigen	O
production	B-Gene_expression
in	O
the	O
chronically	O
infected	O
promonocytic	O
cell	O
line	O
U1	O
.	O

The	O
magnitude	O
and	O
time	O
kinetics	O
of	O
the	O
LIF	O
effects	O
were	O
similar	O
to	O
interleukin	O
1	O
(	O
IL	O
-	O
1	O
)	O
,	O
IL	O
-	O
6	O
,	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
,	O
other	O
cytokines	O
known	O
to	O
induce	O
HIV	O
replication	O
in	O
this	O
cell	O
line	O
.	O

To	O
characterize	O
mechanisms	O
responsible	O
for	O
these	O
LIF	O
effects	O
,	O
levels	O
of	O
HIV	O
mRNA	O
,	O
activation	O
of	O
the	O
DNA	O
binding	O
protein	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kB	O
,	O
signal	O
transduction	O
pathways	O
,	O
and	O
potential	O
interactions	O
with	O
other	O
cytokines	O
were	O
analyzed	O
.	O

LIF	O
increased	O
steady	O
-	O
state	O
levels	O
of	O
HIV	O
mRNA	O
at	O
2.0	O
,	O
4.3	O
,	O
and	O
9.2	O
kB	O
.	O

This	O
was	O
detectable	O
by	O
24	O
h	O
and	O
persisted	O
until	O
72	O
h	O
.	O

The	O
DNA	O
binding	O
protein	O
NF	O
-	O
kB	O
is	O
a	O
central	O
mediator	O
in	O
cytokine	O
activation	O
of	O
HIV	O
transcription	O
.	O

NF	O
-	O
kB	O
levels	O
were	O
higher	O
in	O
unstimulated	O
U1	O
cells	O
as	O
compared	O
to	O
the	O
parent	O
cell	O
line	O
U937	O
.	O

In	O
both	O
cell	O
lines	O
LIF	O
increased	O
NF	O
-	O
kB	O
activity	O
.	O

Induction	O
of	O
NF	O
-	O
kB	O
and	O
HIV	O
replication	O
by	O
cytokines	O
are	O
at	O
least	O
in	O
part	O
dependent	O
on	O
reactive	O
oxygen	O
intermediates	O
.	O

The	O
oxygen	O
radical	O
scavenger	O
N-acetyl-L	O
-	O
cysteine	O
,	O
but	O
not	O
an	O
inhibitor	O
of	O
nitric	O
oxide	O
synthase	O
,	O
inhibited	O
LIF	O
-	O
induced	O
HIV	O
replication	O
.	O

LIF	O
induces	O
the	O
production	O
of	O
other	O
cytokines	O
in	O
monocytes	O
but	O
its	O
effects	O
on	O
HIV	O
replication	O
were	O
not	O
inhibited	O
by	O
antibodies	O
to	O
IL	O
-	O
1	O
,	O
TNF	O
,	O
or	O
IL	O
-	O
6	O
.	O

These	O
results	O
identify	O
LIF	O
as	O
a	O
stimulus	O
of	O
HIV	O
replication	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
Tat	O
upregulates	B-Positive_regulation
interleukin	O
-	O
2	O
secretion	B-Localization
in	O
activated	O
T	O
cells	O
.	O

Dysregulation	O
of	O
cytokines	O
secreted	O
by	O
T	O
cells	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
AIDS	O
.	O

To	O
investigate	O
the	O
effects	B-Regulation
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
Tat	O
on	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
expression	B-Gene_expression
,	O
we	O
used	O
IL	O
-	O
2	O
promoter	O
-	O
chloramphenicol	O
acetyltransferase	O
constructs	O
and	O
IL-2	O
-	O
secreting	B-Localization
Jurkat	O
T	O
cells	O
as	O
a	O
model	O
system	O
.	O

Transient	O
expression	B-Gene_expression
of	O
HIV	O
-	O
1	O
Tat	O
induced	O
a	O
five	O
-	O
to	O
eightfold	O
increase	O
in	O
IL	O
-	O
2	O
promoter	O
activity	O
in	O
Jurkat	O
T	O
cells	O
stimulated	O
with	O
phytohemagglutinin	O
and	O
phorbol	O
myristate	O
acetate	O
.	O

IL	O
-	O
2	O
secretion	B-Localization
was	O
increased	B-Positive_regulation
more	O
than	O
twofold	O
in	O
both	O
Jurkat	O
T	O
cells	O
and	O
primary	O
T	O
cells	O
stimulated	O
by	O
extracellular	O
HIV	O
-	O
1	O
Tat	O
protein	O
.	O

Analysis	O
of	O
mRNA	O
suggested	O
that	O
Tat	O
exerts	O
its	O
effect	B-Regulation
on	O
IL	O
-	O
2	O
primarily	O
at	O
the	O
transcriptional	B-Transcription
level	O
.	O

The	O
NF	O
-	O
kappa	O
B	O
site	O
at	O
positions	O
-	O
206	O
to	O
-	O
195	O
of	O
the	O
IL	O
-	O
2	O
promoter	O
was	O
required	O
but	O
not	O
sufficient	O
for	O
the	O
Tat	O
effect	O
.	O

The	O
Tat	O
-	O
mediated	O
increase	O
in	O
IL	O
-	O
2	O
promoter	O
activity	O
could	O
selectively	O
be	O
blocked	O
by	O
antisense	O
tat	O
or	O
-	O
unlike	O
the	O
analogous	O
effect	O
of	O
human	O
T	O
-	O
cell	O
lymphotropic	O
virus	O
type	O
1	O
Tax	O
-	O
by	O
cyclosporin	O
A	O
.	O

The	O
observed	O
increase	O
in	O
IL	O
-	O
2	O
levels	O
might	O
facilitate	O
virus	O
spread	O
from	O
or	O
to	O
T	O
cells	O
.	O

Furthermore	O
,	O
it	O
might	O
contribute	O
to	O
the	O
hypergammaglobulinemia	O
or	O
,	O
together	O
with	O
other	O
cytokines	O
found	O
to	O
be	O
dysregulated	O
,	O
the	O
T	O
-	O
helper	O
cell	O
dysfunctions	O
observed	O
in	O
AIDS	O
patients	O
.	O

The	O
macrophage	O
transcription	O
factor	O
PU.1	O
directs	B-Positive_regulation
tissue	O
-	O
specific	O
expression	B-Gene_expression
of	O
the	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
receptor	O
.	O

The	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
M	O
-	O
CSF	O
)	O
receptor	O
is	O
expressed	B-Gene_expression
in	O
a	O
tissue	O
-	O
specific	O
fashion	O
from	B-Regulation
two	O
distinct	O
promoters	O
in	O
monocytes/macrophages	O
and	O
the	O
placenta	O
.	O

In	O
order	O
to	O
further	O
understand	O
the	O
transcription	O
factors	O
which	O
play	O
a	O
role	O
in	O
the	O
commitment	O
of	O
multipotential	O
progenitors	O
to	O
the	O
monocyte/macrophage	O
lineage	O
,	O
we	O
have	O
initiated	O
an	O
investigation	O
of	O
the	O
factors	O
which	O
activate	B-Positive_regulation
the	O
M	O
-	O
CSF	O
receptor	O
very	O
early	O
during	O
the	O
monocyte	O
differentiation	O
process	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
human	O
monocytic	O
M	O
-	O
CSF	O
receptor	O
promoter	O
directs	O
reporter	O
gene	O
activity	O
in	O
a	O
tissue	O
-	O
specific	O
fashion	O
.	O

Since	O
one	O
of	O
the	O
few	O
transcription	O
factors	O
which	O
have	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
monocyte	O
genes	O
is	O
the	O
macrophage	O
-	O
and	O
B-cell	O
-	O
specific	O
PU.1	O
transcription	O
factor	O
,	O
we	O
investigated	O
whether	O
PU.1	O
binds	B-Binding
and	O
activates	B-Positive_regulation
the	O
M	O
-	O
CSF	O
receptor	O
promoter	O
.	O

Here	O
we	O
demonstrate	O
that	O
both	O
in	O
vitro	O
-	O
translated	O
PU.1	O
and	O
PU.1	O
from	O
nuclear	O
extracts	O
bind	B-Binding
to	O
a	O
specific	O
site	O
in	O
the	O
M	O
-	O
CSF	O
receptor	O
promoter	O
just	O
upstream	O
from	O
the	O
major	O
transcription	O
initiation	O
site	O
.	O

Mutations	O
in	O
this	O
site	O
which	O
eliminate	B-Negative_regulation
PU.1	O
binding	B-Binding
decrease	B-Negative_regulation
M	O
-	O
CSF	O
receptor	O
promoter	O
activity	O
significantly	O
in	O
macrophage	O
cell	O
lines	O
only	O
.	O

Furthermore	O
,	O
PU.1	O
transactivates	B-Positive_regulation
the	O
M	O
-	O
CSF	O
receptor	O
promoter	O
in	O
nonmacrophage	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
PU.1	O
plays	O
a	O
major	O
role	O
in	O
macrophage	O
gene	O
regulation	O
and	O
development	O
by	O
directing	O
the	O
expression	O
of	O
a	O
receptor	O
for	O
a	O
key	O
macrophage	O
growth	O
factor	O
.	O

Retinoic	O
acid	O
downmodulates	O
erythroid	O
differentiation	O
and	O
GATA1	O
expression	B-Gene_expression
in	O
purified	O
adult	O
-	O
progenitor	O
culture	O
.	O

All	O
-	O
trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
is	O
an	O
important	O
morphogen	O
in	O
vertebrate	O
development	O
,	O
a	O
normal	O
constituent	O
in	O
human	O
adult	O
blood	O
and	O
is	O
also	O
involved	O
in	O
the	O
control	O
of	O
cell	O
growth	O
and	O
differentiation	O
in	O
acute	O
promyelocytic	O
leukemia	O
.	O

We	O
have	O
examined	O
the	O
effects	O
of	O
RA	O
on	O
normal	O
hematopoiesis	O
by	O
using	O
early	O
hematopoietic	O
progenitor	O
cells	O
(	O
HPC	O
)	O
stringently	O
purified	O
from	O
adult	O
peripheral	O
blood	O
.	O

In	O
clonogenetic	O
fetal	O
calf	O
serum	O
-	O
supplemented	O
(	O
FCS+	O
)	O
or	O
-	O
nonsupplemented	O
(	O
FCS	O
-	O
)	O
culture	O
treated	O
with	O
saturating	O
levels	O
of	O
interleukin	O
-	O
3	O
(	O
IL	O
-	O
3	O
)	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
and	O
erythropoietin	O
(	O
Ep	O
)	O
(	O
combined	O
with	O
c	O
-	O
kit	O
ligand	O
in	O
FCS	O
(	O
-	O
)	O
-	O
culture	O
conditions	O
)	O
,	O
RA	O
induces	O
a	O
dramatic	O
dose	O
-	O
dependent	O
shift	O
from	O
erythroid	O
to	O
granulomonocytic	O
colony	O
formation	O
,	O
the	O
latter	O
colonies	O
being	O
essentially	O
represented	O
by	O
granulocytic	O
clones	O
.	O

This	O
shift	O
is	O
apparently	O
not	O
caused	O
by	O
a	O
recruitment	O
phenomenon	O
,	O
because	O
in	O
FCS+	O
culture	O
,	O
the	O
total	O
number	O
of	O
colonies	O
is	O
not	O
significantly	O
modified	O
by	O
RA	O
addition	O
.	O

In	O
FCS	O
-	O
liquid	O
-	O
suspension	O
culture	O
supplemented	O
with	O
saturating	O
Ep	O
level	O
and	O
low	O
-	O
dose	O
IL-3/GM	O
-	O
CSF	O
,	O
adult	O
HPC	O
undergo	O
unilineage	O
erythropoietic	O
differentiation	O
:	O
Here	O
again	O
,	O
treatment	O
with	O
high	O
-	O
dose	O
RA	O
induces	O
a	O
shift	O
from	O
the	O
erythroid	O
to	O
granulocytic	O
differentiation	O
pathway	O
.	O

Studies	O
on	O
RA	O
time	O
-	O
response	O
or	O
pulse	O
treatment	O
in	O
semisolid	O
or	O
liquid	O
culture	O
show	O
that	O
early	O
RA	O
addition	O
is	O
most	O
effective	O
,	O
thus	O
indicating	O
that	O
early	O
but	O
not	O
late	O
HPC	O
are	O
sensitive	O
to	O
its	O
action	O
.	O

We	O
then	O
analyzed	O
the	O
expression	B-Gene_expression
of	O
the	O
master	O
GATA1	O
gene	O
,	O
which	O
encodes	O
a	O
finger	O
transcription	O
factor	O
required	O
for	O
normal	O
erythroid	O
development	O
;	O
addition	O
of	O
RA	O
to	O
HPC	O
stimulated	O
into	O
unilineage	O
erythropoietic	O
differentiation	O
in	O
liquid	O
culture	O
caused	O
a	O
virtually	O
complete	O
inhibition	B-Negative_regulation
of	O
GATA1	O
mRNA	O
induction	B-Positive_regulation
.	O

These	O
results	O
indicate	O
that	O
RA	O
directly	O
inhibits	O
the	O
erythroid	O
differentiation	O
program	O
at	O
the	O
level	O
of	O
early	O
adult	O
HPC	O
,	O
and	O
may	O
lead	O
to	O
a	O
shift	O
from	O
the	O
erythroid	O
to	O
granulocytic	O
differentiation	O
pathway	O
.	O

This	O
phenomenon	O
is	O
correlated	O
with	O
inhibition	B-Negative_regulation
of	O
GATA1	O
induction	B-Positive_regulation
in	O
the	O
early	O
stages	O
of	O
erythropoietic	O
differentiation	O
.	O

Comparative	O
analysis	O
of	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
complex	O
in	O
human	O
T	O
and	O
B	O
lymphocytes	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
is	O
a	O
transcriptional	O
activator	O
that	O
binds	B-Binding
to	O
sequences	O
in	O
the	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
promoter	O
and	O
is	O
thought	O
to	O
be	O
largely	O
responsible	B-Positive_regulation
for	O
the	O
T	O
cell	O
-	O
specific	O
inducibility	B-Positive_regulation
of	O
IL	O
-	O
2	O
expression	B-Gene_expression
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
showed	O
that	O
specific	O
NFAT	O
binding	B-Binding
activity	I-Binding
could	O
also	O
be	O
induced	B-Positive_regulation
in	O
human	O
B	O
cells	O
.	O

The	O
B	O
cell	O
NFAT	O
complex	O
,	O
however	O
,	O
was	O
not	O
functional	O
,	O
since	O
it	O
failed	O
to	O
activate	B-Positive_regulation
transcription	B-Transcription
from	O
an	O
NFAT	O
-	O
driven	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
construct	O
.	O

Competition	O
with	O
an	O
AP	O
-	O
1	O
motif	O
or	O
with	O
anti	O
-	O
Jun	O
and	O
anti	O
-	O
Fos	O
antibodies	O
abolished	O
binding	O
to	O
the	O
NFAT	O
motif	O
in	O
both	O
T	O
and	O
B	O
cells	O
,	O
indicating	O
that	O
Jun	O
and	O
Fos	O
are	O
critical	O
for	O
NFAT	O
complex	O
formation	O
in	O
both	O
cell	O
types	O
.	O

Purified	O
recombinant	O
Jun	O
and	O
Fos	O
proteins	O
failed	O
to	O
bind	O
directly	O
to	O
the	O
NFAT	O
motif	O
.	O

However	O
,	O
when	O
combined	O
with	O
unstimulated	O
B	O
or	O
T	O
cell	O
extracts	O
,	O
full	O
-	O
length	O
,	O
but	O
not	O
truncated	O
,	O
Jun/Fos	O
heterodimers	O
were	O
able	O
to	O
form	O
an	O
NFAT	O
complex	O
,	O
indicating	O
the	O
presence	O
of	O
a	O
constitutively	O
expressed	O
nuclear	O
factor	O
(	O
s	O
)	O
in	O
B	O
and	O
T	O
cells	O
necessary	O
for	O
the	O
formation	O
of	O
the	O
NFAT	O
complex	O
in	O
both	O
cell	O
types	O
.	O

An	O
NFAT	O
oligonucleotide	O
carrying	O
mutations	O
in	O
the	O
5	O
'	O
purine	O
-	O
rich	O
part	O
of	O
the	O
NFAT	O
sequence	O
failed	O
to	O
form	O
a	O
complex	O
and	O
to	O
compete	O
with	O
the	O
wild	O
type	O
motif	O
for	O
NFAT	O
complex	O
formation	O
in	O
both	O
T	O
and	O
B	O
cells	O
.	O

We	O
therefore	O
propose	O
a	O
model	O
whereby	O
a	O
core	O
NFAT	O
complex	O
consisting	O
of	O
Jun	O
,	O
Fos	O
,	O
and	O
a	O
constitutive	O
nuclear	O
factor	O
is	O
formed	O
in	O
both	O
T	O
and	O
B	O
cells	O
,	O
but	O
an	O
additional	O
factor	O
and/or	O
post	O
-	O
translational	O
modification	O
of	O
a	O
factor	O
,	O
missing	O
in	O
B	O
cells	O
,	O
might	O
be	O
required	O
for	O
transactivation	O
by	O
NFAT	O
.	O

Differential	O
autoregulation	B-Regulation
of	O
glucocorticoid	O
receptor	O
expression	B-Gene_expression
in	O
human	O
T	O
-	O
and	O
B	O
-	O
cell	O
lines	O
.	O

Regulation	B-Regulation
of	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
expression	B-Gene_expression
by	O
its	O
cognate	O
ligand	O
was	O
examined	O
in	O
the	O
glucocorticoid	O
-	O
sensitive	O
human	O
leukemic	O
T	O
-	O
cell	O
line	O
6TG1.1	O
and	O
in	O
the	O
human	O
B	O
-	O
cell	O
line	O
IM	O
-	O
9	O
.	O

In	O
contrast	O
to	O
the	O
decrease	B-Negative_regulation
in	O
GR	O
mRNA	O
seen	O
in	O
IM	O
-	O
9	O
cells	O
after	O
treatment	O
with	O
1	O
microM	O
dexamethasone	O
for	O
16	O
-	O
18	O
h	O
,	O
treatment	O
of	O
6TG1.1	O
cells	O
resulted	O
in	O
an	O
8	O
-	O
fold	O
increase	B-Positive_regulation
in	O
GR	O
mRNA	O
,	O
as	O
determined	O
by	O
Northern	O
blot	O
and	O
RNase	O
protection	O
analysis	O
,	O
with	O
a	O
corresponding	O
3	O
-	O
to	O
4	O
-	O
fold	O
increase	B-Positive_regulation
in	O
GR	O
protein	O
.	O

Half	O
-	O
maximal	O
induction	B-Transcription
of	O
GR	O
mRNA	O
and	O
protein	O
in	O
6TG1.1	O
cells	O
was	O
observed	O
between	O
10	O
-	O
100	O
nM	O
dexamethasone	O
,	O
and	O
inclusion	O
of	O
1	O
microM	O
RU	O
38486	O
completely	O
blocked	B-Negative_regulation
the	O
effects	O
of	O
100	O
nM	O
dexamethasone	O
,	O
demonstrating	O
that	O
positive	B-Positive_regulation
autoregulation	I-Positive_regulation
of	O
GR	O
expression	B-Gene_expression
in	O
6TG1.1	O
cells	O
is	O
a	O
receptor	O
-	O
mediated	O
response	O
.	O

Positive	B-Regulation
autoregulation	I-Regulation
of	O
GR	O
expression	B-Gene_expression
was	O
also	O
observed	O
in	O
glucocorticoid	O
-	O
resistant	O
CEM	O
-	O
C1	O
cells	O
,	O
which	O
contain	O
functional	O
GR	O
,	O
but	O
whose	O
growth	O
is	O
unaffected	O
by	O
glucocorticoids	O
.	O

Thus	O
,	O
positive	O
autoregulation	O
is	O
neither	O
a	O
consequence	B-Positive_regulation
nor	O
the	O
sole	O
cause	O
of	O
growth	O
arrest	O
.	O

The	O
degree	O
of	O
negative	B-Negative_regulation
autoregulation	I-Negative_regulation
in	O
IM	O
-	O
9	O
cells	O
and	O
positive	B-Positive_regulation
autoregulation	I-Positive_regulation
in	O
6TG1.1	O
cells	O
was	O
unaffected	B-Regulation
by	O
inhibition	O
of	O
protein	O
synthesis	O
with	O
cycloheximide	O
.	O

Measurement	O
of	O
GR	O
mRNA	O
turnover	O
in	O
6TG1.1	O
cells	O
treated	O
with	O
actinomycin	O
-	O
D	O
revealed	O
a	O
half	O
-	O
life	O
of	O
2.5	O
h	O
,	O
which	O
was	O
unaffected	B-Regulation
by	O
dexamethasone	O
treatment	O
.	O

A	O
similar	O
half	O
-	O
life	O
was	O
determined	O
in	O
IM	O
-	O
9	O
cells	O
and	O
was	O
also	O
unaffected	B-Regulation
by	O
steroid	O
treatment	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
interpretation	O
that	O
glucocorticoid	O
-	O
mediated	O
autoregulation	B-Regulation
of	O
GR	O
expression	O
is	O
a	O
tissue	O
-	O
specific	O
primary	O
transcriptional	B-Transcription
response	O
.	O

Occurrence	O
of	O
a	O
silencer	O
of	O
the	O
interleukin	O
-	O
2	O
gene	O
in	O
naive	O
but	O
not	O
in	O
memory	O
resting	O
T	O
helper	O
lymphocytes	O
.	O

In	O
the	O
immune	O
system	O
the	O
first	O
activation	O
of	O
a	O
naive	O
T	O
cell	O
by	O
antigen	O
is	O
a	O
key	O
step	O
in	O
the	O
shaping	O
of	O
the	O
peripheral	O
T	O
cell	O
specificity	O
repertoire	O
and	O
maintenance	O
of	O
self	O
-	O
tolerance	O
.	O

In	O
the	O
present	O
study	O
,	O
analysis	O
of	O
the	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
gene	O
activation	B-Positive_regulation
shows	O
that	O
naive	O
human	O
helper	O
T	O
cells	O
(	O
cord	O
blood	O
CD4+	O
T	O
cells	O
,	O
adult	O
CD4+CD45RO	O
-	O
T	O
cells	O
)	O
regulate	B-Regulation
IL	O
-	O
2	O
transcription	B-Transcription
by	O
a	O
mechanism	O
involving	O
both	O
a	O
silencer	O
and	O
an	O
activator	O
acting	B-Regulation
on	O
the	O
purine	O
-	O
rich	O
IL	O
-	O
2	O
promoter	O
elements	O
(	O
NF	O
-	O
AT	O
binding	O
sites	O
)	O
.	O

By	O
contrast	O
,	O
memory	O
cells	O
,	O
either	O
in	O
vitro	O
activated	O
helper	O
T	O
cells	O
reverting	O
to	O
a	O
resting	O
state	O
,	O
or	O
CD4+	O
T	O
(	O
memory	O
)	O
clones	O
,	O
or	O
CD4+CD45RO+	O
T	O
cells	O
isolated	O
ex	O
vivo	O
,	O
no	O
longer	O
have	O
a	O
silencer	O
.	O

Their	O
IL	O
-	O
2	O
transcription	B-Transcription
seems	O
to	O
be	O
controlled	B-Regulation
solely	O
by	O
the	O
transition	O
from	O
inactive	O
to	O
active	O
functional	O
state	O
of	O
a	O
positive	O
transcription	O
factor	O
binding	B-Binding
to	O
these	O
promoter	O
elements	O
as	O
well	O
as	O
its	O
cytoplasmic	O
or	O
nuclear	O
location	O
:	O
in	O
resting	O
memory	O
T	O
cells	O
the	O
activator	O
is	O
located	O
in	O
the	O
cytoplasm	O
and	O
is	O
inactive	O
,	O
whereas	O
in	O
stimulated	O
cells	O
it	O
is	O
functional	B-Positive_regulation
in	I-Positive_regulation
promoting	I-Positive_regulation
transcription	O
and	O
now	O
resides	O
in	O
the	O
nucleus	O
.	O

Thus	O
,	O
the	O
regulation	O
of	O
the	O
gene	O
coding	O
for	O
the	O
main	O
T	O
cell	O
growth	O
factor	O
changes	O
irreversibly	O
after	O
the	O
first	O
encounter	O
of	O
T	O
cells	O
with	O
antigen	O
.	O

It	O
is	O
most	O
likely	O
that	O
the	O
presence	O
of	O
a	O
silencer	O
contributes	O
to	O
the	O
more	O
stringent	O
activation	O
requirements	O
of	O
naive	O
CD4+	O
T	O
cells	O
.	O

Stimulation	B-Negative_regulation
of	O
interleukin	O
-	O
1	O
alpha	O
and	O
interleukin	O
-	O
1	O
beta	O
production	B-Gene_expression
in	O
human	O
monocytes	O
by	O
protein	O
phosphatase	O
1	O
and	O
2A	O
inhibitors	B-Negative_regulation
.	O

Protein	O
phosphatases	O
1	O
and	O
2A	O
are	O
important	O
in	O
regulating	O
cellular	O
functions	O
by	O
controlling	O
the	O
phosphorylation	O
state	O
of	O
their	O
substrates	O
.	O

In	O
human	O
monocytes	O
,	O
the	O
inhibitors	B-Negative_regulation
of	O
these	O
phosphatases	O
,	O
okadaic	O
acid	O
and	O
calyculin	O
A	O
,	O
were	O
found	O
to	O
increase	B-Positive_regulation
the	O
mRNA	B-Positive_regulation
accumulation	I-Positive_regulation
and	O
cytokine	B-Gene_expression
production	I-Gene_expression
of	O
interleukin	O
-	O
1	O
beta	O
and	O
interleukin	O
-	O
1	O
alpha	O
.	O

The	O
increased	O
mRNA	O
accumulation	O
was	O
found	O
to	O
be	O
primarily	O
because	B-Positive_regulation
of	I-Positive_regulation
the	O
increase	O
in	O
the	O
transcription	O
rate	O
of	O
the	O
interleukin	O
-	O
1	O
genes	O
.	O

Stimulation	O
of	O
interleukin	O
-	O
1	O
gene	O
transcription	O
may	O
be	O
caused	O
by	O
the	O
stimulation	B-Positive_regulation
of	O
transcription	O
factor	O
activities	O
,	O
including	O
those	O
of	O
AP	O
-	O
1	O
,	O
by	O
these	O
protein	O
phosphatase	O
inhibitors	O
.	O

Okadaic	O
acid	O
increased	B-Positive_regulation
the	O
synthesis	O
of	O
the	O
interleukin	O
-	O
1	O
beta	O
precursor	O
and	O
mature	O
forms	O
and	O
their	O
secretion	B-Localization
.	O

This	O
increased	O
processing	O
and	O
secretion	O
correlated	O
with	O
the	O
stimulation	B-Positive_regulation
of	O
IL	O
-	O
1	O
beta	O
convertase	O
mRNA	O
accumulation	B-Positive_regulation
.	O

The	O
stimulation	B-Positive_regulation
of	O
interleukin	O
-	O
1	O
alpha	O
production	B-Gene_expression
by	O
okadaic	O
acid	O
was	O
more	O
modest	O
than	O
that	O
of	O
interleukin	O
-	O
1	O
beta	O
.	O

However	O
,	O
the	O
phosphorylation	B-Phosphorylation
of	O
the	O
precursor	O
interleukin	O
-	O
1	O
alpha	O
cytokine	O
was	O
increased	B-Positive_regulation
.	O

These	O
results	O
show	O
that	O
protein	O
phosphatase	O
1	O
and	O
2A	O
inhibitors	O
exert	O
multiple	O
effects	O
on	O
cytokine	O
production	O
in	O
human	O
monocytes	O
and	O
suggest	O
that	O
these	O
two	O
phosphatases	O
play	O
important	O
roles	O
in	O
regulating	O
interleukin	O
-	O
1	O
production	O
.	O

Human	O
CD3	O
-	O
CD16+	O
natural	O
killer	O
cells	O
express	B-Transcription
the	O
hGATA	O
-	O
3	O
T	O
cell	O
transcription	O
factor	O
and	O
an	O
unrearranged	O
2.3	O
-	O
kb	O
TcR	O
delta	O
transcript	O
.	O

In	O
this	O
study	O
we	O
analyzed	O
the	O
T	O
cell	O
receptor	O
(	O
TcR	O
)	O
delta	O
transcripts	O
expressed	B-Transcription
by	O
CD3	O
-	O
CD16+	O
cells	O
and	O
we	O
investigated	O
whether	O
these	O
cells	O
expressed	B-Gene_expression
the	O
hGATA	O
-	O
3	O
T	O
cell	O
transcription	O
factor	O
and	O
the	O
recombination	O
-	O
activating	O
gene	O
(	O
RAG	O
)	O
-	O
1	O
.	O

Multiple	O
TcR	O
delta	O
transcripts	O
deriving	B-Transcription
from	O
an	O
unrearranged	O
TcR	O
delta	O
gene	O
were	O
detected	O
in	O
both	O
polyclonal	O
and	O
clonal	O
CD3	O
-	O
CD16+	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
lines	O
.	O

Two	O
unrearranged	O
TcR	O
delta	O
transcripts	O
had	O
a	O
size	O
similar	O
to	O
that	O
of	O
the	O
functional	O
TcR	O
delta	O
mRNA	O
(	O
2.3	O
and	O
1.3	O
kb	O
)	O
found	B-Transcription
in	O
TcR	O
gamma/delta+	O
T	O
lymphocytes	O
.	O

Sequence	O
analysis	O
of	O
nine	O
different	O
2.3	O
-	O
kb	O
cDNA	O
clones	O
obtained	O
from	O
NK	O
-	O
derived	O
polyA+	O
RNA	O
confirmed	O
that	O
they	O
corresponded	O
to	O
an	O
unrearranged	O
TcR	O
delta	O
gene	O
.	O

These	O
cDNA	O
were	O
2343	O
bp	O
long	O
and	O
their	O
transcription	O
initiation	O
site	O
was	O
located	O
814	O
bp	O
upstream	O
from	O
the	O
J	O
delta	O
1	O
segment	O
.	O

The	O
sequence	O
located	O
upstream	O
of	O
the	O
J	O
delta	O
1	O
segment	O
corresponded	O
to	O
the	O
previously	O
reported	O
germ	O
-	O
line	O
sequence	O
.	O

The	O
J	O
delta	O
1	O
segment	O
was	O
correctly	O
spliced	O
to	O
C	O
delta	O
;	O
in	O
addition	O
the	O
four	O
C	O
delta	O
exons	O
were	O
found	O
to	O
be	O
already	O
assembled	O
.	O

Two	O
polyadenylation	O
sites	O
were	O
present	O
in	O
the	O
fourth	O
C	O
delta	O
exon	O
.	O

However	O
,	O
only	O
that	O
located	O
at	O
the	O
3	O
'	O
end	O
appeared	O
to	O
be	O
utilized	O
in	O
the	O
2.3	O
-	O
kb	O
cDNA	O
.	O

The	O
expression	B-Gene_expression
of	O
hGATA	O
-	O
3	O
,	O
a	O
T	O
cell	O
-	O
specific	O
factor	O
known	O
to	O
be	O
involved	B-Regulation
in	I-Regulation
the	I-Regulation
regulation	I-Regulation
of	O
the	O
transcription	B-Transcription
of	O
TcR	O
delta	O
locus	O
,	O
was	O
analyzed	O
by	O
Northern	O
blot	O
,	O
in	O
cultured	O
NK	O
cell	O
population	O
and	O
clones	O
(	O
but	O
not	O
in	O
freshly	O
derived	O
cell	O
populations	O
)	O
.	O

All	O
NK	O
clones	O
and	O
cell	O
lines	O
studied	O
were	O
found	O
to	O
express	B-Transcription
hGATA-3	O
-	O
specific	O
mRNA	O
,	O
suggesting	O
that	O
hGATA	O
-	O
3	O
may	O
be	O
involved	B-Regulation
in	I-Regulation
the	I-Regulation
regulation	I-Regulation
of	O
the	O
unrearranged	O
TcR	O
delta	O
gene	O
expression	B-Gene_expression
in	O
NK	O
cells	O
.	O

Finally	O
,	O
no	O
transcription	B-Transcription
of	O
the	O
RAG	O
-	O
1	O
gene	O
could	O
be	O
detected	O
in	O
all	O
NK	O
cell	O
lines	O
or	O
clones	O
analyzed	O
.	O

Involvement	O
of	O
Alu	O
sequences	O
in	O
the	O
cell	O
-	O
specific	O
regulation	O
of	O
transcription	O
of	O
the	O
gamma	O
chain	O
of	O
Fc	O
and	O
T	O
cell	O
receptors	O
.	O

The	O
Fc	O
epsilon	O
RI	O
-	O
gamma	O
chains	O
are	O
expressed	B-Gene_expression
in	O
a	O
variety	O
of	O
hematopoietic	O
cells	O
where	O
they	O
play	O
a	O
critical	O
role	O
in	O
signal	O
transduction	O
.	O

They	O
are	O
part	O
of	O
the	O
high	O
affinity	O
IgE	O
receptor	O
in	O
mast	O
cells	O
,	O
basophils	O
,	O
Langerhans	O
cells	O
,	O
and	O
possibly	O
other	O
cells	O
;	O
a	O
component	O
of	O
the	O
low	O
affinity	O
receptor	O
for	O
IgG	O
(	O
Fc	O
gamma	O
RIIIA	O
or	O
CD16	O
)	O
in	O
natural	O
killer	O
cells	O
and	O
macrophages	O
;	O
and	O
part	O
of	O
the	O
T	O
cell	O
antigen	O
receptor	O
in	O
subsets	O
of	O
T	O
cells	O
.	O

Here	O
we	O
have	O
investigated	O
the	O
transcriptional	O
regulation	O
of	O
the	O
gamma	O
chain	O
gene	O
by	O
analyzing	O
the	O
2.5	O
-	O
kilobase	O
sequence	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
.	O

This	O
sequence	O
contains	O
a	O
promoter	O
specific	O
to	O
cells	O
of	O
hematopoietic	O
lineage	O
.	O

However	O
,	O
the	O
tissue	O
specificity	O
of	O
this	O
promoter	O
is	O
only	O
partial	O
because	O
it	O
is	O
active	O
in	O
all	O
of	O
the	O
hematopoietic	O
cells	O
tested	O
here	O
,	O
regardless	O
of	O
whether	O
they	O
constitutively	O
express	B-Transcription
Fc	O
epsilon	O
RI	O
-	O
gamma	O
chain	O
transcripts	O
.	O

We	O
have	O
identified	O
two	O
adjacent	O
cis	O
-	O
acting	O
regulatory	O
elements	O
,	O
both	O
of	O
which	O
are	O
part	O
of	O
an	O
Alu	O
repeat	O
.	O

The	O
first	O
(	O
-445/	O
-	O
366	O
)	O
is	O
a	O
positive	O
element	O
active	O
in	O
both	O
basophils	O
and	O
T	O
cells	O
.	O

The	O
second	O
(	O
-365/	O
-	O
264	O
)	O
binds	O
to	O
nuclear	O
factors	O
,	O
which	O
appear	O
to	O
be	O
different	O
in	O
basophils	O
and	O
T	O
cells	O
,	O
and	O
acts	O
as	O
a	O
negative	O
element	O
in	O
basophils	O
and	O
as	O
a	O
positive	O
one	O
in	O
T	O
cells	O
.	O

Thus	O
,	O
this	O
Alu	O
repeat	O
(	O
90	O
%	O
identical	O
to	O
Alu	O
consensus	O
sequences	O
)	O
has	O
evolved	O
to	O
become	O
both	O
a	O
positive	O
and	O
negative	O
regulator	O
.	O

Interleukin	O
-	O
3	O
expression	B-Gene_expression
by	O
activated	O
T	O
cells	O
involves	O
an	O
inducible	O
,	O
T-cell	O
-	O
specific	O
factor	O
and	O
an	O
octamer	O
binding	O
protein	O
.	O

Interleukin	O
-	O
3	O
(	O
IL	O
-	O
3	O
)	O
is	O
exclusively	O
expressed	B-Gene_expression
by	O
activated	O
T	O
and	O
natural	O
killer	O
cells	O
,	O
a	O
function	O
that	O
is	O
tightly	O
controlled	B-Regulation
both	O
in	O
a	O
lineage	O
-	O
specific	O
and	O
in	O
a	O
stimulation	O
-	O
dependent	O
manner	O
.	O

We	O
have	O
investigated	O
the	O
protein	O
binding	O
characteristics	O
and	O
functional	O
importance	O
of	O
the	O
ACT-1	O
-	O
activating	O
region	O
of	O
the	O
IL	O
-	O
3	O
promoter	O
.	O

This	O
region	O
binds	B-Binding
an	O
inducible	O
,	O
T-cell	O
-	O
specific	O
factor	O
over	O
its	O
5	O
'	O
end	O
,	O
a	O
site	O
that	O
is	O
necessary	B-Positive_regulation
for	O
the	O
expression	B-Gene_expression
of	O
IL	O
-	O
3	O
in	O
the	O
absence	O
of	O
other	O
upstream	O
elements	O
.	O

Over	O
its	O
3	O
'	O
end	O
,	O
it	O
binds	B-Binding
a	O
factor	O
that	O
is	O
ubiquitously	O
and	O
constitutively	O
expressed	O
.	O

This	O
factor	O
is	O
Oct	O
-	O
1	O
or	O
an	O
immunologically	O
related	O
octamer	O
-	O
binding	O
protein	O
,	O
and	O
it	O
plays	O
a	O
role	O
in	O
coordinating	O
the	O
activity	O
of	O
several	O
regulatory	O
elements	O
.	O

These	O
characteristics	O
make	O
the	O
ACT	O
-	O
1	O
site	O
analogous	O
to	O
the	O
activating	B-Positive_regulation
ARRE	O
-	O
1	O
site	O
in	O
the	O
IL	O
-	O
2	O
promoter	O
.	O

Furthermore	O
,	O
and	O
despite	O
a	O
lack	O
of	O
sequence	O
homology	O
,	O
the	O
promoters	O
of	O
IL	O
-	O
3	O
and	O
IL	O
-	O
2	O
share	O
an	O
organizational	O
pattern	O
of	O
regulatory	O
elements	O
that	O
is	O
likely	O
to	O
be	O
important	B-Positive_regulation
for	O
the	O
T-cell	O
-	O
specific	O
expression	B-Gene_expression
of	O
these	O
genes	O
.	O

ras	O
protein	O
activity	O
is	O
essential	O
for	O
T	O
-	O
cell	O
antigen	O
receptor	O
signal	O
transduction	O
.	O

In	O
a	O
Jurkat	O
cell	O
model	O
of	O
T	O
-	O
cell	O
activation	O
an	O
interleukin	O
-	O
2	O
promoter/reporter	O
gene	O
construct	O
was	O
activated	O
by	O
antigen	O
receptor	O
agonism	O
in	O
combination	O
with	O
the	O
lymphokine	O
interleukin	O
-	O
1	O
.	O

Antigen	O
receptor	O
signals	O
could	O
be	O
mimicked	O
by	O
suboptimal	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
with	O
phorbol	O
esters	O
in	O
combination	O
with	O
calcium	O
mobilization	O
by	O
an	O
ionophore	O
.	O

In	O
cotransfection	O
experiments	O
,	O
oncogenic	O
rats	O
obviated	O
the	O
need	O
for	O
PKC	O
stimulation	O
but	O
did	O
not	O
replace	O
either	O
the	O
calcium	O
signal	O
or	O
interleukin	O
-	O
1	O
.	O

Activated	O
ras	O
expression	O
also	O
replaced	O
the	O
requirement	O
for	O
PKC	O
stimulation	O
in	O
activation	O
of	O
the	O
T	O
-	O
cell	O
transcription	O
factor	O
NF	O
-	O
AT	O
.	O

A	O
dominant	O
inhibitory	O
ras	O
mutant	O
specifically	O
blocked	O
antigen	O
receptor	O
agonism	O
,	O
indicating	O
that	O
ras	O
activity	O
is	O
required	O
for	O
antigen	O
receptor	O
signaling	O
.	O

In	O
addition	O
,	O
an	O
inhibitor	O
of	O
PKC	O
blocked	O
both	O
activated	O
ras	O
and	O
phorbol	O
ester	O
stimulation	O
,	O
suggesting	O
a	O
role	O
for	O
ras	O
upstream	O
of	O
PKC	O
.	O

Characterization	O
of	O
the	O
nuclear	O
and	O
cytoplasmic	O
components	O
of	O
the	O
lymphoid	O
-	O
specific	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
complex	O
.	O

The	O
lymphoid	O
-	O
specific	O
transcription	O
complex	O
,	O
NF	O
-	O
AT	O
,	O
is	O
involved	O
in	O
early	O
gene	O
activation	O
in	O
T	O
cells	O
and	O
is	O
assembled	O
from	O
a	O
pre	O
-	O
existing	O
,	O
T	O
cell	O
restricted	O
cytoplasmic	O
factor	O
and	O
an	O
inducible	O
ubiquitous	O
nuclear	O
component	O
within	O
30	O
min	O
after	O
activation	O
through	O
the	O
antigen	O
receptor	O
.	O

Recent	O
studies	O
have	O
implicated	O
the	O
family	O
of	O
AP1	O
factors	O
as	O
components	O
of	O
the	O
murine	O
NF	O
-	O
AT	O
complex	O
.	O

Evidence	O
is	O
provided	O
here	O
that	O
the	O
nuclear	O
component	O
of	O
human	O
NF	O
-	O
AT	O
contains	O
the	O
phorbol	O
ester	O
-	O
inducible	O
transcription	O
factor	O
AP1	O
(	O
Jun/Fos	O
)	O
.	O

We	O
further	O
characterize	O
which	O
AP1	O
family	O
members	O
can	O
assume	O
this	O
role	O
.	O

Antisera	O
to	O
Fos	O
inhibits	O
NF	O
-	O
AT	O
DNA	O
binding	O
as	O
does	O
an	O
oligonucleotide	O
containing	O
a	O
binding	O
site	O
for	O
AP1	O
.	O

Constitutive	O
expression	B-Gene_expression
in	O
vivo	O
of	O
Fos	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
Fra	O
-	O
1	O
,	O
eliminates	O
the	O
requirement	O
for	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
stimulation	O
,	O
leaving	O
NF-AT	O
-	O
directed	O
transcription	O
responsive	O
to	O
calcium	O
ionophore	O
alone	O
.	O

Overexpression	B-Gene_expression
of	O
cJun	O
or	O
JunD	O
,	O
but	O
not	O
JunB	O
,	O
also	O
eliminates	O
the	O
requirement	O
for	O
PMA	O
,	O
indicating	O
that	O
many	O
but	O
not	O
all	O
Jun	O
-	O
and	O
Fos	O
-	O
related	O
proteins	O
functionally	O
activate	O
NF-AT	O
-	O
dependent	O
transcription	O
in	O
the	O
presence	O
of	O
the	O
cytoplasmic	O
component	O
.	O

NF	O
-	O
AT	O
DNA	O
binding	O
can	O
be	O
reconstituted	O
in	O
vitro	O
using	O
semi	O
-	O
purified	O
AP1	O
proteins	O
mixed	O
with	O
cytosol	O
from	O
T	O
lymphocytes	O
.	O

Fos	O
proteins	O
are	O
not	O
needed	O
for	O
this	O
reconstitution	O
,	O
and	O
although	O
JunB	O
is	O
not	O
functional	O
,	O
it	O
can	O
participate	O
in	O
the	O
NF	O
-	O
AT	O
DNA	O
binding	O
complex	O
.	O

Finally	O
,	O
we	O
have	O
partially	O
purified	O
the	O
cytoplasmic	O
component	O
of	O
NF	O
-	O
AT	O
and	O
show	O
by	O
elution	O
and	O
renaturation	O
from	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
gels	O
that	O
it	O
has	O
a	O
molecular	O
mass	O
between	O
94	O
and	O
116	O
kDa	O
and	O
may	O
have	O
multiple	O
differentially	O
modified	O
forms	O
.	O

Protease	O
treatment	O
of	O
nuclear	O
extracts	O
distinguishes	O
between	O
class	O
II	O
MHC	O
X1	O
box	O
DNA	O
-	O
binding	O
proteins	O
in	O
wild	O
-	O
type	O
and	O
class	O
II	O
-	O
deficient	O
B	O
cells	O
.	O

The	O
X	O
box	O
region	O
is	O
critical	O
for	O
directing	O
the	O
expression	O
of	O
class	O
II	O
major	O
histocompatibility	O
complex	O
genes	O
in	O
B	O
lymphocytes	O
.	O

Although	O
several	O
class	O
II	O
promoter	O
-	O
specific	O
DNA	O
binding	O
factors	O
have	O
been	O
described	O
,	O
only	O
the	O
X	O
box	O
region	O
factor	O
,	O
RFX	O
,	O
shows	O
a	O
genetic	O
correlation	O
with	O
class	O
II	O
expression	O
,	O
being	O
deficient	O
in	O
some	O
B	O
cell	O
lines	O
derived	O
from	O
patients	O
with	O
class	O
II	O
-	O
deficient	O
congenital	O
immunodeficiency	O
.	O

To	O
further	O
evaluate	O
the	O
role	O
of	O
X	O
box	O
DNA	O
-	O
binding	O
proteins	O
in	O
class	O
II	O
gene	O
expression	O
,	O
the	O
role	O
of	O
the	O
X	O
box	O
region	O
was	O
examined	O
in	O
both	O
class	O
II	O
-	O
positive	O
and	O
-	O
negative	O
lymphoid	O
cells	O
.	O

In	O
addition	O
to	O
the	O
wild	O
-	O
type	O
B	O
cell	O
line	O
Raji	O
,	O
two	O
class	O
II	O
transcriptional	O
mutant	O
cell	O
lines	O
,	O
SJO	O
and	O
RJ2.2.5	O
,	O
and	O
Jurkat	O
,	O
a	O
class	O
II	O
negative	O
T	O
cell	O
line	O
,	O
were	O
examined	O
.	O

In	O
contrast	O
to	O
wild	O
-	O
type	O
B	O
cells	O
,	O
neither	O
of	O
the	O
class	O
II	O
mutant	O
cell	O
lines	O
could	O
use	O
the	O
X	O
box	O
region	O
to	O
direct	O
the	O
expression	O
of	O
a	O
transiently	O
transfected	O
reporter	O
gene	O
,	O
indicating	O
that	O
the	O
X	O
box	O
-	O
dependent	O
transcriptional	O
pathway	O
is	O
defective	O
in	O
these	O
cells	O
.	O

The	O
binding	O
activity	O
of	O
the	O
X1	O
box	O
DNA	O
-	O
binding	O
protein	O
RFX	O
was	O
examined	O
and	O
found	O
to	O
be	O
present	O
in	O
wild	O
-	O
type	O
B	O
cells	O
and	O
the	O
mutant	O
RJ2.2.5	O
but	O
was	O
absent	O
in	O
SJO	O
and	O
Jurkat	O
.	O

However	O
,	O
other	O
X1	O
box	O
-	O
specific	O
activities	O
were	O
detected	O
in	O
all	O
these	O
cell	O
lines	O
.	O

To	O
determine	O
whether	O
these	O
different	O
X1	O
box	O
activities	O
represented	O
distinct	O
DNA	O
binding	O
proteins	O
or	O
multimeric	O
forms	O
of	O
the	O
same	O
factor	O
(	O
s	O
)	O
,	O
protease	O
treatment	O
of	O
the	O
crude	O
nuclear	O
extracts	O
followed	O
by	O
DNA	O
-	O
binding	O
assays	O
were	O
carried	O
out	O
and	O
demonstrated	O
that	O
B	O
cell	O
extracts	O
contain	O
at	O
least	O
two	O
X1	O
-	O
specific	O
factors	O
.	O

One	O
of	O
these	O
cleaved	O
products	O
(	O
band	O
1	O
pk	O
)	O
correlates	O
with	O
RFX	O
activity	O
.	O

A	O
similar	O
comparison	O
with	O
protease	O
-	O
treated	O
extracts	O
prepared	O
from	O
Jurkat	O
cells	O
demonstrated	O
the	O
presence	O
of	O
the	O
band	O
1pk	O
activity	O
despite	O
an	O
absence	O
of	O
the	O
native	O
RFX	O
activity	O
.	O

In	O
contrast	O
,	O
protease	O
treatment	O
and	O
analysis	O
of	O
SJO	O
extracts	O
showed	O
no	O
detectable	O
levels	O
of	O
the	O
band	O
1pk	O
activity	O
.	O

These	O
results	O
demonstrate	O
that	O
multiple	O
X1	O
box	O
-	O
specific	O
DNA	O
-	O
binding	O
activities	O
exist	O
in	O
all	O
lymphoid	O
cells	O
,	O
but	O
the	O
presence	O
of	O
an	O
actively	O
binding	O
RFX	O
species	O
correlates	O
with	O
class	O
II	O
transcription	O
.	O

The	O
human	O
prointerleukin	O
1	O
beta	O
gene	O
requires	B-Positive_regulation
DNA	O
sequences	O
both	O
proximal	O
and	O
distal	O
to	O
the	O
transcription	O
start	O
site	O
for	O
tissue	O
-	O
specific	O
induction	B-Positive_regulation
.	O

In	O
these	O
studies	O
,	O
we	O
have	O
identified	O
DNA	O
sequences	O
and	O
specific	O
protein	O
interactions	O
necessary	B-Positive_regulation
for	O
transcriptional	B-Regulation
regulation	I-Regulation
of	O
the	O
human	O
prointerleukin	O
1	O
beta	O
(	O
proIL	O
-	O
1	O
beta	O
)	O
gene	O
.	O

A	O
cell-type	O
-	O
independent	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
responsive	O
enhancer	O
element	O
located	O
between	O
-	O
3757	O
and	O
-	O
2729	O
bp	O
upstream	O
from	O
the	O
transcription	O
start	O
site	O
(	O
cap	O
site	O
)	O
consisted	O
of	O
at	O
least	O
six	O
discrete	O
subregions	O
which	O
were	O
essential	O
to	O
the	O
maximal	O
induction	O
by	O
LPS	O
in	O
transfected	O
monocytes	O
.	O

The	O
enhancer	O
also	O
appeared	O
to	O
mediate	O
phorbol	O
myristate	O
acetate	O
induction	O
in	O
monocytes	O
and	O
IL	O
-	O
1	O
responsiveness	O
in	O
fibroblasts	O
.	O

Deletion	O
and	O
base	O
substitution	O
mutations	O
along	O
with	O
DNA	O
binding	O
studies	O
demonstrated	O
that	O
the	O
enhancer	O
contained	O
a	O
minimum	O
of	O
three	O
functional	O
protein	O
binding	O
sequences	O
,	O
two	O
of	O
which	O
appeared	O
to	O
be	O
important	B-Positive_regulation
for	O
gene	O
induction	B-Gene_expression
.	O

One	O
of	O
the	O
essential	O
proteins	O
which	O
bound	O
to	O
the	O
enhancer	O
was	O
similar	O
or	O
identical	O
to	O
members	O
of	O
the	O
C/EBP	O
family	O
of	O
transcription	O
factors	O
required	B-Positive_regulation
for	O
both	O
IL-1	O
-	O
and	O
LPS	O
-	O
specific	O
induction	B-Positive_regulation
of	O
the	O
IL	O
-	O
6	O
gene	O
(	O
i.e.	O
,	O
the	O
NF	O
-	O
IL6	O
proteins	O
)	O
.	O

When	O
ligated	O
to	O
the	O
proIL	O
-	O
1	O
beta	O
cap	O
site	O
-	O
proximal	O
region	O
(	O
located	O
between	O
-	O
131	O
to	O
+12	O
)	O
,	O
both	O
the	O
proIL	O
-	O
1	O
beta	O
and	O
the	O
simian	O
virus	O
40	O
enhancer	O
elements	O
functioned	O
more	O
efficiently	O
in	O
monocytes	O
than	O
in	O
HeLa	O
cells	O
,	O
which	O
are	O
not	O
normally	O
competent	O
for	O
IL	O
-	O
1	O
beta	O
expression	B-Gene_expression
.	O

When	B-Positive_regulation
ligated	O
to	O
the	O
murine	O
c	O
-	O
fos	O
promoter	O
,	O
however	O
,	O
the	O
proIL	O
-	O
1	O
beta	O
enhancer	O
was	O
inducible	B-Positive_regulation
in	O
phorbol	O
myristate	O
acetate	O
-	O
stimulated	O
HeLa	O
cells	O
,	O
suggesting	O
the	O
existence	O
of	O
a	O
proIL	O
-	O
1	O
beta	O
promoter	O
-	O
proximal	O
requirement	B-Positive_regulation
for	O
tissue	O
specificity	O
.	O

Expression	B-Gene_expression
of	O
PILOT	O
,	O
a	O
putative	O
transcription	O
factor	O
,	O
requires	B-Positive_regulation
two	O
signals	O
and	O
is	O
cyclosporin	O
A	O
sensitive	O
in	O
T	O
cells	O
.	O

Few	O
known	O
genes	O
(	O
IL	O
-	O
2	O
,	O
members	O
of	O
the	O
IL	O
-	O
8	O
family	O
,	O
interferon	O
-	O
gamma	O
)	O
are	O
induced	B-Positive_regulation
in	O
T	O
cells	O
only	O
through	O
the	O
combined	O
effect	O
of	O
phorbol	O
myristic	O
acetate	O
(	O
PMA	O
)	O
and	O
a	O
Ca	O
(	O
2+	O
)	O
-	O
ionophore	O
,	O
and	O
expression	B-Gene_expression
of	O
only	O
these	O
genes	O
can	O
be	O
fully	O
suppressed	B-Negative_regulation
by	O
Cyclosporin	O
A	O
(	O
CyA	O
)	O
.	O

We	O
have	O
identified	O
a	O
putative	O
transcription	O
factor	O
,	O
designated	O
PILOT	O
,	O
with	O
an	O
identical	O
dual	O
signal	O
requirement	B-Positive_regulation
for	O
expression	B-Gene_expression
.	O

Induction	B-Positive_regulation
of	O
the	O
PILOT	O
gene	O
is	O
detectable	O
in	O
human	O
T	O
cells	O
20	O
min	O
following	O
activation	O
in	O
the	O
presence	O
of	O
cycloheximide	O
and	O
is	O
fully	O
suppressed	B-Negative_regulation
by	O
CyA	O
.	O

The	O
PILOT	O
protein	O
has	O
a	O
calculated	O
M	O
(	O
r	O
)	O
of	O
42.6	O
kDa	O
and	O
contains	O
three	O
zinc	O
fingers	O
of	O
the	O
C2H2	O
-	O
type	O
at	O
the	O
carboxyl	O
-	O
terminus	O
which	O
are	O
highly	O
homologous	O
to	O
the	O
zinc	O
finger	O
regions	O
of	O
the	O
transcription	O
factors	O
EGR1	O
,	O
EGR2	O
,	O
and	O
pAT	O
133	O
.	O

In	O
contrast	O
to	O
T	O
cells	O
,	O
in	O
fibroblasts	O
PILOT	O
gene	O
expression	B-Gene_expression
requires	B-Positive_regulation
only	O
one	O
signal	O
(	O
PMA	O
)	O
and	O
is	O
not	O
affected	B-Regulation
by	O
CyA	O
.	O

This	O
observation	O
directly	O
demonstrates	O
the	O
existence	O
of	O
a	O
Ca2+	O
signal	O
-	O
dependent	O
regulatory	O
element	O
obligatory	O
for	O
expression	O
of	O
some	O
genes	O
in	O
T	O
cells	O
but	O
not	O
in	O
fibroblasts	O
.	O

This	O
differential	O
expression	O
model	O
will	O
be	O
valuable	O
in	O
the	O
dissection	O
of	O
the	O
dual	O
signal	O
pathway	O
in	O
T	O
cells	O
and	O
the	O
effects	O
of	O
CyA	O
upon	O
it	O
.	O

Suppression	O
of	O
a	O
cellular	O
differentiation	O
program	O
by	O
phorbol	O
esters	O
coincides	O
with	O
inhibition	O
of	O
binding	O
of	O
a	O
cell	O
-	O
specific	O
transcription	O
factor	O
(	O
NF	O
-	O
E2	O
)	O
to	O
an	O
enhancer	O
element	O
required	O
for	O
expression	O
of	O
an	O
erythroid	O
-	O
specific	O
gene	O
.	O

Induction	O
by	O
hemin	O
increases	O
,	O
while	O
induction	O
with	O
12-O-tetradecanoylphorbol-13	O
-	O
acetate	O
(	O
TPA	O
)	O
represses	O
,	O
erythroid	O
-	O
specific	O
gene	O
expression	O
in	O
the	O
human	O
cell	O
line	O
K562	O
.	O

We	O
analyzed	O
the	O
effects	O
of	O
hemin	O
or	O
TPA	O
induction	O
on	O
the	O
binding	O
and	O
activity	O
of	O
transcription	O
factors	O
at	O
a	O
regulatory	O
element	O
found	O
within	O
the	O
transcriptional	O
regulatory	O
sequences	O
of	O
many	O
erythroid	O
-	O
specific	O
genes	O
.	O

TPA	O
induction	O
increases	O
the	O
binding	O
of	O
ubiquitous	O
AP	O
-	O
1	O
factors	O
to	O
this	O
element	O
.	O

TPA	O
induction	O
inhibits	O
the	O
binding	O
of	O
the	O
lineage	O
limited	O
transcription	O
factor	O
NF	O
-	O
E2	O
to	O
this	O
transcriptional	O
control	O
element	O
.	O

Hemin	O
induction	O
of	O
K562	O
cells	O
does	O
not	O
facilitate	O
the	O
binding	O
of	O
NF	O
-	O
E2	O
to	O
its	O
recognition	O
site	O
.	O

Hemin	O
induction	O
appears	O
to	O
nonspecifically	O
increase	O
the	O
expression	O
of	O
transiently	O
transfected	O
genes	O
in	O
K562	O
cells	O
.	O

Beyond	O
this	O
nonspecific	O
increase	O
in	O
gene	O
expression	O
,	O
hemin	O
induction	O
acts	O
to	O
increase	O
the	O
activity	O
of	O
the	O
lineage	O
limited	O
transcription	O
factor	O
NF	O
-	O
E2	O
.	O

The	O
divergent	O
effects	O
of	O
hemin	O
and	O
TPA	O
on	O
gene	O
expression	O
in	O
K562	O
cells	O
are	O
mediated	O
,	O
in	O
part	O
,	O
by	O
their	O
contrasting	O
effects	O
on	O
the	O
transcription	O
factor	O
NF	O
-	O
E2	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
pyruvate	O
kinase	O
erythroid	O
-	O
specific	O
promoter	O
.	O

Mammal	O
pyruvate	O
kinases	O
are	O
encoded	O
by	O
two	O
genes	O
.	O

The	O
L	O
gene	O
produces	B-Gene_expression
the	O
erythroid	O
(	O
R	O
-	O
PK	O
)	O
or	O
the	O
hepatic	O
(	O
L	O
-	O
PK	O
)	O
isozymes	O
by	B-Positive_regulation
the	I-Positive_regulation
alternative	I-Positive_regulation
use	I-Positive_regulation
of	I-Positive_regulation
two	O
promoters	O
.	O

We	O
report	O
the	O
characterization	O
of	O
the	O
cis	O
-	O
and	O
trans	O
-	O
acting	O
elements	O
involved	O
in	O
the	O
tissue	O
-	O
specific	O
activity	B-Positive_regulation
of	O
the	O
L	O
gene	O
erythroid	O
promoter	O
.	O

A	O
R	O
-	O
PK	O
DNA	O
fragment	O
extending	O
from	O
-	O
870	O
to	O
+54	O
relative	O
to	O
the	O
cap	O
site	O
confers	O
erythroid	O
specificity	O
to	O
a	O
reporter	O
gene	O
.	O

Within	O
this	O
region	O
,	O
we	O
define	O
a	O
minimal	O
promoter	O
(	O
-	O
62	O
to	O
+54	O
)	O
that	O
displays	O
erythroid	O
-	O
specific	O
activity	O
and	O
contains	O
two	O
DNA	O
binding	O
sites	O
.	O

One	O
,	O
located	O
at	O
-	O
50	O
,	O
binds	O
members	O
of	O
the	O
CCACC/Sp1	O
family	O
and	O
the	O
other	O
,	O
located	O
at	O
-	O
20	O
,	O
binds	B-Binding
the	O
erythroid	O
factor	O
GATA	O
-	O
1	O
.	O

Although	O
the	O
-	O
20	O
GATA	O
binding	O
site	O
(	O
AGATAA	O
)	O
is	O
also	O
a	O
potential	O
TFIID	O
binding	O
site	O
,	O
it	O
does	O
not	O
bind	O
TFIID	O
.	O

Furthermore	O
,	O
the	O
substitution	O
of	O
this	O
GATA	O
binding	O
site	O
by	O
a	O
canonical	O
TFIID	O
binding	O
site	O
suppresses	O
the	O
promoter	O
activity	O
.	O

Mutations	O
and	O
deletions	O
of	O
both	O
sites	O
indicate	O
that	O
only	O
the	O
association	O
of	O
CCACC/Sp1	O
and	O
GATA	O
binding	O
sites	O
can	O
drive	B-Positive_regulation
efficient	O
and	O
tissue	O
-	O
specific	O
expression	B-Gene_expression
of	O
this	O
R	O
-	O
PK	O
minimal	O
promoter	O
.	O

Finally	O
,	O
by	O
co	O
-	O
transfection	O
experiments	O
,	O
we	O
study	O
the	O
elements	O
involved	O
in	O
the	O
hGATA	O
-	O
1	O
transactivation	B-Positive_regulation
of	O
the	O
R	O
-	O
PK	O
promoter	O
in	O
HeLa	O
cells	O
.	O

Transcriptional	B-Transcription
regulation	B-Regulation
of	O
interleukin	O
3	O
(	O
IL3	O
)	O
in	O
primary	O
human	O
T	O
lymphocytes	O
.	O

Role	B-Regulation
of	O
AP-1	O
-	O
and	O
octamer	O
-	O
binding	O
proteins	O
in	O
control	B-Regulation
of	O
IL3	O
gene	O
expression	B-Gene_expression
.	O

We	O
have	O
investigated	O
the	O
molecular	O
and	O
biochemical	O
basis	O
for	O
activation	B-Positive_regulation
of	O
interleukin	O
3	O
(	O
IL3	O
)	O
gene	O
expression	B-Gene_expression
in	O
primary	O
human	O
T	O
lymphocytes	O
following	O
CD3	O
and	O
CD2	O
receptor	O
stimulation	B-Positive_regulation
or	O
activation	B-Positive_regulation
by	O
phytohemagglutinin	O
plus	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
.	O

Using	O
transfection	O
and	O
reporter	O
gene	O
assays	O
specifically	O
designed	O
for	O
primary	O
T	O
lymphocytes	O
in	O
conjunction	O
with	O
gel	O
retardation	O
assays	O
,	O
Western	O
blot	O
analyses	O
and	O
UV	O
cross	O
-	O
linking	O
studies	O
,	O
we	O
found	O
that	O
c	O
-	O
Jun	O
,	O
c	O
-	O
Fos	O
,	O
and	O
octamer	O
-	O
binding	O
proteins	O
play	B-Positive_regulation
a	I-Positive_regulation
major	I-Positive_regulation
role	I-Positive_regulation
in	O
transcriptional	B-Transcription
activation	B-Positive_regulation
of	O
the	O
IL3	O
gene	O
via	O
their	O
interaction	B-Binding
with	O
two	O
specific	O
regions	O
contained	O
within	O
the	O
IL3	O
5'	O
-	O
flanking	O
sequence	O
.	O

Additionally	O
,	O
the	O
region	O
between	O
bases	O
-	O
107	O
and	O
-	O
59	O
of	O
the	O
IL3	O
promoter	O
containing	O
putative	O
AP	O
-	O
2	O
and	O
Sp1	O
binding	O
motifs	O
appears	O
necessary	B-Positive_regulation
for	O
basal	O
level	O
expression	B-Gene_expression
of	O
the	O
IL3	O
gene	O
.	O

The	O
data	O
also	O
indicate	O
that	O
CD2	O
receptor	O
activation	B-Positive_regulation
and	O
phytohemagglutinin	O
plus	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
stimulation	O
augment	B-Positive_regulation
T	O
cell	O
IL3	O
gene	O
expression	B-Gene_expression
through	O
the	O
same	O
cis	O
-	O
and	O
trans	O
-	O
activating	O
signals	O
.	O

These	O
results	O
should	O
contribute	O
to	O
a	O
better	O
understanding	O
of	O
the	O
regulation	B-Regulation
of	O
IL3	O
gene	O
expression	B-Gene_expression
in	O
human	O
T	O
lymphocytes	O
.	O

Transcriptional	B-Positive_regulation
activation	I-Positive_regulation
of	O
human	O
zeta	O
2	O
globin	O
promoter	O
by	O
the	O
alpha	O
globin	O
regulatory	O
element	O
(	O
HS	O
-	O
40	O
)	O
:	O
functional	O
role	O
of	O
specific	O
nuclear	O
factor	O
-	O
DNA	O
complexes	O
.	O

We	O
studied	O
the	O
functional	O
interaction	O
between	O
human	O
embryonic	O
zeta	O
2	O
globin	O
promoter	O
and	O
the	O
alpha	O
globin	O
regulatory	O
element	O
(	O
HS	O
-	O
40	O
)	O
located	O
40	O
kb	O
upstream	O
of	O
the	O
zeta	O
2	O
globin	O
gene	O
.	O

It	O
was	O
shown	O
by	O
transient	O
expression	O
assay	O
that	O
HS	O
-	O
40	O
behaved	B-Positive_regulation
as	I-Positive_regulation
an	I-Positive_regulation
authentic	I-Positive_regulation
enhancer	I-Positive_regulation
for	O
high	O
-	O
level	O
zeta	O
2	O
globin	O
promoter	O
activity	O
in	O
K562	O
cells	O
,	O
an	O
erythroid	O
cell	O
line	O
of	O
embryonic	O
and/or	O
fetal	O
origin	O
.	O

Although	O
sequences	O
located	O
between	O
-	O
559	O
and	O
-	O
88	O
of	O
the	O
zeta	O
2	O
globin	O
gene	O
were	O
dispensable	B-Positive_regulation
for	O
its	O
expression	B-Gene_expression
on	O
enhancerless	O
plasmids	O
,	O
they	O
were	O
required	B-Positive_regulation
for	O
the	O
HS	O
-	O
40	O
enhancer	O
-	O
mediated	B-Positive_regulation
activity	B-Regulation
of	O
the	O
zeta	O
2	O
globin	O
promoter	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
demonstrated	O
that	O
this	O
HS	O
-	O
40	O
enhancer	O
-	O
zeta	O
2	O
globin	O
promoter	O
interaction	O
is	O
mediated	O
by	O
the	O
two	O
GATA	O
-	O
1	O
factor	O
binding	O
motifs	O
located	O
at	O
-	O
230	O
and	O
-	O
104	O
,	O
respectively	O
.	O

The	O
functional	O
domains	O
of	O
HS	O
-	O
40	O
were	O
also	O
mapped	O
.	O

Bal	O
31	O
deletion	O
mapping	O
data	O
suggested	O
that	O
one	O
GATA	O
-	O
1	O
motif	O
,	O
one	O
GT	O
motif	O
,	O
and	O
two	O
NF	O
-	O
E2/AP1	O
motifs	O
together	O
formed	B-Regulation
the	I-Regulation
functional	I-Regulation
core	I-Regulation
of	O
HS	O
-	O
40	O
in	O
the	O
erythroid	O
-	O
specific	O
activation	B-Positive_regulation
of	O
the	O
zeta	O
2	O
globin	O
promoter	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
further	O
demonstrated	O
that	O
the	O
enhancer	O
function	O
of	O
one	O
of	O
the	O
two	O
NF	O
-	O
E2/AP1	O
motifs	O
of	O
HS	O
-	O
40	O
is	O
mediated	O
through	O
its	O
binding	O
to	O
NF	O
-	O
E2	O
but	O
not	O
AP1	O
transcription	O
factor	O
.	O

Finally	O
,	O
we	O
did	O
genomic	O
footprinting	O
of	O
the	O
HS	O
-	O
40	O
enhancer	O
region	O
in	O
K562	O
cells	O
,	O
adult	O
nucleated	O
erythroblasts	O
,	O
and	O
different	O
nonerythroid	O
cells	O
.	O

All	O
sequence	O
motifs	O
within	O
the	O
functional	O
core	O
of	O
HS	O
-	O
40	O
,	O
as	O
mapped	O
by	O
transient	O
expression	O
analysis	O
,	O
appeared	O
to	O
bind	O
a	O
nuclear	O
factor	O
(	O
s	O
)	O
in	O
living	O
K562	O
cells	O
but	O
not	O
in	O
nonerythroid	O
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
only	O
one	O
of	O
the	O
apparently	O
nonfunctional	O
sequence	O
motifs	O
was	O
bound	O
with	O
factors	O
in	O
vivo	O
.	O

In	O
comparison	O
to	O
K562	O
,	O
nucleated	O
erythroblasts	O
from	O
adult	O
human	O
bone	O
marrow	O
exhibited	O
a	O
similar	O
but	O
nonidentical	O
pattern	O
of	O
nuclear	O
factor	O
binding	O
in	O
vivo	O
at	O
the	O
HS	O
-	O
40	O
region	O
.	O

These	O
data	O
suggest	O
that	O
transcriptional	B-Transcription
activation	B-Positive_regulation
of	O
human	O
embryonic	O
zeta	O
2	O
globin	O
gene	O
and	O
the	O
fetal/adult	O
alpha	O
globin	O
genes	O
is	O
mediated	B-Positive_regulation
by	O
erythroid	O
cell	O
-	O
specific	O
and	O
developmental	O
stage	O
-	O
specific	O
nuclear	O
factor	O
-	O
DNA	O
complexes	O
which	O
form	O
at	O
the	O
enhancer	O
(	O
HS	O
-	O
40	O
)	O
and	O
the	O
globin	O
promoters	O
.	O

Costimulation	O
of	O
peripheral	O
blood	O
T	O
cell	O
activation	O
by	O
human	O
endothelial	O
cells	O
.	O

Enhanced	B-Positive_regulation
IL	O
-	O
2	O
transcription	B-Transcription
correlates	O
with	O
increased	O
c	O
-	O
fos	O
synthesis	O
and	O
increased	O
Fos	O
content	B-Binding
of	I-Binding
AP	I-Binding
-	I-Binding
1	I-Binding
.	O

Endothelial	O
cells	O
(	O
EC	O
)	O
act	O
as	O
APC	O
for	O
resting	O
PBL	O
in	O
vitro	O
,	O
and	O
may	O
have	O
important	O
roles	O
in	O
vivo	O
in	O
the	O
pathogenesis	O
of	O
allograft	O
rejection	O
and	O
delayed	O
hypersensitivity	O
.	O

We	O
previously	O
reported	O
that	O
human	O
umbilical	O
vein	O
EC	O
provide	B-Positive_regulation
costimulatory	I-Positive_regulation
signals	I-Positive_regulation
to	O
PHA	O
-	O
stimulated	O
PBL	O
via	O
CD2	O
:	B-Binding
lymphocyte	O
function	O
-	O
associated	O
Ag	O
-	O
3	O
and	O
an	O
unidentified	O
ligand	O
pair	B-Binding
,	O
resulting	O
in	O
a	O
three	O
-	O
to	O
eight	O
-	O
fold	O
enhancement	B-Positive_regulation
of	O
IL	O
-	O
2	O
production	B-Gene_expression
.	O

The	O
physiologic	O
relevance	O
of	O
this	O
increase	O
was	O
demonstrated	O
by	O
the	O
proliferative	O
advantage	O
provided	O
by	O
EC	O
to	O
PBL	O
suboptimally	O
stimulated	O
with	O
mAb	O
OKT3	O
.	O

We	O
now	O
report	O
that	O
EC	O
costimulation	O
causes	B-Positive_regulation
increased	B-Positive_regulation
levels	O
of	O
IL	O
-	O
2	O
mRNA	O
as	O
a	O
result	O
of	O
increased	B-Positive_regulation
IL	O
-	O
2	O
transcription	B-Transcription
in	O
PBL	O
.	O

We	O
therefore	O
examined	O
the	O
effects	B-Regulation
of	O
EC	O
on	O
T	O
cell	O
nuclear	O
factors	O
known	O
to	O
regulate	B-Regulation
IL	O
-	O
2	O
transcription	B-Transcription
,	O
including	O
c	O
-	O
jun	O
and	O
c-fos	O
-	O
two	O
components	O
of	O
the	O
transcription	O
factor	O
AP	O
-	O
1	O
,	O
NFAT	O
,	O
and	O
others	O
.	O

PBL	O
constitutively	O
express	B-Gene_expression
c	O
-	O
jun	O
transcripts	O
,	O
and	O
the	O
level	O
of	O
c	O
-	O
jun	O
mRNA	O
is	O
not	O
altered	B-Regulation
by	O
PHA	O
activation	O
in	O
the	O
absence	O
or	O
presence	O
of	O
EC	O
.	O

In	O
contrast	O
,	O
c	O
-	O
fos	O
mRNA	O
is	O
absent	B-Transcription
from	O
resting	O
T	O
cells	O
and	O
is	O
induced	B-Positive_regulation
on	O
PHA	O
activation	O
.	O

EC	O
alone	O
do	O
not	O
induce	B-Positive_regulation
c	O
-	O
fos	O
mRNA	O
but	O
augment	B-Positive_regulation
the	O
level	O
of	O
c	O
-	O
fos	O
mRNA	O
in	O
PHA	O
-	O
activated	O
T	O
cells	O
by	O
3	O
-	O
to	O
10	O
-	O
fold	O
.	O

This	O
effect	O
is	O
largely	O
independent	O
of	O
the	O
CD2	O
:	O
lymphocyte	O
function	O
-	O
associated	O
Ag	O
-	O
3	O
pathway	O
.	O

Gel	O
-	O
shift	O
analysis	O
reveals	O
the	O
constitutive	O
presence	O
of	O
nuclear	O
factors	O
in	O
resting	O
PBL	O
that	O
bind	B-Binding
to	O
the	O
proximal	O
AP	O
-	O
1	O
site	O
of	O
the	O
IL	O
-	O
2	O
promoter	O
and	O
that	O
contain	O
immunoreactive	O
c	O
-	O
Jun	O
but	O
not	O
c	O
-	O
Fos	O
protein	O
.	O

In	O
contrast	O
,	O
AP	O
-	O
1	O
from	O
PHA	O
-	O
activated	O
cells	O
contains	O
c	O
-	O
Jun	O
and	O
low	O
levels	O
of	O
c	O
-	O
Fos	O
.	O

Strikingly	O
,	O
costimulation	O
with	O
EC	O
results	O
in	O
a	O
dramatic	O
increase	O
(	O
up	O
to	O
15	O
-	O
fold	O
)	O
in	O
the	O
c	O
-	O
Fos	O
content	O
of	O
AP	O
-	O
1	O
.	O

Levels	O
of	O
other	O
nuclear	O
factors	O
involved	B-Regulation
in	O
IL	O
-	O
2	O
regulation	B-Regulation
were	O
not	O
altered	O
by	O
EC	O
,	O
although	O
NFAT	O
-	O
DNA	O
complexes	O
migrated	O
at	O
a	O
slightly	O
different	O
mobility	O
.	O

In	O
summary	O
,	O
our	O
data	O
suggest	O
that	O
changes	O
in	O
the	O
composition	O
of	O
transcription	O
factor	O
AP	O
-	O
1	O
is	B-Regulation
a	I-Regulation
key	I-Regulation
molecular	I-Regulation
mechanism	I-Regulation
for	O
increasing	B-Positive_regulation
IL	O
-	O
2	O
transcription	B-Transcription
and	O
may	O
underlie	O
the	O
phenomenon	O
of	O
costimulation	O
by	O
EC	O
.	O

Negative	B-Negative_regulation
transcriptional	I-Negative_regulation
regulation	I-Negative_regulation
of	O
human	O
interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
gene	O
by	O
glucocorticoids	O
through	O
interference	O
with	O
nuclear	O
transcription	O
factors	O
AP	O
-	O
1	O
and	O
NF	O
-	O
AT	O
.	O

IL	O
-	O
2	O
gene	O
transcription	B-Transcription
is	O
affected	B-Regulation
by	O
several	O
nuclear	O
proteins	O
.	O

We	O
asked	O
whether	O
dexamethasone	O
(	O
Dex	O
)	O
and	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
inhibit	B-Negative_regulation
IL	O
-	O
2	O
gene	O
transcription	B-Transcription
by	O
interfering	O
with	O
the	O
activity	O
of	O
nuclear	O
proteins	O
that	O
bind	B-Binding
to	O
the	O
IL	O
-	O
2	O
promoter	O
.	O

Nuclear	O
extracts	O
from	O
primary	O
human	O
T	O
lymphocytes	O
were	O
analyzed	O
by	O
electrophoretic	O
DNA	O
mobility	O
shift	O
assays	O
.	O

Both	O
Dex	O
and	O
CsA	O
inhibited	B-Negative_regulation
the	O
binding	B-Binding
of	O
transcription	O
factors	O
AP	O
-	O
1	O
and	O
NF	O
-	O
AT	O
,	O
but	O
not	O
of	O
NF	O
-	O
kB	O
and	O
OCT	O
-	O
1/OAF	O
,	O
to	O
their	O
corresponding	O
sites	O
on	O
the	O
IL	O
-	O
2	O
gene	O
promoter	O
.	O

To	O
correlate	O
changes	O
in	O
nuclear	O
factor	O
binding	O
in	O
vitro	O
with	O
transcriptional	O
activity	O
in	O
vivo	O
and	O
define	O
the	O
structural	O
requirements	B-Positive_regulation
for	O
IL	O
-	O
2	O
promoter	O
repression	B-Negative_regulation
,	O
we	O
used	O
transient	O
DNA	O
transfections	O
.	O

Jurkat	O
cells	O
were	O
transfected	O
with	O
plasmids	O
containing	O
either	O
the	O
intact	O
IL	O
-	O
2	O
promoter	O
or	O
its	O
AP	O
-	O
1	O
,	O
NF	O
-	O
AT	O
,	O
and	O
NF	O
-	O
kB	O
motifs	O
.	O

Dex	O
inhibited	B-Negative_regulation
the	O
IL	O
-	O
2	O
promoter	O
and	O
the	O
AP	O
-	O
1	O
,	O
but	O
not	O
the	O
NF	O
-	O
AT	O
and	O
NF	O
-	O
kB	O
plasmids	O
.	O

In	O
contrast	O
,	O
CsA	O
inhibited	B-Negative_regulation
the	O
IL	O
-	O
2	O
promoter	O
and	O
the	O
NF	O
-	O
AT	O
,	O
but	O
not	O
the	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kB	O
plasmids	O
.	O

These	O
results	O
suggest	O
that	O
in	O
human	O
T	O
lymphocytes	O
both	O
Dex	O
and	O
CsA	O
inhibited	B-Negative_regulation
IL	O
-	O
2	O
gene	O
transcription	B-Transcription
through	O
interference	O
with	O
transcription	O
factors	O
AP	O
-	O
1	O
and	O
NF	O
-	O
AT	O
.	O

We	O
propose	O
that	O
,	O
while	O
maximum	O
inhibition	B-Negative_regulation
may	O
involve	B-Positive_regulation
interaction	O
with	O
both	O
transcription	O
factors	O
,	O
AP	O
-	O
1	O
is	O
the	O
primary	O
target	O
of	O
Dex	O
.	O

Cell	O
-	O
specific	O
expression	B-Gene_expression
of	O
helix-loop	O
-	O
helix	O
transcription	O
factors	O
encoded	O
by	O
the	O
E2A	O
gene	O
.	O

The	O
E2A	O
gene	O
encodes	O
transcription	O
factors	O
of	O
the	O
helix-loop	O
-	O
helix	O
family	O
that	O
are	O
implicated	O
in	O
cell	O
-	O
specific	O
gene	O
expression	O
as	O
part	O
of	O
dimeric	O
complexes	O
that	O
interact	O
with	O
E	O
box	O
enhancer	O
elements	O
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
transcripts	O
of	O
the	O
E2A	O
gene	O
can	O
be	O
detected	B-Gene_expression
in	O
a	O
wide	O
range	O
of	O
cell	O
types	O
.	O

We	O
have	O
now	O
examined	O
expression	B-Gene_expression
of	O
the	O
mouse	O
E2A	O
gene	O
at	O
the	O
protein	O
level	O
using	O
polyclonal	O
antisera	O
directed	O
against	O
distinct	O
portions	O
of	O
the	O
E2A	O
protein	O
to	O
probe	O
blots	O
of	O
cellular	O
extracts	O
.	O

A	O
73	O
kDa	O
protein	O
was	O
identified	O
by	O
this	O
analysis	O
:	O
this	O
protein	O
is	O
highly	O
enriched	O
in	O
cell	O
lines	O
of	O
B	O
lymphoid	O
origin	O
as	O
compared	O
to	O
pancreatic	O
beta	O
-	O
cells	O
and	O
fibroblast	O
cells	O
.	O

The	O
detection	O
of	O
this	O
protein	O
selectively	O
in	O
extracts	O
of	O
lymphoid	O
cells	O
correlates	O
with	O
the	O
presence	O
of	O
the	O
E	O
box	O
-	O
binding	O
activity	O
LEF1/BCF1	O
in	O
these	O
cells	O
;	O
this	O
binding	O
activity	O
was	O
previously	O
shown	O
to	O
be	O
efficiently	O
recognized	O
by	O
antiserum	O
directed	O
against	O
E2A	O
gene	O
products	O
.	O

Transfection	B-Gene_expression
of	O
cells	O
with	O
full	O
length	O
E2A	O
cDNA	O
leads	O
to	O
appearance	O
of	O
protein	O
co	O
-	O
migrating	O
with	O
the	O
73	O
kDa	O
protein	O
on	O
SDS	O
gel	O
electrophoresis	O
and	O
co	O
-	O
migrating	O
with	O
LEF1/BCF1	O
on	O
mobility	O
shift	O
analysis	O
.	O

Our	O
results	O
are	O
consistent	O
with	O
the	O
view	O
that	O
the	O
DNA	O
-	O
binding	B-Binding
activity	I-Binding
LEF1/BCF1	O
is	O
a	O
homodimer	O
of	O
E2A	O
proteins	O
;	O
the	O
selective	O
appearance	B-Gene_expression
of	O
this	O
putative	O
cell	O
-	O
specific	O
transcription	O
factor	O
in	O
B	O
lymphoid	O
cells	O
seems	O
to	O
be	O
attributable	B-Positive_regulation
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
elevated	B-Positive_regulation
E2A	O
protein	O
concentrations	O
in	O
these	O
cells	O
.	O

HIV	O
-	O
1	O
Nef	O
protein	O
inhibits	O
the	O
recruitment	O
of	O
AP	O
-	O
1	O
DNA	O
-	O
binding	O
activity	O
in	O
human	O
T	O
-	O
cells	O
.	O

The	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
,	O
HIV-1	O
-	O
LTR	O
,	O
contains	O
binding	O
sites	O
for	O
several	O
cellular	O
transcription	O
factors	O
which	O
contribute	O
to	O
HIV	O
-	O
1	O
gene	O
expression	O
.	O

Our	O
previous	O
studies	O
on	O
the	O
function	O
of	O
the	O
HIV-1	O
-	O
encoded	O
Nef	O
protein	O
suggested	O
that	O
Nef	O
may	O
be	O
an	O
inhibitor	O
HIV	O
-	O
1	O
transcription	O
.	O

To	O
determine	O
whether	O
Nef	O
affects	O
the	O
binding	O
of	O
cellular	O
factors	O
implicated	O
in	O
HIV	O
-	O
1	O
regulation	O
,	O
32P	O
-	O
labeled	O
oligonucleotides	O
corresponding	O
to	O
the	O
binding	O
sites	O
were	O
incubated	O
with	O
nuclear	O
extracts	O
prepared	O
from	O
Nef	O
-	O
expressing	B-Gene_expression
T	O
-	O
cell	O
lines	O
that	O
were	O
not	O
stimulated	O
or	O
were	O
stimulated	O
with	O
T	O
-	O
cell	O
mitogens	O
.	O

We	O
found	O
that	O
Nef	O
inhibited	O
the	O
recruitment	O
of	O
AP	O
-	O
1	O
DNA	O
-	O
binding	O
activity	O
in	O
mitogen	O
-	O
stimulated	O
human	O
T	O
-	O
cells	O
.	O

Additionally	O
,	O
Nef	O
expressing	B-Gene_expression
cells	O
were	O
transiently	O
transfected	O
with	O
a	O
plasmid	O
in	O
which	O
HIV	O
-	O
1	O
AP	O
-	O
1	O
DNA	O
recognition	O
sequences	O
were	O
cloned	O
downstream	O
of	O
the	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
gene	O
.	O

Mitogen	O
-	O
mediated	O
transcriptional	B-Transcription
activation	B-Positive_regulation
of	O
the	O
CAT	O
gene	O
in	O
this	O
construct	O
was	O
inhibited	B-Negative_regulation
in	O
Nef	O
-	O
expressing	B-Gene_expression
cells	O
but	O
not	O
in	O
control	O
cells	O
.	O

These	O
studies	O
suggest	O
that	O
,	O
by	O
inhibiting	O
AP	O
-	O
1	O
activation	O
,	O
Nef	O
may	O
play	O
a	O
role	O
in	O
regulating	O
HIV	O
-	O
1	O
gene	O
expression	O
in	O
infected	O
T	O
-	O
cells	O
.	O

Cloning	O
and	O
functional	O
characterization	O
of	O
early	O
B	O
-	O
cell	O
factor	O
,	O
a	O
regulator	O
of	O
lymphocyte	O
-	O
specific	O
gene	O
expression	O
.	O

Early	O
B	O
-	O
cell	O
factor	O
(	O
EBF	O
)	O
was	O
identified	O
previously	O
as	O
a	O
tissue	O
-	O
specific	O
and	O
differentiation	O
stage	O
-	O
specific	O
DNA	O
-	O
binding	B-Binding
protein	I-Binding
that	O
participates	B-Regulation
in	I-Regulation
the	I-Regulation
regulation	I-Regulation
of	O
the	O
pre	O
-	O
B	O
and	O
B	O
lymphocyte	O
-	O
specific	O
mb	O
-	O
1	O
gene	O
.	O

Partial	O
amino	O
acid	O
sequences	O
obtained	O
from	O
purified	O
EBF	O
were	O
used	O
to	O
isolate	O
cDNA	O
clones	O
,	O
which	O
by	O
multiple	O
criteria	O
encode	O
EBF	O
.	O

The	O
recombinant	O
polypeptide	O
formed	O
sequence	O
-	O
specific	O
complexes	O
with	O
the	O
EBF	O
-	O
binding	O
site	O
in	O
the	O
mb	O
-	O
1	O
promoter	O
.	O

The	B-Transcription
cDNA	I-Transcription
hybridized	I-Transcription
to	O
multiple	O
transcripts	O
in	O
pre	O
-	O
B	O
and	O
B	O
-	O
cell	O
lines	O
,	O
but	O
transcripts	O
were	O
not	O
detected	B-Transcription
at	O
significant	O
levels	O
in	O
plasmacytoma	O
,	O
T	O
-	O
cell	O
,	O
and	O
nonlymphoid	O
cell	O
lines	O
.	O

Expression	O
of	O
recombinant	O
EBF	O
in	O
transfected	O
nonlymphoid	O
cells	O
strongly	O
activated	O
transcription	O
from	O
reporter	O
plasmids	O
containing	O
functional	O
EBF	O
-	O
binding	O
sites	O
.	O

Analysis	O
of	O
DNA	O
binding	O
by	O
deletion	O
mutants	O
of	O
EBF	O
identified	O
an	O
amino	O
-	O
terminal	O
cysteine	O
-	O
rich	O
DNA	O
-	O
binding	O
domain	O
lacking	O
obvious	O
sequence	O
similarity	O
to	O
known	O
transcription	O
factors	O
.	O

DNA	O
-	O
binding	O
assays	O
with	O
cotranslated	O
wild	O
-	O
type	O
and	O
truncated	O
forms	O
of	O
EBF	O
indicated	O
that	O
the	O
protein	O
interacts	B-Binding
with	O
its	O
site	O
as	O
a	O
homodimer	B-Binding
.	O

Deletions	O
delineated	O
a	O
carboxy	O
-	O
terminal	O
dimerization	O
region	O
containing	O
two	O
repeats	O
of	O
15	O
amino	O
acids	O
that	O
show	O
similarity	O
with	O
the	O
dimerization	O
domains	O
of	O
basic-helix-loop	O
-	O
helix	O
proteins	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
EBF	O
represents	O
a	O
novel	O
regulator	O
of	O
B	O
lymphocyte	O
-	O
specific	O
gene	O
expression	O
.	O

Regulation	B-Regulation
of	O
the	O
Ets	O
-	O
related	O
transcription	O
factor	O
Elf	O
-	O
1	O
by	O
binding	B-Binding
to	O
the	O
retinoblastoma	O
protein	O
.	O

The	O
retinoblastoma	O
gene	O
product	O
(	O
Rb	O
)	O
is	O
a	O
nuclear	O
phosphoprotein	O
that	O
regulates	O
cell	O
cycle	O
progression	O
.	O

Elf	O
-	O
1	O
is	O
a	O
lymphoid	O
-	O
specific	O
Ets	O
transcription	O
factor	O
that	O
regulates	O
inducible	O
gene	O
expression	O
during	O
T	O
cell	O
activation	O
.	O

In	O
this	O
report	O
,	O
it	O
is	O
demonstrated	O
that	O
Elf	O
-	O
1	O
contains	O
a	O
sequence	O
motif	O
that	O
is	O
highly	O
related	O
to	O
the	O
Rb	O
binding	O
sites	O
of	O
several	O
viral	O
oncoproteins	O
and	O
binds	B-Binding
to	O
the	O
pocket	O
region	O
of	O
Rb	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Elf	O
-	O
1	O
binds	B-Binding
exclusively	O
to	O
the	O
underphosphorylated	B-Phosphorylation
form	O
of	O
Rb	O
and	O
fails	O
to	O
bind	B-Binding
to	O
Rb	O
mutants	O
derived	O
from	O
patients	O
with	O
retinoblastoma	O
.	O

Co	O
-	O
immunoprecipitation	O
experiments	O
demonstrated	O
an	O
association	B-Binding
between	O
Elf	O
-	O
1	O
and	O
Rb	O
in	O
resting	O
normal	O
human	O
T	O
cells	O
.	O

After	O
T	O
cell	O
activation	O
,	O
the	O
phosphorylation	B-Phosphorylation
of	O
Rb	O
results	B-Positive_regulation
in	O
the	O
release	B-Localization
of	O
Elf	O
-	O
1	O
,	O
which	O
is	O
correlated	O
temporally	O
with	O
the	O
activation	O
of	O
Elf-1	O
-	O
mediated	O
transcription	O
.	O

Overexpression	B-Gene_expression
of	O
a	O
phosphorylation	B-Phosphorylation
-	I-Phosphorylation
defective	I-Phosphorylation
form	I-Phosphorylation
of	O
Rb	O
inhibited	O
Elf-1	O
-	O
dependent	O
transcription	O
during	O
T	O
cell	O
activation	O
.	O

These	O
results	O
demonstrate	O
that	O
Rb	O
interacts	B-Binding
specifically	O
with	O
a	O
lineage	O
-	O
restricted	O
Ets	O
transcription	O
factor	O
.	O

This	O
regulated	O
interaction	O
may	O
be	O
important	O
for	O
the	O
coordination	O
of	O
lineage	O
-	O
specific	O
effector	O
functions	O
such	O
as	O
lymphokine	O
production	O
with	O
cell	O
cycle	O
progression	O
in	O
activated	O
T	O
cells	O
.	O

Expression	B-Gene_expression
levels	O
of	O
the	O
thyrotropin	O
receptor	O
gene	O
in	O
autoimmune	O
thyroid	O
disease	O
:	O
coregulation	B-Regulation
with	O
parameters	O
of	O
thyroid	O
function	O
and	O
inverse	O
relation	O
to	O
major	O
histocompatibility	O
complex	O
classes	O
I	O
and	O
II	O
.	O

Using	O
a	O
human	O
TSH	O
receptor	O
(	O
TSH	O
-	O
R	O
)	O
cDNA	O
probe	O
,	O
we	O
investigated	O
TSH	O
-	O
R	O
transcript	B-Transcription
levels	I-Transcription
in	O
13	O
human	O
thyroid	O
fragments	O
by	O
Northern	O
blot	O
analysis	O
;	O
7	O
Graves	O
'	O
disease	O
,	O
2	O
Hashimoto	O
's	O
disease	O
,	O
3	O
endemic	O
goiter	O
,	O
and	O
1	O
healthy	O
thyroid	O
gland	O
were	O
studied	O
.	O

TSH	O
-	O
R	O
expression	B-Gene_expression
levels	O
were	O
variable	O
,	O
but	O
displayed	O
a	O
close	O
correlation	O
to	O
the	O
expression	B-Gene_expression
of	O
thyroid	O
peroxidase	O
(	O
r	O
=	O
0.703	O
;	O
P	O
<	O
0.05	O
)	O
,	O
thyroglobulin	O
(	O
r	O
=	O
0.817	O
;	O
P	O
<	O
0.01	O
)	O
,	O
and	O
the	O
nuclear	O
oncogene	O
c	O
-	O
fos	O
(	O
r	O
=	O
0.935	O
;	O
P	O
<	O
0.001	O
)	O
,	O
but	O
not	O
c	O
-	O
myc	O
.	O

Overall	O
,	O
TSH	O
-	O
R	O
transcript	B-Transcription
levels	I-Transcription
were	O
low	O
or	O
absent	O
in	O
those	O
thyroids	O
in	O
which	O
expression	O
of	O
the	O
major	O
histocompatibility	O
complex	O
class	O
I	O
or	O
II	O
(	O
MHC	O
I	O
or	O
II	O
)	O
was	O
high	O
,	O
thus	O
establishing	O
an	O
inverse	O
relation	O
(	O
MHC	O
I	O
,	O
r	O
=	O
-	O
0.791	O
;	O
P	O
<	O
0.01	O
;	O
MHC	O
II	O
,	O
r	O
=	O
-	O
0.784	O
;	O
P	O
<	O
0.01	O
)	O
.	O

In	O
situ	O
hybridization	O
showed	O
that	O
apart	O
from	O
lymphocytes	O
,	O
thyroid	O
cells	O
themselves	O
were	O
the	O
source	O
of	O
MHC	O
II	O
transcripts	O
.	O

gamma	O
-	O
Interferon	O
expression	B-Gene_expression
was	O
only	O
detectable	O
in	O
1	O
Hashimoto	O
's	O
goiter	O
.	O

Our	O
findings	O
suggest	O
that	O
next	O
to	O
lymphocyte	O
infiltration	O
,	O
active	O
regulatory	O
events	O
in	O
the	O
thyrocyte	O
are	O
responsible	O
for	O
the	O
inverse	O
relation	O
between	O
functional	O
parameters	O
(	O
TSH	O
-	O
R	O
,	O
thyroid	O
peroxidase	O
,	O
thyroglobulin	O
,	O
and	O
c	O
-	O
fos	O
)	O
and	O
immunological	O
markers	O
(	O
MHC	O
I	O
and	O
II	O
)	O
.	O

Regulation	B-Regulation
of	O
the	O
beta	O
-	O
globin	O
locus	O
.	O

Transcription	B-Transcription
of	O
the	O
human	O
beta	O
-	O
globin	O
gene	O
cluster	O
depends	B-Regulation
upon	O
upstream	O
regulatory	O
sequences	O
,	O
which	O
are	O
collectively	O
termed	O
the	O
locus	O
control	O
region	O
.	O

Recent	O
studies	O
have	O
provided	O
new	O
insights	O
into	O
how	O
the	O
individual	O
genes	O
of	O
the	O
cluster	O
are	O
regulated	B-Regulation
through	O
development	O
.	O

The	O
crux	O
of	O
transcriptional	O
activation	O
is	O
how	O
the	O
locus	O
control	O
region	O
communicates	O
with	O
the	O
gene	O
-	O
proximal	O
regulatory	O
elements	O
.	O

Ectopic	O
expression	O
of	O
a	O
conditional	O
GATA	O
-	O
2/estrogen	O
receptor	O
chimera	O
arrests	O
erythroid	O
differentiation	O
in	O
a	O
hormone	O
-	O
dependent	O
manner	O
.	O

The	O
GATA	O
factors	O
are	O
a	O
family	O
of	O
transcriptional	O
regulatory	O
proteins	O
in	O
eukaryotes	O
that	O
share	O
extensive	O
homology	O
in	O
their	O
DNA	O
-	O
binding	O
domains	O
.	O

One	O
enigmatic	O
aspect	O
of	O
GATA	O
factor	O
expression	O
is	O
that	O
several	O
GATA	O
proteins	O
,	O
which	O
ostensibly	O
share	O
the	O
same	O
DNA	O
-	O
binding	O
site	O
specificity	O
,	O
are	O
coexpressed	O
in	O
erythroid	O
cells	O
.	O

To	O
elucidate	O
the	O
roles	O
of	O
individual	O
GATA	O
factors	O
in	O
erythropoiesis	O
,	O
conditional	O
alleles	O
of	O
GATA	O
-	O
1	O
,	O
GATA	O
-	O
2	O
,	O
and	O
GATA	O
-	O
3	O
were	O
prepared	O
by	O
fusing	O
each	O
of	O
the	O
factors	O
to	O
the	O
hormone	O
-	O
binding	O
domain	O
of	O
the	O
human	O
estrogen	O
receptor	O
(	O
ER	O
)	O
.	O

These	O
GATA/ER	O
chimeric	O
factors	O
were	O
shown	O
to	O
be	O
hormone	O
-	O
inducible	O
trans	O
-	O
activating	O
proteins	O
in	O
transient	O
transfection	O
assays	O
.	O

When	O
stably	O
introduced	O
into	O
primary	O
erythroblasts	O
or	O
conditionally	O
transformed	O
erythroid	O
progenitors	O
cells	O
,	O
exogenous	O
GATA	O
-	O
2/ER	O
promoted	O
proliferation	O
and	O
inhibited	O
terminal	O
differentiation	O
in	O
an	O
estrogen	O
-	O
dependent	O
manner	O
.	O

These	O
phenotypic	O
effects	O
are	O
specifically	O
attributable	O
to	O
the	O
action	O
of	O
ectopically	O
expressed	O
GATA	O
-	O
2/ER	O
because	O
erythroblasts	O
expressing	B-Gene_expression
exogenous	O
GATA	O
-	O
2	O
are	O
constitutively	O
arrested	O
in	O
differentiation	O
and	O
because	O
erythroid	O
progenitors	O
expressing	O
either	O
Gal/ER	O
or	O
GATA	O
-	O
3/ER	O
do	O
not	O
display	O
a	O
hormone	O
-	O
responsive	O
block	O
in	O
differentiation	O
.	O

Thus	O
,	O
the	O
GATA	O
-	O
2	O
transcription	O
factor	O
appears	O
to	O
play	O
a	O
role	O
in	O
regulating	O
the	O
self	O
-	O
renewal	O
capacity	O
of	O
early	O
erythroid	O
progenitor	O
cells	O
.	O

Molecular	O
basis	O
of	O
a	O
multiple	O
lymphokine	O
deficiency	O
in	O
a	O
patient	O
with	O
severe	O
combined	O
immunodeficiency	O
.	O

We	O
have	O
previously	O
reported	O
that	O
the	O
T	O
lymphocytes	O
of	O
a	O
child	O
with	O
severe	O
combined	O
immunodeficiency	O
are	O
defective	O
in	O
the	O
transcription	B-Transcription
of	O
several	O
lymphokine	O
genes	O
that	O
include	O
IL2	O
,	O
IL3	O
,	O
IL4	O
,	O
and	O
IL5	O
,	O
which	O
encode	O
interleukins	O
2	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
(	O
IL	O
-	O
2	O
,	O
-	O
3	O
,	O
-	O
4	O
,	O
and	O
-	O
5	O
)	O
.	O

To	O
determine	O
whether	O
the	O
defect	O
in	O
the	O
patient	O
's	O
T	O
lymphocytes	O
involved	B-Regulation
a	O
trans	O
-	O
acting	O
factor	O
common	O
to	O
the	O
affected	O
lymphokine	O
genes	O
,	O
we	O
examined	O
the	O
ability	O
of	O
nuclear	O
factors	O
from	O
the	O
patient	O
's	O
T	O
lymphocytes	O
to	O
bind	B-Binding
response	O
elements	O
present	O
in	O
the	O
regulatory	O
region	O
of	O
IL2	O
.	O

Nuclear	O
factor	O
NF	O
-	O
kB	O
,	O
activation	O
protein	O
1	O
(	O
AP	O
-	O
1	O
)	O
,	O
OCT	O
-	O
1	O
,	O
and	O
NF-IL	O
-	O
2B	O
binding	B-Binding
activity	O
were	O
normal	O
.	O

In	O
contrast	O
,	O
the	O
binding	B-Binding
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
to	O
its	O
response	O
element	O
in	O
the	O
IL2	O
enhancer	O
and	O
to	O
an	O
NF-AT	O
-	O
like	O
response	O
element	O
present	O
in	O
the	O
IL4	O
enhancer	O
was	O
abnormal	O
.	O

To	O
ascertain	O
whether	O
the	O
abnormal	O
NF	O
-	O
AT	O
binding	O
activity	O
was	O
related	O
to	O
an	O
impaired	O
function	O
,	O
we	O
transfected	B-Gene_expression
patient	O
and	O
control	O
T	O
lymphocytes	O
with	O
constructs	O
containing	O
the	O
reporter	O
gene	O
encoding	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
under	B-Regulation
the	I-Regulation
control	I-Regulation
of	O
the	O
entire	O
IL2	O
regulatory	O
region	O
or	O
of	O
multimers	O
of	O
individual	O
enhancer	O
sequences	O
.	O

CAT	O
expression	B-Gene_expression
directed	B-Regulation
by	O
the	O
IL2	O
regulatory	O
region	O
or	O
by	O
a	O
multimer	O
of	O
the	O
NF-AT	O
-	O
binding	O
site	O
was	O
markedly	O
lower	B-Negative_regulation
in	O
the	O
patient	O
relative	O
to	O
controls	O
.	O

In	O
contrast	O
,	O
CAT	O
gene	O
expression	B-Gene_expression
directed	O
by	O
a	O
multimer	O
of	O
the	O
OCT	O
-	O
1	O
proximal	O
(	O
OCT	O
-	O
1p	O
)	O
-	O
binding	O
site	O
was	O
equivalent	B-Negative_regulation
in	O
patient	O
and	O
controls	O
.	O

These	O
results	O
indicate	O
that	O
an	O
abnormality	O
of/or	O
influencing	O
NF	O
-	O
AT	O
may	O
underlie	O
the	O
multiple	O
lymphokine	O
deficiency	O
in	O
this	O
patient	O
.	O

Expression	O
of	O
mRNA	O
for	O
the	O
GATA	O
-	O
binding	O
proteins	O
in	O
human	O
eosinophils	O
and	O
basophils	O
:	O
potential	O
role	O
in	O
gene	O
transcription	O
.	O

The	O
expression	B-Gene_expression
of	O
the	O
hematopoietic	O
transcription	O
factors	O
GATA	O
-	O
1	O
,	O
GATA	O
-	O
2	O
,	O
and	O
GATA	O
-	O
3	O
was	O
studied	O
in	O
eosinophils	O
and	O
basophils	O
.	O

Eosinophils	O
express	B-Transcription
mRNA	I-Transcription
for	O
GATA	O
-	O
1	O
,	O
GATA	O
-	O
2	O
,	O
and	O
GATA	O
-	O
3	O
.	O

Basophils	O
express	B-Gene_expression
GATA	O
-	O
2	O
and	O
GATA	O
-	O
3	O
.	O

Treatment	O
of	O
HL	O
-	O
60	O
eosinophilic	O
sublines	O
with	O
either	O
interleukin	O
-	O
5	O
or	O
butyric	O
acid	O
increased	B-Positive_regulation
the	O
expression	B-Transcription
of	O
GATA	O
-	O
1	O
mRNA	O
concomitant	O
with	O
the	O
expression	O
of	O
eosinophil	O
-	O
specific	O
genes	O
,	O
whereas	O
levels	O
of	O
GATA	O
-	O
2	O
mRNA	O
remained	O
relatively	O
constant	B-Positive_regulation
.	O

The	O
presence	B-Localization
of	O
mRNA	O
for	O
these	O
proteins	O
in	O
eosinophils	O
and	O
basophils	O
suggests	O
that	O
gene	O
transcription	O
in	O
these	O
lineages	O
may	O
be	O
regulated	O
by	O
GATA	O
-	O
binding	O
proteins	O
.	O

Dependence	O
for	O
the	O
proliferative	O
response	O
to	O
erythropoietin	O
on	O
an	O
established	O
erythroid	O
differentiation	O
program	O
in	O
a	O
human	O
hematopoietic	O
cell	O
line	O
,	O
UT	O
-	O
7	O
.	O

Erythroid	O
differentiation	O
involves	O
the	O
activation	O
of	O
a	O
number	O
of	O
erythroid	O
-	O
specific	O
genes	O
,	O
most	O
of	O
which	O
,	O
including	O
the	O
globin	O
genes	O
and	O
the	O
erythropoietin	O
receptor	O
(	O
Epo	O
-	O
R	O
)	O
gene	O
,	O
are	O
,	O
at	O
least	O
in	O
part	O
,	O
regulated	B-Regulation
by	O
the	O
transcription	O
factor	O
GATA	O
-	O
1	O
.	O

In	O
order	O
to	O
understand	O
the	O
relationship	O
,	O
if	O
any	O
,	O
between	O
expression	B-Gene_expression
of	O
GATA	O
-	O
1	O
,	O
response	O
to	O
Epo	O
and	O
erythroid	O
differentiation	O
,	O
we	O
analyzed	O
the	O
expression	B-Gene_expression
of	O
GATA	O
-	O
1	O
,	O
Epo	O
-	O
R	O
and	O
globin	O
genes	O
in	O
an	O
Epo	O
-	O
dependent	O
human	O
cell	O
line	O
,	O
UT	O
-	O
7	O
Epo	O
.	O

The	O
results	O
were	O
compared	O
to	O
those	O
obtained	O
with	O
the	O
parental	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
-	O
dependent	O
cell	O
line	O
,	O
UT	O
-	O
7	O
,	O
which	O
has	O
a	O
predominantly	O
megakaryoblastic	O
phenotype	O
and	O
is	O
unable	O
to	O
proliferate	O
continuously	O
in	O
the	O
presence	O
of	O
Epo	O
.	O

UT	O
-	O
7	O
Epo	O
and	O
UT	O
-	O
7	O
expressed	B-Transcription
similar	O
levels	O
of	O
GATA	O
-	O
1	O
mRNA	O
and	O
binding	B-Binding
activity	I-Binding
.	O

The	O
two	O
lines	O
also	O
expressed	B-Transcription
comparable	O
levels	O
of	O
Epo	O
-	O
R	O
mRNA	O
while	O
the	O
number	O
of	O
Epo	O
-	O
binding	O
sites	O
on	O
UT	O
-	O
7	O
Epo	O
cells	O
was	O
one	O
-	O
sixth	O
the	O
number	O
of	O
UT	O
-	O
7	O
cells	O
(	O
2400	O
+/	O
-	O
3	O
vs.	O
13	O
,	O
800	O
+/	O
-	O
300	O
)	O
.	O

This	O
difference	O
in	O
the	O
number	O
of	O
binding	O
sites	O
could	O
be	O
due	O
to	O
differences	O
in	O
cell	O
surface	O
(	O
UT	O
-	O
7	O
cells	O
are	O
20	O
%	O
smaller	O
than	O
the	O
parental	O
UT	O
-	O
7	O
cells	O
)	O
or	O
in	O
receptor	O
turnover	O
.	O

By	O
Northern	O
analysis	O
,	O
UT	O
-	O
7	O
cells	O
expressed	B-Gene_expression
detectable	O
levels	O
of	O
beta	O
-	O
and	O
gamma	O
-	O
globin	O
but	O
not	O
alpha	O
-	O
globin	O
.	O

In	O
comparison	O
,	O
UT	O
-	O
7	O
Epo	O
cells	O
expressed	B-Gene_expression
alpha	O
-	O
globin	O
and	O
higher	O
levels	O
of	O
gamma	O
-	O
globin	O
(	O
5	O
-	O
fold	O
)	O
and	O
beta	O
-	O
globin	O
(	O
from	O
barely	O
to	O
clearly	O
detectable	O
)	O
.	O

Globin	O
chains	O
(	O
alpha	O
,	O
beta	O
and	O
gamma	O
)	O
were	O
clearly	O
detectable	B-Gene_expression
by	O
affinity	O
chromatography	O
in	O
UT	O
-	O
7	O
Epo	O
but	O
not	O
in	O
UT	O
-	O
7	O
cells	O
.	O

The	O
frequency	O
of	O
the	O
cells	O
which	O
expressed	O
beta	O
-	O
and	O
gamma	O
-	O
globin	O
genes	O
in	O
the	O
two	O
cell	O
populations	O
was	O
measured	O
by	O
immunofluorescence	O
with	O
beta	O
-	O
and	O
gamma	O
-	O
specific	O
antibodies	O
.	O

The	O
number	O
of	O
gamma	O
-	O
positive	O
cells	O
and	O
their	O
fluorescence	O
intensity	O
were	O
higher	O
in	O
UT	O
-	O
7	O
Epo	O
than	O
in	O
UT	O
-	O
7	O
cells	O
(	O
0	O
to	O
17	O
%	O
barely	O
positive	O
cells	O
and	O
23	O
to	O
40	O
%	O
clearly	O
positive	O
cells	O
,	O
respectively	O
)	O
,	O
indicating	O
that	O
the	O
increase	O
in	O
globin	O
mRNA	O
observed	O
in	O
UT	O
-	O
7	O
Epo	O
is	O
due	O
to	O
both	O
an	O
increase	O
of	O
gene	O
expression	O
per	O
cell	O
and	O
an	O
increase	O
in	O
numbers	O
of	O
cells	O
containing	O
gamma	O
-	O
globin	O
.	O

The	O
levels	O
of	O
GATA	O
-	O
1	O
,	O
Epo	O
-	O
R	O
and	O
globin	O
mRNA	O
expressed	B-Transcription
were	O
not	O
affected	B-Regulation
by	O
a	O
24	O
-	O
hour	O
incubation	O
of	O
either	O
cell	O
line	O
with	O
Epo	O
,	O
GM	O
-	O
CSF	O
or	O
interleukin	O
-	O
3	O
(	O
IL	O
-	O
3	O
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Protein	O
kinase	O
C	O
-	O
zeta	O
mediates	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
human	O
immunodeficiency	O
virus	O
-	O
infected	O
monocytes	O
.	O

The	O
molecular	O
mechanisms	O
regulating	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
persistence	O
in	O
a	O
major	O
cell	O
reservoir	O
such	O
as	O
the	O
macrophage	O
remain	O
unknown	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
a	O
transcription	O
factor	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
and	O
is	O
selectively	O
activated	O
following	O
HIV	O
infection	O
of	O
human	O
macrophages	O
.	O

Although	O
little	O
information	O
as	O
to	O
what	O
signal	O
transduction	O
pathways	O
mediate	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
monocytes	O
-	O
macrophages	O
is	O
available	O
,	O
our	O
previous	O
work	O
indicated	O
that	O
classical	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
isoenzymes	O
were	O
not	O
involved	O
in	O
the	O
HIV	O
-	O
mediated	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
focused	O
on	O
atypical	O
PKC	O
isoenzymes	O
.	O

PKC	O
-	O
zeta	O
belongs	O
to	O
this	O
family	O
and	O
is	O
known	O
to	O
be	O
an	O
important	O
step	O
in	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
other	O
cell	O
systems	O
.	O

Immunoblotting	O
experiments	O
with	O
U937	O
cells	O
demonstrate	O
that	O
PKC	O
-	O
zeta	O
is	O
present	B-Gene_expression
in	O
these	O
cells	O
,	O
and	O
its	O
expression	O
can	O
be	O
downmodulated	B-Negative_regulation
by	O
antisense	O
oligonucleotides	O
(	O
AO	O
)	O
.	O

The	O
HIV	O
-	O
mediated	O
NF	O
-	O
kappa	O
B	O
activation	O
is	O
selectively	O
reduced	O
by	O
AO	O
to	O
PKC	O
-	O
zeta	O
.	O

In	O
addition	O
,	O
cotransfection	B-Gene_expression
of	O
a	O
negative	O
dominant	O
molecule	O
of	O
PKC	O
-	O
zeta	O
(	O
PKC	O
-	O
zeta	O
mut	O
)	O
with	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
reporter	O
genes	O
selectively	O
inhibits	O
the	O
HIV	O
-	O
but	O
not	O
phorbol	O
myristate	O
acetate	O
-	O
or	O
lipopolysaccharide	O
-	O
mediated	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

That	O
PKC	O
-	O
zeta	O
is	O
specific	O
in	O
regulating	O
NF	O
-	O
kappa	O
B	O
is	O
concluded	O
from	O
the	O
inability	O
of	O
PKC	O
-	O
zeta	O
(	O
mut	O
)	O
to	O
interfere	O
with	O
the	O
basal	O
or	O
phorbol	O
myristate	O
acetate	O
-	O
inducible	O
CREB	O
-	O
or	O
AP1	O
-	O
dependent	O
transcriptional	O
activity	O
.	O

Lastly	O
,	O
we	O
demonstrate	O
a	O
selective	O
inhibition	O
of	O
p24	O
production	O
by	O
HIV	O
-	O
infected	O
human	O
macrophages	O
when	O
treated	O
with	O
AO	O
to	O
PKC	O
-	O
zeta	O
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
that	O
atypical	O
PKC	O
isoenzymes	O
,	O
including	O
PKC	O
-	O
zeta	O
,	O
participate	O
in	O
the	O
signal	O
transduction	O
pathways	O
by	O
which	O
HIV	O
infection	O
results	O
in	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
human	O
monocytic	O
cells	O
and	O
macrophages	O
.	O

Inhibition	O
of	O
NF-AT	O
-	O
dependent	O
transcription	O
by	O
NF	O
-	O
kappa	O
B	O
:	O
implications	O
for	O
differential	O
gene	O
expression	O
in	O
T	O
helper	O
cell	O
subsets	O
.	O

Activation	O
of	O
individual	O
CD4+	O
T	O
cells	O
results	O
in	O
differential	O
lymphokine	O
expression	O
:	O
interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
is	O
preferentially	O
produced	B-Gene_expression
by	O
T	O
helper	O
type	O
1	O
(	O
TH1	O
)	O
cells	O
,	O
which	O
are	O
involved	O
in	O
cell	O
-	O
mediated	O
immune	O
responses	O
,	O
whereas	O
IL	O
-	O
4	O
is	O
synthesized	B-Gene_expression
by	O
TH2	O
cells	O
,	O
which	O
are	O
essential	O
for	O
humoral	O
immunity	O
.	O

The	O
Ca	O
(	O
2+	O
)	O
-	O
dependent	B-Positive_regulation
factor	O
NF	O
-	O
ATp	O
plays	O
a	O
key	B-Positive_regulation
role	I-Positive_regulation
in	O
the	O
inducible	B-Positive_regulation
transcription	B-Transcription
of	O
both	O
these	O
lymphokine	O
genes	O
.	O

However	O
,	O
while	O
IL2	O
expression	B-Gene_expression
requires	B-Positive_regulation
the	O
contribution	O
of	O
Ca	O
(	O
2+	O
)	O
-	O
and	O
protein	O
kinase	O
C	O
-	O
dependent	O
signals	O
,	O
we	O
report	O
that	O
activation	B-Positive_regulation
of	O
human	O
IL4	O
transcription	B-Transcription
through	O
the	O
Ca	O
(	O
2+	O
)	O
-	O
dependent	O
pathway	O
is	O
diminished	B-Negative_regulation
by	O
protein	O
kinase	O
C	O
stimulation	O
in	O
Jurkat	O
T	O
cells	O
.	O

This	O
phenomenon	O
is	O
due	B-Positive_regulation
to	I-Positive_regulation
mutually	O
exclusive	O
binding	B-Binding
of	O
NF	O
-	O
ATp	O
and	O
NF	O
-	O
kappa	O
B	O
to	O
the	O
P	O
sequence	O
,	O
an	O
element	O
located	O
69	O
bp	O
upstream	O
of	O
the	O
IL4	O
transcription	O
initiation	O
site	O
.	O

Human	O
IL4	O
promoter	O
-	O
mediated	O
transcription	O
is	O
downregulated	O
in	O
Jurkat	O
cells	O
stimulated	O
with	O
the	O
NF	O
-	O
kappa	O
B	O
-	O
activating	O
cytokine	O
tumor	O
necrosis	O
factor	O
alpha	O
and	O
suppressed	O
in	O
RelA	O
-	O
overexpressing	B-Gene_expression
cells	O
.	O

In	O
contrast	O
,	O
protein	O
kinase	O
C	O
stimulation	O
or	O
RelA	O
overexpression	B-Positive_regulation
does	O
not	O
affect	B-Regulation
the	O
activity	O
of	O
a	O
human	O
IL4	O
promoter	O
containing	O
a	O
mouse	O
P	O
sequence	O
,	O
which	O
is	O
a	O
higher	B-Binding
-	I-Binding
affinity	I-Binding
site	I-Binding
for	O
NF	O
-	O
ATp	O
and	O
a	O
lower	B-Binding
-	I-Binding
affinity	I-Binding
site	I-Binding
for	O
RelA	O
.	O

Thus	O
,	O
competition	B-Binding
between	O
two	O
general	O
transcriptional	O
activators	O
,	O
RelA	O
and	O
NF	O
-	O
ATp	O
,	O
mediates	B-Positive_regulation
the	O
inhibitory	B-Negative_regulation
effect	O
of	O
protein	O
kinase	O
C	O
stimulation	O
on	O
IL4	O
expression	B-Gene_expression
and	O
may	O
contribute	O
to	O
differential	O
gene	O
expression	O
in	O
TH	O
cells	O
.	O

Functional	O
characterization	O
of	O
the	O
murine	O
homolog	O
of	O
the	O
B	O
cell	O
-	O
specific	O
coactivator	O
BOB.1/OBF.1	O
.	O

B	O
cell	O
-	O
specific	O
transcriptional	O
promoter	O
activity	O
mediated	O
by	O
the	O
octamer	O
motif	O
requires	O
the	O
Oct1	O
or	O
Oct2	O
protein	O
and	O
additional	O
B	O
cell	O
-	O
restricted	O
cofactors	O
.	O

One	O
such	O
cofactor	O
,	O
BOB.1/OBF.1	O
,	O
was	O
recently	O
isolated	O
from	O
human	O
B	O
cells	O
.	O

Here	O
,	O
we	O
describe	O
the	O
isolation	O
and	O
detailed	O
characterization	O
of	O
the	O
murine	O
homolog	O
.	O

Full	O
-	O
length	O
cDNAs	O
and	O
genomic	O
clones	O
were	O
isolated	O
,	O
and	O
the	O
gene	O
structure	O
was	O
determined	O
.	O

Comparison	O
of	O
the	O
deduced	O
amino	O
acids	O
shows	O
88	O
%	O
sequence	O
identity	O
between	O
mouse	O
and	O
human	O
BOB.1/OBF.1	O
.	O

The	O
NH2	O
-	O
terminal	O
126	O
amino	O
acids	O
of	O
BOB.1/OBF.1	O
are	O
both	O
essential	B-Positive_regulation
and	I-Positive_regulation
sufficient	I-Positive_regulation
for	O
interaction	B-Binding
with	O
the	O
POU	O
domains	O
of	O
either	O
Oct1	O
or	O
Oct2	O
.	O

This	O
protein	O
-	O
protein	O
interaction	O
does	O
not	O
require	B-Positive_regulation
the	O
simultaneous	O
binding	O
of	O
Oct	O
proteins	O
to	O
DNA	O
,	O
and	O
high	O
resolution	O
footprinting	O
of	O
the	O
Oct	O
-	O
DNA	O
interaction	O
reveals	O
that	O
binding	B-Binding
of	O
BOB.1/OBF.1	O
to	O
Oct1	O
or	O
Oct2	O
does	O
not	O
alter	O
the	O
interaction	O
with	O
DNA	O
.	O

BOB.1/OBF.1	O
can	O
efficiently	O
activate	O
octamer	O
-	O
dependent	O
promoters	O
in	O
fibroblasts	O
;	O
however	O
,	O
it	O
fails	O
to	O
stimulate	O
octamer	O
-	O
dependent	O
enhancer	O
activity	O
.	O

Fusion	O
of	O
subdomains	O
of	O
BOB.1/OBF.1	O
with	O
the	O
GAL4	O
DNA	O
binding	O
domain	O
reveals	O
that	O
both	O
NH2	O
-	O
and	O
COOH	O
-	O
terminal	O
domains	O
of	O
BOB.1/OBF.1	O
contribute	O
to	O
full	O
transactivation	O
function	O
,	O
the	O
COOH	O
-	O
terminal	O
domain	O
is	O
more	O
efficient	O
in	O
this	O
transactivation	O
assay	O
.	O

Consistent	O
with	O
the	O
failure	O
of	O
full	O
-	O
length	O
BOB.1/OBF.1	O
to	O
stimulate	O
octamer	O
-	O
dependent	O
enhancer	O
elements	O
in	O
non	O
B	O
cells	O
,	O
the	O
GAL4	O
fusions	O
likewise	O
only	O
stimulate	O
from	O
a	O
promoter	O
-	O
proximal	O
position	O
.	O

Polymorphic	O
nucleotides	O
within	O
the	O
human	O
IL	O
-	O
4	O
promoter	O
that	O
mediate	B-Positive_regulation
overexpression	B-Positive_regulation
of	O
the	O
gene	O
.	O

Atopy	O
,	O
which	O
predisposes	O
individuals	O
to	O
develop	O
asthma	O
,	O
severe	O
systemic	O
anaphylaxis	O
,	O
and	O
atopic	O
dermatitis	O
,	O
is	O
usually	O
associated	O
with	O
dramatically	O
elevated	O
total	O
serum	O
IgE	O
levels	O
and	O
is	O
thought	O
to	O
be	O
controlled	O
by	O
a	O
major	O
susceptibility	O
gene	O
and	O
multiple	O
minor	O
susceptibility	O
genes	O
.	O

A	O
recent	O
sib	O
-	O
pair	O
analysis	O
revealed	O
a	O
tight	O
linkage	O
between	O
markers	O
on	O
5q31.1	O
and	O
a	O
major	O
susceptibility	O
gene	O
controlling	O
total	O
serum	O
IgE	O
levels	O
.	O

Due	O
to	O
its	O
location	O
within	O
this	O
cluster	O
and	O
its	O
biologic	O
role	O
in	O
Ig	O
class	O
switching	O
and	O
Th2	O
cell	O
differentiation	O
,	O
the	O
IL	O
-	O
4	O
gene	O
has	O
emerged	O
as	O
one	O
major	O
candidate	O
for	O
the	O
atopy	O
gene	O
.	O

In	O
one	O
model	O
,	O
polymorphisms	O
within	O
IL	O
-	O
4	O
regulatory	O
elements	O
might	O
result	B-Positive_regulation
in	O
overexpression	B-Gene_expression
of	O
the	O
gene	O
,	O
amplifying	O
Th2	O
cell	O
differentiation	O
and	O
class	O
switching	O
to	O
IgE	O
.	O

In	O
support	O
of	O
this	O
model	O
,	O
we	O
report	O
that	O
the	O
human	O
IL	O
-	O
4	O
promoter	O
exists	O
in	O
multiple	O
allelic	O
forms	O
that	O
exhibit	O
distinct	O
transcriptional	B-Transcription
activities	O
in	O
IL-4	O
-	O
positive	B-Gene_expression
T	O
cells	O
.	O

A	O
particular	O
allele	O
has	O
an	O
unusually	O
high	B-Positive_regulation
transcriptional	B-Transcription
activity	I-Transcription
.	O

A	O
nucleotide	O
substitution	O
within	O
a	O
recently	O
described	O
OAP40	O
element	O
located	O
just	O
upstream	O
of	O
an	O
NF	O
-	O
AT	O
site	O
(	O
P	O
sequence	O
)	O
appears	O
to	O
be	O
largely	O
responsible	O
for	O
the	O
increased	O
promotor	O
strength	O
of	O
this	O
particular	O
allelic	O
form	O
of	O
the	O
IL	O
-	O
4	O
promoter	O
.	O

In	O
EMSAs	O
,	O
this	O
substitution	O
results	O
in	O
a	O
markedly	O
enhanced	O
affinity	O
for	O
sequence	O
-	O
specific	O
complexes	O
exhibiting	O
an	O
AP	O
-	O
1	O
specificity	O
.	O

The	O
identification	O
of	O
allelic	O
nucleotides	O
,	O
which	O
results	B-Positive_regulation
in	O
overexpression	B-Positive_regulation
of	O
the	O
IL	O
-	O
4	O
gene	O
,	O
provides	O
specific	O
targets	O
for	O
a	O
comprehensive	O
screening	O
of	O
atopic	O
and	O
nonatopic	O
individuals	O
and	O
may	O
provide	O
a	O
clue	O
for	O
genetic	O
predisposition	O
for	O
atopy	O
.	O

IL	O
-	O
10	O
cooperates	O
with	O
TNF	O
-	O
alpha	O
to	O
activate	O
HIV	O
-	O
1	O
from	O
latently	O
and	O
acutely	O
infected	O
cells	O
of	O
monocyte/macrophage	O
lineage	O
.	O

IL	O
-	O
10	O
is	O
elevated	B-Positive_regulation
in	O
HIV-1	O
-	O
infected	O
individuals	O
and	O
has	O
been	O
implicated	O
in	O
disease	O
progression	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
IL	O
-	O
10	O
on	O
the	O
activation	O
of	O
HIV	O
-	O
1	O
from	O
infected	O
monocytes	O
and	O
macrophages	O
.	O

Although	O
IL	O
-	O
10	O
alone	O
did	O
not	O
induce	O
HIV	O
-	O
1	O
replication	O
,	O
in	O
the	O
presence	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
10	O
markedly	O
enhanced	O
virion	O
production	O
from	O
a	O
chronically	O
infected	O
promonocytic	O
cell	O
line	O
(	O
U1	O
)	O
and	O
in	O
acutely	O
infected	O
monocyte	O
-	O
derived	O
macrophages	O
.	O

Neutralizing	O
mAbs	O
to	O
IL	O
-	O
10	O
and	O
TNF	O
-	O
alpha	O
indicated	O
that	O
both	O
cytokines	O
were	O
essential	O
for	O
the	O
induction	O
and	O
were	O
required	O
to	O
generate	O
a	O
synergistic	O
increase	O
in	O
virus	O
expression	O
.	O

The	O
effects	O
of	O
the	O
two	O
cytokines	O
were	O
distinguishable	O
functionally	O
since	O
pretreatment	O
with	O
TNF	O
-	O
alpha	O
attenuated	O
the	O
cytokine	O
cooperativity	O
,	O
while	O
pretreatment	O
with	O
IL	O
-	O
10	O
potentiated	O
their	O
cooperativity	O
,	O
suggesting	O
that	O
IL	O
-	O
10	O
and	O
TNF	O
-	O
alpha	O
play	O
different	O
roles	O
in	O
the	O
activation	O
of	O
virus	O
.	O

Northern	O
blot	O
analysis	O
as	O
well	O
as	O
Ab	O
blocking	O
and	O
cytokine	O
secretion	O
studies	O
indicated	O
that	O
the	O
induction	B-Positive_regulation
of	O
either	O
endogenous	O
TNF	O
-	O
alpha	O
or	O
IL	O
-	O
10	O
was	O
not	O
involved	O
in	O
the	O
cooperativity	O
,	O
nor	O
was	O
an	O
up	O
-	O
regulation	O
of	O
TNF	O
-	O
alpha	O
receptors	O
.	O

In	O
combination	O
with	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
10	O
stimulated	O
activating	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
and	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
binding	O
activities	O
and	O
cooperated	O
to	O
increase	O
HIV	O
-	O
1	O
steady	O
-	O
state	O
mRNA	O
levels	O
and	O
enhance	O
long	O
terminal	O
repeat	O
-	O
directed	O
transcription	O
through	O
activation	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
binding	O
sites	O
,	O
suggesting	O
the	O
IL	O
-	O
10	O
effect	O
occurs	O
at	O
least	O
in	O
part	O
at	O
the	O
transcriptional	O
level	O
.	O

These	O
results	O
indicate	O
that	O
IL	O
-	O
10	O
,	O
in	O
addition	O
to	O
down	O
-	O
regulating	O
the	O
cellular	O
immune	O
response	O
to	O
HIV	O
-	O
1	O
,	O
may	O
also	O
play	O
a	O
role	O
in	O
TNF-alpha	O
-	O
mediated	O
activation	O
of	O
HIV	O
-	O
1	O
replication	O
in	O
the	O
monocyte/macrophage	O
lineage	O
.	O

The	O
promoter	O
and	O
5	O
'	O
flanking	O
sequences	O
controlling	B-Regulation
human	O
B29	O
gene	O
expression	B-Gene_expression
.	O

The	O
product	O
of	O
the	O
B-cell	O
-	O
specific	O
B29	O
gene	O
(	O
B29	O
,	O
Ig	O
beta	O
,	O
CD79b	O
)	O
is	O
essential	O
for	O
Ig	O
-	O
mediated	O
B	O
-	O
cell	O
activation	O
via	O
the	O
B	O
-	O
cell	O
antigen	O
receptor	O
complex	O
(	O
BCR	O
)	O
on	O
human	O
and	O
murine	O
B	O
lymphocytes	O
.	O

To	O
better	O
understand	O
the	O
regulation	B-Regulation
of	O
this	O
pivotal	O
gene	O
,	O
we	O
have	O
analyzed	O
the	O
human	O
genomic	O
DNA	O
sequence	O
upstream	O
of	O
the	O
B29	O
ATG	O
start	O
codon	O
for	O
transcriptional	O
control	O
activity	O
.	O

The	O
human	O
B29	O
gene	O
lacks	O
either	O
a	O
TATA	O
or	O
a	O
CAAT	O
box	O
and	O
transcription	O
is	O
initiated	B-Transcription
at	O
multiple	O
sites	O
.	O

The	O
minimal	O
promoter	O
of	O
the	O
human	O
B29	O
gene	O
is	O
contained	O
within	O
a	O
193	O
-	O
bp	O
region	O
5	O
'	O
of	O
these	O
multiple	O
start	O
sites	O
.	O

This	O
minimal	O
promoter	O
exhibits	O
B-cell	O
-	O
specific	O
activity	O
and	O
contains	O
SP1	O
,	O
ETS	O
,	O
OCT	O
,	O
and	O
IKAROS/LYF	O
-	O
1	O
transcription	O
factor	O
motifs	O
.	O

All	O
these	O
motifs	O
are	O
strikingly	O
conserved	O
in	O
sequence	O
and	O
placement	O
relative	O
to	O
the	O
previously	O
characterized	O
murine	O
B29	O
promoter	O
.	O

Additional	O
upstream	O
gene	O
segments	O
dramatically	O
affected	B-Regulation
B29	O
minimal	O
promoter	O
activity	O
.	O

A	O
newly	O
identified	O
motif	O
called	O
the	O
B29	O
conserved	O
sequence	O
(	O
BCS	O
)	O
,	O
found	O
upstream	O
of	O
both	O
human	O
and	O
murine	O
B29	O
promoters	O
,	O
appears	O
to	O
stimulate	B-Regulation
B29	O
transcription	B-Transcription
through	O
a	O
novel	O
mechanism	O
.	O

A	O
single	O
BCS	O
had	O
little	O
effect	B-Regulation
either	O
on	O
the	O
minimal	O
B29	O
promoter	O
or	O
on	O
a	O
heterologous	O
promoter	O
.	O

Instead	O
,	O
the	O
BCS	O
stimulated	B-Positive_regulation
transcription	O
by	O
counteracting	O
5	O
'	O
negative	O
regulatory	O
DNA	O
sequences	O
that	O
block	B-Negative_regulation
the	O
activity	O
of	O
the	O
B29	O
minimal	O
promoter	O
in	O
its	O
absence	O
.	O

These	O
findings	O
indicate	O
that	O
B29	O
gene	O
expression	B-Gene_expression
is	O
controlled	B-Regulation
by	O
the	O
complex	O
interplay	O
of	O
positive	O
and	O
negative	O
regulatory	O
elements	O
.	O

MEK1	O
and	O
the	O
extracellular	O
signal	O
-	O
regulated	O
kinases	O
are	O
required	B-Positive_regulation
for	O
the	O
stimulation	B-Positive_regulation
of	O
IL	O
-	O
2	O
gene	O
transcription	B-Transcription
in	O
T	O
cells	O
.	O

TCR	O
engagement	O
stimulates	B-Positive_regulation
the	I-Positive_regulation
activation	I-Positive_regulation
of	O
the	O
protein	O
kinase	O
Raf	O
-	O
1	O
.	O

Active	O
Raf	O
-	O
1	O
phosphorylates	B-Phosphorylation
and	O
activates	B-Positive_regulation
the	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase/extracellular	O
signal	O
-	O
regulated	O
kinase	O
kinase	O
1	O
(	O
MEK1	O
)	O
,	O
which	O
in	O
turn	O
phosphorylates	B-Phosphorylation
and	O
activates	B-Positive_regulation
the	O
MAP	O
kinases/extracellular	O
signal	O
regulated	O
kinases	O
,	O
ERK1	O
and	O
ERK2	O
.	O

Raf	O
-	O
1	O
activity	O
promotes	B-Positive_regulation
IL	O
-	O
2	O
production	B-Gene_expression
in	O
activated	O
T	O
lymphocytes	O
.	O

Therefore	O
,	O
we	O
sought	O
to	O
determine	O
whether	O
MEK1	O
and	O
ERK	O
activities	O
also	O
stimulate	B-Positive_regulation
IL	O
-	O
2	O
gene	O
transcription	B-Transcription
.	O

Expression	B-Positive_regulation
of	O
constitutively	O
active	O
Raf	O
-	O
1	O
or	O
MEK1	O
in	O
Jurkat	O
T	O
cells	O
enhanced	O
the	O
stimulation	O
of	O
IL	O
-	O
2	O
promoter	O
-	O
driven	O
transcription	O
stimulated	O
by	O
a	O
calcium	O
ionophore	O
and	O
PMA	O
,	O
and	O
together	O
with	O
a	O
calcium	O
ionophore	O
the	O
expression	B-Gene_expression
of	O
each	O
protein	O
was	O
sufficient	O
to	O
stimulate	O
NF	O
-	O
AT	O
activity	O
.	O

Expression	O
of	O
MEK1	O
-	O
interfering	O
mutants	O
inhibited	O
the	O
stimulation	O
of	O
IL	O
-	O
2	O
promoter	O
-	O
driven	O
transcription	O
and	O
blocked	O
the	O
ability	O
of	O
constitutively	O
active	O
Ras	O
and	O
Raf	O
-	O
1	O
to	O
costimulate	O
NF	O
-	O
AT	O
activity	O
with	O
a	O
calcium	O
ionophore	O
.	O

Expression	B-Gene_expression
of	O
the	O
MAP	O
kinase	O
-	O
specific	O
phosphatase	O
,	O
MKP	O
-	O
1	O
,	O
which	O
blocks	O
ERK	O
activation	O
,	O
inhibited	O
IL	O
-	O
2	O
promoter	O
and	O
NF-AT	O
-	O
driven	O
transcription	O
stimulated	O
by	O
a	O
calcium	O
ionophore	O
and	O
PMA	O
,	O
and	O
in	O
addition	O
,	O
MKP	O
-	O
1	O
neutralized	O
the	O
transcriptional	O
enhancement	O
caused	O
by	O
active	O
Raf	O
-	O
1	O
and	O
MEK1	O
expression	B-Positive_regulation
.	O

We	O
conclude	O
that	O
the	O
MAP	O
kinase	O
signal	O
transduction	O
pathway	O
consisting	O
of	O
Raf	O
-	O
1	O
,	O
MEK1	O
,	O
and	O
ERK1	O
and	O
ERK2	O
functions	B-Regulation
in	O
the	O
stimulation	B-Positive_regulation
IL	O
-	O
2	O
gene	O
transcription	B-Transcription
in	O
activated	O
T	O
lymphocytes	O
.	O

Cross	O
-	O
linking	O
of	O
Fc	O
gamma	O
receptors	O
activates	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
-	O
driven	O
transcription	O
in	O
human	O
monocytes	O
.	O

Elevation	O
of	O
the	O
levels	O
of	O
circulating	O
immune	O
complexes	O
frequently	O
accompanies	O
HIV	O
-	O
1	O
infection	O
and	O
is	O
a	O
prognostic	O
indicator	O
of	O
clinical	O
progression	O
from	O
asymptomatic	O
infection	O
to	O
AIDS	O
.	O

Here	O
we	O
report	O
that	O
cross	B-Binding
-	I-Binding
linking	I-Binding
of	O
Fc	O
gamma	O
RI	O
or	O
Fc	O
gamma	O
RII	O
by	O
adherent	O
human	O
IgG	O
or	O
by	O
specific	O
anti	O
-	O
Fc	O
gamma	O
R	O
mAb	O
activates	O
HIV	O
-	O
1	O
gene	O
expression	O
in	O
the	O
human	O
monocytic	O
cell	O
line	O
BF24	O
and	O
increased	O
HIV	O
RNA	O
expression	O
in	O
monocytes	O
from	O
HIV	O
infected	O
patients	O
as	O
assayed	O
by	O
reverse	O
transcription	O
-	O
PCR	O
.	O

In	O
THP	O
-	O
1	O
cells	O
,	O
Fc	O
gamma	O
R	O
cross	O
-	O
linking	O
induced	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
is	O
known	O
to	O
bind	O
to	O
the	O
regulatory	O
region	O
of	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
HIV	O
-	O
1	O
and	O
to	O
activate	O
HIV	O
-	O
1	O
transcription	O
.	O

Anti-TNF	O
-	O
alpha	O
antibody	O
but	O
not	O
anti-IL	O
-	O
1	O
beta	O
antibody	O
strongly	O
inhibited	O
both	O
the	O
induction	O
of	O
HIV-1-LTR	O
-	O
driven	O
transcription	O
and	O
the	O
induction	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
Fc	O
gamma	O
R	O
cross	O
-	O
linking	O
.	O

These	O
results	O
indicate	O
that	O
Fc	O
gamma	O
R	O
can	O
mediate	O
a	O
TNF-alpha	O
-	O
dependent	O
induction	O
of	O
HIV	O
-	O
1	O
gene	O
transcription	O
and	O
suggest	O
that	O
immune	O
complexes	O
may	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
HIV	O
-	O
1	O
infection	O
by	O
augmenting	O
viral	O
replication	O
in	O
monocytes	O
.	O

The	O
effect	O
of	O
Toremifene	O
on	O
the	O
expression	O
of	O
some	O
genes	O
in	O
human	O
mononuclear	O
cells	O
.	O

Toremifene	O
exerts	O
multiple	O
and	O
varied	O
effects	O
on	O
the	O
gene	O
expression	O
of	O
human	O
peripheral	O
mononuclear	O
cells	O
.	O

After	O
short	O
-	O
term	O
,	O
in	O
vitro	O
exposure	O
to	O
therapeutical	O
levels	O
,	O
distinct	O
changes	B-Regulation
in	O
P	O
-	O
glycoprotein	O
,	O
steroid	O
receptors	O
,	O
p53	O
and	O
Bcl	O
-	O
2	O
expression	B-Gene_expression
take	O
place	O
.	O

In	O
view	O
of	O
the	O
increasing	O
use	O
of	O
antiestrogens	O
in	O
cancer	O
therapy	O
and	O
prevention	O
,	O
there	O
is	O
obvious	O
merit	O
in	O
long	O
-	O
term	O
in	O
vivo	O
studies	O
to	O
be	O
conducted	O
.	O

Identification	O
of	O
an	O
ionomycin/cyclosporin	O
A	O
-	O
responsive	O
element	O
within	O
the	O
human	O
T	O
cell	O
receptor	O
gamma	O
enhancer	O
.	O

Activation	O
through	O
the	O
Ca2+/calcineurin	O
pathway	O
is	O
essential	O
to	O
the	O
transcription	O
of	O
many	O
cytokine	O
genes	O
.	O

The	O
conserved	O
cis	O
-	O
acting	O
sequence	O
,	O
GGAAAA	O
,	O
and	O
transcription	O
factors	O
binding	O
to	O
this	O
sequence	O
are	O
involved	O
in	O
the	O
response	O
to	O
increased	O
intracellular	O
Ca2+	O
concentrations	O
.	O

Here	O
we	O
report	O
the	O
identification	O
and	O
importance	O
of	O
the	O
same	O
sequence	O
in	O
a	O
non	O
-	O
cytokine	O
gene	O
,	O
the	O
human	O
T	O
cell	O
receptor	O
gamma	O
(	O
TCRG	O
)	O
enhancer	O
.	O

Results	O
from	O
site	O
-	O
directed	O
mutations	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
strongly	O
suggest	O
that	O
this	O
sequence	O
mediates	B-Positive_regulation
the	O
ionomycin	O
-	O
induced	O
activation	B-Positive_regulation
of	O
the	O
TCRG	O
enhancer	O
.	O

Our	O
studies	O
provide	O
an	O
explanation	O
for	O
a	O
previous	O
observation	O
that	O
TCRG	O
mRNA	O
levels	O
,	O
but	O
not	O
mRNA	O
levels	O
for	O
T	O
cell	O
receptor	O
alpha	O
and	O
-	O
beta	O
,	O
are	O
increased	B-Positive_regulation
by	O
ionomycin	O
treatment	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
human	O
T	O
-	O
cell	O
lines	O
by	O
anetholdithiolthione	O
.	O

Nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
is	O
a	O
redox	O
sensitive	O
cytosolic	O
transcription	O
factor	O
.	O

Redox	O
regulation	O
of	O
NF	O
-	O
kappa	O
B	O
has	O
been	O
implicated	O
in	O
the	O
activation	O
of	O
the	O
human	O
immuno	O
-	O
deficiency	O
virus	O
(	O
HIV	O
)	O
.	O

Therefore	O
,	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
may	O
be	O
an	O
effective	O
strategy	O
for	O
acquired	O
immunodeficiency	O
syndrome	O
therapy	O
.	O

Anetholdithiolthione	O
(	O
ADT	O
,	O
5	O
-	O
[	O
p	O
-	O
methoxyphenyl	O
]	O
-3H	O
-	O
1	O
,	O
2-dithiol-3	O
-	O
thione	O
)	O
is	O
an	O
antioxidant	O
which	O
has	O
been	O
used	O
to	O
protect	O
against	O
acetaminophen	O
-	O
and	O
CCl4	O
-	O
induced	O
hepatotoxicity	O
,	O
lipid	O
peroxidation	O
,	O
radiation	O
injury	O
,	O
and	O
also	O
has	O
been	O
used	O
clinically	O
as	O
an	O
anti	O
-	O
choleretic	O
agent	O
.	O

The	O
present	O
study	O
examined	O
the	O
effect	O
of	O
ADT	O
pretreatment	O
on	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
response	O
to	O
a	O
variety	O
of	O
stimuli	O
such	O
as	O
H2O2	O
,	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
or	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
.	O

PMA	O
and	O
TNF	O
alpha	O
induced	O
activation	O
of	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
in	O
human	O
Jurkat	O
T	O
-	O
cells	O
was	O
partially	O
inhibited	O
by	O
ADT	O
(	O
0.1	O
mM	O
)	O
pretreatment	O
.	O

ADT	O
(	O
0.1	O
mM	O
)	O
also	O
inhibited	O
H2O2	O
induced	O
activation	O
of	O
the	O
transcription	O
factor	O
in	O
the	O
peroxide	O
sensitive	O
human	O
Wurzburg	O
T	O
-	O
cells	O
.	O

Furthermore	O
,	O
ADT	O
treated	O
Wurzburg	O
cells	O
had	O
significantly	O
higher	O
glutathione	O
levels	O
as	O
compared	O
with	O
untreated	O
cells	O
.	O

H2O2	O
induced	O
lipid	O
peroxidation	O
in	O
Wurzburg	O
cells	O
was	O
remarkably	O
inhibited	O
by	O
ADT	O
pretreatment	O
.	O

ADT	O
,	O
a	O
pro	O
-	O
glutathione	O
antioxidant	O
,	O
was	O
observed	O
to	O
be	O
capable	O
of	O
modulating	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

In	O
vivo	O
anergized	O
CD4+	O
T	O
cells	O
express	O
perturbed	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
.	O

Anergy	O
is	O
a	O
major	O
mechanism	O
to	O
ensure	O
antigen	O
-	O
specific	O
tolerance	O
in	O
T	O
lymphocytes	O
in	O
the	O
adult	O
.	O

In	O
vivo	O
,	O
anergy	O
has	O
mainly	O
been	O
studied	O
at	O
the	O
cellular	O
level	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
the	O
T-cell	O
-	O
activating	O
superantigen	O
staphylococcal	O
enterotoxin	O
A	O
(	O
SEA	O
)	O
to	O
investigate	O
molecular	O
mechanisms	O
of	O
T	O
-	O
lymphocyte	O
anergy	O
in	O
vivo	O
.	O

Injection	O
of	O
SEA	O
to	O
adult	O
mice	O
activates	O
CD4+	O
T	O
cells	O
expressing	O
certain	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
variable	O
region	O
beta	O
-	O
chain	O
families	O
and	O
induces	B-Positive_regulation
strong	O
and	O
rapid	O
production	B-Gene_expression
of	O
interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
.	O

In	O
contrast	O
,	O
repeated	O
injections	O
of	O
SEA	O
cause	O
CD4+	O
T	O
-	O
cell	O
deletion	O
and	O
anergy	O
in	O
the	O
remaining	O
CD4+	O
T	O
cells	O
,	O
characterized	O
by	O
reduced	B-Negative_regulation
expression	O
of	O
IL	O
-	O
2	O
at	O
mRNA	B-Transcription
and	O
protein	B-Gene_expression
levels	O
.	O

We	O
analyzed	O
expression	O
of	O
AP	O
-	O
1	O
,	O
NF	O
-	O
kappa	O
B	O
,	O
NF	O
-	O
AT	O
,	O
and	O
octamer	O
binding	O
transcription	O
factors	O
,	O
which	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
IL	O
-	O
2	O
gene	O
promoter	O
activity	O
.	O

Large	O
amounts	O
of	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
and	O
significant	O
quantities	O
of	O
NF	O
-	O
AT	O
were	O
induced	O
in	O
SEA	O
-	O
activated	O
CD4+	O
spleen	O
T	O
cells	O
,	O
whereas	O
Oct	O
-	O
1	O
and	O
Oct	O
-	O
2	O
DNA	O
binding	B-Binding
activity	I-Binding
was	O
similar	O
in	O
both	O
resting	O
and	O
activated	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
anergic	O
CD4+	O
T	O
cells	O
contained	O
severely	O
reduced	B-Negative_regulation
levels	O
of	O
AP	O
-	O
1	O
and	O
Fos/Jun	O
-	O
containing	O
NF	O
-	O
AT	O
complexes	O
but	O
expressed	O
significant	O
amounts	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
Oct	O
binding	O
proteins	O
after	O
SEA	O
stimulation	O
.	O

Resolution	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
demonstrated	O
predominant	O
expression	B-Gene_expression
of	O
p50	O
-	O
p65	O
heterodimers	O
in	O
activated	O
CD4+	O
T	O
cells	O
,	O
while	O
anergic	O
cells	O
mainly	O
expressed	B-Gene_expression
the	O
transcriptionally	O
inactive	O
p50	O
homodimer	O
.	O

These	O
alterations	O
of	O
transcription	O
factors	O
are	O
likely	O
to	O
be	O
responsible	O
for	O
repression	B-Negative_regulation
of	O
IL	O
-	O
2	O
in	O
anergic	O
T	O
cells	O
.	O

Surfactant	O
suppresses	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
human	O
monocytic	O
cells	O
.	O

In	O
addition	O
to	O
biophysical	O
properties	O
,	O
pulmonary	O
surfactant	O
has	O
immunomodulatory	O
activity	O
.	O

We	O
previously	O
demonstrated	O
that	O
both	O
synthetic	O
(	O
Exosurf	O
)	O
and	O
modified	O
natural	O
surfactant	O
(	O
Survanta	O
)	O
downregulated	B-Negative_regulation
endotoxin	O
-	O
stimulated	B-Positive_regulation
inflammatory	O
cytokine	O
mRNA	O
levels	O
and	O
protein	O
products	O
(	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
[	O
TNF	O
]	O
,	O
interleukin-1	O
-	O
beta	O
[	O
IL	O
-	O
1	O
]	O
,	O
interleukin	O
-	O
6	O
[	O
IL	O
-	O
6	O
]	O
)	O
in	O
human	O
alveolar	O
macrophages	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
that	O
both	O
Exosurf	O
and	O
Survanta	O
suppress	B-Negative_regulation
TNF	O
mRNA	O
and	O
secretion	B-Localization
(	O
85	O
+/	O
-	O
4	O
%	O
mean	O
percent	O
inhibition	O
+/	O
-	O
SEM	O
by	O
Exosurf	O
;	O
71	O
+/	O
-	O
6	O
%	O
by	O
Survanta	O
)	O
by	O
endotoxin	O
-	O
stimulated	O
THP	O
-	O
1	O
,	O
a	O
human	O
monocytic	O
cell	O
line	O
.	O

Because	O
surfactant	O
downregulated	O
inflammatory	O
cytokine	O
production	O
similarly	O
in	O
both	O
normal	O
human	O
alveolar	O
macrophages	O
and	O
the	O
THP	O
-	O
1	O
cell	O
line	O
,	O
we	O
used	O
this	O
cell	O
line	O
to	O
investigate	O
whether	O
surfactant	O
affected	O
transcriptional	O
mechanisms	O
.	O

Specifically	O
,	O
we	O
examined	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
activation	O
because	O
it	O
is	O
crucial	O
in	O
transcriptional	B-Regulation
regulation	I-Regulation
of	O
many	O
inflammatory	O
cytokine	O
genes	O
including	O
TNF	O
,	O
IL	O
-	O
1	O
,	O
and	O
IL	O
-	O
6	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
both	O
surfactants	O
decreased	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
presence	B-Gene_expression
of	O
both	O
p65	O
and	O
p50	O
NF	O
-	O
kappa	O
B	O
components	O
in	O
LPS	O
-	O
activated	O
THP	O
-	O
1	O
cells	O
was	O
confirmed	O
by	O
specific	O
antibody	O
induction	O
of	O
supershifts	O
in	O
mobility	O
assays	O
.	O

These	O
results	O
are	O
the	O
first	O
to	O
suggest	O
that	O
surfactant	O
's	O
suppressive	O
effects	O
on	O
inflammatory	O
cytokine	O
production	O
may	O
involve	O
transcriptional	O
regulation	O
through	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

A	O
mammalian	O
histone	O
deacetylase	O
related	O
to	O
the	O
yeast	O
transcriptional	O
regulator	O
Rpd3p	O
[	O
see	O
comments	O
]	O

Trapoxin	O
is	O
a	O
microbially	O
derived	O
cyclotetrapeptide	O
that	O
inhibits	O
histone	O
deacetylation	O
in	O
vivo	O
and	O
causes	O
mammalian	O
cells	O
to	O
arrest	O
in	O
the	O
cell	O
cycle	O
.	O

A	O
trapoxin	O
affinity	O
matrix	O
was	O
used	O
to	O
isolate	O
two	O
nuclear	O
proteins	O
that	O
copurified	O
with	O
histone	O
deacetylase	O
activity	O
.	O

Both	O
proteins	O
were	O
identified	O
by	O
peptide	O
microsequencing	O
,	O
and	O
a	O
complementary	O
DNA	O
encoding	O
the	O
histone	O
deacetylase	O
catalytic	O
subunit	O
(	O
HD1	O
)	O
was	O
cloned	O
from	O
a	O
human	O
Jurkat	O
T	O
cell	O
library	O
.	O

As	O
the	O
predicted	O
protein	O
is	O
very	O
similar	O
to	O
the	O
yeast	O
transcriptional	O
regulator	O
Rpd3p	O
,	O
these	O
results	O
support	O
a	O
role	O
for	O
histone	O
deacetylase	O
as	O
a	O
key	O
regulator	O
of	O
eukaryotic	O
transcription	O
.	O

Coexpression	B-Gene_expression
of	O
the	O
interleukin	O
-	O
13	O
and	O
interleukin	O
-	O
4	O
genes	O
correlates	O
with	O
their	O
physical	O
linkage	B-Binding
in	O
the	O
cytokine	O
gene	O
cluster	O
on	O
human	O
chromosome	O
5q23	O
-	O
31	O
.	O

Interleukin	O
-	O
13	O
(	O
IL	O
-	O
13	O
)	O
and	O
IL	O
-	O
4	O
are	O
cytokines	O
produced	B-Gene_expression
by	O
T	O
cells	O
that	O
are	O
encoded	O
by	O
the	O
q23	O
-	O
31	O
region	O
of	O
human	O
chromosome	O
5	O
.	O

To	O
investigate	O
the	O
regulation	B-Regulation
of	O
IL	O
-	O
13	O
gene	O
expression	B-Gene_expression
by	O
T	O
cells	O
,	O
we	O
isolated	O
and	O
sequenced	O
the	O
human	O
IL	O
-	O
13	O
gene	O
,	O
analyzed	O
its	O
5'	O
-	O
flanking	O
region	O
for	O
potential	O
transcriptional	O
activation	O
elements	O
,	O
and	O
examined	O
its	O
expression	B-Gene_expression
in	O
nontransformed	O
T	O
-	O
lineage	O
cell	O
populations	O
.	O

The	O
human	O
IL	O
-	O
13	O
gene	O
was	O
located	O
12.5	O
-	O
kb	O
upstream	O
of	O
the	O
IL	O
-	O
4	O
gene	O
and	O
2	O
-	O
kb	O
downstream	O
of	O
a	O
CpG	O
island	O
.	O

The	O
IL	O
-	O
13	O
gene	O
5	O
'	O
flank	O
region	O
included	O
a	O
segment	O
with	O
sequence	O
homology	O
to	O
P	O
elements	O
of	O
the	O
IL	O
-	O
4	O
promoter	O
involved	B-Regulation
in	O
transcriptional	B-Positive_regulation
activation	I-Positive_regulation
in	O
T	O
cells	O
.	O

Mutation	O
of	O
the	O
IL	O
-	O
13	O
P	O
element	O
site	O
significantly	O
reduced	B-Negative_regulation
IL	O
-	O
13	O
promoter	O
activity	O
in	B-Regulation
response	I-Regulation
to	I-Regulation
T	O
-	O
cell	O
activation	O
.	O

Oligonucleotides	O
containing	O
the	O
IL	O
-	O
13	O
or	O
IL	O
-	O
4	O
P	O
element	O
sites	O
specifically	O
bound	B-Binding
the	O
transcriptional	O
activator	O
protein	O
,	O
nuclear	O
factor	O
-	O
activated	O
T	O
cells	O
,	O
preformed	O
(	O
NF	O
-	O
ATp	O
)	O
,	O
when	O
incubated	O
with	O
nuclear	O
protein	O
extracts	O
from	O
activated	O
T	O
cells	O
.	O

Similar	O
to	O
IL	O
-	O
4	O
,	O
IL	O
-	O
13	O
mRNA	O
expression	B-Transcription
was	O
highest	O
in	O
T	O
-	O
cell	O
populations	O
enriched	O
for	O
cells	O
that	O
had	O
previously	O
been	O
primed	O
in	O
vivo	O
or	O
in	O
vitro	O
,	O
indicating	O
that	O
priming	O
increases	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
the	O
IL	O
-	O
13	O
and	O
IL	O
-	O
4	O
genes	O
in	O
a	O
coordinate	O
manner	O
.	O

Because	O
the	O
primed	O
T	O
cells	O
contain	O
higher	B-Positive_regulation
levels	I-Positive_regulation
of	O
nuclear	O
NF	O
-	O
ATp	O
,	O
capable	O
of	O
binding	B-Binding
to	O
P	O
elements	O
of	O
the	O
IL	O
-	O
4	O
and	O
IL	O
-	O
13	O
promoters	O
,	O
than	O
do	O
freshly	O
-	O
isolated	O
T	O
cells	O
,	O
the	O
NF-AT	O
-	O
binding	O
P	O
elements	O
are	O
attractive	O
candidates	O
to	O
mediate	B-Positive_regulation
the	O
coordinate	O
expression	B-Gene_expression
of	O
these	O
two	O
cytokine	O
genes	O
.	O

Transactivation	B-Positive_regulation
of	O
the	O
interleukin	O
-	O
1alpha	O
promoter	O
by	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
and	O
type	O
II	O
Tax	O
proteins	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
-	O
infected	O
T	O
-	O
cell	O
lines	O
constitutively	O
produce	B-Gene_expression
high	B-Positive_regulation
levels	I-Positive_regulation
of	O
interleukin	O
-	O
1alpha	O
(	O
IL	O
-	O
1alpha	O
)	O
.	O

To	O
analyze	O
the	O
mechanisms	O
that	O
lead	O
to	O
the	O
expression	B-Gene_expression
of	O
IL	O
-	O
1alpha	O
in	O
HTLV-I	O
-	O
infected	O
cell	O
lines	O
,	O
we	O
studied	O
regulatory	O
regions	O
of	O
the	O
human	O
IL	O
-	O
1alpha	O
promoter	O
involved	O
in	O
activation	B-Positive_regulation
of	O
the	O
IL	O
-	O
1alpha	O
gene	O
.	O

IL	O
-	O
1alpha	O
promoter	O
constructs	O
drive	O
transcription	O
of	O
the	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
reporter	O
gene	O
in	O
HTLV-I	O
-	O
positive	O
MT	O
-	O
2	O
cells	O
,	O
which	O
constitutively	O
produce	B-Gene_expression
IL	O
-	O
1alpha	O
.	O

In	O
a	O
cotransfection	O
assay	O
,	O
the	O
Tax	O
protein	O
of	O
both	O
HTLV	O
-	O
I	O
and	O
HTLV	O
-	O
II	O
specifically	O
activated	O
transcription	O
from	O
the	O
IL	O
-	O
1alpha	O
promoter	O
in	O
an	O
uninfected	O
Jurkat	O
cell	O
line	O
.	O

A	O
mutant	O
Tax	O
protein	O
deficient	O
in	O
transactivation	O
of	O
genes	O
by	O
the	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
pathway	O
was	O
unable	O
to	O
induce	O
transcriptional	O
activity	O
of	O
IL	O
-	O
1alpha	O
promoter	O
-	O
CAT	O
constructs	O
,	O
but	O
was	O
rescued	O
by	O
exogenous	O
provision	O
of	O
p65/p50	O
NF	O
-	O
kappaB	O
.	O

We	O
found	O
that	O
two	O
IL	O
-	O
1alpha	O
kappaB	O
-	O
like	O
sites	O
(	O
positions	O
-	O
1	O
,	O
065	O
to	O
-	O
1	O
,	O
056	O
and	O
+646	O
to	O
+655	O
)	O
specifically	O
formed	O
a	O
complex	O
with	O
NF-kappaB	O
-	O
containing	O
nuclear	O
extract	O
from	O
MT	O
-	O
2	O
cells	O
and	O
that	O
NF	O
-	O
kappaB	O
bound	O
with	O
higher	O
affinity	O
to	O
the	O
3	O
'	O
NF	O
-	O
kappaB	O
binding	O
site	O
than	O
to	O
the	O
5	O
'	O
NF	O
-	O
kappaB	O
site	O
.	O

Moreover	O
,	O
deletion	O
of	O
either	O
5	O
'	O
or	O
3	O
'	O
NF	O
-	O
kappaB	O
sites	O
reduced	B-Negative_regulation
IL	O
-	O
1alpha	O
promoter	O
activity	O
in	O
MT	O
-	O
2	O
cells	O
and	O
transactivation	B-Positive_regulation
of	O
the	O
IL	O
-	O
1alpha	O
promoter	O
by	O
exogenous	O
NF	O
-	O
kappaB	O
and	O
Tax	O
in	O
Jurkat	O
cells	O
.	O

These	O
data	O
suggest	O
a	O
general	B-Regulation
role	I-Regulation
for	O
Tax	O
induction	B-Positive_regulation
of	O
IL	O
-	O
1alpha	O
gene	O
transcription	B-Transcription
by	B-Positive_regulation
the	O
NF	O
-	O
kappaB	O
pathway	O
.	O

Expression	B-Gene_expression
of	O
IL	O
-	O
1alpha	O
by	O
HTLV	O
-	O
I	O
productively	O
infected	O
cells	O
may	O
be	O
important	O
in	O
the	O
hypercalcemia	O
,	O
osteolytic	O
bone	O
lesions	O
,	O
neutrophilia	O
,	O
elevation	O
of	O
C	O
-	O
reactive	O
protein	O
,	O
and	O
fever	O
frequently	O
seen	O
in	O
patients	O
with	O
HTLV-I	O
-	O
induced	O
adult	O
T	O
-	O
cell	O
leukemia/lymphoma	O
.	O

Soluble	O
tumor	O
necrosis	O
factor	O
receptors	O
inhibit	O
phorbol	O
myristate	O
acetate	O
and	O
cytokine	O
-	O
induced	O
HIV	O
-	O
1	O
expression	O
chronically	O
infected	O
U1	O
cells	O
.	O

Recombinant	O
human	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
binding	O
protein	O
-	O
1	O
(	O
r	O
-	O
h	O
TBP	O
-	O
1	O
)	O
and	O
recombinant	O
human	O
soluble	O
dimeric	O
TNF	O
receptor	O
(	O
rhu	O
TNFR	O
:	O
Fc	O
)	O
were	O
used	O
to	O
determine	O
the	O
relative	O
contributions	O
of	O
TNF	O
to	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
cytokine	O
-	O
induced	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
replication	O
in	O
chronically	O
infected	O
cell	O
lines	O
.	O

Treatment	O
of	O
HIV-1	O
-	O
infected	O
promonocytic	O
U1	O
cells	O
with	O
r-h-TBP	O
-	O
1	O
or	O
rhu	O
TNFR	O
:	O
Fc	O
reduced	B-Negative_regulation
PMA	O
-	O
induced	B-Positive_regulation
HIV	O
-	O
1	O
p24	O
antigen	O
production	B-Gene_expression
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
,	O
with	O
a	O
maximal	O
inhibition	O
of	O
approximately	O
90	O
%	O
.	O

Maximal	O
inhibition	B-Negative_regulation
of	O
p24	O
antigen	O
production	B-Gene_expression
in	O
T	O
-	O
lymphocytic	O
ACH	O
-	O
2	O
cells	O
was	O
47	O
%	O
with	O
r-hTBP	O
-	O
1	O
and	O
42	O
%	O
with	O
rhu	O
TNFR	O
:	O
Fc.	O
r-hTBP	O
-	O
1	O
and	O
rhu	O
TNFR	O
:	O
Fc	O
also	O
decreased	B-Negative_regulation
p24	O
antigen	O
synthesized	B-Gene_expression
by	O
U1	O
cells	O
in	B-Positive_regulation
response	I-Positive_regulation
to	I-Positive_regulation
other	O
stimuli	O
,	O
including	O
phytohemagglutinin	O
(	O
PHA	O
)	O
-	O
induced	O
supernatant	O
,	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
,	O
interleukin	O
-	O
6	O
,	O
and	O
TNF	O
.	O

Addition	O
of	O
r-hTBP	O
-	O
1	O
to	O
U1	O
cells	O
during	O
the	O
last	O
4	O
h	O
of	O
a	O
24	O
h	O
incubation	O
with	O
PMA	O
still	O
inhibited	B-Negative_regulation
p24	O
antigen	O
production	B-Gene_expression
by	O
15	O
%	O
.	O

U1	O
cells	O
stimulated	O
with	O
10	O
(	O
-	O
7	O
)	O
M	O
PMA	O
released	B-Localization
approximately	O
1	O
ng/ml	O
endogenous	O
TBP	O
-	O
1	O
with	O
an	O
initial	O
peak	O
observed	O
at	O
1	O
h	O
and	O
a	O
second	O
peak	O
at	O
24	O
h	O
after	B-Positive_regulation
PMA	O
stimulation	O
.	O

r-hTBP	O
-	O
1	O
also	O
partially	O
reversed	O
inhibition	O
of	O
U1	O
cellular	O
proliferation	O
caused	O
by	O
PMA	O
.	O

Both	O
r-hTBP	O
-	O
1	O
and	O
rhu	O
TNFR	O
:	O
Fc	O
blocked	O
PMA	O
induction	O
of	O
nuclear	O
factor	O
(	O
NK	O
)	O
-	O
kappa	O
B	O
DNA	O
-	O
binding	O
activity	O
in	O
U1	O
cells	O
in	O
association	O
with	O
decreases	O
in	O
HIV	O
-	O
1	O
replication	O
.	O

We	O
conclude	O
that	O
soluble	O
TNF	O
receptors	O
can	O
inhibit	O
stimuli	O
-	O
induced	O
HIV	O
-	O
1	O
expression	O
and	O
NK	O
-	O
kappa	O
B	O
DNA	O
-	O
binding	O
activity	O
in	O
chronically	O
infected	O
U1	O
cells	O
.	O

AM580	O
,	O
a	O
stable	O
benzoic	O
derivative	O
of	O
retinoic	O
acid	O
,	O
has	O
powerful	O
and	O
selective	O
cyto	O
-	O
differentiating	O
effects	O
on	O
acute	O
promyelocytic	O
leukemia	O
cells	O
.	O

All	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
is	O
successfully	O
used	O
in	O
the	O
cyto	O
-	O
differentiating	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

Paradoxically	O
,	O
APL	O
cells	O
express	B-Gene_expression
PML	O
-	O
RAR	O
,	O
an	O
aberrant	O
form	O
of	O
the	O
retinoic	O
acid	O
receptor	O
type	O
alpha	O
(	O
RAR	O
alpha	O
)	O
derived	B-Positive_regulation
from	O
the	O
leukemia	O
-	O
specific	O
t	O
(	O
15	O
;	O
17	O
)	O
chromosomal	O
translocation	O
.	O

We	O
show	O
here	O
that	O
AM580	O
,	O
a	O
stable	O
retinobenzoic	O
derivative	O
originally	O
synthesized	O
as	O
a	O
RAR	O
alpha	O
agonist	O
,	O
is	O
a	O
powerful	O
inducer	O
of	O
granulocytic	O
maturation	O
in	O
NB4	O
,	O
an	O
APL	O
-	O
derived	O
cell	O
line	O
,	O
and	O
in	O
freshly	O
isolated	O
APL	O
blasts	O
.	O

After	O
treatment	O
of	O
APL	O
cells	O
with	O
AM580	O
either	O
alone	O
or	O
in	O
combination	O
with	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)	O
,	O
the	O
compound	O
induces	O
granulocytic	O
maturation	O
,	O
as	O
assessed	O
by	O
determination	O
of	O
the	O
levels	O
of	O
leukocyte	O
alkaline	O
phosphatase	O
,	O
CD11b	O
,	O
CD33	O
,	O
and	O
G	O
-	O
CSF	O
receptor	O
mRNA	O
,	O
at	O
concentrations	O
that	O
are	O
10	O
-	O
to	O
100	O
-	O
fold	O
lower	O
than	O
those	O
of	O
ATRA	O
necessary	O
to	O
produce	O
similar	O
effects	O
.	O

By	O
contrast	O
,	O
AM580	O
is	O
not	O
effective	O
as	O
ATRA	O
in	O
modulating	B-Regulation
the	O
expression	B-Gene_expression
of	O
these	O
differentiation	O
markers	O
in	O
the	O
HL	O
-	O
60	O
cell	O
line	O
and	O
in	O
freshly	O
isolated	O
granulocytes	O
obtained	O
from	O
the	O
peripheral	O
blood	O
of	O
chronic	O
myelogenous	O
leukemia	O
patients	O
during	O
the	O
stable	O
phase	O
of	O
the	O
disease	O
.	O

In	O
NB4	O
cells	O
,	O
two	O
other	O
synthetic	O
nonselective	O
RAR	O
ligands	O
are	O
capable	O
of	O
inducing	B-Positive_regulation
LAP	O
as	O
much	O
as	O
AM580	O
,	O
whereas	O
RAR	O
beta	O
-	O
or	O
RAR	O
gamma	O
-	O
specific	O
ligands	O
are	O
totally	O
ineffective	O
.	O

These	O
results	O
show	O
that	O
AM580	O
is	O
more	O
powerful	O
than	O
ATRA	O
in	O
modulating	O
the	O
expression	O
of	O
differentiation	O
antigens	O
only	O
in	O
cells	O
in	O
which	O
PML	O
-	O
RAR	O
is	O
present	B-Gene_expression
.	O

Binding	O
experiments	O
,	O
using	O
COS	O
-	O
7	O
cells	O
transiently	O
transfected	O
with	O
PML	O
-	O
RAR	O
and	O
the	O
normal	O
RAR	O
alpha	O
,	O
show	O
that	O
AM580	O
has	O
a	O
lower	O
affinity	B-Binding
than	O
ATRA	O
for	O
both	O
receptors	O
.	O

However	O
,	O
in	O
the	O
presence	O
of	O
PML	O
-	O
RAR	O
,	O
the	O
synthetic	O
retinoid	O
is	O
a	O
much	O
better	O
transactivator	O
of	O
retinoic	O
acid	O
-	O
responsive	O
element	O
-	O
containing	O
promoters	O
than	O
the	O
natural	O
retinoid	O
,	O
whereas	O
,	O
in	O
the	O
presence	O
of	O
RAR	O
alpha	O
,	O
AM580	O
and	O
ATRA	O
have	O
similar	O
activity	O
.	O

This	O
may	O
explain	O
the	O
strong	O
cyto	O
-	O
differentiating	O
potential	O
of	O
AM580	O
in	O
PML-RAR	O
-	O
containing	B-Gene_expression
leukemic	O
cells	O
.	O

Transcriptional	O
basis	O
for	O
hyporesponsiveness	B-Regulation
of	O
the	O
human	O
inducible	O
nitric	O
oxide	O
synthase	O
gene	O
to	O
lipopolysaccharide/interferon	O
-	O
gamma	O
.	O

The	O
work	O
reported	O
here	O
resolves	O
,	O
at	O
the	O
level	O
of	O
gene	O
regulation	O
,	O
the	O
controversy	O
as	O
to	O
whether	O
or	O
not	O
human	O
monocytes/macrophages	O
can	O
produce	O
nitric	O
oxide	O
(	O
NO	O
)	O
when	O
stimulated	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
with	O
or	O
without	O
co	O
-	O
stimulation	O
by	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
.	O

Studies	O
included	O
structural	O
comparison	O
of	O
the	O
promoters	O
for	O
human	O
and	O
mouse	O
inducible	O
NO	O
synthase	O
(	O
iNOS	O
)	O
genes	O
,	O
transfection	O
and	O
assay	O
of	O
human	O
and	O
mouse	O
iNOS	O
promoter	O
regions	O
in	O
response	B-Regulation
to	O
LPS	O
+/	O
-	O
IFN	O
-	O
gamma	O
,	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
of	O
kappa	O
B	O
response	O
elements	O
.	O

Two	O
explanations	B-Positive_regulation
for	O
hyporesponsiveness	B-Regulation
of	O
the	O
human	O
iNOS	O
promoter	O
to	O
LPS	O
+/	O
-	O
IFN	O
-	O
gamma	O
were	O
found	O
:	O
(	O
1	O
)	O
multiple	O
inactivating	O
nucleotide	O
substitutions	O
in	O
the	O
human	O
counterpart	O
of	O
the	O
enhancer	O
element	O
that	O
has	O
been	O
shown	O
to	O
regulate	B-Negative_regulation
LPS/IFN	O
-	O
gamma	O
induced	B-Positive_regulation
expression	B-Gene_expression
of	O
the	O
mouse	O
iNOS	O
gene	O
;	O
and	O
(	O
2	O
)	O
and	O
absence	O
of	O
one	O
or	O
more	O
nuclear	O
factors	O
in	O
human	O
macrophages	O
(	O
e.g.	O
,	O
an	O
LPS	O
-	O
inducible	O
nuclear	O
factor	O
-	O
kappa	O
B/Rel	O
complex	O
)	O
,	O
that	O
is	O
(	O
are	O
)	O
required	B-Positive_regulation
for	O
maximal	O
expression	B-Gene_expression
of	O
the	O
gene	O
.	O

The	O
importance	O
of	O
resolution	O
of	O
this	O
controversy	O
is	O
that	O
future	O
research	O
in	O
this	O
area	O
should	O
be	O
directed	O
toward	O
the	O
understanding	O
of	O
alternative	O
mechanisms	O
that	O
can	O
result	O
in	O
the	O
successful	O
production	O
of	O
NO	O
.	O

GATA	O
transcription	O
factors	O
associate	O
with	O
a	O
novel	O
class	O
of	O
nuclear	O
bodies	O
in	O
erythroblasts	O
and	O
megakaryocytes	O
.	O

The	O
nuclear	O
distribution	O
of	O
GATA	O
transcription	O
factors	O
in	O
murine	O
haemopoietic	O
cells	O
was	O
examined	O
by	O
indirect	O
immunofluorescence	O
.	O

Specific	O
bright	B-Gene_expression
foci	I-Gene_expression
of	O
GATA	O
-	O
1	O
fluorescence	O
were	O
observed	O
in	O
erythroleukaemia	O
cells	O
and	O
primary	O
murine	O
erythroblasts	O
and	O
megakaryocytes	O
,	O
in	O
addition	O
to	O
diffuse	O
nucleoplasmic	O
localization	B-Localization
.	O

These	O
foci	O
,	O
which	O
were	O
preferentially	O
found	B-Localization
adjacent	O
to	O
nucleoli	O
or	O
at	O
the	O
nuclear	O
periphery	O
,	O
did	O
not	O
represent	O
sites	O
of	O
active	O
transcription	O
or	O
binding	B-Binding
of	O
GATA	O
-	O
1	O
to	O
consensus	O
sites	O
in	O
the	O
beta	O
-	O
globin	O
loci	O
.	O

Immunoelectron	O
microscopy	O
demonstrated	O
the	O
presence	O
of	O
intensely	O
labelled	O
structures	O
likely	O
to	O
represent	O
the	O
GATA	O
-	O
1	O
foci	O
seen	O
by	O
immunofluorescence	O
.	O

The	O
GATA	O
-	O
1	O
nuclear	O
bodies	O
differed	O
from	O
previously	O
described	O
nuclear	O
structures	O
and	O
there	O
was	O
no	O
co	B-Localization
-	I-Localization
localization	I-Localization
with	O
nuclear	O
antigens	O
involved	O
in	O
RNA	O
processing	O
or	O
other	O
ubiquitous	O
(	O
Spl	O
,	O
c	O
-	O
Jun	O
and	O
TBP	O
)	O
or	O
haemopoietic	O
(	O
NF	O
-	O
E2	O
)	O
transcription	O
factors	O
.	O

Interestingly	O
,	O
GATA	O
-	O
2	O
and	O
GATA	O
-	O
3	O
proteins	O
also	O
localized	B-Localization
to	O
the	O
same	O
nuclear	O
bodies	O
in	O
cell	O
lines	O
co	B-Gene_expression
-	I-Gene_expression
expressing	I-Gene_expression
GATA	O
-	O
1	O
and	O
-	O
2	O
or	O
GATA	O
-	O
1	O
and	O
-	O
3	O
gene	O
products	O
.	O

This	O
pattern	O
of	O
distribution	O
is	O
,	O
thus	O
far	O
,	O
unique	O
to	O
the	O
GATA	O
transcription	O
factors	O
and	O
suggests	O
a	O
protein	O
-	O
protein	O
interaction	O
with	O
other	O
components	O
of	O
the	O
nuclear	O
bodies	O
via	O
the	O
GATA	O
zinc	O
finger	O
domain	O
.	O

Permanent	O
occupancy	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
enhancer	O
by	O
NF	O
-	O
kappa	O
B	O
is	O
needed	O
for	O
persistent	O
viral	O
replication	O
in	O
monocytes	O
.	O

This	O
work	O
aimed	O
to	O
ascertain	O
the	O
role	O
of	O
kappaB	O
-	O
responsive	O
elements	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
enhancer	O
not	O
only	O
in	O
early	O
initiation	O
but	O
also	O
in	O
long	O
-	O
term	O
maintenance	O
of	O
proviral	O
transcription	O
in	O
cells	O
of	O
the	O
monocytic	O
lineage	O
.	O

For	O
this	O
purpose	O
,	O
we	O
used	O
three	O
main	O
approaches	O
.	O

The	O
first	O
was	O
to	O
abruptly	O
terminate	O
tumor	O
necrosis	O
factor	O
-	O
induced	O
NF	O
-	O
kappaB	O
binding	O
to	O
the	O
enhancer	O
sequences	O
in	O
U1	O
monocytic	O
cells	O
,	O
using	O
a	O
short	O
pulse	O
of	O
exogenous	O
tumor	O
necrosis	O
factor	O
.	O

This	O
resulted	O
in	O
concomitant	O
decrease	O
in	O
nuclear	O
NF	O
-	O
kappaB	O
DNA	O
-	O
binding	O
activity	O
and	O
endogenous	O
long	O
terminal	O
repeat	O
transcriptional	O
activity	O
.	O

The	O
second	O
was	O
to	O
suppress	O
the	O
permanent	O
NF	O
-	O
kappaB	O
translocation	O
induced	O
by	O
HIV	O
-	O
1	O
replication	O
itself	O
in	O
chronically	O
infected	O
U937	O
cells	O
,	O
using	O
a	O
specific	O
proteasome	O
inhibitor	O
(	O
Z-LLL	O
-	O
H	O
)	O
.	O

As	O
early	O
as	O
2	O
h	O
after	O
addition	O
of	O
the	O
inhibitor	O
to	O
the	O
culture	O
medium	O
,	O
there	O
was	O
an	O
inhibition	O
of	O
both	O
constitutive	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
HIV	O
-	O
1	O
genome	O
expression	O
.	O

The	O
third	O
approach	O
was	O
to	O
monitor	O
the	O
replication	O
competence	O
in	O
U937	O
cells	O
of	O
an	O
infectious	O
HIV	O
-	O
1	O
provirus	O
carrying	O
point	O
mutations	O
in	O
the	O
kappaB	O
-	O
responsive	O
elements	O
of	O
both	O
long	O
terminal	O
repeats	O
.	O

Compared	O
with	O
its	O
wild	O
-	O
type	O
counterpart	O
,	O
this	O
mutated	O
provirus	O
showed	O
a	O
profoundly	O
decreased	O
,	O
Z-LLL-H	O
-	O
insensitive	O
transcriptional	O
and	O
replicative	O
activity	O
in	O
U937	O
monocytes	O
.	O

Together	O
,	O
our	O
results	O
indicate	O
that	O
occupancy	B-Binding
of	O
the	O
viral	O
enhancer	O
by	O
NF	O
-	O
kappaB	O
(	O
p50/p65	O
)	O
heterodimers	O
is	O
required	O
for	O
ongoing	O
transcription	O
of	O
integrated	O
HIV	O
provirus	O
in	O
monocytes	O
,	O
even	O
in	O
cells	O
chronically	O
infected	O
and	O
permanently	O
producing	B-Gene_expression
functional	O
HIV	O
Tat	O
protein	O
.	O

Thus	O
,	O
the	O
ability	O
of	O
HIV	O
-	O
1	O
replication	O
to	O
activate	O
NF	O
-	O
kappaB	O
is	O
crucial	O
to	O
the	O
intense	O
self	O
-	O
perpetuated	O
viral	O
transcription	O
observed	O
in	O
cells	O
of	O
the	O
monocytic	O
lineage	O
.	O

Efficient	O
transcription	O
and	O
replication	O
of	O
simian	O
immunodeficiency	O
virus	O
in	O
the	O
absence	O
of	O
NF	O
-	O
kappaB	O
and	O
Sp1	O
binding	O
elements	O
.	O

Ten	O
mutants	O
of	O
the	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
SIVmac239	O
bearing	O
deletions	O
(	O
delta	O
)	O
or	O
substitutions	O
(	O
subst	O
)	O
in	O
the	O
NF	O
-	O
kappaB	O
and/or	O
Sp1	O
binding	O
elements	O
were	O
created	O
,	O
and	O
the	O
replicative	O
capacities	O
of	O
the	O
mutants	O
were	O
analyzed	O
.	O

All	O
mutants	O
,	O
including	O
one	O
extensively	O
mutagenized	O
strain	O
entirely	O
missing	O
the	O
NF	O
-	O
kappaB	O
and	O
four	O
Spl	O
binding	O
elements	O
,	O
replicated	O
with	O
wild	O
-	O
type	O
kinetics	O
and	O
to	O
a	O
wild	O
-	O
type	O
level	O
in	O
peripheral	O
blood	O
mononuclear	O
cell	O
cultures	O
in	O
50	O
to	O
100	O
%	O
of	O
the	O
experiments	O
.	O

One	O
group	O
of	O
mutants	O
replicated	O
very	O
similarly	O
to	O
SIVmac239	O
in	O
kinetics	O
and	O
yield	O
in	O
CEMxl74	O
cells	O
(	O
2xNFKappaB	O
>	O
or	O
=	O
SlVmac239	O
approximately	O
deltaNFkappaB	O
approximately	O
deltaSpl234	O
approximately	O
substNFkappaB	O
approximately	O
substSpl2	O
approximately	O
substSp23	O
)	O
,	O
while	O
a	O
second	O
group	O
replicated	O
with	O
delayed	O
or	O
slightly	O
delayed	O
kinetics	O
in	O
CEMxl74	O
cells	O
(	O
SIVmac239	O
>	O
substSp34	O
>	O
deltaNFkappaBdeltaSpl234	O
approximately	O
deltaNFkappaBdeltaSp1	O
>	O
substSpl234	O
)	O
.	O

Reversions	O
or	O
additional	O
mutations	O
were	O
not	O
detected	O
in	O
the	O
U3	O
and	O
R	O
regions	O
of	O
proviral	O
DNA	O
from	O
CEMxl74	O
cells	O
infected	O
with	O
the	O
SIVmac239	O
mutants	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
mutants	O
of	O
SIVmacMER	O
(	O
a	O
macrophage	O
-	O
competent	O
derivative	O
of	O
SIVmac239	O
)	O
were	O
tested	O
in	O
peripheral	O
blood	O
mononuclear	O
cell	O
and	O
CEMx174	O
cultures	O
.	O

However	O
,	O
the	O
growth	O
of	O
most	O
mutated	O
viruses	O
was	O
suppressed	O
in	O
primary	O
rhesus	O
monkey	O
alveolar	O
macrophages	O
(	O
SIVmacMER	O
approximately	O
2xNFkappaB	O
approximately	O
substNFkappaB	O
>	O
deltaNFkappaB	O
>	O
deltaNFkappaBdeltaSpl234	O
approximately	O
deltaNFkappaBdeltaSpl	O
>	O
deltaSpl234	O
approximately	O
substSpl2	O
>	O
substSp23	O
approximately	O
substSp34	O
approximately	O
substSpl234	O
>	O
or	O
=	O
SIVmac239	O
)	O
.	O

Thus	O
,	O
changes	O
in	O
the	O
Sp1	O
binding	O
sites	O
had	O
the	O
most	O
dramatic	O
effects	O
on	O
SIVmac	O
replication	O
in	O
primary	O
macrophage	O
cultures	O
.	O

Analysis	O
of	O
long	O
terminal	O
repeat	O
-	O
driven	O
secreted	O
alkaline	O
phosphatase	O
activity	O
in	O
transient	O
assays	O
showed	O
that	O
,	O
unlike	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
the	O
SIV	O
long	O
terminal	O
repeat	O
possesses	O
an	O
enhancer	O
region	O
just	O
upstream	O
of	O
the	O
NF	O
-	O
kappaB	O
element	O
which	O
maintains	O
significant	O
levels	O
of	O
basal	O
transcription	O
in	O
the	O
absence	O
of	O
NF	O
-	O
kappaB	O
and	O
Sp1	O
sites	O
.	O

This	O
region	O
is	O
responsive	O
to	O
transactivation	O
by	O
Tat	O
.	O

In	O
addition	O
,	O
the	O
SIV	O
TATA	O
box	O
was	O
shown	O
to	O
be	O
stronger	O
than	O
that	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

Therefore	O
,	O
the	O
surprisingly	O
high	O
replicative	O
capacity	O
of	O
NF	O
-	O
kappaB	O
and	O
Sp1	O
binding	O
site	O
mutants	O
of	O
SIVmac	O
is	O
due	O
to	O
unique	O
features	O
or	O
the	O
enhancer/promoter	O
region	O
.	O

Inactivation	B-Negative_regulation
of	O
IkappaBbeta	O
by	O
the	O
tax	O
protein	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
:	O
a	O
potential	O
mechanism	O
for	O
constitutive	O
induction	O
of	O
NF	O
-	O
kappaB	O
.	O

In	O
resting	O
T	O
lymphocytes	O
,	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
is	O
sequestered	O
in	O
the	O
cytoplasm	O
via	O
interactions	B-Binding
with	O
members	O
of	O
the	O
I	O
kappa	O
B	O
family	O
of	O
inhibitors	O
,	O
including	O
IkappaBalpha	O
and	O
IkappaBbeta	O
.	O

During	O
normal	O
T	O
-	O
cell	O
activation	O
,	O
IkappaBalpha	O
is	O
rapidly	O
phosphorylated	B-Phosphorylation
,	O
ubiquitinated	O
,	O
and	O
degraded	B-Protein_catabolism
by	B-Positive_regulation
the	O
26S	O
proteasome	O
,	O
thus	O
permitting	O
the	O
release	O
of	O
functional	O
NF	O
-	O
kappaB	O
.	O

In	O
contrast	O
to	O
its	O
transient	O
pattern	O
of	O
nuclear	O
induction	O
during	O
an	O
immune	O
response	O
,	O
NF	O
-	O
kappaB	O
is	O
constitutively	O
activated	O
in	O
cells	O
expressing	B-Gene_expression
the	O
Tax	O
transforming	O
protein	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
1	O
)	O
.	O

Recent	O
studies	O
indicate	O
that	O
HTLV	O
-	O
1	O
Tax	O
targets	B-Positive_regulation
IkappaBalpha	O
to	O
the	O
ubiquitin	B-Protein_catabolism
-	I-Protein_catabolism
proteasome	I-Protein_catabolism
pathway	I-Protein_catabolism
.	O

However	O
,	O
it	O
remains	O
unclear	O
how	O
this	O
viral	O
protein	O
induces	O
a	O
persistent	O
rather	O
than	O
transient	O
NF	O
-	O
kappaB	O
response	O
.	O

In	O
this	O
report	O
,	O
we	O
provide	O
evidence	O
that	O
in	O
addition	O
to	O
acting	B-Regulation
on	O
IkappaBalpha	O
,	O
Tax	O
stimulates	O
the	O
turnover	O
Of	O
IkappaBbeta	O
via	O
a	O
related	O
targeting	O
mechanism	O
.	O

Like	O
IkappaBalpha	O
,	O
Tax	O
-	O
mediated	B-Positive_regulation
breakdown	B-Protein_catabolism
of	O
IkappaBbeta	O
in	O
transfected	B-Gene_expression
T	O
lymphocytes	O
is	O
blocked	B-Negative_regulation
either	O
by	O
cell	O
-	O
permeable	O
proteasome	O
inhibitors	O
or	O
by	O
mutation	O
Of	O
IkappaBbeta	O
at	O
two	O
serine	O
residues	O
present	O
within	O
its	O
N	O
-	O
terminal	O
region	O
.	O

Despite	O
the	O
dual	O
specificity	O
of	O
HTLV	O
-	O
1	O
Tax	O
for	O
IkappaBalpha	O
and	O
IkappaBbeta	O
at	O
the	O
protein	O
level	O
,	O
Tax	O
selectively	O
stimulates	B-Positive_regulation
NF-kappaB	O
-	O
directed	B-Positive_regulation
transcription	B-Transcription
of	O
the	O
IkappaBalpha	O
gene	O
.	O

Consequently	O
,	O
IkappaBbeta	O
protein	O
expression	B-Gene_expression
is	O
chronically	O
downregulated	B-Negative_regulation
in	O
HTLV-1	O
-	O
infected	O
T	O
lymphocytes	O
.	O

These	O
findings	O
with	O
IkappaBbeta	O
provide	O
a	O
potential	O
mechanism	O
for	O
the	O
constitutive	O
activation	O
of	O
NF	O
-	O
kappaB	O
in	O
Tax	O
-	O
expressing	B-Gene_expression
cells	O
.	O

Role	B-Regulation
of	O
EGR1	O
in	O
regulation	B-Regulation
of	O
stimulus	O
-	O
dependent	B-Positive_regulation
CD44	O
transcription	B-Transcription
in	O
B	O
lymphocytes	O
.	O

The	O
immediate	O
-	O
early	O
gene	O
egr	O
-	O
1	O
encodes	O
a	O
transcription	O
factor	O
(	O
EGR1	O
)	O
that	O
links	O
B	O
-	O
cell	O
antigen	O
receptor	O
(	O
BCR	O
)	O
signals	O
to	O
downstream	O
activation	O
events	O
through	O
the	O
regulation	O
of	O
previously	O
unidentified	O
target	O
genes	O
.	O

Here	O
we	O
identify	O
the	O
gene	O
encoding	O
the	O
lymphocyte	O
homing	O
and	O
migration	O
protein	O
CD44	O
as	O
a	O
target	O
of	O
EGR1	O
regulation	B-Regulation
in	O
B	O
cells	O
.	O

BCR	O
-	O
induced	O
increases	B-Positive_regulation
in	O
CD44	O
mRNA	O
expression	B-Transcription
and	I-Transcription
transcription	I-Transcription
levels	O
are	O
shown	O
to	O
occur	O
in	O
EGR1	O
-	O
expressing	B-Gene_expression
but	O
not	O
in	O
nonexpressing	B-Gene_expression
subclones	O
of	O
the	O
B	O
-	O
cell	O
line	O
WEHI	O
-	O
231	O
.	O

Kinetics	O
of	O
egr	O
-	O
1	O
transcription	B-Transcription
and	O
the	O
appearance	B-Localization
of	O
nuclear	O
EGR1	O
protein	O
precede	O
CD44	O
induction	B-Positive_regulation
and	O
occur	B-Positive_regulation
within	O
30	O
min	O
after	O
stimulation	O
in	O
the	O
EGR1	O
-	O
expressing	B-Gene_expression
subclone	O
.	O

A	O
single	O
EGR1	O
binding	O
motif	O
is	O
demonstrated	O
at	O
bp	O
-	O
301	O
of	O
the	O
human	O
CD44	O
promoter	O
.	O

Cotransfection	B-Positive_regulation
of	O
a	O
CD44	O
promoter	O
-	O
chloramphenicol	O
acetyltransferase	O
reporter	O
construct	O
with	O
an	O
egr	O
-	O
1	O
expression	B-Gene_expression
vector	O
resulted	O
in	O
a	O
6.5	O
-	O
to	O
8.5	O
-	O
fold	O
induction	B-Positive_regulation
of	O
transcriptional	B-Transcription
activity	I-Transcription
relative	O
to	O
an	O
empty	O
expression	O
vector	O
.	O

The	O
EGR1	O
binding	O
motif	O
was	O
shown	O
to	O
be	O
necessary	O
for	O
stimulus	O
-	O
induced	O
expression	O
of	O
a	O
CD44	O
promoter	O
-	O
chloramphenicol	O
acetyltransferase	O
reporter	O
construct	O
in	O
nontransformed	O
B	O
lymphocytes	O
and	O
was	O
required	O
for	O
transactivation	O
by	O
an	O
EGR1	O
expression	O
vector	O
in	O
a	O
B	O
-	O
cell	O
line	O
.	O

These	O
studies	O
identify	O
EGR1	O
as	O
an	O
intermediary	B-Positive_regulation
linking	I-Positive_regulation
BCR	O
-	O
derived	O
signals	O
to	O
the	O
induction	B-Positive_regulation
of	O
CD44	O
.	O

The	O
relevance	O
of	O
these	O
molecular	O
events	O
to	O
BCR	O
signal	O
transduction	O
and	O
antigen	O
-	O
stimulated	O
B-cell	O
-	O
mediated	O
immune	O
responses	O
is	O
discussed	O
.	O

Identification	O
of	O
an	O
inducible	O
regulator	B-Regulation
of	O
c	O
-	O
myb	O
expression	B-Gene_expression
during	O
T	O
-	O
cell	O
activation	O
.	O

Resting	O
T	O
cells	O
express	B-Gene_expression
very	O
low	O
levels	O
of	O
c	O
-	O
Myb	O
protein	O
.	O

During	O
T	O
-	O
cell	O
activation	O
,	O
c	O
-	O
myb	O
expression	B-Gene_expression
is	O
induced	B-Positive_regulation
and	O
much	O
of	O
the	O
increase	O
in	O
expression	O
occurs	O
at	O
the	O
transcriptional	O
level	O
.	O

We	O
identified	O
a	O
region	O
of	O
the	O
c	O
-	O
myb	O
5	O
'	O
flanking	O
sequence	O
that	O
increased	B-Positive_regulation
c	O
-	O
myb	O
expression	B-Gene_expression
during	O
T	O
-	O
cell	O
activation	O
.	O

In	O
vivo	O
footprinting	O
by	O
ligation	O
-	O
mediated	O
PCR	O
was	O
performed	O
to	O
correlate	O
in	O
vivo	O
protein	O
binding	O
with	O
functional	O
activity	O
.	O

A	O
protein	O
footprint	O
was	O
visible	O
over	O
this	O
region	O
of	O
the	O
c	O
-	O
myb	O
5	O
'	O
flanking	O
sequence	O
in	O
activated	O
T	O
cells	O
but	O
not	O
in	O
unactivated	O
T	O
cells	O
.	O

An	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
with	O
nuclear	O
extract	O
from	O
activated	O
T	O
cells	O
and	O
an	O
oligonucleotide	O
of	O
this	O
binding	O
site	O
demonstrated	O
a	O
new	O
protein	O
-	O
DNA	O
complex	O
,	O
referred	O
to	O
as	O
CMAT	O
for	O
c	O
-	O
myb	O
in	O
activated	O
T	O
cells	O
;	O
this	O
complex	O
was	O
not	O
present	O
in	O
unactivated	O
T	O
cells	O
.	O

Because	O
the	O
binding	O
site	O
showed	O
some	O
sequence	O
similarity	O
with	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
binding	O
site	O
,	O
we	O
compared	O
the	O
kinetics	O
of	O
induction	O
of	O
the	O
two	O
binding	O
complexes	O
and	O
the	O
molecular	O
masses	O
of	O
the	O
two	O
proteins	O
.	O

Studies	O
of	O
the	O
kinetics	O
of	O
induction	O
showed	O
that	O
the	O
NFAT	O
EMSA	O
binding	O
complex	O
appeared	O
earlier	O
than	O
the	O
CMAT	O
complex	O
.	O

The	O
NFAT	O
protein	O
migrated	O
more	O
slowly	O
in	O
a	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
than	O
the	O
CMAT	O
protein	O
did	O
.	O

In	O
addition	O
,	O
an	O
antibody	O
against	O
NFAT	O
did	O
not	O
cross	O
-	O
react	O
with	O
the	O
CMAT	O
protein	O
.	O

The	O
appearance	O
of	O
the	O
CMAT	O
binding	O
complex	O
was	O
inhibited	O
by	O
both	O
cyclosporin	O
A	O
and	O
rapamycin	O
.	O

The	O
CMAT	O
protein	O
appears	O
to	O
be	O
a	O
novel	O
inducible	O
protein	O
involved	O
in	O
the	O
regulation	B-Regulation
of	O
c	O
-	O
myb	O
expression	B-Gene_expression
during	O
T	O
-	O
cell	O
activation	O
.	O

Structural	O
and	O
functional	O
characterization	O
of	O
the	O
human	O
CD36	O
gene	O
promoter	O
:	O
identification	O
of	O
a	O
proximal	O
PEBP2/CBF	O
site	O
.	O

CD36	O
is	O
a	O
cell	O
surface	O
glycoprotein	O
composed	O
of	O
a	O
single	O
polypeptide	O
chain	O
,	O
which	O
interacts	B-Binding
with	O
thrombospondin	O
,	O
collagens	O
type	O
I	O
and	O
IV	O
,	O
oxidized	O
low	O
density	O
lipoprotein	O
,	O
fatty	O
acids	O
,	O
anionic	O
phospholipids	O
,	O
and	O
erythrocytes	O
parasitized	O
with	O
Plasmodium	O
falciparum	O
.	O

Its	O
expression	B-Gene_expression
is	O
restricted	O
to	O
a	O
few	O
cell	O
types	O
,	O
including	O
monocyte/macrophages	O
.	O

In	O
these	O
cells	O
,	O
CD36	O
is	O
involved	O
in	O
phagocytosis	O
of	O
apoptotic	O
cells	O
,	O
and	O
foam	O
cell	O
formation	O
by	O
uptake	O
of	O
oxidized	O
low	O
density	O
lipoprotein	O
.	O

To	O
study	O
the	O
molecular	O
mechanisms	O
that	O
control	B-Regulation
the	O
transcription	B-Transcription
of	O
the	O
CD36	O
gene	O
in	O
monocytic	O
cells	O
we	O
have	O
isolated	O
and	O
analyzed	O
the	O
CD36	O
promoter	O
.	O

Transient	O
expression	O
experiments	O
of	O
5'	O
-	O
deletion	O
fragments	O
of	O
the	O
CD36	O
promoter	O
coupled	O
to	O
luciferase	O
demonstrated	O
that	O
as	O
few	O
as	O
158	O
base	O
pairs	O
upstream	O
from	O
the	O
transcription	O
initiation	O
site	O
were	O
sufficient	O
to	O
direct	O
the	O
monocyte	O
-	O
specific	O
transcription	O
of	O
the	O
reporter	O
gene	O
.	O

Within	O
the	O
above	O
region	O
,	O
the	O
fragment	O
spanning	O
nucleotides	O
-	O
158	O
to	O
-	O
90	O
was	O
required	O
for	O
optimal	O
transcription	O
in	O
monocytic	O
cells	O
.	O

Biochemical	O
analysis	O
of	O
the	O
region	O
-158/	O
-	O
90	O
revealed	O
a	O
binding	O
site	O
for	O
transcription	O
factors	O
of	O
the	O
polyomavirus	O
enhancer	O
-	O
binding	O
protein	O
2/core	O
-	O
binding	O
factor	O
(	O
PEBP2/CBF	O
)	O
family	O
at	O
position	O
-	O
103	O
.	O

Disruption	O
of	O
the	O
PEBP2/CBF	O
site	O
markedly	O
diminished	B-Negative_regulation
the	O
role	B-Regulation
of	O
the	O
PEBP2/CBF	O
factors	O
in	O
the	O
constitutive	O
transcription	B-Transcription
of	O
the	O
CD36	O
gene	O
.	O

The	O
involvement	O
of	O
members	O
of	O
the	O
PEBP2/CBF	O
family	O
in	O
chromosome	O
translocations	O
associated	O
with	O
acute	O
myeloid	O
leukemia	O
,	O
and	O
in	O
the	O
transcriptional	B-Regulation
regulation	I-Regulation
of	O
the	O
myeloid	O
-	O
specific	O
genes	O
encoding	O
for	O
myeloperoxidase	O
,	O
elastase	O
,	O
and	O
the	O
colony	O
-	O
stimulating	O
factor	O
receptor	O
,	O
highlights	O
the	O
relevance	O
of	O
the	O
regulation	B-Regulation
of	O
the	O
CD36	O
gene	O
promoter	O
in	O
monocytic	O
cells	O
by	O
members	O
of	O
the	O
PEBP2/CBF	O
family	O
.	O

CNI	O
-	O
1493	O
inhibits	O
monocyte/macrophage	O
tumor	O
necrosis	O
factor	O
by	O
suppression	O
of	O
translation	O
efficiency	O
.	O

Tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
mediates	O
a	O
wide	O
variety	O
of	O
disease	O
states	O
including	O
septic	O
shock	O
,	O
acute	O
and	O
chronic	O
inflammation	O
,	O
and	O
cachexia	O
.	O

Recently	O
,	O
a	O
multivalent	O
guanylhydrazone	O
(	O
CNI	O
-	O
1493	O
)	O
developed	O
as	O
an	O
inhibitor	O
of	O
macrophage	O
activation	O
was	O
shown	O
to	O
suppress	O
TNF	O
production	O
and	O
protect	O
against	O
tissue	O
inflammation	O
and	O
endotoxin	O
lethality	O
[	O
Bianchi	O
,	O
M.	O
,	O
Ulrich	O
,	O
P.	O
,	O
Bloom	O
,	O
O.	O
,	O
Meistrell	O
,	O
M.	O
,	O
Zimmerman	O
,	O
G.A.	O
,	O
Schmidtmayerova	O
,	O
H.	O
,	O
Bukrinsky	O
,	O
M.	O
,	O
Donnelley	O
,	O
T.	O
,	O
Bucala	O
,	O
R.	O
,	O
Sherry	O
,	O
B.	O
,	O
Manogue	O
,	O
K.R.	O
,	O
Tortolani	O
,	O
A.J.	O
,	O
Cerami	O
,	O
A.	O
&	O
Tracey	O
,	O
K.J.	O
(	O
1995	O
)	O
Mol.Med.1	O
,	O
254	O
-	O
266	O
,	O
and	O
Bianchi	O
,	O
M.	O
,	O
Bloom	O
,	O
O.	O
,	O
Raabe	O
,	O
T.	O
,	O
Cohen	O
,	O
P.	O
S.	O
,	O
Chesney	O
,	O
J.	O
,	O
Sherry	O
,	O
B.	O
,	O
Schmidtmayerova	O
,	O
H.	O
,	O
Zhang	O
,	O
X.	O
,	O
Bukrinsky	O
,	O
M.	O
,	O
Ulrich	O
,	O
P.	O
,	O
Cerami	O
,	O
A.	O
&	O
Tracey	O
,	O
J.	O
(	O
1996	O
)	O
J.Exp.Med.	O
,	O
in	O
press	O
]	O
.	O

We	O
have	O
now	O
elucidated	O
the	O
mechanism	O
by	O
which	O
CNI	O
-	O
1493	O
inhibits	O
macrophage	O
TNF	O
synthesis	O
and	O
show	O
here	O
that	O
it	O
acts	O
through	O
suppression	O
of	O
TNF	O
translation	O
efficiency	O
.	O

CNI	O
-	O
1493	O
blocked	O
neither	O
the	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
induced	O
increases	O
in	O
the	O
expression	O
of	O
TNF	O
mRNA	O
nor	O
the	O
translocation	O
of	O
nuclear	O
factor	O
NF	O
-	O
kappa	O
B	O
to	O
the	O
nucleus	O
in	O
macrophages	O
activated	O
by	O
15	O
min	O
of	O
LPS	O
stimulation	O
,	O
indicating	O
that	O
CNI	O
-	O
1493	O
does	O
not	O
interfere	O
with	O
early	O
NF	O
-	O
kappa	O
B	O
-	O
mediated	O
transcriptional	O
regulation	O
of	O
TNF	O
.	O

However	O
,	O
synthesis	O
of	O
the	O
26	O
-	O
kDa	O
membrane	O
form	O
of	O
TNF	O
was	O
effectively	O
blocked	O
by	O
CNI	O
-	O
1493	O
.	O

Further	O
evidence	O
for	O
the	O
translational	O
suppression	O
of	O
TNF	O
is	O
given	O
by	O
experiments	O
using	O
chloram	O
-	O
phenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
constructs	O
containing	O
elements	O
of	O
the	O
TNF	O
gene	O
that	O
are	O
involved	O
in	O
TNF	O
translational	O
regulation	O
.	O

Both	O
the	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
regions	O
of	O
the	O
TNF	O
gene	O
were	O
required	O
to	O
elicit	O
maximal	O
translational	O
suppression	O
by	O
CNI	O
-	O
1493	O
.	O

Identification	O
of	O
the	O
molecular	O
target	O
through	O
which	O
CNI	O
-	O
1493	O
inhibits	O
TNF	O
translation	O
should	O
provide	O
insight	O
into	O
the	O
regulation	O
of	O
macrophage	O
activation	O
and	O
mechanisms	O
of	O
inflammation	O
.	O

STAT	O
-	O
related	O
transcription	O
factors	O
are	O
constitutively	O
activated	O
in	O
peripheral	O
blood	O
cells	O
from	O
acute	O
leukemia	O
patients	O
.	O

A	O
signal	O
transduction	O
pathway	O
activated	O
by	O
many	O
cytokines	O
has	O
recently	O
been	O
elaborated	O
.	O

The	O
JAK	O
kinases	O
and	O
the	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
factors	O
have	O
been	O
found	O
to	O
be	O
essential	O
components	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
presence	O
of	O
constitutively	O
activated	O
STAT	O
factors	O
in	O
peripheral	O
blood	O
cells	O
from	O
patients	O
with	O
acute	O
leukemia	O
.	O

We	O
used	O
oligonucleotide	O
probes	O
from	O
the	O
beta	O
-	O
casein	O
and	O
IRF	O
-	O
1	O
gene	O
promoters	O
and	O
the	O
ISRE	O
probe	O
to	O
detect	O
STAT	O
proteins	O
in	O
nuclear	O
extracts	O
from	O
acute	O
leukemia	O
cells	O
in	O
bandshift	O
assays	O
.	O

Specific	O
DNA	O
protein	O
complex	B-Binding
formation	I-Binding
was	O
observed	O
with	O
the	O
probes	O
from	O
the	O
beta	O
-	O
casein	O
and	O
IRF	O
-	O
1	O
gene	O
promoters	O
,	O
but	O
not	O
with	O
the	O
ISRE	O
oligonucleotide	O
probe	O
,	O
when	O
cell	O
extracts	O
from	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
and	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
were	O
investigated	O
.	O

We	O
used	O
nonradioactive	O
oligonucleotides	O
as	O
competitors	O
to	O
show	O
the	O
specificity	O
of	O
the	O
complex	O
formation	O
.	O

Specific	O
antibodies	O
directed	O
against	O
the	O
individual	O
STAT	O
proteins	O
were	O
used	O
in	O
supershift	O
experiments	O
.	O

STAT5	O
-	O
and	O
STAT1	O
-	O
related	O
factors	O
were	O
detected	O
in	O
ALL	O
and	O
STAT1	O
-	O
,	O
STAT3	O
-	O
,	O
and	O
STAT5	O
-	O
related	O
proteins	O
were	O
present	O
in	O
nuclear	O
cell	O
extracts	O
from	O
AML	O
.	O

Since	O
the	O
cells	O
were	O
not	O
treated	O
with	O
cytokines	O
before	O
the	O
nuclear	O
proteins	O
were	O
extracted	O
,	O
we	O
conclude	O
that	O
these	O
factors	O
are	O
constitutively	O
activated	O
in	O
vivo	O
.	O

It	O
is	O
likely	O
that	O
the	O
constitutive	O
activation	O
of	O
STAT	O
proteins	O
is	O
a	O
part	O
of	O
the	O
events	O
of	O
leukemogenesis	O
.	O

Reversible	O
differentiation	O
of	O
human	O
monoblastic	O
leukemia	O
U937	O
cells	O
by	O
ML	O
-	O
9	O
,	O
an	O
inhibitor	O
of	O
myosin	O
light	O
chain	O
kinase	O
.	O

Human	O
monoblastic	O
leukemia	O
U937	O
cells	O
are	O
induced	O
to	O
differentiate	O
into	O
monocytes	O
and	O
macrophages	O
by	O
various	O
agents	O
.	O

We	O
have	O
shown	O
that	O
1	O
-	O
(	O
5-chloronaphthalene-1	O
-	O
sulfonyl	O
)	O
-1H-hexahydro	O
-	O
1	O
,	O
4	O
-	O
diazepine	O
hydrochloride	O
(	O
ML	O
-	O
9	O
)	O
,	O
an	O
inhibitor	O
of	O
myosin	O
light	O
chain	O
kinase	O
,	O
induces	O
differentiation	O
of	O
monocytoid	O
leukemia	O
cell	O
lines	O
U937	O
and	O
THP	O
-	O
1	O
but	O
not	O
of	O
myeloblastic	O
leukemic	O
ML	O
-	O
1	O
cell	O
or	O
erythroleukemia	O
K562	O
cells	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
further	O
analyzed	O
the	O
effect	O
of	O
ML	O
-	O
9	O
in	O
comparison	O
with	O
that	O
of	O
1	O
alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
(	O
VD3	O
)	O
a	O
typical	O
inducer	O
of	O
monocytic	O
differentiation	O
.	O

ML	O
-	O
9	O
induced	O
nitroblue	O
tetrazolium	O
(	O
NBT	O
)	O
-	O
reducing	O
activity	O
of	O
U937	O
cell	O
more	O
rapidly	O
than	O
VD3	O
:	O
This	O
differentiation	O
marker	O
was	O
induced	O
significantly	O
after	O
incubation	O
with	O
ML	O
-	O
9	O
and	O
VD3	O
for	O
4	O
hours	O
and	O
1	O
day	O
,	O
respectively	O
.	O

ML	O
-	O
9	O
also	O
induced	O
alpha	O
-	O
naphthyl	O
acetate	O
esterase	O
(	O
ANAE	O
)	O
activity	O
,	O
another	O
monocytic	O
differentiation	O
marker	O
,	O
more	O
rapidly	O
than	O
VD3	O
.	O

The	O
maximum	O
levels	O
of	O
these	O
markers	O
induced	O
by	O
ML	O
-	O
9	O
were	O
comparable	O
to	O
those	O
induced	O
by	O
VD3	O
,	O
but	O
after	O
removal	O
of	O
ML	O
-	O
9	O
from	O
the	O
medium	O
by	O
washing	O
the	O
cells	O
,	O
the	O
expressions	O
of	O
theses	O
markers	O
decreased	O
within	O
4	O
hours	O
and	O
reached	O
basal	O
levels	O
in	O
1	O
day	O
,	O
indicating	O
that	O
ML	O
-	O
9	O
's	O
induction	O
of	O
expression	O
of	O
differentiation	O
-	O
associated	O
phenotypes	O
was	O
reversible	O
.	O

The	O
growth	O
inhibition	O
of	O
U937	O
cells	O
by	O
ML	O
-	O
9	O
was	O
also	O
reversible	O
.	O

Similar	O
effects	O
were	O
observed	O
in	O
another	O
line	O
of	O
human	O
monoblastic	O
cells	O
,	O
THP	O
-	O
1	O
.	O

ML	O
-	O
9	O
had	O
little	O
or	O
no	O
effect	O
on	O
the	O
morphology	O
of	O
U937	O
cells	O
but	O
increased	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
monocyte	O
-	O
macrophage	O
lineage	O
-	O
associated	O
surface	O
antigen	O
,	O
CD14	O
,	O
to	O
some	O
extent	O
.	O

Irreversible	O
terminal	O
differentiation	O
induced	O
by	O
VD3	O
is	O
associated	O
with	O
down	B-Negative_regulation
regulation	I-Negative_regulation
of	O
the	O
expression	B-Gene_expression
of	O
c	O
-	O
myc	O
and	O
upregulation	B-Positive_regulation
of	O
the	O
expression	B-Gene_expression
of	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
,	O
but	O
ML	O
-	O
9	O
did	O
not	O
affect	B-Regulation
the	O
expression	B-Gene_expression
of	O
these	O
oncogenes	O
appreciably	O
.	O

ML-9	O
-	O
induced	O
differentiation	O
was	O
also	O
reversible	O
when	O
the	O
cells	O
were	O
cultured	O
with	O
cultured	O
with	O
ML	O
-	O
9	O
plus	O
an	O
anti	O
-	O
cancer	O
drug	O
such	O
as	O
1-beta-D-arabino	O
-	O
furanosylcytosine	O
or	O
daunomycin	O
.	O

it	O
became	O
irreversible	O
,	O
however	O
,	O
upon	O
simultaneous	O
treatment	O
with	O
dexamethasone	O
and	O
transforming	O
growth	O
factor	O
-	O
beta	O
1	O
(	O
TGF	O
-	O
beta	O
1	O
)	O
,	O
which	O
did	O
not	O
induce	O
differentiation	O
of	O
U937	O
cells	O
but	O
caused	O
growth	O
arrest	O
of	O
the	O
cells	O
in	O
the	O
G0/G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

These	O
results	O
suggest	O
that	O
ML	O
-	O
9	O
should	O
be	O
useful	O
for	O
studying	O
the	O
mechanisms	O
of	O
monocytic	O
differentiation	O
.	O

Interferon	O
-	O
gamma	O
modulates	O
the	O
lipopolysaccharide	O
-	O
induced	O
expression	O
of	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
at	O
the	O
mRNA	O
and	O
protein	O
level	O
in	O
human	O
monocytes	O
.	O

Interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
modulates	O
the	O
expression	O
of	O
several	O
cytokines	O
by	O
human	O
monocytes	O
at	O
the	O
transcriptional	O
level	O
.	O

In	O
view	O
of	O
these	O
findings	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
IFN	O
-	O
gamma	O
on	O
the	O
expression	O
of	O
different	O
transcription	O
factors	O
in	O
activated	O
human	O
monocytes	O
.	O

Priming	O
of	O
human	O
monocytes	O
with	O
IFN	O
-	O
gamma	O
resulted	O
in	O
the	O
down	B-Negative_regulation
regulation	I-Negative_regulation
of	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
mRNA	O
in	O
response	O
to	O
stimulation	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
compared	O
to	O
the	O
effects	O
of	O
LPS	O
alone	O
.	O

Not	O
only	O
was	O
this	O
effect	O
observed	O
at	O
the	O
mRNA	O
level	O
,	O
but	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
DNA	O
binding	O
capacity	O
was	O
affected	O
as	O
well	O
,	O
A	O
strong	O
reduction	O
was	O
observed	O
in	O
the	O
LPS	O
-	O
induced	O
DNA	O
-	O
binding	O
activity	O
of	O
AP	O
-	O
1	O
in	O
the	O
presence	O
of	O
IFN	O
-	O
gamma	O
.	O

LPS	O
-	O
stimulated	O
monocytes	O
showed	O
an	O
increased	B-Positive_regulation
expression	B-Transcription
of	O
p105	O
mRNA	O
,	O
the	O
precursor	O
of	O
the	O
p50	O
subunit	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
,	O
while	O
no	O
effect	B-Regulation
was	O
noticed	O
on	O
the	O
expression	B-Transcription
of	O
p65	O
mRNA	O
.	O

In	O
contrast	O
,	O
IFN	O
-	O
gamma	O
priming	O
did	O
not	O
affect	B-Regulation
the	O
expression	B-Transcription
of	O
p105	O
transcripts	O
but	O
enhanced	B-Positive_regulation
the	O
expression	B-Transcription
of	O
p65	O
mRNA	O
(	O
two	O
-	O
fold	O
)	O
.	O

Priming	O
with	O
IFN	O
-	O
gamma	O
followed	O
by	O
LPS	O
stimulation	O
resulted	O
in	O
a	O
further	O
increase	B-Positive_regulation
in	O
the	O
expression	B-Transcription
of	O
p65	O
mRNA	O
.	O

This	O
was	O
due	B-Positive_regulation
to	I-Positive_regulation
an	O
increase	B-Positive_regulation
in	O
the	O
half	O
-	O
life	O
of	O
p65	O
mRNA	O
(	O
75	O
vs	O
150	O
minutes	O
)	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
demonstrated	O
that	O
unstimulated	O
monocytes	O
predominantly	O
expressed	B-Gene_expression
p50	O
NF	O
-	O
kappa	O
B	O
.	O

Stimulation	O
with	O
LPS	O
or	O
IFN	O
-	O
gamma	O
resulted	B-Positive_regulation
in	O
the	O
expression	B-Gene_expression
of	O
p50	O
and	O
p65	O
subunits	O
,	O
while	O
the	O
combination	O
of	O
IFN	O
-	O
gamma	O
plus	O
LPS	O
caused	O
a	O
further	O
increase	O
in	O
the	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

With	O
Western	O
blotting	O
,	O
it	O
was	O
shown	O
that	O
nuclear	O
extracts	O
from	O
monocytes	O
contained	B-Gene_expression
p50	O
and	O
p65	O
protein	O
in	B-Positive_regulation
response	I-Positive_regulation
to	I-Positive_regulation
LPS	O
and	O
IFN	O
-	O
gamma	O
stimulation	O
.	O

However	O
,	O
the	O
combined	O
stimulation	O
did	O
not	O
result	O
in	O
enhanced	B-Positive_regulation
p50	O
and	O
p65	O
protein	O
expression	B-Gene_expression
.	O

The	O
effects	O
of	O
IFN	O
-	O
gamma	O
on	O
the	O
transcription	O
factors	O
were	O
specific	O
,	O
since	O
no	O
change	B-Regulation
was	O
observed	O
in	O
the	O
expression	B-Gene_expression
of	O
NF-IL	O
-	O
6	O
or	O
I	O
kappa	O
B	O
alpha	O
,	O
the	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

We	O
conclude	O
that	O
the	O
effects	O
of	O
IFN	O
-	O
gamma	O
on	O
the	O
expression	O
of	O
the	O
transcription	O
factors	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
may	O
be	O
important	O
for	O
the	O
modulatory	O
effects	O
of	O
IFN	O
-	O
gamma	O
on	O
the	O
cytokine	O
expression	O
in	O
activated	O
human	O
monocytes	O
.	O

Expression	B-Gene_expression
of	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
proteins	O
and	O
AP	O
-	O
1	O
binding	O
activity	O
during	O
cell	O
cycle	O
progression	O
of	O
HL60	O
cells	O
and	O
phytohemagglutinin	O
-	O
stimulated	O
lymphocytes	O
.	O

The	O
protein	O
products	O
of	O
the	O
c	O
-	O
fos	O
(	O
p62c	O
-	O
fos	O
)	O
and	O
c	O
-	O
jun	O
(	O
p39c	O
-	O
jun	O
)	O
genes	O
are	O
members	O
of	O
the	O
AP	O
-	O
1	O
transcription	O
factor	O
family	O
and	O
are	O
thought	O
to	O
play	O
important	O
roles	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
during	O
the	O
cell	O
cycle	O
.	O

Most	O
studies	O
on	O
the	O
expression	O
of	O
these	O
proteins	O
in	O
relation	O
to	O
the	O
cell	O
cycle	O
have	O
been	O
performed	O
at	B-Transcription
the	I-Transcription
mRNA	I-Transcription
level	I-Transcription
,	O
and	O
therefore	O
do	O
not	O
give	O
direct	O
information	O
about	O
the	O
presence	B-Gene_expression
of	O
the	O
proteins	O
during	O
the	O
cell	O
cycle	O
.	O

We	O
have	O
used	O
Western	O
blotting	O
to	O
investigate	O
the	O
presence	B-Gene_expression
of	O
these	O
proteins	O
during	O
the	O
cell	O
cycles	O
of	O
two	O
different	O
cellular	O
systems	O
:	O
a	O
continuously	O
growing	O
myeloid	O
leukemic	O
cell	O
line	O
,	O
HL60	O
,	O
and	O
normal	O
cells	O
stimulated	O
into	O
cycle	O
,	O
phyto	O
-	O
hemagglutinin	O
(	O
PHA	O
)	O
-	O
stimulated	O
normal	O
human	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
.	O

The	O
binding	O
activity	O
of	O
transcription	O
factor	O
AP	O
-	O
1	O
,	O
which	O
consists	O
of	O
dimers	O
of	O
Fos	O
and	O
Jun	O
family	O
proteins	O
,	O
was	O
also	O
studied	O
using	O
a	O
gel	O
shift	O
assay	O
.	O

We	O
found	B-Localization
nuclear	O
p62c	O
-	O
fos	O
,	O
p39c	O
-	O
jun	O
,	O
and	O
AP	O
-	O
1	O
binding	O
activity	O
throughout	O
the	O
cell	O
cycle	O
both	O
in	O
HL60	O
cells	O
and	O
in	O
PHA	O
-	O
stimulated	O
PBL	O
,	O
and	O
we	O
postulate	O
that	O
these	O
proteins	O
are	O
required	O
throughout	O
the	O
cell	O
cycle	O
and	O
not	O
transiently	O
in	O
the	O
G0	O
to	O
G1	O
transition	O
as	O
previous	O
mRNA	O
studies	O
have	O
indicated	O
.	O

We	O
demonstrated	O
an	O
uncoupling	O
of	O
AP	O
-	O
1	O
binding	O
activity	O
from	O
p62c	O
-	O
fos	O
,	O
and	O
p39c	O
-	O
jun	O
AP	O
-	O
1	O
activity	O
was	O
expressed	O
more	O
strongly	O
in	O
the	O
G1	O
-	O
and	O
G2/M	O
-	O
phase	O
enriched	O
samples	O
than	O
in	O
the	O
S	O
-	O
phase	O
enriched	O
samples	O
of	O
HL60	O
cells	O
,	O
while	O
levels	O
of	O
nuclear	O
p62c	O
-	O
fos	O
and	O
p39c	O
-	O
jun	O
were	O
constant	B-Positive_regulation
.	O

Nuclei	O
of	O
unstimulated	O
PBL	O
from	O
different	O
donors	O
expressed	B-Localization
p62c	O
-	O
fos	O
and	O
p39c	O
-	O
jun	O
,	O
but	O
AP	O
-	O
1	O
was	O
not	O
detected	O
in	O
the	O
majority	O
of	O
samples	O
.	O

Following	O
PHA	O
stimulation	O
of	O
PBL	O
,	O
the	O
increase	O
in	O
AP	O
-	O
1	O
activity	O
was	O
delayed	O
with	O
respect	O
to	O
the	O
augmentation	B-Positive_regulation
of	O
p39c	O
-	O
jun	O
expression	B-Gene_expression
.	O

We	O
also	O
observed	O
that	O
cytoplasmic	O
p62c	O
-	O
fos	O
and	O
p39c	O
-	O
jun	O
were	O
present	B-Gene_expression
in	O
HL60	O
cells	O
and	O
PHA	O
-	O
stimulated	O
PBL	O
.	O

However	O
,	O
no	O
cytoplasmic	O
p62c	O
-	O
fos	O
was	O
detected	B-Gene_expression
in	O
unstimulated	O
PBL	O
,	O
although	O
in	O
some	O
cases	O
cytoplasmic	O
p39c	O
-	O
jun	O
was	O
detected	B-Gene_expression
,	O
suggesting	O
that	O
subcellular	O
compartmentalization	O
of	O
these	O
proteinsmay	O
occur	O
under	O
certain	O
circumstances	O
.	O

Involvement	O
of	O
intracellular	O
Ca2+	O
in	O
oxidant	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

In	O
human	O
Jurkat	O
T	O
cells	O
and	O
its	O
subclone	O
Wurzburg	O
cells	O
oxidant	O
challenge	O
elevated	O
[	O
Ca2+	O
]	O
i	O
by	O
mobilizing	O
Ca2+	O
from	O
intracellular	O
stores	O
.	O

In	O
Jurkat	O
cells	O
this	O
effect	O
was	O
rapid	O
and	O
transient	O
,	O
but	O
in	O
Wurzburg	O
cells	O
the	O
response	O
was	O
slow	O
and	O
sustained	O
.	O

H2O2	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
in	O
Wurzburg	O
cells	O
was	O
not	O
influenced	O
by	O
the	O
presence	O
of	O
extracellular	O
EGTA	O
but	O
was	O
totally	O
inhibited	O
in	O
cells	O
that	O
were	O
loaded	O
with	O
esterified	O
EGTA	O
.	O

In	O
Jurkat	O
cells	O
that	O
are	O
not	O
sensitive	O
to	O
H2O2	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
,	O
H2O2	O
potentiated	O
NF	O
-	O
kappaB	O
activation	O
in	O
the	O
presence	O
of	O
sustained	O
high	O
[	O
Ca2+	O
]	O
i	O
following	O
thapsigargin	O
treatment	O
.	O

NF	O
-	O
kappaB	O
regulatory	O
effect	O
of	O
alpha	O
-	O
lipoate	O
and	O
N	O
-	O
acetylcysteine	O
appeared	O
to	O
be	O
,	O
at	O
least	O
in	O
part	O
,	O
due	O
to	O
their	O
ability	O
to	O
stabilize	O
elevation	O
of	O
[	O
Ca2+	O
]	O
i	O
following	O
oxidant	O
challenge	O
.	O

Results	O
of	O
this	O
study	O
indicate	O
that	O
a	O
sustained	O
elevated	O
[	O
Ca2+	O
]	O
i	O
is	O
a	O
significant	O
factor	O
in	O
oxidant	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
.	O

A	O
cell	O
type	O
-	O
specific	O
enhancer	O
in	O
the	O
human	O
B7.1	O
gene	O
regulated	B-Regulation
by	O
NF	O
-	O
kappaB	O
.	O

The	O
costimulatory	O
molecule	O
B7.1	O
provides	O
a	O
second	O
signal	O
critical	O
for	O
T	O
cell	O
activation	O
.	O

The	O
distribution	B-Gene_expression
of	O
this	O
integral	O
membrane	O
protein	O
is	O
restricted	O
to	O
certain	O
tissues	O
where	O
its	O
level	O
of	O
expression	B-Gene_expression
is	O
modulated	B-Regulation
by	O
multiple	O
exogenous	O
stimuli	O
.	O

To	O
identify	O
the	O
molecular	O
basis	O
for	O
specificity	O
and	O
inducibility	O
,	O
the	O
chromatin	O
configuration	O
of	O
the	O
human	O
B7.1	O
gene	O
was	O
examined	O
in	O
intact	O
nuclei	O
from	O
various	O
cell	O
types	O
.	O

The	O
identification	O
of	O
a	O
tissue	O
-	O
specific	O
deoxyribonuclease	O
I	O
hypersensitive	O
site	O
approximately	O
3kb	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
led	O
to	O
the	O
characterization	O
of	O
a	O
cell	O
type	O
-	O
specific	O
enhancer	O
region	O
.	O

This	O
183	O
-	O
bp	O
region	O
was	O
both	O
cell	O
type	O
specific	O
and	O
responsive	O
to	O
two	O
distinct	O
stimuli	O
,	O
lipopolysaccharide	O
and	O
dibutyryl	O
cAMP	O
,	O
known	O
to	O
regulate	B-Regulation
B7.1	O
expression	B-Gene_expression
.	O

Deletional	O
and	O
site	O
-	O
directed	O
mutagenesis	O
revealed	O
the	O
presence	O
of	O
multiple	O
functionally	O
critical	O
cis	O
elements	O
within	O
this	O
region	O
,	O
one	O
of	O
which	O
was	O
a	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
consensus	O
sequence	O
.	O

In	O
B7.1	O
-	O
positive	B-Gene_expression
B	O
cells	O
,	O
this	O
element	O
bound	O
several	O
members	O
of	O
the	O
NF	O
-	O
kappaB	O
family	O
,	O
transcription	O
factors	O
already	O
implicated	O
in	O
signal	O
transduction	O
pathways	O
relevant	O
to	O
B7.1	O
expression	B-Gene_expression
.	O

This	O
is	O
the	O
first	O
description	O
,	O
to	O
our	O
knowledge	O
,	O
of	O
regulatory	O
elements	O
that	O
control	O
expression	O
of	O
a	O
gene	O
encoding	O
a	O
B7	O
costimulatory	O
molecule	O
.	O

Heat	O
shock	O
induces	O
HIV	O
-	O
1	O
replication	O
in	O
chronically	O
infected	O
promyelocyte	O
cell	O
line	O
OM10.1	O
.	O

A	O
long	O
period	O
of	O
clinical	O
latency	O
before	O
development	O
of	O
symptoms	O
is	O
characteristic	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
infection	O
.	O

OM10.1	O
,	O
a	O
promyelocyte	O
cell	O
line	O
latently	O
infected	O
with	O
HIV	O
-	O
1	O
,	O
has	O
been	O
developed	O
as	O
a	O
model	O
for	O
studying	O
the	O
mechanism	O
of	O
viral	O
latency	O
and	O
the	O
activation	O
of	O
virus	O
expression	O
.	O

We	O
found	O
that	O
this	O
latently	O
infected	O
cell	O
line	O
with	O
heat	O
shock	O
at	O
42	O
degrees	O
C	O
for	O
2	O
h	O
resulted	O
in	O
a	O
high	O
level	O
of	O
HIV	O
-	O
1	O
production	O
without	O
addition	O
of	O
any	O
cytokines	O
.	O

The	O
mechanism	O
of	O
activation	O
was	O
analyzed	O
by	O
using	O
anti-TNF	O
-	O
alpha	O
antibody	O
and	O
various	O
inhibitors	O
.	O

Although	O
the	O
TNF	O
-	O
alpha	O
level	O
in	O
culture	O
supernatants	O
was	O
below	O
the	O
sensitivity	O
of	O
an	O
ELISA	O
assay	O
system	O
,	O
addition	O
of	O
anti-TNF	O
-	O
alpha	O
antibody	O
in	O
culture	O
medium	O
could	O
partially	O
suppress	O
the	O
heat	O
shock	O
induced	O
HIV	O
-	O
1	O
production	O
.	O

Staurosporine	O
(	O
PKC	O
inhibitor	O
)	O
,	O
pentoxifylline	O
(	O
NF	O
-	O
kappa	O
B	O
inhibitor	O
)	O
,	O
and	O
Ro5	O
-	O
3335	O
(	O
HIV	O
-	O
1	O
Tat	O
inhibitor	B-Negative_regulation
)	O
also	O
inhibited	O
significantly	O
the	O
heat	O
shock	O
induced	O
virus	O
activation	O
.	O

In	O
particular	O
,	O
staurosporine	O
achieved	O
approximately	O
90	O
%	O
inhibition	O
of	O
the	O
HIV	O
-	O
1	O
antigen	O
expression	O
in	O
heat	O
shock	O
-	O
treated	O
OM10.1	O
at	O
a	O
non	O
-	O
toxic	O
concentration	O
.	O

Although	O
the	O
mechanism	O
of	O
HIV	O
-	O
1	O
activation	O
with	O
heat	O
shock	O
has	O
not	O
been	O
fully	O
elucidated	O
yet	O
,	O
it	O
is	O
presumed	O
PKC	O
plays	O
an	O
important	O
role	O
in	O
HIV	O
-	O
1	O
activation	O
.	O

Thus	O
,	O
the	O
present	O
observations	O
will	O
provide	O
a	O
further	O
insight	O
into	O
the	O
pathogenesis	O
of	O
HIV	O
-	O
1	O
infections	O
.	O

Abundant	O
expression	B-Transcription
of	O
erythroid	O
transcription	O
factor	O
P45	O
NF	O
-	O
E2	O
mRNA	O
in	O
human	O
peripheral	O
granurocytes	O
.	O

Transcription	O
factor	O
NF	O
-	O
E2	O
is	O
crucial	O
for	O
regulation	O
of	O
erythroid	O
-	O
specific	O
gene	O
expression	O
.	O

p45	O
subunit	O
of	O
NF	O
-	O
E2	O
contains	O
a	O
basic	O
-	O
leucine	O
zipper	O
domain	O
and	O
dimerizes	B-Binding
with	O
the	O
small	O
Maf	O
family	O
protein	O
to	O
form	O
functional	O
NF	O
-	O
E2	O
complex	O
.	O

While	O
p45	O
expression	B-Gene_expression
was	O
shown	O
to	O
be	O
restricted	O
to	O
erythroid	O
cells	O
,	O
megakaryocytes	O
and	O
mast	O
cells	O
in	O
hematopoietic	O
lineage	O
,	O
we	O
found	O
in	O
this	O
study	O
that	O
p45	O
mRNA	O
is	O
abundantly	O
transcribed	B-Transcription
in	O
the	O
granulocyte	O
fraction	O
of	O
human	O
peripheral	O
blood	O
cells	O
.	O

As	O
neutrophils	O
occupy	O
approximately	O
92	O
%	O
of	O
the	O
cells	O
in	O
granulocyte	O
fraction	O
of	O
human	O
peripheral	O
blood	O
cells	O
.	O

As	O
neutrophils	O
occupy	O
approximately	O
92	O
%	O
of	O
the	O
cells	O
in	O
this	O
fraction	O
,	O
the	O
cells	O
expressing	B-Gene_expression
p45	O
is	O
most	O
likely	O
to	O
be	O
neutrophils	O
.	O

p45	O
mRNA	O
is	O
also	O
expressed	B-Transcription
in	O
HL	O
-	O
60	O
promyelocytes	O
,	O
albeit	O
the	O
expression	B-Transcription
level	O
is	O
much	O
lower	O
than	O
that	O
of	O
the	O
granulocyte	O
fraction	O
.	O

HL	O
-	O
60	O
cells	O
were	O
found	O
to	O
express	B-Transcription
mafK	O
mRNA	O
,	O
indicating	O
the	O
presence	O
of	O
genuine	O
NF	O
-	O
E2	O
complex	O
in	O
the	O
cells	O
.	O

Although	O
p45	O
mRNA	O
is	O
transcribed	B-Transcription
from	B-Positive_regulation
two	O
different	O
promoters	O
,	O
aNF	O
-	O
E2	O
promoter	O
and	O
fNF	O
-	O
E2	O
promoter	O
,	O
in	O
erythroid	O
and	O
megakaryocytic	O
lineage	O
cells	O
,	O
p45	O
mRNA	O
is	O
transcribed	B-Transcription
only	O
from	B-Positive_regulation
aNF	O
-	O
E2	O
promoter	O
.	O

The	O
expression	B-Gene_expression
of	O
p45	O
megakaryocytic	O
lineage	O
cells	O
,	O
p45	O
mRNA	O
is	O
transcribed	B-Transcription
only	O
from	B-Positive_regulation
aNF	O
-	O
E2	O
promoter	O
.	O

The	O
expression	B-Transcription
of	O
p45	O
mRNA	O
in	O
the	O
neutrophils	O
declined	B-Negative_regulation
rapidly	O
after	O
transfer	O
of	O
the	O
cells	O
to	O
in	O
vitro	O
culture	O
and	O
G	O
-	O
CSF	O
could	O
not	O
sustain	B-Negative_regulation
the	O
expression	O
from	O
the	O
down	O
-	O
regulation	O
,	O
suggesting	O
the	O
E2	O
may	O
also	O
participate	O
in	O
the	O
regulation	O
of	O
neutrophil	O
-	O
specific	O
gene	O
expression	O
.	O

Identification	O
of	O
a	O
human	O
LIM	O
-	O
Hox	O
gene	O
,	O
hLH	O
-	O
2	O
,	O
aberrantly	O
expressed	B-Gene_expression
in	O
chronic	O
myelogenous	O
leukaemia	O
and	O
located	O
on	O
9q33	O
-	O
34.1	O
.	O

We	O
describe	O
the	O
isolation	O
of	O
human	O
LH	O
-	O
2	O
,	O
a	O
putative	O
transcription	O
factor	O
containing	O
two	O
cysteine	O
-	O
rich	O
regions	O
(	O
LIM	O
domains	O
)	O
and	O
a	O
homeobox	O
(	O
Hox	O
)	O
DNA	O
-	O
binding	O
domain	O
.	O

High	B-Positive_regulation
levels	I-Positive_regulation
of	O
hLH	O
-	O
2	O
expression	B-Gene_expression
were	O
observed	O
in	O
all	O
cases	O
of	O
chronic	O
myelogenous	O
leukaemia	O
(	O
CML	O
)	O
tested	O
,	O
regardless	O
of	O
disease	O
status	O
.	O

hLH	O
-	O
2	O
was	O
mapped	O
to	O
chromosome	O
9Q33	O
-	O
34.1	O
,	O
in	O
the	O
same	O
region	O
as	O
the	O
reciprocal	O
translocation	O
that	O
creates	O
the	O
BCR	O
-	O
ABL	O
chimera	O
of	O
the	O
Philadelphia	O
chromosome	O
(	O
Ph	O
'	O
)	O
,	O
the	O
hallmark	O
of	O
CML	O
;	O
hLH	O
-	O
2	O
was	O
retained	O
on	O
the	O
derivative	O
9	O
chromosome	O
and	O
is	O
therefore	O
centromeric	O
of	O
c	O
-	O
ABL	O
.	O

The	O
proximity	O
of	O
hLH	O
-	O
2	O
to	O
the	O
breakpoint	O
on	O
chromosome	O
9	O
raises	O
the	O
possibility	O
of	O
cis	B-Positive_regulation
-	I-Positive_regulation
activation	I-Positive_regulation
by	O
the	O
t	O
(	O
9	O
;	O
22	O
)	O
(	O
q34	O
;	O
q11	O
)	O
translocation	O
.	O

In	O
addition	O
to	O
finding	O
hLH	O
-	O
2	O
expression	B-Gene_expression
in	O
all	O
cases	O
of	O
CML	O
,	O
expression	B-Gene_expression
was	O
observed	O
in	O
lymphoid	O
malignancies	O
and	O
myeloid	O
cell	O
lines	O
,	O
but	O
not	O
in	O
primary	O
cases	O
of	O
acute	O
myelogenous	O
leukaemia	O
.	O

The	O
role	O
of	O
hLH	O
-	O
2	O
in	O
the	O
development	O
or	O
progression	O
of	O
leukaemia	O
is	O
not	O
known	O
.	O

However	O
,	O
hLH	O
-	O
2	O
may	O
prove	O
useful	O
as	O
a	O
marker	O
of	O
CML	O
for	O
monitoring	O
residual	O
disease	O
.	O

BCL	O
-	O
6	O
expression	B-Gene_expression
during	O
B	O
-	O
cell	O
activation	O
.	O

Translocations	O
involving	O
the	O
BCL	O
-	O
6	O
gene	O
are	O
common	O
in	O
the	O
diffuse	O
large	O
cell	O
subtype	O
of	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
.	O

Invariably	O
,	O
the	O
BCL	O
-	O
6	O
coding	O
region	O
is	O
intact	O
,	O
but	O
its	O
5	O
'	O
untranslated	O
region	O
is	O
replaced	O
with	O
sequences	O
from	O
the	O
translocation	O
partner	O
.	O

The	O
present	O
study	O
shows	O
that	O
BCL	O
-	O
6	O
expression	B-Gene_expression
is	O
regulated	B-Regulation
in	O
lymphocytes	O
during	O
mitogenic	O
stimulation	O
.	O

Resting	O
B	O
and	O
T	O
lymphocytes	O
contain	O
high	O
levels	O
of	O
BCL	O
-	O
6	O
mRNA	O
.	O

Stimulation	O
of	O
mouse	O
B	O
cells	O
with	O
anti	O
-	O
IgM	O
or	O
IgD	O
antibodies	O
,	O
bacterial	O
lipopolysaccharide	O
,	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
plus	O
ionomycin	O
,	O
or	O
CD40	O
ligand	O
led	O
to	O
a	O
five	O
-	O
fold	O
to	O
35	O
-	O
fold	O
decrease	B-Negative_regulation
in	O
BCL	O
-	O
6	O
mRNA	O
levels	O
.	O

Similar	O
downregulation	B-Negative_regulation
of	O
BCL	O
-	O
6	O
mRNA	O
was	O
seen	O
in	O
human	O
B	O
cells	O
stimulated	O
with	O
Staphylococcus	O
aureus	O
plus	O
interleukin	O
-	O
2	O
or	O
anti	O
-	O
IgM	O
antibodies	O
and	O
in	O
human	O
T	O
lymphocytes	O
stimulated	O
with	O
phytohemagglutinin	O
.	O

BCL	O
-	O
6	O
mRNA	O
levels	O
began	O
to	O
decrease	B-Negative_regulation
8	O
to	O
16	O
hours	O
after	O
stimulation	O
,	O
before	O
cells	O
entered	O
S	O
phase	O
.	O

Although	O
polyclonal	O
activation	O
of	O
B	O
cells	O
in	O
vitro	O
invariably	O
decreased	B-Negative_regulation
BCL	O
-	O
6	O
MRNA	O
expression	B-Transcription
,	O
activated	O
B	O
cells	O
from	O
human	O
germinal	O
centers	O
expressed	B-Transcription
BCL	O
-	O
6	O
mRNA	O
at	O
levels	O
comparable	O
to	O
the	O
levels	O
in	O
resting	O
B	O
cells	O
.	O

Despite	O
these	O
similar	O
mRNA	O
levels	O
,	O
BCL	O
-	O
6	O
protein	O
expression	B-Gene_expression
was	O
threefold	O
to	O
34	O
-	O
fold	O
higher	O
in	O
germinal	O
center	O
B	O
cells	O
than	O
in	O
resting	O
B	O
cells	O
,	O
suggesting	O
that	O
BCL	O
-	O
6	O
protein	O
levels	O
are	O
controlled	B-Regulation
by	O
translational	O
or	O
posttranslational	O
mechanisms	O
.	O

These	O
observations	O
suggest	O
that	O
the	O
germinal	O
center	O
reaction	O
provides	O
unique	O
activation	O
signals	O
to	O
B	O
cells	O
that	O
allow	B-Positive_regulation
for	O
continued	O
,	O
high	B-Positive_regulation
-	I-Positive_regulation
level	I-Positive_regulation
BCL	O
-	O
6	O
expression	B-Gene_expression
.	O

A	O
novel	O
interferon	O
regulatory	O
factor	O
family	O
transcription	O
factor	O
,	O
ICSAT/Pip/LSIRF	O
,	O
that	O
negatively	O
regulates	O
the	O
activity	O
of	O
interferon	O
-	O
regulated	O
genes	O
.	O

We	O
have	O
isolated	O
a	O
novel	O
cDNA	O
clone	O
encoding	O
interferon	O
(	O
IFN	O
)	O
consensus	O
sequence	O
-	O
binding	O
protein	O
in	O
adult	O
T	O
-	O
cell	O
leukemia	O
cell	O
line	O
or	O
activated	O
T	O
cells	O
(	O
ICSAT	O
)	O
;	O
this	O
protein	O
is	O
the	O
human	O
homolog	O
of	O
the	O
recently	O
cloned	O
Pip/LSIRF	O
.	O

ICSAT	O
is	O
structurally	O
most	O
closely	O
related	O
to	O
the	O
previously	O
cloned	O
ICSBP	O
,	O
a	O
member	O
of	O
the	O
IFN	O
regulatory	O
factor	O
(	O
IRF	O
)	O
family	O
of	O
proteins	O
that	O
binds	B-Binding
to	O
interferon	O
consensus	O
sequences	O
(	O
ICSs	O
)	O
found	O
in	O
many	O
promoters	O
of	O
the	O
IFN	O
-	O
regulated	O
genes	O
.	O

Among	O
T	O
-	O
cell	O
lines	O
investigated	O
,	O
ICSAT	O
was	O
abundantly	O
expressed	B-Gene_expression
in	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
-	O
infected	O
T	O
cells	O
.	O

When	O
the	O
HTLV	O
-	O
1	O
tax	O
gene	O
was	O
expressed	B-Gene_expression
or	O
phorbol	O
myristake	O
acetate	O
-	O
A23187	O
stimulation	O
was	O
used	O
,	O
ICSAT	O
expression	B-Gene_expression
was	O
induced	B-Positive_regulation
in	O
Jurkat	O
cells	O
which	O
otherwise	O
do	O
not	O
express	B-Gene_expression
ICSAT	O
.	O

When	O
the	O
binding	B-Binding
of	O
ICSAT	O
to	O
four	O
different	O
ICSs	O
was	O
tested	O
,	O
the	O
relative	O
differences	O
in	O
binding	O
affinities	O
for	O
those	O
ICSs	O
were	O
determined	O
.	O

To	O
study	O
the	O
functional	O
role	O
of	O
ICSAT	O
,	O
we	O
performed	O
cotransfection	O
experiments	O
with	O
the	O
human	O
embryonal	O
carcinoma	O
cell	O
line	O
N	O
-	O
Tera2	O
.	O

ICSAT	O
was	O
demonstrated	O
to	O
possess	O
repressive	O
function	O
over	O
the	O
gene	O
activation	O
induced	O
by	O
IFN	O
stimulation	O
or	O
by	O
IRF	O
-	O
1	O
cotransfection	B-Gene_expression
.	O

Such	O
repressive	O
function	O
is	O
similar	O
to	O
that	O
seen	O
in	O
IRF	O
-	O
2	O
or	O
ICSBP	O
.	O

However	O
,	O
we	O
have	O
found	O
that	O
ICSAT	O
has	O
a	O
different	O
repressive	O
effect	O
from	O
that	O
of	O
IRF	O
-	O
2	O
or	O
ICSBP	O
in	O
some	O
IFN	O
-	O
responsive	O
reporter	O
constructs	O
.	O

These	O
results	O
suggest	O
that	O
a	O
novel	O
mechanism	O
of	O
gene	O
regulation	O
by	O
"	O
differential	O
repression	O
"	O
is	O
used	O
by	O
multiple	O
members	O
of	O
repressor	O
proteins	O
with	O
different	O
repressive	O
effects	O
on	O
the	O
IFN	O
-	O
responsive	O
genes	O
.	O

Transcription	O
factors	O
of	O
T	O
and	O
B	O
lymphocytes	O
-	O
-	O
basic	O
research	O
and	O
clinical	O
perspectives	O
for	O
gastroenterology	O
.	O

Tissue	O
specific	O
regulation	O
of	O
gene	O
expression	O
by	O
transcription	O
factors	O
is	O
a	O
fascinating	O
new	O
field	O
in	O
molecular	O
immunology	O
.	O

This	O
review	O
summarizes	O
data	O
on	O
specific	O
regulation	O
of	O
promoters	O
and	O
enhancers	O
by	O
nuclear	O
trans	O
-	O
acting	O
factors	O
in	O
lymphocytes	O
.	O

The	O
structural	O
classes	O
of	O
transcription	O
factors	O
are	O
described	O
and	O
basic	O
methods	O
for	O
detection	O
and	O
analysis	O
of	O
transcription	O
factors	O
are	O
detailed	O
.	O

Furthermore	O
,	O
the	O
most	O
important	O
trans	O
-	O
acting	O
factors	O
of	O
T	O
and	O
B	O
lymphocytes	O
(	O
e.g.	O
NF	O
-	O
kB	O
,	O
NF	O
-	O
AT	O
and	O
STAT	O
families	O
)	O
and	O
their	O
functional	O
importance	O
are	O
described	O
.	O

Several	O
methods	O
for	O
specific	O
down	O
-	O
regulation	O
of	O
transcription	O
factors	O
are	O
shown	O
that	O
may	O
be	O
relevant	O
to	O
treatment	O
of	O
human	O
disease	O
.	O

The	O
data	O
are	O
discussed	O
with	O
regard	O
to	O
their	O
potential	O
clinical	O
relevance	O
for	O
gastroenterology	O
.	O

DNA	O
triplex	O
formation	O
selectively	O
inhibits	B-Negative_regulation
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
gene	O
expression	B-Gene_expression
in	O
human	O
T	O
cells	O
.	O

Granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
is	O
a	O
hemopoietic	O
growth	O
factor	O
that	O
is	O
expressed	B-Gene_expression
in	O
activated	O
T	O
cells	O
,	O
fibroblasts	O
,	O
macrophages	O
,	O
and	O
endothelial	O
cells	O
.	O

Although	O
GM	O
-	O
CSF	O
does	O
not	O
appear	O
to	O
be	O
essential	O
for	O
normal	O
hemopoiesis	O
,	O
overexpression	B-Positive_regulation
of	O
GM	O
-	O
CSF	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
some	O
diseases	O
such	O
as	O
myeloid	O
leukemia	O
and	O
chronic	O
inflammation	O
.	O

An	O
NF	O
-	O
kappaB/Rel	O
binding	O
site	O
within	O
the	O
GM	O
-	O
CSF	O
promoter	O
,	O
termed	O
the	O
kappaB	O
element	O
appears	O
to	O
be	O
important	O
for	O
controlling	O
expression	O
in	O
reporter	O
gene	O
assays	O
in	O
response	O
to	O
a	O
number	O
of	O
stimuli	O
in	O
T	O
cells	O
.	O

We	O
investigated	O
oligonucleotide	O
-	O
directed	O
triple	O
helix	O
formation	O
across	O
this	O
regulatory	O
sequence	O
as	O
a	O
potential	O
tool	O
to	O
inhibit	B-Negative_regulation
GM	O
-	O
CSF	O
gene	O
transcription	B-Transcription
.	O

A	O
15	O
-	O
base	O
oligonucleotide	O
,	O
GM3	O
,	O
was	O
targeted	B-Binding
to	O
a	O
purine	O
-	O
rich	O
region	O
in	O
the	O
GM	O
-	O
CSF	O
proximal	O
promoter	O
,	O
which	O
overlaps	O
the	O
kappaB	O
element	O
.	O

Gel	O
mobility	O
shift	O
assays	O
and	O
DNase	O
I	O
footprinting	O
demonstrated	O
that	O
GM3	O
formed	O
a	O
sequence	O
-	O
specific	O
collinear	O
triplex	O
with	O
its	O
double	O
-	O
stranded	O
DNA	O
target	O
.	O

Triplex	O
formation	O
by	O
GM3	O
blocked	O
recombinant	O
and	O
nuclear	O
NF	O
-	O
kappaB	O
proteins	O
binding	O
to	O
the	O
GM	O
-	O
CSF	O
element	O
.	O

GM3	O
also	O
caused	O
selective	O
inhibition	O
of	O
the	O
human	O
T	O
-	O
cell	O
lymphotrophic	O
virus	O
-	O
1	O
Tax	O
transactivator	O
-	O
induced	O
luciferase	O
activity	O
from	O
a	O
reporter	O
construct	O
driven	O
by	O
the	O
GM	O
-	O
CSF	O
promoter	O
in	O
Jurkat	O
T	O
cells	O
.	O

Finally	O
,	O
GM3	O
greatly	O
reduced	B-Negative_regulation
the	O
concentration	O
of	O
endogenous	O
GM	O
-	O
CSF	O
mRNA	O
induced	B-Positive_regulation
by	O
different	O
stimuli	O
in	O
Jurkat	O
T	O
cells	O
but	O
did	O
not	O
affect	B-Regulation
interleukin	O
3	O
mRNA	O
levels	O
in	O
the	O
same	O
cells	O
.	O

We	O
conclude	O
that	O
the	O
kappaB	O
element	O
in	O
the	O
GM	O
-	O
CSF	O
promoter	O
plays	O
a	O
central	B-Positive_regulation
role	I-Positive_regulation
in	O
the	O
transcriptional	B-Positive_regulation
activation	I-Positive_regulation
of	O
the	O
endogenous	O
GM	O
-	O
CSF	O
gene	O
.	O

Colinear	O
triplex	O
formation	O
acts	O
as	O
a	O
selective	O
transcriptional	B-Negative_regulation
repressor	I-Negative_regulation
of	O
the	O
GM	O
-	O
CSF	O
gene	O
and	O
may	O
have	O
potential	O
therapeutic	O
application	O
in	O
cases	O
of	O
undesirable	O
overexpression	B-Positive_regulation
of	O
this	O
protein	O
.	O

Cooperation	O
between	O
core	O
binding	O
factor	O
and	O
adjacent	O
promoter	O
elements	O
contributes	B-Positive_regulation
to	O
the	O
tissue	O
-	O
specific	O
expression	B-Gene_expression
of	O
interleukin	O
-	O
3	O
.	O

Tissue	O
-	O
specific	O
expression	B-Gene_expression
of	O
interleukin	O
-	O
3	O
(	O
IL	O
-	O
3	O
)	O
is	O
mediated	B-Positive_regulation
via	O
cis	O
-	O
acting	O
elements	O
located	O
within	O
315	O
base	O
pairs	O
of	O
the	O
transcription	O
start	O
.	O

This	O
is	O
achieved	O
in	O
part	O
through	O
the	O
positive	O
activities	O
of	O
the	O
AP	O
-	O
1	O
and	O
Elf	O
-	O
1	O
sites	O
in	O
the	O
IL	O
-	O
3	O
promoter	O
.	O

The	O
contribution	O
to	O
T	O
cell	O
-	O
specific	O
expression	O
by	O
other	O
promoter	O
sites	O
was	O
assessed	O
in	O
a	O
transient	O
expression	O
assay	O
with	O
IL	O
-	O
3	O
promoter	O
constructs	O
linked	O
to	O
a	O
luciferase	O
gene	O
,	O
focusing	O
initially	O
on	O
the	O
core	O
binding	O
factor	O
(	O
CBF	O
)	O
site	O
,	O
which	O
is	O
footprinted	O
in	O
vivo	O
upon	O
T	O
cell	O
activation	O
.	O

Activity	O
of	O
the	O
CBF	O
site	O
is	O
shown	O
to	O
be	O
critically	O
dependent	O
on	O
the	O
adjacent	O
activator	O
site	O
Act	O
-	O
1	O
.	O

Together	O
the	O
Act	O
-	O
1	O
and	O
CBF	O
sites	O
form	O
a	O
functional	O
unit	O
(	O
AC	O
unit	O
)	O
with	O
dual	O
activity	O
.	O

The	O
AC	O
unit	O
is	O
demonstrated	O
to	O
enhance	O
basal	O
activity	O
of	O
promoters	O
both	O
in	O
fibroblasts	O
and	O
T	O
cells	O
.	O

This	O
activity	O
is	O
further	O
inducible	O
in	O
activated	O
T	O
cells	O
,	O
but	O
not	O
in	O
fibroblasts	O
.	O

In	O
addition	O
to	O
the	O
already	O
identified	O
NIP	O
repressor	O
site	O
,	O
evidence	O
is	O
presented	O
for	O
a	O
second	O
repressor	O
region	O
that	O
restricts	O
promoter	O
activity	O
in	O
fibroblasts	O
.	O

Finally	O
,	O
a	O
novel	O
positive	O
regulatory	O
element	O
has	O
been	O
mapped	O
in	O
the	O
IL	O
-	O
3	O
promoter	O
between	O
nucleotide	O
-	O
180	O
and	O
-	O
210	O
that	O
leads	O
to	O
increased	O
expression	O
in	O
T	O
cells	O
.	O

Together	O
these	O
results	O
demonstrate	O
that	O
T	O
cell	O
expression	B-Gene_expression
of	O
IL	O
-	O
3	O
is	O
not	O
specified	B-Positive_regulation
by	O
the	O
activity	O
of	O
a	O
single	O
tissue	O
-	O
specific	O
element	O
,	O
but	O
instead	O
involves	O
multiple	O
interacting	O
elements	O
that	O
provide	O
both	O
specific	O
positive	O
regulation	O
in	O
T	O
cells	O
and	O
specific	O
negative	O
regulation	O
in	O
fibroblasts	O
.	O

Octamer	O
binding	O
factors	O
and	O
their	O
coactivator	O
can	O
activate	B-Positive_regulation
the	O
murine	O
PU.1	O
(	O
spi	O
-	O
1	O
)	O
promoter	O
.	O

PU.1	O
(	O
spi	O
-	O
1	O
)	O
,	O
a	O
member	O
of	O
the	O
Ets	O
transcription	O
factor	O
family	O
,	O
is	O
predominantly	O
expressed	B-Gene_expression
in	O
myeloid	O
and	O
B	O
cells	O
,	O
activates	O
many	O
B	O
cell	O
and	O
myeloid	O
genes	O
,	O
and	O
is	O
critical	O
for	O
development	O
of	O
both	O
of	O
these	O
lineages	O
.	O

Our	O
previous	O
studies	O
(	O
Chen	O
,	O
H.M.	O
,	O
Ray	O
-	O
Gallet	O
,	O
D.	O
,	O
Zhang	O
,	O
P.	O
,	O
Hetherington	O
,	O
C.J.	O
,	O
Gonzalez	O
,	O
D.A.	O
,	O
Zhang	O
,	O
D.	O
-	O
E.	O
,	O
Moreau	O
-	O
Gachelin	O
,	O
F.	O
,	O
and	O
Tenen	O
,	O
D.G.	O
(	O
1995	O
)	O
Oncogene	O
11	O
,	O
1549	O
-	O
1560	O
)	O
demonstrate	O
that	O
the	O
PU.1	O
promoter	O
directs	O
cell	O
type	O
-	O
specific	O
reporter	O
gene	O
expression	O
in	O
myeloid	O
cell	O
lines	O
,	O
and	O
that	O
PU.1	O
activates	B-Positive_regulation
its	O
own	O
promoter	O
in	O
an	O
autoregulatory	O
loop	O
.	O

Here	O
we	O
show	O
that	O
the	O
murine	O
PU.1	O
promoter	O
is	O
also	O
specifically	O
and	O
highly	O
functional	O
in	O
B	O
cell	O
lines	O
as	O
well	O
.	O

Oct	O
-	O
1	O
and	O
Oct	O
-	O
2	O
can	O
bind	B-Binding
specifically	O
to	O
a	O
site	O
at	O
base	O
pair	O
-	O
55	O
in	O
vitro	O
,	O
and	O
this	O
site	O
is	O
specifically	O
protected	O
in	O
B	O
cells	O
in	O
vivo	O
.	O

We	O
also	O
demonstrate	O
that	O
two	O
other	O
sites	O
contribute	O
to	O
promoter	O
activity	O
in	O
B	O
cells	O
;	O
an	O
Sp1	O
binding	O
site	O
adjacent	O
to	O
the	O
octamer	O
site	O
,	O
and	O
the	O
PU.1	O
autoregulatory	O
site	O
.	O

Finally	O
,	O
we	O
show	O
that	O
the	O
B	O
cell	O
coactivator	O
OBF-1/Bob1/OCA	O
-	O
B	O
is	O
only	O
expressed	B-Gene_expression
in	O
B	O
cells	O
and	O
not	O
in	O
myeloid	O
cells	O
,	O
and	O
that	O
OBF-1/Bob1/OCA	O
-	O
B	O
can	O
transactivate	B-Positive_regulation
the	O
PU.1	O
promoter	O
in	O
HeLa	O
and	O
myeloid	O
cells	O
.	O

This	O
B	O
cell	O
restricted	O
coactivator	O
may	O
be	O
responsible	B-Positive_regulation
for	O
the	O
B	O
cell	O
specific	O
expression	B-Gene_expression
of	O
PU.1	O
mediated	B-Positive_regulation
by	O
the	O
octamer	O
site	O
.	O

Tissue	O
-	O
specific	O
activity	O
of	O
the	O
gammac	O
chain	O
gene	O
promoter	O
depends	O
upon	O
an	O
Ets	O
binding	O
site	O
and	O
is	O
regulated	O
by	O
GA	O
-	O
binding	O
protein	O
.	O

The	O
gammac	O
chain	O
is	O
a	O
subunit	O
of	O
multiple	O
cytokine	O
receptors	O
(	O
interleukin	O
(	O
IL	O
)	O
-	O
2	O
,	O
IL	O
-	O
4	O
,	O
IL	O
-	O
7	O
,	O
IL	O
-	O
9	O
,	O
and	O
IL	O
-	O
15	O
)	O
,	O
the	O
expression	O
of	O
which	O
is	O
restricted	O
to	O
hematopoietic	O
lineages	O
.	O

A	O
defect	B-Negative_regulation
in	O
gammac	O
leads	O
to	O
the	O
X	O
-	O
linked	O
severe	O
combined	O
immunodeficiency	O
characterized	O
by	O
a	O
block	O
in	O
T	O
cell	O
differentiation	O
.	O

In	O
order	O
to	O
better	O
characterize	O
the	O
human	O
gammac	O
promoter	O
and	O
define	O
the	O
minimal	O
tissue	O
-	O
specific	O
promoter	O
region	O
,	O
progressive	O
5'	O
-	O
deletion	O
constructs	O
of	O
a	O
segment	O
extending	O
1053	O
base	O
pairs	O
upstream	O
of	O
the	O
major	O
transcription	O
start	O
site	O
were	O
generated	O
and	O
tested	O
for	O
promoter	O
activity	O
in	O
various	O
hematopoietic	O
and	O
nonhematopoietic	O
cell	O
types	O
.	O

The	O
-	O
1053/+34	O
construct	O
allowed	O
promoter	O
activity	O
only	O
in	O
cells	O
of	O
hematopoietic	O
origin	O
,	O
and	O
tissue	O
specificity	O
was	O
conserved	O
in	O
all	O
other	O
constructs	O
tested	O
.	O

The	O
region	O
downstream	O
of	O
-	O
90	O
appeared	O
critical	O
for	O
basal	O
promoter	O
activity	O
.	O

It	O
contains	O
two	O
potential	O
Ets	O
binding	O
sites	O
conserved	O
in	O
the	O
murine	O
gammac	O
promoter	O
gene	O
,	O
one	O
of	O
which	O
was	O
found	O
essential	O
for	O
functional	O
promoter	O
activity	O
as	O
determined	O
by	O
mutational	O
analysis	O
.	O

The	O
functional	O
Ets	O
binding	O
site	O
was	O
found	O
to	O
bind	B-Binding
Ets	O
family	O
proteins	O
,	O
principally	O
GA	O
-	O
binding	O
protein	O
and	O
Elf	O
-	O
1	O
and	O
could	O
be	O
transactivated	O
by	O
GABPalpha	O
and	O
-	O
beta	O
synergistically	O
.	O

These	O
results	O
indicate	O
that	O
,	O
as	O
already	O
reported	O
for	O
the	O
IL2Rbeta	O
promoter	O
,	O
GA	O
-	O
binding	O
protein	O
is	O
an	O
essential	O
component	O
of	O
gammac	O
basal	O
promoter	O
activity	O
.	O

Although	O
GABP	O
expression	B-Gene_expression
is	O
not	O
restricted	O
to	O
the	O
hematopoietic	O
lineage	O
,	O
its	O
interaction	B-Binding
with	O
other	O
specific	O
factors	O
may	O
contribute	B-Positive_regulation
to	O
the	O
tissue	O
-	O
specific	O
expression	B-Gene_expression
of	O
the	O
gammac	O
gene	O
.	O

Multiple	O
transcription	O
factors	O
are	O
required	B-Positive_regulation
for	O
activation	B-Positive_regulation
of	O
human	O
interleukin	O
9	O
gene	O
in	O
T	O
cells	O
.	O

The	O
genetic	O
elements	O
and	O
regulatory	O
mechanisms	O
responsible	B-Positive_regulation
for	O
human	O
interleukin	O
9	O
(	O
IL	O
-	O
9	O
)	O
gene	O
expression	B-Gene_expression
in	O
a	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
-	O
transformed	O
human	O
T	O
cell	O
line	O
,	O
C5MJ2	O
,	O
were	O
investigated	O
.	O

We	O
demonstrated	O
that	O
IL	O
-	O
9	O
gene	O
expression	B-Gene_expression
is	O
controlled	B-Regulation
,	O
at	O
least	O
in	O
part	O
,	O
by	O
transcriptional	O
activation	O
.	O

Transient	O
expression	O
of	O
the	O
luciferase	O
reporter	O
gene	O
linked	O
to	O
serially	O
deleted	O
sequences	O
of	O
the	O
5'	O
-	O
flanking	O
region	O
of	O
the	O
IL	O
-	O
9	O
gene	O
has	O
revealed	O
several	O
positive	O
and	O
negative	O
regulatory	O
elements	O
involved	O
in	O
the	O
basal	O
and	O
inducible	O
expression	B-Gene_expression
of	O
the	O
IL	O
-	O
9	O
gene	O
in	O
C5MJ2	O
cells	O
.	O

An	O
AP	O
-	O
1	O
site	O
at	O
-	O
146	O
to	O
-	O
140	O
was	O
shown	O
to	O
be	O
involved	O
in	O
the	O
expression	B-Gene_expression
of	O
the	O
IL	O
-	O
9	O
gene	O
.	O

A	O
proximal	O
region	O
between	O
-	O
46	O
and	O
-	O
80	O
was	O
identified	O
as	B-Positive_regulation
the	I-Positive_regulation
minimum	I-Positive_regulation
sequence	I-Positive_regulation
for	O
the	O
basal	O
and	O
inducible	O
expression	B-Gene_expression
of	O
the	O
IL	O
-	O
9	O
gene	O
in	O
C5MJ2	O
cells	O
.	O

Within	O
this	O
region	O
,	O
an	O
NF	O
-	O
kappaB	O
site	O
at	O
-	O
59	O
to	O
-	O
50	O
and	O
its	O
adjacent	O
20	O
-	O
base	O
pair	O
upstream	O
sequence	O
were	O
demonstrated	O
to	O
play	B-Positive_regulation
a	I-Positive_regulation
critical	I-Positive_regulation
role	I-Positive_regulation
for	O
the	O
IL	O
-	O
9	O
promoter	O
activity	O
.	O

DNA	O
-	O
protein	O
binding	O
studies	O
indicated	O
that	O
NF	O
-	O
kappaB	O
,	O
c	O
-	O
Jun	O
,	O
and	O
potentially	O
novel	O
proteins	O
(	O
around	O
35	O
kDa	O
)	O
can	O
bind	B-Binding
to	O
this	O
important	O
sequence	O
.	O

Mutations	O
at	O
different	O
sites	O
within	O
this	O
proximal	O
promoter	O
region	O
abolished	B-Negative_regulation
the	O
promoter	O
activity	O
as	O
well	O
as	O
the	O
DNA	O
binding	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
cooperation	O
of	O
different	O
transcription	O
factors	O
is	O
essential	B-Positive_regulation
for	O
IL	O
-	O
9	O
gene	O
expression	B-Gene_expression
in	O
T	O
cells	O
.	O

Mapping	O
of	O
the	O
transcriptional	O
repression	O
domain	O
of	O
the	O
lymphoid	O
-	O
specific	O
transcription	O
factor	O
oct	O
-	O
2A	O
.	O

The	O
lymphoid	O
-	O
specific	O
transcription	O
factor	O
Oct	O
-	O
2a	O
is	O
implicated	O
in	O
B	O
cell	O
-	O
specific	O
transcriptional	O
activity	O
via	O
the	O
octamer	O
motif	O
.	O

Structure/function	O
analysis	O
of	O
various	O
Oct	O
-	O
2a	O
effector	O
regions	O
in	O
the	O
context	O
of	O
the	O
GAL4	O
DNA	O
-	O
binding	O
domain	O
revealed	O
that	O
Oct	O
-	O
2a	O
contains	O
two	O
functionally	O
different	O
activation	O
domains	O
at	O
the	O
N	O
and	O
the	O
C	O
termini	O
.	O

The	O
transcriptional	O
activity	O
of	O
both	O
domains	O
is	O
strongly	O
potentiated	B-Positive_regulation
by	O
interactions	B-Binding
with	O
distinct	O
B	O
cell	O
-	O
specific	O
coactivators	O
.	O

Recently	O
,	O
we	O
have	O
identified	O
a	O
repression	O
domain	O
located	O
within	O
the	O
N	O
terminus	O
of	O
Oct	O
-	O
2a	O
(	O
amino	O
acids	O
2	O
-	O
99	O
)	O
.	O

When	O
this	O
domain	O
was	O
transferred	O
to	O
a	O
potent	O
activator	O
,	O
transcription	O
was	O
strongly	O
inhibited	O
.	O

In	O
this	O
study	O
we	O
present	O
a	O
deletion	O
analysis	O
of	O
the	O
N	O
-	O
terminal	O
region	O
of	O
Oct	O
-	O
2a	O
to	O
determine	O
the	O
minimal	O
repression	O
domain	O
.	O

We	O
identified	O
a	O
stretch	O
of	O
23	O
amino	O
acids	O
,	O
rich	O
in	O
serine	O
and	O
threonine	O
residues	O
,	O
which	O
was	O
responsible	O
for	O
most	O
of	O
the	O
repression	O
activity	O
.	O

We	O
show	O
that	O
repression	O
is	O
strongly	O
dependent	O
on	O
the	O
type	O
of	O
enhancer	O
present	O
in	O
the	O
reporter	O
plasmid	O
as	O
well	O
as	O
on	O
the	O
cell	O
line	O
tested	O
.	O

The	O
possibility	O
that	O
Oct	O
-	O
2a	O
can	O
act	O
as	O
an	O
activator	O
and/or	O
a	O
repressor	O
may	O
have	O
important	O
consequences	O
for	O
the	O
function	O
of	O
Oct	O
-	O
2a	O
in	O
B	O
cell	O
differentiation	O
and	O
other	O
developmental	O
processes	O
.	O

The	O
role	O
of	O
BSAP	O
(	O
Pax	O
-	O
5	O
)	O
in	O
B	O
-	O
cell	O
development	O
.	O

The	O
hierarchy	O
of	O
transcriptional	O
control	O
in	O
B	O
-	O
cell	O
development	O
has	O
recently	O
been	O
analyzed	O
by	O
targeted	O
gene	O
inactivation	O
in	O
the	O
mouse	O
.	O

In	O
this	O
manner	O
,	O
the	O
paired	O
box	O
containing	O
gene	O
Pax	O
-	O
5	O
,	O
encoding	O
the	O
B	O
cell	O
specific	O
transcription	O
factor	O
BSAP	O
,	O
has	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
early	O
B	O
lymphopoiesis	O
.	O

Other	O
experimental	O
strategies	O
have	O
implicated	O
BSAP	O
in	O
the	O
control	O
of	O
cell	O
proliferation	O
,	O
isotype	O
switching	O
and	O
transcription	O
of	O
the	O
immunoglobulin	O
heavy	O
-	O
chain	O
gene	O
at	O
late	O
stages	O
of	O
B	O
-	O
cell	O
differentiation	O
.	O

Modulation	B-Regulation
of	O
the	O
expression	B-Gene_expression
of	O
the	O
IFN	O
-	O
gamma	O
receptor	O
beta	O
-	O
chain	O
controls	O
responsiveness	O
to	O
IFN	O
-	O
gamma	O
in	O
human	O
peripheral	O
blood	O
T	O
cells	O
.	O

IFN	O
-	O
gamma	O
has	O
potent	O
antiproliferative	O
and	O
apoptotic	O
effects	O
in	O
T	O
cells	O
that	O
are	O
important	O
in	O
determining	O
T	O
cell	O
development	O
and	O
polarized	O
differentiation	O
.	O

Therefore	O
,	O
any	O
event	O
that	O
enables	O
T	O
cells	O
to	O
become	O
less	O
responsive	O
to	O
IFN	O
-	O
gamma	O
may	O
potentially	O
alter	O
immune	O
responsiveness	O
to	O
Ag	O
.	O

In	O
this	O
work	O
,	O
we	O
show	O
that	O
human	O
peripheral	O
blood	O
T	O
cells	O
that	O
are	O
stimulated	O
through	O
the	O
TCR	O
and	O
expanded	O
with	O
IL	O
-	O
2	O
are	O
unresponsive	O
to	O
IFN	O
-	O
gamma	O
,	O
as	O
determined	O
by	O
a	O
lack	O
of	O
activation	B-Positive_regulation
of	O
jak	O
kinases	O
and	O
the	O
transcription	O
factor	O
,	O
STAT1	O
(	O
alpha	O
)	O
,	O
a	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
.	O

This	O
nonresponsiveness	O
occurs	O
because	O
of	O
a	O
lack	O
of	O
expression	O
of	O
the	O
beta	O
-	O
chain	O
(	O
accessory	O
factor	O
)	O
of	O
the	O
IFN	O
-	O
gamma	O
receptor	O
,	O
while	O
at	O
the	O
same	O
time	O
maintaining	O
IFN	O
-	O
gamma	O
receptor	O
alpha	O
-	O
chain	O
expression	B-Gene_expression
.	O

Expression	O
of	O
the	O
beta	O
-	O
chain	O
can	O
be	O
restored	O
by	O
secondary	O
TCR	O
ligation	O
or	O
PMA	O
treatment	O
.	O

T	O
cell	O
blasts	O
treated	O
with	O
PMA	O
are	O
now	O
responsive	O
to	O
IFN	O
-	O
gamma	O
.	O

When	O
freshly	O
isolated	O
,	O
highly	O
enriched	O
(	O
>	O
98	O
%	O
)	O
T	O
cells	O
are	O
examined	O
for	O
IFN	O
-	O
gamma	O
responsiveness	O
;	O
these	O
cells	O
can	O
respond	O
to	O
IFN	O
-	O
gamma	O
and	O
express	O
beta	O
-	O
chain	O
.	O

Therefore	O
,	O
as	O
T	O
cells	O
progress	O
from	O
primary	O
TCR	O
activation	O
through	O
IL-2	O
-	O
dependent	O
proliferation	O
,	O
followed	O
by	O
secondary	O
TCR	O
stimulation	O
,	O
their	O
responsiveness	O
to	O
IFN	O
-	O
gamma	O
varies	O
,	O
and	O
this	O
may	O
affect	O
their	O
ability	O
to	O
participate	O
in	O
an	O
ongoing	O
immune	O
response	O
.	O

Induction	B-Positive_regulation
of	O
CIITA	O
and	O
modification	O
of	O
in	O
vivo	O
HLA	O
-	O
DR	O
promoter	O
occupancy	O
in	O
normal	O
thymic	O
epithelial	O
cells	O
treated	O
with	O
IFN	O
-	O
gamma	O
:	O
similarities	O
and	O
distinctions	O
with	O
respect	O
to	O
HLA-DR	O
-	O
constitutive	O
B	O
cells	O
.	O

In	O
this	O
study	O
,	O
the	O
IFN	O
-	O
gamma	O
induction	O
of	O
MHC	O
class	O
II	O
gene	O
expression	O
in	O
primary	O
cultures	O
of	O
thymic	O
epithelial	O
cells	O
(	O
TEC	O
)	O
was	O
analyzed	O
.	O

This	O
cellular	O
system	O
offers	O
the	O
advantage	O
that	O
MHC	O
class	O
II	O
induction	O
is	O
studied	O
in	O
a	O
"	O
physiologic	O
"	O
cell	O
lineage	O
that	O
,	O
as	O
a	O
result	O
of	O
this	O
expression	O
within	O
the	O
thymus	O
,	O
is	O
thought	O
to	O
participate	O
to	O
the	O
selection	O
and	O
maturation	O
of	O
the	O
T	O
cells	O
.	O

It	O
was	O
found	O
that	O
the	O
MHC	O
class	O
II	O
gene	O
expression	O
was	O
associated	O
with	O
the	O
de	O
novo	O
transcription	B-Transcription
of	O
the	O
gene	O
encoding	O
the	O
CIITA	O
trans	O
-	O
activator	O
,	O
a	O
crucial	O
MHC	O
class	O
II	O
gene	O
regulatory	O
factor	O
.	O

Furthermore	O
,	O
the	O
anatomy	O
of	O
interaction	O
between	O
the	O
MHC	O
class	O
II	O
DRA	O
promoter	O
and	O
corresponding	O
binding	O
factors	O
was	O
analyzed	O
by	O
in	O
vivo	O
DNAse	O
I	O
footprint	O
.	O

It	O
was	O
found	O
that	O
treatment	O
with	O
IFN	O
-	O
gamma	O
induces	O
changes	O
in	O
the	O
occupancy	O
of	O
the	O
DRA	O
gene	O
regulatory	O
sequences	O
by	O
nuclear	O
factors	O
.	O

The	O
resulting	O
occupancy	O
displays	O
strong	O
similarities	O
with	O
the	O
one	O
observed	O
in	O
the	O
MHC	O
class	O
II	O
-	O
constitutive	O
B	O
cells	O
,	O
represented	O
by	O
both	O
the	O
Burkitt	O
lymphoma	O
line	O
Raji	O
and	O
normal	O
tonsil	O
-	O
derived	O
B	O
cells	O
.	O

However	O
,	O
some	O
peculiar	O
differences	O
were	O
observed	O
between	O
the	O
TEC	O
,	O
either	O
IFN-gamma	O
-	O
induced	O
or	O
not	O
,	O
and	O
the	O
constitutive	O
B	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
both	O
common	O
mechanisms	O
,	O
such	O
as	O
the	O
one	O
mediated	O
by	O
the	O
CIITA	O
trans	O
-	O
activator	O
,	O
and	O
distinct	O
tissue	O
-	O
specific	O
constraints	O
contribute	O
to	O
the	O
transcriptional	O
control	O
of	O
constitutive	O
and	O
IFN-gamma	O
-	O
induced	O
MHC	O
class	O
II	O
gene	O
expression	O
.	O

Recombinant	O
NFAT1	O
(	O
NFATp	O
)	O
is	O
regulated	O
by	O
calcineurin	O
in	O
T	O
cells	O
and	O
mediates	O
transcription	O
of	O
several	O
cytokine	O
genes	O
.	O

Transcription	O
factors	O
of	O
the	O
NFAT	O
family	O
play	O
a	O
key	O
role	O
in	O
the	O
transcription	O
of	O
cytokine	O
genes	O
and	O
other	O
genes	O
during	O
the	O
immune	O
response	O
.	O

We	O
have	O
identified	O
two	O
new	O
isoforms	O
of	O
the	O
transcription	O
factor	O
NFAT1	O
(	O
previously	O
termed	O
NFATp	O
)	O
that	O
are	O
the	O
predominant	O
isoforms	O
expressed	O
in	O
murine	O
and	O
human	O
T	O
cells	O
.	O

When	O
expressed	O
in	O
Jurkat	O
T	O
cells	O
,	O
recombinant	O
NFAT1	O
is	O
regulated	O
,	O
as	O
expected	O
,	O
by	O
the	O
calmodulin	O
-	O
dependent	O
phosphatase	O
calcineurin	O
,	O
and	O
its	O
function	O
is	O
inhibited	O
by	O
the	O
immunosuppressive	O
agent	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

Transactivation	O
by	O
recombinant	O
NFAT1	O
in	O
Jurkat	O
T	O
cells	O
requires	O
dual	O
stimulation	O
with	O
ionomycin	O
and	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
;	O
this	O
activity	O
is	O
potentiated	O
by	O
coexpression	O
of	O
constitutively	O
active	O
calcineurin	O
and	O
is	O
inhibited	O
by	O
CsA	O
.	O

Immunocytochemical	O
analysis	O
indicates	O
that	O
recombinant	O
NFAT1	O
localizes	O
in	O
the	O
cytoplasm	O
of	O
transiently	O
transfected	O
T	O
cells	O
and	O
translocates	O
into	O
the	O
nucleus	O
in	O
a	O
CsA	O
-	O
sensitive	O
manner	O
following	O
ionomycin	O
stimulation	O
.	O

When	O
expressed	B-Gene_expression
in	O
COS	O
cells	O
,	O
however	O
,	O
NFAT1	O
is	O
capable	O
of	O
transactivation	O
,	O
but	O
it	O
is	O
not	O
regulated	O
correctly	O
:	O
its	O
subcellular	O
localization	O
and	O
transcriptional	O
function	O
are	O
not	O
affected	O
by	O
stimulation	O
of	O
the	O
COS	O
cells	O
with	O
ionomycin	O
and	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
.	O

Recombinant	O
NFAT1	O
can	O
mediate	B-Positive_regulation
transcription	B-Transcription
of	O
the	O
interleukin	O
-	O
2	O
,	O
interleukin	O
-	O
4	O
,	O
tumor	O
necrosis	O
factor	O
alpha	O
,	O
and	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
promoters	O
in	O
T	O
cells	O
,	O
suggesting	O
that	O
NFAT1	O
contributes	B-Positive_regulation
to	O
the	O
CsA	O
-	O
sensitive	O
transcription	B-Transcription
of	O
these	O
genes	O
during	O
the	O
immune	O
response	O
.	O

An	O
alternatively	O
spliced	O
isoform	O
of	O
the	O
Spi	O
-	O
B	O
transcription	O
factor	O
.	O

Spi	O
-	O
B	O
is	O
an	O
Ets	O
transcription	O
factor	O
related	O
to	O
the	O
oncoprotein	O
Spi	O
-	O
1/PU.1	O
and	O
highly	O
expressed	B-Gene_expression
in	O
B	O
lymphoid	O
cells	O
.	O

The	O
Ets	O
proteins	O
share	O
a	O
conserved	O
Ets	O
domain	O
that	O
mediates	O
specific	O
DNA	O
binding	O
.	O

Spi	O
-	O
B	O
binds	B-Binding
DNA	O
sequences	O
containing	O
a	O
core	O
5'-GGAA	O
-	O
3	O
'	O
and	O
activates	O
transcription	O
through	O
this	O
motif	O
.	O

Up	O
to	O
date	O
,	O
the	O
biological	O
function	O
of	O
Spi	O
-	O
B	O
remains	O
unknown	O
.	O

Here	O
,	O
we	O
describe	O
the	O
characterization	O
of	O
an	O
alternatively	O
spliced	O
variant	O
of	O
Spi	O
-	O
B	O
,	O
named	O
deltaSpi	O
-	O
B	O
,	O
which	O
has	O
lost	O
the	O
Ets	O
domain	O
.	O

In	O
B	O
lymphoid	O
cells	O
,	O
deltaspi	O
-	O
B	O
and	O
spi	O
-	O
B	O
mRNAs	O
were	O
present	B-Transcription
simultaneously	O
in	O
a	O
ratio	O
of	O
around	O
10	O
%	O
.	O

DeltaSpi	O
-	O
B	O
product	O
was	O
not	O
able	O
to	O
bind	B-Binding
DNA	O
and	O
was	O
recovered	B-Localization
in	O
cytoplasmic	O
cellular	O
extracts	O
.	O

We	O
raise	O
the	O
hypothesis	O
that	O
delta	O
Spi	O
-	O
B	O
might	O
affect	B-Regulation
Spi	O
-	O
B	O
function	O
by	O
recruiting	O
factors	O
involved	O
in	O
Spi	O
-	O
B	O
activity	O
.	O

Activation	O
protein	O
1	O
-	O
dependent	B-Positive_regulation
transcriptional	B-Positive_regulation
activation	I-Positive_regulation
of	O
interleukin	O
2	O
gene	O
by	O
Ca2+/calmodulin	O
kinase	O
type	O
IV/Gr	O
.	O

The	O
Ca2+/calmodulin	O
-	O
dependent	O
protein	O
kinase	O
(	O
CaMK	O
)	O
type	O
IV/Gr	O
is	O
selectively	O
expressed	B-Gene_expression
in	O
T	O
lymphocytes	O
and	O
is	O
activated	B-Positive_regulation
after	O
signaling	O
via	O
the	O
T	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
,	O
indicating	O
that	O
it	O
mediates	O
some	O
of	O
the	O
Ca	O
(	O
2+	O
)	O
-	O
dependent	O
transcriptional	O
events	O
that	O
follow	O
TCR	O
engagement	O
.	O

Here	O
we	O
show	O
that	O
CaMKIV/Gr	O
induces	O
the	O
transcription	O
factor	O
activation	O
protein	O
1	O
(	O
AP	O
-	O
1	O
)	O
alone	O
or	O
in	O
synergy	O
with	O
T	O
cell	O
mitogens	O
and	O
with	O
the	O
p21ras	O
oncoprotein	O
.	O

CaMKIV/	O
Gr	O
signaling	O
is	O
associated	O
with	O
transcriptional	B-Positive_regulation
activation	I-Positive_regulation
of	O
c	O
-	O
fos	O
but	O
is	O
independent	O
of	O
p21ras	O
or	O
calcineurin	O
.	O

AP	O
-	O
1	O
is	O
an	O
integral	O
component	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
transcriptional	O
complex	O
,	O
which	O
is	O
required	B-Positive_regulation
for	O
interleukin	O
2	O
gene	O
expression	B-Gene_expression
in	O
T	O
cells	O
.	O

We	O
demonstrate	O
that	O
CaMKIV/Gr	O
reconstitutes	O
the	O
capacity	O
of	O
the	O
cytosolic	O
component	O
of	O
NFAT	O
to	O
direct	O
transcription	O
from	O
NFAT	O
sites	O
in	O
non	O
-	O
T	O
cells	O
.	O

These	O
results	O
reveal	O
a	O
central	O
role	O
for	O
CaMKIV/Gr	O
as	O
a	O
Ca	O
(	O
2+	O
)	O
-	O
regulated	O
activator	O
of	O
gene	O
transcription	O
in	O
T	O
lymphocytes	O
.	O

Mechanisms	O
of	O
transactivation	O
by	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
-	O
1	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
-	O
family	O
proteins	O
(	O
NFAT1/NFATp	O
,	O
NFATc	O
,	O
NFAT3	O
,	O
and	O
NFAT4/NFATx/NFATc3	O
)	O
play	O
a	O
key	O
role	O
in	O
the	O
transcription	O
of	O
cytokine	O
genes	O
and	O
other	O
genes	O
during	O
the	O
immune	O
response	O
.	O

We	O
have	O
defined	O
the	O
mechanisms	O
of	O
transactivation	O
by	O
NFAT1	O
.	O

NFAT1	O
possesses	O
two	O
transactivation	O
domains	O
whose	O
sequences	O
are	O
not	O
conserved	O
in	O
the	O
other	O
NFAT	O
-	O
family	O
proteins	O
,	O
and	O
a	O
conserved	O
DNA	O
-	O
binding	O
domain	O
that	O
mediates	O
the	O
recruitment	O
of	O
cooperating	O
nuclear	O
transcription	O
factors	O
even	O
when	O
it	O
is	O
expressed	B-Gene_expression
in	O
the	O
absence	O
of	O
other	O
regions	O
of	O
the	O
protein	O
.	O

The	O
activity	O
of	O
the	O
NH2	O
-	O
terminal	O
transactivation	O
domain	O
is	O
modulated	O
by	O
an	O
adjacent	O
regulatory	O
region	O
that	O
contains	O
several	O
conserved	O
sequence	O
motifs	O
represented	O
only	O
in	O
the	O
NFAT	O
family	O
.	O

Our	O
results	O
emphasize	O
the	O
multiple	O
levels	O
at	O
which	O
NFAT	O
-	O
dependent	O
transactivation	O
is	O
regulated	O
,	O
and	O
predict	O
significant	O
differences	O
in	O
the	O
architecture	O
of	O
cooperative	O
transcription	O
complexes	O
containing	O
different	O
NFAT	O
-	O
family	O
proteins	O
.	O

BCL	O
-	O
6	O
,	O
a	O
POZ/zinc	O
-	O
finger	O
protein	O
,	O
is	O
a	O
sequence	O
-	O
specific	O
transcriptional	O
repressor	O
.	O

Approximately	O
40	O
%	O
of	O
diffuse	O
large	O
cell	O
lymphoma	O
are	O
associated	O
with	O
chromosomal	O
translocations	O
that	O
deregulate	B-Regulation
the	O
expression	B-Gene_expression
of	O
the	O
BCL6	O
gene	O
by	O
juxtaposing	O
heterologous	O
promoters	O
to	O
the	O
BCL	O
-	O
6	O
coding	O
domain	O
.	O

The	O
BCL6	O
gene	O
encodes	O
a	O
95	O
-	O
kDa	O
protein	O
containing	O
six	O
C	O
-	O
terminal	O
zinc	O
-	O
finger	O
motifs	O
and	O
an	O
N	O
-	O
terminal	O
POZ	O
domain	O
,	O
suggesting	O
that	O
it	O
may	O
function	O
as	O
a	O
transcription	O
factor	O
.	O

By	O
using	O
a	O
DNA	O
sequence	O
selected	O
for	O
its	O
ability	O
to	O
bind	O
recombinant	O
BCL	O
-	O
6	O
in	O
vitro	O
,	O
we	O
show	O
here	O
that	O
BCL	O
-	O
6	O
is	O
present	O
in	O
DNA	O
-	O
binding	O
complexes	O
in	O
nuclear	O
extracts	O
from	O
various	O
B	O
-	O
cell	O
lines	O
.	O

In	O
transient	O
transfectin	O
experiments	O
,	O
BCL6	O
can	O
repress	O
transcription	O
from	O
promoters	O
linked	O
to	O
its	O
DNA	O
target	O
sequence	O
and	O
this	O
activity	O
is	O
dependent	O
upon	O
specific	O
DNA	O
-	O
binding	O
and	O
the	O
presence	O
of	O
an	O
intact	O
N	O
-	O
terminal	O
half	O
of	O
the	O
protein	O
.	O

We	O
demonstrate	O
that	O
this	O
part	O
of	O
the	O
BCL6	O
molecule	O
contains	O
an	O
autonomous	O
transrepressor	O
domain	O
and	O
that	O
two	O
noncontiguous	O
regions	O
,	O
including	O
the	O
POZ	O
motif	O
,	O
mediate	O
maximum	O
transrepressive	O
activity	O
.	O

These	O
results	O
indicate	O
that	O
the	O
BCL	O
-	O
6	O
protein	O
can	O
function	O
as	O
a	O
sequence	O
-	O
specific	O
transcriptional	O
repressor	O
and	O
have	O
implications	O
for	O
the	O
role	O
of	O
BCL6	O
in	O
normal	O
lymphoid	O
development	O
and	O
lymphomagenesis	O
.	O

Constitutive	O
expression	O
of	O
specific	O
interferon	O
isotypes	O
in	O
peripheral	O
blood	O
leukocytes	O
from	O
normal	O
individuals	O
and	O
in	O
promonocytic	O
U937	O
cells	O
.	O

Constitutive	O
expression	B-Gene_expression
of	O
IFN	O
-	O
alpha5	O
and	O
IFN	O
-	O
beta	O
was	O
detected	O
in	O
different	O
lymphoid	O
cells	O
including	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
normal	O
individuals	O
following	O
amplification	O
of	O
IFN	O
mRNA	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
of	O
the	O
amplified	O
product	O
.	O

The	O
activated	O
form	O
of	O
the	O
interferon	O
-	O
induced	O
transcription	O
factor	O
complex	O
ISGF3	O
was	O
also	O
detected	O
in	O
nuclear	O
extracts	O
from	O
uninduced	O
cells	O
.	O

Culture	O
supernatants	O
from	O
uninduced	O
U937	O
cells	O
were	O
also	O
found	O
to	O
activate	O
an	O
ISRE	O
cloned	O
upstream	O
of	O
the	O
luciferase	O
reporter	O
gene	O
,	O
indicating	O
the	O
presence	O
of	O
endogenous	O
IFN	O
activity	O
equivalent	O
to	O
approximately	O
0.3	O
to	O
0.5	O
IU/mL	O
.	O

This	O
endogenous	O
IFN	O
was	O
also	O
shown	O
to	O
play	O
a	O
role	O
in	O
maintaining	O
the	O
basal	O
level	O
of	O
expression	O
of	O
the	O
major	O
histocompatibility	O
class	O
I	O
genes	O
in	O
lymphoid	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
IFN	O
-	O
alpha5	O
and	O
IFN	O
-	O
beta	O
are	O
produced	B-Gene_expression
at	O
low	O
levels	O
in	O
normal	O
tissues	O
and	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cell	O
function	O
and	O
in	O
the	O
maintenance	O
of	O
homeostasis	O
.	O

Characterization	O
of	O
a	O
new	O
isoform	O
of	O
the	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
gene	O
family	O
member	O
NFATc	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1996	O
Dec	O
27	O
;	O
271	O
(	O
52	O
)	O
:	O
33705	O
]	O

The	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
/FK506	O
-	O
sensitive	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
plays	O
a	O
key	O
role	O
in	O
the	O
inducible	O
expression	O
of	O
cytokine	O
genes	O
in	O
T	O
cells	O
.	O

Although	O
NFAT	O
has	O
been	O
recently	O
shown	O
to	O
be	O
inducible	O
in	O
several	O
non	O
-	O
T	O
immune	O
cells	O
,	O
the	O
NFAT	O
gene	O
family	O
members	O
characterized	O
to	O
date	O
have	O
been	O
isolated	O
only	O
from	O
T	O
cells	O
.	O

To	O
further	O
characterize	O
NFAT	O
function	O
in	O
human	O
B	O
cells	O
and	O
to	O
demonstrate	O
cytokine	O
gene	O
specificity	O
of	O
NFAT	O
proteins	O
,	O
we	O
report	O
here	O
the	O
isolation	O
and	O
characterization	O
of	O
a	O
cDNA	O
clone	O
from	O
the	O
Raji	O
B	O
cell	O
line	O
.	O

The	O
cDNA	O
clone	O
encodes	O
a	O
new	O
isoform	O
,	O
NFATc.beta	O
,	O
of	O
the	O
NFAT	O
gene	O
family	O
member	O
NFATc	O
(	O
designated	O
here	O
NFATc.alpha	O
)	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
NFATc.beta	O
differs	O
from	O
that	O
of	O
NFATc.alpha	O
in	O
the	O
first	O
NH2	O
-	O
terminal	O
29	O
residues	O
and	O
contains	O
an	O
additional	O
region	O
of	O
142	O
residues	O
at	O
the	O
COOH	O
terminus	O
.	O

Northern	O
analysis	O
using	O
a	O
probe	O
encompassing	O
a	O
common	O
region	O
of	O
both	O
isoforms	O
showed	O
two	O
mRNA	O
species	O
of	O
2.7	O
and	O
4.5	O
kilobase	O
pairs	O
,	O
while	O
an	O
NFATc.beta	O
-	O
specific	O
probe	O
detected	O
only	O
the	O
4.5	O
-	O
kilobase	O
pair	O
mRNA	O
which	O
was	O
preferentially	O
expressed	O
in	O
the	O
spleen	O
.	O

Transient	O
expression	B-Gene_expression
of	O
NFATc.beta	O
was	O
capable	O
of	O
activating	O
an	O
interleukin	O
-	O
2	O
NFAT	O
-	O
driven	O
reporter	O
gene	O
in	O
stimulated	O
Jurkat	O
cells	O
in	O
a	O
CsA	O
-	O
sensitive	O
manner	O
.	O

However	O
,	O
NFATc.beta	O
neither	O
bound	B-Binding
to	O
the	O
kappa3	O
element	O
(	O
an	O
NFAT	O
-	O
binding	O
site	O
)	O
in	O
the	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
promoter	O
nor	O
activated	B-Positive_regulation
the	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
promoter	O
in	O
cotransfection	O
assays	O
.	O

These	O
data	O
suggest	O
that	O
different	O
members	O
or	O
isoforms	O
of	O
NFAT	O
gene	O
family	O
may	O
regulate	O
inducible	O
expression	O
of	O
different	O
cytokine	O
genes	O
.	O

Cytokine	O
-	O
modulating	O
activity	O
of	O
tepoxalin	O
,	O
a	O
new	O
potential	O
antirheumatic	O
.	O

Tepoxalin	O
is	O
a	O
new	O
dual	O
cyclooxygenase/5	O
-	O
lipoxygenase	O
anti	O
-	O
inflammatory	O
compound	O
currently	O
under	O
clinical	O
investigation	O
.	O

It	O
has	O
been	O
shown	O
to	O
possess	O
anti	O
-	O
inflammatory	O
activity	O
in	O
a	O
variety	O
of	O
animal	O
models	O
and	O
more	O
recently	O
to	O
inhibit	O
IL	O
-	O
2	O
induced	O
signal	O
transduction	O
.	O

The	O
current	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
cytokine	O
modulating	O
activity	O
of	O
tepoxalin	O
and	O
the	O
role	O
of	O
iron	O
in	O
these	O
effects	O
.	O

In	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
stimulated	O
with	O
OKT3/PMA	O
,	O
tepoxalin	O
inhibited	O
lymphocyte	O
proliferation	O
with	O
an	O
IC50	O
of	O
6	O
microM	O
.	O

Additionally	O
,	O
it	O
inhibited	B-Negative_regulation
the	O
production	B-Gene_expression
of	O
LTB4	O
(	O
IC50	O
=	O
0.5	O
microM	O
)	O
and	O
the	O
cytokines	O
IL	O
-	O
2	O
,	O
IL	O
-	O
6	O
and	O
TNF	O
alpha	O
(	O
IC50	O
=	O
10	O
-	O
12	O
microM	O
)	O
.	O

Cytotoxicity	O
was	O
not	O
demonstrated	O
at	O
these	O
concentrations	O
.	O

Add	O
-	O
back	O
experiments	O
with	O
either	O
cytokines	O
(	O
IL	O
-	O
2	O
or	O
IL	O
-	O
6	O
)	O
,	O
LTB4	O
or	O
conditioned	O
media	O
failed	O
to	O
restore	O
the	O
proliferative	O
response	O
in	O
the	O
presence	O
of	O
tepoxalin	O
.	O

However	O
,	O
the	O
concurrent	O
addition	O
of	O
iron	O
(	O
in	O
the	O
form	O
of	O
ferrous	O
or	O
ferric	O
chloride	O
and	O
other	O
iron	O
salts	O
)	O
reversed	O
the	O
inhibition	O
of	O
proliferation	O
caused	O
by	O
tepoxalin	O
.	O

Tepoxalin	O
also	O
inhibits	O
the	O
activation	O
of	O
NF	O
kappa	O
B	O
,	O
a	O
transcription	O
factor	O
which	O
acts	O
on	O
several	O
cytokine	O
genes	O
.	O

Tepoxalin	O
's	O
effect	O
on	O
NF	O
kappa	O
B	O
is	O
also	O
reversed	O
by	O
the	O
addition	O
of	O
iron	O
salts	O
.	O

These	O
data	O
suggest	O
that	O
the	O
action	O
of	O
tepoxalin	O
to	O
inhibit	O
proliferation	O
in	O
PBMC	O
may	O
be	O
at	O
least	O
in	O
part	O
due	O
to	O
its	O
ability	O
to	O
reduce	O
the	O
amount	O
of	O
available	O
iron	O
resulting	O
in	O
decreased	O
activation	O
of	O
NF	O
kappa	O
B	O
and	O
subsequent	O
inhibition	O
of	O
cytokine	O
production	O
.	O

oriP	O
is	O
essential	O
for	O
EBNA	O
gene	O
promoter	O
activity	O
in	O
Epstein	O
-	O
Barr	O
virus	O
-	O
immortalized	O
lymphoblastoid	O
cell	O
lines	O
.	O

During	O
Epstein	O
-	O
Barr	O
virus	O
latent	O
infection	O
of	O
B	O
lymphocytes	O
in	O
vitro	O
,	O
six	O
viral	O
nuclear	O
antigens	O
(	O
EBNAs	O
)	O
are	O
expressed	O
from	O
one	O
of	O
two	O
promoters	O
,	O
Cp	O
or	O
Wp	O
,	O
whose	O
activities	O
are	O
mutually	O
exclusive	O
.	O

Upon	O
infection	O
,	O
Wp	O
is	O
initially	O
active	B-Positive_regulation
,	O
followed	O
by	O
a	O
switch	B-Negative_regulation
to	O
Cp	O
for	O
the	O
duration	O
of	O
latency	O
.	O

In	O
this	O
study	O
,	O
the	O
region	O
upstream	O
of	O
Cp	O
was	O
analyzed	O
for	O
the	O
presence	O
of	O
cis	O
elements	O
involved	O
in	O
regulating	O
the	O
activities	O
of	O
the	O
EBNA	O
gene	O
promoters	O
in	O
established	O
in	O
vitro	O
immortalized	O
lymphoblastoid	O
cell	O
lines	O
(	O
LCLs	O
)	O
.	O

It	O
was	O
determined	O
that	O
oriP	O
,	O
the	O
origin	O
for	O
episomal	O
maintenance	O
during	O
latency	O
,	O
is	O
essential	O
for	O
efficient	O
transcription	O
initiation	O
from	O
either	O
Cp	O
or	O
Wp	O
in	O
LCLs	O
,	O
as	O
well	O
as	O
in	O
some	O
Burkitt	O
's	O
lymphoma	O
cell	O
lines	O
.	O

Deletion	O
of	O
the	O
EBNA2	O
-	O
dependent	O
enhancer	O
located	O
upstream	O
of	O
Cp	O
resulted	O
in	O
a	O
ca.	O
two	O
-	O
to	O
fivefold	O
reduction	B-Negative_regulation
in	O
Cp	O
activity	O
in	O
the	O
LCLs	O
assayed	O
.	O

More	O
extensive	O
deletion	O
of	O
sequences	O
upstream	O
of	O
Cp	O
,	O
including	O
the	O
EBNA2	O
-	O
dependent	O
enhancer	O
,	O
resulted	O
in	O
nearly	O
complete	O
loss	B-Negative_regulation
of	O
Cp	O
activity	O
.	O

This	O
loss	O
of	O
activity	O
was	O
shown	O
to	O
correlate	O
with	O
deletion	O
of	O
two	O
CCAAT	O
boxes	O
,	O
a	O
proximal	O
CCAAT	O
box	O
located	O
at	O
bp	O
-	O
61	O
to	O
-	O
65	O
and	O
a	O
distal	O
CCAAT	O
box	O
located	O
at	O
bp	O
-	O
253	O
to	O
-	O
257	O
,	O
upstream	O
of	O
Cp	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
these	O
cis	O
elements	O
demonstrated	O
that	O
Cp	O
activity	O
is	O
highly	O
dependent	B-Positive_regulation
on	O
the	O
presence	O
of	O
a	O
properly	O
positioned	O
CCAAT	O
box	O
,	O
with	O
the	O
dependence	B-Positive_regulation
on	O
the	O
distal	O
CCAAT	O
box	O
apparent	O
only	O
when	O
the	O
proximal	O
CCAAT	O
box	O
was	O
deleted	O
or	O
mutated	O
.	O

Deletion	O
of	O
the	O
glucocorticoid	O
response	O
elements	O
located	O
at	O
ca.	O
bp	O
-	O
850	O
upstream	O
of	O
Cp	O
did	O
not	O
result	O
in	O
a	O
significant	O
loss	B-Negative_regulation
in	O
activity	O
.	O

In	O
general	O
,	O
deletions	O
which	O
diminished	B-Negative_regulation
Cp	O
activity	O
resulted	O
in	O
induction	B-Positive_regulation
of	O
Wp	O
activity	O
,	O
consistent	O
with	O
suppression	B-Negative_regulation
of	O
Wp	O
activity	O
by	O
transcriptional	O
interference	O
from	O
Cp	O
.	O

The	O
identification	O
of	O
oriP	O
and	O
the	O
EBNA2	O
-	O
dependent	O
enhancer	O
as	O
the	O
major	O
positive	O
cis	O
elements	O
involved	O
in	O
regulating	B-Regulation
Cp	O
activity	O
in	O
LCL	O
suggests	O
that	O
EBNA	O
gene	O
transcription	O
is	O
largely	O
autoregulated	O
by	O
EBNA	O
1	O
and	O
EBNA	O
2	O
.	O

Various	O
modes	O
of	O
basic	O
helix-loop	O
-	O
helix	O
protein	O
-	O
mediated	O
regulation	O
of	O
murine	O
leukemia	O
virus	O
transcription	O
in	O
lymphoid	O
cell	O
lines	O
.	O

The	O
transcriptionally	O
regulatory	O
regions	O
of	O
the	O
lymphomagenic	O
Akv	O
and	O
SL3	O
-	O
3	O
murine	O
leukemia	O
retroviruses	O
(	O
MLVs	O
)	O
contain	O
two	O
types	O
of	O
E	O
-	O
box	O
consensus	O
motifs	O
,	O
CAGATG	O
.	O

One	O
type	O
,	O
EA/S	O
,	O
is	O
located	O
in	O
the	O
upstream	O
promoter	O
region	O
,	O
and	O
the	O
other	O
,	O
E	O
(	O
gre	O
)	O
,	O
is	O
located	O
in	O
a	O
tandem	O
repeat	O
with	O
enhancer	O
properties	O
.	O

We	O
have	O
examined	O
the	O
requirements	O
of	O
the	O
individual	O
E	O
-	O
boxes	O
in	O
MLV	O
transcriptional	O
regulation	O
.	O

In	O
lymphoid	O
cell	O
lines	O
only	O
,	O
the	O
E	O
(	O
gre	O
)	O
-	O
binding	B-Binding
protein	O
complexes	O
included	O
ALF1	O
or	O
HEB	O
and	O
E2A	O
basic	O
helix-loop	O
-	O
helix	O
proteins	O
.	O

Ectopic	O
ALF1	O
and	O
E2A	O
proteins	O
required	O
intact	O
E	O
(	O
gre	O
)	O
motifs	O
for	O
mediating	O
transcriptional	O
activation	O
.	O

ALF1	O
transactivated	O
transcription	O
of	O
Akv	O
MLV	O
through	O
the	O
two	O
E	O
(	O
gre	O
)	O
motifs	O
equally	O
,	O
whereas	O
E2A	O
protein	O
required	O
the	O
promoter	O
-	O
proximal	O
E	O
(	O
gre	O
)	O
motif	O
.	O

In	O
T	O
-	O
and	O
B	O
-	O
cell	O
lines	O
,	O
the	O
E	O
(	O
gre	O
)	O
motifs	O
were	O
of	O
major	O
importance	O
for	O
Akv	O
MLV	O
transcriptional	O
activity	O
,	O
while	O
the	O
EA/S	O
motif	O
had	O
some	O
effect	O
.	O

In	O
contrast	O
,	O
neither	O
E	O
(	O
gre	O
)	O
nor	O
EA/S	O
motifs	O
contributed	O
pronouncedly	O
to	O
Akv	O
MLV	O
transcription	O
in	O
NIH	O
3T3	O
cells	O
lacking	B-Negative_regulation
DNA	O
-	O
binding	B-Binding
ALF1	O
or	O
HEB	O
and	O
E2A	O
proteins	O
.	O

The	O
Id1	O
protein	O
was	O
found	O
to	O
repress	O
ALF1	O
activity	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Moreover	O
,	O
ectopic	O
Id1	O
repressed	O
E	O
(	O
gre	O
)	O
-	O
directed	O
but	O
not	O
EA/S	O
-	O
directed	O
MLV	O
transcription	O
in	O
lymphoid	O
cell	O
lines	O
.	O

In	O
conclusion	O
,	O
E	O
(	O
gre	O
)	O
motifs	O
and	O
interacting	B-Binding
basic	O
helix-loop	O
-	O
helix	O
proteins	O
are	O
important	O
determinants	O
for	O
MLV	O
transcriptional	O
activity	O
in	O
lymphocytic	O
cell	O
lines	O
.	O

Gene	O
transcription	O
through	O
activation	O
of	O
G-protein	O
-	O
coupled	O
chemoattractant	O
receptors	O
.	O

Receptors	O
for	O
leukocyte	O
chemoattractants	O
,	O
including	O
chemokines	O
,	O
are	O
traditionally	O
considered	O
to	O
be	O
responsible	O
for	O
the	O
activation	O
of	O
special	O
leukocyte	O
functions	O
such	O
as	O
chemotaxis	O
,	O
degranulation	O
,	O
and	O
the	O
release	O
of	O
superoxide	O
anions	O
.	O

Recently	O
,	O
these	O
G-protein	O
-	O
coupled	O
serpentine	O
receptors	O
have	O
been	O
found	O
to	O
transduce	O
signals	O
leading	O
to	O
gene	O
transcription	O
and	O
translation	O
in	O
leukocytes	O
.	O

Transcription	O
factors	O
,	O
such	O
as	O
NF	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
,	O
are	O
activated	O
upon	O
stimulation	O
of	O
the	O
cells	O
with	O
several	O
chemoattractants	O
at	O
physiologically	O
relevant	O
concentrations	O
.	O

Activation	O
of	O
transcription	O
factors	O
through	O
these	O
receptors	O
involves	O
G	O
-	O
protein	O
coupling	O
and	O
the	O
activation	O
of	O
protein	O
kinases	O
.	O

The	O
underlying	O
signaling	O
pathways	O
appear	O
to	O
be	O
different	O
from	O
those	O
utilized	O
by	O
TNF	O
-	O
alpha	O
,	O
a	O
better	O
characterized	O
cytokine	O
that	O
induces	O
the	O
transcription	O
of	O
immediate	O
-	O
early	O
genes	O
.	O

Chemoattractants	O
stimulate	O
the	O
expression	O
of	O
several	O
inflammatory	O
cytokines	O
and	O
chemokines	O
,	O
which	O
in	O
turn	O
may	O
activate	O
their	O
respective	O
receptors	O
and	O
initiate	O
an	O
autocrine	O
regulatory	O
mechanism	O
for	O
persistent	O
cytokine	O
and	O
chemokine	O
gene	O
expression	O
.	O

Regulation	O
of	O
gene	O
expression	O
at	O
early	O
stages	O
of	O
B	O
-	O
cell	O
and	O
T	O
-	O
cell	O
differentiation	O
.	O

The	O
expression	O
of	O
distinct	O
sets	O
of	O
genes	O
at	O
different	O
stages	O
of	O
B	O
-	O
lymphocyte	O
and	O
T	O
-	O
lymphocyte	O
differentiation	O
is	O
controlled	O
at	O
the	O
level	O
of	O
transcription	O
.	O

A	O
number	O
of	O
recent	O
studies	O
have	O
described	O
interactions	O
between	O
transcription	O
factors	O
in	O
lymphocytes	O
that	O
provide	O
new	O
insights	O
into	O
mechanisms	O
regulating	O
gene	O
expression	O
.	O

These	O
mechanisms	O
include	O
the	O
assembly	O
of	O
higher	O
order	O
nucleoprotein	O
complexes	O
and	O
other	O
protein	O
-	O
protein	O
interactions	O
that	O
enhance	O
the	O
functional	O
specificity	O
of	O
transcriptional	O
regulators	O
in	O
lymphocytes	O
.	O

Involvement	O
of	O
tyrosine	O
phosphorylation	O
in	O
endothelial	O
adhesion	O
molecule	O
induction	O
.	O

Induction	O
of	O
endothelial	O
adhesion	O
molecules	O
by	O
the	O
cytokine	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
)	O
can	O
occur	O
independently	O
of	O
protein	O
kinase	O
C	O
and	O
activation	O
of	O
a	O
protein	O
tyrosine	O
kinase	O
(	O
PTK	O
)	O
has	O
recently	O
been	O
implicated	O
in	O
the	O
upregulation	B-Positive_regulation
of	O
vascular	O
cell	O
adhesion	O
molecule	O
1	O
(	O
VCAM	O
-	O
1	O
)	O
by	O
interleukin	O
-	O
4	O
(	O
IL	O
-	O
4	O
)	O
on	O
endothelial	O
cells	O
.	O

We	O
demonstrate	O
that	O
the	O
PTK	O
inhibitors	O
herbimycin	O
A	O
or	O
genistein	O
suppress	B-Negative_regulation
induction	B-Positive_regulation
of	O
endothelial	O
VCAM	O
-	O
1	O
and	O
E	O
-	O
selectin	O
,	O
as	O
well	O
as	O
subsequent	O
monocytic	O
cell	O
adhesion	O
to	O
endothelial	O
cells	O
stimulated	O
by	O
TNF	O
.	O

Inhibition	O
studies	O
indicate	O
that	O
specific	O
tyrosine	O
phosphorylation	O
following	O
PTK	O
activation	O
is	O
involved	O
in	O
the	O
mobilization	O
of	O
the	O
transcription	O
factor	O
,	O
nuclear	O
factor	O
kappa	O
B	O
,	O
and	O
VCAM	O
-	O
1	O
mRNA	O
expression	B-Transcription
.	O

This	O
may	O
have	O
implications	O
for	O
pathophysiological	O
conditions	O
that	O
involve	O
the	O
upregulation	O
of	O
these	O
molecules	O
(	O
e.g.	O
inflammation	O
and	O
atherosclerosis	O
)	O
.	O

Transcription	O
specific	O
differences	O
visualized	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
pattern	O
on	O
interphase	O
nuclei	O
of	O
different	O
cell	O
types	O
.	O

Application	O
of	O
a	O
"	O
formamide	O
free	O
"	O
and	O
thus	O
"	O
material	O
preserving	O
"	O
in	O
situ	O
hybridization	O
technique	O
using	O
the	O
cDNA	O
of	O
the	O
myf3	O
gene	O
revealed	O
the	O
following	O
results	O
:	O
Human	O
rhabdomyosarcoma	O
cells	O
,	O
characterized	O
by	O
a	O
high	O
expression	B-Gene_expression
of	O
myf3	O
show	O
intensive	B-Positive_regulation
hybridization	B-Gene_expression
signals	I-Gene_expression
in	O
their	O
interphase	O
.	O

RNase	O
treatment	O
prior	O
to	O
hybridization	O
considerably	O
reduces	O
the	O
size	O
of	O
this	O
signals	O
.	O

In	O
comparison	O
,	O
isolated	O
nuclei	O
of	O
human	O
lymphocytes	O
in	O
which	O
no	O
need	O
for	O
the	O
expression	B-Gene_expression
of	O
this	O
gene	O
exists	O
,	O
show	O
barely	O
hybridization	O
signals	O
.	O

Correspondingly	O
,	O
RNase	O
treatment	O
had	O
no	O
effect	O
on	O
hybridization	O
pattern	O
at	O
all	O
.	O

In	O
conclusion	O
an	O
increased	O
transcription	O
efficiency	O
of	O
a	O
cell	O
type	O
specific	O
gene	O
is	O
accompanied	O
by	O
a	O
higher	O
hybridization	O
accessibility	O
in	O
the	O
corresponding	O
cell	O
nuclei	O
.	O

Precise	O
alignment	O
of	O
sites	O
required	O
for	O
mu	O
enhancer	O
activation	O
in	O
B	O
cells	O
.	O

The	O
lymphocyte	O
-	O
specific	O
immunoglobulin	O
mu	O
heavy	O
-	O
chain	O
gene	O
intronic	O
enhancer	O
is	O
regulated	O
by	O
multiple	O
nuclear	O
factors	O
.	O

The	O
previously	O
defined	O
minimal	O
enhancer	O
containing	O
the	O
muA	O
,	O
muE3	O
,	O
and	O
muB	O
sites	O
is	O
transactivated	O
by	O
a	O
combination	B-Binding
of	O
the	O
ETS	O
-	O
domain	O
proteins	O
PU.1	O
and	O
Ets	O
-	O
1	O
in	O
nonlymphoid	O
cells	O
.	O

The	O
core	O
GGAAs	O
of	O
the	O
muA	O
and	O
muB	O
sites	O
are	O
separated	O
by	O
30	O
nucleotides	O
,	O
suggesting	O
that	O
ETS	O
proteins	O
bind	O
to	O
these	O
sites	O
from	O
these	O
same	O
side	O
of	O
the	O
DNA	O
helix	O
.	O

We	O
tested	O
the	O
necessity	O
for	O
appropriate	O
spatial	O
alignment	O
of	O
these	O
elements	O
by	O
using	O
mutated	O
enhancers	O
with	O
altered	O
spacings	O
.	O

A	O
4	O
-	O
or	O
10	O
-	O
bp	O
insertion	O
between	O
muE3	O
and	O
muB	O
inactivated	O
the	O
mu	O
enhancer	O
in	O
S194	O
plasma	O
cells	O
but	O
did	O
not	O
affect	B-Regulation
in	O
vitro	O
binding	B-Binding
of	O
Ets	O
-	O
1	O
,	O
PU.1	O
,	O
or	O
the	O
muE3	O
-	O
binding	O
protein	O
TFE3	O
,	O
alone	O
or	O
in	O
pairwise	O
combinations	O
.	O

Circular	O
permutation	O
and	O
phasing	O
analyses	O
demonstrated	O
that	O
PU.1	O
binding	B-Binding
but	O
not	O
TFE3	O
or	O
Ets	O
-	O
1	O
bends	O
mu	O
enhancer	O
DNA	O
toward	O
the	O
major	O
groove	O
.	O

We	O
propose	O
that	O
the	O
requirement	O
for	O
precise	O
spacing	O
of	O
the	O
muA	O
and	O
muB	O
elements	O
is	O
due	O
in	O
part	O
to	O
a	O
directed	O
DNA	O
bend	O
induced	O
by	O
PU.1	O
.	O

Alpha	O
4	O
beta	O
1	O
(	O
CD49d/CD29	O
)	O
integrin	O
costimulation	O
of	O
human	O
T	O
cells	O
enhances	O
transcription	O
factor	O
and	O
cytokine	O
induction	O
in	O
the	O
absence	O
of	O
altered	O
sensitivity	O
to	O
anti	O
-	O
CD3	O
stimulation	O
.	O

The	O
integrin	O
alpha	O
4	O
beta	O
1	O
can	O
provide	O
a	O
costimulus	O
to	O
induce	B-Positive_regulation
IL	O
-	O
2	O
secretion	B-Localization
and	O
IL	O
-	O
2R	O
expression	B-Gene_expression
leading	O
to	O
enhanced	O
proliferation	O
of	O
purified	O
,	O
peripheral	O
blood	O
T	O
cells	O
.	O

Similar	O
to	O
expression	B-Gene_expression
of	O
IL	O
-	O
2	O
,	O
we	O
demonstrated	O
that	O
recombinant	O
vascular	O
-	O
cell	O
adhesion	O
molecule	O
-	O
1	O
,	O
when	O
co	O
-	O
immobilized	O
with	O
anti	O
-	O
CD3	O
mAb	O
,	O
significantly	O
enhanced	O
the	O
induction	O
of	O
transcription	O
factors	O
NF	O
-	O
AT	O
,	O
AP	O
-	O
1	O
,	O
and	O
NF	O
-	O
kappa	O
B	O
as	O
determined	O
by	O
electromobility	O
shift	O
assays	O
.	O

alpha	O
4	O
beta	O
1	O
ligation	B-Binding
alone	O
had	O
no	O
effect	O
on	O
transcription	O
factor	O
binding	O
.	O

The	O
requirements	O
for	O
induction	O
of	O
transcription	O
factors	O
reflected	O
the	O
requirements	O
for	O
the	O
secretion	B-Localization
of	O
multiple	O
cytokines	O
,	O
including	O
IL	O
-	O
2	O
,	O
TNF	O
-	O
alpha	O
,	O
IFN	O
-	O
gamma	O
,	O
and	O
granulocyte	O
macrophage	O
-	O
CSF	O
.	O

In	O
contrast	O
to	O
freshly	O
isolated	O
T	O
cells	O
,	O
in	O
vitro	O
-	O
cultured	O
T	O
cells	O
did	O
not	O
require	O
costimulation	O
for	O
cytokine	O
secretion	O
in	O
response	O
to	O
anti	O
-	O
CD3	O
alone	O
.	O

Comparison	O
of	O
the	O
dose	O
response	O
to	O
anti	O
-	O
CD3	O
stimulation	O
demonstrated	O
that	O
half	O
-	O
maximal	O
induction	B-Positive_regulation
of	O
IL	O
-	O
2	O
was	O
achieved	O
using	O
the	O
same	O
dose	O
of	O
anti	O
-	O
CD3	O
for	O
both	O
freshly	O
isolated	O
and	O
cultured	O
T	O
cells	O
.	O

Furthermore	O
,	O
the	O
dose	O
of	O
OKT3	O
required	O
to	O
achieve	O
half	O
-	O
maximal	O
activation	O
was	O
the	O
same	O
using	O
PMA	O
or	O
different	O
concentrations	O
of	O
alpha	O
4	O
beta	O
1	O
ligands	O
.	O

Therefore	O
,	O
costimulation	O
by	O
alpha	O
4	O
beta	O
1	O
ligands	O
was	O
not	O
due	O
to	O
stabilization	O
of	O
the	O
interaction	O
of	O
the	O
cells	O
with	O
its	O
substrate	O
.	O

We	O
conclude	O
,	O
rather	O
,	O
that	O
alpha	O
4	O
beta	O
1	O
in	O
freshly	O
isolated	O
T	O
cells	O
delivers	O
a	O
distinct	O
signal	O
that	O
synergizes	O
early	O
with	O
signals	O
initiated	O
by	O
TCR/CD3	O
ligation	O
to	O
induce	O
DNA	O
binding	O
of	O
multiple	O
transcription	O
factors	O
required	O
for	O
cytokine	O
gene	O
induction	O
.	O

Defective	B-Negative_regulation
transcription	B-Transcription
of	O
the	O
IL	O
-	O
2	O
gene	O
is	O
associated	O
with	O
impaired	B-Negative_regulation
expression	B-Gene_expression
of	O
c	O
-	O
Fos	O
,	O
FosB	O
,	O
and	O
JunB	O
in	O
anergic	O
T	O
helper	O
1	O
cells	O
.	O

Anergic	O
CD4+	O
Th	O
cells	O
do	O
not	O
produce	B-Gene_expression
IL	O
-	O
2	O
when	B-Positive_regulation
challenged	O
with	O
Ag	O
-	O
pulsed	O
accessory	O
cells	O
because	B-Positive_regulation
of	I-Positive_regulation
a	O
transcriptional	O
defect	O
.	O

In	O
this	O
work	O
,	O
we	O
report	O
that	O
these	O
anergic	O
T	O
cells	O
are	O
defective	O
in	O
their	O
ability	O
to	O
up	O
-	O
regulate	O
protein	O
binding	O
and	O
transactivation	O
at	O
two	O
critical	O
IL	O
-	O
2	O
DNA	O
enhancer	O
elements	O
:	O
NF	O
-	O
AT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
;	O
a	O
sequence	O
that	O
binds	B-Binding
a	O
heterotrimeric	O
NFATp	O
,	O
Fos	O
,	O
and	O
Jun	O
protein	O
complex	O
)	O
and	O
Activator	O
Protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
(	O
that	O
binds	B-Binding
Fos	O
and	O
Jun	O
heterodimers	O
)	O
.	O

Western	O
blot	O
analysis	O
of	O
nuclear	O
extracts	O
showed	O
that	O
the	O
impaired	O
DNA	O
-	O
protein	O
interactions	O
in	O
anergic	O
T	O
cells	O
were	O
associated	O
with	O
poor	B-Negative_regulation
expression	B-Gene_expression
of	O
the	O
inducible	O
AP	O
-	O
1	O
family	O
members	O
c	O
-	O
Fos	O
,	O
FosB	O
,	O
and	O
JunB	O
.	O

However	O
,	O
the	O
reduced	B-Negative_regulation
expression	B-Gene_expression
of	O
these	O
proteins	O
was	O
not	O
the	O
result	O
of	O
a	O
global	O
TCR/CD3	O
-	O
signaling	O
defect	O
because	O
CD3	O
cross	O
-	O
linking	O
induced	B-Positive_regulation
an	O
equivalent	O
increase	O
in	O
intracellular	O
-	O
free	O
calcium	O
ions	O
,	O
as	O
well	O
as	O
NFATp	O
dephosphorylation	O
,	O
translocation	B-Localization
to	O
the	O
nucleus	O
,	O
and	O
DNA	O
binding	B-Binding
in	O
both	O
normal	O
and	O
anergic	O
T	O
cells	O
.	O

Thus	O
,	O
defective	B-Negative_regulation
IL	O
-	O
2	O
gene	O
transcription	B-Transcription
appears	O
to	O
be	O
due	B-Positive_regulation
,	O
at	O
least	O
in	O
part	O
,	O
to	O
a	O
selective	O
block	B-Negative_regulation
in	O
the	O
expression	B-Gene_expression
of	O
the	O
AP	O
-	O
1	O
Fos	O
and	O
Jun	O
family	O
members	O
in	O
anergic	O
T	O
cells	O
.	O

C/EBP	O
activators	O
are	O
required	O
for	O
HIV	O
-	O
1	O
replication	O
and	O
proviral	O
induction	O
in	O
monocytic	O
cell	O
lines	O
.	O

Previous	O
work	O
has	O
shown	O
that	O
C/EBP	O
sites	O
and	O
C/EBP	O
transcriptional	O
activators	O
are	O
necessary	O
for	O
HIV	O
-	O
1	O
LTR	O
activity	O
in	O
monocytes/macrophages	O
.	O

We	O
have	O
investigated	O
the	O
role	O
that	O
C/EBP	O
proteins	O
play	O
in	O
induction	O
and	O
replication	O
of	O
HIV	O
-	O
1	O
.	O

Ectopic	O
expression	O
of	O
the	O
dominant	O
negative	O
C/EBP	O
protein	O
LIP	O
inhibited	O
HIV	O
-	O
1	O
mRNA	O
and	O
virus	O
production	O
in	O
activated	O
U1	O
cells	O
,	O
demonstrating	O
that	O
C/EBP	O
proteins	O
are	O
required	O
for	O
provirus	O
induction	O
.	O

U1	O
lines	O
overexpressing	B-Gene_expression
C/EBP	O
activator	O
NF-IL	O
-	O
6	O
produced	O
more	O
viral	O
mRNA	O
and	O
virus	O
particles	O
following	O
cellular	O
activation	O
than	O
control	O
lines	O
,	O
demonstrating	O
that	O
C/EBP	O
proteins	O
are	O
limiting	O
for	O
virus	O
transcription	O
.	O

HIV	O
-	O
1	O
harboring	O
mutations	O
within	O
two	O
C/EBP	O
sites	O
were	O
crippled	O
in	O
their	O
ability	O
to	O
replicate	O
in	O
U937	O
promonocytic	O
cells	O
,	O
indicating	O
that	O
these	O
sites	O
are	O
required	O
for	O
replication	O
.	O

These	O
data	O
identify	O
C/EBP	O
proteins	O
as	O
regulators	O
of	O
HIV	O
-	O
1	O
expression	O
in	O
monocytes/macrophages	O
.	O

Inhibition	B-Negative_regulation
of	O
transcription	O
factor	O
Stat1	O
activity	O
in	O
mononuclear	O
cell	O
cultures	O
and	O
T	O
cells	O
by	O
the	O
cyclic	O
AMP	O
signaling	O
pathway	O
.	O

Activation	O
of	O
T	O
cells	O
results	O
in	O
a	O
cascade	O
of	O
gene	O
activation	O
and	O
subsequent	O
proliferation	O
and	O
differentiation	O
into	O
effector	O
phenotypes	O
.	O

The	O
regulation	O
of	O
transcription	O
factors	O
belonging	O
to	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
family	O
was	O
analyzed	O
in	O
PHA	O
-	O
activated	O
mononuclear	O
cells	O
and	O
in	O
purified	O
T	O
cells	O
activated	O
by	O
cross	O
-	O
linking	O
cell	O
surface	O
CD3	O
.	O

Cell	O
activation	O
resulted	O
in	O
a	O
delayed	O
induction	O
of	O
STAT	O
DNA	O
-	O
binding	O
activity	O
,	O
which	O
was	O
sustained	O
for	O
several	O
days	O
,	O
was	O
composed	O
predominantly	O
of	O
Stat1	O
and	O
Stat3	O
,	O
and	O
was	O
blocked	O
by	O
cycloheximide	O
and	O
actinomycin	O
D	O
.	O

Increased	O
Stat1	O
and	O
Stat3	O
mRNA	O
and	O
protein	O
levels	O
were	O
detected	O
,	O
respectively	O
4	O
and	O
24	O
h	O
after	O
activation	O
.	O

Stimulation	O
of	O
the	O
cAMP	O
signal	O
transduction	O
pathway	O
,	O
which	O
skews	O
cytokine	O
production	O
toward	O
a	O
Th2	O
pattern	O
,	O
resulted	B-Regulation
in	O
the	O
preferential	O
suppression	B-Negative_regulation
of	O
Stat1	O
activity	O
.	O

cAMP	O
inhibited	O
the	O
induction	O
of	O
expression	O
of	O
IL	O
-	O
2	O
receptor	O
components	O
,	O
but	O
did	O
not	O
inhibit	B-Negative_regulation
IL	O
-	O
4	O
receptor	O
alpha	O
-	O
chain	O
and	O
CD69	O
expression	B-Gene_expression
or	O
the	O
induction	O
of	O
activator	O
protein	O
1	O
transcription	O
factors	O
.	O

cAMP	O
signaling	O
inhibited	B-Negative_regulation
Stat1	O
at	O
several	O
different	O
levels	O
,	O
including	O
suppression	B-Negative_regulation
of	O
DNA	O
binding	B-Binding
and	O
down	B-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
of	O
Stat1	O
protein	O
and	O
mRNA	O
levels	B-Transcription
.	O

Our	O
results	O
demonstrate	O
the	O
regulation	O
of	O
STAT	O
activity	O
by	O
a	O
signaling	O
pathway	O
that	O
regulates	O
the	O
T	O
cell	O
functional	O
phenotype	O
and	O
is	O
distinct	O
from	O
the	O
cytokine	O
-	O
activated	O
Janus	O
kinase	O
-	O
STAT	O
signaling	O
pathway	O
.	O

Transcriptional	O
analysis	O
of	O
Epstein	O
-	O
Barr	O
virus	O
gene	O
expression	O
in	O
EBV	O
-	O
positive	O
gastric	O
carcinoma	O
:	O
unique	O
viral	O
latency	O
in	O
the	O
tumour	O
cells	O
.	O

Although	O
case	O
-	O
oriented	O
evidence	O
for	O
an	O
association	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
with	O
gastric	O
carcinoma	O
has	O
been	O
accumulating	O
recently	O
,	O
the	O
interaction	O
(	O
s	O
)	O
between	O
EBV	O
and	O
gastric	O
epithelial	O
cells	O
is/are	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
seven	O
EBV	O
-	O
positive	O
gastric	O
carcinoma	O
tissues	O
for	O
viral	O
gene	O
expression	O
at	O
the	O
mRNA	O
level	O
,	O
from	O
which	O
studies	O
on	O
the	O
EBV	O
oncogenicity	O
in	O
human	O
epithelial	O
cells	O
will	O
benefit	O
.	O

Reverse	O
transcription	O
-	O
PCR	O
analysis	O
showed	O
that	O
all	O
seven	O
EBV	O
-	O
positive	O
tumour	O
tissues	O
constitutively	O
expressed	B-Transcription
EBV	O
nuclear	O
antigen	O
(	O
EBNA	O
)	O
1	O
mRNA	O
,	O
but	O
not	O
EBNA2	O
mRNA	O
.	O

The	O
EBNA	O
transcription	O
was	O
initiated	O
from	O
one	O
of	O
three	O
EBNA	O
promoters	O
,	O
Qp	O
:	O
by	O
contrast	O
,	O
both	O
Cp	O
and	O
Wp	O
were	O
silent	O
,	O
thus	O
resulting	B-Positive_regulation
in	O
the	O
lack	B-Transcription
of	O
EBNA2	O
mRNA	O
.	O

Latent	O
membrane	O
protein	O
(	O
LMP	O
)	O
2A	O
mRNA	O
was	O
detected	B-Transcription
in	O
three	O
of	O
seven	O
cases	O
;	O
however	O
,	O
neither	O
LMP1	O
nor	O
LMP2B	O
mRNA	O
was	O
detected	B-Transcription
in	O
any	O
of	O
the	O
tumours	O
tested	O
.	O

Transcripts	O
from	O
the	O
BamHI	O
-	O
A	O
region	O
of	O
the	O
viral	O
genome	O
were	O
detectable	O
in	O
all	O
cases	O
.	O

BZLF1	O
mRNA	O
and	O
the	O
product	O
,	O
an	O
immediate	O
-	O
early	O
gene	O
for	O
EBV	O
replication	O
,	O
was	O
not	O
expressed	B-Transcription
in	O
any	O
of	O
them	O
,	O
thereby	O
suggesting	O
that	O
the	O
tumour	O
cells	O
carried	O
EBV	O
genomes	O
in	O
a	O
tightly	O
latent	O
form	O
.	O

These	O
findings	O
further	O
extended	O
our	O
previous	O
data	O
regarding	O
EBV	O
latency	O
in	O
gastric	O
carcinoma	O
cells	O
at	O
the	O
protein	O
level	O
,	O
and	O
have	O
affirmed	O
that	O
the	O
programme	O
of	O
viral	O
gene	O
expression	O
in	O
the	O
tumour	O
more	O
closely	O
resembles	O
'latency	O
I	O
'	O
represented	O
by	O
Burkitt	O
's	O
lymphoma	O
than	O
'latency	O
II	O
'	O
represented	O
by	O
the	O
majority	O
of	O
nasopharyngeal	O
carcinomas	O
.	O

The	O
role	O
of	O
early	O
growth	O
response	O
gene	O
1	O
(	O
egr	O
-	O
1	O
)	O
in	O
regulation	O
of	O
the	O
immune	O
response	O
.	O

The	O
induction	O
of	O
immediate	O
early	O
genes	O
in	O
cells	O
of	O
the	O
immune	O
system	O
is	O
critical	O
to	O
determining	O
the	O
ultimate	O
outcome	O
of	O
exposure	O
to	O
antigen	O
.	O

The	O
importance	O
of	O
many	O
of	O
these	O
genes	O
relates	O
to	O
the	O
role	O
their	O
transcription	O
factor	O
products	O
play	O
in	O
dictating	O
patterns	O
of	O
expression	O
of	O
downstream	O
,	O
function	O
-	O
related	O
genes	O
.	O

Evidence	O
from	O
several	O
systems	O
indicates	O
that	O
the	O
immediate	O
early	O
gene	O
,	O
egr	O
-	O
1	O
may	O
be	O
of	O
particular	O
importance	O
in	O
the	O
immune	O
system	O
.	O

Recently	O
,	O
the	O
egr	O
-	O
1	O
promoter	O
has	O
been	O
shown	O
to	O
be	O
highly	O
responsive	O
to	O
the	O
diverse	O
biochemical	O
signals	O
generated	O
by	O
antigen	O
and	O
cytokines	O
in	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Furthermore	O
,	O
an	O
important	O
role	O
for	O
egr	O
-	O
1	O
in	O
determining	O
the	O
differentiation	O
pathway	O
of	O
myeloid	O
cell	O
precursors	O
has	O
been	O
recently	O
elaborated	O
.	O

Finally	O
,	O
potential	O
targets	O
of	O
regulation	B-Regulation
by	O
the	O
zinc	O
-	O
finger	O
transcription	O
factor	O
encoded	O
by	O
egr	O
-	O
1	O
include	O
the	O
interleukin	O
-	O
2	O
,	O
CD44	O
,	O
ICAM	O
-	O
1	O
,	O
and	O
tumor	O
necrosis	O
factor	O
genes	O
.	O

The	O
role	O
of	O
egr	O
-	O
1	O
in	O
regulation	O
of	O
the	O
immune	O
response	O
will	O
be	O
discussed	O
in	O
the	O
context	O
of	O
these	O
recent	O
studies	O
.	O

Apoptosis	O
mediated	O
by	O
HIV	O
protease	O
is	O
preceded	O
by	O
cleavage	B-Protein_catabolism
of	O
Bcl	O
-	O
2	O
.	O

Expression	B-Gene_expression
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
)	O
protease	O
in	O
cultured	O
cells	O
leads	O
to	O
apoptosis	O
,	O
preceded	O
by	O
cleavage	B-Protein_catabolism
of	O
bcl	O
-	O
2	O
,	O
a	O
key	O
negative	O
regulator	O
of	O
cell	O
death	O
.	O

In	O
contrast	O
,	O
a	O
high	O
level	O
of	O
bcl	O
-	O
2	O
protects	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
from	O
the	O
viral	O
protease	O
and	O
prevents	O
cell	O
death	O
following	O
HIV	O
infection	O
of	O
human	O
lymphocytes	O
,	O
while	O
reducing	B-Negative_regulation
the	O
yields	O
of	O
viral	O
structural	O
proteins	O
,	O
infectivity	O
,	O
and	O
tumor	O
necrosis	O
factor	O
alpha	O
.	O

We	O
present	O
a	O
model	O
for	O
HIV	O
replication	O
in	O
which	O
the	O
viral	O
protease	O
depletes	B-Negative_regulation
the	O
infected	O
cells	O
of	O
bcl	O
-	O
2	O
,	O
leading	O
to	O
oxidative	O
stress	O
-	O
dependent	O
activation	O
of	O
NF	O
kappa	O
B	O
,	O
a	O
cellular	O
factor	O
required	O
for	O
HIV	O
transcription	O
,	O
and	O
ultimately	O
to	O
cell	O
death	O
.	O

Purified	O
bcl	O
-	O
2	O
is	O
cleaved	B-Protein_catabolism
by	O
HIV	O
protease	O
between	O
phenylalanine	O
112	O
and	O
alanine	O
113	O
.	O

The	O
results	O
suggest	O
a	O
new	O
option	O
for	O
HIV	O
gene	O
therapy	O
;	O
bcl	O
-	O
2	O
muteins	O
that	O
have	O
noncleavable	O
alterations	O
surrounding	O
the	O
HIV	O
protease	O
cleavage	O
site	O
.	O

Activation	B-Positive_regulation
of	O
Stat	O
5b	O
in	O
erythroid	O
progenitors	O
correlates	O
with	O
the	O
ability	O
of	O
ErbB	O
to	O
induce	O
sustained	O
cell	O
proliferation	O
.	O

Self	O
renewal	O
of	O
normal	O
erythroid	O
progenitors	O
is	O
induced	O
by	O
the	O
receptor	O
tyrosine	O
kinase	O
c	O
-	O
ErbB	O
,	O
whereas	O
other	O
receptors	O
(	O
c-Kit/Epo	O
-	O
R	O
)	O
regulate	O
erythroid	O
differentiation	O
.	O

To	O
address	O
possible	O
mechanisms	O
that	O
could	O
explain	O
this	O
selective	O
activity	O
of	O
c	O
-	O
ErbB	O
,	O
we	O
analyzed	O
the	O
ability	O
of	O
these	O
receptors	O
to	O
activate	O
the	O
different	O
members	O
of	O
the	O
Stat	O
transcription	O
factor	O
family	O
.	O

Ligand	O
activation	O
of	O
c	O
-	O
ErbB	O
induced	B-Positive_regulation
the	O
tyrosine	O
phosphorylation	B-Phosphorylation
,	O
DNA	O
-	O
binding	B-Binding
,	O
and	O
reporter	O
gene	O
transcription	O
of	O
Stat	O
5b	O
in	O
erythroblasts	O
.	O

In	O
contrast	O
,	O
ligand	O
activation	B-Positive_regulation
of	O
c	O
-	O
Kit	O
was	O
unable	O
to	O
induce	B-Positive_regulation
any	O
of	O
these	O
effects	O
in	O
the	O
same	O
cells	O
.	O

Activation	B-Positive_regulation
of	O
the	O
erythropoietin	O
receptor	O
caused	B-Positive_regulation
specific	O
DNA	O
-	O
binding	B-Binding
of	O
Stat	O
5b	O
,	O
but	O
failed	O
to	O
induce	O
reporter	O
gene	O
transcription	O
.	O

These	O
biochemical	O
findings	O
correlate	O
perfectly	O
with	O
the	O
selective	O
ability	O
of	O
c	O
-	O
ErbB	O
to	O
cause	O
sustained	O
self	O
renewal	O
in	O
erythroid	O
progenitors	O
.	O

Evidence	O
for	O
lowered	O
induction	O
of	O
nuclear	O
factor	O
kappa	O
B	O
in	O
activated	O
human	O
T	O
lymphocytes	O
during	O
aging	O
.	O

Transcription	O
factor	O
NF	O
kappa	O
B	O
(	O
nuclear	O
factor	O
kappa	O
B	O
)	O
is	O
induced	O
in	O
T	O
lymphocytes	O
from	O
young	O
individuals	O
following	O
activation	O
with	O
a	O
variety	O
of	O
stimuli	O
including	O
anti	O
-	O
CD3	O
,	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
.	O

In	O
contrast	O
,	O
activated	O
T	O
lymphocytes	O
from	O
older	O
individuals	O
show	O
a	O
significant	O
reduction	O
in	O
the	O
induction	O
of	O
NF	O
kappa	O
B	O
in	O
response	O
to	O
the	O
same	O
stimuli	O
.	O

The	O
age	O
-	O
related	O
decline	O
in	O
induction	O
of	O
NF	O
kappa	O
B	O
could	O
not	O
be	O
attributed	O
to	O
alteration	O
in	O
the	O
composition	O
of	O
subunits	O
,	O
p50	O
and	O
p65	O
were	O
found	O
to	O
be	B-Positive_regulation
the	I-Positive_regulation
predominant	I-Positive_regulation
subunits	I-Positive_regulation
of	O
induced	B-Positive_regulation
NF	O
kappa	O
B	O
in	O
T	O
cells	O
from	O
young	O
as	O
well	O
as	O
elderly	O
donors	O
.	O

Furthermore	O
,	O
similar	O
levels	O
of	O
NF	O
kappa	O
B	O
were	O
found	O
in	O
the	O
cytosols	O
of	O
unactivated	O
T	O
cells	O
from	O
both	O
young	O
and	O
elderly	O
donors	O
suggesting	O
that	O
precursor	O
levels	O
of	O
NF	O
kappa	O
B	O
remain	O
unaltered	O
during	O
aging	O
.	O

These	O
results	O
suggest	O
that	O
an	O
age	O
-	O
associated	O
decline	O
in	O
the	O
induction	O
of	O
NF	O
kappa	O
B	O
in	O
activated	O
T	O
cells	O
from	O
elderly	O
individuals	O
may	O
be	O
attributable	O
to	O
altered	O
regulation	O
of	O
the	O
inhibitor	O
,	O
I	O
kappa	O
B	O
,	O
and	O
may	O
play	O
an	O
important	O
role	O
in	O
immune	O
dysregulation	O
accompanying	O
aging	O
.	O

Interaction	B-Binding
of	O
HTLV	O
-	O
I	O
Tax	O
with	O
the	O
human	O
proteasome	O
:	O
implications	O
for	O
NF	O
-	O
kappa	O
B	O
induction	O
.	O

The	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
has	O
been	O
etiologically	O
associated	O
with	O
the	O
development	O
of	O
the	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
as	O
well	O
as	O
degenerative	O
neurologic	O
syndrome	O
termed	O
tropical	O
spastic	O
paraparesis	O
(	O
TSP	O
)	O
.	O

HTLV	O
-	O
I	O
encodes	O
a	O
potent	O
transactivator	O
protein	O
termed	O
Tax	O
that	O
appears	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
process	O
of	O
T	O
-	O
cell	O
immortalization	O
.	O

Even	O
though	O
the	O
mechanisms	O
by	O
which	O
Tax	O
induces	O
transformation	O
are	O
still	O
unknown	O
,	O
it	O
seems	O
likely	O
that	O
the	O
ability	O
of	O
Tax	O
to	O
alter	O
the	O
expression	O
of	O
many	O
cellular	O
genes	O
plays	O
an	O
important	O
part	O
in	O
this	O
process	O
.	O

Tax	O
does	O
not	O
bind	B-Binding
directly	O
to	O
DNA	O
but	O
rather	O
deregulates	O
the	O
activity	O
of	O
cellular	O
transcription	O
factors	O
.	O

One	O
family	O
of	O
host	O
transcription	O
factors	O
whose	O
activity	O
is	O
altered	O
by	O
Tax	O
includes	O
NF	O
-	O
kappa	O
B/Rel	O
.	O

These	O
transcription	O
factors	O
are	O
post	O
-	O
transcriptionally	O
regulated	O
by	O
their	O
assembly	O
with	O
a	O
second	O
family	O
of	O
inhibitory	O
proteins	O
termed	O
I	O
kappa	O
B	O
that	O
serve	O
to	O
sequester	O
the	O
NF	O
-	O
kappa	O
B/Rel	O
complexes	O
in	O
the	O
cytoplasm	O
.	O

Upon	B-Positive_regulation
cellular	O
activation	O
,	O
I	O
kappa	O
B	O
alpha	O
is	O
phosphorylated	B-Phosphorylation
,	O
polyubiquitinated	O
,	O
and	O
degraded	B-Protein_catabolism
in	O
the	O
proteasome	O
.	O

This	O
proteolytic	O
event	O
liberates	O
NF	O
-	O
kappa	O
B	O
,	O
permitting	O
its	O
rapid	O
translocation	O
into	O
the	O
nucleus	O
where	O
it	O
binds	O
to	O
its	O
cognate	O
enhancer	O
elements	O
.	O

Similarly	O
,	O
the	O
p105	O
precursor	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
p50	O
subunit	O
is	O
also	O
post	O
-	O
translationally	O
processed	O
in	O
the	O
proteasome	O
.	O

The	O
mechanisms	O
by	O
which	O
Tax	O
activates	O
NF	O
-	O
kappa	O
B	O
remain	O
unclear	O
,	O
and	O
findings	O
presented	O
in	O
the	O
literature	O
are	O
often	O
controversial	O
.	O

We	O
identified	O
a	O
physical	B-Binding
interaction	I-Binding
between	O
Tax	O
and	O
the	O
HsN3	O
subunit	O
of	O
the	O
human	O
proteasome	O
.	O

This	O
raises	O
the	O
intriguing	O
possibility	O
that	O
physical	B-Binding
association	I-Binding
of	O
the	O
HsN3	O
proteasome	O
subunit	O
with	O
HTLV	O
-	O
I	O
Tax	O
coupled	O
with	O
the	O
independent	O
interaction	B-Binding
of	O
Tax	O
with	O
either	O
p100	O
or	O
p65	O
-	O
I	O
kappa	O
B	O
alpha	O
targets	O
these	O
cytoplasmic	O
NF	O
-	O
kappa	O
B/Rel	O
complexes	O
to	O
the	O
proteasome	O
for	O
processing	O
.	O

Epstein	O
-	O
Barr	O
viral	O
latency	O
is	O
disrupted	O
by	O
the	O
immediate	O
-	O
early	O
BRLF1	O
protein	O
through	O
a	O
cell	O
-	O
specific	O
mechanism	O
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
,	O
the	O
causative	O
agent	O
of	O
infectious	O
mononucleosis	O
,	O
is	O
a	O
human	O
herpesvirus	O
associated	O
with	O
epithelial	O
cell	O
malignancies	O
(	O
nasopharyngeal	O
carcinoma	O
)	O
as	O
well	O
as	O
B	O
-	O
cell	O
malignancies	O
.	O

Understanding	O
how	O
viral	O
latency	O
is	O
disrupted	O
is	O
a	O
central	O
issue	O
in	O
herpesvirus	O
biology	O
.	O

Epithelial	O
cells	O
are	O
the	O
major	O
site	O
of	O
lytic	O
EBV	O
replication	O
within	O
the	O
human	O
host	O
,	O
and	O
viral	O
reactivation	O
occurs	O
in	O
EBV	O
-	O
associated	O
nasopharyngeal	O
carcinomas	O
.	O

It	O
is	O
known	O
that	O
expression	B-Gene_expression
of	O
a	O
single	O
viral	O
immediate	O
-	O
early	O
protein	O
,	O
BZLF1	O
,	O
is	O
sufficient	O
to	O
initiate	O
the	O
switch	O
from	O
latent	O
to	O
lytic	O
infection	O
in	O
B	O
cells	O
.	O

Cellular	O
regulation	B-Regulation
of	O
BZLF1	O
transcription	B-Transcription
is	O
therefore	O
thought	O
to	O
play	O
a	O
key	O
role	O
in	O
regulating	O
the	O
stringency	O
of	O
viral	O
latency	O
.	O

Here	O
we	O
show	O
that	O
,	O
unexpectedly	O
,	O
expression	B-Gene_expression
of	O
another	O
viral	O
immediate	O
-	O
early	O
protein	O
,	O
BRLF1	O
,	O
can	O
disrupt	O
viral	O
latency	O
in	O
an	O
epithelial	O
cell	O
-	O
specific	O
fashion	O
.	O

Therefore	O
,	O
the	O
mechanisms	O
leading	O
to	O
disruption	O
of	O
EBV	O
latency	O
appear	O
to	O
be	O
cell	O
-	O
type	O
specific	O
.	O

Attenuated	B-Negative_regulation
function	I-Negative_regulation
of	O
a	O
variant	O
form	O
of	O
the	O
helix-loop	O
-	O
helix	O
protein	O
,	O
Id	O
-	O
3	O
,	O
generated	B-Positive_regulation
by	I-Positive_regulation
an	O
alternative	O
splicing	O
mechanism	O
.	O

The	O
Id	O
family	O
of	O
helix-loop	O
-	O
helix	O
proteins	O
function	O
as	O
negative	O
regulators	O
of	O
DNA	O
binding	O
,	O
basic	O
helix-loop	O
-	O
helix	O
proteins	O
in	O
the	O
regulation	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

We	O
report	O
here	O
on	O
the	O
identification	O
of	O
a	O
17	O
kDa	O
variant	O
of	O
the	O
14	O
kDa	O
Id	O
-	O
3	O
protein	O
termed	O
Id	O
-	O
3L	O
(	O
long	O
version	O
)	O
which	O
possesses	O
a	O
unique	O
60	O
amino	O
acid	O
carboxy	O
-	O
terminus	O
generated	O
by	O
read	B-Transcription
through	I-Transcription
of	O
a	O
'coding	O
intron	O
'	O
and	O
alternative	O
splicing	O
.	O

Northern	O
analysis	O
revealed	O
expression	B-Transcription
of	O
a	O
minor	O
1.1	O
kb	O
Id	O
-	O
3L	O
transcript	O
together	O
with	O
the	O
predominant	O
0.95	O
kb	O
Id	O
-	O
3	O
transcript	O
in	O
the	O
majority	O
of	O
adult	O
human	O
tissues	O
analysed	O
.	O

The	O
variant	O
Id	O
-	O
3L	O
protein	O
is	O
functionally	O
distinguishable	O
from	O
conventional	O
Id	O
-	O
3	O
since	O
in	O
in	O
vitro	O
DNA	O
mobility	O
shift	O
assays	O
,	O
it	O
was	O
greatly	O
impaired	O
in	O
its	O
ability	O
to	O
abrogate	B-Negative_regulation
binding	B-Binding
of	O
the	O
basic	O
helix-loop	O
-	O
helix	O
protein	O
,	O
E47	O
,	O
to	O
an	O
E	O
box	O
recognition	O
sequence	O
.	O

Multifactor	O
cis	O
-	O
dominant	B-Negative_regulation
negative	I-Negative_regulation
regulation	I-Negative_regulation
of	O
IL	O
-	O
2	O
gene	O
expression	B-Gene_expression
in	O
anergized	O
T	O
cells	O
.	O

The	O
molecular	O
mechanism	O
underlying	O
IL	O
-	O
2	O
transcriptional	B-Negative_regulation
blockade	I-Negative_regulation
in	O
anergic	O
T	O
cell	O
clones	O
is	O
not	O
fully	O
understood	O
.	O

To	O
examine	O
whether	O
an	O
active	O
negative	O
regulatory	O
process	O
occurs	O
,	O
we	O
created	O
a	O
reporter	O
construct	O
containing	O
as	O
an	O
enhancer	O
four	O
copies	O
of	O
the	O
NF	O
-	O
AT	O
site	O
and	O
one	O
copy	O
of	O
the	O
octamer	O
site	O
(	O
4X	O
NF-AT	O
-	O
Oct	O
)	O
.	O

This	O
construct	O
was	O
only	O
slightly	O
reduced	O
(	O
1.3	O
-	O
fold	O
)	O
in	O
its	O
expression	O
when	O
stimulated	O
under	O
anergic	O
conditions	O
,	O
while	O
a	O
whole	O
mouse	O
IL	O
-	O
2	O
enhancer	O
construct	O
showed	O
a	O
reduction	O
of	O
4.3	O
-	O
fold	O
.	O

Addition	O
of	O
the	O
-	O
176	O
to	O
-	O
96	O
sequence	O
to	O
the	O
4X	O
NF-AT	O
-	O
Oct	O
construct	O
did	O
not	O
impart	O
the	O
ability	O
to	O
be	O
affected	O
by	O
anergy	O
,	O
but	O
addition	O
of	O
the	O
-	O
236	O
to	O
-	O
96	O
sequence	O
did	O
,	O
demonstrating	O
that	O
anergy	O
is	O
an	O
active	O
inhibitory	O
process	O
and	O
that	O
more	O
than	O
the	O
presence	O
of	O
the	O
-	O
150	O
AP	O
-	O
1	O
binding	O
site	O
(	O
-	O
152	O
to	O
-	O
147	O
)	O
is	O
required	O
to	O
mediate	O
the	O
effect	O
.	O

Mutational	O
studies	O
of	O
the	O
-	O
236	O
to	O
-	O
96	O
sequence	O
indicated	O
that	O
the	O
presence	O
of	O
both	O
the	O
-	O
130	O
AP-1	O
-	O
like	O
site	O
(	O
-	O
187	O
to	O
-	O
181	O
)	O
and	O
the	O
-	O
150	O
proximal	O
AP	O
-	O
1	O
site	O
were	O
necessary	O
to	O
observe	O
anergy	O
.	O

Because	O
the	O
-	O
180	O
site	O
is	O
not	O
required	O
for	O
trans	O
-	O
activation	O
,	O
it	O
was	O
possible	O
to	O
confirm	O
by	O
mutation	O
in	O
the	O
normal	O
mouse	O
IL	O
-	O
2	O
enhancer	O
that	O
this	O
site	O
is	O
absolutely	O
essential	O
for	O
anergy	O
induction	O
.	O

The	O
simplest	O
model	O
to	O
explain	O
these	O
results	O
is	O
that	O
anergy	O
is	O
mediated	O
by	O
a	O
complex	O
of	O
multiple	O
transcription	O
factors	O
that	O
exert	B-Positive_regulation
a	O
cis	O
-	O
acting	O
dominant	B-Negative_regulation
negative	I-Negative_regulation
regulatory	I-Negative_regulation
effect	I-Negative_regulation
on	O
the	O
trans	B-Positive_regulation
-	I-Positive_regulation
activation	I-Positive_regulation
of	O
the	O
IL	O
-	O
2	O
gene	O
.	O

Characterization	O
of	O
the	O
human	O
myeloid	O
cell	O
nuclear	O
differentiation	O
antigen	O
gene	O
promoter	O
.	O

MNDA	O
(	O
myeloid	O
cell	O
nuclear	O
differentiation	O
antigen	O
)	O
is	O
an	O
interferon	O
alpha	O
regulated	B-Regulation
nuclear	O
protein	O
expressed	B-Gene_expression
only	O
in	O
cells	O
of	O
the	O
human	O
myelomonocytic	O
lineage	O
.	O

To	O
identify	O
mechanisms	O
responsible	B-Positive_regulation
for	O
this	O
lineage	O
-	O
specific	O
and	O
interferon	O
-	O
regulated	B-Regulation
expression	B-Gene_expression
,	O
the	O
5	O
'	O
flanking	O
sequence	O
of	O
the	O
gene	O
has	O
been	O
characterized	O
.	O

Two	O
interferon	O
-	O
stimulated	O
response	O
elements	O
(	O
ISRE	O
)	O
flank	O
a	O
multiple	O
transcription	O
start	O
site	O
region	O
identifying	O
MNDA	O
as	O
a	O
TATA	O
-	O
less	O
interferon	O
-	O
regulated	B-Regulation
gene	O
.	O

Other	O
DNA	O
elements	O
present	O
include	O
a	O
cluster	O
of	O
Myb	O
sites	O
,	O
several	O
Ets	O
,	O
an	O
Ets	O
related	O
PU.1	O
site	O
and	O
an	O
Sp1	O
site	O
located	O
within	O
600	O
bp	O
of	O
the	O
transcription	O
start	O
sites	O
.	O

In	O
addition	O
,	O
DNA	O
methylation	O
was	O
revealed	O
as	O
one	O
of	O
the	O
possible	O
factors	O
in	O
establishing	B-Positive_regulation
MNDA	O
expression	B-Gene_expression
.	O

The	O
5	O
'	O
flanking	O
sequence	O
has	O
promoter	O
activity	O
which	O
is	O
elevated	O
by	O
interferon	O
alpha	O
.	O

The	O
findings	O
indicate	O
that	O
MNDA	O
expression	B-Gene_expression
is	O
regulated	B-Regulation
by	O
mechanisms	O
similar	O
to	O
other	O
myelomonocytic	O
cell	O
specific	O
genes	O
and	O
genes	O
up	O
-	O
regulated	O
by	O
interferon	O
alpha	O
.	O

Regulation	B-Regulation
of	O
GM	O
-	O
CSF	O
gene	O
transcription	B-Transcription
by	O
core	O
-	O
binding	O
factor	O
.	O

GM	O
-	O
CSF	O
gene	O
activation	B-Positive_regulation
in	O
T	O
cells	O
is	O
known	O
to	O
involve	O
the	O
transcription	O
factors	O
nuclear	O
factor	O
-	O
kappa	O
B	O
,	O
AP	O
-	O
1	O
,	O
NFAT	O
,	O
and	O
Sp1	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
human	O
GM	O
-	O
CSF	O
promoter	O
and	O
enhancer	O
also	O
encompass	O
binding	B-Binding
sites	O
for	O
core	O
-	O
binding	O
factor	O
(	O
CBF	O
)	O
.	O

Significantly	O
,	O
the	O
CBF	O
sites	O
are	O
in	O
each	O
case	O
contained	O
within	O
the	O
minimum	O
essential	O
core	O
regions	O
required	O
for	O
inducible	O
activation	O
of	O
transcription	O
.	O

Furthermore	O
,	O
these	O
core	O
regions	O
of	O
the	O
enhancer	O
and	O
promoter	O
each	O
encompass	O
closely	O
linked	O
binding	B-Binding
sites	O
for	O
CBF	O
,	O
AP	O
-	O
1	O
,	O
and	O
NFATp	O
.	O

The	O
GM	O
-	O
CSF	O
promoter	O
CBF	O
site	O
TGTGGTCA	O
is	O
located	O
51	O
bp	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
and	O
also	O
overlaps	O
a	O
YY	O
-	O
1	O
binding	O
site	O
.	O

A	O
2	O
-	O
bp	O
mutation	O
within	O
the	O
CBF	O
site	O
resulted	O
in	O
a	O
2-3	O
-	O
fold	O
decrease	O
in	O
the	O
activities	O
of	O
both	O
a	O
69	O
-	O
bp	O
proximal	O
promoter	O
fragment	O
and	O
a	O
627	O
-	O
bp	O
full	O
-	O
length	O
promoter	O
fragment	O
.	O

Stepwise	O
deletions	O
into	O
the	O
proximal	O
promoter	O
also	O
revealed	O
that	O
the	O
CBF	O
site	O
,	O
but	O
not	O
the	O
YY	O
-	O
1	O
site	O
,	O
was	O
required	O
for	O
efficient	O
induction	O
of	O
transcriptional	O
activation	O
.	O

The	O
AML1	O
and	O
CBF	O
beta	O
genes	O
that	O
encode	O
CBF	O
each	O
have	O
the	O
ability	O
to	O
influence	O
cell	O
growth	O
and	O
differentiation	O
and	O
have	O
been	O
implicated	O
as	O
proto	O
-	O
oncogenes	O
in	O
acute	O
myeloid	O
leukemia	O
.	O

This	O
study	O
adds	O
GM	O
-	O
CSF	O
to	O
a	O
growing	O
list	O
of	O
cytokines	O
and	O
receptors	O
that	O
are	O
regulated	O
by	O
CBF	O
and	O
which	O
control	O
the	O
growth	O
,	O
differentiation	O
,	O
and	O
activation	O
of	O
hemopoietic	O
cells	O
.	O

The	O
GM	O
-	O
CSF	O
locus	O
may	O
represent	O
one	O
of	O
several	O
target	O
genes	O
that	O
are	O
dysregulated	B-Regulation
in	O
acute	O
myeloid	O
leukemia	O
.	O

Requirements	O
for	O
induction	O
of	O
vitamin	O
D	O
-	O
mediated	O
gene	O
regulation	O
in	O
normal	O
human	O
B	O
lymphocytes	O
.	O

Mature	O
human	O
lymphocytes	O
are	O
unique	O
targets	O
of	O
1	O
alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
(	O
1	O
alpha	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
in	O
that	O
vitamin	O
D	O
receptors	O
(	O
VDR	O
)	O
are	O
not	O
constitutively	O
expressed	B-Gene_expression
,	O
and	O
specific	O
cellular	O
activation	O
signals	O
are	O
required	B-Positive_regulation
for	O
both	O
the	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
VDR	O
and	O
establishment	O
of	O
reactivity	B-Binding
to	O
the	O
lipophilic	O
ligand	O
.	O

Treatment	O
of	O
B	O
lymphocytes	O
with	O
the	O
cytokine	O
IL	O
-	O
4	O
(	O
IL	O
-	O
4	O
)	O
,	O
in	O
the	O
absence	O
of	O
prior	O
activation	O
,	O
induces	B-Positive_regulation
a	O
weak	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
VDR	O
expression	B-Gene_expression
but	O
fails	O
to	O
generate	O
vitamin	O
D	O
-	O
responsive	O
element	O
(	O
VDRE	O
)	O
-	O
reactive	O
nuclear	O
protein	O
complexes	O
or	O
to	O
initiate	B-Positive_regulation
the	O
genomic	O
transcription	B-Transcription
of	O
25	O
-	O
hydroxyvitamin	O
D3	O
24	O
-	O
hydroxylase	O
.	O

Stimulation	O
of	O
B	O
lymphocytes	O
by	O
either	O
ligation	B-Binding
of	O
CD40	O
Ag	O
or	O
cross	O
-	O
linking	O
the	O
Ig	O
receptor	O
is	O
also	O
insufficient	O
to	O
render	O
B	O
lymphocytes	O
responsive	O
to	O
1	O
alpha	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

However	O
,	O
this	O
apparent	O
lack	O
of	O
response	O
to	O
the	O
secosterol	O
can	O
be	O
overcome	O
by	O
stimulation	O
of	O
B	O
lymphocytes	O
with	O
a	O
combination	O
of	O
these	O
cellular	O
activation	O
signals	O
,	O
which	O
are	O
sufficient	O
to	O
lead	O
to	O
G1	O
cell	O
cycle	O
progression	O
.	O

In	B-Positive_regulation
the	I-Positive_regulation
presence	I-Positive_regulation
of	I-Positive_regulation
1	O
alpha	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
cellular	O
activation	O
associated	O
with	O
stimulation	O
of	O
such	O
a	O
progression	O
appears	O
to	O
be	O
sufficient	B-Positive_regulation
for	I-Positive_regulation
the	I-Positive_regulation
up	I-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
VDR	O
message	O
and	O
protein	O
and	O
necessary	B-Positive_regulation
for	O
the	O
establishment	O
of	O
VDRE	O
binding	O
complexes	O
and	O
the	O
induction	B-Positive_regulation
of	O
24	O
-	O
hydroxylase	O
message	O
.	O

Furthermore	O
,	O
biologic	O
functions	O
are	O
modulated	O
,	O
in	O
that	O
the	O
hormone	O
inhibits	O
proliferation	O
in	O
a	O
subset	O
of	O
the	O
activated	O
B	O
cells	O
.	O

These	O
observations	O
suggest	O
that	O
reactivity	O
to	O
1	O
alpha	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
is	O
tightly	O
regulated	O
in	O
B	O
lymphocytes	O
,	O
requiring	O
specific	O
signals	O
for	O
its	O
initiation	O
.	O

Regulation	B-Regulation
of	O
sialoadhesin	O
expression	B-Gene_expression
on	O
rat	O
macrophages	O
.	O

Induction	B-Positive_regulation
by	O
glucocorticoids	O
and	O
enhancement	B-Positive_regulation
by	O
IFN	O
-	O
beta	O
,	O
IFN	O
-	O
gamma	O
,	O
IL	O
-	O
4	O
,	O
and	O
lipopolysaccharide	O
.	O

Sialoadhesin	O
is	O
a	O
macrophage	O
-	O
restricted	O
member	O
of	O
the	O
Ig	O
superfamily	O
that	O
mediates	O
adhesion	O
with	O
lymphoid	O
and	O
myeloid	O
cells	O
.	O

It	O
is	O
expressed	B-Gene_expression
on	O
a	O
subpopulation	O
of	O
macrophages	O
in	O
lymphoid	O
tissues	O
and	O
in	O
chronic	O
inflammation	O
(	O
e.g.	O
,	O
during	O
autoimmune	O
diseases	O
)	O
.	O

We	O
have	O
studied	O
the	O
regulation	B-Regulation
of	O
sialoadhesin	O
expression	B-Gene_expression
in	O
vitro	O
and	O
show	O
that	O
glucocorticoids	O
(	O
GC	O
)	O
induce	B-Positive_regulation
sialoadhesin	O
expression	B-Gene_expression
on	O
freshly	O
isolated	O
rat	O
macrophages	O
and	O
the	O
rat	O
macrophage	O
cell	O
line	O
R2	O
.	O

The	O
cytokines	O
IFN	O
-	O
beta	O
,	O
IFN	O
-	O
gamma	O
,	O
IL	O
-	O
4	O
,	O
and	O
LPS	O
,	O
although	O
unable	O
to	O
induce	B-Positive_regulation
sialoadhesin	O
expression	B-Gene_expression
by	O
themselves	O
,	O
were	O
able	O
to	O
enhance	B-Positive_regulation
GC	O
-	O
mediated	O
induction	B-Positive_regulation
of	O
sialoadhesin	O
.	O

Sialoadhesin	O
expression	B-Gene_expression
was	O
functional	B-Positive_regulation
as	O
shown	O
by	O
cell	O
adhesion	O
assays	O
with	O
human	O
RBCs	O
.	O

Northern	O
blotting	O
experiments	O
indicated	O
that	O
regulation	B-Positive_regulation
predominantly	O
occurred	O
at	O
the	O
mRNA	B-Transcription
level	I-Transcription
.	O

Comparison	O
of	O
the	O
different	O
combinations	O
of	O
GC	O
and	O
cytokines/LPS	O
revealed	O
differences	O
in	O
the	O
level	B-Positive_regulation
of	O
GC	O
-	O
dependent	O
enhancement	B-Positive_regulation
of	O
sialoadhesin	O
expression	B-Gene_expression
,	O
with	O
IFN	O
-	O
beta	O
and	O
IL	O
-	O
4	O
being	O
more	O
potent	B-Binding
than	O
IFN	O
-	O
gamma	O
and	O
LPS	O
.	O

Moreover	O
,	O
the	O
effects	O
of	O
IFN	O
-	O
gamma	O
and	O
LPS	O
could	O
be	O
reproduced	O
by	O
priming	O
,	O
whereas	O
IFN	O
-	O
beta	O
and	O
IL	O
-	O
4	O
were	O
required	O
simultaneously	O
with	O
GC	O
.	O

The	O
regulation	B-Regulation
of	O
sialoadhesin	O
expression	B-Gene_expression
was	O
mediated	B-Positive_regulation
by	O
the	O
GC	O
receptor	O
,	O
and	O
not	O
by	O
mineralocorticoid	O
receptor	O
,	O
as	O
shown	O
by	O
inhibition	O
experiments	O
with	O
specific	O
antagonists	O
.	O

Finally	O
,	O
it	O
is	O
demonstrated	O
that	O
macrophages	O
in	O
the	O
adrenal	O
gland	O
,	O
the	O
major	O
site	O
of	O
endogenous	O
GC	O
production	O
,	O
express	B-Gene_expression
sialoadhesin	O
.	O

This	O
study	O
demonstrates	O
that	O
GC	O
act	O
as	O
a	O
primary	O
inducer	B-Positive_regulation
of	O
sialoadhesin	O
expression	B-Gene_expression
on	O
rat	O
macrophages	O
,	O
and	O
that	O
the	O
response	O
can	O
be	O
enhanced	B-Positive_regulation
by	O
IFN	O
-	O
beta	O
,	O
T	O
cell	O
-	O
derived	O
cytokines	O
,	O
or	O
LPS	O
.	O

Cell-type	O
-	O
specific	O
regulation	B-Regulation
of	O
the	O
human	O
tumor	O
necrosis	O
factor	O
alpha	O
gene	O
in	O
B	O
cells	O
and	O
T	O
cells	O
by	O
NFATp	O
and	O
ATF	O
-	O
2/JUN	O
.	O

The	O
human	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
gene	O
is	O
one	O
of	O
the	O
earliest	O
genes	O
transcribed	B-Transcription
after	O
the	O
stimulation	O
of	O
a	O
B	O
cell	O
through	B-Regulation
its	O
antigen	O
receptor	O
or	O
via	B-Regulation
the	O
CD	O
-	O
40	O
pathway	O
.	O

In	O
both	O
cases	O
,	O
induction	B-Positive_regulation
of	O
TNF	O
-	O
alpha	O
gene	O
transcription	B-Transcription
can	O
be	O
blocked	B-Negative_regulation
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
and	O
FK506	O
,	O
which	O
suggested	O
a	O
role	B-Regulation
for	O
the	O
NFAT	O
family	O
of	O
proteins	O
in	O
the	O
regulation	B-Regulation
of	O
the	O
gene	O
in	O
B	O
cells	O
.	O

Furthermore	O
,	O
in	O
T	O
cells	O
,	O
two	O
molecules	O
of	O
NFATp	O
bind	B-Binding
to	O
the	O
TNF	O
-	O
alpha	O
promoter	O
element	O
kappa	O
3	O
in	O
association	O
with	O
ATF	O
-	O
2	O
and	O
Jun	O
proteins	O
bound	B-Binding
to	O
an	O
immediately	O
adjacent	O
cyclic	O
AMP	O
response	O
element	O
(	O
CRE	O
)	O
site	O
.	O

Here	O
,	O
using	O
the	O
murine	O
B	O
-	O
cell	O
lymphoma	O
cell	O
line	O
A20	O
,	O
we	O
show	O
that	O
the	O
TNF	O
-	O
alpha	O
gene	O
is	O
regulated	B-Regulation
in	O
a	O
cell-type	O
-	O
specific	O
manner	O
.	O

In	O
A20	O
B	O
cells	O
,	O
the	O
TNF	O
-	O
alpha	O
gene	O
is	O
not	O
regulated	B-Regulation
by	O
NFATp	O
bound	B-Binding
to	O
the	O
kappa	O
3	O
element	O
.	O

Instead	O
,	O
ATF	O
-	O
2	O
and	O
Jun	O
proteins	O
bind	B-Binding
to	O
the	O
composite	O
kappa	O
3/CRE	O
site	O
and	O
NFATp	O
binds	B-Binding
to	O
a	O
newly	O
identified	O
second	O
NFAT	O
site	O
centered	O
at	O
-	O
76	O
nucleotides	O
relative	O
to	O
the	O
TNF	O
-	O
alpha	O
transcription	O
start	O
site	O
.	O

This	O
new	O
site	O
plays	O
a	O
critical	O
role	B-Regulation
in	O
the	O
calcium	O
-	O
mediated	O
,	O
cyclosporin	O
A	O
-	O
sensitive	O
induction	B-Positive_regulation
of	O
TNF	O
-	O
alpha	O
in	O
both	O
A20	O
B	O
cells	O
and	O
Ar	O
-	O
5	O
cells	O
.	O

Consistent	O
with	O
these	O
results	O
,	O
quantitative	O
DNase	O
footprinting	O
of	O
the	O
TNF	O
-	O
alpha	O
promoter	O
using	O
increasing	O
amounts	O
of	O
recombinant	O
NFATp	O
demonstrated	O
that	O
the	O
-	O
76	O
site	O
binds	B-Binding
to	O
NFATp	O
with	O
a	O
higher	O
affinity	O
than	O
the	O
kappa	O
3	O
site	O
.	O

Two	O
other	O
previously	O
unrecognized	O
NFATp	O
-	O
binding	B-Binding
sites	O
in	O
the	O
proximal	O
TNF	O
-	O
alpha	O
promoter	O
were	O
also	O
identified	O
by	O
this	O
analysis	O
.	O

Thus	O
,	O
through	B-Regulation
the	O
differential	O
use	O
of	O
the	O
same	O
promoter	O
element	O
,	O
the	O
composite	O
kappa	O
3/CRE	O
site	O
,	O
the	O
TNF	O
-	O
alpha	O
gene	O
is	O
regulated	B-Regulation
in	O
a	O
cell-type	O
-	O
specific	O
manner	O
in	O
response	O
to	O
the	O
same	O
extracellular	O
signal	O
.	O

Analysis	O
of	O
the	O
ligand	O
-	O
binding	B-Binding
domain	O
of	O
human	O
retinoic	O
acid	O
receptor	O
alpha	O
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O

Three	O
subtypes	O
of	O
retinoic	O
acid	O
receptors	O
(	O
RAR	O
)	O
,	O
termed	O
RAR	O
alpha	O
,	O
RAR	O
beta	O
,	O
and	O
RAR	O
gamma	O
,	O
have	O
been	O
described	O
.	O

They	O
are	O
composed	O
of	O
different	O
structural	O
domains	O
,	O
including	O
distinct	O
domains	O
for	O
DNA	O
and	O
ligand	O
binding	O
.	O

RARs	O
specifically	O
bind	O
all-trans	O
-	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
9-cis	O
-	O
RA	O
,	O
and	O
retinoid	O
analogs	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
functional	O
role	O
of	O
cysteine	O
and	O
arginine	O
residues	O
in	O
the	O
ligand	O
-	O
binding	O
domain	O
of	O
hRAR	O
alpha	O
(	O
hRAR	O
alpha	O
-	O
LBD	O
,	O
amino	O
acids	O
154	O
to	O
462	O
)	O
.	O

All	O
conserved	O
cysteine	O
and	O
arginine	O
residues	O
in	O
this	O
domain	O
were	O
mutated	O
by	O
site	O
-	O
directed	O
mutagenesis	O
,	O
and	O
the	O
mutant	O
proteins	O
were	O
characterized	O
by	O
blocking	O
reactions	O
,	O
ligand	O
-	O
binding	O
experiments	O
,	O
transactivation	O
assays	O
,	O
and	O
protease	O
mapping	O
.	O

Changes	O
of	O
any	O
cysteine	O
residue	O
of	O
the	O
hRAR	O
alpha	O
-	O
LBD	O
had	O
no	O
significant	O
influence	O
on	O
the	O
binding	O
of	O
all	O
-	O
trans	O
RA	O
or	O
9	O
-	O
cis	O
RA	O
.	O

Interestingly	O
,	O
residue	O
C	O
-	O
235	O
is	O
specifically	O
important	O
in	O
antagonist	O
binding	O
.	O

With	O
respect	O
to	O
arginine	O
residues	O
,	O
only	O
the	O
two	O
single	O
mutations	O
of	O
R	O
-	O
276	O
and	O
R	O
-	O
394	O
to	O
alanine	O
showed	O
a	O
dramatic	O
decrease	O
of	O
agonist	O
and	O
antagonist	O
binding	O
whereas	O
the	O
R272A	O
mutation	O
showed	O
only	O
a	O
slight	O
effect	O
.	O

For	O
all	O
other	O
arginine	O
mutations	O
,	O
no	O
differences	O
in	O
affinity	O
were	O
detectable	O
.	O

The	O
two	O
mutations	O
R217A	O
and	O
R294A	O
caused	O
an	O
increased	O
binding	O
efficiency	O
for	O
antagonists	O
but	O
no	O
change	O
in	O
agonist	O
binding	O
.	O

From	O
these	O
results	O
,	O
we	O
can	O
conclude	O
that	O
electrostatic	O
interactions	O
of	O
retinoids	O
with	O
the	O
RAR	O
alpha	O
-	O
LBD	O
play	O
a	O
significant	B-Positive_regulation
role	I-Positive_regulation
in	O
ligand	O
binding	B-Binding
.	O

In	O
addition	O
,	O
antagonists	O
show	O
distinctly	O
different	O
requirements	O
for	O
efficient	O
binding	O
,	O
which	O
may	O
contribute	O
to	O
their	O
interference	B-Negative_regulation
in	O
the	O
ligand	O
-	O
inducible	O
transactivation	B-Positive_regulation
function	O
of	O
RAR	O
alpha	O
.	O

Cloning	O
and	O
characterization	O
of	O
the	O
beta	O
subunit	O
of	O
human	O
proximal	O
sequence	O
element	O
-	O
binding	O
transcription	O
factor	O
and	O
its	O
involvement	O
in	O
transcription	B-Transcription
of	O
small	O
nuclear	O
RNA	O
genes	O
by	B-Positive_regulation
RNA	O
polymerases	O
II	O
and	O
III	O
.	O

The	O
proximal	O
sequence	O
element	O
(	O
PSE	O
)	O
-	O
binding	O
transcription	O
factor	O
(	O
PTF	O
)	O
,	O
which	O
binds	B-Binding
the	O
PSE	O
of	O
both	O
RNA	O
polymerase	O
II	O
-	O
and	O
RNA	O
polymerase	O
III	O
-	O
transcribed	B-Transcription
mammalian	O
small	O
nuclear	O
RNA	O
(	O
snRNA	O
)	O
genes	O
,	O
is	O
essential	B-Positive_regulation
for	O
their	O
transcription	B-Transcription
.	O

We	O
previously	O
reported	O
the	O
purification	O
of	O
human	O
PTF	O
,	O
a	O
complex	O
of	O
four	O
subunits	O
,	O
and	O
the	O
molecular	O
cloning	O
and	O
characterization	O
of	O
PTF	O
gamma	O
and	O
delta	O
subunits	O
.	O

Here	O
we	O
describe	O
the	O
isolation	O
and	O
expression	B-Gene_expression
of	O
a	O
cDNA	O
encoding	O
PTF	O
beta	O
,	O
as	O
well	O
as	O
functional	O
studies	O
using	O
anti	O
-	O
PTF	O
beta	O
antibodies	O
.	O

Native	O
PTF	O
beta	O
,	O
in	O
either	O
protein	O
fractions	O
or	O
a	O
PTF-Oct-1	O
-	O
DNA	O
complex	O
,	O
can	O
be	O
recognized	B-Binding
by	O
polyclonal	O
antibodies	O
raised	O
against	O
recombinant	O
PTF	O
beta	O
.	O

Immunodepletion	O
studies	O
show	O
that	O
PTF	O
beta	O
is	O
required	B-Positive_regulation
for	O
transcription	B-Transcription
of	O
both	O
classes	O
of	O
snRNA	O
genes	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
immunoprecipitation	O
analyses	O
demonstrate	O
that	O
substantial	O
and	O
similar	O
molar	O
amounts	O
of	O
TATA	O
-	O
binding	O
protein	O
(	O
TBP	O
)	O
and	O
TFIIIB90	O
can	O
weakly	O
associate	B-Binding
with	O
PTF	O
at	O
low	O
salt	O
conditions	O
,	O
but	O
this	O
association	O
is	O
dramatically	O
reduced	O
at	O
high	O
salt	O
concentrations	O
.	O

Along	O
with	O
our	O
previous	O
demonstration	O
of	O
both	O
physical	B-Binding
interactions	I-Binding
between	O
PTF	O
gamma/PTF	O
delta	O
and	O
TBP	O
and	O
the	O
involvement	O
of	O
TFIIIB90	O
in	O
the	O
transcription	B-Transcription
of	O
class	O
III	O
snRNA	O
genes	O
,	O
these	O
results	O
are	O
consistent	O
with	O
the	O
notion	O
that	O
a	O
TBP	O
-	O
containing	O
complex	O
related	O
to	O
TFIIIB	O
is	O
required	B-Positive_regulation
for	O
the	O
transcription	B-Transcription
of	O
class	O
III	O
snRNA	O
genes	O
,	O
and	O
acts	B-Positive_regulation
through	O
weak	O
interaction	B-Binding
with	O
the	O
four	O
-	O
subunit	O
PTF	O
.	O

Induction	B-Positive_regulation
of	O
bcl	O
-	O
2	O
expression	B-Gene_expression
by	O
phosphorylated	O
CREB	O
proteins	O
during	O
B	O
-	O
cell	O
activation	O
and	O
rescue	O
from	O
apoptosis	O
.	O

Engagement	O
of	O
surface	O
immunoglobulin	O
on	O
mature	O
B	O
cells	O
leads	O
to	O
rescue	O
from	O
apoptosis	O
and	O
to	O
proliferation	O
.	O

Levels	B-Transcription
of	O
bcl	O
-	O
2	O
mRNA	O
and	O
protein	O
increase	B-Positive_regulation
with	O
cross	B-Binding
-	I-Binding
linking	I-Binding
of	O
surface	O
immunoglobulin	O
.	O

We	O
have	O
located	O
the	O
major	O
positive	B-Regulation
regulatory	I-Regulation
region	O
for	O
control	B-Regulation
of	O
bcl	O
-	O
2	O
expression	B-Gene_expression
in	O
B	O
cells	O
in	O
the	O
5'	O
-	O
flanking	O
region	O
.	O

The	O
positive	O
region	O
can	O
be	O
divided	O
into	O
an	O
upstream	O
and	O
a	O
downstream	O
regulatory	O
region	O
.	O

The	O
downstream	O
regulatory	O
region	O
contains	O
a	O
cyclic	O
AMP	O
-	O
responsive	O
element	O
(	O
CRE	O
)	O
.	O

We	O
show	O
by	O
antibody	O
supershift	O
experiments	O
and	O
UV	O
cross	O
-	O
linking	O
followed	O
by	O
denaturing	O
polyacrylamide	O
gel	O
electrophoresis	O
that	O
both	O
CREB	O
and	O
ATF	O
family	O
members	O
bind	O
to	O
this	O
region	O
in	O
vitro	O
.	O

Mutations	O
of	O
the	O
CRE	O
site	O
that	O
result	O
in	O
loss	O
of	O
CREB	O
binding	O
also	O
lead	O
to	O
loss	B-Negative_regulation
of	O
functional	B-Positive_regulation
activity	I-Positive_regulation
of	O
the	O
bcl	O
-	O
2	O
promoter	O
in	O
transient	O
-	O
transfection	O
assays	O
.	O

The	O
presence	O
of	O
an	O
active	O
CRE	O
site	O
in	O
the	O
bcl	O
-	O
2	O
promoter	O
implies	O
that	O
the	O
regulation	B-Regulation
of	O
bcl	O
-	O
2	O
expression	B-Gene_expression
is	O
linked	O
to	O
a	O
signal	O
transduction	O
pathway	O
in	O
B	O
cells	O
.	O

Treatment	O
of	O
the	O
mature	O
B	O
-	O
cell	O
line	O
BAL	O
-	O
17	O
with	O
either	O
anti	O
-	O
immunoglobulin	O
M	O
or	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
leads	O
to	O
an	O
increase	B-Positive_regulation
in	O
bcl	O
-	O
2	O
expression	B-Gene_expression
that	O
is	O
mediated	B-Positive_regulation
by	O
the	O
CRE	O
site	O
.	O

Treatment	O
of	O
the	O
more	O
immature	O
B	O
-	O
cell	O
line	O
,	O
Ramos	O
,	O
with	O
phorbol	O
esters	O
rescues	O
the	O
cells	O
from	O
calcium	O
-	O
dependent	O
apoptosis	O
.	O

bcl	O
-	O
2	O
expression	B-Gene_expression
is	O
increased	B-Positive_regulation
following	O
phorbol	O
ester	O
treatment	O
,	O
and	O
the	O
increased	O
expression	O
is	O
dependent	B-Positive_regulation
on	O
the	O
CRE	O
site	O
.	O

These	O
stimuli	O
result	O
in	O
phosphorylation	O
of	O
CREB	O
at	O
serine	O
133	O
.	O

The	O
phosphorylation	O
of	O
CREB	O
that	O
results	O
in	O
activation	O
is	O
mediated	O
by	O
protein	O
kinase	O
C	O
rather	O
than	O
by	O
protein	O
kinase	O
A	O
.	O

Although	O
the	O
CRE	O
site	O
is	O
necessary	B-Positive_regulation
,	O
optimal	B-Positive_regulation
induction	I-Positive_regulation
of	O
bcl	O
-	O
2	O
expression	B-Gene_expression
requires	B-Positive_regulation
participation	O
of	O
the	O
upstream	O
regulatory	O
element	O
,	O
suggesting	O
that	O
phosphorylation	O
of	O
CREB	O
alters	O
its	O
interaction	O
with	O
the	O
upstream	O
regulatory	O
element	O
.	O

The	O
CRE	O
site	O
in	O
the	O
bcl	O
-	O
2	O
promoter	O
appears	O
to	O
play	O
a	O
major	O
role	B-Positive_regulation
in	O
the	O
induction	B-Positive_regulation
of	O
bcl	O
-	O
2	O
expression	B-Gene_expression
during	O
the	O
activation	O
of	O
mature	O
B	O
cells	O
and	O
during	O
the	O
rescue	O
of	O
immature	O
B	O
cells	O
from	O
apoptosis	O
.	O

It	O
is	O
possible	O
that	O
the	O
CRE	O
site	O
is	O
responsible	B-Regulation
for	O
induction	B-Positive_regulation
of	O
bcl	O
-	O
2	O
expression	B-Gene_expression
in	O
other	O
cell	O
types	O
,	O
particularly	O
those	O
in	O
which	O
protein	O
kinase	O
C	O
is	O
involved	B-Regulation
.	O

E3	O
,	O
a	O
hematopoietic	O
-	O
specific	O
transcript	B-Transcription
directly	O
regulated	B-Regulation
by	O
the	O
retinoic	O
acid	O
receptor	O
alpha	O
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
-	O
induced	O
maturation	O
mediated	O
by	O
the	O
retinoic	O
acid	O
receptor	O
alpha	O
(	O
RAR	O
alpha	O
)	O
has	O
been	O
implicated	O
in	O
myeloid	O
development	O
.	O

We	O
have	O
used	O
differential	O
hybridization	O
analysis	O
of	O
a	O
cDNA	O
library	O
constructed	O
from	O
the	O
murine	O
RA	O
-	O
inducible	O
MPRO	O
promyelocyte	O
cell	O
line	O
to	O
identify	O
immediate	O
-	O
early	O
genes	O
induced	O
by	O
RA	O
during	O
granulocytic	O
differentiation	O
.	O

E3	O
,	O
one	O
of	O
nine	O
sequences	O
identified	O
,	O
was	O
upregulated	B-Positive_regulation
in	O
an	O
immediate	O
-	O
early	O
manner	O
,	O
with	O
transcript	B-Transcription
levels	B-Positive_regulation
peaking	I-Positive_regulation
after	O
60	O
minutes	O
exposure	O
to	O
RA	O
.	O

E3	O
transcripts	B-Transcription
were	O
RA	O
-	O
inducible	B-Positive_regulation
in	O
HL60	O
cells	O
,	O
but	O
not	O
in	O
an	O
RA	O
-	O
resistant	O
subclone	O
,	O
HL60R	O
,	O
that	O
harbors	O
a	O
mutated	O
RAR	O
alpha	O
gene	O
.	O

However	O
,	O
when	O
HL60R	O
cells	O
were	O
transduced	O
with	O
a	O
functional	O
copy	O
of	O
the	O
RAR	O
alpha	O
gene	O
,	O
RA	O
induced	B-Positive_regulation
a	O
10	O
-	O
fold	O
increase	B-Positive_regulation
in	O
E3	O
mRNA	O
levels	B-Transcription
.	O

E3	O
transcripts	B-Transcription
are	O
present	O
in	O
the	O
myeloid	O
,	O
B	O
-	O
lymphoid	O
,	O
and	O
erythroid	O
lineages	O
,	O
absent	O
in	O
nonhematopoietic	O
cells	O
,	O
and	O
encode	O
a	O
highly	O
hydrophobic	O
,	O
potentially	O
phosphorylated	O
polypeptide	O
of	O
unknown	O
function	O
with	O
significant	O
homology	O
to	O
a	O
putative	O
protein	O
expressed	O
in	O
myeloid	O
cells	O
.	O

The	O
murine	O
E3	O
promoter	O
harbors	O
a	O
single	O
bipartite	O
retinoic	O
acid	O
response	O
element	O
which	O
in	O
transient	O
transfection	O
assays	O
conferred	O
RA	O
sensitivity	B-Regulation
.	O

These	O
results	O
indicate	O
that	O
E3	O
is	O
a	O
hematopoietic	O
-	O
specific	O
gene	O
that	O
is	O
an	O
immediate	O
target	B-Regulation
for	O
the	O
activated	B-Positive_regulation
RAR	O
alpha	O
during	O
myelopoiesis	O
.	O

Transcriptional	O
control	O
of	O
steroid	O
-	O
regulated	O
apoptosis	O
in	O
murine	O
thymoma	O
cells	O
.	O

Early	O
studies	O
in	O
murine	O
T	O
cell	O
lines	O
indicated	O
that	O
transcriptional	O
transactivation	B-Positive_regulation
functions	O
encoded	O
in	O
the	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
N	O
-	O
terminal	O
domain	O
are	O
required	O
for	O
glucocorticoid	O
-	O
mediated	O
apoptosis	O
.	O

However	O
,	O
more	O
recent	O
studies	O
in	O
human	O
T	O
cell	O
lines	O
have	O
suggested	O
that	O
the	O
N	O
-	O
terminal	O
domain	O
is	O
not	O
necessary	O
for	O
steroid	O
-	O
regulated	O
apoptosis	O
and	O
that	O
GR	O
-	O
mediated	O
transrepression	O
may	O
be	O
the	O
more	O
critical	O
mechanism	O
.	O

To	O
better	O
understand	O
the	O
contribution	O
of	O
the	O
GR	O
N	O
-	O
terminal	O
transactivation	O
domain	O
in	O
mediating	O
murine	O
thymocyte	O
apoptosis	O
,	O
we	O
stably	O
transfected	B-Positive_regulation
GR	O
,	O
GR	O
variants	O
,	O
and	O
the	O
androgen	O
receptor	O
(	O
AR	O
)	O
into	O
receptor	O
-	O
negative	O
S49	O
murine	O
thymoma	O
cells	O
.	O

GR	O
expression	B-Gene_expression
levels	O
were	O
shown	O
to	O
be	O
rate	O
-	O
limiting	O
for	O
initiating	O
the	O
apoptotic	O
pathway	O
,	O
and	O
a	O
positive	O
correlation	O
between	O
steroid	O
sensitivity	O
and	O
GR	O
-	O
mediated	O
induction	O
of	O
an	O
integrated	O
mouse	O
mammary	O
tumor	O
virus	O
(	O
MMTV	O
)	O
LTR	O
reporter	O
gene	O
was	O
observed	O
.	O

Analysis	O
of	O
GR	O
chimeric	O
receptors	O
containing	O
the	O
potent	O
VP16	O
and	O
E1A	O
viral	O
transactivation	O
domains	O
in	O
place	O
of	O
the	O
GR	O
N	O
terminus	O
revealed	O
that	O
even	O
low	O
level	O
expression	O
of	O
these	O
receptors	O
resulted	O
in	O
both	O
enhanced	O
steroid	O
sensitivity	O
and	O
MMTV	O
induction	O
,	O
thus	O
supporting	O
a	O
role	O
for	O
transactivation	O
in	O
apoptosis	O
.	O

In	O
contrast	O
,	O
we	O
found	O
that	O
AR	O
can	O
initiate	O
apoptosis	O
in	O
S49	O
cells	O
after	O
treatment	O
with	O
5	O
alpha	O
-	O
dihydrotestosterone	O
,	O
despite	O
its	O
relative	O
inability	O
to	O
induce	O
high	O
level	O
expression	O
of	O
MMTV	O
.	O

To	O
investigate	O
this	O
further	O
,	O
we	O
examined	O
the	O
steroid	O
-	O
regulated	O
expression	B-Gene_expression
of	O
an	O
endogenous	O
thymocyte	O
-	O
specific	O
gene	O
called	O
GIG18	O
.	O

We	O
found	O
that	O
GIG18	O
was	O
rapidly	O
induced	B-Positive_regulation
to	O
comparable	O
levels	O
by	O
both	O
AR	O
and	O
GR	O
,	O
demonstrating	O
that	O
AR	O
can	O
indeed	O
function	O
as	O
a	O
transcriptional	O
activator	O
in	O
S49	O
cells	O
and	O
,	O
moreover	O
,	O
that	O
GIG18	O
induction	B-Positive_regulation
may	O
be	O
a	O
marker	O
of	O
early	O
apoptotic	O
events	O
in	O
steroid	O
-	O
treated	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
support	O
our	O
conclusion	O
that	O
transcriptional	O
transactivation	O
is	O
a	O
necessary	O
signaling	O
component	O
of	O
S49	O
cell	O
apoptosis	O
,	O
although	O
an	O
additional	O
role	O
for	O
GR	O
-	O
mediated	O
transrepression	O
can	O
not	O
be	O
excluded	O
.	O

Selenium	O
-	O
mediated	O
inhibition	O
of	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
and	O
HIV	O
-	O
1	O
LTR	O
promoter	O
activity	O
.	O

The	O
eukaryotic	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
is	O
involved	O
in	O
the	O
inducible	O
expression	O
of	O
various	O
inflammatory	O
genes	O
as	O
well	O
as	O
in	O
HIV	O
-	O
1	O
replication	O
.	O

Activation	O
of	O
NF	O
-	O
kappa	O
B	O
is	O
induced	O
by	O
prooxidants	O
and	O
several	O
stimuli	O
eliciting	O
oxidative	O
stress	O
,	O
such	O
as	O
cytokines	O
,	O
lipopolysaccharide	O
,	O
UV	O
irradiation	O
and	O
other	O
mediators	O
.	O

Various	O
antioxidants	O
inhibit	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
response	O
to	O
these	O
stimuli	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
effects	O
of	O
selenium	O
,	O
an	O
integral	O
component	O
of	O
glutathione	O
peroxidase	O
(	O
GPX	O
)	O
,	O
on	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

In	O
selenium	O
-	O
deprived	O
Jurkat	O
and	O
ESb	O
-	O
L	O
T	O
lymphocytes	O
,	O
supplementation	O
of	O
selenium	O
led	O
to	O
a	O
substantial	O
increase	B-Positive_regulation
of	O
GPX	O
activity	O
.	O

Analysis	O
of	O
DNA	O
binding	O
revealed	O
that	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
response	O
to	O
TNF	O
was	O
significantly	O
inhibited	O
under	O
these	O
conditions	O
.	O

Likewise	O
,	O
reporter	O
gene	O
assays	O
using	O
luciferase	O
constructs	O
driven	O
by	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
showed	O
a	O
dose	O
-	O
dependent	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
controlled	O
gene	O
expression	O
by	O
selenium	O
.	O

The	O
effects	O
of	O
selenium	O
were	O
specific	O
for	O
NF	O
-	O
kappa	O
B	O
,	O
since	O
the	O
activity	O
of	O
the	O
transcription	O
factor	O
AP	O
-	O
1	O
was	O
not	O
suppressed	O
.	O

These	O
data	O
suggest	O
that	O
selenium	O
supplementation	O
may	O
be	O
used	O
to	O
modulate	O
the	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
target	O
genes	O
and	O
HIV	O
-	O
1	O
.	O

Transcriptional	O
and	O
posttranscriptional	O
regulation	O
of	O
erythroid	O
gene	O
expression	O
in	O
anthracycline	O
-	O
induced	O
differentiation	O
of	O
human	O
erythroleukemic	O
cells	O
.	O

Aclacinomycin	O
(	O
ACLA	O
)	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
were	O
used	O
at	O
subtoxic	O
concentrations	O
to	O
induce	O
erythroid	O
differentiation	O
in	O
the	O
human	O
leukemic	O
cell	O
line	O
K562	O
.	O

Cell	O
hemoglobinization	O
was	O
accompanied	O
by	O
the	O
increased	B-Positive_regulation
expression	B-Gene_expression
of	O
genes	O
encoding	O
gamma	O
-	O
globin	O
and	O
porphobilinogen	O
deaminase	O
(	O
PBGD	O
)	O
,	O
an	O
enzyme	O
of	O
heme	O
synthesis	O
.	O

By	O
using	O
run	O
-	O
on	O
assays	O
,	O
ACLA	O
was	O
shown	O
to	O
induce	B-Positive_regulation
an	I-Positive_regulation
enhancement	I-Positive_regulation
of	O
the	O
transcription	B-Transcription
of	O
erythroid	O
genes	O
,	O
including	O
gamma	O
-	O
globin	O
,	O
PBGD	O
,	O
erythropoietin	O
receptor	O
,	O
and	O
GATA	O
-	O
1	O
transcription	O
factor	O
.	O

In	O
contrast	O
,	O
in	O
DOX	O
-	O
treated	O
cells	O
,	O
the	O
transcription	B-Transcription
rate	I-Transcription
of	O
these	O
genes	O
was	O
unchanged	B-Regulation
in	O
comparison	O
with	O
control	O
cells	O
.	O

In	O
addition	O
,	O
inhibition	O
of	O
mRNA	O
synthesis	O
with	O
actinomycin	O
D	O
indicated	O
that	O
DOX	O
induced	O
an	O
increased	B-Positive_regulation
stability	I-Positive_regulation
of	O
PBGD	O
and	O
GATA	O
-	O
1	O
mRNAs	O
,	O
whereas	O
ACLA	O
did	O
not	O
affect	B-Regulation
the	I-Regulation
half	I-Regulation
-	I-Regulation
lives	I-Regulation
of	O
these	O
mRNAs	O
.	O

Because	O
the	O
increase	O
in	O
erythroid	O
mRNA	O
steady	O
-	O
state	O
level	O
in	O
anthracycline	O
-	O
treated	O
cells	O
was	O
inhibited	O
by	O
cycloheximide	O
,	O
this	O
suggests	O
that	O
transcriptional	O
activation	O
in	O
ACLA	O
-	O
treated	O
cells	O
and	O
mRNA	O
stabilization	O
in	O
DOX	O
-	O
treated	O
cells	O
were	O
dependent	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O

Finally	O
,	O
GATA	O
-	O
1	O
protein	O
level	O
was	O
shown	O
to	O
be	O
increased	B-Positive_regulation
in	O
ACLA	O
-	O
treated	O
but	O
not	O
in	O
DOX	O
-	O
treated	O
cells	O
.	O

These	O
two	O
anthracyclines	O
,	O
although	O
closely	O
related	O
in	O
their	O
structures	O
,	O
appeared	O
to	O
act	O
as	O
differentiation	O
inducers	O
by	O
distinct	O
mechanisms	O
.	O

Indeed	O
,	O
erythroid	O
gene	O
expression	O
was	O
demonstrated	O
to	O
be	O
regulated	O
transcriptionally	O
by	O
ACLA	O
and	O
mainly	O
posttranscriptionally	O
by	O
DOX	O
.	O

Human	O
TAFII	O
105	O
is	O
a	O
cell	O
type	O
-	O
specific	O
TFIID	O
subunit	O
related	O
to	O
hTAFII130	O
.	O

We	O
previously	O
characterized	O
Drosophila	O
and	O
human	O
TAF	O
subunits	O
that	O
make	O
up	O
the	O
core	O
TFIID	O
complex	O
found	O
in	O
all	O
cells	O
.	O

Here	O
,	O
we	O
report	O
that	O
differentiated	O
B	O
cells	O
contain	O
a	O
novel	O
substoichiometric	O
TAF	O
of	O
105	O
kDa	O
not	O
found	O
associated	O
with	O
TFIID	O
isolated	O
from	O
other	O
cell	O
types	O
.	O

The	O
cDNA	O
encoding	O
hTAFII105	O
reveals	O
a	O
highly	O
conserved	O
C	O
-	O
terminal	O
domain	O
shared	O
by	O
hTAFII130	O
and	O
oTAFII110	O
,	O
while	O
the	O
N	O
-	O
terminal	O
coactivator	O
domain	O
has	O
diverged	O
significantly	O
.	O

All	O
cells	O
tested	O
express	B-Transcription
TAFII105	O
mRNA	O
,	O
but	O
only	O
B	O
cells	O
contain	O
significant	O
levels	O
of	O
protein	O
associated	B-Binding
with	O
TFIID	O
.	O

Transient	O
overexpression	B-Positive_regulation
of	O
hTAFII105	O
selectively	O
squelches	O
the	O
transcription	O
of	O
some	O
genes	O
in	O
B	O
cells	O
.	O

These	O
properties	O
suggest	O
that	O
TAFII105	O
is	O
a	O
cell	O
type	O
-	O
specific	O
subunit	O
of	O
TFIID	O
that	O
may	O
be	O
responsible	O
for	O
mediating	O
transcription	O
by	O
a	O
subset	O
of	O
activators	O
in	O
B	O
cells	O
.	O

IL-12	O
-	O
induced	O
activation	O
of	O
NK	O
and	O
T	O
cells	O
occurs	O
in	O
the	O
absence	O
of	O
immediate	O
-	O
early	O
activation	O
gene	O
expression	O
.	O

The	O
responses	O
of	O
lymphocytes	O
to	O
IL	O
-	O
2	O
and	O
IL	O
-	O
12	O
,	O
involving	O
proliferation	O
,	O
differentiation	O
,	O
and	O
cytokine	O
production	O
,	O
are	O
only	O
partially	O
overlapping	O
,	O
and	O
may	O
depend	O
on	O
induced	O
differential	O
expression	O
of	O
specific	O
sets	O
of	O
genes	O
.	O

Using	O
reverse	O
-	O
transcription	O
PCR	O
differential	O
display	O
,	O
we	O
isolated	O
an	O
mRNA	O
species	O
expressed	O
in	O
IL-2	O
-	O
but	O
not	O
IL-12	O
-	O
stimulated	O
NK	O
cells	O
.	O

This	O
was	O
identified	O
as	O
the	O
mRNA	O
encoding	O
the	O
transcription	O
factor	O
egr	O
-	O
1	O
,	O
which	O
is	O
expressed	B-Gene_expression
with	O
fast	O
kinetics	O
in	O
T	O
and	O
NK	O
cells	O
upon	O
IL	O
-	O
2	O
,	O
but	O
not	O
IL	O
-	O
12	O
,	O
stimulation	O
.	O

Analysis	O
of	O
the	O
accumulation	O
of	O
mRNA	O
-	O
encoding	O
members	O
of	O
the	O
AP	O
-	O
1	O
transcription	O
factor	O
family	O
demonstrated	O
that	O
c	O
-	O
fos	O
and	O
junB	O
are	O
also	O
expressed	B-Gene_expression
upon	B-Positive_regulation
stimulation	O
of	O
NK	O
and	O
T	O
cells	O
with	O
IL	O
-	O
2	O
,	O
but	O
not	O
IL	O
-	O
12	O
,	O
whereas	O
expression	B-Gene_expression
of	O
c	O
-	O
jun	O
and	O
junD	O
is	O
not	O
modified	B-Positive_regulation
by	O
either	O
cytokine	O
.	O

Accordingly	O
,	O
increased	O
AP	O
-	O
1	O
DNA	O
-	O
binding	O
activity	O
and	O
AP-1	O
-	O
dependent	O
transcriptional	O
activity	O
were	O
detected	O
exclusively	O
in	O
IL-2	O
-	O
stimulated	O
cells	O
.	O

Analysis	O
of	O
the	O
expression	O
of	O
genes	O
reported	O
to	O
regulate	O
cytokine	O
-	O
induced	O
proliferation	O
demonstrated	O
that	O
both	O
IL	O
-	O
2	O
and	O
IL	O
-	O
12	O
induce	B-Positive_regulation
c	O
-	O
myc	O
mRNA	O
accumulation	B-Positive_regulation
in	O
NK	O
and	O
T	O
cells	O
,	O
whereas	O
only	O
IL	O
-	O
2	O
induces	B-Positive_regulation
bcl	O
-	O
2	O
expression	B-Gene_expression
.	O

Our	O
data	O
provide	O
the	O
first	O
demonstration	O
that	O
IL-12	O
-	O
mediated	O
activation	O
of	O
T	O
and	O
NK	O
cells	O
does	O
not	O
involve	O
expression	B-Gene_expression
of	O
members	O
of	O
the	O
immediate	O
-	O
early	O
activation	O
genes	O
family	O
(	O
egr	O
-	O
1	O
,	O
c	O
-	O
fos	O
,	O
and	O
junB	O
)	O
,	O
AP	O
-	O
1	O
transcriptional	O
activity	O
,	O
or	O
bcl	O
-	O
2	O
expression	B-Gene_expression
.	O

This	O
indicates	O
that	O
functional	O
differences	O
observed	O
in	O
IL-2	O
-	O
and	O
IL-12	O
-	O
stimulated	O
cells	O
may	O
depend	O
,	O
at	O
least	O
in	O
part	O
,	O
on	O
differential	O
gene	O
regulation	O
.	O

Induction	O
of	O
activator	O
protein	O
(	O
AP	O
)	O
-	O
1	O
and	O
nuclear	O
factor	O
-	O
kappaB	O
by	O
CD28	O
stimulation	B-Positive_regulation
involves	O
both	O
phosphatidylinositol	O
3	O
-	O
kinase	O
and	O
acidic	O
sphingomyelinase	O
signals	O
.	O

A	O
major	O
obstacle	O
in	O
understanding	O
the	O
signaling	O
events	O
that	O
follow	O
CD28	O
receptor	O
ligation	B-Binding
arises	O
from	O
the	O
fact	O
that	O
CD28	O
acts	O
as	O
a	O
costimulus	O
to	O
TCR	O
engagement	O
,	O
making	O
it	O
difficult	O
to	O
assess	O
the	O
relative	O
contribution	O
of	O
CD28	O
signals	O
as	O
distinct	O
from	O
those	O
of	O
the	O
TCR	O
.	O

To	O
overcome	O
this	O
problem	O
,	O
we	O
have	O
exploited	O
the	O
observation	O
that	O
activated	O
human	O
T	O
cell	O
blasts	O
can	O
be	O
stimulated	O
via	O
the	O
CD28	O
surface	O
molecule	O
in	O
the	O
absence	O
of	O
antigenic	O
challenge	O
;	O
thus	O
,	O
we	O
have	O
been	O
able	O
to	O
observe	O
the	O
response	O
of	O
normal	O
T	O
cells	O
to	O
CD28	O
activation	B-Positive_regulation
in	O
isolation	O
.	O

Using	O
this	O
system	O
,	O
we	O
observed	O
that	O
CD28	O
stimulation	B-Positive_regulation
by	O
B7	O
-	O
transfected	B-Gene_expression
CHO	O
cells	O
induced	O
a	O
proliferative	O
response	O
in	O
T	O
cells	O
that	O
was	O
not	O
accompanied	B-Positive_regulation
by	O
measurable	O
IL	O
-	O
2	O
production	B-Gene_expression
.	O

However	O
,	O
subsequent	O
analysis	O
of	O
transcription	O
factor	O
generation	O
revealed	O
that	O
B7	O
stimulation	O
induced	O
both	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
and	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
complexes	O
,	O
but	O
not	O
NF	O
-	O
AT	O
.	O

In	O
contrast	O
,	O
engagement	O
of	O
the	O
TCR	O
by	O
class	O
II	O
MHC/superantigen	O
,	O
either	O
with	O
or	O
without	O
CD28	O
ligation	B-Binding
,	O
resulted	O
in	O
the	O
induction	B-Positive_regulation
of	O
NF	O
-	O
AT	O
,	O
AP	O
-	O
1	O
,	O
and	O
NF	O
-	O
kappaB	O
as	O
well	O
as	O
IL	O
-	O
2	O
production	B-Gene_expression
.	O

Using	O
selective	O
inhibitors	O
,	O
we	O
investigated	O
the	O
signaling	O
pathways	O
involved	O
in	O
the	O
CD28	O
-	O
mediated	O
induction	O
of	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
.	O

This	O
revealed	O
that	O
NF	O
-	O
kappaB	O
generation	O
was	O
sensitive	O
to	O
chloroquine	O
,	O
an	O
inhibitor	B-Negative_regulation
of	O
acidic	O
sphingomyelinase	O
,	O
but	O
not	O
to	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
inhibitor	O
,	O
wortmannin	O
.	O

In	O
contrast	O
,	O
AP	O
-	O
1	O
generation	O
was	O
inhibited	O
by	O
wortmannin	O
and	O
was	O
also	O
variably	O
sensitive	O
to	O
chloroquine	O
.	O

These	O
data	O
suggest	O
that	O
in	O
activated	O
normal	O
T	O
cells	O
,	O
CD28	O
-	O
derived	O
signals	O
can	O
stimulate	O
proliferation	O
at	O
least	O
in	O
part	O
via	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
generation	O
,	O
and	O
that	O
this	O
response	O
uses	O
both	O
acidic	O
sphingomyelinase	O
and	O
phosphatidylinositol	O
3-kinase	O
-	O
linked	O
pathways	O
.	O

A	O
critical	O
role	B-Regulation
of	O
Sp1	O
-	O
and	O
Ets	O
-	O
related	O
transcription	O
factors	O
in	O
maintaining	O
CTL	O
-	O
specific	O
expression	B-Gene_expression
of	O
the	O
mouse	O
perforin	O
gene	O
.	O

This	O
study	O
was	O
designed	O
to	O
determine	O
the	O
potential	O
cis	O
-	O
elements	O
involved	B-Regulation
in	O
transcriptional	B-Regulation
regulation	I-Regulation
of	O
the	O
mouse	O
perforin	O
gene	O
.	O

DNase	O
I	O
hypersensitive	O
site	O
(	O
DHS	O
)	O
mapping	O
revealed	O
that	O
the	O
perforin	O
locus	O
contained	O
six	O
DHS	O
within	O
7.0	O
kb	O
of	O
the	O
5	O
'	O
upstream	O
sequence	O
(	O
-	O
7.0	O
kb	O
)	O
and	O
two	O
DHS	O
in	O
intron	O
2	O
.	O

The	O
six	O
5	O
'	O
upstream	O
and	O
one	O
intronic	O
DHS	O
were	O
detected	O
in	O
only	O
perforin	O
-	O
expressing	B-Gene_expression
lymphocytes	O
.	O

Chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
activities	O
directed	B-Regulation
by	O
5	O
'	O
upstream	O
promoter	O
were	O
detected	O
preferentially	O
in	O
perforin	O
-	O
expressing	O
cell	O
lines	O
.	O

A	O
construct	O
termed	O
PFP5a	O
containing	O
-	O
795	O
bp	O
exhibited	B-Positive_regulation
the	O
highest	O
CAT	O
activity	O
,	O
and	O
PFP9a20	O
containing	O
only	O
-	O
73	O
bp	O
also	O
produced	B-Positive_regulation
significantly	O
high	O
CAT	O
activity	O
in	O
CTLL	O
-	O
R8	O
cells	O
.	O

The	O
proximal	O
region	O
in	O
PFP9a20	O
contained	O
two	O
potential	O
Sp1	O
binding	O
sites	O
(	O
GC	O
box	O
and	O
GT	O
box	O
)	O
and	O
one	O
Ets	O
binding	O
site	O
(	O
EBS	O
)	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
showed	O
that	O
each	O
of	O
the	O
cis	O
-	O
elements	O
bound	B-Binding
specific	O
protein	O
factors	O
.	O

When	O
single	O
-	O
point	O
mutation	O
was	O
introduced	O
to	O
each	O
GC	O
box	O
,	O
EBS	O
,	O
and	O
GT	O
box	O
in	O
PFP9a20	O
,	O
at	O
least	O
3	O
-	O
fold	O
less	B-Negative_regulation
CAT	O
activity	O
was	O
observed	O
in	O
CTLL	O
-	O
R8	O
cells	O
.	O

To	O
confirm	O
the	O
importance	B-Regulation
of	O
the	O
three	O
cis	O
-	O
acting	O
elements	O
in	O
the	O
perforin	O
gene	O
expression	B-Gene_expression
,	O
point	O
mutation	O
was	O
introduced	O
again	O
to	O
each	O
proximal	O
GC	O
box	O
,	O
EBS	O
,	O
and	O
GT	O
box	O
of	O
PFP5a	O
.	O

The	O
point	O
mutations	O
resulted	B-Regulation
in	O
a	O
2.5	O
-	O
to	O
3	O
-	O
fold	O
reduction	B-Negative_regulation
of	O
CAT	O
activity	O
.	O

The	O
results	O
suggest	O
that	O
a	O
combination	O
of	O
the	O
three	O
proximal	O
cis	O
-	O
acting	O
elements	O
may	O
constitute	O
a	O
minimal	O
region	O
responsible	B-Regulation
for	O
CTL	O
-	O
specific	O
expression	B-Gene_expression
of	O
perforin	O
.	O

Soluble	O
factors	O
secreted	O
by	O
activated	O
T	O
-	O
lymphocytes	O
modulate	B-Regulation
the	O
transcription	B-Transcription
of	O
the	O
immunosuppressive	O
cytokine	O
TGF	O
-	O
beta	O
2	O
in	O
glial	O
cells	O
.	O

Coordination	O
of	O
the	O
immune	O
response	O
to	O
injury	O
or	O
disease	O
in	O
the	O
brain	O
is	O
postulated	O
to	O
involve	O
bi	O
-	O
directional	O
discourse	O
between	O
the	O
immune	O
system	O
and	O
the	O
central	O
nervous	O
system	O
.	O

This	O
cross	O
communication	O
involves	O
soluble	O
mediators	O
,	O
including	O
various	O
growth	O
factors	O
,	O
cytokines	O
,	O
and	O
neuropeptides	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
supernatant	O
from	O
activated	O
T	O
-	O
lymphocytes	O
is	O
able	O
to	O
induce	B-Positive_regulation
the	O
transcription	B-Transcription
of	O
a	O
potent	O
cytokine	O
,	O
TGF	O
-	O
beta	O
2	O
in	O
glial	O
cells	O
.	O

The	O
activating	O
stimulus	O
invokes	O
signaling	O
mechanisms	O
distinct	O
from	O
known	O
kinase	O
or	O
protease	O
pathways	O
.	O

Activation	B-Positive_regulation
of	O
TGF	O
-	O
beta	O
2	O
transcription	B-Transcription
correlates	O
with	O
the	O
loss	B-Negative_regulation
of	O
binding	B-Binding
activity	I-Binding
for	O
an	O
80	O
kDA	O
glial	O
labile	O
repressor	O
protein	O
,	O
GLRP	O
,	O
to	O
a	O
responsive	O
region	O
within	O
the	O
TFG	O
-	O
beta	O
2	O
promoter	O
.	O

Although	O
GLRP	O
shares	O
some	O
characteristics	O
with	O
the	O
inducible	O
transcription	O
factor	O
AP	O
-	O
1	O
,	O
it	O
appears	O
to	O
be	O
distinct	O
from	O
known	O
AP	O
-	O
1	O
family	O
members	O
.	O

These	O
data	O
along	O
with	O
previous	O
observations	O
demonstrating	O
the	O
potent	O
immunosuppressive	O
activity	O
of	O
TGF	O
-	O
beta	O
2	O
,	O
support	O
a	O
model	O
for	O
a	O
feedback	O
mechanism	O
between	O
the	O
activated	O
T	O
-	O
lymphocytes	O
and	O
astrocytes	O
via	O
TGF	O
-	O
beta	O
2	O
to	O
regulate	O
the	O
immune	O
response	O
.	O

Regulation	O
of	O
cytokine	O
and	O
cytokine	O
receptor	O
expression	O
by	O
glucocorticoids	O
.	O

Glucocorticoids	O
(	O
GCS	O
)	O
profoundly	O
inhibit	O
several	O
aspects	O
of	O
T	O
cell	O
immunity	O
largely	O
through	O
inhibition	O
of	O
cytokine	O
expression	O
at	O
the	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

GCS	O
were	O
also	O
reported	O
to	O
act	O
indirectly	O
by	O
inducing	B-Positive_regulation
transforming	O
growth	O
factor	O
-	O
beta	O
expression	B-Gene_expression
,	O
which	O
in	O
turn	O
blocks	O
T	O
cell	O
immunity	O
.	O

In	O
exerting	O
their	O
antiproliferative	O
effects	O
,	O
GCS	O
diffuse	O
into	O
target	O
cells	O
where	O
they	O
bind	O
their	O
cytoplasmic	O
receptor	O
,	O
which	O
in	O
turn	O
translocates	O
to	O
the	O
nucleus	O
where	O
it	O
inhibits	O
transcription	O
of	O
cytokine	O
genes	O
through	O
direct	O
binding	O
to	O
the	O
glucocorticoid	O
response	O
elements	O
(	O
GRE	O
)	O
,	O
which	O
are	O
located	O
in	O
the	O
promoter	O
region	O
of	O
cytokine	O
genes	O
or	O
,	O
alternatively	O
,	O
through	O
antagonism	O
of	O
the	O
action	O
of	O
transcription	O
factors	O
required	O
for	O
optimal	O
transcriptional	O
activation	O
.	O

In	O
contrast	O
to	O
their	O
inhibitory	O
effects	O
on	O
cytokine	O
expression	O
,	O
GCS	O
up	O
-	O
regulate	O
cytokine	O
receptor	O
expression	O
that	O
correlates	O
with	O
enhanced	O
cytokine	O
effects	O
on	O
target	O
cells	O
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
the	O
current	O
state	O
of	O
knowledge	O
of	O
the	O
mechanism	O
of	O
action	O
of	O
GCS	O
,	O
including	O
the	O
phenomenon	O
of	O
steroid	O
-	O
induced	O
rebound	O
,	O
which	O
ensues	O
upon	O
GCS	O
withdrawal	O
.	O

The	O
Oct	O
-	O
2	O
transcription	O
factor	O
.	O

The	O
Oct	O
-	O
2	O
transcription	O
factor	O
is	O
a	O
member	O
of	O
the	O
POU	O
(	O
Pit-Oct	O
-	O
Unc	O
)	O
family	O
of	O
transcription	O
factors	O
and	O
is	O
expressed	B-Gene_expression
only	O
in	O
B	O
lymphocytes	O
and	O
in	O
neuronal	O
cells	O
but	O
not	O
in	O
other	O
cell	O
types	O
.	O

The	O
primary	O
RNA	B-Transcription
transcript	I-Transcription
of	O
the	O
gene	O
is	O
subject	B-Regulation
to	O
alternative	O
splicing	O
to	O
yield	O
different	O
variants	O
which	O
can	O
either	O
activate	O
or	O
repress	O
gene	O
expression	O
.	O

The	O
forms	O
produced	O
in	O
B	O
lymphocytes	O
have	O
a	O
predominantly	O
activating	O
effect	O
on	O
gene	O
expression	O
whereas	O
those	O
produced	O
in	O
neuronal	O
cells	O
have	O
a	O
predominantly	O
inhibitory	B-Negative_regulation
effect	I-Negative_regulation
and	O
can	O
repress	B-Negative_regulation
the	O
expression	B-Gene_expression
of	O
both	O
the	O
herpes	O
simplex	O
virus	O
immediate	O
-	O
early	O
genes	O
and	O
the	O
cellular	O
tyrosine	O
hydroxylase	O
gene	O
.	O

Thus	O
Oct	O
-	O
2	O
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cellular	O
gene	O
expression	O
in	O
both	O
B	O
cells	O
and	O
neuronal	O
cells	O
as	O
well	O
as	O
in	O
the	O
control	O
of	O
viral	O
latency	O
.	O

Tissue	O
and	O
cell	O
-	O
type	O
specific	O
expression	B-Gene_expression
of	O
the	O
tuberous	O
sclerosis	O
gene	O
,	O
TSC2	O
,	O
in	O
human	O
tissues	O
.	O

TSC2	O
is	O
a	O
gene	O
on	O
chromosome	O
16p13.3	O
associated	O
with	O
the	O
autosomal	O
dominant	O
neurocutaneous	O
disorder	O
,	O
tuberous	O
sclerosis	O
complex	O
(	O
TSC	O
)	O
.	O

By	O
using	O
a	O
partial	O
nucleotide	O
sequence	O
from	O
the	O
cloned	O
TSC2	O
and	O
polymerase	O
chain	O
reaction	O
methodology	O
,	O
we	O
constructed	O
a	O
digoxigenin	O
-	O
labeled	O
complementary	O
DNA	O
probe	O
to	O
examine	O
TSC2	O
gene	O
expression	B-Gene_expression
in	O
autopsy	O
-	O
or	O
biopsy	O
-	O
derived	O
human	O
tissues	O
by	O
in	O
situ	O
hybridization	O
.	O

TSC2	O
messenger	O
RNA	O
was	O
widely	O
expressed	B-Transcription
in	O
various	O
cell	O
types	O
throughout	O
the	O
body	O
,	O
including	O
epithelia	O
,	O
lymphocytes	O
,	O
and	O
cells	O
with	O
endocrine	O
functions	O
,	O
e.g.	O
,	O
adrenal	O
cortex	O
and	O
anterior	O
pituitary	O
.	O

It	O
was	O
prominently	O
and	O
selectively	O
(	O
within	O
the	O
central	O
nervous	O
system	O
)	O
expressed	B-Transcription
in	O
pyramidal	O
cells	O
of	O
the	O
cerebral	O
cortex	O
and	O
other	O
motor	O
neurons	O
,	O
e.g.	O
,	O
in	O
spinal	O
cord	O
and	O
brainstem	O
nuclei	O
.	O

Visceral	O
TSC2	O
expression	B-Gene_expression
was	O
comparable	O
in	O
autopsy	O
tissues	O
from	O
patients	O
with	O
and	O
without	O
TSC	O
;	O
TSC2	O
messenger	O
RNA	O
expression	B-Transcription
was	O
most	O
prominent	B-Positive_regulation
in	O
cells	O
with	O
a	O
rapid	O
mitotic	O
rate	O
and	O
turnover	O
,	O
e.g.	O
,	O
epithelia	O
and	O
lymphocytes	O
,	O
with	O
central	O
nervous	O
system	O
pyramidal	O
cells	O
and	O
other	O
neurons	O
being	O
an	O
obvious	O
exception	O
,	O
and/or	O
in	O
cells	O
with	O
important	O
secretory/transport	O
functions	O
.	O

This	O
widespread	O
expression	B-Gene_expression
of	O
the	O
TSC2	O
gene	O
supports	O
the	O
view	O
that	O
it	O
encodes	O
a	O
protein	O
vital	O
to	O
cell	O
growth	O
and	O
metabolism	O
or	O
one	O
that	O
functions	O
as	O
a	O
tumor/growth	O
suppressor	O
.	O

Cell	O
specific	O
expression	B-Gene_expression
of	O
human	O
Bruton	O
's	O
agammaglobulinemia	O
tyrosine	O
kinase	O
gene	O
(	O
Btk	O
)	O
is	O
regulated	B-Regulation
by	O
Sp1	O
-	O
and	O
Spi-1/PU.1	O
-	O
family	O
members	O
.	O

Bruton	O
's	O
agammaglobulinemia	O
tyrosine	O
kinase	O
(	O
Btk	O
)	O
is	O
a	O
cytoplasmic	O
tyrosine	O
kinase	O
involved	O
in	O
the	O
human	O
disease	O
X	O
-	O
linked	O
agammaglobulinemia	O
(	O
XLA	O
)	O
.	O

The	O
gene	O
is	O
expressed	B-Gene_expression
in	O
all	O
hematopoietic	O
cells	O
with	O
the	O
exception	O
of	O
T	O
-	O
cells	O
and	O
plasma	O
cells	O
.	O

For	O
this	O
expression	O
pattern	O
the	O
first	O
280	O
bp	O
upstream	O
of	O
the	O
major	O
transcriptional	O
start	O
site	O
seems	O
to	O
be	O
sufficient	B-Positive_regulation
.	O

In	O
vitro	O
footprinting	O
analysis	O
within	O
this	O
part	O
of	O
the	O
promoter	O
revealed	O
two	O
Sp1	O
binding	O
sites	O
as	O
well	O
as	O
a	O
PU	O
-	O
box	O
.	O

The	O
transcription	O
factor	O
Spi	O
-	O
1/PU.1	O
as	O
well	O
as	O
the	O
closely	O
related	O
factor	O
Spi	O
-	O
B	O
bound	B-Binding
to	O
the	O
PU	O
-	O
box	O
in	O
B	O
-	O
cells	O
.	O

In	O
the	O
erythroleukemia	O
cell	O
line	O
K562	O
,	O
due	O
to	O
the	O
absence	B-Gene_expression
of	O
Spi	O
-	O
B	O
,	O
only	O
PU.1	O
bound	B-Binding
to	O
the	O
Btk	O
promoter	O
.	O

Mutation	O
of	O
either	O
site	O
reduced	B-Negative_regulation
the	O
expression	B-Gene_expression
in	O
transient	O
transfection	O
experiments	O
.	O

However	O
,	O
mutation	O
of	O
the	O
PU	O
box	O
had	O
no	O
effect	B-Regulation
in	O
the	O
T	O
-	O
cell	O
line	O
Jurkat	O
,	O
where	O
none	O
of	O
the	O
Spi	O
-	O
1	O
family	O
members	O
is	O
expressed	B-Gene_expression
.	O

In	O
addition	O
Spi	O
-	O
B	O
as	O
well	O
as	O
PU.1	O
were	O
able	O
to	O
transactivate	B-Positive_regulation
Btk	O
expression	B-Gene_expression
.	O

In	O
fetal	O
liver	O
of	O
PU.1-/	O
-	O
mice	O
,	O
which	O
lack	O
lymphoid	O
and	O
myeloid	O
cells	O
,	O
expression	B-Gene_expression
of	O
Btk	O
was	O
reduced	B-Negative_regulation
two	O
-	O
to	O
threefold	O
but	O
not	O
abolished	B-Negative_regulation
.	O

Collectively	O
this	O
study	O
shows	O
that	O
expression	B-Gene_expression
of	O
the	O
Btk	O
gene	O
is	O
regulated	B-Regulation
by	O
the	O
combined	O
action	O
of	O
Sp1	O
-	O
and	O
PU.1	O
-	O
family	O
members	O
.	O

Elf	O
-	O
1	O
and	O
Stat5	O
bind	B-Binding
to	O
a	O
critical	O
element	O
in	O
a	O
new	O
enhancer	O
of	O
the	O
human	O
interleukin	O
-	O
2	O
receptor	O
alpha	O
gene	O
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1997	O
Apr	O
;	O
17	O
(	O
4	O
)	O
:	O
2351	O
]	O

The	O
interleukin	O
2	O
receptor	O
alpha	O
-	O
chain	O
(	O
IL	O
-	O
2R	O
alpha	O
)	O
gene	O
is	O
a	O
key	O
regulator	O
of	O
lymphocyte	O
proliferation	O
.	O

IL	O
-	O
2R	O
alpha	O
is	O
rapidly	O
and	O
potently	O
induced	B-Positive_regulation
in	O
T	O
cells	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
.	O

Interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
stimulates	O
IL	O
-	O
2R	O
alpha	O
transcription	O
,	O
thereby	O
amplifying	O
expression	O
of	O
its	O
own	O
high	O
-	O
affinity	O
receptor	O
.	O

IL	O
-	O
2R	O
alpha	O
transcription	B-Transcription
is	O
at	O
least	O
in	O
part	O
controlled	B-Regulation
by	O
two	O
positive	O
regulatory	O
regions	O
,	O
PRRI	O
and	O
PRRII	O
.	O

PRRI	O
is	O
an	O
inducible	O
proximal	O
enhancer	O
,	O
located	O
between	O
nucleotides	O
-	O
276	O
and	O
-	O
244	O
,	O
which	O
contains	O
NF	O
-	O
kappaB	O
and	O
SRE/CArG	O
motifs	O
.	O

PRRII	O
is	O
a	O
T-cell	O
-	O
specific	O
enhancer	O
,	O
located	O
between	O
nucleotides	O
-	O
137	O
and	O
-	O
64	O
,	O
which	O
binds	B-Binding
the	O
T-cell	O
-	O
specific	O
Ets	O
protein	O
Elf	O
-	O
1	O
and	O
HMG	O
-	O
I	O
(	O
Y	O
)	O
proteins	O
.	O

However	O
,	O
none	O
of	O
these	O
proximal	O
regions	O
account	O
for	O
the	O
induction	B-Positive_regulation
of	O
IL	O
-	O
2R	O
alpha	O
transcription	B-Transcription
by	O
IL	O
-	O
2	O
.	O

To	O
find	O
new	O
regulatory	O
regions	O
of	O
the	O
IL	O
-	O
2R	O
alpha	O
gene	O
,	O
8.5	O
kb	O
of	O
the	O
5	O
'	O
end	O
noncoding	O
sequence	O
of	O
the	O
IL	O
-	O
2R	O
alpha	O
gene	O
have	O
been	O
sequenced	O
.	O

We	O
identified	O
an	O
86	O
-	O
nucleotide	O
fragment	O
that	O
is	O
90	O
%	O
identical	O
to	O
the	O
recently	O
characterized	O
murine	O
IL-2	O
-	O
responsive	O
element	O
(	O
mIL	O
-	O
2rE	O
)	O
.	O

This	O
putative	O
human	O
IL	O
-	O
2rE	O
,	O
designated	O
PRRIII	O
,	O
confers	O
IL	O
-	O
2	O
responsiveness	O
on	O
a	O
heterologous	O
promoter	O
.	O

PRRIII	O
contains	O
a	O
Stat	O
protein	O
binding	O
site	O
that	O
overlaps	O
with	O
an	O
EBS	O
motif	O
(	O
GASd/EBSd	O
)	O
.	O

These	O
are	O
essential	O
for	O
IL	O
-	O
2	O
inducibility	O
of	O
PRRIII/CAT	O
reporter	O
constructs	O
.	O

IL	O
-	O
2	O
induced	O
the	O
binding	O
of	O
Stat5a	O
and	O
b	O
proteins	O
to	O
the	O
human	O
GASd	O
element	O
.	O

To	O
confirm	O
the	O
physiological	O
relevance	O
of	O
these	O
findings	O
,	O
we	O
carried	O
out	O
in	O
vivo	O
footprinting	O
experiments	O
which	O
showed	O
that	O
stimulation	B-Positive_regulation
of	O
IL	O
-	O
2R	O
alpha	O
expression	B-Gene_expression
correlated	O
with	O
occupancy	O
of	O
the	O
GASd	O
element	O
.	O

Our	O
data	O
demonstrate	O
a	O
major	O
role	B-Regulation
of	O
the	O
GASd/EBSd	O
element	O
in	O
IL	O
-	O
2R	O
alpha	O
regulation	B-Regulation
and	O
suggest	O
that	O
the	O
T-cell	O
-	O
specific	O
Elf	O
-	O
1	O
factor	O
can	O
serve	O
as	O
a	O
transcriptional	O
repressor	O
.	O

Sterol	O
dependent	B-Positive_regulation
LDL	O
-	O
receptor	O
gene	O
transcription	B-Transcription
in	O
lymphocytes	O
from	O
normal	O
and	O
CML	O
patients	O
.	O

Sterol	O
regulatory	O
element	O
(	O
SRE	O
)	O
has	O
been	O
recognized	O
to	O
regulate	B-Regulation
various	O
key	O
genes	O
coding	O
for	O
especially	O
low	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
-	O
receptor	O
,	O
3-hydroxy-3	O
-	O
methylglutaryl	O
coenzyme	O
A	O
(	O
HMG	O
-	O
CoA	O
)	O
reductase	O
and	O
HMG	O
-	O
CoA	O
synthase	O
known	O
to	O
play	O
a	O
crucial	O
role	O
in	O
the	O
cholesterol	O
feedback	O
mechanism	O
.	O

The	O
deranged	O
cholesterol	O
feedback	O
mechanism	O
has	O
been	O
widely	O
recognised	O
in	O
initiation	O
as	O
well	O
as	O
progression	O
of	O
various	O
types	O
of	O
cancers	O
including	O
chronic	O
myeloid	O
leukaemia	O
(	O
CML	O
)	O
.	O

Consequently	O
,	O
the	O
present	O
study	O
was	O
addressed	O
to	O
understand	O
this	O
phenomenon	O
and	O
revealed	O
the	O
existence	O
of	O
a	O
unique	O
47	O
kDa	O
protein	O
factor	O
having	O
affinity	O
for	O
this	O
SRE	O
sequence	O
in	O
lymphocytes	O
from	O
normal	O
subjects	O
as	O
well	O
as	O
its	O
absence	O
in	O
lymphocytes	O
from	O
untreated	O
CML	O
patients	O
.	O

However	O
,	O
this	O
factor	O
appeared	O
when	O
the	O
CML	O
patients	O
achieved	O
complete	O
haematological	O
remission	O
(	O
CHR	O
)	O
through	O
alpha	O
-	O
interferon	O
therapy	O
.	O

Further	O
,	O
an	O
inverse	O
relationship	O
was	O
also	O
observed	O
between	O
sterol	O
modulated	B-Regulation
LDL	O
-	O
receptor	O
gene	O
transcription	B-Transcription
and	O
the	O
binding	O
affinity	O
of	O
this	O
47	O
kDa	O
factor	O
to	O
the	O
SRE	O
sequence	O
.	O

Based	O
upon	O
these	O
results	O
we	O
propose	O
that	O
alpha	O
-	O
interferon	O
through	O
its	O
receptor	O
initiates	O
phosphatidic	O
acid	O
dependent	O
signalling	O
which	O
in	O
turn	O
regulates	O
the	O
affinity	O
of	O
47	O
kDa	O
sterol	O
regulatory	O
element	O
binding	O
factor	O
as	O
well	O
as	O
LDL	O
-	O
receptor	O
gene	O
transcription	B-Transcription
in	O
lymphocytes	O
from	O
CML	O
patients	O
.	O

Lymphocytes	O
from	O
CML	O
patients	O
lack	O
a	O
47	O
kDa	O
factor	O
having	O
affinity	O
for	O
a	O
genomic	O
sterol	O
regulatory	O
sequence	O
.	O

Deranged	O
cellular	O
cholesterol	O
homeostasis	O
has	O
been	O
widely	O
recognized	O
in	O
the	O
initiation	O
as	O
well	O
as	O
progression	O
of	O
various	O
types	O
of	O
cancers	O
including	O
chronic	O
myeloid	O
leukaemia	O
(	O
CML	O
)	O
.	O

Since	O
the	O
human	O
genomic	O
sterol	O
regulatory	O
element	O
(	O
SRE	O
)	O
has	O
been	O
shown	O
to	O
regulate	O
various	O
key	O
genes	O
involved	O
in	O
this	O
phenomenon	O
,	O
the	O
present	O
study	O
revealed	O
the	O
existence	O
of	O
a	O
unique	O
47	O
kDa	O
protein	O
factor	O
having	O
affinity	O
for	O
this	O
SRE	O
sequence	O
in	O
lymphocytes	O
from	O
normal	O
subjects	O
,	O
as	O
well	O
as	O
its	O
absence	O
in	O
lymphocytes	O
from	O
untreated	O
CML	O
patients	O
.	O

However	O
,	O
this	O
factor	O
appeared	O
when	O
these	O
CML	O
patients	O
achieved	O
complete	O
haematological	O
remission	O
(	O
CHR	O
)	O
through	O
alpha	O
-	O
interferon	O
therapy	O
.	O

Furthermore	O
,	O
an	O
inverse	O
relationship	O
was	O
also	O
observed	O
between	O
the	O
LDL	O
receptor	O
gene	O
expression	B-Transcription
at	I-Transcription
the	I-Transcription
transcriptional	I-Transcription
level	I-Transcription
and	O
the	O
binding	O
affinity	O
of	O
this	O
47	O
kDa	O
protein	O
factor	O
to	O
the	O
SRE	O
sequence	O
.	O

Based	O
upon	O
these	O
results	O
we	O
propose	O
that	O
this	O
factor	O
may	O
have	O
a	O
role	O
in	O
pathophysiology	O
of	O
chronic	O
myeloid	O
leukaemia	O
.	O

A	O
novel	O
immunosuppressive	O
factor	O
in	O
bovine	O
colostrum	O
blocks	B-Negative_regulation
activation	B-Positive_regulation
of	O
the	O
interleukin	O
2	O
gene	O
enhancer	O
at	O
the	O
NFAT	O
site	O
.	O

A	O
factor	O
in	O
bovine	O
colostrum	O
(	O
colostrum	O
inhibitory	O
factor	O
,	O
CIF	O
)	O
inhibits	B-Negative_regulation
interleukin	O
2	O
(	O
IL2	O
)	O
production	B-Gene_expression
in	O
activated	O
T	O
helper	O
cells	O
by	O
blocking	B-Negative_regulation
the	O
accumulation	B-Positive_regulation
of	O
IL2	O
mRNA	O
.	O

To	O
determine	O
whether	O
CIF	O
blocks	B-Negative_regulation
at	O
the	O
level	O
of	O
IL2	O
transcription	B-Transcription
,	O
we	O
introduced	O
reporter	O
plasmids	O
into	O
the	O
human	O
T	O
leukemia	O
cell	O
line	O
Jurkat	O
by	O
transient	O
transfection	O
.	O

These	O
contained	O
the	O
luciferase	O
gene	O
under	O
the	O
control	O
of	O
either	O
the	O
human	O
IL2	O
upstream	O
enhancer	O
region	O
(	O
segments	O
-	O
326	O
to	O
+45	O
)	O
or	O
three	O
repeats	O
of	O
the	O
NFAT	O
element	O
contained	O
within	O
it	O
(	O
segments	O
-	O
255	O
to	O
-	O
285	O
)	O
.	O

Expression	O
of	O
luciferase	O
in	O
these	O
cells	O
was	O
induced	O
by	O
phorbol	O
myristate	O
acetate	O
plus	O
a	O
calcium	O
ionophore	O
.	O

CIF	O
inhibited	O
induction	O
of	O
either	O
construct	O
as	O
did	O
cyclosporine	O
,	O
which	O
is	O
known	O
to	O
block	O
activation	O
of	O
the	O
NFAT	O
element	O
.	O

CIF	O
failed	O
to	O
inhibit	O
several	O
other	O
enhancer	O
elements	O
.	O

The	O
NFAT	O
-	O
controlled	O
luciferase	O
gene	O
system	O
distinguishes	O
CIF	O
from	O
other	O
T	O
cell	O
inhibitory	O
activities	O
present	B-Localization
in	O
colostrum	O
,	O
in	O
particular	O
,	O
TGF	O
beta	O
1	O
and	O
TGF	O
beta	O
2	O
and	O
the	O
glucocorticoids	O
.	O

Stably	O
transfected	O
Jurkat	O
cells	O
behaved	O
similarly	O
to	O
the	O
transiently	O
transfected	O
ones	O
with	O
respect	O
to	O
inhibition	O
by	O
CIF	O
and	O
cyclosporine	O
.	O

The	O
NFAT	O
-	O
luc	O
assay	O
is	O
a	O
useful	O
technique	O
for	O
the	O
rapid	O
,	O
sensitive	O
measurement	O
of	O
CIF	O
or	O
other	O
immunosuppressants	O
with	O
a	O
similar	O
mode	O
of	O
action	O
.	O

Octamer	O
independent	O
activation	O
of	O
transcription	O
from	O
the	O
kappa	O
immunoglobulin	O
germline	O
promoter	O
.	O

Previous	O
analyses	O
of	O
immunoglobulin	O
V	O
region	O
promoters	O
has	O
led	O
to	O
the	O
discovery	O
of	O
a	O
common	O
octamer	O
motif	O
which	O
is	O
functionally	O
important	O
in	O
the	O
tissue	O
-	O
specific	O
and	O
developmentally	O
regulated	O
transcriptional	O
activation	O
of	O
immunoglobulin	O
genes	O
.	O

The	O
germline	O
promoters	O
(	O
Ko	O
)	O
located	O
upstream	O
of	O
the	O
J	O
region	O
gene	O
segments	O
of	O
the	O
kappa	O
locus	O
also	O
contain	O
an	O
octamer	O
motif	O
(	O
containing	O
a	O
single	O
base	O
pair	O
mutation	O
and	O
referred	O
to	O
as	O
the	O
variant	O
octamer	O
)	O
which	O
has	O
been	O
shown	O
previously	O
to	O
bind	B-Binding
Oct	O
-	O
1	O
and	O
Oct	O
-	O
2	O
transcription	O
factors	O
in	O
vitro	O
.	O

To	O
further	O
elucidate	O
the	O
role	O
of	O
this	O
variant	O
octamer	O
motif	O
in	O
the	O
regulation	O
of	O
germline	O
transcription	O
from	O
the	O
unrearranged	O
kappa	O
locus	O
,	O
we	O
have	O
quantitated	O
the	O
relative	O
binding	B-Binding
affinity	I-Binding
of	O
Oct	O
-	O
1	O
and	O
Oct	O
-	O
2	O
for	O
the	O
variant	O
octamer	O
motif	O
and	O
determined	O
the	O
functional	O
role	O
of	O
this	O
octamer	O
motif	O
in	O
transcriptional	O
activation	O
.	O

We	O
find	O
that	O
,	O
although	O
the	O
variant	O
octamer	O
motif	O
binds	B-Binding
Oct	O
-	O
1	O
and	O
Oct	O
-	O
2	O
in	O
vitro	O
with	O
5	O
-	O
fold	O
lower	O
affinity	O
than	O
the	O
consensus	O
octamer	O
motif	O
,	O
mutation	O
of	O
the	O
variant	O
octamer	O
motif	O
to	O
either	O
a	O
consensus	O
octamer	O
or	O
non	O
-	O
octamer	O
motif	O
has	O
no	O
effect	O
on	O
transcriptional	O
activation	O
from	O
the	O
germline	O
promoter	O
.	O

We	O
also	O
find	O
significant	O
differences	O
in	O
activation	O
of	O
germline	O
and	O
V	O
region	O
promoters	O
by	O
kappa	O
enhancers	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
germline	O
promoters	O
and	O
V	O
region	O
promoters	O
differ	O
in	O
their	O
dependence	O
on	O
octamer	O
for	O
activation	O
and	O
respond	O
differently	O
to	O
enhancer	O
activation	O
.	O

These	O
findings	O
have	O
important	O
implications	O
in	O
regulation	O
of	O
germline	O
transcription	O
as	O
well	O
as	O
concomitant	O
activation	O
of	O
the	O
V	O
-	O
J	O
recombination	O
of	O
the	O
kappa	O
light	O
chain	O
locus	O
.	O

Characterization	O
of	O
the	O
murine	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
gene	O
p27Kip1	O
.	O

The	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p27Kip1	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
cell	O
-	O
cycle	O
progression	O
.	O

p27Kip1	O
directly	O
inhibits	O
the	O
catalytic	O
activity	O
of	O
cyclin/cdks	O
(	O
cyclin	O
-	O
dependent	O
kinase	O
)	O
complexes	O
and/or	O
interferes	O
physically	O
with	O
cyclin/cdks	O
activation	O
by	O
CAK	O
.	O

Interestingly	O
,	O
the	O
expression	B-Transcription
level	I-Transcription
of	O
p27Kip1	O
mRNA	O
was	O
maximal	O
in	O
resting	O
Go	O
T	O
-	O
cells	O
and	O
rapidly	O
declined	B-Negative_regulation
following	O
anti	O
-	O
CD3	O
activation	O
.	O

We	O
report	O
here	O
the	O
cloning	O
of	O
p27Kip1	O
gene	O
from	O
murine	O
genomic	O
DNA	O
and	O
the	O
functional	O
analysis	O
of	O
the	O
promoter	O
of	O
the	O
p27Kip1	O
gene	O
.	O

The	O
gene	O
consists	O
of	O
at	O
least	O
three	O
exons	O
and	O
spans	O
more	O
than	O
5.6	O
kb	O
of	O
DNA	O
.	O

Primer	O
extension	O
and	O
nuclease	O
S1	O
protection	O
analysis	O
revealed	O
two	O
major	O
transcription	O
initiation	O
sites	O
.	O

The	O
promoter	O
region	O
lacked	O
a	O
TATA	O
box	O
but	O
contained	O
potential	O
binding	O
sites	O
for	O
the	O
transcriptional	O
factors	O
including	O
two	O
Sp1	O
,	O
CRE	O
,	O
Myb	O
and	O
NFkB	O
located	O
at	O
positions	O
-	O
153	O
,	O
-	O
178	O
,	O
-	O
286	O
,	O
-	O
875	O
,	O
and	O
-	O
1011	O
,	O
respectively	O
.	O

To	O
analyze	O
the	O
regulatory	O
mechanisms	O
controlling	B-Regulation
p27Kip1	O
gene	O
expression	B-Gene_expression
,	O
we	O
characterized	O
the	O
5'	O
-	O
flanking	O
region	O
from	O
nt	O
-	O
1609	O
to	O
+178	O
.	O

The	O
-	O
326	O
to	O
-	O
615	O
region	O
contained	O
positive	O
regulatory	O
elements	O
.	O

The	O
state	O
of	O
maturation	O
of	O
monocytes	O
into	O
macrophages	O
determines	O
the	O
effects	O
of	O
IL	O
-	O
4	O
and	O
IL	O
-	O
13	O
on	O
HIV	O
replication	O
.	O

The	O
molecular	O
mechanisms	O
of	O
the	O
effects	O
of	O
IL	O
-	O
4	O
and	O
IL	O
-	O
13	O
on	O
HIV	O
infection	O
in	O
human	O
monocytes	O
as	O
they	O
matured	O
into	O
monocyte	O
-	O
derived	O
macrophages	O
over	O
7	O
days	O
were	O
investigated	O
using	O
HIV	O
-	O
1	O
(	O
BaL	O
)	O
,	O
and	O
low	O
passage	O
clinical	O
strains	O
.	O

IL	O
-	O
4	O
and	O
IL	O
-	O
13	O
up	O
-	O
regulated	O
the	O
expression	O
of	O
both	O
genomic	O
and	O
spliced	O
HIV	O
mRNA	O
in	O
monocytes	O
cultured	O
on	O
Teflon	O
,	O
as	O
determined	O
by	O
Northern	O
analysis	O
and	O
p24	O
Ag	O
assay	O
.	O

Using	O
a	O
nuclear	O
run	O
-	O
on	O
assay	O
,	O
IL	O
-	O
4	O
stimulation	O
was	O
shown	O
to	O
enhance	O
transcription	O
by	O
two	O
-	O
to	O
threefold	O
.	O

IL	O
-	O
4	O
stimulated	O
nuclear	O
factor	O
-	O
kappaB	O
nuclear	O
translocation	O
and	O
binding	O
before	O
enhancement	O
of	O
HIV	O
RNA	O
expression	O
.	O

Conversely	O
,	O
IL	O
-	O
4	O
and	O
IL	O
-	O
13	O
markedly	O
and	O
significantly	O
inhibited	O
HIV	O
replication	O
at	O
the	O
transcriptional	O
level	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
,	O
and	O
this	O
occurred	O
whether	O
these	O
cytokines	O
were	O
added	O
before	O
or	O
after	O
HIV	O
infection	O
.	O

The	O
reversal	O
from	O
stimulation	O
to	O
inhibition	O
occurred	O
after	O
3	O
to	O
5	O
days	O
of	O
adherence	O
to	O
plastic	O
.	O

IL	O
-	O
4	O
had	O
no	O
significant	O
effect	O
on	O
HIV	O
reverse	O
transcription	O
.	O

The	O
effect	B-Regulation
of	O
both	O
cytokines	O
on	O
the	O
monocyte	O
maturation/differentiation	O
(	O
CD11b	O
,	O
CD13	O
,	O
and	O
CD26	O
)	O
and	O
other	O
macrophage	O
markers	O
(	O
CD14	O
and	O
CD68	O
)	O
was	O
examined	O
.	O

IL	O
-	O
4	O
enhanced	B-Positive_regulation
CD11b	O
,	O
but	O
inhibited	B-Negative_regulation
CD26	O
expression	B-Gene_expression
and	O
delayed	B-Negative_regulation
CD13	O
loss	B-Negative_regulation
.	O

IL	O
-	O
13	O
had	B-Positive_regulation
similar	I-Positive_regulation
effects	I-Positive_regulation
on	O
CD11b	O
and	O
CD13	O
,	O
but	O
no	O
effect	B-Regulation
on	O
CD26	O
.	O

Hence	O
,	O
these	O
cytokines	O
do	O
not	O
simply	O
enhance	O
monocyte	O
differentiation	O
,	O
but	O
have	O
complex	O
and	O
slightly	O
divergent	O
effects	O
that	O
impact	O
on	O
HIV	O
replication	O
probably	O
through	O
cell	O
signaling	O
pathways	O
and	O
nuclear	O
factor	O
-	O
kappaB	O
translocation	O
.	O

A	O
novel	O
SP	O
-	O
1	O
site	O
in	O
the	O
human	O
interleukin	O
-	O
1	O
beta	O
promoter	O
confers	O
preferential	O
transcriptional	O
activity	O
in	O
keratinocytes	O
.	O

To	O
investigate	O
the	O
mechanisms	O
of	O
transcriptional	B-Positive_regulation
activation	I-Positive_regulation
of	O
interleukin	O
-	O
1beta	O
(	O
IL	O
-	O
1beta	O
)	O
in	O
non	O
-	O
monocytic	O
cells	O
,	O
we	O
constructed	O
a	O
series	O
of	O
reporter	O
plasmids	O
with	O
the	O
bacterial	O
chloramphenicol	O
acetyltransferase	O
gene	O
linked	O
to	O
various	O
parts	O
of	O
the	O
human	O
IL	O
-	O
1beta	O
promoter	O
and	O
performed	O
transient	O
transfection	O
experiments	O
.	O

We	O
identified	O
a	O
promoter	O
segment	O
that	O
activates	O
transcription	O
most	O
efficiently	O
in	O
keratinocytes	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
with	O
a	O
43	O
-	O
mer	O
oligonucleotide	O
derived	O
from	O
the	O
functionally	O
identified	O
cis	O
-	O
acting	O
element	O
revealed	O
specific	O
complexes	O
.	O

By	O
competition	O
analysis	O
with	O
transcription	O
factor	O
consensus	O
sequence	O
oligonucleotides	O
and	O
by	O
immunosupershift	O
,	O
transcription	O
factor	O
SP	O
-	O
1	O
or	O
a	O
closely	O
related	O
protein	O
was	O
shown	O
to	O
bind	B-Binding
to	O
this	O
regulatory	O
element	O
.	O

The	O
closest	O
match	O
to	O
the	O
known	O
SP	O
-	O
1	O
consensus	O
sequence	O
within	O
the	O
respective	O
region	O
is	O
a	O
TCCCCTCCCCT	O
motif	O
.	O

Mutation	O
of	O
this	O
motif	O
almost	O
completely	O
,	O
and	O
specifically	O
,	O
abolished	O
the	O
binding	O
of	O
two	O
low	O
-	O
mobility	O
complexes	O
and	O
led	O
to	O
a	O
95	O
%	O
decrease	O
of	O
constitutive	O
transcriptional	O
activation	O
of	O
a	O
reporter	O
construct	O
IL	O
-	O
1beta	O
(	O
-	O
170/+108	O
)	O
.	O

Likewise	O
,	O
activation	O
of	O
this	O
reporter	O
construct	O
by	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
depended	O
on	O
the	O
SP	O
-	O
1	O
site	O
.	O

These	O
observations	O
suggest	O
that	O
a	O
so-far	O
-	O
unrecognized	O
SP	O
-	O
1	O
site	O
in	O
the	O
human	O
IL	O
-	O
1beta	O
promoter	O
may	O
participate	B-Positive_regulation
in	O
the	O
transcriptional	B-Regulation
regulation	I-Regulation
of	O
this	O
gene	O
in	O
keratinocytes	O
.	O

Engagement	O
of	O
the	O
Lewis	O
X	O
antigen	O
(	O
CD15	O
)	O
results	O
in	O
monocyte	O
activation	O
.	O

We	O
previously	O
reported	O
that	O
monocyte	O
adhesion	O
to	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
-	O
treated	O
endothelial	O
cells	O
increased	B-Positive_regulation
expression	B-Gene_expression
of	O
tissue	O
factor	O
and	O
CD36	O
on	O
monocytes	O
.	O

Using	O
immunological	O
cross	O
-	O
linking	O
to	O
mimic	O
receptor	O
engagement	O
by	O
natural	O
ligands	O
,	O
we	O
now	O
show	O
that	O
CD15	O
(	O
Lewis	O
X	O
)	O
,	O
a	O
monocyte	O
counter	O
-	O
receptor	O
for	O
endothelial	O
selectins	O
may	O
participate	O
in	O
this	O
response	O
.	O

We	O
used	O
cytokine	O
production	O
as	O
a	O
readout	O
for	O
monocyte	O
activation	O
and	O
found	O
that	O
CD15	O
cross	O
-	O
linking	O
induced	B-Positive_regulation
TNF	O
-	O
alpha	O
release	B-Localization
from	O
peripheral	O
blood	O
monocytes	O
and	O
cells	O
from	O
the	O
monocytic	O
cell	O
line	O
MM6	O
.	O

Quantitative	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
showed	O
an	O
increase	B-Positive_regulation
in	O
steady	O
-	O
state	O
TNF	O
-	O
alpha	O
mRNA	B-Transcription
after	O
3	O
to	O
4	O
hours	O
of	O
cross	O
-	O
linking	O
.	O

CD15	O
cross	O
-	O
linking	O
also	O
concomitantly	O
increased	B-Positive_regulation
interleukin	O
-	O
1	O
beta	O
(	O
IL	O
-	O
1	O
beta	O
)	O
mRNA	B-Transcription
,	O
while	O
no	O
apparent	O
change	B-Regulation
was	O
observed	O
in	O
the	O
levels	O
of	O
beta	O
-	O
actin	O
mRNA	B-Transcription
,	O
indicating	O
specificity	O
.	O

To	O
examine	O
transcriptional	O
regulation	O
of	O
cytokine	O
genes	O
by	O
CD15	O
engagement	O
,	O
a	O
CAT	O
plasmid	O
reporter	O
construct	O
containing	O
IL	O
-	O
1	O
beta	O
promoter/enhancer	O
sequences	O
was	O
introduced	O
into	O
MM6	O
.	O

Subsequent	O
cross	O
-	O
linking	O
of	O
CD15	O
increased	B-Positive_regulation
CAT	O
activity	O
.	O

CD15	O
engagement	O
by	O
monoclonal	O
antibody	O
also	O
attenuated	O
IL	O
-	O
1	O
beta	O
transcript	O
degradation	O
,	O
demonstrating	O
that	O
signaling	O
via	O
CD15	O
also	O
had	O
posttranscriptional	O
effects	O
.	O

Nuclear	O
extracts	O
of	O
anti	O
-	O
CD15	O
cross	O
-	O
linked	O
cells	O
demonstrated	O
enhanced	O
levels	O
of	O
the	O
transcriptional	O
factor	O
activator	O
protein	O
-	O
1	O
,	O
minimally	O
changed	O
nuclear	O
factor	O
-	O
kappa	O
B	O
,	O
and	O
did	O
not	O
affect	B-Regulation
SV40	O
promoter	O
specific	O
protein	O
-	O
1	O
.	O

We	O
conclude	O
that	O
engagement	O
of	O
CD15	O
on	O
monocytes	O
results	O
in	O
monocyte	O
activation	O
.	O

In	O
addition	O
to	O
its	O
well	O
-	O
recognized	O
adhesive	O
role	O
,	O
CD15	O
may	O
function	O
as	O
an	O
important	O
signaling	O
molecule	O
capable	O
of	O
initiating	O
proinflammatory	O
events	O
in	O
monocytes	O
that	O
come	O
into	O
contact	O
with	O
activated	O
endothelium	O
.	O

Sequence	O
analysis	O
and	O
expression	B-Gene_expression
in	O
cultured	O
lymphocytes	O
of	O
the	O
human	O
FOSB	O
gene	O
(	O
G0S3	O
)	O
.	O

G0S3	O
is	O
a	O
member	O
of	O
a	O
set	O
of	O
putative	O
G0/G1	O
switch	O
regulatory	O
genes	O
(	O
G0S	O
genes	O
)	O
selected	B-Gene_expression
by	O
screening	O
cDNA	O
libraries	O
prepared	O
from	O
human	O
blood	O
mononuclear	O
cells	O
cultured	O
for	O
2	O
hr	O
with	O
lectin	O
and	O
cycloheximide	O
.	O

The	O
sequence	O
shows	O
high	O
homology	O
with	O
the	O
murine	O
FOSB	O
gene	O
,	O
which	O
encodes	O
a	O
component	O
of	O
the	O
AP1	O
transcriptional	O
regulator	O
.	O

Comparison	O
of	O
cDNA	O
and	O
genomic	O
sequences	O
reveals	O
a	O
4	O
-	O
exon	O
structure	O
characteristic	O
of	O
the	O
FOS	O
family	O
of	O
genes	O
.	O

Freshly	O
isolated	O
cells	O
show	O
high	O
levels	B-Transcription
of	O
FOSB/G0S3	O
and	O
FOS/G0S7	O
mRNAs	O
,	O
which	O
decline	O
rapidly	O
during	O
incubation	O
in	O
culture	O
medium	O
.	O

The	O
kinetics	O
of	O
expression	O
suggest	O
that	O
the	O
high	O
initial	O
levels	O
are	O
caused	O
by	O
the	O
isolation	O
procedure	O
,	O
and	O
do	O
not	O
reflect	O
constitutive	O
expression	O
.	O

In	O
cells	O
preincubated	O
for	O
a	O
day	O
,	O
levels	B-Transcription
of	O
FOS	O
mRNA	O
reach	B-Positive_regulation
a	I-Positive_regulation
maximum	I-Positive_regulation
20	O
min	O
after	O
the	O
addition	O
of	O
lectin	O
and	O
decline	O
to	O
control	O
levels	O
over	O
the	O
next	O
3	O
hr	O
.	O

Levels	B-Transcription
of	O
FOSB	O
mRNA	O
reach	B-Positive_regulation
a	I-Positive_regulation
maximum	I-Positive_regulation
40	O
min	O
after	O
the	O
addition	O
of	O
lectin	O
and	O
decline	O
to	O
control	O
levels	O
over	O
the	O
next	O
6	O
hr	O
.	O

In	O
freshly	O
isolated	O
cells	O
,	O
both	O
FOS	O
and	O
FOSB	O
mRNAs	O
increase	B-Positive_regulation
dramatically	O
in	O
response	O
to	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
.	O

In	O
preincubated	O
cells	O
,	O
the	O
cycloheximide	O
response	O
is	O
decreased	B-Negative_regulation
,	O
especially	O
in	O
the	O
case	O
of	O
FOSB	O
.	O

These	O
differences	O
in	O
expression	B-Gene_expression
of	O
FOS	O
and	O
FOSB	O
suggest	O
different	O
roles	O
and	O
regulation	O
.	O

Regions	O
of	O
low	O
base	O
order	O
-	O
dependent	O
stem	O
-	O
loop	O
potential	O
in	O
the	O
region	O
of	O
the	O
gene	O
are	O
defined	O
.	O

These	O
indicate	O
where	O
base	O
order	O
has	O
been	O
adapted	O
for	O
purposes	O
other	O
than	O
stem	O
-	O
loop	O
stability	O
(	O
e.g.	O
,	O
encoding	O
proteins	O
or	O
gene	O
regulation	O
)	O
.	O

Regions	O
of	O
low	O
potential	O
in	O
a	O
68.5	O
-	O
kb	O
genomic	O
segment	O
containing	O
the	O
FOSB	O
gene	O
suggest	O
that	O
the	O
potential	O
may	O
help	O
locate	O
genes	O
in	O
uncharted	O
DNA	O
sequences	O
.	O

V3	O
loop	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
suppresses	O
interleukin	O
2	O
-	O
induced	O
T	O
cell	O
growth	O
[	O
published	O
erratum	O
appears	O
in	O
AIDS	O
Res	O
Hum	O
Retroviruses	O
1997	O
May	O
1	O
;	O
13	O
(	O
7	O
)	O
:	O
633	O
]	O

We	O
tested	O
the	O
effect	O
of	O
three	O
linear	O
or	O
two	O
loop	O
peptides	O
derived	O
from	O
the	O
V3	O
region	O
of	O
the	O
HTLV	O
-	O
III	O
BH10	O
clone	O
or	O
the	O
SF2	O
strain	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
on	O
IL-2	O
-	O
driven	O
T	O
cell	O
proliferation	O
.	O

V3	O
-	O
BH10	O
,	O
which	O
consists	O
of	O
42	O
amino	O
acids	O
and	O
has	O
a	O
loop	O
structure	O
,	O
suppressed	O
IL-2	O
-	O
driven	O
proliferation	O
of	O
all	O
IL-2	O
-	O
dependent	O
cells	O
[	O
Kit225	O
,	O
ED	O
-	O
40515	O
(	O
+	O
)	O
,	O
KT	O
-	O
3	O
,	O
7	O
-	O
day	O
PHA	O
-	O
blasts	O
,	O
and	O
fresh	O
peripheral	O
blood	O
mononuclear	O
cells	O
]	O
tested	O
,	O
whereas	O
it	O
did	O
not	O
suppress	O
the	O
cell	O
growth	O
of	O
IL-2	O
-	O
independent	O
cell	O
lines	O
(	O
Hut102	O
,	O
Molt	O
-	O
4	O
,	O
and	O
Jurkat	O
)	O
.	O

This	O
suppressive	O
effect	O
was	O
also	O
seen	O
in	O
IL-2	O
-	O
driven	O
cell	O
growth	O
of	O
CD8	O
-	O
positive	O
lymphocytes	O
purified	O
from	O
7	O
-	O
day	O
PHA	O
-	O
blasts	O
,	O
indicating	O
that	O
CD4	O
molecules	O
were	O
not	O
required	O
for	O
the	O
suppression	O
.	O

The	O
treatment	O
with	O
anti	O
-	O
V3	O
loop	O
monoclonal	O
antibody	O
(	O
902	O
antibody	O
)	O
completely	O
abolished	O
the	O
suppressive	O
effect	O
of	O
V3	O
-	O
BH10	O
.	O

In	O
addition	O
,	O
V3	O
-	O
BH10	O
generated	O
the	O
arrest	O
of	O
Kit225	O
cells	O
and	O
also	O
purified	O
CD8	O
-	O
positive	O
lymphocytes	O
in	O
G1	O
phase	O
in	O
the	O
presence	O
of	O
IL	O
-	O
2	O
.	O

Neither	O
chromatin	O
condensation	O
nor	O
DNA	O
fragmentation	O
was	O
detected	O
in	O
Kit225	O
cells	O
cultured	O
with	O
V3	O
-	O
BH10	O
and	O
IL	O
-	O
2	O
.	O

V3	O
-	O
BH10	O
neither	O
blocked	B-Negative_regulation
radiolabeled	O
IL	O
-	O
2	O
binding	B-Binding
to	O
IL	O
-	O
2	O
receptors	O
nor	O
affected	B-Regulation
tyrosyl	O
phosphorylation	B-Phosphorylation
of	O
several	O
cellular	O
proteins	O
(	O
p120	O
,	O
p98	O
,	O
p96	O
,	O
p54	O
,	O
and	O
p38	O
)	O
,	O
which	O
is	O
immediately	O
induced	B-Positive_regulation
by	O
IL	O
-	O
2	O
stimulation	O
.	O

However	O
,	O
V3	O
-	O
BH10	O
enhanced	B-Positive_regulation
IL-2	O
-	O
induced	B-Positive_regulation
mRNA	B-Transcription
expression	I-Transcription
of	O
c	O
-	O
fos	O
but	O
not	O
c	O
-	O
myc	O
or	O
junB	O
.	O

Thus	O
,	O
the	O
binding	B-Binding
of	O
V3	O
loop	O
of	O
gp120	O
to	O
the	O
cell	O
surface	O
molecule	O
(	O
s	O
)	O
appears	O
to	O
affect	O
intracellular	O
IL	O
-	O
2	O
signaling	O
,	O
which	O
leads	O
to	O
the	O
suppression	O
of	O
IL-2	O
-	O
induced	O
T	O
cell	O
growth	O
.	O

Nuclear	O
factor	O
-	O
kappaB	O
activation	O
in	O
human	O
monocytes	O
stimulated	O
with	O
lipopolysaccharide	O
is	O
inhibited	O
by	O
fibroblast	O
conditioned	O
medium	O
and	O
exogenous	O
PGE2	O
.	O

The	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
is	O
thought	O
to	O
be	O
crucially	O
involved	O
in	O
the	O
gene	B-Positive_regulation
activation	I-Positive_regulation
of	O
several	O
cytokines	O
,	O
including	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
)	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
fibroblast	O
conditioned	O
medium	O
(	O
FCM	O
)	O
is	O
able	O
to	O
inhibit	B-Negative_regulation
both	O
TNF	O
mRNA	O
accumulation	O
and	O
protein	O
release	B-Localization
in	O
peripheral	O
blood	O
-	O
derived	O
human	O
monocytes	O
(	O
PBM	O
)	O
stimulated	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

In	O
this	O
study	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
FCM	O
on	O
the	O
LPS	O
-	O
induced	O
DNA	O
-	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
,	O
by	O
means	O
of	O
electrophoretic	O
shift	O
assay	O
(	O
EMSA	O
)	O
.	O

We	O
provide	O
evidence	O
that	O
FCM	O
strongly	O
inhibits	O
the	O
LPS	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
in	O
PBM	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
exogenous	O
PGE2	O
mimics	O
the	O
NF	O
-	O
kappaB	O
inhibitory	O
effect	O
of	O
FCM	O
.	O

On	O
the	O
other	O
hand	O
,	O
FCM	O
produced	O
in	O
the	O
presence	O
of	O
indomethacin	O
does	O
not	O
inhibit	O
NF	O
-	O
kappaB	O
activation	O
by	O
LPS	O
.	O

Our	O
results	O
lend	O
further	O
support	O
to	O
the	O
hypothesis	O
that	O
inflammatory	O
and	O
immune	O
responses	O
of	O
monocytes/macrophages	O
may	O
be	O
modulated	O
at	O
the	O
molecular	O
level	O
by	O
signals	O
originating	O
from	O
tissue	O
structural	O
cells	O
such	O
as	O
fibroblasts	O
.	O

Glycation	O
-	O
dependent	O
,	O
reactive	O
oxygen	O
species	O
-	O
mediated	O
suppression	O
of	O
the	O
insulin	O
gene	O
promoter	O
activity	O
in	O
HIT	O
cells	O
.	O

Prolonged	O
poor	O
glycemic	O
control	O
in	O
non-insulin	O
-	O
dependent	O
diabetes	O
mellitus	O
patients	O
often	O
leads	O
to	O
a	O
decline	B-Negative_regulation
in	O
insulin	O
secretion	B-Localization
from	O
pancreatic	O
beta	O
cells	O
,	O
accompanied	O
by	O
a	O
decrease	O
in	O
the	O
insulin	O
content	O
of	O
the	O
cells	O
.	O

As	O
a	O
step	O
toward	O
elucidating	O
the	O
pathophysiological	O
background	O
of	O
the	O
so	O
-	O
called	O
glucose	O
toxicity	O
to	O
pancreatic	O
beta	O
cells	O
,	O
we	O
induced	O
glycation	O
in	O
HIT	O
-	O
T15	O
cells	O
using	O
a	O
sugar	O
with	O
strong	O
deoxidizing	O
activity	O
,	O
D	O
-	O
ribose	O
,	O
and	O
examined	O
the	O
effects	B-Regulation
on	O
insulin	O
gene	O
transcription	B-Transcription
.	O

The	O
results	O
of	O
reporter	O
gene	O
analyses	O
revealed	O
that	O
the	O
insulin	O
gene	O
promoter	O
is	O
more	O
sensitive	O
to	O
glycation	O
than	O
the	O
control	O
beta	O
-	O
actin	O
gene	O
promoter	O
;	O
approximately	O
50	O
and	O
80	O
%	O
of	O
the	O
insulin	O
gene	O
promoter	O
activity	O
was	O
lost	B-Negative_regulation
when	O
the	O
cells	O
were	O
kept	O
for	O
3	O
d	O
in	O
the	O
presence	O
of	O
40	O
and	O
60	O
mM	O
D	O
-	O
ribose	O
,	O
respectively	O
.	O

In	O
agreement	O
with	O
this	O
,	O
decrease	B-Negative_regulation
in	O
the	O
insulin	O
mRNA	O
and	O
insulin	O
content	O
was	O
observed	O
in	O
the	O
glycation	O
-	O
induced	O
cells	O
.	O

Also	O
,	O
gel	O
mobility	O
shift	O
analyses	O
using	O
specific	O
antiserum	O
revealed	O
decrease	B-Negative_regulation
in	O
the	O
DNA	O
-	O
binding	B-Binding
activity	I-Binding
of	O
an	O
insulin	O
gene	O
transcription	O
factor	O
,	O
PDX-1/IPF1/STF	O
-	O
1	O
.	O

These	O
effects	O
of	O
D	O
-	O
ribose	O
seemed	O
almost	O
irreversible	O
but	O
could	O
be	O
prevented	B-Negative_regulation
by	O
addition	O
of	O
1	O
mM	O
aminoguanidine	O
or	O
10	O
mM	O
N	O
-	O
acetylcysteine	O
,	O
thus	O
suggesting	O
that	O
glycation	O
and	O
reactive	O
oxygen	O
species	O
,	O
generated	O
through	O
the	O
glycation	O
reaction	O
,	O
serve	B-Positive_regulation
as	I-Positive_regulation
mediators	I-Positive_regulation
of	O
the	O
phenomena	O
.	O

These	O
observations	O
suggest	O
that	O
protein	O
glycation	O
in	O
pancreatic	O
beta	O
cells	O
,	O
which	O
occurs	O
in	O
vivo	O
under	O
chronic	O
hyperglycemia	O
,	O
suppresses	B-Negative_regulation
insulin	O
gene	O
transcription	B-Transcription
and	O
thus	O
can	O
explain	O
part	O
of	O
the	O
beta	O
cell	O
glucose	O
toxicity	O
.	O

Differential	O
interaction	O
of	O
nuclear	O
factors	O
with	O
the	O
PRE	O
-	O
I	O
enhancer	O
element	O
of	O
the	O
human	O
IL	O
-	O
4	O
promoter	O
in	O
different	O
T	O
cell	O
subsets	O
.	O

The	O
immunomodulatory	O
cytokine	O
IL	O
-	O
4	O
affects	O
cells	O
of	O
most	O
hemopoietic	O
lineages	O
.	O

IL	O
-	O
4	O
is	O
secreted	B-Localization
by	O
activated	O
Th2	O
but	O
not	O
Th1	O
cells	O
and	O
plays	O
a	O
major	O
role	O
in	O
the	O
immune	O
response	O
by	O
modulating	O
the	O
differentiation	O
of	O
naive	O
Th	O
cells	O
toward	O
the	O
Th2	O
phenotype	O
.	O

We	O
have	O
previously	O
identified	O
an	O
enhancer	O
element	O
,	O
PRE	O
-	O
I	O
,	O
that	O
is	O
essential	O
for	O
the	O
function	O
of	O
the	O
human	O
IL	O
-	O
4	O
promoter	O
.	O

To	O
investigate	O
the	O
mechanisms	O
responsible	B-Regulation
for	O
tissue	O
-	O
specific	O
expression	B-Gene_expression
of	O
the	O
IL	O
-	O
4	O
gene	O
,	O
we	O
analyzed	O
nuclear	O
factors	O
binding	O
to	O
the	O
PRE	O
-	O
I	O
site	O
and	O
compared	O
the	O
binding	B-Binding
activities	O
of	O
these	O
factors	O
to	O
the	O
IL	O
-	O
4	O
promoter	O
of	O
Th1	O
and	O
Th2	O
cells	O
.	O

We	O
show	O
that	O
PRE	O
-	O
I	O
interacts	O
with	O
PMA	O
-	O
and	O
PMA/ionomycin	O
-	O
inducible	O
,	O
cyclosporin	O
A	O
-	O
sensitive	O
nuclear	O
factors	O
.	O

Using	O
anti	O
-	O
C/EBPbeta	O
(	O
NF	O
-	O
IL6	O
)	O
,	O
anti	O
-	O
C/EBPdelta	O
(	O
NF	O
-	O
IL6beta	O
)	O
,	O
anti-NF	O
-	O
ATc	O
,	O
anti-NF	O
-	O
ATp	O
,	O
anti	O
-	O
Fos	O
,	O
and	O
anti	O
-	O
Jun	O
Abs	O
we	O
demonstrate	O
that	O
the	O
previously	O
identified	O
PRE	O
-	O
I	O
binding	O
factor	O
POS	O
-	O
1	O
is	O
composed	O
of	O
different	O
transcription	O
factors	O
in	O
different	O
Th	O
cell	O
subsets	O
.	O

In	O
the	O
IL-4	O
-	O
producing	B-Gene_expression
Th0	O
-	O
like	O
human	O
Jurkat	O
and	O
mouse	O
EL	O
-	O
4	O
cells	O
,	O
POS	O
-	O
1	O
(	O
designated	O
POS	O
-	O
1a	O
)	O
contains	O
NF	O
-	O
IL6beta	O
and	O
Jun	O
.	O

In	O
the	O
mouse	O
Th2	O
D10	O
cells	O
and	O
in	O
the	O
human	O
Th2	O
clones	O
,	O
POS	O
-	O
1	O
(	O
designated	O
POS	O
-	O
1b	O
)	O
contains	O
NF	O
-	O
IL6beta	O
,	O
Jun	O
,	O
and	O
NF	O
-	O
ATc/p	O
.	O

In	O
contrast	O
,	O
POS	O
-	O
1	O
was	O
not	O
found	O
in	O
nuclear	O
extracts	O
of	O
human	O
Th1	O
clones	O
.	O

These	O
findings	O
suggest	O
that	O
PRE	O
-	O
I	O
may	O
play	O
a	O
role	B-Regulation
in	O
the	O
differential	O
regulation	B-Regulation
of	O
IL	O
-	O
4	O
gene	O
expression	B-Gene_expression
levels	O
.	O

Inhibitory	B-Negative_regulation
effect	I-Negative_regulation
of	O
growth	O
hormone	O
on	O
TNF	O
-	O
alpha	O
secretion	B-Localization
and	O
nuclear	O
factor	O
-	O
kappaB	O
translocation	O
in	O
lipopolysaccharide	O
-	O
stimulated	O
human	O
monocytes	O
.	O

Several	O
studies	O
have	O
pointed	O
to	O
a	O
link	O
between	O
immune	O
and	O
endocrine	O
systems	O
,	O
including	O
a	O
regulatory	O
function	O
of	O
GH	O
on	O
monocyte	O
activation	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
human	O
THP	O
-	O
1	O
promonocytic	O
cells	O
,	O
engineered	O
by	O
gene	O
transfer	O
to	O
constitutively	O
produce	O
human	O
growth	O
hormone	O
(	O
hGH	O
)	O
,	O
secreted	B-Localization
depressed	B-Negative_regulation
amounts	I-Negative_regulation
of	O
TNF	O
-	O
alpha	O
in	B-Positive_regulation
response	I-Positive_regulation
to	O
challenge	O
by	O
LPS	O
.	O

The	O
effect	O
of	O
GH	O
appears	O
to	O
occur	O
in	O
an	O
autocrine	O
fashion	O
,	O
since	O
the	O
inhibitory	B-Negative_regulation
effect	I-Negative_regulation
on	O
TNF	O
-	O
alpha	O
secretion	B-Localization
by	O
constitutive	O
GH	O
production	O
could	O
be	O
abolished	B-Negative_regulation
in	O
the	O
presence	O
of	O
anti	O
-	O
hGH	O
mAb	O
.	O

The	O
GH	O
-	O
induced	O
inhibitory	B-Negative_regulation
effect	I-Negative_regulation
was	O
also	O
observed	O
using	O
normal	O
human	O
monocytes	O
and	O
monocyte	O
-	O
derived	O
macrophages	O
.	O

Inhibition	B-Negative_regulation
of	O
TNF	O
-	O
alpha	O
production	B-Gene_expression
by	O
THP-1-hGH	O
-	O
transfected	O
cells	O
cultured	O
in	O
the	O
presence	O
of	O
LPS	O
is	O
dependent	B-Regulation
on	O
a	O
selective	O
pathway	O
,	O
since	O
no	O
inhibition	B-Negative_regulation
of	O
TNF	O
-	O
alpha	O
production	B-Gene_expression
was	O
observed	O
when	O
cells	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
PMA	O
.	O

Inhibition	B-Negative_regulation
of	O
TNF	O
-	O
alpha	O
secretion	B-Localization
by	O
LPS	O
-	O
stimulated	O
THP-1	O
-	O
hGH	O
cells	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
nuclear	O
translocation	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
.	O

The	O
capacity	O
of	O
GH	O
to	B-Negative_regulation
inhibit	I-Negative_regulation
LPS	O
-	O
induced	B-Positive_regulation
TNF	O
-	O
alpha	O
production	B-Gene_expression
by	O
monocytes	O
without	O
altering	O
other	O
pathways	O
leading	B-Positive_regulation
to	O
TNF	O
-	O
alpha	O
production	B-Gene_expression
may	O
be	O
of	O
potential	O
relevance	O
in	O
septic	O
shock	O
,	O
since	O
GH	O
is	O
available	O
for	O
clinical	O
use	O
.	O

Impaired	B-Negative_regulation
induction	B-Positive_regulation
of	O
c-fos/c	O
-	O
jun	O
genes	O
and	O
of	O
transcriptional	O
regulatory	O
proteins	O
binding	B-Binding
distinct	O
c-fos/c	O
-	O
jun	O
promoter	O
elements	O
in	O
activated	O
human	O
T	O
cells	O
during	O
aging	O
.	O

The	O
activation	B-Positive_regulation
of	O
transcriptional	O
factor	O
c-Fos/c	O
-	O
Jun	O
AP	O
-	O
1	O
is	O
essential	O
for	O
normal	O
T	O
cell	O
responsiveness	O
and	O
is	O
often	O
impaired	B-Negative_regulation
in	O
T	O
cells	O
during	O
aging	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
aberrancies	B-Regulation
in	I-Regulation
the	I-Regulation
regulation	I-Regulation
of	O
c-fos/c	O
-	O
jun	O
at	O
the	O
mRNA	B-Transcription
or	O
protein	O
level	O
might	O
underlie	O
the	O
age	O
-	O
associated	O
impairments	O
of	O
AP	O
-	O
1	O
in	O
human	O
T	O
cells	O
.	O

Whereas	O
T	O
cells	O
from	O
young	O
subjects	O
stimulated	O
with	O
cross	B-Binding
-	I-Binding
linked	I-Binding
anti	O
-	O
CD3epsilon	O
mAb	O
OKT3	O
plus	O
PMA	O
or	O
with	O
the	O
lectin	O
PHA	O
plus	O
PMA	O
demonstrated	O
considerable	O
increases	B-Positive_regulation
in	O
c	O
-	O
Fos	O
protein	O
expression	B-Gene_expression
,	O
the	O
expression	B-Gene_expression
of	O
c	O
-	O
Fos	O
but	O
not	O
c	O
-	O
Jun	O
was	O
markedly	O
reduced	B-Negative_regulation
in	O
stimulated	O
T	O
cells	O
from	O
certain	O
elderly	O
subjects	O
.	O

In	O
addition	O
,	O
RNase	O
protection	O
assays	O
revealed	O
that	O
anti-CD3/PMA	O
-	O
stimulated	O
T	O
cells	O
from	O
a	O
substantial	O
proportion	O
of	O
elderly	O
subjects	O
exhibited	O
decreased	B-Negative_regulation
levels	B-Transcription
of	O
c	O
-	O
fos	O
and/or	O
c	O
-	O
jun	O
mRNA	O
compared	O
to	O
T	O
cells	O
from	O
young	O
subjects	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
the	O
levels	B-Gene_expression
of	O
nuclear	O
regulatory	O
proteins	O
recognizing	O
the	O
AP	O
-	O
1	O
consensus	O
TRE	O
motif	O
,	O
the	O
proximal	O
c	O
-	O
jun	O
TRE	O
-	O
like	O
promoter	O
element	O
,	O
and	O
the	O
c	O
-	O
fos	O
serum	O
response	O
element	O
(	O
SRE	O
)	O
were	O
determined	O
in	O
resting	O
and	O
stimulated	O
T	O
cells	O
.	O

Although	O
the	O
stimulation	O
of	O
T	O
cells	O
from	O
young	O
subjects	O
resulted	O
in	O
coordinated	O
increases	B-Positive_regulation
of	O
nuclear	O
protein	O
complexes	O
binding	B-Binding
the	O
AP	O
-	O
1	O
TRE	O
,	O
c	O
-	O
jun	O
TRE	O
,	O
and	O
c	O
-	O
fos	O
SRE	O
DNA	O
sequence	O
motifs	O
,	O
age	O
-	O
related	O
reductions	O
in	O
the	O
activation	O
of	O
AP	O
-	O
1	O
were	O
accompanied	O
by	O
decreased	O
levels	O
of	O
c	O
-	O
jun	O
TRE	O
and	O
c	O
-	O
fos	O
SRE	O
binding	O
complexes	O
.	O

Furthermore	O
,	O
the	O
nuclear	O
protein	O
complexes	O
binding	O
the	O
SRE	O
motif	O
induced	B-Positive_regulation
in	O
activated	O
T	O
cells	O
of	O
young	O
and	O
elderly	O
subjects	O
contained	O
serum	O
response	O
factor	O
and	O
Elk	O
-	O
1	O
pointing	O
toward	O
age	O
-	O
related	O
defects	O
in	O
the	O
activation	O
of	O
transcriptional	O
regulatory	O
proteins	O
distinct	O
from	O
c-jun/AP	O
-	O
1	O
.	O

These	O
results	O
suggest	O
that	O
underlying	O
aberrancies	B-Regulation
in	O
the	O
induction	B-Positive_regulation
of	O
c-fos/c	O
-	O
jun	O
as	O
well	O
as	O
their	O
nuclear	O
regulatory	O
proteins	O
may	O
contribute	O
to	O
the	O
age	O
-	O
related	O
impairments	O
of	O
AP	O
-	O
1	O
activation	O
in	O
human	O
T	O
cells	O
.	O

Interaction	B-Binding
of	O
transcription	O
factors	O
RFX1	O
and	O
MIBP1	O
with	O
the	O
gamma	O
motif	O
of	O
the	O
negative	O
regulatory	O
element	O
of	O
the	O
hepatitis	O
B	O
virus	O
core	O
promoter	O
.	O

The	O
negative	O
regulatory	O
element	O
(	O
NRE	O
)	O
of	O
the	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
core	O
promoter	O
contains	O
three	O
subregions	O
which	O
act	O
synergistically	O
to	O
suppress	O
core	O
promoter	O
activity	O
.	O

One	O
of	O
these	O
subregions	O
,	O
NRE	O
gamma	O
,	O
is	O
active	O
in	O
both	O
HeLa	O
cervical	O
carcinoma	O
cells	O
and	O
Huh7	O
hepatoma	O
cells	O
and	O
was	O
found	O
to	O
be	O
bound	O
by	O
a	O
protein	O
factor	O
present	O
in	O
both	O
cell	O
types	O
.	O

Here	O
we	O
show	O
that	O
the	O
transcription	O
factor	O
RFX1	O
can	O
bind	B-Binding
to	O
NRE	O
gamma	O
and	O
transactivate	O
the	O
core	O
promoter	O
through	O
this	O
site	O
.	O

Mutations	O
which	O
abrogated	O
the	O
gene	O
-	O
suppressive	O
activity	O
of	O
NRE	O
gamma	O
prevented	B-Negative_regulation
RFX1	O
from	O
binding	B-Binding
to	O
NRE	O
gamma	O
.	O

In	O
addition	O
,	O
RFX1	O
can	O
bind	B-Binding
simultaneously	O
,	O
most	O
likely	O
as	O
a	O
heterodimer	B-Binding
,	O
with	O
the	O
transcription	O
factor	O
MIBP1	O
to	O
NRE	O
gamma	O
.	O

In	O
the	O
absence	O
of	O
a	O
cloned	O
MIBP1	O
gene	O
for	O
further	O
studies	O
,	O
we	O
hypothesize	O
that	O
RFX1	O
acts	O
with	O
MIBP1	O
to	O
negatively	O
regulate	O
the	O
core	O
promoter	O
activity	O
through	O
the	O
NRE	O
gamma	O
site	O
.	O

The	O
ability	O
of	O
RFX1	O
to	O
transactivate	O
the	O
core	O
promoter	O
raises	O
the	O
possibility	O
that	O
RFX1	O
may	O
play	O
a	O
dual	O
role	O
in	O
regulating	O
HBV	O
gene	O
expression	O
.	O

Differentiation	O
-	O
dependent	O
expression	O
of	O
a	O
human	O
carboxylesterase	O
in	O
monocytic	O
cells	O
and	O
transcription	O
factor	O
binding	O
to	O
the	O
promoter	O
.	O

Carboxylesterases	O
play	O
an	O
important	O
role	O
in	O
defense	O
and	O
clearance	O
mechanisms	O
of	O
the	O
monocyte/macrophage	O
system	O
.	O

During	O
the	O
differentiation	O
process	O
of	O
cells	O
from	O
the	O
monocytic	O
cell	O
line	O
THP	O
-	O
1	O
we	O
observed	O
a	O
transient	O
transcriptional	O
upregulation	O
of	O
a	O
human	O
carboxylesterase	O
analyzed	O
by	O
means	O
of	O
Northern	O
blots	O
.	O

In	O
PMA	O
-	O
treated	O
THP	O
-	O
1	O
cells	O
we	O
could	O
detect	O
three	O
major	O
transcription	O
initiation	O
sites	O
as	O
revealed	O
by	O
Nuclease	O
Protection	O
Assay	O
carried	O
out	O
with	O
two	O
overlapping	O
antisense	O
RNA	O
probes	O
.	O

We	O
have	O
recently	O
cloned	O
the	O
carboxylesterase	O
upstream	O
sequence	O
and	O
showed	O
its	O
basal	O
promoter	O
activity	O
in	O
CHO	O
cells	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
analysis	O
we	O
demonstrated	O
that	O
the	O
promoter	O
region	O
spanning	O
base	O
pairs	O
-	O
1	O
to	O
-	O
275	O
,	O
which	O
contains	O
several	O
putative	O
binding	O
sites	O
for	O
transcription	O
factors	O
,	O
is	O
bound	B-Binding
by	O
nuclear	O
factors	O
Sp1	O
and	O
IRBP	O
but	O
not	O
by	O
C/EBPs	O
.	O

Taken	O
together	O
these	O
data	O
indicate	O
that	O
carboxylesterase	O
gene	O
transcription	O
in	O
THP	O
-	O
1	O
cells	O
starts	O
at	O
multiple	O
initiation	O
sites	O
and	O
that	O
Sp1	O
and	O
IRBP	O
may	O
be	O
critical	O
factors	O
for	O
modulating	O
the	O
differentiation	O
-	O
dependent	O
transcription	O
of	O
this	O
human	O
carboxylesterase	O
gene	O
.	O

Characterization	O
of	O
the	O
human	O
platelet/endothelial	O
cell	O
adhesion	O
molecule	O
-	O
1	O
promoter	O
:	O
identification	O
of	O
a	O
GATA	O
-	O
2	O
binding	O
element	O
required	O
for	O
optimal	O
transcriptional	O
activity	O
.	O

Platelet/endothelial	O
cell	O
adhesion	O
molecule	O
-	O
1	O
(	O
PECAM	O
-	O
1	O
)	O
is	O
a	O
130	O
-	O
kD	O
member	O
of	O
the	O
Ig	O
gene	O
superfamily	O
that	O
is	O
expressed	B-Gene_expression
on	O
platelets	O
,	O
endothelial	O
cells	O
,	O
and	O
certain	O
leukocyte	O
subsets	O
.	O

To	O
examine	O
the	O
factors	O
controlling	B-Regulation
vascular	O
-	O
specific	O
expression	B-Gene_expression
of	O
PECAM	O
-	O
1	O
,	O
we	O
cloned	O
the	O
5'	O
-	O
flanking	O
region	O
of	O
the	O
PECAM	O
-	O
1	O
gene	O
and	O
analyzed	O
its	O
transcriptional	O
activity	O
.	O

5'	O
-	O
Rapid	O
amplification	O
of	O
cDNA	O
ends	O
(	O
5'	O
-	O
RACE	O
)	O
analysis	O
showed	O
that	O
transcription	O
initiation	O
occurred	O
at	O
several	O
closely	O
spaced	O
nearby	O
sites	O
originating	O
approximately	O
204	O
bp	O
upstream	O
from	O
the	O
translation	O
start	O
site	O
.	O

Analysis	O
of	O
the	O
sequence	O
immediately	O
upstream	O
from	O
the	O
transcription	O
initiation	O
site	O
(	O
TIS	O
)	O
showed	O
no	O
canonical	O
TATA	O
or	O
CAAT	O
elements	O
,	O
however	O
an	O
initiator	O
element	O
commonly	O
found	O
in	O
TATA	O
-	O
less	O
promoters	O
encompassed	O
the	O
TIS	O
.	O

5'	O
-	O
serially	O
truncated	O
PECAM	O
-	O
1	O
promoter	O
segments	O
cloned	O
in	O
front	O
of	O
a	O
luciferase	O
reporter	O
drove	O
transcription	O
in	O
both	O
a	O
lineage	O
-	O
and	O
orientation	O
-	O
specific	O
manner	O
.	O

Putative	O
cis	O
-	O
acting	O
control	O
elements	O
present	O
within	O
a	O
300	O
-	O
bp	O
core	O
promoter	O
included	O
two	O
ets	O
sites	O
,	O
an	O
Sp1	O
site	O
,	O
tandem	O
E	O
-	O
box	O
domains	O
,	O
two	O
GATA	O
-	O
associated	O
sites	O
(	O
CACCC	O
)	O
,	O
an	O
AP	O
-	O
2	O
binding	O
site	O
,	O
and	O
a	O
GATA	O
element	O
at	O
-	O
24	O
.	O

Mutational	O
analysis	O
showed	O
that	O
optimal	O
transcriptional	O
activity	O
required	O
the	O
GATA	O
sequence	O
at	O
position	O
-	O
24	O
,	O
and	O
gel	O
-	O
shift	O
assays	O
further	O
showed	O
that	O
the	O
GATA	O
-	O
2	O
transcription	O
factor	O
,	O
but	O
not	O
GATA	O
-	O
1	O
,	O
bound	B-Binding
to	O
this	O
region	O
of	O
the	O
PECAM	O
-	O
1	O
promoter	O
.	O

Understanding	O
the	O
cis	O
-	O
and	O
transacting	O
factors	O
that	O
regulate	B-Regulation
the	O
tissue	O
-	O
specific	O
expression	B-Gene_expression
of	O
PECAM	O
-	O
1	O
should	O
increase	O
our	O
understanding	O
of	O
the	O
mechanisms	O
by	O
which	O
vascular	O
-	O
specific	O
gene	O
expression	O
is	O
achieved	O
.	O

Expression	O
of	O
erythroid	O
-	O
specific	O
genes	O
in	O
megakaryoblastic	O
disorders	O
.	O

Currently	O
available	O
data	O
indicate	O
that	O
erythroid	O
and	O
megakaryocytic	O
differentiation	O
pathways	O
are	O
closely	O
related	O
to	O
each	O
other	O
,	O
and	O
there	O
may	O
exist	O
progenitor	O
cells	O
common	O
to	O
those	O
two	O
lineages	O
may	O
exist	O
.	O

Acute	O
megakaryoblastic	O
leukemia	O
(	O
AML	O
-	O
M7	O
)	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
's	O
syndrome	O
(	O
TMD	O
)	O
are	O
characterized	O
by	O
rapid	O
growth	O
of	O
abnormal	O
blast	O
cells	O
which	O
express	O
megakaryocytic	O
markers	O
.	O

These	O
blast	O
cells	O
express	B-Gene_expression
lineage	O
-	O
specific	O
transcription	O
factors	O
such	O
as	O
GATA	O
-	O
1	O
common	O
to	O
these	O
lineages	O
and	O
frequently	O
express	B-Transcription
erythroid	O
-	O
specific	O
mRNAs	O
such	O
as	O
gamma	O
-	O
globin	O
and	O
erythroid	O
delta	O
-	O
aminolevulinate	O
synthase	O
(	O
ALAS	O
-	O
E	O
)	O
,	O
indicating	O
that	O
most	O
of	O
the	O
blasts	O
in	O
M7	O
and	O
TMD	O
cases	O
have	O
erythroid	O
and	O
megakaryocytic	O
phenotypes	O
.	O

These	O
results	O
suggest	O
that	O
blasts	O
in	O
M7	O
and	O
TMD	O
may	O
correspond	O
to	O
progenitors	O
of	O
both	O
erythroid	O
and	O
megakaryocytic	O
lineages	O
.	O

Cloning	O
of	O
the	O
novel	O
human	O
myeloid-cell	O
-	O
specific	O
C/EBP	O
-	O
epsilon	O
transcription	O
factor	O
.	O

Chicken	O
NF	O
-	O
M	O
transcription	O
factor	O
,	O
in	O
cooperation	O
with	O
either	O
c	O
-	O
Myb	O
or	O
v	O
-	O
Myb	O
,	O
is	O
active	O
in	O
the	O
combinatorial	O
activation	O
of	O
myeloid-cell	O
-	O
specific	O
genes	O
in	O
heterologous	O
cell	O
types	O
,	O
such	O
as	O
embryonic	O
fibroblasts	O
.	O

In	O
humans	O
,	O
similar	O
effects	O
were	O
observed	O
with	O
homologous	O
members	O
of	O
the	O
CCAAT/enhancer	O
-	O
binding	O
protein	O
(	O
C/EBP	O
)	O
family	O
of	O
transcriptional	O
regulators	O
,	O
especially	O
the	O
human	O
homolog	O
of	O
chicken	O
NF	O
-	O
M	O
,	O
C/EBP	O
-	O
beta	O
(	O
NF	O
-	O
IL6	O
)	O
.	O

However	O
,	O
the	O
NF	O
-	O
IL6	O
gene	O
is	O
expressed	B-Gene_expression
in	O
a	O
variety	O
of	O
nonmyeloid	O
cell	O
types	O
and	O
is	O
strongly	O
inducible	B-Positive_regulation
in	O
response	O
to	O
inflammatory	O
stimuli	O
,	O
making	O
it	O
an	O
unlikely	O
candidate	O
to	O
have	O
an	O
exclusive	O
role	O
as	O
a	O
combinatorial	O
differentiation	O
switch	O
during	O
myelopoiesis	O
in	O
human	O
cells	O
.	O

By	O
using	O
a	O
reverse	O
transcription-PCR	O
-	O
based	O
approach	O
and	O
a	O
set	O
of	O
primers	O
specific	O
for	O
the	O
DNA	O
-	O
binding	O
domains	O
of	O
highly	O
homologous	O
members	O
of	O
the	O
C/EBP	O
family	O
of	O
transcriptional	O
regulators	O
,	O
we	O
have	O
cloned	O
a	O
novel	O
human	O
gene	O
encoding	O
a	O
member	O
of	O
the	O
C/EBP	O
gene	O
family	O
,	O
identified	O
as	O
the	O
human	O
homolog	O
of	O
CRP1	O
,	O
C/EBP	O
-	O
epsilon	O
.	O

A	O
1.2	O
-	O
kb	O
cDNA	O
encoding	O
full	O
-	O
length	O
human	O
C/EBP	O
-	O
epsilon	O
was	O
cloned	O
from	O
a	O
promyelocyte	O
-	O
late	O
myeloblast	O
-	O
derived	O
lambda	O
gt11	O
library	O
.	O

Molecular	O
analysis	O
of	O
the	O
cDNA	O
and	O
genomic	O
clones	O
indicated	O
the	O
presence	O
of	O
two	O
exons	O
encoding	O
a	O
protein	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
32	O
kDa	O
and	O
a	O
pI	O
of	O
9.5	O
.	O

Primer	O
extension	O
analysis	O
of	O
C/EBP	O
-	O
epsilon	O
mRNA	O
detected	O
a	O
single	O
major	O
transcription	O
start	O
site	O
approximately	O
200	O
bp	O
upstream	O
of	O
the	O
start	O
codon	O
.	O

The	O
putative	O
promoter	O
area	O
is	O
similar	O
to	O
those	O
of	O
several	O
other	O
myeloid-cell	O
-	O
specific	O
genes	O
in	O
that	O
it	O
contains	O
no	O
TATAAA	O
box	O
but	O
has	O
a	O
number	O
of	O
purine	O
-	O
rich	O
stretches	O
with	O
multiple	O
sites	O
for	O
the	O
factors	O
of	O
the	O
Ets	O
family	O
of	O
transcriptional	O
regulators	O
.	O

Northern	O
blot	O
analyses	O
indicated	O
a	O
highly	O
restricted	O
mRNA	O
expression	B-Transcription
pattern	O
,	O
with	O
the	O
strongest	B-Positive_regulation
expression	O
occurring	O
in	O
promyelocyte	O
and	O
late-myeloblast	O
-	O
like	O
cell	O
lines	O
.	O

Western	O
blot	O
and	O
immunoprecipitation	O
studies	O
using	O
rabbit	O
anti-C/EBP	O
-	O
epsilon	O
antibodies	O
raised	O
against	O
the	O
N	O
-	O
terminal	O
portion	O
of	O
C/EBP	O
-	O
epsilon	O
(	O
amino	O
acids	O
1	O
to	O
115	O
)	O
showed	O
that	O
C/EBP	O
-	O
epsilon	O
is	O
a	O
32	O
-	O
kDa	O
nuclear	O
phosphoprotein	O
.	O

The	O
human	O
C/EBP	O
-	O
epsilon	O
protein	O
exhibited	O
strong	O
and	O
specific	O
binding	B-Binding
to	O
double	O
-	O
stranded	O
DNA	O
containing	O
consensus	O
C/EBP	O
sites	O
.	O

Cotransfection	O
of	O
the	O
C/EBP	O
-	O
epsilon	O
sense	O
and	O
antisense	O
expression	O
constructs	O
together	O
with	O
chloramphenicol	O
acetyltransferase	O
reporter	O
vectors	O
containing	O
myeloid-cell	O
-	O
specific	O
c	O
-	O
mim	O
and	O
human	O
myeloperoxidase	O
promoters	O
suggested	O
a	O
role	O
for	O
C/EBP	O
-	O
epsilon	O
transcription	O
factor	O
in	O
the	O
regulation	O
of	O
a	O
subset	O
of	O
myeloid-cell	O
-	O
specific	O
genes	O
.	O

Transient	O
tranfection	B-Gene_expression
of	O
a	O
promyelocyte	O
cell	O
line	O
(	O
NB4	O
)	O
with	O
a	O
C/EBP	O
-	O
epsilon	O
expression	O
plasmid	O
increased	O
cell	O
growth	O
by	O
sevenfold	O
,	O
while	O
antisense	B-Negative_regulation
C/EBP	O
-	O
epsilon	O
caused	O
a	O
fivefold	O
decrease	O
in	O
clonal	O
growth	O
of	O
these	O
cells	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
ferritin	O
heavy	O
-	O
chain	O
gene	O
:	O
the	O
activity	O
of	O
the	O
CCAAT	O
binding	O
factor	O
NF	O
-	O
Y	O
is	O
modulated	O
in	O
heme	O
-	O
treated	O
Friend	O
leukemia	O
cells	O
and	O
during	O
monocyte-to	O
-	O
macrophage	O
differentiation	O
.	O

The	O
ferritin	O
H	O
-	O
chain	O
gene	O
promoter	O
regulation	B-Regulation
was	O
analyzed	O
in	O
heme	O
-	O
treated	O
Friend	O
leukemia	O
cells	O
(	O
FLCs	O
)	O
and	O
during	O
monocyte-to	O
-	O
macrophage	O
differentiation	O
.	O

In	O
the	O
majority	O
of	O
cell	O
lines	O
studied	O
,	O
the	O
regulation	O
of	O
ferritin	O
expression	O
was	O
exerted	O
mostly	O
at	O
the	O
translational	O
level	O
.	O

However	O
,	O
in	O
differentiating	O
erythroid	O
cells	O
,	O
which	O
must	O
incorporate	O
high	O
levels	O
of	O
iron	O
to	O
sustain	O
hemoglobin	O
synthesis	O
,	O
and	O
in	O
macrophages	O
,	O
which	O
are	O
involved	O
in	O
iron	O
storage	O
,	O
transcriptional	O
regulation	O
seemed	O
to	O
be	O
a	O
relevant	O
mechanism	O
.	O

We	O
show	O
here	O
that	O
the	O
minimum	O
region	O
of	O
the	O
ferritin	O
H	O
-	O
gene	O
promoter	O
that	O
is	O
able	O
to	O
confer	O
transcriptional	O
regulation	O
by	O
heme	O
in	O
FLCs	O
to	O
a	O
reporter	O
gene	O
is	O
77	O
nucleotides	O
upstream	O
of	O
the	O
TATA	O
box	O
.	O

This	O
cis	O
element	O
binds	O
a	O
protein	O
complex	O
referred	O
to	O
as	O
HRF	O
(	O
heme	O
-	O
responsive	O
factor	O
)	O
,	O
which	O
is	O
greatly	O
enhanced	O
both	O
in	O
heme	O
-	O
treated	O
FLCs	O
and	O
during	O
monocyte-to	O
-	O
macrophage	O
differentiation	O
.	O

The	O
CCAAT	O
element	O
present	O
in	O
reverse	O
orientation	O
in	O
this	O
promoter	O
region	O
of	O
the	O
ferritin	O
H	O
-	O
chain	O
gene	O
is	O
necessary	B-Positive_regulation
for	O
binding	B-Binding
and	O
for	O
gene	O
activity	O
,	O
since	O
a	O
single	O
point	O
mutation	O
is	O
able	O
to	O
abolish	B-Negative_regulation
the	O
binding	B-Binding
of	O
HRF	O
and	O
the	O
transcriptional	O
activity	O
in	O
transfected	O
cells	O
.	O

By	O
competition	O
experiments	O
and	O
supershift	O
assays	O
,	O
we	O
identified	O
the	O
induced	O
HRF	O
as	O
containing	O
at	O
least	O
the	O
ubiquitous	O
transcription	O
factor	O
NF	O
-	O
Y	O
.	O

NF	O
-	O
Y	O
is	O
formed	O
by	O
three	O
subunits	O
,	O
A	O
,	O
B	O
,	O
and	O
C	O
,	O
all	O
of	O
which	O
are	O
necessary	O
for	O
DNA	O
binding	O
.	O

Cotransfection	O
with	O
a	O
transdominant	O
negative	O
mutant	O
of	O
the	O
NF	O
-	O
YA	O
subunit	O
abolishes	B-Negative_regulation
the	O
transcriptional	B-Positive_regulation
activation	I-Positive_regulation
by	O
heme	O
,	O
indicating	O
that	O
NF	O
-	O
Y	O
plays	O
an	O
essential	O
role	B-Positive_regulation
in	O
this	O
activation	O
.	O

We	O
have	O
also	O
observed	O
a	O
differential	O
expression	O
of	O
the	O
NF	O
-	O
YA	O
subunit	O
in	O
heme	O
-	O
treated	O
and	O
control	O
FLCs	O
and	O
during	O
monocyte-to	O
-	O
macrophage	O
differentiation	O
.	O

Characterization	O
of	O
a	O
mutant	O
cell	O
line	O
that	O
does	O
not	O
activate	O
NF	O
-	O
kappaB	O
in	O
response	O
to	O
multiple	O
stimuli	O
.	O

Numerous	O
genes	O
required	O
during	O
the	O
immune	O
or	O
inflammation	O
response	O
as	O
well	O
as	O
the	O
adhesion	O
process	O
are	O
regulated	O
by	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
.	O

Associated	O
with	O
its	O
inhibitor	O
,	O
I	O
kappaB	O
,	O
NF	O
-	O
kappaB	O
resides	O
as	O
an	O
inactive	O
form	O
in	O
the	O
cytoplasm	O
.	O

Upon	O
stimulation	O
by	O
various	O
agents	O
,	O
I	O
kappaB	O
is	O
proteolyzed	O
and	O
NF	O
-	O
kappaB	O
translocates	O
to	O
the	O
nucleus	O
,	O
where	O
it	O
activates	O
its	O
target	O
genes	O
.	O

The	O
transduction	O
pathways	O
that	O
lead	O
to	O
I	O
kappaB	O
inactivation	O
remain	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
characterized	O
a	O
cellular	O
mutant	O
,	O
the	O
70/Z3	O
-	O
derived	O
1.3E2	O
murine	O
pre	O
-	O
B	O
cell	O
line	O
,	O
that	O
does	O
not	O
activate	O
NF	O
-	O
kappaB	O
in	O
response	O
to	O
several	O
stimuli	O
.	O

We	O
demonstrate	O
that	O
upon	O
stimulation	O
by	O
lipopolysaccharide	O
,	O
Taxol	O
,	O
phorbol	O
myristate	O
acetate	O
,	O
interleukin	O
-	O
1	O
,	O
or	O
double	O
-	O
stranded	O
RNA	O
,	O
I	O
kappaB	O
alpha	O
is	O
not	O
degraded	B-Protein_catabolism
,	O
as	O
a	O
result	B-Positive_regulation
of	O
an	O
absence	B-Negative_regulation
of	O
induced	O
phosphorylation	B-Phosphorylation
on	O
serines	O
32	O
and	O
36	O
.	O

Neither	O
a	O
mutation	O
in	O
I	O
kappaB	O
alpha	O
nor	O
a	O
mutation	O
in	O
p50	O
or	O
relA	O
,	O
the	O
two	O
major	O
subunits	O
of	O
NF	O
-	O
kappaB	O
in	O
this	O
cell	O
line	O
,	O
accounts	B-Positive_regulation
for	I-Positive_regulation
this	O
phosphorylation	O
defect	O
.	O

As	O
well	O
as	O
culminating	B-Positive_regulation
in	O
the	O
inducible	O
phosphorylation	B-Phosphorylation
of	O
I	O
kappaB	O
alpha	O
on	O
serines	O
32	O
and	O
36	O
,	O
all	O
the	O
stimuli	O
that	O
are	O
inactive	O
on	O
1.3E2	O
cells	O
exhibit	O
a	O
sensitivity	O
to	O
the	O
antioxidant	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
.	O

In	O
contrast	O
,	O
stimuli	O
such	O
as	O
hyperosmotic	O
shock	O
or	O
phosphatase	O
inhibitors	O
,	O
which	O
use	O
PDTC	O
-	O
insensitive	O
pathways	O
,	O
induce	B-Positive_regulation
I	O
kappaB	O
alpha	O
degradation	B-Protein_catabolism
in	O
1.3E2	O
.	O

Analysis	O
of	O
the	O
redox	O
status	O
of	O
1.3E2	O
does	O
not	O
reveal	O
any	O
difference	O
from	O
wild	O
-	O
type	O
70Z/3	O
.	O

We	O
also	O
report	O
that	O
the	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
-	O
derived	O
Tax	O
trans	O
-	O
activator	O
induces	O
NF	O
-	O
kappaB	O
activity	O
in	O
1.3E2	O
,	O
suggesting	O
that	O
this	O
viral	O
protein	O
does	O
not	O
operate	B-Regulation
via	O
the	O
defective	O
pathway	O
.	O

Finally	O
,	O
we	O
show	O
that	O
two	O
other	O
I	O
kappaB	O
molecules	O
,	O
I	O
kappaB	O
beta	O
and	O
the	O
recently	O
identified	O
I	O
kappaB	O
epsilon	O
,	O
are	O
not	O
degraded	B-Protein_catabolism
in	O
the	O
1.3E2	O
cell	O
line	O
following	B-Positive_regulation
stimulation	O
.	O

Our	O
results	O
demonstrate	O
that	O
1.3E2	O
is	O
a	O
cellular	O
transduction	O
mutant	O
exhibiting	O
a	O
defect	O
in	O
a	O
step	O
that	O
is	O
required	O
by	O
several	O
different	O
stimuli	O
to	O
activate	O
NF	O
-	O
kappaB	O
.	O

In	O
addition	O
,	O
this	O
analysis	O
suggests	O
a	O
common	O
step	O
in	O
the	O
signaling	O
pathways	O
that	O
trigger	B-Positive_regulation
I	O
kappaB	O
alpha	O
,	O
I	O
kappaB	O
beta	O
,	O
and	O
I	O
kappaB	O
epsilon	O
degradation	B-Protein_catabolism
.	O

Transcription	O
mediated	O
by	O
NFAT	O
is	O
highly	O
inducible	O
in	O
effector	O
CD4+	O
T	O
helper	O
2	O
(	O
Th2	O
)	O
cells	O
but	O
not	O
in	O
Th1	O
cells	O
.	O

Transcriptional	O
factors	O
of	O
the	O
NFAT	O
family	O
play	O
an	O
important	O
role	B-Regulation
in	O
regulating	B-Regulation
the	O
expression	B-Gene_expression
of	O
several	O
cytokine	O
genes	O
during	O
the	O
immune	O
response	O
,	O
such	O
as	O
the	O
genes	O
for	O
interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
and	O
IL	O
-	O
4	O
,	O
among	O
others	O
.	O

Upon	O
antigen	O
stimulation	O
,	O
precursor	O
CD4+	O
T	O
helper	O
(	O
pTh	O
)	O
cells	O
proliferate	O
and	O
differentiate	O
into	O
two	O
populations	O
of	O
effector	O
cells	O
(	O
eTh1	O
and	O
eTh2	O
)	O
,	O
each	O
one	O
expressing	O
a	O
specific	O
pattern	O
of	O
cytokines	O
that	O
distinguishes	O
them	O
from	O
their	O
precursors	O
.	O

eTh2	O
cells	O
are	O
the	O
major	O
source	B-Gene_expression
of	O
IL	O
-	O
4	O
,	O
while	O
gamma	O
interferon	O
is	O
produced	B-Gene_expression
by	O
eTh1	O
cells	O
.	O

Here	O
we	O
have	O
used	O
reporter	O
transgenic	O
mice	O
to	O
show	O
that	O
DNA	O
binding	O
and	O
transcriptional	O
activities	O
of	O
NFAT	O
are	O
transiently	O
induced	O
during	O
the	O
differentiation	O
of	O
pTh	O
cells	O
into	O
either	O
eTh1	O
or	O
eTh2	O
cells	O
to	O
mediate	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
IL	O
-	O
2	O
as	O
a	O
common	O
growth	O
factor	O
in	O
both	O
pathways	O
.	O

However	O
,	O
although	O
NFAT	O
DNA	O
binding	O
is	O
similarly	O
induced	O
in	O
both	O
eTh1	O
and	O
eTh2	O
cells	O
upon	O
antigen	O
stimulation	O
,	O
only	O
the	O
NFAT	O
complexes	O
present	O
in	O
eTh2	O
cells	O
are	O
able	O
to	O
mediate	O
high	O
-	O
level	O
transcription	O
,	O
and	O
relatively	O
little	O
NFAT	O
transcriptional	O
activity	O
was	O
induced	O
in	O
eTh1	O
cells	O
.	O

In	O
contrast	O
to	O
activated	O
pTh	O
cells	O
,	O
neither	O
eTh1	O
nor	O
eTh2	O
cells	O
produced	B-Gene_expression
significant	O
IL	O
-	O
2	O
upon	O
stimulation	O
,	O
but	O
the	O
high	O
levels	O
of	O
NFAT	O
transcriptional	O
activities	O
directly	O
correlate	O
with	O
the	O
IL	O
-	O
4	O
production	B-Gene_expression
induced	B-Positive_regulation
in	O
response	O
to	O
antigen	O
stimulation	O
in	O
eTh2	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
activated	O
NFAT	O
is	O
involved	O
in	O
the	O
effector	O
function	O
of	O
eTh2	O
cells	O
and	O
that	O
the	O
failure	B-Negative_regulation
of	O
eTh1	O
cells	O
to	O
produce	B-Gene_expression
IL	O
-	O
4	O
in	B-Regulation
response	I-Regulation
to	I-Regulation
an	O
antigen	O
is	O
due	O
,	O
at	O
least	O
partially	O
,	O
to	O
a	O
failure	B-Negative_regulation
to	O
induce	B-Positive_regulation
high	O
-	O
level	O
transcription	B-Transcription
of	O
the	O
IL	O
-	O
4	O
gene	O
by	O
NFAT	O
.	O

Regulation	O
of	O
NFAT	O
could	O
be	O
therefore	O
a	O
critical	O
element	O
in	O
the	O
polarization	O
to	O
eTh1	O
or	O
eTh2	O
.	O

Constitutive	O
expression	B-Gene_expression
of	O
p50	O
homodimer	O
in	O
freshly	O
isolated	O
human	O
monocytes	O
decreases	B-Negative_regulation
with	O
in	O
vitro	O
and	O
in	O
vivo	O
differentiation	O
:	O
a	O
possible	O
mechanism	O
influencing	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
monocytes	O
and	O
mature	O
macrophages	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
replicates	O
more	O
efficiently	O
in	O
vitro	O
in	O
differentiated	O
macrophages	O
than	O
in	O
freshly	O
isolated	O
monocytes	O
.	O

We	O
investigated	O
whether	O
this	O
may	O
be	O
partly	O
explained	O
by	O
changes	O
in	O
expression	O
of	O
NF	O
-	O
kappaB	O
with	O
monocyte	O
differentiation	O
.	O

We	O
demonstrated	O
that	O
constitutive	O
expression	O
of	O
NF	O
-	O
kappaB	O
in	O
primary	O
human	O
monocytes	O
changed	O
significantly	O
with	O
differentiation	O
in	O
vitro	O
to	O
monocyte	O
-	O
derived	O
macrophages	O
(	O
MDMs	O
)	O
and	O
differentiation	O
in	O
vivo	O
to	O
alveolar	O
macrophages	O
(	O
AMs	O
)	O
.	O

Freshly	O
isolated	O
monocytes	O
constitutively	O
expressed	B-Gene_expression
high	O
levels	O
of	O
transcriptionally	O
inactive	O
p50	O
homodimer	O
which	O
decreased	B-Negative_regulation
with	O
time	O
in	O
culture	O
in	B-Positive_regulation
favor	I-Positive_regulation
of	I-Positive_regulation
the	O
transcriptionally	O
active	O
p50/p65	O
and	O
p50/RelB	O
heterodimers	O
.	O

As	O
in	O
MDMs	O
,	O
AMs	O
constitutively	O
expressed	B-Gene_expression
p50/p65	O
and	O
p50/RelB	O
although	O
at	O
lower	O
levels	O
.	O

HIV	O
infection	O
of	O
fresh	O
monocytes	O
failed	O
to	O
induce	B-Positive_regulation
p50/p65	O
as	O
seen	O
in	O
MDMs	O
.	O

The	O
replacement	O
of	O
p50	O
homodimers	O
with	O
transcriptionally	O
active	O
heterodimers	O
following	O
time	O
in	O
culture	O
may	O
partially	O
explain	O
the	O
progressive	O
increase	O
in	O
susceptibility	O
of	O
monocytes	O
to	O
HIV	O
infection	O
during	O
in	O
vitro	O
culture	O
.	O

The	O
change	O
in	O
NF	O
-	O
kappaB	O
components	O
with	O
monocyte	O
differentiation	O
in	O
vivo	O
may	O
also	O
explain	O
the	O
different	O
transcriptional	O
activities	O
of	O
these	O
cell	O
populations	O
in	O
HIV	O
-	O
infected	O
individuals	O
.	O

Identification	O
of	O
nucleotide	O
sequences	O
that	O
regulate	O
transcription	O
of	O
the	O
MCF13	O
murine	O
leukemia	O
virus	O
long	O
terminal	O
repeat	O
in	O
activated	O
T	O
cells	O
.	O

The	O
region	O
downstream	O
of	O
the	O
enhancer	O
(	O
DEN	O
)	O
of	O
the	O
long	O
terminal	O
repeat	O
of	O
the	O
mink	O
cell	O
focus	O
-	O
forming	O
murine	O
leukemia	O
virus	O
is	O
important	O
for	O
viral	O
pathogenicity	O
.	O

Another	O
important	O
activity	O
of	O
DEN	O
is	O
its	O
control	O
of	O
transcription	O
in	O
activated	O
T	O
cells	O
,	O
and	O
we	O
have	O
determined	O
that	O
an	O
NF	O
-	O
kappaB	O
site	O
is	O
critical	O
for	O
this	O
activity	O
.	O

Immune	O
hyperactivation	O
of	O
HIV-1	O
-	O
infected	O
T	O
cells	O
mediated	O
by	O
Tat	O
and	O
the	O
CD28	O
pathway	O
.	O

Human	O
immunodeficiency	O
virus	O
-	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
infection	O
is	O
characterized	O
by	O
a	O
chronic	O
state	O
of	O
immune	O
hyperactivation	O
in	O
patients	O
.	O

Infection	O
of	O
human	O
peripheral	O
blood	O
lymphocytes	O
with	O
HIV	O
-	O
1	O
in	O
vitro	O
resulted	O
in	O
increased	B-Positive_regulation
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
secretion	B-Localization
in	B-Positive_regulation
response	I-Positive_regulation
to	I-Positive_regulation
T	O
cell	O
activation	O
via	O
the	O
CD3	O
and	O
CD28	O
receptors	O
.	O

Expression	O
of	O
the	O
HIV	O
-	O
1	O
transactivator	O
Tat	O
recapitulated	O
this	O
phenotype	O
and	O
was	O
associated	O
with	O
increased	B-Positive_regulation
IL	O
-	O
2	O
secretion	B-Localization
in	O
response	O
to	O
costimulation	O
with	O
CD3	O
plus	O
CD28	O
.	O

IL	O
-	O
2	O
superinduction	B-Positive_regulation
by	O
Tat	O
occurred	O
at	O
the	O
transcriptional	O
level	O
,	O
was	O
mediated	B-Positive_regulation
by	O
the	O
CD28	O
-	O
responsive	O
element	O
in	O
the	O
IL	O
-	O
2	O
promoter	O
,	O
and	O
was	O
exclusively	O
dependent	B-Positive_regulation
on	O
the	O
29	O
amino	O
acids	O
encoded	O
by	O
the	O
second	O
exon	O
of	O
Tat	O
.	O

c	O
-	O
Rel	O
is	O
a	O
target	B-Regulation
of	O
pentoxifylline	O
-	O
mediated	O
inhibition	O
of	O
T	O
lymphocyte	O
activation	O
.	O

The	O
possible	O
clinical	O
use	O
of	O
the	O
methyl	O
xanthine	O
derivative	O
,	O
pentoxifylline	O
(	O
PF	O
)	O
,	O
for	O
the	O
treatment	O
of	O
T	O
cell	O
-	O
dependent	O
diseases	O
is	O
being	O
noted	O
with	O
increasing	O
interest	O
.	O

In	O
this	O
paper	O
,	O
we	O
studied	O
the	O
molecular	O
consequences	O
of	O
PF	O
treatment	O
during	O
lymphocyte	O
activation	O
.	O

We	O
found	O
that	O
in	O
T	O
cells	O
,	O
anti-CD3	O
-	O
induced	B-Positive_regulation
c	O
-	O
Rel	O
expression	B-Gene_expression
was	O
blocked	B-Negative_regulation
by	O
PF	O
,	O
whereas	O
the	O
induction	O
of	O
other	O
NF	O
-	O
kappaB	O
family	O
members	O
was	O
not	O
significantly	O
affected	O
.	O

However	O
,	O
induction	O
of	O
NF	O
-	O
AT	O
,	O
which	O
has	O
the	O
same	O
signaling	O
requirements	O
as	O
c	O
-	O
Rel	O
induction	B-Gene_expression
,	O
was	O
not	O
inhibited	O
by	O
PF	O
.	O

Among	O
genes	O
that	O
respond	O
to	O
these	O
transcription	O
factors	O
,	O
IL	O
-	O
2	O
mRNA	O
induction	B-Transcription
was	O
suppressed	B-Negative_regulation
by	O
PF	O
,	O
whereas	O
IL	O
-	O
2R	O
(	O
alpha	O
)	O
chain	O
mRNA	O
induction	B-Transcription
was	O
not	O
affected	B-Negative_regulation
.	O

These	O
observations	O
implicated	O
c	O
-	O
Rel	O
as	O
an	O
IL	O
-	O
2	O
promoter	O
factor	O
,	O
for	O
which	O
experimental	O
support	O
was	O
obtained	O
from	O
transient	O
transfection	O
experiments	O
.	O

In	O
contrast	O
with	O
the	O
observation	O
in	O
T	O
cells	O
,	O
c	O
-	O
Rel	O
induction	B-Gene_expression
was	O
not	O
blocked	B-Negative_regulation
by	O
PF	O
in	O
B	O
cells	O
.	O

The	O
greater	O
selectivity	O
of	O
PF	O
,	O
compared	O
with	O
FK506	O
,	O
at	O
both	O
the	O
molecular	O
and	O
cellular	O
levels	O
may	O
prove	O
advantageous	O
in	O
manipulating	O
T	O
cell	O
responses	O
in	O
vivo	O
.	O

A	O
T	O
cell	O
-	O
specific	O
enhancer	O
in	O
the	O
interleukin	O
-	O
3	O
locus	O
is	O
activated	B-Positive_regulation
cooperatively	I-Positive_regulation
by	O
Oct	O
and	O
NFAT	O
elements	O
within	O
a	O
DNase	O
I	O
-	O
hypersensitive	O
site	O
.	O

Interleukin	O
-	O
3	O
(	O
IL	O
-	O
3	O
)	O
is	O
a	O
cytokine	O
that	O
is	O
expressed	B-Gene_expression
primarily	O
in	O
activated	O
T	O
cells	O
.	O

Here	O
we	O
identified	O
an	O
inducible	B-Positive_regulation
T	O
cell	O
-	O
specific	O
enhancer	O
14	O
kb	O
upstream	O
of	O
the	O
IL	O
-	O
3	O
gene	O
that	O
responded	O
to	O
activation	O
of	O
T	O
cell	O
receptor	O
signaling	O
pathways	O
.	O

The	O
IL	O
-	O
3	O
enhancer	O
spanned	O
an	O
inducible	O
cyclosporin	O
A	O
-	O
sensitive	O
DNase	O
I	O
-	O
hypersensitive	O
site	O
found	O
only	O
in	O
T	O
cells	O
.	O

Four	O
NFAT	O
-	O
like	O
elements	O
exist	O
within	O
the	O
enhancer	O
.	O

The	O
two	O
most	O
active	O
NFAT	O
-	O
like	O
elements	O
were	O
located	O
at	O
the	O
center	O
of	O
the	O
DNase	O
I	O
-	O
hypersensitive	O
site	O
.	O

One	O
of	O
these	O
NFAT	O
-	O
like	O
elements	O
encompassed	O
overlapping	O
Oct	O
-	O
and	O
NFATp/c	O
-	O
binding	O
sites	O
,	O
which	O
functioned	O
in	O
a	O
highly	O
synergistic	O
manner	O
.	O

We	O
suggest	O
that	O
the	O
T	O
cell	O
-	O
specific	O
expression	B-Gene_expression
of	O
the	O
IL	O
-	O
3	O
gene	O
is	O
partly	O
controlled	B-Regulation
through	B-Regulation
the	O
enhancer	O
by	O
cooperation	O
between	O
Oct	O
and	O
NFAT	O
family	O
proteins	O
.	O

A	O
negative	O
regulatory	O
region	O
containing	O
a	O
glucocorticosteroid	O
response	O
element	O
(	O
nGRE	O
)	O
in	O
the	O
human	O
interleukin	O
-	O
1beta	O
gene	O
.	O

Interleukin	O
-	O
1	O
beta	O
(	O
IL	O
-	O
1beta	O
)	O
is	O
one	O
of	O
the	O
most	O
important	O
inflammatory	O
mediators	O
in	O
human	O
inflammatory	O
and	O
immunological	O
diseases	O
.	O

The	O
regulation	B-Regulation
of	O
human	O
IL	O
-	O
1beta	O
gene	O
expression	B-Gene_expression
has	O
been	O
studied	O
for	O
several	O
years	O
,	O
and	O
a	O
few	O
regulatory	O
elements	O
have	O
been	O
discovered	O
in	O
the	O
promoter	O
region	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
negative	B-Negative_regulation
regulation	I-Negative_regulation
of	O
IL	O
-	O
1beta	O
expression	B-Gene_expression
at	O
the	O
transcriptional	O
level	O
,	O
which	O
may	O
play	O
an	O
important	O
role	O
in	O
anti	O
-	O
inflammatory	O
and	O
immunosuppressive	O
effects	O
.	O

We	O
have	O
identified	O
a	O
negative	O
regulatory	O
element	O
located	O
in	O
the	O
region	O
between	O
-	O
685	O
and	O
-	O
395	O
.	O

Within	O
this	O
region	O
,	O
a	O
19	O
-	O
bp	O
nuclear	O
factor	O
binding	O
site	O
(	O
-	O
570	O
to	O
-	O
552	O
)	O
was	O
characterized	O
by	O
DNase	O
I	O
footprinting	O
and	O
electromobility	O
shift	O
assay	O
.	O

A	O
consensus	O
sequence	O
for	O
a	O
negative	O
glucocorticoid	O
response	O
element	O
(	O
nGRE	O
)	O
and	O
a	O
transcription	O
activator	O
protein	O
-	O
2	O
binding	O
site	O
were	O
noted	O
within	O
this	O
footprint	O
.	O

Functional	O
studies	O
showed	O
a	O
2.5	O
-	O
fold	O
increase	O
in	O
promoter	O
activity	O
when	O
this	O
19	O
-	O
bp	O
binding	O
site	O
was	O
deleted	O
in	O
the	O
reporter	O
constructs	O
IL	O
-	O
1beta/CAT	O
and	O
IL	O
-	O
1beta/SV40	O
promoter/CAT	O
.	O

Dexamethasone	O
(	O
10	O
(	O
-	O
8	O
)	O
M	O
)	O
repressed	B-Negative_regulation
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
production	B-Gene_expression
by	O
75	O
%	O
in	O
the	O
wild	O
-	O
type	O
fragment	O
but	O
not	O
in	O
a	O
deletion	O
mutant	O
lacking	O
the	O
19	O
-	O
bp	O
site	O
.	O

A	O
protein	O
of	O
about	O
150	O
kD	O
that	O
bound	O
to	O
this	O
negative	O
regulatory	O
sequence	O
was	O
identified	O
by	O
UV	O
cross	O
-	O
linking	O
.	O

This	O
is	O
the	O
first	O
description	O
of	O
a	O
negative	O
regulatory	O
region	O
responsive	O
to	O
glucocorticoids	O
in	O
a	O
cytokine	O
gene	O
.	O

TRAMP	O
,	O
a	O
novel	O
apoptosis	O
-	O
mediating	O
receptor	O
with	O
sequence	O
homology	O
to	O
tumor	O
necrosis	O
factor	O
receptor	O
1	O
and	O
Fas	O
(	O
Apo	O
-	O
1/CD95	O
)	O
.	O

A	O
novel	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
receptor	O
family	O
,	O
designated	O
TRAMP	O
,	O
has	O
been	O
identified	O
.	O

The	O
structural	O
organization	O
of	O
the	O
393	O
amino	O
acid	O
long	O
human	O
TRAMP	O
is	O
most	O
homologous	O
to	O
TNF	O
receptor	O
1	O
.	O

TRAMP	O
is	O
abundantly	O
expressed	B-Gene_expression
on	O
thymocytes	O
and	O
lymphocytes	O
.	O

Its	O
extracellular	O
domain	O
is	O
composed	O
of	O
four	O
cysteine	O
-	O
rich	O
domains	O
,	O
and	O
the	O
cytoplasmic	O
region	O
contains	O
a	O
death	O
domain	O
known	O
to	O
signal	O
apoptosis	O
.	O

Overexpression	B-Positive_regulation
of	O
TRAMP	O
leads	O
to	O
two	O
major	O
responses	O
,	O
NF	O
-	O
kappaB	O
activation	O
and	O
apoptosis	O
.	O

TRAMP	O
-	O
induced	O
cell	O
death	O
is	O
inhibited	O
by	O
an	O
inhibitor	O
of	O
ICE	O
-	O
like	O
proteases	O
,	O
but	O
not	O
by	O
Bcl	O
-	O
2	O
.	O

In	O
addition	O
,	O
TRAMP	O
does	O
not	O
appear	O
to	O
interact	B-Binding
with	O
any	O
of	O
the	O
known	O
apoptosis	O
-	O
inducing	O
ligands	O
of	O
the	O
TNF	O
family	O
.	O

Involvement	O
of	O
Egr	O
-	O
1/RelA	O
synergy	O
in	O
distinguishing	O
T	O
cell	O
activation	O
from	O
tumor	O
necrosis	O
factor-alpha	O
-	O
induced	B-Positive_regulation
NF	O
-	O
kappa	O
B1	O
transcription	B-Transcription
.	O

NF	O
-	O
kappa	O
B	O
is	O
an	O
important	O
transcription	O
factor	O
required	O
for	O
T	O
cell	O
proliferation	O
and	O
other	O
immunological	O
functions	O
.	O

The	O
NF	O
-	O
kappa	O
B1	O
gene	O
encodes	O
a	O
105	O
-	O
kD	O
protein	O
that	O
is	O
the	O
precursor	O
of	O
the	O
p50	O
component	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Previously	O
,	O
we	O
and	O
others	O
have	O
demonstrated	O
that	O
NF	O
-	O
kappa	O
B	O
regulates	B-Regulation
the	O
NF	O
-	O
kappa	O
B1	O
gene	O
.	O

In	O
this	O
manuscript	O
we	O
have	O
investigated	O
the	O
molecular	O
mechanisms	O
by	O
which	O
T	O
cell	O
lines	O
stimulated	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
and	O
phytohemagglutin	O
(	O
PHA	O
)	O
display	O
significantly	O
higher	B-Positive_regulation
levels	I-Positive_regulation
of	O
NF	O
-	O
kappa	O
B1	O
encoding	O
transcripts	O
than	O
cells	O
stimulated	O
with	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
,	O
despite	O
the	O
fact	O
that	O
both	O
stimuli	O
activate	O
NF	O
-	O
kappa	O
B	O
.	O

Characterization	O
of	O
the	O
NF	O
-	O
kappa	O
B1	O
promoter	O
identified	O
an	O
Egr	O
-	O
1	O
site	O
which	O
was	O
found	O
to	O
be	O
essential	B-Positive_regulation
for	O
both	O
the	O
PMA/PHA	O
-	O
mediated	O
induction	B-Positive_regulation
as	O
well	O
as	O
the	O
synergistic	B-Positive_regulation
activation	I-Positive_regulation
observed	O
after	O
the	O
expression	B-Gene_expression
of	O
the	O
RelA	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
Egr	O
-	O
1	O
.	O

Furthermore	O
,	O
Egr	O
-	O
1	O
induction	B-Positive_regulation
was	O
required	B-Positive_regulation
for	O
endogenous	O
NF	O
-	O
kappa	O
B1	O
gene	O
expression	B-Gene_expression
,	O
since	O
PMA/PHA	O
-	O
stimulated	O
T	O
cell	O
lines	O
expressing	O
antisense	O
Egr	O
-	O
1	O
RNA	O
were	O
inhibited	B-Negative_regulation
in	O
their	O
ability	O
to	O
upregulate	B-Positive_regulation
NF	O
-	O
kappa	O
B1	O
transcription	B-Transcription
.	O

Our	O
studies	O
indicate	O
that	O
transcriptional	O
synergy	O
mediated	O
by	O
activation	B-Positive_regulation
of	O
both	O
Egr	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
may	O
have	O
important	O
ramifications	O
in	O
T	O
cell	O
development	O
by	O
upregulating	B-Positive_regulation
NF	O
-	O
kappa	O
B1	O
gene	O
expression	B-Gene_expression
.	O

Differentiation	O
of	O
U	O
-	O
937	O
promonocytic	O
cells	O
by	O
etoposide	O
and	O
ICRF	O
-	O
193	O
,	O
two	O
antitumour	O
DNA	O
topoisomerase	O
II	O
inhibitors	O
with	O
different	O
mechanisms	O
of	O
action	O
.	O

We	O
have	O
compared	O
the	O
action	O
on	O
U	O
-	O
937	O
human	O
promonocytic	O
leukemia	O
cells	O
of	O
two	O
DNA	O
topoisomerase	O
II	O
inhibitors	O
,	O
namely	O
the	O
epipodophyllotoxin	O
etoposide	O
and	O
the	O
bisdioxopiperazine	O
ICRF	O
-	O
193	O
.	O

One	O
hour	O
pulse	O
-	O
treatment	O
with	O
3	O
microM	O
etoposide	O
caused	O
topoisomerase	O
associated	O
,	O
primary	O
DNA	O
breakage	O
,	O
which	O
was	O
rapidly	O
followed	O
by	O
apoptosis	O
.	O

By	O
contrast	O
,	O
these	O
effects	O
were	O
not	O
observed	O
upon	O
pulse	O
-	O
treatment	O
with	O
6	O
microM	O
ICRF	O
-	O
193	O
.	O

However	O
,	O
continuous	O
treatments	O
with	O
subcytotoxic	O
concentrations	O
of	O
etoposide	O
(	O
0.15	O
microM	O
)	O
and	O
ICRF	O
-	O
193	O
(	O
0.3	O
microM	O
)	O
produced	O
several	O
similar	O
effects	O
,	O
namely	O
decreased	O
cell	O
proliferation	O
,	O
accumulation	O
of	O
cells	O
at	O
G2	O
,	O
increase	O
in	O
cell	O
mass	O
,	O
and	O
induction	O
of	O
differentiation	O
.	O

Under	O
these	O
conditions	O
,	O
etoposide	O
produced	O
a	O
biphasic	O
activation	O
of	O
protein	O
kinase	O
C	O
,	O
which	O
consisted	O
in	O
an	O
early	O
transient	O
activation	O
(	O
from	O
hours	O
1	O
to	O
6	O
)	O
of	O
the	O
membrane	O
-	O
bound	O
enzyme	O
followed	O
by	O
a	O
later	O
activation	O
(	O
hour	O
48	O
)	O
of	O
the	O
total	O
,	O
membrane	O
-	O
bound	O
and	O
cytosolic	O
enzyme	O
.	O

By	O
contrast	O
,	O
ICRF	O
-	O
193	O
only	O
provoked	O
a	O
late	O
activation	O
(	O
from	O
hours	O
72	O
to	O
96	O
)	O
of	O
the	O
total	O
enzyme	O
.	O

When	O
used	O
at	O
differentiation	O
-	O
inducing	O
concentrations	O
,	O
both	O
topoisomerase	O
inhibitors	O
caused	O
a	O
great	O
stimulation	O
of	O
AP	O
-	O
1	O
binding	O
activity	O
,	O
with	O
maximum	O
value	O
at	O
hour	O
12	O
in	O
etoposide	O
-	O
treated	O
cells	O
and	O
at	O
hour	O
48	O
in	O
ICRF-193	O
-	O
treated	O
cells	O
.	O

By	O
contrast	O
,	O
the	O
binding	B-Binding
activity	O
of	O
the	O
NF	O
-	O
kappa	O
(	O
B	O
)	O
and	O
EGR	O
-	O
1	O
transcription	O
factors	O
was	O
little	O
affected	B-Positive_regulation
.	O

It	O
is	O
concluded	O
that	O
topoisomerase	O
II	O
inhibitors	O
may	O
induce	O
the	O
differentiation	O
of	O
promonocytic	O
cells	O
,	O
independently	O
of	O
their	O
capacity	O
to	O
cause	O
DNA	O
strand	O
breaks	O
.	O

However	O
,	O
there	O
are	O
other	O
effects	O
,	O
such	O
as	O
the	O
early	O
activation	O
of	O
protein	O
kinase	O
C	O
,	O
which	O
are	O
probably	O
derived	O
from	O
the	O
production	O
of	O
primary	O
DNA	O
breakage	O
by	O
some	O
anti	O
-	O
topoisomerase	O
drugs	O
.	O

Nuclear	O
Rel	O
-	O
A	O
and	O
c	O
-	O
Rel	O
protein	O
complexes	O
are	O
differentially	O
distributed	B-Localization
within	O
human	O
thymocytes	O
.	O

Nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
/Rel	O
proteins	O
are	O
inducible	O
transcriptional	O
regulators	O
of	O
numerous	O
cellular	O
genes	O
.	O

They	O
are	O
particularly	O
abundant	O
in	O
lymphoid	O
tissues	O
and	O
are	O
thought	O
to	O
be	O
critical	O
for	O
the	O
transcription	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

We	O
have	O
reported	O
previously	O
that	O
a	O
nuclear	O
NF	O
-	O
kappa	O
B	O
activity	O
was	O
present	O
in	O
freshly	O
extracted	O
human	O
thymocytes	O
in	O
the	O
absence	O
of	O
in	O
vitro	O
treatment	O
of	O
these	O
cells	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
identified	O
NF	O
-	O
kappa	O
B	O
proteins	O
extracted	O
from	O
human	O
thymocyte	O
nuclei	O
as	O
being	O
p50/p65	O
and	O
p50/c	O
-	O
Rel	O
complexes	O
.	O

Immunochemical	O
and	O
immunofluorescent	O
staining	O
of	O
thymus	O
sections	O
using	O
specific	O
Abs	O
allowed	O
visualization	O
of	O
nuclear	O
NF	O
-	O
kappa	O
B	O
proteins	O
in	O
both	O
thymocytes	O
and	O
nonthymocyte	O
cells	O
.	O

This	O
detection	O
suggested	O
a	O
preferential	O
activation	B-Positive_regulation
of	O
p50/c	O
-	O
Rel	O
in	O
medullary	O
thymocytes	O
,	O
whereas	O
p50/p65	O
was	O
present	B-Gene_expression
in	O
both	O
cortical	O
and	O
medullary	O
regions	O
of	O
human	O
thymus	O
lobules	O
.	O

However	O
,	O
the	O
intensity	O
of	O
p65	O
labeling	O
was	O
much	O
higher	B-Gene_expression
in	O
several	O
thymocytes	O
from	O
the	O
medulla	O
.	O

p65	O
,	O
p50	O
,	O
and	O
c	O
-	O
Rel	O
activities	O
were	O
found	B-Gene_expression
in	O
both	O
CD4	O
-	O
and	O
CD8	O
-	O
positive	O
thymocytes	O
.	O

These	O
observations	O
suggest	O
that	O
p65	O
and	O
c	O
-	O
Rel	O
complexes	O
play	O
distinct	O
roles	O
in	O
gene	O
expression	O
and	O
that	O
both	O
forms	O
of	O
NF	O
-	O
kappa	O
B	O
play	O
critical	O
roles	O
during	O
late	O
stages	O
of	O
the	O
intrathymic	O
maturation	O
of	O
T	O
cells	O
.	O

Alteration	O
of	O
a	O
single	O
serine	O
in	O
the	O
basic	O
domain	O
of	O
the	O
Epstein	O
-	O
Barr	O
virus	O
ZEBRA	O
protein	O
separates	O
its	O
functions	O
of	O
transcriptional	O
activation	O
and	O
disruption	O
of	O
latency	O
.	O

The	O
ZEBRA	O
protein	O
from	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
activates	O
a	O
switch	O
from	O
the	O
latent	O
to	O
the	O
lytic	O
expression	O
program	O
of	O
the	O
virus	O
.	O

ZEBRA	O
,	O
a	O
member	O
of	O
the	O
bZIP	O
family	O
of	O
DNA	O
-	O
binding	O
proteins	O
,	O
is	O
a	O
transcriptional	O
activator	O
capable	O
of	O
inducing	O
expression	O
from	O
viral	O
lytic	O
cycle	O
promoters	O
.	O

It	O
had	O
previously	O
been	O
thought	O
that	O
ZEBRA	O
's	O
capacity	O
to	O
disrupt	O
EBV	O
latency	O
resided	O
primarily	O
in	O
its	O
ability	O
to	O
activate	O
transcription	O
of	O
genes	O
that	O
encode	O
products	O
required	O
for	O
lytic	O
replication	O
.	O

We	O
generated	O
a	O
point	O
mutant	O
of	O
ZEBRA	O
,	O
Z	O
(	O
S186A	O
)	O
,	O
that	O
was	O
not	O
impaired	O
in	O
its	O
ability	O
to	O
activate	O
transcription	O
;	O
however	O
,	O
this	O
mutation	O
abolished	O
its	O
ability	O
to	O
initiate	O
the	O
viral	O
lytic	O
cascade	O
.	O

The	O
mutant	O
,	O
containing	O
a	O
serine-to	O
-	O
alanine	O
substitution	O
in	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
protein	O
,	O
bound	O
to	O
several	O
known	O
ZEBRA	O
-	O
binding	O
sites	O
and	O
activated	O
transcription	O
from	O
reporters	O
bearing	O
known	O
ZEBRA	O
-	O
responsive	O
promoters	O
but	O
did	O
not	O
disrupt	O
latency	O
in	O
EBV	O
-	O
infected	O
cell	O
lines	O
.	O

Therefore	O
,	O
initiation	O
of	O
the	O
EBV	O
lytic	O
cycle	O
by	O
the	O
ZEBRA	O
protein	O
requires	O
a	O
function	O
in	O
addition	O
to	O
transcriptional	O
activation	O
;	O
a	O
change	O
of	O
serine	O
186	O
to	O
alanine	O
in	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
ZEBRA	O
abolished	O
this	O
additional	O
function	O
and	O
uncovered	O
a	O
new	O
role	O
for	O
the	O
ZEBRA	O
protein	O
in	O
disruption	O
of	O
EBV	O
latency	O
.	O

The	O
additional	O
function	O
that	O
is	O
required	O
for	O
initiation	O
of	O
the	O
lytic	O
viral	O
life	O
cycle	O
is	O
likely	O
to	O
require	O
phosphorylation	B-Phosphorylation
of	O
serine	O
186	O
of	O
the	O
ZEBRA	O
protein	O
,	O
which	O
may	O
influence	B-Regulation
either	O
DNA	O
recognition	B-Binding
or	O
transcriptional	O
activation	O
of	O
lytic	O
viral	O
promoters	O
in	O
a	O
chromatinized	O
viral	O
episome	O
.	O

Activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
in	O
lipopolysaccharide	O
-	O
stimulated	O
U937	O
cells	O
.	O

During	O
the	O
course	O
of	O
serious	O
bacterial	O
infections	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
interacts	O
with	O
monocyte/macrophage	O
receptors	O
,	O
resulting	O
in	O
the	O
generation	O
of	O
inflammatory	O
cytokines	O
.	O

Transcription	O
factor	O
NF	O
-	O
kappaB	O
is	O
crucial	O
in	O
activating	O
the	O
transcription	O
of	O
genes	O
encoding	O
proinflammatory	O
cytokines	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
by	O
LPS	O
in	O
a	O
promonocytic	O
cell	O
line	O
(	O
U937	O
)	O
followed	O
a	O
rather	O
slow	O
kinetics	O
,	O
depending	O
on	O
the	O
rate	O
of	O
IkappaB	O
-	O
alpha	O
inhibitor	O
hydrolysis	O
.	O

No	O
degradation	O
of	O
p105	O
and	O
p100	O
inhibitors	O
was	O
observed	O
under	O
these	O
conditions	O
.	O

The	O
transduction	O
pathway	O
leading	O
to	O
NF	O
-	O
kappaB	O
activation	O
in	O
U937	O
cells	O
involved	O
the	O
intracellular	O
generation	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
as	O
demonstrated	O
by	O
the	O
concomitant	O
inhibitory	O
effects	O
of	O
antioxidants	O
on	O
NF	O
-	O
kappaB	O
activation	O
and	O
the	O
emission	O
of	O
a	O
fluorescent	O
probe	O
reacting	O
intracellularly	O
with	O
hydrogen	O
peroxide	O
.	O

This	O
ROS	O
pathway	O
was	O
also	O
characterized	O
by	O
the	O
use	O
of	O
other	O
inhibitors	O
.	O

This	O
finding	O
indicates	O
that	O
phospholipase	O
A2	O
and	O
5	O
-	O
lipoxygenase	O
are	O
also	O
involved	O
.	O

However	O
,	O
the	O
NF	O
-	O
kappaB	O
activation	O
pathway	O
involving	O
the	O
acidic	O
sphingomyelinase	O
of	O
the	O
endolysosomial	O
membrane	O
did	O
not	O
seem	O
to	O
participate	O
in	O
the	O
LPS	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
in	O
U937	O
cells	O
.	O

Possible	O
role	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
activity	O
in	O
germline	O
C	O
epsilon	O
transcription	O
in	O
a	O
human	O
Burkitt	O
lymphoma	O
B	O
cell	O
line	O
.	O

Nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
plays	O
a	O
broad	O
role	O
in	O
gene	O
regulation	O
,	O
but	O
it	O
is	O
not	O
evident	O
whether	O
NF	O
-	O
kappa	O
B	O
acts	O
as	O
a	O
messenger	O
system	O
for	O
germline	O
C	O
epsilon	O
transcription	O
.	O

We	O
report	O
here	O
that	O
the	O
signaling	O
cascade	O
triggered	O
by	O
interleukin	O
-	O
4	O
(	O
IL	O
-	O
4	O
)	O
or	O
anti	O
-	O
CD40	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
participates	O
in	O
NF	O
-	O
kappa	O
B	O
activation	O
responsible	O
for	O
germline	O
C	O
epsilon	O
transcription	O
in	O
a	O
human	O
Burkitt	O
lymphoma	O
B	O
cell	O
line	O
,	O
DND39	O
.	O

Both	O
IL	O
-	O
4	O
and	O
anti	O
-	O
CD40	O
mAb	O
induced	O
activation	O
of	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3	O
-	O
kinase	O
)	O
,	O
translocation	O
of	O
a	O
zeta	O
isoform	O
of	O
protein	O
kinase	O
C	O
,	O
and	O
nuclear	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

All	O
such	O
events	O
were	O
abrogated	O
by	O
treatment	O
with	O
LY294002	O
,	O
a	O
specific	O
inhibitor	O
of	O
PI3	O
-	O
kinase	O
.	O

In	O
addition	O
,	O
N-acetyl-L	O
-	O
cysteine	O
(	O
NAC	O
)	O
,	O
a	O
potent	O
antioxidant	O
,	O
decreased	O
NF	O
-	O
kappa	O
B	O
activation	O
caused	O
by	O
IL	O
-	O
4	O
,	O
anti	O
-	O
CD40	O
mAb	O
,	O
or	O
their	O
combination	O
.	O

NAC	O
was	O
also	O
effective	O
in	O
diminishing	O
germline	O
C	O
epsilon	O
transcription	O
,	O
and	O
its	O
potency	O
was	O
higher	O
in	O
cultures	O
costimulated	O
with	O
IL	O
-	O
4	O
and	O
anti	O
-	O
CD40	O
mAb	O
than	O
in	O
those	O
stimulated	O
with	O
IL	O
-	O
4	O
alone	O
.	O

These	O
results	O
indicate	O
that	O
IL	O
-	O
4	O
and	O
ligation	B-Binding
of	O
CD40	O
induce	O
NF	O
-	O
kappa	O
B	O
expression	O
via	O
at	O
least	O
a	O
mechanism	O
dependent	O
on	O
the	O
PI3	O
-	O
kinase	O
pathway	O
and	O
suggest	O
that	O
NF	O
-	O
kappa	O
B	O
sensitive	O
to	O
NAC	O
may	O
play	O
a	O
role	O
in	O
regulating	O
germline	O
C	O
epsilon	O
transcription	O
.	O

T	O
-	O
lymphocytes	O
from	O
individuals	O
with	O
filarial	O
inflammatory	O
disease	O
have	O
increased	O
transendothelial	O
migration	O
in	O
vitro	O
.	O

The	O
in	O
vitro	O
transendothelial	O
migration	O
of	O
circulating	O
filarial	O
antigen	O
-	O
specific	O
T	O
-	O
cells	O
was	O
examined	O
in	O
Wuchereria	O
banerofti	O
infection	O
.	O

Circulating	O
T	O
-	O
cells	O
from	O
individuals	O
with	O
filaria	O
-	O
induced	O
lymphatic	O
pathology	O
(	O
LP	O
)	O
had	O
significantly	O
greater	O
migration	O
through	O
unstimulated	O
HUVEC	O
monolayers	O
than	O
did	O
T	O
-	O
cells	O
from	O
asymptomatic	O
infected	O
(	O
MF	O
)	O
individuals	O
(	O
P	O
=	O
0.04	O
)	O
.	O

In	O
contrast	O
to	O
the	O
MF	O
individuals	O
where	O
no	O
effect	O
was	O
seen	O
,	O
transendothelial	O
migration	O
of	O
48	O
-	O
hr	O
filarial	O
antigen	O
stimulated	O
T	O
-	O
cells	O
from	O
LP	O
individuals	O
was	O
significantly	O
(	O
P	O
=	O
0.01	O
)	O
greater	O
than	O
migration	O
of	O
48	O
-	O
hr	O
media	O
-	O
stimulated	O
T	O
-	O
cells	O
.	O

In	O
six	O
of	O
seven	O
patients	O
examined	O
,	O
inhibition	O
of	O
the	O
VLA-4/VCAM	O
-	O
1	O
pathway	O
resulted	O
in	O
greater	O
than	O
50	O
%	O
inhibition	O
of	O
transendothelial	O
migration	O
of	O
T	O
-	O
cells	O
.	O

Suppression	O
by	O
azelastine	O
hydrochloride	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
involved	O
in	O
generation	O
of	O
cytokines	O
and	O
nitric	O
oxide	O
.	O

The	O
influence	O
of	O
the	O
anti	O
-	O
allergy	O
agent	O
azelastine	O
hydrochloride	O
(	O
Azeptin	O
)	O
on	O
NF	O
-	O
kappa	O
B	O
activation	O
associated	O
with	O
the	O
generation	O
of	O
cytokines	O
and	O
nitric	O
oxide	O
(	O
NO	O
)	O
was	O
investigated	O
in	O
various	O
kinds	O
of	O
human	O
and	O
mouse	O
cells	O
.	O

Azeptin	O
dose	O
-	O
dependently	O
suppressed	O
both	O
DNA	O
and	O
protein	O
synthesis	O
in	O
human	O
gingival	O
fibroblasts	O
(	O
HF	O
)	O
and	O
also	O
suppressed	O
blastogenesis	O
of	O
human	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
.	O

Generation	B-Gene_expression
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
,	O
interleukin	O
1	O
-	O
beta	O
,	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
and	O
interleukin	O
-	O
6	O
from	O
10	O
(	O
-	O
5	O
)	O
M	O
Azeptin	O
-	O
treated	O
PBL	O
and	O
human	O
monocytes	O
(	O
HM	O
)	O
was	O
decreased	B-Negative_regulation
to	O
approximately	O
1/3	O
to	O
2/3	O
of	O
the	O
control	O
levels	O
.	O

In	O
parallel	O
with	O
the	O
decreased	O
cytokine	O
generation	O
,	O
each	O
cytokine	O
mRNA	O
was	O
less	O
expressed	O
in	O
the	O
presence	O
of	O
10	O
(	O
-	O
5	O
)	O
M	O
Azeptin	O
.	O

In	O
addition	O
,	O
both	O
inducible	B-Transcription
nitric	O
oxide	O
synthase	O
-	O
mRNA	O
level	O
and	O
NO	O
generation	O
in	O
mouse	O
peritoneal	O
macrophages	O
were	O
suppressed	B-Negative_regulation
by	O
10	O
(	O
-	O
5	O
)	O
M	O
Azeptin	O
.	O

Being	O
compatible	O
with	O
those	O
results	O
,	O
Azeptin	O
(	O
10	O
(	O
-	O
5	O
)	O
M	O
)	O
suppressed	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
PBL	O
,	O
HM	O
and	O
HF	O
.	O

These	O
results	O
appear	O
to	O
indicate	O
that	O
suppression	O
of	O
cytokine	O
and	O
NO	O
generation	O
by	O
Azeptin	O
results	O
at	O
least	O
partially	O
from	O
the	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

The	O
T	O
cell	O
activation	O
factor	O
NF	O
-	O
ATc	O
positively	O
regulates	O
HIV	O
-	O
1	O
replication	O
and	O
gene	O
expression	O
in	O
T	O
cells	O
.	O

Clinical	O
deterioration	O
in	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
infection	O
is	O
associated	O
with	O
increased	O
levels	O
of	O
viral	O
replication	O
and	O
burden	O
in	O
the	O
peripheral	O
blood	O
and	O
lymphoid	O
organs	O
.	O

T	O
cell	O
activation	O
and	O
ensuing	O
cellular	O
gene	O
activation	O
can	O
be	O
critical	O
for	O
HIV	O
-	O
1	O
replication	O
.	O

The	O
hypothesis	O
that	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
may	O
influence	O
HIV	O
-	O
1	O
replication	O
is	O
therefore	O
compelling	O
given	O
the	O
tight	O
correlation	O
of	O
HIV	O
-	O
1	O
transcriptional	O
induction	O
to	O
T	O
cell	O
activation	O
.	O

We	O
report	O
that	O
certain	O
NF	O
-	O
AT	O
(	O
Rel	O
)	O
family	O
members	O
productively	O
bind	O
the	O
kappaB	O
regulatory	O
elements	O
,	O
synergize	O
with	O
NF	O
-	O
kappaB	O
and	O
Tat	O
in	O
transcriptional	O
activation	O
of	O
HIV	O
-	O
1	O
,	O
and	O
enhance	O
HIV	O
-	O
1	O
replication	O
in	O
T	O
cells	O
.	O

These	O
results	O
link	O
regulatory	O
factors	O
critical	O
to	O
T	O
cell	O
commitment	O
directly	O
to	O
HIV	O
-	O
1	O
replication	O
.	O

Differentiation	O
of	O
T	O
-	O
helper	O
lymphocytes	O
:	O
selective	O
regulation	O
by	O
members	O
of	O
the	O
STAT	O
family	O
of	O
transcription	O
factors	O
.	O

Interleukin	O
-	O
4	O
(	O
IL	O
-	O
4	O
)	O
and	O
interleukin	O
-	O
12	O
(	O
IL	O
-	O
12	O
)	O
control	O
the	O
differentiation	O
of	O
T	O
-	O
helper	O
cells	O
.	O

Here	O
we	O
summarize	O
studies	O
which	O
investigate	O
the	O
mechanism	O
by	O
which	O
these	O
cytokines	O
selectively	O
reprogramme	O
gene	O
expression	O
in	O
T	O
-	O
lymphocytes	O
.	O

Cytokine	O
stimulation	O
leads	O
to	O
the	O
phosphorylation	O
of	O
specific	O
tyrosine	O
residues	O
within	O
the	O
intracellular	O
domain	O
of	O
the	O
corresponding	O
cytokine	O
receptor	O
.	O

These	O
phosphotyrosines	O
serve	O
as	O
docking	O
sites	O
for	O
latent	O
,	O
cytoplasmic	O
transcription	O
factors	O
known	O
as	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
Stat	O
)	O
proteins	O
.	O

Receptor/Stat	O
interaction	O
is	O
mediated	O
by	O
the	O
src	O
homology	O
2	O
(	O
SH2	O
)	O
domain	O
of	O
the	O
corresponding	O
Stat	O
protein	O
.	O

Although	O
Stat	O
binding	O
to	O
the	O
intracellular	O
domain	O
of	O
the	O
cytokine	O
receptor	O
strongly	O
depends	O
on	O
the	O
phosphotyrosine	O
residue	O
,	O
the	O
recruitment	O
of	O
a	O
specific	O
Stat	O
protein	O
is	O
dictated	O
by	O
amino	O
acid	O
residues	O
C	O
-	O
terminal	O
to	O
the	O
phosphotyrosine	O
.	O

Specific	O
docking	O
sites	O
within	O
individual	O
cytokine	O
receptors	O
have	O
been	O
identified	O
for	O
almost	O
all	O
Stat	O
proteins	O
.	O

The	O
direct	O
coupling	O
between	O
cytokine	O
receptor	O
and	O
transcription	O
factor	O
helps	O
to	O
explain	O
how	O
different	O
cytokines	O
elicit	O
distinct	O
patterns	O
of	O
gene	O
expression	O
.	O

Regulation	B-Regulation
of	O
the	O
tissue	O
factor	O
gene	O
in	O
human	O
monocytic	O
cells	O
.	O

Role	O
of	O
AP	O
-	O
1	O
,	O
NF	O
-	O
kappa	O
B/Rel	O
,	O
and	O
Sp1	O
proteins	O
in	O
uninduced	O
and	O
lipopolysaccharide	O
-	O
induced	O
expression	O
.	O

Tissue	O
factor	O
(	O
TF	O
)	O
expression	B-Gene_expression
by	O
peripheral	O
blood	O
monocytes	O
during	O
sepsis	O
initiates	O
intravascular	O
thrombosis	O
.	O

Bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
rapidly	O
induces	B-Positive_regulation
TF	O
gene	O
transcription	B-Transcription
in	O
monocytes	O
.	O

The	O
human	O
TF	O
promoter	O
contains	O
binding	O
sites	O
for	O
the	O
transcription	O
factors	O
AP	O
-	O
1	O
,	O
c	O
-	O
Rel/p65	O
,	O
Egr	O
-	O
1	O
,	O
and	O
Sp1	O
.	O

NF	O
-	O
kappa	O
B/Rel	O
proteins	O
have	O
been	O
shown	O
to	O
physically	O
interact	B-Binding
with	O
both	O
AP	O
-	O
1	O
and	O
Sp1	O
proteins	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
role	B-Regulation
of	O
these	O
transcription	O
factors	O
in	O
uninduced	O
and	O
LPS	O
-	O
induced	B-Positive_regulation
TF	O
gene	O
expression	B-Gene_expression
in	O
human	O
monocytic	O
THP	O
-	O
1	O
cells	O
.	O

Deletional	O
analysis	O
indicated	O
that	O
five	O
Sp1	O
sites	O
mediated	B-Positive_regulation
basal	O
expression	B-Gene_expression
in	O
uninduced	O
cells	O
.	O

The	O
two	O
AP	O
-	O
1	O
sites	O
bound	B-Binding
c-Fos/c	O
-	O
Jun	O
heterodimers	O
in	O
both	O
unstimulated	O
and	O
LPS	O
-	O
stimulated	O
cells	O
.	O

Maximal	O
LPS	O
induction	B-Positive_regulation
of	O
the	O
TF	O
promoter	O
required	B-Positive_regulation
the	O
two	O
AP	O
-	O
1	O
sites	O
and	O
the	O
kappa	O
B	O
site	O
within	O
the	O
LPS	O
response	O
element	O
.	O

Disruption	O
of	O
the	O
conserved	O
spacing	O
between	O
the	O
proximal	O
AP	O
-	O
1	O
site	O
and	O
the	O
kappa	O
B	O
site	O
abolished	B-Negative_regulation
LPS	O
induction	B-Positive_regulation
.	O

Replacement	O
of	O
the	O
two	O
AP	O
-	O
1	O
sites	O
with	O
intrinsically	O
bent	O
DNA	O
partially	O
restored	B-Positive_regulation
LPS	O
induction	B-Positive_regulation
,	O
suggesting	O
an	O
additional	O
structural	O
role	O
for	O
the	O
AP	O
-	O
1	O
sites	O
.	O

Synergistic	O
transactivation	O
of	O
the	O
LPS	O
response	O
element	O
in	O
Drosophila	O
Schneider	O
cells	O
by	O
coexpression	B-Gene_expression
of	O
c	O
-	O
Fos	O
,	O
c	O
-	O
Jun	O
,	O
c	O
-	O
Rel	O
,	O
and	O
p65	O
or	O
c	O
-	O
Jun	O
and	O
p65	O
required	O
the	O
transactivation	O
domains	O
of	O
c	O
-	O
Jun	O
and	O
p65	O
.	O

These	O
data	O
indicated	O
that	O
c-Fos/c	O
-	O
Jun	O
,	O
c	O
-	O
Rel/p65	O
,	O
and	O
Sp1	O
regulate	B-Regulation
TF	O
gene	O
expression	B-Gene_expression
in	O
human	O
monocytic	O
cells	O
.	O

Physical	O
interactions	O
between	O
Ets	O
and	O
NF	O
-	O
kappaB/NFAT	O
proteins	O
play	O
an	O
important	O
role	O
in	O
their	O
cooperative	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
enhancer	O
in	O
T	O
cells	O
.	O

The	O
transcriptional	O
regulatory	O
elements	O
of	O
many	O
inducible	O
T	O
-	O
cell	O
genes	O
contain	O
adjacent	O
or	O
overlapping	O
binding	O
sites	O
for	O
the	O
Ets	O
and	O
NF	O
-	O
kappaB/NFAT	O
families	O
of	O
transcription	O
factors	O
.	O

Similar	O
arrays	O
of	O
functionally	O
important	O
NF	O
-	O
kappaB/NFAT	O
and	O
Ets	O
binding	O
sites	O
are	O
present	O
in	O
the	O
transcriptional	O
enhancers	O
of	O
human	O
immunodeficiency	O
viruses	O
types	O
1	O
and	O
2	O
(	O
HIV	O
-	O
1	O
and	O
HIV	O
-	O
2	O
)	O
,	O
suggesting	O
that	O
this	O
pattern	O
of	O
nuclear	O
protein	O
binding	O
sites	O
reflects	O
an	O
evolutionarily	O
conserved	O
mechanism	O
for	O
regulating	O
inducible	O
T	O
-	O
cell	O
gene	O
expression	O
that	O
has	O
been	O
co	O
-	O
opted	O
during	O
HIV	O
evolution	O
.	O

Despite	O
these	O
findings	O
,	O
the	O
molecular	O
mechanisms	O
by	O
which	O
Ets	O
and	O
NF	O
-	O
kappaB/NFAT	O
proteins	O
cooperatively	O
regulate	O
inducible	O
T	O
-	O
cell	O
gene	O
expression	O
remained	O
unknown	O
.	O

In	O
the	O
studies	O
described	O
in	O
this	O
report	O
,	O
we	O
demonstrated	O
a	O
physical	O
interaction	O
between	O
multiple	O
Ets	O
and	O
NF	O
-	O
kappaB/NFAT	O
proteins	O
both	O
in	O
vitro	O
and	O
in	O
activated	O
normal	O
human	O
T	O
cells	O
.	O

This	O
interaction	O
is	O
mediated	O
by	O
the	O
Ets	O
domain	O
of	O
Ets	O
proteins	O
and	O
the	O
C	O
-	O
terminal	O
region	O
of	O
the	O
Rel	O
homology	O
domains	O
of	O
NF	O
-	O
kappaB/NFAT	O
proteins	O
.	O

In	O
addition	O
,	O
the	O
Ets-NF	O
-	O
kappaB/NFAT	O
interaction	O
requires	O
the	O
presence	O
of	O
DNA	O
binding	O
sites	O
for	O
both	O
proteins	O
,	O
as	O
it	O
is	O
abolished	O
by	O
the	O
DNA	O
intercalating	O
agents	O
propidium	O
iodide	O
and	O
ethidium	O
bromide	O
and	O
enhanced	O
by	O
the	O
presence	O
of	O
synthetic	O
oligonucleotides	O
containing	O
binding	O
sites	O
for	O
Ets	O
and	O
NF	O
-	O
kappaB	O
proteins	O
.	O

A	O
dominant	O
-	O
negative	O
mutant	O
of	O
NF	O
-	O
kappaB	O
p50	O
that	O
binds	B-Binding
DNA	O
but	O
fails	B-Binding
to	I-Binding
interact	I-Binding
with	O
Ets	O
proteins	O
inhibits	O
the	O
synergistic	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
and	O
HIV	O
-	O
2	O
enhancers	O
by	O
NF	O
-	O
kappaB	O
(	O
p50	O
+	O
p65	O
)	O
and	O
Ets	O
-	O
1	O
,	O
suggesting	O
that	O
physical	O
interaction	O
between	O
Ets	O
and	O
NF	O
-	O
kappaB	O
proteins	O
is	O
required	O
for	O
the	O
transcriptional	O
activity	O
of	O
the	O
HIV	O
-	O
1	O
and	O
HIV	O
-	O
2	O
enhancers	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
evolutionarily	O
conserved	O
physical	O
interactions	O
between	O
Ets	O
and	O
NF	O
-	O
kappaB/NFAT	O
proteins	O
are	O
important	O
in	O
regulating	O
the	O
inducible	O
expression	O
of	O
T	O
-	O
cell	O
genes	O
and	O
viruses	O
.	O

These	O
interactions	O
represent	O
a	O
potential	O
target	O
for	O
the	O
development	O
of	O
novel	O
immunosuppressive	O
and	O
antiviral	O
therapies	O
.	O

Oxidant	O
-	O
regulation	O
of	O
gene	O
expression	O
in	O
the	O
chronically	O
inflamed	O
intestine	O
.	O

It	O
is	O
becoming	O
increasingly	O
apparent	O
that	O
the	O
chronic	O
gut	O
inflammation	O
observed	O
in	O
the	O
idiopathic	O
inflammatory	O
bowel	O
diseases	O
(	O
e.g.	O
ulcerative	O
colitis	O
,	O
Crohn	O
's	O
disease	O
)	O
is	O
associated	O
with	O
enhanced	O
production	O
of	O
leukocyte	O
-	O
derived	O
oxidants	O
.	O

Oxidants	O
such	O
as	O
hydrogen	O
peroxide	O
are	O
known	O
to	O
activate	O
certain	O
transcription	O
factors	O
such	O
as	O
nuclear	O
transcription	O
factor	O
kappa	O
beta	O
.	O

Nuclear	O
transcription	O
factor	O
kB	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
is	O
a	O
ubiquitous	O
transcription	O
factor	O
and	O
pleiotropic	O
regulator	O
of	O
numerous	O
genes	O
involved	O
in	O
the	O
immune	O
and	O
inflammatory	O
responses	O
.	O

This	O
transcription	O
factor	O
is	O
activated	O
via	O
the	O
selective	O
phosphorylation	O
,	O
ubiquination	O
and	O
degradation	O
of	O
its	O
inhibitor	O
protein	O
I	O
-	O
kB	O
thereby	O
allowing	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
into	O
the	O
nucleus	O
where	O
it	O
upregulates	B-Regulation
the	O
transcription	B-Transcription
of	O
a	O
variety	O
of	O
adhesion	O
molecules	O
(	O
e.g.	O
ICAM	O
-	O
1	O
,	O
VCAM	O
-	O
1	O
)	O
,	O
cytokines	O
(	O
TNF	O
,	O
IL	O
-	O
1	O
,	O
IL	O
-	O
6	O
)	O
and	O
enzymes	O
(	O
iNOS	O
)	O
.	O

The	O
proteolytic	O
degradation	O
of	O
the	O
post	O
-	O
translationally	O
modified	O
I	O
-	O
kappa	O
B	O
is	O
known	O
to	O
be	O
mediated	O
by	O
the	O
26S	O
proteasome	O
complex	O
.	O

Based	O
upon	O
work	O
from	O
our	O
laboratory	O
,	O
we	O
propose	O
that	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
produces	O
significant	O
anti	O
inflammatory	O
activity	O
which	O
may	O
be	O
mediated	O
by	O
the	O
inhibition	O
of	O
transcription	O
of	O
certain	O
pro	O
-	O
inflammatory	O
mediators	O
and	O
adhesion	O
molecules	O
.	O

Expression	B-Gene_expression
of	O
LAZ3/BCL6	O
in	O
follicular	O
center	O
(	O
FC	O
)	O
B	O
cells	O
of	O
reactive	O
lymph	O
nodes	O
and	O
FC	O
-	O
derived	O
non	O
-	O
Hodgkin	O
lymphomas	O
.	O

Chromosomal	O
translocation	O
resulting	B-Regulation
in	I-Regulation
abnormal	I-Regulation
expression	B-Gene_expression
of	O
the	O
LAZ3/BCL6	O
gene	O
in	O
B	O
cells	O
has	O
been	O
implicated	O
in	O
the	O
tumorigenesis	O
of	O
non	O
-	O
Hodgkin	O
lymphoma	O
(	O
NHL	O
)	O
.	O

Therefore	O
we	O
studied	O
the	O
expression	B-Gene_expression
pattern	O
of	O
LAZ3/BCL6	O
by	O
in	O
situ	O
hybridization	O
with	O
synthetic	O
oligonucleotide	O
probes	O
in	O
frozen	O
tissue	O
sections	O
from	O
five	O
reactive	O
lymph	O
nodes	O
and	O
38	O
B	O
cell	O
and	O
non	O
-	O
B	O
NHL	O
.	O

In	O
addition	O
,	O
we	O
investigated	O
the	O
expression	B-Gene_expression
of	O
LAZ3/BCL6	O
by	O
Northern	O
blot	O
analysis	O
on	O
multiple	O
human	O
tissues	O
.	O

The	O
LAZ3/BCL6	O
transcript	O
was	O
found	B-Transcription
in	O
a	O
variety	O
of	O
tissues	O
,	O
including	O
skeletal	O
muscle	O
,	O
peripheral	O
blood	O
leukocytes	O
,	O
and	O
weakly	O
in	O
normal	O
lymph	O
nodes	O
.	O

In	O
the	O
tumor	O
samples	O
,	O
expression	B-Gene_expression
of	O
LAZ3/BCL6	O
was	O
observed	O
in	O
68	O
%	O
of	O
all	O
B	O
cell	O
NHL	O
and	O
none	O
of	O
the	O
non	O
-	O
B	O
lymphomas	O
.	O

All	O
cases	O
of	O
follicular	O
,	O
mixed	O
small	O
and	O
large	O
cell	O
lymphomas	O
showed	O
LAZ3/BCL6	O
expression	B-Gene_expression
confined	B-Positive_regulation
to	O
the	O
neoplastic	O
follicles	O
.	O

A	O
follicular	O
expression	B-Gene_expression
pattern	O
was	O
also	O
found	O
in	O
all	O
non	O
-	O
malignant	O
reactive	O
lymph	O
nodes	O
.	O

Hence	O
,	O
the	O
expression	B-Gene_expression
of	O
LAZ3/BCL6	O
does	O
not	O
correlate	O
to	O
malignancy	O
,	O
but	O
reflects	O
the	O
origin	O
of	O
B	O
cells	O
from	O
the	O
germinal	O
centers	O
.	O

Induction	B-Positive_regulation
of	O
relA	O
(	O
p65	O
)	O
and	O
I	O
kappa	O
B	O
alpha	O
subunit	O
expression	B-Gene_expression
during	O
differentiation	O
of	O
human	O
peripheral	O
blood	O
monocytes	O
to	O
macrophages	O
.	O

We	O
evaluated	O
the	O
expression	O
and	O
DNA	O
binding	O
activity	O
of	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
subunits	O
in	O
human	O
peripheral	O
blood	O
monocytes	O
and	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
(	O
MDMs	O
)	O
.	O

Constitutive	O
DNA	O
binding	B-Binding
activity	O
consisting	O
of	O
p50	O
homodimers	O
was	O
detected	O
in	O
nuclear	O
extracts	O
from	O
both	O
cell	O
types	O
.	O

An	O
additional	O
complex	O
composed	O
of	O
p50/RelA	O
(	O
p65	O
)	O
heterodimers	O
appeared	B-Gene_expression
only	O
in	O
nuclear	O
extracts	O
from	O
7	O
-	O
day	O
MDMs	O
.	O

Immunoblot	O
analysis	O
showed	O
that	O
the	O
p50	O
subunit	O
was	O
constitutively	O
expressed	B-Gene_expression
in	O
monocytes	O
and	O
MDMs	O
.	O

In	O
contrast	O
,	O
the	O
RelA	O
(	O
p65	O
)	O
subunit	O
was	O
barely	O
detectable	B-Gene_expression
in	O
monocytes	O
,	O
but	O
its	O
level	O
increased	B-Positive_regulation
markedly	O
in	O
MDMs	O
.	O

Analysis	O
of	O
RelA	O
(	O
p65	O
)	O
mRNA	O
revealed	O
that	O
the	O
stability	O
of	O
RelA	O
(	O
p65	O
)	O
mRNA	O
was	O
significantly	O
higher	B-Positive_regulation
in	O
MDMs	O
,	O
compared	O
with	O
monocytes	O
.	O

In	O
MDMs	O
,	O
an	O
upregulation	B-Positive_regulation
of	O
I	O
kappa	O
B	O
alpha	O
synthesis	B-Gene_expression
as	O
well	O
as	O
the	O
appearance	B-Gene_expression
of	O
a	O
novel	O
M	O
(	O
r	O
)	O
40	O
,	O
000	O
form	O
of	O
I	O
kappa	O
B	O
alpha	O
were	O
also	O
observed	O
.	O

These	O
results	O
suggest	O
that	O
macrophage	O
differentiation	O
results	B-Positive_regulation
in	O
the	O
expression	B-Gene_expression
of	O
active	O
p50/RelA	O
(	O
p65	O
)	O
heterodimers	O
with	O
the	O
capacity	O
to	O
activate	O
target	O
gene	O
expression	O
.	O

The	O
parallel	O
induction	B-Positive_regulation
of	O
I	O
kappa	O
B	O
alpha	O
synthesis	B-Gene_expression
may	O
allow	B-Positive_regulation
for	O
the	O
continuous	O
presence	O
of	O
a	O
cytoplasmic	O
reservoir	B-Localization
of	O
p50/RelA	O
(	O
p65	O
)	O
complexes	O
that	O
are	O
readily	O
available	O
for	O
inducer	O
-	O
mediated	O
stimulation	O
.	O

Two	O
distinct	O
pathways	O
of	O
interleukin	O
-	O
5	O
synthesis	B-Gene_expression
in	O
allergen	O
-	O
specific	O
human	O
T	O
-	O
cell	O
clones	O
are	O
suppressed	B-Negative_regulation
by	O
glucocorticoids	O
.	O

Glucocorticoids	O
(	O
GC	O
)	O
have	O
long	O
been	O
used	O
as	O
the	O
most	O
effective	O
agents	O
for	O
the	O
treatment	O
of	O
allergic	O
diseases	O
accompanied	O
by	O
eosinophilia	O
such	O
as	O
chronic	O
asthma	O
and	O
atopic	O
dermatitis	O
.	O

The	O
development	O
of	O
chronic	O
eosinophilic	O
inflammation	O
is	O
dependent	O
on	O
interleukin	O
-	O
5	O
(	O
IL	O
-	O
5	O
)	O
,	O
a	O
selective	O
eosinophil	O
-	O
activating	O
factor	O
,	O
produced	B-Gene_expression
by	O
helper	O
T	O
cells	O
.	O

To	O
delineate	O
the	O
regulatory	B-Regulation
mechanisms	O
of	O
human	O
IL	O
-	O
5	O
synthesis	B-Gene_expression
,	O
we	O
established	O
allergen	O
-	O
specific	O
CD4+	O
T	O
-	O
cell	O
clones	O
from	O
asthmatic	O
patients	O
.	O

GC	O
efficiently	O
suppressed	B-Negative_regulation
IL	O
-	O
5	O
synthesis	B-Gene_expression
of	O
T	O
-	O
cell	O
clones	O
activated	O
via	O
either	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
or	O
IL	O
-	O
2	O
receptor	O
(	O
IL	O
-	O
2R	O
)	O
.	O

Induction	B-Positive_regulation
of	O
IL	O
-	O
5	O
mRNA	B-Transcription
upon	O
TCR	O
and	O
IL	O
-	O
2R	O
stimulation	O
was	O
totally	O
inhibited	B-Negative_regulation
by	O
dexamethasone	O
.	O

Human	O
IL	O
-	O
5	O
promoter/enhancer	O
-	O
luciferase	O
gene	O
construct	O
transfected	O
to	O
T	O
-	O
cell	O
clones	O
was	O
transcribed	B-Transcription
on	O
either	O
TCR	O
or	O
IL	O
-	O
2R	O
stimulation	B-Regulation
and	O
was	O
clearly	O
downregulated	B-Negative_regulation
by	O
dexamethasone	O
,	O
indicating	O
that	O
the	O
approximately	O
500	O
-	O
bp	O
human	O
IL	O
-	O
5	O
gene	O
segment	O
located	O
5	O
'	O
upstream	O
of	O
the	O
coding	O
region	O
contains	O
activation	O
-	O
inducible	O
enhancer	O
elements	O
responsible	O
for	O
the	O
regulation	O
by	O
GC	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
analysis	O
suggested	O
that	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
are	O
among	O
the	O
possible	O
targets	O
of	O
GC	O
actions	O
on	O
TCR	O
-	O
stimulated	O
T	O
cells	O
.	O

NF	O
-	O
AT	O
and	O
NF	O
-	O
kappaB	O
were	O
not	O
significantly	O
induced	O
by	O
IL	O
-	O
2	O
stimulation	O
.	O

Our	O
results	O
showing	O
that	O
GC	O
suppressed	B-Negative_regulation
IL	O
-	O
5	O
production	B-Gene_expression
by	O
human	O
CD4+	O
T	O
cells	O
activated	O
by	O
two	O
distinct	O
stimuli	O
,	O
TCR	O
and	O
IL	O
-	O
2R	O
stimulation	O
,	O
underscore	O
the	O
efficacy	B-Regulation
of	O
GC	O
in	O
the	O
treatment	O
of	O
allergic	O
diseases	O
via	O
suppression	B-Negative_regulation
of	O
T	O
-	O
cell	O
IL	O
-	O
5	O
synthesis	B-Gene_expression
.	O

Involvement	B-Regulation
of	O
an	O
SAF	O
-	O
like	O
transcription	O
factor	O
in	O
the	O
activation	B-Positive_regulation
of	O
serum	O
amyloid	O
A	O
gene	O
in	O
monocyte/macrophage	O
cells	O
by	O
lipopolysaccharide	O
.	O

Serum	O
amyloid	O
A	O
(	O
SAA	O
)	O
has	O
been	O
linked	B-Binding
to	O
atherosclerosis	O
because	O
of	O
its	O
ability	O
to	O
remodel	O
high	O
-	O
density	O
lipoprotein	O
by	O
the	O
depletion	O
of	O
apolipoprotein	O
A1	O
,	O
its	O
ability	O
to	O
bind	B-Binding
cholesterol	O
,	O
and	O
its	O
presence	O
in	O
the	O
atherosclerotic	O
plaques	O
of	O
coronary	O
and	O
carotid	O
arteries	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
induction	B-Positive_regulation
mechanism	O
of	O
SAA	O
gene	O
in	O
THP	O
-	O
1	O
monocyte/macrophage	O
cells	O
which	O
play	O
a	O
critical	O
role	O
in	O
the	O
development	O
of	O
atherosclerotic	O
fatty	O
streak	O
and	O
plaque	O
formation	O
.	O

We	O
and	O
others	O
have	O
shown	O
that	O
SAA	O
gene	O
is	O
induced	B-Positive_regulation
in	O
monocyte/macrophage	O
cells	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

By	O
promoter	O
function	O
analysis	O
,	O
we	O
show	O
that	O
the	O
SAA	O
promoter	O
sequence	O
between	O
-	O
280	O
and	O
-	O
226	O
can	O
confer	O
LPS	O
responsiveness	B-Regulation
.	O

Gel	O
electrophoretic	O
mobility	O
shift	O
assay	O
detected	O
an	O
induced	O
DNA	O
-	O
binding	O
activity	O
in	O
these	O
cells	O
in	O
response	O
to	O
LPS	O
.	O

Characterization	O
of	O
the	O
DNA	O
-	O
binding	O
protein	O
by	O
UV	O
cross	O
-	O
linking	O
,	O
Southwestern	O
blot	O
,	O
and	O
antibody	O
ablation/supershift	O
assays	O
revealed	O
that	O
it	O
is	O
similar	O
to	O
a	O
recently	O
reported	O
nuclear	O
factor	O
designated	O
SAF	O
.	O

These	O
results	O
demonstrated	O
that	O
LPS	O
-	O
mediated	O
SAA	O
gene	O
induction	B-Positive_regulation
in	O
monocyte/macrophage	O
cells	O
is	O
primarily	O
due	O
to	O
the	O
induction	O
of	O
SAF	O
activity	O
.	O

Oncogenic	O
forms	O
of	O
NOTCH1	O
lacking	O
either	O
the	O
primary	O
binding	O
site	O
for	O
RBP	O
-	O
Jkappa	O
or	O
nuclear	O
localization	O
sequences	O
retain	O
the	O
ability	O
to	O
associate	B-Binding
with	O
RBP	O
-	O
Jkappa	O
and	O
activate	O
transcription	O
.	O

Truncated	O
forms	O
of	O
the	O
NOTCH1	O
transmembrane	O
receptor	O
engineered	O
to	O
resemble	O
mutant	O
forms	O
of	O
NOTCH1	O
found	O
in	O
certain	O
cases	O
of	O
human	O
T	O
cell	O
leukemia/lymphoma	O
(	O
T	O
-	O
ALL	O
)	O
efficiently	O
induce	O
T	O
-	O
ALL	O
when	O
expressed	O
in	O
the	O
bone	O
marrow	O
of	O
mice	O
.	O

Unlike	O
full	O
-	O
sized	O
NOTCH1	O
,	O
two	O
such	O
truncated	O
forms	O
of	O
the	O
protein	O
either	O
lacking	O
a	O
major	O
portion	O
of	O
the	O
extracellular	O
domain	O
(	O
DeltaE	O
)	O
or	O
consisting	O
only	O
of	O
the	O
intracellular	O
domain	O
(	O
ICN	O
)	O
were	O
found	O
to	O
activate	O
transcription	O
in	O
cultured	O
cells	O
,	O
presumably	O
through	O
RBP	O
-	O
Jkappa	O
response	O
elements	O
within	O
DNA	O
.	O

Both	O
truncated	O
forms	O
also	O
bound	B-Binding
to	O
the	O
transcription	O
factor	O
RBP	O
-	O
Jkappa	O
in	O
extracts	O
prepared	O
from	O
human	O
and	O
murine	O
T	O
-	O
ALL	O
cell	O
lines	O
.	O

Transcriptional	O
activation	O
required	O
the	O
presence	O
of	O
a	O
weak	O
RBP-Jkappa	O
-	O
binding	O
site	O
within	O
the	O
NOTCH1	O
ankyrin	O
repeat	O
region	O
of	O
the	O
intracellular	O
domain	O
.	O

Unexpectedly	O
,	O
a	O
second	O
,	O
stronger	O
RBP-Jkappa	O
-	O
binding	O
site	O
,	O
which	O
lies	O
within	O
the	O
intracellular	O
domain	O
close	O
to	O
the	O
transmembrane	O
region	O
and	O
significantly	O
augments	B-Positive_regulation
association	B-Binding
with	O
RBP	O
-	O
Jkappa	O
,	O
was	O
not	O
needed	O
for	O
oncogenesis	O
or	O
for	O
transcriptional	O
activation	O
.	O

While	O
ICN	O
appeared	O
primarily	O
in	O
the	O
nucleus	O
,	O
DeltaE	O
localized	O
to	O
cytoplasmic	O
and	O
nuclear	O
membranes	O
,	O
suggesting	O
that	O
intranuclear	O
localization	O
is	O
not	O
essential	O
for	O
oncogenesis	O
or	O
transcriptional	O
activation	O
.	O

In	O
support	O
of	O
this	O
interpretation	O
,	O
mutation	O
of	O
putative	O
nuclear	O
localization	O
sequences	O
decreased	B-Negative_regulation
nuclear	O
localization	B-Localization
and	O
increased	O
transcriptional	O
activation	O
by	O
membrane	O
-	O
bound	O
DeltaE	O
.	O

Transcriptional	O
activation	O
by	O
this	O
mutant	O
form	O
of	O
membrane	O
-	O
bound	O
DeltaE	O
was	O
approximately	O
equivalent	O
to	O
that	O
produced	O
by	O
intranuclear	O
ICN	O
.	O

These	O
data	O
are	O
most	O
consistent	O
with	O
NOTCH1	O
oncogenesis	O
and	O
transcriptional	O
activation	O
being	O
independent	O
of	O
association	B-Binding
with	O
RBP	O
-	O
Jkappa	O
at	O
promoter	O
sites	O
.	O

Transcriptional	B-Positive_regulation
induction	I-Positive_regulation
of	O
collagenase	O
-	O
1	O
in	O
differentiated	O
monocyte	O
-	O
like	O
(	O
U937	O
)	O
cells	O
is	O
regulated	B-Regulation
by	O
AP	O
-	O
1	O
and	O
an	O
upstream	O
C/EBP	O
-	O
beta	O
site	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
AP	O
-	O
1	O
site	O
and	O
a	O
distal	O
promoter	O
element	O
regulate	B-Regulation
transcriptional	B-Positive_regulation
induction	I-Positive_regulation
of	O
collagenase	O
-	O
1	O
during	O
monocytic	O
differentiation	O
.	O

Chloramphenicol	O
acetyltransferase	O
expression	O
constructs	O
containing	O
regions	O
of	O
the	O
human	O
collagenase	O
-	O
1	O
promoter	O
were	O
stably	O
or	O
transiently	O
transfected	O
into	O
U937	O
cells	O
,	O
and	O
reporter	O
activity	O
was	O
assessed	O
at	O
various	O
times	O
after	O
the	O
onset	O
of	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
-	O
mediated	O
differentiation	O
.	O

Rapid	O
and	O
strong	O
induction	O
of	O
promoter	O
activity	O
was	O
lost	O
in	O
constructs	O
with	O
a	O
mutant	O
AP	O
-	O
1	O
element	O
;	O
however	O
,	O
at	O
16	O
-	O
96	O
h	O
post	O
-	O
PMA	O
,	O
the	O
mutant	O
collagenase	O
-	O
1	O
promoter	O
displayed	O
AP	O
-	O
1	O
independent	O
PMA	O
-	O
mediated	O
transactivation	B-Positive_regulation
.	O

The	O
AP	O
-	O
1	O
mutant	O
constructs	O
also	O
showed	O
delayed	O
transcriptional	O
activation	O
in	O
PMA	O
-	O
treated	O
fibroblasts	O
.	O

Western	O
and	O
supershift	O
analyses	O
indicated	O
that	O
functional	O
Jun	O
and	O
Fos	O
proteins	O
were	O
present	O
in	O
nuclear	O
extracts	O
of	O
PMA	O
-	O
differentiated	O
U937	O
cells	O
.	O

Promoter	O
deletion	O
constructs	O
demonstrated	O
the	O
potential	B-Positive_regulation
role	I-Positive_regulation
of	O
distal	O
promoter	O
sequences	O
in	O
regulating	B-Regulation
collagenase	O
-	O
1	O
transcription	B-Transcription
.	O

In	O
particular	O
,	O
Western	O
,	O
supershift	O
,	O
and	O
promoter	O
deletion	O
analyses	O
suggested	O
a	O
role	B-Positive_regulation
for	O
CCAAT/enhancer	O
-	O
binding	O
protein	O
-	O
beta	O
(	O
C/EBP	O
-	O
beta	O
)	O
binding	O
site	O
between	O
-	O
2010	O
and	O
-	O
1954	O
in	O
regulating	B-Regulation
transcription	B-Transcription
of	O
collagenase	O
-	O
1	O
in	O
monocytic	O
cells	O
.	O

Our	O
findings	O
suggest	O
that	O
distinct	O
regulatory	O
elements	O
,	O
acting	O
somewhat	O
independently	O
of	O
each	O
other	O
,	O
control	B-Regulation
expression	B-Gene_expression
of	O
collagenase	O
-	O
1	O
.	O

In	O
addition	O
,	O
our	O
data	O
suggests	O
that	O
the	O
rapid	O
PMA	O
-	O
mediated	O
induction	B-Positive_regulation
of	O
collagenase	O
-	O
1	O
transcription	B-Transcription
is	O
controlled	B-Regulation
by	O
a	O
mechanism	O
distinct	B-Regulation
from	I-Regulation
that	I-Regulation
regulating	I-Regulation
the	O
sustained	O
expression	B-Gene_expression
of	O
this	O
proteinase	O
in	O
activated	O
macrophages	O
.	O

A	O
novel	O
genetic	O
system	O
to	O
isolate	O
a	O
dominant	O
negative	O
effector	O
on	O
DNA	O
-	O
binding	B-Binding
activity	O
of	O
Oct	O
-	O
2	O
.	O

Recent	O
studies	O
have	O
revealed	O
that	O
interactions	O
between	O
transcription	O
factors	O
play	O
an	O
important	O
role	O
in	O
regulation	O
of	O
gene	O
expression	O
in	O
eukaryotic	O
cells	O
.	O

To	O
isolate	O
cDNA	O
clones	O
that	O
dominantly	O
inhibit	B-Negative_regulation
the	O
DNA	O
-	O
binding	B-Binding
activity	O
of	O
Oct	O
-	O
2	O
,	O
chosen	O
as	O
a	O
representative	O
factor	O
,	O
we	O
have	O
developed	O
a	O
novel	O
screening	O
system	O
.	O

This	O
employs	O
an	O
Escherichia	O
coli	O
tester	O
strain	O
carrying	O
a	O
modified	O
lac	O
operon	O
as	O
a	O
reporter	O
gene	O
,	O
with	O
the	O
lac	O
operator	O
sequence	O
replaced	O
by	O
an	O
octamer	O
sequence	O
.	O

Oct	O
-	O
2	O
expressed	B-Gene_expression
in	O
this	O
tester	O
strain	O
represses	O
the	O
expression	O
of	O
the	O
reporter	O
gene	O
and	O
changes	O
the	O
phenotype	O
of	O
the	O
cell	O
from	O
Lac+to	O
Lac	O
-	O
.	O

Introduction	O
of	O
a	O
cDNA	O
expression	O
library	O
prepared	O
from	O
a	O
human	O
T	O
-	O
cell	O
line	O
into	O
the	O
Oct-2	O
-	O
harboring	O
tester	O
strain	O
allowed	O
selection	O
of	O
three	O
Lac+clones	O
out	O
of	O
1	O
x	O
10	O
(	O
5	O
)	O
transformants	O
.	O

One	O
of	O
them	O
,	O
hT86	O
,	O
encoding	O
a	O
putative	O
zinc	O
finger	O
protein	O
was	O
found	O
to	O
derepress	B-Positive_regulation
beta	O
-	O
galactosidase	O
activity	O
in	O
the	O
Oct-2	O
-	O
harboring	O
tester	O
strain	O
at	O
the	O
transcriptional	O
level	O
.	O

In	O
gel	O
mobility	O
shift	O
assays	O
,	O
hT86	O
attenuated	O
the	O
intensity	O
of	O
the	O
retarded	O
band	O
composed	O
of	O
the	O
octamer	O
probe	O
and	O
Oct	O
-	O
2	O
,	O
suggesting	O
a	O
dominant	O
negative	B-Negative_regulation
effect	I-Negative_regulation
on	O
the	O
DNA	O
-	O
binding	B-Binding
activity	O
of	O
Oct	O
-	O
2	O
.	O

The	O
strategy	O
described	O
here	O
provides	O
a	O
new	O
approach	O
for	O
studying	O
protein	O
-	O
protein	O
interactions	O
that	O
govern	O
the	O
complex	O
regulation	O
of	O
gene	O
expression	O
.	O

A	O
negative	O
role	O
for	O
phosphoinositide	O
3	O
-	O
kinase	O
in	O
T	O
-	O
cell	O
antigen	O
receptor	O
function	O
.	O

BACKGROUND	O
:	O
A	O
delicate	O
balance	O
between	O
positive	O
and	O
negative	O
regulatory	O
mechanisms	O
during	O
T	O
-	O
cell	O
activation	O
determines	O
the	O
specificity	O
and	O
magnitude	O
of	O
an	O
immune	O
response	O
.	O

Phosphoinositide	O
3	O
-	O
kinase	O
(	O
PI	O
3	O
-	O
kinase	O
)	O
is	O
activated	B-Positive_regulation
by	O
a	O
diverse	O
set	O
of	O
receptors	O
that	O
determine	O
T	O
-	O
cell	O
function	O
,	O
including	O
the	O
T	O
-	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
,	O
the	O
costimulatory	O
receptor	O
CD28	O
,	O
and	O
negative	B-Negative_regulation
regulators	I-Negative_regulation
of	O
T	O
-	O
cell	O
activation	O
such	O
as	O
CTLA	O
-	O
4	O
.	O

PI	O
3	O
-	O
kinase	O
is	O
also	O
regulated	B-Regulation
by	O
the	O
haematopoietic	O
cytokines	O
that	O
determine	O
T	O
-	O
cell	O
differentiation	O
and	O
lymphocyte	O
proliferation	O
.	O

PI	O
3	O
-	O
kinase	O
can	O
thus	O
dynamically	O
influence	O
the	O
outcome	O
of	O
the	O
immune	O
reactions	O
at	O
various	O
stages	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
importance	O
of	O
PI	O
3	O
-	O
kinase	O
in	O
TCR	O
-	O
directed	O
T	O
-	O
cell	O
activation	O
using	O
activated	O
or	O
inhibitory	O
versions	O
of	O
PI	O
3	O
-	O
kinase	O
.	O

RESULTS	O
:	O
Certain	O
aspects	O
of	O
TCR	O
responses	O
such	O
as	O
the	O
induction	O
of	O
transcriptional	O
activity	O
of	O
AP1	O
and	O
serum	O
response	O
factor	O
were	O
not	O
affected	O
by	O
expression	B-Gene_expression
of	O
the	O
mutant	O
forms	O
of	O
PI	O
3	O
-	O
kinase	O
.	O

We	O
found	O
,	O
however	O
,	O
that	O
PI	O
3	O
-	O
kinase	O
profoundly	O
influenced	O
the	O
transactivation	O
capacity	O
of	O
'nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
'	O
(	O
NF	O
-	O
AT	O
)	O
elicited	O
by	O
the	O
TCR	O
:	O
expression	B-Gene_expression
of	O
an	O
activated	O
form	O
of	O
PI	O
3	O
-	O
kinase	O
inhibited	O
TCR	O
-	O
mediated	O
NF	O
-	O
AT	O
responses	O
,	O
whereas	O
expression	O
of	O
a	O
dominant	O
negative	O
mutant	O
of	O
PI	O
3	O
-	O
kinase	O
potently	O
enhanced	O
TCR	O
-	O
controlled	O
NF	O
-	O
AT	O
induction	O
.	O

These	O
effects	O
of	O
PI	O
3	O
-	O
kinase	O
were	O
not	O
mediated	O
by	O
previously	O
identified	O
PI	O
3	O
-	O
kinase	O
effectors	O
,	O
such	O
as	O
protein	O
kinase	O
B	O
,	O
a	O
positive	B-Positive_regulation
regulator	I-Positive_regulation
of	O
PI	O
3	O
-	O
kinase	O
,	O
or	O
the	O
GTPase	O
Rac	O
,	O
and	O
are	O
therefore	O
likely	O
to	O
involve	O
a	O
novel	O
,	O
as	O
yet	O
unknown	O
,	O
effector	O
molecule	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
establish	O
that	O
PI	O
3	O
-	O
kinase	O
can	O
both	O
positively	O
and	O
negatively	O
regulate	O
T	O
-	O
cell	O
function	O
,	O
and	O
uncover	O
a	O
previously	O
unrecognized	O
function	O
for	O
PI	O
3	O
-	O
kinase	O
in	O
T	O
cells	O
as	O
a	O
selective	O
negative	O
regulator	O
of	O
TCR	O
-	O
signalling	O
events	O
and	O
therefore	O
as	O
a	O
determinant	O
of	O
T	O
-	O
cell	O
homeostasis	O
.	O

NF	O
-	O
kappa	O
B	O
-	O
independent	O
suppression	O
of	O
HIV	O
expression	O
by	O
ascorbic	O
acid	O
.	O

Ascorbic	O
acid	O
(	O
ascorbate	O
or	O
vitamin	O
C	O
)	O
has	O
been	O
shown	O
to	O
suppress	O
the	O
induction	O
of	O
HIV	O
in	O
latently	O
infected	O
T	O
lymphocytic	O
cells	O
following	O
stimulation	O
with	O
a	O
tumor	O
promoter	O
(	O
PMA	O
)	O
and	O
inflammatory	O
cytokine	O
(	O
TNF	O
-	O
alpha	O
)	O
.	O

To	O
assess	O
whether	O
this	O
inhibition	O
was	O
mediated	O
via	O
modulation	O
of	O
the	O
cellular	O
transcription	O
factor	O
,	O
NF	O
-	O
kappa	O
B	O
,	O
we	O
carried	O
out	O
gel	O
shift	O
analysis	O
on	O
nuclear	O
extracts	O
prepared	O
under	O
different	O
conditions	O
of	O
cell	O
stimulation	O
in	O
the	O
presence	O
or	O
absence	O
of	O
ascorbate	O
,	O
N	O
-	O
acetylcysteine	O
(	O
NAC	O
)	O
,	O
or	O
zidovudine	O
(	O
AZT	O
)	O
.	O

Pretreatment	O
of	O
ACH	O
-	O
2	O
T	O
cells	O
by	O
NAC	O
followed	O
by	O
stimulation	O
with	O
PMA	O
,	O
TNF	O
-	O
alpha	O
,	O
or	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
resulted	O
in	O
strong	O
suppression	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

In	O
contrast	O
,	O
neither	O
ascorbate	O
nor	O
AZT	O
affected	O
NF	O
-	O
kappa	O
B	O
activity	O
under	O
all	O
three	O
induction	O
conditions	O
in	O
the	O
ACH	O
-	O
2	O
cell	O
line	O
.	O

Ascorbate	O
and	O
AZT	O
also	O
had	O
no	O
effect	O
on	O
NF	O
-	O
kappa	O
B	O
activation	O
following	O
TNF-alpha	O
-	O
or	O
PMA	O
-	O
induced	O
stimulation	O
of	O
U1	O
promonocytic	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
molecular	O
mechanism	O
of	O
HIV	O
inhibition	O
by	O
ascorbate	O
is	O
not	O
mediated	O
via	O
NF	O
-	O
kappa	O
B	O
inhibition	O
,	O
unlike	O
that	O
seen	O
with	O
other	O
antioxidants	O
.	O

Lineage	O
-	O
and	O
stage	O
-	O
specific	O
expression	O
of	O
runt	O
box	O
polypeptides	O
in	O
primitive	O
and	O
definitive	O
hematopoiesis	O
.	O

Translocations	O
involving	O
the	O
human	O
CBFA2	O
locus	O
have	O
been	O
associated	O
with	O
leukemia	O
.	O

This	O
gene	O
,	O
originally	O
named	O
AML1	O
,	O
is	O
a	O
human	O
homologue	O
of	O
the	O
Drosophila	O
gene	O
runt	O
that	O
controls	O
early	O
events	O
in	O
fly	O
embryogenesis	O
.	O

To	O
clarify	O
the	O
role	O
of	O
mammalian	O
runt	O
products	O
in	O
normal	O
and	O
leukemic	O
hematopoiesis	O
,	O
we	O
have	O
studied	O
their	O
pattern	O
of	O
expression	O
in	O
mouse	O
hematopoietic	O
tissues	O
in	O
the	O
adult	O
and	O
during	O
ontogeny	O
using	O
an	O
anti	O
-	O
runt	O
box	O
antiserum	O
.	O

In	O
the	O
adult	O
bone	O
marrow	O
,	O
we	O
found	O
expression	O
of	O
runt	O
polypeptides	O
in	O
differentiating	O
myeloid	O
cells	O
and	O
in	O
B	O
lymphocytes	O
.	O

Within	O
the	O
erythroid	O
lineage	O
,	O
runt	O
expression	B-Gene_expression
is	O
biphasic	O
,	O
clearly	O
present	O
in	O
the	O
erythroblasts	O
of	O
early	O
blood	O
islands	O
and	O
of	O
the	O
fetal	O
liver	O
,	O
but	O
absent	B-Gene_expression
in	O
the	O
adult	O
.	O

Biochemical	O
analysis	O
by	O
Western	O
blotting	O
of	O
fetal	O
and	O
adult	O
hematopoietic	O
populations	O
shows	O
several	O
runt	O
isoforms	O
.	O

At	O
least	O
one	O
of	O
them	O
appears	O
to	O
be	O
myeloid	O
specific	O
.	O

Cell-to	O
-	O
cell	O
contact	O
activates	O
the	O
long	O
terminal	O
repeat	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
through	O
its	O
kappaB	O
motif	O
.	O

Cell-to	O
-	O
cell	O
contact	O
between	O
peripheral	O
blood	O
lymphocytes	O
and	O
transfected	O
human	O
colonic	O
carcinoma	O
cell	O
line	O
HT29	O
activates	O
transcription	O
of	O
the	O
long	O
terminal	O
repeats	O
(	O
LTR	O
)	O
of	O
human	O
immunodeficiency	O
virus	O
.	O

HIV	O
-	O
1	O
LTR	O
transcription	O
is	O
controlled	O
by	O
a	O
complex	O
array	O
of	O
virus	O
-	O
encoded	O
and	O
cellular	O
proteins	O
.	O

Using	O
various	O
constructs	O
expressing	O
a	O
lacZ	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
intact	O
or	O
three	O
deleted	O
forms	O
of	O
HIV	O
-	O
1	O
LTR	O
,	O
we	O
obtained	O
evidence	O
that	O
the	O
kappaB	O
regulatory	O
elements	O
located	O
in	O
the	O
U3	O
region	O
are	O
involved	O
in	O
cell-to	O
-	O
cell	O
activation	O
of	O
HIV	O
-	O
1	O
LTR	O
.	O

Cell-to	O
-	O
cell	O
contact	O
activates	B-Positive_regulation
in	O
vitro	O
binding	B-Binding
of	O
the	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
p50/p65	O
heterodimer	O
to	O
an	O
HIV	O
-	O
1	O
kappaB	O
oligonucleotide	O
.	O

Cell-to	O
-	O
cell	O
contact	O
activation	O
of	O
NF	O
-	O
kappaB	O
was	O
only	O
partially	O
inhibited	O
by	O
100	O
microM	O
pyrrolidine	O
dithiocarbamate	O
and	O
was	O
not	O
correlated	O
with	O
a	O
significant	O
decrease	B-Negative_regulation
of	O
cellular	O
inhibitor	O
kappaB	O
alpha	O
.	O

NF	O
-	O
kappaB	O
nuclear	O
activation	O
was	O
not	O
detectable	O
before	O
1	O
h	O
after	O
cell	O
contact	O
and	O
was	O
dependent	O
on	O
protein	O
synthesis	O
.	O

HIV	O
does	O
not	O
replicate	O
in	O
naive	O
CD4	O
T	O
cells	O
stimulated	O
with	O
CD3/CD28	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
T	O
cell	O
tropic	O
strain	O
of	O
HIV	O
,	O
LAI	O
,	O
does	O
not	O
replicate	O
in	O
naive	O
CD4	O
T	O
cells	O
stimulated	O
by	O
cross	B-Binding
-	I-Binding
linking	I-Binding
CD3	O
and	O
CD28	O
.	O

In	O
contrast	O
,	O
LAI	O
replicates	O
well	O
in	O
memory	O
CD4	O
T	O
cells	O
stimulated	O
in	O
the	O
same	O
way	O
.	O

Unlike	O
this	O
physiologically	O
relevant	O
stimulation	O
,	O
PHA	O
stimulates	O
productive	O
LAI	O
replication	O
in	O
both	O
naive	O
and	O
memory	O
T	O
cells	O
.	O

These	O
studies	O
were	O
conducted	O
with	O
highly	O
purified	O
(	O
FACS	O
-	O
isolated	O
)	O
subsets	O
of	O
CD4	O
T	O
cells	O
identified	O
by	O
expression	O
of	O
both	O
CD45RA	O
and	O
CD62L	O
.	O

Remixing	O
of	O
purified	O
T	O
cells	O
showed	O
that	O
naive	O
T	O
cells	O
do	O
not	O
suppress	O
LAI	O
replication	O
in	O
memory	O
T	O
cells	O
and	O
that	O
memory	O
T	O
cells	O
do	O
not	O
restore	O
LAI	O
expression	O
in	O
naive	O
T	O
cells	O
.	O

The	O
suppression	O
of	O
productive	O
LAI	O
replication	O
in	O
naive	O
T	O
cells	O
is	O
not	O
due	O
to	O
differential	O
expression	O
of	O
viral	O
coreceptors	O
,	O
nor	O
is	O
it	O
due	O
to	O
inhibition	O
of	O
activation	O
of	O
the	O
important	O
HIV	O
transcription	O
factors	O
,	O
nuclear	O
factor	O
-	O
kappaB	O
and	O
activator	O
protein	O
-	O
1	O
.	O

The	O
inherent	O
resistance	O
of	O
naive	O
T	O
cells	O
to	O
productive	O
HIV	O
infection	O
,	O
coupled	O
with	O
their	O
proliferative	O
advantage	O
as	O
demonstrated	O
here	O
,	O
provides	O
a	O
sound	O
basis	O
for	O
proposed	O
clinical	O
therapies	O
using	O
ex	O
vivo	O
expansion	O
and	O
reinfusion	O
of	O
CD4	O
T	O
cells	O
from	O
HIV	O
-	O
infected	O
adults	O
.	O

Control	B-Regulation
of	O
NFATx1	O
nuclear	O
translocation	B-Localization
by	O
a	O
calcineurin	O
-	O
regulated	O
inhibitory	O
domain	O
.	O

The	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
regulates	O
cytokine	O
gene	O
expression	O
in	O
T	O
cells	O
through	O
cis	O
-	O
acting	O
elements	O
located	O
in	O
the	O
promoters	O
of	O
several	O
cytokine	O
genes	O
.	O

NFATx1	O
,	O
which	O
is	O
preferentially	O
expressed	B-Gene_expression
in	O
the	O
thymus	O
and	O
peripheral	O
blood	O
leukocytes	O
,	O
is	O
one	O
of	O
four	O
members	O
of	O
the	O
NFAT	O
family	O
of	O
transcription	O
factors	O
.	O

We	O
have	O
performed	O
domain	O
analysis	O
of	O
NFATx1	O
by	O
examining	O
the	O
effects	O
of	O
deletion	O
mutations	O
.	O

We	O
found	O
that	O
NFATx1	O
DNA	O
binding	B-Binding
activity	O
and	O
interaction	O
with	O
AP	O
-	O
1	O
polypeptides	O
were	O
dependent	B-Positive_regulation
on	O
its	O
central	O
Rel	O
similarity	O
region	O
and	O
that	O
transcriptional	B-Positive_regulation
activation	I-Positive_regulation
was	O
reduced	B-Negative_regulation
by	O
deletions	O
of	O
either	O
its	O
N	O
-	O
terminal	O
domain	O
or	O
its	O
C	O
-	O
terminal	O
domain	O
,	O
suggesting	O
the	O
presence	O
of	O
intrinsic	O
transcriptional	O
activation	O
motifs	O
in	O
both	O
regions	O
.	O

We	O
also	O
identified	O
a	O
potent	O
inhibitory	O
sequence	O
within	O
its	O
N	O
-	O
terminal	O
domain	O
.	O

We	O
show	O
that	O
the	O
inactivation	O
of	O
the	O
inhibition	O
was	O
dependent	O
on	O
the	O
activity	O
of	O
calcineurin	O
,	O
a	O
calcium-calmodulin	O
-	O
dependent	O
phosphatase	O
.	O

We	O
also	O
show	O
that	O
calcineurin	O
associated	B-Binding
with	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
NFATx1	O
at	O
multiple	O
docking	O
sites	O
and	O
caused	O
a	O
reduction	O
of	O
size	O
,	O
indicative	O
of	O
dephosphorylation	O
,	O
in	O
NFATx1	O
.	O

We	O
have	O
mapped	O
the	O
inhibitory	O
activity	O
to	O
less	O
than	O
60	O
residues	O
,	O
containing	O
motifs	O
that	O
are	O
conserved	O
in	O
all	O
NFAT	O
proteins	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
deletion	O
in	O
NFATx1	O
of	O
the	O
mapped	O
60	O
residues	O
leads	B-Positive_regulation
to	O
its	O
nuclear	O
translocation	B-Localization
independent	B-Positive_regulation
of	O
calcium	O
signaling	O
.	O

Our	O
results	O
support	O
the	O
model	O
proposing	O
that	O
the	O
N	O
-	O
terminal	O
domain	O
confers	O
calcium	O
-	O
signaling	O
dependence	O
on	O
NFATx1	O
transactivation	O
activity	O
by	O
regulating	B-Regulation
its	O
intracellular	O
localization	B-Localization
through	B-Regulation
a	O
protein	O
module	O
that	O
associates	O
with	O
calcineurin	O
and	O
is	O
a	O
target	O
of	O
its	O
phosphatase	O
activity	O
.	O

Neuronal	O
(	O
type	O
I	O
)	O
nitric	O
oxide	O
synthase	O
regulates	B-Regulation
nuclear	O
factor	O
kappaB	O
activity	O
and	O
immunologic	O
(	O
type	O
II	O
)	O
nitric	O
oxide	O
synthase	O
expression	B-Gene_expression
.	O

Nitric	O
oxide	O
subserves	O
diverse	O
physiologic	O
roles	O
in	O
the	O
nervous	O
system	O
.	O

NO	O
is	O
produced	O
from	O
at	O
least	O
three	O
different	O
NO	O
synthase	O
(	O
NOS	O
)	O
isoforms	O
:	O
neuronal	O
NOS	O
(	O
nNOS	O
)	O
,	O
endothelial	O
NOS	O
,	O
and	O
immunologic	O
NOS	O
(	O
iNOS	O
)	O
.	O

We	O
show	O
that	O
nNOS	O
is	O
the	O
predominant	O
isoform	O
constitutively	O
expressed	B-Gene_expression
in	O
glia	O
.	O

NO	O
derived	O
from	O
nNOS	O
in	O
glia	O
inhibits	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
kappaB	O
)	O
as	O
NOS	O
inhibitors	O
enhance	O
basal	O
NF	O
kappaB	O
activation	O
.	O

Pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
is	O
an	O
inhibitor	O
of	O
NF	O
kappaB	O
in	O
most	O
cells	O
;	O
however	O
,	O
we	O
show	O
that	O
PDTC	O
is	O
also	O
a	O
potent	O
scavenger	O
of	O
NO	O
through	O
formation	O
of	O
mononitrosyl	O
iron	O
complexes	O
with	O
PDTC	O
.	O

In	O
Jurkat	O
cells	O
,	O
a	O
human	O
T	O
-	O
cell	O
lymphoma	O
cell	O
line	O
,	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
induces	O
NF	O
kappaB	O
activation	O
that	O
is	O
inhibited	O
by	O
PDTC	O
.	O

Contrary	O
to	O
the	O
results	O
in	O
Jurkat	O
cells	O
,	O
PDTC	O
did	O
not	O
inhibit	O
tumor	O
necrosis	O
factor-alpha	O
-	O
induced	O
NF	O
kappaB	O
activation	O
in	O
astrocytes	O
;	O
instead	O
PDTC	O
itself	O
induces	O
NF	O
kappaB	O
activation	O
in	O
astrocytes	O
,	O
and	O
this	O
may	O
be	O
related	O
to	O
scavenging	O
of	O
endogenously	O
produced	O
NO	O
by	O
the	O
PDTC	O
iron	O
complex	O
.	O

In	O
astrocytes	O
PDTC	O
also	O
dramatically	O
induces	B-Positive_regulation
the	O
NF	O
kappaB	O
-	O
dependent	B-Positive_regulation
enzyme	O
,	O
iNOS	O
,	O
supporting	O
the	O
physiologic	O
relevance	O
of	O
endogenous	O
NO	O
regulation	O
of	O
NF	O
kappaB	O
.	O

NF	O
kappaB	O
activation	O
in	O
glia	O
from	O
mice	O
lacking	B-Negative_regulation
nNOS	O
responds	O
more	O
rapidly	O
to	O
PDTC	O
compared	O
with	O
astrocytes	O
from	O
wild	O
-	O
type	O
mice	O
.	O

Our	O
data	O
suggest	O
that	O
nNOS	O
in	O
astrocytes	O
regulates	B-Regulation
NF	O
kappaB	O
activity	O
and	O
iNOS	O
expression	B-Gene_expression
,	O
and	O
indicate	O
a	O
novel	O
regulatory	O
role	O
for	O
nNOS	O
in	O
tonically	O
suppressing	O
central	O
nervous	O
system	O
,	O
NF	O
kappaB	O
-	O
regulated	O
genes	O
.	O

Regulation	O
of	O
human	O
epsilon	O
germline	O
transcription	O
:	O
role	O
of	O
B-cell	O
-	O
specific	O
activator	O
protein	O
.	O

Germline	O
transcripts	O
initiate	O
from	O
promoters	O
upstream	O
of	O
the	O
immunoglobulin	O
switch	O
region	O
,	O
and	O
are	O
necessary	O
to	O
target	O
the	O
appropriate	O
switch	O
region	O
for	O
recombination	O
and	O
switching	O
.	O

Different	O
cytokines	O
activate	O
transcription	O
at	O
the	O
appropriate	O
germline	O
promoter	O
.	O

Because	O
binding	O
sites	O
for	O
B-cell	O
-	O
specific	O
activator	O
protein	O
(	O
BSAP	O
)	O
are	O
located	O
upstream	O
of	O
several	O
switch	O
regions	O
in	O
the	O
immunoglobulin	O
heavy	O
chain	O
gene	O
cluster	O
,	O
BSAP	O
might	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
germline	O
transcription	O
and	O
isotype	O
switching	O
.	O

We	O
investigated	O
whether	O
BSAP	O
plays	O
a	O
role	O
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
epsilon	O
germline	O
promoter	O
in	O
human	O
B	O
cells	O
.	O

Our	O
results	O
showed	O
that	O
BSAP	O
plays	O
a	O
role	O
in	O
both	O
IL-4	O
-	O
dependent	O
induction	O
and	O
CD40	O
-	O
mediated	O
upregulation	O
of	O
human	O
epsilon	O
germline	O
transcription	O
.	O

BSAP	O
is	O
unique	O
among	O
the	O
transcription	O
factors	O
that	O
regulate	O
epsilon	O
germline	O
expression	O
,	O
because	O
it	O
is	O
B	O
cell	O
specific	O
,	O
and	O
is	O
at	O
the	O
merging	O
point	O
of	O
two	O
signalling	O
pathways	O
that	O
are	O
critical	O
for	O
IgE	O
switching	O
.	O

Retinoic	O
acid	O
-	O
induced	O
modulation	B-Regulation
of	O
IL	O
-	O
2	O
mRNA	O
production	B-Transcription
and	O
IL	O
-	O
2	O
receptor	O
expression	O
on	O
T	O
cells	O
.	O

BACKGROUND	O
:	O
Retinoic	O
acid	O
(	O
RA	O
)	O
has	O
important	O
immune	O
-	O
modulating	O
effects	O
on	O
both	O
T	O
and	O
B	O
cell	O
function	O
.	O

Our	O
laboratory	O
has	O
shown	O
that	O
RA	O
can	O
enhance	O
in	O
vitro	O
polyclonal	O
B	O
cell	O
immunoglobulin	O
(	O
Ig	O
)	O
response	O
.	O

Investigating	O
cytokines	O
known	O
to	O
affect	O
B	O
cell	O
differentiation	O
,	O
we	O
have	O
recently	O
shown	O
that	O
IL	O
-	O
6	O
production	B-Gene_expression
is	O
augmented	B-Positive_regulation
by	O
RA	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
examined	O
the	O
immune	B-Regulation
modulating	I-Regulation
effects	I-Regulation
of	O
RA	O
on	O
IL	O
-	O
2	O
mRNA	B-Transcription
,	O
another	O
important	O
cytokine	O
for	O
B	O
cell	O
immunoglobulin	O
production	O
,	O
the	O
expression	O
of	O
IL	O
-	O
2	O
receptors	O
on	O
T	O
cells	O
,	O
and	O
the	O
RA	O
nuclear	O
receptors	O
.	O

METHODS	O
:	O
Purified	O
T	O
cells	O
were	O
obtained	O
from	O
adenoidal	O
tissues	O
,	O
and	O
incubated	O
with	O
RA	O
(	O
10	O
(	O
-	O
7	O
)	O
M	O
)	O
or	O
DMSO	O
solvent/media	O
control	O
for	O
0	O
,	O
6	O
-	O
8	O
,	O
and	O
24	O
h	O
.	O

Total	O
mRNA	O
was	O
extracted	O
from	O
T	O
cells	O
,	O
and	O
using	O
RT	O
-	O
PCR	O
,	O
changes	B-Regulation
in	O
the	O
production	B-Transcription
of	O
IL	O
-	O
2	O
and	O
RA	O
receptors	O
(	O
RAR	O
)	O
-	O
alpha	O
,	O
beta	O
,	O
gamma	O
mRNA	O
were	O
determined	O
.	O

The	O
effects	B-Regulation
of	O
RA	O
on	O
IL-2	O
-	O
alpha	O
receptor	O
expression	B-Gene_expression
was	O
determined	O
by	O
flow	O
cytometry	O
on	O
T	O
cells	O
.	O

CONCLUSION	O
:	O
These	O
studies	O
suggest	O
that	O
RA	O
can	O
augment	B-Positive_regulation
IL	O
-	O
2	O
mRNA	O
production	B-Transcription
by	O
T	O
cells	O
with	O
a	O
possible	O
paracrine	O
effect	B-Regulation
on	O
IL-2R	O
-	O
alpha	O
expression	B-Gene_expression
.	O

These	O
changes	O
appear	O
to	O
be	O
mediated	B-Positive_regulation
by	O
RAR	O
-	O
alpha	O
.	O

Thus	O
,	O
IL	O
-	O
2	O
may	O
be	O
another	O
important	O
cytokine	O
modulated	B-Regulation
by	O
RA	O
in	O
the	O
immune	O
response	O
.	O

Itk	O
,	O
a	O
T	O
cell	O
-	O
specific	O
tyrosine	O
kinase	O
,	O
is	O
required	B-Positive_regulation
for	O
CD2	O
-	O
mediated	O
interleukin	O
-	O
2	O
promoter	O
activation	B-Positive_regulation
in	O
the	O
human	O
T	O
cell	O
line	O
Jurkat	O
.	O

We	O
investigated	O
the	O
functional	O
role	O
of	O
Itk	O
,	O
a	O
member	O
of	O
the	O
cytoplasmic	O
tyrosine	O
kinase	O
Tec	O
family	O
,	O
in	O
T	O
cell	O
activation	O
.	O

Stimulation	B-Positive_regulation
of	O
either	O
CD2	O
or	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
/CD3	O
on	O
Tcells	O
by	O
monoclonal	O
antibody	O
-	O
mediated	O
cross	B-Binding
-	I-Binding
linking	I-Binding
induced	B-Positive_regulation
tyrosine	O
phosphorylation	B-Phosphorylation
of	O
Itk	O
,	O
which	O
was	O
maximal	B-Positive_regulation
as	O
early	O
as	O
1	O
min	O
after	O
stimulation	O
.	O

The	O
tyrosine	O
kinase	O
activity	O
in	O
the	O
anti	O
-	O
Itk	O
immunoprecipitate	O
was	O
significantly	O
activated	O
upon	O
these	O
stimulations	O
.	O

Interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
promoter	O
activity	O
stimulated	B-Positive_regulation
by	O
cross	B-Binding
-	I-Binding
linking	I-Binding
of	O
CD2	O
,	O
TCR/CD3	O
,	O
and	O
CD28	O
with	O
antibodies	O
was	O
significantly	O
reduced	B-Negative_regulation
by	O
transient	O
expression	B-Gene_expression
of	O
an	O
Itk	O
mutant	O
lacking	O
the	O
kinase	O
activity	O
.	O

The	O
reduction	O
paralleled	O
a	O
decrease	B-Negative_regulation
in	O
tyrosine	O
phosphorylation	B-Phosphorylation
of	O
endogenous	O
wild	O
-	O
type	O
Itk	O
.	O

Stimulation	B-Positive_regulation
of	O
CD2	O
or	O
TCR/CD3	O
induced	O
activation	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
,	O
the	O
binding	O
site	O
of	O
which	O
is	O
included	B-Positive_regulation
in	O
the	O
IL	O
-	O
2	O
gene	O
promoter	O
.	O

The	O
activation	O
of	O
NFAT	O
was	O
also	O
impaired	O
by	O
expression	B-Gene_expression
of	O
the	O
Itk	O
mutant	O
.	O

These	O
results	O
demonstrate	O
that	O
Itk	O
plays	B-Regulation
a	I-Regulation
role	I-Regulation
in	O
IL	O
-	O
2	O
production	B-Gene_expression
,	O
indicating	O
a	O
critical	O
involvement	O
of	O
Itk	O
in	O
the	O
initial	O
stage	O
of	O
T	O
cell	O
activation	O
by	O
mediating	O
signals	O
from	O
the	O
TCR/CD3	O
complex	O
,	O
CD2	O
,	O
and	O
CD28	O
.	O

Jak3	O
is	O
associated	B-Binding
with	O
CD40	O
and	O
is	O
critical	O
for	O
CD40	O
induction	O
of	O
gene	O
expression	O
in	O
B	O
cells	O
.	O

CD40	O
is	O
a	O
receptor	O
that	O
is	O
critical	O
for	O
the	O
survival	O
,	O
growth	O
,	O
differentiation	O
,	O
and	O
isotype	O
switching	O
of	O
B	O
lymphocytes	O
.	O

Although	O
CD40	O
lacks	O
intrinsic	O
tyrosine	O
kinase	O
activity	O
,	O
its	O
ligation	B-Binding
induces	O
protein	O
tyrosine	O
phosphorylation	O
,	O
which	O
is	O
necessary	O
for	O
several	O
CD40	O
-	O
mediated	O
events	O
.	O

We	O
show	O
that	O
engagement	O
of	O
CD40	O
induces	B-Positive_regulation
tyrosine	O
phosphorylation	B-Phosphorylation
and	O
activation	B-Positive_regulation
of	O
Jak3	O
as	O
well	O
as	O
of	O
STAT3	O
.	O

Jak3	O
is	O
constitutively	O
associated	B-Binding
with	O
CD40	O
,	O
and	O
this	O
interaction	O
requires	B-Positive_regulation
a	O
proline	O
-	O
rich	O
sequence	O
in	O
the	O
membrane	O
-	O
proximal	O
region	O
of	O
CD40	O
.	O

Deletion	O
of	O
this	O
sequence	O
abolishes	B-Negative_regulation
the	O
capacity	O
of	O
CD40	O
to	O
induce	B-Positive_regulation
expression	B-Gene_expression
of	O
CD23	O
,	O
ICAM	O
-	O
1	O
,	O
and	O
lymphotoxin	O
-	O
alpha	O
genes	O
in	O
B	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
signaling	O
through	O
Jak3	O
is	O
activated	O
by	O
CD40	O
and	O
plays	O
an	O
important	O
role	B-Regulation
in	O
CD40	O
-	O
mediated	O
functions	O
.	O

The	O
tumour	O
associated	O
cell	O
surface	O
antigen	O
A6H	O
is	O
costimulatory	O
for	O
human	O
CD4+	O
but	O
not	O
CD8+	O
T	O
cells	O
.	O

The	O
A6H	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
recognizes	O
a	O
120	O
,	O
000	O
-	O
140	O
,	O
000	O
MW	O
antigen	O
that	O
is	O
expressed	O
at	O
similar	O
densities	O
on	O
85	O
-	O
90	O
%	O
of	O
human	O
CD4+	O
and	O
CD8+	O
T	O
cells	O
and	O
on	O
renal	O
cell	O
carcinomas	O
.	O

The	O
binding	O
of	O
the	O
A6H	O
mAb	O
induced	O
a	O
costimulatory	O
signal	O
in	O
anti	O
-	O
CD3	O
activated	O
T	O
cells	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
show	O
that	O
A6H	O
costimulated	O
cell	O
proliferation	O
and	O
cytokine	O
production	O
in	O
purified	O
CD4+	O
T	O
cells	O
.	O

Unexpectedly	O
,	O
the	O
CD8+	O
T	O
-	O
cell	O
subpopulation	O
failed	O
to	O
respond	O
.	O

CD4+	O
T	O
cells	O
costimulated	O
with	O
the	O
A6H	O
mAb	O
upregulated	B-Positive_regulation
CD80	O
,	O
CD86	O
,	O
CD71	O
,	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
R	O
alpha	O
,	O
IL	O
-	O
2R	O
beta	O
and	O
IL	O
-	O
2R	O
gamma	O
,	O
while	O
no	O
corresponding	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
these	O
cell	O
surface	O
molecules	O
was	O
seen	O
in	O
CD8+	O
T	O
cells	O
.	O

In	O
order	O
to	O
investigate	O
the	O
nature	O
of	O
the	O
A6H	O
mAb	O
costimulus	O
at	O
the	O
transcriptional	O
level	O
we	O
have	O
examined	O
induction	B-Positive_regulation
of	O
the	O
transcription	O
factors	O
OCT	O
-	O
1	O
,	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
which	O
are	O
known	O
to	O
be	O
transcriptional	B-Regulation
regulators	I-Regulation
of	O
several	O
cytokine	O
and	O
cytokine	O
receptor	O
genes	O
,	O
including	O
the	O
IL	O
-	O
2	O
and	O
IL	O
-	O
2R	O
genes	O
.	O

Co	O
-	O
ligation	O
of	O
the	O
A6H	O
antigen	O
and	O
the	O
CD3	O
complex	O
induced	O
expression	O
of	O
the	O
transcription	O
factor	O
AP	O
-	O
1	O
in	O
CD4+	O
T	O
cells	O
,	O
whereas	O
no	O
increase	O
in	O
NF	O
-	O
kappa	O
B	O
and	O
octamer	O
-	O
binding	O
(	O
Oct	O
)	O
proteins	O
was	O
seen	O
compared	O
to	O
T	O
cells	O
stimulated	O
with	O
anti	O
-	O
CD3	O
alone	O
.	O

Furthermore	O
,	O
no	O
induction	O
of	O
AP	O
-	O
1	O
was	O
seen	O
in	O
A6H	O
costimulated	O
CD8+	O
T	O
cells	O
.	O

These	O
results	O
suggests	O
that	O
both	O
proximal	O
steps	O
in	O
CD8+	O
T	O
-	O
cell	O
activation	O
as	O
well	O
as	O
the	O
later	O
phases	O
are	O
unresponsive	O
to	O
A6H	O
ligation	O
.	O

Molecular	O
differences	O
of	O
the	O
A6H	O
molecule	O
or	O
distinct	O
regulation	O
of	O
the	O
A6H	O
transduced	O
AP	O
-	O
1	O
activation	O
pathway	O
may	O
exist	O
in	O
CD4+	O
and	O
CD8+	O
T	O
cell	O
subpopulations	O
.	O

Structure	O
and	O
function	O
analysis	O
of	O
the	O
human	O
myeloid	O
cell	O
nuclear	O
differentiation	O
antigen	O
promoter	O
:	O
evidence	O
for	O
the	O
role	B-Regulation
of	O
Sp1	O
and	O
not	O
of	O
c	O
-	O
Myb	O
or	O
PU.1	O
in	O
myelomonocytic	O
lineage	O
-	O
specific	O
expression	B-Gene_expression
.	O

The	O
human	O
myeloid	O
nuclear	O
differentiation	O
antigen	O
(	O
MNDA	O
)	O
is	O
expressed	B-Gene_expression
specifically	O
in	O
maturing	O
cells	O
of	O
the	O
myelomonocytic	O
lineage	O
and	O
in	O
monocytes	O
and	O
granulocytes	O
.	O

Epitope	O
enhancement	O
was	O
used	O
to	O
confirm	O
the	O
strict	O
lineage	O
-	O
and	O
stage	O
-	O
specific	O
expression	B-Gene_expression
of	O
MNDA	O
in	O
bone	O
marrow	O
as	O
well	O
as	O
in	O
other	O
paraffin	O
-	O
embedded	O
fixed	O
tissues	O
.	O

A	O
1	O
-	O
kb	O
region	O
of	O
the	O
gene	O
that	O
includes	O
5	O
'	O
flanking	O
sequence	O
was	O
reported	O
earlier	O
to	O
contain	B-Positive_regulation
functional	I-Positive_regulation
promoter	I-Positive_regulation
activity	I-Positive_regulation
and	O
was	O
specifically	O
demethylated	O
in	O
expressing	O
cells	O
in	O
contrast	O
to	O
null	O
cells	O
.	O

Further	O
analysis	O
has	O
revealed	O
that	O
this	O
1	O
-	O
kb	O
fragment	O
promotes	O
higher	O
reporter	O
gene	O
activity	O
in	O
MNDA	O
-	O
expressing	B-Gene_expression
cells	O
than	O
non	B-Gene_expression
-	I-Gene_expression
expressing	I-Gene_expression
cells	O
,	O
indicating	O
cell	O
-	O
specific	O
differences	O
in	O
transactivation	O
.	O

This	O
sequence	O
contains	O
consensus	O
elements	O
consistent	O
with	O
myeloid	O
-	O
specific	O
gene	O
expression	B-Gene_expression
,	O
including	O
a	O
PU.1	O
consensus	O
site	O
near	O
the	O
major	O
transcription	O
start	O
site	O
and	O
a	O
cluster	O
of	O
c	O
-	O
Myb	O
sites	O
located	O
several	O
hundred	O
bases	O
upstream	O
of	O
this	O
region	O
.	O

However	O
,	O
analysis	O
of	O
deletion	O
mutants	O
localized	O
nearly	O
all	O
of	O
the	O
promoter	B-Positive_regulation
activity	I-Positive_regulation
to	O
a	O
short	O
region	O
(	O
-	O
73	O
to	O
-	O
16	O
)	O
that	O
did	O
not	O
include	O
the	O
cluster	O
of	O
c	O
-	O
Myb	O
sites	O
.	O

A	O
4	O
-	O
bp	O
mutation	O
of	O
the	O
core	O
Sp1	O
consensus	O
element	O
(	O
GC	O
box	O
)	O
(	O
-	O
20	O
)	O
reduced	B-Negative_regulation
overall	O
promoter	B-Positive_regulation
activity	I-Positive_regulation
of	O
the	O
1	O
-	O
kb	O
fragment	O
.	O

Mutation	O
of	O
the	O
PU.1	O
site	O
did	O
not	O
significantly	O
affect	B-Regulation
promoter	O
activity	O
.	O

Only	O
a	O
small	O
region	O
(	O
-	O
35	O
to	O
+22	O
)	O
including	O
the	O
Sp1	O
element	O
and	O
transcription	O
start	O
site	O
,	O
but	O
not	O
the	O
PU.1	O
site	O
was	O
footprinted	O
.	O

The	O
4	O
-	O
bp	O
mutation	O
of	O
the	O
core	O
Sp1	O
consensus	O
element	O
abolished	O
footprinting	O
at	O
the	O
site	O
and	O
an	O
antibody	O
super	O
-	O
shift	O
reaction	O
showed	O
that	O
Sp1	O
is	O
one	O
of	O
the	O
factors	O
binding	B-Binding
the	O
consensus	O
site	O
.	O

The	O
Sp1	O
site	O
also	O
co	O
-	O
localizes	O
with	O
a	O
DNase	O
I	O
hypersensitive	O
site	O
.	O

The	O
results	O
indicate	O
that	O
DNA	O
methylation	O
,	O
chromatin	O
structure	O
,	O
and	O
transactivation	O
at	O
an	O
Sp1	O
site	O
contribute	B-Regulation
to	O
the	O
highly	O
restricted	O
expression	B-Gene_expression
of	O
this	O
myelomonocytic	O
lineage	O
specific	O
gene	O
.	O

Inhibitor	O
(	O
IK	O
)	O
of	O
IFN	O
-	O
gamma	O
induced	O
HLA	O
class	O
II	O
antigens	O
expression	O
also	O
inhibits	O
HLA	O
class	O
II	O
constitutive	O
expression	O
in	O
the	O
human	O
Raji	O
B	O
cell	O
line	O
.	O

The	O
expression	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
antigens	O
is	O
constitutive	O
in	O
professional	O
antigen	O
presenting	O
cells	O
(	O
APCs	O
)	O
but	O
can	O
also	O
be	O
induced	O
by	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
on	O
the	O
majority	O
of	O
the	O
non	O
professional	O
APCs	O
(	O
e.g.	O
fibroblasts	O
)	O
.	O

We	O
have	O
recently	O
characterised	O
a	O
new	O
factor	O
called	O
IK	O
which	O
is	O
an	O
efficient	O
inhibitor	O
of	O
IFN	O
-	O
gamma	O
induction	O
of	O
MHC	O
class	O
II	O
antigens	O
expression	O
.	O

Here	O
,	O
we	O
demonstrate	O
a	O
novel	O
role	O
for	O
IK	O
in	O
MHC	O
class	O
II	O
expression	O
since	O
over	B-Gene_expression
-	I-Gene_expression
expression	I-Gene_expression
of	O
this	O
protein	O
by	O
stable	O
transfection	O
into	O
human	O
B	O
cells	O
led	O
to	O
a	O
total	O
disappearance	O
of	O
constitutive	O
MHC	O
class	O
II	O
mRNA	O
expression	O
.	O

The	O
class	O
II	O
transactivator	O
(	O
CIITA	O
)	O
is	O
necessary	O
for	O
both	O
constitutive	O
and	O
IFN	O
-	O
gamma	O
induced	O
MHC	O
class	O
II	O
expressions	O
.	O

Examination	O
of	O
CIITA	O
mRNA	B-Transcription
in	O
IK	O
stably	O
transfected	B-Positive_regulation
clones	O
revealed	O
a	O
marked	O
reduction	B-Negative_regulation
of	O
CIITA	O
mRNA	O
transcription	B-Transcription
.	O

Taken	O
together	O
these	O
results	O
demonstrate	O
that	O
the	O
IK	O
protein	O
plays	O
a	O
key	O
role	O
in	O
the	O
constitutive	O
expression	O
of	O
MHC	O
class	O
II	O
antigens	O
and	O
that	O
inhibition	B-Negative_regulation
induced	O
by	O
IK	O
is	O
upstream	O
of	O
CIITA	O
in	O
this	O
regulatory	O
pathway	O
.	O

An	O
enhancer	O
-	O
blocking	O
element	O
between	O
alpha	O
and	O
delta	O
gene	O
segments	O
within	O
the	O
human	O
T	O
cell	O
receptor	O
alpha/delta	O
locus	O
.	O

T	O
cell	O
receptor	O
(	O
TCR	O
)	O
alpha	O
and	O
delta	O
gene	O
segments	O
are	O
organized	O
within	O
a	O
single	O
genetic	O
locus	O
but	O
are	O
differentially	O
regulated	O
during	O
T	O
cell	O
development	O
.	O

An	O
enhancer	O
-	O
blocking	O
element	O
(	O
BEAD	O
-	O
1	O
,	O
for	O
blocking	O
element	O
alpha/delta	O
1	O
)	O
was	O
localized	O
to	O
a	O
2.0	O
-	O
kb	O
region	O
3	O
'	O
of	O
TCR	O
delta	O
gene	O
segments	O
and	O
5	O
'	O
of	O
TCR	O
alpha	O
joining	O
gene	O
segments	O
within	O
this	O
locus	O
.	O

BEAD	O
-	O
1	O
blocked	O
the	O
ability	O
of	O
the	O
TCR	O
delta	O
enhancer	O
(	O
Edelta	O
)	O
to	O
activate	O
a	O
promoter	O
when	O
located	O
between	O
the	O
two	O
in	O
a	O
chromatin	O
-	O
integrated	O
construct	O
.	O

We	O
propose	O
that	O
BEAD	O
-	O
1	O
functions	O
as	O
a	O
boundary	O
that	O
separates	O
the	O
TCR	O
alpha/delta	O
locus	O
into	O
distinct	O
regulatory	O
domains	O
controlled	O
by	O
Edelta	O
and	O
the	O
TCR	O
alpha	O
enhancer	O
,	O
and	O
that	O
it	O
prevents	O
Edelta	O
from	O
opening	O
the	O
chromatin	O
of	O
the	O
TCR	O
alpha	O
joining	O
gene	O
segments	O
for	O
VDJ	O
recombination	O
at	O
an	O
early	O
stage	O
of	O
T	O
cell	O
development	O
.	O

Quantification	O
of	O
vitamin	O
D	O
receptor	O
mRNA	O
by	O
competitive	O
polymerase	O
chain	O
reaction	O
in	O
PBMC	O
:	O
lack	O
of	O
correspondence	O
with	O
common	O
allelic	O
variants	O
.	O

It	O
has	O
been	O
recently	O
claimed	O
that	O
polymorphism	O
for	O
the	O
vitamin	O
D	O
receptor	O
(	O
VDR	O
)	O
influences	O
several	O
aspects	O
of	O
calcium	O
and	O
bone	O
metabolism	O
.	O

To	O
evaluate	O
the	O
physiologic	O
plausibility	O
of	O
these	O
claims	O
,	O
we	O
compared	O
the	O
abundance	B-Transcription
of	O
the	O
VDR	O
mRNA	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
between	O
different	O
VDR	O
genotypes	O
using	O
a	O
quantitative	O
reverse	O
transcribed	O
polymerase	O
chain	O
reaction	O
-	O
based	O
method	O
.	O

The	O
method	O
is	O
based	O
on	O
the	O
coamplification	O
of	O
VDR	O
cDNA	O
and	O
an	O
internal	O
standard	O
consisting	O
of	O
known	O
concentrations	O
of	O
a	O
human	O
VDR	O
CDNA	O
mutated	O
at	O
a	O
BglII	O
restriction	O
site	O
;	O
the	O
interassay	O
coefficient	O
of	O
variation	O
is	O
11	O
%	O
.	O

To	O
validate	O
the	O
method	O
,	O
we	O
made	O
use	O
of	O
earlier	O
receptor	O
binding	O
studies	O
indicating	O
that	O
normal	O
human	O
monocytes	O
and	O
activated	O
,	O
but	O
not	O
resting	O
,	O
lymphocytes	O
expressed	B-Gene_expression
the	O
VDR	O
.	O

The	O
concentration	O
of	O
the	O
VDR	O
mRNA	O
was	O
10	O
(	O
-	O
8	O
)	O
to	O
10	O
(	O
-	O
7	O
)	O
g/g	O
of	O
total	O
RNA	O
in	O
cell	O
-	O
sorted	O
monocytes	O
and	O
in	O
in	O
vitro	O
activated	O
lymphocytes	O
,	O
but	O
only	O
10	O
(	O
-	O
12	O
)	O
g/g	O
of	O
total	O
mRNA	O
in	O
resting	O
lymphocytes	O
,	O
establishing	O
that	O
the	O
VDR	O
mRNA	O
determined	O
by	O
our	O
method	O
in	O
PBMCs	O
is	O
due	O
to	O
constitutive	O
expression	B-Transcription
in	O
monocytes	O
.	O

Following	O
an	O
initial	O
genotype	O
screening	O
of	O
85	O
normal	O
volunteers	O
by	O
polymerase	O
chain	O
reaction	O
or	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
,	O
14	O
individuals	O
with	O
the	O
Bb	O
genotype	O
,	O
12	O
with	O
the	O
bb	O
genotype	O
,	O
and	O
12	O
with	O
the	O
BB	O
genotype	O
were	O
selected	O
.	O

The	O
concentration	B-Transcription
of	O
the	O
VDR	O
mRNA	O
,	O
corrected	O
for	O
the	O
number	O
of	O
monocytes	O
,	O
was	O
similar	O
among	O
the	O
three	O
genotype	O
groups	O
,	O
as	O
were	O
the	O
other	O
variables	O
examined	O
:	O
serum	O
calcitriol	O
,	O
serum	O
osteocalcin	O
,	O
and	O
vertebral	O
and	O
hip	O
bone	O
density	O
.	O

We	O
conclude	O
that	O
VDR	O
polymorphism	O
does	O
not	O
affect	B-Regulation
the	O
abundance	B-Transcription
of	O
the	O
VDR	O
mRNA	O
.	O

Regulation	B-Regulation
of	O
CD95	O
(	O
Fas	O
)	O
ligand	O
expression	B-Gene_expression
by	O
TCR	O
-	O
mediated	O
signaling	O
events	O
.	O

Stimulation	O
of	O
mature	O
peripheral	O
T	O
cells	O
by	O
TCR	O
engagement	O
results	O
in	O
activation	O
of	O
signals	O
that	O
drive	O
induction	O
of	O
cytokine	O
gene	O
expression	O
and	O
clonal	O
expansion	O
.	O

However	O
,	O
under	O
some	O
conditions	O
,	O
engagement	O
of	O
the	O
TCR	O
leads	O
instead	O
to	O
apoptosis	O
.	O

Recent	O
studies	O
demonstrate	O
that	O
TCR	O
-	O
stimulated	O
apoptosis	O
requires	O
expression	B-Gene_expression
of	O
CD95	O
ligand	O
on	O
activated	O
T	O
cells	O
followed	O
by	O
an	O
interaction	B-Binding
between	O
CD95	O
ligand	O
and	O
the	O
CD95	O
receptor	O
also	O
expressed	O
on	O
this	O
population	O
.	O

The	O
experiments	O
reported	O
in	O
this	O
study	O
were	O
designed	O
to	O
address	O
the	O
signaling	O
events	O
triggered	O
by	O
TCR	O
engagement	O
that	O
are	O
important	B-Regulation
for	I-Regulation
regulating	I-Regulation
CD95	O
ligand	O
gene	O
expression	B-Gene_expression
.	O

To	O
approach	O
this	O
,	O
we	O
generated	O
a	O
luciferase	O
reporter	O
construct	O
containing	O
elements	O
of	O
the	O
CD95	O
ligand	O
promoter	O
.	O

Using	O
a	O
previously	O
described	O
mutant	O
of	O
the	O
Jurkat	O
T	O
cell	O
line	O
,	O
we	O
show	O
that	O
proximal	O
signaling	O
events	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
CD45	O
tyrosine	O
phosphatase	O
are	O
required	B-Positive_regulation
for	O
TCR	O
-	O
stimulated	B-Positive_regulation
CD95	O
ligand	O
expression	B-Gene_expression
.	O

Transient	O
transfection	O
studies	O
demonstrate	O
further	O
that	O
TCR	O
-	O
stimulated	O
activation	O
of	O
the	O
Ras	O
signaling	O
pathway	O
is	O
required	B-Positive_regulation
for	O
optimal	O
activation	B-Positive_regulation
of	O
CD95	O
ligand	O
.	O

Next	O
,	O
in	O
an	O
effort	O
to	O
determine	O
critical	O
transcription	O
factors	O
that	O
regulate	B-Regulation
CD95	O
ligand	O
expression	B-Gene_expression
,	O
we	O
demonstrate	O
a	O
cyclosporin	O
A	O
-	O
sensitive	O
nuclear	O
factor	O
-	O
AT	O
response	O
element	O
in	O
the	O
promoter	O
region	O
of	O
this	O
gene	O
that	O
is	O
critical	B-Positive_regulation
for	O
optimal	O
CD95	O
ligand	O
reporter	O
activity	O
in	O
stimulated	O
T	O
cells	O
.	O

Together	O
,	O
these	O
studies	O
begin	O
a	O
dissection	O
of	O
the	O
biochemical	O
events	O
that	O
lead	O
to	O
expression	B-Gene_expression
of	O
CD95	O
ligand	O
,	O
a	O
required	O
step	O
for	O
TCR	O
-	O
induced	O
apoptosis	O
.	O

CD40	O
is	O
a	O
functional	O
activation	O
antigen	O
and	O
B7	O
-	O
independent	O
T	O
cell	O
costimulatory	O
molecule	O
on	O
normal	O
human	O
lung	O
fibroblasts	O
.	O

CD40	O
is	O
an	O
important	O
signaling	O
and	O
activation	O
Ag	O
found	B-Gene_expression
on	O
certain	O
bone	O
marrow	O
-	O
derived	O
cells	O
.	O

Recently	O
,	O
CD40	O
also	O
has	O
been	O
shown	O
to	O
be	O
expressed	B-Gene_expression
by	O
mesenchymal	O
cells	O
,	O
including	O
human	O
fibroblasts	O
.	O

Little	O
is	O
known	O
about	O
the	O
role	O
of	O
CD40	O
in	O
fibroblasts	O
.	O

The	O
current	O
study	O
investigates	O
the	O
hypothesis	O
that	O
CD40	O
expressed	B-Gene_expression
on	O
lung	O
fibroblasts	O
is	O
an	O
activation	O
structure	O
and	O
mechanism	O
for	O
interaction	O
with	O
hemopoietic	O
cells	O
.	O

Communication	O
between	O
resident	O
tissue	O
fibroblasts	O
and	O
T	O
cells	O
is	O
necessary	O
for	O
normal	O
wound	O
healing	O
,	O
and	O
can	O
be	O
pathologic	O
,	O
resulting	O
in	O
tissue	O
fibrosis	O
.	O

Signaling	O
through	O
CD40	O
with	O
soluble	O
CD40	O
ligand	O
stimulated	O
fibroblast	O
activation	O
,	O
as	O
evidenced	O
by	O
mobilization	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
and	O
by	O
induction	B-Positive_regulation
of	O
the	O
proinflammatory	O
and	O
chemoattractant	O
cytokines	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
.	O

IFN-gamma	O
-	O
primed	O
lung	O
fibroblasts	O
costimulate	O
T	O
lymphocyte	O
proliferation	O
utilizing	O
CD40	O
,	O
but	O
not	O
the	O
well	O
-	O
studied	O
costimulatory	O
molecules	O
B7	O
-	O
1	O
and	O
B7	O
-	O
2	O
.	O

Data	O
reported	O
herein	O
support	O
the	O
hypothesis	O
that	O
cognate	O
interactions	O
between	O
tissue	O
fibroblasts	O
and	O
infiltrating	O
T	O
lymphocytes	O
,	O
via	O
the	O
CD40/CD40L	O
pathway	O
,	O
augment	O
inflammation	O
and	O
may	O
promote	O
fibrogenesis	O
by	O
activating	O
both	O
cell	O
types	O
.	O

Tap	O
:	O
a	O
novel	O
cellular	O
protein	O
that	O
interacts	O
with	O
tip	O
of	O
herpesvirus	O
saimiri	O
and	O
induces	O
lymphocyte	O
aggregation	O
.	O

Tip	O
of	O
herpesvirus	O
saimiri	O
associates	B-Binding
with	O
Lck	O
and	O
down	O
-	O
regulates	O
Lck	O
-	O
mediated	O
activation	O
.	O

We	O
identified	O
a	O
novel	O
cellular	O
Tip	O
-	O
associated	O
protein	O
(	O
Tap	O
)	O
by	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
.	O

Tap	O
associated	O
with	O
Tip	O
following	O
transient	O
expression	O
in	O
COS	O
-	O
1	O
cells	O
and	O
stable	O
expression	O
in	O
human	O
Jurkat	O
-	O
T	O
cells	O
.	O

Expression	O
of	O
Tip	O
and	O
Tap	O
in	O
Jurkat	O
-	O
T	O
cells	O
induced	O
dramatic	O
cell	O
aggregation	O
.	O

Aggregation	O
was	O
likely	O
caused	O
by	O
the	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
surface	O
expression	B-Gene_expression
of	O
adhesion	O
molecules	O
including	O
integrin	O
alpha	O
,	O
L	O
-	O
selectin	O
,	O
ICAM	O
-	O
3	O
,	O
and	O
H	O
-	O
CAM	O
.	O

Furthermore	O
,	O
NF	O
-	O
kappaB	O
transcriptional	O
factor	O
of	O
aggregated	O
cells	O
had	O
approximately	O
40	O
-	O
fold	O
higher	O
activity	O
than	O
that	O
of	O
parental	O
cells	O
.	O

Thus	O
,	O
Tap	O
is	O
likely	O
to	O
be	O
an	O
important	O
cellular	O
mediator	O
of	O
Tip	O
function	O
in	O
T	O
cell	O
transformation	O
by	O
herpesvirus	O
saimiri	O
.	O

Transactivation	O
by	O
CIITA	O
,	O
the	O
type	O
II	O
bare	O
lymphocyte	O
syndrome	O
-	O
associated	O
factor	O
,	O
requires	O
participation	O
of	O
multiple	O
regions	O
of	O
the	O
TATA	O
box	O
binding	O
protein	O
.	O

CIITA	O
is	O
a	O
positive	O
regulator	O
of	O
class	O
II	O
major	O
histocompatibility	O
complex	O
gene	O
transcription	O
that	O
has	O
been	O
found	O
to	O
be	O
defective	B-Negative_regulation
in	O
one	O
of	O
the	O
five	O
complementation	O
groups	O
of	O
class	O
II	O
major	O
histocompatibility	O
complex	O
-	O
negative	O
cell	O
lines	O
.	O

Its	O
N	O
-	O
terminal	O
region	O
is	O
capable	O
of	O
activating	O
transcription	O
from	O
a	O
reporter	O
gene	O
when	O
fused	O
to	O
a	O
DNA	O
binding	O
domain	O
.	O

We	O
have	O
investigated	O
the	O
mechanism	O
of	O
transactivation	O
mediated	O
by	O
the	O
CIITA	O
activation	O
domain	O
by	O
studying	O
its	O
role	O
in	O
the	O
process	O
of	O
transcription	O
initiation	O
and	O
elongation	O
.	O

Specifically	O
the	O
altered	O
specificity	O
TBP	O
(	O
TATA	O
box	O
binding	O
protein	O
)	O
assay	O
has	O
been	O
used	O
to	O
analyze	O
the	O
response	O
of	O
the	O
CIITA	O
activation	O
domain	O
to	O
mutations	O
in	O
TBP	O
known	O
to	O
disrupt	B-Negative_regulation
its	O
interaction	B-Binding
with	O
its	O
associated	O
general	O
factors	O
.	O

Transactivation	O
by	O
CIITA	O
was	O
extremely	O
sensitive	O
to	O
a	O
mutation	O
in	O
TBP	O
that	O
in	O
yeast	O
is	O
known	O
to	O
abolish	O
VP16	O
-	O
mediated	O
transcription	O
but	O
leaves	O
basal	O
transcription	O
unaffected	O
.	O

A	O
TBP	O
mutant	O
defective	O
in	O
interaction	B-Binding
with	O
TBP	O
-	O
associated	O
factor	O
TAFII250	O
also	O
failed	O
to	O
mediate	O
transactivation	O
through	O
the	O
CIITA	O
activation	O
domain	O
.	O

Certain	O
interactions	B-Binding
between	O
TBP	O
and	O
general	O
factors	O
that	O
are	O
specifically	O
required	O
for	O
acidic	O
activation	O
domains	O
were	O
also	O
required	O
for	O
CIITA	O
-	O
mediated	O
transactivation	O
to	O
reach	O
its	O
full	O
potential	O
.	O

Finally	O
,	O
like	O
VP16	O
,	O
CIITA	O
was	O
able	O
to	O
stimulate	O
elongation	O
of	O
transcription	O
.	O

Overall	O
the	O
mechanism	O
of	O
transactivation	O
by	O
the	O
human	O
B-cell	O
-	O
specific	O
CIITA	O
is	O
very	O
similar	O
to	O
that	O
mediated	O
by	O
the	O
herpes	O
virus	O
transactivator	O
VP16	O
in	O
the	O
ways	O
that	O
have	O
been	O
tested	O
.	O

Specific	O
complex	B-Binding
formation	I-Binding
between	O
the	O
type	O
II	O
bare	O
lymphocyte	O
syndrome	O
-	O
associated	O
transactivators	O
CIITA	O
and	O
RFX5	O
.	O

Two	O
of	O
the	O
genes	O
defective	B-Negative_regulation
in	O
the	O
five	O
complementation	O
groups	O
identified	O
in	O
the	O
class	O
II	O
-	O
negative	O
bare	O
lymphocyte	O
syndrome	O
or	O
corresponding	O
laboratory	O
mutants	O
have	O
been	O
cloned	O
.	O

One	O
gene	O
encodes	O
a	O
protein	O
,	O
RFX5	O
,	O
that	O
is	O
a	O
member	O
of	O
the	O
RFX	O
family	O
of	O
DNA	O
binding	O
proteins	O
.	O

The	O
other	O
,	O
CIITA	O
,	O
encodes	O
a	O
large	O
protein	O
with	O
a	O
defined	O
acidic	O
transcriptional	O
activation	O
domain	O
;	O
this	O
protein	O
does	O
not	O
interact	B-Binding
with	O
DNA	O
.	O

Expression	O
plasmids	O
encoding	O
regions	O
of	O
RFX5	O
fused	O
to	O
the	O
GAL4	O
DNA	O
binding	O
domain	O
activated	O
transcription	O
from	O
a	O
reporter	O
construct	O
containing	O
GAL4	O
sites	O
in	O
a	O
cotransfection	O
assay	O
in	O
the	O
Raji	O
human	O
B	O
cell	O
line	O
.	O

However	O
,	O
these	O
plasmids	O
produced	O
transcriptional	O
activity	O
in	O
HeLa	O
cells	O
only	O
in	O
conjunction	O
with	O
interferon	O
gamma	O
stimulation	O
,	O
a	O
condition	O
in	O
which	O
expression	B-Gene_expression
of	O
both	O
CIITA	O
and	O
class	O
II	O
major	O
histocompatibility	O
complex	O
surface	O
proteins	O
are	O
induced	B-Positive_regulation
.	O

Furthermore	O
,	O
these	O
plasmids	O
were	O
not	O
active	O
in	O
RJ2.2.5	O
,	O
an	O
in	O
vitro	O
mutagenized	O
derivative	O
of	O
Raji	O
in	O
which	O
both	O
copies	O
of	O
CIITA	O
are	O
defective	B-Negative_regulation
.	O

Transcriptional	O
activation	O
by	O
the	O
RFX5	O
fusion	O
protein	O
could	O
be	O
restored	O
in	O
RJ2.2.5	O
by	O
cotransfection	B-Positive_regulation
with	O
a	O
CIITA	O
expression	B-Gene_expression
plasmid	O
.	O

Finally	O
,	O
a	O
direct	O
interaction	B-Binding
between	O
RFX5	O
and	O
CIITA	O
was	O
detected	O
with	O
the	O
yeast	O
two	O
-	O
hybrid	O
and	O
far	O
-	O
Western	O
blot	O
assays	O
.	O

Thus	O
,	O
RFX5	O
can	O
activate	O
transcription	O
only	O
in	O
cooperation	O
with	O
CIITA	O
.	O

RFX5	O
and	O
CIITA	O
associate	B-Binding
to	I-Binding
form	I-Binding
a	I-Binding
complex	I-Binding
capable	O
of	O
activating	O
transcription	O
from	O
class	O
II	O
major	O
histocompatibility	O
complex	O
promoters	O
.	O

In	O
this	O
complex	O
,	O
promoter	O
specificity	B-Binding
is	O
determined	O
by	O
the	O
DNA	O
binding	O
domain	O
of	O
RFX5	O
and	O
the	O
general	O
transcription	O
apparatus	O
is	O
recruited	O
by	O
the	O
acidic	O
activation	O
domain	O
of	O
CIITA	O
.	O

Reactive	O
oxygen	O
species	O
and	O
antioxidants	O
in	O
inflammatory	O
diseases	O
.	O

This	O
paper	O
aims	O
to	O
review	O
the	O
role	O
of	O
free	O
radical	O
-	O
induced	O
tissue	O
damage	O
and	O
antioxidant	O
defence	O
mechanisms	O
in	O
inflammatory	O
diseases	O
that	O
involve	O
pathogenic	O
processes	O
similar	O
to	O
the	O
periodontal	O
diseases	O
.	O

There	O
is	O
a	O
clearly	O
defined	O
and	O
substantial	O
role	O
for	O
free	O
radicals	O
or	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
periodontitis	O
,	O
but	O
little	O
research	O
has	O
been	O
performed	O
in	O
this	O
area	O
.	O

This	O
paper	O
reviews	O
the	O
considerable	O
data	O
available	O
relating	O
ROS	O
activity	O
and	O
antioxidant	O
defence	O
to	O
inflammatory	O
diseases	O
and	O
attempts	O
to	O
draw	O
parallels	O
with	O
periodontitis	O
,	O
in	O
an	O
effort	O
to	O
stimulate	O
more	O
periodontal	O
research	O
in	O
this	O
important	O
area	O
.	O

The	O
recent	O
discovery	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
is	O
reviewed	O
and	O
several	O
potential	O
pathways	O
for	O
cytokine	O
-	O
induced	O
periodontal	O
tissue	O
damage	O
,	O
mediated	O
by	O
NF	O
-	O
kappa	O
B1	O
are	O
discussed	O
.	O

Emphasis	O
is	O
placed	O
on	O
cytokines	O
that	O
have	O
been	O
studied	O
in	O
periodontitis	O
,	O
principally	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
and	O
beta	O
-	O
interferon	O
.	O

The	O
link	O
between	O
cellular	O
production	B-Gene_expression
of	O
such	O
important	O
mediators	O
of	O
inflammation	O
and	O
the	O
antioxidant	O
(	O
AO	O
)	O
thiols	O
,	O
cysteine	O
and	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
,	O
is	O
discussed	O
and	O
it	O
is	O
hypothesised	O
that	O
NF	O
-	O
kappa	O
B	O
antagonists	O
may	O
offer	O
important	O
therapeutic	O
benefits	O
.	O

Transcriptional	O
activity	O
and	O
constitutive	O
nuclear	O
localization	B-Localization
of	O
the	O
ETS	O
protein	O
Elf	O
-	O
1	O
.	O

Elf	O
-	O
1	O
is	O
a	O
lymphoid	O
-	O
specific	O
transcription	O
factor	O
that	O
belongs	O
to	O
the	O
ETS	O
protein	O
family	O
.	O

It	O
can	O
bind	B-Binding
to	O
DNA	O
target	O
sequences	O
within	O
a	O
variety	O
of	O
cytokine	O
genes	O
.	O

We	O
demonstrate	O
that	O
Elf	O
-	O
1	O
is	O
constitutively	O
localized	B-Localization
in	O
the	O
nucleus	O
which	O
is	O
dependent	B-Positive_regulation
on	O
the	O
presence	O
of	O
amino	O
acids	O
86	O
-	O
265	O
.	O

Analysis	O
of	O
Gal4-Elf	O
-	O
1	O
fusion	O
proteins	O
revealed	O
that	O
the	O
N	O
-	O
terminal	O
86	O
amino	O
acids	O
of	O
Elf	O
-	O
1	O
contain	O
a	O
transcriptional	O
activation	O
domain	O
,	O
the	O
activity	O
of	O
which	O
is	O
attenuated	O
by	O
an	O
internal	O
repression	O
domain	O
.	O

Furthermore	O
,	O
Elf	O
-	O
1	O
interacts	B-Binding
specifically	O
with	O
the	O
E74	O
target	O
sequence	O
and	O
can	O
stimulate	O
transcription	O
driven	O
by	O
the	O
E74	O
site	O
independent	O
of	O
mitogenic	O
signaling	O
.	O

Thus	O
,	O
Elf	O
-	O
1	O
is	O
able	O
to	O
stimulate	O
gene	O
transcription	O
which	O
may	O
be	O
required	O
for	O
the	O
development	O
and	O
activity	O
of	O
lymphocytes	O
.	O

Overexpression	B-Positive_regulation
of	O
HSF2	O
-	O
beta	O
inhibits	O
hemin	O
-	O
induced	O
heat	O
shock	O
gene	O
expression	O
and	O
erythroid	O
differentiation	O
in	O
K562	O
cells	O
.	O

Acquisition	O
of	O
heat	O
shock	O
factor	O
2	O
(	O
HSF2	O
)	O
DNA	O
binding	B-Binding
activity	O
is	O
accompanied	B-Regulation
by	O
induced	O
transcription	O
of	O
heat	O
shock	O
genes	O
in	O
hemin	O
-	O
treated	O
K562	O
cells	O
undergoing	O
erythroid	O
differentiation	O
.	O

Previous	O
studies	O
revealed	O
that	O
HSF2	O
consists	O
of	O
two	O
alternatively	O
spliced	O
isoforms	O
,	O
HSF2	O
-	O
alpha	O
and	O
HSF2	O
-	O
beta	O
,	O
whose	O
relative	O
abundance	O
is	O
developmentally	O
regulated	B-Regulation
and	O
varies	B-Regulation
between	O
different	O
tissues	O
.	O

To	O
investigate	O
whether	O
the	O
molar	O
ratio	O
of	O
HSF2	O
-	O
alpha	O
and	O
HSF2	O
-	O
beta	O
isoforms	O
is	O
crucial	B-Regulation
for	O
the	O
activation	B-Positive_regulation
of	O
HSF2	O
and	O
whether	O
the	O
HSF2	O
isoforms	O
play	O
functionally	O
distinct	O
roles	O
during	O
the	O
hemin	O
-	O
mediated	O
erythroid	O
differentiation	O
,	O
we	O
generated	O
cell	O
clones	O
expressing	B-Gene_expression
different	O
levels	O
of	O
HSF2	O
-	O
alpha	O
and	O
HSF2	O
-	O
beta	O
.	O

We	O
show	O
that	O
in	O
parental	O
K562	O
cells	O
,	O
the	O
HSF2	O
-	O
alpha	O
isoform	O
is	O
predominantly	O
expressed	B-Gene_expression
and	O
HSF2	O
can	O
be	O
activated	B-Positive_regulation
upon	O
hemin	O
treatment	O
.	O

In	O
contrast	O
,	O
when	O
HSF2	O
-	O
beta	O
is	O
expressed	B-Gene_expression
at	O
levels	B-Positive_regulation
exceeding	O
those	O
of	O
endogenous	O
HSF2	O
-	O
alpha	O
,	O
the	O
hemin	O
-	O
induced	O
DNA	O
binding	O
activity	O
and	O
transcription	O
of	O
heat	O
shock	O
genes	O
are	O
repressed	O
,	O
whereas	O
overexpression	B-Positive_regulation
of	O
HSF2	O
-	O
alpha	O
results	O
in	O
an	O
enhanced	O
hemin	O
response	O
.	O

Furthermore	O
,	O
the	O
hemin	O
-	O
induced	O
accumulation	O
of	O
globin	O
,	O
known	O
as	O
a	O
marker	O
of	O
erythroid	O
differentiation	O
,	O
is	O
decreased	B-Negative_regulation
in	O
cells	O
overexpressing	B-Gene_expression
HSF2	O
-	O
beta	O
.	O

We	O
suggest	O
that	O
HSF2	O
-	O
beta	O
acts	O
as	O
a	O
negative	B-Negative_regulation
regulator	I-Negative_regulation
of	O
HSF2	O
activity	O
during	O
hemin	O
-	O
mediated	O
erythroid	O
differentiation	O
of	O
K562	O
cells	O
.	O

Glucocorticoid	O
-	O
mediated	O
repression	O
of	O
cytokine	O
gene	O
transcription	O
in	O
human	O
arteritis	O
-	O
SCID	O
chimeras	O
.	O

Giant	O
cell	O
arteritis	O
(	O
GCA	O
)	O
is	O
a	O
vasculitic	O
syndrome	O
that	O
preferentially	O
affects	O
medium	O
and	O
large	O
-	O
sized	O
arteries	O
.	O

Glucocorticoid	O
therapy	O
resolves	O
clinical	O
symptoms	O
within	O
hours	O
to	O
days	O
,	O
but	O
therapy	O
has	O
to	O
be	O
continued	O
over	O
several	O
years	O
to	O
prevent	O
disease	O
relapses	O
.	O

It	O
is	O
not	O
known	O
whether	O
and	O
how	O
glucocorticoids	O
affect	O
the	O
function	O
of	O
the	O
inflammatory	O
infiltrate	O
or	O
why	O
the	O
disease	O
persists	O
subclinically	O
despite	O
chronic	O
treatment	O
.	O

GCA	O
is	O
self	O
-	O
sustained	O
in	O
temporal	O
arteries	O
engrafted	O
into	O
SCID	O
mice	O
,	O
providing	O
a	O
model	O
in	O
which	O
the	O
mechanisms	O
of	O
action	O
and	O
limitations	O
of	O
glucocorticoid	O
therapy	O
can	O
be	O
examined	O
in	O
vivo	O
.	O

Administration	O
of	O
dexamethasone	O
to	O
temporal	O
artery	O
-	O
SCID	O
chimeras	O
for	O
1	O
wk	O
induced	O
a	O
partial	O
suppression	O
of	O
T	O
cell	O
and	O
macrophage	O
function	O
as	O
indicated	O
by	O
the	O
reduced	B-Negative_regulation
tissue	O
concentrations	O
of	O
IL	O
-	O
2	O
,	O
IL	O
-	O
1beta	O
,	O
and	O
IL	O
-	O
6	O
mRNA	O
,	O
and	O
by	O
the	O
diminished	O
expression	O
of	O
inducible	O
NO	O
synthase	O
.	O

In	O
contrast	O
,	O
synthesis	B-Transcription
of	O
IFN	O
-	O
gamma	O
mRNA	O
was	O
only	O
slightly	O
decreased	B-Negative_regulation
,	O
and	O
expression	B-Gene_expression
of	O
TGF	O
-	O
beta1	O
was	O
unaffected	B-Negative_regulation
.	O

These	O
findings	O
correlated	O
with	O
activation	B-Positive_regulation
of	O
the	O
IkappaBalpha	O
gene	O
and	O
blockade	O
of	O
the	O
nuclear	O
translocation	O
of	O
NFkappaB	O
in	O
the	O
xenotransplanted	O
tissue	O
.	O

Dose	O
-	O
response	O
experiments	O
suggested	O
that	O
steroid	O
doses	O
currently	O
used	O
in	O
clinical	O
medicine	O
are	O
suboptimal	O
in	O
repressing	O
NFkappaB	O
-	O
mediated	O
cytokine	O
production	O
in	O
the	O
inflammatory	O
lesions	O
.	O

Chronic	O
steroid	O
therapy	O
was	O
able	O
to	O
deplete	B-Negative_regulation
the	O
T	O
cell	O
products	B-Gene_expression
IL	O
-	O
2	O
and	O
IFN	O
-	O
gamma	O
,	O
whereas	O
the	O
activation	O
of	O
tissue	O
-	O
infiltrating	O
macrophages	O
was	O
only	O
partially	O
affected	O
.	O

IL	O
-	O
1beta	O
transcription	B-Transcription
was	O
abrogated	B-Negative_regulation
;	O
in	O
contrast	O
,	O
TGF	O
-	O
beta1	O
mRNA	O
synthesis	B-Transcription
was	O
steroid	O
resistant	B-Regulation
.	O

The	O
persistence	B-Negative_regulation
of	O
TGF-beta1	O
-	O
transcribing	B-Transcription
macrophages	O
,	O
despite	O
paralysis	O
of	O
T	O
cell	O
function	O
,	O
may	O
provide	O
an	O
explanation	O
for	O
the	O
chronicity	O
of	O
the	O
disease	O
,	O
and	O
may	O
identify	O
a	O
novel	O
therapeutic	O
target	O
in	O
this	O
inflammatory	O
vasculopathy	O
.	O

Histamine	O
modulates	B-Regulation
the	O
expression	B-Gene_expression
of	O
c	O
-	O
fos	O
through	O
cyclic	O
AMP	O
production	O
via	O
the	O
H2	O
receptor	O
in	O
the	O
human	O
promonocytic	O
cell	O
line	O
U937	O
.	O

We	O
examined	O
the	O
effects	B-Regulation
of	O
histamine	O
and	O
its	O
agonists	O
on	O
the	O
expression	O
of	O
the	O
c	O
-	O
fos	O
and	O
c	O
-	O
myc	O
proto	O
-	O
oncogenes	O
at	O
the	O
transcriptional	B-Transcription
and	O
translational	O
levels	O
in	O
the	O
human	O
promonocytic	O
U937	O
cell	O
line	O
.	O

Histamine	O
transiently	O
increased	B-Positive_regulation
cAMP	O
and	O
c	O
-	O
fos	O
expression	B-Gene_expression
through	O
H2	O
receptors	O
.	O

Dibutyryl	O
cAMP	O
also	O
increased	B-Positive_regulation
c	O
-	O
fos	O
mRNA	O
and	O
protein	O
,	O
and	O
levels	O
remained	B-Positive_regulation
elevated	I-Positive_regulation
even	O
after	O
12	O
hr	O
of	O
treatment	O
.	O

Dose	O
-	O
dependence	O
studies	O
using	O
histamine	O
and	O
dimaprit	O
showed	O
that	O
the	O
EC50	B-Regulation
values	I-Regulation
for	O
cAMP	O
production	O
and	O
c	O
-	O
fos	O
increase	B-Positive_regulation
were	O
similar	O
,	O
suggesting	O
that	O
cAMP	O
might	O
be	O
involved	O
in	O
c	O
-	O
fos	O
induction	B-Positive_regulation
via	O
H2	O
receptors	O
.	O

Furthermore	O
,	O
studies	O
carried	O
out	O
using	O
H7	O
,	O
a	O
protein	O
kinase	O
A/protein	O
kinase	O
C	O
inhibitor	O
,	O
blocked	B-Negative_regulation
c	O
-	O
fos	O
induction	B-Positive_regulation
,	O
whereas	O
no	O
effect	B-Regulation
was	O
observed	O
with	O
bisindolylmaleimide	O
,	O
a	O
specific	O
protein	O
kinase	O
C	O
inhibitor	O
.	O

No	O
modification	B-Regulation
of	O
c	O
-	O
myc	O
expression	B-Gene_expression
could	O
be	O
detected	O
on	O
treatment	O
with	O
histamine	O
or	O
its	O
analogues	O
.	O

Nevertheless	O
,	O
dibutyryl	O
cAMP	O
induced	B-Negative_regulation
a	I-Negative_regulation
down	I-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
of	O
the	O
levels	O
of	O
this	O
proto	O
-	O
oncogene	O
.	O

In	O
addition	O
,	O
dibutyryl	O
cAMP	O
inhibited	O
cell	O
growth	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
whereas	O
histamine	O
failed	O
to	O
affect	O
proliferation	O
and	O
differentiation	O
of	O
U937	O
cells	O
.	O

Cells	O
pretreated	O
with	O
dimaprit	O
showed	O
a	O
decrease	O
in	O
the	O
cAMP	O
response	O
to	O
subsequent	O
addition	O
of	O
H2	O
agonists	O
,	O
whereas	O
the	O
cAMP	O
response	O
to	O
prostaglandin	O
E2	O
remained	O
unaltered	O
.	O

This	O
homologous	O
mechanism	O
of	O
H2	O
receptor	O
desensitization	B-Negative_regulation
was	O
time	O
dependent	O
.	O

These	O
results	O
indicate	O
that	O
histamine	O
activates	B-Positive_regulation
several	O
mechanisms	O
involved	O
in	O
the	O
induction	O
of	O
differentiation	O
,	O
such	O
as	O
cAMP	O
and	O
c	O
-	O
fos	O
production	B-Gene_expression
,	O
but	O
fails	O
to	O
promote	O
differentiation	O
of	O
U937	O
cells	O
,	O
apparently	O
due	O
to	O
the	O
rapid	O
desensitization	B-Negative_regulation
of	O
H2	O
receptors	O
.	O

Human	O
cytomegalovirus	O
induces	B-Positive_regulation
interleukin	O
-	O
8	O
production	B-Gene_expression
by	O
a	O
human	O
monocytic	O
cell	O
line	O
,	O
THP	O
-	O
1	O
,	O
through	O
acting	O
concurrently	O
on	O
AP-1	O
-	O
and	O
NF-kappaB	O
-	O
binding	O
sites	O
of	O
the	O
interleukin	O
-	O
8	O
gene	O
.	O

Cytomegalovirus	O
(	O
CMV	O
)	O
infection	O
induced	B-Positive_regulation
interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
)	O
gene	O
transcription	B-Transcription
in	O
a	O
human	O
monocytic	O
cell	O
line	O
,	O
THP	O
-	O
1	O
cells	O
,	O
leading	B-Positive_regulation
to	O
IL	O
-	O
8	O
secretion	B-Localization
.	O

The	O
functional	O
analysis	O
of	O
the	O
IL	O
-	O
8	O
gene	O
revealed	O
that	O
both	O
AP-1	O
-	O
and	O
NF	O
-	O
kappaB	O
factor	O
-	O
binding	O
elements	O
were	O
involved	O
in	O
conferring	O
the	O
responsiveness	O
to	O
CMV	O
.	O

Moreover	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
CMV	O
induced	O
the	O
formation	O
of	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
complexes	O
.	O

These	O
results	O
suggest	O
that	O
CMV	O
activates	O
these	O
transcriptional	O
factors	O
,	O
resulting	B-Positive_regulation
in	O
IL	O
-	O
8	O
gene	O
expression	B-Gene_expression
.	O

Concomitant	O
downregulation	B-Negative_regulation
of	O
IgH	O
3	O
'	O
enhancer	O
activity	O
and	O
c	O
-	O
myc	O
expression	B-Gene_expression
in	O
a	O
plasmacytoma	O
x	O
fibroblast	O
environment	O
:	O
implications	O
for	O
dysregulation	B-Regulation
of	O
translocated	B-Localization
c	O
-	O
myc	O
.	O

Regulation	O
of	O
immunoglobulin	O
heavy	O
chain	O
(	O
IgH	O
)	O
gene	O
expression	O
is	O
controlled	O
by	O
a	O
B	O
cell	O
-	O
specific	O
promoter	O
,	O
intronic	O
enhancer	O
and	O
additional	O
B	O
cell	O
-	O
specific	O
enhancer	O
elements	O
identified	O
recently	O
in	O
the	O
3	O
'	O
end	O
of	O
the	O
IgH	O
locus	O
.	O

One	O
of	O
the	O
latter	O
elements	O
,	O
the	O
IgH	O
3	O
'	O
enhancer	O
,	O
is	O
of	O
particular	O
interest	O
:	O
(	O
1	O
)	O
it	O
is	O
B	O
cell	O
-	O
specific	O
and	O
active	O
only	O
in	O
late	O
B	O
cell	O
development	O
;	O
(	O
2	O
)	O
in	O
rodent	O
plasmacytomas	O
and	O
in	O
some	O
human	O
Burkitt	O
's	O
lymphomas	O
it	O
is	O
part	O
of	O
a	O
locus	O
control	O
region	O
(	O
LCR	O
)	O
that	O
is	O
involved	B-Regulation
in	O
deregulation	B-Regulation
of	O
the	O
c	O
-	O
myc	O
oncogene	O
as	O
a	O
result	B-Regulation
of	O
translocation	B-Localization
into	O
the	O
IgH	O
locus	O
;	O
and	O
(	O
3	O
)	O
it	O
has	O
been	O
implicated	O
in	O
the	O
mechanisms	O
that	O
control	O
Ig	O
gene	O
class	O
switch	O
recombination	O
.	O

We	O
have	O
used	O
a	O
somatic	O
cell	O
hybridization	O
approach	O
to	O
genetically	O
analyse	O
regulation	O
of	O
the	O
activity	O
of	O
the	O
IgH	O
3	O
'	O
enhancer	O
.	O

When	O
mouse	O
MPC11	O
plasmacytoma	O
cells	O
,	O
in	O
which	O
the	O
IgH	O
3	O
'	O
enhancer	O
is	O
active	O
,	O
are	O
fused	O
with	O
fibroblasts	O
,	O
Ig	O
expression	O
is	O
extinguished	O
at	O
the	O
level	O
of	O
transcription	O
.	O

Here	O
we	O
show	O
that	O
in	O
a	O
MPC11	O
plasmacytoma	O
x	O
fibroblast	O
environment	O
,	O
the	O
IgH	O
3	O
'	O
enhancer	O
is	O
transcriptionally	O
inactive	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
binding	O
of	O
several	O
B	O
cell	O
-	O
specific	O
transcription	O
factors	O
,	O
essential	O
for	O
IgH	O
3	O
'	O
enhancer	O
activity	O
,	O
is	O
lacking	O
,	O
which	O
may	O
explain	O
3	O
'	O
enhancer	O
inactivity	O
,	O
although	O
the	O
binding	O
of	O
repressors	O
can	O
not	O
be	O
excluded	O
.	O

Moreover	O
,	O
the	O
high	O
expression	B-Gene_expression
level	O
of	O
c	O
-	O
myc	O
,	O
characteristic	O
of	O
the	O
parental	O
MPC11	O
cells	O
carrying	O
the	O
t	O
(	O
12	O
;	O
15	O
)	O
translocation	O
,	O
is	O
down	B-Negative_regulation
-	I-Negative_regulation
regulated	I-Negative_regulation
in	O
the	O
hybrids	O
to	O
that	O
in	O
unfused	O
fibroblasts	O
.	O

Therefore	O
,	O
inactivation	O
of	O
the	O
IgH	O
3	O
'	O
enhancer	O
is	O
a	O
multifactorial	O
process	O
affecting	O
several	O
transcription	O
factors	O
that	O
control	O
the	O
cell	O
-	O
specific	O
and	O
developmental	O
activity	O
of	O
the	O
enhancer	O
.	O

ETS1	O
,	O
NFkappaB	O
and	O
AP1	O
synergistically	B-Positive_regulation
transactivate	I-Positive_regulation
the	O
human	O
GM	O
-	O
CSF	O
promoter	O
.	O

Activation	O
of	O
helper	O
T	O
cells	O
results	O
in	O
coordinate	O
expression	O
of	O
a	O
number	O
of	O
cytokines	O
involved	O
in	O
differentiation	O
,	O
proliferation	O
and	O
activation	O
of	O
the	O
haematopoietic	O
system	O
.	O

Granulocyte	O
-	O
macrophage	O
colony	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
is	O
one	O
such	O
cytokine	O
,	O
whose	O
increased	B-Positive_regulation
expression	B-Gene_expression
results	O
mostly	O
from	O
increases	B-Positive_regulation
in	O
transcription	B-Transcription
.	O

Cis	O
-	O
acting	O
elements	O
with	O
NFkappaB	O
,	O
AP1	O
and	O
ETS	O
-	O
like	O
binding	O
motifs	O
have	O
been	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
,	O
and	O
are	O
important	B-Positive_regulation
or	I-Positive_regulation
essential	I-Positive_regulation
for	O
transcriptional	B-Transcription
activity	I-Transcription
following	B-Positive_regulation
T	O
cell	O
activation	O
.	O

ETS1	O
is	O
a	O
transcription	O
factor	O
of	O
the	O
ETS	O
family	O
that	O
is	O
expressed	B-Gene_expression
in	O
T	O
cells	O
.	O

We	O
have	O
previously	O
shown	O
that	O
ETS1	O
can	O
transactivate	B-Positive_regulation
GM	O
-	O
CSF	O
in	O
Jurkat	O
T	O
cells	O
,	O
but	O
only	O
after	O
the	O
cells	O
have	O
been	O
stimulated	O
by	O
treatment	O
with	O
PMA	O
and	O
ionomycin	O
,	O
agents	O
that	O
mimic	O
T	O
cell	O
activation	O
.	O

Thus	O
we	O
proposed	O
that	O
ETS1	O
,	O
which	O
is	O
expressed	B-Gene_expression
constitutively	O
in	O
Jurkat	O
cells	O
,	O
may	O
act	O
in	O
concert	O
with	O
PMA/ionomycin	O
inducible	O
factors	O
.	O

Here	O
we	O
show	O
that	O
ETS1	O
can	O
transactivate	O
a	O
GM	O
-	O
CSF	O
reporter	O
construct	O
in	O
unstimulated	O
Jurkat	O
cells	O
,	O
providing	O
that	O
either	O
NFkappaB	O
or	O
AP1	O
transcription	O
factors	O
are	O
supplied	O
by	O
co	O
-	O
transfection	O
.	O

We	O
confirm	O
that	O
binding	O
of	O
endogenous	O
NFkappaB	O
and	O
AP1	O
is	O
induced	O
following	O
PMA/ionomycin	O
treatment	O
of	O
T	O
cells	O
.	O

Transactivation	O
by	O
ETS1	O
,	O
NFkappaB	O
and	O
AP1	O
is	O
synergistic	O
,	O
and	O
mutation	O
of	O
the	O
individual	O
binding	O
sites	O
reveals	O
that	O
the	O
transcriptional	O
activities	O
of	O
these	O
factors	O
are	O
interdependent	O
.	O

Our	O
results	O
suggest	O
that	O
constitutive	O
ETS1	O
,	O
and	O
inducible	O
NFkappaB	O
and	O
AP1	O
,	O
cooperate	O
as	O
part	O
of	O
a	O
higher	O
order	O
transcriptional	O
complex	O
in	O
activated	O
T	O
cells	O
.	O

Relief	B-Negative_regulation
of	O
cyclin	O
A	O
gene	O
transcriptional	B-Negative_regulation
inhibition	I-Negative_regulation
during	O
activation	O
of	O
human	O
primary	O
T	O
lymphocytes	O
via	O
CD2	O
and	O
CD28	O
adhesion	O
molecules	O
.	O

Cyclin	O
A	O
transcription	B-Transcription
is	O
cell	O
cycle	O
regulated	B-Regulation
and	O
induced	B-Positive_regulation
by	O
cell	O
proliferative	O
signals	O
.	O

To	O
understand	O
the	O
mechanisms	O
underlined	O
in	O
this	O
regulation	O
in	O
normal	O
human	O
cells	O
,	O
we	O
have	O
analysed	O
in	O
vivo	O
protein	O
-	O
DNA	O
interactions	B-Binding
at	O
the	O
Cyclin	O
A	O
locus	O
in	O
primary	O
T	O
lymphocytes	O
.	O

Stimulation	O
of	O
purified	O
T	O
lymphocytes	O
by	O
a	O
combination	O
of	O
monoclonal	O
antibodies	O
directed	O
at	O
CD2	O
and	O
CD28	O
adhesion	O
molecules	O
gives	O
rise	O
to	O
a	O
long	O
lasting	O
proliferation	O
in	O
the	O
absence	O
of	O
accessory	O
cells	O
.	O

Cyclin	O
A	O
was	O
observed	B-Transcription
after	O
4	O
days	O
of	O
costimulation	O
with	O
anti	O
CD2	O
+	O
CD28	O
whereas	O
stimulation	O
by	O
anti	O
CD2	O
or	O
anti	O
CD28	O
alone	O
was	O
not	O
effective	B-Positive_regulation
.	O

In	O
vivo	O
genomic	O
DMS	O
footprinting	O
revealed	O
upstream	O
of	O
the	O
major	O
transcription	O
initiation	O
sites	O
,	O
the	O
presence	O
of	O
at	O
least	O
three	O
protein	O
binding	O
sites	O
,	O
two	O
of	O
which	O
were	O
constitutively	O
occupied	O
.	O

They	O
bind	B-Binding
in	O
vitro	O
respectively	O
ATF	O
-	O
1	O
and	O
NF	O
-	O
Y	O
proteins	O
.	O

The	O
third	O
site	O
was	O
occupied	O
in	O
quiescent	O
cells	O
or	O
in	O
cells	O
stimulated	O
by	O
anti	O
CD2	O
or	O
anti	O
CD28	O
alone	O
.	O

The	O
mitogenic	O
combination	O
of	O
anti	O
CD2	O
+	O
anti	O
CD28	O
released	O
the	O
footprint	O
as	O
cells	O
were	O
committed	O
to	O
proliferation	O
.	O

Consistent	O
with	O
theses	O
results	O
,	O
nuclear	O
extracts	O
prepared	O
from	O
quiescent	O
cells	O
formed	O
a	O
specific	O
complex	O
with	O
this	O
element	O
,	O
whereas	O
extracts	O
prepared	O
from	O
cells	O
treated	O
with	O
anti	O
CD2	O
+	O
anti	O
CD28	O
failed	O
to	O
do	O
so	O
after	O
cells	O
entered	O
a	O
proliferative	O
state	O
.	O

Biphasic	O
control	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
induced	O
by	O
the	O
triggering	O
of	O
HLA	O
-	O
DR	O
antigens	O
expressed	O
on	O
B	O
cells	O
.	O

The	O
regulation	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
following	O
the	O
triggering	O
of	O
HLA	O
-	O
DR	O
antigens	O
by	O
mAb	O
L243	O
has	O
been	O
studied	O
at	O
various	O
times	O
in	O
Raji	O
cells	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
a	O
strong	O
increase	O
of	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
after	O
triggering	O
of	O
HLA	O
-	O
DR	O
antigens	O
.	O

Using	O
TNF-alpha	O
-	O
activity	O
neutralizing	O
antibodies	O
,	O
the	O
authors	O
demonstrated	O
that	O
the	O
upregulation	O
of	O
NF	O
-	O
kappa	O
B	O
was	O
found	O
to	O
depend	O
,	O
at	O
later	O
time	O
point	O
,	O
on	O
an	O
autocrine	O
effect	O
of	O
TNF	O
-	O
alpha	O
secreted	B-Localization
following	B-Positive_regulation
triggering	O
of	O
HLA	O
-	O
DR	O
antigens	O
.	O

In	O
contrast	O
,	O
it	O
was	O
found	O
to	O
be	O
TNF	O
-	O
alpha	O
independent	O
in	O
the	O
early	O
time	O
point	O
.	O

Moreover	O
,	O
the	O
upregulation	O
of	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
is	O
regulated	O
by	O
the	O
triggering	O
of	O
selected	O
epitopes	O
of	O
HLA	O
-	O
DR	O
antigens	O
.	O

In	O
fact	O
,	O
mAb	O
L243	O
but	O
not	O
the	O
staphylococcal	O
superantigens	O
,	O
staphylococcal	O
exotoxin	O
toxic	O
shock	O
syndrome	O
toxin	O
-	O
I	O
or	O
staphylococcal	O
enterotoxin	O
B	O
,	O
regulate	O
the	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
.	O

Comparison	O
of	O
the	O
transactivation	O
domains	O
of	O
Stat5	O
and	O
Stat6	O
in	O
lymphoid	O
cells	O
and	O
mammary	O
epithelial	O
cells	O
.	O

Stat	O
(	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
)	O
and	O
Jak	O
(	O
Janus	O
kinases	O
)	O
proteins	O
are	O
central	O
components	O
in	O
the	O
signal	O
transduction	O
events	O
in	O
hematopoietic	O
and	O
epithelial	O
cells	O
.	O

They	O
are	O
rapidly	O
activated	O
by	O
various	O
cytokines	O
,	O
hormones	O
,	O
and	O
growth	O
factors	O
.	O

Upon	O
ligand	O
binding	O
and	O
cytokine	O
receptor	O
dimerization	O
,	O
Stat	O
proteins	O
are	O
phosphorylated	O
on	O
tyrosine	O
residues	O
by	O
Jak	O
kinases	O
.	O

Activated	O
Stat	O
proteins	O
form	O
homo	O
-	O
or	O
heterodimers	O
,	O
translocate	O
to	O
the	O
nucleus	O
,	O
and	O
induce	O
transcription	O
from	O
responsive	O
genes	O
.	O

Stat5	O
and	O
Stat6	O
are	O
transcription	O
factors	O
active	B-Positive_regulation
in	O
mammary	O
epithelial	O
cells	O
and	O
immune	O
cells	O
.	O

Prolactin	O
activates	B-Positive_regulation
Stat5	O
,	O
and	O
interleukin	O
-	O
4	O
(	O
IL	O
-	O
4	O
)	O
activates	B-Positive_regulation
Stat6	O
.	O

Both	O
cytokines	O
are	O
able	O
to	O
stimulate	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
and	O
survival	O
.	O

We	O
investigated	O
the	O
transactivation	B-Positive_regulation
potential	O
of	O
Stat6	O
and	O
found	O
that	O
it	O
is	O
not	O
restricted	B-Negative_regulation
to	O
lymphocytes	O
.	O

IL-4	O
-	O
dependent	O
activation	B-Positive_regulation
of	O
Stat6	O
was	O
also	O
observed	O
in	O
HC11	O
mammary	O
epithelial	O
cells	O
.	O

In	O
these	O
cells	O
,	O
Stat6	O
activation	B-Positive_regulation
led	O
to	O
the	O
induction	O
of	O
the	O
beta	O
-	O
casein	O
gene	O
promoter	O
.	O

The	O
induction	O
of	O
this	O
promoter	O
was	O
confirmed	O
in	O
COS7	O
cells	O
.	O

The	O
glucocorticoid	O
receptor	O
was	O
able	O
to	O
further	O
enhance	B-Positive_regulation
IL-4	O
-	O
induced	O
gene	O
transcription	O
through	O
the	O
action	O
of	O
Stat6	O
.	O

Deletion	O
analysis	O
of	O
the	O
carboxyl	O
-	O
terminal	O
region	O
of	O
Stat6	O
and	O
recombination	O
of	O
this	O
region	O
with	O
a	O
heterologous	O
DNA	O
binding	O
domain	O
allowed	O
the	O
delimitation	O
and	O
characterization	O
of	O
the	O
transactivation	O
domain	O
of	O
Stat6	O
.	O

The	O
potencies	O
of	O
the	O
transactivation	O
domains	O
of	O
Stat5	O
,	O
Stat6	O
,	O
and	O
viral	O
protein	O
VP16	O
were	O
compared	O
.	O

Stat6	O
had	O
a	O
transactivation	O
domain	O
which	O
was	O
about	O
10	O
-	O
fold	O
stronger	O
than	O
that	O
of	O
Stat5	O
.	O

In	O
pre	O
-	O
B	O
cells	O
(	O
Ba/F3	O
)	O
,	O
the	O
transactivation	O
domain	O
of	O
Stat6	O
was	O
IL	O
-	O
4	O
regulated	B-Regulation
,	O
independently	B-Positive_regulation
from	O
its	O
DNA	O
binding	B-Binding
function	O
.	O

The	O
immediate	O
-	O
early	O
gene	O
product	O
Egr	O
-	O
1	O
regulates	O
the	O
human	O
interleukin	O
-	O
2	O
receptor	O
beta	O
-	O
chain	O
promoter	O
through	B-Regulation
noncanonical	O
Egr	O
and	O
Sp1	O
binding	O
sites	O
.	O

The	O
interleukin	O
-	O
2	O
IL	O
-	O
2	O
receptor	O
beta	O
-	O
chain	O
(	O
IL	O
-	O
2Rbeta	O
)	O
is	O
an	O
essential	O
component	O
of	O
the	O
receptors	O
for	O
IL	O
-	O
2	O
and	O
IL	O
-	O
15	O
.	O

Although	O
IL	O
-	O
2Rbeta	O
is	O
constitutively	O
expressed	B-Gene_expression
by	O
lymphocytes	O
,	O
its	O
expression	O
can	O
be	O
further	O
induced	B-Positive_regulation
by	O
a	O
number	O
of	O
stimuli	O
,	O
including	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
.	O

We	O
have	O
now	O
characterized	O
factors	O
that	O
bind	B-Binding
to	O
an	O
enhancer	O
region	O
located	O
between	O
nucleotides	O
-	O
170	O
and	O
-	O
139	O
of	O
the	O
human	O
IL	O
-	O
2Rbeta	O
promoter	O
.	O

Both	O
Sp1	O
and	O
Sp3	O
bound	B-Binding
to	O
the	O
5	O
'	O
portion	O
of	O
this	O
region	O
,	O
whereas	O
a	O
PMA	O
-	O
inducible	O
factor	O
(	O
PIF	O
)	O
mainly	O
bound	O
to	O
its	O
3	O
'	O
portion	O
and	O
bound	O
to	O
the	O
Sp	O
binding	O
motifs	O
as	O
well	O
.	O

In	O
Jurkat	O
T	O
cells	O
,	O
induction	O
of	O
PIF	O
DNA	O
binding	O
activity	O
was	O
rapidly	O
induced	O
,	O
required	O
de	O
novo	O
protein	O
synthesis	O
,	O
and	O
was	O
sustained	O
at	O
a	O
high	O
level	O
for	O
at	O
least	O
23	O
h	O
.	O

Interestingly	O
,	O
PIF	O
was	O
constitutively	O
activated	O
in	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
-	O
transformed	O
MT	O
-	O
2	O
cells	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
PIF	O
is	O
Egr	O
-	O
1	O
based	O
on	O
its	O
recognition	B-Binding
by	O
anti-Egr	O
-	O
1	O
antisera	O
in	O
gel	O
mobility	O
shift	O
assays	O
,	O
even	O
though	O
the	O
IL	O
-	O
2Rbeta	O
DNA	O
binding	O
motif	O
differed	O
substantially	O
from	O
the	O
canonical	O
Egr	O
-	O
1	O
binding	O
site	O
.	O

In	O
addition	O
,	O
Egr	O
-	O
1	O
bound	B-Binding
to	O
the	O
Sp	O
binding	O
site	O
.	O

In	O
Jurkat	O
cells	O
,	O
both	O
sites	O
were	O
required	B-Positive_regulation
for	O
maximal	O
IL	O
-	O
2Rbeta	O
promoter	O
activity	O
,	O
and	O
in	O
HeLaS3	O
cells	O
,	O
transfection	B-Gene_expression
of	O
Egr	O
-	O
1	O
could	O
drive	O
activity	O
of	O
a	O
reporter	O
construct	O
containing	O
both	O
sites	O
.	O

Moreover	O
,	O
Sp1	O
and	O
Egr	O
-	O
1	O
could	O
form	B-Binding
a	I-Binding
complex	I-Binding
with	O
kinetics	O
that	O
correlated	O
with	O
the	O
production	B-Gene_expression
of	O
Egr	O
-	O
1	O
in	O
Jurkat	O
cells	O
upon	O
PMA	O
stimulation	O
.	O

Thus	O
,	O
Sp1	O
and	O
Egr	O
-	O
1	O
physically	O
and	O
functionally	O
cooperate	O
to	O
mediate	B-Positive_regulation
maximal	O
IL	O
-	O
2Rbeta	O
promoter	O
activity	O
.	O

Anti	O
-	O
Ehrlichia	O
chaffeensis	O
antibody	O
complexed	O
with	O
E.	O
chaffeensis	O
induces	O
potent	O
proinflammatory	O
cytokine	O
mRNA	O
expression	O
in	O
human	O
monocytes	O
through	O
sustained	O
reduction	B-Negative_regulation
of	O
IkappaB	O
-	O
alpha	O
and	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O

Ehrlichia	O
chaffeensis	O
is	O
an	O
obligatory	O
intracellular	O
bacterium	O
that	O
infects	O
monocytes	O
and	O
macrophages	O
and	O
is	O
the	O
etiologic	O
agent	O
of	O
human	O
ehrlichiosis	O
in	O
the	O
United	O
States	O
.	O

Our	O
previous	O
studies	O
showed	O
that	O
the	O
exposure	O
of	O
human	O
monocytes	O
to	O
E.	O
chaffeensis	O
induces	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
interleukin	O
-	O
1beta	O
(	O
IL	O
-	O
1beta	O
)	O
,	O
IL	O
-	O
8	O
,	O
and	O
IL	O
-	O
10	O
genes	O
in	O
vitro	O
but	O
not	O
the	O
expression	B-Transcription
of	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
IL	O
-	O
6	O
mRNAs	O
.	O

In	O
this	O
study	O
,	O
the	O
effect	O
of	O
anti	O
-	O
E.	O
chaffeensis	O
antibody	O
complexed	O
with	O
E.	O
chaffeensis	O
on	O
the	O
expression	O
of	O
major	O
proinflammatory	O
cytokines	O
in	O
human	O
monocytes	O
was	O
examined	O
.	O

Human	O
monocytic	O
cell	O
line	O
THP	O
-	O
1	O
was	O
treated	O
with	O
E.	O
chaffeensis	O
which	O
had	O
been	O
preincubated	O
with	O
human	O
anti	O
-	O
E.	O
chaffeensis	O
serum	O
for	O
2	O
h	O
,	O
and	O
the	O
levels	O
of	O
cytokine	O
mRNAs	O
were	O
evaluated	O
by	O
competitive	O
reverse	O
transcription	O
-	O
PCR	O
.	O

Anti	O
-	O
E.	O
chaffeensis	O
antibody	O
complexed	O
with	O
E.	O
chaffeensis	O
significantly	O
enhanced	B-Positive_regulation
mRNA	B-Transcription
expression	I-Transcription
of	O
IL	O
-	O
1beta	O
in	O
THP	O
-	O
1	O
cells	O
.	O

The	O
expression	B-Transcription
of	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
6	O
mRNAs	O
was	O
also	O
induced	B-Positive_regulation
.	O

The	O
levels	O
of	O
secreted	O
IL	O
-	O
1beta	O
,	O
TNF	O
-	O
alpha	O
,	O
and	O
IL	O
-	O
6	O
during	O
24	O
h	O
of	O
stimulation	O
were	O
comparable	O
to	O
those	O
induced	O
by	O
Escherichia	O
coli	O
lipopolysaccharide	O
at	O
1	O
microg/ml	O
.	O

Fab	O
fragment	O
of	O
anti	O
-	O
E.	O
chaffeensis	O
immunoglobulin	O
G	O
complexed	O
with	O
E.	O
chaffeensis	O
did	O
not	O
induce	B-Positive_regulation
any	O
of	O
these	O
three	O
cytokines	O
,	O
indicating	O
that	O
ehrlichial	O
binding	O
is	O
required	B-Positive_regulation
for	O
IL	O
-	O
1beta	O
mRNA	O
expression	B-Transcription
and	O
that	O
binding	B-Binding
of	O
the	O
immune	O
complex	O
to	O
the	O
Fc	O
gamma	O
receptor	O
is	O
required	B-Positive_regulation
for	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
6	O
mRNA	O
expression	B-Transcription
and	O
enhanced	B-Positive_regulation
IL	O
-	O
1beta	O
mRNA	O
expression	B-Transcription
.	O

Furthermore	O
,	O
prolonged	O
degradation	B-Protein_catabolism
of	O
IkappaB	O
-	O
alpha	O
and	O
activation	O
of	O
NF	O
-	O
kappaB	O
were	O
demonstrated	B-Positive_regulation
in	O
THP	O
-	O
1	O
cells	O
exposed	O
to	O
anti	O
-	O
E.	O
chaffeensis	O
serum	O
and	O
E.	O
chaffeensis	O
.	O

This	O
result	O
implies	O
that	O
development	O
of	O
anti	O
-	O
E.	O
chaffeensis	O
antibody	O
in	O
patients	O
can	O
result	O
in	O
the	O
production	O
of	O
major	O
proinflammatory	O
cytokines	O
,	O
which	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
ehrlichiosis	O
and	O
immune	O
responses	O
to	O
it	O
.	O

S	O
-	O
allyl	O
cysteine	O
inhibits	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
in	O
human	O
T	O
cells	O
.	O

Reactive	O
oxygen	O
species	O
are	O
involved	O
in	O
signal	O
transduction	O
pathways	O
leading	O
to	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
activation	O
which	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
gene	O
transcription	O
.	O

We	O
recently	O
reported	O
that	O
a	O
garlic	O
compound	O
,	O
S	O
-	O
allyl	O
cysteine	O
(	O
SAC	O
)	O
,	O
protects	O
bovine	O
pulmonary	O
artery	O
endothelial	O
cells	O
from	O
oxidant	O
injury	O
induced	O
by	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
.	O

In	O
this	O
study	O
we	O
determined	O
the	O
effects	O
of	O
SAC	O
on	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
human	O
T	O
lymphocytes	O
(	O
Jurkat	O
cells	O
)	O
induced	O
by	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
H2O2	O
.	O

Activated	O
NF	O
-	O
kappa	O
B	O
in	O
nuclear	O
extracts	O
was	O
measured	O
by	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
32P	O
-	O
labeled	O
probe	O
.	O

SAC	O
consistently	O
exhibited	O
a	O
dose	O
-	O
dependent	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
induced	O
by	O
both	O
TNF	O
-	O
alpha	O
and	O
H2O2	O
.	O

Supershift	O
with	O
specific	O
antibodies	O
to	O
NF	O
-	O
kappa	O
B	O
subunits	O
confirmed	O
that	O
the	O
inducible	O
retarded	O
bands	O
observed	O
in	O
the	O
EMSA	O
and	O
p65	O
-	O
p50	O
heterodimer	B-Binding
of	O
the	O
NF	O
-	O
kappa	O
B/Rel	O
protein	O
.	O

Our	O
data	O
suggest	O
that	O
SAC	O
may	O
act	O
via	O
antioxidant	O
mechanisms	O
to	O
block	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
Jurkat	O
cells	O
.	O

Effect	O
of	O
adenovirus	O
2	O
on	O
cellular	O
gene	O
activation	O
in	O
blood	O
-	O
derived	O
monocytes	O
and	O
macrophages	O
.	O

We	O
have	O
investigated	O
the	O
effect	B-Regulation
of	O
adenovirus	O
2	O
(	O
Ad2	O
)	O
infection	O
on	O
human	O
monocytes	O
and	O
monocyte	O
-	O
derived	O
macrophages	O
with	O
regard	O
to	O
expression	B-Gene_expression
of	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
1	O
beta	O
.	O

In	O
monocytes	O
,	O
the	O
virus	O
was	O
bound	O
to	O
the	O
surface	O
without	O
being	O
internalized	O
.	O

On	O
the	O
other	O
hand	O
,	O
Ad2	O
was	O
internalized	O
by	O
macrophages	O
.	O

No	O
virus	O
replication	O
and	O
no	O
transcription	O
of	O
the	O
Ad2	O
early	O
genes	O
was	O
observed	O
in	O
either	O
of	O
the	O
cells	O
.	O

Ad2	O
infection	O
induced	B-Positive_regulation
transient	O
increase	B-Positive_regulation
in	O
the	O
mRNA	B-Transcription
levels	I-Transcription
for	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
1	O
beta	O
in	O
both	O
monocytes	O
and	O
in	O
macrophages	O
,	O
although	O
the	O
kinetics	O
of	O
the	O
transcription	O
was	O
slightly	O
different	O
.	O

The	O
production	B-Gene_expression
of	O
both	O
cytokines	O
,	O
measured	O
by	O
ELISA	O
tests	O
,	O
was	O
enhanced	B-Positive_regulation
in	O
monocytes	O
.	O

In	O
macrophages	O
,	O
a	O
slight	O
enhancement	B-Positive_regulation
of	O
TNF	O
-	O
alpha	O
production	B-Gene_expression
was	O
seen	O
,	O
whereas	O
IL	O
-	O
1	O
beta	O
was	O
not	O
detected	B-Gene_expression
.	O

The	O
data	O
indicate	O
that	O
cellular	O
genes	O
might	O
be	O
activated	O
by	O
Ad2	O
virus	O
infection	O
in	O
nonpermissive	O
cells	O
where	O
no	O
viral	O
gene	O
products	O
could	O
be	O
detected	O
.	O

Activation	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
by	O
beta	O
-	O
amyloid	O
peptides	O
and	O
interferon	O
-	O
gamma	O
in	O
murine	O
microglia	O
.	O

An	O
increasing	O
body	O
of	O
evidence	O
suggests	O
that	O
amyloid	O
-	O
beta	O
(	O
A	O
beta	O
)	O
peptides	O
and	O
microglia	O
are	O
crucially	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Alzheimer	O
's	O
disease	O
.	O

In	O
an	O
effort	O
to	O
further	O
elucidate	O
the	O
biological	O
effects	O
of	O
A	O
beta	O
towards	O
microglia	O
,	O
we	O
investigated	O
the	O
ability	O
of	O
A	O
beta	O
peptides	O
to	O
activate	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
in	O
the	O
N9	O
murine	O
microglial	O
cell	O
line	O
.	O

Co	O
-	O
stimulation	O
of	O
microglia	O
with	O
suboptimal	O
concentrations	O
of	O
A	O
beta	O
(	O
25	O
-	O
35	O
)	O
and	O
100	O
U/ml	O
IFN	O
gamma	O
resulted	O
in	O
the	O
detection	O
of	O
a	O
specific	O
NF	O
-	O
kappa	O
B	O
DNA	O
-	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
,	O
as	O
determined	O
in	O
gel	O
mobility	O
shift	O
assays	O
.	O

This	O
response	O
required	O
at	O
least	O
120	O
min	O
to	O
be	O
evident	O
and	O
supershift	O
experiments	O
revealed	O
that	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
contains	O
both	O
RelA	O
and	O
p50	O
.	O

Accordingly	O
,	O
immunoblot	O
experiments	O
showed	O
that	O
amongst	O
NF	O
-	O
kappa	O
B/Rel	O
proteins	O
,	O
RelA	O
and	O
p50	O
are	O
mobilized	B-Localization
to	O
the	O
nucleus	O
following	B-Positive_regulation
microglial	O
cell	O
stimulation	O
with	O
A	O
beta	O
(	O
25	O
-	O
35	O
)	O
plus	O
IFN	O
gamma	O
.	O

Higher	O
concentrations	O
of	O
A	O
beta	O
(	O
25	O
-	O
35	O
)	O
were	O
effective	O
by	O
themselves	O
in	O
inducing	O
NF	O
-	O
kappa	O
B	O
activation	O
,	O
both	O
in	O
the	O
N9	O
microglial	O
cell	O
line	O
and	O
in	O
rat	O
primary	O
microglia	O
,	O
as	O
well	O
as	O
in	O
human	O
monocytes	O
.	O

For	O
purposes	O
of	O
comparison	O
,	O
microglia	O
were	O
also	O
stimulated	O
with	O
bacterial	O
LPS	O
,	O
a	O
known	O
NF	O
-	O
kappa	O
B	O
inducer	O
.	O

As	O
expected	O
,	O
LPS	O
strongly	O
induced	B-Positive_regulation
the	I-Positive_regulation
formation	I-Positive_regulation
of	O
two	O
NF	O
-	O
kappa	O
B	O
DNA	O
-	O
binding	B-Binding
activities	O
,	O
one	O
of	O
which	O
was	O
identified	O
as	O
RelA/p50	O
.	O

The	O
LPS	O
response	O
was	O
also	O
more	O
rapid	O
,	O
as	O
it	O
was	O
already	O
evident	O
by	O
40	O
min	O
and	O
remained	O
sustained	O
for	O
up	O
to	O
3	O
h	O
.	O

Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
NF	O
-	O
kappa	O
B	O
activation	O
might	O
constitute	O
one	O
of	O
the	O
mechanisms	O
underlying	O
the	O
inducible	O
expression	O
of	O
kappa	O
B	O
-	O
dependent	O
genes	O
in	O
microglia	O
stimulated	O
by	O
A	O
beta	O
peptides	O
and	O
IFN	O
gamma	O
,	O
or	O
by	O
LPS	O
.	O

AP	O
-	O
1	O
derived	O
from	O
mature	O
monocytes	O
and	O
astrocytes	O
preferentially	O
interacts	O
with	O
the	O
HTLV	O
-	O
I	O
promoter	O
central	O
21	O
bp	O
repeat	O
.	O

Characterization	O
of	O
the	O
cellular	O
transcription	O
factors	O
interacting	O
with	O
the	O
human	O
T	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
is	O
essential	O
to	O
dissecting	O
the	O
mechanisms	O
involved	O
in	O
viral	O
transcription	O
that	O
may	O
be	O
pertinent	O
to	O
the	O
oncogenic	O
and	O
neuropathogenic	O
processes	O
associated	O
with	O
HTLV	O
-	O
I	O
infection	O
in	O
both	O
the	O
immune	O
and	O
nervous	O
systems	O
.	O

Electrophoretic	O
mobility	O
shift	O
(	O
EMS	O
)	O
analyses	O
utilizing	O
oligonucleotides	O
homologous	O
to	O
each	O
of	O
the	O
21	O
bp	O
repeat	O
elements	O
reacted	O
with	O
nuclear	O
extracts	O
derived	O
from	O
cell	O
lines	O
of	O
lymphocytic	O
,	O
monocytic	O
,	O
neuronal	O
,	O
and	O
glial	O
cell	O
origin	O
have	O
demonstrated	O
differential	O
binding	O
of	O
cellular	O
factors	O
to	O
the	O
three	O
21	O
bp	O
repeats	O
(	O
1	O
-	O
4	O
)	O
.	O

ATF/CREB	O
and	O
Sp	O
family	O
members	O
interacted	O
with	O
the	O
21	O
bp	O
repeats	O
to	O
form	O
DNA	O
-	O
protein	O
complexes	O
common	O
to	O
all	O
cell	O
types	O
examined	O
.	O

However	O
,	O
a	O
unique	O
DNA	O
-	O
protein	O
complex	O
was	O
detected	O
when	O
the	O
promoter	O
central	O
21	O
bp	O
repeat	O
was	O
reacted	O
with	O
nuclear	O
extracts	O
derived	O
from	O
either	O
the	O
U	O
-	O
373	O
MG	O
glioblastoma	O
cell	O
line	O
or	O
the	O
THP	O
-	O
1	O
mature	O
monocytic	O
cell	O
line	O
.	O

Based	O
on	O
nucleotide	O
sequence	O
requirements	O
and	O
immunoreactivity	O
,	O
we	O
demonstrate	O
that	O
this	O
DNA	O
-	O
protein	O
complex	O
is	O
comprised	O
of	O
the	O
AP	O
-	O
1	O
components	O
,	O
Fos	O
and	O
Jun	O
.	O

Of	O
the	O
GATA	O
-	O
binding	O
proteins	O
,	O
only	O
GATA	O
-	O
4	O
selectively	O
regulates	B-Regulation
the	O
human	O
IL	O
-	O
5	O
gene	O
promoter	O
in	O
IL	O
-	O
5	O
producing	B-Gene_expression
cells	O
which	O
express	O
multiple	O
GATA	O
-	O
binding	O
proteins	O
.	O

Interleukin	O
-	O
5	O
(	O
IL	O
-	O
5	O
)	O
is	O
produced	B-Gene_expression
by	O
T	O
lymphocytes	O
and	O
known	O
to	O
support	O
B	O
cell	O
growth	O
and	O
eosinophilic	O
differentiation	O
of	O
the	O
progenitor	O
cells	O
.	O

Using	O
ATL	O
-	O
16T	O
cells	O
which	O
express	B-Transcription
IL	O
-	O
5	O
mRNA	O
,	O
we	O
have	O
identified	O
a	O
region	O
,	O
within	O
the	O
human	O
IL	O
-	O
5	O
gene	O
promoter	O
,	O
that	O
regulates	B-Regulation
IL	O
-	O
5	O
gene	O
transcription	B-Transcription
.	O

This	O
cis	O
-	O
acting	O
sequence	O
contains	O
the	O
core	O
binding	O
motif	O
,	O
(	O
A/T	O
)	O
GATA	O
(	O
A/G	O
)	O
,	O
for	O
GATA	O
-	O
binding	O
family	O
proteins	O
and	O
thus	O
suggests	O
the	O
involvement	O
of	O
these	O
family	O
members	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
cloning	O
of	O
human	O
GATA	O
-	O
4	O
(	O
hGATA	O
-	O
4	O
)	O
and	O
show	O
that	O
hGATA	O
-	O
4	O
selectively	O
interacts	B-Binding
with	O
the	O
-	O
70	O
GATA	O
site	O
within	O
the	O
IL	O
-	O
5	O
proximal	O
promoter	O
region	O
.	O

By	O
promoter	O
deletion	O
and	O
mutation	O
analyses	O
,	O
we	O
established	O
this	O
region	O
as	O
a	O
positive	O
regulatory	O
element	O
.	O

Cotransfection	O
experiments	O
revealed	O
that	O
both	O
hGATA	O
-	O
4	O
and	O
PMA/A23187	O
stimulation	O
are	O
necessary	B-Positive_regulation
for	O
the	O
IL	O
-	O
5	O
promoter	O
activation	B-Positive_regulation
.	O

The	O
requirement	B-Positive_regulation
of	O
another	O
regulatory	O
element	O
called	O
CLE0	O
,	O
which	O
lies	O
downstream	O
of	O
the	O
-	O
70	O
GATA	O
site	O
,	O
was	O
also	O
demonstrated	O
.	O

ATL	O
-	O
16T	O
cells	O
express	B-Gene_expression
mRNA	O
of	O
three	O
GATA	O
-	O
binding	O
proteins	O
,	O
hGATA	O
-	O
2	O
,	O
hGATA	O
-	O
3	O
and	O
hGATA	O
-	O
4	O
,	O
and	O
each	O
of	O
them	O
has	O
a	O
potential	O
to	O
bind	B-Binding
to	O
the	O
consensus	O
(	O
A/T	O
)	O
GATA	O
(	O
G/	O
A	O
)	O
motif	O
.	O

However	O
,	O
using	O
ATL	O
-	O
16T	O
nuclear	O
extract	O
,	O
we	O
demonstrated	O
that	O
GATA	O
-	O
4	O
is	O
the	O
only	O
GATA	O
-	O
binding	O
protein	O
that	O
forms	B-Binding
specific	I-Binding
DNA	I-Binding
-	I-Binding
protein	I-Binding
complex	I-Binding
with	O
the	O
-	O
70	O
GATA	O
site	O
.	O

The	O
electrophoretic	O
mobility	O
shift	O
assay	O
with	O
extracts	O
of	O
COS	O
cells	O
expressing	O
GATA	O
-	O
binding	O
proteins	O
showed	O
that	O
GATA	O
-	O
4	O
has	B-Binding
the	I-Binding
highest	I-Binding
binding	I-Binding
affinity	I-Binding
to	O
the	O
-	O
70	O
GATA	O
site	O
among	O
the	O
three	O
GATA	O
-	O
binding	O
proteins	O
.	O

When	O
the	O
transactivation	O
ability	O
was	O
compared	O
among	O
the	O
three	O
,	O
GATA	O
-	O
4	O
showed	O
the	O
highest	O
activity	O
.	O

These	O
results	O
demonstrate	O
the	O
selective	O
role	B-Regulation
of	O
GATA	O
-	O
4	O
in	O
the	O
transcriptional	B-Regulation
regulation	I-Regulation
of	O
the	O
IL	O
-	O
5	O
gene	O
in	O
a	O
circumstance	O
where	O
multiple	O
members	O
of	O
the	O
GATA	O
-	O
binding	O
proteins	O
are	O
expressed	O
.	O

Inducible	B-Positive_regulation
expression	B-Gene_expression
and	O
phosphorylation	B-Phosphorylation
of	O
coactivator	O
BOB.1/OBF.1	O
in	O
T	O
cells	O
[	O
see	O
comments	O
]	O

BOB.1/OBF.1	O
is	O
a	O
transcriptional	O
coactivator	O
that	O
is	O
constitutively	O
expressed	B-Gene_expression
in	O
B	O
cells	O
and	O
interacts	B-Binding
with	O
the	O
Oct1	O
and	O
Oct2	O
transcription	O
factors	O
.	O

Upon	O
activation	O
of	O
Jurkat	O
T	O
cells	O
and	O
primary	O
murine	O
thymocytes	O
with	O
phorbol	O
esters	O
and	O
ionomycin	O
,	O
BOB.1/OBF.1	O
expression	B-Gene_expression
and	O
transactivation	O
function	O
were	O
induced	B-Positive_regulation
.	O

BOB.1/OBF.1	O
was	O
phosphorylated	B-Phosphorylation
at	O
Ser184	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
and	O
this	O
modification	O
was	O
required	B-Positive_regulation
for	O
inducible	O
activation	O
.	O

Mutation	O
of	O
Ser184	O
also	O
diminished	O
transactivation	O
function	O
in	O
B	O
cells	O
,	O
suggesting	O
that	O
the	O
activating	B-Positive_regulation
phosphorylation	O
that	O
is	O
inducible	B-Positive_regulation
in	O
T	O
cells	O
is	O
constitutively	O
present	O
in	O
B	O
cells	O
.	O

Thus	O
,	O
BOB.1/OBF.1	O
is	O
a	O
transcriptional	O
coactivator	O
that	O
is	O
critically	O
regulated	B-Regulation
by	O
posttranslational	O
modifications	O
to	O
mediate	O
cell	O
type	O
-	O
specific	O
gene	O
expression	O
.	O

Role	O
of	O
the	O
X2	O
box	O
in	O
activated	O
transcription	O
from	O
the	O
DRA	O
promoter	O
in	O
B	O
cells	O
.	O

We	O
investigated	O
the	O
function	O
of	O
the	O
evolutionary	O
conserved	O
X2	O
box	O
in	O
the	O
promoter	O
of	O
the	O
HLA	O
-	O
DRA	O
gene	O
from	O
the	O
human	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
in	O
resting	O
and	O
activated	O
B	O
cells	O
.	O

NF	O
-	O
X2	O
,	O
which	O
contains	O
members	O
of	O
the	O
AP	O
-	O
1/ATF/CREB	O
families	O
of	O
transcription	O
factors	O
,	O
interacts	O
with	O
the	O
X2	O
box	O
(	O
5'-TGCGTCA	O
-	O
3	O
'	O
)	O
from	O
positions	O
-	O
97	O
to	O
-	O
91	O
in	O
the	O
DRA	O
promoter	O
.	O

In	O
resting	O
Raji	O
cells	O
,	O
little	O
to	O
no	O
binding	O
to	O
the	O
X2	O
box	O
was	O
observed	O
.	O

In	O
sharp	O
contrast	O
,	O
in	O
B	O
cells	O
treated	O
with	O
the	O
phorbol	O
ester	O
12-O-tetradecanoylphorbol-13	O
-	O
acetate	O
(	O
TPA	O
)	O
,	O
strong	O
interactions	O
between	O
the	O
X2	O
box	O
and	O
NF	O
-	O
X2	O
containing	O
c	O
-	O
Fos	O
were	O
observed	O
.	O

As	O
determined	O
by	O
transient	O
expression	O
and	O
RNA	O
analyses	O
,	O
the	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
also	O
increased	O
rates	O
of	O
transcription	O
from	O
the	O
wild	O
-	O
type	O
DRA	O
promoter	O
but	O
not	O
from	O
a	O
DRA	O
promoter	O
bearing	O
clustered	O
point	O
mutations	O
in	O
the	O
X2	O
box	O
.	O

Since	O
the	O
co	B-Gene_expression
-	I-Gene_expression
expression	I-Gene_expression
with	O
a	O
dominant	O
negative	O
c	O
-	O
Fos	O
abolished	O
the	O
responsiveness	O
to	O
TPA	O
,	O
we	O
conclude	O
that	O
activated	O
transcription	O
of	O
the	O
DRA	O
gene	O
depends	O
on	O
interactions	O
between	O
the	O
X2	O
box	O
and	O
NF	O
-	O
X2	O
,	O
which	O
contains	O
c	O
-	O
Fos	O
.	O

Rescue	O
by	O
cytokines	O
of	O
apoptotic	O
cell	O
death	O
induced	O
by	O
IL	O
-	O
2	O
deprivation	B-Negative_regulation
of	O
human	O
antigen	O
-	O
specific	O
T	O
cell	O
clones	O
.	O

The	O
control	O
of	O
cell	O
survival	O
and	O
cell	O
death	O
is	O
of	O
central	O
importance	O
in	O
tissues	O
with	O
high	O
cell	O
turnover	O
such	O
as	O
the	O
lymphoid	O
system	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
cytokines	O
on	O
IL	O
-	O
2	O
deprivation	B-Negative_regulation
-	O
induced	O
apoptosis	O
of	O
human	O
antigen	O
-	O
specific	O
T	O
helper	O
clones	O
with	O
different	O
cytokine	O
production	O
profiles	O
.	O

We	O
found	O
that	O
IL	O
-	O
2	O
,	O
interferon	O
-	O
alpha	O
(	O
IFN	O
-	O
alpha	O
)	O
,	O
and	O
IFN	O
-	O
beta	O
inhibited	O
IL	O
-	O
2	O
deprivation	B-Negative_regulation
apoptosis	O
in	O
Th0	O
,	O
Th1	O
,	O
and	O
Th2	O
clones	O
.	O

We	O
also	O
found	O
that	O
IL	O
-	O
2	O
protects	O
T	O
cell	O
clones	O
from	O
IL	O
-	O
2	O
deprivation	B-Negative_regulation
apoptosis	O
accompanying	O
active	O
proliferation	O
and	O
enhanced	B-Positive_regulation
expression	B-Gene_expression
of	O
P53	O
,	O
Rb	O
and	O
Bcl	O
-	O
xL	O
proteins	O
.	O

In	O
contrast	O
,	O
IFN	O
-	O
alpha/beta	O
rescued	O
T	O
cell	O
clones	O
from	O
apoptosis	O
without	O
active	O
proliferation	O
,	O
and	O
expression	O
of	O
apoptosis	O
-	O
associated	O
proteins	O
tested	O
so	O
far	O
was	O
unaffected	O
.	O

This	O
may	O
be	O
due	O
to	O
the	O
fact	O
that	O
T	O
cells	O
treated	O
with	O
IL	O
-	O
2	O
contained	O
those	O
located	O
in	O
S	O
+	O
G2/M	O
phases	O
of	O
the	O
cell	O
cycle	O
,	O
whereas	O
the	O
vast	O
majority	O
of	O
T	O
cells	O
treated	O
with	O
IFN	O
-	O
alpha/beta	O
were	O
located	O
in	O
G0/G1	O
phase	O
.	O

IFN	O
-	O
alpha/beta	O
specifically	O
induced	B-Positive_regulation
tyrosine	O
phosphorylation	B-Phosphorylation
and	O
translocation	B-Localization
into	O
nucleus	O
of	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
2	O
protein	O
in	O
the	O
T	O
cell	O
clones	O
.	O

In	O
addition	O
,	O
over	B-Gene_expression
-	I-Gene_expression
expression	I-Gene_expression
of	O
STAT2	O
by	O
transfection	O
of	O
the	O
cDNA	O
prevented	O
apoptosis	O
of	O
the	O
T	O
cell	O
clones	O
.	O

Our	O
present	O
study	O
shows	O
that	O
IFN	O
-	O
alpha	O
and	O
-	O
beta	O
mediate	O
anti	O
-	O
apoptotic	O
effect	O
through	O
other	O
pathways	O
than	O
that	O
of	O
IL	O
-	O
2	O
in	O
growth	O
factor	O
deprivation	O
apoptosis	O
.	O

Association	O
between	O
expression	B-Gene_expression
of	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
and	O
integration	O
of	O
human	O
T-cell	O
-	O
leukemia	O
virus	O
type	O
1	O
in	O
adult	O
T	O
-	O
cell	O
leukemia	O
cells	O
.	O

It	O
is	O
known	O
that	O
the	O
expression	B-Gene_expression
levels	O
of	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
in	O
adult	O
T	O
cell	O
leukemia	O
(	O
ATL	O
)	O
cells	O
are	O
high	O
,	O
whereas	O
those	O
in	O
T	O
-	O
lymphoid	O
cells	O
are	O
not	O
.	O

In	O
order	O
to	O
investigate	O
the	O
factors	O
that	O
influence	B-Regulation
the	O
induction	B-Positive_regulation
of	O
ICAM	O
-	O
1	O
molecules	O
,	O
Northern	O
blot	O
analysis	O
to	O
measure	O
the	O
expression	B-Transcription
level	O
of	O
ICAM	O
-	O
1	O
mRNAs	O
and	O
Southern	O
blot	O
hybridization	O
to	O
analyze	O
the	O
integration	O
of	O
human	O
T-cell	O
-	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
provirus	O
were	O
done	O
.	O

The	O
levels	O
of	O
ICAM	O
-	O
1	O
mRNA	O
expression	B-Transcription
of	O
ATL	O
cells	O
were	O
generally	O
higher	O
than	O
those	O
of	O
T	O
-	O
lymphoid	O
cells	O
.	O

However	O
,	O
ILT	O
-	O
mat	O
cells	O
and	O
ATL16T	O
(	O
-	O
)	O
cells	O
,	O
although	O
they	O
were	O
ATL	O
cells	O
,	O
showed	O
rather	O
low	O
surface	O
ICAM	O
-	O
1	O
expression	B-Gene_expression
and	O
ICAM	O
-	O
1	O
mRNA	O
expression	B-Transcription
.	O

Southern	O
blot	O
hybridization	O
showed	O
that	O
only	O
two	O
and	O
four	O
bands	O
were	O
found	O
in	O
ILT	O
-	O
mat	O
and	O
ATL16T	O
(	O
-	O
)	O
cells	O
,	O
respectively	O
,	O
whereas	O
>	O
10	O
bands	O
were	O
detected	O
in	O
other	O
ATL	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
monoclonal	O
integration	O
of	O
HTLV	O
-	O
1	O
provirus	O
to	O
the	O
genome	O
of	O
T	O
cell	O
,	O
especially	O
the	O
number	O
of	O
integration	O
sites	O
,	O
is	O
one	O
of	O
the	O
factors	O
for	O
induction	B-Positive_regulation
of	O
ICAM	O
-	O
1	O
molecules	O
.	O

Transcription	O
factor	O
binding	O
sites	O
downstream	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
start	O
site	O
are	O
important	O
for	O
virus	O
infectivity	O
.	O

When	O
transcriptionally	O
active	O
,	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
promoter	O
contains	O
a	O
nucleosome	O
-	O
free	O
region	O
encompassing	O
both	O
the	O
promoter/enhancer	O
region	O
and	O
a	O
large	O
region	O
(	O
255	O
nucleotides	O
[	O
nt	O
]	O
)	O
downstream	O
of	O
the	O
transcription	O
start	O
site	O
.	O

We	O
have	O
previously	O
identified	O
new	O
binding	O
sites	O
for	O
transcription	O
factors	O
downstream	O
of	O
the	O
transcription	O
start	O
site	O
(	O
nt	O
465	O
to	O
720	O
)	O
:	O
three	O
AP	O
-	O
1	O
sites	O
(	O
I	O
,	O
II	O
,	O
and	O
III	O
)	O
,	O
an	O
AP3	O
-	O
like	O
motif	O
(	O
AP3	O
-	O
L	O
)	O
,	O
a	O
downstream	O
binding	O
factor	O
(	O
DBF	O
)	O
site	O
,	O
and	O
juxtaposed	O
Sp1	O
sites	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
DBF	O
site	O
is	O
an	O
interferon	O
-	O
responsive	O
factor	O
(	O
IRF	O
)	O
binding	O
site	O
and	O
that	O
the	O
AP3	O
-	O
L	O
motif	O
binds	O
the	O
T-cell	O
-	O
specific	O
factor	O
NF	O
-	O
AT	O
.	O

Mutations	O
that	O
abolish	O
the	O
binding	O
of	O
each	O
factor	O
to	O
its	O
cognate	O
site	O
are	O
introduced	O
in	O
an	O
infectious	O
HIV	O
-	O
1	O
molecular	O
clone	O
to	O
study	O
their	O
effect	O
on	O
HIV	O
-	O
1	O
transcription	O
and	O
replication	O
.	O

Individual	O
mutation	O
of	O
the	O
DBF	O
or	O
AP3	O
-	O
L	O
site	O
as	O
well	O
as	O
the	O
double	O
mutation	O
AP	O
-	O
1	O
(	O
III	O
)	O
/AP3	O
-	O
L	O
did	O
not	O
affect	O
HIV	O
-	O
1	O
replication	O
compared	O
to	O
that	O
of	O
the	O
wild	O
-	O
type	O
virus	O
.	O

In	O
contrast	O
,	O
proviruses	O
carrying	O
mutations	O
in	O
the	O
Sp1	O
sites	O
were	O
totally	O
defective	O
in	O
terms	O
of	O
replication	O
.	O

Virus	O
production	O
occurred	O
with	O
slightly	O
delayed	O
kinetics	O
for	O
viruses	O
containing	O
combined	O
mutations	O
in	O
the	O
AP	O
-	O
1	O
(	O
III	O
)	O
,	O
AP3	O
-	O
L	O
,	O
and	O
DBF	O
sites	O
and	O
in	O
the	O
AP3	O
-	O
L	O
and	O
DBF	O
-	O
sites	O
,	O
whereas	O
viruses	O
mutated	O
in	O
the	O
AP	O
-	O
1	O
(	O
I	O
,	O
II	O
,	O
III	O
)	O
and	O
AP3	O
-	O
L	O
sites	O
and	O
in	O
the	O
AP	O
-	O
1	O
(	O
I	O
,	O
II	O
,	O
III	O
)	O
,	O
AP3	O
-	O
L	O
,	O
and	O
DBF	O
sites	O
exhibited	O
a	O
severely	O
defective	O
replicative	O
phenotype	O
.	O

No	O
RNA	O
-	O
packaging	O
defect	O
could	O
be	O
measured	O
for	O
any	O
of	O
the	O
mutant	O
viruses	O
as	O
determined	O
by	O
quantification	O
of	O
their	O
HIV	O
genomic	O
RNA	O
.	O

Measurement	O
of	O
the	O
transcriptional	O
activity	O
of	O
the	O
HIV	O
-	O
1	O
promoter	O
after	O
transient	O
transfection	O
of	O
the	O
HIV	O
-	O
1	O
provirus	O
DNA	O
or	O
of	O
long	O
terminal	O
repeat	O
-	O
luciferase	O
constructs	O
showed	O
a	O
positive	O
correlation	O
between	O
the	O
transcriptional	O
and	O
the	O
replication	O
defects	O
for	O
most	O
mutants	O
.	O

The	O
role	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
in	O
cytokine	O
gene	O
regulation	O
.	O

Transcription	O
factors	O
are	O
DNA	O
-	O
binding	O
proteins	O
that	O
regulate	O
gene	O
expression	O
.	O

Nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
is	O
a	O
critical	O
transcription	O
factor	O
for	O
maximal	O
expression	O
of	O
many	O
cytokines	O
that	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
diseases	O
,	O
such	O
as	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
sepsis	O
syndrome	O
.	O

Activation	O
and	O
regulation	O
of	O
NF	O
-	O
kappa	O
B	O
are	O
tightly	O
controlled	O
by	O
a	O
group	O
of	O
inhibitory	O
proteins	O
(	O
I	O
kappa	O
B	O
)	O
that	O
sequester	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
cytoplasm	O
of	O
immune/inflammatory	O
effector	O
cells	O
.	O

NF	O
-	O
kappa	O
B	O
activation	O
involves	O
signaled	O
phosphorylation	O
,	O
ubiquitination	O
,	O
and	O
proteolysis	O
of	O
I	O
kappa	O
B	O
.	O

Liberated	O
NF	O
-	O
kappa	O
B	O
migrates	O
to	O
the	O
nucleus	O
,	O
where	O
it	O
binds	O
to	O
specific	O
promoter	O
sites	O
and	O
activates	O
gene	O
transcription	O
.	O

The	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
initiates	O
both	O
extracellular	O
and	O
intracellular	O
regulatory	O
events	O
that	O
result	O
in	O
autoregulation	O
of	O
the	O
inflammatory	O
cascade	O
through	O
modulation	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

Recently	O
,	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
has	O
been	O
linked	O
to	O
ARDS	O
and	O
has	O
been	O
shown	O
to	O
be	O
a	O
critical	O
proximal	O
step	O
in	O
the	O
initiation	O
of	O
neutrophilic	O
inflammation	O
in	O
animal	O
models	O
.	O

Activation	O
of	O
NF	O
-	O
kappa	O
B	O
can	O
be	O
inhibited	O
in	O
vivo	O
by	O
treatment	O
with	O
antioxidants	O
,	O
corticosteroids	O
,	O
and	O
the	O
induction	O
of	O
endotoxin	O
tolerance	O
.	O

Identification	O
of	O
more	O
specific	O
and	O
efficacious	O
inhibitors	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
might	O
prove	O
beneficial	O
for	O
the	O
treatment	O
of	O
cytokine	O
-	O
mediated	O
inflammatory	O
diseases	O
.	O

Role	O
of	O
ascorbate	O
in	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
by	O
tumour	O
necrosis	O
factor	O
-	O
alpha	O
in	O
T	O
-	O
cells	O
.	O

The	O
first	O
product	O
of	O
ascorbate	O
oxidation	O
,	O
the	O
ascorbate	O
free	O
radical	O
(	O
AFR	O
)	O
,	O
acts	O
in	O
biological	O
systems	O
mainly	O
as	O
an	O
oxidant	O
,	O
and	O
through	O
its	O
role	O
in	O
the	O
plasma	O
membrane	O
redox	O
system	O
exerts	O
different	O
effects	O
on	O
the	O
cell	O
.	O

We	O
have	O
investigated	O
the	O
role	O
of	O
ascorbate	O
,	O
AFR	O
and	O
dehydroascorbate	O
(	O
DHA	O
)	O
in	O
the	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
in	O
Jurkat	O
T	O
-	O
cells	O
stimulated	O
by	O
tumour	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
.	O

Here	O
we	O
show	O
,	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
that	O
ascorbate	O
increases	O
the	O
binding	O
of	O
NF	O
-	O
kappaB	O
to	O
DNA	O
in	O
TNF-alpha	O
-	O
stimulated	O
Jurkat	O
cells	O
.	O

The	O
ability	O
of	O
ascorbate	O
to	O
enhance	B-Positive_regulation
cytoplasmic	O
inhibitory	O
IkBalpha	O
protein	O
degradation	B-Protein_catabolism
correlates	O
completely	O
with	O
its	O
capacity	O
to	O
induce	O
NF	O
-	O
kappaB	O
binding	O
to	O
DNA	O
and	O
to	O
potentiate	O
NF-kappaB	O
-	O
mediated	O
transactivation	O
of	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
promoter	O
in	O
TNF-alpha	O
-	O
stimulated	O
Jurkat	O
cells	O
but	O
not	O
in	O
cells	O
stimulated	O
with	O
PMA	O
plus	O
ionomycin	O
.	O

AFR	O
behaves	O
like	O
ascorbate	O
,	O
while	O
DHA	O
and	O
ascorbate	O
phosphate	O
do	O
not	O
affect	O
TNF-alpha	O
-	O
mediated	O
NF	O
-	O
kappaB	O
activation	O
.	O

These	O
results	O
provide	O
new	O
evidence	O
for	O
a	O
possible	O
relationship	O
between	O
the	O
activation	O
of	O
the	O
electron	O
-	O
transport	O
system	O
at	O
the	O
plasma	O
membrane	O
by	O
ascorbate	O
or	O
its	O
free	O
radical	O
and	O
redox	O
-	O
dependent	O
gene	O
transcription	O
in	O
T	O
-	O
cells	O
.	O

Pancreatic	O
islet	O
expression	B-Gene_expression
studies	I-Gene_expression
and	O
polymorphic	O
DNA	O
markers	O
in	O
the	O
genes	O
encoding	O
hepatocyte	O
nuclear	O
factor	O
-	O
3alpha	O
,	O
-	O
3beta	O
,	O
-	O
3gamma	O
,	O
-	O
4gamma	O
,	O
and	O
-	O
6	O
.	O

The	O
genes	O
encoding	O
the	O
functionally	O
related	O
hepatocyte	O
nuclear	O
factors	O
HNF	O
-	O
1alpha	O
and	O
HNF	O
-	O
4alpha	O
play	O
a	O
critical	O
role	O
in	O
normal	O
pancreatic	O
beta	O
-	O
cell	O
function	O
.	O

Mutations	O
in	O
these	O
liver	O
-	O
enriched	O
transcription	O
factors	O
result	O
in	O
two	O
forms	O
of	O
early	O
-	O
onset	O
type	O
2	O
diabetes	O
(	O
maturity	O
-	O
onset	O
diabetes	O
of	O
the	O
young	O
[	O
MODY	O
]	O
)	O
,	O
MODY3	O
and	O
MODY1	O
,	O
which	O
are	O
characterized	O
by	O
impaired	O
glucose	O
-	O
stimulated	O
insulin	O
secretion	O
,	O
early	O
disease	O
onset	O
,	O
and	O
autosomal	O
dominant	O
inheritance	O
.	O

The	O
transcriptional	O
hierarchy	O
of	O
HNFs	O
suggests	O
that	O
other	O
proteins	O
of	O
the	O
regulatory	O
cascade	O
might	O
be	O
responsible	O
for	O
other	O
forms	O
of	O
MODY	O
and/or	O
late	O
-	O
onset	O
type	O
2	O
diabetes	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
HNF	O
-	O
3alpha	O
,	O
-	O
3beta	O
,	O
-	O
3gamma	O
,	O
-	O
4gamma	O
,	O
and	O
-	O
6	O
are	O
expressed	B-Gene_expression
in	O
pancreatic	O
beta	O
-	O
cells	O
.	O

We	O
report	O
the	O
identification	O
and	O
characterization	O
of	O
simple	O
tandem	O
repeat	O
DNA	O
polymorphisms	O
in	O
the	O
genes	O
encoding	O
HNF	O
-	O
3alpha	O
,	O
-	O
3beta	O
,	O
-	O
3gamma	O
,	O
-	O
4gamma	O
,	O
and	O
-	O
6	O
and	O
the	O
mapping	O
of	O
HNF	O
-	O
6	O
to	O
chromosome	O
bands	O
15q21.1	O
-	O
21.2	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O

These	O
markers	O
will	O
be	O
useful	O
to	O
study	O
the	O
role	O
of	O
genetic	O
variation	O
in	O
these	O
genes	O
in	O
the	O
pathogenesis	O
of	O
type	O
2	O
diabetes	O
.	O

RP1	O
,	O
a	O
new	O
member	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
-	O
binding	O
EB1	O
-	O
like	O
gene	O
family	O
,	O
is	O
differentially	O
expressed	B-Gene_expression
in	O
activated	O
T	O
cells	O
.	O

Cross	B-Binding
-	I-Binding
linking	I-Binding
of	O
the	O
CD3	O
and	O
CD28	O
molecules	O
on	O
T	O
lymphocytes	O
represents	O
one	O
of	O
the	O
most	O
effective	O
signals	O
for	O
T	O
lymphocyte	O
activation	O
and	O
triggering	O
of	O
their	O
cytotoxic	O
effector	O
function	O
.	O

To	O
identify	O
genes	O
that	O
are	O
expressed	O
in	O
T	O
cells	O
after	O
stimulation	O
,	O
mRNA	O
from	O
T	O
lymphocytes	O
that	O
had	O
been	O
activated	O
by	O
the	O
simultaneous	O
stimulation	O
of	O
the	O
CD3	O
and	O
CD28	O
trigger	O
molecules	O
was	O
transcribed	O
for	O
a	O
differential	O
mRNA	O
display	O
analysis	O
into	O
cDNA	O
and	O
was	O
compared	O
with	O
cDNA	O
from	O
CD28	O
-	O
or	O
CD3	O
-	O
activated	O
or	O
resting	O
lymphocytes	O
.	O

Differential	O
expression	O
was	O
confirmed	O
subsequently	O
by	O
Northern	O
blot	O
analysis	O
.	O

One	O
of	O
the	O
cDNA	O
fragments	O
expressed	O
specifically	O
in	O
CD3	O
-	O
and	O
CD28	O
-	O
activated	O
T	O
cells	O
was	O
designated	O
RP1	O
.	O

The	O
predictive	O
protein	O
-	O
coding	O
region	O
of	O
RP1	O
had	O
a	O
significant	O
homology	O
to	O
members	O
of	O
the	O
recently	O
found	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
protein	O
-	O
binding	O
EB1	O
gene	O
family	O
,	O
which	O
codes	O
for	O
yet	O
unknown	O
protein	O
(	O
s	O
)	O
.	O

Bacterially	O
expressed	B-Gene_expression
RP1	O
protein	O
revealed	O
specific	O
binding	B-Binding
to	O
wild	O
-	O
type	O
but	O
not	O
to	O
mutated	O
APC	O
protein	O
.	O

The	O
rapid	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
RP1	O
mRNA	O
in	O
properly	O
activated	O
T	O
cells	O
suggests	O
that	O
this	O
gene	O
might	O
belong	O
to	O
the	O
immediate/early	O
gene	O
family	O
,	O
which	O
controls	O
the	O
signal	O
transduction	O
cascade	O
downstream	O
of	O
the	O
TCR	O
.	O

As	O
the	O
expression	B-Gene_expression
level	O
of	O
the	O
RP1	O
gene	O
in	O
activated	O
T	O
cells	O
and	O
a	O
spectrum	O
of	O
tumor	O
-	O
derived	O
cell	O
lines	O
correlates	O
with	O
the	O
proliferative	O
status	O
of	O
the	O
cells	O
,	O
members	O
of	O
the	O
EB1	O
-	O
like	O
gene	O
family	O
may	O
not	O
only	O
be	O
involved	O
in	O
the	O
tumorigenesis	O
of	O
colorectal	O
cancers	O
but	O
may	O
also	O
play	O
a	O
role	O
in	O
the	O
proliferative	O
control	O
of	O
normal	O
cells	O
.	O

Induction	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
in	O
monocytic	O
cells	O
by	O
Cryptococcus	O
neoformans	O
and	O
Candida	O
albicans	O
.	O

Because	O
candidiasis	O
and	O
cryptococcosis	O
are	O
common	O
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-	O
infected	O
persons	O
,	O
the	O
effect	O
of	O
Cryptococcus	O
neoformans	O
and	O
Candida	O
albicans	O
on	O
HIV	O
expression	O
in	O
monocytic	O
cells	O
was	O
examined	O
.	O

Stimulation	O
of	O
the	O
latently	O
HIV	O
-	O
infected	O
myelomonocytic	O
cell	O
line	O
OM	O
-	O
10.1	O
with	O
C.	O
neoformans	O
and	O
C.	O
albicans	O
in	O
the	O
presence	O
of	O
pooled	O
human	O
serum	O
caused	O
a	O
ratio	O
-	O
dependent	O
increase	O
in	O
HIV	O
production	O
.	O

Induction	O
of	O
HIV	O
by	O
C.	O
neoformans	O
was	O
enhanced	O
by	O
anti	O
-	O
capsular	O
antibody	O
,	O
while	O
induction	O
by	O
both	O
organisms	O
was	O
inhibited	O
by	O
anti-TNF	O
-	O
alpha	O
antibody	O
.	O

In	O
THP	O
-	O
1	O
cells	O
transfected	O
with	O
HIV	O
plasmid	O
constructs	O
,	O
both	O
organisms	O
induced	O
transcription	O
from	O
the	O
HIV	O
long	O
terminal	O
repeat	O
that	O
was	O
dependent	O
on	O
intact	O
NF	O
-	O
kappaB	O
binding	O
sequences	O
.	O

Thus	O
,	O
C.	O
neoformans	O
and	O
C.	O
albicans	O
enhance	O
HIV	O
expression	O
in	O
monocytic	O
cells	O
through	O
a	O
TNF-alpha	O
-	O
and	O
NF-kappaB	O
-	O
dependent	O
mechanism	O
.	O

In	O
HIV	O
-	O
infected	O
patients	O
,	O
such	O
enhancement	O
may	O
further	O
impair	O
host	O
immunity	O
and	O
could	O
accelerate	O
the	O
course	O
of	O
HIV	O
disease	O
.	O

Bcl	O
-	O
2	O
protein	O
inhibits	O
bufalin	O
-	O
induced	O
apoptosis	O
through	O
inhibition	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
activation	O
in	O
human	O
leukemia	O
U937	O
cells	O
.	O

In	O
a	O
previous	O
study	O
,	O
we	O
demonstrated	O
that	O
bufalin	O
,	O
which	O
is	O
an	O
active	O
principle	O
of	O
Chinese	O
medicine	O
,	O
chan'su	O
,	O
caused	O
apoptosis	O
in	O
human	O
leukemia	O
U937	O
cells	O
by	O
anomalous	O
activation	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
via	O
the	O
signaling	O
pathway	O
of	O
Ras	O
,	O
Raf	O
-	O
1	O
,	O
and	O
MAPK	O
kinase	O
-	O
1	O
.	O

Here	O
,	O
we	O
report	O
the	O
effect	O
of	O
overexpression	B-Gene_expression
of	O
bcl	O
-	O
2	O
in	O
U937	O
cells	O
on	O
the	O
signaling	O
pathway	O
of	O
apoptosis	O
that	O
is	O
induced	O
by	O
bufalin	O
.	O

The	O
results	O
indicated	O
that	O
the	O
apoptosis	O
induced	O
by	O
bufalin	O
in	O
U937	O
cells	O
was	O
significantly	O
inhibited	O
by	O
overexpression	B-Gene_expression
of	O
the	O
Bcl	O
-	O
2	O
protein	O
.	O

No	O
significant	O
difference	O
was	O
detected	O
in	O
the	O
activation	B-Positive_regulation
of	O
MAPK	O
kinase	O
-	O
1	O
that	O
is	O
induced	O
by	O
bufalin	O
in	O
wild	O
-	O
type	O
or	O
Bcl-2	O
-	O
overexpressed	B-Positive_regulation
U937	O
cells	O
;	O
however	O
,	O
the	O
activation	O
of	O
MAPK	O
by	O
bufalin	O
was	O
significantly	O
attenuated	O
in	O
the	O
cells	O
overexpressing	B-Positive_regulation
Bcl	O
-	O
2	O
.	O

Bufalin	O
treatment	O
activated	O
activator	O
protein	O
-	O
1	O
transcriptional	O
activity	O
;	O
however	O
,	O
this	O
activation	O
was	O
decreased	O
to	O
40	O
%	O
in	O
bcl-2	O
-	O
overexpressed	B-Positive_regulation
U937	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
Bcl	O
-	O
2	O
acts	B-Regulation
downstream	O
of	O
MAPK	O
kinase	O
-	O
1	O
but	O
upstream	O
of	O
MAPK	O
and	O
suggest	O
that	O
,	O
in	O
the	O
signaling	O
pathway	O
of	O
the	O
apoptotic	O
process	O
induced	O
by	O
bufalin	O
,	O
the	O
transcriptional	O
activity	O
of	O
activator	O
protein	O
-	O
1	O
may	O
be	O
down	O
-	O
regulated	O
through	O
the	O
inhibition	O
of	O
MAPK	O
activity	O
by	O
Bcl	O
-	O
2	O
.	O

A	O
shortened	O
life	O
span	O
of	O
EKLF-/	O
-	O
adult	O
erythrocytes	O
,	O
due	O
to	O
a	O
deficiency	B-Negative_regulation
of	O
beta	O
-	O
globin	O
chains	O
,	O
is	O
ameliorated	O
by	O
human	O
gamma	O
-	O
globin	O
chains	O
.	O

Using	O
homologous	O
recombination	O
,	O
both	O
EKLF	O
alleles	O
in	O
murine	O
embryonic	O
stem	O
(	O
ES	O
)	O
cells	O
were	O
inactivated	O
.	O

These	O
EKLF-/	O
-	O
ES	O
cells	O
were	O
capable	O
of	O
undergoing	O
in	O
vitro	O
differentiation	O
to	O
form	O
definitive	O
erythroid	O
colonies	O
that	O
were	O
similar	O
in	O
size	O
and	O
number	O
to	O
those	O
formed	O
by	O
wild	O
-	O
type	O
ES	O
cells	O
.	O

However	O
,	O
the	O
EKLF-/	O
-	O
colonies	O
were	O
poorly	O
hemoglobinized	O
and	O
enucleated	O
erythrocytes	O
in	O
these	O
colonies	O
contained	O
numerous	O
Heinz	O
bodies	O
.	O

Reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analyses	O
revealed	O
that	O
adult	O
and	O
embryonic	O
globin	O
genes	O
were	O
appropriately	O
regulated	B-Regulation
,	O
with	O
the	O
exception	O
of	O
beta	O
h1	O
-	O
globin	O
,	O
which	O
continued	B-Negative_regulation
to	I-Negative_regulation
be	O
expressed	B-Gene_expression
at	O
a	O
very	O
low	O
level	O
.	O

The	O
ratio	O
of	O
adult	O
beta-globin/alpha	O
-	O
globin	O
mRNA	O
in	O
the	O
mutant	O
ES	O
cells	O
was	O
1/15	O
of	O
that	O
in	O
wild	O
-	O
type	O
ES	O
cells	O
.	O

When	O
the	O
EKLF-/	O
-	O
cells	O
were	O
injected	O
into	O
blastocysts	O
,	O
they	O
did	O
not	O
contribute	O
at	O
a	O
detectable	O
level	O
to	O
the	O
mature	O
erythrocyte	O
compartment	O
of	O
the	O
chimeric	O
animals	O
,	O
based	O
on	O
analysis	O
of	O
glucose	O
phosphate	O
isomerase	O
-	O
1	O
(	O
GPI	O
-	O
1	O
)	O
isozymes	O
and	O
hemoglobins	O
that	O
distinguish	O
ES	O
cell	O
-	O
derived	O
erythrocytes	O
from	O
host	O
blastocyst	O
-	O
derived	O
erythrocytes	O
.	O

In	O
contrast	O
,	O
semiquantitative	O
RT	O
-	O
PCR	O
analysis	O
of	O
RNA	O
from	O
reticulocytes	O
of	O
the	O
same	O
chimeric	O
animals	O
suggested	O
that	O
the	O
ES	O
cell	O
-	O
derived	O
reticulocytes	O
were	O
present	O
at	O
a	O
level	O
of	O
6	O
%	O
to	O
8	O
%	O
.	O

This	O
indicated	O
that	O
the	O
EKLF-/	O
-	O
erythrocytes	O
in	O
adult	O
animals	O
must	O
be	O
short	O
-	O
lived	O
,	O
apparently	O
due	O
to	O
the	O
imbalance	O
of	O
beta	O
-	O
versus	O
alpha	O
-	O
globin	O
chains	O
,	O
leading	B-Positive_regulation
to	O
the	O
precipitation	B-Localization
of	O
excess	B-Positive_regulation
alpha	O
-	O
globin	O
chains	O
to	O
form	O
Heinz	O
bodies	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
the	O
short	O
life	O
span	O
was	O
ameliorated	O
by	O
introduction	O
into	O
the	O
EKLF-/	O
-	O
ES	O
cells	O
of	O
a	O
human	O
LCR/gamma	O
-	O
globin	O
gene	O
,	O
as	O
evidenced	O
by	O
the	O
presence	O
of	O
ES	O
cell	O
-	O
derived	O
reticulocytes	O
as	O
well	O
as	O
mature	O
erythrocytes	O
in	O
the	O
blood	O
of	O
the	O
chimeric	O
animals	O
.	O

Induction	O
of	O
nuclear	O
factor	O
kappa	O
B/Rel	O
nuclear	O
activity	O
in	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
by	O
anti	O
-	O
HLA	O
class	O
I	O
monoclonal	O
antibodies	O
.	O

Monoclonal	O
antibodies	O
against	O
either	O
monomorphic	O
or	O
polymorphic	O
determinants	O
of	O
class	O
I	O
antigen	O
induced	O
in	O
PBMC	O
and	O
highly	O
purified	O
T	O
lymphocytes	O
the	O
nuclear	O
activity	O
of	O
NF	O
-	O
kappa	O
B/Rel	O
complexes	O
.	O

These	O
included	O
both	O
p50/p50	O
and	O
p50/p65	O
dimers	O
,	O
recognized	B-Binding
by	O
specific	O
antibodies	O
in	O
EMSA	O
.	O

The	O
induced	O
complexes	O
were	O
detectable	B-Gene_expression
in	O
extracts	O
of	O
cells	O
incubated	O
with	O
anti	O
-	O
class	O
I	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
for	O
1.5	O
h	O
;	O
the	O
induction	O
was	O
maximal	O
at	O
5	O
h	O
,	O
persistent	O
at	O
16	O
h	O
and	O
no	O
longer	O
observed	O
at	O
40	O
h	O
.	O

The	O
mAb	O
failed	O
to	O
induce	O
NF	O
-	O
kappa	O
B/Rel	O
nuclear	O
activity	O
in	O
cells	O
incubated	O
in	O
the	O
presence	O
of	O
3	O
,	O
4	O
-	O
dichloroisocoumarin	O
,	O
an	O
inhibitor	B-Negative_regulation
of	O
I	O
kappa	O
B	O
-	O
alpha	O
degradation	B-Protein_catabolism
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
class	O
I	O
triggering	O
can	O
induce	O
the	O
activity	O
of	O
NF	O
-	O
kappa	O
B/Rel	O
nuclear	O
activity	O
in	O
peripheral	O
blood	O
T	O
lymphocytes	O
,	O
thereby	O
modulating	O
the	O
expression	O
of	O
genes	O
regulated	O
by	O
these	O
transcription	O
factors	O
.	O

Cyclosporin	O
A	O
interferes	O
with	O
the	O
inducible	O
degradation	O
of	O
NF	O
-	O
kappa	O
B	O
inhibitors	O
,	O
but	O
not	O
with	O
the	O
processing	O
of	O
p105/NF	O
-	O
kappa	O
B1	O
in	O
T	O
cells	O
.	O

The	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
controls	O
the	O
induction	O
of	O
numerous	O
cytokine	O
promoters	O
during	O
the	O
activation	O
of	O
T	O
lymphocytes	O
.	O

Inhibition	O
of	O
T	O
cell	O
activation	O
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
exerts	O
a	O
suppressive	O
effect	O
on	O
the	O
induction	O
of	O
these	O
NF	O
-	O
kappa	O
B	O
-	O
controlled	O
cytokine	O
promoters	O
.	O

We	O
show	O
for	O
human	O
Jurkat	O
T	O
leukemia	O
cells	O
,	O
as	O
well	O
as	O
human	O
and	O
mouse	O
primary	O
T	O
lymphocytes	O
,	O
that	O
this	O
inhibitory	O
effect	O
is	O
accompanied	O
by	O
an	O
impaired	B-Negative_regulation
nuclear	O
translocation	B-Localization
of	O
the	O
Rel	O
proteins	O
c	O
-	O
Rel	O
,	O
RelA/p65	O
and	O
NF	O
-	O
kappa	O
B1/p50	O
,	O
whereas	O
the	O
nuclear	O
appearance	B-Localization
of	O
RelB	O
remains	O
unaffected	B-Negative_regulation
.	O

CsA	O
does	O
not	O
interfere	O
with	O
the	O
synthesis	O
of	O
Rel	O
proteins	O
,	O
but	O
prevents	B-Negative_regulation
the	O
inducible	B-Positive_regulation
degradation	B-Protein_catabolism
of	O
cytosolic	O
NF	O
-	O
kappa	O
B	O
inhibitors	O
I	O
kappa	O
B	O
alpha	O
and	O
I	O
kappa	O
B	O
beta	O
upon	O
T	O
cell	O
activation	O
.	O

CsA	O
neither	O
inhibits	O
the	O
processing	O
of	O
the	O
NF	O
-	O
kappa	O
B1	O
precursor	O
p105	O
to	O
p50	O
,	O
nor	O
does	O
it	O
"	B-Negative_regulation
stabilize	I-Negative_regulation
"	I-Negative_regulation
the	O
C	O
-	O
terminal	O
portion	O
of	O
p105	O
,	O
I	O
kappa	O
B	O
gamma	O
,	O
which	O
is	O
degraded	B-Protein_catabolism
during	O
p105	O
processing	O
to	O
mature	O
p50	O
.	O

These	O
results	O
indicate	O
that	O
CsA	O
interferes	B-Negative_regulation
with	O
a	O
specific	O
event	O
in	O
the	O
signal	O
-	O
induced	O
degradation	B-Protein_catabolism
of	O
I	O
kappa	O
B	O
alpha	O
and	O
I	O
kappa	O
B	O
beta	O
,	O
but	O
does	O
not	O
affect	O
the	O
processing	O
of	O
NF	O
-	O
kappa	O
B1/p105	O
to	O
p50	O
.	O

EBF	O
and	O
E47	O
collaborate	O
to	O
induce	O
expression	O
of	O
the	O
endogenous	O
immunoglobulin	O
surrogate	O
light	O
chain	O
genes	O
.	O

Early	O
B	O
cell	O
factor	O
(	O
EBF	O
)	O
and	O
E47	O
participate	O
in	O
the	O
transcriptional	O
control	O
of	O
early	O
B	O
lymphocyte	O
differentiation	O
.	O

With	O
the	O
aim	O
of	O
identifying	O
genetic	O
targets	O
for	O
these	O
transcription	O
factors	O
,	O
we	O
stably	O
transfected	B-Gene_expression
cDNAs	O
encoding	O
EBF	O
or	O
a	O
covalent	O
homodimer	O
of	O
E47	O
,	O
individually	O
or	O
together	O
,	O
into	O
immature	O
hematopoietic	O
Ba/F3	O
cells	O
,	O
which	O
lack	B-Gene_expression
both	O
factors	O
.	O

In	O
combination	O
,	O
EBF	O
and	O
E47	O
induce	B-Positive_regulation
efficient	O
expression	B-Gene_expression
of	O
the	O
endogenous	O
immunoglobulin	O
surrogate	O
light	O
chain	O
genes	O
,	O
lambda5	O
and	O
VpreB	O
,	O
whereas	O
other	O
pre	O
-	O
B	O
cell	O
-	O
specific	O
genes	O
remain	O
silent	O
.	O

Multiple	O
functionally	O
important	O
EBF	O
and	O
E47	O
binding	O
sites	O
were	O
identified	O
in	O
the	O
lambda5	O
promoter/enhancer	O
region	O
,	O
indicating	O
that	O
lambda5	O
is	O
a	O
direct	O
genetic	O
target	B-Regulation
for	O
these	O
transcription	O
factors	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
EBF	O
and	O
E47	O
synergize	O
to	O
activate	O
expression	O
of	O
a	O
subset	O
of	O
genes	O
that	O
define	O
an	O
early	O
stage	O
of	O
the	O
B	O
cell	O
lineage	O
.	O

Nuclear	O
levels	O
of	O
NF	O
-	O
kappaB	O
correlate	O
with	O
syncytium	O
-	O
forming	O
capacity	O
of	O
8e51	O
cells	O
,	O
expressing	O
a	O
defective	O
HIV	O
virus	O
.	O

The	O
double	O
NF	O
-	O
kappaB	O
site	O
identified	O
in	O
the	O
LTR	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
(	O
HIV	O
-	O
1	O
)	O
has	O
been	O
demonstrated	O
to	O
be	O
necessary	O
for	O
efficient	O
viral	O
transcription	O
.	O

In	O
this	O
report	O
we	O
present	O
the	O
characterisation	O
of	O
NF	O
-	O
kappaB	O
subunits	O
engaged	O
in	O
complexes	O
binding	O
to	O
the	O
HIV	O
-	O
1	O
NF	O
-	O
kappaB	O
site	O
in	O
human	O
8e51	O
T	O
-	O
cells	O
,	O
that	O
harbour	O
a	O
defective	O
HIV	O
-	O
1	O
.	O

At	O
least	O
four	O
different	O
specific	O
NF	O
-	O
kappaB	O
complexes	O
are	O
present	O
in	O
the	O
nucleus	O
of	O
these	O
cells	O
.	O

With	O
the	O
use	O
of	O
specific	O
antibodies	O
we	O
have	O
determined	O
the	O
composition	O
of	O
each	O
complex	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

The	O
results	O
show	O
the	O
presence	O
of	O
several	O
NF	O
-	O
kappaB	O
family	O
members	O
,	O
with	O
the	O
transactivating	O
RelA	O
being	O
engaged	O
in	O
multiple	O
complexes	O
.	O

The	O
importance	O
of	O
NF	O
-	O
kappaB	O
complexes	O
in	O
viral	O
functions	O
has	O
been	O
established	O
comparing	O
the	O
level	O
of	O
NF	O
-	O
kappaB	O
DNA	O
-	O
binding	O
complexes	O
with	O
syncytia	O
-	O
forming	O
activity	O
of	O
8e51	O
cells	O
.	O

In	O
fact	O
,	O
8e51	O
cells	O
that	O
had	O
almost	O
lost	O
their	O
syncytia	O
-	O
forming	O
capacity	O
were	O
found	O
to	O
contain	O
at	O
least	O
10	O
times	O
less	O
active	O
NF	O
-	O
kappaB	O
DNA	O
-	O
binding	O
complex	O
than	O
the	O
actively	O
fusing	O
cells	O
.	O

The	O
correlation	O
is	O
specific	O
as	O
the	O
level	O
of	O
at	O
least	O
three	O
other	O
transcription	O
factors	O
did	O
not	O
change	O
.	O

Differential	O
interaction	O
of	O
nuclear	O
factors	O
with	O
the	O
leukocyte	O
-	O
specific	O
pp52	O
promoter	O
in	O
B	O
and	O
T	O
cells	O
.	O

The	O
leukocyte	O
-	O
specific	O
,	O
cytoskeleton	O
-	O
binding	O
pp52	O
(	O
LSP	O
-	O
1	O
,	O
WP	O
-	O
34	O
)	O
protein	O
is	O
widely	O
expressed	B-Gene_expression
in	O
multiple	O
leukocyte	O
lineages	O
,	O
including	O
B	O
and	O
T	O
lymphocytes	O
,	O
granulocytes	O
,	O
and	O
macrophages	O
.	O

We	O
previously	O
detected	O
a	O
tissue	O
-	O
specific	O
promoter	O
preceding	O
the	O
exon	O
encoding	O
the	O
N	O
terminus	O
of	O
the	O
pp52	O
leukocyte	O
protein	O
.	O

Here	O
we	O
describe	O
the	O
functional	O
characterization	O
of	O
this	O
promoter	O
and	O
identification	O
of	O
the	O
factors	O
in	O
B	O
and	O
T	O
cells	O
that	O
regulate	O
its	O
activity	O
.	O

The	O
pp52	O
promoter	O
contains	O
an	O
initiator	O
specifying	B-Regulation
the	O
unique	O
5	O
'	O
terminus	O
of	O
pp52	O
mRNA	O
,	O
tandem	O
pairs	O
of	O
Ets	O
and	O
SP1	O
motifs	O
,	O
and	O
a	O
lone	O
C/EBP	O
motif	O
.	O

All	O
these	O
motifs	O
are	O
essential	O
and	O
collectively	O
control	O
transcriptional	O
activity	O
.	O

DNA	O
binding	O
studies	O
and	O
Ab	O
supershift	O
assays	O
revealed	O
that	O
different	O
combinations	O
of	O
factors	O
interact	B-Binding
with	O
these	O
motifs	O
in	O
B	O
cells	O
vs	O
T	O
cells	O
.	O

The	O
Ets	O
motifs	O
are	O
preferentially	O
bound	B-Binding
by	O
PU	O
-	O
1	O
in	O
B	O
cell	O
extracts	O
from	O
all	O
stages	O
of	O
development	O
,	O
whereas	O
a	O
different	O
Ets	O
family	O
member	O
reacts	O
with	O
these	O
motifs	O
in	O
T	O
cell	O
extracts	O
.	O

The	O
C/EBP	O
motif	O
is	O
bound	B-Binding
by	O
Ig/EBP	O
-	O
1	O
in	O
pre	O
-	O
B	O
cell	O
and	O
T	O
cell	O
extracts	O
,	O
but	O
is	O
replaced	B-Binding
by	O
nuclear	O
factor-IL	O
-	O
6beta	O
or	O
a	O
nuclear	O
factor-IL-6beta-Ig/EBP	O
-	O
1	O
heterodimer	O
in	O
plasmacytoma	O
cell	O
extracts	O
.	O

Despite	O
its	O
reported	O
role	O
as	O
a	O
negative	O
regulator	O
of	O
transcription	O
,	O
Ig/EBP	O
-	O
1	O
appears	O
to	O
exert	B-Positive_regulation
a	I-Positive_regulation
stimulatory	I-Positive_regulation
effect	I-Positive_regulation
on	O
this	O
promoter	O
.	O

These	O
findings	O
reveal	O
the	O
features	O
controlling	B-Regulation
the	O
pp52	O
promoter	O
in	O
B	O
and	O
T	O
cells	O
and	O
provide	O
the	O
foundation	O
for	O
determining	O
the	O
regulation	B-Regulation
of	O
this	O
promoter	O
in	O
other	O
leukocyte	O
lineages	O
.	O

Transcription	O
factor	O
GATA	O
-	O
3	O
is	O
differentially	O
expressed	B-Gene_expression
in	O
murine	O
Th1	O
and	O
Th2	O
cells	O
and	O
controls	B-Regulation
Th2	O
-	O
specific	O
expression	B-Gene_expression
of	O
the	O
interleukin	O
-	O
5	O
gene	O
.	O

Interleukin	O
-	O
5	O
(	O
IL	O
-	O
5	O
)	O
,	O
which	O
is	O
produced	B-Gene_expression
by	O
CD4	O
(	O
+	O
)	O
T	O
helper	O
2	O
(	O
Th2	O
)	O
cells	O
,	O
but	O
not	O
by	O
Th1	O
cells	O
,	O
plays	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
eosinophilia	O
in	O
asthma	O
.	O

Despite	O
increasing	O
evidence	O
that	O
the	O
outcome	O
of	O
many	O
diseases	O
is	O
determined	O
by	O
the	O
ratio	O
of	O
the	O
two	O
subsets	O
of	O
CD4	O
(	O
+	O
)	O
T	O
helper	O
cells	O
,	O
Th1	O
and	O
Th2	O
,	O
the	O
molecular	O
basis	O
for	O
Th1	O
-	O
and	O
Th2	O
-	O
specific	O
gene	O
expression	O
remains	O
to	O
be	O
elucidated	O
.	O

We	O
previously	O
established	O
a	O
critical	B-Positive_regulation
role	I-Positive_regulation
for	O
the	O
transcription	O
factor	O
GATA	O
-	O
3	O
in	O
IL	O
-	O
5	O
promoter	O
activation	B-Positive_regulation
in	O
EL	O
-	O
4	O
cells	O
,	O
which	O
express	O
both	O
Th1	O
-	O
and	O
Th2	O
-	O
type	O
cytokines	O
.	O

Our	O
studies	O
reported	O
here	O
demonstrate	O
that	O
GATA	O
-	O
3	O
is	O
critical	B-Positive_regulation
for	O
expression	B-Gene_expression
of	O
the	O
IL	O
-	O
5	O
gene	O
in	O
bona	O
fide	O
Th2	O
cells	O
.	O

Whereas	O
mutations	O
in	O
the	O
GATA	O
-	O
3	O
site	O
abolished	B-Negative_regulation
antigen	O
-	O
or	O
cAMP	O
-	O
stimulated	O
IL	O
-	O
5	O
promoter	O
activation	B-Positive_regulation
in	O
Th2	O
cells	O
,	O
ectopic	O
expression	B-Gene_expression
of	O
GATA	O
-	O
3	O
in	O
Th1	O
cells	O
or	O
in	O
a	O
non	O
-	O
lymphoid	O
,	O
non-IL-5	O
-	O
producing	B-Gene_expression
cell	O
line	O
activated	B-Positive_regulation
the	O
IL	O
-	O
5	O
promoter	O
.	O

During	O
the	O
differentiation	O
of	O
naive	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
isolated	O
from	O
T	O
cell	O
receptor	O
transgenic	O
mice	O
,	O
GATA	O
-	O
3	O
gene	O
expression	B-Gene_expression
was	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
in	O
developing	O
Th2	O
cells	O
,	O
but	O
was	O
down	B-Negative_regulation
-	I-Negative_regulation
regulated	I-Negative_regulation
in	O
Th1	O
cells	O
,	O
and	O
antigen	O
-	O
or	O
cAMP	O
-	O
activated	O
Th2	O
cells	O
(	O
but	O
not	O
Th1	O
cells	O
)	O
expressed	B-Gene_expression
the	O
GATA	O
-	O
3	O
protein	O
.	O

Thus	O
,	O
GATA	O
-	O
3	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
balance	O
between	O
Th1	O
and	O
Th2	O
subsets	O
in	O
immune	O
responses	O
.	O

Inhibition	B-Negative_regulation
of	O
GATA	O
-	O
3	O
activity	O
has	O
therapeutic	O
potential	O
in	O
the	O
treatment	O
of	O
asthma	O
and	O
other	O
hypereosinophilic	O
diseases	O
.	O

Inhibition	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
replication	O
in	O
vitro	O
by	O
a	O
novel	O
combination	O
of	O
anti	O
-	O
Tat	O
single	O
-	O
chain	O
intrabodies	O
and	O
NF	O
-	O
kappa	O
B	O
antagonists	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
Tat	O
,	O
an	O
early	O
regulatory	O
protein	O
that	O
is	O
critical	O
for	O
viral	O
gene	O
expression	O
and	O
replication	O
,	O
transactivates	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
via	O
its	O
binding	B-Binding
to	O
the	O
transactivation	O
response	O
element	O
(	O
TAR	O
)	O
and	O
,	O
along	O
with	O
other	O
cellular	O
factors	O
,	O
increases	O
viral	O
transcription	O
initiation	O
and	O
elongation	O
.	O

Tat	O
also	O
superactivates	O
the	O
HIV	O
-	O
1	O
promoter	O
through	O
a	O
TAR	O
-	O
independent	O
mechanism	O
,	O
including	O
tumor	O
necrosis	O
factor	O
alpha	O
-	O
induced	O
and	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
-	O
dependent	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
inhibitors	O
of	O
Tat	O
and	O
NF	O
-	O
kappa	O
B	O
cooperatively	O
down	O
-	O
regulate	O
this	O
Tat	O
-	O
mediated	O
LTR	O
superactivation	O
.	O

In	O
this	O
study	O
,	O
a	O
combined	O
pharmacologic	O
and	O
genetic	O
strategy	O
using	O
two	O
PKC	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
inhibitors	O
,	O
pentoxifylline	O
(	O
PTX	O
)	O
and	O
Go	O
-	O
6976	O
,	O
and	O
a	O
stably	O
expressed	O
anti	O
-	O
Tat	O
single	O
-	O
chain	O
intracellular	O
antibody	O
(	O
sFv	O
intrabody	O
)	O
was	O
employed	O
to	O
obtain	O
cooperative	O
inhibition	O
of	O
both	O
HIV	O
-	O
1	O
LTR	O
-	O
driven	O
gene	O
expression	O
and	O
HIV	O
-	O
1	O
replication	O
.	O

Treatment	O
of	O
cells	O
with	O
PTX	O
and	O
Go	O
-	O
6976	O
resulted	O
in	O
cooperative	O
inhibition	O
of	O
both	O
HIV	O
-	O
1	O
LTR	O
-	O
driven	O
gene	O
expression	O
and	O
HIV	O
-	O
1	O
replication	O
.	O

In	O
addition	O
,	O
the	O
combined	O
use	O
of	O
anti	O
-	O
Tat	O
sFv	O
intrabodies	O
and	O
the	O
two	O
NF	O
-	O
kappa	O
B	O
inhibitors	O
retained	O
the	O
virus	O
in	O
the	O
latent	O
state	O
for	O
as	O
long	O
as	O
45	O
days	O
.	O

The	O
combined	O
treatment	O
resulted	O
in	O
more	O
durable	O
inhibition	O
of	O
HIV	O
-	O
1	O
replication	O
than	O
was	O
seen	O
with	O
the	O
NF	O
-	O
kappa	O
B	O
inhibitors	O
alone	O
or	O
the	O
anti	O
-	O
Tat	O
sFv	O
intrabodies	O
alone	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
in	O
future	O
clinical	O
gene	O
therapy	O
trials	O
,	O
a	O
combined	O
pharmacologic	O
and	O
genetic	O
strategy	O
like	O
the	O
one	O
reported	O
here	O
may	O
improve	O
the	O
survival	O
of	O
transduced	O
cells	O
and	O
prolong	O
clinical	O
benefit	O
.	O

Transcription	O
factors	O
in	O
immune	O
-	O
mediated	O
disease	O
.	O

A	O
large	O
amount	O
of	O
detailed	O
information	O
about	O
the	O
intracellular	O
proteins	O
regulating	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
the	O
cellular	O
response	O
to	O
NF	O
-	O
kappa	O
B	O
activation	O
has	O
emerged	O
recently	O
.	O

Several	O
small	O
molecules	O
,	O
an	O
antisense	O
oligonucleotide	O
,	O
and	O
gene	O
therapeutic	O
agents	O
that	O
inhibit	O
NF	O
-	O
kappa	O
b	O
activation	O
have	O
been	O
described	O
.	O

Despite	O
this	O
,	O
there	O
are	O
still	O
significant	O
gaps	O
in	O
our	O
understanding	O
of	O
this	O
process	O
and	O
its	O
consequences	O
.	O

In	O
contrast	O
,	O
the	O
characterization	O
of	O
transcription	O
factors	O
selectively	O
regulating	O
cytokine	O
production	O
by	O
CD4+	O
T	O
cell	O
subsets	O
is	O
at	O
a	O
very	O
early	O
stage	O
.	O

Three	O
interacting	O
proteins	O
have	O
recently	O
been	O
shown	O
to	O
contribute	B-Regulation
to	O
subset	O
-	O
restricted	O
expression	B-Gene_expression
of	O
the	O
IL	O
-	O
4	O
gene	O
.	O

There	O
are	O
other	O
elements	O
regulating	B-Regulation
IL	O
-	O
4	O
gene	O
expression	B-Gene_expression
,	O
however	O
,	O
and	O
the	O
relative	O
importance	O
of	O
these	O
recently	O
identified	O
proteins	O
has	O
yet	O
to	O
be	O
determined	O
.	O

CholecystokininB	O
receptor	O
from	O
human	O
Jurkat	O
lymphoblastic	O
T	O
cells	O
is	O
involved	O
in	O
activator	O
protein-1	O
-	O
responsive	O
gene	O
activation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
role	O
of	O
cholecystokinin	O
(	O
CCK	O
(	O
B	O
)	O
)	O
receptor	O
in	O
human	O
lymphoblastic	O
Jurkat	O
T	O
cells	O
.	O

We	O
investigated	O
the	O
trophic	O
effect	O
resulting	O
from	O
activation	B-Positive_regulation
of	O
such	O
a	O
receptor	O
by	O
using	O
the	O
reporter	O
gene	O
strategy	O
.	O

For	O
this	O
purpose	O
,	O
we	O
transiently	O
transfected	O
Jurkat	O
T	O
cells	O
with	O
the	O
reporter	O
plasmid	O
p	O
[	O
(	O
TRE	O
)	O
3-tk	O
-	O
Luc	O
]	O
and	O
found	O
that	O
CCK	O
-	O
8	O
was	O
able	O
to	O
dose	O
-	O
dependently	O
induce	B-Positive_regulation
luciferase	O
expression	B-Gene_expression
related	O
to	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
activation	O
with	O
a	O
maximal	O
response	O
identical	O
to	O
that	O
obtained	O
with	O
compounds	O
known	O
to	O
activate	O
AP	O
-	O
1	O
complex	O
(	O
quantitatively	O
,	O
the	O
same	O
level	O
of	O
induction	B-Positive_regulation
was	I-Positive_regulation
obtained	I-Positive_regulation
with	O
1	O
nM	O
12-O-tetradecanoylphorbol-13	O
-	O
acetate	O
,	O
100	O
microM	O
diacylglycerol	O
,	O
or	O
4	O
nM	O
epidermal	O
growth	O
factor	O
)	O
.	O

The	O
involvement	B-Regulation
of	O
the	O
CCK	O
(	O
B	O
)	O
receptor	O
in	O
such	O
a	O
stimulation	O
was	O
demonstrated	O
by	O
the	O
inhibiting	B-Negative_regulation
effect	I-Negative_regulation
of	O
the	O
selective	O
CCK	O
(	O
B	O
)	O
receptor	O
antagonist	B-Negative_regulation
PD	O
-	O
135	O
,	O
158	O
.	O

This	O
effect	O
was	O
confirmed	O
in	O
COS	O
-	O
7	O
cells	O
transfected	O
with	O
the	O
cDNA	O
of	O
CCK	O
(	O
B	O
)	O
receptor	O
cloned	O
from	O
Jurkat	O
T	O
cells	O
.	O

To	O
better	O
understand	O
the	O
AP-1	O
-	O
dependent	B-Positive_regulation
luciferase	O
expression	B-Gene_expression
in	O
Jurkat	O
T	O
cells	O
,	O
we	O
tested	O
two	O
specific	O
inhibitors	B-Negative_regulation
of	O
serine/threonine	O
phosphatases	O
-	O
1	O
and	O
-	O
2A	O
:	O
okadaic	O
acid	O
and	O
calyculin	O
A	O
.	O

These	O
compounds	O
strongly	O
increased	O
the	O
phorbol-12-myristate-13	O
-	O
acetate	O
response	O
,	O
whereas	O
we	O
have	O
not	O
observed	O
a	O
contribution	O
of	O
phosphatase	O
inhibitors	O
on	O
a	O
CCK-8	O
-	O
induced	B-Positive_regulation
luciferase	O
activity	O
.	O

To	O
confirm	O
that	O
CCK	O
(	O
B	O
)	O
receptors	O
are	O
involved	O
in	O
AP	O
-	O
1	O
response	O
,	O
we	O
investigated	O
the	O
CCK	O
-	O
8	O
effect	B-Regulation
on	O
interleukin	O
-	O
2	O
expression	B-Gene_expression
,	O
a	O
natural	O
endogenous	O
gene	O
regulated	B-Regulation
by	O
several	O
factors	O
,	O
including	O
AP	O
-	O
1	O
.	O

In	O
Jurkat	O
T	O
cells	O
activated	O
by	O
phorbol-12-myristate-13	O
-	O
acetate	O
and	O
phytohemagglutinin	O
,	O
CCK	O
-	O
8	O
induced	B-Positive_regulation
IL	O
-	O
2	O
expression	B-Gene_expression
.	O

This	O
induction	O
was	O
abolished	B-Negative_regulation
by	O
PD	O
-	O
135	O
,	O
158	O
.	O

Our	O
results	O
indicate	O
that	O
CCK	O
-	O
8	O
exerts	O
a	O
trophic	O
effect	O
in	O
Jurkat	O
T	O
cells	O
through	O
stimulation	B-Positive_regulation
of	O
CCK	O
(	O
B	O
)	O
receptors	O
by	O
modulation	O
of	O
expression	O
of	O
AP-1	O
-	O
regulated	O
genes	O
.	O

Epstein	O
-	O
Barr	O
virus	O
binding	O
to	O
CD21	O
activates	O
the	O
initial	O
viral	O
promoter	O
via	O
NF	O
-	O
kappaB	O
induction	O
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
,	O
an	O
oncogenic	O
human	O
herpesvirus	O
,	O
binds	O
to	O
and	O
infects	O
normal	O
human	O
B	O
lymphocytes	O
via	O
CD21	O
,	O
the	O
CR2	O
complement	O
receptor	O
.	O

Studies	O
of	O
the	O
mechanisms	O
that	O
enable	O
EBV	O
to	O
infect	O
nonactivated	O
,	O
noncycling	O
B	O
cells	O
provide	O
compelling	O
evidence	O
for	O
a	O
sequence	O
of	O
events	O
in	O
which	O
EBV	O
binding	O
to	O
CD21	O
on	O
purified	O
resting	O
human	O
B	O
cells	O
rapidly	O
activates	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
,	O
which	O
,	O
in	O
turn	O
,	O
binds	O
to	O
and	O
mediates	O
transcriptional	O
activation	O
of	O
Wp	O
,	O
the	O
initial	O
viral	O
latent	O
gene	O
promoter	O
.	O

Thus	O
,	O
EBV	O
binding	O
to	O
its	O
cellular	O
receptor	O
on	O
resting	O
B	O
cells	O
triggers	O
an	O
NF-kappaB	O
-	O
dependent	O
intracellular	O
signaling	O
pathway	O
which	O
is	O
required	O
for	O
infection	O
.	O

Activation	O
of	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
by	O
phagocytic	O
stimuli	O
in	O
human	O
neutrophils	O
.	O

Phagocytosis	O
represents	O
an	O
important	O
physiological	O
trigger	O
for	O
the	O
inducible	O
expression	O
of	O
several	O
genes	O
in	O
human	O
neutrophils	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
DNA	O
-	O
binding	B-Binding
activity	O
primarily	O
consisting	O
of	O
the	O
classical	O
NF	O
-	O
kappa	O
B	O
heterodimer	O
,	O
p50/RelA	O
,	O
is	O
induced	B-Positive_regulation
in	O
phagocytosing	O
neutrophils	O
.	O

Under	O
these	O
conditions	O
,	O
NF	O
-	O
kappa	O
B	O
activation	O
was	O
found	O
to	O
be	O
a	O
rapid	O
and	O
transient	O
response	O
,	O
reaching	O
a	O
maximum	O
by	O
10	O
-	O
15	O
min	O
,	O
and	O
returning	O
to	O
near	O
-	O
basal	O
levels	O
by	O
30	O
min	O
.	O

In	O
neutrophils	O
undergoing	O
the	O
phagocytosis	O
of	O
opsonized	O
yeasts	O
,	O
the	O
onset	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
was	O
paralleled	O
by	O
a	O
decline	B-Negative_regulation
in	O
immunoreactive	O
I	O
kappa	O
B	O
-	O
alpha	O
protein	O
levels	O
,	O
and	O
the	O
cellular	O
I	O
kappa	O
B	O
-	O
alpha	O
pool	O
was	O
replenished	B-Negative_regulation
by	O
30	O
min	O
,	O
in	O
agreement	O
with	O
our	O
gel	O
shift	O
data	O
.	O

We	O
conclude	O
that	O
NF	O
-	O
kappa	O
B	O
activation	O
could	O
constitute	O
one	O
of	O
the	O
mechanisms	O
whereby	O
the	O
expression	O
of	O
kappa	O
B	O
-	O
responsive	O
genes	O
is	O
enhanced	O
in	O
phagocytosing	O
neutrophils	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
represents	O
the	O
first	O
demonstration	O
that	O
phagocytic	O
stimuli	O
can	O
induce	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
human	O
neutrophils	O
.	O

Surfactant	O
protein	O
A	O
activates	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
THP	O
-	O
1	O
monocytic	O
cell	O
line	O
.	O

The	O
expression	O
of	O
many	O
genes	O
for	O
which	O
products	O
are	O
involved	O
in	O
inflammation	O
is	O
controlled	O
by	O
the	O
transcriptional	O
regulator	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
.	O

Because	O
surfactant	O
protein	O
(	O
SP	O
)	O
A	O
is	O
involved	O
in	O
local	O
host	O
defense	O
in	O
the	O
lung	O
and	O
alters	O
immune	O
cell	O
function	O
by	O
modulating	O
the	O
expression	O
of	O
proinflammatory	O
cytokines	O
as	O
well	O
as	O
surface	O
proteins	O
involved	O
in	O
inflammation	O
,	O
we	O
hypothesized	O
that	O
SP	O
-	O
A	O
exerts	O
its	O
action	O
,	O
at	O
least	O
in	O
part	O
,	O
via	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

We	O
used	O
gel	O
shift	O
assays	O
to	O
determine	O
whether	O
SP	O
-	O
A	O
activated	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
THP	O
-	O
1	O
cell	O
line	O
,	O
a	O
human	O
monocytic	O
cell	O
line	O
.	O

Activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
THP	O
-	O
1	O
cells	O
by	O
SP	O
-	O
A	O
doses	O
as	O
low	O
as	O
1	O
microgram/ml	O
occurred	O
within	O
30	O
min	O
of	O
SP	O
-	O
A	O
treatment	O
,	O
peaked	O
at	O
60	O
min	O
,	O
and	O
then	O
declined	O
.	O

This	O
activation	O
is	O
inhibited	O
by	O
known	O
inhibitors	O
of	O
NF	O
-	O
kappa	O
B	O
or	O
by	O
simultaneous	O
treatment	O
of	O
the	O
cells	O
with	O
surfactant	O
lipids	O
.	O

Moreover	O
,	O
the	O
NF	O
-	O
kappa	O
B	O
inhibitors	O
blocked	B-Negative_regulation
SP-A	O
-	O
dependent	O
increases	B-Positive_regulation
in	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
mRNA	O
levels	O
.	O

These	O
observations	O
suggest	O
a	O
mechanism	O
by	O
which	O
SP	O
-	O
A	O
plays	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
some	O
lung	O
conditions	O
and	O
point	O
to	O
potential	O
therapeutic	O
measures	O
that	O
could	O
be	O
used	O
to	O
prevent	O
SP	O
-	O
A	O
induced	O
inflammation	O
in	O
the	O
lung	O
.	O

alpha	O
-	O
Tocopheryl	O
succinate	O
inhibits	O
monocytic	O
cell	O
adhesion	O
to	O
endothelial	O
cells	O
by	O
suppressing	O
NF	O
-	O
kappa	O
B	O
mobilization	O
.	O

The	O
adherence	O
of	O
monocytes	O
to	O
activated	O
endothelium	O
is	O
an	O
early	O
event	O
in	O
atherogenesis	O
.	O

Because	O
antioxidants	O
have	O
been	O
considered	O
to	O
be	O
of	O
antiatherosclerotic	O
potential	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
alpha	O
-	O
tocopherol	O
(	O
TCP	O
)	O
and	O
its	O
acetate	O
and	O
succinate	O
esters	O
on	O
monocyte	O
adhesion	O
to	O
cytokine	O
-	O
stimulated	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
.	O

Endothelial	O
cells	O
were	O
treated	O
with	O
TCP	O
,	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
TCP	O
acetate	O
)	O
,	O
or	O
alpha	O
-	O
tocopheryl	O
succinate	O
(	O
TCP	O
succinate	O
)	O
before	O
stimulation	O
with	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
;	O
10	O
U/ml	O
,	O
6	O
h	O
)	O
or	O
interleukin	O
-	O
1	O
beta	O
(	O
IL	O
-	O
1	O
beta	O
;	O
10	O
U/ml	O
,	O
6	O
h	O
)	O
.	O

Cytokine	O
-	O
stimulated	B-Positive_regulation
cell	O
surface	O
expression	B-Gene_expression
of	O
vascular	O
cell	O
adhesion	O
molecule	O
-	O
1	O
(	O
VCAM	O
-	O
1	O
,	O
CD106	O
)	O
and	O
E	O
-	O
selectin	O
(	O
ELAM	O
-	O
1	O
,	O
CD62E	O
)	O
,	O
but	O
not	O
of	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
,	O
CD54	O
)	O
,	O
was	O
time	O
-	O
and	O
dose	O
-	O
dependently	O
inhibited	B-Negative_regulation
by	O
TCP	O
succinate	O
but	O
not	O
by	O
TCP	O
or	O
TCP	O
acetate	O
.	O

TCP	O
succinate	O
(	O
200	O
microM	O
,	O
24	O
h	O
)	O
reduced	B-Negative_regulation
TNF	O
-	O
induced	B-Positive_regulation
VCAM	O
-	O
1	O
and	O
E	O
-	O
selectin	O
expression	B-Gene_expression
from	O
a	O
specific	O
mean	O
fluorescence	O
intensity	O
of	O
151	O
+/	O
-	O
28	O
to	O
12	O
+/	O
-	O
4	O
channels	O
and	O
from	O
225	O
+/	O
-	O
38	O
to	O
79	O
+/	O
-	O
21	O
channels	O
,	O
respectively	O
.	O

Succinate	O
alone	O
had	O
no	O
effect	B-Regulation
.	O

Decreased	B-Negative_regulation
adhesion	O
molecule	O
expression	O
was	O
associated	O
with	O
a	O
reduction	O
of	O
monocytic	O
cell	O
adhesion	O
.	O

TCP	O
succinate	O
(	O
20	O
microM	O
,	O
72	O
h	O
)	O
,	O
but	O
not	O
TCP	O
(	O
200	O
microM	O
,	O
72	O
h	O
)	O
,	O
reduced	O
U	O
-	O
937	O
cell	O
adhesion	O
to	O
TNF-alpha	O
-	O
stimulated	O
(	O
10	O
U/ml	O
,	O
6	O
h	O
)	O
HUVEC	O
by	O
30	O
%	O
(	O
P	O
<	O
0.025	O
)	O
and	O
to	O
IL	O
-	O
1	O
beta	O
-	O
stimulated	O
HUVEC	O
by	O
56	O
%	O
(	O
P	O
<	O
0.010	O
)	O
.	O

Electrophoretic	O
mobility	O
-	O
shift	O
assays	O
of	O
HUVEC	O
nuclear	O
proteins	O
revealed	O
a	O
decrease	O
in	O
TNF-alpha	O
-	O
stimulated	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
activation	O
after	O
pretreatment	O
of	O
HUVEC	O
with	O
TCP	O
succinate	O
but	O
not	O
with	O
TCP	O
,	O
TCP	O
acetate	O
,	O
or	O
succinate	O
alone	O
.	O

In	O
conclusion	O
,	O
we	O
demonstrate	O
that	O
the	O
vitamin	O
E	O
derivative	O
TCP	O
succinate	O
prevents	O
monocytic	O
cell	O
adhesion	O
to	O
cytokine	O
-	O
stimulated	O
endothelial	O
cells	O
by	O
inhibiting	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
further	O
emphasizing	O
the	O
antiatherosclerotic	O
potential	O
of	O
lipid	O
soluble	O
antioxidants	O
.	O

Distinct	O
mechanisms	O
for	O
N	O
-	O
acetylcysteine	O
inhibition	B-Negative_regulation
of	O
cytokine	O
-	O
induced	B-Positive_regulation
E	O
-	O
selectin	O
and	O
VCAM	O
-	O
1	O
expression	B-Gene_expression
.	O

We	O
have	O
examined	O
the	O
effects	O
of	O
N-acetyl-L	O
-	O
cysteine	O
(	O
NAC	O
)	O
,	O
a	O
well	O
-	O
characterized	O
,	O
thiol	O
-	O
containing	O
antioxidant	O
,	O
on	O
agonist	O
-	O
induced	O
monocytic	O
cell	O
adhesion	O
to	O
endothelial	O
cells	O
(	O
EC	O
)	O
.	O

NAC	O
inhibited	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
beta	O
)	O
-	O
induced	O
,	O
but	O
not	O
basal	O
,	O
adhesion	O
with	O
50	O
%	O
inhibition	O
at	O
approximately	O
20	O
mM	O
.	O

Monocytic	O
cell	O
adhesion	O
to	O
EC	O
in	O
response	O
to	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
alpha	O
-	O
thrombin	O
,	O
or	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
was	O
similarly	O
inhibited	O
by	O
NAC	O
.	O

Unlike	O
published	O
studies	O
with	O
pyrrolidinedithiocarbamate	O
,	O
which	O
specifically	O
inhibited	B-Negative_regulation
vascular	O
cell	O
adhesion	O
molecule	O
1	O
(	O
VCAM	O
-	O
1	O
)	O
,	O
NAC	O
inhibited	B-Negative_regulation
IL	O
-	O
1	O
beta	O
-	O
induced	B-Positive_regulation
mRNA	B-Transcription
and	O
cell	O
surface	O
expression	B-Gene_expression
of	O
both	O
E	O
-	O
selectin	O
and	O
VCAM	O
-	O
1	O
.	O

NAC	O
had	O
no	O
effect	B-Regulation
on	I-Regulation
the	I-Regulation
half	I-Regulation
-	I-Regulation
life	I-Regulation
of	O
E	O
-	O
selectin	O
or	O
VCAM	O
-	O
1	O
mRNA	O
.	O

Although	O
NAC	O
reduced	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
activation	O
in	O
EC	O
as	O
measured	O
by	O
gel	O
-	O
shift	O
assays	O
using	O
an	O
oligonucleotide	O
probe	O
corresponding	O
to	O
the	O
consensus	O
NF	O
-	O
kappa	O
B	O
binding	O
sites	O
of	O
the	O
VCAM	O
-	O
1	O
gene	O
(	O
VCAM-NF	O
-	O
kappa	O
B	O
)	O
,	O
the	O
antioxidant	O
had	O
no	O
appreciable	O
effect	O
when	O
an	O
oligomer	O
corresponding	O
to	O
the	O
consensus	O
NF	O
-	O
kappa	O
B	O
binding	O
site	O
of	O
the	O
E	O
-	O
selectin	O
gene	O
(	O
E-selectin-NF	O
-	O
kappa	O
B	O
)	O
was	O
used	O
.	O

Because	O
NF	O
-	O
kappa	O
B	O
has	O
been	O
reported	O
to	O
be	O
redox	O
sensitive	O
,	O
we	O
studied	O
the	O
effects	O
of	O
NAC	O
on	O
the	O
EC	O
redox	O
environment	O
.	O

NAC	O
caused	O
an	O
expected	O
dramatic	O
increase	O
in	O
the	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
levels	O
in	O
EC	O
.	O

In	O
vitro	O
studies	O
demonstrated	O
that	O
whereas	O
the	O
binding	O
affinity	O
of	O
NF	O
-	O
kappa	O
B	O
to	O
the	O
VCAM-NF	O
-	O
kappa	O
B	O
oligomer	O
peaked	O
at	O
a	O
GSH-to	O
-	O
oxidized	O
glutathione	O
(	O
GSSG	O
)	O
ratio	O
of	O
approximately	O
200	O
and	O
decreased	O
at	O
higher	O
ratios	O
,	O
the	O
binding	O
to	O
the	O
E-selectin-NF	O
-	O
kappa	O
B	O
oligomer	O
appeared	O
relatively	O
unaffected	O
even	O
at	O
ratios	O
>	O
400	O
,	O
i.e.	O
,	O
those	O
achieved	O
in	O
EC	O
treated	O
with	O
40	O
mM	O
NAC	O
.	O

These	O
results	O
suggest	O
that	O
NF	O
-	O
kappa	O
B	O
binding	B-Binding
to	O
its	O
consensus	O
sequences	O
in	O
the	O
VCAM	O
-	O
1	O
and	O
E	O
-	O
selectin	O
gene	O
exhibits	O
marked	O
differences	O
in	O
redox	O
sensitivity	O
,	O
allowing	O
for	O
differential	O
gene	O
expression	B-Gene_expression
regulated	B-Regulation
by	O
the	O
same	O
transcription	O
factor	O
.	O

Our	O
data	O
also	O
demonstrate	O
that	O
NAC	O
increases	O
the	O
GSH-to	O
-	O
GSSG	O
ratio	O
within	O
the	O
EC	O
suggesting	O
one	O
possible	O
mechanism	O
through	O
which	O
this	O
antioxidant	O
inhibits	O
agonist	O
-	O
induced	O
monocyte	O
adhesion	O
to	O
EC	O
.	O

Human	O
monocyte	O
binding	O
to	O
fibronectin	O
enhances	O
IFN-gamma	O
-	O
induced	O
early	O
signaling	O
events	O
.	O

Leukocyte	O
integrins	O
are	O
fundamentally	O
important	O
in	O
modulating	O
adhesion	O
to	O
extracellular	O
matrix	O
components	O
and	O
to	O
other	O
cells	O
.	O

This	O
integrin	O
-	O
mediated	O
adhesion	O
controls	O
leukocyte	O
arrest	O
and	O
extravasation	O
during	O
the	O
onset	O
of	O
inflammatory	O
responses	O
.	O

Moreover	O
,	O
integrin	O
-	O
ligand	O
interactions	O
trigger	O
signaling	O
pathways	O
that	O
may	O
influence	O
leukocyte	O
phenotype	O
and	O
function	O
at	O
sites	O
of	O
inflammation	O
.	O

In	O
the	O
current	O
studies	O
,	O
we	O
evaluated	O
the	O
combinatorial	O
effects	O
of	O
monocyte	O
adhesion	O
and	O
IFN	O
-	O
gamma	O
on	O
intracellular	O
signaling	O
pathways	O
.	O

IFN	O
-	O
gamma	O
triggers	O
a	O
well	O
-	O
defined	O
signal	O
transduction	O
pathway	O
,	O
which	O
although	O
not	O
directly	O
stimulated	O
by	O
monocyte	O
adherence	O
to	O
fibronectin	O
or	O
arginine-glycine	O
-	O
aspartate	O
(	O
RGD	O
)	O
-	O
coated	O
substrata	O
,	O
was	O
enhanced	O
significantly	O
in	O
these	O
matrix	O
-	O
adherent	O
cells	O
.	O

Compared	O
with	O
monocytes	O
in	O
suspension	O
or	O
adherent	O
on	O
plastic	O
surfaces	O
,	O
monocytes	O
adherent	O
to	O
fibronectin	O
or	O
RGD	O
exhibited	O
a	O
greater	O
than	O
threefold	O
increase	B-Positive_regulation
in	O
steady	O
state	O
levels	B-Transcription
of	O
IFN-gamma	O
-	O
induced	B-Positive_regulation
mRNA	O
for	O
the	O
high	O
affinity	O
Fc	O
gammaRI	O
receptor	O
.	O

By	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
this	O
increase	B-Positive_regulation
in	O
mRNA	O
was	O
associated	O
with	O
a	O
5	O
-	O
to	O
10	O
-	O
fold	O
increase	B-Positive_regulation
in	O
the	O
STAT1	O
-	O
containing	O
DNA	O
-	O
binding	B-Binding
complex	I-Binding
that	O
binds	B-Binding
to	O
Fc	O
gammaRI	O
promoter	O
elements	O
.	O

Furthermore	O
,	O
the	O
tyrosine	O
phosphorylation	B-Phosphorylation
of	O
STAT1	O
and	O
the	O
tyrosine	O
kinases	O
JAK1	O
and	O
JAK2	O
was	O
enhanced	B-Positive_regulation
significantly	O
in	O
RGD	O
-	O
adherent	O
monocytes	O
compared	O
with	O
control	O
cells	O
.	O

These	O
results	O
suggest	O
a	O
novel	O
mechanism	O
by	O
which	O
integrin	O
-	O
mediated	O
cell	O
adhesion	O
can	O
modulate	O
the	O
magnitude	O
of	O
cytokine	O
-	O
induced	O
signal	O
transduction	O
pathways	O
,	O
thereby	O
amplifying	O
cellular	O
events	O
leading	O
to	O
monocyte	O
activation	O
and	O
inflammation	O
.	O

The	O
carboxyl	O
-	O
terminal	O
cytoplasmic	O
domain	O
of	O
CD36	O
is	O
required	O
for	O
oxidized	O
low	O
-	O
density	O
lipoprotein	O
modulation	O
of	O
NF	O
-	O
kappaB	O
activity	O
by	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
.	O

The	O
binding	O
of	O
oxidized	O
low	O
-	O
density	O
lipoprotein	O
(	O
Ox	O
LDL	O
)	O
by	O
monocyte	O
-	O
macrophages	O
causes	O
pleiotropic	O
effects	O
,	O
including	O
changes	O
in	O
gene	O
expression	O
,	O
and	O
is	O
thought	O
to	O
represent	O
an	O
early	O
event	O
in	O
atherogenesis	O
.	O

The	O
integral	O
membrane	O
glycoprotein	O
CD36	O
appears	O
to	O
play	O
a	O
physiological	O
role	O
in	O
binding	O
and	O
uptake	O
of	O
Ox	O
LDL	O
by	O
monocyte	O
-	O
macrophages	O
,	O
although	O
the	O
molecular	O
events	O
associated	O
with	O
CD36	O
-	O
Ox	O
LDL	O
interaction	B-Binding
are	O
unknown	O
.	O

To	O
approach	O
this	O
issue	O
,	O
we	O
used	O
CD36	O
transfected	O
Chinese	O
hampster	O
ovary	O
(	O
CHO	O
)	O
cells	O
,	O
exposed	O
them	O
to	O
Ox	O
LDL	O
,	O
and	O
determined	O
changes	O
in	O
the	O
activity	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

We	O
report	O
here	O
that	O
Ox	O
LDL	O
enhanced	O
DNA	O
binding	O
activity	O
of	O
nuclear	O
extracts	O
to	O
an	O
NF	O
-	O
kappaB	O
sequence	O
following	O
activation	O
of	O
CD36	O
-	O
producing	B-Gene_expression
CHO	O
cells	O
with	O
the	O
proinflammatory	O
cytokine	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
.	O

This	O
enhanced	O
DNA	O
binding	O
activity	O
was	O
inhibited	O
by	O
coincubation	O
of	O
CD36	O
transfected	O
cells	O
with	O
the	O
human	O
CD36	O
-	O
specific	O
antibody	O
OKM5	O
.	O

We	O
also	O
determined	O
that	O
activation	O
of	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
required	O
an	O
intact	O
carboxyl	O
-	O
terminal	O
cytoplasmic	O
segment	O
on	O
CD36	O
.	O

Our	O
results	O
support	O
the	O
idea	O
that	O
human	O
CD36	O
mediates	O
signal	O
transduction	O
events	O
in	O
response	O
to	O
Ox	O
LDL	O
.	O

Transcriptional	O
regulation	O
during	O
myelopoiesis	O
.	O

The	O
coordinated	O
production	O
of	O
all	O
blood	O
cells	O
from	O
a	O
common	O
stem	O
cell	O
is	O
a	O
highly	O
regulated	O
process	O
involving	O
successive	O
stages	O
of	O
commitment	O
and	O
differentiation	O
.	O

From	O
analyses	O
of	O
mice	O
deficient	O
in	O
transcription	O
factor	O
genes	O
and	O
from	O
the	O
characterizations	O
of	O
chromosome	O
breakpoints	O
in	O
human	O
leukemias	O
,	O
it	O
has	O
become	O
evident	O
that	O
transcription	O
factors	O
are	O
important	O
regulators	O
of	O
hematopoiesis	O
.	O

During	O
myelopoiesis	O
,	O
which	O
includes	O
the	O
development	O
of	O
granulocytic	O
and	O
monocytic	O
lineages	O
,	O
transcription	O
factors	O
from	O
several	O
families	O
are	O
active	B-Positive_regulation
,	O
including	O
AML1/CBF	O
beta	O
,	O
C/EBP	O
,	O
Ets	O
,	O
c	O
-	O
Myb	O
,	O
HOX	O
,	O
and	O
MZF	O
-	O
1	O
.	O

Few	O
of	O
these	O
factors	O
are	O
expressed	B-Gene_expression
exclusively	O
in	O
myeloid	O
cells	O
;	O
instead	O
it	O
appears	O
that	O
they	O
cooperatively	O
regulate	O
transcription	O
of	O
myeloid	O
-	O
specific	O
genes	O
.	O

Here	O
we	O
discuss	O
recent	O
advances	O
in	O
transcriptional	O
regulation	O
during	O
myelopoiesis	O
.	O

Rel/NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
and	O
the	O
control	O
of	O
apoptosis	O
.	O

The	O
process	O
of	O
apoptosis	O
is	O
used	O
to	O
eliminate	O
unwanted	O
cells	O
from	O
a	O
wide	O
variety	O
of	O
organisms	O
.	O

Various	O
extracellular	O
signals	O
,	O
often	O
converging	O
in	O
common	O
intracellular	O
pathways	O
,	O
can	O
induce	O
apoptosis	O
in	O
a	O
cell-type	O
-	O
specific	O
fashion	O
.	O

Recent	O
work	O
from	O
several	O
laboratories	O
has	O
demonstrated	O
that	O
Rel/NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
regulate	O
apoptosis	O
in	O
many	O
cell	O
types	O
.	O

In	O
most	O
cells	O
,	O
Rel/NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
appear	O
to	O
mediate	O
survival	O
signals	O
that	O
protect	O
cells	O
from	O
apoptosis	O
;	O
however	O
,	O
under	O
some	O
circumstances	O
,	O
activation	O
of	O
these	O
factors	O
may	O
also	O
promote	O
apoptosis	O
.	O

The	O
role	O
of	O
Rel/NF	O
-	O
kappa	O
B	O
proteins	O
in	O
viral	O
oncogenesis	O
and	O
the	O
regulation	O
of	O
viral	O
transcription	O
.	O

Rel/NF	O
-	O
kappa	O
B	O
is	O
a	O
ubiquitous	O
transcription	O
factor	O
that	O
consists	O
of	O
multiple	O
polypeptide	O
subunits	O
,	O
and	O
is	O
subject	O
to	O
complex	O
regulatory	O
mechanisms	O
that	O
involve	O
protein	O
-	O
protein	O
interactions	O
,	O
phosphorylation	O
,	O
ubiquitination	O
,	O
proteolytic	O
degradation	O
,	O
and	O
nucleocytoplasmic	O
translocation	O
.	O

The	O
sophisticated	O
control	O
of	O
Rel/NF	O
-	O
kappa	O
B	O
activity	O
is	O
not	O
surprising	O
since	O
this	O
transcription	O
factor	O
is	O
involved	O
in	O
a	O
wide	O
array	O
of	O
cellular	O
responses	O
to	O
extracellular	O
cues	O
,	O
associated	O
with	O
growth	O
,	O
development	O
,	O
apoptosis	O
,	O
and	O
pathogen	O
invasion	O
.	O

Thus	O
,	O
it	O
is	O
not	O
unexpected	O
that	O
this	O
versatile	O
cellular	O
homeostatic	O
switch	O
would	O
be	O
affected	O
by	O
a	O
variety	O
of	O
viral	O
pathogens	O
,	O
which	O
have	O
evolved	O
mechanisms	O
to	O
utilize	O
various	O
aspects	O
of	O
Rel/NF	O
-	O
kappa	O
B	O
activity	O
to	O
facilitate	O
their	O
replication	O
,	O
cell	O
survival	O
and	O
possibly	O
evasion	O
of	O
immune	O
responses	O
.	O

This	O
review	O
will	O
cover	O
the	O
molecular	O
mechanisms	O
that	O
are	O
utilized	O
by	O
mammalian	O
oncogenic	O
viruses	O
to	O
affect	O
the	O
activity	O
of	O
Rel/NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
and	O
the	O
role	O
of	O
Rel/NF	O
-	O
kappa	O
B	O
in	O
the	O
regulation	O
of	O
viral	O
gene	O
expression	O
and	O
replication	O
.	O

Abnormal	O
apoptosis	O
and	O
cell	O
cycle	O
progression	O
in	O
humans	O
exposed	O
to	O
methyl	O
tertiary	O
-	O
butyl	O
ether	O
and	O
benzene	O
contaminating	O
water	O
.	O

1.	O
In	O
this	O
study	O
we	O
hypothesized	O
that	O
in	O
individuals	O
with	O
certain	O
genetic	O
makeup	O
,	O
MTBE	O
,	O
benzene	O
or	O
their	O
metabolites	O
act	O
as	O
adducts	O
and	O
may	O
induce	O
programmed	O
cell	O
death	O
.	O

2	O
.	O

Our	O
study	O
involved	O
a	O
group	O
of	O
60	O
male	O
and	O
female	O
subjects	O
who	O
were	O
exposed	O
to	O
MTBE	O
and	O
benzene	O
-	O
contaminated	O
water	O
concentrations	O
up	O
to	O
76	O
PPB	O
for	O
MTBE	O
and	O
14	O
PPB	O
for	O
benzene	O
,	O
for	O
a	O
period	O
of	O
5	O
to	O
8	O
years	O
.	O

For	O
comparison	O
,	O
we	O
recruited	O
a	O
control	O
group	O
consisting	O
of	O
32	O
healthy	O
males	O
and	O
females	O
with	O
similar	O
age	O
distribution	O
and	O
without	O
a	O
history	O
of	O
exposure	O
to	O
MTBE	O
or	O
benzene	O
.	O

3	O
.	O

Peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
of	O
both	O
groups	O
were	O
tested	O
for	O
the	O
percentage	O
of	O
apoptotic	O
cells	O
and	O
cell	O
cycle	O
progression	O
using	O
flow	O
cytometry	O
.	O

4	O
.	O

When	O
apoptotic	O
lymphocytes	O
from	O
exposed	O
individuals	O
were	O
compared	O
to	O
apoptotic	O
lymphocytes	O
from	O
the	O
control	O
group	O
,	O
statistically	O
-	O
significant	O
differences	O
between	O
each	O
mean	O
group	O
were	O
detected	O
(	O
26.4	O
+/	O
-	O
1.8	O
and	O
12.1	O
+/	O
-	O
1.3	O
,	O
respectively	O
)	O
,	O
indicating	O
an	O
increased	O
rate	O
of	O
apoptosis	O
in	O
80.5	O
%	O
of	O
exposed	O
individuals	O
(	O
P	O
<	O
0.0001	O
,	O
Mann	O
-	O
Whitney	O
U	O
-	O
Test	O
)	O
.	O

MTBE	O
and	O
benzene	O
-	O
induced	O
apoptosis	O
is	O
attributed	O
to	O
a	O
discrete	O
block	O
within	O
the	O
cell	O
cycle	O
progression	O
.	O

Because	O
cell	O
cycle	O
analysis	O
showed	O
that	O
in	O
PBL	O
from	O
chemically	O
-	O
exposed	O
individuals	O
,	O
between	O
20	O
-	O
50	O
%	O
of	O
cells	O
were	O
accumulated	O
at	O
the	O
S	O
-	O
G2/M	O
boundaries	O
.	O

5	O
.	O

One	O
of	O
the	O
signaling	O
molecules	O
which	O
mediates	O
programmed	O
cell	O
death	O
is	O
nuclear	O
factor	O
Kappa	O
-	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
.	O

NF	O
-	O
kappa	O
B	O
was	O
examined	O
as	O
one	O
of	O
the	O
many	O
molecular	O
mechanisms	O
for	O
mediating	O
cell	O
death	O
by	O
MTBE	O
and	O
benzene	O
.	O

Indeed	O
,	O
addition	O
of	O
inhibitors	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
to	O
the	O
lymphocytes	O
of	O
the	O
chemically	O
-	O
exposed	O
group	O
was	O
capable	O
of	O
inhibiting	O
programmed	O
cell	O
death	O
by	O
40	O
%	O
.	O

This	O
reversal	O
of	O
apoptosis	O
almost	O
to	O
the	O
control	O
level	O
by	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
may	O
indicate	O
involvement	O
of	O
this	O
signaling	O
molecule	O
in	O
MTBE	O
and	O
benzene	O
induction	O
of	O
programmed	O
cell	O
death	O
.	O

Activation	O
of	O
a	O
novel	O
gene	O
in	O
3q21	O
and	O
identification	O
of	O
intergenic	O
fusion	O
transcripts	O
with	O
ecotropic	O
viral	O
insertion	O
site	O
I	O
in	O
leukemia	O
.	O

We	O
have	O
identified	O
a	O
novel	O
gene	O
,	O
GR6	O
,	O
located	O
within	O
the	O
leukemia	O
breakpoint	O
region	O
of	O
3q21	O
,	O
that	O
is	O
normally	O
expressed	B-Gene_expression
in	O
early	O
fetal	O
development	O
but	O
not	O
in	O
adult	O
peripheral	O
blood	O
.	O

GR6	O
is	O
activated	B-Positive_regulation
in	O
the	O
UCSD	O
-	O
AML1	O
cell	O
line	O
and	O
in	O
a	O
leukemic	O
sample	O
,	O
both	O
of	O
which	O
carry	O
a	O
t	O
(	O
3	O
;	O
3	O
)	O
(	O
q21	O
;	O
q26	O
)	O
.	O

In	O
UCSD	O
-	O
AML1	O
,	O
we	O
have	O
also	O
identified	O
fusion	O
transcripts	O
between	O
the	O
ecotropic	O
viral	O
insertion	O
site	O
I	O
(	O
EVI1	O
)	O
gene	O
in	O
3q26	O
and	O
GR6	O
and	O
between	O
EVI1	O
and	O
Ribophorin	O
I	O
that	O
maps	O
30	O
kb	O
telomeric	O
to	O
GR6	O
in	O
3q21	O
.	O

All	O
fusions	O
splice	O
the	O
5	O
'	O
ends	O
of	O
the	O
3q21	O
genes	O
into	O
exon	O
2	O
of	O
the	O
EVI1	O
gene	O
,	O
an	O
event	O
that	O
is	O
similar	O
to	O
the	O
normal	O
intergenic	O
splicing	O
of	O
MDS1	O
-	O
EVI1	O
and	O
to	O
those	O
previously	O
documented	O
in	O
leukemias	O
with	O
t	O
(	O
3	O
;	O
21	O
)	O
and	O
t	O
(	O
3	O
;	O
12	O
)	O
,	O
in	O
which	O
acute	O
myelogenous	O
leukemia	O
1	O
-	O
EVI1	O
fusions	O
and	O
ETV6	O
-	O
EVI1	O
fusions	O
,	O
respectively	O
,	O
occur	O
.	O

The	O
Ribophorin	O
I	O
-	O
EVI1	O
fusion	O
in	O
particular	O
may	O
be	O
a	O
common	O
occurrence	O
in	O
t	O
(	O
3	O
;	O
3	O
)	O
.	O

Alcohol	O
-	O
induced	O
regulation	O
of	O
nuclear	O
regulatory	O
factor	O
-	O
kappa	O
beta	O
in	O
human	O
monocytes	O
.	O

Acute	O
ethanol	O
exposure	O
has	O
the	O
capacity	O
to	O
modulate	O
immune	O
functions	O
,	O
particularly	O
,	O
to	O
down	O
regulate	O
monocyte	O
production	O
of	O
inflammatory	O
cytokines	O
.	O

However	O
,	O
the	O
intracellular	O
mechanisms	O
for	O
these	O
effects	O
of	O
ethanol	O
are	O
yet	O
to	O
be	O
understood	O
.	O

Considering	O
that	O
nuclear	O
regulatory	O
factor	O
-	O
kappa	O
beta	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
/Rel	O
is	O
a	O
common	O
regulatory	O
element	O
of	O
the	O
promoter	O
region	O
of	O
the	O
inflammatory	O
cytokine	O
genes	O
,	O
herein	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
acute	O
ethanol	O
affects	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
human	O
monocytes	O
.	O

Adherence	O
-	O
isolated	O
monocytes	O
showed	O
constitutive	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

A	O
clinically	O
relevant	O
dose	O
(	O
25	O
mM	O
)	O
of	O
acute	O
ethanol	O
treatment	O
in	O
vitro	O
increased	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
in	O
monocytes	O
with	O
a	O
preferential	O
induction	B-Positive_regulation
of	O
the	O
inhibitory	O
,	O
p50/p50	O
,	O
NF	O
-	O
kappa	O
B/Rel	O
homodimer	O
,	O
and	O
resulted	O
in	O
no	O
induction	O
of	O
the	O
p65/p50	O
heterodimer	O
.	O

In	O
contrast	O
,	O
lipopolysaccharide	O
stimulation	O
primarily	O
induced	B-Positive_regulation
the	O
p65/p50	O
heterodimer	O
that	O
has	O
been	O
shown	O
to	O
result	O
in	O
gene	O
activation	O
.	O

Thus	O
,	O
such	O
unique	O
activation	B-Positive_regulation
of	O
the	O
inhibitory	O
p50/p50	O
homodimer	O
by	O
acute	O
ethanol	O
treatment	O
may	O
result	O
in	O
inhibition	O
rather	O
than	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
regulated	O
inflammatory	O
cytokine	O
genes	O
.	O

Consequently	O
,	O
these	O
results	O
suggest	O
that	O
physiologically	O
relevant	O
concentrations	O
of	O
ethanol	O
may	O
affect	B-Regulation
production	B-Gene_expression
of	O
inflammatory	O
cytokines	O
,	O
such	O
as	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
,	O
interleukin	O
-	O
1	O
beta	O
,	O
and	O
interleukin	O
-	O
6	O
by	O
disrupting	O
NF	O
-	O
kappa	O
B	O
signaling	O
in	O
monocytes	O
.	O

Four	O
P	O
-	O
like	O
elements	O
are	O
required	B-Positive_regulation
for	O
optimal	O
transcription	B-Transcription
of	O
the	O
mouse	O
IL	O
-	O
4	O
gene	O
:	O
involvement	O
of	O
a	O
distinct	O
set	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
and	O
activator	O
protein	O
-	O
1	O
family	O
proteins	O
.	O

We	O
previously	O
identified	O
the	O
P	O
sequence	O
as	O
a	O
critical	O
regulatory	O
element	O
of	O
the	O
human	O
IL	O
-	O
4	O
promoter	O
.	O

In	O
the	O
mouse	O
IL	O
-	O
4	O
promoter	O
,	O
there	O
are	O
five	O
elements	O
homologous	O
to	O
the	O
human	O
P	O
sequence	O
designated	O
conserved	O
lymphokine	O
element	O
0	O
(	O
CLE0	O
)	O
,	O
P	O
,	O
P2	O
,	O
P3	O
and	O
P4	O
.	O

To	O
characterize	O
the	O
role	O
of	O
these	O
P	O
-	O
like	O
elements	O
and	O
their	O
binding	O
factors	O
in	O
the	O
native	O
promoter	O
,	O
we	O
did	O
transient	O
transfection	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
.	O

Transfection	O
of	O
EL	O
-	O
4	O
cells	O
with	O
the	O
IL	O
-	O
4	O
promoter	O
-	O
reporter	O
constructs	O
carrying	O
mutated	O
P	O
-	O
like	O
elements	O
showed	O
that	O
four	O
P	O
-	O
like	O
elements	O
,	O
CLE0	O
,	O
P	O
,	O
P2	O
and	O
P4	O
,	O
but	O
not	O
P3	O
,	O
were	O
required	O
for	O
optimal	O
activation	B-Positive_regulation
of	O
the	O
IL	O
-	O
4	O
promoter	O
.	O

EMSA	O
showed	O
that	O
both	O
constitutive	O
and	O
inducible	O
complexes	O
bound	O
to	O
CLE0	O
,	O
P	O
,	O
P2	O
and	O
P4	O
,	O
whereas	O
only	O
a	O
constitutive	O
complex	O
bound	O
to	O
P3	O
.	O

In	O
competition	O
and	O
antibody	O
supershift	O
assays	O
in	O
EMSA	O
,	O
complexes	O
formed	O
with	O
P	O
or	O
P2	O
proved	O
to	O
contain	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
family	O
proteins	O
as	O
major	O
components	O
.	O

Activator	O
protein	O
(	O
AP	O
)	O
-	O
1	O
family	O
proteins	O
interacted	O
with	O
CLE0	O
,	O
P	O
,	O
P2	O
and	O
P4	O
.	O

NFAT/AP	O
-	O
1	O
complex	O
formed	O
only	O
with	O
P	O
and	O
P2	O
.	O

Cross	O
-	O
competition	O
assays	O
among	O
the	O
P	O
-	O
like	O
elements	O
revealed	O
element	O
-	O
specific	O
and	O
common	O
complexes	O
.	O

Six	O
tandem	O
repeats	O
of	O
the	O
P	O
element	O
linked	O
to	O
the	O
SV40	O
promoter	O
responded	O
to	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
,	O
while	O
that	O
of	O
other	O
elements	O
did	O
not	O
.	O

It	O
would	O
thus	O
appear	O
that	O
components	O
of	O
each	O
P	O
-	O
like	O
element	O
-	O
binding	O
complexes	O
are	O
not	O
identical	O
and	O
may	O
coordinately	O
contribute	O
to	O
transcriptional	O
activity	O
.	O

The	O
ability	O
of	O
BHRF1	O
to	O
inhibit	O
apoptosis	O
is	O
dependent	O
on	O
stimulus	O
and	O
cell	O
type	O
.	O

The	O
development	O
of	O
resistance	O
to	O
host	O
defense	O
mechanisms	O
such	O
as	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
and	O
Fas	O
-	O
mediated	O
apoptosis	O
of	O
transformed	O
or	O
virus	O
-	O
infected	O
cells	O
may	O
be	O
a	O
critical	O
component	O
in	O
the	O
development	O
of	O
disease	O
.	O

To	O
find	O
genes	O
that	O
protect	O
cells	O
from	O
apoptosis	O
,	O
we	O
used	O
an	O
expression	O
cloning	O
strategy	O
and	O
identified	O
BHRF1	O
,	O
an	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
early-lytic	O
-	O
cycle	O
protein	O
with	O
distant	O
homology	O
to	O
Bcl	O
-	O
2	O
,	O
as	O
an	O
anti	O
-	O
apoptosis	O
protein	O
.	O

Expression	B-Gene_expression
of	O
BHRF1	O
in	O
MCF	O
-	O
Fas	O
cells	O
conferred	O
nearly	O
complete	O
resistance	O
against	O
both	O
anti	O
-	O
Fas	O
antibody	O
and	O
TNF	O
-	O
mediated	O
apoptosis	O
.	O

In	O
addition	O
,	O
BHRF1	O
protected	O
these	O
cells	O
from	O
monocyte	O
-	O
mediated	O
killing	O
but	O
failed	O
to	O
protect	O
them	O
from	O
killing	O
mediated	O
by	O
lymphokine	O
-	O
activated	O
killer	O
cells	O
.	O

The	O
ability	O
of	O
BHRF1	O
to	O
protect	O
MCF	O
-	O
Fas	O
cells	O
from	O
apoptosis	O
induced	O
by	O
various	O
stimuli	O
was	O
identical	O
to	O
that	O
of	O
Bcl	O
-	O
2	O
and	O
Bcl	O
-	O
xL	O
.	O

Moreover	O
,	O
the	O
mechanism	O
of	O
action	O
of	O
BHRF1	O
resembled	O
that	O
of	O
Bcl	O
-	O
2	O
and	O
Bcl	O
-	O
xL	O
as	O
it	O
inhibited	B-Negative_regulation
TNF	O
-	O
and	O
anti-Fas	O
-	O
induced	O
activation	B-Positive_regulation
of	O
two	O
enzymes	O
participating	O
in	O
the	O
apoptosis	O
pathway	O
,	O
cytosolic	O
phospholipase	O
A2	O
and	O
caspase	O
-	O
3/CPP32	O
,	O
but	O
did	O
not	O
interfere	O
with	O
the	O
activation	O
of	O
NF-kappaB	O
-	O
like	O
transcription	O
factors	O
.	O

A	O
putative	O
function	O
of	O
BHRF1	O
in	O
EBV	O
-	O
infected	O
epithelial	O
cells	O
may	O
be	O
to	O
protect	O
virus	O
-	O
infected	O
cells	O
from	O
TNF	O
-	O
and/or	O
anti-Fas	O
-	O
induced	O
cell	O
death	O
in	O
order	O
to	O
maximize	O
virus	O
production	O
.	O

Surprisingly	O
,	O
expression	B-Gene_expression
of	O
neither	O
BHRF1	O
nor	O
Bcl	O
-	O
2	O
in	O
a	O
B	O
-	O
cell	O
line	O
,	O
BJAB	O
,	O
protected	O
the	O
cells	O
from	O
anti-Fas	O
-	O
mediated	O
apoptosis	O
even	O
though	O
they	O
increased	O
the	O
survival	O
of	O
serum	O
-	O
starved	O
cells	O
.	O

Thus	O
,	O
the	O
protective	O
role	O
of	O
BHRF1	O
against	O
apoptosis	O
resembles	O
that	O
of	O
Bcl	O
-	O
2	O
in	O
being	O
cell	O
type	O
specific	O
and	O
dependent	O
on	O
the	O
apoptotic	O
stimulus	O
.	O

NF	O
-	O
AT	O
activation	O
induced	O
by	O
a	O
CAML	O
-	O
interacting	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
superfamily	O
.	O

Activation	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
transcription	O
factor	O
(	O
NF	O
-	O
AT	O
)	O
is	O
a	O
key	O
event	O
underlying	O
lymphocyte	O
action	O
.	O

The	O
CAML	O
(	O
calcium	O
-	O
modulator	O
and	O
cyclophilin	O
ligand	O
)	O
protein	O
is	O
a	O
coinducer	O
of	O
NF	O
-	O
AT	O
activation	O
when	O
overexpressed	B-Gene_expression
in	O
Jurkat	O
T	O
cells	O
.	O

A	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
superfamily	O
was	O
isolated	O
by	O
virtue	O
of	O
its	O
affinity	B-Binding
for	O
CAML	O
.	O

Cross	O
-	O
linking	O
of	O
this	O
lymphocyte	O
-	O
specific	O
protein	O
,	O
designated	O
TACI	O
(	O
transmembrane	O
activator	O
and	O
CAML	O
-	O
interactor	O
)	O
,	O
on	O
the	O
surface	O
of	O
transfected	O
Jurkat	O
cells	O
with	O
TACI	O
-	O
specific	O
antibodies	O
led	O
to	O
activation	O
of	O
the	O
transcription	O
factors	O
NF	O
-	O
AT	O
,	O
AP	O
-	O
1	O
,	O
and	O
NFkappaB	O
.	O

TACI	O
-	O
induced	O
activation	O
of	O
NF	O
-	O
AT	O
was	O
specifically	O
blocked	O
by	O
a	O
dominant	O
-	O
negative	O
CAML	O
mutant	O
,	O
thus	O
implicating	O
CAML	O
as	O
a	O
signaling	O
intermediate	O
.	O

The	O
DNA	O
binding	O
domain	O
of	O
the	O
A	O
-	O
MYB	O
transcription	O
factor	O
is	O
responsible	O
for	O
its	O
B	O
cell	O
-	O
specific	O
activity	O
and	O
binds	B-Binding
to	O
a	O
B	O
cell	O
110	O
-	O
kDa	O
nuclear	O
protein	O
.	O

Expression	O
studies	O
as	O
well	O
as	O
the	O
use	O
of	O
transgenic	O
animals	O
have	O
demonstrated	O
that	O
the	O
A	O
-	O
MYB	O
transcription	O
factor	O
plays	O
central	O
and	O
specific	O
role	O
in	O
the	O
regulation	O
of	O
mature	O
B	O
cell	O
proliferation	O
and/or	O
differentiation	O
.	O

Furthermore	O
,	O
it	O
is	O
highly	O
expressed	B-Gene_expression
in	O
Burkitt	O
's	O
lymphoma	O
cells	O
and	O
may	O
participate	O
in	O
the	O
pathogenesis	O
of	O
this	O
disease	O
.	O

We	O
have	O
therefore	O
investigated	O
the	O
transcriptional	O
activity	O
of	O
A	O
-	O
MYB	O
and	O
its	O
regulation	B-Regulation
in	O
several	O
human	O
lymphoid	O
cell	O
lines	O
using	O
co	O
-	O
transfection	O
assays	O
and	O
show	O
that	O
A	O
-	O
MYB	O
is	O
transcriptionally	B-Positive_regulation
active	I-Positive_regulation
in	O
all	O
the	O
B	O
cell	O
lines	O
studied	O
,	O
but	O
not	O
in	O
T	O
cells	O
.	O

In	O
particular	O
the	O
best	O
responder	B-Positive_regulation
cell	O
line	O
was	O
the	O
Burkitt	O
's	O
cell	O
line	O
Namalwa	O
.	O

The	O
activity	O
of	O
A	O
-	O
MYB	O
in	O
B	O
and	O
not	O
T	O
cells	O
was	O
observed	B-Positive_regulation
when	O
either	O
an	O
artificial	O
construct	O
or	O
the	O
c	O
-	O
MYC	O
promoter	O
was	O
used	O
as	O
a	O
reporter	O
.	O

Furthermore	O
,	O
the	O
functional	O
domains	O
responsible	O
for	O
DNA	O
binding	B-Binding
,	O
transactivation	O
,	O
and	O
negative	B-Negative_regulation
regulation	I-Negative_regulation
,	O
previously	O
characterized	O
in	O
a	O
fibroblast	O
context	O
,	O
were	O
found	O
to	O
have	O
similar	O
activity	O
in	O
B	O
cells	O
.	O

The	O
region	O
of	O
A	O
-	O
MYB	O
responsible	O
for	O
the	O
B	O
cell	O
specific	O
activity	O
was	O
defined	O
to	O
be	O
the	O
N	O
-	O
terminal	O
218	O
amino	O
acids	O
containing	O
the	O
DNA	O
binding	O
domain	O
.	O

Finally	O
,	O
a	O
110	O
-	O
kDa	O
protein	O
has	O
been	O
identified	O
in	O
the	O
nuclei	O
of	O
all	O
the	O
B	O
,	O
but	O
not	O
T	O
,	O
cell	O
lines	O
that	O
specifically	O
binds	B-Binding
to	O
this	O
A	O
-	O
MYB	O
N	O
-	O
terminal	O
domain	O
.	O

We	O
hypothesize	O
that	O
this	O
110	O
-	O
kDa	O
protein	O
may	O
be	O
a	O
functionally	O
important	O
B	O
cell	O
-	O
specific	O
co	B-Positive_regulation
-	I-Positive_regulation
activator	I-Positive_regulation
of	O
A	O
-	O
MYB	O
.	O

Evidence	O
that	O
calcineurin	O
is	O
rate	O
-	O
limiting	O
for	O
primary	O
human	O
lymphocyte	O
activation	O
.	O

Cyclosporine	O
(	O
CsA	O
)	O
is	O
both	O
a	O
clinical	O
immunosuppressive	O
drug	O
and	O
a	O
probe	O
to	O
dissect	O
intracellular	O
signaling	O
pathways	O
.	O

In	O
vitro	O
,	O
CsA	O
inhibits	O
lymphocyte	O
gene	O
activation	O
by	O
inhibiting	O
the	O
phosphatase	O
activity	O
of	O
calcineurin	O
(	O
CN	O
)	O
.	O

In	O
clinical	O
use	O
,	O
CsA	O
treatment	O
inhibits	O
50	O
-	O
75	O
%	O
of	O
CN	O
activity	O
in	O
circulating	O
leukocytes	O
.	O

We	O
modeled	O
this	O
degree	O
of	O
CN	O
inhibition	O
in	O
primary	O
human	O
leukocytes	O
in	O
vitro	O
in	O
order	O
to	O
study	O
the	O
effect	O
of	O
partial	O
CN	O
inhibition	O
on	O
the	O
downstream	O
signaling	O
events	O
that	O
lead	O
to	O
gene	O
activation	O
.	O

In	O
CsA	O
-	O
treated	O
leukocytes	O
stimulated	O
by	O
calcium	O
ionophore	O
,	O
the	O
degree	O
of	O
reduction	O
in	O
CN	O
activity	O
was	O
accompanied	O
by	O
a	O
similar	O
degree	O
of	O
inhibition	B-Negative_regulation
of	O
each	O
event	O
tested	O
:	O
dephosphorylation	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
proteins	O
,	O
nuclear	O
DNA	O
binding	O
,	O
activation	O
of	O
a	O
transfected	O
reporter	O
gene	O
construct	O
,	O
IFN	O
-	O
gamma	O
and	O
IL	O
-	O
2	O
mRNA	O
accumulation	B-Positive_regulation
,	O
and	O
IFN	O
-	O
gamma	O
production	B-Gene_expression
.	O

Furthermore	O
,	O
the	O
degree	O
of	O
CN	O
inhibition	O
was	O
reflected	O
by	O
a	O
similar	O
degree	O
of	O
reduction	B-Negative_regulation
in	O
lymphocyte	O
proliferation	O
and	O
IFN	O
-	O
gamma	O
production	B-Gene_expression
in	O
the	O
allogeneic	O
mixed	O
lymphocyte	O
cultures	O
.	O

These	O
data	O
support	O
the	O
conclusion	O
that	O
CN	O
activity	O
is	O
rate	O
-	O
limiting	O
for	O
the	O
activation	O
of	O
primary	O
human	O
T	O
lymphocytes	O
.	O

Thus	O
,	O
the	O
reduction	O
of	O
CN	O
activity	O
observed	O
in	O
CsA	O
-	O
treated	O
patients	O
is	O
accompanied	O
by	O
a	O
similar	O
degree	O
of	O
reduction	O
in	O
lymphocyte	O
gene	O
activation	O
,	O
and	O
accounts	O
for	O
the	O
immunosuppression	O
observed	O
.	O

Cooperation	B-Positive_regulation
of	O
binding	O
sites	O
for	O
STAT6	O
and	O
NF	O
kappa	O
B/rel	O
in	O
the	O
IL-4	O
-	O
induced	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
the	O
human	O
IgE	O
germline	O
promoter	O
.	O

Ig	O
heavy	O
chain	O
class	O
switching	O
is	O
directed	O
by	O
cytokines	O
inducing	O
transcription	O
from	O
unrearranged	O
CH	O
genes	O
.	O

Subsequently	O
,	O
such	O
primed	O
cells	O
can	O
undergo	O
switch	O
recombination	O
to	O
express	O
the	O
selected	O
new	O
isotype	O
.	O

In	O
the	O
case	O
of	O
IgE	O
class	O
switching	O
,	O
IL	O
-	O
4	O
activates	O
the	O
IgE	O
germline	O
promoter	O
by	O
inducing	B-Positive_regulation
the	O
interaction	B-Binding
of	O
the	O
transcription	O
factor	O
STAT6	O
(	O
IL	O
-	O
4STAT	O
)	O
with	O
a	O
responsive	O
DNA	O
element	O
in	O
the	O
proximal	O
region	O
of	O
the	O
promoter	O
.	O

This	O
study	O
describes	O
the	O
characterization	O
of	O
two	O
additional	O
cis	O
-	O
acting	O
elements	O
that	O
interact	O
with	O
members	O
of	O
the	O
NF	O
kappa	O
B/rel	O
transcription	O
factor	O
family	O
in	O
an	O
IL-4	O
-	O
independent	O
fashion	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
show	O
that	O
the	O
nucleoprotein	O
complex	B-Binding
formed	I-Binding
on	O
the	O
upstream	O
site	O
(	O
NF	O
kappa	O
B1	O
)	O
contains	O
the	O
classical	O
p50/p65	O
heterodimer	O
.	O

The	O
complex	O
on	O
the	O
proximal	O
site	O
(	O
NF	O
kappa	O
B2	O
)	O
appears	O
to	O
be	O
composed	O
of	O
p50	O
and	O
relB	O
.	O

IgE	O
germline	O
promoter	O
reporter	O
gene	O
constructs	O
carrying	O
point	O
mutations	O
in	O
the	O
NF	O
kappa	O
B2	O
site	O
were	O
largely	O
unresponsive	O
to	O
IL	O
-	O
4	O
stimulation	O
in	O
transient	O
transfection	O
experiments	O
,	O
while	O
plasmids	O
with	O
similar	O
mutations	O
in	O
the	O
NF	O
kappa	O
B1	O
site	O
responded	O
to	O
cytokine	O
stimulation	O
better	O
than	O
the	O
wild	O
-	O
type	O
promoter	O
.	O

The	O
NF	O
kappa	O
B2	O
effect	O
was	O
dependent	B-Regulation
on	O
the	O
presence	O
of	O
the	O
STAT6	O
binding	O
site	O
,	O
demonstrating	O
that	O
the	O
NF	O
kappa	O
B2	O
motif	O
is	O
necessary	O
but	O
not	O
sufficient	O
for	O
mediating	O
cytokine	O
up	O
-	O
regulation	O
.	O

In	O
addition	O
,	O
the	O
combination	O
of	O
a	O
NF	O
kappa	O
B/rel	O
binding	O
site	O
and	O
the	O
STAT6	O
response	O
element	O
conferred	B-Positive_regulation
IL	O
-	O
4	O
inducibility	B-Positive_regulation
to	O
a	O
heterologous	O
minimal	O
promoter	O
,	O
while	O
the	O
individual	O
sites	O
had	O
no	O
effect	B-Positive_regulation
.	O

The	O
available	O
data	O
suggest	O
that	O
the	O
NF	O
kappa	O
B2	O
nucleoprotein	O
complex	O
may	O
cooperate	O
with	O
DNA	O
-	O
bound	B-Binding
STAT6	O
to	O
achieve	O
IL-4	O
-	O
dependent	O
activation	O
of	O
the	O
human	O
IgE	O
germline	O
gene	O
.	O

Dual	O
effects	O
of	O
LPS	O
antibodies	O
on	O
cellular	O
uptake	O
of	O
LPS	O
and	O
LPS	O
-	O
induced	O
proinflammatory	O
functions	O
.	O

Human	O
phagocytes	O
recognize	O
bacterial	O
LPS	O
(	O
endotoxin	O
)	O
through	O
membrane	O
CD14	O
(	O
mCD14	O
)	O
,	O
a	O
proinflammatory	O
LPS	O
receptor	O
.	O

This	O
study	O
tested	O
the	O
hypothesis	O
that	O
anti	O
-	O
LPS	O
Abs	O
neutralize	O
endotoxin	O
by	O
blocking	O
cellular	O
uptake	O
through	O
mCD14	O
.	O

Ab	O
-	O
associated	O
changes	O
in	O
the	O
uptake	O
and	O
cellular	O
distribution	O
of	O
FITC	O
-	O
LPS	O
were	O
assessed	O
by	O
flow	O
cytometry	O
and	O
laser	O
scanning	O
confocal	O
microscopy	O
in	O
human	O
CD14	O
-	O
transfected	O
Chinese	O
hamster	O
ovary	O
fibroblasts	O
(	O
CHO	O
-	O
CD14	O
cells	O
)	O
and	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

LPS	O
core	O
-	O
and	O
O	O
-	O
side	O
chain	O
-	O
specific	O
mAbs	O
inhibited	O
mCD14	O
-	O
mediated	O
LPS	O
uptake	O
by	O
both	O
cell	O
types	O
in	O
the	O
presence	O
of	O
serum	O
.	O

O	O
-	O
side	O
chain	O
-	O
specific	O
mAb	O
concurrently	O
enhanced	O
complement	O
-	O
dependent	O
LPS	O
uptake	O
by	O
monocytes	O
through	O
complement	O
receptor	O
-	O
1	O
(	O
CR1	O
)	O
and	O
uptake	O
by	O
CHO	O
-	O
CD14	O
cells	O
involving	O
another	O
heat	O
-	O
labile	O
serum	O
factor	O
(	O
s	O
)	O
and	O
cell	O
-	O
associated	O
recognition	O
molecule	O
(	O
s	O
)	O
.	O

Core	O
-	O
specific	O
mAb	O
inhibited	O
mCD14	O
-	O
mediated	O
uptake	O
of	O
homologous	O
and	O
heterologous	O
LPS	O
,	O
while	O
producing	O
less	O
concurrent	O
enhancement	O
of	O
non-mCD14	O
-	O
mediated	O
LPS	O
uptake	O
.	O

The	O
modulation	O
by	O
anti	O
-	O
LPS	O
mAbs	O
of	O
mCD14	O
-	O
mediated	O
LPS	O
uptake	O
was	O
associated	O
with	O
inhibition	B-Negative_regulation
of	O
LPS	O
-	O
induced	B-Positive_regulation
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
translocation	O
and	O
TNF	O
-	O
alpha	O
secretion	B-Localization
in	O
CHO	O
-	O
CD14	O
cells	O
and	O
monocytes	O
,	O
respectively	O
,	O
while	O
mAb	O
enhancement	O
of	O
non-mCD14	O
-	O
mediated	O
LPS	O
uptake	O
stimulated	B-Positive_regulation
these	O
activities	O
.	O

LPS	O
-	O
specific	O
Abs	O
thus	O
mediate	O
anti	O
-	O
inflammatory	O
and	O
proinflammatory	O
functions	O
,	O
respectively	O
,	O
by	O
preventing	O
target	O
cell	O
uptake	O
of	O
LPS	O
through	O
mCD14	O
and	O
augmenting	O
uptake	O
through	O
CR1	O
or	O
other	O
cell	O
receptors	O
.	O

Human	O
neutrophils	O
express	B-Gene_expression
GH	O
-	O
N	O
gene	O
transcripts	O
and	O
the	O
pituitary	O
transcription	O
factor	O
Pit	O
-	O
1b	O
.	O

Since	O
GH	O
stimulates	O
the	O
development	O
and	O
function	O
of	O
granulocytes	O
,	O
we	O
investigated	O
the	O
expression	B-Gene_expression
of	O
GH	O
in	O
granulocyte	O
subsets	O
.	O

By	O
immunocytochemistry	O
,	O
25	O
+/	O
-	O
7	O
%	O
of	O
the	O
human	O
neutrophils	O
were	O
shown	O
to	O
express	B-Gene_expression
immunoreactive	O
GH	O
,	O
whereas	O
eosinophils	O
were	O
negative	B-Gene_expression
.	O

Reversed	O
transcription	O
(	O
RT	O
)	O
-	O
PCR	O
analysis	O
demonstrated	B-Transcription
GH	O
mRNA	O
in	O
neutrophils	O
.	O

Restriction	O
analysis	O
revealed	O
that	O
neutrophils	O
express	B-Gene_expression
the	O
GH	O
-	O
N	O
gene	O
but	O
not	O
the	O
GH	O
-	O
V	O
gene	O
.	O

Furthermore	O
,	O
we	O
demonstrated	O
by	O
western	O
blot	O
analysis	O
that	O
neutrophils	O
express	B-Gene_expression
an	O
alternatively	O
spliced	O
variant	O
of	O
the	O
pituitary	O
transcription	O
factor	O
Pit	O
-	O
1	O
,	O
designated	O
Pit	O
-	O
1b	O
.	O

Interleukin	O
-	O
7	O
upregulates	B-Positive_regulation
the	O
interleukin-2	O
-	O
gene	O
expression	O
in	O
activated	O
human	O
T	O
lymphocytes	O
at	B-Transcription
the	I-Transcription
transcriptional	I-Transcription
level	I-Transcription
by	O
enhancing	O
the	O
DNA	O
binding	O
activities	O
of	O
both	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
and	O
activator	O
protein	O
-	O
1	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
studied	O
the	O
role	B-Regulation
of	O
the	O
stromal	O
-	O
derived	O
cytokine	O
interleukin	O
-	O
7	O
(	O
IL	O
-	O
7	O
)	O
in	O
the	O
IL-2	O
-	O
gene	O
regulation	B-Regulation
in	O
activated	O
T	O
lymphocytes	O
.	O

Production	B-Gene_expression
of	O
IL	O
-	O
2	O
requires	B-Regulation
the	O
formation	O
of	O
transcription	O
factors	O
involved	B-Regulation
in	O
the	O
IL-2	O
-	O
gene	O
regulation	B-Regulation
.	O

T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
/CD3	O
engagement	O
results	O
in	O
the	O
activation	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
,	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
,	O
and	O
nuclear	O
factor	O
kappaB	O
(	O
NFkappaB	O
)	O
,	O
whereas	O
the	O
CD28	O
responsive	O
complex	O
(	O
CD28RC	O
)	O
is	O
activated	O
in	O
response	O
to	O
the	O
CD28	O
signal	O
.	O

Costimulation	O
of	O
phytohemagglutinin/anti	O
-	O
CD28	O
activated	O
T	O
lymphocytes	O
with	O
IL	O
-	O
7	O
induces	O
a	O
fivefold	O
enhanced	B-Positive_regulation
IL-2	O
-	O
mRNA	O
accumulation	B-Positive_regulation
and	O
a	O
2.5	O
-	O
fold	O
enhanced	O
protein	O
secretion	O
.	O

The	O
IL-2	O
-	O
gene	O
transcription	B-Transcription
rate	O
is	O
increased	B-Positive_regulation
3.4	O
-	O
fold	O
,	O
indicating	O
that	O
the	O
effect	O
of	O
IL	O
-	O
7	O
is	O
in	O
part	O
mediated	B-Positive_regulation
at	O
the	O
transcriptional	O
level	O
.	O

The	O
molecular	O
mechanisms	O
underlying	O
the	O
IL	O
-	O
7	O
effect	O
involve	O
the	O
upregulation	O
of	O
the	O
DNA	O
binding	O
activity	O
of	O
NFAT	O
(	O
60	O
%	O
)	O
and	O
AP	O
-	O
1	O
(	O
120	O
%	O
)	O
,	O
without	O
affecting	O
the	O
activities	O
of	O
NFkappaB	O
and	O
CD28RC	O
,	O
which	O
was	O
confirmed	O
by	O
transfection	O
assays	O
.	O

We	O
also	O
show	O
that	O
the	O
IL-7	O
-	O
induced	O
enhancement	O
of	O
the	O
AP-1	O
-	O
DNA	O
binding	O
activity	O
is	O
not	O
cyclosporin	O
A	O
-	O
sensitive	O
.	O

Since	O
AP	O
-	O
1	O
is	O
part	O
of	O
the	O
NFAT	O
complex	O
,	O
we	O
conclude	O
that	O
the	O
IL-7	O
-	O
signaling	O
pathway	O
is	O
involved	B-Regulation
in	O
the	O
activation	B-Positive_regulation
of	O
the	O
fos	O
and	O
jun	O
proteins	O
of	O
which	O
AP	O
-	O
1	O
consists	O
.	O

Monochloramine	O
inhibits	O
phorbol	O
ester	O
-	O
inducible	O
neutrophil	O
respiratory	O
burst	O
activation	O
and	O
T	O
cell	O
interleukin	O
-	O
2	O
receptor	O
expression	O
by	O
inhibiting	O
inducible	O
protein	O
kinase	O
C	O
activity	O
.	O

Monochloramine	O
derivatives	O
are	O
long	O
lived	O
physiological	O
oxidants	O
produced	O
by	O
neutrophils	O
during	O
the	O
respiratory	O
burst	O
.	O

The	O
effects	O
of	O
chemically	O
prepared	O
monochloramine	O
(	O
NH2Cl	O
)	O
on	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
and	O
PKC	O
-	O
mediated	O
cellular	O
responses	O
were	O
studied	O
in	O
elicited	O
rat	O
peritoneal	O
neutrophils	O
and	O
human	O
Jurkat	O
T	O
cells	O
.	O

Neutrophils	O
pretreated	O
with	O
NH2Cl	O
(	O
30	O
-	O
50	O
microM	O
)	O
showed	O
a	O
marked	O
decrease	O
in	O
the	O
respiratory	O
burst	O
activity	O
induced	O
by	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
,	O
which	O
is	O
a	O
potent	O
PKC	O
activator	O
.	O

These	O
cells	O
,	O
however	O
,	O
were	O
viable	O
and	O
showed	O
a	O
complete	O
respiratory	O
burst	O
upon	O
arachidonic	O
acid	O
stimulation	O
,	O
which	O
induces	O
the	O
respiratory	O
burst	O
by	O
a	O
PKC	O
-	O
independent	O
mechanism	O
.	O

The	O
NH2Cl	O
-	O
treated	O
neutrophils	O
showed	O
a	O
decrease	B-Negative_regulation
in	O
both	O
PKC	O
activity	O
and	O
PMA	O
-	O
induced	B-Positive_regulation
phosphorylation	B-Phosphorylation
of	O
a	O
47	O
-	O
kDa	O
protein	O
,	O
which	O
corresponds	O
to	O
the	O
cytosolic	O
factor	O
of	O
NADPH	O
oxidase	O
,	O
p47	O
(	O
phox	O
)	O
.	O

Jurkat	O
T	O
cells	O
pretreated	O
with	O
NH2Cl	O
(	O
20	O
-	O
70	O
microM	O
)	O
showed	O
a	O
decrease	B-Negative_regulation
in	O
the	O
expression	B-Gene_expression
of	O
the	O
interleukin	O
-	O
2	O
receptor	O
alpha	O
chain	O
following	O
PMA	O
stimulation	O
.	O

This	O
was	O
also	O
accompanied	O
by	O
a	O
decrease	O
in	O
both	O
PKC	O
activity	O
and	O
nuclear	O
transcription	O
factor	O
-	O
kappaB	O
activation	O
,	O
also	O
without	O
loss	O
of	O
cell	O
viability	O
.	O

These	O
results	O
show	O
that	O
NH2Cl	O
inhibits	O
PKC	O
-	O
mediated	O
cellular	O
responses	O
through	O
inhibition	O
of	O
the	O
inducible	O
PKC	O
activity	O
.	O

HIV	O
-	O
1	O
Vpr	O
suppresses	O
immune	O
activation	O
and	O
apoptosis	O
through	O
regulation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
[	O
see	O
comments	O
]	O

The	O
HIV	O
-	O
1	O
accessory	O
gene	O
product	O
Vpr	O
can	O
influence	O
viral	O
pathogenesis	O
by	O
affecting	O
viral	O
replication	O
as	O
well	O
as	O
host	O
cell	O
transcription	O
and	O
proliferation	O
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
Vpr	O
on	O
host	O
cell	O
activation	O
and	O
confirm	O
that	O
it	O
influences	O
cellular	O
proliferation	O
.	O

However	O
,	O
we	O
have	O
also	O
found	O
that	O
Vpr	O
modulates	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
-	O
triggered	O
apoptosis	O
in	O
a	O
manner	O
similar	O
to	O
that	O
of	O
glucocorticoids	O
.	O

In	O
the	O
absence	O
of	O
TCR	O
-	O
mediated	O
activation	O
,	O
Vpr	O
induces	O
apoptosis	O
whereas	O
in	O
its	O
presence	O
,	O
Vpr	O
interrupts	O
the	O
expected	O
induction	O
of	O
apoptosis	O
.	O

This	O
regulation	O
of	O
apoptosis	O
is	O
linked	O
to	O
Vpr	O
suppression	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
via	O
the	O
induction	O
of	O
I	O
kappa	O
B	O
,	O
an	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Further	O
,	O
Vpr	O
suppresses	B-Negative_regulation
expression	B-Gene_expression
of	O
IL	O
-	O
2	O
,	O
IL	O
-	O
10	O
,	O
IL	O
-	O
12	O
,	O
TNF	O
alpha	O
and	O
IL	O
-	O
4	O
,	O
all	O
of	O
which	O
are	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	B-Regulation
.	O

The	O
effects	O
of	O
Vpr	O
could	O
be	O
reversed	B-Negative_regulation
by	O
RU486	O
.	O

Our	O
finding	O
that	O
Vpr	O
can	O
regulate	O
NF	O
-	O
kappa	O
B	O
supports	O
the	O
hypothesis	O
that	O
some	O
aspects	O
of	O
viral	O
pathogenesis	O
are	O
the	O
consequence	O
of	O
cell	O
dysregulation	O
by	O
Vpr	O
.	O

The	O
tax	O
protein	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
mediates	O
the	O
transactivation	B-Positive_regulation
of	O
the	O
c-sis/platelet	O
-	O
derived	O
growth	O
factor	O
-	O
B	O
promoter	O
through	O
interactions	B-Binding
with	O
the	O
zinc	O
finger	O
transcription	O
factors	O
Sp1	O
and	O
NGFI-A/Egr	O
-	O
1	O
.	O

Transcriptional	B-Positive_regulation
up	I-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
the	O
c-sis/platelet	O
-	O
derived	O
growth	O
factor	O
-	O
B	O
(	O
PDGF	O
-	O
B	O
)	O
proto	O
-	O
oncogene	O
by	O
the	O
Tax	O
protein	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
has	O
been	O
implicated	O
as	O
one	O
possible	O
mechanism	O
of	O
cellular	O
transformation	O
by	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
.	O

In	O
previous	O
work	O
,	O
we	O
identified	O
an	O
essential	O
site	O
in	O
the	O
c-sis/PDGF	O
-	O
B	O
promoter	O
,	O
Tax	O
-	O
responsive	O
element	O
1	O
(	O
TRE1	O
)	O
,	O
necessary	O
for	O
transactivation	O
by	O
Tax	O
.	O

We	O
also	O
identified	O
Sp1	O
,	O
Sp3	O
,	O
and	O
NGFI-A/Egr	O
-	O
1	O
as	O
the	O
primary	O
nuclear	O
transcription	O
factors	O
binding	B-Binding
to	O
TRE1	O
which	O
mediate	O
Tax	O
responsiveness	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
have	O
investigated	O
the	O
mechanism	O
(	O
s	O
)	O
whereby	O
Tax	O
transactivates	B-Positive_regulation
the	O
c-sis/PDGF	O
-	O
B	O
proto	O
-	O
oncogene	O
.	O

In	O
vitro	O
transcription	O
assays	O
showed	O
that	O
Tax	O
was	O
able	O
to	O
significantly	O
increase	B-Positive_regulation
the	O
transcriptional	B-Transcription
activity	I-Transcription
of	O
a	O
template	O
containing	O
the	O
-	O
257	O
to	O
+74	O
region	O
of	O
the	O
c-sis/PDGF	O
-	O
B	O
promoter	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
analysis	O
showed	O
that	O
Tax	O
increased	B-Positive_regulation
the	O
DNA	O
binding	B-Binding
activity	I-Binding
of	O
both	O
Sp1	O
and	O
NGFI-A/Egr	O
-	O
1	O
using	O
a	O
TRE1	O
probe	O
.	O

Analysis	O
of	O
Tax	O
mutants	O
showed	O
that	O
two	O
mutants	O
,	O
IEXC29S	O
and	O
IEXL320G	O
,	O
were	O
unable	O
to	O
significantly	O
transactivate	B-Positive_regulation
the	O
c-sis/PDGF	O
-	O
B	O
promoter	O
.	O

Finally	O
,	O
co	O
-	O
immunoprecipitation	O
analysis	O
revealed	O
that	O
Tax	O
is	O
able	O
to	O
stably	O
bind	B-Binding
to	O
both	O
Sp1	O
and	O
NGFI-A/Egr	O
-	O
1	O
.	O

Interestingly	O
,	O
co	O
-	O
immunoprecipitation	O
analysis	O
also	O
revealed	O
that	O
Tax	O
mutant	O
IEXC29S	O
is	O
unable	O
to	O
interact	B-Binding
with	O
NGFI-A/Egr	O
-	O
1	O
,	O
whereas	O
Tax	O
mutant	O
IEXL320G	O
is	O
able	O
to	O
interact	B-Binding
with	O
NGFI-A/Egr	O
-	O
1	O
.	O

Induction	O
of	O
endothelial	O
cell	O
surface	O
adhesion	O
molecules	O
by	O
tumor	O
necrosis	O
factor	O
is	O
blocked	O
by	O
protein	O
tyrosine	O
phosphatase	O
inhibitors	O
:	O
role	O
of	O
the	O
nuclear	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
.	O

Recent	O
studies	O
from	O
our	O
laboratory	O
have	O
indicated	O
that	O
protein	O
tyrosine	O
phosphatase	O
(	O
PTPase	O
)	O
inhibitors	O
can	O
down	O
-	O
modulate	O
the	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
mediated	O
activation	O
of	O
the	O
nuclear	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
in	O
ML	O
-	O
1a	O
,	O
a	O
monocytic	O
cell	O
line	O
(	O
Singh	O
and	O
Aggarwal	O
,	O
J.	O
Biol	O
.	O

Chem	O
.	O

1995	O
:	O
270	O
:	O
10631	O
)	O
.	O

Since	O
TNF	O
is	O
one	O
of	O
the	O
major	O
inducers	O
of	O
various	O
adhesion	O
molecules	O
in	O
human	O
endothelial	O
cells	O
and	O
their	O
expression	O
is	O
known	O
to	O
require	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
we	O
examined	O
the	O
effect	B-Regulation
of	O
PTPase	O
inhibitors	O
on	O
the	O
TNF	O
-	O
mediated	O
induction	B-Positive_regulation
of	O
intracellular	O
adhesion	O
molecule	O
(	O
ICAM	O
)	O
-	O
1	O
,	O
vascular	O
cell	O
adhesion	O
molecule	O
(	O
VCAM	O
)	O
-	O
1	O
and	O
endothelial	O
leukocyte	O
adhesion	O
molecule	O
(	O
ELAM	O
)	O
-	O
1	O
.	O

Like	O
ML	O
-	O
1a	O
,	O
human	O
dermal	O
microvessel	O
endothelial	O
cells	O
(	O
MVEC	O
)	O
treated	O
with	O
TNF	O
rapidly	O
activated	O
(	O
within	O
30	O
min	O
)	O
NF	O
-	O
kappa	O
B	O
;	O
this	O
effect	O
was	O
completely	O
abolished	O
by	O
co	O
-	O
treatment	O
with	O
phenylarsine	O
oxide	O
(	O
PAO	O
)	O
,	O
a	O
specific	O
inhibitor	O
of	O
PTPase	O
.	O

The	O
induction	B-Positive_regulation
of	O
ICAM	O
-	O
1	O
,	O
VCAM	O
-	O
1	O
,	O
and	O
ELAM	O
-	O
1	O
by	O
TNF	O
in	O
MVEC	O
occurred	O
within	O
6	O
h	O
and	O
was	O
also	O
completely	O
down	B-Negative_regulation
-	I-Negative_regulation
regulated	I-Negative_regulation
by	O
PAO	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

PAO	O
was	O
found	O
to	O
be	O
effective	O
even	O
when	O
added	O
3	O
h	O
after	O
TNF	O
,	O
suggesting	O
a	O
rapid	O
mode	O
of	O
action	O
of	O
this	O
inhibitor	O
.	O

Besides	O
PAO	O
,	O
other	O
inhibitors	O
of	O
PTPase	O
,	O
including	O
pervanadate	O
and	O
diamide	O
,	O
also	O
blocked	B-Negative_regulation
TNF	O
-	O
dependent	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
induction	B-Positive_regulation
of	O
all	O
the	O
three	O
adhesion	O
proteins	O
.	O

Consistent	O
with	O
these	O
results	O
,	O
the	O
attachment	O
of	O
monocytes	O
to	O
MVEC	O
was	O
also	O
blocked	O
by	O
the	O
PTPase	O
inhibitors	O
.	O

Thus	O
,	O
overall	O
,	O
our	O
results	O
demonstrate	O
that	O
a	O
PTPase	O
is	O
involved	O
either	O
directly	O
or	O
indirectly	O
in	O
the	O
pathway	O
leading	O
to	O
the	O
induction	O
of	O
endothelial	O
cell	O
adhesion	O
molecules	O
by	O
TNF	O
.	O

Because	O
of	O
their	O
role	O
in	O
cell	O
adhesion	O
,	O
PTPase	O
may	O
provide	O
a	O
novel	O
target	O
of	O
drug	O
development	O
for	O
treatment	O
of	O
inflammation	O
,	O
atherogenesis	O
,	O
and	O
tumor	O
metastasis	O
.	O

The	O
spatial	O
distribution	O
of	O
human	O
immunoglobulin	O
genes	O
within	O
the	O
nucleus	O
:	O
evidence	O
for	O
gene	O
topography	O
independent	O
of	O
cell	O
type	O
and	O
transcriptional	O
activity	O
.	O

The	O
three	O
-	O
dimensional	O
positioning	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
genes	O
within	O
the	O
nucleus	O
of	O
human	O
cells	O
was	O
investigated	O
using	O
in	O
situ	O
hybridization	O
and	O
confocal	O
microscopy	O
.	O

The	O
visualization	O
of	O
heavy	O
and	O
light	O
chain	O
genes	O
in	O
B	O
-	O
lymphoid	O
cells	O
showed	O
that	O
the	O
three	O
Ig	O
genes	O
are	O
differentially	O
and	O
nonrandomly	O
distributed	O
in	O
different	O
nuclear	O
subvolumes	O
:	O
the	O
kappa	O
genes	O
were	O
found	O
to	O
be	O
preferentially	O
confined	O
to	O
an	O
outer	O
nuclear	O
volume	O
,	O
whereas	O
the	O
gamma	O
and	O
lambda	O
genes	O
consistently	O
occupied	O
more	O
central	O
positions	O
within	O
the	O
nucleus	O
,	O
the	O
lambda	O
genes	O
being	O
more	O
interior	O
when	O
compared	O
with	O
the	O
gamma	O
genes	O
.	O

The	O
data	O
further	O
show	O
that	O
these	O
overall	O
topographical	O
distributions	O
are	O
independent	O
of	O
gene	O
transcriptional	O
activity	O
and	O
are	O
conserved	O
in	O
different	O
cell	O
types	O
.	O

Although	O
subtle	O
gene	O
movements	O
within	O
those	O
defined	O
topographical	O
regions	O
can	O
not	O
be	O
excluded	O
by	O
this	O
study	O
,	O
the	O
results	O
indicate	O
that	O
tissue	O
specificity	O
of	O
gene	O
expression	O
is	O
not	O
accompanied	O
by	O
drastic	O
changes	O
in	O
gene	O
nuclear	O
topography	O
,	O
rather	O
suggesting	O
that	O
gene	O
organization	O
within	O
the	O
nucleus	O
may	O
be	O
primarily	O
dependent	O
on	O
structural	O
constraints	O
imposed	O
on	O
the	O
respective	O
chromosomes	O
.	O

Transcriptional	B-Positive_regulation
activation	I-Positive_regulation
of	O
the	O
vascular	O
cell	O
adhesion	O
molecule	O
-	O
1	O
gene	O
in	O
T	O
lymphocytes	O
expressing	B-Gene_expression
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
Tax	O
protein	O
.	O

Recruitment	O
and	O
extravasation	O
of	O
T	O
cells	O
through	O
the	O
blood	O
-	O
brain	O
barrier	O
are	O
favored	O
by	O
adhesion	O
molecule	O
-	O
mediated	O
interactions	O
of	O
circulating	O
T	O
cells	O
with	O
endothelial	O
cells	O
.	O

Since	O
a	O
common	O
pathological	O
finding	O
in	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
-	O
associated	O
diseases	O
is	O
the	O
infiltration	O
of	O
HTLV-1	O
-	O
infected	O
T	O
lymphocytes	O
into	O
various	O
organs	O
,	O
we	O
have	O
looked	O
for	O
the	O
profile	O
of	O
adhesion	O
molecules	O
expressed	O
by	O
HTLV-1	O
-	O
transformed	O
T	O
cells	O
.	O

Flow	O
cytometry	O
analysis	O
indicated	O
that	O
these	O
cells	O
were	O
expressing	B-Gene_expression
high	B-Positive_regulation
levels	I-Positive_regulation
of	O
vascular	O
cell	O
adhesion	O
molecule	O
1	O
(	O
VCAM	O
-	O
1	O
[	O
CD106	O
]	O
)	O
,	O
a	O
110	O
-	O
kDa	O
member	O
of	O
the	O
immunoglobulin	O
gene	O
superfamily	O
,	O
first	O
identified	B-Gene_expression
on	O
endothelial	O
cells	O
stimulated	O
with	O
inflammatory	O
cytokines	O
.	O

This	O
adhesion	O
molecule	O
was	O
also	O
expressed	B-Gene_expression
by	O
T	O
cells	O
obtained	O
from	O
one	O
patient	O
with	O
HTLV-1	O
-	O
associated	O
myelopathy/tropical	O
spastic	O
paraparesis	O
but	O
not	O
by	O
activated	O
T	O
cells	O
isolated	O
from	O
one	O
normal	O
blood	O
donor	O
.	O

The	O
role	B-Regulation
of	O
the	O
viral	O
trans	O
-	O
activator	O
Tax	O
protein	O
in	O
the	O
induction	B-Positive_regulation
of	O
VCAM	O
-	O
1	O
was	O
first	O
indicated	O
by	O
the	O
detection	B-Gene_expression
of	O
this	O
adhesion	O
molecule	O
on	O
Jurkat	O
T	O
-	O
cell	O
clones	O
stably	O
expressing	B-Gene_expression
the	O
tax	O
gene	O
.	O

The	O
effect	B-Regulation
of	O
Tax	O
on	O
VCAM	O
-	O
1	O
gene	O
transcription	B-Transcription
was	O
next	O
confirmed	O
in	O
JPX	O
-	O
9	O
cells	O
,	O
a	O
subclone	O
of	O
Jurkat	O
cells	O
,	O
carrying	O
the	O
tax	O
sequences	O
under	O
the	O
control	O
of	O
an	O
inducible	O
promoter	O
.	O

Furthermore	O
,	O
deletion	O
and	O
mutation	O
analyses	O
of	O
the	O
VCAM	O
-	O
1	O
promoter	O
performed	O
with	O
chloramphenicol	O
acetyltransferase	O
constructs	O
revealed	O
that	O
Tax	O
was	O
trans	B-Positive_regulation
activating	I-Positive_regulation
the	O
VCAM	O
-	O
1	O
promoter	O
via	B-Binding
two	O
NF	O
-	O
kappaB	O
sites	O
present	O
at	O
bp	O
-	O
72	O
and	O
-	O
57	O
in	O
the	O
VCAM	O
-	O
1	O
gene	O
promoter	O
,	O
with	O
both	O
of	O
them	O
being	O
required	B-Positive_regulation
for	O
the	O
Tax	O
-	O
induced	B-Positive_regulation
expression	B-Gene_expression
of	O
this	O
adhesion	O
molecule	O
.	O

Finally	O
,	O
gel	O
mobility	O
shift	O
assays	O
demonstrated	O
the	O
nuclear	O
translocation	O
of	O
proteins	O
specifically	O
bound	O
to	O
these	O
two	O
NF	O
-	O
kappaB	O
motifs	O
,	O
confirming	O
that	O
VCAM	O
-	O
1	O
was	O
induced	B-Positive_regulation
on	O
Tax	O
-	O
expressing	B-Gene_expression
cells	O
in	O
a	O
kappaB	O
-	O
dependent	B-Regulation
manner	O
.	O

Collectively	O
,	O
these	O
results	O
therefore	O
suggest	O
that	O
the	O
exclusive	O
Tax	O
-	O
induced	B-Positive_regulation
expression	B-Gene_expression
of	O
VCAM	O
-	O
1	O
on	O
T	O
cells	O
may	O
represent	O
a	O
pivotal	O
event	O
in	O
the	O
progression	O
of	O
HTLV-1	O
-	O
associated	O
diseases	O
.	O

Blockade	O
of	O
T	O
-	O
cell	O
activation	O
by	O
dithiocarbamates	O
involves	O
novel	O
mechanisms	O
of	O
inhibition	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
.	O

Dithiocarbamates	O
(	O
DTCs	O
)	O
have	O
recently	O
been	O
reported	O
as	O
powerful	O
inhibitors	O
of	O
NF	O
-	O
kappaB	O
activation	O
in	O
a	O
number	O
of	O
cell	O
types	O
.	O

Given	O
the	O
role	O
of	O
this	O
transcription	O
factor	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
in	O
the	O
inflammatory	O
response	O
,	O
NF	O
-	O
kappaB	O
inhibitors	O
have	O
been	O
suggested	O
as	O
potential	O
therapeutic	O
drugs	O
for	O
inflammatory	O
diseases	O
.	O

We	O
show	O
here	O
that	O
DTCs	O
inhibited	B-Negative_regulation
both	O
interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
synthesis	B-Gene_expression
and	O
membrane	O
expression	O
of	O
antigens	O
which	O
are	O
induced	O
during	O
T	O
-	O
cell	O
activation	O
.	O

This	O
inhibition	O
,	O
which	O
occurred	O
with	O
a	O
parallel	O
activation	B-Positive_regulation
of	O
c	O
-	O
Jun	O
transactivating	O
functions	O
and	O
expression	B-Gene_expression
,	O
was	O
reflected	O
by	O
transfection	O
experiments	O
at	O
the	O
IL	O
-	O
2	O
promoter	O
level	O
,	O
and	O
involved	O
not	O
only	O
the	O
inhibition	O
of	O
NF-kappaB	O
-	O
driven	O
reporter	O
activation	O
but	O
also	O
that	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
.	O

Accordingly	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
indicated	O
that	O
pyrrolidine	O
DTC	O
(	O
PDTC	O
)	O
prevented	O
NF	O
-	O
kappaB	O
,	O
and	O
NFAT	O
DNA	O
-	O
binding	O
activity	O
in	O
T	O
cells	O
stimulated	O
with	O
either	O
phorbol	O
myristate	O
acetate	O
plus	O
ionophore	O
or	O
antibodies	O
against	O
the	O
CD3-T	O
-	O
cell	O
receptor	O
complex	O
and	O
simultaneously	O
activated	O
the	O
binding	O
of	O
AP	O
-	O
1	O
.	O

Furthermore	O
,	O
PDTC	O
differentially	O
targeted	B-Regulation
both	O
NFATp	O
and	O
NFATc	O
family	O
members	O
,	O
inhibiting	O
the	O
transactivation	O
functions	O
of	O
NFATp	O
and	O
mRNA	O
induction	O
of	O
NFATc	O
.	O

Strikingly	O
,	O
Western	O
blotting	O
and	O
immunocytochemical	O
experiments	O
indicated	O
that	O
PDTC	O
promoted	B-Positive_regulation
a	O
transient	O
and	O
rapid	O
shuttling	B-Localization
of	O
NFATp	O
and	O
NFATc	O
,	O
leading	B-Positive_regulation
to	I-Positive_regulation
their	I-Positive_regulation
accelerated	I-Positive_regulation
export	B-Localization
from	O
the	O
nucleus	O
of	O
activated	O
T	O
cells	O
.	O

We	O
propose	O
that	O
the	O
activation	O
of	O
an	O
NFAT	O
kinase	O
by	O
PDTC	O
could	O
be	O
responsible	O
for	O
the	O
rapid	O
shuttling	O
of	O
the	O
NFAT	O
,	O
therefore	O
transiently	O
converting	O
the	O
sustained	O
transactivation	O
of	O
this	O
transcription	O
factor	O
that	O
occurs	O
during	O
lymphocyte	O
activation	O
,	O
and	O
show	O
that	O
c	O
-	O
Jun	O
NH2	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
can	O
act	O
by	O
directly	O
phosphorylating	B-Phosphorylation
NFATp	O
.	O

In	O
addition	O
,	O
the	O
combined	O
inhibitory	O
effects	O
on	O
NFAT	O
and	O
NF	O
-	O
KB	O
support	O
a	O
potential	O
use	O
of	O
DTCs	O
as	O
immunosuppressants	O
.	O

Suppression	O
of	O
nuclear	O
factor	O
kappa	O
B	O
and	O
CD18	O
-	O
mediated	O
leukocyte	O
adhesion	O
to	O
the	O
corneal	O
endothelium	O
by	O
dexamethasone	O
.	O

PURPOSE	O
:	O
To	O
demonstrate	O
that	O
leukocyte	O
adhesion	O
to	O
cultured	O
corneal	O
endothelial	O
cells	O
is	O
mediated	O
by	O
the	O
CD18	O
antigen	O
,	O
and	O
to	O
determine	O
whether	O
dexamethasone	O
directly	O
suppresses	O
adhesion	O
by	O
inhibiting	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NFkappaB	O
)	O
.	O

METHODS	O
:	O
Cultured	O
bovine	O
corneal	O
endothelium	O
was	O
stimulated	O
for	O
6	O
hours	O
by	O
40	O
micron/ml	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNFalpha	O
)	O
.	O

Dexamethasone	O
was	O
added	O
1	O
hour	O
before	O
TNFalpha	O
stimulation	O
in	O
the	O
dexamethasone	O
group	O
.	O

After	O
stimulation	O
,	O
neutrophils	O
separated	O
from	O
a	O
healthy	O
human	O
volunteer	O
were	O
added	O
with	O
or	O
without	O
anti	O
-	O
CD18	O
antibody	O
.	O

The	O
culture	O
plate	O
was	O
settled	O
for	O
15	O
minutes	O
at	O
37	O
degrees	O
C	O
,	O
and	O
then	O
neutrophils	O
were	O
activated	O
by	O
N-formyl-methionyl-leucyl	O
-	O
phenylalanine	O
for	O
5	O
minutes	O
.	O

Nonadherent	O
neutrophils	O
were	O
removed	O
by	O
sealing	O
and	O
inverting	O
the	O
culture	O
well	O
.	O

The	O
intracellular	O
localization	O
of	O
NFkappaB	O
after	O
TNFalpha	O
simulation	O
was	O
determined	O
by	O
confocal	O
immunocytochemistry	O
using	O
an	O
anti	O
-	O
p65	O
antibody	O
.	O

RESULTS	O
:	O
Neutrophil	O
adhesion	O
to	O
cultured	O
corneal	O
endothelial	O
cells	O
increased	O
significantly	O
on	O
exposure	O
to	O
TNFalpha	O
(	O
451.4+/	O
-	O
45.4	O
cells/mm2	O
,	O
n	O
=	O
16	O
)	O
compared	O
to	O
control	O
(	O
156.7+/	O
-	O
27.3	O
cells/mm2	O
,	O
n	O
=	O
16	O
,	O
P	O
<	O
0.01	O
)	O
.	O

This	O
increased	O
adhesion	O
was	O
suppressed	O
by	O
the	O
addition	O
of	O
anti	O
-	O
CD18	O
antibody	O
(	O
157.6+/	O
-	O
25.1	O
cells/mm2	O
,	O
n	O
=	O
8	O
,	O
P	O
<	O
0.01	O
)	O
and	O
by	O
pretreatment	O
with	O
10	O
(	O
-	O
7	O
)	O
M	O
dexamethasone	O
(	O
207.9+/	O
-	O
31.5	O
cells/mm2	O
,	O
n	O
=	O
10	O
,	O
P	O
<	O
0.01	O
)	O
.	O

Immunocytochemistry	O
60	O
minutes	O
after	O
stimulation	O
revealed	O
that	O
NFkappaB	O
was	O
located	O
in	O
the	O
cytoplasm	O
in	O
unstimulated	O
cells	O
;	O
however	O
,	O
the	O
addition	O
of	O
TNFalpha	O
caused	O
NFkappaB	O
to	O
translocate	O
into	O
the	O
nucleus	O
.	O

Pretreatment	O
with	O
dexamethasone	O
tapered	O
NFkappaB	O
translocation	O
into	O
the	O
nucleus	O
.	O

CONCLUSIONS	O
:	O
Leukocyte	O
adhesion	O
to	O
the	O
corneal	O
endothelium	O
was	O
shown	O
to	O
be	O
mediated	O
by	O
CD18	O
expressed	B-Gene_expression
on	O
activated	O
leukocytes	O
.	O

Pretreatment	O
of	O
the	O
endothelium	O
with	O
dexamethasone	O
inhibited	O
leukocyte	O
adhesion	O
;	O
this	O
may	O
be	O
due	O
in	O
part	O
to	O
the	O
suppression	O
of	O
NFkappaB	O
entry	O
into	O
the	O
nucleus	O
.	O

Helenalin	O
,	O
an	O
anti	O
-	O
inflammatory	O
sesquiterpene	O
lactone	O
from	O
Arnica	O
,	O
selectively	O
inhibits	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
[	O
see	O
comments	O
]	O

Alcoholic	O
extracts	O
prepared	O
form	O
Arnicae	O
flos	O
,	O
the	O
collective	O
name	O
for	O
flowerheads	O
from	O
Arnica	O
montana	O
and	O
A.	O
chamissonis	O
ssp	O
.	O

foliosa	O
,	O
are	O
used	O
therapeutically	O
as	O
anti	O
-	O
inflammatory	O
remedies	O
.	O

The	O
active	O
ingredients	O
mediating	O
the	O
pharmacological	O
effect	O
are	O
mainly	O
sesquiterpene	O
lactones	O
,	O
such	O
as	O
helenalin	O
,	O
11alpha	O
,	O
13	O
-	O
dihydrohelenalin	O
,	O
chamissonolid	O
and	O
their	O
ester	O
derivatives	O
.	O

While	O
these	O
compounds	O
affect	O
various	O
cellular	O
processes	O
,	O
current	O
data	O
do	O
not	O
fully	O
explain	O
how	O
sesquiterpene	O
lactones	O
exert	O
their	O
anti	O
-	O
inflammatory	O
effect	O
.	O

We	O
show	O
here	O
that	O
helenalin	O
,	O
and	O
,	O
to	O
a	O
much	O
lesser	O
degree	O
,	O
11alpha	O
,	O
13	O
-	O
dihydrohelenalin	O
and	O
chamissonolid	O
,	O
inhibit	O
activation	O
of	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

This	O
difference	O
in	O
efficacy	O
,	O
which	O
correlates	O
with	O
the	O
compounds	O
'	O
anti	O
-	O
inflammatory	O
potency	O
in	O
vivo	O
,	O
may	O
be	O
explained	O
by	O
differences	O
in	O
structure	O
and	O
conformation	O
.	O

NF	O
-	O
kappaB	O
,	O
which	O
resides	O
in	O
an	O
inactive	O
,	O
cytoplasmic	O
complex	O
in	O
unstimulated	O
cells	O
,	O
is	O
activated	O
by	O
phosphorylation	O
and	O
degradation	O
of	O
its	O
inhibitory	O
subunit	O
,	O
IkappaB	O
.	O

Helenalin	O
inhibits	O
NF	O
-	O
kappaB	O
activation	O
in	O
response	O
to	O
four	O
different	O
stimuli	O
in	O
T	O
-	O
cells	O
,	O
B	O
-	O
cells	O
and	O
epithelial	O
cells	O
and	O
abrogates	O
kappaB	O
-	O
driven	O
gene	O
expression	O
.	O

This	O
inhibition	O
is	O
selective	O
,	O
as	O
the	O
activity	O
of	O
four	O
other	O
transcription	O
factors	O
,	O
Oct	O
-	O
1	O
,	O
TBP	O
,	O
Sp1	O
and	O
STAT	O
5	O
was	O
not	O
affected	B-Regulation
.	O

We	O
show	O
that	O
inhibition	O
is	O
not	O
due	O
to	O
a	O
direct	O
modification	O
of	O
the	O
active	O
NF	O
-	O
kappaB	O
heterodimer	O
.	O

Rather	O
,	O
helenalin	O
modifies	O
the	O
NF	O
-	O
kappaB/IkappaB	O
complex	O
,	O
preventing	O
the	O
release	O
of	O
IkappaB	O
.	O

These	O
data	O
suggest	O
a	O
molecular	O
mechanism	O
for	O
the	O
anti	O
-	O
inflammatory	O
effect	O
of	O
sesquiterpene	O
lactones	O
,	O
which	O
differs	O
from	O
that	O
of	O
other	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
indomethacin	O
and	O
acetyl	O
salicylic	O
acid	O
.	O

Nuclear	O
accumulation	B-Localization
of	O
NFAT4	O
opposed	B-Negative_regulation
by	O
the	O
JNK	O
signal	O
transduction	O
pathway	O
.	O

The	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
group	O
of	O
transcription	O
factors	O
is	O
retained	O
in	O
the	O
cytoplasm	O
of	O
quiescent	O
cells	O
.	O

NFAT	O
activation	O
is	O
mediated	O
in	O
part	O
by	O
induced	O
nuclear	O
import	O
.	O

This	O
process	O
requires	O
calcium	O
-	O
dependent	O
dephosphorylation	O
of	O
NFAT	O
caused	O
by	O
the	O
phosphatase	O
calcineurin	O
.	O

The	O
c	O
-	O
Jun	O
amino	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
phosphorylates	B-Phosphorylation
NFAT4	O
on	O
two	O
sites	O
.	O

Mutational	O
removal	O
of	O
the	O
JNK	O
phosphorylation	O
sites	O
caused	B-Positive_regulation
constitutive	O
nuclear	O
localization	B-Localization
of	O
NFAT4	O
.	O

In	O
contrast	O
,	O
JNK	O
activation	O
in	O
calcineurin	O
-	O
stimulated	O
cells	O
caused	B-Positive_regulation
nuclear	O
exclusion	B-Localization
of	O
NFAT4	O
.	O

These	O
findings	O
show	O
that	O
the	O
nuclear	O
accumulation	B-Localization
of	O
NFAT4	O
promoted	B-Positive_regulation
by	O
calcineurin	O
is	O
opposed	B-Negative_regulation
by	O
the	O
JNK	O
signal	O
transduction	O
pathway	O
.	O

Hypoxia	O
enhances	B-Positive_regulation
induction	B-Positive_regulation
of	O
endothelial	O
ICAM	O
-	O
1	O
:	O
role	O
for	O
metabolic	O
acidosis	O
and	O
proteasomes	O
.	O

Intercellular	O
adhesion	O
molecule	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
is	O
an	O
important	O
molecule	O
in	O
promotion	O
of	O
polymorphonuclear	O
neutrophil	O
transendothelial	O
migration	O
during	O
inflammation	O
.	O

Coincident	O
with	O
many	O
inflammatory	O
diseases	O
is	O
tissue	O
hypoxia	O
.	O

Thus	O
we	O
hypothesized	O
that	O
combinations	O
of	O
hypoxia	O
and	O
inflammatory	O
stimuli	O
may	O
differentially	O
regulate	B-Regulation
expression	B-Gene_expression
of	O
endothelial	O
ICAM	O
-	O
1	O
.	O

Human	O
endothelial	O
cells	O
were	O
exposed	O
to	O
hypoxia	O
in	O
the	O
presence	O
or	O
absence	O
of	O
added	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
examined	O
for	O
expression	B-Gene_expression
of	O
functional	O
ICAM	O
-	O
1	O
.	O

Although	O
hypoxia	O
alone	O
did	O
not	O
induce	B-Positive_regulation
ICAM	O
-	O
1	O
,	O
the	O
combination	O
of	O
LPS	O
and	O
hypoxia	O
enhanced	B-Positive_regulation
(	O
3	O
+/	O
-	O
0.4	O
-	O
fold	O
over	O
normoxia	O
)	O
ICAM	O
-	O
1	O
expression	B-Gene_expression
.	O

Combinations	O
of	O
hypoxia	O
and	O
LPS	O
significantly	O
increased	O
lymphocyte	O
binding	O
,	O
and	O
such	O
increases	O
were	O
inhibited	O
by	O
addition	O
of	O
anti-ICAM	O
-	O
1	O
antibodies	O
or	O
antisense	O
oligonucleotides	O
.	O

Hypoxic	O
endothelia	O
showed	O
a	O
>	O
10	O
-	O
fold	O
increase	O
in	O
sensitivity	O
to	O
inhibitors	O
of	O
proteasome	O
activation	O
,	O
and	O
combinations	O
of	O
hypoxia	O
and	O
LPS	O
enhanced	B-Positive_regulation
proteasome	O
-	O
dependent	B-Regulation
cytoplasmic-to	O
-	O
nuclear	O
localization	B-Localization
of	O
the	O
nuclear	O
transcription	O
factor	O
-	O
kappa	O
B	O
p65	O
(	O
Rel	O
A	O
)	O
subunit	O
.	O

Such	O
proteasome	O
activation	O
correlated	O
with	O
hypoxia	O
-	O
evoked	O
decreases	O
in	O
both	O
extracellular	O
and	O
intracellular	O
pH	O
.	O

We	O
conclude	O
from	O
these	O
studies	O
that	O
endothelial	O
hypoxia	O
provides	O
a	O
novel	O
,	O
proteasome	O
-	O
dependent	B-Regulation
stimulus	B-Positive_regulation
for	O
ICAM	O
-	O
1	O
induction	B-Positive_regulation
.	O

Modulation	B-Regulation
of	O
mRNA	B-Transcription
expression	I-Transcription
of	O
a	O
novel	O
human	O
myeloid	O
-	O
selective	O
CCAAT/enhancer	O
binding	O
protein	O
gene	O
(	O
C/EBP	O
epsilon	O
)	O
.	O

Human	O
C/EBP	O
epsilon	O
is	O
a	O
newly	O
cloned	O
gene	O
coding	O
for	O
a	O
CCAAT/enhancer	O
binding	O
protein	O
that	O
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
myeloid	O
differentiation	O
.	O

Our	O
studies	O
showed	O
that	O
levels	O
of	O
C/EBP	O
epsilon	O
mRNA	O
were	O
markedly	O
increased	B-Positive_regulation
in	O
NB4	O
cells	O
(	O
promyelocytic	O
leukemia	O
line	O
)	O
,	O
because	O
they	O
were	O
induced	B-Positive_regulation
by	O
9	O
-	O
cis	O
retinoic	O
acid	O
(	O
9	O
-	O
cis	O
RA	O
)	O
to	O
differentiate	O
towards	O
granulocytes	O
.	O

Accumulation	O
of	O
C/EBP	O
epsilon	O
mRNA	O
occurred	B-Positive_regulation
as	O
early	O
as	O
1	O
hour	O
after	O
exposure	O
of	O
NB4	O
cells	O
to	O
9	O
-	O
cis	O
RA	O
(	O
5	O
x	O
10	O
(	O
-	O
7	O
)	O
mol/L	O
)	O
;	O
and	O
at	O
48	O
hours	O
,	O
levels	O
were	O
increased	B-Positive_regulation
by	O
5.1	O
-	O
fold	O
.	O

Dose	O
-	O
response	O
studies	O
showed	O
that	O
10	O
(	O
-	O
7	O
)	O
to	O
10	O
(	O
-	O
6	O
)	O
mol/L	O
9	O
-	O
cis	O
RA	O
(	O
12	O
hours	O
)	O
resulted	B-Positive_regulation
in	I-Positive_regulation
peak	I-Positive_regulation
levels	I-Positive_regulation
of	O
C/EBP	O
epsilon	O
mRNA	O
;	O
but	O
even	O
10	O
(	O
-	O
10	O
)	O
mol/L	O
9	O
-	O
cis	O
RA	O
increased	B-Positive_regulation
levels	I-Positive_regulation
of	O
these	O
transcripts	O
.	O

NB4	O
cells	O
pulse	O
-	O
exposed	O
(	O
30	O
minutes	O
)	O
to	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
washed	O
,	O
and	O
cultured	O
(	O
3	O
days	O
)	O
with	O
either	O
dimethylsulfoxide	O
(	O
DMSO	O
)	O
or	O
hexamethylene	O
bisacetamide	O
(	O
HMBA	O
)	O
had	B-Positive_regulation
a	I-Positive_regulation
prominent	I-Positive_regulation
increase	I-Positive_regulation
in	O
levels	O
of	O
C/EBP	O
epsilon	O
mRNA	O
and	O
an	O
increase	O
in	O
granulocytic	O
differentiation	O
,	O
but	O
exposure	O
to	O
either	O
DMSO	O
or	O
HMBA	O
alone	O
had	B-Regulation
no	I-Regulation
effect	I-Regulation
on	O
base	O
levels	O
of	O
C/EBP	O
epsilon	O
and	O
did	O
not	O
induce	O
differentiation	O
.	O

Macrophage	O
-	O
differentiation	O
of	O
NB4	O
reduced	B-Negative_regulation
levels	O
of	O
C/EBP	O
epsilon	O
mRNA	O
.	O

Nuclear	O
run	O
-	O
off	O
assays	O
and	O
half	O
-	O
life	O
studies	O
showed	O
that	O
accumulation	B-Positive_regulation
of	O
C/EBP	O
epsilon	O
mRNA	O
by	O
9	O
-	O
cis	O
RA	O
was	O
due	B-Positive_regulation
to	I-Positive_regulation
enhanced	B-Positive_regulation
transcription	B-Transcription
.	O

Furthermore	O
,	O
this	O
C/EBP	O
epsilon	O
mRNA	O
accumulation	B-Positive_regulation
did	O
not	B-Positive_regulation
require	I-Positive_regulation
synthesis	O
of	O
new	O
protein	O
factors	O
because	O
9	O
-	O
cis	O
RA	O
induced	B-Positive_regulation
C/EBP	O
epsilon	O
mRNA	O
accumulation	B-Positive_regulation
in	O
the	O
absence	O
of	O
new	O
protein	O
synthesis	O
.	O

ATRA	O
also	O
induced	B-Positive_regulation
expression	B-Gene_expression
of	O
C/EBP	O
epsilon	O
protein	O
in	O
NB4	O
cells	O
,	O
as	O
shown	O
by	O
Western	O
blotting	O
.	O

In	O
contrast	O
to	O
the	O
increase	B-Positive_regulation
of	O
C/EBP	O
epsilon	O
in	O
9	O
-	O
cis	O
RA	O
-	O
mediated	O
granulocytic	O
differentiation	O
,	O
the	O
DMSO	O
-	O
induced	O
differentiation	O
of	O
HL	O
-	O
60	O
cells	O
down	O
the	O
granulocytic	O
pathway	O
was	O
associated	O
with	O
an	O
initial	O
reduction	B-Negative_regulation
of	O
C/EBP	O
epsilon	O
mRNA	O
levels	O
.	O

In	O
summary	O
,	O
we	O
have	O
discovered	O
that	O
expression	B-Transcription
of	O
C/EBP	O
epsilon	O
mRNA	O
is	O
markedly	O
enhanced	B-Positive_regulation
as	O
the	O
NB4	O
promyelocytes	O
are	O
induced	O
by	O
retinoids	O
to	O
differentiate	O
towards	O
granulocytes	O
.	O

This	O
induction	B-Positive_regulation
of	O
C/EBP	O
epsilon	O
mRNA	O
expression	B-Transcription
is	O
transcriptionally	B-Positive_regulation
mediated	I-Positive_regulation
and	O
occurs	O
in	O
the	O
absence	O
of	O
synthesis	O
of	O
additional	O
protein	O
factors	O
.	O

We	O
suspect	O
that	O
the	O
C/EBP	O
epsilon	O
promoter/enhancer	O
contains	O
a	O
retinoic	O
acid	O
-	O
response	O
element	O
that	O
is	O
directly	O
stimulated	B-Positive_regulation
by	O
retinoids	O
.	O

Regulation	B-Regulation
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
and	O
its	O
inhibitor	O
I	O
kappa	O
B-alpha/MAD	O
-	O
3	O
in	O
monocytes	O
by	O
Mycobacterium	O
tuberculosis	O
and	O
during	O
human	O
tuberculosis	O
.	O

Blood	O
monocytes	O
from	O
patients	O
with	O
active	O
tuberculosis	O
are	O
activated	O
in	O
vivo	O
,	O
as	O
evidenced	O
by	O
an	O
increase	B-Positive_regulation
in	O
the	O
stimulated	B-Positive_regulation
release	B-Localization
of	O
proinflammatory	O
cytokines	O
,	O
such	O
as	O
TNF	O
-	O
alpha	O
,	O
and	O
the	O
spontaneous	B-Gene_expression
expression	I-Gene_expression
of	O
IL	O
-	O
2R	O
.	O

Further	O
,	O
monocytes	O
from	O
patients	O
demonstrate	O
an	O
augmented	O
susceptibility	O
to	O
a	O
productive	O
infection	O
with	O
HIV	O
-	O
1	O
in	O
vitro	O
.	O

Mycobacterium	O
tuberculosis	O
and	O
its	O
components	O
are	O
strong	O
signals	O
to	O
activate	O
monocytes	O
to	O
production	O
of	O
cytokines	O
.	O

In	O
this	O
study	O
we	O
examined	O
the	O
basis	O
of	O
activation	O
of	O
monocytes	O
during	O
active	O
tuberculosis	O
and	O
by	O
M.	O
tuberculosis	O
.	O

We	O
found	O
a	O
constitutive	O
degradation	B-Protein_catabolism
of	O
I	O
kappa	O
B	O
-	O
alpha	O
,	O
the	O
major	O
cytoplasmic	O
inhibitor	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
,	O
in	O
freshly	O
isolated	O
PBMC	O
and	O
monocytes	O
from	O
patients	O
with	O
tuberculosis	O
.	O

In	O
contrast	O
,	O
I	O
kappa	O
B	O
-	O
alpha	O
levels	O
in	O
PBMC	O
and	O
monocytes	O
from	O
healthy	O
subjects	O
or	O
from	O
patients	O
with	O
nontuberculous	O
pulmonary	O
conditions	O
were	O
intact	B-Protein_catabolism
.	O

Further	O
,	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
NF	O
-	O
kappa	O
B	O
was	O
activated	O
in	O
monocytes	O
from	O
tuberculous	O
patients	O
.	O

The	O
expression	B-Gene_expression
of	O
I	O
kappa	O
B	O
-	O
alpha	O
gene	O
,	O
which	O
is	O
responsive	O
to	O
activation	B-Positive_regulation
by	O
NF	O
-	O
kappa	O
B	O
,	O
was	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
in	O
PBMC	O
and	O
monocytes	O
from	O
patients	O
,	O
but	O
not	O
in	O
mononuclear	O
cells	O
from	O
healthy	O
subjects	O
or	O
those	O
with	O
nontuberculous	O
lung	O
diseases	O
.	O

By	O
contrast	O
,	O
the	O
expression	B-Gene_expression
of	O
other	O
adherence	O
-	O
associated	O
early	O
genes	O
,	O
such	O
as	O
IL	O
-	O
8	O
and	O
IL	O
-	O
1	O
beta	O
,	O
was	O
not	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
in	O
PBMC	O
of	O
tuberculous	O
patients	O
.	O

Further	O
,	O
M.	O
tuberculosis	O
and	O
its	O
tuberculin	O
,	O
purified	O
protein	O
derivative	O
,	O
induced	B-Positive_regulation
the	O
degradation	B-Protein_catabolism
of	O
I	O
kappa	O
B	O
-	O
alpha	O
and	O
the	O
expression	B-Transcription
of	O
I	O
kappa	O
B	O
-	O
alpha	O
mRNA	O
,	O
and	O
purified	O
protein	O
derivative	O
induced	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
monocytes	O
.	O

Expression	B-Gene_expression
of	O
c	O
-	O
fos	O
correlates	O
with	O
IFN	O
-	O
alpha	O
responsiveness	O
in	O
Philadelphia	O
chromosome	O
positive	O
chronic	O
myelogenous	O
leukemia	O
.	O

This	O
study	O
evaluates	O
(	O
i	O
)	O
constitutive	O
levels	B-Transcription
of	O
oncogene	O
and	O
p53	O
transcripts	O
in	O
chronic	O
phase	O
CML	O
patients	O
and	O
(	O
ii	O
)	O
their	O
modulations	O
subsequent	O
to	O
in	O
vivo	O
therapy	O
with	O
rIFN	O
-	O
alpha	O
2c	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
(	O
pbmc	O
)	O
and	O
bone	O
marrow	O
cells	O
of	O
26	O
patients	O
were	O
examined	O
for	O
c	O
-	O
fos	O
,	O
c	O
-	O
myc	O
,	O
p53	O
and	O
the	O
hybrid	O
bcr/abl	O
mRNA	O
levels	B-Transcription
.	O

Results	O
indicated	O
that	O
(	O
i	O
)	O
constitutive	O
c	O
-	O
fos	O
transcript	O
levels	O
are	O
significantly	O
higher	O
in	O
patients	O
subsequently	O
responding	O
to	O
IFN	O
-	O
alpha	O
therapy	O
(	O
p	O
<	O
0.01	O
)	O
and	O
positively	O
correlated	O
with	O
the	O
proportion	O
of	O
lymphocytes	O
(	O
r	O
=	O
0.6895	O
,	O
p	O
<	O
0.01	O
)	O
and	O
negatively	O
with	O
the	O
proportion	O
of	O
immature	O
cells	O
(	O
r	O
=	O
-	O
0.568	O
,	O
p	O
<	O
0.01	O
)	O
contained	O
in	O
the	O
pbmc	O
preparations	O
tested	O
,	O
(	O
ii	O
)	O
constitutive	O
mRNA	O
levels	O
of	O
the	O
hybrid	O
bcr/abl	O
,	O
c	O
-	O
myc	O
and	O
p53	O
are	O
positively	O
correlated	O
with	O
each	O
other	O
,	O
but	O
failed	O
to	O
relate	O
to	O
disease	O
parameters	O
,	O
and	O
(	O
iii	O
)	O
acute	O
and	O
chronic	O
in	O
vivo	O
exposure	O
to	O
IFN	O
-	O
alpha	O
is	O
accompanied	B-Positive_regulation
by	I-Positive_regulation
upregulation	I-Positive_regulation
of	O
c	O
-	O
fos	O
and	O
downregulation	B-Negative_regulation
of	O
c	O
-	O
myc	O
mRNA	O
levels	O
in	O
responder	O
patients	O
.	O

Molecular	O
cloning	O
and	O
functional	O
characterization	O
of	O
murine	O
cDNA	O
encoding	O
transcription	O
factor	O
NFATc	O
.	O

Transcription	O
factors	O
of	O
the	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
family	O
play	O
important	O
roles	O
in	O
immune	O
and	O
inflammatory	O
responses	O
by	O
regulating	O
the	O
expression	O
of	O
genes	O
encoding	O
cytokines	O
and	O
immunoregulatory	O
proteins	O
.	O

Here	O
we	O
describe	O
cloning	O
and	O
characterization	O
of	O
full	O
-	O
length	O
cDNA	O
encoding	O
murine	O
(	O
m	O
)	O
NFATc	O
which	O
predicts	O
that	O
the	O
protein	O
has	O
all	O
the	O
conserved	O
structural	O
motifs	O
of	O
NFAT	O
family	O
members	O
,	O
including	O
the	O
rel	O
homology	O
domain	O
,	O
the	O
NFAT	O
homology	O
domain	O
and	O
the	O
nuclear	O
translocation	O
signals	O
.	O

mNFATc	O
complexed	B-Binding
with	O
AP	O
-	O
1	O
bound	B-Binding
specifically	O
to	O
the	O
murine	O
IL	O
-	O
2	O
NFAT	O
recognition	O
sequence	O
and	O
activated	B-Positive_regulation
transcription	B-Transcription
from	O
the	O
co	O
-	O
transfected	O
IL	O
-	O
2	O
promoter	O
in	O
COS	O
-	O
7	O
cells	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
the	O
cDNA	O
probe	O
hybridized	O
with	O
a	O
4.5	O
kb	O
transcript	O
which	O
is	O
highly	O
inducible	O
in	O
murine	O
T	O
cells	O
.	O

By	O
Northern	O
and	O
in	O
situ	O
hybridization	O
,	O
mNFATc	O
transcript	O
was	O
detected	B-Transcription
from	O
the	O
early	O
stage	O
of	O
development	O
.	O

In	O
the	O
mouse	O
embryo	O
,	O
mNFATc	O
transcript	O
was	O
strongly	O
expressed	B-Transcription
in	O
thymus	O
,	O
lung	O
and	O
submandibular	O
gland	O
and	O
weakly	O
in	O
skeletal	O
muscle	O
and	O
heart	O
suggesting	O
that	O
mNFATc	O
may	O
have	O
a	O
role	O
both	O
in	O
embryogenesis	O
and	O
in	O
mature	O
T	O
cells	O
.	O

Phosphatidylinositol	O
3	O
-	O
kinase	O
couples	O
the	O
interleukin	O
-	O
2	O
receptor	O
to	O
the	O
cell	O
cycle	O
regulator	O
E2F	O
.	O

Cell	O
cycle	O
progression	O
initiated	O
by	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
in	O
T	O
cells	O
is	O
critical	O
for	O
lymphoproliferation	O
and	O
an	O
immune	O
response	O
.	O

Phosphatidyl	O
inositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
is	O
activated	O
by	O
IL	O
-	O
2	O
.	O

However	O
,	O
nuclear	O
targets	O
for	O
PI3K	O
are	O
not	O
known	O
.	O

Here	O
we	O
identify	O
the	O
cell	O
cycle	O
regulator	O
E2F	O
as	O
an	O
IL	O
-	O
2	O
target	O
in	O
T	O
lymphocytes	O
and	O
PI3K	O
as	O
the	O
critical	O
signaling	O
pathway	O
.	O

We	O
eliminate	O
both	O
Stat5	O
and	O
Raf/MEK	O
pathways	O
from	O
E2F	O
regulation	O
.	O

Protein	O
kinase	O
B	O
(	O
PKB	O
)	O
is	O
activated	B-Positive_regulation
by	O
IL	O
-	O
2	O
via	O
PI3K	O
.	O

The	O
expression	B-Gene_expression
of	O
an	O
active	O
PKB	O
is	O
sufficient	O
to	O
induce	O
E2F	O
activity	O
.	O

Inhibition	O
of	O
PI3K	O
inhibits	B-Negative_regulation
phosphorylation	B-Phosphorylation
of	O
Rb	O
,	O
induction	O
of	O
cyclin	O
D3	O
,	O
and	O
degradation	B-Protein_catabolism
of	O
p27kip1	O
.	O

These	O
results	O
establish	O
a	O
crucial	O
PI3K/PKB	O
-	O
mediated	O
link	O
between	O
the	O
IL	O
-	O
2	O
teceptor	O
and	O
the	O
cell	O
cycle	O
machinery	O
.	O

Thiol	O
modulation	O
inhibits	O
the	O
interleukin	O
(	O
IL	O
)	O
-1	O
-	O
mediated	O
activation	O
of	O
an	O
IL	O
-	O
1	O
receptor	O
-	O
associated	O
protein	O
kinase	O
and	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
interleukin	O
-	O
1	O
receptor	O
type	O
I	O
(	O
IL	O
-	O
1RI	O
)	O
is	O
associated	B-Binding
with	O
other	O
proteins	O
thus	O
forming	O
a	O
complex	O
system	O
by	O
which	O
IL	O
-	O
1	O
exerts	O
its	O
various	O
signals	O
.	O

The	O
initiating	O
event	O
is	O
still	O
uncertain	O
,	O
but	O
activation	O
of	O
a	O
recently	O
described	O
receptor	O
-	O
associated	O
protein	O
kinase	O
is	O
one	O
of	O
the	O
earliest	O
events	O
detectable	O
(	O
Martin	O
et	O
al.	O
,	O
Eur.J.Immunol.1994.24	O
:	O
1566	O
)	O
.	O

IL	O
-	O
1	O
signaling	O
is	O
commonly	O
accompanied	O
by	O
oxidative	O
processes	O
and	O
is	O
thought	O
to	O
be	O
subject	O
to	O
redox	O
regulation	O
.	O

We	O
therefore	O
investigated	O
whether	O
the	O
activation	O
of	O
the	O
IL-1RI	O
-	O
associated	O
protein	O
kinase	O
could	O
be	O
a	O
target	O
for	O
redox	O
regulation	O
and	O
whether	O
an	O
altered	O
activity	O
of	O
the	O
kinase	O
could	O
influence	O
IL-1	O
-	O
mediated	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

A	O
murine	O
T	O
cell	O
line	O
,	O
EL4	O
,	O
was	O
stimulated	O
with	O
IL	O
-	O
1	O
with	O
and	O
without	O
pretreatment	O
with	O
different	O
compounds	O
known	O
to	O
influence	O
the	O
cellular	O
redox	O
status	O
.	O

Thiol	O
modifying	O
agents	O
like	O
diamide	O
,	O
menadione	O
,	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
diethyl	O
dithiocarbamate	O
or	O
phenylarsine	O
oxide	O
inhibited	O
the	O
IL-1	O
-	O
induced	O
activation	O
of	O
the	O
IL-1RI	O
-	O
associated	O
protein	O
kinase	O
.	O

N	O
-	O
Acetylcysteine	O
,	O
alpha	O
,	O
alpha'	O
-	O
dipyridyl	O
,	O
aminotriazole	O
or	O
nitrofurantoin	O
did	O
not	O
show	O
any	O
effect	O
.	O

The	O
inhibition	O
by	O
PDTC	O
was	O
reversible	O
unless	O
glutathione	O
synthesis	O
was	O
blocked	O
by	O
buthionine	O
sulfoximine	O
.	O

The	O
described	O
conditions	O
which	O
inhibited	O
or	O
prevented	O
the	O
activation	O
of	O
the	O
IL-1RI	O
-	O
associated	O
kinase	O
similarly	O
impaired	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
EL4	O
cells	O
.	O

From	O
these	O
observations	O
we	O
conclude	O
that	O
free	O
thiols	O
in	O
the	O
IL	O
-	O
1RI	O
complex	O
are	O
essential	O
for	O
the	O
activation	O
of	O
the	O
IL-1RI	O
-	O
associated	O
protein	O
kinase	O
and	O
that	O
this	O
process	O
is	O
mandatory	O
for	O
IL	O
-	O
1	O
signaling	O
leading	O
to	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

ATF1	O
and	O
CREB	O
trans	B-Positive_regulation
-	I-Positive_regulation
activate	I-Positive_regulation
a	O
cell	O
cycle	O
regulated	B-Regulation
histone	O
H4	O
gene	O
at	O
a	O
distal	O
nuclear	O
matrix	O
associated	O
promoter	O
element	O
.	O

Proteins	O
of	O
the	O
ATF/CREB	O
class	O
of	O
transcription	O
factors	O
stimulate	O
gene	O
expression	O
of	O
several	O
cell	O
growth	O
-	O
related	O
genes	O
through	O
protein	O
kinase	O
A	O
-	O
related	O
cAMP	O
response	O
elements	O
.	O

The	O
promoter	O
activity	O
of	O
cell	O
cycle	O
regulated	B-Regulation
histone	O
H4	O
genes	O
is	O
regulated	B-Regulation
by	O
at	O
least	O
four	O
principal	O
cis	O
-	O
acting	O
elements	O
which	O
mediate	B-Positive_regulation
G1/S	O
phase	O
control	O
and/or	O
enhancement	B-Positive_regulation
of	O
transcription	B-Transcription
during	O
the	O
cell	O
cycle	O
.	O

Using	O
protein	O
-	O
DNA	O
interaction	O
assays	O
we	O
show	O
that	O
the	O
H4	O
promoter	O
contains	O
two	O
ATF/CREB	O
recognition	O
motifs	O
which	O
interact	B-Binding
with	O
CREB	O
,	O
ATF1	O
,	O
and	O
ATF2	O
but	O
not	O
with	O
ATF4/CREB2	O
.	O

One	O
ATF/CRE	O
motif	O
is	O
located	O
in	O
the	O
distal	O
promoter	O
at	O
the	O
nuclear	O
matrix	O
-	O
associated	O
Site	O
IV	O
,	O
and	O
the	O
second	O
motif	O
is	O
present	O
in	O
the	O
proximal	O
promoter	O
at	O
Site	O
I	O
.	O

Both	O
ATF/CRE	O
motifs	O
overlap	O
binding	O
sequences	O
for	O
the	O
multifunctional	O
YY1	O
transcription	O
factor	O
,	O
which	O
has	O
previously	O
been	O
shown	O
to	O
be	O
nuclear	O
matrix	O
associated	O
.	O

Subnuclear	O
fractionation	O
reveals	O
that	O
there	O
are	O
two	O
ATF1	O
isoforms	O
which	O
appear	O
to	O
differ	O
with	O
respect	O
to	O
DNA	O
binding	B-Binding
activity	O
and	O
partition	O
selectively	O
between	O
nuclear	O
matrix	O
and	O
nonmatrix	O
compartments	O
,	O
consistent	O
with	O
the	O
role	O
of	O
the	O
nuclear	O
matrix	O
in	O
regulating	O
gene	O
expression	O
.	O

Site	O
-	O
directed	O
mutational	O
studies	O
demonstrate	O
that	O
Site	O
I	O
and	O
Site	O
IV	O
together	O
support	B-Positive_regulation
ATF1	O
-	O
and	O
CREB	O
-	O
induced	O
trans	B-Positive_regulation
-	I-Positive_regulation
activation	I-Positive_regulation
of	O
the	O
H4	O
promoter	O
.	O

Thus	O
,	O
our	O
data	O
establish	O
that	O
ATF/CREB	O
factors	O
functionally	O
modulate	B-Regulation
histone	O
H4	O
gene	O
transcription	B-Transcription
at	B-Positive_regulation
distal	O
and	O
proximal	O
promoter	O
elements	O
.	O

IL	O
-	O
2	O
and	O
IL	O
-	O
7	O
induce	O
heterodimerization	O
of	O
STAT5	O
isoforms	O
in	O
human	O
peripheral	O
blood	O
T	O
lymphoblasts	O
.	O

Despite	O
differences	O
in	O
T	O
cell	O
responses	O
induced	O
by	O
interleukin	O
(	O
IL	O
)	O
-	O
2	O
and	O
IL	O
-	O
7	O
,	O
both	O
cytokines	O
modulate	O
T	O
cell	O
functions	O
by	O
activation	O
of	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
proteins	O
.	O

We	O
examined	O
the	O
contribution	O
of	O
the	O
two	O
isoforms	O
of	O
STAT5	O
,	O
STAT5A	O
and	O
STAT5B	O
,	O
to	O
IL-2	O
-	O
and	O
IL-7	O
-	O
induced	O
activation	O
of	O
human	O
peripheral	O
blood	O
T	O
lymphoblasts	O
.	O

Both	O
cytokines	O
induced	B-Positive_regulation
assembly	O
of	O
STAT5A	O
and	O
STAT5B	O
containing	O
complexes	B-Binding
capable	O
of	O
binding	B-Binding
to	O
the	O
interferon	O
-	O
gamma	O
activation	O
sequence	O
(	O
GAS	O
)	O
,	O
and	O
these	O
complexes	O
rapidly	O
translocated	B-Localization
(	O
within	O
1	O
min	O
)	O
into	O
the	O
nucleus	O
of	O
IL-2	O
-	O
or	O
IL-7	O
-	O
treated	B-Positive_regulation
cells	O
.	O

The	O
kinetics	O
of	O
this	O
translocation	O
were	O
delayed	O
in	O
IL-7	O
-	O
treated	O
as	O
compared	O
to	O
IL-2	O
-	O
treated	O
cells	O
.	O

IL	O
-	O
2	O
and	O
IL	O
-	O
7	O
were	O
equivalent	O
in	O
their	O
ability	O
to	O
induce	B-Positive_regulation
tyrosine	O
phosphorylation	B-Phosphorylation
of	O
STAT5A	O
and	O
STAT5B	O
and	O
to	O
facilitate	B-Positive_regulation
binding	B-Binding
of	O
these	O
STATs	O
to	O
an	O
immobilized	O
GAS	O
element	O
.	O

Both	O
IL	O
-	O
2	O
and	O
IL	O
-	O
7	O
induced	O
substantial	O
amounts	O
of	O
STAT5A/STAT5B	O
heterodimerization	B-Binding
.	O

Moreover	O
,	O
we	O
observed	O
constitutive	O
association	B-Binding
of	O
STAT3	O
with	O
each	O
STAT5	O
isomer	O
.	O

These	O
data	O
suggest	O
that	O
IL	O
-	O
2	O
and	O
IL	O
-	O
7	O
induce	O
assembly	O
of	O
STAT	O
heterodimers	O
in	O
a	O
similar	O
manner	O
and	O
that	O
subsequent	O
cellular	O
responses	O
may	O
be	O
driven	O
by	O
induction	O
of	O
similar	O
sets	O
of	O
genes	O
.	O

Molecular	O
mechanisms	O
of	O
anoxia/reoxygenation	O
-	O
induced	O
neutrophil	O
adherence	O
to	O
cultured	O
endothelial	O
cells	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
(	O
1	O
)	O
determine	O
the	O
time	O
course	O
of	O
neutrophil	O
adhesion	O
to	O
monolayers	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
that	O
were	O
exposed	O
to	O
60	O
minutes	O
of	O
anoxia	O
followed	O
by	O
30	O
to	O
600	O
minutes	O
of	O
reoxygenation	O
and	O
(	O
2	O
)	O
define	O
the	O
mechanisms	O
responsible	O
for	O
both	O
the	O
early	O
(	O
minutes	O
)	O
and	O
late	O
(	O
hours	O
)	O
hyperadhesivity	O
of	O
postanoxic	O
HUVECs	O
to	O
human	O
neutrophils	O
.	O

The	O
results	O
clearly	O
demonstrate	O
that	O
anoxia/reoxygenation	O
(	O
A/R	O
)	O
leads	O
to	O
a	O
biphasic	O
increase	O
in	O
neutrophil	O
adhesion	O
to	O
HUVECs	O
,	O
with	O
peak	O
responses	O
occurring	O
at	O
30	O
minutes	O
(	O
phase	O
1	O
)	O
and	O
240	O
minutes	O
(	O
phase	O
2	O
)	O
after	O
reoxygenation	O
.	O

Oxypurinol	O
and	O
catalase	O
inhibited	O
phase	O
-	O
1	O
adhesion	O
,	O
suggesting	O
a	O
role	O
for	O
xanthine	O
oxidase	O
and	O
H2O2	O
.	O

In	O
comparison	O
,	O
platelet	O
activating	O
factor	O
(	O
PAF	O
)	O
contributed	O
to	O
both	O
phases	O
of	O
neutrophil	O
adhesion	O
.	O

Anti	O
-	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
and	O
anti-P	O
-	O
selectin	O
antibodies	O
(	O
monoclonal	O
antibodies	O
[	O
mAbs	O
]	O
)	O
attenuated	O
phase	O
-	O
1	O
neutrophil	O
adhesion	O
,	O
consistent	O
with	O
roles	B-Regulation
for	O
constitutively	O
expressed	B-Gene_expression
ICAM	O
-	O
1	O
and	O
enhanced	B-Positive_regulation
surface	O
expression	B-Gene_expression
of	O
preformed	O
P	O
-	O
selectin	O
.	O

Phase	O
-	O
2	O
neutrophil	O
adhesion	O
was	O
attenuated	O
by	O
an	O
anti-E	O
-	O
selectin	O
mAb	O
,	O
indicating	O
a	O
dominant	O
role	O
of	O
this	O
adhesion	O
molecule	O
in	O
the	O
late	O
phase	O
response	O
.	O

Pretreatment	O
with	O
actinomycin	O
D	O
and	O
cycloheximide	O
or	O
with	O
competing	O
ds	O
-	O
oligonucleotides	O
containing	O
the	O
nuclear	O
factor	O
-	O
kappa	O
B	O
or	O
activator	O
protein	O
-	O
1	O
cognate	O
DNA	O
sequences	O
significantly	O
attenuated	O
phase	O
-	O
2	O
response	O
,	O
suggesting	O
a	O
role	O
for	O
de	O
novo	O
macromolecule	O
synthesis	O
.	O

Surface	O
expression	B-Gene_expression
of	O
ICAM	O
-	O
1	O
,	O
P	O
-	O
selectin	O
,	O
and	O
E	O
-	O
selectin	O
on	O
HUVECs	O
correlated	O
with	O
the	O
phase	O
-	O
1	O
and	O
-	O
2	O
neutrophil	O
adhesion	O
responses	O
.	O

Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
A/R	O
elicits	O
a	O
two	O
-	O
phase	O
neutrophil	O
-	O
endothelial	O
cell	O
adhesion	O
response	O
that	O
involves	O
transcription	O
-	O
independent	O
and	O
transcription	O
-	O
dependent	O
surface	O
expression	O
of	O
different	O
endothelial	O
cell	O
adhesion	O
molecules	O
.	O

c	O
-	O
Rel	O
and	O
p65	O
subunits	O
bind	B-Binding
to	O
an	O
upstream	O
NF	O
-	O
kappaB	O
site	O
in	O
human	O
granulocyte	O
macrophage	O
-	O
colony	O
stimulating	O
factor	O
promoter	O
involved	O
in	O
phorbol	O
ester	O
response	O
in	O
5637	O
cells	O
.	O

To	O
further	O
clarify	O
the	O
complex	O
transcriptional	B-Regulation
regulation	I-Regulation
of	O
the	O
human	O
GM	O
-	O
CSF	O
gene	O
,	O
which	O
was	O
extensively	O
investigated	O
in	O
activated	O
T	O
cells	O
,	O
we	O
have	O
studied	O
the	O
role	O
of	O
an	O
upstream	O
NF	O
-	O
kappaB	O
like	O
site	O
in	O
the	O
5637	O
non	O
-	O
lymphoid	O
cell	O
line	O
,	O
which	O
derives	O
from	O
a	O
bladder	O
carcinoma	O
and	O
constitutively	O
produces	B-Gene_expression
GM	O
-	O
CSF	O
.	O

This	O
sequence	O
,	O
named	O
the	O
A	O
element	O
,	O
has	O
an	O
active	O
role	B-Regulation
on	O
GM	O
-	O
CSF	O
transcription	B-Transcription
and	O
is	O
responsive	O
to	O
the	O
tumor	O
promoter	O
PMA	O
in	O
transient	O
transfection	O
experiments	O
.	O

We	O
describe	O
here	O
a	O
heterodimeric	B-Binding
binding	I-Binding
complex	I-Binding
of	O
NF	O
-	O
kappaB	O
subunits	O
(	O
c	O
-	O
Rel	O
and	O
p65	O
)	O
which	O
is	O
identical	O
to	O
the	O
one	O
obtained	O
using	O
the	O
HIV-LTR	O
-	O
kappaB	O
site	O
as	O
recognition	O
sequence	O
and	O
different	O
from	O
the	O
one	O
(	O
c	O
-	O
Rel	O
and	O
p50	O
)	O
observed	O
with	O
nuclear	O
extracts	O
from	O
Mo	O
T	O
-	O
lymphoid	O
HTLV	O
-	O
II	O
infected	O
cells	O
.	O

Cyclosporin	O
A	O
inhibits	B-Negative_regulation
monocyte	O
tissue	O
factor	O
activation	B-Positive_regulation
in	O
cardiac	O
transplant	O
recipients	O
.	O

BACKGROUND	O
:	O
Fibrin	O
deposition	O
and	O
thrombosis	O
have	O
been	O
implicated	O
in	O
both	O
allograft	O
rejection	O
and	O
vasculopathy	O
after	O
cardiac	O
transplantation	O
.	O

Because	O
monocytes	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
pathophysiology	O
of	O
intravascular	O
coagulation	O
activation	O
through	O
their	O
ability	O
to	O
synthesize	B-Gene_expression
tissue	O
factor	O
(	O
TF	O
)	O
,	O
we	O
asked	O
(	O
1	O
)	O
whether	O
monocyte	O
TF	O
activation	B-Positive_regulation
occurs	B-Positive_regulation
in	O
cardiac	O
transplant	O
recipients	O
and	O
(	O
2	O
)	O
whether	O
monocyte	O
TF	O
expression	B-Gene_expression
is	O
affected	B-Regulation
by	O
treatment	O
with	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
measured	O
levels	O
of	O
TF	O
activity	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
highly	O
purified	O
monocytes/macrophages	O
from	O
10	O
consecutive	O
cardiac	O
transplant	O
recipients	O
and	O
10	O
healthy	O
control	O
subjects	O
.	O

TF	O
activity	O
generated	B-Positive_regulation
by	O
both	O
unstimulated	O
and	O
endotoxin	O
-	O
stimulated	O
cells	O
was	O
significantly	O
higher	O
in	O
transplant	O
recipients	O
than	O
in	O
control	O
subjects	O
(	O
P	O
<	O
.05	O
)	O
.	O

Increased	B-Positive_regulation
monocyte	O
TF	O
expression	B-Gene_expression
in	O
transplant	O
recipients	O
was	O
shown	O
to	O
be	O
adversely	B-Negative_regulation
affected	I-Negative_regulation
by	O
treatment	O
with	O
CsA	O
:	O
TF	O
induction	B-Positive_regulation
was	O
markedly	O
reduced	B-Negative_regulation
by	O
CsA	O
serum	O
concentrations	O
reaching	O
peak	O
CsA	O
drug	O
levels	O
.	O

Inhibition	B-Negative_regulation
of	O
TF	O
induction	B-Positive_regulation
in	O
the	O
presence	O
of	O
high	O
CsA	O
blood	O
concentrations	O
was	O
also	O
observed	O
when	B-Negative_regulation
stimulation	O
of	O
cells	O
was	O
performed	O
with	O
interferon	O
-	O
gamma	O
or	O
interleukin	O
-	O
1beta	O
.	O

As	O
shown	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
respectively	O
,	O
treatment	O
with	O
CsA	O
leads	O
to	O
decreased	B-Negative_regulation
TF	O
mRNA	O
expression	B-Transcription
and	O
reduced	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
,	O
which	O
is	O
known	O
to	O
contribute	B-Positive_regulation
to	O
the	O
induction	B-Positive_regulation
of	O
the	O
TF	O
promotor	O
in	O
human	O
monocytes	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
demonstrates	O
that	O
TF	O
activation	B-Positive_regulation
,	O
occurring	O
in	O
mononuclear	O
cells	O
of	O
cardiac	O
transplant	O
recipients	O
,	O
is	O
inhibited	B-Negative_regulation
by	O
treatment	O
with	O
CsA	O
.	O

Inhibition	B-Negative_regulation
of	O
monocyte	O
TF	O
induction	B-Positive_regulation
by	O
CsA	O
may	O
contribute	O
to	O
its	O
successful	O
use	O
in	O
cardiac	O
transplant	O
medicine	O
and	O
might	O
be	O
useful	O
in	O
managing	O
further	O
settings	O
of	O
vascular	O
pathology	O
also	O
known	O
to	O
involve	O
TF	O
expression	B-Gene_expression
and	O
NF	O
-	O
kappaB	O
activation	O
.	O

Agonistic	O
activity	O
of	O
a	O
CD40	O
-	O
specific	O
single	O
-	O
chain	O
Fv	O
constructed	O
from	O
the	O
variable	O
regions	O
of	O
mAb	O
G28	O
-	O
5	O
.	O

A	O
single	O
-	O
chain	O
Fv	O
(	O
sFv	O
)	O
was	O
expressed	O
from	O
the	O
variable	O
regions	O
of	O
the	O
CD40	O
-	O
specific	O
mAb	O
G28	O
-	O
5	O
.	O

The	O
molecule	O
bound	B-Binding
CD40	O
with	O
a	O
high	O
affinity	O
(	O
2.2	O
nM	O
)	O
and	O
was	O
a	O
monomer	O
in	O
solution	O
.	O

Surprisingly	O
,	O
G28	O
-	O
5	O
sFv	O
was	O
a	O
potent	O
CD40	O
agonist	O
that	O
rapidly	O
crosslinked	B-Binding
CD40	O
on	O
the	O
cell	O
surface	O
but	O
did	O
not	O
crosslink	B-Binding
CD40	O
-	O
Ig	O
in	O
solution	O
.	O

G28	O
-	O
5	O
sFv	O
was	O
a	O
more	O
potent	O
agonist	O
than	O
G28	O
-	O
5	O
IgG	O
and	O
was	O
able	O
to	O
stimulate	O
CD40	O
responses	O
by	O
B	O
cells	O
and	O
monocytes	O
.	O

G28	O
-	O
5	O
IgG	O
partially	O
blocked	O
,	O
whereas	O
G28	O
-	O
5	O
sFv	O
augmented	O
CD40	O
responses	O
during	O
stimulation	O
with	O
natural	O
ligand	O
(	O
gp39	O
-	O
CD8	O
fusion	O
protein	O
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
functional	O
activity	O
of	O
ligands	O
built	O
from	O
the	O
binding	O
site	O
of	O
G28	O
-	O
5	O
is	O
highly	O
dependent	O
upon	O
the	O
size	O
and	O
physical	O
properties	O
of	O
the	O
molecule	O
both	O
in	O
solution	O
and	O
on	O
the	O
cell	O
surfaces	O
.	O

Competent	O
transcription	O
initiation	O
by	O
RNA	O
polymerase	O
II	O
in	O
cell	O
-	O
free	O
extracts	O
from	O
xeroderma	O
pigmentosum	O
groups	O
B	O
and	O
D	O
in	O
an	O
optimized	O
RNA	O
transcription	O
assay	O
.	O

The	O
human	O
autosomal	O
recessive	O
disease	O
,	O
xeroderma	O
pigmentosum	O
(	O
XP	O
)	O
,	O
can	O
result	O
from	O
mutations	O
in	O
any	O
one	O
of	O
seven	O
genes	O
,	O
designated	O
XPA	O
through	O
XPG	O
.	O

Of	O
these	O
,	O
the	O
XPB	O
and	O
XPD	O
genes	O
encode	O
proteins	O
that	O
are	O
subunits	O
of	O
a	O
general	O
transcription	O
factor	O
,	O
TFIIH	O
,	O
involved	O
in	O
both	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
and	O
initiation	O
of	O
mRNA	O
transcription	O
by	O
RNA	O
polymerase	O
II	O
.	O

In	O
humans	O
,	O
mutation	O
of	O
the	O
XPB	O
or	O
XPD	O
gene	O
impairs	O
NER	O
,	O
resulting	O
in	O
hyper	O
-	O
sensitivity	O
to	O
sunlight	O
and	O
greatly	O
increased	O
skin	O
tumor	O
formation	O
.	O

However	O
,	O
no	O
transcription	O
deficiency	O
has	O
been	O
demonstrated	O
in	O
either	O
XP	O
-	O
B	O
or	O
XP	O
-	O
D	O
.	O

We	O
have	O
employed	O
an	O
optimized	O
cell	O
-	O
free	O
RNA	O
transcription	O
assay	O
to	O
analyze	O
transcription	O
activity	O
of	O
XP	O
-	O
B	O
and	O
XP	O
-	O
D	O
.	O

Although	O
the	O
growth	O
rate	O
was	O
normal	O
,	O
the	O
XP	O
-	O
B	O
and	O
XP	O
-	O
D	O
cells	O
contained	O
reduced	O
amounts	O
of	O
TFIIH	O
.	O

Extracts	O
prepared	O
from	O
XP	O
-	O
B	O
and	O
XP	O
-	O
D	O
lymphoblastoid	O
cells	O
exhibited	O
similar	O
transcription	O
activity	O
from	O
the	O
adenovirus	O
major	O
late	O
promoter	O
when	O
compared	O
to	O
that	O
in	O
extracts	O
from	O
normal	O
cells	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
the	O
XP	O
-	O
B	O
and	O
XP	O
-	O
D	O
lymphoblastoid	O
cells	O
do	O
not	O
have	O
impaired	O
RNA	O
transcription	O
activity	O
.	O

We	O
consider	O
the	O
possible	O
consequences	O
of	O
the	O
reduced	O
cellular	O
content	O
of	O
TFIIH	O
for	O
the	O
clinical	O
symptoms	O
in	O
XP	O
-	O
B	O
or	O
XP	O
-	O
D	O
patients	O
,	O
and	O
discuss	O
a	O
'conditional	O
phenotype	O
'	O
that	O
may	O
involve	O
an	O
impairment	O
of	O
cellular	O
function	O
only	O
under	O
certain	O
growth	O
conditions	O
.	O

Cyclosporin	O
A	O
inhibits	B-Negative_regulation
early	O
mRNA	B-Transcription
expression	I-Transcription
of	O
G0/G1	O
switch	O
gene	O
2	O
(	O
G0S2	O
)	O
in	O
cultured	O
human	O
blood	O
mononuclear	O
cells	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
may	O
achieve	O
its	O
immunosuppressive	O
effects	O
by	O
inhibiting	O
the	O
calcium	O
-	O
and	O
calmodulin	O
-	O
dependent	O
phosphatase	O
calcineurin	O
which	O
is	O
required	O
for	O
activation	O
of	O
target	O
genes	O
by	O
members	O
of	O
the	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
transcription	O
factor	O
family	O
.	O

Among	O
these	O
target	O
genes	O
is	O
the	O
gene	O
encoding	O
interleukin	O
-	O
2	O
(	O
IL2	O
)	O
,	O
a	O
cytokine	O
facilitating	O
progression	O
through	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

However	O
,	O
IL2	O
does	O
not	O
reverse	O
CsA	O
inhibition	O
,	O
suggesting	O
that	O
at	O
least	O
one	O
other	O
NFAT	O
-	O
sensitive	O
gene	O
may	O
be	O
involved	O
.	O

The	O
human	O
G0/G1	O
switch	O
gene	O
,	O
G0S2	O
,	O
has	O
potential	O
NFAT	O
-	O
binding	O
sites	O
in	O
the	O
5	O
'	O
flank	O
and	O
encodes	O
a	O
small	O
basic	O
potential	O
phosphoprotein	O
of	O
unknown	O
function	O
.	O

Using	O
a	O
sensitive	O
,	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
,	O
G0S2	O
mRNA	O
levels	B-Transcription
were	O
assayed	O
in	O
cultured	O
blood	O
mononuclear	O
cells	O
.	O

Freshly	O
isolated	O
cells	O
contain	O
high	B-Positive_regulation
levels	B-Transcription
of	O
G0S2	O
mRNA	O
which	O
rapidly	O
decline	O
.	O

This	O
"	O
spontaneous	O
stimulation	B-Positive_regulation
"	O
is	O
also	O
noted	O
with	O
some	O
other	O
G0S	O
genes	O
and	O
has	O
been	O
attributed	O
to	O
some	O
aspect	O
of	O
the	O
isolation	O
procedure	O
.	O

In	O
cells	O
that	O
have	O
been	O
preincubated	O
to	O
lower	O
mRNA	O
levels	O
,	O
there	O
is	O
a	O
transient	O
increase	B-Positive_regulation
in	O
G0S2	O
mRNA	O
,	O
peaking	O
between	O
1	O
-	O
2	O
h	O
,	O
in	O
response	O
to	O
Concanavalin	O
-	O
A	O
(	O
ConA	O
)	O
,	O
or	O
to	O
the	O
combination	O
of	O
phorbol	O
ester	O
(	O
TPA	O
)	O
,	O
and	O
the	O
calcium	O
ionophore	O
,	O
ionomycin	O
.	O

Both	O
these	O
responses	O
are	O
inhibited	B-Negative_regulation
by	O
CsA	O
.	O

Our	O
results	O
suggest	O
that	O
G0S2	O
expression	B-Gene_expression
is	O
required	O
to	O
commit	O
cells	O
to	O
enter	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
that	O
,	O
while	O
not	O
excluding	O
other	O
possible	O
targets	O
,	O
early	O
inhibition	B-Negative_regulation
of	O
G0S2	O
expression	B-Gene_expression
by	O
CsA	O
may	O
be	O
important	O
in	O
achieving	O
immunosuppression	O
.	O

G0S2	O
may	O
be	O
of	O
value	O
as	O
a	O
reporter	O
gene	O
for	O
analyzing	O
the	O
mechanism	O
of	O
action	O
of	O
CsA	O
and	O
its	O
influence	O
on	O
the	O
positive	O
and	O
negative	O
selection	O
of	O
lymphocytes	O
in	O
response	O
to	O
self	O
and	O
not	O
-	O
self	O
antigens	O
.	O

Estrogen	O
receptor	O
diminishes	B-Negative_regulation
DNA	O
-	O
binding	B-Binding
activities	I-Binding
of	O
chicken	O
GATA	O
-	O
1	O
and	O
CACCC	O
-	O
binding	O
proteins	O
.	O

The	O
estrogen	O
receptor	O
(	O
ER	O
)	O
repressed	O
erythroid	O
differentiation	O
and	O
erythroid	O
-	O
specific	O
gene	O
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
ER	O
alpha	O
(	O
referred	O
to	O
throughout	O
as	O
ER	O
)	O
on	O
DNA	O
-	O
binding	O
activities	O
of	O
transcription	O
factors	O
involved	B-Regulation
in	I-Regulation
regulating	I-Regulation
the	O
expression	B-Gene_expression
of	O
erythroid	O
-	O
specific	O
genes	O
,	O
and	O
,	O
in	O
particular	O
,	O
the	O
histone	O
H5	O
gene	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
found	O
that	O
in	O
the	O
presence	O
of	O
rabbit	O
reticulocyte	O
lysate	O
,	O
human	O
ER	O
reduced	O
the	O
binding	O
activities	O
of	O
chicken	O
immature	O
erythrocyte	O
nuclear	O
extracted	O
proteins	O
to	O
GATA	O
and	O
CACCC	O
sites	O
in	O
the	O
H5	O
promoter	O
and	O
enhancer	O
.	O

In	O
contrast	O
,	O
the	O
binding	B-Binding
activities	I-Binding
of	O
NF1	O
and	O
Sp1	O
were	O
not	B-Regulation
affected	I-Regulation
by	O
ER	O
.	O

Binding	B-Binding
of	O
ER	O
to	O
an	O
estrogen	O
response	O
element	O
was	O
enhanced	B-Positive_regulation
by	O
addition	O
of	O
rabbit	O
reticulocyte	O
lysate	O
.	O

This	O
lysate	O
was	O
also	O
necessary	B-Positive_regulation
for	O
ER	O
to	B-Negative_regulation
diminish	I-Negative_regulation
the	O
DNA	O
-	O
binding	B-Binding
activity	I-Binding
of	O
GATA	O
-	O
1	O
.	O

These	O
results	O
suggest	O
that	O
additional	O
factor	O
(	O
s	O
)	O
are	O
necessary	B-Positive_regulation
for	O
full	O
ER	O
function	O
.	O

Both	O
GATA	O
-	O
1	O
and	O
CACCC	O
-	O
binding	O
proteins	O
are	O
critical	O
for	O
the	O
developmentally	O
regulated	O
expression	O
of	O
erythroid	O
-	O
specific	O
genes	O
.	O

We	O
hypothesize	O
that	O
interference	B-Negative_regulation
in	O
DNA	O
-	O
binding	B-Binding
activities	I-Binding
of	O
GATA	O
-	O
1	O
and	O
CACCC	O
-	O
binding	O
proteins	O
is	O
the	O
mechanism	O
by	O
which	O
the	O
ER	O
inhibits	O
regulation	O
of	O
these	O
genes	O
.	O

Constitutive	O
expression	B-Transcription
c	O
-	O
fos	O
,	O
c	O
-	O
jun	O
,	O
and	O
NF	O
kappa	O
B	O
mRNA	O
is	O
in	O
nucleated	O
fetal	O
blood	O
cells	O
and	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
with	O
anti	O
-	O
CD3	O
stimulation	O
.	O

Fetal	O
and	O
neonatal	O
lymphocytes	O
are	O
relatively	O
resistant	O
to	O
activation	O
and	O
cytokine	O
production	O
when	O
stimulated	O
either	O
via	O
their	O
T	O
-	O
cell	O
antigen	O
receptors	O
or	O
lectins	O
.	O

The	O
molecular	O
mechanism	O
(	O
s	O
)	O
responsible	O
for	O
this	O
phenomenon	O
have	O
not	O
been	O
clearly	O
elucidated	O
.	O

We	O
have	O
hypothesized	O
that	O
such	O
defects	O
in	O
fetal/neonatal	O
T	O
-	O
cell	O
activation	O
may	O
be	O
due	O
to	O
lack	O
of	O
expression	O
of	O
the	O
transcriptional	O
regulatory	O
elements	O
required	O
for	O
T	O
-	O
cell	O
activation	O
.	O

We	O
used	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
to	O
examine	O
both	O
fetal	O
and	O
term	O
neonatal	O
cord	O
bloods	O
for	O
mRNA	B-Transcription
expression	I-Transcription
of	O
three	O
transcription	O
factors	O
implicated	O
in	O
T	O
-	O
cell	O
activation	O
:	O
c	O
-	O
jun	O
,	O
c	O
-	O
fos	O
,	O
and	O
NF	O
kappa	O
B	O
(	O
p50	O
subunit	O
)	O
.	O

We	O
demonstrate	O
that	O
mRNAs	O
for	O
all	O
three	O
of	O
these	O
regulatory	O
factors	O
are	O
expressed	B-Transcription
in	O
fetal	O
blood	O
cells	O
by	O
the	O
27th	O
week	O
of	O
gestation	O
and	O
in	O
term	O
cord	O
bloods	O
.	O

Activation	O
of	O
term	O
infant	O
cord	O
blood	O
mononuclear	O
cells	O
with	O
anti	O
-	O
CD3	O
monoclonal	O
antibodies	O
resulted	B-Positive_regulation
in	I-Positive_regulation
up	I-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
both	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
mRNAs	O
within	O
15	O
min	O
of	O
stimulation	O
.	O

However	O
,	O
secretion	B-Localization
of	O
IL	O
-	O
2	O
by	O
anti-CD3	O
-	O
stimulated	O
cord	O
blood	O
mononuclear	O
cells	O
was	O
still	O
blunted	B-Positive_regulation
compared	O
with	O
control	O
cells	O
from	O
adults	O
.	O

We	O
conclude	O
that	O
fetal	O
nucleated	O
blood	O
cells	O
constitutively	O
express	O
important	O
genes	O
for	O
cytokine	O
regulation	O
and	O
are	O
able	O
to	O
increase	B-Positive_regulation
intracellular	O
accumulation	B-Positive_regulation
of	O
the	O
mRNAs	O
for	O
these	O
factors	O
in	O
response	O
to	O
anti	O
-	O
CD3	O
stimulation	O
.	O

Thus	O
,	O
qualitative	O
differences	O
in	O
the	O
capacity	O
to	O
regulate	B-Regulation
these	O
factors	O
could	O
not	O
be	O
shown	O
in	O
fetal	O
blood	O
cells	O
.	O

Quantitative	O
experiments	O
comparing	O
binding	B-Binding
of	O
these	O
transcription	O
factors	O
to	O
the	O
IL	O
-	O
2	O
promoter	O
are	O
currently	O
under	O
investigation	O
.	O

Replication	O
of	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
in	O
primary	O
human	O
T	O
cells	O
is	O
dependent	O
on	O
the	O
autocrine	O
secretion	O
of	O
tumor	O
necrosis	O
factor	O
through	O
the	O
control	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
activation	O
.	O

Tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
alpha	O
controls	O
T	O
-	O
cell	O
activation	O
and	O
is	O
a	O
major	O
inducer	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-	O
1	O
replication	O
in	O
chronically	O
infected	O
cells	O
.	O

Therefore	O
,	O
we	O
have	O
investigated	O
its	O
role	O
in	O
primary	O
cultures	O
of	O
HIV	O
-	O
infected	O
human	O
T	O
lymphocytes	O
by	O
using	O
neutralizing	O
anti-TNF	O
-	O
alpha	O
antibodies	O
or	O
TNF	O
-	O
alpha	O
.	O

Primary	O
resting	O
T	O
lymphocytes	O
produced	B-Gene_expression
TNF	O
-	O
alpha	O
and	O
supported	O
HIV	O
replication	O
after	O
T	O
-	O
cell	O
receptor	O
activation	O
.	O

Addition	O
of	O
neutralizing	B-Negative_regulation
anti-TNF	O
-	O
alpha	O
antibodies	O
drastically	O
reduced	B-Negative_regulation
p24	O
antigen	O
release	B-Localization
and	O
prevented	O
CD4+	O
cell	O
depletion	O
associated	O
with	O
infection	O
.	O

Anti-TNF	O
-	O
alpha	O
also	O
prevented	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
activation	O
,	O
and	O
a	O
good	O
correlation	O
between	O
this	O
inhibition	O
and	O
inhibition	O
of	O
HIV	O
replication	O
was	O
observed	O
.	O

Moreover	O
,	O
supplementing	O
the	O
cultures	O
with	O
high	O
doses	O
of	O
IL	O
-	O
2	O
reverted	O
anti-TNF	O
-	O
alpha	O
inhibition	O
of	O
cell	O
proliferation	O
but	O
did	O
not	O
affect	B-Regulation
the	O
inhibition	B-Negative_regulation
of	O
HIV	O
p24	O
antigen	O
release	B-Localization
or	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
the	O
same	O
cultures	O
.	O

Moreover	O
,	O
anti-TNF	O
-	O
alpha	O
inhibited	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
-	O
driven	O
transcription	O
of	O
a	O
reporter	O
gene	O
in	O
primary	O
T	O
cells	O
in	O
response	O
to	O
activation	O
,	O
either	O
in	O
the	O
presence	O
or	O
the	O
absence	O
of	O
HIV	O
-	O
1	O
Tat	O
.	O

Our	O
results	O
support	O
an	O
important	O
role	O
for	O
autocrine	O
TNF	O
-	O
alpha	O
secretion	B-Localization
in	O
controlling	O
HIV	O
replication	O
in	O
primary	O
T	O
cells	O
because	O
of	O
its	O
ability	O
to	O
maintain	O
NF	O
-	O
kappa	O
B	O
elevated	O
in	O
the	O
nucleus	O
of	O
T	O
cells	O
.	O

A	O
thiol	O
antioxidant	O
regulates	O
IgE	O
isotype	O
switching	O
by	O
inhibiting	O
activation	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
.	O

The	O
binding	O
site	O
for	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
is	O
present	O
at	O
the	O
promoter	O
region	O
of	O
the	O
germline	O
Cepsilon	O
gene	O
,	O
but	O
there	O
is	O
little	O
information	O
on	O
whether	O
this	O
factor	O
is	O
involved	O
in	O
regulating	O
IgE	O
synthesis	O
by	O
human	O
B	O
cells	O
.	O

Accordingly	O
,	O
we	O
studied	O
the	O
role	O
of	O
NF	O
-	O
kappaB	O
in	O
germline	O
Cepsilon	O
transcription	O
by	O
using	O
two	O
human	O
Burkitt	O
's	O
lymphoma	O
B	O
cell	O
lines	O
,	O
DND39	O
and	O
DG75	O
.	O

In	O
both	O
cell	O
lines	O
,	O
n-acetyl-L	O
-	O
cysteine	O
(	O
NAC	O
)	O
,	O
a	O
potent	O
thiol	O
antioxidant	O
,	O
inhibited	O
the	O
triggering	O
of	O
the	O
nuclear	O
expression	O
of	O
NF	O
-	O
kappaB	O
by	O
IL	O
-	O
4	O
and	O
by	O
anti	O
-	O
CD40	O
monoclonal	O
antibody	O
.	O

Although	O
IL	O
-	O
4	O
activated	B-Positive_regulation
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
6	O
in	O
addition	O
to	O
NF	O
-	O
kappaB	O
,	O
NAC	O
treatment	O
or	O
the	O
transfection	O
of	O
decoy	O
oligodeoxynucleotides	O
for	O
NF	O
-	O
kappaB	O
or	O
STAT6	O
only	O
partly	O
blocked	O
IL-4	O
-	O
induced	O
germline	O
Cepsilon	O
transcription	O
.	O

However	O
,	O
these	O
two	O
decoy	O
oligodeoxynucleotides	O
together	O
almost	O
completely	O
abrogated	O
IL-4	O
-	O
induced	O
germline	O
Cepsilon	O
transcription	O
.	O

Of	O
note	O
,	O
CD40	O
-	O
mediated	O
enhancement	O
of	O
IL-4	O
-	O
driven	O
germline	O
Cepsilon	O
transcription	O
was	O
markedly	O
decreased	O
by	O
NAC	O
or	O
by	O
a	O
decoy	O
oligodeoxynucleotide	O
for	O
NF	O
-	O
kappaB	O
.	O

The	O
effect	O
of	O
NAC	O
was	O
also	O
examined	O
on	O
deletional	O
switch	O
recombination	O
underlying	O
the	O
isotype	O
switch	O
to	O
IgE	O
.	O

NAC	O
inhibited	O
the	O
generation	O
of	O
Smu/Sepsilon	O
switch	O
fragments	O
in	O
normal	O
human	O
B	O
cells	O
costimulated	O
with	O
IL	O
-	O
4	O
and	O
anti	O
-	O
CD40	O
monoclonal	O
antibody	O
.	O

It	O
also	O
abolished	B-Negative_regulation
IL-4	O
-	O
induced	O
upregulation	B-Positive_regulation
of	O
CD40	O
but	O
promoted	B-Positive_regulation
upregulation	B-Positive_regulation
of	O
CD23	O
.	O

These	O
results	O
suggest	O
that	O
coordination	O
of	O
NF	O
-	O
kappaB	O
and	O
STAT6	O
may	O
be	O
required	O
for	O
induction	O
of	O
germline	O
Cepsilon	O
transcription	O
by	O
IL	O
-	O
4	O
,	O
and	O
that	O
CD40	O
-	O
mediated	O
NF	O
-	O
kappaB	O
activation	O
may	O
be	O
important	O
in	O
regulating	O
both	O
enhancement	O
of	O
germline	O
Cepsilon	O
transcription	O
and	O
class	O
switching	O
to	O
IgE	O
.	O

Cellular	O
and	O
molecular	O
mechanisms	O
of	O
IL	O
-	O
5	O
synthesis	B-Gene_expression
in	O
atopic	O
diseases	O
:	O
a	O
study	O
with	O
allergen	O
-	O
specific	O
human	O
helper	O
T	O
cells	O
.	O

BACKGROUND	O
:	O
Cytokines	O
produced	O
by	O
helper	O
T	O
cells	O
are	O
intimately	O
involved	O
in	O
chronic	O
allergic	O
diseases	O
associated	O
with	O
eosinophilic	O
inflammation	O
.	O

OBJECTIVE	O
:	O
We	O
investigated	O
the	O
production	B-Gene_expression
of	O
IL	O
-	O
5	O
,	O
a	O
potent	O
growth	O
factor	O
and	O
chemotactic	O
factor	O
for	O
eosinophils	O
,	O
by	O
CD4+	O
T	O
lymphocytes	O
in	O
patients	O
with	O
asthma	O
.	O

METHODS	O
:	O
Allergen	O
-	O
specific	O
T	O
cell	O
clones	O
and	O
T	O
cell	O
hybridomas	O
were	O
established	O
from	O
the	O
peripheral	O
blood	O
lymphocytes	O
of	O
patients	O
with	O
asthma	O
,	O
and	O
the	O
responses	O
to	O
various	O
stimuli	O
were	O
determined	O
.	O

RESULTS	O
:	O
After	O
nonspecific	O
stimulation	O
,	O
IL	O
-	O
5	O
production	B-Gene_expression
by	O
CD4+	O
T	O
cells	O
from	O
both	O
atopic	O
and	O
nonatopic	O
subjects	O
with	O
asthma	O
was	O
significantly	O
enhanced	B-Positive_regulation
compared	O
with	O
that	O
by	O
cells	O
from	O
healthy	O
controls	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
from	O
atopic	O
asthma	O
patients	O
both	O
proliferated	O
and	O
produced	B-Gene_expression
IL	O
-	O
5	O
after	B-Positive_regulation
incubation	I-Positive_regulation
with	I-Positive_regulation
mite	O
allergen	O
,	O
suggesting	O
that	O
mite	O
-	O
specific	O
helper	O
T	O
cells	O
were	O
involved	O
in	O
the	O
eosinophilic	O
inflammation	O
of	O
atopic	O
asthma	O
.	O

A	O
human	O
IL	O
-	O
5	O
promoter/enhancer	O
luciferase	O
gene	O
construct	O
transfected	O
into	O
IL-5	O
-	O
producing	B-Gene_expression
T	O
cell	O
clones	O
was	O
clearly	O
transcribed	B-Transcription
after	B-Positive_regulation
stimulation	O
,	O
indicating	O
that	O
the	O
515	O
base	O
pair	O
IL	O
-	O
5	O
gene	O
segment	O
upstream	O
of	O
the	O
coding	O
region	O
was	O
sufficient	B-Positive_regulation
to	I-Positive_regulation
respond	I-Positive_regulation
to	O
activating	O
signals	O
in	O
human	O
helper	O
T	O
cells	O
.	O

The	O
same	O
gene	O
segment	O
was	O
not	B-Transcription
transcribed	I-Transcription
in	O
IL-5	O
-	O
nonproducing	B-Gene_expression
T	O
cell	O
clones	O
,	O
suggesting	O
that	O
human	O
T	O
cell	O
IL	O
-	O
5	O
synthesis	B-Gene_expression
is	O
regulated	B-Regulation
at	O
the	O
transcriptional	B-Transcription
level	I-Transcription
.	O

Experiments	O
with	O
T	O
cell	O
hybridomas	O
confirmed	O
these	O
findings	O
and	O
suggested	O
that	O
a	O
unique	O
transcription	O
factor	O
may	O
be	O
essential	B-Positive_regulation
for	O
human	O
IL	O
-	O
5	O
gene	O
transcription	B-Transcription
.	O

CONCLUSION	O
:	O
Enhanced	B-Positive_regulation
IL	O
-	O
5	O
production	B-Gene_expression
by	O
helper	O
T	O
cells	O
seems	O
to	O
cause	O
the	O
eosinophilic	O
inflammation	O
of	O
both	O
atopic	O
and	O
nonatopic	O
asthma	O
.	O

Elucidation	O
of	O
IL-5	O
-	O
specific	O
regulatory	O
mechanisms	O
may	O
facilitate	O
the	O
development	O
of	O
novel	O
treatments	O
for	O
allergic	O
diseases	O
associated	O
with	O
eosinophilic	O
inflammation	O
.	O

Regulation	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
by	O
I	O
kappa	O
B	O
alpha	O
and	O
I	O
kappa	O
B	O
beta	O
stability	B-Protein_catabolism
.	O

Transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
must	O
be	O
released	O
from	O
cytoplasmic	O
inhibitory	O
molecules	O
(	O
I	O
kappa	O
Bs	O
)	O
in	O
order	O
to	O
move	O
to	O
the	O
nucleus	O
and	O
to	O
activate	O
its	O
target	O
genes	O
.	O

Little	O
is	O
known	O
about	O
the	O
mechanisms	O
regulating	O
the	O
maintenance	O
of	O
constitutive	O
nuclear	O
NF	O
-	O
kappa	O
B	O
in	O
some	O
cell	O
-	O
types	O
and	O
of	O
sustained	O
nuclear	O
NF	O
-	O
kappa	O
B	O
activity	O
after	O
stimulation	O
.	O

Increased	O
turnover	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
constitutive	O
NF	O
-	O
kappa	O
B	O
activity	O
in	O
mature	O
B	O
cells	O
.	O

We	O
therefore	O
compared	O
the	O
turnover	O
of	O
I	O
kappa	O
B	O
alpha	O
and	O
I	O
kappa	O
B	O
beta	O
in	O
mature	O
B	O
cells	O
and	O
HeLa	O
cells	O
.	O

Both	O
proteins	O
display	O
a	O
high	O
turnover	O
in	O
B	O
cells	O
although	O
I	O
kappa	O
B	O
beta	O
is	O
considerably	O
more	O
stable	O
than	O
I	O
kappa	O
B	O
alpha	O
.	O

The	O
half	O
-	O
life	O
of	O
both	O
inhibitors	O
is	O
increased	B-Positive_regulation
in	O
HeLa	O
cells	O
.	O

In	O
contrast	O
,	O
all	O
other	O
NF	O
-	O
kappa	O
B/I	O
kappa	O
B	O
molecules	O
tested	O
are	O
relatively	O
stable	O
in	O
both	O
cell	O
-	O
types	O
.	O

The	O
elevated	O
turnover	O
of	O
endogenous	O
I	O
kappa	O
B	O
alpha	O
in	O
Namalwa	O
cells	O
is	O
inhibited	O
by	O
a	O
proteasome	O
inhibitor	O
and	O
thus	O
seems	O
to	O
be	O
driven	O
by	O
the	O
same	O
degradation	O
machinery	O
as	O
the	O
slower	O
turnover	O
in	O
non	O
-	O
B	O
cells	O
.	O

Furthermore	O
,	O
we	O
investigated	O
the	O
processes	O
involved	O
in	O
persistent	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

TNF	O
-	O
alpha	O
signaling	O
leads	B-Positive_regulation
to	O
a	O
rapid	O
depletion	B-Negative_regulation
of	O
cellular	O
I	O
kappa	O
B	O
beta	O
pools	O
.	O

I	O
kappa	O
B	O
alpha	O
is	O
efficiently	O
resynthesized	B-Gene_expression
whereas	O
I	O
kappa	O
B	O
beta	O
levels	B-Gene_expression
stay	I-Gene_expression
low	I-Gene_expression
for	O
a	O
prolonged	O
time	O
.	O

NF	O
-	O
kappa	O
B	O
binding	O
activity	O
can	O
be	O
detected	O
for	O
several	O
hours	O
after	O
stimulation	O
.	O

We	O
found	O
that	O
removal	B-Negative_regulation
of	O
the	O
TNF	O
-	O
alpha	O
containing	O
medium	O
causes	O
a	O
rapid	O
decrease	O
in	O
nuclear	O
NF	O
-	O
kappa	O
B	O
.	O

A	O
phosphoform	B-Phosphorylation
of	O
newly	O
synthesized	B-Gene_expression
I	O
kappa	O
B	O
alpha	O
is	O
visible	O
when	B-Positive_regulation
degradation	B-Protein_catabolism
by	B-Positive_regulation
the	O
proteasome	O
is	O
inhibited	B-Negative_regulation
and	O
new	O
I	O
kappa	O
B	O
alpha	O
displays	O
the	O
same	O
properties	O
regarding	O
phosphorylation	B-Phosphorylation
and	O
degradation	B-Protein_catabolism
in	B-Positive_regulation
response	I-Positive_regulation
to	I-Positive_regulation
a	O
second	O
inducer	O
.	O

There	O
is	O
no	O
significant	O
difference	O
in	O
the	O
turnover	O
of	O
pre	O
-	O
and	O
post	O
-	O
inductive	O
I	O
kappa	O
B	O
alpha	O
.	O

These	O
observations	O
suggest	O
that	O
resynthesis	B-Gene_expression
of	O
I	O
kappa	O
B	O
alpha	O
and	O
removal	O
of	O
the	O
stimulus	O
are	O
obligatory	O
steps	O
for	O
the	O
inactivation	O
of	O
nuclear	O
NF	O
kappa	O
B	O
.	O

Control	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
by	O
the	O
I	O
kappa	O
B	O
beta	O
inhibitor	O
.	O

The	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
is	O
maintained	O
in	O
an	O
inactive	O
cytoplasmic	O
state	O
by	O
I	O
kappa	O
B	O
inhibitors	O
.	O

In	O
mammalian	O
cells	O
,	O
I	O
kappa	O
B	O
alpha	O
and	O
I	O
kappa	O
B	O
beta	O
proteins	O
have	O
been	O
purified	O
and	O
shown	O
to	O
be	O
the	O
inhibitors	O
of	O
NF	O
-	O
kappa	O
B	O
through	O
their	O
association	B-Binding
with	O
the	O
p65	O
or	O
c	O
-	O
Rel	O
subunits	O
.	O

In	O
addition	O
,	O
we	O
have	O
isolated	O
a	O
third	O
NF	O
-	O
kappa	O
B	O
inhibitor	O
,	O
I	O
kappa	O
B	O
epsilon	O
(	O
1	O
)	O
.	O

Upon	O
treatment	O
with	O
a	O
large	O
variety	O
of	O
inducers	O
,	O
I	O
kappa	O
B	O
alpha	O
,	O
I	O
kappa	O
B	O
beta	O
are	O
proteolytically	B-Protein_catabolism
degraded	I-Protein_catabolism
,	O
resulting	O
in	O
NF	O
-	O
kappa	O
B	O
translocation	O
into	O
the	O
nucleus	O
.	O

Here	O
we	O
show	O
that	O
in	O
E29.1	O
T	O
cell	O
hybridoma	O
I	O
kappa	O
B	O
alpha	O
and	O
I	O
kappa	O
B	O
beta	O
are	O
equally	O
associated	B-Binding
with	O
p65	O
and	O
that	O
I	O
kappa	O
B	O
beta	O
is	O
degraded	B-Protein_catabolism
in	B-Positive_regulation
response	I-Positive_regulation
to	I-Positive_regulation
TNF	O
alpha	O
in	O
contrast	O
to	O
what	O
has	O
been	O
originally	O
published	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
,	O
unlike	O
I	O
kappa	O
B	O
alpha	O
,	O
I	O
kappa	O
B	O
beta	O
is	O
constitutively	O
phosphorylated	B-Phosphorylation
and	O
resynthesized	O
as	O
a	O
hypophosphorylated	O
form	O
.	O

The	O
absence	B-Negative_regulation
of	O
slow	B-Localization
migrating	I-Localization
forms	I-Localization
of	O
I	O
kappa	O
B	O
beta	O
following	O
stimulation	O
suggests	O
that	O
the	O
phosphorylation	B-Phosphorylation
does	O
not	O
necessarily	O
constitute	O
the	O
signal	O
-	O
induced	O
event	O
which	O
targets	B-Positive_regulation
the	O
molecule	O
for	O
proteolysis	B-Protein_catabolism
.	O

NF	O
-	O
kappa	O
B/Rel	O
family	O
members	O
regulating	B-Regulation
the	O
ICAM	O
-	O
1	O
promoter	O
in	O
monocytic	O
THP	O
-	O
1	O
cells	O
.	O

A	O
kappa	O
B	O
-	O
site	O
was	O
identified	O
in	O
the	O
promoter	O
of	O
the	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
gene	O
,	O
which	O
is	O
involved	B-Regulation
in	O
regulation	B-Regulation
of	O
ICAM	O
-	O
1	O
expression	B-Gene_expression
by	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
glucocorticoids	O
.	O

We	O
now	O
report	O
on	O
the	O
transcription	O
factors	O
which	O
bind	O
and	O
transactivate	O
this	O
enhancer	O
sequence	O
.	O

In	O
vitro	O
,	O
the	O
ICAM	O
-	O
1	O
kappa	O
B	O
site	O
appeared	O
to	O
bind	B-Binding
RelA	O
and	O
c	O
-	O
Rel	O
homodimers	O
as	O
well	O
as	O
heterodimers	O
with	O
NF	O
-	O
kappa	O
B1	O
,	O
but	O
weakly	O
NF	O
-	O
kappa	O
B1	O
homodimers	O
.	O

In	O
addition	O
,	O
both	O
RelA	O
and	O
c	O
-	O
Rel	O
,	O
but	O
not	O
NF	O
-	O
kappa	O
B1	O
,	O
were	O
shown	O
to	O
transactivate	O
an	O
ICAM	O
-	O
1	O
kappa	O
B	O
-	O
reporter	O
construct	O
.	O

In	O
monocytic	O
THP	O
-	O
1	O
cells	O
TNF	O
-	O
alpha	O
induced	O
two	O
nuclear	O
complexes	O
which	O
in	O
vitro	O
bound	O
to	O
the	O
ICAM	O
-	O
1	O
kappa	O
B	O
site	O
.	O

Using	O
antibodies	O
in	O
an	O
electrophoretic	O
mobility	O
supershift	O
assay	O
,	O
one	O
of	O
these	O
complexes	O
was	O
shown	O
to	O
contain	O
NF	O
-	O
kappa	O
B1	O
and	O
RelA	O
,	O
and	O
to	O
bind	O
with	O
higher	O
affinity	O
to	O
the	O
consensus	O
kappa	O
B	O
site	O
in	O
the	O
HIV	O
long	O
terminal	O
repeat	O
.	O

The	O
second	O
complex	O
contained	O
RelA	O
,	O
and	O
exhibited	O
higher	O
affinity	O
towards	O
the	O
ICAM	O
-	O
1	O
kappa	O
B	O
than	O
to	O
the	O
HIV	O
kappa	O
B	O
site	O
.	O

The	O
glucocorticoid	O
receptor	O
was	O
shown	O
to	O
repress	B-Negative_regulation
activity	O
of	O
both	O
the	O
RelA	O
homodimer	O
and	O
the	O
NF	O
-	O
kappa	O
B1/RelA	O
heterodimer	O
.	O

We	O
argue	O
that	O
in	O
vivo	O
RelA	O
homodimers	O
are	O
likely	O
to	O
play	O
a	O
dominant	O
role	B-Regulation
in	O
TNF-alpha	O
-	O
induced	B-Positive_regulation
ICAM	O
-	O
1	O
transcription	B-Transcription
in	O
monocytic	O
cells	O
.	O

LPS	O
tolerance	O
in	O
monocytes/macrophages	O
:	O
three	O
3	O
'	O
cytosins	O
are	O
required	O
in	O
the	O
DNA	O
binding	O
motif	O
for	O
detection	O
of	O
upregulated	B-Positive_regulation
NF	O
-	O
kappa	O
B	O
p50	O
homodimers	O
.	O

When	O
monocytes	O
are	O
stimulated	O
with	O
LPS	O
(	O
lipopolysaccharide	O
)	O
repeatedly	O
then	O
the	O
initially	O
high	O
expression	B-Gene_expression
of	O
the	O
TNF	O
(	O
tumor	O
necrosis	O
factor	O
)	O
gene	O
is	O
only	O
very	O
low	B-Negative_regulation
,	O
i.e.	O
the	O
cells	O
are	O
tolerant	O
to	O
LPS	O
.	O

Tolerant	O
cells	O
still	O
express	B-Gene_expression
the	O
CD14	O
receptor	O
and	O
they	O
can	O
still	O
be	O
activated	O
to	O
mobilize	O
NF	O
-	O
kappa	O
B	O
into	O
nucleus	O
.	O

Analysis	O
of	O
the	O
binding	B-Binding
proteins	O
employing	O
the	O
-	O
605	O
motif	O
of	O
the	O
human	O
TNF	O
promoter	O
(	O
GGGGCTGTCCC	O
)	O
revealed	O
that	O
in	O
tolerant	O
cells	O
of	O
the	O
human	O
monocytic	O
cell	O
line	O
Mono	O
Mac	O
6	O
there	O
is	O
a	O
predominance	O
of	O
p50p50	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

We	O
now	O
show	O
that	O
a	O
mutant	O
motif	O
that	O
exchanges	O
the	O
terminal	O
3	O
'	O
C	O
for	O
a	O
G	O
fails	O
to	O
bind	B-Binding
the	O
p50	O
homodimer	O
that	O
is	O
upregulated	B-Positive_regulation
in	O
LPS	O
toler	O
ant	O
human	O
Mono	O
Mac	O
6	O
cells	O
.	O

The	O
same	O
is	B-Binding
true	I-Binding
for	O
nuclear	O
extracts	O
taken	O
from	O
the	O
murine	O
P388D1	O
macrophage	O
cell	O
line	O
when	O
tested	O
with	O
the	O
-	O
516	O
motif	O
of	O
the	O
murine	O
TNF	O
promoter	O
(	O
GGGGGCTTTCCC	O
)	O
.	O

Here	O
the	O
wild	O
type	O
motif	O
gives	O
efficient	O
binding	B-Binding
of	O
p50p50	O
that	O
again	O
is	O
upregulated	B-Positive_regulation
in	O
tolerant	O
cells	O
whereas	O
a	O
mutant	O
with	O
a	O
3	O
'	O
G	O
shows	O
hardly	O
any	O
binding	B-Binding
of	O
p50p50	O
.	O

Conversely	O
,	O
the	O
murine	O
kappa	O
light	O
chain	O
enhancer	O
motif	O
(	O
GGGGACTTTCCG	O
)	O
does	O
not	O
efficiently	O
bind	B-Binding
the	O
nuclear	O
p50p50	O
from	O
tolerant	O
murine	O
P388	O
macrophages	O
.	O

Binding	O
is	O
,	O
however	O
,	O
readily	O
detected	B-Negative_regulation
when	O
the	O
3	O
'	O
G	O
is	O
replaced	O
by	O
a	O
C	O
.	O

These	O
data	O
show	O
that	O
the	O
detection	O
of	O
upregulated	B-Positive_regulation
p50	O
homodimers	O
in	O
LPS	O
tolerant	O
cells	O
is	O
dependent	B-Regulation
on	O
subtle	O
differences	O
in	O
the	O
sequence	O
of	O
the	O
DNA	O
binding	O
motif	O
.	O

Temporal	O
control	B-Regulation
of	O
IgH	O
gene	O
expression	B-Gene_expression
in	O
developing	O
B	O
cells	O
by	O
the	O
3	O
'	O
locus	O
control	O
region	O
.	O

The	O
suggested	O
roles	O
of	O
the	O
downstream	O
3	O
'	O
regions	O
acting	O
as	O
a	O
Locus	O
Control	O
Region	O
(	O
LCR	O
)	O
,	O
have	O
allowed	O
comparisons	O
to	O
be	O
made	O
between	O
the	O
regulation	B-Regulation
of	O
the	O
IgH	O
locus	O
with	O
other	O
model	O
systems	O
whose	O
gene	O
expression	O
is	O
governed	O
by	O
LCR	O
activity	O
.	O

Here	O
we	O
summarize	O
the	O
importance	O
of	O
the	O
IgH	O
3'LCR	O
and	O
its	O
putative	O
functional	B-Regulation
role	I-Regulation
in	O
IgH	O
gene	O
expression	B-Gene_expression
and	O
compare	O
it	O
with	O
the	O
5'LCR	O
regulatory	O
region	O
of	O
the	O
human	O
beta	O
-	O
globin	O
locus	O
.	O

Expression	O
of	O
transcription	O
factor	O
genes	O
after	O
influenza	O
A	O
virus	O
infection	O
.	O

Infection	O
of	O
human	O
monocytes	O
with	O
influenza	O
A	O
virus	O
induces	O
a	O
broad	O
range	O
of	O
proinflammatory	O
cytokines	O
and	O
mononuclear	O
cell	O
attracting	O
chemokines	O
before	O
the	O
infected	O
cells	O
undergo	O
apoptosis	O
.	O

The	O
underlying	O
mechanisms	O
by	O
which	O
the	O
corresponding	O
genes	O
are	O
transcriptionally	O
initiated	O
after	O
virus	O
infection	O
are	O
still	O
poorly	O
understood	O
.	O

Activation	O
of	O
NF	O
-	O
kappa	O
B	O
seems	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
many	O
proinflammatory	O
cytokine	O
genes	O
,	O
but	O
can	O
not	O
be	O
the	O
only	O
mechanism	O
,	O
since	O
several	O
cytokine	O
genes	O
lack	O
respective	O
binding	O
sites	O
in	O
their	O
promoter	O
regions	O
.	O

Therefore	O
,	O
we	O
additionally	O
investigated	O
other	O
transcription	O
factors	O
of	O
possible	O
importance	B-Regulation
such	O
as	O
CREB	O
,	O
CTF	O
,	O
OTF	O
-	O
1	O
,	O
and	O
OTF	O
-	O
2	O
.	O

To	O
explore	O
long	O
-	O
term	O
regulatory	O
mechanisms	O
,	O
we	O
investigated	O
the	O
induction	O
of	O
transcription	O
factors	O
on	O
the	O
gene	O
expression	O
level	O
which	O
may	O
be	O
important	O
to	O
substitute	O
for	O
metabolized	O
transcription	O
factor	O
proteins	O
after	O
their	O
activation	O
.	O

We	O
identified	O
a	O
cell-type	O
-	O
specific	O
differential	O
response	O
:	O
CREB	O
,	O
CTF	O
,	O
OTF	O
-	O
1	O
,	O
OFT	O
-	O
2	O
,	O
and	O
NF	O
-	O
kappa	O
B	O
genes	O
were	O
strongly	O
induced	B-Positive_regulation
1	O
to	O
4	O
hours	O
after	O
influenza	O
A	O
virus	O
infection	O
in	O
the	O
monocytic	O
cell	O
line	O
Mono	O
Mac	O
6	O
,	O
while	O
in	O
freshly	O
prepared	O
human	O
monocytes	O
no	O
significant	O
changes	B-Positive_regulation
were	O
detected	O
.	O

In	O
infected	O
monocytes	O
,	O
which	O
die	O
by	O
apoptosis	O
,	O
the	O
expression	B-Gene_expression
of	O
CREB	O
,	O
CTF	O
,	O
and	O
OTF	O
-	O
2	O
was	O
rather	O
suppressed	B-Negative_regulation
8	O
hours	O
after	O
infection	O
.	O

In	O
conclusion	O
,	O
the	O
long	O
-	O
term	O
regulation	O
of	O
transcription	O
factor	O
gene	O
expression	O
in	O
non	O
-	O
proliferating	O
cells	O
seems	O
to	O
be	O
of	O
minor	O
importance	O
after	O
influenza	O
infection	O
since	O
in	O
apoptosisprone	O
cells	O
an	O
immediate	O
availability	O
of	O
transcription	O
factor	O
proteins	O
is	O
required	O
.	O

[	O
Molecular	O
-	O
biologic	O
aspects	O
of	O
interaction	O
between	O
nervous	O
and	O
immune	O
systems	O
]	O

The	O
problem	O
of	O
the	O
neuro	O
-	O
immuno	O
interactions	O
on	O
the	O
level	O
of	O
the	O
protein	O
trans	O
-	O
factors	O
,	O
stimulating	B-Regulation
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
gene	B-Gene_expression
expression	I-Gene_expression
was	O
discussed	O
.	O

The	O
physico	O
-	O
chemical	O
and	O
functional	O
parameters	O
of	O
the	O
low	O
molecular	O
nuclear	O
proteins	O
(	O
SP	O
and	O
BP	O
-	O
14	O
,	O
18	O
,	O
19	O
kDs	O
)	O
isolated	O
from	O
splenic	O
and	O
brain	O
cells	O
of	O
immunized	O
rats	O
were	O
studied	O
.	O

The	O
binding	O
of	O
these	O
proteins	O
to	O
the	O
regulatory	O
region	O
of	O
IL	O
-	O
2	O
gene	O
in	O
vitro	O
and	O
stimulation	B-Positive_regulation
of	O
the	O
IL	O
-	O
2mRNA	O
synthesis	B-Transcription
in	O
splenic	O
T	O
-	O
lymphocytes	O
culture	O
in	O
normal	O
conditions	O
were	O
shown	O
.	O

The	O
protective	B-Negative_regulation
effect	I-Negative_regulation
of	O
SP	O
and	O
BP	O
on	O
the	O
IL	O
-	O
2mRNA	O
synthesis	B-Transcription
in	O
stressful	O
conditions	O
and	O
by	O
the	O
T	O
-	O
cells	O
treatment	O
with	O
the	O
CsA	O
was	O
demonstrated	O
.	O

Induction	B-Positive_regulation
of	O
interleukin	O
-	O
12	O
p40	O
transcript	B-Transcription
by	O
CD40	O
ligation	B-Binding
via	O
activation	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
.	O

Interleukin	O
-	O
12	O
is	O
produced	O
in	O
response	O
to	O
infection	O
with	O
bacteria	O
or	O
parasites	O
or	O
to	O
bacterial	O
constituents	O
such	O
as	O
LPS	O
in	O
monocytes/macrophages	O
and	O
dendritic	O
cells	O
,	O
and	O
also	O
generated	O
by	O
the	O
interaction	O
between	O
activated	O
T	O
cells	O
and	O
antigen	O
-	O
presenting	O
cells	O
via	O
CD40	O
-	B-Binding
CD40	O
ligand	O
(	O
CD40L	O
)	O
.	O

So	O
far	O
,	O
transcriptional	B-Transcription
analyses	O
of	O
p40	O
have	O
been	O
carried	O
out	O
only	O
using	O
bacterial	O
constituents	O
such	O
as	O
LPS	O
as	B-Positive_regulation
stimuli	I-Positive_regulation
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
characterized	O
the	O
transcriptional	B-Positive_regulation
induction	I-Positive_regulation
of	O
p40	O
by	O
CD40	O
ligation	B-Binding
in	O
a	O
human	O
B	O
lymphoblastoid	O
cell	O
line	O
,	O
Daudi	O
,	O
and	O
a	O
human	O
acute	O
monocytic	O
leukemia	O
cell	O
line	O
,	O
THP	O
-	O
1	O
.	O

These	O
cells	O
,	O
stimulated	O
by	O
an	O
agonistic	O
monoclonal	O
antibody	O
against	O
CD40	O
or	O
by	O
transfection	O
with	O
a	O
CD40L	O
expression	O
vector	O
,	O
secreted	B-Localization
p40	O
and	O
showed	O
enhanced	B-Positive_regulation
p40	O
mRNA	O
expression	B-Transcription
.	O

Sequence	O
analysis	O
of	O
the	O
p40	O
promoter	O
region	O
identified	O
two	O
potential	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
binding	O
sites	O
conserved	O
between	O
mouse	O
and	O
human	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
revealed	O
that	O
the	O
potential	O
NF	O
-	O
kappaB	O
binding	O
sequence	O
which	O
is	O
located	O
around	O
120	O
bp	O
upstream	O
of	O
the	O
transcription	O
initiation	O
site	O
in	O
murine	O
and	O
human	O
p40	O
genes	O
formed	O
an	O
NF	O
-	O
kappaB	O
complex	O
with	O
nuclear	O
extract	O
from	O
Daudi	O
cells	O
stimulated	O
by	O
CD40	O
ligation	B-Binding
.	O

Moreover	O
,	O
transfection	O
of	O
Daudi	O
cells	O
with	O
the	O
polymerized	O
NF	O
-	O
kappaB	O
binding	O
sequence	O
ligated	O
to	O
a	O
thymidine	O
kinase/chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
reporter	O
plasmid	O
greatly	O
induced	B-Positive_regulation
CAT	O
activity	O
,	O
but	O
transfection	O
with	O
the	O
polymerized	O
mutated	O
NF	O
-	O
kappaB	O
binding	O
sequence	O
did	O
not	O
.	O

These	O
results	O
suggest	O
that	O
the	O
NF	O
-	O
kappaB	O
binding	O
site	O
located	O
around	O
120	O
bp	O
upstream	O
of	O
the	O
transcription	O
initiation	O
site	O
in	O
murine	O
and	O
human	O
p40	O
promoter	O
regions	O
could	O
be	O
important	B-Positive_regulation
for	O
the	O
p40	O
induction	B-Positive_regulation
by	O
CD40	O
ligation	B-Binding
via	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O

Oxidants	O
,	O
transcription	O
factors	O
,	O
and	O
intestinal	O
inflammation	O
.	O

It	O
is	O
now	O
well	O
appreciated	O
that	O
chronic	O
gut	O
inflammation	O
is	O
characterized	O
by	O
enhanced	O
production	O
of	O
reactive	O
metabolites	O
of	O
oxygen	O
and	O
nitrogen	O
.	O

Some	O
of	O
these	O
oxidants	O
are	O
known	O
to	O
modulate	O
the	O
expression	O
of	O
a	O
variety	O
of	O
genes	O
that	O
are	O
involved	O
in	O
the	O
immune	O
and	O
inflammatory	O
responses	O
.	O

For	O
example	O
,	O
certain	O
oxidants	O
are	O
known	O
to	O
activate	O
the	O
nuclear	O
transcription	O
factor	O
kappa	O
B	O
,	O
which	O
regulates	O
the	O
expression	O
of	O
a	O
variety	O
of	O
different	O
adhesion	O
molecules	O
,	O
cytokines	O
,	O
and	O
enzymes	O
.	O

Oxidants	O
are	O
also	O
known	O
to	O
activate	O
another	O
transcription	O
factor	O
,	O
activator	O
protein	O
-	O
1	O
.	O

This	O
transcription	O
factor	O
is	O
composed	O
of	O
products	B-Gene_expression
from	O
the	O
fos	O
and	O
jun	O
proto	O
-	O
oncogene	O
family	O
and	O
is	O
believed	O
to	O
be	O
important	O
in	O
regulating	O
cell	O
growth	O
and	O
proliferation	O
.	O

Finally	O
,	O
oxidants	O
are	O
believed	O
to	O
promote	O
intestinal	O
epithelial	O
cell	O
apoptosis	O
,	O
and	O
the	O
B	O
-	O
cell	O
lymphoma/leukemia	O
-	O
2	O
gene	O
product	O
is	O
believed	O
to	O
inhibit	O
this	O
phenomenon	O
in	O
an	O
antioxidant	O
-	O
dependent	O
manner	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
nontoxic	O
concentrations	O
of	O
reactive	O
metabolites	O
of	O
oxygen	O
and	O
nitrogen	O
play	O
an	O
important	O
role	O
in	O
regulating	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
the	O
inflammatory	O
response	O
and	O
in	O
modulating	O
apoptosis	O
.	O

Differential	O
induction	O
of	O
DNA	O
-	O
binding	O
activities	O
following	O
CD19	O
cross	B-Binding
-	I-Binding
linking	I-Binding
in	O
human	O
B	O
lineage	O
cells	O
.	O

The	O
B	O
cell	O
-	O
specific	O
cell	O
surface	O
molecule	O
CD19	O
is	O
expressed	B-Gene_expression
at	O
all	O
stages	O
of	O
B	O
cell	O
development	O
,	O
including	O
normal	O
plasma	O
cells	O
,	O
and	O
mediates	O
signal	O
transduction	O
via	O
interaction	B-Binding
with	O
cytoplasmic	O
effector	O
proteins	O
.	O

Cross	B-Binding
-	I-Binding
linking	I-Binding
CD19	O
on	O
early	O
human	O
B	O
lineage	O
cells	O
induces	B-Positive_regulation
the	O
formation	O
of	O
a	O
CD19/Vav/phosphatidylinositol	O
-	O
3	O
kinase	O
complex	B-Binding
,	O
tyrosine	O
phosphorylation	B-Phosphorylation
of	O
CD19	O
and	O
Vav	O
,	O
and	O
activation	O
of	O
the	O
Ras	O
pathway	O
.	O

To	O
further	O
explore	O
the	O
ramifications	O
of	O
CD19	O
signaling	O
,	O
the	O
current	O
study	O
examined	O
whether	O
phosphorylation	B-Phosphorylation
of	O
Elk	O
-	O
1	O
,	O
activation	O
of	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
,	O
or	O
activation	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
transcription	O
factors	O
occurred	O
following	B-Positive_regulation
CD19	O
cross	B-Binding
-	I-Binding
linking	I-Binding
.	O

The	O
cells	O
used	O
were	O
the	O
BLIN	O
-	O
1	O
pre	O
-	O
B	O
cell	O
line	O
expressing	O
low	O
levels	O
of	O
cell	O
surface	O
mu	O
heavy	O
chain	O
associated	O
with	O
surrogate	O
light	O
chain	O
and	O
the	O
1E8	O
immature	O
B	O
cell	O
line	O
expressing	O
cell	O
surface	O
mu/kappa	O
.	O

Lysates	O
from	O
CD19	O
cross	B-Binding
-	I-Binding
linked	I-Binding
1E8	O
cells	O
induced	B-Positive_regulation
robust	O
phosphorylation	B-Phosphorylation
of	O
an	O
Elk	O
-	O
1	O
fusion	O
protein	O
in	O
vitro	O
,	O
whereas	O
no	O
phosphorylation	B-Phosphorylation
of	O
Elk	O
-	O
1	O
fusion	O
protein	O
occurred	B-Positive_regulation
using	O
lysates	O
from	O
CD19	O
cross	B-Binding
-	I-Binding
linked	I-Binding
BLIN	O
-	O
1	O
cells	O
.	O

An	O
electrophoretic	O
mobility	O
shift	O
assay	O
employing	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
consensus	O
oligonucleotides	O
was	O
used	O
to	O
demonstrate	O
that	O
AP	O
-	O
1	O
-	O
binding	O
activity	O
increased	O
,	O
while	O
constitutive	O
NF-kappaB	O
-	O
binding	O
activity	O
was	O
not	O
enhanced	O
,	O
following	O
2	O
h	O
of	O
CD19	O
cross	B-Binding
-	I-Binding
linking	I-Binding
in	O
1E8	O
cells	O
.	O

Supershift	O
experiments	O
revealed	O
that	O
JunD	O
and	O
c	O
-	O
Fos	O
proteins	O
mediated	O
anti	O
-	O
CD19	O
induced	O
AP-1	O
-	O
binding	O
activity	O
in	O
1E8	O
cells	O
.	O

In	O
contrast	O
,	O
CD19	O
cross	B-Binding
-	I-Binding
linking	I-Binding
in	O
BLIN	O
-	O
1	O
cells	O
resulted	O
in	O
the	O
induction	O
of	O
NF	O
-	O
kappaB	O
,	O
but	O
had	O
no	O
apparent	O
effect	O
on	O
AP-1	O
-	O
binding	O
activity	O
.	O

These	O
data	O
suggest	O
that	O
CD19	O
-	O
mediated	O
signal	O
transduction	O
activates	O
different	O
transcription	O
factors	O
at	O
juxtaposed	O
stages	O
of	O
B	O
cell	O
development	O
that	O
may	O
culminate	O
in	O
the	O
activation	O
or	O
suppression	O
of	O
distinct	O
sets	O
of	O
genes	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
quasispecies	O
differ	O
in	O
basal	O
transcription	O
and	O
nuclear	O
factor	O
recruitment	O
in	O
human	O
glial	O
cells	O
and	O
lymphocytes	O
.	O

The	O
generation	O
of	O
genomic	O
diversity	O
during	O
the	O
course	O
of	O
infection	O
has	O
the	O
potential	O
to	O
affect	O
all	O
aspects	O
of	O
HIV	O
-	O
1	O
replication	O
,	O
including	O
expression	O
of	O
the	O
proviral	O
genome	O
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
impact	O
of	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
sequence	O
diversity	O
on	O
LTR	O
-	O
directed	O
gene	O
expression	O
in	O
cells	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
and	O
immune	O
system	O
,	O
we	O
amplified	O
and	O
cloned	O
LTRs	O
from	O
proviral	O
DNA	O
in	O
HIV-1	O
-	O
infected	O
peripheral	O
blood	O
.	O

Sequence	O
analysis	O
of	O
nineteen	O
LTRs	O
cloned	O
from	O
2	O
adult	O
and	O
3	O
pediatric	O
patients	O
revealed	O
an	O
average	O
of	O
33	O
nucleotide	O
changes	O
(	O
with	O
respect	O
to	O
the	O
sequence	O
of	O
the	O
LAI	O
LTR	O
)	O
within	O
the	O
455	O
-	O
bp	O
U3	O
region	O
.	O

Transient	O
expression	O
analyses	O
in	O
cells	O
of	O
neuroglial	O
and	O
lymphocytic	O
origin	O
demonstrated	O
that	O
some	O
of	O
these	O
LTRs	O
had	O
activities	O
which	O
varied	O
significantly	O
from	O
the	O
LAI	O
LTR	O
in	O
U	O
-	O
373	O
MG	O
cells	O
(	O
an	O
astrocytoma	O
cell	O
line	O
)	O
as	O
well	O
as	O
in	O
Jurkat	O
cells	O
(	O
a	O
CD4	O
-	O
positive	O
lymphocyte	O
cell	O
line	O
)	O
.	O

While	O
LTRs	O
which	O
demonstrated	O
the	O
highest	O
activities	O
in	O
U	O
-	O
373	O
MG	O
cells	O
also	O
yielded	O
high	O
activities	O
in	O
Jurkat	O
cells	O
,	O
the	O
LTRs	O
were	O
generally	O
more	O
active	O
in	O
Jurkat	O
cells	O
when	O
compared	O
to	O
the	O
LAI	O
LTR	O
.	O

Differences	O
in	O
LTR	O
sequence	O
also	O
resulted	O
in	O
differences	O
in	O
transcription	O
factor	O
recruitment	O
to	O
cis	O
-	O
acting	O
sites	O
within	O
the	O
U3	O
region	O
of	O
the	O
LTR	O
,	O
as	O
demonstrated	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

In	O
particular	O
,	O
naturally	O
occurring	O
sequence	O
variation	O
impacted	O
transcription	O
factor	O
binding	O
to	O
an	O
activating	O
transcription	O
factor/cAMP	O
response	O
element	O
binding	O
(	O
ATF/CREB	O
)	O
binding	O
site	O
(	O
located	O
between	O
the	O
LEF	O
-	O
1	O
and	O
distal	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
binding	O
sites	O
)	O
that	O
we	O
identified	O
in	O
previous	O
studies	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
.	O

These	O
findings	O
suggest	O
that	O
LTR	O
sequence	O
changes	O
can	O
significantly	O
affect	O
basal	O
LTR	O
function	O
and	O
transcription	O
factor	O
recruitment	O
,	O
which	O
may	O
,	O
in	O
turn	O
,	O
alter	O
the	O
course	O
of	O
viral	O
replication	O
in	O
cells	O
of	O
CNS	O
and	O
immune	O
system	O
origin	O
.	O

Inhibition	O
of	O
nuclear	O
factor	O
kappaB	O
activation	O
attenuates	O
apoptosis	O
resistance	O
in	O
lymphoid	O
cells	O
.	O

Death	O
-	O
inducing	O
ligands	O
(	O
DILs	O
)	O
such	O
as	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNFalpha	O
)	O
or	O
the	O
cytotoxic	O
drug	O
doxorubicin	O
have	O
been	O
shown	O
to	O
activate	O
a	O
nuclear	O
factor	O
kappaB	O
(	O
NFkappaB	O
)	O
-	O
dependent	O
program	O
that	O
may	O
rescue	O
cells	O
from	O
apoptosis	O
induction	O
.	O

We	O
demonstrate	O
here	O
that	O
TRAIL	O
(	O
TNF	O
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	O
)	O
,	O
a	O
recently	O
identified	O
DIL	O
,	O
also	O
activates	O
NFkappaB	O
in	O
lymphoid	O
cell	O
lines	O
in	O
a	O
kinetic	O
similar	O
to	O
TNFalpha	O
.	O

NFkappaB	O
activity	O
is	O
independent	O
from	O
FADD	O
,	O
caspases	O
,	O
and	O
apoptosis	O
induction	O
.	O

To	O
study	O
the	O
influence	O
of	O
NFkappaB	O
activity	O
on	O
apoptosis	O
mediated	O
by	O
TRAIL	O
,	O
CD95	O
,	O
TNFalpha	O
,	O
or	O
doxorubicin	O
,	O
NFkappaB	O
activation	O
was	O
inhibited	O
using	O
the	O
proteasome	O
inhibitor	O
N-acetyl-L-leucinyl-L-leucinyl-L	O
-	O
norleucinal	O
or	O
transient	O
overexpression	B-Positive_regulation
of	O
mutant	O
IkappaBalpha	O
.	O

Sensitivity	O
for	O
induction	O
of	O
apoptosis	O
was	O
markedly	O
increased	O
by	O
these	O
treatments	O
in	O
apoptosis	O
sensitive	O
cell	O
lines	O
.	O

Moreover	O
,	O
both	O
in	O
cell	O
lines	O
and	O
in	O
primary	O
leukemia	O
cells	O
that	O
are	O
resistant	O
towards	O
induction	O
of	O
apoptosis	O
by	O
DILs	O
and	O
doxorubicin	O
,	O
antagonization	O
of	O
NFkappaB	O
activity	O
partially	O
restored	O
apoptosis	O
sensitivity	O
.	O

These	O
data	O
suggest	O
that	O
inhibition	O
of	O
NFkappaB	O
activation	O
may	O
provide	O
a	O
molecular	O
approach	O
to	O
increase	O
apoptosis	O
sensitivity	O
in	O
anticancer	O
treatment	O
.	O

The	O
human	O
toll	O
signaling	O
pathway	O
:	O
divergence	O
of	O
nuclear	O
factor	O
kappaB	O
and	O
JNK/SAPK	O
activation	O
upstream	O
of	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factor	O
6	O
(	O
TRAF6	O
)	O
.	O

The	O
human	O
homologue	O
of	O
Drosophila	O
Toll	O
(	O
hToll	O
)	O
is	O
a	O
recently	O
cloned	O
receptor	O
of	O
the	O
interleukin	O
1	O
receptor	O
(	O
IL	O
-	O
1R	O
)	O
superfamily	O
,	O
and	O
has	O
been	O
implicated	O
in	O
the	O
activation	O
of	O
adaptive	O
immunity	O
.	O

Signaling	O
by	O
hToll	O
is	O
shown	O
to	O
occur	O
through	O
sequential	O
recruitment	B-Binding
of	O
the	O
adapter	O
molecule	O
MyD88	O
and	O
the	O
IL-1R	O
-	O
associated	O
kinase	O
.	O

Tumor	O
necrosis	O
factor	O
receptor	O
-	O
activated	O
factor	O
6	O
(	O
TRAF6	O
)	O
and	O
the	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
-	O
inducing	O
kinase	O
(	O
NIK	O
)	O
are	O
both	O
involved	O
in	O
subsequent	O
steps	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O

Conversely	O
,	O
a	O
dominant	O
negative	O
version	O
of	O
TRAF6	O
failed	O
to	O
block	O
hToll	O
-	O
induced	O
activation	O
of	O
stress	O
-	O
activated	O
protein	O
kinase/c	O
-	O
Jun	O
NH2	O
-	O
terminal	O
kinases	O
,	O
thus	O
suggesting	O
an	O
early	O
divergence	O
of	O
the	O
two	O
pathways	O
.	O

Coactivation	O
by	O
OCA	O
-	O
B	O
:	O
definition	O
of	O
critical	O
regions	O
and	O
synergism	O
with	O
general	O
cofactors	O
.	O

Molecular	O
dissection	O
of	O
the	O
B-cell	O
-	O
specific	O
transcription	O
coactivator	O
OCA	O
-	O
B	O
has	O
revealed	O
distinct	O
regions	O
important	O
,	O
respectively	O
,	O
for	O
recruitment	B-Binding
to	O
immunoglobulin	O
promoters	O
through	B-Positive_regulation
interaction	B-Binding
with	O
octamer	O
-	O
bound	O
Oct	O
-	O
1	O
and	O
for	O
subsequent	O
coactivator	O
function	O
.	O

Further	O
analysis	O
of	O
general	O
coactivator	O
requirements	O
showed	O
that	O
selective	O
removal	B-Negative_regulation
of	O
PC4	O
from	O
the	O
essential	O
USA	O
fraction	O
severely	O
impairs	B-Negative_regulation
Oct	O
-	O
1	O
and	O
OCA	O
-	O
B	O
function	O
in	O
a	O
cell	O
-	O
free	O
system	O
reconstituted	O
with	O
partially	O
purified	O
factors	O
.	O

Full	O
activity	O
can	O
be	O
restored	B-Positive_regulation
by	O
the	O
combined	O
action	O
of	O
recombinant	O
PC4	O
and	O
the	O
PC4	O
-	O
depleted	B-Negative_regulation
USA	O
fraction	O
,	O
thus	O
suggesting	O
a	O
joint	B-Positive_regulation
requirement	I-Positive_regulation
for	O
PC4	O
and	O
another	O
,	O
USA	O
-	O
derived	O
component	O
(	O
s	O
)	O
for	O
optimal	O
function	O
of	O
Oct-1/OCA	O
-	O
B	O
in	O
the	O
reconstituted	O
system	O
.	O

Indeed	O
,	O
USA	O
-	O
derived	O
PC2	O
was	O
found	O
to	O
act	O
synergistically	O
with	O
PC4	O
in	O
reproducing	O
the	O
function	O
of	O
intact	O
USA	O
in	O
the	O
assay	O
system	O
.	O

Consistent	O
with	O
the	O
requirement	O
for	O
PC4	O
in	O
the	O
reconstituted	O
system	O
,	O
OCA	O
-	O
B	O
was	O
found	O
to	O
interact	B-Binding
directly	O
with	O
PC4	O
.	O

Surprisingly	O
,	O
however	O
,	O
removal	B-Negative_regulation
of	O
PC4	O
from	O
the	O
unfractionated	O
nuclear	O
extract	O
has	O
no	O
detrimental	O
effect	O
on	O
OCA-B/Oct-1	O
-	O
dependent	O
transcription	O
.	O

These	O
results	O
lead	O
to	O
a	O
general	O
model	O
for	O
the	O
synergistic	O
function	O
of	O
activation	O
domains	O
in	O
Oct	O
-	O
1	O
and	O
OCA	O
-	O
B	O
(	O
mediated	O
by	O
the	O
combined	O
action	O
of	O
the	O
multiple	O
USA	O
components	O
)	O
and	O
,	O
further	O
,	O
suggest	O
a	O
functional	O
redundancy	O
in	O
general	O
coactivators	O
.	O

Limited	O
proteolysis	O
for	O
assaying	O
ligand	O
binding	O
affinities	O
of	O
nuclear	O
receptors	O
.	O

The	O
binding	O
of	O
natural	O
or	O
synthetic	O
ligands	O
to	O
nuclear	O
receptors	O
is	O
the	O
triggering	O
event	O
leading	O
to	O
gene	O
transcription	O
activation	O
or	O
repression	O
.	O

Ligand	O
binding	O
to	O
the	O
ligand	O
binding	O
domain	O
of	O
these	O
receptors	O
induces	O
conformational	O
changes	O
that	O
are	O
evidenced	O
by	O
an	O
increased	O
resistance	O
of	O
this	O
domain	O
to	O
proteases	O
.	O

In	O
vitro	O
labeled	O
receptors	O
were	O
incubated	O
with	O
various	O
synthetic	O
or	O
natural	O
agonists	O
or	O
antagonists	O
and	O
submitted	O
to	O
trypsin	O
digestion	O
.	O

Proteolysis	O
products	O
were	O
separated	O
by	O
SDS	O
-	O
PAGE	O
and	O
quantified	O
.	O

The	O
amount	O
of	O
trypsin	O
-	O
resistant	O
fragments	O
was	O
proportional	O
to	O
receptor	O
occupancy	O
by	O
the	O
ligand	O
,	O
and	O
allowed	O
the	O
determination	O
of	O
dissociation	O
constants	O
(	O
kDa	O
)	O
.	O

Using	O
the	O
wild	O
-	O
type	O
or	O
mutated	O
human	O
retinoic	O
acid	O
receptor	O
alpha	O
as	O
a	O
model	O
,	O
kDa	O
values	O
determined	O
by	O
classical	O
competition	O
binding	O
assays	O
using	O
tritiated	O
ligands	O
are	O
in	O
agreement	O
with	O
those	O
measured	O
by	O
the	O
proteolytic	O
assay	O
.	O

This	O
method	O
was	O
successfully	O
extended	O
to	O
human	O
retinoic	O
X	O
receptor	O
alpha	O
,	O
glucocorticoid	O
receptor	O
,	O
and	O
progesterone	O
receptor	O
,	O
thus	O
providing	O
a	O
basis	O
for	O
a	O
new	O
,	O
faster	O
assay	O
to	O
determine	O
simultaneously	O
the	O
affinity	O
and	O
conformation	O
of	O
receptors	O
when	O
bound	O
to	O
a	O
given	O
ligand	O
.	O

Mycobacterium	O
tuberculosis	O
mannose	O
-	O
capped	O
lipoarabinomannan	O
can	O
induce	O
NF-kappaB	O
-	O
dependent	O
activation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
in	O
T	O
cells	O
.	O

Tuberculosis	O
has	O
emerged	O
as	O
an	O
epidemic	O
,	O
extended	O
by	O
the	O
large	O
number	O
of	O
individuals	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
.	O

The	O
major	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
mycobacterial	O
cell	O
wall	O
component	O
mannose	O
-	O
capped	O
lipoarabinomannan	O
(	O
ManLAM	O
)	O
of	O
Mycobacterium	O
tuberculosis	O
(	O
M.	O
tuberculosis	O
)	O
could	O
activate	O
transcription	O
of	O
HIV	O
-	O
1	O
in	O
T	O
cells	O
with	O
the	O
use	O
of	O
an	O
in	O
vitro	O
cell	O
culture	O
system	O
.	O

These	O
experiments	O
are	O
of	O
prime	O
importance	O
considering	O
that	O
CD4	O
-	O
expressing	B-Gene_expression
T	O
lymphocytes	O
represent	O
the	O
major	O
virus	O
reservoir	O
in	O
the	O
peripheral	O
blood	O
of	O
infected	O
individuals	O
.	O

Using	O
the	O
1G5	O
cell	O
line	O
harbouring	O
the	O
luciferase	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
,	O
it	O
was	O
first	O
found	O
that	O
culture	O
protein	O
filtrates	O
(	O
CFP	O
)	O
from	O
M.	O
tuberculosis	O
or	O
purified	O
ManLAM	O
could	O
activate	O
HIV	O
-	O
1	O
LTR	O
-	O
dependent	O
gene	O
expression	O
unlike	O
similarly	O
prepared	O
CFP	O
extracts	O
devoid	O
of	O
ManLAM	O
.	O

The	O
implication	O
of	O
protein	O
tyrosine	O
kinase	O
(	O
s	O
)	O
,	O
protein	O
kinase	O
A	O
and/or	O
protein	O
kinase	O
C	O
was	O
highlighted	O
by	O
the	O
abrogation	O
of	O
the	O
ManLAM	O
-	O
mediated	O
activation	O
of	O
HIV	O
-	O
1	O
LTR	O
-	O
driven	O
gene	O
expression	O
using	O
herbimycin	O
A	O
and	O
H7	O
.	O

It	O
was	O
also	O
determined	O
,	O
using	O
electrophoresis	O
mobility	O
shift	O
assays	O
,	O
that	O
M.	O
tuberculosis	O
ManLAM	O
led	O
to	O
the	O
nuclear	O
translocation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

M.	O
tuberculosis	O
ManLAM	O
resulted	O
in	O
clear	O
induction	O
of	O
the	O
luciferase	O
gene	O
placed	O
under	O
the	O
control	O
of	O
the	O
wild	O
-	O
type	O
,	O
but	O
not	O
the	O
kappaB	O
-	O
mutated	O
,	O
HIV	O
-	O
1	O
LTR	O
region	O
.	O

Finally	O
,	O
the	O
ManLAM	O
-	O
mediated	O
activation	O
of	O
HIV	O
-	O
1	O
LTR	O
transcription	O
was	O
found	O
to	O
be	O
independent	O
of	O
the	O
autocrine	O
or	O
paracrine	O
action	O
of	O
endogenous	O
TNF	O
-	O
alpha	O
.	O

The	O
results	O
suggest	O
that	O
M.	O
tuberculosis	O
can	O
upregulate	O
HIV	O
-	O
1	O
expression	O
in	O
T	O
cells	O
and	O
could	O
thus	O
have	O
the	O
potential	O
to	O
influence	O
the	O
pathogenesis	O
of	O
HIV	O
-	O
1	O
infection	O
.	O

Oxidative	O
stress	O
suppresses	O
transcription	O
factor	O
activities	O
in	O
stimulated	O
lymphocytes	O
.	O

Effects	O
of	O
oxidative	O
stress	O
on	O
stimulation	O
-	O
dependent	O
signal	O
transduction	O
,	O
leading	B-Positive_regulation
to	O
IL	O
-	O
2	O
expression	B-Gene_expression
,	O
were	O
studied	O
.	O

Purified	O
quiescent	O
human	O
blood	O
T	O
lymphocytes	O
were	O
subjected	O
to	O
:	O
(	O
i	O
)	O
acute	O
exposure	O
to	O
hydrogen	O
peroxide	O
;	O
(	O
ii	O
)	O
chronic	O
exposure	O
to	O
hydrogen	O
peroxide	O
;	O
and	O
(	O
iii	O
)	O
acute	O
exposure	O
to	O
ionizing	O
radiation	O
.	O

The	O
cells	O
were	O
then	O
stimulated	O
for	O
6	O
h	O
.	O

DNA	O
-	O
binding	O
activities	O
(	O
determined	O
by	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
)	O
of	O
three	O
transcription	O
factors	O
:	O
NFkappaB	O
,	O
AP	O
-	O
1	O
and	O
NFAT	O
,	O
were	O
abolished	O
in	O
the	O
lymphocytes	O
by	O
all	O
three	O
modes	O
of	O
oxidative	O
stress	O
.	O

The	O
lymphocytes	O
exhibited	O
lipid	O
peroxidation	O
only	O
upon	O
exposure	O
to	O
the	O
lowest	O
level	O
of	O
hydrogen	O
peroxide	O
used	O
(	O
20	O
microM	O
)	O
.	O

All	O
three	O
modes	O
of	O
oxidative	O
stress	O
induced	O
catalase	O
activity	O
in	O
the	O
lymphocytes	O
.	O

The	O
only	O
exception	O
was	O
hydrogen	O
peroxide	O
at	O
20	O
microM	O
,	O
which	O
did	O
not	O
induce	O
catalase	O
activity	O
.	O

We	O
conclude	O
that	O
:	O
(	O
i	O
)	O
suppression	O
of	O
specific	O
transcription	O
factor	O
functions	O
can	O
potentially	O
serve	O
as	O
a	O
marker	O
of	O
exposure	O
to	O
oxidative	O
stress	O
and	O
its	O
effects	O
on	O
human	O
lymphocytes	O
;	O
(	O
ii	O
)	O
lipid	O
peroxidation	O
is	O
only	O
detectable	O
in	O
human	O
lymphocytes	O
upon	O
exposure	O
to	O
weak	O
oxidative	O
stress	O
which	O
does	O
not	O
induce	O
catalase	O
activity	O
;	O
(	O
iii	O
)	O
therefore	O
,	O
transcription	O
factor	O
DNA	O
-	O
binding	O
activities	O
are	O
more	O
sensitive	O
to	O
oxidative	O
stress	O
than	O
lipid	O
peroxidation	O
.	O

Thrombopoietin	O
supports	O
in	O
vitro	O
erythroid	O
differentiation	O
via	O
its	B-Binding
specific	I-Binding
receptor	I-Binding
c	O
-	O
Mpl	O
in	O
a	O
human	O
leukemia	O
cell	O
line	O
.	O

Thrombopoietin	O
(	O
TPO	O
)	O
acts	O
on	O
megakaryopoiesis	O
and	O
erythropoiesis	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
isolated	O
a	O
novel	O
subline	O
,	O
UT	O
-	O
7/GMT	O
,	O
from	O
the	O
human	O
leukemia	O
cell	O
line	O
UT	O
-	O
7/GM	O
(	O
N	O
.	O

Komatsu	O
,	O
et	O
al.	O
,	O
Blood	O
,	O
89	O
:	O
4021	O
-	O
4033	O
,	O
1997	O
)	O
.	O

A	O
small	O
population	O
of	O
UT	O
-	O
7/GM	O
cells	O
positively	O
stained	O
for	O
hemoglobin	O
(	O
Hb	O
)	O
after	O
a	O
7	O
-	O
day	O
exposure	O
to	O
TPO	O
.	O

More	O
than	O
50	O
%	O
of	O
TPO	O
-	O
treated	O
UT	O
-	O
7/GMT	O
cells	O
positively	O
stained	O
for	O
Hb	O
.	O

Using	O
UT	O
-	O
7/GMT	O
cells	O
,	O
we	O
examined	O
how	O
TPO	O
promotes	O
hemoglobinization	O
.	O

TPO	O
induced	B-Positive_regulation
tyrosine	O
phosphorylation	B-Phosphorylation
of	O
the	O
TPO	O
receptor	O
but	O
not	O
the	O
erythropoietin	O
(	O
EPO	O
)	O
receptor	O
.	O

There	O
was	O
no	O
competition	O
between	O
TPO	O
and	O
EPO	O
for	O
binding	B-Binding
to	O
EPO	O
receptor	O
.	O

These	O
findings	O
suggest	O
that	O
TPO	O
has	O
a	O
direct	O
effect	O
on	O
hemoglobinization	O
via	O
a	O
specific	O
receptor	O
on	O
UT	O
-	O
7/GMT	O
cells	O
.	O

Isoelectric	O
focusing	O
demonstrated	O
that	O
TPO	O
induced	O
fetal	O
and	O
adult	O
Hb	O
synthesis	O
,	O
whereas	O
EPO	O
induced	O
embryonic	O
,	O
fetal	O
,	O
and	O
adult	O
Hb	O
synthesis	O
.	O

Thus	O
,	O
our	O
data	O
suggest	O
that	O
TPO	O
has	O
a	O
distinct	O
action	O
on	O
erythropoiesis	O
.	O

Redox	O
signals	O
and	O
NF	O
-	O
kappaB	O
activation	O
in	O
T	O
cells	O
.	O

Accumulating	O
data	O
from	O
a	O
number	O
of	O
laboratories	O
have	O
recently	O
indicated	O
that	O
the	O
response	O
of	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
to	O
alterations	O
in	O
the	O
redox	O
homeostasis	O
of	O
cells	O
may	O
play	O
an	O
important	O
role	O
in	O
modulating	O
immune	O
function	O
.	O

The	O
activation	O
of	O
NF	O
-	O
kappaB	O
has	O
been	O
recognized	O
to	O
regulate	B-Regulation
a	O
number	O
of	O
genes	O
necessary	O
for	O
normal	O
T	O
cell	O
responses	O
including	O
IL	O
-	O
2	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
and	O
several	O
T	O
cell	O
surface	O
receptors	O
.	O

Diminished	O
NF	O
-	O
kappaB	O
activity	O
has	O
been	O
shown	O
to	O
occur	O
in	O
T	O
cells	O
with	O
aging	O
,	O
suggesting	O
that	O
impaired	O
activation	O
of	O
NF	O
-	O
kappaB	O
might	O
occur	O
during	O
cellular	O
senescence	O
.	O

In	O
addition	O
,	O
aberrancies	O
in	O
NF	O
-	O
kappaB	O
activity	O
have	O
been	O
implicated	O
in	O
the	O
immunopathogenesis	O
of	O
diseases	O
involving	O
immune	O
or	O
inflammatory	O
processes	O
such	O
as	O
atherosclerosis	O
and	O
HIV	O
-	O
1	O
infection	O
.	O

The	O
role	O
of	O
H2O2	O
and	O
other	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
as	O
an	O
integratory	O
secondary	O
messenger	O
for	O
divergent	O
T	O
cell	O
signals	O
has	O
been	O
complicated	O
by	O
the	O
fact	O
that	O
various	O
T	O
cell	O
lines	O
and	O
peripheral	O
blood	O
T	O
cells	O
differ	O
markedly	O
in	O
the	O
levels	O
of	O
NF	O
-	O
kappaB	O
activation	O
induced	O
by	O
oxidant	O
stress	O
.	O

Additionally	O
,	O
proposed	O
pathways	O
of	O
NF	O
-	O
kappaB	O
activation	O
have	O
been	O
based	O
on	O
indirect	O
evidence	O
provided	O
by	O
experiments	O
which	O
used	O
antioxidants	O
to	O
inhibit	O
active	O
NF	O
-	O
kappaB	O
formation	O
.	O

Further	O
,	O
complete	O
activation	O
of	O
T	O
cells	O
requires	O
at	O
least	O
two	O
signals	O
,	O
one	O
that	O
stimulates	O
an	O
increase	O
in	O
intracellular	O
calcium	O
and	O
one	O
that	O
stimulates	O
enzymatic	O
processes	O
including	O
kinases	O
.	O

Similarly	O
,	O
substantial	O
evidence	O
indicates	O
that	O
full	O
activation	O
of	O
NF	O
-	O
kappaB	O
requires	O
dual	O
signals	O
.	O

The	O
ability	O
of	O
H2O2	O
or	O
other	O
ROS	O
to	O
induce	O
T	O
cell	O
signals	O
and	O
functional	O
responses	O
by	O
these	O
two	O
mechanisms	O
is	O
reviewed	O
and	O
the	O
specific	O
response	O
of	O
NF	O
-	O
kappaB	O
to	O
redox	O
changes	O
in	O
T	O
cells	O
is	O
examined	O
.	O

Data	O
are	O
also	O
presented	O
to	O
suggest	O
that	O
the	O
redox	O
regulation	O
in	O
NF	O
-	O
kappaB	O
activation	O
may	O
be	O
relevant	O
to	O
immune	O
-	O
related	O
diseases	O
and	O
to	O
aging	O
.	O

Fibrinogen	O
activates	O
NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
in	O
mononuclear	O
phagocytes	O
.	O

Adhesion	O
to	O
extracellular	O
matrices	O
is	O
known	O
to	O
modulate	O
leukocyte	O
activation	O
,	O
although	O
the	O
mechanisms	O
are	O
not	O
fully	O
understood	O
.	O

Mononuclear	O
phagocytes	O
are	O
exposed	O
to	O
fibrinous	O
provisional	O
matrix	O
throughout	O
migration	O
into	O
inflammatory	O
foci	O
,	O
so	O
this	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
fibrinogen	O
triggers	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
.	O

U937	O
cells	O
differentiated	O
with	O
PMA	O
in	O
nonadherent	O
culture	O
were	O
shown	O
to	O
express	B-Gene_expression
two	O
fibrinogen	O
-	O
binding	O
integrins	O
,	O
predominately	O
CD11b/CD18	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
CD11c/CD18	O
.	O

Cells	O
stimulated	O
with	O
fibrinogen	O
(	O
10	O
-	O
100	O
microg/ml	O
)	O
/Mn2+	O
(	O
50	O
microM	O
)	O
for	O
2	O
h	O
were	O
examined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

NF	O
-	O
kappa	O
B	O
activation	O
,	O
minimal	O
in	O
unstimulated	O
cells	O
,	O
was	O
substantially	O
up	O
-	O
regulated	O
by	O
fibrinogen	O
.	O

Fibrinogen	O
also	O
caused	B-Positive_regulation
activation	B-Positive_regulation
of	O
AP	O
-	O
1	O
,	O
but	O
not	O
SP1	O
or	O
cAMP	O
response	O
element	O
-	O
binding	O
protein	O
(	O
CREB	O
)	O
factors	O
.	O

Blocking	B-Binding
mAbs	O
against	O
CD18	O
and	O
CD11b	O
abrogated	O
fibrinogen	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

To	O
determine	O
the	O
effects	O
on	O
transcriptional	O
regulation	O
,	O
U937	O
cells	O
were	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
HIV	O
-	O
1	O
enhancer	O
(	O
bearing	O
two	O
NF	O
-	O
kappa	O
B	O
sites	O
)	O
coupled	O
to	O
a	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
reporter	O
.	O

Cells	O
were	O
subsequently	O
stimulated	O
with	O
1	O
)	O
PMA	O
for	O
24	O
h	O
,	O
inducing	B-Positive_regulation
CAT	O
activity	O
by	O
2.6	O
-	O
fold	O
,	O
2	O
)	O
fibrinogen/Mn2+	O
for	O
2	O
h	O
,	O
inducing	B-Positive_regulation
CAT	O
activity	O
by	O
3.2	O
-	O
fold	O
,	O
or	O
3	O
)	O
costimulation	O
with	O
fibrinogen	O
and	O
PMA	O
,	O
inducing	B-Positive_regulation
5.7	O
-	O
fold	O
the	O
CAT	O
activity	O
induced	B-Positive_regulation
by	O
PMA	O
alone	O
.	O

We	O
conclude	O
that	O
contact	O
with	O
fibrinogen	O
-	O
derived	O
proteins	O
may	O
contribute	O
to	O
mononuclear	O
phagocyte	O
activation	O
by	O
signaling	O
through	O
CD11b/CD18	O
,	O
resulting	O
in	O
selective	O
activation	O
of	O
transcriptional	O
regulatory	O
factors	O
,	O
including	O
NF	O
-	O
kappa	O
B	O
.	O

Ex	O
vivo	O
activation	O
of	O
tumor	O
-	O
draining	O
lymph	O
node	O
T	O
cells	O
reverses	O
defects	O
in	O
signal	O
transduction	O
molecules	O
.	O

The	O
adoptive	O
transfer	O
of	O
tumor	O
-	O
draining	O
lymph	O
node	O
(	O
LN	O
)	O
T	O
cells	O
activated	O
ex	O
vivo	O
with	O
anti	O
-	O
CD3	O
and	O
interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
mediates	O
the	O
regression	O
of	O
the	O
poorly	O
immunogenic	O
murine	O
melanoma	O
D5	O
.	O

The	O
efficacy	O
of	O
the	O
activated	O
LN	O
cells	O
is	O
augmented	O
when	O
the	O
sensitizing	O
tumor	O
is	O
a	O
genetically	O
modified	O
variant	O
(	O
designated	O
D5G6	O
)	O
that	O
secretes	B-Localization
granulocyte/macrophage-colony	O
-	O
stimulating	O
factor	O
.	O

In	O
contrast	O
to	O
anti-CD3/IL-2	O
-	O
activated	O
LN	O
cells	O
,	O
adoptive	O
transfer	O
of	O
freshly	O
isolated	O
tumor	O
-	O
draining	O
LN	O
T	O
cells	O
has	O
no	O
therapeutic	O
activity	O
.	O

To	O
determine	O
whether	O
the	O
acquisition	O
of	O
antitumor	O
function	O
during	O
ex	O
vivo	O
activation	O
is	O
associated	O
with	O
modifications	O
in	O
signal	O
transduction	O
capacity	O
,	O
the	O
protein	O
tyrosine	O
kinases	O
p56lck	O
and	O
p59fyn	O
and	O
proteins	O
of	O
the	O
NF	O
-	O
kappaB	O
family	O
were	O
analyzed	B-Gene_expression
in	O
tumor	O
-	O
draining	O
LN	O
T	O
cells	O
.	O

The	O
levels	B-Gene_expression
of	O
p56lck	O
and	O
p59fyn	O
were	O
lower	O
in	O
tumor	O
-	O
draining	O
than	O
in	O
normal	O
LN	O
T	O
cells	O
and	O
production	O
of	O
tyrosine	O
-	O
phosphorylated	O
substrates	O
was	O
markedly	O
depressed	O
following	O
anti	O
-	O
CD3	O
stimulation	O
.	O

After	O
5	O
-	O
day	O
anti-CD3/IL	O
-	O
2	O
activation	O
,	O
levels	B-Gene_expression
of	O
p56lck	O
and	O
p59fyn	O
and	O
protein	O
tyrosine	O
kinase	O
activity	O
increased	B-Positive_regulation
.	O

Interestingly	O
,	O
the	O
levels	B-Gene_expression
of	O
p56lck	O
,	O
p59fyn	O
,	O
and	O
tyrosine	O
kinase	O
activity	O
were	O
higher	B-Positive_regulation
in	O
activated	O
T	O
cells	O
derived	O
from	O
LN	O
that	O
drained	O
D5G6	O
than	O
they	O
were	O
in	O
those	O
from	O
D5	O
tumors	O
.	O

In	O
contrast	O
,	O
the	O
cytoplasmic	O
levels	B-Gene_expression
of	O
c	O
-	O
Rel	O
and	O
Rel	O
A	O
were	O
normal	O
in	O
freshly	O
isolated	O
tumor	O
-	O
draining	O
LN	O
,	O
as	O
was	O
nuclear	O
kappaB	O
DNA	O
-	O
binding	O
activity	O
induced	O
by	O
anti	O
-	O
CD3	O
mAb	O
or	O
phorbol	O
myristate	O
acetate	O
.	O

Stimulation	O
of	O
activated	O
LN	O
cells	O
with	O
D5	O
tumor	O
cells	O
induced	O
the	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
recovery	O
of	O
proteins	O
mediating	O
signal	O
transduction	O
through	O
the	O
T	O
cell	O
receptor/CD3	O
complex	O
in	O
LN	O
T	O
cells	O
activated	O
ex	O
vivo	O
was	O
associated	O
with	O
the	O
acquisition	O
of	O
antitumor	O
function	O
.	O

Targeted	O
disruption	O
of	O
the	O
MyD88	O
gene	O
results	O
in	O
loss	O
of	O
IL-1	O
-	O
and	O
IL-18	O
-	O
mediated	O
function	O
.	O

MyD88	O
,	O
originally	O
isolated	O
as	O
a	O
myeloid	O
differentiation	O
primary	O
response	O
gene	O
,	O
is	O
shown	O
to	O
act	O
as	O
an	O
adaptor	O
in	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
signaling	O
by	O
interacting	B-Binding
with	O
both	O
the	O
IL	O
-	O
1	O
receptor	O
complex	O
and	O
IL	O
-	O
1	O
receptor	O
-	O
associated	O
kinase	O
(	O
IRAK	O
)	O
.	O

Mice	O
generated	O
by	O
gene	O
targeting	O
to	O
lack	O
MyD88	O
have	O
defects	O
in	O
T	O
cell	O
proliferation	O
as	O
well	O
as	O
induction	O
of	O
acute	O
phase	O
proteins	O
and	O
cytokines	O
in	O
response	O
to	O
IL	O
-	O
1	O
.	O

Increases	O
in	O
interferon	O
-	O
gamma	O
production	O
and	O
natural	O
killer	O
cell	O
activity	O
in	O
response	O
to	O
IL	O
-	O
18	O
are	O
abrogated	O
.	O

In	O
vivo	O
Th1	O
response	O
is	O
also	O
impaired	O
.	O

Furthermore	O
,	O
IL-18	O
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
is	O
blocked	O
in	O
MyD88-/	O
-	O
Th1	O
-	O
developing	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
MyD88	O
is	O
a	O
critical	O
component	O
in	O
the	O
signaling	O
cascade	O
that	O
is	O
mediated	O
by	O
IL	O
-	O
1	O
receptor	O
as	O
well	O
as	O
IL	O
-	O
18	O
receptor	O
.	O

Epstein	O
-	O
Barr	O
virus	O
-	O
transforming	O
protein	O
latent	O
infection	O
membrane	O
protein	O
1	O
activates	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
through	O
a	O
pathway	O
that	O
includes	O
the	O
NF-kappaB	O
-	O
inducing	O
kinase	O
and	O
the	O
IkappaB	O
kinases	O
IKKalpha	O
and	O
IKKbeta	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
oncoprotein	O
latent	O
infection	O
membrane	O
protein	O
1	O
(	O
LMP1	O
)	O
is	O
a	O
constitutively	O
aggregated	B-Binding
pseudo	O
-	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
TNFR	O
)	O
that	O
activates	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
through	O
two	O
sites	O
in	O
its	O
C	O
-	O
terminal	O
cytoplasmic	O
domain	O
.	O

One	O
site	O
is	O
similar	O
to	O
activated	B-Positive_regulation
TNFRII	O
in	O
associating	B-Binding
with	O
TNFR	O
-	O
associated	O
factors	O
TRAF1	O
and	O
TRAF2	O
,	O
and	O
the	O
second	O
site	O
is	O
similar	O
to	O
TNFRI	O
in	O
associating	B-Binding
with	O
the	O
TNFRI	O
death	O
domain	O
interacting	B-Binding
protein	O
TRADD	O
.	O

TNFRI	O
has	O
been	O
recently	O
shown	O
to	O
activate	O
NF	O
-	O
kappaB	O
through	O
association	B-Binding
with	O
TRADD	O
,	O
RIP	O
,	O
and	O
TRAF2	O
;	O
activation	B-Positive_regulation
of	O
the	O
NF-kappaB	O
-	O
inducing	O
kinase	O
(	O
NIK	O
)	O
;	O
activation	B-Positive_regulation
of	O
the	O
IkappaB	O
alpha	O
kinases	O
(	O
IKKalpha	O
and	O
IKKbeta	O
)	O
;	O
and	O
phosphorylation	B-Phosphorylation
of	O
IkappaB	O
alpha	O
.	O

IkappaB	O
alpha	O
phosphorylation	B-Phosphorylation
on	O
Ser	O
-	O
32	O
and	O
Ser	O
-	O
36	O
is	O
followed	B-Positive_regulation
by	O
its	O
degradation	B-Protein_catabolism
and	O
NF	O
-	O
kappaB	O
activation	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
NF	O
-	O
kappaB	O
activation	O
by	O
LMP1	O
or	O
by	O
each	O
of	O
its	O
effector	O
sites	O
is	O
mediated	O
by	O
a	O
pathway	O
that	O
includes	O
NIK	O
,	O
IKKalpha	O
,	O
and	O
IKKbeta	O
.	O

Dominant	O
negative	O
mutants	O
of	O
NIK	O
,	O
IKKalpha	O
,	O
or	O
IKKbeta	O
substantially	O
inhibited	O
NF	O
-	O
kappaB	O
activation	O
by	O
LMP1	O
or	O
by	O
each	O
of	O
its	O
effector	O
sites	O
.	O

Dimethyldithiocarbamate	O
inhibits	O
in	O
vitro	O
activation	O
of	O
primary	O
human	O
CD4+	O
T	O
lymphocytes	O
.	O

Dithiocarbamates	O
(	O
DTC	O
)	O
,	O
a	O
diverse	O
group	O
of	O
industrial	O
and	O
therapeutic	O
chemicals	O
,	O
have	O
been	O
reported	O
to	O
inhibit	O
,	O
enhance	O
or	O
have	O
no	O
effect	O
on	O
the	O
immune	O
system	O
.	O

These	O
apparent	O
inconsistencies	O
reflect	O
the	O
complexity	O
of	O
the	O
DTCs	O
biological	O
activities	O
and	O
are	O
probably	O
due	O
in	O
part	O
to	O
differences	O
in	O
dose	O
,	O
route	O
of	O
exposure	O
,	O
animal	O
species	O
used	O
and/or	O
specific	O
compound	O
tested	O
.	O

The	O
studies	O
described	O
herein	O
were	O
undertaken	O
to	O
investigate	O
the	O
immunotoxicity	O
of	O
one	O
member	O
of	O
this	O
family	O
,	O
dimethyldithiocarbamate	O
(	O
DMDTC	O
)	O
.	O

We	O
demonstrate	O
that	O
0.1	O
-	O
0.5	O
microM	O
DMDTC	O
inhibits	O
TNF-alpha	O
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
in	O
primary	O
human	O
CD4+	O
T	O
cells	O
.	O

This	O
inhibition	O
is	O
not	O
accompanied	O
by	O
a	O
loss	O
in	O
viability	O
,	O
and	O
DMDTC	O
-	O
treated	O
T	O
cells	O
retain	O
other	O
active	O
signaling	O
pathways	O
throughout	O
the	O
exposure	O
duration	O
.	O

The	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
is	O
apparently	O
permanent	O
as	O
DMDTC	O
-	O
treated	O
T	O
cells	O
did	O
not	O
regain	B-Positive_regulation
normal	O
TNF	O
-	O
alpha	O
activation	B-Positive_regulation
,	O
even	O
after	O
72	O
h	O
in	O
culture	O
.	O

DMDTC	O
does	O
not	O
appear	O
to	O
alter	O
NF	O
-	O
kappaB	O
directly	O
as	O
pre	O
-	O
incubation	O
of	O
nuclear	O
extracts	O
with	O
DMDTC	O
does	O
not	O
diminish	O
binding	O
activity	O
of	O
this	O
protein	O
.	O

We	O
further	O
demonstrate	O
that	O
0.1	O
-	O
0.5	O
microM	O
DMDTC	O
inhibits	B-Negative_regulation
intracellular	O
IL	O
-	O
2	O
production	B-Gene_expression
and	O
decreases	B-Negative_regulation
surface	O
expression	B-Gene_expression
of	O
CD25	O
(	O
the	O
alpha	O
subunit	O
of	O
the	O
IL	O
-	O
2	O
receptor	O
)	O
in	O
T	O
cells	O
stimulated	O
with	O
phorbol	O
ester	O
.	O

These	O
data	O
demonstrate	O
that	O
DMDTC	O
is	O
a	O
potent	O
immunosuppressive	O
compound	O
in	O
vitro	O
.	O

The	O
small	O
GTP	O
-	O
binding	O
protein	O
Rho	O
potentiates	O
AP	O
-	O
1	O
transcription	O
in	O
T	O
cells	O
.	O

The	O
Rho	O
family	O
of	O
small	O
GTP	O
-	O
binding	O
proteins	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
cytoskeletal	O
structure	O
,	O
gene	O
transcription	O
,	O
specific	O
cell	O
fate	O
development	O
,	O
and	O
transformation	O
.	O

We	O
demonstrate	O
in	O
this	O
report	O
that	O
overexpression	O
of	O
an	O
activated	O
form	O
of	O
Rho	O
enhances	O
AP	O
-	O
1	O
activity	O
in	O
Jurkat	O
T	O
cells	O
in	O
the	O
presence	O
of	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
but	O
activated	O
Rho	O
(	O
V14Rho	O
)	O
has	O
little	O
or	O
no	O
effect	B-Regulation
on	O
NFAT	O
,	O
Oct	O
-	O
1	O
,	O
and	O
NF	O
-	O
kappaB	O
enhancer	O
element	O
activities	O
under	O
similar	O
conditions	O
.	O

Overexpression	O
of	O
a	O
V14Rho	O
construct	O
incapable	O
of	O
membrane	O
localization	O
(	O
CAAX	O
deleted	O
)	O
abolishes	O
PMA	O
-	O
induced	O
AP	O
-	O
1	O
transcriptional	O
activation	O
.	O

The	O
effect	O
of	O
Rho	O
on	O
AP	O
-	O
1	O
is	O
independent	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
pathway	O
,	O
as	O
a	O
dominant	O
-	O
negative	O
MEK	O
and	O
a	O
MEK	O
inhibitor	O
(	O
PD98059	O
)	O
did	O
not	O
affect	O
Rho	O
-	O
induced	O
AP	O
-	O
1	O
activity	O
.	O

V14Rho	O
binds	B-Binding
strongly	O
to	O
protein	O
kinase	O
Calpha	O
(	O
PKCalpha	O
)	O
in	O
vivo	O
;	O
however	O
,	O
deletion	O
of	O
the	O
CAAX	O
site	O
on	O
V14Rho	O
severely	O
diminished	B-Negative_regulation
this	O
association	O
.	O

Evidence	O
for	O
a	O
role	O
for	O
PKCalpha	O
as	O
an	O
effector	O
of	O
Rho	O
was	O
obtained	O
by	O
the	O
observation	O
that	O
coexpression	B-Gene_expression
of	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
PKCalpha	O
blocked	O
the	O
effects	O
of	O
activated	O
Rho	O
plus	O
PMA	O
on	O
AP	O
-	O
1	O
transcriptional	O
activity	O
.	O

These	O
data	O
suggest	O
that	O
Rho	O
potentiates	O
AP	O
-	O
1	O
transcription	O
during	O
T	O
-	O
cell	O
activation	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
Tax	O
induction	O
of	O
NF	O
-	O
kappaB	O
involves	O
activation	B-Positive_regulation
of	O
the	O
IkappaB	O
kinase	O
alpha	O
(	O
IKKalpha	O
)	O
and	O
IKKbeta	O
cellular	O
kinases	O
.	O

Tax	O
corresponds	O
to	O
a	O
40	O
-	O
kDa	O
transforming	O
protein	O
from	O
the	O
pathogenic	O
retrovirus	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
that	O
activates	O
nuclear	O
expression	O
of	O
the	O
NF	O
-	O
kappaB/Rel	O
family	O
of	O
transcription	O
factors	O
by	O
an	O
unknown	O
mechanism	O
.	O

Tax	O
expression	B-Gene_expression
promotes	B-Positive_regulation
N	O
-	O
terminal	O
phosphorylation	B-Phosphorylation
and	O
degradation	B-Protein_catabolism
of	O
IkappaB	O
alpha	O
,	O
a	O
principal	O
cytoplasmic	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
.	O

Our	O
studies	O
now	O
demonstrate	O
that	O
HTLV	O
-	O
1	O
Tax	O
activates	B-Positive_regulation
the	O
recently	O
identified	O
cellular	O
kinases	O
IkappaB	O
kinase	O
alpha	O
(	O
IKKalpha	O
)	O
and	O
IKKbeta	O
,	O
which	O
normally	O
phosphorylate	B-Positive_regulation
IkappaB	O
alpha	O
on	O
both	O
of	O
its	O
N	O
-	O
terminal	O
regulatory	O
serines	O
in	O
response	B-Positive_regulation
to	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
stimulation	O
.	O

In	O
contrast	O
,	O
a	O
mutant	O
of	O
Tax	O
termed	O
M22	O
,	O
which	O
does	O
not	O
induce	O
NF	O
-	O
kappaB	O
,	O
fails	O
to	O
activate	B-Positive_regulation
either	O
IKKalpha	O
or	O
IKKbeta	O
.	O

Furthermore	O
,	O
endogenous	O
IKK	O
enzymatic	O
activity	O
was	O
significantly	O
elevated	O
in	O
HTLV-1	O
-	O
infected	O
and	O
Tax	O
-	O
expressing	B-Gene_expression
T	O
-	O
cell	O
lines	O
.	O

Transfection	B-Positive_regulation
of	O
kinase	O
-	O
deficient	O
mutants	O
of	O
IKKalpha	O
and	O
IKKbeta	O
into	O
either	O
human	O
Jurkat	O
T	O
or	O
293	O
cells	O
also	O
inhibits	O
NF-kappaB	O
-	O
dependent	O
reporter	O
gene	O
expression	O
induced	O
by	O
Tax	O
.	O

Similarly	O
,	O
a	O
kinase	O
-	O
deficient	O
mutant	O
of	O
NIK	O
(	O
NF-kappaB	O
-	O
inducing	O
kinase	O
)	O
,	O
which	O
represents	O
an	O
upstream	O
kinase	O
in	O
the	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
1	O
signaling	O
pathways	O
leading	B-Positive_regulation
to	O
IKKalpha	O
and	O
IKKbeta	O
activation	B-Positive_regulation
,	O
blocks	O
Tax	O
induction	O
of	O
NF	O
-	O
kappaB	O
.	O

However	O
,	O
plasma	O
membrane	O
-	O
proximal	O
elements	O
in	O
these	O
proinflammatory	O
cytokine	O
pathways	O
are	O
apparently	O
not	O
involved	O
since	O
dominant	O
negative	O
mutants	O
of	O
the	O
TRAF2	O
and	O
TRAF6	O
adaptors	O
,	O
which	O
effectively	O
block	O
signaling	O
through	O
the	O
cytoplasmic	O
tails	O
of	O
the	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
1	O
receptors	O
,	O
respectively	O
,	O
do	O
not	O
inhibit	O
Tax	O
induction	O
of	O
NF	O
-	O
kappaB	O
.	O

Together	O
,	O
these	O
studies	O
demonstrate	O
that	O
HTLV	O
-	O
1	O
Tax	O
exploits	O
a	O
distal	O
part	O
of	O
the	O
proinflammatory	O
cytokine	O
signaling	O
cascade	O
leading	O
to	O
induction	O
of	O
NF	O
-	O
kappaB	O
.	O

The	O
pathological	O
alteration	O
of	O
this	O
cytokine	O
pathway	O
leading	O
to	O
NF	O
-	O
kappaB	O
activation	O
by	O
Tax	O
may	O
play	O
a	O
central	O
role	O
in	O
HTLV-1	O
-	O
mediated	O
transformation	O
of	O
human	O
T	O
cells	O
,	O
clinically	O
manifested	O
as	O
the	O
adult	O
T	O
-	O
cell	O
leukemia	O
.	O

A	O
CD28	O
-	O
associated	O
signaling	O
pathway	O
leading	O
to	O
cytokine	O
gene	O
transcription	O
and	O
T	O
cell	O
proliferation	O
without	O
TCR	O
engagement	O
.	O

Stimulation	O
of	O
resting	O
human	O
T	O
cells	O
with	O
the	O
CD28	O
-	O
specific	O
mAb	O
BW	O
828	O
induces	O
proliferation	O
and	O
cytokine	O
synthesis	O
without	O
further	O
requirement	O
for	O
TCR	O
coengagement	O
.	O

This	O
observation	O
prompted	O
us	O
to	O
postulate	O
that	O
signal	O
2	O
(	O
costimulatory	O
signal	O
)	O
alone	O
without	O
signal	O
1	O
(	O
TCR	O
signal	O
)	O
can	O
activate	O
T	O
cells	O
.	O

To	O
test	O
whether	O
this	O
putative	O
function	O
of	O
CD28	O
is	O
mediated	B-Positive_regulation
via	O
a	O
particular	O
signaling	O
pathway	O
,	O
we	O
compared	O
early	O
signaling	O
events	O
initiated	O
in	O
resting	O
T	O
cells	O
by	O
the	O
stimulatory	O
mAb	O
BW	O
828	O
with	O
signals	O
triggered	O
by	O
the	O
nonstimulating	O
CD28	O
mAb	O
9.3	O
.	O

Stimulation	O
of	O
T	O
cells	O
with	O
BW	O
828	O
induced	O
an	O
increase	O
in	O
intracellular	O
Ca2+	O
,	O
but	O
did	O
not	B-Positive_regulation
lead	I-Positive_regulation
to	I-Positive_regulation
detectable	I-Positive_regulation
activation	I-Positive_regulation
of	O
the	O
protein	O
kinases	O
p56	O
(	O
lck	O
)	O
and	O
c-Raf	O
-	O
1	O
.	O

This	O
pathway	O
resulted	O
in	O
the	O
induction	O
of	O
the	O
transcription	O
factors	O
NF	O
-	O
kappa	O
B	O
,	O
NF	O
-	O
AT	O
,	O
and	O
proteins	O
binding	O
to	O
the	O
CD28	O
response	O
element	O
of	O
the	O
IL	O
-	O
2	O
promoter	O
.	O

On	O
the	O
other	O
hand	O
,	O
stimulation	O
of	O
T	O
cells	O
with	O
mAb	O
9.3	O
increased	O
the	O
level	O
of	O
intracellular	O
Ca2+	O
and	O
triggered	B-Positive_regulation
the	I-Positive_regulation
activation	I-Positive_regulation
of	O
p56	O
(	O
lck	O
)	O
and	O
c-Raf	O
-	O
1	O
,	O
but	O
was	O
unable	B-Positive_regulation
to	I-Positive_regulation
induce	I-Positive_regulation
the	O
binding	B-Binding
of	O
transcription	O
factors	O
to	O
the	O
IL	O
-	O
2	O
promoter	O
.	O

In	O
contrast	O
to	O
the	O
differential	O
signaling	O
of	O
BW	O
828	O
and	O
9.3	O
in	O
resting	O
T	O
cells	O
,	O
the	O
two	O
mAbs	O
exhibited	B-Positive_regulation
a	O
similar	O
pattern	O
of	O
early	O
signaling	O
events	O
in	O
activated	O
T	O
cells	O
and	O
Jurkat	O
cells	O
(	O
p56	O
(	O
lck	O
)	O
activation	B-Positive_regulation
,	O
association	O
of	O
phosphatidylinositol	O
3	O
-	O
kinase	O
with	O
CD28	O
)	O
,	O
indicating	O
that	O
the	O
signaling	O
capacity	O
of	O
CD28	O
changes	O
with	O
activation	O
.	O

These	O
data	O
support	O
the	O
view	O
that	O
stimulation	B-Positive_regulation
through	O
CD28	O
can	O
induce	O
some	O
effector	O
functions	O
in	O
T	O
cells	O
and	O
suggest	O
that	O
this	O
capacity	O
is	O
associated	O
with	O
a	O
particular	O
pattern	O
of	O
early	O
signaling	O
events	O
.	O

Cyclosporin	O
A	O
-	O
resistant	B-Regulation
transactivation	B-Positive_regulation
of	O
the	O
IL	O
-	O
2	O
promoter	O
requires	B-Positive_regulation
activity	O
of	O
okadaic	O
acid	O
-	O
sensitive	O
serine/threonine	O
phosphatases	O
.	O

Expression	B-Gene_expression
of	O
the	O
IL	O
-	O
2	O
gene	O
requires	B-Positive_regulation
activation	O
of	O
T	O
cells	O
through	O
stimulation	O
of	O
the	O
TCR	O
and	O
costimulation	O
through	O
accessory	O
receptors	O
.	O

We	O
have	O
found	O
recently	O
that	O
okadaic	O
acid	O
-	O
sensitive	O
Ser/Thr	O
phosphatases	O
are	O
involved	O
in	O
a	O
cyclosporin	O
A	O
-	O
insensitive	O
pathway	O
that	O
selectively	O
transmits	O
costimulatory	O
signals	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
whether	O
activities	O
of	O
these	O
phosphatases	O
are	O
necessary	B-Positive_regulation
for	O
the	O
expression	B-Gene_expression
of	O
the	O
IL	O
-	O
2	O
gene	O
.	O

In	O
both	O
activated	O
peripheral	O
blood	O
T	O
lymphocytes	O
and	O
activated	O
tumorigenic	O
T	O
cell	O
lines	O
,	O
IL	O
-	O
2	O
gene	O
expression	O
was	O
blocked	B-Negative_regulation
at	B-Transcription
the	I-Transcription
transcriptional	I-Transcription
level	I-Transcription
by	O
okadaic	O
acid	O
.	O

The	O
transcription	O
factors	O
active	O
at	B-Binding
the	O
IL	O
-	O
2	O
promoter	O
were	O
differentially	O
influenced	O
:	O
upon	O
down	O
-	O
modulation	O
of	O
okadaic	O
acid	O
-	O
sensitive	O
phosphatases	O
,	O
transactivation	B-Positive_regulation
by	O
octamer	O
,	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
NF	O
of	O
activated	O
T	O
cells	O
proteins	O
was	O
abrogated	B-Negative_regulation
,	O
while	O
transactivation	B-Positive_regulation
by	O
AP	O
-	O
1	O
proteins	O
was	O
even	O
enhanced	B-Positive_regulation
.	O

Inducible	O
nitric	O
oxide	O
:	O
an	O
autoregulatory	O
feedback	O
inhibitor	O
of	O
vascular	O
inflammation	O
.	O

Inducible	O
nitric	O
oxide	O
(	O
iNO	O
)	O
is	O
produced	O
at	O
sites	O
of	O
vascular	O
inflammation	O
by	O
resident	O
and	O
nonresident	O
vascular	O
wall	O
cells	O
,	O
but	O
its	O
role	O
in	O
the	O
inflammatory	O
process	O
is	O
not	O
known	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
a	O
novel	O
function	O
of	O
iNO	O
is	O
to	O
terminate	O
inflammatory	O
processes	O
.	O

We	O
find	O
that	O
iNO	O
produced	O
by	O
murine	O
macrophage	O
-	O
like	O
cells	O
,	O
RAW264.7	O
,	O
can	O
inhibit	O
cytokine	O
-	O
induced	O
endothelial	O
cell	O
activation	O
in	O
a	O
separated	O
and	O
mixed	O
endothelial	O
-	O
RAW264.7	O
coculture	O
system	O
.	O

Both	O
iNO	O
production	O
and	O
endothelial	O
VCAM	O
-	O
1	O
expression	B-Gene_expression
were	O
induced	B-Positive_regulation
simultaneously	O
with	O
bacterial	O
LPS	O
and	O
murine	O
-	O
specific	O
IFN	O
-	O
gamma	O
.	O

Inhibition	B-Negative_regulation
of	O
iNO	O
synthase	O
(	O
iNOS	O
)	O
activity	O
with	O
N	O
omega-monomethyl-L	O
-	O
arginine	O
in	O
endothelial	O
-	O
RAW264.7	O
cocultures	O
,	O
stimulated	O
with	O
murine	O
-	O
specific	O
IFN	O
-	O
gamma	O
and	O
LPS	O
,	O
decreased	O
iNO	O
production	O
by	O
86	O
%	O
,	O
augmented	B-Positive_regulation
VCAM	O
-	O
1	O
and	O
iNOS	O
expression	B-Gene_expression
in	O
endothelial	O
and	O
RAW264.7	O
cells	O
,	O
respectively	O
,	O
and	O
increased	O
monocyte	O
adhesion	O
to	O
the	O
endothelial	O
cell	O
surface	O
.	O

Transient	O
transfection	O
studies	O
using	O
various	O
VCAM	O
-	O
1	O
promoter	O
constructs	O
demonstrated	O
that	O
inhibitory	B-Negative_regulation
effects	I-Negative_regulation
of	O
iNO	O
on	O
VCAM	O
-	O
1	O
gene	O
transcription	B-Transcription
were	O
mediated	B-Positive_regulation
,	O
in	O
part	O
,	O
by	O
inhibitory	O
effects	O
of	O
iNO	O
on	O
kappa	O
B	O
cis	O
-	O
acting	O
elements	O
.	O

Immunofluorescence	O
studies	O
using	O
an	O
Ab	O
to	O
the	O
RelA	O
(	O
p65	O
)	O
subunit	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
revealed	O
that	O
iNO	O
inhibited	O
the	O
activation	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
.	O

These	O
studies	O
indicate	O
that	O
iNO	O
attenuates	B-Negative_regulation
iNOS	O
expression	B-Gene_expression
in	O
macrophages	O
and	O
inhibits	O
monocyte	O
adhesion	O
to	O
endothelial	O
cells	O
,	O
and	O
suggest	O
that	O
endogenously	O
derived	O
iNO	O
may	O
be	O
an	O
important	O
autoregulatory	O
inhibitor	O
of	O
vascular	O
inflammation	O
.	O

Inhibition	O
of	O
HIV	O
-	O
1	O
replication	O
by	O
combination	O
of	O
a	O
novel	O
inhibitor	B-Negative_regulation
of	O
TNF	O
-	O
alpha	O
with	O
AZT	O
.	O

The	O
small	O
molecule	O
S9a	O
was	O
derived	O
from	O
an	O
established	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
inhibitor	O
(	O
Canventol	O
)	O
by	O
replacement	O
of	O
the	O
isopropylidine	O
group	O
with	O
a	O
phenyl	O
ring	O
.	O

S9a	O
at	O
10	O
to	O
100	O
nM	O
inhibited	O
HIV	O
production	O
as	O
potently	O
as	O
3'-azido-3'	O
-	O
deoxythymidine	O
(	O
AZT	O
)	O
,	O
an	O
inhibitor	O
of	O
viral	O
reverse	O
transcriptase	O
.	O

Furthermore	O
,	O
S9a	O
and	O
AZT	O
in	O
combination	O
,	O
at	O
noncytoxic	O
concentrations	O
strongly	O
inhibited	O
HIV	O
-	O
1	O
replication	O
that	O
was	O
more	O
than	O
additive	O
and	O
substantially	O
prolonged	O
the	O
appearance	O
of	O
virus	O
both	O
in	O
acutely	O
infected	O
CD4+	O
lymphocytes	O
(	O
SupT	O
)	O
in	O
culture	O
and	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
infected	O
with	O
a	O
primary	O
HIV	O
-	O
1	O
isolate	O
.	O

S9a	O
inhibited	O
TNF	O
-	O
alpha	O
promoter	O
-	O
driven	O
reporter	O
gene	O
activity	O
.	O

It	O
was	O
proposed	O
that	O
the	O
mechanism	O
of	O
antiviral	O
action	O
of	O
S9a	O
was	O
on	O
the	O
host	O
cell	O
,	O
by	O
blocking	B-Negative_regulation
TNF	O
-	O
alpha	O
transcription	B-Transcription
via	B-Positive_regulation
a	O
Tat	O
-	O
induced	B-Positive_regulation
tar	O
-	O
independent	O
loop	O
,	O
which	O
decreases	O
downstream	O
NF	O
-	O
kappaB	O
activation	O
of	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

S9a	O
was	O
superior	O
to	O
the	O
first	O
generation	O
compound	O
Canventol	O
,	O
which	O
was	O
superior	O
to	O
the	O
natural	O
compound	O
sarcophytol	O
A	O
,	O
demonstrating	O
that	O
further	O
structure	O
-	O
based	O
enhancement	O
of	O
potency	O
of	O
these	O
compounds	O
is	O
feasible	O
.	O

This	O
study	O
suggests	O
a	O
therapeutic	O
approach	O
against	O
AIDS	O
by	O
application	O
of	O
two	O
drugs	O
,	O
one	O
against	O
a	O
cellular	O
and	O
the	O
other	O
a	O
viral	O
target	O
,	O
which	O
may	O
provide	O
an	O
approach	O
to	O
the	O
problem	O
of	O
frequent	O
emergence	O
of	O
resistant	O
variants	O
to	O
combinations	O
of	O
drugs	O
that	O
target	O
only	O
HIV	O
genes	O
.	O

Retinoic	O
acid	O
inhibits	O
CD40	O
+	O
interleukin-4	O
-	O
mediated	O
IgE	O
production	O
in	O
vitro	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
retinoic	O
acid	O
(	O
RA	O
)	O
in	O
anti	O
-	O
CD40	O
+	O
interleukin	O
-	O
4	O
(	O
IL	O
-	O
4	O
)	O
-	O
mediated	O
B	O
-	O
cell	O
activation	O
,	O
the	O
effect	O
of	O
10	O
(	O
-	O
12	O
)	O
to	O
10	O
(	O
-	O
6	O
)	O
mol/L	O
RA	O
was	O
studied	O
in	O
anti	O
-	O
CD40	O
(	O
1	O
microgram/mL	O
)	O
+	O
IL	O
-	O
4	O
(	O
5	O
ng/mL	O
)	O
-	O
mediated	O
proliferation	O
and	O
Ig	O
synthesis	O
by	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
and	O
B	O
cells	O
in	O
healthy	O
donors	O
.	O

Anti	O
-	O
CD40	O
+	O
IL-4	O
-	O
mediated	O
proliferation	O
of	O
PBMC	O
and	O
B	O
cells	O
was	O
inhibited	O
by	O
RA	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
with	O
maximal	O
inhibition	O
of	O
62	O
%	O
+/	O
-	O
5	O
%	O
in	O
PBMC	O
and	O
55	O
%	O
+/	O
-	O
4.4	O
%	O
in	O
B	O
cells	O
by	O
all	O
-	O
trans	O
RA	O
,	O
and	O
58	O
%	O
+/	O
-	O
6.7	O
%	O
and	O
51	O
%	O
+/	O
-	O
4.7	O
%	O
,	O
respectively	O
by	O
13	O
-	O
cis	O
RA	O
.	O

IgE	O
synthesis	O
was	O
even	O
more	O
markedly	O
inhibited	O
by	O
RA	O
starting	O
at	O
concentrations	O
of	O
>	O
10	O
(	O
-	O
14	O
)	O
mol/L	O
for	O
B	O
cells	O
and	O
>	O
10	O
(	O
-	O
10	O
)	O
mol/L	O
for	O
PBMC	O
.	O

Maximal	O
inhibition	O
of	O
IgE	O
production	O
for	O
B	O
cells	O
was	O
at	O
10	O
(	O
-	O
8	O
)	O
mol/L	O
for	O
all	O
-	O
trans	O
RA	O
(	O
94	O
%	O
+/	O
-	O
1.8	O
%	O
)	O
and	O
96	O
%	O
+/	O
-	O
3.2	O
%	O
for	O
13	O
-	O
cis	O
RA	O
.	O

Low	O
concentrations	O
of	O
RA	O
inhibiting	O
IgE	O
synthesis	O
(	O
10	O
(	O
-	O
10	O
)	O
mol/L	O
)	O
affected	O
neither	O
B	O
-	O
cell	O
proliferation	O
nor	O
the	O
production	O
of	O
IgA	O
,	O
IgG	O
,	O
and	O
IgM	O
.	O

Elucidation	O
of	O
the	O
mechanism	O
involved	O
in	O
this	O
inhibition	O
of	O
IgE	O
production	O
shows	O
that	O
epsilon	O
germline	O
transcription	O
is	O
decreased	O
by	O
RA	O
,	O
whereas	O
production	B-Gene_expression
of	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
was	O
not	O
enhanced	B-Positive_regulation
in	O
the	O
presence	O
of	O
RA	O
.	O

To	O
differentiate	O
whether	O
the	O
RA	O
effect	O
was	O
mediated	O
by	O
RA	O
receptors	O
alpha	O
,	O
beta	O
,	O
and	O
gamma	O
,	O
the	O
expression	O
of	O
the	O
retinoic	O
acid	O
receptors	O
(	O
RAR	O
)	O
was	O
examined	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

The	O
data	O
show	O
that	O
unstimulated	O
human	O
peripheral	O
B	O
cells	O
express	B-Transcription
mRNA	O
of	O
the	O
RA	O
receptor	O
alpha	O
,	O
beta	O
,	O
and	O
gamma	O
.	O

Using	O
retinoids	O
with	O
different	O
receptor	O
binding	O
specificity	O
(	O
CD336	O
,	O
CD437	O
,	O
CD2019	O
,	O
CD367	O
)	O
,	O
dose	O
-	O
dependent	O
inhibition	O
of	O
IgE	O
synthesis	O
was	O
shown	O
by	O
all	O
four	O
derivates	O
,	O
but	O
was	O
most	O
marked	O
by	O
an	O
RA	O
binding	O
the	O
alpha	O
receptor	O
with	O
high	O
specificity	O
.	O

Taken	O
together	O
,	O
this	O
study	O
shows	O
that	O
RA	O
inhibits	O
IgE	O
production	O
of	O
anti	O
-	O
CD40	O
+	O
IL-4	O
-	O
stimulated	O
B	O
cells	O
in	O
vitro	O
.	O

Copyright	O
1998	O
by	O
The	O
American	O
Society	O
of	O
Hematology	O
.	O

Nuclear	O
factor	O
-	O
kappaB	O
induction	O
in	O
CD45RO+	O
and	O
CD45RA+	O
T	O
cell	O
subsets	O
during	O
aging	O
.	O

An	O
increase	O
in	O
the	O
ratio	O
of	O
memory	O
to	O
naive	O
T	O
cells	O
has	O
been	O
postulated	O
to	O
underlie	O
immune	O
hyporesponsiveness	O
accompanying	O
aging	O
.	O

Our	O
analyses	O
of	O
the	O
induction	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NFkappaB	O
)	O
in	O
activated	O
memory	O
(	O
CD45RO+	O
)	O
and	O
naive	O
(	O
CD45RA+	O
)	O
T	O
cell	O
subsets	O
from	O
young	O
and	O
elderly	O
donors	O
has	O
demonstrated	O
that	O
,	O
regardless	O
of	O
donor	O
age	O
,	O
memory	O
T	O
cells	O
are	O
not	O
significantly	O
altered	O
in	O
their	O
responsiveness	O
to	O
TNF-alpha	O
-	O
mediated	O
induction	O
of	O
NFkappaB	O
.	O

Although	O
treatment	O
with	O
TNF	O
-	O
alpha	O
induced	O
nuclear	O
localization	O
of	O
NFkappaB	O
in	O
both	O
memory	O
and	O
naive	O
T	O
cell	O
subsets	O
,	O
irrespective	O
of	O
the	O
age	O
of	O
the	O
donor	O
,	O
the	O
levels	O
of	O
induced	O
NFkappaB	O
were	O
significantly	O
lower	O
in	O
both	O
subsets	O
of	O
T	O
cells	O
obtained	O
from	O
the	O
elderly	O
,	O
when	O
compared	O
to	O
those	O
in	O
young	O
.	O

Examination	O
of	O
IkappaB	O
alpha	O
regulation	B-Regulation
revealed	O
that	O
TNF-alpha	O
-	O
mediated	B-Positive_regulation
degradation	B-Protein_catabolism
of	O
IkappaB	O
alpha	O
in	O
both	O
memory	O
and	O
naive	O
T	O
cells	O
from	O
the	O
elderly	O
was	O
severely	O
impaired	B-Negative_regulation
,	O
thus	O
contributing	O
to	O
the	O
lowered	O
induction	O
of	O
the	O
observed	O
NFkappaB	O
.	O

In	O
addition	O
,	O
this	O
age	O
-	O
related	O
decrease	O
in	O
induction	O
of	O
nuclear	O
NFkappaB	O
correlated	O
with	O
decrease	O
in	O
intracellular	O
IL	O
-	O
2	O
receptor	O
expression	O
and	O
anti-CD3	O
-	O
induced	O
proliferation	O
of	O
both	O
memory	O
and	O
naive	O
T	O
cells	O
subsets	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
the	O
age	O
-	O
related	O
hyporesponsiveness	O
can	O
not	O
be	O
attributed	O
to	O
a	O
skewing	O
of	O
the	O
T	O
cell	O
population	O
towards	O
a	O
memory	O
phenotype	O
in	O
the	O
elderly	O
.	O

Activation	O
of	O
E2F	O
-	O
mediated	O
transcription	O
by	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
Tax	O
protein	O
in	O
a	O
p16	O
(	O
INK4A	O
)	O
-	O
negative	B-Gene_expression
T	O
-	O
cell	O
line	O
.	O

The	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
a	O
causative	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
.	O

Although	O
the	O
exact	O
mechanism	O
by	O
which	O
HTLV	O
-	O
I	O
contributes	O
to	O
leukemogenesis	O
is	O
still	O
unclear	O
,	O
the	O
Tax	O
protein	O
is	O
thought	O
to	O
play	O
a	O
major	O
role	O
in	O
this	O
process	O
.	O

This	O
40	O
-	O
kDa	O
polypeptide	O
is	O
able	O
to	O
interact	B-Binding
with	O
the	O
tumor	O
suppressor	O
p16	O
(	O
INK4A	O
)	O
.	O

Consequently	O
,	O
Tax	O
can	O
activate	O
the	O
signaling	O
pathway	O
that	O
lead	O
to	O
the	O
release	O
of	O
E2F	O
that	O
in	O
turn	O
induces	O
expression	O
of	O
factors	O
required	O
for	O
cell	O
cycle	O
progression	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
Tax	O
can	O
also	O
activate	O
E2F	O
-	O
mediated	O
transcription	O
independently	O
of	O
p16	O
(	O
INK4A	O
)	O
.	O

Indeed	O
,	O
when	O
Tax	O
is	O
coexpressed	B-Gene_expression
with	O
the	O
E2F	O
-	O
1	O
transcription	O
factor	O
in	O
CEM	O
T	O
-	O
cells	O
,	O
which	O
lack	O
expression	O
of	O
p16	O
(	O
INK4A	O
)	O
,	O
it	O
strongly	O
potentiates	O
the	O
E2F	O
-	O
dependent	O
activation	O
of	O
a	O
reporter	O
construct	O
driven	O
by	O
a	O
promoter	O
containing	O
E2F	O
binding	O
sites	O
.	O

This	O
stimulation	O
is	O
abrogated	O
by	O
mutations	O
affecting	O
the	O
E2F	O
-	O
binding	O
sites	O
.	O

In	O
addition	O
,	O
Tax	O
also	O
stimulates	B-Positive_regulation
the	O
transcription	B-Transcription
of	O
the	O
E2F	O
-	O
1	O
gene	O
itself	O
.	O

Using	O
Tax	O
mutants	O
that	O
fail	O
to	O
activate	B-Positive_regulation
either	O
ATF	O
-	O
or	O
NF-kappaB	O
-	O
dependent	O
promoters	O
and	O
different	O
5	O
'	O
truncation	O
mutants	O
of	O
the	O
E2F	O
-	O
1	O
promoter	O
,	O
we	O
show	O
that	O
the	O
Tax	O
-	O
dependent	O
transcriptional	B-Regulation
control	I-Regulation
of	O
the	O
E2F1	O
gene	O
involves	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
ATF	O
binding	O
site	O
located	O
in	O
the	O
E2F	O
-	O
1	O
promoter	O
.	O

Glucocorticoid	O
-	O
induced	O
apoptosis	O
and	O
regulation	O
of	O
NF	O
-	O
kappaB	O
activity	O
in	O
human	O
leukemic	O
T	O
cells	O
.	O

Glucocorticoid	O
-	O
induced	O
apoptosis	O
was	O
investigated	O
in	O
glucocorticoid	O
-	O
sensitive	O
6TG1.1	O
and	O
resistant	O
ICR27TK.3	O
human	O
leukemic	O
T	O
cells	O
.	O

Following	O
glucocorticoid	O
treatment	O
of	O
6TG1.1	O
cells	O
,	O
chromatin	O
fragmentation	O
was	O
observed	O
after	O
a	O
delay	O
of	O
24	O
h	O
.	O

Fragmentation	O
was	O
not	O
observed	O
in	O
ICR27TK.3	O
cells	O
containing	O
mutant	O
glucocorticoid	O
receptors	O
(	O
L753F	O
)	O
that	O
are	O
activation	O
-	O
deficient	O
but	O
retain	O
the	O
ability	O
to	O
repress	O
AP	O
-	O
1	O
activity	O
.	O

Nor	O
was	O
fragmentation	O
observed	O
after	O
treatment	O
with	O
RU38486	O
,	O
indicating	O
that	O
repression	O
of	O
AP	O
-	O
1	O
activity	O
is	O
not	O
involved	O
.	O

As	O
described	O
in	O
other	O
systems	O
,	O
fragmentation	O
required	O
ongoing	O
protein	O
synthesis	O
.	O

However	O
,	O
inhibition	O
of	O
protein	O
synthesis	O
with	O
cycloheximide	O
anytime	O
during	O
the	O
first	O
18	O
h	O
of	O
steroid	O
treatment	O
was	O
as	O
effective	O
in	O
blocking	O
chromatin	O
fragmentation	O
as	O
inhibition	O
for	O
the	O
entire	O
period	O
,	O
suggesting	O
that	O
synthesis	O
of	O
a	O
component	O
with	O
a	O
rapid	O
turnover	O
rate	O
is	O
required	O
.	O

Dexamethasone	O
treatment	O
completely	O
blocked	O
12-O	O
-	O
tetradecanoylphorbol	O
13	O
-	O
acetate	O
induction	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
activity	O
and	O
elicited	O
an	O
increase	B-Positive_regulation
in	O
the	O
amount	O
of	O
immunoreactive	O
IkappaB	O
alpha	O
in	O
sensitive	O
6TG1.1	O
cells	O
but	O
not	O
in	O
resistant	O
ICR27TK.3	O
cells	O
.	O

In	O
addition	O
,	O
mild	O
detergent	O
treatment	O
of	O
cell	O
extracts	O
indicated	O
that	O
a	O
substantial	O
amount	O
of	O
cytoplasmic	O
NF	O
-	O
kappaB	O
is	O
complexed	B-Binding
with	O
IkappaB	O
alpha	O
or	O
some	O
other	O
inhibitory	O
factor	O
.	O

These	O
results	O
suggest	O
that	O
induction	B-Positive_regulation
of	O
a	O
labile	O
inhibitory	O
factor	O
such	O
as	O
IkappaB	O
alpha	O
may	O
contribute	O
to	O
glucocorticoid	O
-	O
induced	O
apoptosis	O
.	O

Peripheral	O
T	O
lymphocytes	O
from	O
women	O
with	O
breast	O
cancer	O
exhibit	O
abnormal	O
protein	O
expression	O
of	O
several	O
signaling	O
molecules	O
.	O

We	O
examined	O
signaling	O
molecules	O
of	O
peripheral	O
blood	O
T	O
lymphocytes	O
obtained	O
from	O
women	O
with	O
breast	O
cancer	O
.	O

In	O
6	O
of	O
14	O
patients	O
,	O
T	O
lymphocytes	O
displayed	O
an	O
impaired	B-Negative_regulation
ability	O
to	O
translocate	B-Localization
NFeB	O
p65	O
(	O
Rel	O
-	O
A	O
)	O
following	B-Positive_regulation
activation	O
by	O
anti	O
-	O
CD3	O
and	O
IL	O
-	O
2	O
.	O

This	O
observation	O
was	O
made	O
despite	O
normal	O
cytoplasmic	O
levels	B-Gene_expression
of	O
the	O
Rel	O
-	O
A	O
protein	O
.	O

We	O
also	O
detected	O
abnormally	B-Negative_regulation
low	I-Negative_regulation
levels	I-Negative_regulation
of	O
the	O
signaling	O
molecules	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
-	O
zeta	O
,	O
ZAP	O
-	O
70	O
and	O
p56lck	O
in	O
4	O
of	O
14	O
breast	O
cancer	O
patients	O
,	O
i.e.	O
,	O
defects	O
in	O
T	O
-	O
cell	O
signaling	O
molecules	O
.	O

T	O
lymphocytes	O
from	O
6	O
of	O
the	O
14	O
patients	O
also	O
exhibited	O
an	O
increased	B-Positive_regulation
expression	B-Gene_expression
of	O
the	O
dual	O
specificity	O
phosphatase	O
,	O
map	O
kinase	O
phosphatase	O
-	O
1	O
(	O
MKP	O
-	O
1	O
)	O
.	O

MKP	O
-	O
1	O
inactivates	O
MAP	O
kinase	O
and	O
therefore	O
may	O
interfere	B-Negative_regulation
with	O
the	O
activation	B-Positive_regulation
of	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
.	O

Abnormalities	O
of	O
I	O
or	O
more	O
signaling	O
molecules	O
were	O
found	O
in	O
9	O
of	O
14	O
patients	O
;	O
however	O
,	O
only	O
3	O
patients	O
had	O
T	O
cells	O
that	O
exhibited	O
all	O
5	O
defects	O
.	O

Our	O
data	O
have	O
implications	O
for	O
the	O
detection	O
of	O
potentially	O
dysfunctional	O
T	O
cells	O
in	O
patients	O
with	O
cancer	O
.	O

For	O
example	O
,	O
the	O
analysis	O
of	O
only	O
1	O
signaling	O
molecule	O
may	O
allow	O
patients	O
with	O
significant	O
defects	O
in	O
T	O
-	O
cell	O
signaling	O
to	O
go	O
unnoticed	O
.	O

Finally	O
,	O
despite	B-Negative_regulation
impaired	B-Negative_regulation
Rel	O
-	O
A	O
translocation	B-Localization
,	O
T	O
cells	O
were	O
capable	O
of	O
transcribing	B-Transcription
IL	O
-	O
2	O
.	O

Impairments	B-Negative_regulation
in	O
the	O
translocation	B-Localization
of	O
Rel	O
-	O
B	O
and	O
c	O
-	O
Rel	O
further	O
suggest	O
that	O
the	O
NFKB	O
family	O
members	O
Rel	O
-	O
A	O
,	O
Rel	O
-	O
B	O
and	O
c	O
-	O
Rel	O
are	O
not	O
required	B-Regulation
for	O
the	O
transcription	B-Transcription
of	O
IL	O
-	O
2	O
in	O
the	O
peripheral	O
T	O
lymphocytes	O
of	O
patients	O
with	O
breast	O
cancer	O
.	O

Transcription	O
of	O
a	O
minimal	O
promoter	O
from	O
the	O
NF	O
-	O
IL6	O
gene	O
is	O
regulated	O
by	O
CREB/ATF	O
and	O
SP1	O
proteins	O
in	O
U937	O
promonocytic	O
cells	O
.	O

NF	O
-	O
IL6	O
is	O
an	O
important	O
transcriptional	O
regulator	O
of	O
genes	O
induced	O
in	O
activated	O
monocytes/macrophages	O
,	O
and	O
NF	O
-	O
IL6	O
is	O
the	O
only	O
CCAAT/enhancer	O
-	O
binding	O
protein	O
(	O
C/EBP	O
)	O
family	O
member	O
whose	O
steady	O
-	O
state	O
mRNA	O
levels	O
increase	B-Positive_regulation
upon	O
activation	O
of	O
monocytes	O
(	O
1	O
)	O
.	O

We	O
show	O
that	O
increased	B-Positive_regulation
transcription	B-Transcription
of	O
the	O
NF	O
-	O
IL6	O
gene	O
is	O
responsible	B-Positive_regulation
,	O
at	O
least	O
in	O
part	O
,	O
for	O
induction	B-Positive_regulation
of	O
NF	O
-	O
IL6	O
mRNA	O
following	O
activation	O
of	O
U937	O
promonocytic	O
cells	O
.	O

We	O
have	O
identified	O
a	O
104	O
-	O
bp	O
minimal	O
promoter	O
region	O
of	O
the	O
NF	O
-	O
IL6	O
gene	O
that	O
is	O
sufficient	B-Positive_regulation
for	O
basal	O
and	O
activation	O
-	O
dependent	O
induction	B-Positive_regulation
of	O
transcription	B-Transcription
in	O
U937	O
cells	O
.	O

This	O
region	O
contains	O
binding	O
sites	O
for	O
the	O
cAMP	O
response	O
element	O
-	O
binding	O
protein/activation	O
transcription	O
factor	O
(	O
CREB/ATF	O
)	O
and	O
Sp1	O
families	O
of	O
transcription	O
factors	O
.	O

Each	O
site	O
is	O
functionally	O
important	O
and	O
contributes	O
independently	O
to	O
transcription	O
of	O
the	O
NF	O
-	O
IL6	O
gene	O
in	O
U937	O
cells	O
.	O

CD30	O
is	O
a	O
CD40	O
-	O
inducible	B-Positive_regulation
molecule	O
that	O
negatively	O
regulates	O
CD40	O
-	O
mediated	O
immunoglobulin	O
class	O
switching	O
in	O
non-antigen	O
-	O
selected	O
human	O
B	O
cells	O
.	O

We	O
used	O
our	O
monoclonal	O
model	O
of	O
germinal	O
center	O
maturation	O
,	O
CL	O
-	O
01	O
B	O
cells	O
,	O
to	O
investigate	O
the	O
role	O
of	O
CD30	O
in	O
human	O
B	O
cell	O
differentiation	O
.	O

CL	O
-	O
01	O
cells	O
are	O
IgM+	O
IgD+	O
CD30+	O
and	O
switch	B-Negative_regulation
to	O
IgG	O
,	O
IgA	O
,	O
and	O
IgE	O
when	O
exposed	O
to	O
CD40L	O
and	O
IL	O
-	O
4	O
.	O

Switching	O
is	O
hampered	O
by	O
CD30	O
coengagement	B-Binding
,	O
possibly	O
through	O
interference	O
with	O
the	O
CD40	O
-	O
mediated	O
NF-kappaB	O
-	O
dependent	O
transcriptional	O
activation	O
of	O
downstream	O
C	O
(	O
H	O
)	O
genes	O
.	O

The	O
physiological	O
relevance	O
of	O
this	O
phenomenon	O
is	O
emphasized	O
by	O
similar	O
CD30	O
-	O
mediated	O
effects	O
in	O
naive	O
B	O
cells	O
.	O

Expression	B-Gene_expression
of	O
CD30	O
by	O
these	O
cells	O
is	B-Positive_regulation
induced	I-Positive_regulation
by	O
CD40L	O
but	O
is	O
inhibited	B-Negative_regulation
by	O
B	O
cell	O
receptor	O
coengagement	O
and/or	O
exposure	O
to	O
IL	O
-	O
6	O
and	O
IL	O
-	O
12	O
.	O

Our	O
data	O
suggest	O
that	O
CD30	O
critically	O
regulates	O
the	O
CD40	O
-	O
mediated	O
differentiation	O
of	O
non-antigen	O
-	O
selected	O
human	O
B	O
cells	O
.	O

Induction	B-Positive_regulation
of	O
Mn	O
SOD	O
in	O
human	O
monocytes	O
without	O
inflammatory	O
cytokine	O
production	O
by	O
a	O
mutant	O
endotoxin	O
.	O

Endotoxin	O
selectively	O
induces	B-Positive_regulation
monocyte	O
Mn	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
without	O
affecting	B-Regulation
levels	O
of	O
Cu	O
,	O
Zn	O
SOD	O
,	O
catalase	O
,	O
or	O
glutathione	O
peroxidase	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
structure	O
-	O
activity	O
relationship	O
and	O
the	O
mechanism	O
by	O
which	O
endotoxin	O
induces	B-Positive_regulation
Mn	O
SOD	O
.	O

In	O
this	O
study	O
we	O
demonstrated	O
that	O
a	O
mutant	O
Escherichia	O
coli	O
endotoxin	O
lacking	O
myristoyl	O
fatty	O
acid	O
at	O
the	O
3	O
'	O
R-3	O
-	O
hydroxymyristate	O
position	O
of	O
the	O
lipid	O
A	O
moiety	O
retained	O
its	O
full	O
capacity	O
to	O
coagulate	O
Limulus	O
amoebocyte	O
lysate	O
compared	O
with	O
the	O
wild	O
-	O
type	O
E.	O
coli	O
endotoxin	O
and	O
markedly	O
stimulated	B-Positive_regulation
the	O
activation	O
of	O
human	O
monocyte	O
nuclear	O
factor	O
-	O
kappaB	O
and	O
the	O
induction	B-Transcription
of	O
Mn	O
SOD	O
mRNA	O
and	O
enzyme	O
activity	O
.	O

However	O
,	O
in	O
contrast	O
to	O
the	O
wild	O
-	O
type	O
endotoxin	O
,	O
it	O
failed	O
to	O
induce	B-Positive_regulation
significant	O
production	B-Gene_expression
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
and	O
macrophage	O
inflammatory	O
protein	O
-	O
1alpha	O
by	O
monocytes	O
and	O
did	O
not	O
induce	O
the	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
.	O

These	O
results	O
suggest	O
that	O
1	O
)	O
lipid	O
A	O
myristoyl	O
fatty	O
acid	O
,	O
although	O
it	O
is	O
important	O
for	O
the	O
induction	O
of	O
inflammatory	O
cytokine	O
production	O
by	O
human	O
monocytes	O
,	O
is	O
not	O
necessary	B-Positive_regulation
for	O
the	O
induction	B-Positive_regulation
of	O
Mn	O
SOD	O
,	O
2	O
)	O
endotoxin	O
-	O
mediated	O
induction	B-Positive_regulation
of	O
Mn	O
SOD	O
and	O
inflammatory	O
cytokines	O
are	O
regulated	B-Regulation
,	O
at	O
least	O
in	O
part	O
,	O
through	O
different	O
signal	O
transduction	O
pathways	O
,	O
and	O
3	O
)	O
failure	O
of	O
the	O
mutant	O
endotoxin	O
to	O
induce	B-Positive_regulation
tumor	O
necrosis	O
factor	O
-	O
alpha	O
production	B-Gene_expression
is	O
,	O
at	O
least	O
in	O
part	O
,	O
due	B-Positive_regulation
to	O
its	O
inability	O
to	O
activate	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
.	O

An	O
allosteric	O
drug	O
,	O
o	O
,	O
o'	O
-	O
bismyristoyl	O
thiamine	O
disulfide	O
,	O
suppresses	O
HIV	O
-	O
1	O
replication	O
through	O
prevention	B-Negative_regulation
of	O
nuclear	O
translocation	B-Localization
of	O
both	O
HIV	O
-	O
1	O
Tat	O
and	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
efficacy	O
of	O
o	O
,	O
o'	O
-	O
bismyristoyl	O
thiamine	O
disulfide	O
(	O
BMT	O
)	O
was	O
examined	O
in	O
detail	O
against	O
HIV	O
-	O
1	O
laboratory	O
isolates	O
(	O
HTLV	O
-	O
IIIB	O
,	O
JRFL	O
,	O
and	O
MN	O
)	O
,	O
primary	O
isolates	O
(	O
KMT	O
and	O
KMO	O
)	O
,	O
and	O
simian	O
immunodeficiency	O
virus	O
(	O
SIVmac251	O
)	O
in	O
vitro	O
.	O

BMT	O
inhibited	O
the	O
replication	O
of	O
HIV	O
-	O
1	O
in	O
both	O
laboratory	O
and	O
primary	O
isolates	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
BMT	O
exhibited	O
antiviral	O
activity	O
against	O
SIVmac251	O
.	O

Minimizing	O
energy	O
studies	O
of	O
BMT	O
structure	O
reveal	O
that	O
a	O
trans	O
-	O
disulfide	O
of	O
thiamine	O
(	O
holo	O
drug	O
)	O
disulfide	O
(	O
TDS	O
,	O
protodrug	O
)	O
is	O
allosterically	O
transited	O
to	O
the	O
reactive	O
twisted	O
disulfide	O
of	O
BMT	O
(	O
allo	O
drug	O
)	O
by	O
o	O
,	O
o'	O
-	O
bismyristoyl	O
esterification	O
of	O
TDS	O
.	O

BMT	O
inhibits	B-Negative_regulation
nuclear	O
translocation	B-Localization
of	O
both	O
HIV	O
-	O
1	O
transactivator	O
(	O
TAT	O
)	O
and	O
the	O
cellular	O
transcriptional	O
nuclear	O
factor	O
-	O
KB	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
,	O
resulting	O
in	O
the	O
suppression	O
of	O
HIV	O
-	O
1	O
replication	O
.	O

Retinoid	O
X	O
receptor	O
and	O
c	O
-	O
cerbA/thyroid	O
hormone	O
receptor	O
regulate	O
erythroid	O
cell	O
growth	O
and	O
differentiation	O
.	O

Nuclear	O
receptors	O
are	O
important	O
regulators	O
of	O
erythroid	O
cell	O
development	O
.	O

Here	O
we	O
investigated	O
the	O
impact	O
of	O
retinoid	O
X	O
receptor	O
(	O
RXR	O
)	O
,	O
retinoic	O
acid	O
receptor	O
(	O
RAR	O
)	O
,	O
and	O
of	O
the	O
c	O
-	O
erbA/thyroid	O
hormone	O
(	O
T3	O
)	O
receptor	O
(	O
c	O
-	O
erbA/TR	O
)	O
on	O
growth	O
and	O
differentiation	O
of	O
erythroid	O
cells	O
using	O
an	O
in	O
vitro	O
culture	O
system	O
of	O
stem	O
cell	O
factor	O
-	O
dependent	O
erythroid	O
progenitors	O
.	O

RXR	O
,	O
RAR	O
,	O
and	O
c-erbA/TR	O
-	O
specific	O
ligands	O
were	O
found	O
to	O
induce	O
erythroid	O
-	O
specific	O
gene	O
expression	O
and	O
to	O
accelerate	O
erythroid	O
differentiation	O
in	O
culture	O
,	O
with	O
T3	O
being	O
most	O
effective	O
.	O

Furthermore	O
,	O
while	O
ligand	O
-	O
activated	O
c	O
-	O
erbA/TR	O
accelerated	O
differentiation	O
,	O
unliganded	O
c	O
-	O
erbA/TR	O
effectively	O
blocked	O
differentiation	O
and	O
supported	O
sustained	O
progenitor	O
growth	O
in	O
culture	O
.	O

Thus	O
,	O
c	O
-	O
erbA/TR	O
appears	O
to	O
act	O
as	O
a	O
binary	O
switch	O
affecting	O
erythroid	O
cell	O
fate	O
:	O
unliganded	O
c	O
-	O
erbA/TR	O
supports	O
growth	O
while	O
ligand	O
-	O
activated	O
c	O
-	O
erbA/TR	O
induces	O
differentiation	O
.	O

Additionally	O
,	O
to	O
determine	O
the	O
impact	O
of	O
RXR	O
for	O
erythroid	O
cell	O
development	O
,	O
dominant	O
interfering	O
mutant	O
RXRs	O
,	O
lacking	O
the	O
transcriptional	O
activator	O
functions	O
AF	O
-	O
1	O
and	O
AF	O
-	O
2	O
,	O
or	O
AF	O
-	O
2	O
only	O
,	O
or	O
the	O
entire	O
DNA	O
-	O
binding	O
domain	O
,	O
were	O
introduced	O
into	O
erythroid	O
progenitor	O
cells	O
via	O
recombinant	O
retrovirus	O
vectors	O
and	O
analyzed	O
for	O
RXR	O
-	O
specific	O
effects	O
.	O

It	O
was	O
found	O
that	O
expression	O
of	O
wild	O
-	O
type	O
RXR	O
and	O
of	O
the	O
RXR	O
mutants	O
devoid	O
of	O
AF	O
-	O
1	O
and/or	O
AF	O
-	O
2	O
supported	O
a	O
transient	O
outgrowth	O
of	O
erythroid	O
cells	O
.	O

In	O
marked	O
contrast	O
,	O
expression	O
of	O
the	O
dominant	O
interfering	O
deltaDNA	O
-	O
binding	O
domain	O
RXR	O
,	O
containing	O
a	O
deletion	O
of	O
the	O
entire	O
DNA	O
-	O
binding	O
domain	O
,	O
was	O
incompatible	O
with	O
erythroid	O
cell	O
growth	O
in	O
vitro	O
,	O
suggesting	O
a	O
pivotal	O
role	O
of	O
RXR	O
for	O
erythroid	O
cell	O
development	O
.	O

Phosphatidylinositides	O
bind	B-Binding
to	O
plasma	O
membrane	O
CD14	O
and	O
can	O
prevent	O
monocyte	O
activation	O
by	O
bacterial	O
lipopolysaccharide	O
.	O

Although	O
bacterial	O
lipopolysaccharides	O
(	O
LPS	O
)	O
and	O
several	O
other	O
microbial	O
agonists	O
can	O
bind	B-Binding
to	O
mCD14	O
(	O
membrane	O
CD14	O
)	O
,	O
a	O
cell	O
-	O
surface	O
receptor	O
found	O
principally	O
on	O
monocytes	O
and	O
neutrophils	O
,	O
host	O
-	O
derived	O
mCD14	O
ligands	O
are	O
poorly	O
defined	O
.	O

We	O
report	O
here	O
that	O
phosphatidylinositol	O
(	O
PtdIns	O
)	O
,	O
phosphatidylinositol-4	O
-	O
phosphate	O
,	O
and	O
other	O
phosphatidylinositides	O
can	O
bind	B-Binding
to	O
mCD14	O
.	O

Phosphatidylserine	O
(	O
PS	O
)	O
,	O
another	O
anionic	O
glycerophospholipid	O
,	O
binds	B-Binding
to	O
mCD14	O
with	O
lower	O
apparent	O
affinity	O
than	O
does	O
PtdIns	O
.	O

LPS	O
-	O
binding	O
protein	O
,	O
a	O
lipid	O
transfer	O
protein	O
found	O
in	O
serum	O
,	O
facilitates	B-Positive_regulation
both	O
PS	O
-	O
and	O
PtdIns	O
-	O
mCD14	O
binding	B-Binding
.	O

PtdIns	O
binding	B-Binding
to	O
mCD14	O
can	O
be	O
blocked	B-Negative_regulation
by	O
anti	O
-	O
CD14	O
monoclonal	O
antibodies	O
that	O
inhibit	B-Negative_regulation
LPS	O
-	O
mCD14	O
binding	B-Binding
,	O
and	O
PtdIns	O
can	O
inhibit	B-Negative_regulation
both	O
LPS	O
-	O
mCD14	O
binding	B-Binding
and	O
LPS	O
-	O
induced	O
responses	O
in	O
monocytes	O
.	O

Serum	O
-	O
equilibrated	O
PtdIns	O
also	O
binds	O
to	O
mCD14	O
-	O
expressing	B-Gene_expression
cells	O
,	O
raising	O
the	O
possibility	O
that	O
endogenous	O
PtdIns	O
may	O
modulate	O
cellular	O
responses	O
to	O
LPS	O
and	O
other	O
mCD14	O
ligands	O
in	O
vivo	O
.	O

Low	O
CD3+CD28	O
-	O
induced	B-Positive_regulation
interleukin	O
-	O
2	O
production	B-Gene_expression
correlates	O
with	O
decreased	O
reactive	O
oxygen	O
intermediate	O
formation	O
in	O
neonatal	O
T	O
cells	O
.	O

The	O
capacity	O
of	O
neonatal	O
T	O
cells	O
to	O
secrete	B-Localization
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
has	O
been	O
reported	O
to	O
be	O
variable	O
.	O

We	O
analysed	O
IL	O
-	O
2	O
production	B-Gene_expression
in	O
purified	O
neonatal	O
and	O
adult	O
T	O
cells	O
using	B-Regulation
polyclonal	O
activator	O
phorbol	O
ester	O
+	O
calcium	O
ionophore	O
(	O
PDBu	O
+	O
iono	O
)	O
or	O
receptor	O
-	O
mediated	O
anti-CD3/anti	O
-	O
CD3+	O
anti	O
-	O
CD28	O
stimulation	O
.	O

PDBu	O
+	O
iono	O
induced	B-Positive_regulation
equally	O
high	O
IL	O
-	O
2	O
levels	O
in	O
both	O
groups	O
and	O
,	O
when	O
stimulated	O
with	O
plate	O
-	O
bound	O
anti	O
-	O
CD3	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
,	O
the	O
IL	O
-	O
2	O
secretion	B-Localization
by	O
neonatal	O
cells	O
was	B-Negative_regulation
undetectable	I-Negative_regulation
and	O
adult	O
cells	O
produced	B-Gene_expression
low	B-Negative_regulation
amounts	I-Negative_regulation
of	O
IL	O
-	O
2	O
(	O
mean	O
331	O
+/	O
-	O
86	O
pg/ml	O
)	O
.	O

The	O
addition	O
of	O
anti	O
-	O
CD28	O
mAb	O
to	O
anti-CD3	O
-	O
stimulated	O
cells	O
markedly	O
increased	B-Positive_regulation
IL	O
-	O
2	O
production	B-Gene_expression
in	O
both	O
cell	O
types	O
,	O
but	O
levels	O
of	O
IL	O
-	O
2	O
in	O
neonatal	O
T	O
cells	O
remained	O
clearly	O
lower	O
than	O
those	O
of	O
adult	O
T	O
cells	O
(	O
respective	O
mean	O
values	O
:	O
385	O
+/	O
-	O
109	O
pg/ml	O
and	O
4494	O
+/	O
-	O
1199	O
pg/ml	O
)	O
.	O

As	O
NF	O
-	O
kappa	O
B	O
is	O
a	O
critical	O
transcription	O
factor	O
in	O
the	O
control	B-Regulation
of	O
IL	O
-	O
2	O
expression	B-Gene_expression
,	O
we	O
next	O
analysed	O
its	O
nuclear	O
translocation	O
in	O
neonatal	O
and	O
adult	O
T	O
cells	O
using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
and	O
,	O
because	O
induction	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
is	O
required	O
for	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
we	O
also	O
analysed	O
levels	O
of	O
intracellular	O
ROI	O
in	O
these	O
cells	O
using	O
the	O
ROI	O
-	O
reactive	O
fluorochrome	O
DCFH	O
-	O
DA	O
and	O
flow	O
cytometry	O
.	O

In	O
neonatal	O
T	O
cells	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
ROI	O
formation	O
after	O
anti	O
-	O
CD3	O
stimulation	O
were	O
low	O
compared	O
with	O
adult	O
T	O
cells	O
and	O
,	O
although	O
addition	O
of	O
anti	O
-	O
CD28	O
mAb	O
increased	O
induction	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
ROI	O
formation	O
,	O
levels	O
similar	O
to	O
those	O
of	O
adults	O
were	O
not	O
achieved	O
.	O

After	O
PDBu	O
+	O
iono	O
stimulation	O
,	O
the	O
cells	O
showed	O
similar	O
ROI	O
formation	O
and	O
IL	O
-	O
2	O
secretion	B-Localization
.	O

Our	O
results	O
suggest	O
that	O
reduced	B-Negative_regulation
IL	O
-	O
2	O
production	B-Gene_expression
by	O
neonatal	O
T	O
cells	O
is	O
specific	B-Regulation
for	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD3+	O
anti-CD28	O
-	O
mediated	O
stimulation	O
and	O
that	O
these	O
activators	O
can	O
not	O
effectively	O
activate	O
the	O
ROI-NF	O
-	O
kappa	O
B	O
signalling	O
pathway	O
in	O
neonatal	O
T	O
cells	O
.	O

Activated	O
platelets	O
induce	B-Positive_regulation
monocyte	O
chemotactic	O
protein	O
-	O
1	O
secretion	B-Localization
and	O
surface	O
expression	B-Gene_expression
of	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
on	O
endothelial	O
cells	O
[	O
see	O
comments	O
]	O

BACKGROUND	O
:	O
Platelet/endothelium	O
interaction	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
inflammation	O
and	O
atherosclerosis	O
.	O

The	O
role	B-Regulation
of	O
platelets	O
for	O
monocyte	O
chemotactic	O
protein	O
-	O
1	O
(	O
MCP	O
-	O
1	O
)	O
secretion	B-Localization
and	O
surface	O
expression	B-Gene_expression
of	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
on	O
endothelial	O
cells	O
has	O
been	O
assessed	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Monolayers	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
were	O
incubated	O
with	O
nonstimulated	O
or	O
ADP	O
-	O
activated	O
platelets	O
for	O
6	O
hours	O
,	O
and	O
secretion	B-Localization
of	O
MCP	O
-	O
1	O
and	O
surface	O
expression	B-Localization
of	O
ICAM	O
-	O
1	O
were	O
determined	O
by	O
ELISA	O
and	O
flow	O
cytometry	O
,	O
respectively	O
.	O

In	O
the	O
presence	O
of	O
ADP	O
-	O
activated	O
platelets	O
,	O
both	O
MCP	O
-	O
1	O
secretion	B-Localization
and	O
ICAM	O
-	O
1	O
surface	O
expression	B-Localization
were	O
significantly	O
increased	B-Positive_regulation
compared	O
with	O
nonstimulated	O
platelets	O
(	O
P	O
<	O
0.02	O
)	O
.	O

Activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
and	O
kappaB	O
-	O
dependent	O
transcriptional	O
activity	O
was	O
enhanced	O
in	O
the	O
presence	O
of	O
activated	O
platelets	O
.	O

In	O
addition	O
,	O
ADP	O
-	O
activated	O
platelets	O
induced	O
MCP	O
-	O
1	O
and	O
ICAM	O
-	O
1	O
promoter	O
-	O
dependent	O
transcription	O
.	O

Liposomal	O
transfection	O
of	O
a	O
double	O
-	O
stranded	O
kappaB	O
phosphorothioate	O
oligonucleotide	O
,	O
but	O
not	O
of	O
the	O
mutated	O
form	O
,	O
inhibited	B-Negative_regulation
MCP	O
-	O
1	O
secretion	B-Localization
and	O
surface	O
expression	B-Localization
of	O
ICAM	O
-	O
1	O
on	O
activated	O
endothelium	O
(	O
P	O
<	O
0.05	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
present	O
study	O
indicates	O
that	O
activated	O
platelets	O
modulate	B-Positive_regulation
chemotactic	O
(	O
MCP	O
-	O
1	O
)	O
and	O
adhesive	O
(	O
ICAM	O
-	O
1	O
)	O
properties	O
of	O
endothelial	O
cells	O
via	O
an	O
NF-kappaB	O
-	O
dependent	B-Regulation
mechanism	O
.	O

Platelet	O
-	O
induced	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
system	O
might	O
contribute	O
to	O
early	O
inflammatory	O
events	O
in	O
atherogenesis	O
.	O

Altered	O
DNA	O
-	O
binding	B-Binding
specificity	I-Binding
mutants	O
of	O
EKLF	O
and	O
Sp1	O
show	O
that	O
EKLF	O
is	O
an	O
activator	O
of	O
the	O
beta	O
-	O
globin	O
locus	O
control	O
region	O
in	O
vivo	O
.	O

The	O
locus	O
control	O
region	O
of	O
the	O
beta	O
-	O
globin	O
cluster	O
contains	O
five	O
DNase	O
I	O
hypersensitive	O
sites	O
(	O
5'HS1	O
-	O
5	O
)	O
required	B-Positive_regulation
for	O
locus	O
activation	B-Positive_regulation
.	O

5'HS3	O
contains	O
six	O
G	O
-	O
rich	O
motifs	O
that	O
are	O
essential	B-Positive_regulation
for	O
its	O
activity	O
.	O

Members	O
of	O
a	O
protein	O
family	O
,	O
characterized	O
by	O
three	O
zinc	O
fingers	O
highly	O
homologous	O
to	O
those	O
found	O
in	O
transcription	O
factor	O
Sp1	O
,	O
interact	B-Binding
with	O
these	O
motifs	O
.	O

Because	O
point	O
mutagenesis	O
can	O
not	O
distinguish	O
between	O
family	O
members	O
,	O
it	O
is	O
not	O
known	O
which	O
protein	O
activates	O
5'HS3	O
.	O

We	O
show	O
that	O
the	O
function	O
of	O
such	O
closely	O
related	O
proteins	O
can	O
be	O
distinguished	O
in	O
vivo	O
by	O
matching	O
point	O
mutations	O
in	O
5'HS3	O
with	O
amino	O
acid	O
changes	O
in	O
the	O
zinc	O
fingers	O
of	O
Sp1	O
and	O
EKLF	O
.	O

Testing	O
their	O
activity	O
in	O
transgenic	O
mice	O
shows	O
that	O
EKLF	O
is	O
a	O
direct	O
activator	O
of	O
5'HS3	O
.	O

Activation	B-Positive_regulation
of	O
distinct	O
transcription	O
factors	O
in	O
neutrophils	O
by	O
bacterial	O
LPS	O
,	O
interferon	O
-	O
gamma	O
,	O
and	O
GM	O
-	O
CSF	O
and	O
the	O
necessity	O
to	O
overcome	O
the	O
action	O
of	O
endogenous	O
proteases	O
.	O

Human	O
neutrophils	O
can	O
be	O
induced	B-Positive_regulation
to	O
actively	O
transcribe	B-Transcription
a	O
number	O
of	O
early	O
-	O
response	O
genes	O
,	O
in	O
particular	O
those	O
encoding	O
cytokines	O
,	O
chemokines	O
,	O
and	O
the	O
high	O
-	O
affinity	O
surface	O
receptor	O
for	O
IgG	O
,	O
FcgammaRI	O
.	O

Although	O
little	O
is	O
known	O
to	O
date	O
about	O
the	O
regulation	O
of	O
gene	O
transcription	O
in	O
neutrophils	O
,	O
several	O
indications	O
point	O
to	O
a	O
role	O
for	O
distinct	O
transcription	O
factors	O
,	O
such	O
as	O
members	O
of	O
the	O
NF	O
-	O
kappaB	O
and	O
STAT	O
families	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
these	O
transcription	O
factors	O
become	O
activated	O
under	O
stimulatory	O
conditions	O
which	O
are	O
known	O
to	O
induce	O
gene	O
transcription	O
in	O
neutrophils	O
.	O

Unexpectedly	O
,	O
we	O
found	O
that	O
conventional	O
procedures	O
employed	O
to	O
prepare	O
cellular	O
extracts	O
cause	O
the	O
release	O
of	O
proteolytic	O
activities	O
that	O
are	O
normally	O
stored	O
in	O
intracellular	O
granules	O
,	O
resulting	O
in	O
the	O
degradation	O
of	O
various	O
NF	O
-	O
kappaB/Rel	O
and	O
STAT	O
proteins	O
.	O

To	O
circumvent	O
this	O
problem	O
,	O
we	O
developed	O
an	O
alternative	O
procedure	O
which	O
allowed	O
us	O
to	O
show	O
that	O
in	O
neutrophils	O
,	O
LPS	O
and	O
TNFalpha	O
induce	O
a	O
NF	O
-	O
kappaB	O
DNA	O
-	O
binding	B-Binding
activity	O
which	O
essentially	O
consists	O
of	O
p50/RelA	O
dimers	O
,	O
and	O
that	O
IFNgamma	O
promotes	B-Positive_regulation
the	O
binding	B-Binding
of	O
STAT1	O
homodimers	O
to	O
the	O
IFNgamma	O
response	O
region	O
of	O
the	O
FcgammaRI	O
promoter	O
.	O

Moreover	O
,	O
we	O
report	O
that	O
neutrophil	O
stimulation	O
with	O
GM	O
-	O
CSF	O
results	O
in	O
the	O
formation	O
of	O
a	O
STAT5	O
-	O
containing	O
DNA	O
-	O
binding	O
activity	O
.	O

Collectively	O
,	O
the	O
current	O
findings	O
open	O
new	O
perspectives	O
about	O
mechanisms	O
that	O
are	O
likely	O
to	O
regulate	O
gene	O
transcription	O
in	O
neutrophils	O
.	O

In	O
addition	O
,	O
the	O
procedure	O
described	O
herein	O
could	O
prove	O
useful	O
in	O
other	O
cell	O
types	O
that	O
express	O
high	O
levels	O
of	O
endogenous	O
proteases	O
.	O

Transcription	O
factor	O
activation	O
in	O
lymphokine	O
activated	O
killer	O
cells	O
and	O
lymphocytes	O
from	O
patients	O
receiving	O
IL	O
-	O
2	O
immunotherapy	O
.	O

Administration	O
of	O
the	O
cytokine	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
can	O
result	O
in	O
therapeutic	O
benefits	O
for	O
individuals	O
with	O
renal	O
cell	O
carcinoma	O
and	O
melanoma	O
.	O

Here	O
we	O
report	O
an	O
analysis	O
of	O
the	O
transcription	O
factor	O
families	O
AP	O
-	O
1	O
,	O
Sp1	O
,	O
NF	O
-	O
kappaB	O
,	O
and	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
in	O
cancer	O
patients	O
'	O
lymphocytes	O
before	O
and	O
after	O
IL	O
-	O
2	O
immunotherapy	O
,	O
as	O
assessed	O
by	O
a	O
gel	O
-	O
shift	O
assay	O
.	O

An	O
in	O
vitro	O
surrogate	O
of	O
IL	O
-	O
2	O
immunotherapy	O
is	O
the	O
incubation	O
of	O
fresh	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
from	O
healthy	O
individuals	O
in	O
IL	O
-	O
2	O
for	O
several	O
days	O
,	O
resulting	O
in	O
the	O
production	O
of	O
lymphokine	O
-	O
activated	O
killer	O
(	O
LAK	O
)	O
activity	O
in	O
these	O
cultures	O
.	O

One	O
purpose	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
profile	O
of	O
transcription	O
factor	O
activation	O
in	O
these	O
different	O
populations	O
,	O
and	O
assess	O
whether	O
the	O
patterns	O
observed	O
correlated	O
with	O
functional	O
differences	O
in	O
these	O
cells	O
.	O

Prior	O
to	O
in	O
vivo	O
IL	O
-	O
2	O
administration	O
,	O
the	O
typical	O
binding	O
pattern	O
of	O
transcription	O
factors	O
in	O
PBMC	O
from	O
patients	O
resembled	O
that	O
seen	O
in	O
fresh	O
PBMC	O
from	O
healthy	O
individuals	O
.	O

Over	O
a	O
3	O
-	O
week	O
course	O
of	O
IL	O
-	O
2	O
therapy	O
,	O
in	O
most	O
patients	O
the	O
binding	B-Binding
patterns	O
of	O
AP	O
-	O
1	O
,	O
Sp1	O
,	O
and	O
NF	O
-	O
kappaB	O
proteins	O
changed	B-Positive_regulation
to	O
resemble	O
those	O
seen	O
in	O
PBMC	O
activated	O
by	O
IL	O
-	O
2	O
in	O
vitro	O
.	O

However	O
,	O
the	O
cells	O
obtained	O
from	O
IL-2	O
-	O
treated	O
patients	O
did	O
not	O
have	O
low	O
-	O
level	O
constitutive	O
expression	O
of	O
STAT	O
binding	O
factors	O
as	O
did	O
LAK	O
cells	O
.	O

When	O
these	O
patient	O
cells	O
were	O
further	O
stimulated	O
by	O
IL	O
-	O
2	O
in	O
vitro	O
,	O
additional	O
differences	O
in	O
STAT	O
induction	O
patterns	O
were	O
noted	O
.	O

These	O
data	O
provide	O
further	O
information	O
on	O
the	O
molecular	O
events	O
occurring	O
in	O
immune	O
cells	O
generated	O
through	O
in	O
vivo	O
and	O
in	O
vitro	O
administration	O
of	O
IL	O
-	O
2	O
,	O
and	O
further	O
document	O
that	O
there	O
is	O
not	O
a	O
precise	O
congruence	O
between	O
PBMC	O
activated	O
in	O
vivo	O
and	O
in	O
vitro	O
by	O
IL	O
-	O
2	O
.	O

A	O
critical	O
role	O
of	O
the	O
p75	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
p75TNF	O
-	O
R	O
)	O
in	O
organ	O
inflammation	O
independent	O
of	O
TNF	O
,	O
lymphotoxin	O
alpha	O
,	O
or	O
the	O
p55TNF	O
-	O
R	O
.	O

Despite	O
overwhelming	O
evidence	O
that	O
enhanced	B-Positive_regulation
production	B-Gene_expression
of	O
the	O
p75	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
p75TNF	O
-	O
R	O
)	O
accompanies	O
development	O
of	O
specific	O
human	O
inflammatory	O
pathologies	O
such	O
as	O
multi	O
-	O
organ	O
failure	O
during	O
sepsis	O
,	O
inflammatory	O
liver	O
disease	O
,	O
pancreatitis	O
,	O
respiratory	O
distress	O
syndrome	O
,	O
or	O
AIDS	O
,	O
the	O
function	O
of	O
this	O
receptor	O
remains	O
poorly	O
defined	O
in	O
vivo	O
.	O

We	O
show	O
here	O
that	O
at	O
levels	O
relevant	O
to	O
human	O
disease	O
,	O
production	B-Gene_expression
of	O
the	O
human	O
p75TNF	O
-	O
R	O
in	O
transgenic	O
mice	O
results	O
in	O
a	O
severe	O
inflammatory	O
syndrome	O
involving	O
mainly	O
the	O
pancreas	O
,	O
liver	O
,	O
kidney	O
,	O
and	O
lung	O
,	O
and	O
characterized	O
by	O
constitutively	O
increased	O
NF	O
-	O
kappaB	O
activity	O
in	O
the	O
peripheral	O
blood	O
mononuclear	O
cell	O
compartment	O
.	O

This	O
process	O
is	O
shown	O
to	O
evolve	B-Regulation
independently	I-Regulation
of	O
the	O
presence	O
of	O
TNF	O
,	O
lymphotoxin	O
alpha	O
,	O
or	O
the	O
p55TNF	O
-	O
R	O
,	O
although	O
coexpression	O
of	O
a	O
human	O
TNF	O
transgene	O
accelerated	O
pathology	O
.	O

These	O
results	O
establish	O
an	O
independent	O
role	O
for	O
enhanced	B-Positive_regulation
p75TNF	O
-	O
R	O
production	B-Gene_expression
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
disease	O
and	O
implicate	O
the	O
direct	O
involvement	O
of	O
this	O
receptor	O
in	O
a	O
wide	O
range	O
of	O
human	O
inflammatory	O
pathologies	O
.	O

Potent	O
inhibition	O
of	O
HIV	O
type	O
1	O
replication	O
by	O
an	O
antiinflammatory	O
alkaloid	O
,	O
cepharanthine	O
,	O
in	O
chronically	O
infected	O
monocytic	O
cells	O
.	O

Cepharanthine	O
is	O
a	O
biscoclaurine	O
alkaloid	O
isolated	O
from	O
Stephania	O
cepharantha	O
Hayata	O
and	O
has	O
been	O
shown	O
to	O
have	O
antiinflammatory	O
,	O
antiallergic	O
,	O
and	O
immunomodulatory	O
activities	O
in	O
vivo	O
.	O

As	O
several	O
inflammatory	O
cytokines	O
and	O
oxidative	O
stresses	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
HIV	O
-	O
1	O
infection	O
,	O
we	O
investigated	O
the	O
inhibitory	O
effects	O
of	O
cepharanthine	O
on	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
-	O
and	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
-	O
induced	O
HIV	O
-	O
1	O
replication	O
in	O
chronically	O
infected	O
cell	O
lines	O
.	O

Two	O
chronically	O
HIV-1	O
-	O
infected	O
cell	O
lines	O
,	O
U1	O
(	O
monocytic	O
)	O
and	O
ACH	O
-	O
2	O
(	O
T	O
lymphocytic	O
)	O
,	O
were	O
stimulated	O
with	O
TNF	O
-	O
alpha	O
or	O
PMA	O
and	O
cultured	O
in	O
the	O
presence	O
of	O
various	O
concentrations	O
of	O
the	O
compound	O
.	O

HIV	O
-	O
1	O
replication	O
was	O
determined	O
by	O
p24	O
antigen	O
level	O
.	O

The	O
inhibitory	O
effects	O
of	O
cepharanthine	O
on	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
-	O
driven	O
gene	O
expression	O
and	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
activation	O
were	O
also	O
examined	O
.	O

Cepharanthine	O
dose	O
dependently	O
inhibited	O
HIV	O
-	O
1	O
replication	O
in	O
TNF-alpha	O
-	O
and	O
PMA	O
-	O
stimulated	O
U1	O
cells	O
but	O
not	O
in	O
ACH	O
-	O
2	O
cells	O
.	O

Its	O
50	O
%	O
effective	O
and	O
cytotoxic	O
concentrations	O
were	O
0.016	O
and	O
2.2	O
microg/ml	O
in	O
PMA	O
-	O
stimulated	O
U1	O
cells	O
,	O
respectively	O
.	O

Cepharanthine	O
was	O
found	O
to	O
suppress	O
HIV	O
-	O
1	O
LTR	O
-	O
driven	O
gene	O
expression	O
through	O
the	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O

These	O
results	O
indicate	O
that	O
cepharanthine	O
is	O
a	O
highly	O
potent	O
inhibitor	O
of	O
HIV	O
-	O
1	O
replication	O
in	O
a	O
chronically	O
infected	O
monocytic	O
cell	O
line	O
.	O

Since	O
biscoclaurine	O
alkaloids	O
,	O
containing	O
cepharanthine	O
as	O
a	O
major	O
component	O
,	O
are	O
widely	O
used	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
various	O
inflammatory	O
diseases	O
in	O
Japan	O
,	O
cepharanthine	O
should	O
be	O
further	O
pursued	O
for	O
its	O
chemotherapeutic	O
potential	O
in	O
HIV-1	O
-	O
infected	O
patients	O
.	O

Prostaglandin	O
E2	O
Up	O
-	O
regulates	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
-	O
driven	O
gene	O
activity	O
in	O
T	O
cells	O
via	O
NF-kappaB	O
-	O
dependent	O
and	O
-	O
independent	O
signaling	O
pathways	O
.	O

Replication	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
-	O
1	O
(	O
HIV	O
-	O
1	O
)	O
is	O
highly	O
dependent	O
on	O
the	O
state	O
of	O
activation	O
of	O
the	O
infected	O
cells	O
and	O
is	O
modulated	O
by	O
interactions	O
between	O
viral	O
and	O
host	O
cellular	O
factors	O
.	O

Prostaglandin	O
E2	O
(	O
PGE2	O
)	O
,	O
a	O
pleiotropic	O
immunomodulatory	O
molecule	O
,	O
is	O
observed	O
at	O
elevated	O
levels	O
during	O
HIV	O
-	O
1	O
infection	O
as	O
well	O
as	O
during	O
the	O
course	O
of	O
other	O
pathogenic	O
infections	O
.	O

In	O
1G5	O
,	O
a	O
Jurkat	O
-	O
derived	O
T	O
cell	O
line	O
stably	O
transfected	O
with	O
a	O
luciferase	O
gene	O
driven	O
by	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
,	O
we	O
found	O
that	O
PGE2	O
markedly	O
enhanced	O
HIV	O
-	O
1	O
LTR	O
-	O
mediated	O
reporter	O
gene	O
activity	O
.	O

Experiments	O
have	O
been	O
conducted	O
to	O
identify	O
second	O
messengers	O
involved	O
in	O
this	O
PGE2	O
-	O
dependent	O
up	O
-	O
regulating	O
effect	O
on	O
the	O
regulatory	O
element	O
of	O
HIV	O
-	O
1	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
evidence	O
indicating	O
that	O
signal	O
transduction	O
pathways	O
induced	O
by	O
PGE2	O
necessitate	O
the	O
participation	O
of	O
cyclic	O
AMP	O
,	O
protein	O
kinase	O
A	O
,	O
and	O
Ca2+	O
.	O

Experiments	O
conducted	O
with	O
different	O
HIV	O
-	O
1	O
LTR	O
-	O
based	O
vectors	O
suggested	O
that	O
PGE2	O
-	O
mediated	O
activation	O
effect	O
on	O
HIV	O
-	O
1	O
transcription	O
was	O
transduced	O
via	O
both	O
NF-kappaB	O
-	O
dependent	O
and	O
-	O
independent	O
signaling	O
pathways	O
.	O

The	O
involvement	O
of	O
NF	O
-	O
kappaB	O
in	O
the	O
PGE2	O
-	O
dependent	O
activating	O
effect	O
on	O
HIV	O
-	O
1	O
transcription	O
was	O
further	O
confirmed	O
using	O
a	O
kappaB	O
-	O
regulated	O
luciferase	O
encoding	O
vector	O
and	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

Results	O
from	O
Northern	O
blot	O
and	O
flow	O
cytometric	O
analyses	O
,	O
as	O
well	O
as	O
the	O
use	O
of	O
a	O
selective	O
antagonist	O
indicated	O
that	O
PGE2	O
modulation	O
of	O
HIV	O
-	O
1	O
LTR	O
-	O
driven	O
reporter	O
gene	O
activity	O
in	O
studied	O
T	O
lymphoid	O
cells	O
is	O
transduced	O
via	O
the	O
EP4	O
receptor	O
subtype	O
.	O

These	O
results	O
suggest	O
that	O
secretion	O
of	O
PGE2	O
by	O
macrophages	O
in	O
response	O
to	O
infection	O
or	O
inflammatory	O
activators	O
could	O
induce	O
signaling	O
events	O
resulting	O
in	O
activation	O
of	O
proviral	O
DNA	O
present	O
into	O
T	O
cells	O
latently	O
infected	O
with	O
HIV	O
-	O
1	O
.	O

Fcgamma	O
receptor	O
-	O
mediated	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
activation	O
in	O
monocytes	O
is	O
independent	O
of	O
Ras	O
.	O

Receptors	O
for	O
the	O
Fc	O
portion	O
of	O
immunoglobulin	O
molecules	O
(	O
FcR	O
)	O
present	O
on	O
leukocyte	O
cell	O
membranes	O
mediate	O
a	O
large	O
number	O
of	O
cellular	O
responses	O
that	O
are	O
very	O
important	O
in	O
host	O
defense	O
,	O
including	O
phagocytosis	O
,	O
cell	O
cytotoxicity	O
,	O
production	O
and	O
secretion	O
of	O
inflammatory	O
mediators	O
,	O
and	O
modulation	O
of	O
the	O
immune	O
response	O
.	O

Cross	O
-	O
linking	O
of	O
FcR	O
with	O
immune	O
complexes	O
leads	O
,	O
first	O
to	O
activation	O
of	O
protein	O
-	O
tyrosine	O
kinases	O
.	O

The	O
molecular	O
events	O
that	O
follow	O
and	O
that	O
transduce	O
signals	O
from	O
these	O
receptors	O
to	O
the	O
nucleus	O
are	O
still	O
poorly	O
defined	O
.	O

We	O
have	O
investigated	O
the	O
signal	O
transduction	O
pathway	O
from	O
Fc	O
receptors	O
that	O
leads	O
to	O
gene	O
activation	O
and	O
production	O
of	O
cytokines	O
in	O
monocytes	O
.	O

Cross	O
-	O
linking	O
of	O
FcR	O
,	O
on	O
the	O
THP	O
-	O
1	O
monocytic	O
cell	O
line	O
,	O
by	O
immune	O
complexes	O
resulted	O
in	O
both	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
and	O
interleukin	O
1	O
production	O
.	O

These	O
responses	O
were	O
completely	O
blocked	O
by	O
tyrosine	O
kinase	O
inhibitors	O
.	O

In	O
contrast	O
,	O
expression	B-Gene_expression
of	O
dominant	O
negative	O
mutants	O
of	O
Ras	O
and	O
Raf	O
-	O
1	O
,	O
in	O
these	O
cells	O
,	O
did	O
not	O
have	O
any	O
effect	O
on	O
FcR	O
-	O
mediated	O
nuclear	O
factor	O
activation	O
,	O
suggesting	O
that	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
signaling	O
pathway	O
was	O
not	O
used	O
by	O
these	O
receptors	O
.	O

However	O
,	O
MAPK	O
activation	O
was	O
easily	O
detected	O
by	O
in	O
vitro	O
kinase	O
assays	O
,	O
after	O
FcR	O
cross	O
-	O
linking	O
with	O
immune	O
complexes	O
.	O

Using	O
the	O
specific	O
MAPK/extracellular	O
signal	O
-	O
regulated	O
kinase	O
kinase	O
(	O
MAPK	O
kinase	O
)	O
inhibitor	O
PD98059	O
,	O
we	O
found	O
that	O
MAPK	O
activation	O
is	O
necessary	O
for	O
FcR	O
-	O
dependent	O
activation	O
of	O
the	O
nuclear	O
factor	O
NF	O
-	O
kappaB	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
the	O
signaling	O
pathway	O
from	O
Fc	O
receptors	O
leading	O
to	O
expression	O
of	O
different	O
genes	O
important	O
to	O
leukocyte	O
biology	O
,	O
initiates	O
with	O
tyrosine	O
kinases	O
and	O
requires	O
MAPK	O
activation	O
;	O
but	O
in	O
contrast	O
to	O
other	O
tyrosine	O
kinase	O
receptors	O
,	O
FcR	O
-	O
mediated	O
MAPK	O
activation	O
does	O
not	O
involve	O
Ras	O
and	O
Raf	O
.	O

Differential	O
RNA	O
display	O
identifies	O
novel	O
genes	O
associated	O
with	O
decreased	B-Negative_regulation
vitamin	O
D	O
receptor	O
expression	B-Gene_expression
.	O

To	O
characterize	O
further	O
the	O
function	O
of	O
the	O
intracellular	O
vitamin	O
D	O
receptor	O
(	O
VDR	O
)	O
,	O
we	O
have	O
developed	O
stable	O
transfectant	O
variants	O
of	O
a	O
vitamin	O
D	O
-	O
responsive	O
cell	O
line	O
(	O
U937	O
)	O
which	O
express	B-Gene_expression
either	O
decreased	O
or	O
increased	B-Positive_regulation
numbers	I-Positive_regulation
of	O
VDR	O
.	O

In	O
this	O
study	O
we	O
have	O
analyzed	O
changes	O
in	O
gene	O
expression	O
associated	O
with	O
this	O
variable	O
VDR	O
expression	B-Gene_expression
.	O

Initial	O
experiments	O
indicated	O
that	O
a	O
50	O
%	O
decrease	B-Negative_regulation
in	O
VDR	O
levels	O
was	O
associated	O
with	O
a	O
2	O
-	O
fold	O
increase	O
in	O
cell	O
proliferation	O
and	O
a	O
similar	O
rise	B-Positive_regulation
in	O
c	O
-	O
myc	O
mRNA	O
expression	B-Transcription
.	O

Further	O
studies	O
were	O
carried	O
out	O
using	O
differential	O
RNA	O
display	O
(	O
DD	O
)	O
.	O

Sequence	O
analysis	O
of	O
DD	O
products	O
revealed	O
two	O
cDNAs	O
with	O
identity	O
to	O
known	O
gene	O
products	O
:	O
the	O
catalytic	O
sub	O
-	O
unit	O
of	O
DNA	O
-	O
protein	O
kinase	O
(	O
DNA	O
-	O
PK	O
(	O
CS	O
)	O
)	O
,	O
and	O
the	O
peroxisomal	O
enzyme	O
17beta	O
-	O
hydroxysteroid	O
dehydrogenase	O
type	O
IV	O
(	O
17beta	O
-	O
HSD	O
IV	O
)	O
.	O

Northern	O
analysis	O
confirmed	O
that	O
expression	B-Transcription
of	O
both	O
mRNAs	O
was	O
reduced	B-Negative_regulation
in	O
cells	O
with	O
decreased	B-Negative_regulation
numbers	I-Negative_regulation
of	O
VDR	O
.	O

Down	B-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
of	O
17beta	O
-	O
HSD	O
IV	O
mRNA	O
expression	B-Transcription
was	O
associated	O
with	O
enhanced	O
estradiol	O
inactivation	O
by	O
U937	O
cells	O
,	O
suggesting	O
a	O
link	O
between	O
estrogenic	O
pathways	O
and	O
cell	O
proliferation	O
.	O

Further	O
Northern	O
analyses	O
indicated	O
that	O
there	O
was	O
no	O
significant	O
change	B-Regulation
in	O
17beta	O
-	O
HSD	O
IV	O
or	O
DNA	O
-	O
PK	O
(	O
CS	O
)	O
mRNA	O
levels	O
following	O
treatment	O
with	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
although	O
expression	B-Gene_expression
of	O
both	O
genes	O
varied	O
with	O
changes	O
in	O
cell	O
proliferation	O
.	O

These	O
data	O
suggest	O
that	O
,	O
in	O
addition	O
to	O
its	O
established	O
role	O
as	O
a	O
hormone	O
-	O
dependent	O
trans	O
-	O
activator	O
,	O
VDR	O
may	O
influence	O
gene	O
expression	O
by	O
ligand	O
-	O
independent	O
mechanisms	O
.	O

Downstream	O
activation	O
of	O
a	O
TATA	O
-	O
less	O
promoter	O
by	O
Oct	O
-	O
2	O
,	O
Bob1	O
,	O
and	O
NF	O
-	O
kappaB	O
directs	B-Positive_regulation
expression	B-Gene_expression
of	O
the	O
homing	O
receptor	O
BLR1	O
to	O
mature	O
B	O
cells	O
.	O

The	O
chemokine	O
receptor	O
,	O
BLR1	O
,	O
is	O
a	O
major	O
regulator	O
of	O
the	O
microenvironmental	O
homing	O
of	O
B	O
cells	O
in	O
lymphoid	O
organs	O
.	O

In	O
vitro	O
studies	O
identify	O
three	O
essential	O
elements	O
of	O
the	O
TATA	O
-	O
less	O
blr1	O
core	O
promoter	O
that	O
confer	B-Positive_regulation
cell	O
type	O
-	O
and	O
differentiation	O
-	O
specific	O
expression	B-Gene_expression
in	O
the	O
B	O
cells	O
of	O
both	O
humans	O
and	O
mice	O
,	O
a	O
functional	O
promoter	O
region	O
(	O
-	O
36	O
with	O
respect	O
to	O
the	O
transcription	O
start	O
site	O
)	O
,	O
a	O
NF	O
-	O
kappaB	O
motif	O
(	O
+44	O
)	O
,	O
and	O
a	O
noncanonical	O
octamer	O
motif	O
(	O
+157	O
)	O
.	O

The	O
importance	O
of	O
these	O
sites	O
was	O
confirmed	O
by	O
in	O
vivo	O
studies	O
in	O
gene	O
-	O
targeted	O
mice	O
deficient	O
of	O
either	O
Oct	O
-	O
2	O
,	O
Bob1	O
,	O
or	O
both	O
NF	O
-	O
kappaB	O
subunits	O
p50	O
and	O
p52	O
.	O

In	O
all	O
of	O
these	O
animals	O
,	O
the	O
expression	B-Gene_expression
of	O
BLR1	O
was	O
reduced	B-Negative_regulation
or	O
absent	O
.	O

In	O
mice	O
deficient	O
only	O
of	O
p52/NF	O
-	O
kappaB	O
,	O
BLR1	O
expression	B-Gene_expression
was	O
unaffected	B-Regulation
.	O

Thus	O
our	O
data	O
demonstrate	O
that	O
BLR1	O
is	O
a	O
target	B-Regulation
gene	O
for	O
Oct	O
-	O
2	O
,	O
Bob1	O
,	O
and	O
members	O
of	O
the	O
NF	O
-	O
kappaB/Rel	O
family	O
and	O
provides	O
a	O
link	O
to	O
the	O
impaired	O
B	O
cell	O
functions	O
in	O
mice	O
deficient	B-Gene_expression
for	O
these	O
factors	O
.	O

Interaction	O
of	O
sickle	O
erythrocytes	O
with	O
endothelial	O
cells	O
in	O
the	O
presence	O
of	O
endothelial	O
cell	O
conditioned	O
medium	O
induces	O
oxidant	O
stress	O
leading	O
to	O
transendothelial	O
migration	O
of	O
monocytes	O
.	O

The	O
abnormal	O
adherence	O
of	O
sickle	O
red	O
blood	O
cells	O
(	O
SS	O
RBC	O
)	O
to	O
endothelial	O
cells	O
has	O
been	O
thought	O
to	O
contribute	O
to	O
vascular	O
occlusion	O
,	O
a	O
major	O
cause	O
of	O
morbidity	O
in	O
sickle	O
cell	O
disease	O
(	O
SCD	O
)	O
.	O

We	O
determined	O
whether	O
the	O
interaction	O
of	O
SS	O
RBC	O
with	O
cultured	O
endothelial	O
cells	O
induced	O
cellular	O
oxidant	O
stress	O
that	O
would	O
culminate	O
in	O
expression	O
of	O
cell	O
adhesion	O
molecules	O
(	O
CAMs	O
)	O
involved	O
in	O
the	O
adhesion	O
and	O
diapedesis	O
of	O
monocytes	O
and	O
the	O
adherence	O
of	O
SS	O
reticulocytes	O
.	O

We	O
showed	O
that	O
the	O
interaction	O
of	O
SS	O
RBC	O
at	O
2	O
%	O
concentration	O
in	O
the	O
presence	O
of	O
multimers	B-Binding
of	O
von	O
Willebrand	O
factor	O
(	O
vWf	O
)	O
,	O
derived	O
from	O
endothelial	O
cell	O
-	O
derived	O
conditioned	O
medium	O
(	O
E	O
-	O
CM	O
)	O
with	O
cultured	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
,	O
resulted	O
in	O
a	O
fivefold	O
increased	O
formation	O
of	O
thiobarbituric	O
acid	O
-	O
reactive	O
substances	O
(	O
TBARS	O
)	O
and	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kB	O
,	O
both	O
indicators	O
of	O
cellular	O
oxidant	O
stress	O
.	O

Normal	O
RBC	O
show	O
none	O
of	O
these	O
phenomena	O
.	O

The	O
oxidant	O
stress	O
-	O
induced	O
signaling	O
resulted	B-Positive_regulation
in	I-Positive_regulation
an	I-Positive_regulation
increased	I-Positive_regulation
surface	O
expression	B-Localization
of	O
a	O
subset	O
of	O
CAMs	O
,	O
ICAM	O
-	O
1	O
,	O
E	O
-	O
selectin	O
,	O
and	O
VCAM	O
-	O
1	O
in	O
HUVEC	O
.	O

The	O
addition	O
of	O
oxygen	O
radical	O
scavenger	O
enzymes	O
(	O
catalase	O
,	O
superoxide	O
dismutase	O
)	O
and	O
antioxidant	O
(	O
probucol	O
)	O
inhibited	B-Negative_regulation
these	O
events	O
.	O

Additionally	O
,	O
preincubation	O
of	O
HUVEC	O
with	O
a	O
synthetic	O
peptide	O
Arg-Gly	O
-	O
Asp	O
(	O
RGD	O
)	O
that	O
prevents	O
vWf	O
-	O
mediated	O
adhesion	O
of	O
SS	O
RBC	O
reduced	B-Negative_regulation
the	O
surface	O
expression	B-Gene_expression
of	O
VCAM	O
-	O
1	O
and	O
NF	O
-	O
kB	O
activation	O
.	O

Furthermore	O
,	O
SS	O
RBC	O
-	O
induced	O
oxidant	O
stress	O
resulted	O
in	O
a	O
twofold	O
increase	O
in	O
the	O
transendothelial	O
migration	O
of	O
both	O
monocyte	O
-	O
like	O
HL	O
-	O
60	O
cells	O
and	O
human	O
peripheral	O
blood	O
monocytes	O
,	O
and	O
approximately	O
a	O
sixfold	O
increase	B-Positive_regulation
in	O
platelet	O
-	O
endothelial	O
cell	O
adhesion	O
molecule	O
-	O
1	O
(	O
PECAM	O
-	O
1	O
)	O
phosphorylation	B-Phosphorylation
,	O
each	O
of	O
which	O
was	O
blocked	B-Negative_regulation
by	O
protein	O
kinase	O
C	O
inhibitor	O
and	O
antioxidants	O
.	O

These	O
results	O
suggest	O
that	O
the	O
adherence/contact	O
of	O
SS	O
RBC	O
to	O
endothelial	O
cells	O
in	O
large	O
vessel	O
can	O
generate	O
enhanced	O
oxidant	O
stress	O
leading	O
to	O
increased	O
adhesion	O
and	O
diapedesis	O
of	O
monocytes	O
,	O
as	O
well	O
as	O
heightened	O
adherence	O
of	O
SS	O
reticulocytes	O
,	O
indicating	O
that	O
injury/activation	O
of	O
endothelium	O
can	O
contribute	O
to	O
vaso	O
-	O
occlusion	O
in	O
SCD	O
.	O

Tobacco	O
smoke	O
induces	O
coordinate	O
activation	O
of	O
HSF	O
and	O
inhibition	O
of	O
NFkappaB	O
in	O
human	O
monocytes	O
:	O
effects	B-Regulation
on	O
TNFalpha	O
release	B-Localization
.	O

Tobacco	O
smoke	O
(	O
TS	O
)	O
exposure	O
is	O
a	O
major	O
risk	O
factor	O
for	O
human	O
disease	O
,	O
and	O
macrophages	O
of	O
healthy	O
smokers	O
have	O
a	O
depressed	O
capacity	O
to	O
release	O
cytokines	O
,	O
including	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
alpha	O
.	O

TS	O
induces	O
the	O
synthesis	O
of	O
heat	O
shock	O
(	O
HS	O
)	O
/stress	O
proteins	O
(	O
HSP	O
)	O
,	O
and	O
,	O
in	O
particular	O
,	O
of	O
Hsp70	O
.	O

We	O
determined	O
whether	O
Hsp70	O
induction	O
by	O
TS	O
was	O
mediated	O
by	O
the	O
activation	O
of	O
the	O
HS	O
transcription	O
factor	O
,	O
HSF	O
.	O

HSF	O
activation	O
has	O
been	O
shown	O
to	O
inhibit	O
NFkappaB	O
.	O

Thus	O
,	O
we	O
also	O
determined	O
the	O
effects	O
of	O
TS	O
on	O
NFkappaB	O
.	O

U937	O
cells	O
and	O
human	O
peripheral	O
blood	O
monocytes	O
were	O
exposed	O
to	O
TS	O
,	O
binding	O
activities	O
of	O
the	O
respective	O
transcription	O
factors	O
were	O
analyzed	O
,	O
and	O
Hsp70	O
expression	O
and	O
TNFalpha	O
release	B-Localization
were	O
determined	O
in	O
parallel	O
.	O

TS	O
activated	O
HSF	O
,	O
which	O
was	O
associated	O
with	O
Hsp70	O
overexpression	O
and	O
inhibition	O
of	O
NFkappaB	O
binding	O
activity	O
and	O
TNFalpha	O
release	B-Localization
.	O

The	O
altered	O
cytokine	O
profile	O
observed	O
in	O
smokers	O
may	O
relate	O
to	O
an	O
HSF/Hsp70	O
-	O
mediated	O
inhibition	O
of	O
NFkappaB	O
activity	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Transcriptional	B-Regulation
regulation	I-Regulation
of	O
the	O
beta	O
-	O
casein	O
gene	O
by	O
cytokines	O
:	O
cross	O
-	O
talk	O
between	O
STAT5	O
and	O
other	O
signaling	O
molecules	O
.	O

The	O
beta	O
-	O
casein	O
promoter	O
has	O
been	O
widely	O
used	O
to	O
monitor	O
the	O
activation	B-Positive_regulation
of	O
STAT	O
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
)	O
5	O
since	O
STAT5	O
was	O
originally	O
found	O
as	O
a	O
mediator	B-Positive_regulation
of	O
PRL	O
-	O
inducible	B-Positive_regulation
beta	O
-	O
casein	O
expression	B-Gene_expression
.	O

However	O
,	O
not	O
only	O
is	O
expression	B-Gene_expression
of	O
the	O
beta	O
-	O
casein	O
gene	O
regulated	B-Regulation
by	O
STAT5	O
but	O
it	O
is	O
also	O
affected	B-Regulation
by	O
other	O
molecules	O
such	O
as	O
glucocorticoid	O
and	O
Ras	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
transcriptional	B-Regulation
regulation	I-Regulation
of	O
the	O
beta	O
-	O
casein	O
gene	O
by	O
cytokines	O
in	O
T	O
cells	O
.	O

We	O
have	O
found	O
that	O
the	O
beta	O
-	O
casein	O
gene	O
is	O
expressed	B-Gene_expression
in	O
a	O
cytotoxic	O
T	O
cell	O
line	O
,	O
CTLL	O
-	O
2	O
,	O
in	B-Positive_regulation
response	I-Positive_regulation
to	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
,	O
which	O
activates	B-Positive_regulation
STAT5	O
.	O

While	O
IL	O
-	O
4	O
does	O
not	O
activate	B-Positive_regulation
STAT5	O
,	O
it	O
induces	B-Positive_regulation
expression	B-Gene_expression
of	O
STAT5	O
-	O
regulated	B-Regulation
genes	O
in	O
CTLL	O
-	O
2	O
,	O
i.e.	O
beta	O
-	O
casein	O
,	O
a	O
cytokine	O
-	O
inducible	O
SH2	O
-	O
containing	O
protein	O
(	O
CIS	O
)	O
,	O
and	O
oncostatin	O
M	O
(	O
OSM	O
)	O
,	O
suggesting	O
that	O
STAT6	O
activated	B-Positive_regulation
by	O
IL	O
-	O
4	O
substitutes	O
for	O
the	O
function	O
of	O
STAT5	O
in	O
T	O
cells	O
.	O

IL-2	O
-	O
induced	B-Positive_regulation
beta	O
-	O
casein	O
expression	B-Gene_expression
was	O
enhanced	B-Positive_regulation
by	O
dexamethasone	O
,	O
and	O
this	O
synergistic	O
effect	O
of	O
Dexamethasone	O
requires	O
the	O
sequence	O
between	O
-	O
155	O
and	O
-	O
193	O
in	O
the	O
beta	O
-	O
casein	O
promoter	O
.	O

Coincidentally	O
,	O
a	O
deletion	B-Negative_regulation
of	O
this	O
region	O
enhanced	B-Positive_regulation
the	O
IL-2	O
-	O
induced	B-Positive_regulation
expression	B-Gene_expression
of	O
beta	O
-	O
casein	O
.	O

Expression	B-Gene_expression
of	O
an	O
active	O
form	O
of	O
Ras	O
,	O
Ras	O
(	O
G12V	O
)	O
,	O
suppressed	B-Negative_regulation
the	O
IL-2	O
-	O
induced	B-Positive_regulation
beta	O
-	O
casein	O
and	O
OSM	O
gene	O
expression	B-Gene_expression
,	O
and	O
the	O
negative	O
effect	O
of	O
Ras	O
is	O
mediated	B-Positive_regulation
by	O
the	O
region	O
between	O
-	O
105	O
and	O
-	O
193	O
in	O
the	O
beta	O
-	O
casein	O
promoter	O
.	O

In	O
apparent	O
contradiction	O
,	O
expression	O
of	O
a	O
dominant	O
negative	O
form	O
of	O
Ras	O
,	O
RasN17	O
,	O
also	O
inhibited	B-Negative_regulation
IL-2	O
-	O
induced	O
activation	B-Positive_regulation
of	O
the	O
promoter	O
containing	O
the	O
minimal	O
beta	O
-	O
casein	O
STAT5	O
element	O
as	O
well	O
as	O
the	O
promoters	O
of	O
CIS	O
and	O
OSM	O
.	O

In	O
addition	O
,	O
Ras	O
(	O
G12V	O
)	O
complemented	O
signaling	O
by	O
an	O
erythropoietin	O
receptor	O
mutant	O
defective	O
in	O
Ras	O
activation	O
and	O
augmented	B-Positive_regulation
the	O
activation	B-Positive_regulation
of	O
the	O
beta	O
-	O
casein	O
promoter	O
by	O
the	O
mutant	O
erythropoietin	O
receptor	O
signaling	B-Regulation
,	O
suggesting	O
a	O
possible	O
role	O
of	O
Ras	O
in	O
Stat5	O
-	O
mediated	O
gene	O
expression	O
.	O

These	O
results	O
collectively	O
reveal	O
a	O
complex	O
interaction	O
of	O
STAT5	O
with	O
other	O
signaling	O
pathways	O
and	O
illustrate	O
that	O
regulation	O
of	O
gene	O
expression	O
requires	O
integration	O
of	O
opposing	O
signals	O
.	O

Transcription	O
factor	O
NF	O
-	O
kappaB	O
regulation	O
of	O
renal	O
fibrosis	O
during	O
ureteral	O
obstruction	O
.	O

Irrespective	O
of	O
the	O
etiology	O
,	O
many	O
kidney	O
diseases	O
result	O
in	O
inflammation	O
and	O
fibrosis	O
of	O
the	O
tubulointerstitium	O
,	O
with	O
the	O
subsequent	O
loss	O
of	O
renal	O
function	O
.	O

To	O
initiate	O
any	O
disease	O
process	O
or	O
for	O
any	O
disease	O
process	O
to	O
progress	O
,	O
there	O
must	O
be	O
changes	O
in	O
the	O
transcription	O
of	O
genes	O
within	O
the	O
affected	O
tissue	O
.	O

The	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
family	O
of	O
transcription	O
factors	O
regulates	O
genes	O
involved	O
in	O
inflammation	O
,	O
cell	O
proliferation	O
,	O
and	O
cell	O
differentiation	O
.	O

This	O
review	O
discusses	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
family	O
in	O
general	O
and	O
the	O
association	O
of	O
NF	O
-	O
kappaB	O
activation	O
with	O
cellular/molecular	O
events	O
of	O
renal	O
inflammation	O
and	O
fibrosis	O
.	O

TAL1	O
and	O
LIM	O
-	O
only	O
proteins	O
synergistically	O
induce	B-Positive_regulation
retinaldehyde	O
dehydrogenase	O
2	O
expression	B-Gene_expression
in	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
by	O
acting	O
as	O
cofactors	O
for	O
GATA3	O
.	O

Previously	O
,	O
we	O
have	O
shown	O
that	O
TAL1	O
and	O
the	O
LIM	O
-	O
only	O
protein	O
gene	O
(	O
LMO	O
)	O
are	O
regularly	O
coactivated	B-Positive_regulation
in	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T	O
-	O
ALL	O
)	O
.	O

This	O
observation	O
is	O
likely	O
to	O
relate	O
to	O
the	O
findings	O
that	O
TAL1	O
and	O
LMO	O
are	O
highly	O
synergistic	O
in	O
T	O
-	O
cell	O
tumorigenesis	O
in	O
double	O
-	O
transgenic	O
mice	O
.	O

To	O
understand	O
the	O
molecular	O
mechanisms	O
of	O
functional	O
synergy	O
between	O
TAL1	O
and	O
LMO	O
in	O
tumorigenesis	O
and	O
transcriptional	O
regulation	O
,	O
we	O
tried	O
to	O
identify	O
downstream	O
target	O
genes	O
regulated	O
by	O
TAL1	O
and	O
LMO	O
by	O
a	O
subtractive	O
PCR	O
method	O
.	O

One	O
of	O
the	O
isolated	O
genes	O
,	O
that	O
for	O
retinaldehyde	O
dehydrogenase	O
2	O
(	O
RALDH2	O
)	O
,	O
was	O
regularly	O
expressed	B-Gene_expression
in	O
most	O
of	O
the	O
T	O
-	O
ALL	O
cell	O
lines	O
that	O
coexpressed	B-Gene_expression
TAL1	O
and	O
LMO	O
.	O

Exogenously	O
transfected	B-Positive_regulation
TAL1	O
and	O
LMO	O
,	O
but	O
not	O
either	O
alone	O
,	O
induced	B-Positive_regulation
RALDH2	O
expression	B-Gene_expression
in	O
a	O
T	O
-	O
ALL	O
cell	O
line	O
,	O
HPB	O
-	O
ALL	O
,	O
not	O
expressing	B-Gene_expression
endogeneous	O
TAL1	O
or	O
LMO	O
.	O

The	O
RALDH2	O
transcripts	O
in	O
T	O
-	O
ALL	O
were	O
,	O
however	O
,	O
mostly	O
initiated	B-Transcription
within	O
the	O
second	O
intron	O
.	O

Promoter	O
analysis	O
revealed	O
that	O
a	O
GATA	O
site	O
in	O
a	O
cryptic	O
promoter	O
in	O
the	O
second	O
intron	O
was	O
essential	O
and	O
sufficient	O
for	O
the	O
TAL1	O
-	O
and	O
LMO	O
-	O
dependent	O
transcriptional	O
activation	O
,	O
and	O
GATA3	O
binds	B-Binding
to	O
this	O
site	O
.	O

In	O
addition	O
,	O
forced	B-Positive_regulation
expression	B-Gene_expression
of	O
GATA3	O
potentiated	B-Positive_regulation
the	O
induction	B-Positive_regulation
of	O
RALDH2	O
by	O
TAL1	O
and	O
LMO	O
,	O
and	O
these	O
three	O
factors	O
formed	B-Binding
a	I-Binding
complex	I-Binding
in	O
vivo	O
.	O

Furthermore	O
,	O
a	O
TAL1	O
mutant	O
not	O
binding	B-Binding
to	O
DNA	O
also	O
activated	B-Positive_regulation
the	O
transcription	B-Transcription
of	O
RALDH2	O
in	B-Positive_regulation
the	I-Positive_regulation
presence	I-Positive_regulation
of	I-Positive_regulation
LMO	O
and	O
GATA3	O
.	O

Collectively	O
,	O
we	O
have	O
identified	O
the	O
RALDH2	O
gene	O
as	O
a	O
first	O
example	O
of	O
direct	O
transcriptional	O
target	O
genes	O
regulated	B-Regulation
by	O
TAL1	O
and	O
LMO	O
in	O
T	O
-	O
ALL	O
.	O

In	O
this	O
case	O
,	O
TAL1	O
and	O
LMO	O
act	O
as	O
cofactors	O
for	O
GATA3	O
to	O
activate	B-Positive_regulation
the	O
transcription	B-Transcription
of	O
RALDH2	O
.	O

Granulocyte	O
colony	O
-	O
stimulating	O
factor	O
activates	O
a	O
72	O
-	O
kDa	O
isoform	O
of	O
STAT3	O
in	O
human	O
neutrophils	O
.	O

Granulocyte	O
colony	O
-	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)	O
signaling	O
involves	O
activation	O
of	O
STATs	O
,	O
proteins	O
that	O
serve	O
the	O
dual	O
function	O
of	O
signal	O
transduction	O
and	O
activation	O
of	O
transcription	O
.	O

We	O
previously	O
demonstrated	O
that	O
G	O
-	O
CSF	O
activated	B-Positive_regulation
a	O
distinct	O
Stat3	O
-	O
like	O
protein	O
in	O
immature	O
and	O
mature	O
normal	O
myeloid	O
cells	O
,	O
StatG	O
.	O

StatG	O
in	O
normal	O
immature	O
human	O
myeloid	O
cells	O
,	O
i.e.	O
adult	O
CD34+	O
bone	O
marrow	O
cells	O
,	O
was	O
composed	O
of	O
Stat3beta	O
.	O

This	O
investigation	O
was	O
undertaken	O
to	O
determine	O
the	O
composition	O
of	O
StatG	O
in	O
mature	O
normal	O
human	O
myeloid	O
cells	O
,	O
i.e.	O
polymorphonuclear	O
neutrophilic	O
granulocytes	O
(	O
PMN	O
)	O
.	O

These	O
studies	O
revealed	O
that	O
the	O
major	O
protein	O
in	O
extracts	O
of	O
PMN	O
activated	O
by	O
G	O
-	O
CSF	O
to	O
bind	O
the	O
high	O
-	O
affinity	O
serum	O
-	O
inducible	O
element	O
(	O
hSIE	O
)	O
is	O
a	O
72	O
-	O
kDa	O
protein	O
that	O
cross	B-Binding
-	I-Binding
reacts	I-Binding
with	O
Stat3	O
monoclonal	O
antibody	O
,	O
which	O
we	O
have	O
designated	O
Stat3gamma	O
.	O

Stat3gamma	O
is	O
derived	B-Positive_regulation
from	O
Stat3alpha	O
by	O
limited	O
proteolysis	B-Protein_catabolism
and	O
lacks	O
the	O
carboxyl	O
-	O
terminal	O
portion	O
of	O
Stat3alpha	O
.	O

Because	O
this	O
region	O
of	O
Stat3alpha	O
is	O
involved	O
in	O
transcriptional	O
activation	O
,	O
our	O
findings	O
suggest	O
the	O
possibility	O
that	O
Stat3gamma	O
may	O
be	O
transcriptionally	O
inactive	O
and	O
may	O
compete	B-Negative_regulation
with	O
Stat3alpha	O
for	O
Stat3	O
binding	B-Binding
sites	O
in	O
these	O
terminally	O
differentiated	O
myeloid	O
cells	O
.	O

Differential	O
effects	B-Regulation
of	O
protein	O
kinase	O
C	O
inhibitors	O
on	O
fibronectin	O
-	O
induced	B-Positive_regulation
interleukin	O
-	O
beta	O
gene	O
transcription	B-Transcription
,	O
protein	O
synthesis	O
and	O
secretion	B-Localization
in	O
human	O
monocytic	O
cells	O
.	O

Human	O
monocytic	O
cells	O
express	B-Gene_expression
interleukin	O
-	O
1beta	O
(	O
IL	O
-	O
1beta	O
)	O
when	B-Positive_regulation
stimulated	O
with	O
the	O
extracellular	O
matrix	O
glycoprotein	O
,	O
fibronectin	O
(	O
FN	O
)	O
.	O

Protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activation	O
is	O
considered	O
important	B-Positive_regulation
for	O
this	O
process	O
;	O
however	O
,	O
the	O
metabolic	O
steps	O
at	O
which	O
PKC	O
acts	B-Positive_regulation
upon	I-Positive_regulation
to	I-Positive_regulation
mediate	I-Positive_regulation
the	O
FN	O
-	O
induced	B-Positive_regulation
IL	O
-	O
1beta	O
response	O
remain	O
unclear	O
.	O

We	O
performed	O
an	O
analysis	O
of	O
the	O
mechanisms	O
by	O
which	O
two	O
PKC	O
inhibitors	O
,	O
Calphostin	O
C	O
and	O
Staurosporine	O
,	O
prevent	B-Negative_regulation
the	O
FN	O
-	O
induced	B-Positive_regulation
IL	O
-	O
1beta	O
response	O
.	O

Both	O
inhibitors	O
blocked	B-Negative_regulation
the	O
secretion	B-Localization
of	O
IL	O
-	O
1beta	O
protein	O
into	B-Positive_regulation
the	O
media	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
exposed	O
to	O
FN	O
.	O

Immunoprecipitation	O
analysis	O
revealed	O
that	O
under	O
these	O
circumstances	O
,	O
Calphostin	O
C	O
inhibited	B-Negative_regulation
the	O
production	B-Gene_expression
of	O
IL	O
-	O
1beta	O
protein	O
,	O
whereas	O
Staurosporine	O
allowed	B-Negative_regulation
protein	O
production	B-Gene_expression
,	O
but	O
inhibited	B-Negative_regulation
its	O
secretion	B-Localization
.	O

To	O
determine	O
the	O
mechanisms	O
responsible	O
for	O
these	O
differences	O
,	O
we	O
turned	O
to	O
human	O
U937	O
promonocytic	O
cells	O
.	O

U937	O
cells	O
transfected	O
with	O
the	O
human	O
full	O
-	O
length	O
IL	O
-	O
1beta	O
promoter	O
connected	O
to	O
a	O
luciferase	O
reporter	O
gene	O
were	O
submitted	O
to	O
transcription	O
assays	O
,	O
Northern	O
blotting	O
,	O
and	O
DNA	O
electrophoresis	O
mobility	O
gel	O
shift	O
assays	O
.	O

These	O
studies	O
revealed	O
that	O
Calphostin	O
C	O
inhibited	O
the	O
nuclear	O
translocation	O
of	O
the	O
transcription	O
factor	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
which	O
is	O
considered	O
necessary	B-Positive_regulation
for	O
FN	O
induction	B-Positive_regulation
of	O
IL	O
-	O
1beta	O
gene	O
transcription	B-Transcription
,	O
and	O
prevented	B-Negative_regulation
the	O
transcription	B-Transcription
of	O
the	O
IL	O
-	O
1beta	O
gene	O
.	O

In	O
contrast	O
,	O
Staurosporine	O
alone	O
induced	B-Positive_regulation
AP	O
-	O
1	O
translocation	O
and	O
stimulation	B-Positive_regulation
of	O
the	O
gene	O
.	O

Overall	O
,	O
our	O
data	O
indicate	O
that	O
Calphostin	O
C	O
prevents	B-Negative_regulation
the	O
transcription	B-Transcription
of	O
the	O
IL	O
-	O
1beta	O
gene	O
thereby	O
inhibiting	B-Negative_regulation
protein	O
synthesis	B-Gene_expression
.	O

Based	O
on	O
the	O
high	O
specificity	O
of	O
this	O
compound	O
for	O
PKC	O
,	O
we	O
conclude	O
that	O
PKC	O
is	O
necessary	B-Positive_regulation
for	O
FN	O
-	O
induced	B-Positive_regulation
IL	O
-	O
1beta	O
protein	O
production	B-Gene_expression
.	O

In	O
contrast	O
,	O
Staurosporine	O
prevented	B-Negative_regulation
secretion	B-Localization
of	O
IL	O
-	O
1beta	O
by	O
unknown	O
mechanisms	O
.	O

Cloning	O
of	O
ARE	O
-	O
containing	O
genes	O
by	O
AU-motif	O
-	O
directed	O
display	O
.	O

A	O
procedure	O
suitable	O
for	O
cloning	O
labile	O
mRNAs	O
that	O
contain	O
AU	O
motifs	O
is	O
presented	O
(	O
AU	O
-	O
DD	O
)	O
.	O

These	O
motifs	O
are	O
regulatory	O
sequences	O
within	O
the	O
so	O
-	O
called	O
AU	O
-	O
rich	O
elements	O
(	O
AREs	O
)	O
often	O
found	O
in	O
3	O
'	O
untranslated	O
regions	O
of	O
genes	O
such	O
as	O
cytokines	O
,	O
proto	O
-	O
oncogenes	O
,	O
and	O
transcription	O
factors	O
.	O

AU	O
-	O
DD	O
is	O
an	O
AU-motif	O
-	O
directed	O
differential	O
display	O
that	O
permits	O
the	O
identification	O
of	O
ARE	O
-	O
containing	O
genes	O
differentially	O
expressed	O
after	O
cell	O
activation	O
.	O

It	O
has	O
been	O
applied	O
to	O
peripheral	O
blood	O
monocytes	O
and	O
a	O
T	O
cell	O
clone	O
to	O
isolate	O
59	O
cDNA	O
fragments	O
associated	O
to	O
activation	O
.	O

Fourteen	O
percent	O
of	O
isolated	O
fragments	O
belong	O
to	O
already	O
known	O
genes	O
that	O
certainly	O
are	O
cytokines	O
and	O
transduction/transcription	O
factors	O
.	O

The	O
remaining	O
86	O
%	O
correspond	O
to	O
unknown	O
genes	O
of	O
which	O
92	O
%	O
have	O
been	O
confirmed	O
to	O
be	O
differentially	O
expressed	O
.	O

These	O
data	O
demonstrate	O
the	O
efficiency	O
of	O
the	O
system	O
and	O
support	O
the	O
notion	O
that	O
numerous	O
genes	O
falling	O
into	O
those	O
categories	O
remain	O
unidentified	O
and	O
that	O
they	O
can	O
be	O
cloned	O
by	O
this	O
method	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Signaling	O
pathways	O
mediated	O
by	O
the	O
TNF	O
-	O
and	O
cytokine	O
-	O
receptor	O
families	O
target	B-Regulation
a	O
common	O
cis	O
-	O
element	O
of	O
the	O
IFN	O
regulatory	O
factor	O
1	O
promoter	O
.	O

CD40	O
activation	O
of	O
B	O
cells	O
is	O
strongly	O
influenced	O
by	O
the	O
presence	O
of	O
cytokines	O
.	O

However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
interplay	O
between	O
these	O
distinct	O
stimuli	O
is	O
not	O
clearly	O
delineated	O
.	O

IFN	O
regulatory	O
factor	O
1	O
(	O
IRF	O
-	O
1	O
)	O
is	O
a	O
transcription	O
factor	O
activated	B-Positive_regulation
by	O
either	O
CD40	O
or	O
cytokines	O
.	O

We	O
have	O
found	O
that	O
these	O
different	O
sets	O
of	O
signals	O
target	O
a	O
common	O
cis	O
-	O
acting	O
element	O
in	O
the	O
promoter	O
of	O
this	O
gene	O
,	O
the	O
IRF	O
-	O
1	O
gamma	O
-	O
activated	O
site	O
(	O
GAS	O
)	O
.	O

Targeting	O
of	O
the	O
IRF	O
-	O
1	O
GAS	O
is	O
not	O
confined	O
to	O
activation	B-Positive_regulation
via	O
CD40	O
but	O
extends	O
to	O
other	O
stimuli	O
that	O
mimic	O
the	O
CD40	O
signaling	O
cascade	O
,	O
like	O
TNF	O
-	O
alpha	O
and	O
EBV	O
.	O

In	O
contrast	O
to	O
induction	O
of	O
STATs	O
by	O
cytokines	O
,	O
the	O
IRF	O
-	O
1	O
GAS	O
-	O
binding	O
complex	O
activated	B-Positive_regulation
by	O
CD40	O
,	O
TNF	O
-	O
alpha	O
,	O
or	O
EBV	O
contains	B-Binding
Rel	O
proteins	O
,	O
specifically	O
p50	O
and	O
p65	O
.	O

In	O
this	O
system	O
,	O
simultaneous	O
exposure	O
to	O
CD40L	O
together	O
with	O
either	O
IL	O
-	O
4	O
or	O
IFN	O
-	O
gamma	O
does	O
not	O
lead	O
to	O
the	O
activation	O
of	O
novel	O
Rel/STAT	O
complexes	O
.	O

Given	O
the	O
importance	O
of	O
IRF	O
-	O
1	O
in	O
a	O
variety	O
of	O
biologic	O
functions	O
from	O
proliferation	O
to	O
apoptosis	O
,	O
our	O
findings	O
support	O
the	O
notion	O
that	O
modulation	B-Regulation
of	O
IRF	O
-	O
1	O
levels	O
may	O
be	O
a	O
critical	O
control	O
point	O
in	O
B	O
cell	O
activation	O
.	O

Regulation	B-Regulation
of	O
NF	O
-	O
kappa	O
B	O
,	O
AP	O
-	O
1	O
,	O
NFAT	O
,	O
and	O
STAT1	O
nuclear	O
import	B-Localization
in	O
T	O
lymphocytes	O
by	O
noninvasive	O
delivery	O
of	O
peptide	O
carrying	O
the	O
nuclear	O
localization	O
sequence	O
of	O
NF	O
-	O
kappa	O
B	O
p50	O
.	O

Activation	O
of	O
T	O
lymphocytes	O
by	O
Ags	O
or	O
cytokines	O
results	O
in	O
translocation	O
of	O
the	O
transcription	O
factors	O
NF	O
-	O
kappa	O
B	O
,	O
AP	O
-	O
1	O
,	O
NFAT	O
,	O
and	O
STAT	O
from	O
the	O
cytoplasm	O
into	O
the	O
nucleus	O
.	O

The	O
first	O
step	O
in	O
the	O
nuclear	O
import	O
process	O
is	O
recognition	O
of	O
a	O
nuclear	O
localization	O
sequence	O
(	O
NLS	O
)	O
within	O
the	O
karyophilic	O
protein	O
by	O
a	O
cytoplasmic	O
receptor	O
such	O
as	O
the	O
importin	O
(	O
karyopherin	O
)	O
-	O
alpha	O
subunit	O
.	O

The	O
NLSs	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
AP	O
-	O
1	O
,	O
and	O
NFAT	O
differ	O
and	O
the	O
NLS	O
of	O
STAT1	O
has	O
not	O
yet	O
been	O
identified	O
.	O

Herein	O
we	O
demonstrate	O
that	O
the	O
inducible	B-Positive_regulation
nuclear	O
import	B-Localization
of	O
NF	O
-	O
kappa	O
B	O
,	O
AP	O
-	O
1	O
,	O
NFAT	O
,	O
and	O
STAT1	O
in	O
Jurkat	O
T	O
lymphocytes	O
is	O
significantly	O
inhibited	B-Negative_regulation
by	O
a	O
cell	O
-	O
permeable	O
peptide	O
carrying	O
the	O
NLS	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
p50	O
subunit	O
.	O

NLS	O
peptide	O
-	O
mediated	O
disruption	B-Negative_regulation
of	O
the	O
nuclear	O
import	B-Localization
of	O
these	O
transcription	O
factors	O
results	O
in	O
inhibition	B-Negative_regulation
of	O
I	O
kappa	O
B	O
alpha	O
and	O
IL	O
-	O
2	O
gene	O
expression	B-Gene_expression
,	O
processes	O
dependent	B-Regulation
on	O
NF	O
-	O
kappa	O
B	O
or	O
the	O
combination	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
AP	O
-	O
1	O
,	O
and	O
NFAT	O
.	O

Further	O
,	O
we	O
show	O
that	O
inhibitory	O
NLS	O
peptide	O
interacts	O
in	O
vitro	O
with	O
a	O
cytoplasmic	O
NLS	O
receptor	O
complex	O
comprised	O
of	O
the	O
Rch1/importin	O
(	O
karyopherin	O
)	O
-	O
beta	O
heterodimer	O
expressed	B-Gene_expression
in	O
Jurkat	O
T	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
the	O
inducible	B-Positive_regulation
nuclear	O
import	B-Localization
of	O
NF	O
-	O
kappa	O
B	O
,	O
AP	O
-	O
1	O
,	O
NFAT	O
,	O
and	O
STAT1	O
in	O
Jurkat	O
T	O
cells	O
can	O
be	O
regulated	B-Regulation
by	O
NLS	O
peptide	O
delivered	O
noninvasively	O
to	O
the	O
cytoplasm	O
of	O
Jurkat	O
T	O
cells	O
to	O
target	O
members	O
of	O
the	O
importin	O
(	O
karyopherin	O
)	O
-	O
alpha	O
beta	O
NLS	O
receptor	O
complex	O
.	O

Epithelial	O
cell	O
-	O
initiated	O
inflammation	O
plays	O
a	O
crucial	O
role	O
in	O
early	O
tissue	O
damage	O
in	O
amebic	O
infection	O
of	O
human	O
intestine	O
.	O

BACKGROUND	O
&	O
AIMS	O
:	O
Entamoeba	O
histolytica	O
infection	O
of	O
the	O
intestine	O
can	O
induce	O
severe	O
gut	O
inflammation	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
assess	O
the	O
role	O
of	O
the	O
host	O
inflammatory	O
response	O
in	O
the	O
tissue	O
damage	O
observed	O
with	O
amebiasis	O
and	O
the	O
role	O
of	O
the	O
intestinal	O
epithelial	O
cell	O
in	O
initiating	O
that	O
response	O
.	O

METHODS	O
:	O
E.	O
histolytica	O
infection	O
was	O
established	O
in	O
human	O
intestinal	O
xenografts	O
in	O
severe	O
combined	O
immunodeficient	O
(	O
SCID-HU	O
-	O
INT	O
)	O
mice	O
.	O

Human	O
intestinal	O
epithelial	O
cell	O
inflammatory	O
responses	O
to	O
amebic	O
infection	O
were	O
inhibited	O
by	O
the	O
intraluminal	O
administration	O
of	O
an	O
antisense	O
oligonucleotide	O
to	O
the	O
human	O
p65	O
subunit	O
of	O
nuclear	O
factor	O
kappaB	O
,	O
and	O
the	O
role	O
of	O
neutrophils	O
in	O
tissue	O
damage	O
observed	O
with	O
amebiasis	O
was	O
studied	O
by	O
depleting	O
neutrophils	O
from	O
SCID-HU	O
-	O
INT	O
mice	O
.	O

RESULTS	O
:	O
Administration	O
of	O
the	O
antisense	O
oligonucleotide	O
blocked	B-Negative_regulation
the	O
production	B-Gene_expression
of	O
human	O
interleukin	O
1beta	O
and	O
interleukin	O
8	O
by	O
intestinal	O
epithelial	O
cells	O
and	O
inhibited	O
neutrophil	O
influx	O
into	O
the	O
E.	O
histolytica	O
-	O
infected	O
intestinal	O
xenografts	O
.	O

Inhibition	O
of	O
the	O
gut	O
inflammatory	O
response	O
by	O
the	O
antisense	O
oligonucleotide	O
or	O
the	O
depletion	O
of	O
neutrophils	O
from	O
SCID-HU	O
-	O
INT	O
mice	O
blocked	O
the	O
increase	O
in	O
intestinal	O
permeability	O
observed	O
with	O
amebic	O
infection	O
.	O

CONCLUSIONS	O
:	O
Intestinal	O
epithelial	O
cells	O
initiate	O
an	O
inflammatory	O
response	O
with	O
resulting	O
neutrophil	O
-	O
mediated	O
tissue	O
damage	O
in	O
response	O
to	O
E.	O
histolytica	O
infection	O
;	O
this	O
inflammatory	O
cascade	O
can	O
be	O
blocked	O
by	O
inhibiting	O
the	O
transcription	O
of	O
genes	O
regulated	O
by	O
nuclear	O
factor	O
kappaB	O
.	O

In	O
vitro	O
suppression	O
of	O
programmed	O
cell	O
death	O
of	O
B	O
cells	O
by	O
tissue	O
inhibitor	O
of	O
metalloproteinases	O
-	O
1	O
.	O

Cellular	O
pathways	O
for	O
induction	O
of	O
programmed	O
cell	O
death	O
(	O
PCD	O
)	O
have	O
been	O
identified	O
,	O
but	O
little	O
is	O
known	O
about	O
specific	O
extracellular	O
matrix	O
processes	O
that	O
may	O
affect	O
apoptosis	O
along	O
those	O
pathways	O
.	O

In	O
this	O
study	O
,	O
a	O
series	O
of	O
Burkitt	O
's	O
lymphoma	O
(	O
BL	O
)	O
cell	O
lines	O
were	O
assayed	O
for	O
their	O
expression	B-Gene_expression
of	O
tissue	O
inhibitor	O
of	O
metalloproteinases	O
(	O
TIMP	O
)	O
-	O
1	O
.	O

Results	O
indicate	O
that	O
TIMP-1	O
-	O
positive	O
BL	O
lines	O
show	O
resistance	O
to	O
cold-shock	O
-	O
induced	O
apoptosis	O
.	O

Furthermore	O
,	O
recombinant	O
TIMP	O
-	O
1	O
,	O
but	O
not	O
TIMP	O
-	O
2	O
or	O
a	O
synthetic	O
metalloproteinase	O
inhibitor	O
(	O
BB	O
-	O
94	O
)	O
,	O
confers	O
resistance	O
to	O
apoptosis	O
induced	O
by	O
both	O
CD95	O
-	O
dependent	O
and	O
-	O
independent	O
(	O
cold	O
shock	O
,	O
serum	O
deprivation	O
,	O
and	O
gamma	O
-	O
radiation	O
)	O
pathways	O
in	O
TIMP-1	O
-	O
negative	O
BL	O
lines	O
.	O

TIMP	O
-	O
1	O
suppression	O
of	O
PCD	O
is	O
not	O
due	O
to	O
metalloproteinase	O
inhibition	O
,	O
as	O
reduction	B-Negative_regulation
and	O
alkylation	O
of	O
the	O
TIMP	O
-	O
1	O
did	O
not	O
abolish	O
this	O
activity	O
.	O

Retroviral	O
induction	B-Positive_regulation
of	O
TIMP	O
-	O
1	O
not	O
only	O
resulted	O
in	O
cell	O
survival	O
but	O
also	O
in	O
continued	O
DNA	O
synthesis	O
for	O
up	O
to	O
5	O
d	O
in	O
the	O
absence	O
of	O
serum	O
,	O
while	O
controls	O
underwent	O
apoptosis	O
.	O

This	O
resistance	O
to	O
apoptosis	O
is	O
reversed	O
by	O
anti-TIMP	O
-	O
1	O
antibodies	O
,	O
demonstrating	O
that	O
secreted	B-Localization
TIMP	O
-	O
1	O
is	O
active	O
in	O
blocking	O
apoptosis	O
.	O

Furthermore	O
,	O
TIMP	O
-	O
1	O
upregulation	B-Positive_regulation
induced	B-Positive_regulation
expression	B-Gene_expression
of	O
Bcl	O
-	O
XL	O
but	O
not	O
Bcl	O
-	O
2	O
as	O
well	O
as	O
decreased	O
NF	O
-	O
kappaB	O
activity	O
as	O
compared	O
with	O
controls	O
.	O

These	O
results	O
demonstrate	O
that	O
TIMP	O
-	O
1	O
suppresses	O
apoptosis	O
in	O
B	O
cells	O
and	O
suggests	O
a	O
novel	O
activity	O
for	O
TIMP	O
-	O
1	O
in	O
tissue	O
homeostasis	O
.	O

Interleukin	O
-	O
12	O
expression	O
in	O
B	O
cells	O
by	O
transformation	O
with	O
Epstein	O
-	O
Barr	O
virus	O
.	O

Although	O
interleukin	O
(	O
IL	O
)	O
-	O
12	O
was	O
originally	O
purified	O
from	O
an	O
Epstein	O
-	O
Barr	O
(	O
EBV	O
)	O
-	O
transformed	O
B	O
cell	O
line	O
and	O
the	O
high	O
correlation	O
of	O
EBV	O
infection	O
and	O
IL	O
-	O
12	O
expression	O
has	O
been	O
suggested	O
,	O
no	O
study	O
has	O
reported	O
whether	O
EBV	O
infection	O
is	O
directly	O
linked	O
to	O
IL	O
-	O
12	O
expression	O
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
have	O
investigated	O
IL	O
-	O
12	O
expression	O
in	O
B	O
cells	O
during	O
in	O
vitro	O
transformation	O
with	O
EBV	O
.	O

Human	O
peripheral	O
B	O
cells	O
became	B-Positive_regulation
capable	I-Positive_regulation
of	O
constitutively	O
producing	B-Gene_expression
p40	O
by	O
in	O
vitro	O
transformation	O
with	O
EBV	O
,	O
coincident	O
with	O
the	O
expression	B-Gene_expression
of	O
latent	O
membrane	O
protein	O
1	O
(	O
LMP1	O
)	O
of	O
EBV	O
.	O

These	O
B	O
cells	O
expressed	B-Transcription
p40	O
and	O
p35	O
mRNA	O
,	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
stimulation	O
strongly	O
enhanced	B-Positive_regulation
p40	O
and	O
p70	O
production	B-Gene_expression
.	O

Furthermore	O
,	O
transfection	O
with	O
LMP1	O
expression	O
vector	O
into	O
a	O
human	O
B	O
lymphoma	O
cell	O
line	O
,	O
Daudi	O
,	O
led	B-Positive_regulation
to	O
p40	O
production	B-Gene_expression
with	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
activation	O
.	O

These	O
results	O
suggest	O
that	O
transformation	O
of	O
primary	O
B	O
cells	O
with	O
EBV	O
induces	B-Positive_regulation
IL	O
-	O
12	O
expression	O
potentially	O
through	O
LMP1	O
expression	B-Gene_expression
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Anaphylatoxins	O
C5a	O
and	O
C3a	O
induce	O
nuclear	O
factor	O
kappaB	O
activation	O
in	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

The	O
anaphylatoxins	O
C5a	O
and	O
C3a	O
are	O
involved	O
in	O
the	O
regulation	O
of	O
cytokine	O
production	O
.	O

In	O
this	O
study	O
the	O
capability	O
of	O
C5a	O
and	O
C3a	O
to	O
induce	O
transcription	O
factor	O
activation	O
was	O
examined	O
.	O

C5a	O
and	O
C3a	O
stimulation	O
of	O
human	O
peripheral	O
blood	O
monocytes	O
resulted	O
in	O
nuclear	O
expression	O
of	O
a	O
DNA	O
binding	O
activity	O
with	O
specificity	O
to	O
the	O
kappaB	O
sequence	O
.	O

The	O
p50	O
and	O
p65	O
proteins	O
,	O
constituents	O
of	O
the	O
prototypic	O
nuclear	O
factor	O
kappaB	O
,	O
were	O
identified	O
as	O
components	O
of	O
the	O
DNA	O
-	O
protein	O
complexes	O
by	O
anti	O
-	O
peptide	O
antibodies	O
in	O
gel	O
supershift	O
assays	O
.	O

C5a	O
induced	O
kappaB	O
binding	O
activity	O
was	O
detected	O
15	O
min	O
after	O
agonist	O
stimulation	O
,	O
peaked	O
at	O
30	O
-	O
40	O
min	O
,	O
and	O
remained	O
detectable	O
at	O
2	O
h	O
.	O

Binding	O
to	O
kappaB	O
sequence	O
was	O
accompanied	O
by	O
an	O
initial	O
decrease	B-Negative_regulation
and	O
subsequent	O
increase	B-Positive_regulation
in	O
the	O
cytoplasmic	O
IkappaBalpha	O
levels	O
,	O
as	O
detected	O
by	O
Western	O
blotting	O
using	O
an	O
anti	O
-	O
IkappaBalpha	O
antibody	O
.	O

Pertussis	O
toxin	O
treatment	O
markedly	O
decreased	O
kappaB	O
binding	O
activities	O
induced	O
by	O
both	O
C5a	O
and	O
C3a	O
,	O
whereas	O
cholera	O
toxin	O
displayed	O
no	O
inhibitory	O
effect	O
.	O

Neither	O
of	O
the	O
two	O
toxins	O
affected	O
kappaB	O
binding	O
activity	O
induced	O
by	O
TNFalpha	O
in	O
the	O
same	O
cells	O
.	O

These	O
results	O
imply	O
a	O
potential	O
role	O
of	O
the	O
anaphylatoxins	O
C5a	O
and	O
C3a	O
in	O
regulating	O
leukocytes	O
gene	O
expression	O
through	O
G	O
protein	O
-	O
coupled	O
transcription	O
factor	O
activation	O
.	O

Tpl	O
-	O
2	O
induces	B-Positive_regulation
IL	O
-	O
2	O
expression	B-Gene_expression
in	O
T	O
-	O
cell	O
lines	O
by	O
triggering	O
multiple	O
signaling	O
pathways	O
that	O
activate	O
NFAT	O
and	O
NF	O
-	O
kappaB	O
.	O

The	O
Tpl	O
-	O
2	O
kinase	O
activates	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
and	O
induces	B-Positive_regulation
IL	O
-	O
2	O
expression	B-Gene_expression
in	O
T	O
-	O
cell	O
lines	O
.	O

Here	O
we	O
show	O
that	O
the	O
activation	B-Positive_regulation
of	O
the	O
IL	O
-	O
2	O
promoter	O
by	O
Tpl	O
-	O
2	O
is	O
inhibited	B-Negative_regulation
by	O
mutant	O
signaling	O
molecules	O
that	O
inhibit	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
or	O
the	O
calcineurin/NFAT	O
pathways	O
and	O
is	O
promoted	B-Positive_regulation
by	O
combinations	O
of	O
signaling	O
molecules	O
that	O
activate	O
these	O
pathways	O
.	O

We	O
,	O
therefore	O
,	O
conclude	O
that	O
signals	O
generated	O
by	O
the	O
convergence	O
of	O
the	O
MAPK	O
and	O
the	O
calcineurin/NFAT	O
pathway	O
are	O
necessary	B-Positive_regulation
and	I-Positive_regulation
sufficient	I-Positive_regulation
for	O
the	O
activation	B-Positive_regulation
of	O
the	O
IL	O
-	O
2	O
promoter	O
by	O
Tpl	O
-	O
2	O
.	O

The	O
activation	B-Positive_regulation
of	O
both	O
the	O
IL	O
-	O
2	O
promoter	O
and	O
an	O
NFAT	O
-	O
driven	O
minimal	O
promoter	O
were	O
shown	O
to	O
depend	B-Regulation
on	O
signals	O
transduced	O
by	O
Raf1	O
.	O

However	O
,	O
it	O
was	O
only	O
the	O
IL	O
-	O
2	O
promoter	O
whose	O
activation	B-Positive_regulation
by	O
Tpl	O
-	O
2	O
was	O
fully	O
blocked	B-Negative_regulation
by	O
the	O
dominant	O
negative	O
mutant	O
MEK1S218/222A	O
and	O
the	O
MEK1/MEK2	O
inhibitor	B-Negative_regulation
PD098059	O
.	O

Since	O
the	O
activation	O
of	O
NFAT	O
is	O
MAPK	O
-	O
dependent	O
these	O
findings	O
suggested	O
that	O
the	O
activation	O
of	O
MAPK	O
by	O
Tpl	O
-	O
2	O
is	O
either	O
independent	O
or	O
only	O
partially	O
dependent	O
on	O
MEK1	O
and	O
MEK2	O
.	O

In	O
addition	O
,	O
they	O
suggested	O
that	O
the	O
activation	B-Positive_regulation
of	O
the	O
IL	O
-	O
2	O
promoter	O
is	O
under	B-Regulation
the	I-Regulation
control	I-Regulation
of	O
not	O
only	O
NFAT	O
but	O
also	O
a	O
second	O
factor	O
whose	O
activation	O
is	O
MEK	O
-	O
dependent	O
.	O

Experiments	O
in	O
COS	O
-	O
1	O
and	O
EL	O
-	O
4	O
cells	O
confirmed	O
both	O
hypotheses	O
and	O
revealed	O
that	O
the	O
second	O
factor	O
activated	O
by	O
Tpl	O
-	O
2	O
is	O
NF	O
-	O
kappaB	O
.	O

While	O
the	O
activation	B-Positive_regulation
of	O
the	O
IL	O
-	O
2	O
promoter	O
and	O
an	O
NFAT	O
-	O
driven	O
minimal	O
promoter	O
by	O
Tpl	O
-	O
2	O
was	O
fully	O
blocked	B-Negative_regulation
by	O
the	O
dominant	O
negative	O
mutant	O
NFAT	O
delta418	O
,	O
it	O
was	O
only	O
partially	O
blocked	B-Negative_regulation
by	O
the	O
calcineurin	O
inhibitor	O
cyclosporin	O
A	O
suggesting	O
that	O
the	O
Tpl-2	O
-	O
mediated	O
NFAT	O
activation	O
is	O
under	O
the	O
control	O
of	O
a	O
combination	O
of	O
calcineurin	O
-	O
dependent	O
and	O
independent	O
pathways	O
.	O

Both	O
pathways	O
were	O
fully	O
blocked	O
by	O
Bcl	O
-	O
2	O
or	O
Bcl	O
-	O
X	O
(	O
L	O
)	O
.	O

Activation	O
of	O
human	O
macrophages	O
by	O
mechanical	O
ventilation	O
in	O
vitro	O
.	O

Positive	O
-	O
pressure	O
mechanical	O
ventilation	O
supports	O
gas	O
exchange	O
in	O
patients	O
with	O
respiratory	O
failure	O
but	O
is	O
also	O
responsible	O
for	O
significant	O
lung	O
injury	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
developed	O
an	O
in	O
vitro	O
model	O
in	O
which	O
isolated	O
lung	O
cells	O
can	O
be	O
submitted	O
to	O
a	O
prolonged	O
cyclic	O
pressure	O
-	O
stretching	O
strain	O
resembling	O
that	O
of	O
conventional	O
mechanical	O
ventilation	O
.	O

In	O
this	O
model	O
,	O
cells	O
cultured	O
on	O
a	O
Silastic	O
membrane	O
were	O
elongated	O
up	O
to	O
7	O
%	O
of	O
their	O
initial	O
diameter	O
,	O
corresponding	O
to	O
a	O
12	O
%	O
increase	O
in	O
cell	O
surface	O
.	O

The	O
lung	O
macrophage	O
was	O
identified	O
as	O
the	O
main	O
cellular	O
source	B-Gene_expression
for	O
critical	O
inflammatory	O
mediators	O
such	O
as	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
,	O
the	O
chemokines	O
interleukin	O
(	O
IL	O
)	O
-	O
8	O
and	O
-	O
6	O
,	O
and	O
matrix	O
metalloproteinase	O
-	O
9	O
in	O
this	O
model	O
system	O
of	O
mechanical	O
ventilation	O
.	O

These	O
mediators	O
were	O
measured	O
in	O
supernatants	O
from	O
ventilated	O
alveolar	O
macrophages	O
,	O
monocyte	O
-	O
derived	O
macrophages	O
,	O
and	O
promonocytic	O
THP	O
-	O
1	O
cells	O
.	O

Nuclear	O
factor	O
-	O
kappaB	O
was	O
found	O
to	O
be	O
activated	O
in	O
ventilated	O
macrophages	O
.	O

Synergistic	O
proinflammatory	O
effects	O
of	O
mechanical	O
stress	O
and	O
molecules	O
such	O
as	O
bacterial	O
endotoxin	O
were	O
observed	O
,	O
suggesting	O
that	O
mechanical	O
ventilation	O
might	O
be	O
particularly	O
deleterious	O
in	O
preinjured	O
or	O
infected	O
lungs	O
.	O

Dexamethasone	O
prevented	B-Negative_regulation
IL	O
-	O
8	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
secretion	B-Localization
in	O
ventilated	O
macrophages	O
.	O

Mechanical	O
ventilation	O
induced	B-Positive_regulation
low	O
levels	O
of	O
IL	O
-	O
8	O
secretion	B-Localization
by	O
alveolar	O
type	O
II	O
-	O
like	O
cells	O
.	O

Other	O
lung	O
cell	O
types	O
such	O
as	O
endothelial	O
cells	O
,	O
bronchial	O
cells	O
,	O
and	O
fibroblasts	O
failed	O
to	O
produce	B-Gene_expression
IL	O
-	O
8	O
in	B-Positive_regulation
response	I-Positive_regulation
to	I-Positive_regulation
a	O
prolonged	O
cyclic	O
pressure	O
-	O
stretching	O
load	O
.	O

This	O
model	O
is	O
of	O
particular	O
value	O
for	O
exploring	O
physical	O
stress	O
-	O
induced	O
signaling	O
pathways	O
,	O
as	O
well	O
as	O
for	O
testing	O
the	O
effects	O
of	O
novel	O
ventilatory	O
strategies	O
or	O
adjunctive	O
substances	O
aimed	O
at	O
modulating	O
cell	O
activation	O
induced	O
by	O
mechanical	O
ventilation	O
.	O

Stat6	O
inhibits	B-Negative_regulation
human	O
interleukin	O
-	O
4	O
promoter	O
activity	O
in	O
T	O
cells	O
.	O

The	O
differentiation	O
of	O
naive	O
T	O
-	O
helper	O
(	O
Th	O
)	O
cells	O
into	O
cytokine	O
-	O
secreting	O
effector	O
Th	O
cells	O
requires	O
exposure	O
to	O
multiple	O
signals	O
,	O
including	O
exogenous	O
cytokines	O
.	O

Interleukin	O
-	O
4	O
(	O
IL	O
-	O
4	O
)	O
plays	O
a	O
major	O
role	O
in	O
this	O
process	O
by	O
promoting	O
the	O
differentiation	O
of	O
IL-4	O
-	O
secreting	B-Localization
Th2	O
cells	O
.	O

In	O
Th2	O
cells	O
,	O
IL	O
-	O
4	O
gene	O
expression	O
is	O
tightly	O
controlled	B-Regulation
at	B-Transcription
the	I-Transcription
level	I-Transcription
of	I-Transcription
transcription	I-Transcription
by	O
the	O
coordinated	O
binding	O
of	O
multiple	O
transcription	O
factors	O
to	O
regulatory	O
elements	O
in	O
the	O
proximal	O
promoter	O
region	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
(	O
NFAT	O
)	O
family	O
members	O
play	O
a	O
critical	O
role	B-Regulation
in	O
regulating	B-Regulation
IL	O
-	O
4	O
transcription	B-Transcription
and	O
interact	B-Binding
with	O
up	O
to	O
five	O
sequences	O
(	O
termed	O
P0	O
through	O
P4	O
)	O
in	O
the	O
IL	O
-	O
4	O
promoter	O
.	O

The	O
molecular	O
mechanisms	O
by	O
which	O
IL	O
-	O
4	O
induces	B-Positive_regulation
expression	B-Gene_expression
of	O
the	O
IL	O
-	O
4	O
gene	O
are	O
not	O
known	O
,	O
although	O
the	O
IL-4	O
-	O
activated	B-Positive_regulation
transcription	O
factor	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
6	O
(	O
Stat6	O
)	O
is	O
required	B-Positive_regulation
for	O
this	O
effect	O
.	O

We	O
report	O
here	O
that	O
Stat6	O
interacts	B-Binding
with	O
three	O
binding	O
sites	O
in	O
the	O
human	O
IL	O
-	O
4	O
promoter	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

These	O
sites	O
overlap	O
the	O
P1	O
,	O
P2	O
,	O
and	O
P4	O
NFAT	O
elements	O
.	O

To	O
investigate	O
the	O
role	B-Regulation
of	O
Stat6	O
in	O
regulating	B-Regulation
IL	O
-	O
4	O
transcription	B-Transcription
,	O
we	O
used	O
Stat6	O
-	O
deficient	O
Jurkat	O
T	O
cells	O
with	O
different	O
intact	O
IL	O
-	O
4	O
promoter	O
constructs	O
in	O
cotransfection	O
assays	O
.	O

We	O
show	O
that	O
,	O
whereas	O
a	O
multimerized	O
response	O
element	O
from	O
the	O
germline	O
IgE	O
promoter	O
was	O
highly	O
induced	O
by	O
IL	O
-	O
4	O
in	O
Stat6	O
-	O
expressing	B-Gene_expression
Jurkat	O
cells	O
,	O
the	O
intact	O
human	O
IL	O
-	O
4	O
promoter	O
was	O
repressed	B-Negative_regulation
under	O
similar	O
conditions	O
.	O

We	O
conclude	O
that	O
the	O
function	O
of	O
Stat6	O
is	O
highly	O
dependent	B-Regulation
on	O
promoter	O
context	O
and	O
that	O
this	O
factor	O
promotes	B-Positive_regulation
IL	O
-	O
4	O
gene	B-Gene_expression
expression	I-Gene_expression
in	O
an	O
indirect	O
manner	O
.	O

Interleukin	O
-	O
10	O
and	O
transforming	O
growth	O
factor	O
-	O
beta	O
promoter	O
polymorphisms	O
in	O
allergies	O
and	O
asthma	O
.	O

Interleukin	O
-	O
10	O
(	O
IL	O
-	O
10	O
)	O
and	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
are	O
inhibitory	O
for	O
B	O
and	O
T	O
cells	O
,	O
IgE	O
production	O
,	O
and	O
mast	O
cell	O
proliferation	O
,	O
and	O
they	O
induce	O
apoptosis	O
in	O
eosinophils	O
.	O

These	O
cytokines	O
are	O
therefore	O
candidate	O
genes	O
which	O
could	O
contribute	O
to	O
the	O
development	O
of	O
asthma	O
or	O
allergies	O
.	O

We	O
investigated	O
the	O
hypothesis	O
that	O
polymorphic	O
nucleotides	O
within	O
the	O
IL	O
-	O
10	O
and	O
TGF	O
-	O
beta	O
gene	O
promoters	O
would	O
link	O
to	O
the	O
expression	O
of	O
allergies	O
and	O
asthma	O
.	O

DNA	O
taken	O
from	O
families	O
with	O
an	O
asthmatic	O
proband	O
was	O
examined	O
for	O
base	O
exchanges	O
by	O
single	O
-	O
stranded	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
.	O

We	O
demonstrated	O
the	O
presence	O
of	O
a	O
polymorphism	O
in	O
the	O
promoter	O
region	O
of	O
the	O
IL	O
-	O
10	O
gene	O
and	O
four	O
in	O
the	O
TGF	O
-	O
beta	O
gene	O
promoters	O
(	O
3	O
in	O
TGF	O
-	O
beta1	O
and	O
1	O
in	O
TGF	O
-	O
beta2	O
)	O
.	O

The	O
IL	O
-	O
10	O
gene	O
polymorphism	O
was	O
a	O
C-to	O
-	O
A	O
exchange	O
571	O
base	O
pairs	O
upstream	O
from	O
the	O
translation	O
start	O
site	O
and	O
was	O
present	O
between	O
consensus	O
binding	O
sequences	O
for	O
Sp1	O
and	O
elevated	O
total	O
serum	O
.	O

This	O
polymorphism	O
was	O
associated	O
with	O
elevated	O
total	O
serum	O
IgE	O
in	O
subjects	O
heterozygotic	O
or	O
homozygotic	O
for	O
this	O
base	O
exchange	O
(	O
p	O
<	O
0.009	O
)	O
.	O

The	O
base	O
exchange	O
at	O
-	O
509	O
(	O
from	O
the	O
transcription	O
initiation	O
site	O
)	O
in	O
the	O
TGF	O
-	O
beta	O
promoter	O
also	O
linked	O
to	O
elevated	O
total	O
IgE	O
(	O
p	O
<	O
0.01	O
)	O
.	O

This	O
polymorphism	O
represented	O
a	O
C-to	O
-	O
T	O
base	O
exchange	O
which	O
induced	O
a	O
YY1	O
consensus	O
sequence	O
and	O
is	O
present	O
in	O
a	O
region	O
of	O
the	O
promoter	O
associated	O
with	O
negative	O
transcription	O
regulation	O
.	O

The	O
control	O
of	O
lytic	O
replication	O
of	O
Epstein	O
-	O
Barr	O
virus	O
in	O
B	O
lymphocytes	O
(	O
Review	O
)	O
.	O

Uncontrolled	O
replication	O
of	O
a	O
virus	O
,	O
which	O
is	O
harmful	O
to	O
the	O
host	O
is	O
also	O
disadvantageous	O
to	O
the	O
virus	O
.	O

Most	O
viruses	O
can	O
not	O
compete	O
with	O
the	O
various	O
immune	O
mechanisms	O
and	O
become	O
eliminated	O
in	O
the	O
course	O
of	O
infection	O
.	O

Therefore	O
,	O
only	O
the	O
time	O
between	O
infection	O
and	O
eradication	O
remains	O
for	O
these	O
viruses	O
to	O
proliferate	O
.	O

A	O
few	O
viruses	O
,	O
like	O
the	O
Herpesviruses	O
or	O
the	O
papillomaviruses	O
,	O
however	O
,	O
have	O
developed	O
a	O
sophisticated	O
strategy	O
for	O
persisting	O
lifelong	O
,	O
usually	O
asymptomatically	O
in	O
the	O
host	O
,	O
hiding	O
from	O
the	O
immune	O
system	O
and	O
producing	O
infectious	O
progeny	O
at	O
the	O
same	O
time	O
.	O

This	O
strategy	O
depends	O
on	O
a	O
separation	O
of	O
latency	O
and	O
the	O
lytic	O
replication	O
,	O
either	O
by	O
time	O
due	O
to	O
differentiation	O
-	O
dependent	O
mechanisms	O
or	O
by	O
spatial	O
separation	O
as	O
the	O
result	O
of	O
different	O
host	O
cell	O
types	O
.	O

Both	O
are	O
true	O
for	O
the	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
.	O

B	O
cells	O
and	O
epithelial	O
cells	O
have	O
a	O
pivotal	O
role	O
in	O
the	O
life	O
cycle	O
of	O
the	O
virus	O
.	O

The	O
former	O
can	O
become	O
latently	O
infected	O
and	O
are	O
thought	O
to	O
be	O
the	O
virus	O
reservoir	O
in	O
vivo	O
,	O
whereas	O
the	O
latter	O
were	O
shown	O
to	O
be	O
permissive	O
for	O
lytic	O
replication	O
.	O

However	O
,	O
replication	O
of	O
EBV	O
in	O
vivo	O
is	O
controlled	O
primarily	O
by	O
host	O
immune	O
mechanisms	O
selecting	O
for	O
cells	O
that	O
are	O
not	O
permissive	O
for	O
viral	O
replication	O
as	O
the	O
result	O
of	O
a	O
particular	O
set	O
of	O
transcription	O
factors	O
.	O

These	O
factors	O
control	O
the	O
activity	O
of	O
the	O
regulatory	O
immediate	O
-	O
early	O
genes	O
and	O
,	O
in	O
addition	O
,	O
lytic	O
and	O
latent	O
cycle	O
regulatory	O
genes	O
negatively	O
interfere	O
with	O
each	O
other	O
and	O
thus	O
link	O
cellular	O
and	O
viral	O
gene	O
regulatory	O
mechanisms	O
.	O

Disturbance	O
of	O
both	O
the	O
immune	O
surveillance	O
as	O
well	O
as	O
viral	O
gene	O
regulation	O
may	O
result	O
in	O
EBV	O
-	O
associated	O
disease	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
-	O
1	O
transcription	O
:	O
role	O
of	O
the	O
5'	O
-	O
untranslated	O
leader	O
region	O
(	O
review	O
)	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
-	O
1	O
(	O
HIV	O
-	O
1	O
)	O
transcription	O
is	O
dependent	O
on	O
the	O
interaction	O
of	O
host	O
-	O
cell	O
transcription	O
factors	O
with	O
cis	O
-	O
regulatory	O
DNA	O
elements	O
within	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

Much	O
attention	O
has	O
focused	O
on	O
the	O
series	O
of	O
sequence	O
elements	O
upstream	O
of	O
the	O
transcriptional	O
initiation	O
site	O
in	O
the	O
U3	O
region	O
of	O
the	O
LTR	O
including	O
the	O
Sp1	O
and	O
NF	O
-	O
kappaB	O
binding	O
sites	O
.	O

Recent	O
studies	O
,	O
however	O
,	O
demonstrate	O
that	O
the	O
transcribed	O
5'	O
-	O
untranslated	O
leader	O
region	O
(	O
5'	O
-	O
UTR	O
)	O
also	O
contains	O
important	O
transcriptional	O
elements	O
.	O

These	O
regulatory	O
elements	O
situated	O
downstream	O
of	O
transcription	O
interact	O
with	O
constitutive	O
and	O
inducible	O
transcription	O
factors	O
,	O
mediate	O
transmission	O
of	O
cellular	O
activation	O
signals	O
,	O
and	O
are	O
important	O
for	O
efficient	O
HIV	O
-	O
1	O
transcription	O
and	O
replication	O
.	O

The	O
5'	O
-	O
UTR	O
contains	O
binding	O
sites	O
for	O
the	O
transcription	O
factors	O
AP	O
-	O
1	O
,	O
NF	O
-	O
kappaB	O
,	O
NF	O
-	O
AT	O
,	O
IRF	O
,	O
and	O
Sp1	O
.	O

Mutations	O
in	O
these	O
binding	O
sites	O
can	O
interfere	O
with	O
the	O
viral	O
response	O
to	O
cell	O
activation	O
signals	O
,	O
decrease	O
LTR	O
transcription	O
,	O
and	O
inhibit	O
viral	O
replication	O
.	O

The	O
5'	O
-	O
UTR	O
also	O
interacts	O
with	O
a	O
specific	O
nucleosome	O
that	O
is	O
rapidly	O
displaced	O
during	O
transcriptional	O
activation	O
of	O
the	O
latent	O
provirus	O
.	O

We	O
propose	O
that	O
the	O
inducible	O
transcription	O
factor	O
binding	O
sites	O
in	O
the	O
5'	O
-	O
UTR	O
comprise	O
a	O
downstream	O
enhancer	O
domain	O
that	O
can	O
function	O
independent	O
of	O
,	O
or	O
in	O
concert	O
with	O
,	O
the	O
LTR	O
promoter	O
to	O
rapidly	O
increase	O
latent	O
proviral	O
transcription	O
in	O
response	O
to	O
cell	O
activation	O
signals	O
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
the	O
host	O
-	O
cell	O
transcription	O
factors	O
that	O
interact	O
with	O
the	O
5'	O
-	O
UTR	O
and	O
discuss	O
their	O
role	O
in	O
the	O
transcriptional	O
regulation	O
of	O
HIV	O
-	O
1	O
gene	O
expression	O
.	O

Molecular	O
cloning	O
of	O
FKHRL1P2	O
,	O
a	O
member	O
of	O
the	O
developmentally	B-Regulation
regulated	I-Regulation
fork	O
head	O
domain	O
transcription	O
factor	O
family	O
.	O

Here	O
we	O
report	O
the	O
expression	O
of	O
a	O
fork	O
head	O
domain	O
protein	O
in	O
human	O
T	O
helper	O
cells	O
.	O

We	O
cloned	O
and	O
characterized	O
a	O
fork	O
head	O
cDNA	O
from	O
human	O
T	O
helper	O
cell	O
mRNA	O
using	O
differential	O
display	O
RT	O
-	O
PCR	O
.	O

The	O
cDNA	O
contains	O
a	O
546	O
-	O
nucleotide	O
(	O
nt	O
)	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
that	O
codes	O
for	O
the	O
carboxyl	O
-	O
terminal	O
180	O
amino	O
acids	O
(	O
aa	O
)	O
of	O
the	O
recently	O
identified	O
fkhrl1	O
gene	O
.	O

This	O
ORF	O
does	O
not	O
contain	O
the	O
characteristic	O
DNA	O
-	O
binding	O
domain	O
found	O
in	O
members	O
of	O
the	O
forkhead	O
protein	O
family	O
.	O

In	O
-	O
vitro	O
transcription/translation	O
of	O
this	O
cDNA	O
expressed	O
a	O
protein	O
of	O
approximately	O
20	O
kDa	O
.	O

We	O
have	O
generated	O
antibodies	O
that	O
specifically	O
immunoprecipitated	O
the	O
in-vitro	O
-	O
translated	O
20	O
-	O
kDa	O
protein	O
.	O

This	O
antibody	O
also	O
recognizes	B-Binding
in	O
human	O
T	O
lymphocytes	O
a	O
70	O
-	O
kDa	O
protein	O
corresponding	O
in	O
size	O
to	O
that	O
predicted	O
for	O
the	O
fkhrl1	O
gene	O
product	B-Gene_expression
.	O

The	O
mRNA	B-Transcription
levels	I-Transcription
for	O
fkhrl1	O
is	O
elevated	B-Positive_regulation
in	O
T	O
helper	O
-	O
induced	O
lymphocytes	O
in	O
comparison	O
to	O
PHA	O
-	O
stimulated	O
T	O
lymphocytes	O
.	O

Further	O
characterization	O
of	O
FKHRL1	O
and	O
its	O
related	O
family	O
members	O
should	O
shed	O
light	O
on	O
the	O
transcriptional	O
mechanisms	O
of	O
this	O
fork	O
head	O
gene	O
subfamily	O
and	O
their	O
role	O
in	O
T	O
helper	O
cell	O
differentiation	O
and	O
regulation	O
of	O
cell	O
growth	O
.	O

Activation	B-Positive_regulation
of	O
the	O
human	O
delta	O
-	O
globin	O
gene	O
promoter	O
in	O
primary	O
adult	O
erythroid	O
cells	O
.	O

Restoration	O
of	O
the	O
CCAAT	O
box	O
or	O
insertion	O
of	O
an	O
erythroid	O
Kruppel	O
-	O
like	O
factor	O
(	O
EKLF	O
)	O
binding	O
site	O
in	O
the	O
delta	O
promoter	O
activates	B-Positive_regulation
its	O
expression	B-Gene_expression
in	O
several	O
erythroid	O
cell	O
lines	O
.	O

We	O
extended	O
these	O
studies	O
using	O
a	O
novel	O
primary	O
human	O
adult	O
erythroid	O
cell	O
(	O
hAEC	O
)	O
system	O
to	O
investigate	O
these	O
effects	O
at	O
the	O
late	O
erythroblast	O
stage	O
.	O

Restoration	O
of	O
the	O
CCAAT	O
box	O
at	O
-	O
70	O
bp	O
,	O
or	O
insertion	O
of	O
an	O
EKLF	O
binding	O
site	O
at	O
-	O
85	O
bp	O
or	O
-	O
95	O
bp	O
in	O
the	O
promoter	O
significantly	O
increased	B-Positive_regulation
delta	O
globin	O
gene	O
expression	B-Gene_expression
in	O
hAEC	O
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
altered	O
CCAAT	O
box	O
(	O
CCAAC	O
)	O
and	O
the	O
lack	O
of	O
an	O
EKLF	O
binding	O
site	O
in	O
delta	O
-	O
globin	O
contribute	B-Positive_regulation
to	O
its	O
low	B-Negative_regulation
level	I-Negative_regulation
of	O
expression	B-Gene_expression
in	O
the	O
hAEC	O
model	O
as	O
well	O
.	O

Interactions	B-Binding
between	O
the	O
class	O
II	O
transactivator	O
and	O
CREB	O
binding	O
protein	O
increase	O
transcription	O
of	O
major	O
histocompatibility	O
complex	O
class	O
II	O
genes	O
.	O

Class	O
II	O
major	O
histocompatibility	O
(	O
class	O
II	O
)	O
genes	O
are	O
regulated	O
in	O
a	O
B-cell	O
-	O
specific	O
and	O
gamma	O
interferon	O
-	O
inducible	O
fashion	O
.	O

The	O
master	O
switch	O
for	O
the	O
expression	O
of	O
these	O
genes	O
is	O
the	O
class	O
II	O
transactivator	O
(	O
CIITA	O
)	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
one	O
of	O
the	O
functions	B-Positive_regulation
of	O
CIITA	O
is	O
to	O
recruit	B-Binding
the	O
CREB	O
binding	O
protein	O
(	O
CBP	O
)	O
to	O
class	O
II	O
promoters	O
.	O

Not	O
only	O
functional	O
but	O
also	O
specific	O
binding	B-Binding
interactions	I-Binding
between	O
CIITA	O
and	O
CBP	O
were	O
demonstrated	O
.	O

Moreover	O
,	O
a	O
dominant	O
negative	O
form	O
of	O
CBP	O
decreased	O
the	O
activity	O
of	O
class	O
II	O
promoters	O
and	O
levels	O
of	O
class	O
II	O
determinants	O
on	O
the	O
surface	O
of	O
cells	O
.	O

Finally	O
,	O
the	O
inhibition	O
of	O
class	O
II	O
gene	O
expression	O
by	O
the	O
glucocorticoid	O
hormone	O
could	O
be	O
attributed	O
to	O
the	O
squelching	B-Negative_regulation
of	O
CBP	O
by	O
the	O
glucocorticoid	O
receptor	O
.	O

We	O
conclude	O
that	O
CBP	O
,	O
a	O
histone	O
acetyltransferase	O
,	O
plays	O
an	O
important	O
role	O
in	O
the	O
transcription	O
of	O
class	O
II	O
genes	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
and	O
AP	O
-	O
1	O
are	O
insufficient	B-Positive_regulation
for	O
IL	O
-	O
2	O
promoter	O
activation	B-Positive_regulation
:	O
requirement	B-Positive_regulation
for	O
CD28	O
up	O
-	O
regulation	O
of	O
RE/AP	O
.	O

IL	O
-	O
2	O
gene	O
transcription	B-Transcription
in	O
T	O
cells	O
requires	B-Positive_regulation
both	O
TCR	O
and	O
costimulatory	O
signals	O
.	O

IL	O
-	O
2	O
promoter	O
activation	B-Positive_regulation
in	O
Jurkat	O
T	O
cells	O
stimulated	O
with	O
superantigen	O
presented	O
by	O
Raji	O
B	O
cells	O
requires	B-Positive_regulation
CD28	O
activation	B-Positive_regulation
.	O

The	O
addition	O
of	O
rCTLA4Ig	O
,	O
which	O
blocks	B-Negative_regulation
CD28	O
binding	B-Binding
to	O
its	O
ligand	O
,	O
to	O
the	O
cultures	O
decreased	B-Negative_regulation
IL	O
-	O
2	O
promoter	O
activation	B-Positive_regulation
by	O
>	O
80	O
%	O
.	O

Interestingly	O
,	O
CTLA4Ig	O
did	O
not	O
significantly	O
inhibit	O
the	O
activation	O
of	O
either	O
NF	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
or	O
AP	O
-	O
1	O
reporters	O
.	O

Therefore	O
,	O
activation	O
of	O
NFAT	O
and	O
AP	O
-	O
1	O
is	O
insufficient	B-Positive_regulation
for	O
IL	O
-	O
2	O
promoter	O
activation	B-Positive_regulation
.	O

In	O
contrast	O
,	O
an	O
RE/AP	O
reporter	O
was	O
blocked	O
by	O
CTLA4Ig	O
by	O
>	O
90	O
%	O
.	O

Thus	O
,	O
the	O
requirement	B-Positive_regulation
for	O
CD28	O
in	O
IL	O
-	O
2	O
promoter	O
activation	B-Positive_regulation
appears	O
to	O
be	O
due	B-Regulation
to	O
RE/AP	O
and	O
not	O
the	O
NFAT	O
or	O
AP	O
-	O
1	O
sites	O
.	O

In	O
addition	O
,	O
these	O
data	O
suggest	O
that	O
transcriptional	O
activation	O
of	O
RE/AP	O
is	O
not	O
mediated	O
by	O
NFAT	O
,	O
because	O
activation	O
of	O
a	O
NFAT	O
reporter	O
is	O
not	O
affected	O
by	O
the	O
addition	O
of	O
CTLA4Ig	O
.	O

Phenylarsine	O
oxide	O
inhibits	O
ex	O
vivo	O
HIV	O
-	O
1	O
expression	O
.	O

Phenylarsine	O
oxide	O
(	O
PAO	O
)	O
,	O
which	O
is	O
described	O
as	O
an	O
inhibitor	O
of	O
tyrosine	O
phosphatase	O
activity	O
,	O
inhibits	O
H2O2	O
release	O
from	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
as	O
measured	O
by	O
electrochemistry	O
.	O

Since	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
replication	O
is	O
known	O
to	O
be	O
favored	O
under	O
oxidative	O
stress	O
conditions	O
,	O
ex	O
vivo	O
experiments	O
using	O
uninfected	O
PBMCs	O
,	O
primary	O
monocytes	O
or	O
a	O
latently	O
infected	O
promonocytic	O
U1	O
cell	O
line	O
show	O
that	O
HIV	O
-	O
1	O
replication	O
and	O
reactivation	O
,	O
monitored	O
by	O
p24	O
antigen	O
measurement	O
,	O
are	O
inhibited	O
by	O
PAO	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
.	O

These	O
observations	O
can	O
be	O
linked	O
with	O
the	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
when	O
uninfected	O
monocytes	O
are	O
induced	O
by	O
either	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
or	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Interleukin	O
-	O
10	O
stabilizes	B-Positive_regulation
inhibitory	O
kappaB	O
-	O
alpha	O
in	O
human	O
monocytes	O
.	O

Interleukin	O
-	O
10	O
(	O
IL	O
-	O
10	O
)	O
protects	O
animals	O
from	O
lethal	O
endotoxemia	O
.	O

This	O
beneficial	O
effect	O
is	O
mediated	O
,	O
in	O
part	O
,	O
by	O
inhibition	B-Negative_regulation
of	O
inflammatory	O
cytokine	O
production	B-Gene_expression
,	O
including	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
.	O

Evidence	O
suggests	O
that	O
IL	O
-	O
10	O
may	O
inhibit	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
through	O
an	O
unknown	O
mechanism	O
.	O

NF	O
-	O
kappaB	O
activation	O
in	O
response	O
to	O
inflammatory	O
signals	O
is	O
dependent	O
upon	O
degradation	B-Protein_catabolism
of	O
its	O
associated	B-Binding
inhibitory	O
peptide	O
,	O
inhibitory	O
kappaB	O
-	O
alpha	O
(	O
IkappaB	O
-	O
alpha	O
)	O
.	O

We	O
hypothesized	O
that	O
IL	O
-	O
10	O
prevents	B-Negative_regulation
human	O
monocyte	O
NF	O
-	O
kappaB	O
activation	O
and	O
resultant	B-Positive_regulation
TNF	O
-	O
alpha	O
production	B-Gene_expression
by	O
stabilization	B-Positive_regulation
of	O
IkappaB	O
-	O
alpha	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	B-Regulation
of	O
IL	O
-	O
10	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
induced	B-Positive_regulation
human	O
monocyte	O
TNF	O
-	O
alpha	O
production	B-Gene_expression
,	O
NF	O
-	O
kappaB	O
activation	O
,	O
and	O
IkappaB	O
-	O
alpha	O
degradation	B-Protein_catabolism
.	O

Monocytes	O
were	O
isolated	O
from	O
human	O
donors	O
.	O

Cells	O
were	O
stimulated	O
with	O
endotoxin	O
(	O
LPS	O
,	O
100	O
ng/mL	O
)	O
with	O
and	O
without	O
human	O
IL	O
-	O
10	O
(	O
10	O
ng/mL	O
)	O
.	O

Following	O
stimulation	O
,	O
TNF	O
-	O
alpha	O
was	O
measured	B-Regulation
in	O
cell	O
supernatants	O
by	O
ELISA	O
,	O
NF	O
-	O
kappaB	O
activity	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
and	O
IkappaB	O
-	O
alpha	O
levels	B-Gene_expression
by	O
Western	O
blot	O
.	O

We	O
observed	O
that	O
after	O
LPS	O
stimulation	O
of	O
human	O
monocytes	O
,	O
TNF	O
-	O
alpha	O
increased	B-Positive_regulation
to	O
798+/	O
-	O
67	O
pg/mL	O
(	O
p	O
<	O
.001	O
versus	O
control	O
)	O
.	O

IL	O
-	O
10	O
attenuated	B-Negative_regulation
LPS	O
-	O
stimulated	B-Positive_regulation
TNF	O
-	O
alpha	O
production	B-Gene_expression
(	O
297+/	O
-	O
54	O
;	O
p	O
<	O
.001	O
versus	O
LPS	O
alone	O
)	O
.	O

After	O
LPS	O
stimulation	O
in	O
human	O
monocytes	O
,	O
IkappaB	O
-	O
alpha	O
protein	O
levels	O
decreased	B-Negative_regulation
,	O
and	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
increased	O
.	O

IL	O
-	O
10	O
pretreatment	O
prevented	B-Negative_regulation
LPS	O
-	O
induced	O
decreases	B-Negative_regulation
in	O
IkappaB	O
-	O
alpha	O
protein	O
levels	O
and	O
attenuated	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
.	O

IL	O
-	O
10	O
appears	O
to	O
prevent	O
activation	O
of	O
NF	O
-	O
kappaB	O
by	O
preserving	B-Positive_regulation
IkappaB	O
-	O
alpha	O
protein	O
levels	O
,	O
leading	O
to	O
a	O
reduction	B-Negative_regulation
in	O
TNF	O
-	O
alpha	O
release	B-Localization
.	O

Regulation	B-Regulation
of	O
fas	O
-	O
ligand	O
expression	B-Gene_expression
during	O
activation	O
-	O
induced	O
cell	O
death	O
in	O
T	O
lymphocytes	O
via	O
nuclear	O
factor	O
kappaB	O
.	O

T	O
cell	O
receptor	O
engagement	O
activates	O
transcription	O
factors	O
important	O
for	O
cytokine	O
gene	O
regulation	O
.	O

Additionally	O
,	O
this	O
signaling	O
pathway	O
also	O
leads	O
to	O
activation	O
-	O
induced	O
apoptosis	O
in	O
T	O
lymphocytes	O
that	O
is	O
dependent	O
on	O
FasL	O
transcription	B-Transcription
and	O
expression	B-Gene_expression
.	O

Here	O
we	O
demonstrate	O
that	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
,	O
which	O
is	O
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
many	O
cytokine	O
genes	O
expressed	O
in	O
activated	O
lymphocytes	O
,	O
also	O
plays	B-Regulation
a	I-Regulation
role	I-Regulation
in	O
T	O
cell	O
activation	O
-	O
induced	B-Positive_regulation
FasL	O
expression	B-Gene_expression
.	O

Inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
in	O
a	O
T	O
cell	O
hybridoma	O
leads	B-Positive_regulation
to	O
decreased	B-Negative_regulation
FasL	O
expression	B-Gene_expression
and	O
apoptosis	O
upon	O
T	O
cell	O
receptor	O
stimulation	O
.	O

We	O
identified	O
the	O
NF	O
-	O
kappaB	O
site	O
in	O
the	O
FasL	O
promoter	O
that	O
contributes	B-Positive_regulation
to	O
such	O
regulation	O
.	O

Co	B-Gene_expression
-	I-Gene_expression
expression	I-Gene_expression
of	O
p65	O
(	O
Rel	O
A	O
)	O
with	O
the	O
FasL	O
promoter	O
enhanced	B-Positive_regulation
its	O
activity	O
,	O
and	O
co	O
-	O
expression	O
of	O
IkappaB	O
dramatically	O
inhibited	B-Negative_regulation
the	O
inducible	B-Positive_regulation
promoter	O
activity	O
.	O

In	O
contrast	O
,	O
the	O
transcription	O
factor	O
AP	O
-	O
1	O
is	O
not	O
required	B-Positive_regulation
for	O
activation	O
-	O
induced	O
FasL	O
promoter	O
activity	O
.	O

These	O
results	O
define	O
a	O
role	B-Regulation
for	O
NF	O
-	O
kappaB	O
in	O
mediating	B-Positive_regulation
FasL	O
expression	B-Gene_expression
during	O
T	O
cell	O
activation	O
.	O

X-rays	O
-	O
induced	O
secretion	O
of	O
cellular	O
factor	O
(	O
s	O
)	O
that	O
enhance	O
(	O
s	O
)	O
HIV	O
-	O
1	O
promoter	O
transcription	O
in	O
various	O
non	O
-	O
irradiated	O
transfected	O
cell	O
lines	O
.	O

Various	O
cellular	O
stress	O
agents	O
like	O
ionizing	O
radiation	O
exposure	O
could	O
activate	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
replication	O
or	O
reporter	O
gene	O
expression	O
.	O

In	O
addition	O
,	O
extracellular	O
factor	O
(	O
s	O
)	O
released	O
by	O
X-ray	O
-	O
treated	O
human	O
colonic	O
carcinoma	O
cell	O
line	O
(	O
HT29	O
)	O
might	O
activate	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
HIV	O
-	O
1	O
in	O
non	O
-	O
irradiated	O
HT29	O
cells	O
.	O

In	O
the	O
present	O
report	O
we	O
show	O
that	O
in	O
various	O
transiently	O
or	O
stably	O
transfected	O
cell	O
lines	O
,	O
X	O
-	O
ray	O
irradiation	O
up	O
-	O
regulates	O
HIV	O
-	O
1	O
LTR	O
transcription	O
through	O
the	O
kappaB	O
regulatory	O
elements	O
.	O

A	O
factor	O
(	O
s	O
)	O
,	O
which	O
is	O
processed	O
by	O
and	O
acts	O
upon	O
a	O
variety	O
of	O
cell	O
types	O
,	O
was	O
detected	O
by	O
addition	O
to	O
non	O
-	O
irradiated	O
cells	O
of	O
either	O
X-ray	O
-	O
treated	O
cells	O
or	O
a	O
conditioned	O
medium	O
taken	O
from	O
irradiated	O
cultures	O
.	O

The	O
magnitude	O
of	O
responsiveness	O
is	O
cell	O
type	O
dependent	O
.	O

In	O
addition	O
,	O
X	O
-	O
ray	O
activation	O
of	O
HIV	O
-	O
1	O
LTR	O
in	O
transiently	O
or	O
stably	O
transfected	O
cell	O
lines	O
is	O
inhibited	O
by	O
a	O
potent	O
antioxidant	O
drug	O
,	O
pyrrolidine	O
dithiocarbamate	O
and	O
by	O
another	O
drug	O
,	O
known	O
for	O
its	O
role	O
in	O
the	O
trapping	O
of	O
growth	O
factors	O
,	O
suramin	O
.	O

The	O
importance	O
of	O
these	O
observations	O
in	O
the	O
pathophysiology	O
of	O
patients	O
with	O
AIDS	O
-	O
related	O
cancers	O
treated	O
by	O
radiotherapy	O
remains	O
to	O
be	O
established	O
.	O

Reactivation	O
of	O
Kaposi	O
's	O
sarcoma	O
-	O
associated	O
herpesvirus	O
infection	O
from	O
latency	O
by	O
expression	B-Gene_expression
of	O
the	O
ORF	O
50	O
transactivator	O
,	O
a	O
homolog	O
of	O
the	O
EBV	O
R	O
protein	O
.	O

Kaposi	O
's	O
sarcoma	O
(	O
KS	O
)	O
-	O
associated	O
herpesvirus	O
(	O
KSHV	O
)	O
,	O
or	O
human	O
herpesvirus	O
8	O
,	O
is	O
a	O
lymphotropic	O
virus	O
strongly	O
linked	O
to	O
several	O
AIDS	O
-	O
related	O
neoplasms	O
.	O

The	O
primary	O
reservoir	O
of	O
infection	O
consists	O
of	O
latently	O
infected	O
B	O
lymphocytes	O
and	O
possibly	O
other	O
mononuclear	O
cells	O
.	O

Viral	O
reactivation	O
from	O
latency	O
and	O
spread	O
from	O
this	O
lymphoid	O
reservoir	O
is	O
presumably	O
required	O
for	O
development	O
of	O
nonlymphoid	O
tumors	O
like	O
KS	O
.	O

Here	O
we	O
show	O
that	O
deregulated	B-Regulation
expression	B-Gene_expression
of	O
a	O
single	O
viral	O
gene	O
,	O
ORF	O
50	O
,	O
which	O
encodes	O
a	O
transactivator	O
able	O
to	O
selectively	O
upregulate	O
delayed	O
-	O
early	O
viral	O
genes	O
,	O
suffices	O
to	O
disrupt	O
latency	O
and	O
induce	O
the	O
lytic	O
gene	O
cascade	O
in	O
latently	O
infected	O
B	O
cells	O
.	O

The	O
identification	O
of	O
this	O
gene	O
opens	O
the	O
way	O
to	O
studies	O
of	O
the	O
physiologic	O
mechanisms	O
controlling	O
reactvation	O
of	O
KSHV	O
from	O
latency	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
tax	O
protein	O
abrogates	O
interleukin	O
-	O
2	O
dependence	O
in	O
a	O
mouse	O
T	O
-	O
cell	O
line	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
is	O
the	O
etiologic	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
.	O

Tax	O
,	O
the	O
viral	O
protein	O
,	O
is	O
thought	O
to	O
be	O
crucial	O
in	O
the	O
development	O
of	O
the	O
disease	O
,	O
since	O
it	O
transforms	O
healthy	O
T	O
cells	O
in	O
vitro	O
and	O
induces	O
tumors	O
in	O
transgenic	O
animals	O
.	O

We	O
examined	O
the	O
effect	O
of	O
Tax	O
activity	O
on	O
the	O
growth	O
of	O
the	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
-	O
dependent	O
T	O
-	O
cell	O
line	O
CTLL	O
-	O
2	O
.	O

Stable	O
expression	B-Gene_expression
of	O
Tax	O
in	O
CTLL	O
-	O
2	O
transformed	O
cell	O
growth	O
from	O
being	O
IL	O
-	O
2	O
dependent	O
to	O
IL	O
-	O
2	O
independent	O
.	O

Tax	O
stimulated	O
transcription	O
through	O
NF	O
-	O
kappaB	O
and	O
the	O
cyclic	O
AMP	O
-	O
responsive	O
element	O
-	O
like	O
sequence	O
in	O
the	O
HTLV	O
-	O
1	O
promoter	O
.	O

The	O
finding	O
of	O
Tax	O
mutants	O
segregating	O
these	O
two	O
pathways	O
suggested	O
that	O
the	O
NF	O
-	O
kappaB	O
pathway	O
was	O
essential	O
for	O
IL-2	O
-	O
independent	O
growth	O
of	O
CTLL	O
-	O
2	O
cells	O
while	O
the	O
CRE	O
pathway	O
was	O
unnecessary	O
.	O

However	O
,	O
both	O
pathways	O
were	O
necessary	O
for	O
another	O
transformation	O
-	O
related	O
activity	O
(	O
colony	O
formation	O
in	O
soft	O
agar	O
)	O
of	O
CTLL	O
-	O
2/Tax	O
.	O

Our	O
results	O
show	O
that	O
Tax	O
has	O
at	O
least	O
two	O
distinct	O
activities	O
on	O
T	O
cells	O
,	O
and	O
suggest	O
that	O
Tax	O
plays	O
a	O
crucial	O
role	O
in	O
IL-2	O
-	O
independent	O
T	O
-	O
cell	O
transformation	O
induced	O
by	O
HTLV	O
-	O
1	O
,	O
in	O
addition	O
to	O
its	O
well	O
-	O
known	O
IL-2	O
-	O
dependent	O
cell	O
transformation	O
.	O

Regulation	B-Regulation
of	O
IL	O
-	O
6	O
synthesis	B-Gene_expression
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
C3a	O
and	O
C3a	O
(	O
desArg	O
)	O
.	O

The	O
anaphylatoxin	O
C3a	O
has	O
been	O
reported	O
to	O
have	O
immunomodulatory	O
effects	O
on	O
a	O
number	O
of	O
different	O
cell	O
types	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
effects	B-Regulation
of	O
C3a	O
and	O
C3a	O
(	O
desArg	O
)	O
on	O
gene	B-Gene_expression
expression	I-Gene_expression
and	O
protein	B-Localization
secretion	I-Localization
of	O
IL	O
-	O
6	O
in	O
human	O
PBMCs	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
LPS	O
or	O
IL	O
-	O
1beta	O
.	O

C3a	O
or	O
C3a	O
(	O
desArg	O
)	O
alone	O
exhibited	O
no	O
effect	B-Regulation
on	O
the	O
expression	B-Gene_expression
or	O
secretion	B-Localization
of	O
IL	O
-	O
6	O
.	O

However	O
,	O
when	B-Positive_regulation
PBMC	O
were	O
stimulated	O
with	O
LPS	O
or	O
IL	O
-	O
1beta	O
,	O
both	O
C3a	O
and	O
C3a	O
(	O
desArg	O
)	O
were	O
found	O
to	O
enhance	B-Positive_regulation
IL	O
-	O
6	O
release	B-Localization
by	O
PBMC	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Since	O
C3a	O
has	O
been	O
shown	O
to	O
induce	O
PGE2	O
production	O
by	O
monocytes	O
,	O
and	O
PGE2	O
has	O
been	O
shown	O
to	O
influence	O
cytokine	O
production	O
,	O
we	O
investigated	O
the	O
potential	O
role	B-Regulation
of	O
PGE2	O
in	O
C3a	O
-	O
mediated	O
enhancement	B-Positive_regulation
of	O
LPS	O
-	O
and	O
IL-1beta	O
-	O
induced	B-Positive_regulation
IL	O
-	O
6	O
production	B-Gene_expression
.	O

Indomethacin	O
blocked	O
PGE2	O
release	O
,	O
but	O
had	O
no	O
influence	B-Regulation
on	O
the	O
observed	O
effects	O
of	O
C3a	O
,	O
suggesting	O
that	O
the	O
effects	B-Regulation
of	O
C3a	O
on	O
IL	O
-	O
6	O
production	B-Gene_expression
are	O
independent	B-Regulation
of	O
PGE2	O
formation	O
by	O
monocytes	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
C3a	O
as	O
well	O
as	O
C3a	O
(	O
desArg	O
)	O
enhanced	B-Positive_regulation
LPS	O
-	O
induced	B-Positive_regulation
mRNA	O
levels	O
for	O
IL	O
-	O
6	O
.	O

Pretreatment	O
of	O
PBMCs	O
with	O
pertussis	O
toxin	O
blocked	B-Negative_regulation
the	O
functions	O
of	O
C3a	O
and	O
C3a	O
(	O
desArg	O
)	O
,	O
indicating	O
that	O
the	O
actions	O
of	O
these	O
two	O
molecules	O
are	O
mediated	B-Positive_regulation
by	O
a	O
G	O
protein	O
-	O
coupled	O
pathway	O
.	O

Furthermore	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
C3a	O
and	O
C3a	O
(	O
desArg	O
)	O
on	O
induction	O
of	O
NF	O
-	O
kappaB	O
and	O
activating	O
protein	O
-	O
1	O
binding	O
.	O

Both	O
molecules	O
enhanced	O
LPS	O
-	O
induced	O
NF	O
-	O
kappaB	O
and	O
activating	O
protein	O
-	O
1	O
binding	O
activity	O
.	O

These	O
results	O
demonstrate	O
the	O
capacity	O
of	O
intact	O
C3a	O
and	O
its	O
circulating	O
des	O
-	O
Arg	O
form	O
to	O
exert	O
immunmodulatory	O
effects	O
in	O
vitro	O
.	O

Differential	O
monocyte	O
adhesion	O
and	O
adhesion	O
molecule	O
expression	O
in	O
venous	O
and	O
arterial	O
endothelial	O
cells	O
.	O

We	O
compared	O
U	O
-	O
937	O
cell	O
adhesion	O
and	O
adhesion	O
molecule	O
expression	O
in	O
human	O
umbilical	O
venous	O
(	O
HUVECs	O
)	O
and	O
arterial	O
(	O
HUAECs	O
)	O
endothelial	O
cells	O
exposed	O
to	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
,	O
interleukin	O
-	O
1	O
,	O
and	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

TNF	O
and	O
LPS	O
stimulated	B-Positive_regulation
vascular	O
cell	O
adhesion	O
molecule	O
(	O
VCAM	O
)	O
-	O
1	O
surface	O
expression	B-Gene_expression
and	O
adhesion	O
of	O
U	O
-	O
937	O
monocyte	O
-	O
like	O
cells	O
to	O
HUVECs	O
but	O
not	O
to	O
HUAECs	O
.	O

Antibody	O
studies	O
demonstrated	O
that	O
in	O
HUVECs	O
at	O
least	O
75	O
%	O
of	O
the	O
adhesion	O
response	O
is	O
VCAM	O
-	O
1	O
mediated	O
.	O

Interleukin	O
-	O
1	O
stimulated	B-Positive_regulation
U	O
-	O
937	O
cell	O
adhesion	O
to	O
and	O
VCAM	O
-	O
1	O
surface	O
expression	B-Gene_expression
in	O
both	O
HUVECs	O
and	O
HUAECs	O
.	O

Pyrrolidinedithiocarbamate	O
and	O
the	O
proteasome	O
inhibitor	O
MG	O
-	O
132	O
blocked	O
TNF	O
-	O
and	O
LPS	O
-	O
stimulated	O
U	O
-	O
937	O
cell	O
adhesion	O
to	O
HUVECs	O
.	O

These	O
agents	O
also	O
significantly	O
decreased	B-Negative_regulation
TNF	O
-	O
and	O
LPS	O
-	O
stimulated	O
increases	B-Positive_regulation
in	O
HUVEC	O
surface	O
VCAM	O
-	O
1	O
.	O

TNF	O
increased	B-Positive_regulation
VCAM	O
-	O
1	O
protein	O
and	O
mRNA	O
in	O
HUVECs	O
that	O
was	O
blocked	B-Negative_regulation
by	O
pyrrolidinedithiocarbamate	O
.	O

However	O
,	O
neither	O
TNF	O
or	O
LPS	O
stimulated	B-Positive_regulation
VCAM	O
-	O
1	O
expression	B-Gene_expression
in	O
HUAECs	O
.	O

TNF	O
stimulated	B-Positive_regulation
expression	B-Gene_expression
of	O
both	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
and	O
E	O
-	O
selectin	O
in	O
HUVECs	O
,	O
but	O
in	O
HUAECs	O
,	O
only	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
was	O
increased	B-Positive_regulation
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
no	O
difference	O
in	O
the	O
pattern	O
of	O
TNF	O
-	O
stimulated	O
nuclear	O
factor	O
-	O
kappaB	O
activation	O
between	O
HUVECs	O
and	O
HUAECs	O
.	O

These	O
studies	O
demonstrate	O
a	O
novel	O
and	O
striking	O
insensitivity	O
of	O
arterial	O
endothelium	O
to	O
the	O
effects	O
of	O
TNF	O
and	O
LPS	O
and	O
indicate	O
a	O
dissociation	O
between	O
the	O
ability	O
of	O
HUAECs	O
to	O
upregulate	B-Positive_regulation
nuclear	O
factor	O
-	O
kappaB	O
and	O
VCAM	O
-	O
1	O
.	O

Tissue	O
factor	O
expression	B-Gene_expression
of	O
human	O
monocytes	O
is	O
suppressed	B-Negative_regulation
by	O
lysophosphatidylcholine	O
.	O

The	O
expression	B-Gene_expression
of	O
tissue	O
factor	O
(	O
TF	O
)	O
,	O
the	O
principal	O
initiator	O
of	O
coagulation	O
,	O
is	O
increased	B-Positive_regulation
during	O
inflammation	O
and	O
atherosclerosis	O
.	O

Both	O
conditions	O
are	O
promoted	B-Positive_regulation
by	O
lysophosphatidylcholine	O
(	O
lysoPC	O
)	O
.	O

We	O
observed	O
in	O
the	O
present	O
study	O
that	O
lysoPC	O
(	O
1	O
to	O
10	O
micromol/L	O
)	O
dose	O
-	O
dependently	O
reduced	B-Negative_regulation
TF	O
activity	O
in	O
human	O
monocytes	O
,	O
as	O
elicited	B-Positive_regulation
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Lysophosphatidylethanolamine	O
(	O
lysoPE	O
)	O
and	O
other	O
lysophospholipids	O
did	O
not	O
affect	B-Regulation
LPS	O
-	O
induced	B-Positive_regulation
TF	O
activity	O
of	O
human	O
monocytes	O
.	O

TF	O
antigen	O
expression	B-Gene_expression
as	O
elicited	B-Positive_regulation
by	O
LPS	O
was	O
also	O
lowered	B-Negative_regulation
by	O
lysoPC	O
.	O

Phospholipid	O
analyses	O
indicated	O
a	O
selective	O
increase	O
in	O
the	O
lysoPC	O
content	O
of	O
the	O
monocytes	O
after	O
preincubation	O
with	O
the	O
lysophospholipid	O
.	O

LysoPC	O
inhibited	B-Negative_regulation
the	O
TF	O
activity	O
of	O
Mono	O
Mac	O
-	O
6	O
cells	O
to	O
a	O
similar	O
extent	O
as	O
in	O
the	O
monocytes	O
.	O

LPS	O
binding	O
to	O
plasma	O
membrane	O
receptors	O
and	O
internalization	O
of	O
LPS	O
into	O
monocytes	O
were	O
not	O
affected	O
by	O
lysoPC	O
.	O

In	O
contrast	O
,	O
LPS	O
-	O
mediated	O
nuclear	O
binding	O
of	O
nuclear	O
factor	O
-	O
kappaB/Rel	O
to	O
a	O
TF	O
-	O
specific	O
kappaB	O
site	O
was	O
inhibited	O
by	O
lysoPC	O
.	O

Induction	B-Positive_regulation
of	O
TF	O
mRNA	O
expression	B-Transcription
by	O
LPS	O
tended	O
to	O
be	O
partially	O
reduced	B-Negative_regulation
by	O
the	O
lysophospholipid	O
.	O

Preincubation	O
with	O
lysoPC	O
increased	O
monocytic	O
cAMP	O
levels	O
.	O

Inhibition	O
of	O
adenylyl	O
cyclase	O
by	O
pretreatment	O
with	O
2'-deoxy-3'	O
-	O
adenosine	O
monophosphate	O
partially	O
reversed	B-Negative_regulation
the	O
inhibition	B-Negative_regulation
of	O
TF	O
activity	O
promoted	O
by	O
lysoPC	O
.	O

In	O
conclusion	O
,	O
lysoPC	O
markedly	O
decreases	B-Negative_regulation
LPS	O
-	O
mediated	B-Positive_regulation
TF	O
expression	B-Gene_expression
of	O
human	O
monocytes	O
,	O
the	O
effect	O
probably	O
being	O
mediated	B-Positive_regulation
by	O
both	O
transcriptional	O
and	O
posttranscriptional	O
mechanisms	O
.	O

LysoPC	O
may	O
thus	O
attenuate	O
activation	O
of	O
coagulation	O
during	O
inflammation	O
and	O
atherosclerosis	O
.	O

Intranuclear	O
targeted	O
delivery	O
of	O
functional	O
NF	O
-	O
kappaB	O
by	O
70	O
kDa	O
heat	O
shock	O
protein	O
.	O

The	O
70	O
kDa	O
heat	O
shock	O
protein	O
(	O
Hsp70	O
)	O
is	O
a	O
highly	O
conserved	O
,	O
ubiquitous	O
protein	O
involved	O
in	O
chaperoning	O
proteins	O
to	O
various	O
cellular	O
organelles	O
.	O

Here	O
we	O
show	O
that	O
when	O
added	O
exogenously	O
to	O
cells	O
,	O
Hsp70	O
is	O
readily	O
imported	O
into	O
both	O
cytoplasmic	O
and	O
nuclear	O
compartments	O
in	O
a	O
cell-type	O
-	O
specific	O
fashion	O
.	O

We	O
exploited	O
this	O
ability	O
of	O
Hsp70	O
to	O
deliver	O
NF	O
-	O
kappaB	O
,	O
a	O
key	O
transcriptional	O
regulator	O
of	O
inflammatory	O
responses	O
.	O

We	O
demonstrate	O
that	O
a	O
fusion	O
protein	O
composed	O
of	O
a	O
C	O
-	O
terminal	O
Hsp70	O
peptide	O
and	O
the	O
p50	O
subunit	O
of	O
NF	O
-	O
kappaB	O
was	O
directed	B-Localization
into	O
the	O
nucleus	O
of	O
cells	O
,	O
could	O
bind	B-Binding
DNA	O
specifically	O
,	O
and	O
activated	B-Positive_regulation
Igkappa	O
expression	B-Gene_expression
and	O
TNFalpha	O
production	B-Gene_expression
.	O

We	O
therefore	O
propose	O
that	O
Hsp70	O
can	O
be	O
used	O
as	O
a	O
vehicle	O
for	O
intracytoplasmic	O
and	O
intranuclear	O
delivery	O
of	O
proteins	O
or	O
DNA	O
to	O
modulate	O
gene	O
expression	O
and	O
thereby	O
control	O
immune	O
responses	O
.	O

CD2	O
signalling	O
induces	B-Positive_regulation
phosphorylation	B-Phosphorylation
of	O
CREB	O
in	O
primary	O
lymphocytes	O
.	O

Promoter	O
sequences	O
responsive	O
to	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
are	O
found	O
in	O
a	O
number	O
of	O
cellular	O
genes	O
,	O
and	O
bind	O
transcription	O
factors	O
of	O
the	O
cAMP	O
response	O
element	O
binding	O
protein	O
(	O
CREB	O
)	O
/activating	O
transcription	O
factor	O
-	O
1	O
(	O
ATF	O
-	O
1	O
)	O
family	O
.	O

We	O
have	O
used	O
a	O
human	O
T	O
-	O
lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
model	O
of	O
cAMP	O
response	O
element	O
(	O
CRE	O
)	O
transcription	O
to	O
investigate	O
the	O
influence	O
of	O
lymphocyte	O
activation	O
on	O
transcription	O
from	O
homologous	O
regions	O
in	O
the	O
viral	O
promoter	O
.	O

We	O
previously	O
demonstrated	O
increased	O
HTLV	O
-	O
1	O
transcription	O
following	O
CD2	O
but	O
not	O
CD3	O
receptor	O
cross	B-Binding
-	I-Binding
linking	I-Binding
.	O

We	O
hypothesized	O
that	O
this	O
increased	O
viral	O
transcription	O
was	O
mediated	O
,	O
in	O
part	O
,	O
through	O
the	O
phosphorylation	B-Phosphorylation
of	O
CREB	O
.	O

Therefore	O
,	O
we	O
investigated	O
CD2	O
and	O
CD3	O
receptor	O
-	O
mediated	O
signalling	O
in	O
primary	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O

CD2	O
,	O
but	O
not	O
CD3	O
,	O
cross	B-Binding
-	I-Binding
linking	I-Binding
increased	O
cAMP	O
detected	O
by	O
competitive	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
approximately	O
fourfold	O
.	O

CD2	O
cross	B-Binding
-	I-Binding
linking	I-Binding
concurrently	O
increased	B-Positive_regulation
phosphorylation	B-Phosphorylation
of	O
CREB	O
detected	O
by	O
immunoblot	O
assay	O
eightfold	O
.	O

Consistent	O
with	O
post	O
-	O
translational	O
regulation	O
,	O
no	O
change	O
in	O
total	O
level	O
of	O
CREB	O
protein	O
was	O
observed	O
.	O

Phosphorylation	B-Phosphorylation
of	O
CREB	O
occurred	O
through	B-Positive_regulation
a	O
herbimycin	O
A	O
and	O
Rp-cAMP	O
-	O
sensitive	O
pathway	O
,	O
suggesting	O
phosphorylation	O
required	B-Positive_regulation
antecedent	O
activation	O
of	O
both	O
protein	O
tyrosine	O
kinases	O
(	O
PTK	O
)	O
and	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
.	O

Both	O
CD2	O
and	O
CD3	O
cross	B-Binding
-	I-Binding
linking	I-Binding
increased	O
binding	O
of	O
nuclear	O
proteins	O
to	O
a	O
radiolabelled	O
CRE	O
oligonucleotide	O
probe	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggesting	O
that	O
lymphocyte	O
activation	O
enhances	O
binding	O
independently	O
of	O
phosphorylation	B-Phosphorylation
of	O
CREB	O
at	O
serine	O
133	O
.	O

These	O
data	O
indicate	O
specific	O
modulation	B-Regulation
of	O
the	O
CREB/ATF	O
-	O
1	O
family	O
of	O
transcription	O
factors	O
by	O
the	O
CD2	O
signalling	O
pathway	O
and	O
suggest	O
CD2	O
receptor	O
modulation	O
of	O
CRE	O
-	O
mediated	O
transcription	O
following	O
ligand	O
engagement	O
(	O
e.g.	O
cell-to	O
-	O
cell	O
contact	O
)	O
.	O

Anoxia/reoxygenation	O
-	O
induced	O
tolerance	O
with	O
respect	O
to	O
polymorphonuclear	O
leukocyte	O
adhesion	O
to	O
cultured	O
endothelial	O
cells	O
.	O

A	O
nuclear	O
factor-kappaB	O
-	O
mediated	O
phenomenon	O
.	O

Exposing	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
to	O
anoxia/reoxygenation	O
(	O
A/R	O
)	O
results	O
in	O
an	O
increase	O
in	O
polymorphonuclear	O
leukocyte	O
(	O
PMN	O
)	O
adhesion	O
to	O
HUVECs	O
.	O

This	O
A/R	O
-	O
induced	O
hyperadhesion	O
is	O
completely	O
prevented	O
by	O
a	O
previous	O
(	O
24	O
hours	O
earlier	O
)	O
exposure	O
of	O
HUVECs	O
to	O
A/R	O
.	O

This	O
phenomenon	O
has	O
been	O
termed	O
"	O
A/R	O
tolerance.	O
"	O
Exposing	O
HUVECs	O
to	O
A/R	O
induces	O
an	O
increase	O
in	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
in	O
HUVEC	O
nuclei	O
within	O
4	O
hours	O
.	O

Interfering	O
with	O
either	O
NF	O
-	O
kappaB	O
activation	O
(	O
proteasome	O
inhibitor	O
)	O
or	O
translocation	O
(	O
double	O
-	O
stranded	O
oligonucleotides	O
containing	O
NF	O
-	O
kappaB	O
binding	O
sequence	O
)	O
prevents	O
the	O
development	O
of	O
A/R	O
tolerance	O
(	O
ie	O
,	O
the	O
increase	O
in	O
A/R	O
-	O
induced	O
PMN	O
adhesion	O
to	O
HUVECs	O
is	O
the	O
same	O
after	O
the	O
first	O
and	O
second	O
A/R	O
challenges	O
)	O
.	O

NO	O
production	O
by	O
HUVECs	O
is	O
increased	O
after	O
the	O
second	O
A/R	O
challenge	O
,	O
but	O
not	O
after	O
the	O
first	O
A/R	O
challenge	O
.	O

Inhibition	B-Negative_regulation
of	O
NO	O
synthase	O
(	O
NOS	O
)	O
during	O
the	O
second	O
A/R	O
challenge	O
prevents	O
the	O
development	O
of	O
A/R	O
tolerance	O
with	O
respect	O
to	O
PMN	O
adhesion	O
.	O

However	O
,	O
while	O
HUVECs	O
contained	B-Gene_expression
endothelial	O
NOS	O
protein	O
,	O
no	O
inducible	B-Positive_regulation
NOS	O
was	O
detected	O
in	O
either	O
tolerant	O
or	O
nontolerant	O
cells	O
.	O

Further	O
studies	O
indicated	O
that	O
inhibition	B-Negative_regulation
of	O
GTP	O
-	O
cyclohydrolase	O
I	O
(	O
an	O
enzyme	O
involved	O
in	O
de	O
novo	O
synthesis	O
of	O
an	O
important	O
cofactor	O
for	O
NOS	O
activity	O
,	O
tetrahydrobiopterin	O
)	O
prevented	O
the	O
generation	O
of	O
NO	O
in	O
A/R	O
-	O
tolerant	O
cells	O
.	O

Extracellular	O
generation	O
of	O
NO	O
(	O
NO	O
donor	O
)	O
did	O
not	O
effect	O
the	O
hyperadhesion	O
response	O
induced	O
by	O
the	O
initial	O
A/R	O
challenge	O
.	O

A/R	O
also	O
induced	O
an	O
oxidant	O
stress	O
in	O
naive	O
HUVECs	O
,	O
but	O
not	O
in	O
A/R	O
-	O
tolerant	O
HUVECs	O
.	O

Inhibition	B-Negative_regulation
of	O
NOS	O
during	O
the	O
second	O
A/R	O
insult	O
results	O
in	O
the	O
generation	O
of	O
an	O
oxidant	O
stress	O
similar	O
to	O
that	O
observed	O
after	O
the	O
first	O
A/R	O
challenge	O
.	O

Taken	O
together	O
,	O
the	O
findings	O
of	O
the	O
present	O
study	O
are	O
consistent	O
with	O
a	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
the	O
development	O
of	O
A/R	O
tolerance	O
(	O
with	O
respect	O
to	O
PMN	O
adhesion	O
)	O
,	O
perhaps	O
by	O
transcriptional	B-Regulation
regulation	I-Regulation
of	O
GTP	O
-	O
cyclohydrolase	O
.	O

The	O
increased	O
NO	O
production	O
during	O
the	O
second	O
A/R	O
insult	O
reduces	O
PMN	O
adhesion	O
most	O
likely	O
by	O
reducing	O
the	O
intracellular	O
oxidant	O
stress	O
induced	O
by	O
A/R	O
.	O

Role	B-Regulation
of	O
Egr	O
-	O
2	O
in	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
Fas	O
ligand	O
in	O
normal	O
T	O
cells	O
and	O
aberrant	O
double	O
-	O
negative	O
lpr	O
and	O
gld	O
T	O
cells	O
.	O

We	O
previously	O
identified	O
a	O
Fas	O
ligand	O
regulatory	O
element	O
(	O
FLRE	O
)	O
in	O
the	O
Fas	O
ligand	O
(	O
fasL	O
)	O
promoter	O
that	O
binds	B-Binding
Egr	O
family	O
proteins	O
and	O
demonstrated	O
that	O
Egr	O
-	O
3	O
(	O
PILOT	O
)	O
but	O
not	O
Egr	O
-	O
1	O
(	O
NGFI	O
-	O
A	O
,	O
Krox	O
-	O
24	O
,	O
Tis	O
-	O
8	O
,	O
and	O
Zif	O
-	O
268	O
)	O
induces	B-Positive_regulation
transcription	B-Transcription
of	O
fasL	O
.	O

The	O
aberrant	O
CD4	O
(	O
-	O
)	O
CD8	O
(	O
-	O
)	O
T	O
cells	O
from	O
lpr/lpr	O
and	O
gld/gld	O
mice	O
,	O
which	O
have	O
mutations	O
in	O
the	O
genes	O
encoding	O
Fas	O
and	O
FasL	O
,	O
respectively	O
,	O
have	O
an	O
activated	O
phenotype	O
and	O
constitutively	O
express	B-Transcription
high	B-Positive_regulation
levels	I-Positive_regulation
of	O
fasL	O
mRNA	O
,	O
prompting	O
us	O
to	O
ask	O
what	O
role	B-Regulation
if	O
any	O
the	O
FLRE	O
and	O
Egr	O
family	O
proteins	O
have	O
in	O
this	O
aberrant	O
expression	O
of	O
fasL	O
.	O

Unstimulated	O
MRL	O
-	O
lpr/lpr	O
and	O
C3H	O
-	O
gld/gld	O
CD4	O
(	O
-	O
)	O
CD8	O
(	O
-	O
)	O
T	O
cells	O
constitutively	O
contained	O
high	O
levels	O
of	O
two	O
proteins	O
that	O
bound	O
to	O
the	O
FLRE	O
.	O

Supershift	O
analysis	O
revealed	O
these	O
proteins	O
to	O
be	O
Egr	O
-	O
1	O
and	O
Egr	O
-	O
2	O
(	O
Krox	O
-	O
20	O
)	O
;	O
Egr	O
-	O
3	O
was	O
not	O
detected	B-Gene_expression
.	O

Activation	O
of	O
normal	O
lymph	O
node	O
cells	O
resulted	B-Positive_regulation
in	I-Positive_regulation
increased	I-Positive_regulation
expression	B-Gene_expression
of	O
Egr	O
-	O
1	O
,	O
-	O
2	O
,	O
and	O
-	O
3	O
.	O

As	O
with	O
egr	O
-	O
3	O
,	O
expression	B-Gene_expression
of	O
egr	O
-	O
2	O
was	O
blocked	B-Negative_regulation
by	O
cyclosporin	O
A	O
.	O

Although	O
overexpressed	B-Gene_expression
Egr	O
-	O
1	O
was	O
ineffective	O
,	O
overexpressed	B-Gene_expression
Egr	O
-	O
2	O
was	O
as	O
potent	O
as	O
Egr	O
-	O
3	O
in	O
inducing	O
fasL	O
promoter	O
-	O
dependent	O
reporter	O
constructs	O
in	O
T	O
cell	O
hybridomas	O
and	O
HeLa	O
cells	O
,	O
and	O
both	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
endogenous	O
fasL	O
mRNA	O
in	O
HeLa	O
cells	O
.	O

FasL	O
-	O
dependent	O
reporter	O
constructs	O
in	O
MRL	O
-	O
lpr/lpr	O
and	O
C3H	O
-	O
gld/gld	O
CD4	O
(	O
-	O
)	O
CD8	O
(	O
-	O
)	O
T	O
cells	O
were	O
constitutively	O
active	O
,	O
and	O
this	O
activity	O
was	O
largely	O
prevented	O
by	O
mutation	O
of	O
the	O
critical	O
Egr	O
family	O
binding	O
element	O
.	O

Thus	O
,	O
Egr	O
-	O
2	O
,	O
in	O
addition	O
to	O
Egr	O
-	O
3	O
,	O
regulates	B-Regulation
FasL	O
expression	B-Gene_expression
in	O
activated	O
normal	O
T	O
cells	O
,	O
and	O
Egr	O
-	O
2	O
is	O
likely	O
to	O
play	O
a	O
direct	O
role	B-Regulation
in	O
aberrant	O
fasL	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
in	O
lpr/lpr	O
and	O
gld/gld	O
CD4	O
(	O
-	O
)	O
CD8	O
(	O
-	O
)	O
T	O
cells	O
.	O

Involvement	B-Regulation
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
pathways	O
in	O
interleukin	O
-	O
8	O
production	B-Gene_expression
by	O
human	O
monocytes	O
and	O
polymorphonuclear	O
cells	O
stimulated	O
with	O
lipopolysaccharide	O
or	O
Mycoplasma	O
fermentans	O
membrane	O
lipoproteins	O
.	O

Interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
)	O
is	O
a	O
chemokine	O
that	O
belongs	O
to	O
the	O
alpha	O
-	O
chemokine	O
or	O
CXC	O
subfamily	O
and	O
is	O
produced	B-Gene_expression
by	O
a	O
wide	O
variety	O
of	O
human	O
cells	O
,	O
including	O
monocytes	O
and	O
polymorphonuclear	O
cells	O
(	O
PMN	O
)	O
.	O

IL	O
-	O
8	O
is	O
secreted	B-Localization
in	B-Positive_regulation
response	I-Positive_regulation
to	I-Positive_regulation
inflammatory	O
stimuli	O
,	O
notably	O
bacterial	O
products	O
such	O
as	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
mechanisms	O
by	O
which	O
these	O
agents	O
mediate	O
IL	O
-	O
8	O
induction	B-Positive_regulation
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
Mycoplasma	O
fermentans	O
lipid	O
-	O
associated	O
membrane	O
proteins	O
(	O
LAMPf	O
)	O
induce	B-Positive_regulation
the	O
production	B-Gene_expression
of	O
high	B-Positive_regulation
levels	I-Positive_regulation
of	O
IL	O
-	O
8	O
by	O
THP	O
-	O
1	O
(	O
human	O
monocyte	O
)	O
cells	O
and	O
PMN	O
at	O
the	O
same	O
extent	O
as	O
LPS	O
.	O

It	O
was	O
previously	O
demonstrated	O
that	O
stimulation	O
of	O
monocytic	O
cells	O
with	O
either	O
LPS	O
or	O
LAMPf	O
led	O
to	O
a	O
series	O
of	O
common	O
downstream	O
signaling	O
events	O
,	O
including	O
the	O
activation	O
of	O
protein	O
tyrosine	O
kinase	O
and	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
cascades	O
.	O

By	O
using	O
PD	O
-	O
98059	O
and	O
SB203580	O
,	O
two	O
potent	O
and	O
selective	O
inhibitors	B-Negative_regulation
of	O
MEK1	O
(	O
a	O
kinase	O
upstream	O
of	O
ERK1/2	O
)	O
and	O
p38	O
,	O
respectively	O
,	O
we	O
have	O
demonstrated	O
that	O
both	O
ERK1/2	O
and	O
p38	O
cascades	O
play	O
a	O
key	O
role	B-Positive_regulation
in	O
the	O
production	B-Gene_expression
of	O
IL	O
-	O
8	O
by	O
monocytes	O
and	O
PMN	O
stimulated	O
with	O
bacterial	O
fractions	O
.	O

T	O
cell	O
priming	O
enhances	B-Positive_regulation
IL	O
-	O
4	O
gene	O
expression	B-Gene_expression
by	O
increasing	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
.	O

The	O
repetitive	O
activation	O
of	O
T	O
cells	O
(	O
priming	O
)	O
enhances	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
many	O
cytokines	O
,	O
such	O
as	O
IL	O
-	O
4	O
,	O
but	O
not	O
others	O
,	O
such	O
as	O
IL	O
-	O
2	O
.	O

Molecular	O
mechanisms	O
underlying	O
selective	O
expression	O
of	O
cytokines	O
by	O
T	O
cells	O
remain	O
poorly	O
understood	O
.	O

Here	O
we	O
show	O
that	O
priming	O
of	O
CD4	O
T	O
cells	O
selectively	O
enhances	O
IL	O
-	O
4	O
expression	O
relative	O
to	O
IL	O
-	O
2	O
expression	B-Gene_expression
by	O
a	O
transcriptional	O
mechanism	O
involving	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
proteins	O
.	O

As	O
detected	O
by	O
in	O
vivo	O
footprinting	O
,	O
priming	O
markedly	O
increases	B-Positive_regulation
the	O
activation	B-Positive_regulation
-	O
dependent	B-Regulation
engagement	B-Binding
of	O
the	O
P0	O
and	O
P1	O
NFAT	O
-	O
binding	O
elements	O
of	O
the	O
IL	O
-	O
4	O
promoter	O
.	O

Moreover	O
,	O
each	O
proximal	O
P	O
element	O
is	O
essential	B-Positive_regulation
for	O
optimal	O
IL	O
-	O
4	O
promoter	O
activity	O
.	O

Activated	O
primed	O
CD4	O
T	O
cells	O
contain	B-Gene_expression
more	B-Positive_regulation
NFAT1	O
and	O
support	O
greater	O
NFAT	O
-	O
directed	O
transcription	O
than	O
unprimed	O
CD4	O
T	O
cells	O
,	O
while	O
activator	O
protein	O
1	O
binding	O
and	O
activator	O
protein	O
1	O
-	O
mediated	O
transcription	O
by	O
both	O
cell	O
types	O
is	O
similar	O
.	O

Increased	O
expression	B-Gene_expression
of	O
wild	O
-	O
type	O
NFAT1	O
substantially	O
increases	B-Positive_regulation
IL	O
-	O
4	O
promoter	O
activity	O
in	O
unprimed	O
CD4	O
T	O
cells	O
,	O
suggesting	O
NFAT1	O
may	O
be	O
limiting	B-Negative_regulation
for	O
IL	O
-	O
4	O
gene	B-Gene_expression
expression	I-Gene_expression
in	O
this	O
cell	O
type	O
.	O

Furthermore	O
,	O
a	O
truncated	O
form	O
of	O
NFAT1	O
acts	O
as	O
a	O
dominant	O
-	O
negative	O
,	O
reducing	B-Negative_regulation
IL	O
-	O
4	O
promoter	O
activity	O
in	O
primed	O
CD4	O
T	O
cells	O
and	O
confirming	O
the	O
importance	B-Regulation
of	O
endogenous	O
NFAT	O
to	O
increased	B-Positive_regulation
IL	O
-	O
4	O
gene	B-Gene_expression
expression	I-Gene_expression
by	O
effector	O
T	O
cells	O
.	O

NFAT1	O
appears	O
to	O
be	O
the	O
major	O
NFAT	O
family	O
member	O
responsible	B-Regulation
for	O
the	O
initial	O
increased	B-Positive_regulation
expression	B-Gene_expression
of	O
IL	O
-	O
4	O
by	O
primed	O
CD4	O
T	O
cells	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
vitro	O
and	O
in	O
vivo	O
:	O
role	O
of	O
26S	O
proteasome	O
.	O

It	O
is	O
becoming	O
increasingly	O
apparent	O
that	O
NF	O
-	O
kappa	O
B	O
plays	O
a	O
critical	O
role	O
in	O
regulating	O
the	O
inflammatory	O
response	O
.	O

Data	O
obtained	O
from	O
studies	O
in	O
our	O
laboratories	O
demonstrate	O
that	O
the	O
proteasome	O
plays	O
an	O
important	O
role	O
in	O
the	O
inflammatory	O
cascade	O
by	O
regulating	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Indeed	O
,	O
the	O
availability	O
of	O
selective	O
and	O
orally	O
active	O
proteasome	O
inhibitors	O
should	O
prove	O
useful	O
in	O
delineating	O
the	O
roles	O
of	O
the	O
proteasome	O
and	O
NF	O
-	O
kappa	O
B	O
in	O
other	O
pathophysiological	O
conditions	O
such	O
as	O
cancer	O
and	O
heart	O
disease	O
.	O

NF	O
-	O
kappaB	O
activation	O
is	O
a	O
critical	O
regulator	O
of	O
human	O
granulocyte	O
apoptosis	O
in	O
vitro	O
.	O

During	O
beneficial	O
inflammation	O
,	O
potentially	O
tissue	O
-	O
damaging	O
granulocytes	O
undergo	O
apoptosis	O
before	O
being	O
cleared	O
by	O
phagocytes	O
in	O
a	O
non	O
-	O
phlogistic	O
manner	O
.	O

Here	O
we	O
show	O
that	O
the	O
rate	O
of	O
constitutive	O
apoptosis	O
in	O
human	O
neutrophils	O
and	O
eosinophils	O
is	O
greatly	O
accelerated	O
in	O
both	O
a	O
rapid	O
and	O
concentration	O
-	O
dependent	O
manner	O
by	O
the	O
fungal	O
metabolite	O
gliotoxin	O
,	O
but	O
not	O
by	O
its	O
inactive	O
analog	O
methylthiogliotoxin	O
.	O

This	O
induction	O
of	O
apoptosis	O
was	O
abolished	O
by	O
the	O
caspase	O
inhibitor	O
zVAD	O
-	O
fmk	O
,	O
correlated	O
with	O
the	O
inhibition	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
,	O
and	O
was	O
mimicked	O
by	O
a	O
cell	O
permeable	O
inhibitory	O
peptide	O
of	O
NF	O
-	O
kappaB	O
,	O
SN	O
-	O
50	O
;	O
other	O
NF	O
-	O
kappaB	O
inhibitors	O
,	O
curcumin	O
and	O
pyrrolidine	O
dithiocarbamate	O
;	O
and	O
the	O
proteasome	O
inhibitor	O
,	O
MG	O
-	O
132	O
.	O

Gliotoxin	O
also	O
augmented	O
dramatically	O
the	O
early	O
(	O
2	O
-	O
6	O
h	O
)	O
pro	O
-	O
apoptotic	O
effects	O
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
in	O
neutrophils	O
and	O
unmasked	O
the	O
ability	O
of	O
TNF	O
-	O
alpha	O
to	O
induce	O
eosinophil	O
apoptosis	O
.	O

In	O
neutrophils	O
,	O
TNF	O
-	O
alpha	O
caused	O
a	O
gliotoxin	O
-	O
inhibitable	O
activation	O
of	O
an	O
inducible	O
form	O
of	O
NF	O
-	O
kappaB	O
,	O
a	O
response	O
that	O
may	O
underlie	B-Positive_regulation
the	I-Positive_regulation
ability	I-Positive_regulation
of	O
TNF	O
-	O
alpha	O
to	O
delay	O
apoptosis	O
at	O
later	O
times	O
(	O
12	O
-	O
24	O
h	O
)	O
and	O
limit	O
its	O
early	O
killing	O
effect	O
.	O

Furthermore	O
,	O
cycloheximide	O
displayed	O
a	O
similar	O
capacity	O
to	O
enhance	O
TNF	O
-	O
alpha	O
induced	O
neutrophil	O
apoptosis	O
even	O
at	O
time	O
points	O
when	O
cycloheximide	O
alone	O
had	O
no	O
pro	O
-	O
apoptotic	O
effect	O
,	O
suggesting	O
that	O
NF	O
-	O
kappaB	O
may	O
regulate	O
the	O
production	O
of	O
protein	O
(	O
s	O
)	O
which	O
protect	O
neutrophils	O
from	O
the	O
cytotoxic	O
effects	O
of	O
TNF	O
-	O
alpha	O
.	O

These	O
data	O
shed	O
light	O
on	O
the	O
biochemical	O
and	O
molecular	O
mechanisms	O
regulating	O
human	O
granulocyte	O
apoptosis	O
and	O
,	O
in	O
particular	O
,	O
indicate	O
that	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
plays	O
a	O
crucial	O
role	O
in	O
regulating	O
the	O
physiological	O
cell	O
death	O
pathway	O
in	O
granulocytes	O
.	O

Lactobacilli	O
and	O
vaginal	O
host	O
defense	O
:	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
,	O
cytokine	O
production	O
,	O
and	O
NF	O
-	O
kappaB	O
.	O

Lactobacilli	O
,	O
a	O
component	O
of	O
the	O
normal	O
vaginal	O
flora	O
,	O
can	O
activate	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
in	O
the	O
Jurkat	O
T	O
lymphocyte	O
and	O
THP	O
-	O
1	O
macrophage	O
cell	O
lines	O
.	O

Activation	O
of	O
the	O
LTR	O
in	O
Jurkat	O
cells	O
was	O
strongly	O
enhanced	O
by	O
vanadate	O
and	O
inhibited	O
by	O
catalase	O
,	O
implicating	O
H2O2	O
.	O

In	O
contrast	O
,	O
activation	O
in	O
THP	O
-	O
1	O
cells	O
occurred	O
in	O
the	O
absence	O
of	O
vanadate	O
and	O
was	O
unaffected	O
by	O
catalase	O
.	O

The	O
active	O
material	O
partitioned	O
into	O
the	O
phenol	O
layer	O
on	O
hot	O
aqueous	O
phenol	O
extraction	O
.	O

Lactobacilli	O
also	O
increased	B-Positive_regulation
tumor	O
necrosis	O
factor	O
-	O
alphaand	O
interleukin	O
-	O
1betaproduction	O
and	O
activated	O
NF	O
-	O
kappaB	O
in	O
THP	O
-	O
1	O
cells	O
and	O
increased	B-Positive_regulation
tumor	O
necrosis	O
factor	O
-	O
alphaproduction	O
by	O
human	O
monocytes	O
.	O

Human	O
vaginal	O
fluid	O
specimens	O
had	O
comparable	O
properties	O
,	O
which	O
correlated	O
with	O
their	O
bacterial	O
content	O
.	O

These	O
findings	O
suggest	O
the	O
presence	O
in	O
vaginal	O
fluid	O
of	O
agent	O
(	O
s	O
)	O
derived	O
from	O
indigenous	O
bacteria	O
that	O
can	O
activate	O
the	O
HIV	O
-	O
1	O
LTR	O
,	O
cytokine	O
production	O
,	O
and	O
NF	O
-	O
kappaB	O
in	O
cells	O
of	O
macrophage	O
lineage	O
,	O
with	O
possible	O
influence	O
on	O
vaginal	O
physiology	O
and	O
host	O
defense	O
.	O

High	O
-	O
level	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
in	O
thymocytes	O
requires	O
NF	O
-	O
kappaB	O
activation	O
through	O
interaction	O
with	O
thymic	O
epithelial	O
cells	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
interaction	O
of	O
infected	O
thymocytes	O
with	O
autologous	O
thymic	O
epithelial	O
cells	O
(	O
TEC	O
)	O
is	O
a	O
prerequisite	O
for	O
a	O
high	O
level	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
replication	O
in	O
thymocytes	O
(	O
M.Rothe	O
,	O
L.Chene	O
,	O
M.Nugeyre	O
,	O
F.Barre	O
-	O
Sinoussi	O
,	O
and	O
N.Israel	O
,	O
J.Virol.72	O
:	O
5852	O
-	O
5861	O
,	O
1998	O
)	O
.	O

We	O
report	O
here	O
that	O
this	O
activation	O
of	O
HIV	O
replication	O
takes	O
place	O
at	O
the	O
transcriptional	O
level	O
through	O
activation	O
of	O
the	O
Rel/NF	O
-	O
kappaB	O
transcription	O
factors	O
.	O

We	O
first	O
demonstrate	O
that	O
an	O
HIV	O
-	O
1	O
provirus	O
(	O
SF	O
-	O
2	O
strain	O
)	O
very	O
effectively	O
replicates	O
in	O
thymocytes	O
cocultured	O
with	O
TEC	O
whereas	O
this	O
provirus	O
,	O
with	O
kappaB	O
sites	O
deleted	O
,	O
fails	O
to	O
replicate	O
.	O

We	O
provide	O
evidence	O
that	O
several	O
NF	O
-	O
kappaB	O
complexes	O
are	O
constitutively	O
found	O
in	O
the	O
nuclei	O
of	O
thymocytes	O
either	O
freshly	O
isolated	O
from	O
the	O
thymus	O
or	O
maintained	O
in	O
coculture	O
with	O
autologous	O
or	O
heterologous	O
TEC	O
.	O

The	O
prevalent	O
complex	O
is	O
the	O
heterodimer	O
p50	O
-	O
p65	O
.	O

NF	O
-	O
kappaB	O
activity	O
is	O
tightly	O
correlated	O
with	O
the	O
transcriptional	O
activity	O
of	O
a	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
HIV	O
-	O
1	O
transfected	O
in	O
thymocytes	O
.	O

The	O
cotransfection	B-Positive_regulation
of	O
this	O
LTR	O
with	O
a	O
mutated	O
IkappaBalpha	O
molecule	O
formally	O
demonstrates	O
that	O
LTR	O
transactivation	O
is	O
regulated	O
by	O
members	O
of	O
the	O
Rel/NF	O
-	O
kappaB	O
family	O
in	O
thymocytes	O
.	O

We	O
also	O
showed	O
that	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
and	O
to	O
a	O
lesser	O
extent	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
,	O
secreted	O
within	O
the	O
coculture	O
,	O
induce	O
NF	O
-	O
kappaB	O
activity	O
and	O
a	O
correlative	O
LTR	O
transactivation	O
.	O

However	O
IL	O
-	O
7	O
,	O
a	O
crucial	O
factor	O
for	O
thymopoiesis	O
that	O
is	O
secreted	B-Localization
mainly	O
by	O
TEC	O
,	O
is	O
a	O
necessary	O
cofactor	O
for	O
NF	O
-	O
kappaB	O
activation	O
elicited	O
by	O
TNF	O
or	O
IL	O
-	O
1	O
.	O

Together	O
,	O
these	O
data	O
indicate	O
that	O
NF	O
-	O
kappaB	O
activation	O
,	O
required	O
for	O
a	O
high	O
level	O
of	O
HIV	O
replication	O
in	O
thymocytes	O
,	O
is	O
regulated	O
in	O
a	O
specific	O
manner	O
in	O
the	O
thymic	O
microenvironment	O
which	O
provides	B-Gene_expression
the	O
necessary	O
cytokines	O
:	O
TNF	O
,	O
IL	O
-	O
1	O
,	O
and	O
IL	O
-	O
7	O
.	O

Cross	O
-	O
linking	O
of	O
CD44	O
on	O
rheumatoid	O
synovial	O
cells	O
up	B-Positive_regulation
-	I-Positive_regulation
regulates	I-Positive_regulation
VCAM	O
-	O
1	O
.	O

CD44	O
is	O
a	O
ubiquitous	O
molecule	O
also	O
known	O
as	O
hyaluronic	O
acid	O
or	O
homing	O
receptor	O
.	O

However	O
,	O
the	O
cellular	O
functions	O
and	O
its	O
role	O
in	O
inflammation	O
,	O
for	O
example	O
,	O
rheumatoid	O
synovitis	O
,	O
are	O
currently	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
propose	O
a	O
novel	O
function	O
for	O
CD44	O
.	O

Using	O
synovial	O
cells	O
from	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
patients	O
,	O
we	O
demonstrated	O
that	O
CD44	O
cross	B-Binding
-	I-Binding
linking	I-Binding
and	O
binding	B-Binding
to	O
hyaluronan	O
augmented	B-Positive_regulation
VCAM	O
-	O
1	O
expression	B-Gene_expression
and	O
subsequently	O
VCAM-1	O
-	O
mediated	O
cell	O
adhesion	O
.	O

Briefly	O
,	O
we	O
found	O
that	O
1	O
)	O
rheumatoid	O
synovial	O
cells	O
highly	O
expressed	B-Gene_expression
CD44	O
;	O
2	O
)	O
cross	B-Binding
-	I-Binding
linking	I-Binding
of	O
CD44	O
markedly	O
but	O
transiently	O
augmented	B-Positive_regulation
VCAM	O
-	O
1	O
expression	B-Gene_expression
and	O
its	O
mRNA	O
transcription	B-Transcription
much	O
more	O
than	O
did	O
IL	O
-	O
1beta	O
and	O
TNF	O
-	O
alpha	O
;	O
3	O
)	O
hyaluronan	O
,	O
especially	O
when	O
fragmented	O
,	O
also	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
VCAM	O
-	O
1	O
;	O
4	O
)	O
CD44	O
activated	B-Positive_regulation
the	O
transcription	O
factor	O
AP	O
-	O
1	O
;	O
and	O
5	O
)	O
the	O
integrin	O
-	O
dependent	O
adhesive	O
function	O
of	O
RA	O
synovial	O
cells	O
to	O
T	O
cells	O
was	O
also	O
amplified	O
by	O
CD44	O
cross	B-Binding
-	I-Binding
linking	I-Binding
.	O

These	O
results	O
indicate	O
that	O
the	O
adhesion	O
of	O
RA	O
synovial	O
cells	O
to	O
matrices	O
such	O
as	O
hyaluronic	O
acid	O
through	O
CD44	O
could	O
up	B-Positive_regulation
-	I-Positive_regulation
regulate	I-Positive_regulation
VCAM	O
-	O
1	O
expression	B-Gene_expression
and	O
VCAM-1	O
-	O
mediated	O
adhesion	O
to	O
T	O
cells	O
,	O
which	O
might	O
in	O
turn	O
cause	O
activation	O
of	O
T	O
cells	O
and	O
synovial	O
cells	O
in	O
RA	O
synovitis	O
.	O

We	O
therefore	O
propose	O
that	O
such	O
cross	O
-	O
talking	O
among	O
distinct	O
adhesion	O
molecules	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
inflammation	O
,	O
including	O
RA	O
synovitis	O
.	O

Oleic	O
acid	O
inhibits	O
endothelial	O
activation	O
:	O
A	O
direct	O
vascular	O
antiatherogenic	O
mechanism	O
of	O
a	O
nutritional	O
component	O
in	O
the	O
mediterranean	O
diet	O
.	O

Because	O
oleic	O
acid	O
is	O
implicated	O
in	O
the	O
antiatherogenic	O
effects	O
attributed	O
to	O
the	O
Mediterranean	O
diet	O
,	O
we	O
investigated	O
whether	O
this	O
fatty	O
acid	O
can	O
modulate	O
endothelial	O
activation	O
,	O
ie	O
,	O
the	O
concerted	O
expression	O
of	O
gene	O
products	O
involved	O
in	O
leukocyte	O
recruitment	O
and	O
early	O
atherogenesis	O
.	O

We	O
incubated	O
sodium	O
oleate	O
with	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
for	O
0	O
to	O
72	O
hours	O
,	O
followed	O
by	O
coincubation	O
of	O
oleate	O
with	O
human	O
recombinant	O
tumor	O
necrosis	O
factor	O
,	O
interleukin	O
(	O
IL	O
)	O
-	O
1alpha	O
,	O
IL	O
-	O
1beta	O
,	O
IL	O
-	O
4	O
,	O
Escherichia	O
coli	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
or	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
for	O
a	O
further	O
6	O
to	O
24	O
hours	O
.	O

The	O
endothelial	O
expression	B-Gene_expression
of	O
vascular	O
cell	O
adhesion	O
molecule	O
-	O
1	O
(	O
VCAM	O
-	O
1	O
)	O
,	O
E	O
-	O
selectin	O
,	O
and	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
was	O
monitored	O
by	O
cell	O
surface	O
enzyme	O
immunoassays	O
or	O
flow	O
cytometry	O
,	O
and	O
steady	O
-	O
state	O
levels	B-Transcription
of	O
VCAM	O
-	O
1	O
mRNA	O
were	O
assessed	O
by	O
Northern	O
blot	O
analysis	O
.	O

At	O
10	O
to	O
100	O
micromol/L	O
for	O
>	O
24	O
hours	O
,	O
oleate	O
inhibited	B-Negative_regulation
the	O
expression	B-Gene_expression
of	O
all	O
adhesion	O
molecules	O
tested	O
.	O

After	O
a	O
72	O
-	O
hour	O
incubation	O
with	O
oleate	O
and	O
a	O
further	O
16	O
-	O
hour	O
incubation	O
with	O
oleate	O
plus	O
1	O
microg/mL	O
LPS	O
,	O
VCAM	O
-	O
1	O
expression	B-Gene_expression
was	O
reduced	B-Negative_regulation
by	O
>	O
40	O
%	O
compared	O
with	O
control	O
.	O

Adhesion	O
of	O
monocytoid	O
U937	O
cells	O
to	O
LPS	O
-	O
treated	O
endothelial	O
cells	O
was	O
reduced	O
concomitantly	O
.	O

Oleate	O
also	O
produced	O
a	O
quantitatively	O
similar	O
reduction	B-Negative_regulation
of	O
VCAM	O
-	O
1	O
mRNA	O
levels	O
on	O
Northern	O
blot	O
analysis	O
and	O
inhibited	O
nuclear	O
factor	O
-	O
kappaB	O
activation	O
on	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

Incubation	O
of	O
endothelial	O
cells	O
with	O
oleate	O
for	O
72	O
hours	O
decreased	O
the	O
relative	O
proportions	O
of	O
saturated	O
(	O
palmitic	O
and	O
stearic	O
)	O
acids	O
in	O
total	O
cell	O
lipids	O
and	O
increased	O
the	O
proportions	O
of	O
oleate	O
in	O
total	O
cell	O
lipids	O
without	O
significantly	O
changing	O
the	O
relative	O
proportions	O
of	O
polyunsaturated	O
fatty	O
acids	O
.	O

Although	O
less	O
potent	O
than	O
polyunsaturated	O
fatty	O
acids	O
in	O
inhibiting	O
endothelial	O
activation	O
,	O
oleic	O
acid	O
may	O
contribute	O
to	O
the	O
prevention	O
of	O
atherogenesis	O
through	O
selective	O
displacement	O
of	O
saturated	O
fatty	O
acids	O
in	O
cell	O
membrane	O
phospholipids	O
and	O
a	O
consequent	O
modulation	O
of	O
gene	O
expression	O
for	O
molecules	O
involved	O
in	O
monocyte	O
recruitment	O
.	O

